


APPROVED DRUG PRODUCTS

With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)



APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

35th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
OFFICE OF GENERIC DRUGS**

2015

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2014.

35th EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
OFFICE OF GENERIC DRUGS

2015

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS
with
Therapeutic Equivalence Evaluations**

CONTENTS

	<i>PAGE</i>
PREFACE TO THIRTY FIFTH EDITION.....	iv
1 INTRODUCTION.....	vi
1.1 Content and Exclusion	vi
1.2 Therapeutic Equivalence-Related Terms	vi
1.3 Statistical Criteria for Bioequivalence	viii
1.4 Reference Listed Drug	x
1.5 General Policies and Legal Status	xi
1.6 Practitioner/User Responsibilities	xi
1.7 Therapeutic Equivalence Evaluations Codes	xiii
1.8 Description of Special Situations.....	xxi
1.9 Therapeutic Equivalence Code Change for a Drug Entity	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product	xxiv
1.11 Discontinued Section	xxiv
1.12 Changes to the Orange Book.....	xxiv
1.13 Availability of the Edition	xxv
2 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
 DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
 APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	 AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
APPROVED DRUG PRODUCTS**

**with
Therapeutic Equivalence Evaluations**

PREFACE TO THIRTY FIFTH EDITION

The publication, *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication, October 1980, of the final version of the List incorporated appropriate corrections and additions. Each subsequent edition has included the new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The *Approved Drug Products with Therapeutic Equivalence Evaluations* publication and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The *Addendum* also provides additional information that may be helpful to those submitting a new drug application to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal & Regulatory Support, Office of Generic Drugs, Center for Drug and Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information regulations.

1. INTRODUCTION

1.1 Content and Exclusion

The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants' names as abbreviated in this publication; in addition, a list of uniform terms is provided.

An *Addendum* contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research because the main purpose of the publication was to provide information to states regarding FDA's recommendation as to which generic prescription drug products were acceptable candidates for drug product selection. The 1984 Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the 1984 Amendments, some drug products are given tentative approvals. The Agency will not include drug products with tentative approval in the List. Tentative approval lists are available at [ANDA \(Generic\) Drug Approvals](#). When the tentative approval becomes a full approval through a subsequent action letter to the application holder, the Agency will list the drug product and the final approval date in the appropriate approved drug product list.

Distributors or repackagers of products on the List are not identified. Because distributors or repackagers are not required to notify FDA when they shift their sources of supply from one approved manufacturer to another, it is not possible to maintain complete information linking product approval with the distributor or repackager handling the products.

1.2 Therapeutic Equivalence-Related Terms

¹ Newly approved products are added to parts 1, 2, or 3, of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

Pharmaceutical Equivalents. Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), are of the same dosage form, route of administration and are identical in strength or concentration (e.g., chlordiazepoxide hydrochloride, 5mg capsules). Pharmaceutically equivalent drug products are formulated to contain the same amount of active ingredient in the same dosage form and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity), but they may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules). Data are generally not available for FDA to make the determination of tablet to capsule bioequivalence. Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents and if they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the List, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., propoxyphene hydrochloride vs. pentazocine hydrochloride for the treatment of pain).* Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. Therapeutic equivalence determinations are not made for unapproved, off-label indications.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and minor aspects of labeling (e.g., the presence of specific pharmacokinetic information) and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for

the prescribing physician to require that a particular brand be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

Bioavailability. This term means the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.

Bioequivalent Drug Products. This term describes pharmaceutical equivalent or pharmaceutical alternative products that display comparable bioavailability when studied under similar experimental conditions. Section 505 (j)(8)(B) of the Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

the rate and extent of absorption of the test drug do not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or

the extent of absorption of the test drug does not show a significant difference from the extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the reference drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

Bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

1.3 Statistical Criteria for Bioequivalence

Under the Drug Price Competition and Patent Term Restoration Act of 1984, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the drug product is bioequivalent to the pioneer (innovator) drug product. A major premise underlying the 1984 law is that bioequivalent drug products are therapeutically equivalent, and therefore, interchangeable.

Bioavailability refers to the rate and extent to which the active ingredient or therapeutic ingredient is absorbed from a drug product and becomes available at the site of drug action (Federal Food, Drug and Cosmetic Act, section 505(j)(8)). Bioequivalence refers to equivalent release of the same drug substance from two or more drug products or formulations. This

leads to an equivalent rate and extent of absorption from these formulations. Underlying the concept of bioequivalence is the thesis that, if a drug product contains a drug substance that is chemically identical and is delivered to the site of action at the same rate and extent as another drug product, then it is equivalent and can be substituted for that drug product. Methods used to define bioequivalence can be found in 21 CFR 320.24, and include (1) pharmacokinetic (PK) studies, (2) pharmacodynamic (PD) studies, (3) comparative clinical trials, and (4) in-vitro studies. The choice of study used is based on the site of action of the drug and the ability of the study design to compare drug delivered to that site by the two products.

The standard bioequivalence (PK) study is conducted using a two-treatment crossover study design in a limited number of volunteers, usually 24 to 36 adults. Alternately, a four-period, replicate design crossover study may also be used. Single doses of the test and reference drug products are administered and blood or plasma levels of the drug are measured over time. Pharmacokinetic parameters characterizing rate and extent of drug absorption are evaluated statistically. The PK parameters of interest are the resulting area under the plasma concentration-time curve (AUC), calculated to the last measured concentration ($AUC_{(0-t)}$) and extrapolated to infinity ($AUC_{(0-inf)}$), for extent of absorption; and the maximum or peak drug concentrations (C_{max}), for rate of absorption. Crossover studies may not be practical in drugs with a long half-life in the body, and a parallel study design may be used instead. Alternate study methods, such as in-vitro studies or equivalence studies with clinical or pharmacodynamic endpoints, are used for drug products where plasma concentrations are not useful to determine delivery of the drug substance to the site of activity (such as inhalers, nasal sprays and topical products applied to the skin).

The statistical methodology for analyzing these bioequivalence studies is called the two one-sided test procedure. Two situations are tested with this statistical methodology. The first of the two one-sided tests determines whether a generic product (test), when substituted for a brand-name product (reference) is significantly less bioavailable. The second of the two one-sided tests determines whether a brand-name product when substituted for a generic product is significantly less bioavailable. Based on the opinions of FDA medical experts, a difference of greater than 20% for each of the above tests was determined to be significant, and therefore, undesirable for all drug products. Numerically, this is expressed as a limit of test-product average/reference-product average of 80% for the first statistical test and a limit of reference-product average/test-product average of 80% for the second statistical test. By convention, all data is expressed as a ratio of the average response (AUC and C_{max}) for test/reference, so the limit expressed in the second statistical test is 125% (reciprocal of 80%).

For statistical reasons, all data is log-transformed prior to conducting statistical testing. In practice, these statistical tests are carried out using an analysis of variance procedure (ANOVA) and calculating a 90% confidence interval for each pharmacokinetic parameter (C_{max} and AUC). The confidence interval for both pharmacokinetic parameters, AUC and C_{max} , must be entirely within the 80% to 125% boundaries cited above. Because the mean of the study data lies in the center of the 90% confidence interval, the mean of the data is usually close to 100% (a test/reference ratio of 1). Different statistical criteria are sometimes used when bioequivalence is demonstrated through comparative clinical trials pharmacodynamic studies, or comparative in-vitro methodology.

The bioequivalence methodology and criteria described above simultaneously control for both differences in the average response between test and reference, as well as the precision with which the average response in the population is estimated. This precision depends on the within-subject

(normal volunteer or patient) variability in the pharmacokinetic parameters (AUC and Cmax) of the two products and on the number of subjects in the study. The width of the 90% confidence interval is a reflection in part of the within-subject variability of the test and reference products in the bioequivalence study. A test product with no differences in the average response when compared to the reference might still fail to pass the bioequivalence criteria if the variability of one or both products is high and the bioequivalence study has insufficient statistical power (i.e., insufficient number of subjects). Likewise, a test product with low variability may pass the bioequivalence criteria, when there are somewhat larger differences in the average response.

This system of assessing bioequivalence of generic products assures that these substitutable products do not deviate substantially in in-vivo performance from the reference product. The Office of Generic Drugs has conducted two surveys to quantify the differences between generic and brand name products. The first survey included 224 bioequivalence studies submitted in approved applications during 1985 and 1986. The observed average differences between reference and generic products for AUC was 3.5% (JAMA, Sept. 4, 1987, Vol. 258, No. 9). The second survey included 127 bioequivalence studies submitted to the agency in 273 ANDAs approved in 1997. The three measures reviewed include $AUC_{(0-t)}$, $AUC_{(0-inf)}$, and Cmax. The observed average differences between the reference and generic products were $\pm 3.47\%$ (SD 2.84) for $AUC_{(0-t)}$, $\pm 3.25\%$ (SD 2.97) for $AUC_{(0-inf)}$, and $\pm 4.29\%$ (SD 3.72) for Cmax (JAMA, Dec. 1, 1999, Vol. 282, No. 21).

The primary concern from the regulatory point of view is the protection of the patient against approval of products that are not bioequivalent. The current practice of carrying out two one-sided tests at the 0.05 level of significance ensures that there is no more than a 5% chance that a generic product that is not truly equivalent to the reference will be approved.

1.4 Reference Listed Drug

A reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence (reference standard) and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when listed drugs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of a listed drug that is not designated as the reference listed drug may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second listed drug will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes products meeting necessary bioequivalence requirements* explains the (AB, AB1, AB2, AB3... coding system for multisource drug products listed under the same heading with two reference listed drugs.

In addition, there are two situations in which two listed drugs that have been shown to be bioequivalent to each other may both be designated as reference listed drugs. The first situation occurs when the *in vivo* determination of bioequivalence is self-evident and a waiver of the *in vivo* bioequivalence may be granted. The second situation occurs when the bioequivalence of two listed products may be determined through *in vitro* methodology. The reference listed drug is identified by the symbol "+" in the Prescription and Over-the-Counter (OTC) Drug Product Lists. These identified reference listed drugs represent the best judgment of the Division of Bioequivalence at this time. The Prescription and OTC Drug Product Lists identify reference drugs for oral dosage forms, Injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, Office of Generic Drugs, to confirm the appropriate reference listed drug.

1.5 General Policies and Legal Status

The List contains public information and advice. It does not mandate the drug products which is purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the List sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the List identifies drug products approved under Section 505 of the Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the List does not necessarily mean that the drug product is either in violation of Section 505 of the Act, or that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion is based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the List.

Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be better

stability of one product over another under adverse storage conditions, or allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's specification of that product is appropriate. Pharmacists must also be familiar with the expiration dates/times and labeling directions for storage of the different products, particularly for reconstituted products, to assure that patients are properly advised when one product is substituted for another.

Multisource and single-source drug products. FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and, in addition, product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included on the List, but no therapeutic equivalence code is included with such products. Any drug product in the List repackaged and/or distributed by other than the application holder is considered to be therapeutically equivalent to the application holder's drug product even if the application holder's drug product is single source or coded as non-equivalent (e.g., **BN**). Also, although not identified in the List, distributors or repackagers of an application holder's drug product are considered to have the same code as the application holder. The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products on the List are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In most instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is permitted by regulation to appear on the label, even when the manufacturer is not the marketer.

Although the products on the List are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations on the List are, in most cases, correct.

To relate firm name information on a product label to that on the List, the following should be noted: the applicant's name always appears on the List. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears on the List and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears on the List and both firm names may appear on the label. Firms with known corporate relationships are

displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears on the List; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the List, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that on the List, the following should be noted: if the applicant is the marketer, its name appears on the List and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established drug name if no trade name exists) appears on the List. If a corporate relationship exists between an application holder and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the application holder to appear on the List. If there is no known corporate relationship between the applicant and the marketer, the established drug name appears on the List.

Every product on the List is subject at all times to regulatory action.

From time to time, approved products may be found in violation of one or more provisions of the Act. In such circumstances, the Agency will commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product on the List. The main criterion for inclusion of a product is that it has an application with an effective approval that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product on the List will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the data upon which the Agency's assessment of whether a product meets the criteria for therapeutic equivalence was made.

1.7 Therapeutic Equivalence Evaluations Codes

The coding system for therapeutic equivalence evaluations is constructed to allow users to determine quickly whether the Agency has evaluated a particular approved product as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With few exceptions, the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting

bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bio-equivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is presumed and considered self-evident based on other data in the application for some dosage forms (e.g., solutions) or satisfied for solid oral dosage forms by a showing that an acceptable *in vitro* dissolution standard is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or
- (2) for those DESI drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional. For example, pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution. An FDA evaluation that such products are therapeutically equivalent is applicable

only when each product is reconstituted, stored, and used under the conditions specified in the labeling of that product.

The Agency will use notes in this publication to point out special situations such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Special Situations*.

For example, in rare instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note will be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts and esters of the same therapeutic moiety are regarded as pharmaceutical alternatives. For the purpose of this publication, such products are not considered to be therapeutically equivalent. There are no instances in this List where pharmaceutical alternatives are evaluated or coded with regard to therapeutic equivalence. Anhydrous and hydrated entities, as well as different polymorphs, are considered pharmaceutical equivalents and must meet the same standards and, where necessary, as in the case of ampicillin/ampicillin trihydrate, their equivalence is supported by appropriate bioavailability/bioequivalence studies.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives may differ among some therapeutically equivalent drug products. Differences in preservatives and other inactive ingredients do not

affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Products coded as **AA** contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents*) generally will be coded **AB** if a study is submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1**, **AB2**, **AB3**, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC (Miles) and Procardia XL® (Pfizer), extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved, Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. The generic drug products bioequivalent to Adalat® CC would be assigned a rating of **AB1** and those bioequivalent to Procardia XL® would be assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the List, they are considered therapeutically equivalent to the application holder's drug product if the application holder's drug product is rated either with an **AB** or three-character code or is single source in the List. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are

coded **BN**, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included on the List (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

The strength of parenteral drugs products is defined as the total drug content of the container. Until recently the strength of liquid parenteral drug products in the Orange Book have not been displayed. The concentration of the liquid parenteral drug product in the Orange Book has been shown as xmg/ml. The amount of dry powder or freeze dried powder in a container has always been identified as the strength.

With the finalization of the Waxman-Hatch amendments that characterized each strength of a drug product as a listed drug, it became evident that the format of the Orange Book should be changed to reflect each strength of a parenteral solution. To this end the OGD has started to display the strength of all new approvals of parenteral solutions. Previously we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/ml. If this drug product had a 20 ml and 60 ml container approved the two products would be shown as 1Gm / 20ml (50mg/ml) and 3Gm / 60ml (50mg/ml).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bio-equivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained medicament available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because firms developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore,

the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard, such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate *in vivo* bioequivalence data are submitted, such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence, such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bio-equivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the product is coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. Following is a description of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

Follitropin Alfa and Beta. Based on available data derived from physico-chemical tests and bioassay, follitropin alfa and follitropin beta are indistinguishable.

Gaviscon®. Gaviscon® is an OTC product which has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test which is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs which cite Gaviscon® tablets as the listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium. Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid

(Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBOTT	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBOTT	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHEROID	LLOYD	0.025MG	AB4	021116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

Patent Certification(s) Reference Listed Drug based upon a suitability petition. An abbreviated new drug application that refers to a Reference Listed Drug (RLD) approved pursuant to a suitability petition must demonstrate that the proposed product is bioequivalent to the RLD, and it must include appropriate patent certification(s) and an exclusivity statement with respect to the listed drug which served as the basis for the approved suitability petition. This concept also applies to an ANDA applicant that cites a RLD that was based upon an NDA that is still covered by patent (s) and/or exclusivity, e.g. a second RLD that was selected when the in vivo determination of bioequivalence of the original RLD is self evident and the waiver of the in vivo determination of bioequivalence may be granted.

Waived exclusivity. If a new drug application (NDA) submitted under

section 505(b) of the Federal Food, Drug, and Cosmetic Act (Act) qualifies for exclusivity under sections 505(c)(3)(D) and 505(j)(5)(D), the exclusivity is listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will delay the approval of a 505(b)(2) application or an abbreviated new drug application (ANDA) under section 505(j) of the Act until the expiration of the exclusivity. If the listed drug is also protected by one or more patents, the approval date for the 505(b)(2) application or ANDA will be determined by the latest expiring patent or exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all 505(b)(2) and ANDA applications referencing the protected drug product. If an NDA sponsor waives its right to the exclusivity protection, qualified 505(b)(2) or ANDA applications may be approved without regard to the NDA holder's exclusivity. An NDA for which the holder has waived its exclusivity as to all 505(b)(2) and ANDA applications will be coded with a W in the Patent and Exclusivity Section of the Orange Book and be referred to this section. The applicant referencing this listed drug should indicate in the exclusivity statement that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Drug Entity

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multi-source drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of drug products in the List (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying a bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of drugs, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comment. Comments, along with scientific data, may be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submission is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. These submissions should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and such submissions are discouraged. Copies

of supporting reports published in the scientific literature or unpublished material, however, are welcome.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The aforementioned procedure does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

1.11 Discontinued Section

Those drug products in the Discontinued Section of the Orange Book in which a determination has already been made that the products were not withdrawn for safety or efficacy reasons have "***Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons***" following the product strength. Those drug products are only reflective of citizen petitions determinations made since 1995. The identification of these drug products in the Discontinued Section of the Orange Book should avoid the submission of multiple citizen petitions for the same drug product. FR notices no longer applicable are removed from the Annual Edition (i.e., there is a currently marketed Reference Listed Drug and no applicable patent or exclusivity). [FR Safety or Effectiveness Determinations List](#) lists products that have current and removed notices. The list is updated quarterly. Notices issued during the year are added to the [Electronic Orange Book Query](#) in the month they become effective.

Generally, approved products are added to the Discontinued Section of the Orange Book when the applicant holder notifies the Orange Book staff of the products' not marketed status. Products may also be added if annual reports indicate the product is no longer marketed or other Agency administrative action (e.g., Withdrawal of an Application). Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. Please inform the OBS when products are no longer marketed. Notification of the Orange Book staff to include the newly approved product in the Discontinued Drug Product List rather than parts 1, 2 or 3 of the List (as discussed in Section 1.1) must occur by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

We can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 301-595-1446; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs,
7620 Standish Place
Rockville, MD 20855-2773

1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the EOB home page, [Electronic Orange Book Query](#), by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Printing Office, 866-512-1800.

2. HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, application holders, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Section of the Orange Book.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by established or trade name. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULAZINE

AB URSA **500MG** **A042222** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SULFASALAZINE

TABLET; ORAL

FAZINE

AB PARKLAND **500MG** **A042999** **001**

SULFASALAZINE

BP BROWN 500MG A041297 001

SOUTH 500MG A067627 001

PRODUCTS CONSIDERED THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO ANY OTHER PRODUCTS LISTED

PRODUCTS CONSIDERED **NOT** THERAPEUTICALLY
EQUIVALENT TO EACH OTHER

NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

3-1 (of 371)

ABACAVIR SULFATE

SOLUTION;ORAL

ZIAGEN

+ VIIIV HLTHCARE

EQ 20MG BASE/ML

N020978 001 Dec 17, 1998

TABLET;ORAL

ABACAVIR SULFATEAB APOTEX INCEQ 300MG BASEA201570 001 Dec 17, 2012AB AUROBINDO PHARMA LTDEQ 300MG BASEA077844 001 Dec 17, 2012AB HETERO LABS LTD IIIEQ 300MG BASEA091560 001 Sep 13, 2013AB MYLAN PHARMS INCEQ 300MG BASEA091294 001 Jun 18, 2012ZIAGENAB + VIIIV HLTHCAREEQ 300MG BASEN020977 001 Dec 17, 1998ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

+ VIIIV HLTHCARE

EQ 600MG BASE;EQ 50MG BASE;300MG

N205551 001 Aug 22, 2014

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

EPZICOM

+ VIIIV HLTHCARE

EQ 600MG BASE;300MG

N021652 001 Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEAB LUPIN LTDEQ 300MG BASE;150MG;300MGA202912 001 Dec 05, 2013TRIZIVIRAB + VIIIV HLTHCAREEQ 300MG BASE;150MG;300MGN021205 001 Nov 14, 2000ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

+ JANSSEN BIOTECH

250MG

N202379 001 Apr 28, 2011

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUMAB BARR LABS DIV TEVA333MGA200143 001 Nov 18, 2013AB GLENMARK GENERICS333MGA202229 001 Jul 16, 2013AB MYLAN PHARMS INC333MGA200142 001 Mar 11, 2014CAMPRALAB + FOREST LABS333MGN021431 001 Jul 29, 2004ACARBOSE

TABLET;ORAL

ACARBOSEAB EMCURE PHARMS LTD25MGA202271 001 Feb 07, 2012AB50MGA202271 002 Feb 07, 2012AB100MGA202271 003 Feb 07, 2012AB IMPAX LABS25MGA078441 001 May 14, 2009AB50MGA078441 002 May 14, 2009AB100MGA078441 003 May 14, 2009AB MYLAN25MGA091053 001 Jan 06, 2011AB50MGA091053 002 Jan 06, 2011AB100MGA091053 003 Jan 06, 2011AB ROXANE25MGA078470 001 May 07, 2008AB50MGA078470 002 May 07, 2008AB100MGA078470 003 May 07, 2008AB STRIDES PHARMA25MGA090912 001 Jul 27, 2011AB50MGA090912 002 Jul 27, 2011AB100MGA090912 003 Jul 27, 2011AB VIRTUS PHARM25MGA091343 001 Oct 17, 2013AB50MGA091343 002 Oct 17, 2013AB100MGA091343 003 Oct 17, 2013AB WATSON LABS25MGA077532 001 May 07, 2008AB50MGA077532 002 May 07, 2008AB100MGA077532 003 May 07, 2008PRECOSEAB + BAYER HLTHCARE25MGN020482 004 May 29, 1997AB50MGN020482 001 Sep 06, 1995AB100MGN020482 002 Sep 06, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-2 (of 371)

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

AB	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047</u>	<u>001</u>	Dec 30, 1999
AB		<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u>	Dec 30, 1999
AB	MYLAN	<u>EQ 200MG BASE</u>	<u>A074288</u>	<u>001</u>	Apr 24, 1995
AB		<u>EQ 400MG BASE</u>	<u>A074288</u>	<u>002</u>	Apr 24, 1995

SECTRAL

AB	PROMIUS PHARMA	<u>EQ 200MG BASE</u>	<u>N018917</u>	<u>001</u>	Dec 28, 1984
AB	+	<u>EQ 400MG BASE</u>	<u>N018917</u>	<u>003</u>	Dec 28, 1984

ACETAMINOPHEN

SOLUTION; IV (INFUSION)

OFIRMEV

+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010
---	----------------	------------------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

+	NEXGEN PHARMA	300MG; 50MG	A090956	001	Aug 23, 2011
---	---------------	-------------	---------	-----	--------------

BUTAPAP

+	MIKART	325MG; 50MG	A089987	001	Oct 26, 1992
---	--------	-------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986
---	--------	-------------------	---------	-----	--------------

+	NEXGEN PHARMA	300MG; 50MG; 40MG	A040885	001	Nov 16, 2009
---	---------------	-------------------	---------	-----	--------------

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+	MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387	001	Jan 31, 2003
---	--------	----------------------------------	---------	-----	--------------

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	HIKMA PHARMS LLC	<u>325MG; 50MG; 40MG</u>	<u>A089718</u>	<u>001</u>	Jun 12, 1995
AA	LANNETT HOLDINGS INC	<u>325MG; 50MG; 40MG</u>	<u>A200243</u>	<u>001</u>	Sep 13, 2012
AA	MALLINCKRODT	<u>325MG; 50MG; 40MG</u>	<u>A087804</u>	<u>001</u>	Jan 24, 1985
AA	MIKART	<u>325MG; 50MG; 40MG</u>	<u>A089175</u>	<u>001</u>	Jan 21, 1987
AA	+	<u>325MG; 50MG; 40MG</u>	<u>A040511</u>	<u>001</u>	Aug 27, 2003

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	HIKMA INTL PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075618</u>	<u>001</u>	Mar 23, 2001
AB	NEXGEN PHARMA INC	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A076560</u>	<u>001</u>	Jun 10, 2004
AB	VINTAGE PHARMS	<u>325MG; 50MG; 40MG; 30MG</u>	<u>A075929</u>	<u>001</u>	Apr 22, 2002

FIORICET W/ CODEINE

AB	+	<u>325MG; 50MG; 40MG; 30MG</u>	<u>N020232</u>	<u>001</u>	Jul 30, 1992
	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE				
	NEXGEN PHARMA INC	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

WRASER PHARMS LLC	320.5MG; 30MG; 16MG	A204785	001	Nov 26, 2014
-------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	HI TECH PHARMA	<u>120MG/5ML; 12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996
AA	MIKART	<u>120MG/5ML; 12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992
AA	+	<u>120MG/5ML; 12MG/5ML</u>	<u>A087508</u>	<u>001</u>	
AA	VINTAGE PHARMS	<u>120MG/5ML; 12MG/5ML</u>	<u>A091238</u>	<u>001</u>	Nov 10, 2011
AA	WOCKHARDT	<u>120MG/5ML; 12MG/5ML</u>	<u>A087006</u>	<u>001</u>	

SUSPENSION; ORAL

CAPITAL AND CODEINE

+	VALEANT PHARMS LLC	120MG/5ML; 12MG/5ML	A086024	001	
---	--------------------	---------------------	---------	-----	--

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	AMNEAL PHARMS NY	<u>300MG; 30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008
AA	AUROLIFE PHARMA LLC	<u>300MG; 15MG</u>	<u>A202800</u>	<u>001</u>	Apr 15, 2013
AA		<u>300MG; 30MG</u>	<u>A202800</u>	<u>002</u>	Apr 15, 2013
AA		<u>300MG; 60MG</u>	<u>A202800</u>	<u>003</u>	Apr 15, 2013
AA	+	<u>300MG; 15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001
AA		<u>300MG; 30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001
AA		<u>300MG; 60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-3 (of 371)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

<u>AA</u>	RANBAXY	<u>300MG;30MG</u>	<u>A085868</u>	<u>001</u>	
<u>AA</u>		<u>300MG;60MG</u>	<u>A087083</u>	<u>001</u>	
<u>AA</u>	TEVA	<u>300MG;15MG</u>	<u>A088627</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>		<u>300MG;30MG</u>	<u>A088628</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	+	<u>300MG;60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985
<u>AA</u>	VINTAGE	<u>300MG;15MG</u>	<u>A089990</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>		<u>300MG;30MG</u>	<u>A089805</u>	<u>001</u>	Sep 30, 1988
<u>AA</u>	VINTAGE PHARMS	<u>300MG;60MG</u>	<u>A089828</u>	<u>001</u>	Sep 30, 1988
	<u>TYLENOL W/ CODEINE NO. 3</u>				
<u>AA</u>	+	<u>JANSSEN PHARMS</u>	<u>300MG;30MG</u>	<u>A085055</u>	<u>003</u>
	<u>TYLENOL W/ CODEINE NO. 4</u>				
<u>AA</u>	JANSSEN PHARMS	<u>300MG;60MG</u>	<u>A085055</u>	<u>004</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	+	MIKART	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003
<u>AA</u>		PHARM ASSOC	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013
<u>AA</u>		VINTAGE PHARMS	<u>325MG/15ML;7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011
<u>AA</u>		VISTAPHARM	<u>325MG/15ML;7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012
	+	MIKART	300MG/15ML;10MG/15ML	A040881	001	Feb 25, 2010
	+	PHARM ASSOC	325MG/15ML;10MG/15ML	A040834	001	Apr 18, 2008

TABLET; ORAL

ANEXSIA 5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000
-----------	--------------	------------------	----------------	------------	--------------

ANEXSIA 7.5/325

<u>AA</u>	MALLINCKRODT	<u>325MG;7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000
-----------	--------------	--------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

<u>AA</u>	AMNEAL PHARMS NY	<u>325MG;5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG;5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201013</u>	<u>002</u>	Apr 11, 2012
<u>AA</u>		<u>325MG;10MG</u>	<u>A201013</u>	<u>003</u>	Apr 11, 2012
<u>AA</u>	MALLINCKRODT	<u>325MG;10MG</u>	<u>A040400</u>	<u>001</u>	Jul 26, 2000
<u>AA</u>	+ MIKART	<u>300MG;5MG</u>	<u>A040658</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>	+	<u>300MG;7.5MG</u>	<u>A040556</u>	<u>002</u>	Mar 24, 2006
<u>AA</u>	+	<u>300MG;10MG</u>	<u>A040556</u>	<u>001</u>	Jun 23, 2004
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040432</u>	<u>001</u>	Jan 22, 2003
<u>AA</u>	SUN PHARM INDS INC	<u>325MG;5MG</u>	<u>A090118</u>	<u>001</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A090118</u>	<u>002</u>	Dec 23, 2008
<u>AA</u>		<u>325MG;10MG</u>	<u>A090118</u>	<u>003</u>	Dec 23, 2008
<u>AA</u>	TRIS PHARMA INC	<u>325MG;5MG</u>	<u>A202214</u>	<u>001</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A202214</u>	<u>002</u>	Mar 27, 2013
<u>AA</u>		<u>325MG;10MG</u>	<u>A202214</u>	<u>003</u>	Mar 27, 2013
<u>AA</u>	VINTAGE PHARMS	<u>300MG;5MG</u>	<u>A090415</u>	<u>001</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;7.5MG</u>	<u>A090415</u>	<u>002</u>	Jan 24, 2011
<u>AA</u>		<u>300MG;10MG</u>	<u>A090415</u>	<u>003</u>	Jan 24, 2011
<u>AA</u>		<u>325MG;5MG</u>	<u>A040655</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A040656</u>	<u>001</u>	Jan 19, 2006
<u>AA</u>		<u>325MG;10MG</u>	<u>A040355</u>	<u>001</u>	May 31, 2000

NORCO

<u>AA</u>	+	ACTAVIS LABS FL INC	<u>325MG;7.5MG</u>	<u>A040148</u>	<u>003</u>	Sep 12, 2000
<u>AA</u>	+		<u>325MG;10MG</u>	<u>A040148</u>	<u>001</u>	Feb 14, 1997
<u>AA</u>	+	WATSON LABS	<u>325MG;5MG</u>	<u>A040099</u>	<u>001</u>	Jun 25, 1997
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	+	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

<u>AA</u>	VINTAGE PHARMS	<u>325MG/5ML; 5MG/5ML</u>	<u>A203573</u>	<u>001</u>	Dec 18, 2014
	<u>ROXICET</u>				
<u>AA</u>	+ ROXANE	<u>325MG/5ML; 5MG/5ML</u>	<u>A089351</u>	<u>001</u>	Dec 03, 1986

TABLET; ORAL

OXYCET

<u>AA</u>	MALLINCKRODT	<u>325MG;5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983
-----------	--------------	------------------	----------------	------------	--------------

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG;2.5MG</u>	<u>A201447</u>	<u>001</u>	Apr 12, 2013
<u>AA</u>		<u>325MG;5MG</u>	<u>A201447</u>	<u>002</u>	Apr 12, 2013
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201447</u>	<u>003</u>	Apr 12, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-4 (of 371)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 10MG</u>	<u>A201447</u>	<u>004</u>	Apr 12, 2013
<u>AA</u>	ALVOGEN INC	<u>325MG; 7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201972</u>	<u>002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201972</u>	<u>003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201972</u>	<u>004</u>	Jul 15, 2013
<u>AA</u>	COASTAL PHARMS	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>	MALLINCKRODT	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278</u>	<u>001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278</u>	<u>002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278</u>	<u>003</u>	Aug 28, 2014
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535</u>	<u>001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535</u>	<u>002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535</u>	<u>003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535</u>	<u>004</u>	Dec 26, 2013
<u>AA</u>	VINTAGE PHARMS	<u>325MG; 2.5MG</u>	<u>A090733</u>	<u>001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A040105</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090734</u>	<u>001</u>	Jul 11, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090734</u>	<u>002</u>	Jul 11, 2013
<u>AA</u>	WATSON LABS	<u>325MG; 5MG</u>	<u>A040171</u>	<u>001</u>	Oct 30, 1997
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A040535</u>	<u>001</u>	Sep 05, 2003
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040535</u>	<u>002</u>	Sep 05, 2003

PERCOCET

<u>AA</u>	+	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	+		<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	+		<u>325MG; 7.5MG</u>	<u>A040434</u>	<u>001</u>	Nov 23, 2001
<u>AA</u>	+		<u>325MG; 10MG</u>	<u>A040434</u>	<u>002</u>	Nov 23, 2001

ROXICET

<u>AA</u>	ROXANE	<u>325MG; 5MG</u>	<u>A087003</u>	<u>001</u>	
	OXYCODONE AND ACETAMINOPHEN				
	+ MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
	+	300MG; 5MG	A040608	002	Dec 30, 2005
	+	300MG; 7.5MG	A040608	003	Dec 30, 2005
	+	300MG; 10MG	A040608	004	Dec 30, 2005

TABLET, EXTENDED RELEASE; ORAL

XARTEMIS XR

+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014
---	------------------	--------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	325MG; 32MG	A083689	001	
-------	-------------	---------	-----	--

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALLIED PHARMA INC	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	APOTEX INC	<u>325MG; 37.5MG</u>	<u>A078778</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	MICRO LABS LTD INDIA	<u>325MG; 37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>	MYLAN	<u>325MG; 37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>	PAR PHARM	<u>325MG; 37.5MG</u>	<u>A076475</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA INC	<u>325MG; 37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012

ULTRACET

<u>AB</u>	+	JANSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001
-----------	---	----------------	----------------------	----------------	------------	--------------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>500MG</u>	<u>A090779</u>	<u>001</u>	Jul 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-5 (of 371)

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

AB	+	DURAMED PHARMS BARR	500MG	<u>N012945</u>	<u>001</u>	
TABLET; ORAL						

ACETAZOLAMIDE

AB		LANNETT	250MG	<u>A084840</u>	<u>001</u>	
AB		MUTUAL PHARM	125MG	<u>A089752</u>	<u>001</u>	Jun 22, 1988
AB		TARO	125MG	<u>A040195</u>	<u>001</u>	May 28, 1997
AB	+		250MG	<u>A040195</u>	<u>002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP		EUROHLTH INTL	EQ 500MG BASE/VIAL	<u>A040089</u>	<u>001</u>	Feb 28, 1995
AP		SAGENT AGILA	EQ 500MG BASE/VIAL	<u>A200880</u>	<u>001</u>	May 09, 2012
AP	+	X GEN PHARMS	EQ 500MG BASE/VIAL	<u>A040784</u>	<u>001</u>	Dec 10, 2008
<u>ACETAZOLAMIDE SODIUM</u>						
AP		EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	<u>A202693</u>	<u>001</u>	Dec 19, 2014

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

AT		B BRAUN	250MG/100ML	<u>N018161</u>	<u>001</u>	
AT		BAXTER HLTHCARE	250MG/100ML	<u>N018523</u>	<u>001</u>	Feb 19, 1982
AT		HOSPIRA	250MG/100ML	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

AT		TARO	2%	<u>A088638</u>	<u>001</u>	Sep 06, 1984
AT		VINTAGE	2%	<u>A040607</u>	<u>001</u>	Feb 24, 2005
AT	+	WOCKHARDT	2%	<u>A040166</u>	<u>001</u>	Jul 26, 1996

VOSOL

AT		HI TECH PHARMA	2%	<u>N012179</u>	<u>001</u>	
-----------	--	----------------	-----------	-----------------------	-------------------	--

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

+	BAUSCH AND LOMB	2%; 0.79%	<u>A040063</u>	<u>001</u>	Feb 25, 1994
---	-----------------	------------------	-----------------------	-------------------	--------------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

AT		ACTAVIS MID ATLANTIC	2%; 1%	<u>A087143</u>	<u>001</u>	Jan 13, 1982
-----------	--	----------------------	---------------	-----------------------	-------------------	--------------

HYDROCORTISONE AND ACETIC ACID

AT		TARO	2%; 1%	<u>A088759</u>	<u>001</u>	Mar 04, 1985
AT		VINTAGE	2%; 1%	<u>A040609</u>	<u>001</u>	Feb 06, 2006

VOSOL HC

AT	+	HI TECH PHARMA	2%; 1%	<u>N012770</u>	<u>001</u>	
-----------	---	----------------	---------------	-----------------------	-------------------	--

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

+	MISSION PHARMA	250MG	<u>N018749</u>	<u>001</u>	May 31, 1983
---	----------------	--------------	-----------------------	-------------------	--------------

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

+	BAUSCH AND LOMB	20MG/VIAL	<u>N020213</u>	<u>001</u>	Sep 22, 1993
---	-----------------	------------------	-----------------------	-------------------	--------------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

AP	+	CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	<u>N021539</u>	<u>001</u>	Jan 23, 2004
-----------	---	-------------------	----------------------------	-----------------------	-------------------	--------------

ACETYLCYSTEINE

AP		INNOPHARMA LICENSING	6GM/30ML (200MG/ML)	<u>A200644</u>	<u>001</u>	Nov 07, 2012
-----------	--	----------------------	----------------------------	-----------------------	-------------------	--------------

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN		HOSPIRA	10%	<u>A073664</u>	<u>001</u>	Aug 30, 1994
AN			20%	<u>A074037</u>	<u>001</u>	Aug 30, 1994
AN		INNOPHARMA LICENSING	10%	<u>A204674</u>	<u>001</u>	Feb 11, 2014
AN			20%	<u>A203853</u>	<u>001</u>	Jun 21, 2012
AN	+	LUITPOLD	10%	<u>A072489</u>	<u>001</u>	Jul 28, 1995
AN	+		20%	<u>A072547</u>	<u>001</u>	Jul 28, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-6 (of 371)

ACITRETIN

CAPSULE; ORAL

ACITRETIN

<u>AB</u>	BARR LABS INC	<u>10MG</u>	<u>A091455</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>25MG</u>	<u>A091455</u>	<u>002</u>	Apr 04, 2013
<u>AB</u>	TEVA PHARMS USA	<u>17.5MG</u>	<u>A202897</u>	<u>001</u>	Apr 04, 2013
<u>AB</u>		<u>22.5MG</u>	<u>A202897</u>	<u>002</u>	Apr 04, 2013

SORIATANE

<u>AB</u>	STIEFEL LABS INC	<u>10MG</u>	<u>N019821</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>17.5MG</u>	<u>N019821</u>	<u>003</u>	Aug 06, 2009
<u>AB</u>		<u>22.5MG</u>	<u>N019821</u>	<u>004</u>	Aug 06, 2009
<u>AB</u>	+	<u>25MG</u>	<u>N019821</u>	<u>002</u>	Oct 28, 1996

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+	FOREST LABS INC	0.375MG/INH	N202450	001	Jul 23, 2012
---	-----------------	-------------	---------	-----	--------------

ACRIVASTINE; PSEUDOPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

SEMPREX-D

+	AUXILIUM PHARMS LLC	8MG; 60MG	N019806	001	Mar 25, 1994
---	---------------------	-----------	---------	-----	--------------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075677</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A201445</u>	<u>001</u>	Mar 06, 2014
<u>AB</u>	DAVA PHARMS INC	<u>200MG</u>	<u>A074833</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074727</u>	<u>001</u>	Apr 22, 1997
<u>AB</u>	RANBAXY	<u>200MG</u>	<u>A074975</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>	STASON	<u>200MG</u>	<u>A075090</u>	<u>001</u>	Jan 26, 1999
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074578</u>	<u>001</u>	Apr 22, 1997

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET	<u>200MG</u>	<u>N018828</u>	<u>001</u>	Jan 25, 1985
-----------	---	--------------	--------------	----------------	------------	--------------

CREAM; TOPICAL

ZOVIRAX

+	VALEANT BERMUDA	5%	N021478	001	Dec 30, 2002
---	-----------------	----	---------	-----	--------------

OINTMENT; TOPICAL

ACYCLOVIR

<u>AB</u>	AMNEAL PHARMS	<u>5%</u>	<u>A204605</u>	<u>001</u>	Jun 18, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>5%</u>	<u>A202459</u>	<u>001</u>	Apr 03, 2013

ZOVIRAX

<u>AB</u>	+	VALEANT BERMUDA	<u>5%</u>	<u>N018604</u>	<u>001</u>	Mar 29, 1982
-----------	---	-----------------	-----------	----------------	------------	--------------

SUSPENSION; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	HI TECH PHARMA	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005

ZOVIRAX

<u>AB</u>	+	DELCOR ASSET	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989
-----------	---	--------------	------------------	----------------	------------	--------------

TABLET; BUCCAL

SITAVIG

+	INNOCUTIS HOLDINGS	50MG	N203791	001	Apr 12, 2013
---	--------------------	------	---------	-----	--------------

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168</u>	<u>001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168</u>	<u>002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	DAVA PHARMS INC	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>800MG</u>	<u>A203834</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075211</u>	<u>001</u>	Sep 28, 1998
<u>AB</u>		<u>800MG</u>	<u>A075211</u>	<u>002</u>	Sep 28, 1998
<u>AB</u>	RANBAXY	<u>400MG</u>	<u>A074980</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>800MG</u>	<u>A074980</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A204314</u>	<u>001</u>	Aug 19, 2014
<u>AB</u>		<u>800MG</u>	<u>A204314</u>	<u>002</u>	Aug 19, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-7 (of 371)

ACYCLOVIR

TABLET; ORAL

ZOVIRAX

AB	DELCOR ASSET	400MG	N020089 001	Apr 30, 1991
AB	+	800MG	N020089 002	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	AUROBINDO PHARMA LTD	EQ 50MG BASE/ML	A203701 001	Oct 11, 2013
AP	BEDFORD	EQ 500MG BASE/VIAL	A074596 002	Apr 22, 1997
AP	+	EQ 50MG BASE/ML	A074930 001	May 13, 1998
AP	+	EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998
	ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997
	+	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997
	ACYCLOVIR SODIUM			
	+	EQ 1GM BASE/VIAL	A074596 001	Apr 22, 1997

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	VALEANT BERMUDA	5%;1%	N022436 001	Jul 31, 2009
---	-----------------	-------	-------------	--------------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010
-----------	----------------	-------------	--------------------	--------------

DIFFERIN

AB	+	GALDERMA LABS LP	0.1%	N020748 001	May 26, 2000
-----------	---	------------------	-------------	--------------------	--------------

GEL; TOPICAL

ADAPALENE

AB	ACTAVIS MID ATLANTIC	0.3%	A201000 001	Oct 27, 2014
AB	GLENMARK GENERICS	0.1%	A091314 001	Jul 01, 2010
AB	PLIVA HRVATSKA DOO	0.1%	A090962 001	Jun 02, 2010
AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012

DIFFERIN

AB	+	GALDERMA LABS LP	0.1%	N020380 001	May 31, 1996
AB	+		0.3%	N021753 001	Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010
---	------------------	------	-------------	--------------

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO

+	GALDERMA LABS LP	0.1%;2.5%	N022320 001	Dec 08, 2008
---	------------------	-----------	-------------	--------------

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

AB	SIGMAPHARM LABS LLC	10MG	A202051 001	Aug 29, 2013
-----------	---------------------	-------------	--------------------	--------------

HEPSERA

AB	+	GILEAD	10MG	N021449 001	Sep 20, 2002
-----------	---	--------	-------------	--------------------	--------------

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

AP	+	ASTELLAS	3MG/ML	N019937 002	Oct 30, 1989
-----------	---	----------	---------------	--------------------	--------------

ADENOSINE

AP	AGILA SPECLTS	3MG/ML	A078640 001	Mar 21, 2014
AP		3MG/ML	A078686 001	May 13, 2009
AP	AKORN	3MG/ML	A078076 001	Oct 31, 2008
AP	BEDFORD	3MG/ML	A076404 001	Jun 16, 2004
AP	FRESENIUS KABI USA	3MG/ML	A077133 001	Apr 27, 2005
AP	GLAND PHARMA LTD	3MG/ML	A077283 001	Jun 14, 2007
AP	HIKMA MAPLE	3MG/ML	A076500 001	Jun 16, 2004
AP	LUITPOLD	3MG/ML	A090010 001	Apr 28, 2009
AP	WOCKHARDT	3MG/ML	A090220 001	Jul 20, 2009

SOLUTION; IV (INFUSION)

ADENOSCAN

AP	+	ASTELLAS	60MG/20ML (3MG/ML)	N020059 001	May 18, 1995
AP	+		90MG/30ML (3MG/ML)	N020059 002	May 18, 1995

ADENOSINE

AP	AKORN	60MG/20ML (3MG/ML)	A090450 001	Oct 02, 2014
-----------	-------	---------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-8 (of 371)

ADENOSINE

SOLUTION; IV (INFUSION)

ADENOSINE

<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090450 002</u>	Oct 02, 2014
<u>AP</u>	EMCURE PHARMS LTD	<u>60MG/20ML (3MG/ML)</u>	<u>A202313 001</u>	Sep 15, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A202313 002</u>	Sep 15, 2014
<u>AP</u>	HOSPIRA INC	<u>60MG/20ML (3MG/ML)</u>	<u>A203883 001</u>	Mar 24, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A203883 002</u>	Mar 24, 2014
<u>AP</u>	SAGENT STRIDES	<u>60MG/20ML (3MG/ML)</u>	<u>A090212 001</u>	Mar 28, 2014
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A090212 002</u>	Mar 28, 2014
<u>AP</u>	TEVA PHARMS USA	<u>60MG/20ML (3MG/ML)</u>	<u>A077425 001</u>	Aug 29, 2013
<u>AP</u>		<u>90MG/30ML (3MG/ML)</u>	<u>A077425 002</u>	Aug 29, 2013

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

BOEHRINGER INGELHEIM

EQ 20MG BASE
EQ 30MG BASE
+

EQ 40MG BASE

N201292 001 Jul 12, 2013
N201292 002 Jul 12, 2013
N201292 003 Jul 12, 2013ALBENDAZOLE

TABLET; ORAL

ALBENZA

+ AMEDRA PHARMS

200MG

N020666 001 Jun 11, 1996

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+ GE HEALTHCARE

10MG/ML

N020899 001 Dec 31, 1997

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

JEANATOPE

ISO TEX

100uCi/10ML (10uCi/ML)
500uCi/0.5ML
+

1,000uCi/ML

N017836 003 Jun 08, 2004
N017836 001
N017836 002ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

+ ISO TEX

0.5mCi/VIAL

+

1mCi/VIAL

N017837 001
N017837 002ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

PROAIR HFA

BX + TEVA BRANDED PHARM EQ 0.09MG BASE/INH

N021457 001 Oct 29, 2004

PROVENTIL-HFA

BX + 3M EQ 0.09MG BASE/INH

N020503 001 Aug 15, 1996

VENTOLIN HFA

BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH

N020983 001 Apr 19, 2001

SOLUTION; INHALATION

ACCUNEBAN + MYLAN SPECLTEQ 0.021% BASEN020949 002 Apr 30, 2001AN +EQ 0.042% BASEN020949 001 Apr 30, 2001ALBUTEROL SULFATEAN + BAUSCH AND LOMBEQ 0.5% BASEA075050 001 Jun 18, 1998AN HI TECH PHARMAEQ 0.083% BASEA075063 001 Feb 09, 1999ANEQ 0.5% BASEA074543 001 Jan 15, 1998AN LANDELA PHARMEQ 0.083% BASEA077569 001 Apr 04, 2006AN + MYLAN SPECLTEQ 0.083% BASEA072652 001 Feb 21, 1992AN NEPHRONEQ 0.021% BASEA076355 002 Mar 31, 2010ANEQ 0.042% BASEA076355 001 Jun 28, 2004ANEQ 0.083% BASEA074880 001 Sep 17, 1997ANEQ 0.5% BASEA075664 001 Jun 26, 2001AN RITEDOSE CORPEQ 0.083% BASEA077839 001 Dec 16, 2008AN TEVA PHARMSEQ 0.083% BASEA075343 001 Nov 09, 1999AN WATSON LABSEQ 0.021% BASEA077772 001 Sep 25, 2007ANEQ 0.042% BASEA077772 002 Sep 25, 2007AN WATSON LABS INCEQ 0.083% BASEA076370 001 Nov 24, 2003

SYRUP; ORAL

ALBUTEROL SULFATEAA ACTAVIS MID ATLANTICEQ 2MG BASE/5MLA074454 001 Sep 25, 1995AA AMNEAL PHARMSEQ 2MG BASE/5MLA079241 001 May 12, 2010AA HI TECH PHARMAEQ 2MG BASE/5MLA074749 001 Jan 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-9 (of 371)

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

AA	+	TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419</u>	<u>001</u>	Mar 30, 1992
AA		VINTAGE	<u>EQ 2MG BASE/5ML</u>	<u>A078105</u>	<u>001</u>	Dec 27, 2006
AA		VISTAPHARM	<u>EQ 2MG BASE/5ML</u>	<u>A077788</u>	<u>001</u>	Jun 26, 2007

TABLET; ORAL

ALBUTEROL SULFATE

AB		MUTUAL PHARM	<u>EQ 2MG BASE</u>	<u>A072637</u>	<u>002</u>	Dec 05, 1989
AB			<u>EQ 4MG BASE</u>	<u>A072637</u>	<u>001</u>	Dec 05, 1989
AB		MYLAN	<u>EQ 2MG BASE</u>	<u>A072894</u>	<u>002</u>	Jan 17, 1991
AB	+		<u>EQ 4MG BASE</u>	<u>A072894</u>	<u>001</u>	Jan 17, 1991

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

AB		MYLAN	<u>EQ 4MG BASE</u>	<u>A078092</u>	<u>002</u>	Jan 29, 2007
AB			<u>EQ 8MG BASE</u>	<u>A078092</u>	<u>001</u>	Jan 29, 2007

VOSPIRE ER

AB		DAVA PHARMS INC	<u>EQ 4MG BASE</u>	<u>A076130</u>	<u>002</u>	Sep 26, 2002
AB	+		<u>EQ 8MG BASE</u>	<u>A076130</u>	<u>003</u>	Sep 26, 2002

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

+	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH; 0.018MG/INH	N020291	001	Oct 24, 1996
---	----------------------	---------------------------------	---------	-----	--------------

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		CIPLA LTD	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007
AN		NEPHRON	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
AN		RITEDOSE CORP	<u>EQ 0.083% BASE; 0.017%</u>	<u>A202496</u>	<u>001</u>	Oct 01, 2012
AN		TEVA PHARMS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076724</u>	<u>001</u>	Dec 31, 2007
AN		WATSON LABS	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077063</u>	<u>001</u>	Dec 31, 2007

DUONEB

AN	+	MYLAN SPECLT	<u>EQ 0.083% BASE; 0.017%</u>	<u>N020950</u>	<u>001</u>	Mar 21, 2001
-----------	---	--------------	-------------------------------	----------------	------------	--------------

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.1MG BASE/INH; 0.02MG/INH	N021747	001	Oct 07, 2011
---	----------------------	-------------------------------	---------	-----	--------------

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010
---	----------	-------	---------	-----	--------------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005
AB		GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
AB		TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
AB		GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
AB		TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% AND DEXTROSE 5%

AP	+	B BRAUN	<u>5ML/100ML; 5GM/100ML</u>	<u>N004589</u>	<u>004</u>	
		ALCOHOL 10% AND DEXTROSE 5%				
	+	B BRAUN	10ML/100ML; 5GM/100ML	N004589	006	

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

AA		ROXANE	<u>EQ 70MG BASE/75ML</u>	<u>A090520</u>	<u>001</u>	Feb 25, 2013
		FOSAMAX				
AA	+	MERCK	<u>EQ 70MG BASE/75ML</u>	<u>N021575</u>	<u>001</u>	Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

AB		APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
AB			<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008
AB			<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
AB			<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
AB		AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
AB			<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-10 (of 371)

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
<u>AB</u>	CADISTA PHARMS	<u>EQ 5MG BASE</u>	<u>A090557</u>	<u>001</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090557</u>	<u>002</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090557</u>	<u>003</u>	Feb 18, 2010
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090557</u>	<u>004</u>	Feb 18, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 5MG BASE</u>	<u>A079109</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079109</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A079049</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A079049</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A076584</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076584</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076584</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076584</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A075710</u>	<u>001</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075710</u>	<u>002</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A075710</u>	<u>003</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075710</u>	<u>004</u>	Feb 06, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A075710</u>	<u>005</u>	Feb 06, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+ MERCK AND CO INC	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000
	TABLET, EFFERVESCENT; ORAL				
	BINOSTO				
	+ MISSION PHARMA	<u>EQ 70MG BASE</u>	<u>N202344</u>	<u>001</u>	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

MERCK

+

EQ 70MG BASE; 2,800 IUN021762 001 Apr 07, 2005EQ 70MG BASE; 5,600 IUN021762 002 Apr 26, 2007ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+ AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353</u>	<u>001</u>	Dec 29, 1986
	<u>ALFENTANIL</u>				
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221</u>	<u>001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060</u>	<u>001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284</u>	<u>001</u>	Jan 17, 2012
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A079014</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG</u>	<u>A079057</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A079056</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	TORRENT PHARMS	<u>10MG</u>	<u>A079054</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	WOCKHARDT LTD	<u>10MG</u>	<u>A090221</u>	<u>001</u>	Aug 10, 2012
	<u>UROXATRAL</u>				
<u>AB</u>	+ COVIS PHARMA SARL	<u>10MG</u>	<u>N021287</u>	<u>001</u>	Jun 12, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-11 (of 371)

ALISKIREN HEMIFUMARATE

TABLET; ORAL

TEKTURNA

NOVARTIS

EQ 150MG BASE

N021985 001 Mar 05, 2007

+

EQ 300MG BASE

N021985 002 Mar 05, 2007

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE

N022545 001 Aug 26, 2010

EQ 150MG BASE; EQ 10MG BASE

N022545 002 Aug 26, 2010

EQ 300MG BASE; EQ 5MG BASE

N022545 003 Aug 26, 2010

+

EQ 300MG BASE; EQ 10MG BASE

N022545 004 Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE; 12.5MG

N200045 001 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 12.5MG

N200045 002 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 25MG

N200045 003 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 12.5MG

N200045 004 Dec 21, 2010

+

EQ 300MG BASE; EQ 10MG BASE; 25MG

N200045 005 Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

NOVARTIS

EQ 150MG BASE; 12.5MG

N022107 001 Jan 18, 2008

EQ 150MG BASE; 25MG

N022107 002 Jan 18, 2008

+

EQ 300MG BASE; 12.5MG

N022107 003 Jan 18, 2008

+

EQ 300MG BASE; 25MG

N022107 004 Jan 18, 2008

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+ EISAI INC

EQ 0.1% BASE

N020886 001 Feb 02, 1999

ALLOPURINOL

TABLET; ORAL

ALLOPURINOLAB ACCORD HLTHCARE100MGA203154 001 May 06, 2013AB300MGA203154 002 May 06, 2013AB APOTEX INC100MGA077353 001 Sep 08, 2005AB300MGA077353 002 Sep 08, 2005AB IPCA LABS LTD100MGA090637 001 Mar 16, 2011AB300MGA090637 002 Mar 16, 2011AB MUTUAL PHARM100MGA071449 001 Jan 09, 1987AB300MGA071450 001 Jan 09, 1987AB MYLAN100MGA018659 001 Oct 24, 1986AB300MGA018659 002 Oct 24, 1986AB NORTHSTAR HLTHCARE100MGA078253 001 Sep 11, 2007AB300MGA078253 002 Sep 11, 2007AB SUN PHARM INDS INC100MGA078390 001 Aug 30, 2007AB300MGA078390 002 Aug 30, 2007AB VINTAGE PHARMS100MGA075798 001 Jun 27, 2003AB300MGA075798 002 Jun 27, 2003AB WATSON LABS100MGN018832 002 Sep 28, 1984AB300MGN018877 001 Sep 28, 1984LOPURINAB DR REDDYS LA100MGA071586 001 Apr 02, 1987AB300MGA071587 001 Apr 02, 1987ZYLOPRIMAB PROMETHEUS LABS100MGN016084 001AB +300MGN016084 002ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUMAP EUROHLTH INTLEQ 500MG BASE/VIALA076870 001 Aug 26, 2004ALOPRIMAP + MYLAN INSTITUTIONALEQ 500MG BASE/VIALN020298 001 May 17, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-12 (of 371)

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

JANSSEN PHARMS

EQ 6.25MG BASE

N021001 001 May 07, 2001

+

EQ 12.5MG BASE

N021001 002 May 07, 2001

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

TAKEDA PHARMS USA

EQ 6.25MG BASE

N022271 001 Jan 25, 2013

EQ 12.5MG BASE

N022271 002 Jan 25, 2013

+

EQ 25MG BASE

N022271 003 Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+ TAKEDA PHARMS USA

EQ 12.5MG BASE; 1GM

N203414 002 Jan 25, 2013

EQ 12.5MG BASE; 500MG

N203414 001 Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSEN

TAKEDA PHARMS USA

EQ 12.5MG BASE; EQ 15MG BASE

N022426 004 Jan 25, 2013

EQ 12.5MG BASE; EQ 30MG BASE

N022426 005 Jan 25, 2013

EQ 12.5MG BASE; EQ 45MG BASE

N022426 006 Jan 25, 2013

EQ 25MG BASE; EQ 15MG BASE

N022426 001 Jan 25, 2013

EQ 25MG BASE; EQ 30MG BASE

N022426 002 Jan 25, 2013

+

EQ 25MG BASE; EQ 45MG BASE

N022426 003 Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTROX

PROMETHEUS LABS

EQ 0.5MG BASE

N021107 002 Dec 23, 2003

+

EQ 1MG BASE

N021107 001 Feb 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 0.03MG/ML

N021163 001 May 18, 2000

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ

2 IU/ML; 40MG/ML; 12MCG/ML; 40
IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1
.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660
IU/ML; 30MCG/ML

N021559 001 Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

+ ROXANE

1MG/ML

A074312 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAMAB ACTAVIS ELIZABETH0.25MGA074342 001 Oct 31, 1993AB0.5MGA074342 002 Oct 31, 1993AB1MGA074342 003 Oct 31, 1993AB2MGA074342 004 Oct 31, 1993AB APOTEX INC0.25MGA077741 001 Jan 19, 2007AB0.5MGA077741 002 Jan 19, 2007AB1MGA077741 003 Jan 19, 2007AB2MGA077741 004 Jan 19, 2007AB DAVA INTL INC0.25MGA074174 001 Oct 19, 1993AB0.5MGA074174 002 Oct 19, 1993AB1MGA074174 003 Oct 19, 1993AB2MGA074174 004 Oct 19, 1993AB MYLAN0.25MGA074215 001 Jan 27, 1994AB0.5MGA074215 002 Jan 27, 1994AB1MGA074215 003 Jan 27, 1994AB2MGA074215 004 Jan 27, 1994AB MYLAN PHARMS INC0.25MGA074046 001 Oct 19, 1993AB0.5MGA074046 002 Oct 19, 1993AB1MGA074046 003 Oct 19, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-13 (of 371)

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A074046</u>	<u>004</u>	May 07, 1997
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A074112</u>	<u>001</u>	Dec 29, 1995
<u>AB</u>		<u>0.5MG</u>	<u>A074112</u>	<u>002</u>	Dec 29, 1995
<u>AB</u>		<u>1MG</u>	<u>A074112</u>	<u>003</u>	Dec 29, 1995
<u>AB</u>		<u>2MG</u>	<u>A074909</u>	<u>001</u>	Mar 25, 1998
<u>AB</u>	SUN PHARMA GLOBAL	<u>0.25MG</u>	<u>A090082</u>	<u>001</u>	Jun 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090082</u>	<u>002</u>	Jun 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090082</u>	<u>003</u>	Jun 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078491</u>	<u>001</u>	Sep 25, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078491</u>	<u>002</u>	Sep 25, 2008
<u>AB</u>		<u>1MG</u>	<u>A078491</u>	<u>003</u>	Sep 25, 2008
<u>AB</u>		<u>2MG</u>	<u>A078491</u>	<u>004</u>	Dec 12, 2008
<u>AB</u>	VINTAGE PHARMS	<u>0.25MG</u>	<u>A090248</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090248</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>1MG</u>	<u>A090248</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>		<u>2MG</u>	<u>A090248</u>	<u>004</u>	Sep 17, 2010

XANAX

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>		<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>		<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A077198</u>	<u>001</u>	May 13, 2010
<u>AB</u>		<u>1MG</u>	<u>A077198</u>	<u>002</u>	May 13, 2010
<u>AB</u>		<u>2MG</u>	<u>A077198</u>	<u>003</u>	May 13, 2010
<u>AB</u>		<u>3MG</u>	<u>A077198</u>	<u>004</u>	May 13, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>	ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>	ANI PHARMS INC	<u>0.5MG</u>	<u>A077725</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>		<u>1MG</u>	<u>A077725</u>	<u>002</u>	Jul 31, 2006
<u>AB</u>		<u>2MG</u>	<u>A077725</u>	<u>004</u>	Jul 31, 2006
<u>AB</u>		<u>3MG</u>	<u>A077725</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>	APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>		<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>		<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>	AUROBINDO PHARMA USA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>		<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>		<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>		<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011
<u>AB</u>	COREPHARMA	<u>0.5MG</u>	<u>A077996</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>		<u>1MG</u>	<u>A077996</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>2MG</u>	<u>A077996</u>	<u>003</u>	Jan 31, 2007
<u>AB</u>		<u>3MG</u>	<u>A077996</u>	<u>004</u>	Jan 31, 2007
<u>AB</u>	IMPAX LABS	<u>0.5MG</u>	<u>A077968</u>	<u>004</u>	May 24, 2007
<u>AB</u>		<u>1MG</u>	<u>A077968</u>	<u>003</u>	May 24, 2007
<u>AB</u>		<u>2MG</u>	<u>A077968</u>	<u>002</u>	May 24, 2007
<u>AB</u>		<u>3MG</u>	<u>A077968</u>	<u>001</u>	May 24, 2007
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A077391</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>1MG</u>	<u>A077391</u>	<u>003</u>	Jan 26, 2006
<u>AB</u>		<u>2MG</u>	<u>A077391</u>	<u>004</u>	Jan 26, 2006
<u>AB</u>		<u>3MG</u>	<u>A077391</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.5MG</u>	<u>A078489</u>	<u>001</u>	Oct 17, 2008
<u>AB</u>		<u>1MG</u>	<u>A078489</u>	<u>002</u>	Oct 17, 2008
<u>AB</u>		<u>2MG</u>	<u>A078489</u>	<u>003</u>	Oct 17, 2008
<u>AB</u>		<u>3MG</u>	<u>A078489</u>	<u>004</u>	Oct 17, 2008

XANAX XR

<u>AB</u>	PHARMACIA AND UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
-----------	----------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-14 (of 371)

ALPRAZOLAM

TABLET, EXTENDED RELEASE;ORAL

XANAX XR

<u>AB</u>		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING;ORAL

ALPRAZOLAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>		<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>		<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>	+	<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE;INJECTION

ALPROSTADIL

<u>AP</u>	EUROHLTH INTL	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998
<u>AP</u>	TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	PHARMACIA AND UPJOHN	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997
<u>AP</u>		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997
<u>AP</u>	+	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	PHARMACIA AND UPJOHN	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>	
		CAVERJECT				
		PHARMACIA AND UPJOHN	0.005MG/VIAL	N020379	003	Jun 27, 1996
		CAVERJECT IMPULSE				
		PHARMACIA AND UPJOHN	0.01MG/VIAL	N021212	001	Jun 11, 2002
			0.02MG/VIAL	N021212	002	Jun 11, 2002
		EDEX				
	+	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998
		SUPPOSITORY;URETHRAL				
		MUSE				
		MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996
			0.25MG	N020700	002	Nov 19, 1996
			0.5MG	N020700	003	Nov 19, 1996
	+		1MG	N020700	004	Nov 19, 1996

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

+	EISAI INC	50MG	N019926	001	Dec 26, 1990
---	-----------	------	---------	-----	--------------

ALVIMOPAN

CAPSULE;ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775	001	May 20, 2008
---	---------------	------	---------	-----	--------------

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

<u>AB</u>		BANNER PHARMACAPS	<u>100MG</u>	<u>A078720</u>	<u>001</u>	May 29, 2008
<u>AB</u>	+	SANDOZ	<u>100MG</u>	<u>A071293</u>	<u>001</u>	Feb 18, 1987
<u>AB</u>		USL PHARMA	<u>100MG</u>	<u>A070589</u>	<u>001</u>	Aug 05, 1986

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

<u>AA</u>	+	CAROLINA MEDCL	<u>50MG/5ML</u>	<u>A075819</u>	<u>001</u>	Sep 11, 2002
<u>AA</u>	+	HI TECH PHARMA	<u>50MG/5ML</u>	<u>A074170</u>	<u>001</u>	Oct 28, 1994
<u>AA</u>	+	MIKART	<u>50MG/5ML</u>	<u>A074028</u>	<u>001</u>	Jun 28, 1993
<u>AA</u>	+	PHARM ASSOC	<u>50MG/5ML</u>	<u>A074509</u>	<u>001</u>	Jul 17, 1995
<u>AA</u>	+	SILARX	<u>50MG/5ML</u>	<u>A076352</u>	<u>001</u>	Sep 10, 2004
<u>AA</u>	+	VINTAGE	<u>50MG/75ML</u>	<u>A077992</u>	<u>001</u>	Dec 12, 2006
<u>AA</u>	+	WOCKHARDT	<u>50MG/5ML</u>	<u>A075060</u>	<u>001</u>	Dec 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-15 (of 371)

AMANTADINE HYDROCHLORIDE

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

+ USL PHARMA

100MG

A076186 001 Dec 16, 2002

AMBRISENTAN

TABLET; ORAL

LETAIRIS

GILEAD

5MG

N022081 001 Jun 15, 2007

+

10MG

N022081 002 Jun 15, 2007

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE**AB** + FOUGERA PHARMS0.1%**A076065 001** May 15, 2003**AB** TARO PHARM INDS0.1%**A076229 001** May 31, 2002

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS

0.1%

A076329 001 Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDE**AB** + FOUGERA PHARMS0.1%**A076096 001** Nov 19, 2002**AB** TARO PHARM INDS0.1%**A076367 001** Mar 19, 2003AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE**AP** SUN PHARMA GLOBAL500MG/VIAL**A077126 001** Mar 14, 2008ETHYOL**AP** + CLINIGEN HLTHCARE500MG/VIAL**N020221 001** Dec 08, 1995AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE**AP** EMCURE PHARMS LTDEQ 250MG BASE/ML**A204040 001** Dec 12, 2013**AP** + EUROHLTH INTLEQ 50MG BASE/ML**A063313 001** Apr 11, 1994**AP** +EQ 250MG BASE/ML**A063315 001** Apr 11, 1994**AP** TEVA PHARMS USAEQ 250MG BASE/ML**A064045 002** Sep 28, 1993AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE**AB** + PAR PHARM5MG**A070346 001** Jan 22, 1986**AB** SIGMAPHARM LABS LLC5MG**A079133 001** Jan 30, 2009MIDAMOR**AB** PADDOCK LLC5MG**N018200 001**AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**AB** BARREQ 5MG ANHYDROUS; 50MG**A071111 001** May 10, 1988**AB** + MYLANEQ 5MG ANHYDROUS; 50MG**A073209 001** Oct 31, 1991AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15% (150GM/1000ML)

A091112 001 Apr 13, 2012

15% (300GM/2000ML)

A091112 002 Apr 13, 2012

AMINOSYN 10%

HOSPIRA

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

HOSPIRA

10% (10GM/100ML)

N017673 008 Nov 18, 1985

AMINOSYN 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 5%

HOSPIRA

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

HOSPIRA

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

HOSPIRA

7% (7GM/100ML)

N017673 006 Nov 18, 1985

AMINOSYN 8.5%

HOSPIRA

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

HOSPIRA

8.5% (8.5GM/100ML)

N017673 007 Nov 18, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-16 (of 371)

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 10%			
HOSPIRA	10% (10GM/100ML)	N019438 005	Apr 03, 1986
AMINOSYN II 10% IN PLASTIC CONTAINER			
HOSPIRA	10% (10GM/100ML)	N020015 001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER			
HOSPIRA	15% (15GM/100ML)	N020041 001	Dec 19, 1991
AMINOSYN II 7%			
HOSPIRA	7% (7GM/100ML)	N019438 003	Apr 03, 1986
AMINOSYN II 8.5%			
HOSPIRA	8.5% (8.5GM/100ML)	N019438 004	Apr 03, 1986
AMINOSYN-HBC 7%			
HOSPIRA	7% (7GM/100ML)	N019374 001	Jul 12, 1985
AMINOSYN-HF 8%			
HOSPIRA	8% (8GM/100ML)	A020345 001	Apr 04, 1996
AMINOSYN-PF 10%			
HOSPIRA	10% (10GM/100ML)	N019492 002	Oct 17, 1986
AMINOSYN-PF 7%			
HOSPIRA	7% (7GM/100ML)	N019398 001	Sep 06, 1985
AMINOSYN-RF 5.2%			
HOSPIRA	5.2% (5.2GM/100ML)	N018429 001	
BRANCHAMIN 4% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4% (4GM/100ML)	N018684 001	Sep 28, 1984
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER			
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996
FREAMINE HBC 6.9%			
B BRAUN	6.9% (6.9GM/100ML)	N016822 006	May 17, 1983
FREAMINE III 10%			
B BRAUN	10% (10GM/100ML)	N016822 005	
FREAMINE III 8.5%			
B BRAUN	8.5% (8.5GM/100ML)	N016822 004	
HEPATAMINE 8%			
B BRAUN	8% (8GM/100ML)	N018676 001	Aug 03, 1982
NEPHRAMINE 5.4%			
B BRAUN	5.4% (5.4GM/100ML)	N017766 001	
PREMASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10GM/100ML)	A075880 002	Jun 19, 2003
PREMASOL 6% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	6% (6GM/100ML)	A075880 001	Jun 19, 2003
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	20% (20GM/100ML)	N020849 001	Aug 26, 1998
TRAVASOL 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	10% (10MG/100ML)	N018931 003	Aug 23, 1984
TRAVASOL 5.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N018931 001	Aug 23, 1984
TRAVASOL 8.5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N018931 002	Aug 23, 1984
TROPHAMINE			
+ B BRAUN	6% (6GM/100ML)	N019018 001	Jul 20, 1984
TROPHAMINE 10%			
+ B BRAUN	10% (10GM/100ML)	N019018 003	Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN	3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML	N018582 001	May 08, 1982
---------	--	-------------	--------------

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678 002	Mar 26, 1997
-------------------	--	-------------	--------------

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678 005	Mar 26, 1997
-------------------	--	-------------	--------------

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678 001	Mar 26, 1997
-------------------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-17 (of 371)

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678 009	Mar 26, 1997
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678 011	Mar 26, 1997
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678 012	Mar 26, 1997
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML	N020678 008	Mar 26, 1997
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678 016	Mar 26, 1997
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678 017	Mar 26, 1997
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678 018	Mar 26, 1997
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678 019	Mar 26, 1997
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML	N020678 021	Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

FRESENIUS KABI USA	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML	N200656 004	Aug 25, 2014
	; 147MG/100ML; 3.9GM/100ML (1026ML)		
	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML)	N200656 005	Aug 25, 2014
	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML)	N200656 006	Aug 25, 2014
+	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML)	N200656 007	Aug 25, 2014
PERIKABIVEN IN PLASTIC CONTAINER			
FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1440ML)	N200656 001	Aug 25, 2014
	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1920ML)	N200656 002	Aug 25, 2014
	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML	N200656 003	Aug 25, 2014
	; 105MG/100ML; 3.5GM/100ML (2400ML)		

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 10GM/100ML	N020734 002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 25GM/100ML	N020734 005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2.75%; 5GM/100ML	N020734 001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 10GM/100ML	N020734 008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 20GM/100ML	N020734 010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 25GM/100ML	N020734 011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4.25%; 5GM/100ML	N020734 007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5%; 10GM/100ML	N020734 014	Sep 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-18 (of 371)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES				
B BRAUN	8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML	N016822	007	Jul 01, 1988

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M				
HOSPIRA	3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML	N017789	003	

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES				
B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML	N016822	003	

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES				
HOSPIRA	10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML	N019437	004	Apr 03, 1986
AMINOSYN II 8.5% W/ ELECTROLYTES				
HOSPIRA	8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML	N019437	005	Apr 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML ;35MG/100ML	N020177	001	Oct 23, 1995
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG/100M L;224MG/100ML	N020173	001	Oct 27, 1995
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER				
BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG/100M L;154MG/100ML	N020173	002	Oct 27, 1995

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES				
HOSPIRA	7%;102MG/100ML;522MG/100ML;410MG/100ML	N017789	002	
AMINOSYN 8.5% W/ ELECTROLYTES				
HOSPIRA	8.5%;102MG/100ML;522MG/100ML;410MG/100M L	N017673	005	

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

AP	LUITPOLD	250MG/ML	A071192	001	Dec 01, 1987
	AMINOCAPROIC ACID IN PLASTIC CONTAINER				
AP	+ HOSPIRA	250MG/ML	A070010	001	Mar 09, 1987
	SYRUP; ORAL				
	AMICAR				
AA	+ CLOVER PHARMS	1.25GM/5ML	N015230	002	
	AMINOCAPROIC ACID				
AA	MIKART	1.25GM/5ML	A074759	001	Sep 02, 1998
	TABLET; ORAL				
	AMICAR				
AB	CLOVER PHARMS	500MG	N015197	001	
	AMINOCAPROIC				
AB	MIKART	500MG	A075602	001	May 24, 2001
	AMICAR				
	+ CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-19 (of 371)

AMINOLEVULINIC ACID HYDROCHLORIDE

SOLUTION; TOPICAL

LEVULAN

+ DUSA

20%

N020965 001 Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINEAP + HOSPIRA 25MG/MLA087242 001 Oct 26, 1983AP LUITPOLD 25MG/MLA087600 001AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

+ JACOBUS

4GM/PACKET

A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDEAP + AKORN 50MG/MLA076232 001 Jul 05, 2006AP + FRESENIUS KABI USA 50MG/MLA075761 001 Oct 15, 2002AP + GLAND PHARMA LTD 50MG/MLA077161 001 Apr 20, 2005AP HIKMA FARMACEUTICA 50MG/MLA077234 001 Feb 25, 2008AP + HOSPIRA 50MG/MLA075955 001 Oct 18, 2002AP HOSPIRA INC 50MG/MLA203884 001 Nov 25, 2013AP 50MG/MLA203885 001 Nov 25, 2013AP + MYLAN INSTITUTIONAL 50MG/MLA076217 001 Oct 15, 2002AP WOCKHARDT 50MG/MLA077610 001 Oct 30, 2008AP 50MG/MLA077834 001 Oct 30, 2008NEXTERONEAP BAXTER HLTHCARE 50MG/MLN022325 001 Dec 24, 2008

+ 150MG/100ML (1.5MG/ML)

N022325 002 Nov 16, 2010

+ 360MG/200ML (1.8MG/ML)

N022325 003 Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDEAB APOTEX CORP 200MGA078578 001 Nov 06, 2008AB BARR 200MGA075389 001 Jan 25, 2001AB MURTY PHARMS 200MGA077069 001 Apr 08, 2005AB 400MGA077069 002 Apr 08, 2005AB MYLAN 200MGA075188 001 Feb 24, 1999AB SANDOZ 200MGA075315 001 Dec 23, 1998AB 400MGA075315 002 Jun 30, 2000AB TARO 100MGA075424 002 Dec 18, 2002AB 200MGA075424 001 Mar 30, 2001AB 400MGA076362 001 Nov 29, 2002AB TEVA PHARMS 200MGA074739 001 Nov 30, 1998AB ZYDUS PHARMS USA INC 200MGA079029 001 Sep 16, 2008CORDARONEAB + WYETH PHARMS INC 200MGN018972 001 Dec 24, 1985PACERONEAB UPSHER SMITH 100MGA075135 002 Apr 12, 2005AB 200MGA075135 001 Apr 30, 1998

AMIODARONE HYDROCHLORIDE

TARO

300MG

A076362 002 Dec 02, 2003

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDEAB ACCORD HLTHCARE 10MGA202446 001 Jun 04, 2014AB 25MGA202446 002 Jun 04, 2014AB 50MGA202446 003 Jun 04, 2014AB 75MGA202446 004 Jun 04, 2014AB 100MGA202446 005 Jun 04, 2014AB 150MGA202446 006 Jun 04, 2014AB MUTUAL PHARM 10MGA089399 002 Jul 14, 1987AB 25MGA089399 001 Jul 14, 1987AB 50MGA089399 003 Jul 14, 1987AB 75MGA089399 004 Jul 14, 1987AB 100MGA089399 005 Jul 14, 1987AB 150MGA089399 006 Jul 14, 1987AB MYLAN 10MGA086009 002AB 25MGA086009 003AB 50MGA086009 001AB 75MGA086009 004

PRESCRIPTION DRUG PRODUCT LIST

3-20 (of 371)

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		<u>100MG</u>	<u>A086009</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>A086009</u>	<u>006</u>	
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A085969</u>	<u>001</u>	
<u>AB</u>	+	<u>25MG</u>	<u>A085966</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>		<u>75MG</u>	<u>A085971</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>A085967</u>	<u>001</u>	
<u>AB</u>		<u>150MG</u>	<u>A085970</u>	<u>001</u>	
<u>AB</u>	SUN PHARM INDS INC	<u>10MG</u>	<u>A040816</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>25MG</u>	<u>A040816</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>50MG</u>	<u>A040816</u>	<u>003</u>	Jun 27, 2008
<u>AB</u>		<u>75MG</u>	<u>A040816</u>	<u>004</u>	Jun 27, 2008
<u>AB</u>		<u>100MG</u>	<u>A040816</u>	<u>005</u>	Jun 27, 2008
<u>AB</u>		<u>150MG</u>	<u>A040816</u>	<u>006</u>	Jun 27, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A040218</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>		<u>25MG</u>	<u>A040218</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		<u>50MG</u>	<u>A040218</u>	<u>003</u>	Sep 11, 1997
<u>AB</u>		<u>75MG</u>	<u>A040218</u>	<u>004</u>	Sep 11, 1997
<u>AB</u>		<u>100MG</u>	<u>A040218</u>	<u>005</u>	Sep 11, 1997
<u>AB</u>		<u>150MG</u>	<u>A040218</u>	<u>006</u>	Sep 11, 1997

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986
+	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN	10MG;2MG	A071443	002	Nov 10, 1988
	10MG;4MG	A071443	003	Nov 10, 1988
+	25MG;2MG	A071443	004	Nov 10, 1988
+	25MG;4MG	A071443	005	Nov 10, 1988
+	50MG;4MG	A071443	001	Nov 10, 1988

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A202553</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202553</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202553</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>	ALKEM	<u>EQ 2.5MG BASE</u>	<u>A078925</u>	<u>001</u>	May 04, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078925</u>	<u>002</u>	May 04, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078925</u>	<u>003</u>	May 04, 2009
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 2.5MG BASE</u>	<u>A078477</u>	<u>001</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078477</u>	<u>002</u>	Jan 16, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078477</u>	<u>003</u>	Jan 16, 2008
<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE</u>	<u>A076719</u>	<u>001</u>	May 23, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076719</u>	<u>002</u>	May 23, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076719</u>	<u>003</u>	May 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 2.5MG BASE</u>	<u>A078021</u>	<u>001</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078021</u>	<u>002</u>	Jul 17, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078021</u>	<u>003</u>	Jul 17, 2007
<u>AB</u>	CIPLA LTD	<u>EQ 2.5MG BASE</u>	<u>A077073</u>	<u>001</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077073</u>	<u>002</u>	Sep 26, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077073</u>	<u>003</u>	Sep 26, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A076692</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076692</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076692</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 2.5MG BASE</u>	<u>A078552</u>	<u>001</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078552</u>	<u>002</u>	Apr 08, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078552</u>	<u>003</u>	Apr 08, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077771</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077771</u>	<u>002</u>	Apr 12, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077771</u>	<u>003</u>	Apr 12, 2011
<u>AB</u>	INVAGEN PHARMS	<u>EQ 2.5MG BASE</u>	<u>A077955</u>	<u>001</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077955</u>	<u>002</u>	Aug 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077955</u>	<u>003</u>	Aug 28, 2007
<u>AB</u>	LUPIN	<u>EQ 2.5MG BASE</u>	<u>A078043</u>	<u>001</u>	Jul 12, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078043</u>	<u>002</u>	Jul 12, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-21 (of 371)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078043</u>	<u>003</u>	Jul 12, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201380</u>	<u>001</u>	Apr 13, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201380</u>	<u>002</u>	Apr 13, 2012
<u>AB</u>	MATRIX LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A078224</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078224</u>	<u>002</u>	Feb 27, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078224</u>	<u>003</u>	Feb 27, 2008
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A076418</u>	<u>001</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076418</u>	<u>002</u>	Oct 03, 2005
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076418</u>	<u>003</u>	Oct 03, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A078453</u>	<u>001</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078453</u>	<u>002</u>	Jul 02, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078453</u>	<u>003</u>	Jul 02, 2009
<u>AB</u>	RANBAXY	<u>EQ 2.5MG BASE</u>	<u>A077974</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077974</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077974</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A077262</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077262</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077262</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	SECAN PHARMS	<u>EQ 5MG BASE</u>	<u>A090752</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090752</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 2.5MG BASE</u>	<u>A078231</u>	<u>001</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078231</u>	<u>002</u>	Nov 30, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078231</u>	<u>003</u>	Nov 30, 2007
<u>AB</u>	TEVA	<u>EQ 2.5MG BASE</u>	<u>A076846</u>	<u>001</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A076846</u>	<u>002</u>	Jun 28, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076846</u>	<u>003</u>	Jun 28, 2007
<u>AB</u>	TORRENT PHARMS	<u>EQ 2.5MG BASE</u>	<u>A078573</u>	<u>001</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078573</u>	<u>002</u>	Sep 22, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078573</u>	<u>003</u>	Sep 22, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2.5MG BASE</u>	<u>A203245</u>	<u>001</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203245</u>	<u>002</u>	Oct 21, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245</u>	<u>003</u>	Oct 21, 2013
<u>AB</u>	UPSHER SMITH	<u>EQ 2.5MG BASE</u>	<u>A077759</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077759</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077759</u>	<u>003</u>	Jul 09, 2007
<u>AB</u>	VINTAGE	<u>EQ 2.5MG BASE</u>	<u>A078414</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078414</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078414</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>	VIVIMED LABS	<u>EQ 2.5MG BASE</u>	<u>A077516</u>	<u>001</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077516</u>	<u>002</u>	Jul 11, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077516</u>	<u>003</u>	Jul 11, 2007
<u>AB</u>	WATSON LABS	<u>EQ 2.5MG BASE</u>	<u>A077671</u>	<u>001</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077671</u>	<u>002</u>	Jul 19, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077671</u>	<u>003</u>	Jul 19, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 2.5MG BASE</u>	<u>A078500</u>	<u>001</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078500</u>	<u>002</u>	Sep 06, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078500</u>	<u>003</u>	Sep 06, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
<u>NORVASC</u>					
<u>AB</u>	PFIZER	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>011</u>	Mar 07, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>001</u>	Nov 29, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-22 (of 371)

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>002</u>	Nov 29, 2013
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>003</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>004</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>005</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>006</u>	Nov 29, 2013
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>007</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>008</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>009</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>010</u>	Nov 29, 2013
AB		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>011</u>	Nov 29, 2013

CADUET

AB	PFIZER	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>009</u>	Jul 29, 2004
AB		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>010</u>	Jul 29, 2004
AB		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>011</u>	Jul 29, 2004
AB		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>001</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>002</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>003</u>	Jan 30, 2004
AB		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>004</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>005</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>006</u>	Jan 30, 2004
AB		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>007</u>	Jan 30, 2004
AB	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431</u>	<u>001</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;10MG</u>	<u>A091431</u>	<u>002</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;20MG</u>	<u>A091431</u>	<u>003</u>	Dec 30, 2013
AB		<u>EQ 5MG BASE;40MG</u>	<u>A091431</u>	<u>004</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;20MG</u>	<u>A091431</u>	<u>005</u>	Dec 30, 2013
AB		<u>EQ 10MG BASE;40MG</u>	<u>A091431</u>	<u>006</u>	Dec 30, 2013
AB	AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE;10MG</u>	<u>A202239</u>	<u>001</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;10MG</u>	<u>A202239</u>	<u>002</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;20MG</u>	<u>A202239</u>	<u>003</u>	Sep 05, 2012
AB		<u>EQ 5MG BASE;40MG</u>	<u>A202239</u>	<u>004</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;20MG</u>	<u>A202239</u>	<u>005</u>	Sep 05, 2012
AB		<u>EQ 10MG BASE;40MG</u>	<u>A202239</u>	<u>006</u>	Sep 05, 2012
AB	DR REDDYS LABS INC	<u>EQ 2.5MG BASE;10MG</u>	<u>A077183</u>	<u>001</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077183</u>	<u>002</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077183</u>	<u>003</u>	Apr 15, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A090149</u>	<u>001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077183</u>	<u>004</u>	Apr 15, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A090149</u>	<u>002</u>	Jul 05, 2011
AB	LUPIN PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A078466</u>	<u>001</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078466</u>	<u>002</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A078466</u>	<u>003</u>	Feb 05, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A078466</u>	<u>005</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A078466</u>	<u>004</u>	Feb 05, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A078466</u>	<u>006</u>	Jul 05, 2011
AB	MYLAN	<u>EQ 2.5MG BASE;10MG</u>	<u>A077375</u>	<u>001</u>	May 21, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077375</u>	<u>002</u>	May 21, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077375</u>	<u>003</u>	May 21, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A079047</u>	<u>001</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077375</u>	<u>004</u>	May 21, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A079047</u>	<u>002</u>	Jul 05, 2011
AB	PAR PHARM	<u>EQ 2.5MG BASE;10MG</u>	<u>A078381</u>	<u>001</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A078381</u>	<u>002</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;20MG</u>	<u>A078381</u>	<u>003</u>	Jul 29, 2010
AB		<u>EQ 5MG BASE;40MG</u>	<u>A078381</u>	<u>005</u>	Jul 29, 2010
AB		<u>EQ 10MG BASE;20MG</u>	<u>A078381</u>	<u>004</u>	Jul 29, 2010
AB		<u>EQ 10MG BASE;40MG</u>	<u>A078381</u>	<u>006</u>	Jul 29, 2010
AB	TEVA PHARMS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077179</u>	<u>001</u>	May 18, 2007
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077179</u>	<u>002</u>	May 18, 2007
AB		<u>EQ 5MG BASE;20MG</u>	<u>A077179</u>	<u>003</u>	May 18, 2007
AB		<u>EQ 5MG BASE;40MG</u>	<u>A077179</u>	<u>005</u>	Jul 05, 2011
AB		<u>EQ 10MG BASE;20MG</u>	<u>A077179</u>	<u>004</u>	May 18, 2007
AB		<u>EQ 10MG BASE;40MG</u>	<u>A077179</u>	<u>006</u>	Jul 05, 2011
AB	WATSON LABS	<u>EQ 2.5MG BASE;10MG</u>	<u>A077890</u>	<u>001</u>	Oct 14, 2010
AB		<u>EQ 5MG BASE;10MG</u>	<u>A077890</u>	<u>002</u>	Oct 14, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-23 (of 371)

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A077890</u>	<u>003</u>	Oct 14, 2010
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>A077890</u>	<u>004</u>	Oct 14, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE;40MG</u>	<u>A090364</u>	<u>001</u>	Jul 05, 2011
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A090364</u>	<u>002</u>	Jul 05, 2011

LOTREL

<u>AB</u>	NOVARTIS	<u>EQ 2.5MG BASE;10MG</u>	<u>N020364</u>	<u>002</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>N020364</u>	<u>003</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>N020364</u>	<u>004</u>	Mar 03, 1995
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>N020364</u>	<u>007</u>	Apr 11, 2006
<u>AB</u>		<u>EQ 10MG BASE;20MG</u>	<u>N020364</u>	<u>005</u>	Jun 20, 2002
<u>AB</u>	+	<u>EQ 10MG BASE;40MG</u>	<u>N020364</u>	<u>006</u>	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

TRIBENZOR

	DAIICHI SANKYO	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
	+	EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

<u>AB</u>	NOVARTIS	<u>5MG;12.5MG;160MG</u>	<u>N022314</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>N022314</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>N022314</u>	<u>003</u>	Apr 30, 2009
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>N022314</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>	+	<u>10MG;25MG;320MG</u>	<u>N022314</u>	<u>005</u>	Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AZOR

	DAIICHI SANKYO	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
	+	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE;40MG</u>	<u>A201586</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A201586</u>	<u>003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A201586</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A201586</u>	<u>004</u>	Jan 08, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE;40MG</u>	<u>A202516</u>	<u>001</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202516</u>	<u>003</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202516</u>	<u>002</u>	Aug 26, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202516</u>	<u>004</u>	Aug 26, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE;40MG</u>	<u>A202517</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>A202517</u>	<u>003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202517</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 10MG BASE;80MG</u>	<u>A202517</u>	<u>004</u>	Jan 08, 2014
<u>TWYNSTA</u>					
<u>AB</u>	BOEHRINGER INGELHEIM	<u>EQ 5MG BASE;40MG</u>	<u>N022401</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>EQ 5MG BASE;80MG</u>	<u>N022401</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>N022401</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>	+	<u>EQ 10MG BASE;80MG</u>	<u>N022401</u>	<u>004</u>	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>	PAR PHARM INC	<u>EQ 5MG BASE;160MG</u>	<u>A090011</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090144</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090011</u>	<u>002</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090011</u>	<u>004</u>	Mar 28, 2013
<u>EXFORGE</u>					
<u>AB</u>	NOVARTIS	<u>EQ 5MG BASE;160MG</u>	<u>N021990</u>	<u>002</u>	Jun 20, 2007
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>N021990</u>	<u>004</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990</u>	<u>003</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990</u>	<u>005</u>	Jun 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-24 (of 371)

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	TEVA PHARMS	<u>5MG;12.5MG;160MG</u>	<u>A200435</u>	<u>001</u>	Sep 25, 2012
<u>AB</u>		<u>5MG;25MG;160MG</u>	<u>A200435</u>	<u>002</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;12.5MG;160MG</u>	<u>A200435</u>	<u>005</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;160MG</u>	<u>A200435</u>	<u>003</u>	Sep 25, 2012
<u>AB</u>		<u>10MG;25MG;320MG</u>	<u>A200435</u>	<u>004</u>	Sep 25, 2012

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700</u>	<u>001</u>	Feb 25, 2013
<u>AP</u>	+ FEINSTEIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119</u>	<u>001</u>	Aug 23, 2007
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465</u>	<u>001</u>	Oct 23, 2014
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514</u>	<u>001</u>	Aug 19, 2014
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938</u>	<u>001</u>	Dec 09, 2013
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321</u>	<u>001</u>	Feb 25, 2013
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535</u>	<u>001</u>	Nov 20, 2014
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496</u>	<u>001</u>	Mar 28, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203933</u>	<u>001</u>	Jun 27, 2014
<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506</u>	<u>001</u>	Feb 07, 2014
	HOUSTON CYCLOTRON	3.75-260mCi/ML	A203543	001	Dec 14, 2012
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014
	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984
-----------	---------	---------	-----	--------------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A076829</u>	<u>001</u>	Feb 07, 2006

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N020508</u>	<u>001</u>	Aug 29, 1996
-----------	-----------	--------------------	----------------	------------	--------------

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	PERRIGO NEW YORK	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>	TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004
<u>AB</u>	WATSON LABS INC	<u>EQ 12% BASE</u>	<u>A075575</u>	<u>001</u>	Jun 11, 2002

LAC-HYDRIN

<u>AB</u>	+ RANBAXY	<u>EQ 12% BASE</u>	<u>N019155</u>	<u>001</u>	Apr 24, 1985
-----------	-----------	--------------------	----------------	------------	--------------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

WATSON LABS	25MG	A072688	001	Aug 28, 1992
	50MG	A072689	001	Aug 28, 1992
	100MG	A072690	001	Aug 28, 1992
+	150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>	AM ANTIBIOTICS	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	DAVA PHARMS INC	<u>250MG</u>	<u>A062884</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>		<u>500MG</u>	<u>A062881</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>		<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065016</u>	<u>001</u>	Apr 08, 1999
<u>AB</u>		<u>500MG</u>	<u>A065016</u>	<u>002</u>	Apr 08, 1999
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>		<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>	TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	+	<u>500MG</u>	<u>A061926</u>	<u>003</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-25 (of 371)

AMOXICILLIN

CAPSULE; ORAL

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>		<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>	HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>	TEVA	<u>125MG/5ML</u>	<u>A061931</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	+	<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>	WOCKHARDT	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>	TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982
-----------	------	----------------	----------------	------------	--------------

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>		<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>		<u>200MG/5ML</u>	<u>N050760</u>	<u>001</u>	Apr 15, 1999
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	
<u>AB</u>		<u>400MG/5ML</u>	<u>N050760</u>	<u>002</u>	Apr 15, 1999

LAROTID

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	RANBAXY	<u>500MG</u>	<u>A065059</u>	<u>001</u>	Nov 24, 2000
<u>AB</u>		<u>875MG</u>	<u>A065059</u>	<u>002</u>	Nov 24, 2000
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	+	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>N050754</u>	<u>002</u>	Jul 10, 1998
<u>AB</u>		<u>875MG</u>	<u>N050754</u>	<u>001</u>	Jul 10, 1998

TABLET, CHEWABLE; ORAL

AMOXICILLIN

<u>AB</u>	RANBAXY	<u>125MG</u>	<u>A065021</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>250MG</u>	<u>A065021</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	TEVA	<u>125MG</u>	<u>A064013</u>	<u>002</u>	Sep 11, 1995
<u>AB</u>	+	<u>250MG</u>	<u>A064013</u>	<u>001</u>	Dec 22, 1992

AMOXIL

<u>AB</u>	DR REDDYS LABS INC	<u>125MG</u>	<u>N050542</u>	<u>002</u>	
<u>AB</u>		<u>250MG</u>	<u>N050542</u>	<u>001</u>	

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008
---	-------------------	-------	---------	-----	--------------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

<u>AB</u>	SANDOZ	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG</u>	<u>A200218</u>	<u>001</u>	Aug 30, 2013

PREVPAC

<u>AB</u>	+	TAKEDA PHARMS USA	<u>500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A,</u>	<u>N050757</u>	<u>001</u>	Dec 02, 1997
-----------	---	-------------------	--	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-26 (of 371)

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVPAC30MGAMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ GASTROENTERO

500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG

N050824 001 Feb 08, 2011

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	RANBAXY	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065132</u>	<u>001</u>	Mar 19, 2003
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065132</u>	<u>002</u>	Mar 19, 2003
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065207</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	SANDOZ	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	+	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	+	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>	WOCKHARDT EU OPERATN	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG/5ML; EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984
-----------	--------------------	---------------------------------------	----------------	------------	--------------

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>N050725</u>	<u>001</u>	May 31, 1996
-----------	--------------------	--------------------------------------	----------------	------------	--------------

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG/5ML; EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984
-----------	---	---------------------------	--------------------------------------	----------------	------------	--------------

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>N050725</u>	<u>002</u>	May 31, 1996
-----------	--------------------	------------------------------------	----------------	------------	--------------

AUGMENTIN ES-600

<u>AB</u>	DR REDDYS LABS INC	<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001
-----------	--------------------	--------------------------------------	----------------	------------	--------------

SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML; EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML; EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML; EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012
<u>AB</u>	RANBAXY	<u>875MG; EQ 125MG BASE</u>	<u>A065102</u>	<u>001</u>	Sep 17, 2002
<u>AB</u>	SANDOZ	<u>250MG; EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG; EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>	SANDOZ INC	<u>500MG; EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG; EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	TEVA	<u>500MG; EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002
<u>AB</u>	TEVA PHARMS USA	<u>875MG; EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002

AUGMENTIN '250'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>250MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>001</u>	Aug 06, 1984
-----------	---	---------------------------	-----------------------------	----------------	------------	--------------

AUGMENTIN '500'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>500MG; EQ 125MG BASE</u>	<u>N050564</u>	<u>002</u>	Aug 06, 1984
-----------	---	---------------------------	-----------------------------	----------------	------------	--------------

AUGMENTIN '875'

<u>AB</u>	+	<u>DR REDDYS LABS INC</u>	<u>875MG; EQ 125MG BASE</u>	<u>N050720</u>	<u>001</u>	Feb 13, 1996
-----------	---	---------------------------	-----------------------------	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	RANBAXY	<u>200MG; EQ 28.5MG BASE</u>	<u>A065161</u>	<u>001</u>	Dec 03, 2003
<u>AB</u>		<u>400MG; EQ 57MG BASE</u>	<u>A065161</u>	<u>002</u>	Dec 03, 2003
<u>AB</u>	SANDOZ	<u>200MG; EQ 28.5MG BASE</u>	<u>A065065</u>	<u>001</u>	Apr 18, 2002
<u>AB</u>		<u>400MG; EQ 57MG BASE</u>	<u>A065065</u>	<u>002</u>	Apr 18, 2002
<u>AB</u>	TEVA	<u>200MG; EQ 28.5MG BASE</u>	<u>A065205</u>	<u>001</u>	Feb 09, 2005
<u>AB</u>	+	<u>400MG; EQ 57MG BASE</u>	<u>A065205</u>	<u>002</u>	Feb 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-27 (of 371)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE; ORAL

AUGMENTIN '125'

<u>AB</u>	DR REDDYS LABS INC	<u>125MG;EQ 31.25MG BASE</u>	<u>N050597 001</u>	Jul 22, 1985
-----------	--------------------	------------------------------	--------------------	--------------

AUGMENTIN '200'

<u>AB</u>	DR REDDYS LABS INC	<u>200MG;EQ 28.5MG BASE</u>	<u>N050726 001</u>	May 31, 1996
-----------	--------------------	-----------------------------	--------------------	--------------

AUGMENTIN '250'

<u>AB</u>	DR REDDYS LABS INC	<u>250MG;EQ 62.5MG BASE</u>	<u>N050597 002</u>	Jul 22, 1985
-----------	--------------------	-----------------------------	--------------------	--------------

AUGMENTIN '400'

<u>AB</u>	DR REDDYS LABS INC	<u>400MG;EQ 57MG BASE</u>	<u>N050726 002</u>	May 31, 1996
-----------	--------------------	---------------------------	--------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	SANDOZ	<u>1GM;EQ 62.5MG BASE</u>	<u>A090227 001</u>	Apr 21, 2010
-----------	--------	---------------------------	--------------------	--------------

AUGMENTIN XR

<u>AB</u>	+ DR REDDYS LABS INC	<u>1GM;EQ 62.5MG BASE</u>	<u>N050785 001</u>	Sep 25, 2002
-----------	----------------------	---------------------------	--------------------	--------------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

<u>AB</u>	SHIRE	<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>N021303 001</u>	Oct 11, 2001
-----------	-------	--------------------------------	--------------------	--------------

ADDERALL XR 15

<u>AB</u>	SHIRE	<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>N021303 006</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 20

<u>AB</u>	SHIRE	<u>5MG;5MG;5MG;5MG</u>	<u>N021303 002</u>	Oct 11, 2001
-----------	-------	------------------------	--------------------	--------------

ADDERALL XR 25

<u>AB</u>	SHIRE	<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>N021303 004</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

ADDERALL XR 30

<u>AB</u>	+ SHIRE	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>N021303 003</u>	Oct 11, 2001
-----------	---------	--------------------------------	--------------------	--------------

ADDERALL XR 5

<u>AB</u>	SHIRE	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>N021303 005</u>	May 22, 2002
-----------	-------	------------------------------------	--------------------	--------------

AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF

<u>AB</u>	TEVA	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077488 001</u>	Apr 29, 2013
-----------	------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077488 002</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077488 003</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077488 004</u>	Apr 29, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077488 005</u>	Apr 29, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077488 006</u>	Apr 29, 2013
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A077302 001</u>	Jun 22, 2012
-----------	-------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A077302 002</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A077302 003</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A077302 004</u>	Jun 22, 2012
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A077302 005</u>	Jun 22, 2012
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A077302 006</u>	Jun 22, 2012
-----------	--	--------------------------------	--------------------	--------------

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	BARR LABS INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A076536 001</u>	Feb 12, 2013
-----------	---------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A076536 002</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A076536 003</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A076536 004</u>	Feb 12, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>6.25MG;6.25MG;6.25MG;6.25MG</u>	<u>A076536 005</u>	Feb 12, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A076536 006</u>	Feb 12, 2013
-----------	--	--------------------------------	--------------------	--------------

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040456 001</u>	May 06, 2003
-----------	-------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040456 002</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040456 003</u>	May 06, 2003
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040456 004</u>	May 06, 2003
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>	AUROLIFE PHARMA LLC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A202424 001</u>	Nov 27, 2013
-----------	---------------------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A202424 002</u>	Nov 27, 2013
-----------	--	--	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A202424 003</u>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A202424 004</u>	Nov 27, 2013
-----------	--	--	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A202424 005</u>	Nov 27, 2013
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A202424 006</u>	Nov 27, 2013
-----------	--	------------------------	--------------------	--------------

<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A202424 007</u>	Nov 27, 2013
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>	BARR	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040422 001</u>	Feb 11, 2002
-----------	------	------------------------------------	--------------------	--------------

<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040422 005</u>	Mar 19, 2003
-----------	--	--	--------------------	--------------

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040422 002</u>	Feb 11, 2002
-----------	--	--------------------------------	--------------------	--------------

<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040422 006</u>	Mar 19, 2003
-----------	--	--	--------------------	--------------

<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040422 007</u>	Mar 19, 2003
-----------	--	------------------------------------	--------------------	--------------

<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040422 003</u>	Feb 11, 2002
-----------	--	------------------------	--------------------	--------------

<u>AB</u>	+ COREPHARMA	<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040422 004</u>	Feb 11, 2002
-----------	--------------	--------------------------------	--------------------	--------------

<u>AB</u>		<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040444 001</u>	Jun 19, 2002
-----------	--	------------------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-28 (of 371)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040444</u>	<u>002</u>	Jun 19, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040444</u>	<u>003</u>	Jun 19, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040444</u>	<u>004</u>	Jun 19, 2002
<u>AB</u>	MALLINCKRODT INC	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040440</u>	<u>001</u>	Oct 07, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040440</u>	<u>002</u>	Oct 07, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040440</u>	<u>003</u>	Oct 07, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040440</u>	<u>004</u>	Oct 07, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040440</u>	<u>005</u>	Oct 07, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040440</u>	<u>006</u>	Oct 07, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040440</u>	<u>007</u>	Oct 07, 2003
<u>AB</u>	MUTUAL PHARM	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040480</u>	<u>001</u>	Sep 09, 2003
<u>AB</u>		<u>1.875MG;1.875MG;1.875MG;1.875MG</u>	<u>A040480</u>	<u>002</u>	Sep 09, 2003
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040480</u>	<u>003</u>	Sep 09, 2003
<u>AB</u>		<u>3.125MG;3.125MG;3.125MG;3.125MG</u>	<u>A040480</u>	<u>004</u>	Sep 09, 2003
<u>AB</u>		<u>3.75MG;3.75MG;3.75MG;3.75MG</u>	<u>A040480</u>	<u>005</u>	Sep 09, 2003
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040480</u>	<u>006</u>	Sep 09, 2003
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040480</u>	<u>007</u>	Sep 09, 2003
<u>AB</u>	SANDOZ	<u>1.25MG;1.25MG;1.25MG;1.25MG</u>	<u>A040439</u>	<u>004</u>	Sep 27, 2002
<u>AB</u>		<u>2.5MG;2.5MG;2.5MG;2.5MG</u>	<u>A040439</u>	<u>001</u>	Jun 14, 2002
<u>AB</u>		<u>5MG;5MG;5MG;5MG</u>	<u>A040439</u>	<u>002</u>	Jun 14, 2002
<u>AB</u>		<u>7.5MG;7.5MG;7.5MG;7.5MG</u>	<u>A040439</u>	<u>003</u>	Jun 14, 2002

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

ARBOR PHARMS LLC

5MG

A200166 001 Aug 09, 2012

+

10MG

A200166 002 Aug 09, 2012

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

+ X GEN PHARMS

50MG/VIAL

A063206 001 Apr 29, 1992

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

+ SIGMA TAU

5MG/ML

N050724 001 Nov 20, 1995

AMPHOTEC

+ ALKOPHARMA USA

50MG/VIAL

N050729 001 Nov 22, 1996

+

100MG/VIAL

N050729 002 Nov 22, 1996

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

+ ASTELLAS

50MG/VIAL

N050740 001 Aug 11, 1997

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A090884</u>	<u>002</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090884</u>	<u>003</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090889</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090884</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>	AGILA SPECLTS	<u>EQ 10GM BASE/VIAL</u>	<u>A202198</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A065499</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A063140</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A063145</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063146</u>	<u>001</u>	Apr 15, 1993
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201404</u>	<u>001</u>	Dec 20, 2013
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A062797</u>	<u>001</u>	Jul 12, 1993
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-29 (of 371)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	
<u>AP</u>	+	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	
<u>AP</u>	+	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
<u>AP</u>	STRIDES ARCOLAB LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201025</u>	<u>003</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A201025</u>	<u>004</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 250MG BASE/VIAL</u>	<u>A201025</u>	<u>001</u>	Apr 09, 2014
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A201025</u>	<u>002</u>	Apr 09, 2014

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>	AGILA SPECLTS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024</u>	<u>002</u>	Apr 07, 2014
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197</u>	<u>001</u>	Apr 07, 2014
<u>AP</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090340</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090340</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010
<u>AP</u>	HANFORD GC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090375</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090653</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090375</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090653</u>	<u>002</u>	Dec 21, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090646</u>	<u>001</u>	Dec 21, 2011
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065316</u>	<u>001</u>	Jun 29, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065316</u>	<u>002</u>	Jun 29, 2007
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
<u>UNASYN</u>					
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901</u>	<u>002</u>	Feb 27, 1992
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

<u>AB</u>	DAVA PHARMS INC	<u>EQ 250MG BASE</u>	<u>A062883</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A062882</u>	<u>001</u>	Feb 25, 1988
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A064082</u>	<u>001</u>	Aug 29, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A064082</u>	<u>002</u>	Aug 29, 1995

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

	DAVA PHARMS INC	<u>EQ 125MG BASE/5ML</u>	<u>A062982</u>	<u>001</u>	Feb 10, 1989
	+	<u>EQ 250MG BASE/5ML</u>	<u>A062982</u>	<u>002</u>	Feb 10, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-30 (of 371)

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997
-----------	-----------	----------------------	--------------------	--------------

ANAGRELIDE HYDROCHLORIDE

AB	BARR	EQ 0.5MG BASE	A076530 001	Apr 18, 2005
AB		EQ 1MG BASE	A076530 002	Apr 18, 2005
AB	IMPAX LABS	EQ 0.5MG BASE	A076910 001	Apr 18, 2005
AB		EQ 1MG BASE	A076910 002	Apr 18, 2005
AB	IVAX SUB TEVA PHARMS	EQ 0.5MG BASE	A076468 001	Apr 18, 2005
AB	+	EQ 1MG BASE	A076468 002	Apr 18, 2005
AB	MYLAN	EQ 0.5MG BASE	A076811 001	Apr 18, 2005
AB		EQ 1MG BASE	A076811 002	Apr 18, 2005
AB	MYLAN PHARMS INC	EQ 0.5MG BASE	A077613 001	Jun 27, 2006
AB		EQ 1MG BASE	A077613 002	Jun 27, 2006

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	ACCORD HLTHCARE	1MG	A090568 001	Jun 28, 2010
AB	APOTEX INC	1MG	A200654 001	May 11, 2012
AB	CIPLA LTD	1MG	A091164 001	Jun 28, 2010
AB	DR REDDYS LABS LTD	1MG	A090732 001	Jun 28, 2010
AB	FRESENIUS KABI ONCOL	1MG	A090088 001	Jun 28, 2010
AB	MYLAN	1MG	A091051 001	Jun 28, 2010
AB	NATCO PHARMA LTD	1MG	A079220 001	Jun 28, 2010
AB	ROXANE	1MG	A078485 001	Jun 28, 2010
AB	SANDOZ	1MG	A079007 001	Jun 28, 2010
AB	SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010
AB	SUN PHARM INDS LTD	1MG	A091177 001	Jul 15, 2011
AB	TEVA PHARMS	1MG	A078058 001	Jun 28, 2010
AB	ZYDUS PHARMS USA INC	1MG	A078921 001	Jun 28, 2010

ARIMIDEX

AB	+	ASTRAZENECA	1MG	N020541 001	Dec 27, 1995
-----------	---	-------------	------------	--------------------	--------------

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N021632 001	Feb 17, 2006
+		100MG/VIAL	N021632 002	Nov 14, 2006

APIXABAN

TABLET; ORAL

ELIQUIS

	BRISTOL MYERS SQUIBB	2.5MG	N202155 001	Dec 28, 2012
+		5MG	N202155 002	Dec 28, 2012

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

+	US WORLDMEDS	30MG/3ML (10MG/ML)	N021264 002	Apr 20, 2004
---	--------------	--------------------	-------------	--------------

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

APRACLOINIDINE HYDROCHLORIDE

AT	AKORN INC	EQ 0.5% BASE	A077764 001	Mar 12, 2009
AT		EQ 0.5% BASE	N020258 001	Jul 30, 1993
AT	+	EQ 1% BASE	N019779 001	Dec 31, 1987

APREMILAST

TABLET; ORAL

OTEZLA

	CELGENE CORP	10MG	N205437 001	Mar 21, 2014
		20MG	N205437 002	Mar 21, 2014
+		30MG	N205437 003	Mar 21, 2014

APREPITANT

CAPSULE; ORAL

APREPITANT

AB	SANDOZ	40MG	A090999 001	Sep 24, 2012
AB		80MG	A090999 002	Sep 24, 2012
AB		125MG	A090999 003	Sep 24, 2012
AB		40MG	N021549 003	Jun 30, 2006
AB	MERCK	80MG	N021549 001	Mar 26, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-31 (of 371)

APREPITANT

CAPSULE; ORAL

EMEND

AB	+	125MG	N021549	002	Mar 26, 2003
-----------	---	--------------	----------------	------------	--------------

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

BROVANA

+ SUNOVION

EQ 0.015MG BASE/2ML

N021912 001 Oct 06, 2006

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000
-----------	---	--------	-------------------------------	----------------	------------	--------------

ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049	001	Jan 05, 2012
-----------	--	--------------------	-------------------------------	----------------	------------	--------------

AP		MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626	001	Jun 30, 2014
-----------	--	---------------------	-------------------------------	----------------	------------	--------------

AP		PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665	001	Jun 30, 2014
-----------	--	----------------------	-------------------------------	----------------	------------	--------------

INJECTABLE; IV (INFUSION)

ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA 250MG/250ML (1MG/ML)

N206769 001 Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

+ EAGLE PHARMS 50MG/50ML (1MG/ML)

N022434 001 Jun 29, 2011

+ SANDOZ 125MG/125ML (1MG/ML)

N022485 001 May 09, 2011

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+ PHARMACIA AND UPJOHN 10GM/100ML

N016931 001

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

OTSUKA PHARM CO LTD 300MG/VIAL

N202971 001 Feb 28, 2013

300MG

N202971 003 Sep 29, 2014

+ 400MG/VIAL

N202971 002 Feb 28, 2013

400MG

N202971 004 Sep 29, 2014

INJECTABLE; INTRAMUSCULAR

ABILIFY

+ OTSUKA 9.75MG/1.3ML (7.5MG/ML)

N021866 001 Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+ OTSUKA 1MG/ML

N021713 001 Dec 10, 2004

TABLET; ORAL

ABILIFY

OTSUKA 2MG

N021436 006 Nov 15, 2002

+ 5MG

N021436 005 Nov 15, 2002

+ 10MG

N021436 001 Nov 15, 2002

15MG

N021436 002 Nov 15, 2002

20MG

N021436 003 Nov 15, 2002

30MG

N021436 004 Nov 15, 2002

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

+ OTSUKA 10MG

N021729 002 Jun 07, 2006

15MG

N021729 003 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

NUVIGIL

CEPHALON 50MG

N021875 001 Jun 15, 2007

150MG

N021875 003 Jun 15, 2007

200MG

N021875 005 Mar 26, 2009

+ 250MG

N021875 004 Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

TRISENOX

+ CEPHALON 1MG/ML

N021248 001 Sep 25, 2000

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+ NOVARTIS 20MG; 120MG

N022268 001 Apr 07, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-32 (of 371)

ARTICAINA HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ARTICAINA HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP	HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138 001	Jun 18, 2010
-----------	---------	--	--------------------	--------------

SEPTOCAINE

AP	+ DEPROCO	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	N020971 001	Apr 03, 2000
-----------	-----------	--	--------------------	--------------

ORABLOC

PIERREL

4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML)

N022466 001 Feb 26, 2010

+

4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+ DEPROCO

4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)

N022010 001 Mar 30, 2006

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+ SANDOZ

80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021646 001 Jan 29, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ HOSPIRA

80MG/VIAL; 0.02MG/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.01MG/VIAL; 0.14MG/VIAL; 17MG/VIAL; 0.2MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; EQ 1.2MG BASE/VIAL; 0.7MG/VIAL; 7MG/VIAL

N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 (WITHOUT VITAMIN K)

+ HOSPIRA

20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML; 0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML

N008809 006 Sep 09, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; IV (INFUSION)

M.V.I. ADULT

+ HOSPIRA

200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ HOSPIRA

200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML

N021643 001 Feb 18, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

+ SALIX PHARMS

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM

N021881 001 Aug 02, 2006

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS INC

EQ 5MG BASE

N022117 001 Aug 13, 2009

+

EQ 10MG BASE

N022117 002 Aug 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-33 (of 371)

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA	+ WATSON LABS INC	325MG; 50MG; 40MG	N017534 005	Apr 16, 1986
-----------	-------------------	--------------------------	--------------------	--------------

LANORINAL

AA	LANNETT	325MG; 50MG; 40MG	A086996 002	Oct 11, 1985
-----------	---------	--------------------------	--------------------	--------------

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	+ HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162 002	Feb 16, 1984
-----------	---------------------	--------------------------	--------------------	--------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	NEXGEN PHARMA INC	325MG; 50MG; 40MG; 30MG	A075231 001	Nov 30, 2001
-----------	-------------------	--------------------------------	--------------------	--------------

AB	STEVENS J	325MG; 50MG; 40MG; 30MG	A074951 001	Aug 31, 1998
-----------	-----------	--------------------------------	--------------------	--------------

FIORINAL W/CODEINE

AB	+ WATSON LABS INC	325MG; 50MG; 40MG; 30MG	N019429 003	Oct 26, 1990
-----------	-------------------	--------------------------------	--------------------	--------------

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

	+ CARACO	356.4MG; 30MG; 16MG	N011483 004	Sep 06, 1983
--	----------	---------------------	-------------	--------------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

NORGESIC

AB	MEDICIS	385MG; 30MG; 25MG	N013416 003	Oct 27, 1982
-----------	---------	--------------------------	--------------------	--------------

NORGESIC FORTE

AB	+ MEDICIS	770MG; 60MG; 50MG	N013416 004	Oct 27, 1982
-----------	-----------	--------------------------	--------------------	--------------

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	SANDOZ	385MG; 30MG; 25MG	A074654 001	Dec 31, 1996
-----------	--------	--------------------------	--------------------	--------------

AB		770MG; 60MG; 50MG	A074654 002	Dec 31, 1996
-----------	--	--------------------------	--------------------	--------------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	HERITAGE PHARMS INC	325MG; 200MG	A089594 001	Mar 31, 1989
-----------	---------------------	---------------------	--------------------	--------------

AB	MIRROR PHARMS	325MG; 200MG	A040832 001	Jan 07, 2010
-----------	---------------	---------------------	--------------------	--------------

AB	PROSAM LABS	325MG; 200MG	A040252 001	Dec 10, 1997
-----------	-------------	---------------------	--------------------	--------------

AB	SANDOZ	325MG; 200MG	A040116 001	Apr 25, 1996
-----------	--------	---------------------	--------------------	--------------

SOMA COMPOUND

AB	+ MEDA PHARMS	325MG; 200MG	N012365 005	Jul 11, 1983
-----------	---------------	---------------------	--------------------	--------------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	SANDOZ	325MG; 200MG; 16MG	A040118 001	Apr 16, 1996
-----------	--------	---------------------------	--------------------	--------------

SOMA COMPOUND W/ CODEINE

AB	+ MEDA PHARMS	325MG; 200MG; 16MG	N012366 002	Jul 11, 1983
-----------	---------------	---------------------------	--------------------	--------------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

AGGRENOL

AB	+ BOEHRINGER INGELHEIM	25MG; 200MG	N020884 001	Nov 22, 1999
-----------	------------------------	--------------------	--------------------	--------------

ASPIRIN AND DIPYRIDAMOLE

AB	BARR	25MG; 200MG	A078804 001	Aug 14, 2009
-----------	------	--------------------	--------------------	--------------

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

	+ STEVENS J	325MG; 400MG	A081145 001	Jan 31, 1995
--	-------------	--------------	-------------	--------------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG; 4.8355MG	A091670 001	Mar 16, 2011
-----------	----------------	------------------------	--------------------	--------------

AA	WATSON LABS	325MG; 4.8355MG	A090084 001	Mar 22, 2011
-----------	-------------	------------------------	--------------------	--------------

PERCODAN

AA	+ ENDO PHARMS	325MG; 4.8355MG	N007337 007	Aug 05, 2005
-----------	---------------	------------------------	--------------------	--------------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB	TEVA PHARMS USA	EQ 150MG BASE	A091673 002	Apr 22, 2014
-----------	-----------------	----------------------	--------------------	--------------

AB		EQ 200MG BASE	A091673 003	Apr 22, 2014
-----------	--	----------------------	--------------------	--------------

AB		EQ 300MG BASE	A091673 004	Apr 22, 2014
-----------	--	----------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-34 (of 371)

ATAZANAVIR SULFATE

CAPSULE;ORAL

REYATAZ

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>EQ 150MG BASE</u>	<u>N021567</u>	<u>002</u>	Jun 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>N021567</u>	<u>003</u>	Jun 20, 2003
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N021567</u>	<u>004</u>	Oct 16, 2006
	ATAZANAVIR SULFATE				
	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014
	POWDER;ORAL				
	REYATAZ				
	+ BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014

ATENOLOL

TABLET;ORAL

ATENOLOL

<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A074099</u>	<u>001</u>	Apr 28, 1992
<u>AB</u>		<u>50MG</u>	<u>A073542</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>		<u>100MG</u>	<u>A073543</u>	<u>001</u>	Dec 19, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	IPR	<u>25MG</u>	<u>A073646</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072303</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A074499</u>	<u>001</u>	Jul 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A073475</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>		<u>100MG</u>	<u>A073476</u>	<u>001</u>	Mar 30, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073457</u>	<u>003</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	NORTHSTAR HLTHCARE	<u>25MG</u>	<u>A078254</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>		<u>50MG</u>	<u>A078254</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>		<u>100MG</u>	<u>A078254</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074052</u>	<u>001</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073025</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A078210</u>	<u>001</u>	Jul 10, 2007
<u>AB</u>		<u>50MG</u>	<u>A078210</u>	<u>002</u>	Jul 10, 2007
<u>AB</u>		<u>100MG</u>	<u>A078210</u>	<u>003</u>	Jul 10, 2007
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005
	<u>TENORMIN</u>				
<u>AB</u>	ASTRAZENECA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	IPR	<u>50MG;25MG</u>	<u>A072301</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>100MG;25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	MUTUAL PHARM	<u>50MG;25MG</u>	<u>A073581</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>		<u>100MG;25MG</u>	<u>A073582</u>	<u>001</u>	Apr 29, 1993
<u>AB</u>	MYLAN	<u>50MG;25MG</u>	<u>A074203</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>100MG;25MG</u>	<u>A074203</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>	WATSON LABS	<u>50MG;25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG;25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992
	<u>TENORETIC 100</u>				
<u>AB</u>	+	<u>100MG;25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984
	<u>TENORETIC 50</u>				
<u>AB</u>	ASTRAZENECA	<u>50MG;25MG</u>	<u>N018760</u>	<u>002</u>	Jun 08, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-35 (of 371)

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

STRATERA

LILLY

10MG

N021411 002 Nov 26, 2002

18MG

N021411 003 Nov 26, 2002

25MG

N021411 004 Nov 26, 2002

40MG

N021411 005 Nov 26, 2002

+

60MG

N021411 006 Nov 26, 2002

80MG

N021411 007 Feb 14, 2005

100MG

N021411 008 Feb 14, 2005

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUMAB APOTEX INCEQ 10MG BASEA090548 001 May 29, 2012ABEQ 20MG BASEA090548 002 May 29, 2012ABEQ 40MG BASEA090548 003 May 29, 2012ABEQ 80MG BASEA090548 004 May 29, 2012AB DR REDDYS LABS LTDEQ 10MG BASEA091650 001 Jul 17, 2012ABEQ 20MG BASEA091650 002 Jul 17, 2012ABEQ 40MG BASEA091650 003 Jul 17, 2012ABEQ 80MG BASEA202357 001 Jul 17, 2012AB KUDCO IRELANDEQ 10MG BASEA091624 001 Apr 05, 2013ABEQ 20MG BASEA091624 002 Apr 05, 2013ABEQ 40MG BASEA091624 003 Apr 05, 2013ABEQ 80MG BASEA091624 004 Apr 05, 2013AB MYLAN PHARMS INCEQ 10MG BASEA091226 001 May 29, 2012ABEQ 20MG BASEA091226 002 May 29, 2012ABEQ 40MG BASEA091226 003 May 29, 2012ABEQ 80MG BASEA091226 004 May 29, 2012AB RANBAXY LABS LTDEQ 10MG BASEA076477 001 Nov 30, 2011ABEQ 20MG BASEA076477 002 Nov 30, 2011ABEQ 40MG BASEA076477 003 Nov 30, 2011ABEQ 80MG BASEA076477 004 Nov 30, 2011AB SANDOZ INCEQ 10MG BASEA077575 001 May 29, 2012ABEQ 20MG BASEA077575 002 May 29, 2012ABEQ 40MG BASEA077575 003 May 29, 2012ABEQ 80MG BASEA077575 004 May 29, 2012LIPITORAB PFIZEREQ 10MG BASEN020702 001 Dec 17, 1996ABEQ 20MG BASEN020702 002 Dec 17, 1996ABEQ 40MG BASEN020702 003 Dec 17, 1996AB +EQ 80MG BASEN020702 004 Apr 07, 2000ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

MERCK SHARP DOHME

EQ 10MG BASE; 10MG

N200153 001 May 03, 2013

EQ 20MG BASE; 10MG

N200153 002 May 03, 2013

EQ 40MG BASE; 10MG

N200153 003 May 03, 2013

+

EQ 80MG BASE; 10MG

N200153 004 May 03, 2013

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONEAB AMNEAL PHARMS750MG/5MLA202960 001 Mar 18, 2014MEPRONAB + GLAXOSMITHKLINE LLC750MG/5MLN020500 001 Feb 08, 1995ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDEAB GLENMARK GENERICS250MG; 100MGA091211 001 Jan 12, 2011AB MYLAN PHARMS INC62.5MG; 25MGA202362 001 May 27, 2014AB250MG; 100MGA202362 002 May 27, 2014MALARONEAB + GLAXOSMITHKLINE250MG; 100MGN021078 001 Jul 14, 2000MALARONE PEDIATRICAB GLAXOSMITHKLINE62.5MG; 25MGN021078 002 Jul 14, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-36 (of 371)

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	EUROHLTH INTL	<u>10MG/ML</u>	<u>A074901</u>	<u>001</u>	Jul 18, 1997
AP		HOSPIRA INC	<u>10MG/ML</u>	<u>A090761</u>	<u>001</u>	Oct 18, 2012
AP		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091489</u>	<u>001</u>	Feb 17, 2012

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL	<u>10MG/ML</u>	<u>A074900</u>	<u>001</u>	Jul 18, 1997
AP		HOSPIRA INC	<u>10MG/ML</u>	<u>A090782</u>	<u>001</u>	Oct 18, 2012
AP		SAGENT PHARMS	<u>10MG/ML</u>	<u>A091488</u>	<u>001</u>	Feb 17, 2012

ATROPINE

INJECTABLE; INJECTION

ATROPEN

+	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+	HOSPIRA	0.05MG/ML	N021146	002	Jul 09, 2001
+		0.1MG/ML	N021146	001	Jul 09, 2001

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

AKORN	1%	N206289	001	Jul 18, 2014
-------	----	---------	-----	--------------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	VALEANT	0.025MG; 1MG	N017744	002
---	---------	--------------	---------	-----

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	<u>0.025MG/5ML; 2.5MG/5ML</u>	<u>A087708</u>	<u>001</u>	May 03, 1982
-----------	---	--------	-------------------------------	-----------------------	-------------------	--------------

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		LANNETT	<u>0.025MG; 2.5MG</u>	<u>A085372</u>	<u>001</u>	
AA		MYLAN	<u>0.025MG; 2.5MG</u>	<u>A085762</u>	<u>001</u>	
AA		PAR PHARM	<u>0.025MG; 2.5MG</u>	<u>A040357</u>	<u>001</u>	May 02, 2000

LOMOTIL

AA	+	GD SEARLE LLC	<u>0.025MG; 2.5MG</u>	<u>N012462</u>	<u>001</u>
-----------	---	---------------	-----------------------	-----------------------	-------------------

LONOX

AA		SANDOZ	<u>0.025MG; 2.5MG</u>	<u>A085311</u>	<u>002</u>
-----------	--	--------	-----------------------	-----------------------	-------------------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+	MYLAN INSTITUTIONAL	0.14MG/ML; 10MG/ML	N019678	001	Nov 06, 1991
---	---------------------	--------------------	---------	-----	--------------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	MERIDIAN MEDCL	2.1MG/0.7ML; 600MG/2ML	N021983	001	Sep 28, 2006
---	----------------	------------------------	---------	-----	--------------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	PROMETHEUS LABS	3MG	N018689	001	May 24, 1985
---	-----------------	-----	---------	-----	--------------

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS	50MG	N202276	001	Apr 27, 2012
	100MG	N202276	002	Apr 27, 2012
+	200MG	N202276	003	Apr 27, 2012

AXITINIB

TABLET; ORAL

INLYTA

PFIZER	1MG	N202324	001	Jan 27, 2012
+	5MG	N202324	002	Jan 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-37 (of 371)

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	DR REDDYS LABS LTD	100MG/VIAL	A201537 001	Sep 16, 2013
-----------	--------------------	-------------------	--------------------	--------------

VIDAZA

AP	+ CELGENE	100MG/VIAL	N050794 001	May 19, 2004
-----------	-----------	-------------------	--------------------	--------------

AZATHIOPRINE

TABLET; ORAL

AZASAN

AB	AAIPHARMA LLC	25MG	A075252 002	Feb 03, 2003
-----------	---------------	-------------	--------------------	--------------

AB		50MG	A075252 001	Jun 07, 1999
-----------	--	-------------	--------------------	--------------

AB		75MG	A075252 003	Feb 03, 2003
-----------	--	-------------	--------------------	--------------

AB		100MG	A075252 004	Feb 03, 2003
-----------	--	--------------	--------------------	--------------

AZATHIOPRINE

AB	AMNEAL PHARMS LLC	50MG	A074069 001	Feb 16, 1996
-----------	-------------------	-------------	--------------------	--------------

AB	MYLAN	50MG	A075568 001	Dec 13, 1999
-----------	-------	-------------	--------------------	--------------

AB	ZYDUS PHARMS USA	25MG	A077621 002	Sep 05, 2008
-----------	------------------	-------------	--------------------	--------------

AB		50MG	A077621 001	Mar 15, 2007
-----------	--	-------------	--------------------	--------------

AB		75MG	A077621 003	Sep 05, 2008
-----------	--	-------------	--------------------	--------------

AB		100MG	A077621 004	Sep 05, 2008
-----------	--	--------------	--------------------	--------------

IMURAN

AB	+ PROMETHEUS LABS	50MG	N016324 001	
-----------	-------------------	-------------	--------------------	--

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

+ EUROHLTH INTL	EQ 100MG BASE/VIAL	A074419 001	Mar 31, 1995
-----------------	--------------------	-------------	--------------

AZELAIC ACID

CREAM; TOPICAL

AZELEX

+ ALLERGAN	20%	N020428 001	Sep 13, 1995
------------	-----	-------------	--------------

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002
------------------	-----	-------------	--------------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT	ALCON PHARMA	0.05%	A202305 001	May 31, 2012
-----------	--------------	--------------	--------------------	--------------

AT	APOTEX INC	0.05%	A078621 001	Aug 03, 2009
-----------	------------	--------------	--------------------	--------------

AT	SUN PHARMA GLOBAL	0.05%	A078738 001	Jun 21, 2010
-----------	-------------------	--------------	--------------------	--------------

OPTIVAR

AT	+ MEDA PHARMS	0.05%	N021127 001	May 22, 2000
-----------	---------------	--------------	--------------------	--------------

SPRAY, METERED; NASAL

ASTELIN

AB	+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY	N020114 001	Nov 01, 1996
-----------	---------------	------------------------------	--------------------	--------------

ASTEPRO

AB	+ MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009
-----------	---------------	-------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE

AB	APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954 001	Apr 30, 2009
-----------	------------	------------------------------	--------------------	--------------

AB		EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012
-----------	--	-------------------------------	--------------------	--------------

AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743 001	May 08, 2014
-----------	----------------	-------------------------------	--------------------	--------------

AB	ROXANE	EQ 0.125MG BASE/SPRAY	A091444 001	Oct 24, 2014
-----------	--------	------------------------------	--------------------	--------------

AB	SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012
-----------	-------------------	------------------------------	--------------------	--------------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+ MEDA PHARMS	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	N202236 001	May 01, 2012
---------------	-------------------------------------	-------------	--------------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011
----------------------	-------------------	-------------	--------------

+	EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011
---	-------------------	-------------	--------------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL; 12.5MG	N202331 001	Dec 20, 2011
----------------------	---------------------------	-------------	--------------

+	EQ 40MG MEDOXOMIL; 25MG	N202331 002	Dec 20, 2011
---	-------------------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-38 (of 371)

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

<u>AB</u>	PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065246</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>	TEVA PHARMS	<u>EQ 100MG BASE/5ML</u>	<u>A065419</u>	<u>001</u>	Jun 24, 2008
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065419</u>	<u>002</u>	Jun 24, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710</u>	<u>001</u>	Oct 19, 1995
<u>AB</u>	+	<u>EQ 200MG BASE/5ML</u>	<u>N050710</u>	<u>002</u>	Oct 19, 1995
	+	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

FOR SUSPENSION, EXTENDED RELEASE; ORAL

ZMAX

+	PF PRISM CV	EQ 2GM BASE/BOT	N050797	001	Jun 10, 2005
---	-------------	-----------------	---------	-----	--------------

INJECTABLE; INJECTION

AZITHROMYCIN

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179</u>	<u>001</u>	Dec 13, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501</u>	<u>001</u>	Nov 09, 2009
<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>	SAGENT STRIDES	<u>EQ 500MG BASE/VIAL</u>	<u>A065506</u>	<u>001</u>	Mar 24, 2009
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923</u>	<u>001</u>	Apr 02, 2013

ZITHROMAX

<u>AP</u>	+	PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733</u>	<u>001</u>	Jan 30, 1997
-----------	---	--------	---------------------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC

AZASITE

+	OAK PHARMS INC	1%	N050810	001	Apr 27, 2007
---	----------------	----	---------	-----	--------------

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	APOTEX CORP	<u>EQ 250MG BASE</u>	<u>A065507</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065509</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065508</u>	<u>001</u>	Jul 13, 2011
<u>AB</u>	MYLAN	<u>EQ 250MG BASE</u>	<u>A065365</u>	<u>001</u>	May 30, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065366</u>	<u>001</u>	May 30, 2007
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065360</u>	<u>001</u>	Jan 08, 2007
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065218</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A065153</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065193</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065150</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	WOCKHARDT	<u>EQ 250MG BASE</u>	<u>A065404</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302</u>	<u>003</u>	Feb 11, 2008

ZITHROMAX

<u>AB</u>	PFIZER	<u>EQ 250MG BASE</u>	<u>N050711</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N050784</u>	<u>001</u>	May 24, 2002
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N050730</u>	<u>001</u>	Jun 12, 1996

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+	GILEAD	75MG/VIAL	N050814	001	Feb 22, 2010
---	--------	-----------	---------	-----	--------------

INJECTABLE; INJECTION

AZACTAM

<u>AP</u>	+	BRISTOL MYERS SQUIBB	<u>1GM/VIAL</u>	<u>N050580</u>	<u>002</u>	Dec 31, 1986
<u>AP</u>	+		<u>2GM/VIAL</u>	<u>N050580</u>	<u>003</u>	Dec 31, 1986

AZTREONAM

<u>AP</u>	EUROHLTH INTL	<u>1GM/VIAL</u>	<u>A065286</u>	<u>001</u>	Mar 23, 2011
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065286</u>	<u>002</u>	Mar 23, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A065439</u>	<u>002</u>	Jun 18, 2010
<u>AP</u>		<u>2GM/VIAL</u>	<u>A065439</u>	<u>003</u>	Jun 18, 2010

AZACTAM IN PLASTIC CONTAINER

+	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989
---	----------------------	---------	---------	-----	--------------

+		40MG/ML	N050632	001	May 24, 1989
---	--	---------	---------	-----	--------------

AZTREONAM

FRESENIUS KABI USA	500MG/VIAL	A065439	001	Jun 18, 2010
--------------------	------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-39 (of 371)

BACITRACIN

INJECTABLE; INJECTION

BACIM

AP	X GEN PHARMS	50,000 UNITS/VIAL	A064153	001	May 09, 1997
-----------	--------------	--------------------------	----------------	------------	--------------

BACITRACIN

AP	FRESENIUS KABI USA	50,000 UNITS/VIAL	A065116	001	Dec 03, 2002
-----------	--------------------	--------------------------	----------------	------------	--------------

AP	+ PHARMACIA AND UPJOHN	50,000 UNITS/VIAL	A060733	002	
-----------	------------------------	--------------------------	----------------	------------	--

AP	SAGENT STRIDES	50,000 UNITS/VIAL	A090211	001	May 11, 2010
-----------	----------------	--------------------------	----------------	------------	--------------

AP	XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014
-----------	-------------------	--------------------------	----------------	------------	--------------

	PHARMACIA AND UPJOHN	10,000 UNITS/VIAL	A060733	001	
--	----------------------	-------------------	---------	-----	--

OINTMENT; OPHTHALMIC

BACITRACIN

	+ PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001	
--	------------------------	--------------	---------	-----	--

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012
-----------	-------	---	----------------	------------	--------------

AT	+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068	001	Oct 30, 1995
-----------	-------------------	---	----------------	------------	--------------

OINTMENT; TOPICAL

CORTISPORIN

	+ MONARCH PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM	N050168	002	May 04, 1984
--	------------------	---	---------	-----	--------------

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	AKORN	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065088	001	Feb 06, 2004
-----------	-------	--	----------------	------------	--------------

AT	+ BAUSCH AND LOMB	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064064	001	Oct 30, 1995
-----------	-------------------	--	----------------	------------	--------------

AT	PERRIGO CO TENNESSEE	400 UNITS/GM;EQ 3.5MG BASE;10,000 UNITS/GM	A060764	002	
-----------	----------------------	---	----------------	------------	--

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	AKORN	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995
-----------	-------	-------------------------------------	----------------	------------	--------------

AT	+ BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995
-----------	-------------------	-------------------------------------	----------------	------------	--------------

AT	PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002
-----------	----------------------	-------------------------------------	----------------	------------	--------------

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	AKORN	500 UNITS/GM;10,000 UNITS/GM	A064028	001	Jan 30, 1995
-----------	-------	-------------------------------------	----------------	------------	--------------

AT	+ BAUSCH AND LOMB	500 UNITS/GM;10,000 UNITS/GM	A064046	001	Jan 26, 1995
-----------	-------------------	-------------------------------------	----------------	------------	--------------

AT	PERRIGO CO TENNESSEE	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002
-----------	----------------------	-------------------------------------	----------------	------------	--------------

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+ PERRIGO CO TENNESSEE	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002	
--	------------------------	--	---------	-----	--

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	MALLINCKRODT INC	0.05MG/ML	N022462	001	Nov 19, 2010
-----------	------------------	------------------	----------------	------------	--------------

AP		0.5MG/ML	N022462	002	Nov 19, 2010
-----------	--	-----------------	----------------	------------	--------------

AP		2MG/ML	N022462	003	Nov 19, 2010
-----------	--	---------------	----------------	------------	--------------

LIORESAL

AP	+ MEDTRONIC NEURO	0.05MG/ML	N020075	003	Nov 07, 1996
-----------	-------------------	------------------	----------------	------------	--------------

AP		0.5MG/ML	N020075	001	Jun 17, 1992
-----------	--	-----------------	----------------	------------	--------------

AP		2MG/ML	N020075	002	Jun 17, 1992
-----------	--	---------------	----------------	------------	--------------

GABLOFEN

	MALLINCKRODT INC	1MG/ML	N022462	004	Jun 22, 2012
--	------------------	--------	---------	-----	--------------

TABLET; ORAL

BACLOFEN

AB	CARACO	10MG	A077984	001	Aug 14, 2006
-----------	--------	-------------	----------------	------------	--------------

AB	IMPAX LABS	10MG	A078146	001	Oct 26, 2007
-----------	------------	-------------	----------------	------------	--------------

AB		20MG	A077971	002	Oct 26, 2007
-----------	--	-------------	----------------	------------	--------------

AB	IVAX SUB TEVA PHARMS	10MG	A072234	001	Jul 21, 1988
-----------	----------------------	-------------	----------------	------------	--------------

AB	+ LANNETT	20MG	A072235	001	Jul 21, 1988
-----------	-----------	-------------	----------------	------------	--------------

AB		10MG	A078220	001	Jul 06, 2007
-----------	--	-------------	----------------	------------	--------------

AB		20MG	A077241	001	Dec 20, 2005
-----------	--	-------------	----------------	------------	--------------

AB	MYLAN	10MG	A077181	001	Jul 29, 2005
-----------	-------	-------------	----------------	------------	--------------

AB		20MG	A077121	002	Jul 29, 2005
-----------	--	-------------	----------------	------------	--------------

AB	MYLAN PHARMS INC	10MG	A090334	001	Feb 18, 2010
-----------	------------------	-------------	----------------	------------	--------------

AB		20MG	A090334	002	Feb 18, 2010
-----------	--	-------------	----------------	------------	--------------

AB	NORTHSTAR HLTHCARE	10MG	A078504	001	Sep 18, 2009
-----------	--------------------	-------------	----------------	------------	--------------

AB		20MG	A078401	001	Sep 18, 2009
-----------	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-40 (of 371)

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007
AB		20MG	A077088 001	Oct 31, 2007
AB	SUN PHARM INDS INC	20MG	A077862 002	Aug 14, 2006
AB	USL PHARMA	10MG	A074584 001	Aug 19, 1996
AB		20MG	A074584 002	Aug 19, 1996
AB	VINTAGE PHARMS	10MG	A077156 001	Aug 30, 2005
AB		20MG	A077068 001	Aug 30, 2005
AB	WATSON LABS	10MG	A072824 001	Sep 18, 1991
AB		20MG	A072825 001	Sep 18, 1991

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	APOTEX INC	750MG	A077883 001	Dec 28, 2007
AB	MYLAN	750MG	A077807 001	Dec 28, 2007
AB	ROXANE	750MG	A077806 001	Dec 28, 2007

COLAZAL

AB	+ SALIX PHARMS	750MG	N020610 001	Jul 18, 2000
TABLET; ORAL				
GIAZO				
	+ SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

	+ WYETH PHARMS PFIZER	EQ 20MG BASE;0.45MG	N022247 001	Oct 03, 2013
--	-----------------------	---------------------	-------------	--------------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR 40

	+ TEVA BRANDED PHARM	0.04MG/INH	N020911 002	Sep 15, 2000
--	----------------------	------------	-------------	--------------

QVAR 80

	+ TEVA BRANDED PHARM	0.08MG/INH	N020911 001	Sep 15, 2000
--	----------------------	------------	-------------	--------------

AEROSOL, METERED; NASAL

QNASL

	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813 002	Dec 17, 2014
		0.08MG/ACTUATION	N202813 001	Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

	+ GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389 001	Jul 27, 1987
--	-------------------	-------------------------	-------------	--------------

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

	+ JANSSEN THERAP	EQ 100MG BASE	N204384 001	Dec 28, 2012
--	------------------	---------------	-------------	--------------

BELINOSTAT

POWDER; IV (INFUSION)

BELEODAQ

	+ SPECTRUM PHARMS	500MG/VIAL	N206256 001	Jul 03, 2014
--	-------------------	------------	-------------	--------------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	5MG	A076267 001	Feb 11, 2004
AB		10MG	A076267 002	Feb 11, 2004
AB		20MG	A076267 003	Feb 11, 2004
AB		40MG	A076267 004	Feb 11, 2004
AB	APOTEX INC	5MG	A077128 001	Mar 08, 2006
AB		10MG	A077128 002	Mar 08, 2006
AB		20MG	A077128 003	Mar 08, 2006
AB		40MG	A077128 004	Mar 08, 2006
AB	AUROBINDO PHARMA	10MG	A078212 001	May 22, 2008
AB		20MG	A078212 002	May 22, 2008
AB		40MG	A078212 003	May 22, 2008
AB	BIOKEY	5MG	A076820 001	Feb 03, 2006
AB		10MG	A076820 002	Feb 03, 2006
AB		20MG	A076820 003	Feb 03, 2006
AB		40MG	A076820 004	Feb 03, 2006
AB	IVAX SUB TEVA PHARMS	5MG	A076333 001	Feb 11, 2004
AB		10MG	A076333 002	Feb 11, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-41 (of 371)

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>		<u>20MG</u>	<u>A076333</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076333</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076430</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076430</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076430</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076430</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008
<u>LOTENSIN</u>					
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG</u>	<u>N019851</u>	<u>001</u>	Jun 25, 1991
<u>AB</u>		<u>10MG</u>	<u>N019851</u>	<u>002</u>	Jun 25, 1991
<u>AB</u>		<u>20MG</u>	<u>N019851</u>	<u>003</u>	Jun 25, 1991
<u>AB</u>	+	<u>40MG</u>	<u>N019851</u>	<u>004</u>	Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	APOTEX INC	<u>5MG; 6.25MG</u>	<u>A078794</u>	<u>001</u>	Aug 21, 2014
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A078794</u>	<u>002</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A078794</u>	<u>003</u>	Aug 21, 2014
<u>AB</u>		<u>20MG; 25MG</u>	<u>A078794</u>	<u>004</u>	Aug 21, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG; 6.25MG</u>	<u>A076348</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076348</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076348</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076348</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	MYLAN	<u>5MG; 6.25MG</u>	<u>A076688</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076688</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076688</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076688</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	RANBAXY	<u>5MG; 6.25MG</u>	<u>A077483</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A077483</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A077483</u>	<u>003</u>	Sep 08, 2005
<u>AB</u>		<u>20MG; 25MG</u>	<u>A077483</u>	<u>004</u>	Sep 08, 2005
<u>AB</u>	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>					
<u>AB</u>	US PHARMS HOLDINGS I	<u>5MG; 6.25MG</u>	<u>N020033</u>	<u>001</u>	May 19, 1992
<u>AB</u>		<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
<u>AB</u>		<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
<u>AB</u>	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-42 (of 371)

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

TREANDA

+ CEPHALON

25MG/VIAL

N022249 002 May 01, 2009

+

100MG/VIAL

N022249 001 Mar 20, 2008

SOLUTION; IV (INFUSION)

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE**AB** KING PHARMS**5MG; 40MG****N018647 001** May 25, 1983**AB** +**5MG; 80MG****N018647 002** May 25, 1983**NADOLOL AND BENDROFLUMETHIAZIDE****AB** IMPAX LABS**5MG; 40MG****A077833 001** Mar 30, 2007**AB****5MG; 80MG****A077833 002** Mar 30, 2007**AB** MYLAN**5MG; 40MG****A078688 001** Feb 15, 2008**AB****5MG; 80MG****A078688 002** Feb 15, 2008BENZONATATE

CAPSULE; ORAL

BENZONATATE**AA** BANNER PHARMACAPS**100MG****A081297 001** Jan 29, 1993**AA****200MG****A081297 002** Oct 30, 2007**AA** MIKART**100MG****A040851 001** Nov 09, 2009**AA****150MG****A040851 002** Nov 09, 2009**AA****200MG****A040851 003** Nov 09, 2009**AA** ORIT LABS LLC**100MG****A040682 001** Jul 30, 2007**AA****200MG****A040682 002** Jul 30, 2007**AA** SUN PHARM INDS INC**100MG****A040587 001** Mar 19, 2008**AA****200MG****A040587 002** Mar 19, 2008**AA** + THE PHARMA NETWORK**100MG****A040627 001** Mar 30, 2007**AA** +**200MG****A040749 001** Jul 25, 2007**AA** + THEPHARMANETWORK LLC**150MG****A201209 001** Sep 24, 2014**AA****100MG****A040597 001** Jun 08, 2007**AA****200MG****A040597 002** Jun 08, 2007**TESSALON****AA** PFIZER**100MG****N011210 001**BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN**AB** + VALEANT BERMUDA**5%; EQ 1% BASE****N050756 001** Dec 21, 2000**CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE****AB** MYLAN PHARMS INC**5%; EQ 1% BASE****A065443 001** Aug 11, 2009**AB****5%; 1.2%****A090979 001** Jun 26, 2012**DUAC****AB** + STIEFEL**5%; 1.2%****N050741 001** Aug 26, 2002

ACANYA

+ DOW PHARM

2.5%; EQ 1.2% BASE

N050819 001 Oct 23, 2008

ONEXTON

DOW PHARM

3.75%; EQ 1.2% BASE

N050819 002 Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN**AB** + VALEANT INTL**5%; 3%****N050557 001** Oct 26, 1984**ERYTHROMYCIN AND BENZOYL PEROXIDE****AB** TOLMAR**5%; 3%****A065112 001** Mar 29, 2004

BENZAMYCIN PAK

+ VALEANT LUXEMBOURG

5%; 3%

N050769 001 Nov 27, 2000

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE**AA** EMCURE PHARMS LTD**50MG****A202061 001** Jan 27, 2012**AA****50MG****A040845 001** Nov 18, 2008**AA****50MG****A090968 001** Jul 20, 2010**AA** MALLINCKRODT INC**50MG****A040773 001** Apr 25, 2007**AA****25MG****A090473 001** Sep 15, 2010**AA****50MG****A090473 002** Sep 15, 2010**AA** PADDOCK**50MG****A040578 001** Apr 17, 2006**AA****50MG****A040747 001** Mar 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-43 (of 371)

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

DIDREX

<u>AA</u>	+	PHARMACIA AND UPJOHN	<u>50MG</u>	<u>N012427</u>	<u>002</u>	
-----------	---	----------------------	-------------	----------------	------------	--

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A091152</u>	<u>001</u>	Mar 29, 2010
<u>AP</u>		NAVINTA LLC	<u>1MG/ML</u>	<u>A091525</u>	<u>001</u>	Feb 05, 2013

COGENTIN

<u>AP</u>	+	OAK PHARMS AKORN	<u>1MG/ML</u>	<u>N012015</u>	<u>001</u>	
-----------	---	------------------	---------------	----------------	------------	--

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>		COREPHARMA	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>			<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		EXCELLIUM	<u>0.5MG</u>	<u>A090168</u>	<u>001</u>	Nov 28, 2012
<u>AA</u>			<u>1MG</u>	<u>A090168</u>	<u>002</u>	Nov 28, 2012
<u>AA</u>			<u>2MG</u>	<u>A090168</u>	<u>003</u>	Nov 28, 2012
<u>AA</u>		INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>			<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>			<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>		PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>			<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>	+	USL PHARMA	<u>0.5MG</u>	<u>A040103</u>	<u>001</u>	Dec 12, 1996
<u>AA</u>	+		<u>1MG</u>	<u>A040103</u>	<u>002</u>	Dec 12, 1996
<u>AA</u>	+		<u>2MG</u>	<u>A040103</u>	<u>003</u>	Dec 12, 1996
<u>AA</u>		VINTAGE	<u>0.5MG</u>	<u>A040738</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>1MG</u>	<u>A040742</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>			<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ SHIONOGI INC

5%

N022129 001 Apr 09, 2009

BENZYL PENICILLOYL POLYLYSINE

INJECTABLE; INJECTION

PRE-PEN

+ ALLERQUEST

60UMOLAR

N050114 001

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+ BAUSCH AND LOMB INC

1.5%

N022288 001 Sep 08, 2009

BERACTANT

SUSPENSION; INTRATRACHEAL

SURVANTA

+ ABBVIE

25MG/ML

N020032 001 Jul 01, 1991

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+ BAUSCH AND LOMB

EQ 0.6% BASE

N022308 001 May 28, 2009

BETAINE HYDROCHLORIDE

FOR SOLUTION; ORAL

CYSTADANE

+ RARE DIS THERAP

1GM/SCOOPFUL

N020576 001 Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>		LUITPOLD	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
-----------	--	----------	------------------------------	----------------	------------	--------------

CELESTONE SOLUSPAN

<u>AB</u>	+	MERCK SHARP DOHME	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>	
-----------	---	-------------------	------------------------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-44 (of 371)

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070885 001	Feb 03, 1987
AB	+ FOUGERA PHARMS	EQ 0.05% BASE	N019137 001	Jun 26, 1984
AB	TARO	EQ 0.05% BASE	A073552 001	Apr 30, 1992

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE	A076215 001	Dec 09, 2003
AB	GLENMARK GENERICS	EQ 0.05% BASE	A078930 001	Sep 23, 2008
AB	PERRIGO NEW YORK	EQ 0.05% BASE	A076592 001	Dec 09, 2003
AB	TARO	EQ 0.05% BASE	A076543 001	Dec 09, 2003
AB	TOLMAR	EQ 0.05% BASE	A076603 001	Jan 23, 2004

DIPROLENE AF

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N019555 001	Apr 27, 1987
-----------	---------------------	----------------------	--------------------	--------------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+ FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003
AB	TARO	EQ 0.05% BASE	A076508 001	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A070281 001	Jul 31, 1985
AB	+ FOUGERA	EQ 0.05% BASE	A070275 001	Aug 12, 1985
AB	PERRIGO NEW YORK	EQ 0.05% BASE	A072538 001	Jan 31, 1990
AB	TEVA	EQ 0.05% BASE	A071467 001	Aug 10, 1987

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007
AB	TARO	EQ 0.05% BASE	A077477 001	May 21, 2007

DIPROLENE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N019716 001	Aug 01, 1988
-----------	---------------------	----------------------	--------------------	--------------

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A071012 001	Feb 03, 1987
AB	+ FOUGERA	EQ 0.05% BASE	N019141 001	Sep 04, 1984
AB	TARO	EQ 0.05% BASE	A074271 001	Sep 15, 1994

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995
AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999
AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004

DIPROLENE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE	N018741 001	Jul 27, 1983
-----------	---------------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	0.064%;0.005%	A200174 001	Dec 12, 2014
AB	TOLMAR	0.064%;0.005%	A201615 001	Jan 14, 2013

TACLONEX

AB	+ LEO PHARMA AS	0.064%;0.005%	N021852 001	Jan 09, 2006
-----------	-----------------	----------------------	--------------------	--------------

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARMA AS	0.064%;0.005%	N022185 001	May 09, 2008
--	-----------------	----------------------	--------------------	--------------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE;1%	A076002 001	Aug 02, 2002
AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502 001	Jun 05, 2001
AB	TARO	EQ 0.05% BASE;1%	A075673 001	May 29, 2001

LOTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N018827 001	Jul 10, 1984
-----------	---------------------	-------------------------	--------------------	--------------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516 001	Jun 16, 2005
AB	TARO	EQ 0.05% BASE;1%	A076493 001	Jul 28, 2004

LOTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010 001	Dec 08, 2000
-----------	---------------------	-------------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-45 (of 371)

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PERRIGO	0.12%	A078337 001	Nov 26, 2012
-----------	---------	--------------	--------------------	--------------

LUXIQ

AB	+ DELCOR ASSET	0.12%	N020934 001	Feb 28, 1999
-----------	----------------	--------------	--------------------	--------------

CREAM; TOPICAL

BETA-VAL

AB	TEVA	EQ 0.1% BASE	N018642 001	Mar 24, 1983
-----------	------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

AB	+ FOUGERA	EQ 0.1% BASE	N018861 001	Aug 31, 1983
-----------	-----------	---------------------	--------------------	--------------

DERMABET

AB	TARO	EQ 0.1% BASE	A072041 001	Jan 06, 1988
-----------	------	---------------------	--------------------	--------------

VALNAC

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070050 001	Oct 10, 1984
-----------	----------------------	---------------------	--------------------	--------------

LOTION; TOPICAL

BETA-VAL

AB	TEVA	EQ 0.1% BASE	A070072 001	Jun 27, 1985
-----------	------	---------------------	--------------------	--------------

BETAMETHASONE VALERATE

AB	+ FOUGERA	EQ 0.1% BASE	N018866 001	Aug 31, 1983
-----------	-----------	---------------------	--------------------	--------------

AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985
-----------	----------------	---------------------	--------------------	--------------

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070051 001	Oct 10, 1984
-----------	----------------------	---------------------	--------------------	--------------

AB	+ FOUGERA	EQ 0.1% BASE	N018865 001	Aug 31, 1983
-----------	-----------	---------------------	--------------------	--------------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	AKORN	EQ 0.5% BASE	A075386 001	Jun 30, 2000
-----------	-------	---------------------	--------------------	--------------

AT	IGI LABS INC	EQ 0.5% BASE	A075630 001	Apr 12, 2001
-----------	--------------	---------------------	--------------------	--------------

AT	WOCKHARDT	EQ 0.5% BASE	A078694 001	Nov 16, 2009
-----------	-----------	---------------------	--------------------	--------------

BETOPTIC

AT	+ ALCON	EQ 0.5% BASE	N019270 001	Aug 30, 1985
-----------	---------	---------------------	--------------------	--------------

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

+ ALCON

EQ 0.25% BASE

N019845 001 Dec 29, 1989

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

AB	EPIC PHARMA	10MG	A075541 001	Oct 22, 1999
-----------	-------------	-------------	--------------------	--------------

AB	+	20MG	A075541 002	Oct 22, 1999
-----------	---	-------------	--------------------	--------------

AB	KVK TECH	10MG	A078962 001	Jun 27, 2008
-----------	----------	-------------	--------------------	--------------

AB		20MG	A078962 002	Jun 27, 2008
-----------	--	-------------	--------------------	--------------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	AMNEAL PHARM	5MG	A040855 001	Nov 21, 2007
-----------	--------------	------------	--------------------	--------------

AA		10MG	A040855 002	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

AA		25MG	A040855 003	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

AA		50MG	A040855 004	Nov 21, 2007
-----------	--	-------------	--------------------	--------------

AA	EMCURE USA	5MG	A091256 001	May 04, 2010
-----------	------------	------------	--------------------	--------------

AA		10MG	A091256 002	May 04, 2010
-----------	--	-------------	--------------------	--------------

AA		25MG	A091256 003	May 04, 2010
-----------	--	-------------	--------------------	--------------

AA		50MG	A091256 004	May 04, 2010
-----------	--	-------------	--------------------	--------------

AA	IMPAX LABS	5MG	A040739 001	Nov 01, 2006
-----------	------------	------------	--------------------	--------------

AA		10MG	A040741 001	Nov 01, 2006
-----------	--	-------------	--------------------	--------------

AA		25MG	A040740 001	Nov 01, 2006
-----------	--	-------------	--------------------	--------------

AA		50MG	A040721 004	Nov 01, 2006
-----------	--	-------------	--------------------	--------------

AA	LANNETT	10MG	A040704 001	Mar 27, 2008
-----------	---------	-------------	--------------------	--------------

AA		25MG	A040678 003	Mar 27, 2008
-----------	--	-------------	--------------------	--------------

AA	PHARMAX	5MG	A040725 001	Oct 26, 2007
-----------	---------	------------	--------------------	--------------

AA		10MG	A040726 001	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

AA		25MG	A040727 001	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

AA		50MG	A040728 001	Oct 26, 2007
-----------	--	-------------	--------------------	--------------

AA	SUN PHARM INDS INC	5MG	A040897 001	Apr 22, 2009
-----------	--------------------	------------	--------------------	--------------

AA		10MG	A040897 002	Apr 22, 2009
-----------	--	-------------	--------------------	--------------

AA		25MG	A040897 003	Apr 22, 2009
-----------	--	-------------	--------------------	--------------

AA		50MG	A040897 004	Apr 22, 2009
-----------	--	-------------	--------------------	--------------

AA	UPSHER SMITH	5MG	A040633 001	Jun 01, 2005
-----------	--------------	------------	--------------------	--------------

AA		10MG	A040634 001	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

AA		25MG	A040635 001	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

AA		50MG	A040636 001	Jun 01, 2005
-----------	--	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-46 (of 371)

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	WOCKHARDT	5MG	A040532	001	Sep 29, 2003
AA		10MG	A040533	001	Sep 29, 2003
AA		25MG	A040534	001	Sep 29, 2003
AA		50MG	A040518	001	Sep 29, 2003

URECHOLINE

AA	+	ODYSSEY PHARMS	5MG	A089095	001	Dec 19, 1985
AA	+		10MG	A088440	001	May 29, 1984
AA	+		25MG	A088441	001	May 29, 1984
AA	+		50MG	A089096	001	Dec 19, 1985

BEXAROTENE

CAPSULE; ORAL

TARGRETIN

+ VALEANT LUXEMBOURG 75MG

N021055 001 Dec 29, 1999

GEL; TOPICAL

TARGRETIN

+ VALEANT LUXEMBOURG 1%

N021056 001 Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009
AB	ACTAVIS TOTOWA	50MG	A078634	001	Aug 28, 2009
AB	FRESENIUS KABI ONCOL	50MG	A079045	001	May 13, 2010
AB	MYLAN	50MG	A079185	001	Jul 06, 2009
AB	SANDOZ	50MG	A078575	001	Jul 06, 2009
AB	SUN PHARMA GLOBAL	50MG	A079110	001	Jul 06, 2009
AB	TEVA	50MG	A076932	001	Jul 06, 2009
AB	ZYDUS PHARMS USA INC	50MG	A079089	001	Jul 06, 2009

CASODEX

AB	+	ASTRAZENECA	50MG	N020498	001	Oct 04, 1995
-----------	---	-------------	-------------	----------------	------------	--------------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

+ ALLERGAN 0.01%

N022184 001 Aug 31, 2010

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT	APOTEX INC	0.03%	A201894	001	Dec 01, 2014
-----------	------------	--------------	----------------	------------	--------------

LATISSE

AT	+	ALLERGAN	0.03%	N022369	001	Dec 24, 2008
-----------	---	----------	--------------	----------------	------------	--------------

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

+ ABBVIE 2MG

N012003 001

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

+ NOVEL LABS INC 5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM A202217 001 Aug 20, 2014

; N/A, 5.6GM

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+ FOREST LABS INC 140MG; 125MG; 125MG

N050786 001 Sep 28, 2006

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	AUROBINDO PHARMA	5MG	A077910	001	Dec 27, 2006
AB		10MG	A077910	002	Dec 27, 2006
AB	MYLAN	5MG	A075831	001	Dec 14, 2005
AB		10MG	A075831	002	Dec 14, 2005
AB	SANDOZ	5MG	A075643	001	Nov 16, 2000
AB		10MG	A075643	002	Nov 16, 2000
AB	TEVA PHARMS	5MG	A075644	001	Jun 26, 2001
AB		10MG	A075644	002	Jun 26, 2001
AB	UNICHEM PHARMS (USA)	5MG	A078635	001	Aug 18, 2009
AB		10MG	A078635	002	Aug 18, 2009

ZEBETA

AB	TEVA WOMENS	5MG	N019982	002	Jul 31, 1992
-----------	-------------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-47 (of 371)

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB	+	10MG	N019982 001	Jul 31, 1992
-----------	---	-------------	--------------------	--------------

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	2.5MG; 6.25MG	A075768 001	Sep 25, 2000
AB		5MG; 6.25MG	A075768 002	Sep 25, 2000
AB		10MG; 6.25MG	A075768 003	Sep 25, 2000
AB	SANDOZ	2.5MG; 6.25MG	A075579 001	Sep 25, 2000
AB		5MG; 6.25MG	A075579 002	Sep 25, 2000
AB		10MG; 6.25MG	A075579 003	Sep 25, 2000
AB	UNICHEM	2.5MG; 6.25MG	A079106 001	Jul 28, 2010
AB		5MG; 6.25MG	A079106 002	Jul 28, 2010
AB		10MG; 6.25MG	A079106 003	Jul 28, 2010

ZIAC

AB	TEVA WOMENS	2.5MG; 6.25MG	N020186 003	Mar 26, 1993
AB		5MG; 6.25MG	N020186 001	Mar 26, 1993
AB	+	10MG; 6.25MG	N020186 002	Mar 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

+ MEDICINES CO 250MG/VIAL

N020873 001 Dec 15, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

AP	EUROHLTH INTL	EQ 15 UNITS BASE/VIAL	A065042 002	Oct 17, 2001
AP		EQ 30 UNITS BASE/VIAL	A065042 001	Oct 17, 2001
AP	+	EQ 15 UNITS BASE/VIAL	A065185 001	Jan 28, 2008
AP	+	EQ 30 UNITS BASE/VIAL	A065185 002	Jan 28, 2008
AP	HOSPIRA	EQ 15 UNITS BASE/VIAL	A065031 001	Mar 10, 2000
AP		EQ 30 UNITS BASE/VIAL	A065031 002	Mar 10, 2000
AP	TEVA PHARMS USA	EQ 15 UNITS BASE/VIAL	A065033 001	Jun 27, 2000
AP		EQ 30 UNITS BASE/VIAL	A065033 002	Jun 27, 2000

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

+ MERCK SHARP DOHME 200MG

N202258 001 May 13, 2011

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL

N021602 001 May 13, 2003

ROSENTAN

TABLET; ORAL

TRACLEER

+ ACTELION PHARMS LTD 62.5MG

N021290 001 Nov 20, 2001

+ 125MG

N021290 002 Nov 20, 2001

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+ WYETH PHARMS INC EQ 100MG BASE

N203341 001 Sep 04, 2012

+ EQ 500MG BASE

N203341 002 Sep 04, 2012

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 100MG/100ML

N019121 001 Apr 29, 1986

+ 200MG/100ML

N019121 002 Apr 29, 1986

+ 400MG/100ML

N019121 003 Apr 29, 1986

BRIMONIDINE TARTRATE

GEL; TOPICAL

MIRVASO

+ GALDERMA LABS LP EQ 0.33% BASE

N204708 001 Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN P

AT	+	ALLERGAN	0.15%	N021262 001	Mar 16, 2001
-----------	---	-----------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-48 (of 371)

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT	AKORN	0.2%	A076439 001	Mar 14, 2006
AT	ALCON PHARMS LTD	0.2%	A076254 001	Sep 16, 2003
AT	+ BAUSCH AND LOMB	0.2%	A076260 001	May 28, 2003
AT	INDOCO REMEDIES	0.2%	A091691 001	Nov 18, 2014
AT	SANDOZ	0.2%	A078075 001	Jan 30, 2008

QOLIANA

AT	ALCON PHARMS LTD	0.15%	N021764 001	May 22, 2006
	ALPHAGAN P			
	+ ALLERGAN	0.1%	N021770 001	Aug 19, 2005

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

	+ ALCON RES LTD	0.2%;1%	N204251 001	Apr 19, 2013
--	-----------------	---------	-------------	--------------

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COMBIGAN

	+ ALLERGAN	0.2%;EQ 0.5% BASE	N021398 001	Oct 30, 2007
--	------------	-------------------	-------------	--------------

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPT

	+ ALCON PHARMS LTD	1%	N020816 001	Apr 01, 1998
--	--------------------	----	-------------	--------------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

AT	+ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664 002	Oct 16, 2010
-----------	-----------------------	----------------------	--------------------	--------------

BROMFENAC SODIUM

AT	APOTEX INC	EQ 0.09% ACID	A202620 001	Jun 23, 2014
AT	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395 001	Jan 22, 2014
AT1	APOTEX INC	EQ 0.09% ACID	A202435 001	Jun 19, 2014
AT1	COASTAL PHARMS	EQ 0.09% ACID	A201211 001	May 11, 2011
AT1	LUITPOLD	EQ 0.09% ACID	A202030 001	Jan 09, 2013
	PROLENSA			
	+ BAUSCH AND LOMB	EQ 0.07% ACID	N203168 001	Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB	MYLAN	EQ 5MG BASE	A077226 001	Apr 04, 2005
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A078899 001	Jul 30, 2008

PARLODEL

AB	+ US PHARMS HOLDINGS I	EQ 5MG BASE	N017962 002	Mar 01, 1982
-----------	------------------------	--------------------	--------------------	--------------

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB	LEK PHARMS	EQ 2.5MG BASE	A074631 001	Jan 13, 1998
AB	MYLAN	EQ 2.5MG BASE	A076962 001	Sep 24, 2004
AB	PADDOCK LLC	EQ 2.5MG BASE	A077646 001	Oct 01, 2008

PARLODEL

AB	+ US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962 001	
	CYCLOSET			
	+ VEROSCIENCE	EQ 0.8MG BASE	N020866 001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	+ WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811 001	Jun 07, 1985
-----------	-------------	----------------------------------	--------------------	--------------

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	PADDOCK LLC	2MG/5ML;10MG/5ML;30MG/5ML	A205292 001	Jul 15, 2014
AA	VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940 001	Jul 21, 2014

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+ SALIX PHARMS INC	2MG/ACTUATION	N205613 001	Oct 07, 2014
--	--------------------	---------------	-------------	--------------

CAPSULE;ORAL

BUDESONIDE

AB	BARR LABS DIV TEVA	3MG	A090379 001	Apr 02, 2014
AB	MYLAN	3MG	A090410 001	May 16, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-49 (of 371)

BUDESONIDE

CAPSULE; ORAL

ENTOCORT EC

AB + ASTRAZENECA **3MG** **N021324 001** Oct 02, 2001
POWDER, METERED; INHALATION
PULMICORT FLEXHALER

ASTRAZENECA 0.08MG/INH

N021949 001 Jul 12, 2006

+ 0.16MG/INH

N021949 002 Jul 12, 2006

SPRAY, METERED; NASAL

BUDESONIDE

AB APOTEX INC **0.032MG/INH** **A078949 001** May 12, 2014

RHINOCORT

AB + ASTRAZENECA PHARMS **0.032MG/INH** **N020746 001** Oct 01, 1999
SUSPENSION; INHALATION

BUDESONIDE

AN SANDOZ **0.25MG/2ML** **A201966 003** Sep 27, 2013

AN **0.5MG/2ML** **A201966 002** Sep 27, 2013

AN **1MG/2ML** **A201966 001** Sep 27, 2013

AN TEVA PHARMS **0.25MG/2ML** **A077519 001** Nov 18, 2008

AN **0.5MG/2ML** **A077519 002** Nov 18, 2008

AN WATSON LABS INC **0.25MG/2ML** **A078404 001** Jul 31, 2012

AN **0.5MG/2ML** **A078404 002** Jul 31, 2012

PULMICORT RESPULES

AN ASTRAZENECA PHARMS **0.25MG/2ML** **N020929 001** Aug 08, 2000

AN **0.5MG/2ML** **N020929 002** Aug 08, 2000

AN + **1MG/2ML** **N020929 003** Aug 08, 2000

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+ SANTARUS INC 9MG

N203634 001 Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH; 0.0045MG/INH

N021929 001 Jul 21, 2006

+ 0.16MG/INH; 0.0045MG/INH

N021929 002 Jul 21, 2006

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP + BEDFORD **0.25MG/ML** **A074441 001** Jan 27, 1995

AP HIKMA MAPLE **0.25MG/ML** **A079196 001** Apr 30, 2008

AP HOSPIRA **0.25MG/ML** **A074332 001** Oct 31, 1994

TABLET; ORAL

BUMETANIDE

AB IVAX SUB TEVA PHARMS **0.5MG** **A074225 001** Apr 24, 1995

AB **1MG** **A074225 002** Apr 24, 1995

AB **2MG** **A074225 003** Apr 24, 1995

AB SANDOZ **0.5MG** **A074700 001** Nov 21, 1996

AB **1MG** **A074700 002** Nov 21, 1996

AB + **2MG** **A074700 003** Nov 21, 1996

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+ PACIRA PHARMS INC 266MG/20ML (13.3MG/ML)

N022496 002 Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP HOSPIRA **0.25%** **A070583 001** Feb 17, 1987

AP **0.25%** **A070586 001** Mar 03, 1987

AP **0.25%** **A070590 001** Feb 17, 1987

AP **0.25%** **N018053 002**

AP **0.5%** **A070584 001** Feb 17, 1986

AP **0.5%** **A070597 001** Mar 03, 1987

AP **0.5%** **A070609 001** Mar 03, 1987

AP **0.5%** **N018053 001**

AP **0.75%** **A070585 001** Mar 03, 1987

AP **0.75%** **N018053 003**

AP SAGENT AGILA **0.25%** **A091503 001** Oct 18, 2011

AP **0.5%** **A091503 002** Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP AUROBINDO PHARMA LTD **0.25%** **A203895 001** Nov 05, 2013

AP **0.5%** **A203895 002** Nov 05, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-50 (of 371)

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		0.75%	<u>A203895</u>	<u>003</u>	Nov 05, 2013
AP	SAGENT AGILA	0.25%	<u>A091487</u>	<u>002</u>	Oct 18, 2011
AP		0.5%	<u>A091487</u>	<u>001</u>	Oct 18, 2011
AP		0.75%	<u>A091487</u>	<u>003</u>	Oct 18, 2011

MARCAINE HYDROCHLORIDE

AP	+	HOSPIRA	0.25%	<u>N016964</u>	<u>001</u>
AP	+		0.5%	<u>N016964</u>	<u>006</u>

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	+	HOSPIRA	0.25%	<u>N016964</u>	<u>012</u>
AP	+		0.5%	<u>N016964</u>	<u>005</u>
AP	+		0.75%	<u>N016964</u>	<u>009</u>

SENSORCAINE

AP		FRESENIUS KABI USA	0.25%	<u>A070552</u>	<u>001</u>	May 21, 1986
AP			0.25%	<u>N018304</u>	<u>001</u>	
AP			0.5%	<u>A070553</u>	<u>001</u>	May 21, 1986
AP			0.5%	<u>N018304</u>	<u>002</u>	
AP			0.75%	<u>A070554</u>	<u>001</u>	May 21, 1986
AP			0.75%	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		HOSPIRA	0.75%	<u>A071810</u>	<u>001</u>	Dec 11, 1987
----	--	---------	-------	----------------	------------	--------------

MARCAINE

AP	+	HOSPIRA	0.75%	<u>N018692</u>	<u>001</u>	May 04, 1984
----	---	---------	-------	----------------	------------	--------------

SENSORCAINE

AP		FRESENIUS KABI USA	0.75%	<u>A071202</u>	<u>001</u>	Apr 15, 1987
----	--	--------------------	-------	----------------	------------	--------------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	+	HOSPIRA	0.5%; 0.005MG/ML	<u>A071168</u>	<u>001</u>	Jun 16, 1988
AP			0.5%; 0.005MG/ML	<u>A071170</u>	<u>001</u>	Jun 16, 1988
	+		0.25%; 0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%; 0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP		SEPTODONT	0.5%; 0.0091MG/ML	<u>A077250</u>	<u>001</u>	Sep 27, 2006
----	--	-----------	-------------------	----------------	------------	--------------

BUPIVACAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	+	HOSPIRA	0.5%; 0.0091MG/ML	<u>N022046</u>	<u>001</u>	Jul 13, 1983
----	---	---------	-------------------	----------------	------------	--------------

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	+	HOSPIRA	0.25%; 0.0091MG/ML	<u>N016964</u>	<u>004</u>
----	---	---------	--------------------	----------------	------------

AP	+		0.5%; 0.0091MG/ML	<u>N016964</u>	<u>008</u>
----	---	--	-------------------	----------------	------------

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	+	HOSPIRA	0.25%; 0.0091MG/ML	<u>N016964</u>	<u>013</u>
----	---	---------	--------------------	----------------	------------

AP	+		0.5%; 0.0091MG/ML	<u>N016964</u>	<u>007</u>
----	---	--	-------------------	----------------	------------

AP	+		0.75%; 0.0091MG/ML	<u>N016964</u>	<u>010</u>
----	---	--	--------------------	----------------	------------

SENSORCAINE

AP		FRESENIUS KABI USA	0.25%; 0.0091MG/ML	<u>A070966</u>	<u>001</u>	Oct 13, 1987
AP			0.25%; 0.0091MG/ML	<u>A070967</u>	<u>001</u>	Oct 13, 1987
AP			0.5%; 0.0091MG/ML	<u>A070968</u>	<u>001</u>	Oct 13, 1987
AP			0.5%; 0.0091MG/ML	<u>N018304</u>	<u>004</u>	Sep 02, 1983
AP			0.75%; 0.0091MG/ML	<u>N018304</u>	<u>005</u>	Sep 02, 1983

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUTRANS

	PURDUE PHARMA LP	5MCG/HR	N021306	001	Jun 30, 2010
		7.5MCG/HR	N021306	005	Jun 30, 2014
		10MCG/HR	N021306	002	Jun 30, 2010
		15MCG/HR	N021306	004	Jul 25, 2013
+		20MCG/HR	N021306	003	Jun 30, 2010

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPRENEX

AP	+	RECKITT BENCKISER	EQ 0.3MG BASE/ML	<u>N018401</u>	<u>001</u>
----	---	-------------------	------------------	----------------	------------

BUPRENORPHINE HYDROCHLORIDE

AP		EUROHLTH INTL	EQ 0.3MG BASE/ML	<u>A076931</u>	<u>001</u>	Mar 02, 2005
AP		HOSPIRA	EQ 0.3MG BASE/ML	<u>A074137</u>	<u>001</u>	Jun 03, 1996
AP		LUITPOLD	EQ 0.3MG BASE/ML	<u>A078331</u>	<u>001</u>	Mar 27, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-51 (of 371)

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	BARR	<u>EQ 2MG BASE</u>	<u>A090360 001</u>	May 07, 2010
AB		<u>EQ 8MG BASE</u>	<u>A090360 002</u>	May 07, 2010
AB	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622 001</u>	Sep 24, 2010
AB		<u>EQ 8MG BASE</u>	<u>A090622 002</u>	Sep 24, 2010
AB	ROXANE	<u>EQ 2MG BASE</u>	<u>A078633 001</u>	Oct 08, 2009
AB	+	<u>EQ 8MG BASE</u>	<u>A078633 002</u>	Oct 08, 2009

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637 001	Jun 06, 2014
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637 002	Jun 06, 2014
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637 003	Jun 06, 2014

FILM;SUBLINGUAL

SUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010
		EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012
		EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010
	+	EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091422 001</u>	Feb 22, 2013
AB	+	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091422 002</u>	Feb 22, 2013
AB	AMNEAL PHARMS	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203136 002</u>	Feb 22, 2013
AB	ROXANE	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203326 001</u>	Jun 27, 2014
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203326 002</u>	Jun 27, 2014
AB	TEVA PHARMS USA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091149 001</u>	Sep 08, 2014
AB		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091149 002</u>	Sep 08, 2014

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203136 001</u>	Feb 22, 2013
	ZUBSOLV			
	OREXO AB	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
	+	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
		EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
		EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT BERMUDA	174MG	N022108 001	Apr 23, 2008
		348MG	N022108 002	Apr 23, 2008
	+	522MG	N022108 003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	APOTEX INC	<u>75MG</u>	<u>A076143 001</u>	Jan 17, 2006
AB		<u>100MG</u>	<u>A076143 002</u>	Jan 17, 2006
AB	MYLAN	<u>75MG</u>	<u>A075491 001</u>	Apr 17, 2000
AB		<u>100MG</u>	<u>A075491 002</u>	Apr 17, 2000
AB	SANDOZ	<u>75MG</u>	<u>A075584 001</u>	Feb 07, 2000
AB		<u>100MG</u>	<u>A075584 002</u>	Feb 07, 2000

WELLBUTRIN

AB	GLAXOSMITHKLINE	<u>75MG</u>	<u>N018644 002</u>	Dec 30, 1985
AB	+	<u>100MG</u>	<u>N018644 003</u>	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	ACTAVIS LABS FL INC	<u>100MG</u>	<u>A079095 001</u>	Mar 24, 2009
AB1		<u>150MG</u>	<u>A079095 002</u>	Mar 24, 2009
AB1		<u>200MG</u>	<u>A079095 003</u>	Mar 24, 2009
AB1	ANCHEN PHARMS	<u>100MG</u>	<u>A091459 001</u>	Jun 09, 2011
AB1		<u>150MG</u>	<u>A091459 002</u>	Jun 09, 2011
AB1		<u>200MG</u>	<u>A091459 003</u>	Jun 09, 2011
AB1	IMPAX LABS	<u>100MG</u>	<u>A075913 001</u>	Jan 28, 2004
AB1		<u>150MG</u>	<u>A075913 002</u>	Mar 22, 2004
AB1		<u>200MG</u>	<u>A076711 001</u>	Dec 03, 2004
AB1	JUBILANT GENERICS	<u>100MG</u>	<u>A202774 001</u>	Oct 11, 2013
AB1		<u>150MG</u>	<u>A202774 002</u>	Oct 11, 2013
AB1		<u>200MG</u>	<u>A202774 003</u>	Oct 11, 2013
AB1	MYLAN	<u>100MG</u>	<u>A090325 001</u>	Apr 08, 2010
AB1		<u>150MG</u>	<u>A090325 002</u>	Apr 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-52 (of 371)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>		<u>200MG</u>	<u>A090325</u>	<u>003</u>	Apr 08, 2010
<u>AB1</u>	SANDOZ	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203969</u>	<u>001</u>	Oct 31, 2014
<u>AB1</u>		<u>150MG</u>	<u>A203969</u>	<u>002</u>	Oct 31, 2014
<u>AB1</u>		<u>200MG</u>	<u>A203969</u>	<u>003</u>	Oct 31, 2014
<u>AB1</u>	WATSON LABS INC	<u>100MG</u>	<u>A077455</u>	<u>001</u>	Jul 19, 2010
<u>AB1</u>		<u>150MG</u>	<u>A077455</u>	<u>002</u>	Mar 12, 2008
<u>AB1</u>		<u>200MG</u>	<u>A077455</u>	<u>003</u>	Jul 19, 2010
<u>AB1</u>	WOCKHARDT LTD	<u>100MG</u>	<u>A201331</u>	<u>001</u>	Aug 30, 2012
<u>AB1</u>		<u>150MG</u>	<u>A201331</u>	<u>002</u>	Aug 30, 2012
<u>AB1</u>		<u>200MG</u>	<u>A201331</u>	<u>003</u>	Aug 30, 2012

WELLBUTRIN SR

<u>AB1</u>	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	ACTAVIS	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>AB2</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>	IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>	JUBILANT GENERICS	<u>150MG</u>	<u>A202775</u>	<u>001</u>	Oct 11, 2013
<u>AB2</u>	MYLAN	<u>150MG</u>	<u>A090941</u>	<u>001</u>	May 03, 2010

ZYBAN

<u>AB2</u>	+	GLAXOSMITHKLINE	<u>150MG</u>	<u>N020711</u>	<u>003</u>	May 14, 1997
------------	---	-----------------	--------------	----------------	------------	--------------

BUPROPION HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>		<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>	IMPAX LABS	<u>150MG</u>	<u>A077415</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>	MYLAN	<u>150MG</u>	<u>A090942</u>	<u>001</u>	Jul 14, 2010
<u>AB3</u>		<u>300MG</u>	<u>A090942</u>	<u>002</u>	Jul 14, 2010
<u>AB3</u>	SUN PHARMA GLOBAL	<u>150MG</u>	<u>A200695</u>	<u>001</u>	Dec 18, 2014
<u>AB3</u>	WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>	WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>	ZYDUS PHARMS USA INC	<u>300MG</u>	<u>A201567</u>	<u>001</u>	Jan 17, 2014

WELLBUTRIN XL

<u>AB3</u>	VALEANT INTL	<u>150MG</u>	<u>N021515</u>	<u>001</u>	Aug 28, 2003
<u>AB3</u>	+	<u>300MG</u>	<u>N021515</u>	<u>002</u>	Aug 28, 2003
	FORFIVO XL				
	+	EDGEMONT PHARMS LLC	450MG	N022497	001
					Nov 10, 2011

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	TAKEDA PHARMS USA	90MG; 8MG	N200063	001	Sep 10, 2014
---	-------------------	-----------	---------	-----	--------------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A202557</u>	<u>001</u>	Dec 30, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202557</u>	<u>002</u>	Dec 30, 2014
<u>AB</u>		<u>10MG</u>	<u>A202557</u>	<u>003</u>	Dec 30, 2014
<u>AB</u>		<u>15MG</u>	<u>A202557</u>	<u>004</u>	Dec 30, 2014
<u>AB</u>		<u>30MG</u>	<u>A202557</u>	<u>005</u>	Dec 30, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A078246</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A078246</u>	<u>002</u>	Feb 27, 2009
<u>AB</u>		<u>15MG</u>	<u>A078246</u>	<u>003</u>	Feb 27, 2009
<u>AB</u>		<u>30MG</u>	<u>A078246</u>	<u>004</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A075272</u>	<u>001</u>	Mar 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075467</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>7.5MG</u>	<u>A075467</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A075272</u>	<u>002</u>	Mar 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075467</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075272</u>	<u>003</u>	Mar 28, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-53 (of 371)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A075467</u>	<u>004</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A076008</u>	<u>001</u>	Jun 28, 2001
<u>AB</u>	PROSAM LABS	<u>30MG</u>	<u>A078302</u>	<u>001</u>	Dec 17, 2007
<u>AB</u>	STRIDES ARCOLAB LTD	<u>5MG</u>	<u>A202330</u>	<u>001</u>	Aug 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A202330</u>	<u>002</u>	Aug 25, 2014
<u>AB</u>		<u>15MG</u>	<u>A202330</u>	<u>003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330</u>	<u>004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>	+	<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A074253</u>	<u>001</u>	Mar 28, 2001
<u>AB</u>		<u>10MG</u>	<u>A074253</u>	<u>002</u>	Mar 28, 2001
<u>AB</u>		<u>15MG</u>	<u>A074253</u>	<u>003</u>	Mar 13, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078888</u>	<u>001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888</u>	<u>002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888</u>	<u>003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888</u>	<u>004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFEX

+ OTSUKA PHARM

6MG/ML

N020954 001 Feb 04, 1999

TABLET; ORAL

MYLERAN

+ ASPEN GLOBAL

2MG

N009386 001

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG/5ML

A085380 001

TABLET; ORAL

BUTISOL SODIUM

+ MEDA PHARMS

30MG

N000793 004

+

50MG

N000793 003

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+ MYLAN

1%

N020524 001 Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	BEDFORD	<u>2MG/ML</u>	<u>A075046</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400</u>	<u>001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400</u>	<u>002</u>	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	BEDFORD	<u>1MG/ML</u>	<u>A075045</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045</u>	<u>002</u>	Aug 12, 1998
<u>AP</u>	HOSPIRA	<u>1MG/ML</u>	<u>A074626</u>	<u>001</u>	Jan 23, 1997
<u>AP</u>		<u>2MG/ML</u>	<u>A074626</u>	<u>002</u>	Jan 23, 1997

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	+	MYLAN	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001
<u>AB</u>		NOVEX	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>		ROXANE	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002

CABAZITAXEL

SOLUTION; IV (INFUSION)

JEVTANA KIT

+ SANOFI AVENTIS US

60MG/1.5ML (40MG/ML)

N201023 001 Jun 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-54 (of 371)

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008
AB	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013
AB	IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007
AB	IVAX SUB TEVA PHARMS	0.5MG	A077750	001	Mar 07, 2007
AB	MYLAN PHARMS INC	0.5MG	A202947	001	Dec 02, 2013
AB	+ PAR PHARM	0.5MG	A076310	001	Dec 29, 2005

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

EXELIXIS

EQ 20MG BASE

N203756 001 Nov 29, 2012

+

EQ 80MG BASE

N203756 002 Nov 29, 2012

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999
-----------	-----------------	---	----------------	------------	--------------

CAFFEINE CITRATE

AP	EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006
AP	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077997	001	Jul 20, 2007
AP	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077906	001	May 15, 2007
AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827	001	Aug 29, 2012
AP	SUN PHARMA GLOBAL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090077	001	Sep 30, 2009

SOLUTION; ORAL

CAFCIT

AA	+ EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000
-----------	-----------------	---	----------------	------------	--------------

CAFFEINE CITRATE

AA	EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006
AA	FRESENIUS KABI USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A078002	001	Jan 31, 2008
AA	LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009
AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102	001	Aug 29, 2012
AA	SUN PHARMA GLOBAL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090357	001	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+ CREALTA PHARMS LLC

100MG; 2MG

A086557 001 Oct 04, 1983

TABLET; ORAL

CAFERGOT

AA	+ SANDOZ	100MG; 1MG	A084294	001	
-----------	----------	-------------------	----------------	------------	--

ERGOTAMINE TARTRATE AND CAFFEINE

AA	HIKMA INTL PHARMS	100MG; 1MG	A040510	001	Sep 17, 2004
AA	MIKART	100MG; 1MG	A040590	001	Sep 16, 2005

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+ STIEFEL LABS INC

0.005%

N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935	001	May 30, 2012
-----------	--------	---------------	----------------	------------	--------------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554	001	Jul 22, 1996
-----------	-----------------	---------------	----------------	------------	--------------

OINTMENT; TOPICAL

CALCIPOTRIENE

+ GLENMARK GENERICS

0.005%

A090633 001 Mar 24, 2010

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305	001	May 06, 2008
AT	G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011
AT	HI TECH PHARMA	0.005%	A077579	001	Nov 19, 2009
AT	+ TOLMAR	0.005%	A077029	001	Nov 20, 2009

CALCITONIN SALMON

INJECTABLE; INJECTION

MIACALCIN

+ SEBELA IRELAND LTD

200 IU/ML

N017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON

AB	APOTEX INC	200 IU/SPRAY	A076396	001	Nov 17, 2008
AB	PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-55 (of 371)

CALCITONIN SALMON

SPRAY, METERED;NASAL

MIACALCIN

AB	+	SEBELA IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995
-----------	----------	---------------------------	---------------------	----------------	------------	--------------

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED;NASAL

FORTICAL

+ UPSHER SMITH

200 IU/SPRAY

N021406 001 Aug 12, 2005

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		BANNER PHARMACAPS	0.25MCG	A091174	001	May 24, 2013
-----------	--	--------------------------	----------------	----------------	------------	--------------

AB			0.5MCG	A091174	002	May 24, 2013
-----------	--	--	---------------	----------------	------------	--------------

AB		ROXANE	0.25MCG	A076917	001	Mar 27, 2006
-----------	--	---------------	----------------	----------------	------------	--------------

AB		STRIDES ARCOLAB LTD	0.25MCG	A091356	001	Dec 12, 2014
-----------	--	----------------------------	----------------	----------------	------------	--------------

AB			0.5MCG	A091356	002	Dec 12, 2014
-----------	--	--	---------------	----------------	------------	--------------

AB		TEVA	0.25MCG	A075765	001	Oct 12, 2001
-----------	--	-------------	----------------	----------------	------------	--------------

AB			0.5MCG	A075765	002	Oct 12, 2001
-----------	--	--	---------------	----------------	------------	--------------

ROCALTROL

AB		VALIDUS PHARMS	0.25MCG	N018044	001	
-----------	--	-----------------------	----------------	----------------	------------	--

AB	+		0.5MCG	N018044	002	
-----------	----------	--	---------------	----------------	------------	--

INJECTABLE;INJECTION

CALCIJEX

AP	+	ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986
-----------	----------	---------------	-------------------	----------------	------------	--------------

AP	+		0.002MG/ML	N018874	002	Sep 25, 1986
-----------	----------	--	-------------------	----------------	------------	--------------

CALCITRIOL

AP		AKORN	0.001MG/ML	A078066	001	Jan 29, 2008
-----------	--	--------------	-------------------	----------------	------------	--------------

AP			0.002MG/ML	A078066	002	Jan 29, 2008
-----------	--	--	-------------------	----------------	------------	--------------

AP		FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002
-----------	--	---------------------------	-------------------	----------------	------------	--------------

AP			0.002MG/ML	A075836	002	Dec 31, 2002
-----------	--	--	-------------------	----------------	------------	--------------

AP		FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003
-----------	--	------------------------	-------------------	----------------	------------	--------------

AP			0.002MG/ML	A075766	002	Feb 20, 2003
-----------	--	--	-------------------	----------------	------------	--------------

AP		LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003
-----------	--	-----------------	-------------------	----------------	------------	--------------

AP			0.002MG/ML	A075746	002	Sep 26, 2003
-----------	--	--	-------------------	----------------	------------	--------------

AP		ROCKWELL MEDCL	0.001MG/ML	A076206	001	Sep 17, 2003
-----------	--	-----------------------	-------------------	----------------	------------	--------------

AP		SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006
-----------	--	----------------------	-------------------	----------------	------------	--------------

OINTMENT;TOPICAL

VECTICAL

+ GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION;ORAL

CALCITRIOL

AA		ROXANE	1MCG/ML	A076242	001	Jul 18, 2003
-----------	--	---------------	----------------	----------------	------------	--------------

ROCALTROL

AA	+	VALIDUS PHARMS	1MCG/ML	N021068	001	Nov 20, 1998
-----------	----------	-----------------------	----------------	----------------	------------	--------------

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		AMNEAL PHARMS	EQ 169MG CALCIUM	A201658	001	Oct 06, 2014
-----------	--	----------------------	-------------------------	----------------	------------	--------------

AB		INVAGEN PHARMS	EQ 169MG CALCIUM	A203135	001	Feb 07, 2013
-----------	--	-----------------------	-------------------------	----------------	------------	--------------

AB		PADDOCK LLC	EQ 169MG CALCIUM	A091312	001	Jun 01, 2012
-----------	--	--------------------	-------------------------	----------------	------------	--------------

AB		ROXANE	EQ 169MG CALCIUM	A077728	001	Feb 26, 2008
-----------	--	---------------	-------------------------	----------------	------------	--------------

PHOSLO GELCAPS

AB	+	FRESENIUS MEDCL	EQ 169MG CALCIUM	N021160	003	Apr 02, 2001
-----------	----------	------------------------	-------------------------	----------------	------------	--------------

SOLUTION;ORAL

PHOSLYRA

+ FRESENIUS MEDCL

EQ 169MG CALCIUM/5ML

N022581 001 Apr 18, 2011

TABLET;ORAL

CALCIUM ACETATE

AB		INVAGEN PHARMS	EQ 169MG CALCIUM	A202420	001	Feb 05, 2013
-----------	--	-----------------------	-------------------------	----------------	------------	--------------

AB		PADDOCK LLC	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011
-----------	--	--------------------	-------------------------	----------------	------------	--------------

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008
-----------	----------	----------------------	-------------------------	----------------	------------	--------------

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

+ HOSPIRA

100MG/ML

N021117 001 Jan 28, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-56 (of 371)

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE
SOLUTION; IRRIGATION

BSS PLUS

AT + ALCON **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N018469 001**

ENDOSOL EXTRA

AT + AKORN **0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML** **N020079 001** Nov 27, 1991

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 010 Oct 10, 2008

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 011 Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML N021703 013 Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 006 Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 002 Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 003 Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 015 Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 004 Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 014 Oct 10, 2008

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ GAMBRO RENAL PRODS 5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML N021703 001 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

+ ALCON PHARMS LTD 0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML N022193 001 Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN 37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML N019864 001 Jun 10, 1993

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML N017390 001

PRESCRIPTION DRUG PRODUCT LIST

3-57 (of 371)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2G M/100ML; 9.6GM/100ML	N018807	001	Aug 26, 1983
+		510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4G M/100ML; 11GM/100ML	N018807	003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

+	B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2G M/100ML; 9.6GM/100ML	N018807	002	Aug 26, 1983
+		510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4G M/100ML; 11GM/100ML	N018807	004	Aug 26, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018379	002	
AT		25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N018883	004	Nov 30, 1984
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N020171	001	Aug 19, 1992
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018379	003	
AT		25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N018883	005	Nov 30, 1984
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N020171	002	Aug 19, 1992
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5 567MG/100ML; 392MG/100ML	N018379	001	
AT		25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5 538MG/100ML; 448MG/100ML	N018883	006	Nov 30, 1984
----	-----------------	--	---------	-----	--------------

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5 538MG/100ML; 448MG/100ML	N020171	003	Aug 19, 1992
----	-----------------	--	---------	-----	--------------

DELFLX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982
----	-----------------	--	---------	-----	--------------

DELFLX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982
----	-----------------	--	---------	-----	--------------

DELFLX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988
----	-----------------	--	---------	-----	--------------

DELFLX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 5 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982
----	-----------------	--	---------	-----	--------------

DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N017512	001	
----	-----------------	--	---------	-----	--

DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N017512	003	
----	-----------------	--	---------	-----	--

DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 5 567MG/100ML; 392MG/100ML	N017512	002	
----	-----------------	--	---------	-----	--

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 5 38MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992
----	-----------------	--	---------	-----	--------------

DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N017512	007	Jul 09, 1984
----	-----------------	--	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-58 (of 371)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	N017512 008	Jul 09, 1984
-----------	-----------------	--	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	N017512 010	Nov 18, 1985
-----------	-----------------	--	--------------------	--------------

DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML</u>	N017512 009	Jul 09, 1984
-----------	-----------------	---	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N017512 004	
-----------	-----------------	--	--------------------	--

AT		<u>25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020163 001	Dec 04, 1992
-----------	--	--	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N017512 005	
-----------	-----------------	--	--------------------	--

AT		<u>25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020163 002	Dec 04, 1992
-----------	--	--	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N017512 011	Nov 18, 1985
-----------	-----------------	--	--------------------	--------------

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N017512 006	
-----------	-----------------	---	--------------------	--

AT		<u>25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020163 003	Dec 04, 1992
-----------	--	---	--------------------	--------------

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

	B BRAUN	<u>26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML</u>	N018460 007	Jan 29, 1986
--	---------	---	--------------------	--------------

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	B BRAUN	<u>26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML</u>	N018460 005	Nov 02, 1983
--	---------	---	--------------------	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	B BRAUN	<u>26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML</u>	N018460 009	Jan 29, 1986
--	---------	--	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020183 002	Dec 04, 1992
--	-----------------	--	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020183 003	Dec 04, 1992
--	-----------------	--	--------------------	--------------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML</u>	N020183 004	Dec 04, 1992
--	-----------------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	LUKARE MEDICAL LLC	<u>0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML</u>	N020577 001	Sep 27, 1996
---	--------------------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

+	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML</u>	N018258 001	
---	---------	--	--------------------	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	N018254 001	
-----------	---------	---	--------------------	--

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML</u>	N020000 001	Apr 17, 1992
-----------	---------	---	--------------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	HOSPIRA	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N017608 001	
-----------	---------	--	--------------------	--

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	N019634 003	Feb 24, 1988
-----------	---------	--	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-59 (of 371)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N016679 001	
----	-----------------	---	-------------	--

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019367 006	Apr 05, 1985
----	-----------------	--	-------------	--------------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019367 004	Apr 05, 1985
----	-----------------	--	-------------	--------------

AP		20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019367 005	Apr 05, 1985
----	--	--	-------------	--------------

AP	HOSPIRA	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 002	Oct 17, 1988
----	---------	--	-------------	--------------

AP		20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 008	Oct 17, 1988
----	--	--	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019367 007	Apr 05, 1985
----	-----------------	--	-------------	--------------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019367 008	Apr 05, 1985
----	-----------------	--	-------------	--------------

AP	HOSPIRA	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 004	Oct 17, 1988
----	---------	--	-------------	--------------

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML	N019634 001	Feb 24, 1988
--	---------	---	-------------	--------------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 002	Apr 05, 1985
--	-----------------	--	-------------	--------------

		20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019367 003	Apr 05, 1985
--	--	--	-------------	--------------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML	N019367 001	Apr 05, 1985
--	-----------------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+ HOSPIRA	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N018895 001	Jul 20, 1984
--	-----------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

	+ B BRAUN	35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019718 001	Sep 29, 1989
--	-----------	--	-------------	--------------

SOLUTION; IRRIGATION

BALANCED SALT

AT	AKORN	0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML	A075503 001	Sep 27, 2006
----	-------	--	-------------	--------------

AT	B BRAUN	0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML	A091387 001	Feb 03, 2010
----	---------	--	-------------	--------------

BSS

AT	+ ALCON	0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML	N020742 001	Dec 10, 1997
----	---------	--	-------------	--------------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML; 640MG/100ML; 496MG/100ML; 89.6MG/100ML	N017438 001	
--	-------------------	--	-------------	--

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	A075323 001	Apr 21, 2000
----	-----------------	---	-------------	--------------

PLEGISOL IN PLASTIC CONTAINER

AT	+ HOSPIRA	17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	N018608 001	Feb 26, 1982
----	-----------	---	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-60 (of 371)

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002</u>	<u>001</u>	Apr 17, 1992
AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693</u>	<u>001</u>	
AP	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251</u>	<u>001</u>	

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156</u>	<u>001</u>	
AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495</u>	<u>001</u>	Feb 19, 1982
AT	HOSPIRA	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635</u>	<u>001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632</u>	<u>001</u>	Feb 29, 1988
AP	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682</u>	<u>001</u>	
AP	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641</u>	<u>001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681</u>	<u>001</u>	Dec 27, 1982
AT		BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494</u>	<u>001</u>	Feb 19, 1982
AT	+		<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921</u>	<u>001</u>	Apr 03, 1984
AT	+		<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019933</u>	<u>001</u>	Aug 29, 1989
AT	+	HOSPIRA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416</u>	<u>001</u>	Jan 17, 1986

CALFACTANT

SUSPENSION; INTRATRACHEAL

INFASURF PRESERVATIVE FREE

+	ONY	35MG/ML	N020521	001	Jul 01, 1998
---	-----	---------	---------	-----	--------------

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
+		300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

	JANSSEN PHARMS	50MG; 500MG	N204353	001	Aug 08, 2014
		50MG; 1GM	N204353	002	Aug 08, 2014
		150MG; 500MG	N204353	003	Aug 08, 2014
+		150MG; 1GM	N204353	004	Aug 08, 2014

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	ASTRAZENECA	<u>4MG</u>	<u>N020838</u>	<u>001</u>	Jun 04, 1998
AB		<u>8MG</u>	<u>N020838</u>	<u>002</u>	Jun 04, 1998
AB		<u>16MG</u>	<u>N020838</u>	<u>003</u>	Jun 04, 1998
AB	+	<u>32MG</u>	<u>N020838</u>	<u>004</u>	Jun 04, 1998

CANDESARTAN CILEXETIL

AB	APOTEX INC	<u>4MG</u>	<u>A202079</u>	<u>001</u>	Jan 10, 2014
AB		<u>8MG</u>	<u>A202079</u>	<u>002</u>	Jan 10, 2014
AB		<u>16MG</u>	<u>A202079</u>	<u>003</u>	Jan 10, 2014
AB		<u>32MG</u>	<u>A202079</u>	<u>004</u>	Jan 10, 2014
AB	SANDOZ	<u>4MG</u>	<u>A078702</u>	<u>001</u>	May 03, 2013
AB		<u>8MG</u>	<u>A078702</u>	<u>002</u>	May 03, 2013
AB		<u>16MG</u>	<u>A078702</u>	<u>003</u>	May 03, 2013
AB		<u>32MG</u>	<u>A078702</u>	<u>004</u>	May 03, 2013

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

AB	ASTRAZENECA	<u>16MG; 12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
AB		<u>32MG; 12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
AB	+	<u>32MG; 25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-61 (of 371)

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>16MG; 12.5MG</u>	<u>A202884</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A202884</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 25MG</u>	<u>A202884</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>16MG; 12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>	MYLAN LABS	<u>16MG; 12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	MYLAN PHARMS INC	<u>150MG</u>	<u>A090943</u>	<u>001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943</u>	<u>002</u>	Aug 08, 2014
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A091649</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>500MG</u>	<u>A091649</u>	<u>002</u>	Sep 16, 2013

XELODA

<u>AB</u>	HOFFMANN LA ROCHE	<u>150MG</u>	<u>N020896</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>500MG</u>	<u>N020896</u>	<u>002</u>	Apr 30, 1998

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+ AKORN

EQ 1GM BASE/VIAL

N050095 001

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+ ACORDA

8%

N022395 001 Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPOTEN

<u>AB</u>	PAR PHARM	<u>12.5MG</u>	<u>N018343</u>	<u>005</u>	Jan 17, 1985
<u>AB</u>		<u>25MG</u>	<u>N018343</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>N018343</u>	<u>001</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N018343</u>	<u>003</u>	

CAPTOPRIL

<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A074737</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>25MG</u>	<u>A074737</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>50MG</u>	<u>A074737</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A074737</u>	<u>004</u>	Oct 28, 1998
<u>AB</u>	HIKMA PHARMS LLC	<u>12.5MG</u>	<u>A074505</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074505</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074505</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074505</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A074434</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074434</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074434</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074434</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	SANDOZ	<u>12.5MG</u>	<u>A074363</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>25MG</u>	<u>A074363</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>50MG</u>	<u>A074363</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>		<u>100MG</u>	<u>A074363</u>	<u>004</u>	Nov 09, 1995
<u>AB</u>	STASON	<u>12.5MG</u>	<u>A074677</u>	<u>004</u>	May 30, 1997
<u>AB</u>		<u>25MG</u>	<u>A074677</u>	<u>002</u>	May 30, 1997
<u>AB</u>		<u>50MG</u>	<u>A074677</u>	<u>001</u>	May 30, 1997
<u>AB</u>		<u>100MG</u>	<u>A074677</u>	<u>003</u>	May 30, 1997
<u>AB</u>	TEVA	<u>12.5MG</u>	<u>A074322</u>	<u>001</u>	Feb 13, 1996
<u>AB</u>		<u>25MG</u>	<u>A074322</u>	<u>002</u>	Feb 13, 1996
<u>AB</u>		<u>50MG</u>	<u>A074322</u>	<u>003</u>	Feb 13, 1996
<u>AB</u>		<u>100MG</u>	<u>A074322</u>	<u>004</u>	Feb 13, 1996
<u>AB</u>	WATSON LABS	<u>12.5MG</u>	<u>A074386</u>	<u>001</u>	May 23, 1996
<u>AB</u>		<u>25MG</u>	<u>A074386</u>	<u>002</u>	May 23, 1996
<u>AB</u>		<u>50MG</u>	<u>A074386</u>	<u>003</u>	May 23, 1996
<u>AB</u>		<u>100MG</u>	<u>A074386</u>	<u>004</u>	May 23, 1996
<u>AB</u>	WOCKHARDT	<u>12.5MG</u>	<u>A074532</u>	<u>001</u>	Mar 28, 1997
<u>AB</u>		<u>25MG</u>	<u>A074532</u>	<u>002</u>	Mar 28, 1997
<u>AB</u>		<u>50MG</u>	<u>A074532</u>	<u>003</u>	Mar 28, 1997
<u>AB</u>		<u>100MG</u>	<u>A074532</u>	<u>004</u>	Mar 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-62 (of 371)

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	MYLAN	<u>25MG; 15MG</u>	<u>A074896</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>	+	<u>25MG; 25MG</u>	<u>A074896</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>	+	<u>50MG; 15MG</u>	<u>A074896</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074896</u>	<u>003</u>	Dec 29, 1997
<u>AB</u>	TEVA	<u>25MG; 15MG</u>	<u>A074827</u>	<u>001</u>	Dec 29, 1997
<u>AB</u>		<u>25MG; 25MG</u>	<u>A074827</u>	<u>002</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 15MG</u>	<u>A074827</u>	<u>004</u>	Dec 29, 1997
<u>AB</u>		<u>50MG; 25MG</u>	<u>A074827</u>	<u>003</u>	Dec 29, 1997

CARBACHOLSOLUTION; INTRAOCULAR
MIOSTAT

+ ALCON 0.01% N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A078986</u>	<u>001</u>	Nov 25, 2011
<u>AB</u>		<u>200MG</u>	<u>A078986</u>	<u>002</u>	Nov 25, 2011
<u>AB</u>		<u>300MG</u>	<u>A078986</u>	<u>003</u>	Nov 25, 2011
<u>AB</u>	NOSTRUM	<u>100MG</u>	<u>A076697</u>	<u>001</u>	May 20, 2011
<u>AB</u>		<u>200MG</u>	<u>A076697</u>	<u>002</u>	May 20, 2011
<u>AB</u>		<u>300MG</u>	<u>A076697</u>	<u>003</u>	May 20, 2011
<u>AB</u>	TARO	<u>100MG</u>	<u>A201106</u>	<u>001</u>	Jun 21, 2013
<u>AB</u>		<u>200MG</u>	<u>A201106</u>	<u>002</u>	Jun 21, 2013
<u>AB</u>		<u>300MG</u>	<u>A201106</u>	<u>003</u>	Jun 21, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A078592</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>200MG</u>	<u>A078592</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>300MG</u>	<u>A078592</u>	<u>003</u>	Sep 20, 2012

CARBATROL

<u>AB</u>	SHIRE	<u>100MG</u>	<u>N020712</u>	<u>003</u>	Sep 30, 1997
<u>AB</u>		<u>200MG</u>	<u>N020712</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020712</u>	<u>002</u>	Sep 30, 1997
EQUETRO					
	VALIDUS PHARMS INC	100MG	N021710	001	Dec 10, 2004
		200MG	N021710	002	Dec 10, 2004
	+	300MG	N021710	003	Dec 10, 2004

SUSPENSION; ORAL

CARBAMAZEPINE

<u>AB</u>	WOCKHARDT	<u>100MG/5ML</u>	<u>A075714</u>	<u>001</u>	Jun 05, 2002
<u>TEGRETOL</u>					
<u>AB</u>	+	<u>100MG/5ML</u>	<u>N018927</u>	<u>001</u>	Dec 18, 1987
<u>TERIL</u>					
<u>AB</u>	TARO	<u>100MG/5ML</u>	<u>A076729</u>	<u>001</u>	Sep 20, 2004

TABLET; ORAL

CARBAMAZEPINE

<u>AB</u>	APOTEX INC	<u>200MG</u>	<u>A075948</u>	<u>001</u>	Feb 27, 2002
<u>AB</u>	TARO	<u>200MG</u>	<u>A074649</u>	<u>001</u>	Oct 03, 1996
<u>AB</u>	TORRENT PHARMS	<u>200MG</u>	<u>A077272</u>	<u>002</u>	Dec 07, 2005
<u>EPITOL</u>					
<u>AB</u>	TEVA	<u>200MG</u>	<u>A070541</u>	<u>001</u>	Sep 17, 1986
<u>TEGRETOL</u>					
<u>AB</u>	+	<u>200MG</u>	<u>N016608</u>	<u>001</u>	
CARBAMAZEPINE					
	TORRENT PHARMS	100MG	A077272	001	Dec 07, 2005
		300MG	A077272	003	Dec 07, 2005
		400MG	A077272	004	Dec 07, 2005

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

<u>AB</u>	TARO PHARM INDS	<u>100MG</u>	<u>A075687</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>	TORRENT PHARMS	<u>100MG</u>	<u>A075712</u>	<u>001</u>	Jul 05, 2001
<u>EPITOL</u>					
<u>AB</u>	TEVA	<u>100MG</u>	<u>A073524</u>	<u>001</u>	Jul 29, 1992
<u>TEGRETOL</u>					
<u>AB</u>	+	<u>100MG</u>	<u>N018281</u>	<u>001</u>	
CARBAMAZEPINE					
	+	TARO PHARM INDS	200MG	A075687	002 Jul 29, 2002
TABLET, EXTENDED RELEASE; ORAL					
<u>CARBAMAZEPINE</u>					
<u>AB</u>	TARO	<u>100MG</u>	<u>A078115</u>	<u>001</u>	Mar 31, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-63 (of 371)

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

<u>AB</u>		<u>200MG</u>	<u>A078115</u>	<u>002</u>	Mar 31, 2009
<u>AB</u>		<u>400MG</u>	<u>A078115</u>	<u>003</u>	Mar 31, 2009
<u>TEGRETOL-XR</u>					
<u>AB</u>	NOVARTIS	<u>100MG</u>	<u>N020234</u>	<u>001</u>	Mar 25, 1996
<u>AB</u>		<u>200MG</u>	<u>N020234</u>	<u>002</u>	Mar 25, 1996
<u>AB</u>	+	<u>400MG</u>	<u>N020234</u>	<u>003</u>	Mar 25, 1996

CARBIDOPA

TABLET; ORAL

CARBIDOPA

<u>AB</u>	AMERIGEN PHARMS LTD	<u>25MG</u>	<u>A203261</u>	<u>001</u>	Mar 10, 2014
<u>LODOSYN</u>					
<u>AB</u>	+	<u>25MG</u>	<u>N017830</u>	<u>001</u>	

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG;200MG;100MG</u>	<u>A079085</u>	<u>001</u>	May 10, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085</u>	<u>002</u>	May 10, 2012
<u>AB</u>	WOCKHARDT LTD	<u>12.5MG;200MG;50MG</u>	<u>A090786</u>	<u>001</u>	Nov 20, 2012
<u>AB</u>		<u>18.75MG;200MG;75MG</u>	<u>A090833</u>	<u>001</u>	Nov 20, 2012
<u>AB</u>		<u>25MG;200MG;100MG</u>	<u>A090833</u>	<u>002</u>	Nov 20, 2012
<u>AB</u>		<u>31.25MG;200MG;125MG</u>	<u>A090833</u>	<u>003</u>	Nov 20, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A090833</u>	<u>004</u>	Nov 20, 2012
<u>AB</u>		<u>50MG;200MG;200MG</u>	<u>A090833</u>	<u>005</u>	Nov 20, 2012
<u>STALEVO 100</u>					
<u>AB</u>	ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485</u>	<u>002</u>	Jun 11, 2003
<u>STALEVO 125</u>					
<u>AB</u>	ORION PHARMA	<u>31.25MG;200MG;125MG</u>	<u>N021485</u>	<u>006</u>	Aug 29, 2008
<u>STALEVO 150</u>					
<u>AB</u>	ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485</u>	<u>003</u>	Jun 11, 2003
<u>STALEVO 200</u>					
<u>AB</u>	+	<u>50MG;200MG;200MG</u>	<u>N021485</u>	<u>004</u>	Aug 02, 2007
<u>STALEVO 50</u>					
<u>AB</u>	+	<u>12.5MG;200MG;50MG</u>	<u>N021485</u>	<u>001</u>	Jun 11, 2003
<u>STALEVO 75</u>					
<u>AB</u>	ORION PHARMA	<u>18.75MG;200MG;75MG</u>	<u>N021485</u>	<u>005</u>	Aug 29, 2008

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008
<u>AB</u>	TEVA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992
<u>SINEMET</u>					
<u>AB</u>	MERCK SHARP DOHME	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	
<u>AB</u>		<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+	<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323</u>	<u>001</u>	Feb 08, 2013
<u>AB</u>		<u>50MG;200MG</u>	<u>A202323</u>	<u>002</u>	Feb 08, 2013
<u>AB</u>	APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>	IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>		<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>	MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>		<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>	SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-64 (of 371)

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007
-----------	--	-------------------	----------------	------------	--------------

SINEMET CR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG;100MG</u>	<u>N019856</u>	<u>002</u>	Dec 24, 1992
-----------	-------------------	-------------------	----------------	------------	--------------

<u>AB</u>	+	<u>50MG;200MG</u>	<u>N019856</u>	<u>001</u>	May 30, 1991
-----------	---	-------------------	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A078893</u>	<u>001</u>	Sep 18, 2008
-----------	-------	-------------------	----------------	------------	--------------

<u>AB</u>		<u>25MG;100MG</u>	<u>A078893</u>	<u>002</u>	Sep 18, 2008
-----------	--	-------------------	----------------	------------	--------------

<u>AB</u>	+	<u>25MG;250MG</u>	<u>A078893</u>	<u>003</u>	Sep 18, 2008
-----------	---	-------------------	----------------	------------	--------------

<u>AB</u>	SUN PHARMA GLOBAL	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009
-----------	-------------------	-------------------	----------------	------------	--------------

<u>AB</u>		<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009
-----------	--	-------------------	----------------	------------	--------------

<u>AB</u>		<u>25MG;250MG</u>	<u>A078690</u>	<u>003</u>	Jul 31, 2009
-----------	--	-------------------	----------------	------------	--------------

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG/5ML</u>	<u>A090418</u>	<u>001</u>	May 04, 2010
-----------	---------------	----------------	----------------	------------	--------------

<u>AA</u>	+	<u>4MG/5ML</u>	<u>A040458</u>	<u>001</u>	Apr 25, 2003
-----------	---	----------------	----------------	------------	--------------

<u>AA</u>	VINTAGE PHARMS	<u>4MG/5ML</u>	<u>A040814</u>	<u>001</u>	Feb 26, 2008
-----------	----------------	----------------	----------------	------------	--------------

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

+	TRIS PHARMA INC	4MG/5ML	N022556	001	Mar 28, 2013
---	-----------------	---------	---------	-----	--------------

TABLET;ORAL

CARBINOXAMINE MALEATE

<u>AA</u>	CYPRESS PHARM	<u>4MG</u>	<u>A090417</u>	<u>001</u>	Aug 23, 2010
-----------	---------------	------------	----------------	------------	--------------

<u>AA</u>	INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010
-----------	----------------	------------	----------------	------------	--------------

<u>AA</u>	+	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003
-----------	---	------------	----------------	------------	--------------

<u>AA</u>	MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011
-----------	----------------------	------------	----------------	------------	--------------

<u>AA</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040639</u>	<u>002</u>	May 30, 2008
-----------	----------------	------------	----------------	------------	--------------

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

<u>AP</u>	ACTAVIS TOTOWA	<u>50MG/5ML (10MG/ML)</u>	<u>A078732</u>	<u>001</u>	Feb 06, 2012
-----------	----------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078732</u>	<u>002</u>	Feb 06, 2012
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078732</u>	<u>003</u>	Feb 06, 2012
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078732</u>	<u>004</u>	Feb 06, 2012
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
-----------	-------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	CIPLA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
-----------	-----------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	EBEWE PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
-----------	--------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	EUROHLTH INTL	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
-----------	---------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	FRESENIUS KABI ONCOL	<u>50MG/5ML (10MG/ML)</u>	<u>A077432</u>	<u>001</u>	Sep 29, 2006
-----------	----------------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077432</u>	<u>002</u>	Sep 29, 2006
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077432</u>	<u>003</u>	Sep 29, 2006
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
-----------	--------------------	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
-----------	---------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077998</u>	<u>001</u>	Apr 24, 2007
-----------	---------------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077998</u>	<u>002</u>	Apr 24, 2007
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077998</u>	<u>003</u>	Apr 24, 2007
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A091063</u>	<u>001</u>	Nov 09, 2011
-----------	--------------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A091063</u>	<u>002</u>	Nov 09, 2011
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A091063</u>	<u>003</u>	Nov 09, 2011
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A091063</u>	<u>004</u>	Nov 09, 2011
-----------	--	-----------------------------	----------------	------------	--------------

<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
-----------	---	---------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-65 (of 371)

CARBOPLATIN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	PLIVA LACHEMA	<u>50MG/5ML (10MG/ML)</u>	<u>A078631</u>	<u>001</u>	Dec 02, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078631</u>	<u>002</u>	Dec 02, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078631</u>	<u>003</u>	Dec 02, 2008
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A078631</u>	<u>004</u>	Dec 02, 2008
<u>AP</u>	SAGENT PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A077096</u>	<u>001</u>	Jun 14, 2005
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077096</u>	<u>002</u>	Jun 14, 2005
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077096</u>	<u>003</u>	Jun 14, 2005
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077096</u>	<u>004</u>	Jun 03, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A077139</u>	<u>001</u>	Sep 21, 2005
<u>AP</u>	+	<u>150MG/15ML (10MG/ML)</u>	<u>A077139</u>	<u>002</u>	Sep 21, 2005
<u>AP</u>	+	<u>450MG/45ML (10MG/ML)</u>	<u>A077139</u>	<u>003</u>	Sep 21, 2005
<u>AP</u>	+	<u>600MG/60ML (10MG/ML)</u>	<u>A077139</u>	<u>004</u>	Sep 21, 2005
	+ ONCO THERAPIES LTD	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

HEMABATE

+ PHARMACIA AND UPJOHN EQ 0.25MG BASE/ML N017989 001

CARELIZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS 60MG/VIAL N202714 001 Jul 20, 2012

CARGLUMIC ACID

TABLET; ORAL

CARBAGLU

+ ORPHAN EUROPE 200MG N022562 001 Mar 18, 2010

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACCELRX LABS	<u>350MG</u>	<u>A040576</u>	<u>001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792</u>	<u>001</u>	Aug 06, 2009
<u>AA</u>	MIRROR PHARMS	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	MUTUAL PHARM	<u>350MG</u>	<u>A089346</u>	<u>001</u>	Oct 17, 1991
<u>AA</u>	NATCO PHARMA LTD	<u>350MG</u>	<u>A090988</u>	<u>001</u>	Oct 28, 2014
<u>AA</u>	ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085</u>	<u>001</u>	Oct 28, 2014
<u>AA</u>	SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>	SUN PHARM INDS LTD	<u>350MG</u>	<u>A040755</u>	<u>001</u>	Feb 27, 2007
<u>AA</u>	VINTAGE PHARMS	<u>350MG</u>	<u>A040245</u>	<u>001</u>	Sep 08, 1997
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
	<u>SOMA</u>				
<u>AA</u>	MEDA PHARMS	<u>350MG</u>	<u>N011792</u>	<u>001</u>	
	+	250MG	N011792	004	Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+ ARBOR PHARMS LLC 7.7MG N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

+ EMCURE PHARMS LTD 100MG/VIAL N017422 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

<u>AT</u>	ALCON	<u>1%</u>	<u>A075476</u>	<u>001</u>	Jan 03, 2000
<u>AT</u>	BAUSCH AND LOMB	<u>1%</u>	<u>A075546</u>	<u>001</u>	Jan 20, 2000
	<u>OCUPRESS</u>				
<u>AT</u>	+	<u>1%</u>	<u>N019972</u>	<u>001</u>	May 23, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-66 (of 371)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>	APOTEX INC	<u>3.125MG</u>	<u>A078165 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078165 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078165 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078165 004</u>	Sep 05, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>3.125MG</u>	<u>A078332 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078332 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078332 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078332 004</u>	Sep 05, 2007
<u>AB</u>	BEXIMCO USA	<u>3.125MG</u>	<u>A078384 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078384 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078384 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078384 004</u>	Sep 05, 2007
<u>AB</u>	CIPLA LTD	<u>3.125MG</u>	<u>A077474 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077474 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077474 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077474 004</u>	Sep 05, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>3.125MG</u>	<u>A076649 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076649 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076649 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076649 004</u>	Sep 05, 2007
<u>AB</u>	GLENMARK GENERICS	<u>3.125MG</u>	<u>A078251 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078251 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078251 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078251 004</u>	Sep 05, 2007
<u>AB</u>	HIKMA	<u>3.125MG</u>	<u>A077887 001</u>	Sep 07, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077887 002</u>	Sep 07, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077887 003</u>	Sep 07, 2007
<u>AB</u>		<u>25MG</u>	<u>A077887 004</u>	Sep 07, 2007
<u>AB</u>	LUPIN	<u>3.125MG</u>	<u>A078217 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078217 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078217 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078217 004</u>	Sep 05, 2007
<u>AB</u>	MYLAN	<u>3.125MG</u>	<u>A077316 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077316 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077316 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077316 004</u>	Sep 05, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>3.125MG</u>	<u>A078240 001</u>	Oct 30, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078240 002</u>	Oct 30, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078240 003</u>	Oct 30, 2007
<u>AB</u>		<u>25MG</u>	<u>A078240 004</u>	Oct 30, 2007
<u>AB</u>	RANBAXY	<u>3.125MG</u>	<u>A076989 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989 004</u>	Sep 05, 2007
<u>AB</u>	SANDOZ	<u>3.125MG</u>	<u>A078227 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A078227 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227 004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS INC	<u>3.125MG</u>	<u>A077346 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077346 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077346 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077346 003</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780 004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373 001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373 002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373 003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373 004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614 004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614 001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614 002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614 003</u>	Sep 05, 2007
<u>COREG</u>				
<u>AB</u>	SMITHKLINE BEECHAM	<u>3.125MG</u>	<u>N020297 004</u>	May 29, 1997
<u>AB</u>		<u>6.25MG</u>	<u>N020297 003</u>	Sep 14, 1995
<u>AB</u>	+	<u>12.5MG</u>	<u>N020297 002</u>	Sep 14, 1995
<u>AB</u>		<u>25MG</u>	<u>N020297 001</u>	Sep 14, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-67 (of 371)

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

COREG CR

SB PHARMCO

10MG

N022012 001 Oct 20, 2006

20MG

N022012 002 Oct 20, 2006

+

40MG

N022012 003 Oct 20, 2006

80MG

N022012 004 Oct 20, 2006

CASPOFUNGIN ACETATE

INJECTABLE; IV (INFUSION)

CANCIDAS

+ MERCK

50MG/VIAL

N021227 001 Jan 26, 2001

+

70MG/VIAL

N021227 002 Jan 26, 2001

CEFACIOR

CAPSULE; ORAL

CEFACIORAB HIKMAEQ 250MG BASEA065350 001 Apr 03, 2007AB +EQ 500MG BASEA065350 002 Apr 03, 2007AB YUNG SHIN PHARMEQ 250MG BASEA065146 001 Jan 22, 2004ABEQ 500MG BASEA065146 002 Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACIORAB YUNG SHIN PHARMEQ 125MG BASE/5MLA065412 001 Feb 17, 2012ABEQ 187MG BASE/5MLA065412 002 Feb 17, 2012ABEQ 250MG BASE/5MLA065412 003 Feb 17, 2012AB +EQ 375MG BASE/5MLA065412 004 Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACIOR

TEVA

EQ 375MG BASE

A065058 001 Sep 04, 2002

+

EQ 500MG BASE

A065058 002 Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXILAB AUROBINDO PHARMAEQ 500MG BASEA065352 001 Jan 25, 2007AB

HIKMA

EQ 500MG BASEA065311 001 Feb 07, 2006AB

LUPIN

EQ 500MG BASEA065392 001 May 29, 2007AB

ORCHID HLTHCARE

EQ 500MG BASEA065309 001 Sep 18, 2006AB

SANDOZ

EQ 500MG BASEA062291 001AB +

TEVA PHARMS

EQ 500MG BASEA065282 001 Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXILAB AUROBINDOEQ 250MG BASE/5MLA065349 001 Apr 25, 2013ABEQ 500MG BASE/5MLA065349 002 Apr 25, 2013AB

HIKMA PHARMS

EQ 250MG BASE/5MLA091036 001 Nov 28, 2012AB

LUPIN

EQ 500MG BASE/5MLA091036 002 Nov 28, 2012AB

LUPIN

EQ 250MG BASE/5MLA065396 001 Feb 21, 2008AB +

LUPIN

EQ 500MG BASE/5MLA065396 002 Feb 21, 2008AB

ORCHID HLTHCARE

EQ 250MG BASE/5MLA065307 002 Oct 16, 2006AB

ORCHID HLTHCARE

EQ 500MG BASE/5MLA065307 003 Oct 16, 2006AB

RANBAXY

EQ 250MG BASE/5MLA065115 002 Mar 26, 2003AB

RANBAXY

EQ 500MG BASE/5MLA065115 003 Mar 26, 2003

EQ 125MG BASE/5ML

A065115 001 Mar 26, 2003

TABLET; ORAL

CEFADROXILAB HIKMAEQ 1GM BASEA065260 001 Mar 30, 2006AB

ORCHID HLTHCARE

EQ 1GM BASEA065301 001 Sep 18, 2006

+

TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUMAP ACS DOBFAREQ 1GM BASE/VIALA065303 002 Oct 22, 2008APEQ 10GM BASE/VIALA065306 001 Oct 22, 2008APEQ 20GM BASE/VIALA065306 002 Aug 18, 2014APEQ 500MG BASE/VIALA065303 001 Oct 22, 2008AP

HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA065047 002 Sep 18, 2001APEQ 10GM BASE/VIALA065143 001 Oct 18, 2004APEQ 500MG BASE/VIALA065047 001 Sep 18, 2001AP +

HOSPIRA INC

EQ 1GM BASE/VIALA065226 002 Apr 21, 2005AP +

HOSPIRA INC

EQ 1GM BASE/VIALA065244 001 Aug 12, 2005AP +

HOSPIRA INC

EQ 10GM BASE/VIALA065247 001 Aug 12, 2005AP +

HOSPIRA INC

EQ 500MG BASE/VIALA065226 001 Apr 21, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-68 (of 371)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062831</u>	<u>002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062831</u>	<u>001</u>	Dec 09, 1988
<u>AP</u>	STERI PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A063207</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A063209</u>	<u>001</u>	Dec 27, 1991
<u>AP</u>	+	<u>EQ 20GM BASE/VIAL</u>	<u>A063209</u>	<u>002</u>	Apr 30, 1999
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A063214</u>	<u>001</u>	Dec 27, 1991

KEFZOL

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A061773</u>	<u>003</u>	
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A061773</u>	<u>004</u>	
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A061773</u>	<u>002</u>	
	ANCEF IN PLASTIC CONTAINER				
	+ BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991
	+	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991
	CEFAZOLIN AND DEXTROSE				
	+ B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012
	CEFAZOLIN SODIUM				
	+ SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
	+	EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	+	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001
	+	400MG	N021222	002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065369</u>	<u>002</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202268</u>	<u>001</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065369</u>	<u>003</u>	Jun 18, 2007
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202268</u>	<u>002</u>	Jul 30, 2012
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065369</u>	<u>001</u>	Jun 18, 2007

MAXIPIME

<u>AP</u>	+	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+		<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996
<u>AP</u>	+		<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

	B BRAUN	EQ 1GM BASE/VIAL	N050821	001	May 06, 2010
		EQ 2GM BASE/VIAL	N050821	002	May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

	+ BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N050817	001	Aug 05, 2008
	+	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N050817	002	Aug 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-69 (of 371)

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001 Jun 01, 2012

FOR SUSPENSION; ORAL

SUPRAX

+ LUPIN LTD

500MG/5ML

N202091 001 Feb 20, 2013

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004

200MG/5ML

A065355 001 Apr 10, 2007

TABLET; ORAL

SUPRAX

+ LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

TABLET, CHEWABLE; ORAL

SUPRAX

LUPIN LTD

100MG

A065380 001 Oct 25, 2010

150MG

A065380 002 Oct 25, 2010

+

200MG

A065380 003 Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

AP HIKMA

EQ 1GM BASE/VIALA065072 002 Nov 20, 2002

AP

EQ 2GM BASE/VIALA065072 003 Nov 20, 2002

AP

EQ 10GM BASE/VIALA065071 001 Nov 20, 2002

AP

EQ 500MG BASE/VIALA065072 001 Nov 20, 2002

AP

WOCKHARDT

EQ 1GM BASE/VIALA065197 001 Aug 29, 2006CEFOTAXIME SODIUM

AP HOSPIRA INC

EQ 1GM BASE/VIALA065290 002 Aug 11, 2006

AP

EQ 1GM BASE/VIALA065293 001 Aug 10, 2006

AP

EQ 2GM BASE/VIALA065290 003 Aug 11, 2006

AP

EQ 2GM BASE/VIALA065293 002 Aug 10, 2006

AP

EQ 10GM BASE/VIALA065292 001 Aug 10, 2006

AP

EQ 500MG BASE/VIALA065290 001 Aug 11, 2006

AP

LUPIN

EQ 1GM BASE/VIALA065124 002 Sep 24, 2003

AP

EQ 2GM BASE/VIALA065124 003 Sep 24, 2003

AP

EQ 500MG BASE/VIALA065124 001 Sep 24, 2003

AP

WOCKHARDT

EQ 2GM BASE/VIALA065197 003 Jun 20, 2008

AP

EQ 500MG BASE/VIALA065197 002 Jun 20, 2008CLAFORAN

AP + SANOFI AVENTIS US

EQ 1GM BASE/VIALA062659 001 Jan 13, 1987

AP

+

EQ 1GM BASE/VIALN050547 002

AP

+

EQ 2GM BASE/VIALA062659 002 Jan 13, 1987

AP

+

EQ 2GM BASE/VIALN050547 003

AP

+

EQ 10GM BASE/VIALN050547 004 Dec 29, 1983

AP

+

EQ 500MG BASE/VIALN050547 001

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ SANOFI AVENTIS US

EQ 20MG BASE/ML

N050596 002 May 20, 1985

+

EQ 40MG BASE/ML

N050596 004 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTETAN

AP + FRESENIUS KABI USA

EQ 1GM BASE/VIALA065374 001 Aug 09, 2007

AP

+

EQ 2GM BASE/VIALA065374 002 Aug 09, 2007

AP

+

EQ 10GM BASE/VIALA065375 001 Aug 09, 2007

AP

WEST-WARD PHARM CORP

EQ 1GM BASE/VIALA091031 001 Oct 26, 2011

AP

EQ 2GM BASE/VIALA091031 002 Oct 26, 2011

AP

EQ 10GM BASE/VIALA091030 001 Oct 26, 2011

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

+ B BRAUN

EQ 1GM BASE/VIAL

A065430 001 Aug 09, 2007

+

EQ 2GM BASE/VIAL

A065430 002 Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP + ACS DOBFAR

EQ 1GM BASE/VIALA065414 001 Jun 12, 2009

AP

+

EQ 2GM BASE/VIALA065414 002 Jun 12, 2009

AP

+

EQ 10GM BASE/VIALA065415 001 May 19, 2010

AP

ANTIBIOTICOS BRASIL

EQ 1GM BASE/VIALA065467 001 Aug 31, 2011

AP

EQ 2GM BASE/VIALA065467 002 Aug 31, 2011

AP

EQ 10GM BASE/VIALA065464 001 Aug 31, 2011

AP

HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA065238 001 Mar 12, 2010

AP

EQ 2GM BASE/VIALA065238 002 Mar 12, 2010

AP

EQ 10GM BASE/VIALA065239 001 Mar 02, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-70 (of 371)

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

<u>AP</u>	HIKMA MAPLE	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
<u>AP</u>	HOSPIRA INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065313</u>	<u>001</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065313</u>	<u>002</u>	Jan 23, 2006
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065312</u>	<u>001</u>	Feb 13, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>A065214</u>	<u>001</u>	Mar 10, 2006
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065214</u>	<u>002</u>	Mar 10, 2006
	MEFOXIN IN PLASTIC CONTAINER				
	+ MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	+	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 50MG BASE/5ML</u>	<u>A065409</u>	<u>001</u>	Jun 08, 2007
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065409</u>	<u>002</u>	Jun 08, 2007
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE/5ML</u>	<u>A065082</u>	<u>001</u>	May 31, 2002
<u>AB</u>		<u>EQ 100MG BASE/5ML</u>	<u>A065082</u>	<u>002</u>	May 31, 2002
<u>AB</u>	SANDOZ	<u>EQ 50MG BASE/5ML</u>	<u>A090031</u>	<u>001</u>	Jan 14, 2009
<u>AB</u>	+	<u>EQ 100MG BASE/5ML</u>	<u>A090031</u>	<u>002</u>	Jan 14, 2009

TABLET; ORAL

CEFPODOXIME PROXETIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
<u>AB</u>	RANBAXY	<u>EQ 100MG BASE</u>	<u>A065083</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A065083</u>	<u>002</u>	Aug 20, 2003
<u>AB</u>	SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>125MG/5ML</u>	<u>A065351</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>250MG/5ML</u>	<u>A065351</u>	<u>002</u>	Feb 29, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
<u>AB</u>	LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>	+	<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065284</u>	<u>002</u>	Dec 30, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065284</u>	<u>001</u>	Dec 30, 2005
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065257</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065257</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065236</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>250MG/5ML</u>	<u>A065236</u>	<u>002</u>	Dec 08, 2005

TABLET; ORAL

CEFPROZIL

<u>AB</u>	APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>		<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	+	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	ORCHID HLTHCARE	<u>250MG</u>	<u>A065267</u>	<u>001</u>	Dec 19, 2005
<u>AB</u>		<u>500MG</u>	<u>A065267</u>	<u>002</u>	Dec 19, 2005
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065428</u>	<u>001</u>	Jun 14, 2007
<u>AB</u>		<u>500MG</u>	<u>A065428</u>	<u>002</u>	Jun 14, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-71 (of 371)

CEFTAROLINE FOSAMIL

POWDER; IV (INFUSION)

TEFLARO

CEREXA

400MG/VIAL

N200327 001 Oct 29, 2010

+

600MG/VIAL

N200327 002 Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AP ACS DOBFAR

1GM/VIALA062640 002 Nov 20, 1985

AP

2GM/VIALA062640 003 Nov 20, 1985

AP

6GM/VIALA062640 004 Feb 03, 1992

AP

500MG/VIALA062640 001 Nov 20, 1985

AP

WOCKHARDT

1GM/VIALA065196 001 Oct 15, 2008FORTAZ

AP + COVIS INJECTABLES

1GM/VIALN050578 002 Jul 19, 1985

AP

+

2GM/VIALN050578 003 Jul 19, 1985

AP

+

6GM/VIALN050578 004 Jul 19, 1985

AP

+

500MG/VIALN050578 001 Jul 19, 1985TAZICEF

AP HOSPIRA

1GM/VIALA062662 002 Mar 06, 1986

AP

1GM/VIALA064032 001 Oct 31, 1993

AP

2GM/VIALA062662 003 Mar 06, 1986

AP

2GM/VIALA064032 002 Oct 31, 1993

AP

6GM/VIALA062662 004 Mar 06, 1986

AP

500MG/VIALA062662 001 Mar 06, 1986

CEFTAZIDIME IN DEXTROSE CONTAINER

B BRAUN

EQ 1GM BASE

N050823 001 Jun 13, 2011

+

EQ 2GM BASE

N050823 002 Jun 13, 2011

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

+ COVIS INJECTABLES

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

+ PERNIX THERAP

EQ 400MG BASE

N050685 002 Dec 20, 1995

FOR SUSPENSION; ORAL

CEDAX

+ PERNIX THERAP

EQ 90MG BASE/5ML

N050686 001 Dec 20, 1995

+

EQ 180MG BASE/5ML

N050686 002 Dec 20, 1995

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)

ZERBAXA

+ CUBIST PHARMS

EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL

N206829 001 Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AP ACS DOBFAR

EQ 1GM BASE/VIALA065329 002 Jul 24, 2008

AP

EQ 2GM BASE/VIALA065329 003 Jul 24, 2008

AP

EQ 10GM BASE/VIALA065328 001 Jul 24, 2008

AP

EQ 500MG BASE/VIALA065329 001 Jul 24, 2008

AP

BEDFORD

EQ 10GM BASE/VIALA065475 001 Aug 18, 2008

AP

HOSPIRA INC

EQ 1GM BASE/VIALA065231 001 Aug 02, 2005

AP

EQ 1GM BASE/VIALA202563 001 Aug 20, 2012

AP

EQ 2GM BASE/VIALA065231 002 Aug 02, 2005

AP

EQ 2GM BASE/VIALA202563 002 Aug 20, 2012

AP

EQ 10GM BASE/VIALA065232 001 Aug 02, 2005

AP

LUPIN

EQ 10GM BASE/VIALA065263 001 Sep 12, 2006

AP

+ SANDOZ

EQ 10GM BASE/VIALA065168 001 May 17, 2005

AP

+ SANDOZ INC

EQ 1GM BASE/VIALA065204 001 May 03, 2005

AP

+

EQ 2GM BASE/VIALA065204 002 May 03, 2005

AP

STERI PHARMA

EQ 10GM BASE/VIALA065269 001 Feb 28, 2007

AP

WOCKHARDT

EQ 1GM BASE/VIALA065180 001 May 12, 2006CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

AP + B BRAUN

EQ 1GM BASE/VIALN050796 001 Apr 20, 2005

AP

+

EQ 2GM BASE/VIALN050796 002 Apr 20, 2005ROCEPHIN

AP + HOFFMANN LA ROCHE

EQ 1GM BASE/VIALA063239 003 Aug 13, 1993

AP

+

EQ 500MG BASE/VIALA063239 002 Aug 13, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-72 (of 371)

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

SAMSON MEDCL

EQ 100GM BASE/VIAL

A090057 001 Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 20MG BASE/ML

A065224 001 Aug 23, 2005

+

EQ 40MG BASE/ML

A065224 002 Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP AKORN INC

EQ 1GM BASE/VIALA065305 003 Jan 11, 2008

AP

EQ 2GM BASE/VIALA065305 004 Jan 11, 2008

AP

EQ 250MG BASE/VIALA065305 001 Jan 11, 2008

AP

EQ 500MG BASE/VIALA065305 002 Jan 11, 2008

AP

BEDFORD

EQ 1GM BASE/VIALA065465 003 Aug 18, 2008

AP

EQ 2GM BASE/VIALA065465 004 Aug 18, 2008

AP

EQ 250MG BASE/VIALA065465 001 Aug 18, 2008

AP

EQ 500MG BASE/VIALA065465 002 Aug 18, 2008

AP

FRESENIUS KABI USA

EQ 250MG BASE/VIALA065245 001 Feb 15, 2006

AP

HIKMA FARMACEUTICA

EQ 1GM BASE/VIALA065342 003 Jan 10, 2008

AP

EQ 2GM BASE/VIALA065342 004 Jan 10, 2008

AP

EQ 250MG BASE/VIALA065342 001 Jan 10, 2008

AP

EQ 500MG BASE/VIALA065342 002 Jan 10, 2008

AP

HOSPIRA INC

EQ 1GM BASE/VIALA065230 003 Aug 02, 2005

AP

EQ 2GM BASE/VIALA065230 004 Aug 02, 2005

AP

EQ 250MG BASE/VIALA065230 001 Aug 02, 2005

AP

EQ 500MG BASE/VIALA065230 002 Aug 02, 2005

AP

LUPIN

EQ 1GM BASE/VIALA065125 003 Sep 30, 2003

AP

EQ 2GM BASE/VIALA065125 004 Sep 30, 2003

AP

EQ 250MG BASE/VIALA065125 001 Sep 30, 2003

AP

EQ 500MG BASE/VIALA065125 002 Sep 30, 2003

AP

+ SANDOZ

EQ 1GM BASE/VIALA065169 003 May 09, 2005

AP

+

EQ 2GM BASE/VIALA065169 004 May 09, 2005

AP

+

EQ 250MG BASE/VIALA065169 001 May 09, 2005

AP

+

EQ 500MG BASE/VIALA065169 002 May 09, 2005

AP

WOCKHARDT

EQ 2GM BASE/VIALA065391 003 Apr 12, 2007

AP

EQ 250MG BASE/VIALA065391 001 Apr 12, 2007

AP

EQ 500MG BASE/VIALA065391 002 Apr 12, 2007CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

AB GLAXOSMITHKLINE

EQ 125MG BASE/5MLN050672 001 Jun 30, 1994

AB

+

EQ 250MG BASE/5MLN050672 002 Apr 29, 1997CEFUROXIME AXETIL

AB RANBAXY

EQ 125MG BASE/5MLA065323 001 Feb 05, 2008

AB

EQ 250MG BASE/5MLA065323 002 Feb 05, 2008

TABLET; ORAL

CEFTIN

AB GLAXOSMITHKLINE

EQ 125MG BASEN050605 001 Dec 28, 1987

AB

EQ 250MG BASEN050605 002 Dec 28, 1987

AB

+

EQ 500MG BASEN050605 003 Dec 28, 1987CEFUROXIME AXETIL

AB ALKEM LABS LTD

EQ 250MG BASEA065496 001 Jun 07, 2010

AB

EQ 500MG BASEA065496 002 Jun 07, 2010

AB

APOTEX

EQ 250MG BASEA065069 001 Oct 02, 2002

AB

EQ 500MG BASEA065069 002 Oct 02, 2002

AB

AUROBINDO PHARMA LTD

EQ 125MG BASEA065308 001 Mar 29, 2006

AB

EQ 250MG BASEA065308 002 Mar 29, 2006

AB

EQ 500MG BASEA065308 003 Mar 29, 2006

AB

LUPIN

EQ 250MG BASEA065135 001 Jul 25, 2003

AB

EQ 500MG BASEA065135 002 Jul 25, 2003

AB

ORCHID HLTHCARE

EQ 125MG BASEA065359 001 Feb 15, 2008

AB

EQ 250MG BASEA065359 002 Feb 15, 2008

AB

EQ 500MG BASEA065359 003 Feb 15, 2008

AB

RANBAXY

EQ 125MG BASEA065118 001 Apr 25, 2003

AB

EQ 250MG BASEA065118 002 Apr 25, 2003

AB

EQ 500MG BASEA065118 003 Apr 25, 2003

AB

TEVA

EQ 250MG BASEA065190 001 Oct 18, 2004

AB

EQ 500MG BASEA065190 002 Oct 18, 2004

AB

WOCKHARDT

EQ 125MG BASEA065166 001 Jul 29, 2005

AB

EQ 250MG BASEA065166 002 Jul 29, 2005

AB

EQ 500MG BASEA065166 003 Jul 29, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-73 (of 371)

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	B BRAUN	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780</u>	<u>002</u>	Feb 21, 2001
<u>AP</u>	+		<u>EQ 750MG BASE/VIAL</u>	<u>N050780</u>	<u>001</u>	Feb 21, 2001

CEFUROXIME SODIUM

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048</u>	<u>002</u>	Jan 09, 2004
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046</u>	<u>001</u>	Jan 09, 2004
<u>AP</u>		HOSPIRA INC	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065483</u>	<u>002</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 1.5GM BASE/VIAL</u>	<u>A065503</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A065484</u>	<u>001</u>	Oct 15, 2008
<u>AP</u>		STERI PHARMA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125</u>	<u>002</u>	May 30, 1997
<u>AP</u>			<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124</u>	<u>001</u>	May 30, 1997

ZINACEF

<u>AP</u>	+	COVIS INJECTABLES	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558</u>	<u>003</u>	Oct 19, 1983
<u>AP</u>	+		<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558</u>	<u>004</u>	Oct 23, 1986

ZINACEF IN PLASTIC CONTAINER

+ COVIS INJECTABLES EQ 30MG BASE/ML

N050643 002 Apr 28, 1989

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

<u>AB</u>		HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048</u>	<u>001</u>	Jan 09, 2004
<u>AB</u>		STERI PHARMA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125</u>	<u>001</u>	May 30, 1997

ZINACEF

<u>AB</u>	+	COVIS INJECTABLES	<u>EQ 750MG BASE/VIAL</u>	<u>N050558</u>	<u>002</u>	Oct 19, 1983
-----------	---	-------------------	---------------------------	----------------	------------	--------------

CEFUROXIME SODIUM

<u>AP</u>		HOSPIRA INC	<u>EQ 750MG BASE/VIAL</u>	<u>A065483</u>	<u>001</u>	Oct 15, 2008
-----------	--	-------------	---------------------------	----------------	------------	--------------

CELECOXIB

CAPSULE; ORAL

CELEBREX

<u>AB</u>		GD SEARLE	<u>50MG</u>	<u>N020998</u>	<u>004</u>	Dec 15, 2006
<u>AB</u>			<u>100MG</u>	<u>N020998</u>	<u>001</u>	Dec 31, 1998
<u>AB</u>			<u>200MG</u>	<u>N020998</u>	<u>002</u>	Dec 31, 1998
<u>AB</u>	+		<u>400MG</u>	<u>N020998</u>	<u>003</u>	Aug 29, 2002

CELECOXIB

<u>AB</u>		LUPIN LTD	<u>50MG</u>	<u>A202240</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		MYLAN PHARMS INC	<u>50MG</u>	<u>A078857</u>	<u>001</u>	May 30, 2014
<u>AB</u>		TEVA	<u>50MG</u>	<u>A076898</u>	<u>001</u>	May 30, 2014
<u>AB</u>			<u>100MG</u>	<u>A076898</u>	<u>002</u>	May 30, 2014
<u>AB</u>			<u>200MG</u>	<u>A076898</u>	<u>003</u>	May 30, 2014
<u>AB</u>			<u>400MG</u>	<u>A076898</u>	<u>004</u>	May 30, 2014

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

<u>AB</u>		ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A090836</u>	<u>001</u>	Dec 20, 2010
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A090836</u>	<u>002</u>	Dec 20, 2010
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A090836</u>	<u>004</u>	Mar 29, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A065253</u>	<u>001</u>	Nov 16, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065253</u>	<u>002</u>	Nov 16, 2005
<u>AB</u>		BELCHER PHARMS	<u>EQ 250MG BASE</u>	<u>A062713</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A062713</u>	<u>002</u>	Jul 15, 1988
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A065215</u>	<u>001</u>	Jan 24, 2006
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065215</u>	<u>002</u>	Jan 24, 2006
<u>AB</u>		LUPIN	<u>EQ 250MG BASE</u>	<u>A065229</u>	<u>001</u>	Nov 25, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065229</u>	<u>002</u>	Nov 25, 2005
<u>AB</u>		ORCHID HLTHCARE	<u>EQ 250MG BASE</u>	<u>A065248</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065248</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		RANBAXY	<u>EQ 250MG BASE</u>	<u>A065007</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065007</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>		SUN PHARM INDS (IN)	<u>EQ 250MG BASE</u>	<u>A062791</u>	<u>001</u>	Jun 11, 1987
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A062791</u>	<u>002</u>	Jun 11, 1987
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A062702</u>	<u>001</u>	Feb 13, 1987
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A062702</u>	<u>002</u>	Feb 13, 1987
<u>AB</u>		YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065152</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A065152</u>	<u>002</u>	Feb 24, 2005

KEFLEX

<u>AB</u>		SHIONOGI INC	<u>EQ 250MG BASE</u>	<u>N050405</u>	<u>002</u>	
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>N050405</u>	<u>003</u>	
<u>AB</u>	+		<u>EQ 750MG BASE</u>	<u>N050405</u>	<u>005</u>	May 12, 2006

CEPHALEXIN

ALKEM LABS LTD EQ 333MG BASE

A090836 003 Mar 29, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-74 (of 371)

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB	LUPIN	<u>EQ 125MG BASE/5ML</u>	<u>A065234</u>	<u>001</u>	Aug 17, 2005
AB		<u>EQ 250MG BASE/5ML</u>	<u>A065234</u>	<u>002</u>	Aug 17, 2005
AB	ORCHID HLTHCARE	<u>EQ 125MG BASE/5ML</u>	<u>A065326</u>	<u>001</u>	Jul 10, 2006
AB		<u>EQ 250MG BASE/5ML</u>	<u>A065326</u>	<u>002</u>	Jul 10, 2006
AB	TEVA	<u>EQ 125MG BASE/5ML</u>	<u>A062703</u>	<u>001</u>	Feb 13, 1987
AB	+	<u>EQ 250MG BASE/5ML</u>	<u>A062703</u>	<u>002</u>	Feb 13, 1987
TABLET; ORAL					
CEPHALEXIN					
	TEVA	EQ 250MG BASE	A063023	001	Jan 12, 1989
	+	EQ 500MG BASE	A063024	001	Jan 12, 1989

CERITINIB

CAPSULE; ORAL

ZYKADIA

+	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014
---	----------------------	-------	---------	-----	--------------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	<u>5MG/5ML</u>	<u>A090766</u>	<u>001</u>	Oct 07, 2009
AA	BIO PHARM INC	<u>5MG/5ML</u>	<u>A078870</u>	<u>001</u>	Apr 27, 2009
AA	BRECKENRIDGE PHARM	<u>5MG/5ML</u>	<u>A078488</u>	<u>001</u>	Oct 06, 2008
AA	PERRIGO R AND D	<u>5MG/5ML</u>	<u>A078398</u>	<u>001</u>	Jun 17, 2008
AA	SILARX	<u>5MG/5ML</u>	<u>A078876</u>	<u>001</u>	May 11, 2012
AA	SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A090191</u>	<u>001</u>	Nov 12, 2009
AA	TARO	<u>5MG/5ML</u>	<u>A076601</u>	<u>001</u>	Jun 20, 2008
AA	TEVA PHARMS	<u>5MG/5ML</u>	<u>A077279</u>	<u>001</u>	May 27, 2008
AA	VINTAGE	<u>5MG/5ML</u>	<u>A078496</u>	<u>001</u>	Sep 25, 2009
AA	WOCKHARDT	<u>5MG/5ML</u>	<u>A078757</u>	<u>001</u>	Aug 28, 2009

ZYRTEC

AA	+	MCNEIL CONSUMER	<u>5MG/5ML</u>	<u>N020346</u>	<u>001</u>	Sep 27, 1996
-----------	---	-----------------	-----------------------	-----------------------	-------------------	--------------

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

+	EMD SERONO INC	EQ 0.25MG BASE/ML	N021197	001	Aug 11, 2000
---	----------------	-------------------	---------	-----	--------------

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE

<u>AB</u>	APOTEX INC	<u>30MG</u>	<u>A091260</u>	<u>001</u>	Aug 25, 2011
<u>CEVIMELINE HYDROCHLORIDE</u>					
<u>AB</u>	PACK PHARMS LLC	<u>30MG</u>	<u>A203775</u>	<u>001</u>	Jun 04, 2014
<u>AB</u>	ROXANE	<u>30MG</u>	<u>A091591</u>	<u>001</u>	Jul 08, 2013
<u>EVOXAC</u>					
<u>AB</u>	+ DAIICHI SANKYO	<u>30MG</u>	<u>N020989</u>	<u>002</u>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

+	NEXGEN PHARMA	250MG	A091019	001	Oct 22, 2009
---	---------------	-------	---------	-----	--------------

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669	002	
---	------------------	-----	---------	-----	--

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

+	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982
---	--------------------	------------------	---------	-----	--------------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	BARR	<u>5MG</u>	<u>A084768</u>	<u>001</u>	
AB		<u>10MG</u>	<u>A083116</u>	<u>001</u>	
AB		<u>25MG</u>	<u>A084769</u>	<u>001</u>	
AB	USL PHARMA	<u>10MG</u>	<u>A084623</u>	<u>001</u>	
<u>LIBRIUM</u>					
AB	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461</u>	<u>001</u>	
AB		<u>10MG</u>	<u>A085472</u>	<u>001</u>	
AB	+	<u>25MG</u>	<u>A085475</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-75 (of 371)

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	<u>0.12%</u>	<u>A074356</u>	<u>001</u>	May 07, 1996
AT	LYNE	<u>0.12%</u>	<u>A074291</u>	<u>001</u>	Dec 28, 1995
AT	TEVA	<u>0.12%</u>	<u>A074522</u>	<u>001</u>	Dec 15, 1995
AT	WOCKHARDT	<u>0.12%</u>	<u>A075006</u>	<u>001</u>	Mar 03, 2004
AT	XTTRIUM	<u>0.12%</u>	<u>A077789</u>	<u>001</u>	Jun 18, 2009
<u>PAROEX</u>					
AT	SUNSTAR AMERICAS	<u>0.12%</u>	<u>A076434</u>	<u>001</u>	Nov 29, 2005
<u>PERIDEX</u>					
AT	+ 3M	<u>0.12%</u>	<u>N019028</u>	<u>001</u>	Aug 13, 1986
<u>PERIOGARD</u>					
AT	COLGATE	<u>0.12%</u>	<u>A073695</u>	<u>001</u>	Jan 14, 1994
TABLET; DENTAL					
PERIOCHIP					
	+ DEXCEL PHARMA	2.5MG	N020774	001	May 15, 1998

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP	EUROHLTH INTL	<u>2%</u>	<u>A040273</u>	<u>001</u>	Sep 09, 1998
AP		<u>3%</u>	<u>A040273</u>	<u>002</u>	Sep 09, 1998
AP	HOSPIRA	<u>2%</u>	<u>A087447</u>	<u>001</u>	Apr 16, 1982
AP		<u>3%</u>	<u>A087446</u>	<u>001</u>	Apr 16, 1982
<u>NESACAINE</u>					
AP	FRESENIUS KABI USA	<u>2%</u>	<u>N009435</u>	<u>002</u>	
<u>NESACAINE-MPF</u>					
AP	+ FRESENIUS KABI USA	<u>2%</u>	<u>N009435</u>	<u>006</u>	May 02, 1996
AP	+ NESACAINE	<u>3%</u>	<u>N009435</u>	<u>007</u>	May 02, 1996
	+ FRESENIUS KABI USA	1%	N009435	001	

CHLOROQUINE PHOSPHATE

TABLET; ORAL

ARALEN

AA	+ SANOFI AVENTIS US	<u>EQ 300MG BASE</u>	<u>N006002</u>	<u>001</u>	
<u>CHLOROQUINE PHOSPHATE</u>					
AA	+ HIKMA PHARMS LLC	<u>EQ 150MG BASE</u>	<u>A083082</u>	<u>001</u>	
AA		<u>EQ 300MG BASE</u>	<u>A083082</u>	<u>002</u>	Sep 17, 1999
AA	IMPAX LABS	<u>EQ 150MG BASE</u>	<u>A080880</u>	<u>001</u>	
AA		<u>EQ 300MG BASE</u>	<u>A040516</u>	<u>001</u>	Aug 29, 2003
AA	IPCA LABS LTD	<u>EQ 150MG BASE</u>	<u>A090610</u>	<u>001</u>	Dec 03, 2009
AA		<u>EQ 300MG BASE</u>	<u>A090249</u>	<u>001</u>	Dec 03, 2009
AA	NATCO PHARMA LTD	<u>EQ 150MG BASE</u>	<u>A091621</u>	<u>001</u>	Jan 21, 2011
AA		<u>EQ 300MG BASE</u>	<u>A090612</u>	<u>001</u>	Jan 21, 2011

CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+ SALIX PHARMS

250MG/5ML

N011870 001

TABLET; ORAL

CHLOROTHIAZIDE

+ MYLAN

250MG

A084388 001

500MG

A084217 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090896</u>	<u>001</u>	Oct 16, 2009
AP	LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202561</u>	<u>001</u>	Apr 22, 2013
AP	MYLAN INSTITUTIONAL	<u>EQ 500MG BASE/VIAL</u>	<u>A202493</u>	<u>001</u>	Jun 18, 2014
AP	SUN PHARMA GLOBAL	<u>EQ 500MG BASE/VIAL</u>	<u>A091546</u>	<u>001</u>	Jul 26, 2011
<u>DIURIL</u>					
AP	+ OAK PHARMS AKORN	<u>EQ 500MG BASE/VIAL</u>	<u>N011145</u>	<u>005</u>	

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+ CYPRESS PHARM

4MG/5ML; 5MG/5ML

N204307 001 Feb 20, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-76 (of 371)

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	TRIS PHARMA INC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A203838 001</u>	Nov 26, 2014
-----------	-----------------	-----------------------------------	--------------------	--------------

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>A204627 001</u>	Apr 29, 2014
-----------	-------------	-----------------------------------	--------------------	--------------

ZUTRIPRO

AA	+ CYPRESS PHARM	<u>4MG/5ML; 5MG/5ML; 60MG/5ML</u>	<u>N022439 001</u>	Jun 08, 2011
-----------	-----------------	-----------------------------------	--------------------	--------------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE; EQ 5MG BITARTRATE

A077273 002 Sep 24, 2007

+

EQ 8MG MALEATE; EQ 10MG BITARTRATE

A077273 001 Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	TRIS PHARMA INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091632 001</u>	Oct 01, 2010
-----------	-----------------	---	--------------------	--------------

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

AB	NEOS THERAP INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>A091671 001</u>	Jun 29, 2012
-----------	-----------------	---	--------------------	--------------

TUSSIONEX PENNKINETIC

AB	+ UCB INC	<u>EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML</u>	<u>N019111 001</u>	Dec 31, 1987
-----------	-----------	---	--------------------	--------------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ HIKMA MAPLE

25MG/ML

A083329 001

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

BP	SANDOZ	10MG	A080439 001	
BP		25MG	A080439 002	
BP		50MG	A080439 003	
BP	+	100MG	A080439 004	
BP		200MG	A080439 005	
BP	USL PHARMA	10MG	A083386 001	
BP		25MG	A084112 001	
BP		50MG	A084113 001	
BP		100MG	A084114 001	
BP		200MG	A084115 001	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

AB	ANI PHARMS INC	<u>100MG</u>	<u>A088921 001</u>	Apr 12, 1985
AB		<u>250MG</u>	<u>A088922 001</u>	Apr 12, 1985
AB	MYLAN	<u>100MG</u>	<u>A088549 002</u>	Jun 01, 1984
AB		<u>250MG</u>	<u>A088549 001</u>	Jun 01, 1984

DIABINESE

AB	PFIZER	<u>100MG</u>	<u>N011641 003</u>	
AB	+	<u>250MG</u>	<u>N011641 006</u>	

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

MYLAN

25MG

A086831 002

+

50MG

A086831 001

THALITONE

+ CITRON PHARMA LLC

15MG

N019574 001 Dec 20, 1988

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLORPRES

MYLAN

15MG; 0.1MG

A071325 003 Feb 09, 1987

15MG; 0.2MG

A071325 002 Feb 09, 1987

+

15MG; 0.3MG

A071325 001 Feb 09, 1987

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	BARR	<u>500MG</u>	<u>A089895 001</u>	May 04, 1988
AA	WATSON LABS	<u>500MG</u>	<u>A089859 001</u>	May 04, 1988
	<u>PARAFON FORTE DSC</u>			
AA	+ JANSSEN R AND D	<u>500MG</u>	<u>N011529 002</u>	Jun 15, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-77 (of 371)

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

MIKART

375MG

A040861 001 Jun 01, 2010

750MG

A040861 002 Jun 01, 2010

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE**AB** PAR PHARMEQ 4GM RESIN/PACKETA077204 001 Aug 26, 2005**AB**EQ 4GM RESIN/SCOOPFULA077204 002 Aug 26, 2005**AB** + SANDOZEQ 4GM RESIN/PACKETA074557 001 Aug 15, 1996**AB**EQ 4GM RESIN/SCOOPFULA074557 002 Aug 15, 1996CHOLESTYRAMINE LIGHT**AB** PAR PHARMEQ 4GM RESIN/PACKETA077203 001 Aug 26, 2005**AB**EQ 4GM RESIN/SCOOPFULA077203 002 Aug 26, 2005**AB** + SANDOZEQ 4GM RESIN/PACKETA074558 001 Aug 15, 1996**AB**EQ 4GM RESIN/SCOOPFULA074558 002 Aug 15, 1996PREVALITE**AB** UPSHER SMITHEQ 4GM RESIN/PACKETA073263 001 Feb 22, 1996**AB**EQ 4GM RESIN/SCOOPFULA073263 002 Oct 30, 1997CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

+ MCPRF

4-33.1mCi/ML

N203155 001 Sep 12, 2012

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID**AB** ANCHEN PHARMSEQ 45MG FENOFIBRIC ACIDA201573 002 Jul 18, 2013**AB**EQ 135MG FENOFIBRIC ACIDA201573 001 Jul 18, 2013**AB** LUPIN LTDEQ 45MG FENOFIBRIC ACIDA200750 001 Dec 04, 2013**AB**EQ 135MG FENOFIBRIC ACIDA200750 002 Dec 04, 2013**AB** MYLAN PHARMS INCEQ 45MG FENOFIBRIC ACIDA200913 001 Mar 25, 2013**AB**EQ 135MG FENOFIBRIC ACIDA200913 002 Mar 25, 2013TRILIPIX**AB** ABBVIEEQ 45MG FENOFIBRIC ACIDN022224 001 Dec 15, 2008**AB** +EQ 135MG FENOFIBRIC ACIDN022224 002 Dec 15, 2008CHORIOGONADOTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

OVIDREL

+ EMD SERONO

EQ 0.25MG /0.5ML

N021149 002 Oct 06, 2003

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.004MG CHROMIUM/ML

N018961 001 Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

+

0.16MG/INH

N021658 003 Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+ TAKEDA GMBH

0.037MG/INH

N202129 001 Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+ TAKEDA GMBH

0.05MG/INH

N022004 001 Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS0.77%A076435 001 Dec 29, 2004**AB** G AND W LABS INC0.77%A078463 001 Dec 20, 2010**AB** GLENMARK PHARMS0.77%A090273 001 Nov 10, 2009**AB** PERRIGO0.77%A077364 001 Mar 03, 2006**AB** TARO0.77%A076790 001 Apr 12, 2005LOPROX**AB** + MEDIMETRIKS PHARMS0.77%N018748 001 Dec 30, 1982

GEL; TOPICAL

CICLOPIROX**AB** FOUGERA PHARMS0.77%A077896 001 Jun 10, 2008**AB** GLENMARK GENERICS0.77%A091595 001 Feb 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-78 (of 371)

CICLOPIROX

GEL; TOPICAL

CICLOPIROX

AB	PADDOCK LLC	<u>0.77%</u>	<u>A078266</u>	<u>001</u>	Jan 07, 2009
-----------	-------------	--------------	-----------------------	-------------------	--------------

LOPROX

AB	+ CNTY LINE PHARMS	<u>0.77%</u>	<u>N020519</u>	<u>001</u>	Jul 21, 1997
-----------	--------------------	--------------	-----------------------	-------------------	--------------

SHAMPOO; TOPICAL

CICLOPIROX

AT	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A090490</u>	<u>001</u>	Nov 24, 2009
-----------	----------------------	-----------	-----------------------	-------------------	--------------

AT	FOUGERA PHARMS	<u>1%</u>	<u>A090146</u>	<u>001</u>	May 25, 2010
-----------	----------------	-----------	-----------------------	-------------------	--------------

AT	PERRIGO	<u>1%</u>	<u>A078594</u>	<u>001</u>	Feb 16, 2010
-----------	---------	-----------	-----------------------	-------------------	--------------

AT	TARO	<u>1%</u>	<u>A090269</u>	<u>001</u>	Feb 23, 2011
-----------	------	-----------	-----------------------	-------------------	--------------

LOPROX

AT	+ MEDICIS	<u>1%</u>	<u>N021159</u>	<u>001</u>	Feb 28, 2003
-----------	-----------	-----------	-----------------------	-------------------	--------------

SOLUTION; TOPICAL

CICLOPIROX

AT	ACTAVIS MID ATLANTIC	<u>8%</u>	<u>A078046</u>	<u>001</u>	Sep 18, 2007
-----------	----------------------	-----------	-----------------------	-------------------	--------------

AT	CIPLA LTD	<u>8%</u>	<u>A078124</u>	<u>001</u>	Sep 18, 2007
-----------	-----------	-----------	-----------------------	-------------------	--------------

AT	G AND W LABS	<u>8%</u>	<u>A078233</u>	<u>001</u>	Sep 18, 2007
-----------	--------------	-----------	-----------------------	-------------------	--------------

AT	HI TECH PHARMA	<u>8%</u>	<u>A078270</u>	<u>001</u>	Sep 18, 2007
-----------	----------------	-----------	-----------------------	-------------------	--------------

AT	PERRIGO NEW YORK	<u>8%</u>	<u>A077623</u>	<u>001</u>	Sep 18, 2007
-----------	------------------	-----------	-----------------------	-------------------	--------------

AT	TARO PHARM INDS	<u>8%</u>	<u>A078144</u>	<u>001</u>	Sep 18, 2007
-----------	-----------------	-----------	-----------------------	-------------------	--------------

AT	TOLMAR	<u>8%</u>	<u>A077687</u>	<u>001</u>	Sep 18, 2007
-----------	--------	-----------	-----------------------	-------------------	--------------

AT	VERSAPHARM	<u>8%</u>	<u>A078975</u>	<u>001</u>	Feb 17, 2010
-----------	------------	-----------	-----------------------	-------------------	--------------

PENLAC

AT	+ VALEANT BERMUDA	<u>8%</u>	<u>N021022</u>	<u>001</u>	Dec 17, 1999
-----------	-------------------	-----------	-----------------------	-------------------	--------------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	<u>0.77%</u>	<u>A076422</u>	<u>001</u>	Aug 06, 2004
-----------	----------------	--------------	-----------------------	-------------------	--------------

AB	PERRIGO NEW YORK	<u>0.77%</u>	<u>A077676</u>	<u>001</u>	Dec 15, 2006
-----------	------------------	--------------	-----------------------	-------------------	--------------

AB	TARO	<u>0.77%</u>	<u>A077092</u>	<u>001</u>	Aug 10, 2005
-----------	------	--------------	-----------------------	-------------------	--------------

LOPROX

AB	+ MEDIMETRIKS PHARMS	<u>0.77%</u>	<u>N019824</u>	<u>001</u>	Dec 30, 1988
-----------	----------------------	--------------	-----------------------	-------------------	--------------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	<u>EQ 75MG BASE/ML</u>	<u>A202501</u>	<u>001</u>	Jul 26, 2012
-----------	-------------------	------------------------	-----------------------	-------------------	--------------

AP	MYLAN INSTITUTIONAL	<u>EQ 75MG BASE/ML</u>	<u>A201276</u>	<u>001</u>	Jun 27, 2012
-----------	---------------------	------------------------	-----------------------	-------------------	--------------

VISTIDE

AP	+ GILEAD SCIENCES INC	<u>EQ 75MG BASE/ML</u>	<u>N020638</u>	<u>001</u>	Jun 26, 1996
-----------	-----------------------	------------------------	-----------------------	-------------------	--------------

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

AP	ACS DOBFAR	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A090577</u>	<u>001</u>	Dec 21, 2011
-----------	------------	---------------------------------------	-----------------------	-------------------	--------------

AP		<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A090577</u>	<u>002</u>	Dec 21, 2011
-----------	--	---------------------------------------	-----------------------	-------------------	--------------

AP	HOSPIRA INC	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>A090825</u>	<u>001</u>	Nov 16, 2011
-----------	-------------	---------------------------------------	-----------------------	-------------------	--------------

AP		<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A090825</u>	<u>002</u>	Nov 16, 2011
-----------	--	---------------------------------------	-----------------------	-------------------	--------------

AP		<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>A091007</u>	<u>001</u>	Nov 16, 2011
-----------	--	---------------------------------------	-----------------------	-------------------	--------------

PRIMAXIN

AP	+ MERCK	<u>EQ 250MG BASE/VIAL; 250MG/VIAL</u>	<u>N050587</u>	<u>001</u>	Nov 26, 1985
-----------	---------	---------------------------------------	-----------------------	-------------------	--------------

AP	+	<u>EQ 500MG BASE/VIAL; 500MG/VIAL</u>	<u>N050587</u>	<u>002</u>	Nov 26, 1985
-----------	---	---------------------------------------	-----------------------	-------------------	--------------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	APOTEX INC	<u>50MG</u>	<u>A077030</u>	<u>001</u>	Dec 10, 2004
-----------	------------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077030</u>	<u>002</u>	Dec 10, 2004
-----------	--	--------------	-----------------------	-------------------	--------------

AB	BIOKEY	<u>50MG</u>	<u>A077722</u>	<u>001</u>	Sep 24, 2012
-----------	--------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077831</u>	<u>001</u>	Sep 24, 2012
-----------	--	--------------	-----------------------	-------------------	--------------

AB	BRECKENRIDGE PHARM	<u>50MG</u>	<u>A077708</u>	<u>001</u>	Sep 28, 2009
-----------	--------------------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077708</u>	<u>002</u>	Sep 28, 2009
-----------	--	--------------	-----------------------	-------------------	--------------

AB	MYLAN	<u>50MG</u>	<u>A077323</u>	<u>002</u>	Apr 20, 2006
-----------	-------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077323</u>	<u>001</u>	Apr 20, 2006
-----------	--	--------------	-----------------------	-------------------	--------------

AB	MYLAN PHARMS INC	<u>50MG</u>	<u>A077019</u>	<u>001</u>	Nov 23, 2004
-----------	------------------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077019</u>	<u>002</u>	Nov 23, 2004
-----------	--	--------------	-----------------------	-------------------	--------------

AB	PLIVA HRVATSKA DOO	<u>50MG</u>	<u>A077898</u>	<u>001</u>	Oct 29, 2007
-----------	--------------------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077898</u>	<u>002</u>	Oct 29, 2007
-----------	--	--------------	-----------------------	-------------------	--------------

AB	ROXANE	<u>50MG</u>	<u>A077024</u>	<u>001</u>	May 17, 2005
-----------	--------	-------------	-----------------------	-------------------	--------------

AB		<u>100MG</u>	<u>A077024</u>	<u>002</u>	May 17, 2005
-----------	--	--------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-79 (of 371)

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A077310</u>	<u>001</u>	Nov 08, 2005
<u>AB</u>		<u>100MG</u>	<u>A077021</u>	<u>001</u>	Nov 23, 2004
<u>AB</u>	TEVA	<u>50MG</u>	<u>A077027</u>	<u>001</u>	Nov 24, 2004
<u>AB</u>		<u>100MG</u>	<u>A077027</u>	<u>002</u>	Nov 24, 2004

PLETAL

<u>AB</u>	+	OTSUKA	<u>50MG</u>	<u>N020863</u>	<u>001</u>	Jan 15, 1999
<u>AB</u>	+		<u>100MG</u>	<u>N020863</u>	<u>002</u>	Jan 15, 1999

CIMETIDINE

TABLET; ORAL

CIMETIDINE

<u>AB</u>	APOTEX	<u>200MG</u>	<u>A074890</u>	<u>001</u>	Dec 18, 1998
<u>AB</u>		<u>300MG</u>	<u>A074890</u>	<u>002</u>	Dec 18, 1998
<u>AB</u>		<u>400MG</u>	<u>A074890</u>	<u>003</u>	Dec 18, 1998
<u>AB</u>		<u>800MG</u>	<u>A074890</u>	<u>004</u>	Dec 18, 1998
<u>AB</u>	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
<u>AB</u>	+	<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
<u>AB</u>	PLIVA	<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
<u>AB</u>	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
<u>AB</u>		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
<u>AB</u>		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
<u>AB</u>		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

<u>AP</u>	DAVA PHARMS INC	<u>EQ 300MG BASE/2ML</u>	<u>A074428</u>	<u>001</u>	Apr 25, 1996
-----------	-----------------	--------------------------	----------------	------------	--------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

<u>AA</u>		ANI PHARMS INC	<u>EQ 300MG BASE/5ML</u>	<u>A074610</u>	<u>001</u>	Sep 26, 1996
<u>AA</u>	+	HI TECH PHARMA	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
<u>AA</u>		PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
<u>AA</u>		WOCKHARDT	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

SENSIPAR

AMGEN

EQ 30MG BASE

N021688 001 Mar 08, 2004

EQ 60MG BASE

N021688 002 Mar 08, 2004

+

EQ 90MG BASE

N021688 003 Mar 08, 2004CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>250MG/5ML</u>	<u>N020780</u>	<u>001</u>	Sep 26, 1997
<u>AB</u>	+	<u>500MG/5ML</u>	<u>N020780</u>	<u>002</u>	Sep 26, 1997

CIPROFLOXACIN

<u>AB</u>	LUPIN LTD	<u>250MG/5ML</u>	<u>A200563</u>	<u>001</u>	Mar 05, 2014
<u>AB</u>		<u>500MG/5ML</u>	<u>A200563</u>	<u>002</u>	Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

<u>AP</u>	+	BAYER HLTHCARE	<u>400MG/40ML (10MG/ML)</u>	<u>N019847</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>200MG/20ML (10MG/ML)</u>	<u>N019847</u>	<u>002</u>	Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	BAYER HLTHCARE	<u>200MG/100ML</u>	<u>N019857</u>	<u>001</u>	Dec 26, 1990
<u>AP</u>	+		<u>400MG/200ML</u>	<u>N019857</u>	<u>002</u>	Dec 26, 1990

CIPROFLOXACIN

<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009
<u>AP</u>	HOSPIRA	<u>200MG/20ML (10MG/ML)</u>	<u>A077245</u>	<u>001</u>	Aug 28, 2006
<u>AP</u>		<u>400MG/40ML (10MG/ML)</u>	<u>A077245</u>	<u>002</u>	Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	CLARIS LIFESCIENCES	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-80 (of 371)

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+ ALCON PHARMS LTD

EQ 0.3% BASE

N020369 001 Mar 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+ ALCON PHARMS LTD	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990
-----------	--------------------	---------------------	----------------	------------	--------------

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>	AKORN INC	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>	FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>	IGI LABS INC	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>	NEXUS PHARMS	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>	PHARMAFORCE	<u>EQ 0.3% BASE</u>	<u>A078598</u>	<u>001</u>	Jan 16, 2008
<u>AT</u>	WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRAXAL

+ WRASER PHARMS

EQ 0.2% BASE

N021918 001 May 01, 2009

TABLET; ORAL

CIPRO

<u>AB</u>	BAYER HLTHCARE	<u>EQ 100MG BASE</u>	<u>N019537</u>	<u>001</u>	Apr 08, 1996
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>N019537</u>	<u>004</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>	CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	MYLAN	<u>EQ 100MG BASE</u>	<u>A075817</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075685</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A075817</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075685</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075685</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075817</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>	RANBAXY	<u>EQ 250MG BASE</u>	<u>A075747</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075747</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075747</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>	TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
<u>AB</u>	UNIQUE PHARM LABS	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
<u>AB</u>	WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
<u>AB</u>		<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-81 (of 371)

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+ ALCON PHARMS LTD EQ 0.2% BASE;1%

N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASEAB ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASEA077417 001 Nov 30, 2010AB 425.2MG;EQ 574.9MG BASEA077809 001 Nov 30, 2010AB ANCHEN PHARMS 212.6MG;EQ 287.5MG BASEA078166 002 Nov 27, 2007AB 425.2MG;EQ 574.9MG BASEA078166 001 Nov 27, 2007AB DR REDDYS LABS LTD 425.2MG;EQ 574.9MG BASEA077701 001 Mar 26, 2007AB + MYLAN PHARMS INC 212.6MG;EQ 287.5MG BASEA078183 001 Mar 22, 2007AB + 425.2MG;EQ 574.9MG BASEA078183 002 Mar 22, 2007CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

+ ALCON PHARMS LTD 0.3%;0.1%

N021537 001 Jul 18, 2003

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATEAP SANDOZ INC EQ 2MG BASE/MLA200159 001 Feb 03, 2012CISATRACURIUM BESYLATE PRESERVATIVE FREEAP SANDOZ INC EQ 2MG BASE/MLA200154 001 Feb 03, 2012AP EQ 10MG BASE/MLA200154 002 Feb 03, 2012NIMBEXAP + ABBVIE EQ 2MG BASE/MLN020551 001 Dec 15, 1995NIMBEX PRESERVATIVE FREEAP + ABBVIE EQ 2MG BASE/MLN020551 003 Dec 15, 1995AP + EQ 10MG BASE/MLN020551 002 Dec 15, 1995CISPLATIN

INJECTABLE;INJECTION

CISPLATINAP EUROHLTH INTL 1MG/MLA075036 001 Nov 07, 2000AP + FRESenius KABI USA 1MG/MLA074735 001 Jul 16, 1999AP HQ SPCLT PHARMA 1MG/MLN018057 004 Nov 08, 1988AP ONCO THERAPIES LTD 1MG/MLA091062 001 Apr 18, 2012AP PHARMACHEMIE BV 1MG/MLA074656 001 May 16, 2000CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

+ EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDEAA AUROBINDO PHARMA LTD EQ 10MG BASE/5MLA077812 001 Aug 28, 2006AA + ROXANE EQ 10MG BASE/5MLA077043 001 Dec 13, 2004AA SILARX EQ 10MG BASE/5MLA077629 001 Jun 15, 2006

TABLET;ORAL

CELEXAAB FOREST LABS EQ 10MG BASEN020822 001 Apr 27, 2000AB EQ 20MG BASEN020822 002 Jul 17, 1998AB + EQ 40MG BASEN020822 003 Jul 17, 1998CITALOPRAM HYDROBROMIDEAB AMNEAL PHARMS NY EQ 10MG BASEA077289 001 Nov 30, 2006AB EQ 20MG BASEA077289 002 Nov 30, 2006AB EQ 40MG BASEA077289 003 Nov 30, 2006AB APOTEX INC EQ 10MG BASEA077046 001 Nov 24, 2004AB EQ 20MG BASEA077046 002 Nov 24, 2004AB EQ 40MG BASEA077046 003 Nov 24, 2004AB AUROBINDO EQ 10MG BASEA077031 001 Oct 28, 2004AB EQ 20MG BASEA077031 002 Oct 28, 2004AB EQ 40MG BASEA077031 003 Oct 28, 2004AB CIPLA LTD EQ 10MG BASEA077044 001 Nov 05, 2004AB EQ 20MG BASEA077044 002 Nov 05, 2004AB EQ 40MG BASEA077044 003 Nov 05, 2004AB DR REDDYS LABS LTD EQ 10MG BASEA077038 001 Oct 28, 2004AB EQ 20MG BASEA077038 002 Oct 28, 2004AB EQ 40MG BASEA077038 003 Oct 28, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-82 (of 371)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	EPIC PHARMA	EQ 10MG BASE	A077045 003	Apr 29, 2005
AB		EQ 20MG BASE	A077045 002	Apr 29, 2005
AB		EQ 40MG BASE	A077045 001	Apr 29, 2005
AB	GLENMARK GENERICS	EQ 10MG BASE	A077654 001	Feb 27, 2009
AB		EQ 20MG BASE	A077654 002	Feb 27, 2009
AB		EQ 40MG BASE	A077654 003	Feb 27, 2009
AB	INVAGEN PHARMS	EQ 10MG BASE	A077534 001	Oct 03, 2006
AB		EQ 20MG BASE	A077534 002	Oct 03, 2006
AB		EQ 40MG BASE	A077534 003	Oct 03, 2006
AB	MYLAN	EQ 10MG BASE	A077039 001	Feb 03, 2005
AB		EQ 10MG BASE	A077042 001	Nov 05, 2004
AB		EQ 20MG BASE	A077039 002	Feb 03, 2005
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004
AB		EQ 40MG BASE	A077039 003	Feb 03, 2005
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004
AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037 001	Nov 05, 2004
AB		EQ 20MG BASE	A077037 002	Nov 05, 2004
AB		EQ 40MG BASE	A077037 003	Nov 05, 2004
AB	PLIVA	EQ 10MG BASE	A077232 001	Oct 31, 2005
AB		EQ 20MG BASE	A077232 002	Oct 31, 2005
AB		EQ 40MG BASE	A077232 003	Oct 31, 2005
AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032 001	Nov 12, 2004
AB		EQ 20MG BASE	A077032 002	Nov 12, 2004
AB		EQ 40MG BASE	A077032 003	Nov 12, 2004
AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004
AB		EQ 20MG BASE	A077048 002	Nov 16, 2004
AB		EQ 40MG BASE	A077048 003	Nov 16, 2004
AB	TORRENT PHARMS	EQ 10MG BASE	A078216 001	Mar 27, 2007
AB		EQ 20MG BASE	A078216 002	Mar 27, 2007
AB		EQ 40MG BASE	A078216 003	Mar 27, 2007

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION

RENACIDIN

+ UNITED GUARDIAN 6.602GM/100ML; 198MG/100ML; 3.177GM/100ML N019481 001 Oct 02, 1990

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+ FERRING PHARMS AS 12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET N202535 001 Jul 16, 2012

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+ EXALENZ BIOSCIENCE N/A, 4GM; 75MG, N/A N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

AP	EUROHLTH INTL	1MG/ML	A075405 001	Feb 28, 2000
AP	+ FRESenius KABI USA	1MG/ML	A076571 001	Apr 22, 2004
AP	ONCO THERAPIES LTD	1MG/ML	A200510 001	Oct 06, 2011

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

AB	ABBVIE	125MG/5ML	N050698 001	Dec 23, 1993
AB	+	250MG/5ML	N050698 002	Dec 23, 1993

CLARITHROMYCIN

AB	RANBAXY	125MG/5ML	A065382 001	Aug 30, 2007
AB		250MG/5ML	A065382 002	Aug 30, 2007
AB	SANDOZ	125MG/5ML	A065283 002	Sep 04, 2007
AB		250MG/5ML	A065283 003	Sep 04, 2007

TABLET; ORAL

BIAXIN

AB	+ ABBVIE	250MG	N050662 001	Oct 31, 1991
AB	+	500MG	N050662 002	Oct 31, 1991

CLARITHROMYCIN

AB	ALLIED PHARMA INC	250MG	A202710 001	Jun 10, 2013
AB		500MG	A202710 002	Jun 10, 2013
AB	APOTEX CORP	250MG	A065384 001	Aug 20, 2007
AB		500MG	A065384 002	Aug 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-83 (of 371)

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

<u>AB</u>	AUROBINDO	<u>250MG</u>	<u>A065489</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>		<u>500MG</u>	<u>A065489</u>	<u>002</u>	Jul 25, 2012
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A065195</u>	<u>001</u>	Mar 11, 2005
<u>AB</u>		<u>500MG</u>	<u>A065195</u>	<u>002</u>	Mar 11, 2005
<u>AB</u>	RANBAXY	<u>250MG</u>	<u>A065174</u>	<u>001</u>	Sep 24, 2004
<u>AB</u>		<u>500MG</u>	<u>A065174</u>	<u>002</u>	Sep 24, 2004
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A065178</u>	<u>002</u>	May 25, 2004
<u>AB</u>		<u>500MG</u>	<u>A065178</u>	<u>001</u>	May 25, 2004
<u>AB</u>	SANDOZ	<u>250MG</u>	<u>A065144</u>	<u>001</u>	Oct 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A065136</u>	<u>001</u>	Aug 25, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065155</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>500MG</u>	<u>A065155</u>	<u>002</u>	May 31, 2005
<u>AB</u>	WOCKHARDT	<u>250MG</u>	<u>A065266</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>500MG</u>	<u>A065266</u>	<u>002</u>	May 31, 2006

TABLET, EXTENDED RELEASE; ORAL

BIAXIN XL

<u>AB</u>	+ ABBVIE	<u>500MG</u>	<u>N050775</u>	<u>001</u>	Mar 03, 2000
-----------	----------	--------------	----------------	------------	--------------

CLARITHROMYCIN

<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A065145</u>	<u>001</u>	Jun 24, 2004
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065154</u>	<u>001</u>	May 18, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

	+ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL; EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987
		EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986
	+	EQ 100MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985
	+	EQ 200MG BASE/VIAL; EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985

TIMENTIN IN PLASTIC CONTAINER

	+ GLAXOSMITHKLINE	EQ 100MG BASE/100ML; EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989
--	-------------------	--	---------	-----	--------------

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

<u>AA</u>	+ TEVA	<u>EQ 0.5MG BASE/5ML</u>	<u>A073399</u>	<u>001</u>	Jun 30, 1994
<u>AA</u>	WOCKHARDT	<u>EQ 0.5MG BASE/5ML</u>	<u>A074863</u>	<u>001</u>	Mar 13, 1998

TABLET; ORAL

CLEMASTINE FUMARATE

<u>AB</u>	SANDOZ	<u>2.68MG</u>	<u>A073459</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>	+ TEVA	<u>2.68MG</u>	<u>A073283</u>	<u>001</u>	Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

	+ MEDICINES CO	25MG/50ML (0.5MG/ML)	N022156	001	Aug 01, 2008
	+	50MG/100ML (0.5MG/ML)	N022156	002	Aug 01, 2008
	+	125MG/250ML (0.5MG/ML)	N022156	003	Nov 08, 2013

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE

<u>AB</u>	PHARMACIA AND UPJOHN	<u>EQ 75MG BASE</u>	<u>N050162</u>	<u>001</u>	
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>N050162</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N050162</u>	<u>003</u>	Apr 14, 1988

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A065442</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065442</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>	COREPHARMA	<u>EQ 150MG BASE</u>	<u>A065194</u>	<u>001</u>	Mar 22, 2004
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065194</u>	<u>002</u>	Mar 22, 2004
<u>AB</u>	LANNETT	<u>EQ 75MG BASE</u>	<u>A065242</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065242</u>	<u>002</u>	Aug 12, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065243</u>	<u>001</u>	Aug 12, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A091225</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091225</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091225</u>	<u>003</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A063029</u>	<u>001</u>	Sep 20, 1989
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063029</u>	<u>002</u>	Aug 05, 2005
<u>AB</u>	WATSON LABS	<u>EQ 150MG BASE</u>	<u>A063083</u>	<u>001</u>	Jul 31, 1991
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A063083</u>	<u>002</u>	Mar 18, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-84 (of 371)

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217 001</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065217 002</u>	Jan 31, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A065217 003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

<u>AA</u>	+ PHARMACIA AND UPJOHN	<u>EQ 75MG BASE/5ML</u>	<u>A062644 001</u>	Apr 07, 1986
-----------	------------------------	-------------------------	--------------------	--------------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 75MG BASE/5ML</u>	<u>A203513 001</u>	Mar 13, 2014
<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE/5ML</u>	<u>A202409 001</u>	Apr 30, 2013
<u>AA</u>	LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821 001</u>	Aug 28, 2012
<u>AA</u>	PADDOCK LABS	<u>EQ 75MG BASE/5ML</u>	<u>A090902 001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

CLINDAMYCIN PHOSPHATE

<u>AT</u>	PERRIGO UK FINCO	<u>1%</u>	<u>A090785 001</u>	Mar 31, 2010
-----------	------------------	-----------	--------------------	--------------

EVOCLIN

<u>AT</u>	+ DELCOR ASSET	<u>1%</u>	<u>N050801 001</u>	Oct 22, 2004
-----------	----------------	-----------	--------------------	--------------

CREAM;VAGINAL

CLEOCIN

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 2% BASE</u>	<u>N050680 002</u>	Mar 02, 1998
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139 001</u>	Dec 27, 2004
-----------	----------------	-------------------	--------------------	--------------

CLINDESSE

+ ELAN PHARMA INTL LTD EQ 2% BASE

N050793 001 Nov 30, 2004

GEL;TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050615 001</u>	Jan 07, 1987
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160 001</u>	Jan 28, 2000
-----------	----------------	-------------------	--------------------	--------------

CLINDAGEL

BT	+ PRECISION DERMAT	EQ 1% BASE	N050782 001	Nov 27, 2000
----	--------------------	------------	-------------	--------------

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

<u>AP</u>	PHARMACIA AND UPJOHN	<u>EQ 150MG BASE/ML</u>	<u>A062803 001</u>	Oct 16, 1987
-----------	----------------------	-------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 150MG BASE/ML</u>	<u>N050441 001</u>	
-----------	---	-------------------------	--------------------	--

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 6MG BASE/ML</u>	<u>N050639 001</u>	Aug 30, 1989
-----------	------------------------	-----------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 12MG BASE/ML</u>	<u>N050639 002</u>	Aug 30, 1989
-----------	---	------------------------	--------------------	--------------

<u>AP</u>	+	<u>EQ 18MG BASE/ML</u>	<u>N050639 003</u>	Apr 10, 1991
-----------	---	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AP</u>	BEDFORD	<u>EQ 150MG BASE/ML</u>	<u>A065206 001</u>	Sep 24, 2004
-----------	---------	-------------------------	--------------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346 001</u>	Mar 29, 2007
-----------	--------------------	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A065347 001</u>	May 09, 2007
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>	HIKMA MAPLE	<u>EQ 150MG BASE/ML</u>	<u>A062889 001</u>	Apr 25, 1988
-----------	-------------	-------------------------	--------------------	--------------

<u>AP</u>	HOSPIRA	<u>EQ 150MG BASE/ML</u>	<u>A062800 001</u>	Jul 24, 1987
-----------	---------	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062801 001</u>	Jul 24, 1987
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 150MG BASE/ML</u>	<u>A062943 001</u>	Sep 29, 1988
-----------	--	-------------------------	--------------------	--------------

<u>AP</u>	SAGENT PHARMS	<u>EQ 150MG BASE/ML</u>	<u>A090108 001</u>	Sep 30, 2011
-----------	---------------	-------------------------	--------------------	--------------

<u>AP</u>	SAGENT STRIDES	<u>EQ 150MG BASE/ML</u>	<u>A090109 001</u>	Sep 30, 2011
-----------	----------------	-------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	AKORN INC	<u>EQ 6MG BASE/ML</u>	<u>A203048 001</u>	Apr 04, 2013
-----------	-----------	-----------------------	--------------------	--------------

<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A203048 002</u>	Apr 04, 2013
-----------	--	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A203048 003</u>	Apr 04, 2013
-----------	--	------------------------	--------------------	--------------

<u>AP</u>	SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692 001</u>	May 31, 2012
-----------	------------	-----------------------	--------------------	--------------

<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A201692 002</u>	May 31, 2012
-----------	--	------------------------	--------------------	--------------

<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A201692 003</u>	May 31, 2012
-----------	--	------------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+ ABRAXIS PHARM EQ 900MG BASE/100ML

N050635 001 Dec 22, 1989

LOTION;TOPICAL

CLEOCIN T

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050600 001</u>	May 31, 1989
-----------	------------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067 001</u>	Jan 31, 2002
-----------	----------------	-------------------	--------------------	--------------

SOLUTION;TOPICAL

CLEOCIN T

<u>AT</u>	+ PHARMACIA AND UPJOHN	<u>EQ 1% BASE</u>	<u>N050537 001</u>	
-----------	------------------------	-------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-85 (of 371)

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDA-DERM

AT	PADDOCK LLC	EQ 1% BASE	A063329 001	Sep 30, 1992
-----------	-------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT	FOUGERA	EQ 1% BASE	A064159 001	Jun 05, 1997
AT	FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006
AT	G AND W LABS INC	EQ 1% BASE	A062811 001	Sep 01, 1988
AT	PERRIGO NEW YORK	EQ 1% BASE	A064050 001	Nov 30, 1995
AT	TARO PHARM INDS	EQ 1% BASE	A065184 001	Mar 31, 2004
AT	WOCKHARDT	EQ 1% BASE	A063304 001	Jul 15, 1997

SUPPOSITORY; VAGINAL

CLEOCIN

+ PHARMACIA AND UPJOHN

100MG

N050767 001 Aug 13, 1999

SWAB; TOPICAL

CLEOCIN

AT	PHARMACIA AND UPJOHN	EQ 1% BASE	N050537 002	Feb 22, 1994
-----------	----------------------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE

AT	PERRIGO NEW YORK	EQ 1% BASE	A065049 001	May 25, 2000
AT	VERSAPHARM	EQ 1% BASE	A065513 001	Jun 17, 2010

CLINDETS

AT	PERRIGO	EQ 1% BASE	A064136 001	Sep 30, 1996
-----------	---------	-------------------	--------------------	--------------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+ STIEFEL GSK	1.2%; 0.025%	N050803 001	Jul 16, 2010
-----------	---------------	--------------	-------------	--------------

ZIANA

BX	+ MEDICIS	1.2%; 0.025%	N050802 001	Nov 07, 2006
-----------	-----------	--------------	-------------	--------------

CLOBAZAM

SUSPENSION; ORAL

ONFI

+ LUNDBECK LLC

2.5MG/ML

N203993 001 Dec 14, 2012

TABLET; ORAL

ONFI

+ LUNDBECK LLC

10MG

N202067 002 Oct 21, 2011

+

20MG

N202067 003 Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008
------------	----------------	--------------	--------------------	--------------

OLUX

AB1	+ DELCOR ASSET	0.05%	N021142 001	May 26, 2000
------------	----------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE

AB2	PERRIGO ISRAEL	0.05%	A201402 001	Aug 14, 2012
------------	----------------	--------------	--------------------	--------------

OLUX E

AB2	+ DELCOR ASSET	0.05%	N022013 001	Jan 12, 2007
------------	----------------	--------------	--------------------	--------------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	FOUGERA	0.05%	A074392 001	Sep 30, 1996
------------	---------	--------------	--------------------	--------------

AB1	G AND W LABS INC	0.05%	A074139 001	Aug 03, 1994
------------	------------------	--------------	--------------------	--------------

AB1	TARO	0.05%	A074249 001	Jul 08, 1996
------------	------	--------------	--------------------	--------------

CORMAX

AB1	HI TECH PHARMA	0.05%	A074220 001	May 16, 1997
------------	----------------	--------------	--------------------	--------------

TEMOVATE

AB1	+ FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985
------------	------------------	--------------	--------------------	--------------

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999
------------	----------------	--------------	--------------------	--------------

AB2	TARO	0.05%	A075633 001	May 17, 2000
------------	------	--------------	--------------------	--------------

EMBELINE E

AB2	HI TECH PHARMA	0.05%	A075325 001	Dec 24, 1998
------------	----------------	--------------	--------------------	--------------

TEMOVATE E

AB2	+ FOUGERA PHARMS	0.05%	N020340 001	Jun 17, 1994
------------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000
-----------	----------------	--------------	--------------------	--------------

AB	PERRIGO	0.05%	A075027 001	Oct 31, 1997
-----------	---------	--------------	--------------------	--------------

AB	TARO	0.05%	A075279 001	May 28, 1999
-----------	------	--------------	--------------------	--------------

EMBELINE

AB	HI TECH PHARMA	0.05%	A076141 001	Apr 12, 2002
-----------	----------------	--------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-86 (of 371)

CLOBETASOL PROPIONATE

GEL; TOPICAL

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994
-----------	------------------	--------------	--------------------	--------------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	A078223 001	Dec 04, 2008
-----------	----------------------	--------------	--------------------	--------------

AB	TARO	0.05%	A200302 001	Jul 02, 2012
-----------	------	--------------	--------------------	--------------

CLOBEX

AB	+ GALDERMA LABS LP	0.05%	N021535 001	Jul 24, 2003
-----------	--------------------	--------------	--------------------	--------------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996
-----------	----------------	--------------	--------------------	--------------

AB	TARO	0.05%	A074248 001	Jul 12, 1996
-----------	------	--------------	--------------------	--------------

AB	TEVA PHARMS	0.05%	A074089 001	Feb 16, 1994
-----------	-------------	--------------	--------------------	--------------

EMBELINE

AB	HI TECH PHARMA	0.05%	A074221 001	Mar 31, 1995
-----------	----------------	--------------	--------------------	--------------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985
-----------	------------------	--------------	--------------------	--------------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	A078854 001	Jun 07, 2011
-----------	----------------------	--------------	--------------------	--------------

AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012
-----------	----------------	--------------	--------------------	--------------

CLOBEX

AB	+ GALDERMA LABS	0.05%	N021644 001	Feb 05, 2004
-----------	-----------------	--------------	--------------------	--------------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999
-----------	----------------	--------------	--------------------	--------------

AT	TARO	0.05%	A075224 001	Nov 16, 1998
-----------	------	--------------	--------------------	--------------

AT		0.05%	A075363 001	Dec 29, 2000
-----------	--	--------------	--------------------	--------------

AT	TOLMAR	0.05%	A076977 001	Aug 05, 2005
-----------	--------	--------------	--------------------	--------------

AT	WOCKHARDT	0.05%	A075205 001	Nov 13, 1998
-----------	-----------	--------------	--------------------	--------------

EMBELINE

AT	+ HI TECH PHARMA	0.05%	A074222 001	Dec 06, 1995
-----------	------------------	--------------	--------------------	--------------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT	PADDOCK LLC	0.05%	A090898 001	Jun 16, 2011
-----------	-------------	--------------	--------------------	--------------

CLOBEX

AT	+ GALDERMA LABS LP	0.05%	N021835 001	Oct 27, 2005
-----------	--------------------	--------------	--------------------	--------------

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLODERM

+ PROMIUS PHARMA LLC 0.1%

N017765 001

CLOFARABINE

INJECTABLE; IV (INFUSION)

CLOLAR

+ GENZYME 20MG/20ML (1MG/ML)

N021673 001 Dec 28, 2004

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

+ NOVARTIS 50MG

N019500 002 Dec 15, 1986

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMID

AB	+ SANOFI AVENTIS US	50MG	N016131 002	
-----------	---------------------	-------------	--------------------	--

CLOMIPHENE CITRATE

AB	PAR PHARM	50MG	A075528 001	Aug 30, 1999
-----------	-----------	-------------	--------------------	--------------

SEROPHENE

AB	EMD SERONO	50MG	N018361 001	Mar 22, 1982
-----------	------------	-------------	--------------------	--------------

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	MALLINCKRODT LLC	25MG	N019906 001	Dec 29, 1989
-----------	------------------	-------------	--------------------	--------------

AB	+	50MG	N019906 002	Dec 29, 1989
-----------	---	-------------	--------------------	--------------

AB		75MG	N019906 003	Dec 29, 1989
-----------	--	-------------	--------------------	--------------

CLOMIPRAMINE HYDROCHLORIDE

AB	MYLAN	25MG	A074947 001	Apr 30, 1998
-----------	-------	-------------	--------------------	--------------

AB		50MG	A074947 002	Apr 30, 1998
-----------	--	-------------	--------------------	--------------

AB		75MG	A074947 003	Apr 30, 1998
-----------	--	-------------	--------------------	--------------

AB	SANDOZ	25MG	A074364 001	Mar 29, 1996
-----------	--------	-------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-87 (of 371)

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A074364</u>	<u>002</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074364</u>	<u>003</u>	Mar 29, 1996
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694</u>	<u>001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074958</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>		<u>50MG</u>	<u>A074958</u>	<u>002</u>	Aug 26, 1997
<u>AB</u>		<u>75MG</u>	<u>A074958</u>	<u>003</u>	Aug 26, 1997

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A075150</u>	<u>001</u>	Oct 05, 1998
<u>AB</u>		<u>1MG</u>	<u>A075150</u>	<u>002</u>	Oct 05, 1998
<u>AB</u>		<u>2MG</u>	<u>A075150</u>	<u>003</u>	Oct 05, 1998
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A074940</u>	<u>001</u>	Oct 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074940</u>	<u>002</u>	Oct 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074940</u>	<u>003</u>	Oct 30, 1997
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	SUN PHARM INDS INC	<u>0.5MG</u>	<u>A075423</u>	<u>001</u>	Apr 27, 2001
<u>AB</u>		<u>1MG</u>	<u>A075423</u>	<u>002</u>	Apr 27, 2001
<u>AB</u>		<u>2MG</u>	<u>A075423</u>	<u>003</u>	Apr 27, 2001
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996
<u>AB</u>	VINTAGE PHARMS	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A074964</u>	<u>001</u>	Dec 30, 1997
<u>AB</u>		<u>1MG</u>	<u>A074964</u>	<u>002</u>	Dec 30, 1997
<u>AB</u>		<u>2MG</u>	<u>A074964</u>	<u>003</u>	Dec 30, 1997

KLONOPIN

<u>AB</u>	ROCHE	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>	
<u>AB</u>	+	<u>1MG</u>	<u>N017533</u>	<u>002</u>	
<u>AB</u>		<u>2MG</u>	<u>N017533</u>	<u>003</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	+	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005
<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654</u>	<u>002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654</u>	<u>003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654</u>	<u>004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654</u>	<u>005</u>	Aug 27, 2014

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984
-----------	----------------------	-------------------	----------------	------------	--------------

CATAPRES-TTS-2

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984
-----------	----------------------	-------------------	----------------	------------	--------------

CATAPRES-TTS-3

<u>AB</u>	+	BOEHRINGER INGELHEIM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984
-----------	---	----------------------	-------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-88 (of 371)

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	BARR	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090</u>	<u>003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166</u>	<u>002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166</u>	<u>003</u>	Jul 16, 2010
<u>AB</u>	WATSON LABS INC	<u>0.1MG/24HR</u>	<u>A090873</u>	<u>001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873</u>	<u>002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873</u>	<u>003</u>	May 06, 2014

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	EXELA PHARMA SCS LLC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167</u>	<u>001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167</u>	<u>002</u>	Oct 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673</u>	<u>001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673</u>	<u>002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300</u>	<u>002</u>	Jan 26, 2011
<u>AP</u>	LUITPOLD	<u>1MG/10ML (0.1MG/ML)</u>	<u>A091104</u>	<u>001</u>	Oct 08, 2009
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A091104</u>	<u>002</u>	Oct 08, 2009
<u>AP</u>	ZYDUS PHARMS USA INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601</u>	<u>001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601</u>	<u>002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996
<u>AP</u>	+	<u>5MG/10ML (0.5MG/ML)</u>	<u>N020615</u>	<u>002</u>	Apr 27, 1999

TABLET; ORAL

CATAPRES

<u>AB</u>	BOEHRINGER INGELHEIM	<u>0.1MG</u>	<u>N017407</u>	<u>001</u>	
<u>AB</u>		<u>0.2MG</u>	<u>N017407</u>	<u>002</u>	
<u>AB</u>	+	<u>0.3MG</u>	<u>N017407</u>	<u>003</u>	

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368</u>	<u>001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368</u>	<u>002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368</u>	<u>003</u>	Dec 06, 2011
<u>AB</u>	CARLSBAD	<u>0.1MG</u>	<u>A202297</u>	<u>001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297</u>	<u>002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297</u>	<u>003</u>	Jun 13, 2013
<u>AB</u>	DAVA PHARMS INC	<u>0.1MG</u>	<u>A071783</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071784</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	MUTUAL PHARM	<u>0.1MG</u>	<u>A070925</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070924</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	MYLAN	<u>0.1MG</u>	<u>A070317</u>	<u>002</u>	Jul 09, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070317</u>	<u>003</u>	Jun 09, 1987
<u>AB</u>		<u>0.3MG</u>	<u>A070317</u>	<u>001</u>	Jun 09, 1987
<u>AB</u>	SUN PHARM INDS INC	<u>0.1MG</u>	<u>A090329</u>	<u>001</u>	Jul 03, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A090329</u>	<u>002</u>	Jul 03, 2014
<u>AB</u>		<u>0.3MG</u>	<u>A090329</u>	<u>003</u>	Jul 03, 2014
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	VINTAGE	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202983</u>	<u>001</u>	Apr 02, 2014
<u>AB</u>		<u>0.2MG</u>	<u>A202983</u>	<u>002</u>	Apr 02, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-89 (of 371)

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984</u>	<u>001</u>	Sep 30, 2013
AB		<u>0.2MG</u>	<u>A202984</u>	<u>002</u>	Sep 30, 2013

KAPVAY

AB	+ CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331</u>	<u>003</u>	Sep 28, 2010
AB		<u>0.2MG</u>	<u>N022331</u>	<u>004</u>	Sep 28, 2010

CLOPIDOGREL

TABLET;ORAL

CLOPIDOGREL

AB	AMNEAL PHARMS	<u>75MG</u>	<u>A203751</u>	<u>001</u>	Apr 11, 2014
-----------	---------------	-------------	----------------	------------	--------------

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925</u>	<u>001</u>	Mar 27, 2013
AB		<u>EQ 300MG BASE</u>	<u>A202925</u>	<u>002</u>	Mar 27, 2013
AB	ACTAVIS TOTOWA	<u>EQ 75MG BASE</u>	<u>A090307</u>	<u>001</u>	May 28, 2013
AB	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274</u>	<u>001</u>	May 17, 2012
AB		<u>EQ 300MG BASE</u>	<u>A076274</u>	<u>002</u>	Mar 04, 2014
AB	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540</u>	<u>001</u>	May 17, 2012
AB	DR REDDYS LABS INC	<u>EQ 75MG BASE</u>	<u>A076273</u>	<u>001</u>	Jan 14, 2008
AB	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023</u>	<u>001</u>	May 17, 2012
AB	GATE PHARMS	<u>EQ 300MG BASE</u>	<u>A091216</u>	<u>001</u>	May 17, 2012
AB	MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928</u>	<u>001</u>	Feb 10, 2014
AB	MUTUAL PHARM	<u>EQ 75MG BASE</u>	<u>A078133</u>	<u>001</u>	Jun 10, 2013
AB	MYLAN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A077665</u>	<u>001</u>	May 17, 2012
AB		<u>EQ 300MG BASE</u>	<u>A077665</u>	<u>002</u>	May 17, 2012
AB	ROXANE	<u>EQ 75MG BASE</u>	<u>A078004</u>	<u>001</u>	May 17, 2012
AB	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165</u>	<u>001</u>	Sep 15, 2014
AB		<u>EQ 300MG BASE</u>	<u>A204165</u>	<u>002</u>	Sep 15, 2014
AB	SUN PHARMA GLOBAL	<u>EQ 75MG BASE</u>	<u>A090494</u>	<u>001</u>	May 17, 2012
AB	TEVA	<u>EQ 75MG BASE</u>	<u>A076999</u>	<u>001</u>	May 17, 2012
AB	TEVA PHARMS	<u>EQ 300MG BASE</u>	<u>A090625</u>	<u>001</u>	May 17, 2012
AB	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844</u>	<u>001</u>	May 17, 2012
AB	WOCKHARDT LTD	<u>EQ 75MG BASE</u>	<u>A202266</u>	<u>001</u>	Aug 14, 2012
AB		<u>EQ 300MG BASE</u>	<u>A202266</u>	<u>002</u>	Nov 20, 2012
AB	ZYDUS PHARMS USA INC	<u>EQ 75MG BASE</u>	<u>A201686</u>	<u>001</u>	Oct 10, 2012

PLAVIX

AB	SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839</u>	<u>001</u>	Nov 17, 1997
AB	+	<u>EQ 300MG BASE</u>	<u>N020839</u>	<u>002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	MYLAN	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
AB		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
AB		<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
AB	RANBAXY	<u>3.75MG</u>	<u>A076911</u>	<u>001</u>	Sep 29, 2004
AB		<u>7.5MG</u>	<u>A076911</u>	<u>002</u>	Sep 29, 2004
AB		<u>15MG</u>	<u>A076911</u>	<u>003</u>	Sep 29, 2004
AB	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
AB		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
AB		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000

GEN-XENE

AB	ALRA	<u>3.75MG</u>	<u>A071787</u>	<u>001</u>	Apr 26, 1988
AB		<u>7.5MG</u>	<u>A071788</u>	<u>001</u>	Apr 26, 1988
AB		<u>15MG</u>	<u>A071789</u>	<u>001</u>	Apr 26, 1988

TRANXENE

AB	RECORDATI RARE	<u>3.75MG</u>	<u>N017105</u>	<u>006</u>	
AB		<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	
AB	+	<u>15MG</u>	<u>N017105</u>	<u>008</u>	

CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	<u>1%</u>	<u>A078338</u>	<u>001</u>	Sep 02, 2008
AB	GLENMARK PHARMS	<u>1%</u>	<u>A090219</u>	<u>001</u>	Aug 03, 2010
AB	+	<u>1%</u>	<u>A072640</u>	<u>001</u>	Aug 31, 1993

SOLUTION;TOPICAL

CLOTRIMAZOLE

AT	+	<u>1%</u>	<u>A074580</u>	<u>001</u>	Jul 29, 1996
-----------	---	-----------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-90 (of 371)

CLOTRIMAZOLE

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT	TEVA	1%	A073306	001	Feb 28, 1995
-----------	------	-----------	----------------	------------	--------------

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB	PADDOCK LLC	10MG	A076763	001	Oct 28, 2005
AB	+	ROXANE	A076387	001	Jul 29, 2004

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+	JAZZ PHARMS III	50MG/ML	N203479	001	Feb 06, 2013
---	-----------------	---------	---------	-----	--------------

TABLET; ORAL

CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003
AB		25MG	A074949	001	Nov 26, 1997
AB		50MG	A074949	004	Apr 25, 2005
AB		50MG	A076809	003	Dec 16, 2005
AB		100MG	A074949	002	Nov 26, 1997
AB		100MG	A076809	002	Dec 16, 2005
AB		200MG	A076809	001	Dec 16, 2005
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010
AB		25MG	A075417	001	May 27, 1999
AB		50MG	A075417	004	Apr 15, 2010
AB		100MG	A075417	002	May 27, 1999
AB		200MG	A075417	005	Apr 15, 2010
AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002
AB		50MG	A075713	003	Aug 19, 2005
AB		100MG	A075713	002	Nov 15, 2002

CLOZARIL

AB	NOVARTIS	25MG	N019758	001	Sep 26, 1989
AB	+	100MG	N019758	002	Sep 26, 1989

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007
		25MG	N021590	001	Feb 10, 2004
+		100MG	N021590	002	Feb 10, 2004
		150MG	N021590	005	Jul 09, 2010
		200MG	N021590	006	Jul 09, 2010

COBICISTAT

TABLET; ORAL

TYBOST

+	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014
---	---------------------	-------	---------	-----	--------------

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG; 150MG; 200MG; 300MG	N203100	001	Aug 27, 2012
---	---------------------	----------------------------	---------	-----	--------------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	VINTAGE	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006
-----------	---------	--------------------------------------	----------------	------------	--------------

PROMETH VC W/ CODEINE

AA	+	ACTAVIS MID ATLANTIC	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A088764	001	Oct 31, 1984
-----------	---	----------------------	--------------------------------------	----------------	------------	--------------

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	HI-TECH PHARMA CO	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014
-----------	-------------------	--------------------------------------	----------------	------------	--------------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	+	ACTAVIS MID ATLANTIC	10MG/5ML; 6.25MG/5ML	A088763	001	Oct 31, 1984
AA		AMNEAL PHARMS	10MG/5ML; 6.25MG/5ML	A200894	001	Apr 24, 2013
AA		HI TECH PHARMA	10MG/5ML; 6.25MG/5ML	A040151	001	Aug 26, 1997
AA		SUN PHARM INDS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010
AA		TRIS PHARMA INC	10MG/5ML; 6.25MG/5ML	A200386	001	Jun 29, 2012
AA		WOCKHARDT	10MG/5ML; 6.25MG/5ML	A088875	001	Dec 17, 1984

PROMETHAZINE WITH CODEINE

AA	VINTAGE	10MG/5ML; 6.25MG/5ML	A040650	001	Jan 31, 2006
-----------	---------	-----------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-91 (of 371)

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

+ STI PHARMA LLC

10MG/5ML; 30MG/5ML; 1.25MG/5ML

A088704 001 Mar 22, 1985

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

+ ROXANE

30MG/5ML

N202245 001 Jun 30, 2011

TABLET; ORAL

CODEINE SULFATE**AB** LANNETT HOLDINGS INC**15MG****A203046 001** Jun 13, 2014**AB** **30MG****A203046 002** Jun 13, 2014**AB** **60MG****A203046 003** Jun 13, 2014**AB** ROXANE **15MG****N022402 001** Jul 16, 2009**AB** **30MG****N022402 002** Jul 16, 2009**AB** + **60MG****N022402 003** Jul 16, 2009COLCHICINE

CAPSULE; ORAL

MITIGARE

HIKMA PHARMS LLC

0.6MG

N204820 001 Sep 26, 2014

TABLET; ORAL

COLCRYS

+ TAKEDA PHARMS USA

0.6MG

N022352 001 Jul 29, 2009

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID**AB** + WATSON LABS**0.5MG; 500MG****A084279 001**PROBENECID AND COLCHICINE**AB** MIRROR PHARMS**0.5MG; 500MG****A040618 001** May 13, 2008COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

WELCHOL

DAIICHI SANKYO

1.875GM/PACKET

N022362 001 Oct 02, 2009

+

3.75GM/PACKET

N022362 002 Oct 02, 2009

TABLET; ORAL

WELCHOL

+ DAIICHI SANKYO

625MG

N021176 001 May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID**AB** PHARMACIA AND UPJOHN**5GM/SCOOPFUL****N017563 003** Sep 22, 1995**AB** + **5GM/PACKET****N017563 004** Sep 22, 1995COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS**5GM/SCOOPFUL****A077277 001** May 02, 2006**AB** **5GM/PACKET****A077277 002** May 02, 2006

FLAVORED COLESTID

PHARMACIA AND UPJOHN

5GM/PACKET

N017563 001

5GM/SCOOPFUL

N017563 002

TABLET; ORAL

COLESTID**AB** + PHARMACIA AND UPJOHN**1GM****N020222 001** Jul 19, 1994COLESTIPOL HYDROCHLORIDE**AB** IMPAX LABS**1GM****A077510 001** Oct 24, 2006COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM**AP** EMCURE PHARMS LTD**EQ 150MG BASE/VIAL****A202359 001** Sep 28, 2012**AP** FRESenius KABI USA**EQ 150MG BASE/VIAL****A065364 001** Apr 17, 2008**AP** PADDOCK LLC**EQ 150MG BASE/VIAL****A065177 001** Mar 19, 2004**AP** SAGENT PHARMS**EQ 150MG BASE/VIAL****A201365 001** Feb 19, 2014**AP** X GEN PHARMS**EQ 150MG BASE/VIAL****A064216 001** Feb 26, 1999COLY-MYCIN M**AP** + PAR STERILE PRODUCTS**EQ 150MG BASE/VIAL****N050108 002**

PRESCRIPTION DRUG PRODUCT LIST

3-92 (of 371)

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+ PAR STERILE PRODUCTS EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG
BASE/ML;0.5MG/ML

N050356 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697 002 Oct 08, 2008

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

PARAGARD T 380A

+ TEVA WOMENS 309MG/COPPER

N018680 001 Nov 15, 1984

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE;INJECTION

ACTHREL

+ FERRING EQ 0.1MG BASE/VIAL

N020162 001 May 23, 1996

CORTICOTROPIN

INJECTABLE;INJECTION

H.P. ACTHAR GEL

+ QUESTCOR PHARMS 80 UNITS/ML

N008372 008

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

+ HIKMA INTL PHARMS 25MG

A080776 002

COSYNTROPIN

INJECTABLE;INJECTION

CORTROSYN**AP** + AMPHASTAR PHARMS INC **0.25MG/VIAL****N016750 001**COSYNTROPIN**AP** MYLAN INSTITUTIONAL **0.25MG/VIAL****A090574 001** Dec 17, 2009**AP** SANDOZ **0.25MG/VIAL****A202147 001** Jun 29, 2012CRIZOTINIB

CAPSULE;ORAL

XALKORI

PF PRISM CV 200MG

N202570 001 Aug 26, 2011

+ 250MG

N202570 002 Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE;ORAL

FULYZAQ

+ SALIX PHARMS 125MG

N202292 001 Dec 31, 2012

CROMOLYN SODIUM

CONCENTRATE;ORAL

CROMOLYN SODIUM**AA** MICRO LABS LTD INDIA **100MG/5ML****A202745 001** Apr 04, 2013**AA** PACK PHARMS LLC **100MG/5ML****A202583 001** Oct 27, 2011GASTROCROM**AA** + MEDA PHARMS **100MG/5ML****N020479 001** Feb 29, 1996

SOLUTION;INHALATION

CROMOLYN SODIUM**AN** BAUSCH AND LOMB **10MG/ML****A075585 001** Dec 21, 2000**AN** MYLAN SPECLT **10MG/ML****A074209 001** Apr 26, 1994**AN** + TEVA PHARMS **10MG/ML****A075271 001** Jan 18, 2000**AN** WOCKHARDT **10MG/ML****A075346 001** Oct 25, 1999

SOLUTION/DROPS;OPHTHALMIC

CROLOM**AT** BAUSCH AND LOMB **4%****A074443 001** Jan 30, 1995CROMOLYN SODIUM**AT** + AKORN **4%****A074706 001** Apr 29, 1998**AT** ALCON **4%****A075282 001** Jun 16, 1999CROTAMITON

CREAM;TOPICAL

EURAX

+ RANBAXY 10%

N006927 001

LOTION;TOPICAL

CROTAN**AT** SUMMERS **10%****A087204 001**

PRESCRIPTION DRUG PRODUCT LIST

3-93 (of 371)

CROTAMITON

LOTION; TOPICAL

EURAX

AT	+	RANBAXY	10%	N009112	003	
-----------	---	---------	------------	----------------	------------	--

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE IN PLASTIC CONTAINER

+ HOSPIRA

EQ 0.4MG COPPER/ML

N018960 001 Jun 26, 1986

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

AP	+	LUITPOLD	1MG/ML	A080737	001	
-----------	---	----------	---------------	----------------	------------	--

VIBISONE

AP	+	FRESENIUS KABI USA	1MG/ML	A080557	003	
-----------	---	--------------------	---------------	----------------	------------	--

SPRAY, METERED; NASAL

NASCOBAL

+ PAR PHARM

0.5MG/SPRAY

N021642 001 Jan 31, 2005

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB		IVAX INTL	15MG	N021777	001	Feb 01, 2007
-----------	--	-----------	-------------	----------------	------------	--------------

AB	+		30MG	N021777	002	Feb 01, 2007
-----------	---	--	-------------	----------------	------------	--------------

CYCLOBENZAPRINE HYDROCHLORIDE

AB		TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013
-----------	--	----------------	-------------	----------------	------------	--------------

AB			30MG	A091281	002	Jan 31, 2013
-----------	--	--	-------------	----------------	------------	--------------

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	5MG	A071611	002	Feb 03, 2006
-----------	--	---------------------	------------	----------------	------------	--------------

AB			7.5MG	A071611	003	Feb 03, 2006
-----------	--	--	--------------	----------------	------------	--------------

AB			10MG	A071611	001	May 03, 1989
-----------	--	--	-------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	5MG	A078643	001	Sep 26, 2008
-----------	--	------------------	------------	----------------	------------	--------------

AB			10MG	A078643	002	Sep 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB		INVAGEN PHARMS	5MG	A090478	001	Jul 23, 2010
-----------	--	----------------	------------	----------------	------------	--------------

AB			10MG	A090478	002	Jul 23, 2010
-----------	--	--	-------------	----------------	------------	--------------

AB		JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006
-----------	--	------------------	------------	----------------	------------	--------------

AB			10MG	A077563	002	Apr 19, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB		KVK TECH	5MG	A078048	001	Feb 28, 2011
-----------	--	----------	------------	----------------	------------	--------------

AB			10MG	A078048	002	Feb 28, 2011
-----------	--	--	-------------	----------------	------------	--------------

AB		MUTUAL PHARM	5MG	A073541	002	Apr 06, 2006
-----------	--	--------------	------------	----------------	------------	--------------

AB			10MG	A073541	001	May 23, 1995
-----------	--	--	-------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	5MG	A073144	002	Feb 03, 2006
-----------	--	------------------	------------	----------------	------------	--------------

AB			7.5MG	A073144	003	Mar 25, 2013
-----------	--	--	--------------	----------------	------------	--------------

AB	+		10MG	A073144	001	May 30, 1991
-----------	---	--	-------------	----------------	------------	--------------

AB		ORIT LABS LLC	10MG	A078218	001	Apr 18, 2008
-----------	--	---------------	-------------	----------------	------------	--------------

AB		PLIVA	10MG	A074421	001	Sep 29, 1995
-----------	--	-------	-------------	----------------	------------	--------------

AB		PROSAM LABS	10MG	A077209	001	Oct 04, 2005
-----------	--	-------------	-------------	----------------	------------	--------------

AB		RANBAXY	5MG	A078722	001	May 12, 2008
-----------	--	---------	------------	----------------	------------	--------------

AB			7.5MG	A078722	002	May 12, 2008
-----------	--	--	--------------	----------------	------------	--------------

AB			10MG	A078722	003	May 12, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB		VINTAGE PHARMS	5MG	A077797	001	Feb 28, 2007
-----------	--	----------------	------------	----------------	------------	--------------

AB			10MG	A077797	002	Feb 28, 2007
-----------	--	--	-------------	----------------	------------	--------------

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT		AKORN	1%	A040164	001	Jan 13, 1997
-----------	--	-------	-----------	----------------	------------	--------------

CYCLOGYL

AT	+	ALCON	1%	A084110	001	
-----------	---	-------	-----------	----------------	------------	--

PENTOLAIR

AT		BAUSCH AND LOMB	1%	A040075	001	Apr 29, 1994
-----------	--	-----------------	-----------	----------------	------------	--------------

CYCLOGYL

+ ALCON

0.5%

A084109 001

+ ALCON LABS INC

2%

A084108 001

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

+ ALCON

0.2%; 1%

A084300 001

PRESCRIPTION DRUG PRODUCT LIST

3-94 (of 371)

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

N203856 001 Sep 16, 2013

+

50MG

N203856 002 Sep 16, 2013

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDEAP + BAXTER HLTHCARE1GM/VIALA040745 002 May 21, 2008AP +2GM/VIALA040745 003 May 21, 2008AP +500MG/VIALA040745 001 May 21, 2008AP JIANGSU HENGRUI MED1GM/VIALA204555 002 Oct 31, 2014AP2GM/VIALA204555 003 Oct 31, 2014AP500MG/VIALA204555 001 Oct 31, 2014CYTOXAN (LYOPHILIZED)AP + BAXTER HLTHCARE1GM/VIALN012142 004 Aug 30, 1982AP +2GM/VIALN012142 005 Aug 30, 1982AP +500MG/VIALN012142 003

TABLET; ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

A040032 001 Aug 17, 1999

+

50MG

A040032 002 Aug 17, 1999

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

+ PURDUE GMP

250MG

A060593 001

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINEAB1 IVAX SUB TEVA PHARMS25MGA065110 003 Mar 29, 2005AB150MGA065110 001 Mar 29, 2005AB1100MGA065110 002 Mar 29, 2005AB1 SANDOZ25MGA065017 002 Jan 13, 2000AB1100MGA065017 001 Jan 13, 2000AB1 WATSON LABS INC25MGA065044 002 Dec 20, 2000AB1100MGA065044 001 Dec 20, 2000GENGRAFAB1 ABBVIE25MGA065003 001 May 12, 2000AB150MGA065003 002 May 12, 2000AB1100MGA065003 003 May 12, 2000NEORALAB1 NOVARTIS25MGN050715 001 Jul 14, 1995AB1 +100MGN050715 002 Jul 14, 1995CYCLOSPORINEAB2 APOTEX25MGA065040 001 May 09, 2002AB2100MGA065040 002 May 09, 2002SANDIMMUNEAB2 NOVARTIS25MGN050625 001 Mar 02, 1990AB2 +100MGN050625 002 Mar 02, 1990

BX

50MG

N050625 003 Nov 23, 1992

EMULSION; OPHTHALMIC

RESTASIS

+ ALLERGAN

0.05%

N050790 001 Dec 23, 2002

INJECTABLE; INJECTION

CYCLOSPORINEAP EUROHLTH INTL50MG/MLA065004 001 Oct 29, 1999AP LUITPOLD50MG/MLA065151 001 Oct 07, 2003SANDIMMUNEAP + NOVARTIS50MG/MLN050573 001 Nov 14, 1983

SOLUTION; ORAL

CYCLOSPORINEAB1 ABBVIE100MG/MLA065025 001 Mar 03, 2000AB1 IVAX SUB TEVA PHARMS100MG/MLA065078 001 Mar 25, 2005AB1 WATSON LABS100MG/MLA065054 001 Dec 18, 2001NEORALAB1 + NOVARTIS100MG/MLN050716 001 Jul 14, 1995CYCLOSPORINEAB2 WOCKHARDT100MG/MLA065133 001 Sep 17, 2004SANDIMMUNEAB2 + NOVARTIS100MG/MLN050574 001 Nov 14, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-95 (of 371)

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	+	LYNE	2MG/5ML	A040668	001	Jun 28, 2006
AA		PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		COREPHARMA	4MG	A040537	001	Sep 30, 2003
AA	+	IVAX SUB TEVA PHARMS	4MG	A087056	001	
AA		PAR PHARM	4MG	A087129	001	
AA		STASON PHARMS	4MG	A040644	001	May 30, 2006

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+		EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

	RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013
+		EQ 75MG BASE	N203389	002	Apr 30, 2013

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+	SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012
---	-----------	---------------	---------	-----	--------------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP		EUROHLTH INTL	1GM/VIAL	A074245	001	Aug 31, 1994
AP			2GM/VIAL	A074245	002	Aug 31, 1994
AP			100MG/VIAL	A071471	001	Aug 02, 1989
AP			500MG/VIAL	A071472	001	Aug 02, 1989
AP	+	FRESENIUS KABI USA	100MG/ML	A076512	001	Jan 15, 2004
AP	+	HOSPIRA	20MG/ML	A071868	001	Jun 04, 1990
AP	+		20MG/ML	A072168	001	Aug 31, 1990
AP	+		20MG/ML	A072945	001	Feb 28, 1994
AP			100MG/ML	A075383	001	Nov 22, 1999
AP		ONCO THERAPIES LTD	20MG/ML	A200914	001	Dec 13, 2011
AP			20MG/ML	A200915	001	Dec 13, 2011
AP			20MG/ML	A200916	001	Dec 13, 2011
AP			100MG/ML	A201784	001	Jan 30, 2012

CYTOSAR-U

AP	+	TEVA PHARMS USA	1GM/VIAL	A075206	004	Dec 30, 1998
AP	+		2GM/VIAL	A075206	003	Dec 30, 1998
AP			100MG/VIAL	A075206	001	Dec 30, 1998
AP	+		500MG/VIAL	A075206	002	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+	PACIRA PHARMS INC	10MG/ML	N021041	001	Apr 01, 1999
---	-------------------	---------	---------	-----	--------------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

	BOEHRINGER INGELHEIM	EQ 75MG BASE	N022512	001	Oct 19, 2010
+		EQ 150MG BASE	N022512	002	Oct 19, 2010

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

	GLAXOSMITHKLINE	EQ 50MG BASE	N202806	001	May 29, 2013
+		EQ 75MG BASE	N202806	002	May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP		EUROHLTH INTL	200MG/VIAL	A075812	001	Jun 15, 2001
AP			500MG/VIAL	A075812	002	Oct 31, 2002
AP		FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999
AP			200MG/VIAL	A075371	002	Aug 27, 1999
AP		HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001
AP		TEVA PHARMS USA	200MG/VIAL	A075259	002	Aug 27, 1998
AP	+		500MG/VIAL	A075259	001	Sep 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-96 (of 371)

DACARBAZINE

INJECTABLE; INJECTION

DTIC-DOME

<u>AP</u>	+	BAYER HLTHCARE	<u>100MG/VIAL</u>	<u>N017575</u>	<u>001</u>	
<u>AP</u>	+		<u>200MG/VIAL</u>	<u>N017575</u>	<u>002</u>	

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

<u>AP</u>	+	RECORDATI RARE	<u>0.5MG/VIAL</u>	<u>N050682</u>	<u>001</u>	
-----------	---	----------------	-------------------	----------------	------------	--

DACTINOMYCIN

<u>AP</u>		EUROHLTH INTL	<u>0.5MG/VIAL</u>	<u>A090304</u>	<u>001</u>	Mar 16, 2010
<u>AP</u>		LUITPOLD	<u>0.5MG/VIAL</u>	<u>A202562</u>	<u>001</u>	Aug 23, 2013

DALBAVANCIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL		N021883	001	May 23, 2014
---	---------------------	--------------------	--	---------	-----	--------------

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

+	ACORDA	10MG		N022250	001	Jan 22, 2010
---	--------	------	--	---------	-----	--------------

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

+	KING PHARMS	350MG/VIAL; 150MG/VIAL		N050748	001	Sep 21, 1999
---	-------------	------------------------	--	---------	-----	--------------

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

	EISAI INC	2,500IU/0.2ML (12,500IU/ML)		N020287	001	Dec 22, 1994
		5,000IU/0.2ML (25,000IU/ML)		N020287	003	Mar 18, 1996
		7,500IU/0.3ML (25,000IU/ML)		N020287	005	Apr 04, 2002
		10,000IU/ML (10,000IU/ML)		N020287	004	Jan 30, 1998
		12,500IU/0.5ML (25,000IU/ML)		N020287	009	May 01, 2007
		15,000IU/0.6ML (25,000IU/ML)		N020287	010	May 01, 2007
		18,000IU/0.72ML (25,000IU/ML)		N020287	011	May 01, 2007
+		95,000IU/3.8ML (25,000IU/ML)		N020287	006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

<u>AB</u>		BARR	<u>50MG</u>	<u>A074582</u>	<u>003</u>	May 29, 1998
<u>AB</u>			<u>100MG</u>	<u>A074582</u>	<u>002</u>	May 29, 1998
<u>AB</u>	+		<u>200MG</u>	<u>A074582</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		LANNETT	<u>50MG</u>	<u>A078214</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>			<u>100MG</u>	<u>A078214</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>			<u>200MG</u>	<u>A077246</u>	<u>001</u>	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

<u>AB</u>		PAR STERILE PRODUCTS	<u>25MG</u>	<u>N017443</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>N017443</u>	<u>003</u>	
<u>AB</u>	+		<u>100MG</u>	<u>N017443</u>	<u>002</u>	

DANTROLENE SODIUM

<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A076856</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>			<u>50MG</u>	<u>A076856</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>			<u>100MG</u>	<u>A076856</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>		MIKAH PHARMA	<u>25MG</u>	<u>A076686</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>			<u>50MG</u>	<u>A076686</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>			<u>100MG</u>	<u>A076686</u>	<u>003</u>	Oct 24, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

	EAGLE PHARMS	250MG/VIAL		N205579	001	Jul 22, 2014
--	--------------	------------	--	---------	-----	--------------

INJECTABLE; INJECTION

DANTRIUM

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>20MG/VIAL</u>	<u>N018264</u>	<u>001</u>	
-----------	---	----------------------	------------------	----------------	------------	--

REVONTO

<u>AP</u>		US WORLDMEDS	<u>20MG/VIAL</u>	<u>A078378</u>	<u>001</u>	Jul 24, 2007
-----------	--	--------------	------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-97 (of 371)

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

ASTRAZENECA AB

5MG

N202293 001 Jan 08, 2014

+

10MG

N202293 002 Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

ASTRAZENECA AB

5MG; 1GM

N205649 002 Oct 29, 2014

5MG; 500MG

N205649 001 Oct 29, 2014

+

10MG; 1GM

N205649 004 Oct 29, 2014

10MG; 500MG

N205649 003 Oct 29, 2014

DAPSONE

GEL; TOPICAL

ACZONE

+ ALLERGAN

5%

N021794 001 Jul 07, 2005

TABLET; ORAL

DAPSONE

JACOBUS

25MG

A086841 001

+

100MG

A086842 001

DAPTOMYCIN

INJECTABLE; IV (INFUSION)

CUBICIN**AP** + CUBIST**500MG/VIAL****N021572 002** Sep 12, 2003DAPTOMYCIN**AP** HOSPIRA INC**500MG/VIAL****A202857 001** Sep 12, 2014DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

WARNER CHILCOTT LLC

EQ 7.5MG BASE

N021513 001 Dec 22, 2004

+

EQ 15MG BASE

N021513 002 Dec 22, 2004

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 100MG BASE/ML

N202895 001 Dec 16, 2011

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 75MG BASE

N021976 004 Dec 18, 2008

EQ 150MG BASE

N021976 005 Dec 18, 2008

EQ 600MG BASE

N021976 002 Feb 25, 2008

+

EQ 800MG BASE

N021976 006 Nov 09, 2012

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+ ABBVIE INC

EQ 250MG BASE, N/A, N/A, N/A;
N/A, 12.5MG, 75MG, 50MG

N206619 001 Dec 19, 2014

DASATINIB

TABLET; ORAL

SPRYCEL

BRISTOL MYERS SQUIBB

20MG

N021986 001 Jun 28, 2006

50MG

N021986 002 Jun 28, 2006

70MG

N021986 003 Jun 28, 2006

80MG

N021986 005 Oct 28, 2010

100MG

N021986 004 May 30, 2008

+

140MG

N021986 006 Oct 28, 2010

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

+ GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE**AP** + EUROHLTH INTL**EQ 20MG BASE/VIAL****A064103 001** Feb 03, 1995DAUNORUBICIN HYDROCHLORIDE**AP** + EUROHLTH INTL**EQ 5MG BASE/ML****N050731 001** Jan 30, 1998**AP** FRESENIUS KABI USA**EQ 20MG BASE/VIAL****A065000 001** May 25, 1999**AP** TEVA PHARMS USA**EQ 5MG BASE/ML****A065035 001** Jan 24, 2000

FRESENIUS KABI USA

EQ 5MG BASE/VIAL

A065034 001 Nov 20, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-98 (of 371)

DECITABINE

INJECTABLE; INTRAVENOUS

DACOGEN

AP	+	EISAI INC	50MG/VIAL	N021790	001	May 02, 2006
-----------	----------	------------------	------------------	----------------	------------	--------------

DECITABINE

AP		DR REDDYS LABS LTD	50MG/VIAL	A203131	001	Jul 11, 2013
-----------	--	---------------------------	------------------	----------------	------------	--------------

AP		SANDOZ	50MG/VIAL	A202969	001	Aug 28, 2014
-----------	--	---------------	------------------	----------------	------------	--------------

POWDER; INTRAVENOUS

DECITABINE

+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014
----------	--------------------------	------------------	----------------	------------	--------------

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

EXJADE

	NOVARTIS	125MG	N021882	001	Nov 02, 2005
--	-----------------	--------------	----------------	------------	--------------

		250MG	N021882	002	Nov 02, 2005
--	--	--------------	----------------	------------	--------------

+		500MG	N021882	003	Nov 02, 2005
----------	--	--------------	----------------	------------	--------------

DEFERIPRONE

TABLET; ORAL

FERRIPROX

+	AOPHARMA INC	500MG	N021825	001	Oct 14, 2011
----------	---------------------	--------------	----------------	------------	--------------

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP		EUROHLTH INTL	2GM/VIAL	A078086	002	May 30, 2007
-----------	--	----------------------	-----------------	----------------	------------	--------------

AP			500MG/VIAL	A078086	001	May 30, 2007
-----------	--	--	-------------------	----------------	------------	--------------

AP		FRESENIUS KABI USA	2GM/VIAL	A078718	002	Sep 15, 2009
-----------	--	---------------------------	-----------------	----------------	------------	--------------

AP			500MG/VIAL	A078718	001	Sep 15, 2009
-----------	--	--	-------------------	----------------	------------	--------------

AP		HOSPIRA	2GM/VIAL	A076019	002	Mar 17, 2004
-----------	--	----------------	-----------------	----------------	------------	--------------

AP			500MG/VIAL	A076019	001	Mar 17, 2004
-----------	--	--	-------------------	----------------	------------	--------------

DESFERAL

AP	+	NOVARTIS	2GM/VIAL	N016267	002	May 25, 2000
-----------	----------	-----------------	-----------------	----------------	------------	--------------

AP	+		500MG/VIAL	N016267	001	
-----------	----------	--	-------------------	----------------	------------	--

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
--	----------------	--------------------------	----------------	------------	--------------

+		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008
----------	--	---------------------------	----------------	------------	--------------

DELAVIDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

	VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997
--	----------------------	--------------	----------------	------------	--------------

+		200MG	N020705	002	Jul 14, 1999
----------	--	--------------	----------------	------------	--------------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

AB		AMNEAL PHARM	150MG	A065425	001	Feb 27, 2008
-----------	--	---------------------	--------------	----------------	------------	--------------

AB	+		300MG	A065425	002	Feb 27, 2008
-----------	----------	--	--------------	----------------	------------	--------------

AB		BARR	150MG	A065171	001	Dec 13, 2004
-----------	--	-------------	--------------	----------------	------------	--------------

AB			300MG	A065171	002	Dec 13, 2004
-----------	--	--	--------------	----------------	------------	--------------

AB		IMPAX LABS	150MG	A065094	001	Mar 22, 2004
-----------	--	-------------------	--------------	----------------	------------	--------------

AB			300MG	A065094	002	Mar 22, 2004
-----------	--	--	--------------	----------------	------------	--------------

AB		VERSAPHARM	150MG	A065389	001	Dec 01, 2008
-----------	--	-------------------	--------------	----------------	------------	--------------

AB			300MG	A065389	002	Dec 01, 2008
-----------	--	--	--------------	----------------	------------	--------------

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992
----------	------------------------	--------------	----------------	------------	--------------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB		ACTAVIS TOTOWA	10MG	A074430	001	Feb 09, 1996
-----------	--	-----------------------	-------------	----------------	------------	--------------

AB			25MG	A071601	001	Jun 05, 1987
-----------	--	--	-------------	----------------	------------	--------------

AB			50MG	A071588	001	Jun 05, 1987
-----------	--	--	-------------	----------------	------------	--------------

AB			75MG	A071602	001	Oct 05, 1987
-----------	--	--	-------------	----------------	------------	--------------

AB			100MG	A071766	001	Oct 05, 1987
-----------	--	--	--------------	----------------	------------	--------------

AB			150MG	A074430	002	Feb 09, 1996
-----------	--	--	--------------	----------------	------------	--------------

AB		SANDOZ	10MG	A072099	001	May 24, 1988
-----------	--	---------------	-------------	----------------	------------	--------------

AB			25MG	A072100	001	May 24, 1988
-----------	--	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-99 (of 371)

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988

NORPRAMIN

<u>AB</u>	SANOFI AVENTIS US	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>		<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>		<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>		<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESIRUDIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPRIVASK

	+	MARATHON PHARMS LLC	15MG/VIAL	N021271	001	Apr 04, 2003
--	---	---------------------	-----------	---------	-----	--------------

DESLORATADINE

SOLUTION; ORAL

CLARINEX

	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004
--	---	-------------------	----------	---------	-----	--------------

TABLET; ORAL

CLARINEX

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001
-----------	---	-------------------	------------	----------------	------------	--------------

DESLORATADINE

<u>AB</u>		BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>5MG</u>	<u>A078351</u>	<u>001</u>	Feb 10, 2012
<u>AB</u>		ORCHID HLTHCARE	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010
<u>AB</u>		PERRIGO R AND D	<u>5MG</u>	<u>A078361</u>	<u>001</u>	Dec 22, 2011
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A078364</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		SUN PHARM INDS	<u>5MG</u>	<u>A078359</u>	<u>001</u>	Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

<u>AB</u>		MERCK SHARP DOHME	<u>2.5MG</u>	<u>N021312</u>	<u>002</u>	Jul 14, 2005
<u>AB</u>	+		<u>5MG</u>	<u>N021312</u>	<u>001</u>	Jun 26, 2002

DESLORATADINE

<u>AB</u>		REDDYS	<u>2.5MG</u>	<u>A078367</u>	<u>001</u>	Jul 12, 2010
<u>AB</u>			<u>5MG</u>	<u>A078367</u>	<u>002</u>	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

<u>AB</u>	+	MERCK SHARP DOHME	<u>5MG; 240MG</u>	<u>N021605</u>	<u>001</u>	Mar 03, 2005
-----------	---	-------------------	-------------------	----------------	------------	--------------

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

<u>AB</u>		DR REDDYS LABS LTD	<u>5MG; 240MG</u>	<u>A078366</u>	<u>001</u>	Apr 26, 2011
-----------	--	--------------------	-------------------	----------------	------------	--------------

CLARINEX-D 12 HOUR

	+	MERCK SHARP DOHME	2.5MG; 120MG	N021313	001	Feb 01, 2006
--	---	-------------------	--------------	---------	-----	--------------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+	FERRING PHARMS INC	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984
-----------	---	--------------------	-------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

<u>AP</u>		HOSPIRA	<u>0.004MG/ML</u>	<u>A075220</u>	<u>001</u>	Aug 28, 2000
<u>AP</u>		SUN PHARM INDS LTD	<u>0.004MG/ML</u>	<u>A091280</u>	<u>001</u>	Jan 25, 2013
<u>AP</u>		TEVA PHARMS USA	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997

SOLUTION; NASAL

DDAVP

<u>AB</u>	+	FERRING PHARMS INC	<u>0.01%</u>	<u>N017922</u>	<u>001</u>	
-----------	---	--------------------	--------------	----------------	------------	--

DESMOPRESSIN ACETATE

<u>AB</u>		SUN PHARM INDS	<u>0.01%</u>	<u>A077212</u>	<u>001</u>	Apr 12, 2012
-----------	--	----------------	--------------	----------------	------------	--------------

SPRAY, METERED; NASAL

DDAVP (NEEDS NO REFRIGERATION)

<u>AB</u>	+	FERRING PHARMS INC	<u>0.01MG/SPRAY</u>	<u>N017922</u>	<u>003</u>	Aug 07, 1996
-----------	---	--------------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE

<u>AB</u>	+	BAUSCH AND LOMB	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999
-----------	---	-----------------	---------------------	----------------	------------	--------------

DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)

<u>AB</u>		APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005
<u>AB</u>		SUN PHARMA GLOBAL	<u>0.01MG/SPRAY</u>	<u>A078271</u>	<u>001</u>	Dec 23, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-100 (of 371)

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

MINIRIN

AB	+	FERRING	0.01MG/SPRAY	N021333	001	Sep 16, 2002
		STIMATE (NEEDS NO REFRIGERATION)				
AB	+	CSL BEHRING	1.5MG/SPRAY	N020355	002	Oct 24, 2007

TABLET;ORAL

DDAVP

AB		SANOFI AVENTIS US	0.1MG	N019955	001	Sep 06, 1995
AB	+		0.2MG	N019955	002	Sep 06, 1995

DESMOPRESSIN ACETATE

AB		ACTAVIS LABS FL INC	0.1MG	A076470	001	Jul 01, 2005
AB			0.2MG	A076470	002	Jul 01, 2005
AB		APOTEX INC	0.1MG	A077414	001	Mar 07, 2006
AB			0.2MG	A077414	002	Mar 07, 2006
AB		MYLAN PHARMS INC	0.1MG	A200653	001	Jun 27, 2014
AB			0.2MG	A200653	002	Jun 27, 2014
AB		TEVA PHARMS	0.1MG	A077122	001	Jan 25, 2006
AB			0.2MG	A077122	002	Jan 25, 2006
		FERRING	0.1MG	N021795	001	May 08, 2008
	+		0.2MG	N021795	002	May 08, 2008

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

CYCLESSA

AB	+	ORGANON USA INC	0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG	N021090	001	Dec 20, 2000
-----------	----------	-----------------	---	----------------	------------	--------------

DESOGEN

AB		ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992
-----------	--	-----------------	----------------------	----------------	------------	--------------

DESOGESTREL AND ETHINYL ESTRADIOL

AB		DURAMED PHARMS BARR	0.15MG;0.03MG	A075256	002	Aug 12, 1999
AB		FAMY CARE LTD	0.15MG,N/A;0.02MG,0.01MG	A202296	001	Aug 30, 2013
AB		NOVAST LABS LTD	0.15MG;0.03MG	A091234	001	Jul 12, 2013
AB		WATSON LABS	0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG	A076916	001	Dec 29, 2008
AB			0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006
AB			0.15MG;0.03MG	A076915	001	Jul 29, 2005
AB		VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675	001	Feb 25, 2011
AB		LUPIN LTD	0.15MG;0.03MG	A201887	001	Mar 07, 2013
AB	+	JANSSEN PHARMS	0.15MG;0.03MG	N020301	002	Dec 14, 1992
AB		NOVAST LABS LTD	0.15MG,N/A;0.02MG,0.01MG	A091247	001	Aug 01, 2013
AB		DURAMED PHARMS BARR	0.125MG;0.15MG;0.1MG;0.025MG;0.025MG;0.025MG	A076455	001	Feb 24, 2004
AB		GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346	001	Apr 02, 2012
	+	KARIVA				
	+	BARR	0.15MG,N/A;0.02MG,0.01MG;0.02MG,0.01MG	A075863	001	Apr 05, 2002

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

+ AQUA PHARMS

0.05%

N021978 001 Sep 19, 2006

CREAM;TOPICAL

DESONIDE

AB	+	PERRIGO NEW YORK	0.05%	N017010	001	
AB		TARO	0.05%	A073548	001	Jun 30, 1992

DESOWEN

AB		GALDERMA LABS LP	0.05%	N019048	001	Dec 14, 1984
-----------	--	------------------	--------------	----------------	------------	--------------

GEL;TOPICAL

DESONATE

+ BAYER HLTHCARE

0.05%

N021844 001 Oct 20, 2006

LOTION;TOPICAL

DESONIDE

AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002
AB		TARO	0.05%	A202161	001	Oct 31, 2014

DESOWEN

AB	+	GALDERMA LABS LP	0.05%	A072354	001	Jan 24, 1992
-----------	----------	------------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-101 (of 371)

DESONIDE

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A075751</u>	<u>001</u>	Mar 12, 2001
AB	+ PERRIGO NEW YORK	<u>0.05%</u>	<u>N017426</u>	<u>001</u>	
AB	TARO	<u>0.05%</u>	<u>A074254</u>	<u>001</u>	Aug 03, 1994

DESOWEN

AB	GALDERMA LABS LP	<u>0.05%</u>	<u>A071425</u>	<u>001</u>	Jun 15, 1988
-----------	------------------	--------------	----------------	------------	--------------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078369</u>	<u>001</u>	Jun 29, 2010
AB	PERRIGO NEW YORK	<u>0.25%</u>	<u>A076510</u>	<u>001</u>	Jul 01, 2003

TOPICORT

AB	+ TARO	<u>0.25%</u>	<u>A073193</u>	<u>001</u>	Nov 30, 1990
	+	0.05%	A073210	001	Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONE

AB	PERRIGO NEW YORK	<u>0.05%</u>	<u>A077552</u>	<u>001</u>	Jan 09, 2006
AB	VERSAPHARM	<u>0.05%</u>	<u>A090727</u>	<u>001</u>	Mar 10, 2011

TOPICORT

AB	+ TARO	<u>0.05%</u>	<u>A074904</u>	<u>001</u>	Jul 14, 1998
-----------	--------	--------------	----------------	------------	--------------

OINTMENT; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	<u>0.25%</u>	<u>A078657</u>	<u>001</u>	Sep 28, 2012
AB	GLENMARK GENERICS	<u>0.25%</u>	<u>A202838</u>	<u>001</u>	Sep 20, 2013
AB	VERSAPHARM INC	<u>0.25%</u>	<u>A201005</u>	<u>001</u>	Apr 24, 2014

TOPICORT

AB	+ TARO	<u>0.25%</u>	<u>A074286</u>	<u>001</u>	Jun 07, 1996
	+ TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985

SPRAY; TOPICAL

TOPICORT

	+ TARO	0.25%	N204141	001	Apr 11, 2013
--	--------	-------	---------	-----	--------------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

BC	+ ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
BC	+ KHEDEZLA	100MG	N204150	002	Mar 04, 2013
BC	OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013
BC		100MG	N204683	002	Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

	+ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014
	+	EQ 100MG BASE	N205583	002	Jan 28, 2014

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

PRISTIQ

	WYETH PHARMS INC	EQ 25MG BASE	N021992	003	Aug 20, 2014
	+	EQ 50MG BASE	N021992	001	Feb 29, 2008
	+	EQ 100MG BASE	N021992	002	Feb 29, 2008

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

	+ ROXANE	1MG/ML	A088252	001	Sep 01, 1983
--	----------	--------	---------	-----	--------------

ELIXIR; ORAL

DEXAMETHASONE

AA	LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011
AA	+ STI PHARMA LLC	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>	
AA	VINTAGE PHARMS	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
AA	WOCKHARDT EU OPERATN	<u>0.5MG/5ML</u>	<u>A088254</u>	<u>001</u>	Jul 27, 1983

IMPLANT; INTRAVITREAL

OZURDEX

	+ ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
--	------------	-------	---------	-----	--------------

SOLUTION; ORAL

DEXAMETHASONE

	+ ROXANE	0.5MG/5ML	A088248	001	Sep 01, 1983
--	----------	-----------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-102 (of 371)

DEXAMETHASONE

SUSPENSION/DROPS;OPHTHALMIC

MAXIDEX

+ ALCON 0.1%

N013422 001

TABLET;ORAL

DEXAMETHASONE

AB	ECR	1.5MG	A040700 001	Aug 15, 2008
AB	ROXANE	1.5MG	A084610 001	
BP	PAR PHARM	0.5MG	A088148 001	Apr 28, 1983
BP		0.75MG	A088160 001	Apr 28, 1983
BP		1.5MG	A088237 001	Apr 28, 1983
BP		4MG	A088238 001	Apr 28, 1983
BP	+	6MG	A088481 001	Nov 28, 1983
BP	ROXANE	0.5MG	A084611 001	
BP		0.75MG	A084613 001	
BP		1MG	A088306 001	Sep 15, 1983
BP		2MG	A087916 001	Aug 26, 1982
BP		4MG	A084612 001	
BP	+	6MG	A088316 001	Sep 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	AGILA SPECLTS	EQ 4MG PHOSPHATE/ML	A040803 001	Aug 29, 2008
AP		EQ 10MG PHOSPHATE/ML	A040802 001	Aug 29, 2008
AP	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916 001	
AP	+	EQ 10MG PHOSPHATE/ML	A040491 001	Apr 11, 2003
AP	+	EQ 10MG PHOSPHATE/ML	A040572 001	Apr 22, 2005
AP	+	EQ 10MG PHOSPHATE/ML	A087702 001	Sep 07, 1982
AP	+	EQ 4MG PHOSPHATE/ML	A087440 001	Jul 21, 1982

SOLUTION/DROPS;OPHTHALMIC, OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AT	+	ALCON PHARMS LTD	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985
AT		BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069 001	Jul 26, 1996

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065 002	
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE					
AT		BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064063 001	Jul 25, 1994
AT		PERRIGO CO TENNESSEE	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938 001	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A064135 001	Sep 13, 1995
MAXITROL					
AT		ALCON	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062341 001	May 22, 1984
AT	+	FALCON PHARMS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023 002	

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+ ALCON 0.1%;0.3%

N050616 001 Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	+	ALCON	0.1%;0.3%	N050592 001	Aug 18, 1988
TOBRAMYCIN AND DEXAMETHASONE					
AB		BAUSCH AND LOMB	0.1%;0.3%	A064134 001	Oct 27, 1999
		TOBRADEX ST			
	+	ALCON PHARMS LTD	0.05%;0.3%	N050818 001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

+ WOCKHARDT 2MG/5ML

A088251 001 Mar 23, 1984

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

TAKEDA PHARMS USA 30MG

N022287 001 Jan 30, 2009

+ 60MG

N022287 002 Jan 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-103 (of 371)

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585</u>	<u>001</u>	Nov 24, 2014
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881</u>	<u>001</u>	Aug 18, 2014
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972</u>	<u>001</u>	Aug 18, 2014
<u>PRECEDEX</u>					
<u>AP</u>	+ HOSPIRA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038</u>	<u>001</u>	Dec 17, 1999
	+	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N021038	002	Mar 13, 2013
	+	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N021038	003	Mar 13, 2013

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	INTELLIPHARMACEUTICS	<u>15MG</u>	<u>A078992</u>	<u>003</u>	Nov 18, 2013
<u>AB</u>		<u>30MG</u>	<u>A078992</u>	<u>004</u>	Nov 18, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>30MG</u>	<u>A202580</u>	<u>001</u>	Aug 28, 2013
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908</u>	<u>001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908</u>	<u>002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908</u>	<u>004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908</u>	<u>003</u>	Nov 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202731</u>	<u>003</u>	May 19, 2014
<u>AB</u>		<u>40MG</u>	<u>A202731</u>	<u>002</u>	Nov 19, 2013
<u>AB</u>	WATSON LABS INC	<u>15MG</u>	<u>A079108</u>	<u>003</u>	May 19, 2014
<u>AB</u>		<u>30MG</u>	<u>A079108</u>	<u>005</u>	Nov 21, 2013
<u>FOCALIN XR</u>					
<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N021802</u>	<u>001</u>	May 26, 2005
<u>AB</u>		<u>10MG</u>	<u>N021802</u>	<u>002</u>	May 26, 2005
<u>AB</u>		<u>15MG</u>	<u>N021802</u>	<u>004</u>	Aug 01, 2006
<u>AB</u>		<u>20MG</u>	<u>N021802</u>	<u>003</u>	May 26, 2005
<u>AB</u>		<u>30MG</u>	<u>N021802</u>	<u>005</u>	Oct 23, 2009
<u>AB</u>	+	<u>40MG</u>	<u>N021802</u>	<u>006</u>	Aug 11, 2010
		25MG	N021802	008	Apr 21, 2011
		35MG	N021802	007	Apr 21, 2011

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A077107</u>	<u>003</u>	Jan 29, 2007
<u>AB</u>		<u>5MG</u>	<u>A077107</u>	<u>001</u>	Jan 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077107</u>	<u>002</u>	Jan 29, 2007

FOCALIN

<u>AB</u>	NOVARTIS	<u>2.5MG</u>	<u>N021278</u>	<u>001</u>	Nov 13, 2001
<u>AB</u>		<u>5MG</u>	<u>N021278</u>	<u>002</u>	Nov 13, 2001
<u>AB</u>	+	<u>10MG</u>	<u>N021278</u>	<u>003</u>	Nov 13, 2001

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 250MG BASE/VIAL</u>	<u>A076068</u>	<u>001</u>	Sep 28, 2004
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A076068</u>	<u>002</u>	Sep 28, 2004
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 250MG BASE/VIAL</u>	<u>A200752</u>	<u>001</u>	Oct 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A200752</u>	<u>002</u>	Oct 19, 2011
<u>ZINECARD</u>					
<u>AP</u>	+ PHARMACIA AND UPJOHN	<u>EQ 250MG BASE/VIAL</u>	<u>N020212</u>	<u>001</u>	May 26, 1995
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>N020212</u>	<u>002</u>	May 26, 1995
TOTECT					
	+ BIOCDEX INC	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+	<u>15MG</u>	<u>N017078</u>	<u>003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901</u>	<u>001</u>	Nov 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>	BARR	<u>5MG</u>	<u>A076137</u>	<u>001</u>	Jan 18, 2002
<u>AB</u>		<u>10MG</u>	<u>A076137</u>	<u>002</u>	Jan 18, 2002
<u>AB</u>		<u>15MG</u>	<u>A076137</u>	<u>003</u>	Jan 18, 2002
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>		<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>		<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-104 (of 371)

DEXTROAMPHETAMINE SULFATE

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	+	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>			<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	+		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		COREPHARMA	<u>5MG</u>	<u>A090652</u>	<u>001</u>	Mar 07, 2014
<u>AA</u>			<u>10MG</u>	<u>A090652</u>	<u>002</u>	Mar 07, 2014
<u>AA</u>		MALLINCKRODT	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>		MIKART	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
			2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

<u>AA</u>	+	VINTAGE	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040649</u>	<u>001</u>	Feb 14, 2006
-----------	---	---------	-----------------------------	----------------	------------	--------------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

<u>AA</u>		HI TECH PHARMA	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A040027</u>	<u>001</u>	Jul 31, 1996
-----------	--	----------------	-----------------------------	----------------	------------	--------------

PROMETHAZINE W/ DEXTROMETHORPHAN

<u>AA</u>		WOCKHARDT	<u>15MG/5ML; 6.25MG/5ML</u>	<u>A088864</u>	<u>001</u>	Jan 04, 1985
-----------	--	-----------	-----------------------------	----------------	------------	--------------

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

NUEDEXTA

+	AVANIR PHARMS	20MG; 10MG	N021879	001	Oct 29, 2010
---	---------------	------------	---------	-----	--------------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>10GM/100ML</u>	<u>N019626</u>	<u>004</u>	Feb 02, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>10GM/100ML</u>	<u>N016694</u>	<u>001</u>	
<u>AP</u>	+	HOSPIRA	<u>10GM/100ML</u>	<u>N018080</u>	<u>001</u>	

DEXTROSE 20% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>20GM/100ML</u>	<u>N017521</u>	<u>004</u>	
<u>AP</u>	+	HOSPIRA	<u>20GM/100ML</u>	<u>N018564</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 30% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>30GM/100ML</u>	<u>N017521</u>	<u>003</u>	
<u>AP</u>	+	HOSPIRA	<u>30GM/100ML</u>	<u>N019345</u>	<u>001</u>	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>40GM/100ML</u>	<u>N017521</u>	<u>002</u>	
<u>AP</u>	+	HOSPIRA	<u>40GM/100ML</u>	<u>N018562</u>	<u>001</u>	Mar 23, 1982

DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>5GM/100ML</u>	<u>N016730</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019626</u>	<u>002</u>	Feb 02, 1988
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016730</u>	<u>002</u>	
<u>AP</u>	+	BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N016673</u>	<u>001</u>	
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N020179</u>	<u>001</u>	Dec 07, 1992
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016673</u>	<u>003</u>	Oct 30, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N020179</u>	<u>002</u>	Dec 07, 1992
<u>AP</u>	+	HOSPIRA	<u>5GM/100ML</u>	<u>N019466</u>	<u>001</u>	Jul 15, 1985
<u>AP</u>	+		<u>5GM/100ML</u>	<u>N019479</u>	<u>001</u>	Sep 17, 1985
<u>AP</u>	+		<u>50MG/ML</u>	<u>N016367</u>	<u>002</u>	
<u>AP</u>	+		<u>50MG/ML</u>	<u>N019222</u>	<u>001</u>	Jul 13, 1984

DEXTROSE 50% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>50GM/100ML</u>	<u>N017521</u>	<u>001</u>	
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N020047</u>	<u>001</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>50GM/100ML</u>	<u>N018563</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>50GM/100ML</u>	<u>N019894</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>			<u>500MG/ML</u>	<u>N019445</u>	<u>001</u>	Jun 03, 1986

DEXTROSE 60% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>60GM/100ML</u>	<u>N017521</u>	<u>005</u>	Mar 26, 1982
-----------	---	-----------------	-------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-105 (of 371)

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>70GM/100ML</u>	<u>N017521</u>	<u>006</u>	Mar 26, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N020047</u>	<u>003</u>	Jul 02, 1991
<u>AP</u>	+	HOSPIRA	<u>70GM/100ML</u>	<u>N018561</u>	<u>001</u>	Mar 23, 1982
<u>AP</u>	+		<u>70GM/100ML</u>	<u>N019893</u>	<u>001</u>	Dec 26, 1989
		DEXTROSE 25%				
	+	HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML	N017385	001
-----------------	---	---------	-----

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610	001
---------	---	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873	001	Jun 10, 1993
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML	N019515	001	May 08, 1986
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484	001
-----------------	---	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML	N019513	001	May 08, 1986
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N019844	001	Jun 10, 1993
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843	001	Aug 09, 1993
---------	--	---------	-----	--------------

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017609	001
---------	--	---------	-----

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001
-----------------	--	---------	-----

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>5GM/100ML; 75MG/100ML</u>	<u>N017634</u>	<u>004</u>
-----------	--	-----------------	------------------------------	----------------	------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>5GM/100ML; 150MG/100ML</u>	<u>N017634</u>	<u>001</u>
-----------	--	-----------------	-------------------------------	----------------	------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>5GM/100ML; 224MG/100ML</u>	<u>N017634</u>	<u>003</u>
-----------	--	-----------------	-------------------------------	----------------	------------

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>5GM/100ML; 300MG/100ML</u>	<u>N017634</u>	<u>002</u>
-----------	--	-----------------	-------------------------------	----------------	------------

PRESCRIPTION DRUG PRODUCT LIST

3-106 (of 371)

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML	N018744	001	Nov 09, 1982
----	---------	-----------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 150MG/100ML	N018744	002	Nov 09, 1982
----	---------	------------------------	---------	-----	--------------

AP		5GM/100ML; 150MG/100ML	N019699	004	Sep 29, 1989
----	--	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 300MG/100ML	N018744	004	Nov 09, 1982
----	---------	------------------------	---------	-----	--------------

AP		5GM/100ML; 300MG/100ML	N019699	006	Sep 29, 1989
----	--	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	5GM/100ML; 224MG/100ML	N018371	003	
----	---------	------------------------	---------	-----	--

	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
--	--	--	--	--	--

	HOSPIRA	5GM/100ML; 149MG/100ML	N018371	001	
--	---------	------------------------	---------	-----	--

	POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER				
--	--	--	--	--	--

	HOSPIRA	5GM/100ML; 298MG/100ML	N018371	002	
--	---------	------------------------	---------	-----	--

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N019870	001	Jun 10, 1993
--	---------	--	---------	-----	--------------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983
--	-----------------	---	---------	-----	--------------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037	006	Apr 13, 1982
----	-----------------	------------------------------------	---------	-----	--------------

AP		5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	007	Apr 13, 1982
----	--	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037	004	
----	-----------------	-------------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	008	Apr 13, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037	001	
----	-----------------	-------------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 200MG/100ML	N018037	005	Apr 13, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 200MG/100ML	N018037	009	Apr 13, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 200MG/100ML	N018037	002	
----	-----------------	------------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 200MG/100ML	N018037	003	
----	-----------------	-------------------------------------	---------	-----	--

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 330MG/100ML	N018629	005	Mar 23, 1982
----	-----------------	------------------------------------	---------	-----	--------------

AP		5GM/100ML; 150MG/100ML; 330MG/100ML	N018629	002	Mar 23, 1982
----	--	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 330MG/100ML	N018629	003	Mar 23, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 330MG/100ML	N018629	004	Mar 23, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

AP		5GM/100ML; 300MG/100ML; 330MG/100ML	N018629	006	Mar 23, 1982
----	--	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 330MG/100ML	N018629	007	Mar 23, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 330MG/100ML	N018629	008	Mar 23, 1982
----	-----------------	-------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 330MG/100ML	N018629	001	Mar 23, 1982
----	-----------------	------------------------------------	---------	-----	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008	010	
----	-----------------	-------------------------------------	---------	-----	--

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N019630	008	Feb 17, 1988
----	---------	------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N019630	014	Feb 17, 1988
----	---------	------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N019630	020	Feb 17, 1988
----	---------	------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 75MG/100ML; 900MG/100ML	N019630	026	Feb 17, 1988
----	---------	------------------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N019630	010	Feb 17, 1988
----	---------	-------------------------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-107 (of 371)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;150MG/100ML;330MG/100ML	N019630 016	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;150MG/100ML;450MG/100ML	N019630 022	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;150MG/100ML;900MG/100ML	N019630 028	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;300MG/100ML;200MG/100ML	N019630 012	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;300MG/100ML;330MG/100ML	N019630 018	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;300MG/100ML;450MG/100ML	N019630 024	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	B BRAUN	5GM/100ML;300MG/100ML;900MG/100ML	N019630 030	Feb	17,	1988
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;450MG/100ML	N018008 005	Apr	28,	1982
AP		5GM/100ML;150MG/100ML;450MG/100ML	N018008 006	Apr	28,	1982
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 005	Mar	28,	1988
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 009	Jul	05,	1983
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308 004	Apr	05,	1985
AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308 002	Apr	05,	1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 002	Mar	24,	1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 004	Mar	24,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 006	Mar	28,	1988
<u>POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 006	Mar	24,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 007	Apr	28,	1982
AP	HOSPIRA	5GM/100ML;149MG/100ML;450MG/100ML	N018362 010	Jul	05,	1983
AP		5GM/100ML;298MG/100ML;450MG/100ML	N018362 007	Mar	28,	1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 005	Apr	05,	1985
AP		5GM/100ML;300MG/100ML;900MG/100ML	N019308 003	Apr	05,	1985
AP	HOSPIRA	5GM/100ML;149MG/100ML;900MG/100ML	N019691 005	Mar	24,	1988
AP		5GM/100ML;298MG/100ML;900MG/100ML	N019691 008	Mar	24,	1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;450MG/100ML	N018008 008	Apr	28,	1982
AP	HOSPIRA	5GM/100ML;224MG/100ML;450MG/100ML	N018362 002			
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML;900MG/100ML	N019308 006	Apr	05,	1985
AP	HOSPIRA	5GM/100ML;224MG/100ML;900MG/100ML	N019691 007	Mar	24,	1988
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;450MG/100ML	N018008 009	Apr	28,	1982
AP	HOSPIRA	5GM/100ML;298MG/100ML;450MG/100ML	N018362 003			
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML;900MG/100ML	N019308 007	Apr	05,	1985
AP	HOSPIRA	5GM/100ML;298MG/100ML;900MG/100ML	N019691 009	Mar	24,	1988
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;450MG/100ML	N018008 004			
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362 008	Mar	28,	1988
AP		5GM/100ML;149MG/100ML;450MG/100ML	N018362 004	Mar	28,	1988
<u>POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML;900MG/100ML	N019308 001	Apr	05,	1985
AP	HOSPIRA	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691 001	Mar	24,	1988
AP		5GM/100ML;149MG/100ML;900MG/100ML	N019691 003	Mar	24,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>						
	B BRAUN	10GM/100ML;37MG/100ML;200MG/100ML	N019630 031	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>						
	B BRAUN	10GM/100ML;37MG/100ML;450MG/100ML	N019630 037	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>						
	B BRAUN	10GM/100ML;37MG/100ML;900MG/100ML	N019630 043	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>						
	B BRAUN	5GM/100ML;37MG/100ML;110MG/100ML	N019630 001	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>						
	B BRAUN	5GM/100ML;37MG/100ML;200MG/100ML	N019630 007	Feb	17,	1988
<u>POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>						
	B BRAUN	5GM/100ML;37MG/100ML;330MG/100ML	N019630 013	Feb	17,	1988

PRESCRIPTION DRUG PRODUCT LIST

3-108 (of 371)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 37MG/100ML; 450MG/100ML	N019630 019 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 37MG/100ML; 900MG/100ML	N019630 025 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 75MG/100ML; 200MG/100ML	N019630 032 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 75MG/100ML; 450MG/100ML	N019630 038 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 75MG/100ML; 900MG/100ML	N019630 044 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN 3.3GM/100ML; 75MG/100ML; 300MG/100ML	N019630 049 May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 75MG/100ML; 110MG/100ML	N019630 002 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 110MG/100ML; 200MG/100ML	N019630 033 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 110MG/100ML; 450MG/100ML	N019630 039 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 110MG/100ML; 900MG/100ML	N019630 045 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN 3.3GM/100ML; 110MG/100ML; 300MG/100ML	N019630 050 May 07, 1992
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 110MG/100ML; 110MG/100ML	N019630 003 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 110MG/100ML; 200MG/100ML	N019630 009 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 110MG/100ML; 330MG/100ML	N019630 015 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 110MG/100ML; 450MG/100ML	N019630 021 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 110MG/100ML; 900MG/100ML	N019630 027 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 150MG/100ML; 200MG/100ML	N019630 034 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 150MG/100ML; 450MG/100ML	N019630 040 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 150MG/100ML; 900MG/100ML	N019630 046 Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN 3.3GM/100ML; 150MG/100ML; 300MG/100ML	N019630 051 May 07, 1992
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 150MG/100ML; 110MG/100ML	N019630 004 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 220MG/100ML; 200MG/100ML	N019630 035 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 220MG/100ML; 450MG/100ML	N019630 041 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 220MG/100ML; 900MG/100ML	N019630 047 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN 3.3GM/100ML; 220MG/100ML; 300MG/100ML	N019630 052 May 07, 1992
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 220MG/100ML; 110MG/100ML	N019630 005 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 220MG/100ML; 200MG/100ML	N019630 011 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 220MG/100ML; 330MG/100ML	N019630 017 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 220MG/100ML; 450MG/100ML	N019630 023 Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 220MG/100ML; 900MG/100ML	N019630 029 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 300MG/100ML; 200MG/100ML	N019630 036 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 300MG/100ML; 450MG/100ML	N019630 042 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
B BRAUN 10GM/100ML; 300MG/100ML; 900MG/100ML	N019630 048 Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
B BRAUN 3.3GM/100ML; 300MG/100ML; 300MG/100ML	N019630 053 May 07, 1992
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
B BRAUN 5GM/100ML; 300MG/100ML; 110MG/100ML	N019630 006 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-109 (of 371)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365 002	Jul 05, 1983
	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365 006	Mar 28, 1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876 001	Jan 17, 1986
	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876 006	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365 008	Mar 28, 1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876 007	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365 001	
	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365 009	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876 008	Mar 28, 1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876 002	Jan 17, 1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365 003	Jul 05, 1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876 003	Jan 17, 1986
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365 004	Jul 05, 1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876 004	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365 005	Mar 28, 1988
	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365 007	Mar 28, 1988
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876 005	Mar 28, 1988
	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876 009	Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	10GM/100ML; 900MG/100ML	N019631 015 Feb 24, 1988
AP	BAXTER HLTHCARE	10GM/100ML; 900MG/100ML	N016696 001
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	2.5GM/100ML; 450MG/100ML	N019631 004 Feb 24, 1988
AP	BAXTER HLTHCARE	2.5GM/100ML; 450MG/100ML	N016697 001
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 200MG/100ML	N019631 007 Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 330MG/100ML	N019631 008 Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 450MG/100ML	N019631 009 Feb 24, 1988
AP	HOSPIRA	5GM/100ML; 450MG/100ML	N017607 001
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	B BRAUN	5GM/100ML; 900MG/100ML	N019631 010 Feb 24, 1988
AP	HOSPIRA	5GM/100ML; 900MG/100ML	N017585 001
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML; 200MG/100ML	N016689 001
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML; 330MG/100ML	N016687 001
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML; 450MG/100ML	N016683 001
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>			
AP	BAXTER HLTHCARE	5GM/100ML; 900MG/100ML	N016678 001
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML; 110MG/100ML	N019631 011 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML; 200MG/100ML	N019631 012 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML; 330MG/100ML	N019631 013 Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>			
	B BRAUN	10GM/100ML; 450MG/100ML	N019631 014 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML; 110MG/100ML	N019631 001 Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>			
	B BRAUN	2.5GM/100ML; 200MG/100ML	N019631 002 Feb 24, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-110 (of 371)

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML; 330MG/100ML	N019631	003	Feb 24, 1988
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	2.5GM/100ML; 900MG/100ML	N019631	005	Feb 24, 1988
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	3.3GM/100ML; 300MG/100ML	N019631	016	Jan 19, 1990
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER				
B BRAUN	5GM/100ML; 110MG/100ML	N019631	006	Feb 24, 1988
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML; 225MG/100ML	N017606	001	
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
HOSPIRA	5GM/100ML; 300MG/100ML	N017799	001	

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAPIN				
BRACCO	30%	N010040	018	
CYSTOGRAPIN DILUTE				
BRACCO	18%	N010040	022	Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R				
AP + MALLINCKRODT	66%;10%	N019292	001	Sep 29, 1989
RENOGRAFIN-76				
AP + BRACCO	66%;10%	N010040	001	
SOLUTION; ORAL, RECTAL				
GASTROGRAFIN				
AA + BRACCO	66%;10%	N011245	003	
MD-GASTROVIEW				
AA MALLINCKRODT	66%;10%	A087388	001	

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAPHIN				
+ BRACCO	52.7%; 26.8%	N011324	002	

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM				
AA LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014
DIAZEPAM INTENSOL				
AA + ROXANE	5MG/ML	A071415	001	Apr 03, 1987
GEL; RECTAL				
DIASAT				
VALEANT PHARMS NORTH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997
DIASAT ACUDIAL				
VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005
+	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005
INJECTABLE; INJECTION				
DIAZEPAM				
AP + HOSPIRA	5MG/ML	A071583	001	Oct 13, 1987
AP	5MG/ML	A072079	001	Dec 20, 1988
SOLUTION; ORAL				
DIAZEPAM				
+	ROXANE	5MG/5ML	A070928	001 Apr 03, 1987
TABLET; ORAL				
DIAZEPAM				
AB BARR	2MG	A070152	001	Nov 01, 1985
AB	10MG	A070154	001	Nov 01, 1985
AB IVAX SUB TEVA PHARMS	2MG	A071307	001	Dec 10, 1986
AB	5MG	A071321	001	Dec 10, 1986
AB	10MG	A071322	001	Dec 10, 1986
AB MYLAN	2MG	A070325	002	Sep 04, 1985
AB	5MG	A070325	003	Sep 04, 1985
AB	10MG	A070325	001	Sep 04, 1985
AB VINTAGE PHARMS	2MG	A077749	001	Mar 31, 2006
AB	5MG	A077749	002	Mar 31, 2006
AB	10MG	A077749	003	Mar 31, 2006
AB WATSON LABS	2MG	A071134	001	Feb 03, 1987
AB	5MG	A071135	001	Feb 03, 1987
AB	10MG	A071136	001	Feb 03, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-111 (of 371)

DIAZEPAM

TABLET; ORAL

VALIUM

AB	ROCHE	2MG	<u>N013263</u>	<u>002</u>	
AB		5MG	<u>N013263</u>	<u>004</u>	
AB	+	10MG	<u>N013263</u>	<u>006</u>	

DIAZOXIDE

SUSPENSION; ORAL

PROGLYCEM

+	TEVA BRANDED PHARM	50MG/ML	N017453	001	
---	--------------------	---------	---------	-----	--

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

	IROKO PHARMS LLC	18MG	N204592	001	Oct 18, 2013
+		35MG	N204592	002	Oct 18, 2013

DICLOFENAC EPOLAMINE

PATCH; TOPICAL

FLECTOR

+	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007
---	--------------	------	---------	-----	--------------

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009
---	-------------	------	---------	-----	--------------

FOR SOLUTION; ORAL

CAMBIA

+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009
---	-------------	------	---------	-----	--------------

TABLET; ORAL

CATAFLAM

AB	+	NOVARTIS	50MG	<u>N020142</u>	<u>002</u>	Nov 24, 1993
-----------	---	----------	-------------	-----------------------	-------------------	--------------

DICLOFENAC POTASSIUM

AB		APOTEX	50MG	<u>A076561</u>	<u>001</u>	Mar 18, 2004
AB		MYLAN	50MG	<u>A075463</u>	<u>001</u>	Jul 26, 1999
AB		SANDOZ	50MG	<u>A075229</u>	<u>001</u>	Nov 20, 1998
AB		TEVA	50MG	<u>A075219</u>	<u>001</u>	Aug 06, 1998

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		TOLMAR	3%	<u>A200936</u>	<u>001</u>	Oct 28, 2013
-----------	--	--------	-----------	-----------------------	-------------------	--------------

SOLARAZE

AB	+	FOUGERA PHARMS	3%	<u>N021005</u>	<u>001</u>	Oct 16, 2000
-----------	---	----------------	-----------	-----------------------	-------------------	--------------

VOLTAREN

+	NOVARTIS	1%	N022122	001	Oct 17, 2007
---	----------	----	---------	-----	--------------

SOLUTION; INTRAVENOUS

DYLOJECT

+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014
---	--------------------	-----------------------	---------	-----	--------------

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AT		APOTEX INC	1.5%	<u>A202027</u>	<u>001</u>	May 27, 2014
AT		PADDOCK LLC	1.5%	<u>A202393</u>	<u>001</u>	Nov 24, 2014
AT		TARO	1.5%	<u>A203818</u>	<u>001</u>	Nov 26, 2014
AT		WATSON LABS INC	1.5%	<u>A202852</u>	<u>001</u>	Nov 24, 2014

PENNSAID

AT	+	NUVO RES INC	1.5%	<u>N020947</u>	<u>001</u>	Nov 04, 2009
		HORIZON PHARMA	2%	N204623	001	Jan 16, 2014

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT		AKORN	0.1%	<u>A077845</u>	<u>001</u>	Apr 17, 2008
AT		ALCON PHARMS LTD	0.1%	<u>A078031</u>	<u>001</u>	Feb 06, 2008
AT		BAUSCH AND LOMB	0.1%	<u>A078792</u>	<u>001</u>	Dec 28, 2007
AT		NEXUS PHARMS	0.1%	<u>A078553</u>	<u>001</u>	Dec 28, 2007

VOLTAREN

AT	+	NOVARTIS	0.1%	<u>N020037</u>	<u>001</u>	Mar 28, 1991
-----------	---	----------	-------------	-----------------------	-------------------	--------------

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB		ACTAVIS ELIZABETH	50MG	<u>A074514</u>	<u>001</u>	Mar 26, 1996
AB			75MG	<u>A074514</u>	<u>002</u>	Mar 26, 1996
AB		CARLSBAD	25MG	<u>A075185</u>	<u>002</u>	Nov 13, 1998
AB			50MG	<u>A075185</u>	<u>003</u>	Nov 13, 1998
AB			75MG	<u>A075185</u>	<u>001</u>	Nov 13, 1998
AB		MYLAN PHARMS INC	50MG	<u>A075281</u>	<u>002</u>	Feb 12, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-112 (of 371)

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>		<u>75MG</u>	<u>A075281</u>	<u>003</u>	Feb 12, 2002
<u>AB</u>	+	<u>25MG</u>	<u>A074376</u>	<u>001</u>	Sep 28, 1995
<u>AB</u>	+	<u>50MG</u>	<u>A074376</u>	<u>002</u>	Sep 28, 1995
<u>AB</u>	+	<u>75MG</u>	<u>A074394</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	UNIQUE PHARM LABS	<u>25MG</u>	<u>A090066</u>	<u>001</u>	Dec 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090066</u>	<u>002</u>	Dec 01, 2010
<u>AB</u>		<u>75MG</u>	<u>A077863</u>	<u>003</u>	Jun 08, 2007

TABLET, EXTENDED RELEASE;ORAL

DICLOFENAC SODIUM

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075910</u>	<u>001</u>	Jan 07, 2002
<u>AB</u>	DEXCEL LTD	<u>100MG</u>	<u>A076201</u>	<u>001</u>	Nov 06, 2002
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A076152</u>	<u>001</u>	Dec 13, 2001
<u>AB</u>	VALEANT INTL	<u>100MG</u>	<u>A075492</u>	<u>001</u>	Feb 11, 2000

VOLTAREN-XR

<u>AB</u>	+	<u>100MG</u>	<u>N020254</u>	<u>001</u>	Mar 08, 1996
-----------	---	--------------	----------------	------------	--------------

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

ARTHROTEC

<u>AB</u>	GD SEARLE LLC	<u>50MG;0.2MG</u>	<u>N020607</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	+	<u>75MG;0.2MG</u>	<u>N020607</u>	<u>002</u>	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG;0.2MG</u>	<u>A201089</u>	<u>001</u>	Jul 09, 2012
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A201089</u>	<u>002</u>	Jul 09, 2012
<u>AB</u>	EAGLE PHARMS	<u>50MG;0.2MG</u>	<u>A200540</u>	<u>001</u>	Mar 14, 2014
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A200540</u>	<u>002</u>	Mar 14, 2014
<u>AB</u>	SANDOZ	<u>50MG;0.2MG</u>	<u>A200158</u>	<u>001</u>	May 09, 2013
<u>AB</u>		<u>75MG;0.2MG</u>	<u>A200158</u>	<u>002</u>	May 09, 2013

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A061454</u>	<u>001</u>	
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>A061454</u>	<u>003</u>	
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982
	SANDOZ	<u>EQ 125MG BASE</u>	<u>A061454</u>	<u>002</u>	

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

BENTYL

<u>AB</u>	+	<u>10MG</u>	<u>N007409</u>	<u>003</u>	Oct 15, 1984
-----------	---	-------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986

INJECTABLE;INJECTION

BENTYL

<u>AP</u>	+	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
-----------	---	----------------	----------------	------------	--------------

BENTYL PRESERVATIVE FREE

<u>AP</u>	+	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984
-----------	---	----------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)

<u>AP</u>	EUROHLTH INTL	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003
-----------	---------------	----------------	----------------	------------	--------------

SYRUP;ORAL

BENTYL

<u>AA</u>	+	<u>10MG/5ML</u>	<u>N007961</u>	<u>002</u>	Oct 15, 1984
-----------	---	-----------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AA</u>	MIKART	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005
-----------	--------	-----------------	----------------	------------	--------------

TABLET;ORAL

BENTYL

<u>AB</u>	+	<u>20MG</u>	<u>N007409</u>	<u>001</u>	Oct 15, 1984
-----------	---	-------------	----------------	------------	--------------

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A040317</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-113 (of 371)

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

<u>AB</u>	AUROBINDO PHARMA	<u>125MG</u>	<u>A090094</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>		<u>200MG</u>	<u>A090094</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		<u>250MG</u>	<u>A090094</u>	<u>003</u>	Sep 24, 2008
<u>AB</u>		<u>400MG</u>	<u>A090094</u>	<u>004</u>	Sep 24, 2008
<u>AB</u>	BARR	<u>200MG</u>	<u>A077167</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>250MG</u>	<u>A077167</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>		<u>400MG</u>	<u>A077167</u>	<u>003</u>	Dec 03, 2004
<u>AB</u>	MYLAN PHARMS INC	<u>125MG</u>	<u>A090788</u>	<u>001</u>	Apr 08, 2010
<u>AB</u>		<u>200MG</u>	<u>A090788</u>	<u>002</u>	Apr 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090788</u>	<u>003</u>	Apr 08, 2010
<u>AB</u>		<u>400MG</u>	<u>A090788</u>	<u>004</u>	Apr 08, 2010

VIDEX EC

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>125MG</u>	<u>N021183</u>	<u>001</u>	Oct 31, 2000
<u>AB</u>		<u>200MG</u>	<u>N021183</u>	<u>002</u>	Oct 31, 2000
<u>AB</u>		<u>250MG</u>	<u>N021183</u>	<u>003</u>	Oct 31, 2000
<u>AB</u>	+	<u>400MG</u>	<u>N021183</u>	<u>004</u>	Oct 31, 2000

FOR SOLUTION;ORAL

DIDANOSINE

<u>AA</u>	AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A078112</u>	<u>001</u>	Mar 08, 2007
-----------	------------------	----------------	----------------	------------	--------------

VIDEX

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>10MG/ML</u>	<u>N020156</u>	<u>001</u>	Oct 09, 1991
-----------	---	----------------------	----------------	----------------	------------	--------------

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

	AUROBINDO	100MG	A077275	001	Aug 14, 2012
		150MG	A077275	002	Aug 14, 2012
	+	200MG	A077275	003	Aug 14, 2012

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

	+	BAYER HLTHCARE	2MG; 3MG; N/A; 1MG; 2MG; 2MG; 3MG; N/A	N022252	001	May 06, 2010
--	---	----------------	--	---------	-----	--------------

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AA</u>	AVANTHI INC	<u>25MG</u>	<u>A201212</u>	<u>001</u>	Dec 22, 2010
<u>AA</u>	COREPHARMA	<u>25MG</u>	<u>A040828</u>	<u>001</u>	Nov 05, 2008
<u>AA</u>	LANNETT HOLDINGS INC	<u>25MG</u>	<u>A200177</u>	<u>001</u>	Jul 18, 2011

TENUATE

<u>AA</u>	+	WATSON PHARMS	<u>25MG</u>	<u>N011722</u>	<u>002</u>	
-----------	---	---------------	-------------	----------------	------------	--

TABLET, EXTENDED RELEASE;ORAL

DIETHYLPROPION HYDROCHLORIDE

<u>AB</u>	LANNETT HOLDINGS INC	<u>75MG</u>	<u>A091680</u>	<u>001</u>	Oct 24, 2011
-----------	----------------------	-------------	----------------	------------	--------------

TENUATE DOSPAN

<u>AB</u>	+	WATSON PHARMS	<u>75MG</u>	<u>N012546</u>	<u>001</u>	
-----------	---	---------------	-------------	----------------	------------	--

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002
BX	+	TARO	0.05%	A075508	001	Apr 24, 2000

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

<u>AB</u>		FOUGERA PHARMS	<u>0.05%</u>	<u>A075374</u>	<u>001</u>	Apr 27, 1999
<u>AB</u>	+	TARO	<u>0.05%</u>	<u>A075331</u>	<u>001</u>	May 14, 1999

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

<u>AB</u>		EMCURE PHARMS USA	<u>500MG</u>	<u>A202845</u>	<u>001</u>	Mar 08, 2012
<u>AB</u>	+	TEVA	<u>500MG</u>	<u>A073673</u>	<u>001</u>	Jul 31, 1992

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

	+	ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008
--	---	------------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-114 (of 371)

DIGOXIN

ELIXIR; ORAL

DIGOXIN

+ ROXANE

0.05MG/ML

N021648 001 Aug 26, 2004

INJECTABLE; INJECTION

DIGOXINAP HIKMA MAPLE0.25MG/MLA083391 001AP SANDOZ0.25MG/MLA040481 001 Aug 21, 2003LANOXINAP + COVIS INJECTABLES0.25MG/MLN009330 002

LANOXIN PEDIATRIC

+ COVIS INJECTABLES

0.1MG/ML

N009330 004

TABLET; ORAL

DIGOXINAB HIKMA INTL PHARMS0.125MGA077002 002 Oct 30, 2007AB0.25MGA077002 001 Oct 30, 2007AB

IMPAX LABS

0.125MGA078556 001 Jul 20, 2009AB0.25MGA078556 002 Jul 20, 2009AB

STEVENS J

0.125MGA076268 001 Jul 26, 2002AB0.25MGA076268 002 Jul 26, 2002LANOXINAB COVIS PHARMA0.125MGN020405 002 Sep 30, 1997AB

+

0.25MGN020405 004 Sep 30, 1997

DIGOXIN

MYLAN PHARMS INC

0.125MG

A040282 001 Dec 23, 1999

0.25MG

A040282 002 Dec 23, 1999

LANOXIN

COVIS PHARMA

0.0625MG

N020405 001 Sep 30, 1997

0.1875MG

N020405 003 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45AP + VALEANT1MG/MLN005929 001DIHYDROERGOTAMINE MESYLATEAP BEDFORD LABS1MG/MLA040453 001 Jun 09, 2003AP PADDOCK LLC1MG/MLA040475 001 Apr 28, 2003

SPRAY, METERED; NASAL

MIGRANAL

+ VALEANT

0.5MG/INH

N020148 001 Dec 08, 1997

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILACOR XRAB2 WATSON LABS120MGN020092 001 May 29, 1992AB2180MGN020092 002 May 29, 1992AB2

+

240MGN020092 003 May 29, 1992DILTIAZEM HYDROCHLORIDEAB2 ACTAVIS LABS FL INC120MGA074852 001 Oct 10, 1997AB2180MGA074852 002 Oct 10, 1997AB2240MGA074852 003 Oct 10, 1997AB2

APOTEX

120MGA074943 003 Dec 19, 2000AB2180MGA074943 002 Dec 19, 2000AB2240MGA074943 001 Aug 06, 1998AB2

MYLAN

120MGA075124 002 Mar 18, 1998AB2180MGA075124 003 Mar 18, 1998AB2240MGA075124 001 Mar 18, 1998CARDIZEM CDAB3 VALEANT INTL120MGN020062 001 Aug 10, 1992AB3180MGN020062 002 Dec 27, 1991AB3240MGN020062 003 Dec 27, 1991AB3300MGN020062 004 Dec 27, 1991AB3

+

360MGN020062 005 Aug 24, 1999CARTIA XTAB3 ACTAVIS LABS FL INC120MGA074752 002 Jul 09, 1998AB3180MGA074752 001 Jul 09, 1998AB3240MGA074752 003 Jul 09, 1998AB3300MGA074752 004 Jul 09, 1998DILT-CDAB3 APOTEX120MGA076151 001 May 20, 2004AB3180MGA076151 002 May 20, 2004AB3240MGA076151 003 May 20, 2004AB3300MGA076151 004 May 20, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-115 (of 371)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999
<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090492</u>	<u>001</u>	Oct 28, 2011
<u>AB3</u>		<u>180MG</u>	<u>A090492</u>	<u>002</u>	Oct 28, 2011
<u>AB3</u>		<u>240MG</u>	<u>A090492</u>	<u>003</u>	Oct 28, 2011
<u>AB3</u>		<u>300MG</u>	<u>A090492</u>	<u>004</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>	VALEANT INTL	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARMA GLOBAL	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010

DILTIZAC

<u>AB4</u>	APOTEX INC	<u>120MG</u>	<u>A076395</u>	<u>001</u>	Feb 01, 2006
<u>AB4</u>		<u>180MG</u>	<u>A076395</u>	<u>002</u>	Feb 01, 2006
<u>AB4</u>		<u>240MG</u>	<u>A076395</u>	<u>003</u>	Feb 01, 2006
<u>AB4</u>		<u>300MG</u>	<u>A076395</u>	<u>004</u>	Feb 01, 2006
<u>AB4</u>		<u>360MG</u>	<u>A076395</u>	<u>005</u>	Feb 01, 2006

TAZTIA XT

<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003

TIAZAC

<u>AB4</u>	VALEANT INTL	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>		<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>		<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>		<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>		<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998

DILTIAZEM HYDROCHLORIDE

BC	+	MYLAN	120MG	A074910	003	May 02, 1997
			60MG	A074910	001	May 02, 1997
			90MG	A074910	002	May 02, 1997

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

<u>AP</u>		AKORN INC	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	+	BEDFORD	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>		HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>		HIKMA MAPLE	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
<u>AP</u>		HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>		INTL MEDICATION	<u>5MG/ML</u>	<u>A075749</u>	<u>001</u>	Nov 21, 2001
	+	HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
	+	TEVA PHARMS USA	10MG/ML	A074894	002	Apr 19, 2002

TABLET; ORAL

CARDIZEM

<u>AB</u>	VALEANT INTL	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>		<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>		<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>30MG</u>	<u>A072838</u>	<u>004</u>	Nov 05, 1992
<u>AB</u>		<u>60MG</u>	<u>A072838</u>	<u>003</u>	Nov 05, 1992
<u>AB</u>		<u>90MG</u>	<u>A072838</u>	<u>002</u>	Nov 05, 1992
<u>AB</u>		<u>120MG</u>	<u>A072838</u>	<u>001</u>	Nov 05, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-116 (of 371)

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	VALEANT INTL	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+	<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>		<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>		<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>		<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>		<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>		<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

+	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004
---	--------------------	---------	---------	-----	--------------

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	AKORN	10%	N005939	001	
---	-------	-----	---------	-----	--

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

TECFIDERA

	BIOGEN IDEC INC	120MG	N204063	001	Mar 27, 2013
+		240MG	N204063	002	Mar 27, 2013

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

<u>AT</u>	MYLAN INSTITUTIONAL	<u>50%</u>	<u>A076185</u>	<u>001</u>	Nov 29, 2002
	<u>RIMSO-50</u>				
<u>AT</u>	+	MYLAN INSTITUTIONAL	<u>50%</u>	<u>N017788</u>	<u>001</u>

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+	PHARMACIA AND UPJOHN	0.5MG/3GM	N019617	001	Dec 09, 1992
---	----------------------	-----------	---------	-----	--------------

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995
---	--------------------	------	---------	-----	--------------

SUPPOSITORY; VAGINAL

PROSTIN E2

+	PHARMACIA AND UPJOHN	20MG	N017810	001	
---	----------------------	------	---------	-----	--

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	BARR	50MG	A080738	001	
---	------	------	---------	-----	--

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

+	PHARM ASSOC	12.5MG/5ML	A087513	001	Feb 10, 1982
---	-------------	------------	---------	-----	--------------

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

<u>AP</u>	APP PHARMS	<u>50MG/ML</u>	<u>A040466</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+	HIKMA MAPLE	<u>50MG/ML</u>	<u>A080817</u>	<u>002</u>
<u>AP</u>	HOSPIRA	<u>50MG/ML</u>	<u>A040140</u>	<u>001</u>	Nov 20, 1998
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A040498</u>	<u>001</u>	Jul 12, 2005
	<u>DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE</u>				
<u>AP</u>	BD RX	<u>50MG/ML</u>	<u>A091526</u>	<u>001</u>	Mar 26, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-117 (of 371)

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

<u>AP</u>	+	BEDFORD	<u>5MG/ML</u>	<u>A074939</u>	<u>001</u>	Apr 13, 1998
<u>AP</u>		FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A074956</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		HIKMA MAPLE	<u>5MG/ML</u>	<u>A074521</u>	<u>001</u>	Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLE

<u>AB</u>		BARR	<u>25MG</u>	<u>A087184</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>50MG</u>	<u>A087716</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>			<u>75MG</u>	<u>A087717</u>	<u>001</u>	Oct 03, 1990
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A040782</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>			<u>50MG</u>	<u>A040782</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>			<u>75MG</u>	<u>A040782</u>	<u>003</u>	Jul 18, 2007
<u>AB</u>		LANNETT	<u>25MG</u>	<u>A040898</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>			<u>50MG</u>	<u>A040898</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>			<u>75MG</u>	<u>A040898</u>	<u>003</u>	Apr 23, 2008
<u>AB</u>		MURTY PHARMS	<u>25MG</u>	<u>A040733</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>			<u>50MG</u>	<u>A040733</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>			<u>75MG</u>	<u>A040733</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>		PUREPAC PHARM	<u>25MG</u>	<u>A089425</u>	<u>001</u>	Jul 12, 1990
<u>AB</u>		ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A040874</u>	<u>001</u>	Jan 28, 2008
<u>AB</u>			<u>50MG</u>	<u>A040874</u>	<u>002</u>	Jan 28, 2008
<u>AB</u>			<u>75MG</u>	<u>A040874</u>	<u>003</u>	Jan 28, 2008

PERSANTINE

<u>AB</u>		BOEHRINGER INGELHEIM	<u>25MG</u>	<u>N012836</u>	<u>003</u>	Dec 22, 1986
<u>AB</u>			<u>50MG</u>	<u>N012836</u>	<u>004</u>	Feb 06, 1987
<u>AB</u>	+		<u>75MG</u>	<u>N012836</u>	<u>005</u>	Feb 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

<u>AB</u>		TEVA	<u>EQ 100MG BASE</u>	<u>A070101</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070102</u>	<u>001</u>	Feb 22, 1985
<u>AB</u>		WATSON LABS	<u>EQ 100MG BASE</u>	<u>A070173</u>	<u>001</u>	May 31, 1985
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A070174</u>	<u>001</u>	May 31, 1985

NORPACE

<u>AB</u>		GD SEARLE LLC	<u>EQ 100MG BASE</u>	<u>N017447</u>	<u>001</u>	
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N017447</u>	<u>002</u>	

CAPSULE, EXTENDED RELEASE; ORAL

NORPACE CR

<u>AB</u>	+	GD SEARLE LLC	<u>EQ 150MG BASE</u>	<u>N018655</u>	<u>002</u>	Jul 20, 1982
			EQ 100MG BASE	<u>N018655</u>	<u>001</u>	Jul 20, 1982

DISULFIRAM

TABLET; ORAL

ANTABUSE

<u>AB</u>		ODYSSEY PHARMS	<u>250MG</u>	<u>A088482</u>	<u>001</u>	Dec 08, 1983
<u>AB</u>	+		<u>500MG</u>	<u>A088483</u>	<u>001</u>	Dec 08, 1983

DISULFIRAM

<u>AB</u>		ROXANE	<u>250MG</u>	<u>A202652</u>	<u>001</u>	Feb 05, 2014
<u>AB</u>			<u>500MG</u>	<u>A202652</u>	<u>002</u>	Feb 05, 2014
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A091619</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A091619</u>	<u>002</u>	Mar 28, 2011
<u>AB</u>		VINTAGE PHARMS	<u>250MG</u>	<u>A091563</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>			<u>500MG</u>	<u>A091563</u>	<u>002</u>	Dec 31, 2012

DISULFIRAM

<u>AB</u>		ALVOGEN PINE BROOK	<u>250MG</u>	<u>A091681</u>	<u>001</u>	Aug 08, 2013
-----------	--	--------------------	--------------	----------------	------------	--------------

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DEPAKOTE

<u>AB</u>	+	ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N019680</u>	<u>001</u>	Sep 12, 1989
-----------	---	--------	-------------------------------	----------------	------------	--------------

DIVALPROEX SODIUM

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078979</u>	<u>001</u>	Jan 23, 2009
<u>AB</u>		MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090407</u>	<u>001</u>	Mar 28, 2011
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A078919</u>	<u>001</u>	Jan 27, 2009

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE

<u>AB</u>		ABBVIE	<u>EQ 125MG VALPROIC ACID</u>	<u>N018723</u>	<u>003</u>	Oct 26, 1984
<u>AB</u>			<u>EQ 250MG VALPROIC ACID</u>	<u>N018723</u>	<u>001</u>	Mar 10, 1983
<u>AB</u>	+		<u>EQ 500MG VALPROIC ACID</u>	<u>N018723</u>	<u>002</u>	Mar 10, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-118 (of 371)

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 500MG VALPROIC ACID</u>	<u>A079080</u>	<u>001</u>	Feb 25, 2011
<u>AB</u>	ANCHEN PHARMS	<u>EQ 500MG VALPROIC ACID</u>	<u>A078411</u>	<u>001</u>	Nov 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A090554</u>	<u>001</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090554</u>	<u>002</u>	Apr 21, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090554</u>	<u>003</u>	Apr 21, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A078755</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078755</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078755</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	LUPIN	<u>EQ 125MG VALPROIC ACID</u>	<u>A078790</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078790</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078790</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	MYLAN	<u>EQ 125MG VALPROIC ACID</u>	<u>A090062</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090062</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090062</u>	<u>003</u>	Mar 17, 2009
<u>AB</u>	NU PHARM	<u>EQ 125MG VALPROIC ACID</u>	<u>A077615</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077615</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077615</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 125MG VALPROIC ACID</u>	<u>A078853</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078853</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078853</u>	<u>003</u>	Nov 25, 2008
<u>AB</u>	SANDOZ	<u>EQ 125MG VALPROIC ACID</u>	<u>A078290</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078290</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078290</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>	SUN PHARM INDS	<u>EQ 125MG VALPROIC ACID</u>	<u>A078597</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078597</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078597</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	TEVA	<u>EQ 125MG VALPROIC ACID</u>	<u>A076941</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A076941</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A076941</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 125MG VALPROIC ACID</u>	<u>A079163</u>	<u>001</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A079163</u>	<u>002</u>	Apr 05, 2011
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A079163</u>	<u>003</u>	Apr 05, 2011
<u>AB</u>	UPSHER SMITH	<u>EQ 125MG VALPROIC ACID</u>	<u>A078182</u>	<u>001</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A078182</u>	<u>002</u>	Jul 29, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078182</u>	<u>003</u>	Jul 29, 2008
<u>AB</u>	VINTAGE	<u>EQ 125MG VALPROIC ACID</u>	<u>A090210</u>	<u>001</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A090210</u>	<u>002</u>	Nov 30, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A090210</u>	<u>003</u>	Nov 30, 2009
<u>AB</u>	WOCKHARDT	<u>EQ 125MG VALPROIC ACID</u>	<u>A077296</u>	<u>001</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077296</u>	<u>002</u>	Jul 31, 2008
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077296</u>	<u>003</u>	Jul 31, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 125MG VALPROIC ACID</u>	<u>A077100</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 250MG VALPROIC ACID</u>	<u>A077100</u>	<u>002</u>	Mar 05, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077100</u>	<u>003</u>	Mar 05, 2009

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000
<u>DIVALPROEX SODIUM</u>					
<u>AB</u>	ANCHEN PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078445</u>	<u>001</u>	Feb 26, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078445</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419</u>	<u>001</u>	Jun 02, 2014
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A202419</u>	<u>002</u>	Jun 02, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>	IMPAX LABS	<u>EQ 250MG VALPROIC ACID</u>	<u>A078791</u>	<u>001</u>	May 06, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078791</u>	<u>002</u>	Aug 04, 2009
<u>AB</u>	MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>	REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>		<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-119 (of 371)

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	EUROHLTH INTL	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
AP	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993
AP	+	<u>EQ 12.5MG BASE/ML</u>	<u>A074292</u>	<u>001</u>	Feb 16, 1995

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
AP	+		<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
AP	+		<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
AP	+		<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
AP	+	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
AP	+		<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
AP	+		<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
AP	+		<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195</u>	<u>003</u>	Apr 20, 2012	
AP		<u>80MG/4ML (20MG/ML)</u>	<u>N201195</u>	<u>004</u>	Apr 20, 2012	
AP	+	<u>160MG/8ML (20MG/ML)</u>	<u>N201195</u>	<u>005</u>	Apr 20, 2012	
AP	ACTAVIS INC	<u>20MG/ML (20MG/ML)</u>	<u>N203551</u>	<u>001</u>	Apr 12, 2013	
AP		<u>80MG/4ML (20MG/ML)</u>	<u>N203551</u>	<u>002</u>	Apr 12, 2013	
AP	DR REDDYS LABS LTD	<u>20MG/ML (20MG/ML)</u>	<u>A204193</u>	<u>001</u>	Nov 05, 2014	
AP		<u>80MG/4ML (20MG/ML)</u>	<u>A204193</u>	<u>002</u>	Nov 05, 2014	
AP	+	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234</u>	<u>001</u>	Mar 08, 2011
AP	+		<u>80MG/8ML (10MG/ML)</u>	<u>N022234</u>	<u>002</u>	Mar 08, 2011
AP	+		<u>160MG/16ML (10MG/ML)</u>	<u>N022234</u>	<u>003</u>	Mar 08, 2011
AP	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525</u>	<u>001</u>	Jun 29, 2011	
AP		<u>80MG/8ML (10MG/ML)</u>	<u>N201525</u>	<u>002</u>	Jun 29, 2011	
AP		<u>160MG/16ML (10MG/ML)</u>	<u>N201525</u>	<u>003</u>	Jun 29, 2011	

TAXOTERE

AP	+	SANOFI AVENTIS US	<u>20MG/ML (20MG/ML)</u>	<u>N020449</u>	<u>003</u>	Aug 03, 2010
AP	+		<u>80MG/4ML (20MG/ML)</u>	<u>N020449</u>	<u>004</u>	Aug 02, 2010
AP	+		<u>160MG/8ML (20MG/ML)</u>	<u>N020449</u>	<u>005</u>	Apr 13, 2012

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011
+		80MG/VIAL	N022534	002	May 03, 2011

DOCETAXEL

ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
	80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
ACTAVIS INC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
	80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
	130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
	200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014

DOFETILIDE

CAPSULE; ORAL

TIKOSYN

PFIZER	0.125MG	N020931	001	Oct 01, 1999
	0.25MG	N020931	002	Oct 01, 1999
+	0.5MG	N020931	003	Oct 01, 1999

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	SANOFI AVENTIS US	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
+		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL

ANZEMET

SANOFI AVENTIS US	50MG	N020623	001	Sep 11, 1997
+	100MG	N020623	002	Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+	VIIIV HLTHCARE	EQ 50MG BASE	N204790	001	Aug 12, 2013
---	----------------	--------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-120 (of 371)

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

ARICEPT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N020690</u>	<u>002</u>	Nov 25, 1996
<u>AB</u>	+	<u>10MG</u>	<u>N020690</u>	<u>001</u>	Nov 25, 1996
<u>AB</u>	+	<u>23MG</u>	<u>N022568</u>	<u>001</u>	Jul 23, 2010

DONEPEZIL HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201724</u>	<u>001</u>	Feb 25, 2013
<u>AB</u>		<u>10MG</u>	<u>A201724</u>	<u>002</u>	Feb 25, 2013
<u>AB</u>	APOTEX	<u>5MG</u>	<u>A078841</u>	<u>001</u>	Jun 02, 2011
<u>AB</u>		<u>10MG</u>	<u>A078841</u>	<u>002</u>	Jun 02, 2011
<u>AB</u>	AUROBINDO	<u>5MG</u>	<u>A090056</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090056</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077518</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077518</u>	<u>002</u>	May 31, 2011
<u>AB</u>	CSPC OUYI PHARM CO	<u>5MG</u>	<u>A202114</u>	<u>001</u>	Jul 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A202114</u>	<u>002</u>	Jul 05, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A201001</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A201001</u>	<u>002</u>	May 31, 2011
<u>AB</u>		<u>23MG</u>	<u>A202723</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	HIKMA PHARMS	<u>5MG</u>	<u>A090247</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090247</u>	<u>002</u>	May 31, 2011
<u>AB</u>	INDICUS PHARMA	<u>5MG</u>	<u>A201634</u>	<u>001</u>	Jun 13, 2012
<u>AB</u>		<u>10MG</u>	<u>A201634</u>	<u>002</u>	Jun 13, 2012
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A090768</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090768</u>	<u>002</u>	May 31, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201146</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>10MG</u>	<u>A201146</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>23MG</u>	<u>A202631</u>	<u>001</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090521</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090521</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PAR PHARM	<u>23MG</u>	<u>A202542</u>	<u>001</u>	Jul 24, 2013
<u>AB</u>	PLIVA HRVATSKA DOO	<u>5MG</u>	<u>A090425</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090425</u>	<u>002</u>	May 31, 2011
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A200292</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A200292</u>	<u>002</u>	May 31, 2011
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076786</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A076786</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078662</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A078662</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A090290</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090290</u>	<u>002</u>	May 31, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203907</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>10MG</u>	<u>A203907</u>	<u>002</u>	Oct 29, 2014
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090493</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090493</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A077344</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A077344</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A090686</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090686</u>	<u>002</u>	May 31, 2011
<u>AB</u>	TWI PHARMS INC	<u>23MG</u>	<u>A203104</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	VIVIMED LABS	<u>5MG</u>	<u>A090551</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A090551</u>	<u>002</u>	May 31, 2011
<u>AB</u>	WOCKHARDT	<u>5MG</u>	<u>A091267</u>	<u>001</u>	May 31, 2011
<u>AB</u>		<u>10MG</u>	<u>A091267</u>	<u>002</u>	May 31, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090100</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>10MG</u>	<u>A090100</u>	<u>002</u>	Oct 24, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

<u>AB</u>	EISAI INC	<u>5MG</u>	<u>N021720</u>	<u>001</u>	Oct 18, 2004
<u>AB</u>	+	<u>10MG</u>	<u>N021720</u>	<u>002</u>	Oct 18, 2004
<u>AB</u>	BARR	<u>5MG</u>	<u>A078388</u>	<u>002</u>	Nov 26, 2010
<u>AB</u>		<u>10MG</u>	<u>A078388</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A201787</u>	<u>001</u>	Dec 14, 2012
<u>AB</u>		<u>10MG</u>	<u>A201787</u>	<u>002</u>	Dec 14, 2012
<u>AB</u>	SANDOZ	<u>5MG</u>	<u>A091198</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A091198</u>	<u>002</u>	May 10, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A090175</u>	<u>001</u>	May 10, 2011
<u>AB</u>		<u>10MG</u>	<u>A090175</u>	<u>002</u>	May 10, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-121 (of 371)

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

FOREST LABS INC

10MG; 14MG

N206439 001 Dec 23, 2014

+

10MG; 28MG

N206439 002 Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDEAP + HOSPIRA40MG/MLN018132 001AP +80MG/100MLN018132 002 Feb 04, 1982AP +80MG/MLN018132 004 Jul 09, 1982AP +160MG/100MLN018132 003 Feb 04, 1982AP + LUITPOLD40MG/MLA070799 001 Feb 11, 1987AP +80MG/MLA070820 001 Feb 11, 1987AP +160MG/MLA070826 001 Feb 11, 1987DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%AP + B BRAUN80MG/100MLN019099 002 Oct 15, 1986AP +320MG/100MLN019099 004 Oct 15, 1986DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN160MG/100MLN019099 003 Oct 15, 1986DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINERAP + BAXTER HLTHCARE80MG/100MLN019615 001 Mar 27, 1987AP +160MG/100MLN019615 002 Mar 27, 1987AP +320MG/100MLN019615 003 Mar 27, 1987AP + HOSPIRA80MG/100MLN018826 001 Sep 30, 1983AP +160MG/100MLN018826 002 Sep 30, 1983AP +320MG/100MLN018826 003 Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+ B BRAUN

40MG/100ML

N019099 001 Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

640MG/100ML

N019615 004 Mar 27, 1987

DORIPENEM

INJECTABLE; IV (INFUSION)

DORIBAX

SHIONOGI INC

250MG/VIAL

N022106 002 Oct 05, 2010

+

500MG/VIAL

N022106 001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDEAT ALCON PHARMS LTDEQ 2% BASEA078981 001 Apr 13, 2009AT BAUSCH AND LOMBEQ 2% BASEA090143 001 Jun 25, 2009AT HI TECH PHARMAEQ 2% BASEA077846 001 Oct 28, 2008AT LUITPOLDEQ 2% BASEA079186 001 Nov 18, 2009AT SANDOZEQ 2% BASEA078748 001 Nov 06, 2008AT TEVA PHARMSEQ 2% BASEA078756 001 Dec 04, 2008AT WATSON LABS INCEQ 2% BASEA202053 001 Sep 11, 2014AT ZACH SYSTEMSEQ 2% BASEA091034 001 Dec 04, 2013TRUSOPTAT + MERCKEQ 2% BASEN020408 001 Dec 09, 1994DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPTAT + OAK PHARMS INCEQ 2% BASE; EQ 0.5% BASEN020869 001 Apr 07, 1998DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATEAT AKORN INCEQ 2% BASE; EQ 0.5% BASEA203058 001 Sep 22, 2014AT ALCON RESEQ 2% BASE; EQ 0.5% BASEA090604 001 Nov 18, 2009AT BAUSCH AND LOMBEQ 2% BASE; EQ 0.5% BASEA090037 001 Jul 14, 2009AT HI TECH PHARMAEQ 2% BASE; EQ 0.5% BASEA077847 001 Oct 28, 2008AT LANNETT HOLDINGS INCEQ 2% BASE; EQ 0.5% BASEA201998 001 Dec 17, 2014AT SANDOZEQ 2% BASE; EQ 0.5% BASEA078749 001 Nov 06, 2008AT TEVA PHARMSEQ 2% BASE; EQ 0.5% BASEA078704 001 Sep 28, 2009AT WATSON LABS INCEQ 2% BASE; EQ 0.5% BASEA202054 001 Sep 03, 2014AT ZACH SYSTEMSEQ 2% BASE; EQ 0.5% BASEA091180 001 Dec 04, 2013

COSOPT PF

+ OAK PHARMS INC

EQ 2% BASE; EQ 0.5% BASE

N202667 001 Feb 01, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-122 (of 371)

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

<u>AP</u>	+	HIKMA MAPLE	<u>20MG/ML</u>	<u>N014879</u>	<u>001</u>	
-----------	---	-------------	----------------	----------------	------------	--

DOXAPRAM HYDROCHLORIDE

<u>AP</u>		BEDFORD	<u>20MG/ML</u>	<u>A076266</u>	<u>001</u>	Jan 10, 2003
-----------	--	---------	----------------	----------------	------------	--------------

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

<u>AB</u>	+	PFIZER	<u>EQ 1MG BASE</u>	<u>N019668</u>	<u>001</u>	Nov 02, 1990
-----------	---	--------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N019668</u>	<u>002</u>	Nov 02, 1990
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N019668</u>	<u>003</u>	Nov 02, 1990
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>N019668</u>	<u>004</u>	Nov 02, 1990
-----------	--	--	--------------------	----------------	------------	--------------

DOXAZOSIN MESYLATE

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824</u>	<u>001</u>	Jun 11, 2014
-----------	--	-----------------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A202824</u>	<u>002</u>	Jun 11, 2014
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A202824</u>	<u>003</u>	Jun 11, 2014
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A202824</u>	<u>004</u>	Jun 11, 2014
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		APOTEX	<u>EQ 1MG BASE</u>	<u>A075580</u>	<u>001</u>	Oct 18, 2000
-----------	--	--------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075580</u>	<u>002</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075580</u>	<u>003</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075580</u>	<u>004</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		DAVA PHARMS INC	<u>EQ 1MG BASE</u>	<u>A076161</u>	<u>001</u>	Jun 10, 2004
-----------	--	-----------------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A076161</u>	<u>002</u>	Jun 10, 2004
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076161</u>	<u>003</u>	Jun 10, 2004
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A076161</u>	<u>004</u>	Jun 10, 2004
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A075509</u>	<u>001</u>	Oct 19, 2000
-----------	--	-------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075509</u>	<u>002</u>	Oct 19, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075509</u>	<u>003</u>	Oct 19, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075509</u>	<u>004</u>	Oct 19, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
-----------	--	-------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
-----------	--	------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000
-----------	--	--	--------------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

PFIZER

EQ 4MG BASE

N021269 001 Feb 22, 2005

+

EQ 8MG BASE

N021269 002 Feb 22, 2005

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>		MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791</u>	<u>002</u>	May 13, 1986
-----------	--	------------------	---------------------	----------------	------------	--------------

<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
-----------	---	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
-----------	--	--	---------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
-----------	--	--	----------------------	----------------	------------	--------------

PAR PHARM

EQ 150MG BASE

A071669 001 Nov 09, 1987

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>		SILARX	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
-----------	--	--------	------------------------	----------------	------------	--------------

<u>AA</u>	+	TEVA PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A071609</u>	<u>001</u>	Nov 09, 1987
-----------	---	-------------	------------------------	----------------	------------	--------------

<u>AA</u>		WOCKHARDT	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988
-----------	--	-----------	------------------------	----------------	------------	--------------

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951</u>	<u>001</u>	Jul 26, 2013
-----------	--	-------------------	--------------------	----------------	------------	--------------

<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A201951</u>	<u>002</u>	Jul 26, 2013
-----------	--	--	--------------------	----------------	------------	--------------

SILENOR

<u>AB</u>		PERNIX THERAPS LLC	<u>EQ 3MG BASE</u>	<u>N022036</u>	<u>001</u>	Mar 17, 2010
-----------	--	--------------------	--------------------	----------------	------------	--------------

<u>AB</u>	+		<u>EQ 6MG BASE</u>	<u>N022036</u>	<u>002</u>	Mar 17, 2010
-----------	---	--	--------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-123 (of 371)

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	ROXANE	<u>0.5MCG</u>	<u>A091433</u>	<u>001</u>	Sep 23, 2011
<u>AB</u>		<u>1MCG</u>	<u>A091433</u>	<u>002</u>	Jan 14, 2014
<u>AB</u>		<u>2.5MCG</u>	<u>A091433</u>	<u>003</u>	Jan 14, 2014

HECTOROL

<u>AB</u>	GENZYME CORP	<u>0.5MCG</u>	<u>N020862</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>1MCG</u>	<u>N020862</u>	<u>003</u>	Jul 13, 2009
<u>AB</u>	+	<u>2.5MCG</u>	<u>N020862</u>	<u>001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	HIKMA PHARMS LLC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101</u>	<u>001</u>	Aug 30, 2013
<u>AP</u>	SANDOZ	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333</u>	<u>001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926</u>	<u>001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	+	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027</u>	<u>001</u>	Apr 06, 2000
		2MCG/ML (2MCG/ML)	<u>N021027</u>	<u>002</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622</u>	<u>001</u>	Jun 27, 2014
<u>AP</u>	ALVOGEN INC	<u>2MG/ML</u>	<u>A065515</u>	<u>001</u>	Nov 08, 2012
<u>AP</u>	+	<u>2MG/ML</u>	<u>A062975</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>10MG/VIAL</u>	<u>A062921</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A062921</u>	<u>002</u>	Mar 17, 1989
<u>AP</u>	+	<u>50MG/VIAL</u>	<u>A062921</u>	<u>003</u>	Mar 17, 1989
<u>AP</u>	+	<u>200MG/100ML</u>	<u>A064097</u>	<u>001</u>	Sep 13, 1994
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277</u>	<u>001</u>	Oct 26, 1995
<u>AP</u>	ONCO THERAPIES LTD	<u>2MG/ML</u>	<u>A200901</u>	<u>001</u>	Feb 14, 2012
<u>AP</u>		<u>10MG/VIAL</u>	<u>A200170</u>	<u>001</u>	Oct 28, 2011
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200170</u>	<u>002</u>	Oct 28, 2011
<u>AP</u>	PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>		<u>10MG/VIAL</u>	<u>A063097</u>	<u>001</u>	May 21, 1990
<u>AP</u>		<u>20MG/VIAL</u>	<u>A063097</u>	<u>002</u>	May 21, 1990
<u>AP</u>		<u>50MG/VIAL</u>	<u>A063097</u>	<u>003</u>	May 21, 1990
<u>AP</u>		<u>200MG/100ML</u>	<u>A063336</u>	<u>004</u>	Feb 28, 1995
<u>AP</u>	SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495</u>	<u>001</u>	Mar 18, 2013
<u>AP</u>	SANDOZ INC	<u>2MG/ML</u>	<u>A200146</u>	<u>001</u>	Jul 18, 2012
<u>AP</u>	SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418</u>	<u>001</u>	Feb 15, 2012
<u>AP</u>	TEVA PHARMS USA	<u>2MG/ML</u>	<u>A064140</u>	<u>001</u>	Jul 28, 1995
<u>AP</u>		<u>200MG/100ML</u>	<u>A064140</u>	<u>002</u>	Jul 28, 1995

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	JANSSEN RES AND DEV	<u>20MG/10ML (2MG/ML)</u>	<u>N050718</u>	<u>001</u>	Nov 17, 1995
<u>AB</u>		<u>50MG/25ML (2MG/ML)</u>	<u>N050718</u>	<u>002</u>	Jun 13, 2000

DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

<u>AB</u>	+	<u>20MG/10ML (2MG/ML)</u>	<u>A203263</u>	<u>001</u>	Feb 04, 2013
<u>AB</u>	+	<u>50MG/25ML (2MG/ML)</u>	<u>A203263</u>	<u>002</u>	Feb 04, 2013

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>	IMPAX LABS INC	<u>EQ 150MG BASE</u>	<u>A200065</u>	<u>001</u>	Feb 17, 2011
<u>AB</u>	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234</u>	<u>001</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A204234</u>	<u>002</u>	Mar 05, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204234</u>	<u>003</u>	Mar 05, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A202778</u>	<u>001</u>	Jun 08, 2012
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>A065055</u>	<u>003</u>	Jul 15, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000

MONODOX

<u>AB</u>	AQUA PHARMS	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989
	ORACEA				
	+	GALDERMA LABS LP	40MG	<u>N050805</u>	001 May 26, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-124 (of 371)

DOXYCYCLINE

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 25MG BASE/5ML</u>	<u>A065454</u>	<u>001</u>	Jul 16, 2008
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678</u>	<u>001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+ PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006</u>	<u>001</u>	
-----------	----------	-------------------------	----------------	------------	--

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 50MG BASE</u>	<u>A091605</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605</u>	<u>003</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091605</u>	<u>004</u>	Dec 20, 2011
<u>AB</u>	LANNETT	<u>EQ 50MG BASE</u>	<u>A065285</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285</u>	<u>003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285</u>	<u>004</u>	Jul 30, 2008
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A065377</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065377</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065377</u>	<u>003</u>	Nov 07, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065427</u>	<u>001</u>	Jun 07, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065070</u>	<u>001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070</u>	<u>003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070</u>	<u>002</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065070</u>	<u>004</u>	Jul 14, 2005
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065356</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356</u>	<u>003</u>	May 31, 2006

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031</u>	<u>002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031</u>	<u>001</u>	
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 50MG BASE</u>	<u>A062500</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500</u>	<u>002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396</u>	<u>002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396</u>	<u>001</u>	May 07, 1984
<u>AB</u>	MUTUAL PHARM	<u>EQ 50MG BASE</u>	<u>A062675</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>	MYLAN	<u>EQ 50MG BASE</u>	<u>A062337</u>	<u>001</u>	Mar 29, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062337</u>	<u>002</u>	Mar 29, 1982

VIBRAMYCIN

<u>AB</u>	PFIZER	<u>EQ 50MG BASE</u>	<u>N050007</u>	<u>001</u>	
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050007</u>	<u>002</u>	

DOXYCYCLINE HYCLATE

+ HIKMA INTL PHARMS

EQ 20MG BASE

A065103 001 May 13, 2005

CAPSULE, DELAYED RELEASE; ORAL

DOXYCYCLINE HYCLATE

MEDICIS

EQ 75MG BASE

A065281 001 Dec 21, 2005

+

EQ 100MG BASE

A065281 002 Dec 21, 2005

INJECTABLE; INJECTION

DOXY 100

<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475</u>	<u>001</u>	Dec 09, 1983
-----------	----------------------	---------------------------	----------------	------------	--------------

DOXYCYCLINE

<u>AP</u>	AGILA SPECLTS	<u>EQ 100MG BASE/VIAL</u>	<u>A091406</u>	<u>001</u>	Aug 21, 2012
<u>AP</u>	+ EUROHLTH INTL	<u>EQ 100MG BASE/VIAL</u>	<u>A062569</u>	<u>001</u>	Mar 09, 1988

DOXY 200

+ FRESENIUS KABI USA

EQ 200MG BASE/VIAL

A062475 002 Dec 09, 1983

SYSTEM, EXTENDED RELEASE; PERIODONTAL

ATRIDOX

+ TOLMAR

50MG

N050751 001 Sep 03, 1998

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983
<u>AB</u>	BLU CARIBE INC	<u>EQ 100MG BASE</u>	<u>A062269</u>	<u>002</u>	Nov 08, 1982
<u>AB</u>	CHARTWELL LIFE SCI	<u>EQ 100MG BASE</u>	<u>A062505</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>	COREPHARMA	<u>EQ 20MG BASE</u>	<u>A065182</u>	<u>001</u>	May 13, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-125 (of 371)

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	+	HIKMA INTL PHARMS	<u>EQ 100MG BASE</u>	<u>A065095</u>	<u>001</u>	Jul 02, 2003
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A065163</u>	<u>001</u>	May 13, 2005
<u>AB</u>	+	LANNETT	<u>EQ 20MG BASE</u>	<u>A065277</u>	<u>001</u>	Nov 10, 2005
<u>AB</u>		LARKEN LABS	<u>EQ 20MG BASE</u>	<u>A065287</u>	<u>001</u>	Feb 28, 2006
<u>AB</u>		MUTUAL PHARM	<u>EQ 100MG BASE</u>	<u>A062677</u>	<u>001</u>	Jul 10, 1986
<u>AB</u>		MUTUAL PHARMA	<u>EQ 20MG BASE</u>	<u>A065134</u>	<u>001</u>	May 13, 2005
<u>AB</u>		MYLAN	<u>EQ 100MG BASE</u>	<u>A062432</u>	<u>001</u>	Feb 15, 1983
<u>AB</u>		VINTAGE PHARMS	<u>EQ 100MG BASE</u>	<u>A062538</u>	<u>001</u>	Apr 07, 1986

ACTICLATE

AQUA PHARMS LLC

EQ 75MG BASE

N205931 001 Jul 25, 2014

+

EQ 150MG BASE

N205931 002 Jul 25, 2014

TABLET, DELAYED RELEASE; ORAL

DORYX

<u>AB</u>		MAYNE PHARMA	<u>EQ 75MG BASE</u>	<u>N050795</u>	<u>001</u>	May 06, 2005
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>N050795</u>	<u>002</u>	May 06, 2005
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>N050795</u>	<u>003</u>	Jun 20, 2008

DOXYCYCLINE HYCLATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 75MG BASE</u>	<u>A090134</u>	<u>001</u>	Dec 14, 2011
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090134</u>	<u>002</u>	Dec 14, 2011
<u>AB</u>		HERITAGE PHARMS INC	<u>EQ 75MG BASE</u>	<u>A200856</u>	<u>001</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200856</u>	<u>002</u>	Apr 30, 2013
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200856</u>	<u>003</u>	Apr 30, 2013
<u>AB</u>		IMPAX LABS INC	<u>EQ 75MG BASE</u>	<u>A090505</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090505</u>	<u>002</u>	Dec 28, 2010
<u>AB</u>		MYLAN	<u>EQ 75MG BASE</u>	<u>A090431</u>	<u>001</u>	Dec 28, 2010
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A090431</u>	<u>002</u>	Dec 28, 2010
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 150MG BASE</u>	<u>A091052</u>	<u>001</u>	Feb 08, 2012

DORYX

MAYNE PHARMA

EQ 80MG BASE

N050795 004 Apr 11, 2013

+

EQ 200MG BASE

N050795 005 Apr 11, 2013

DOXTERIC

MAYNE PHARMA

EQ 50MG BASE

N050795 006 Dec 19, 2014

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

+ DUCHESNAY

10MG; 10MG

N021876 001 Apr 08, 2013

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>		AKORN INC	<u>2.5MG</u>	<u>A079217</u>	<u>001</u>	Jun 20, 2014
<u>AB</u>			<u>5MG</u>	<u>A079217</u>	<u>002</u>	Jun 20, 2014
<u>AB</u>			<u>10MG</u>	<u>A079217</u>	<u>003</u>	Jun 20, 2014
<u>AB</u>		INSYS THERAP	<u>2.5MG</u>	<u>A078501</u>	<u>001</u>	Aug 19, 2011
<u>AB</u>			<u>5MG</u>	<u>A078501</u>	<u>002</u>	Aug 19, 2011
<u>AB</u>			<u>10MG</u>	<u>A078501</u>	<u>003</u>	Aug 19, 2011
<u>AB</u>		SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>			<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>			<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

<u>AB</u>		ABBVIE	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985
<u>AB</u>	+		<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985
<u>AB</u>			<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+ SANOFI AVENTIS US

EQ 400MG BASE

N022425 001 Jul 01, 2009

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

<u>AP</u>		HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>		LUITPOLD	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988
<u>AP</u>	+	AKORN INC	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-126 (of 371)

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

BAYER HLTHCARE	0.25MG; 0.5MG	N021355 001	Feb 29, 2012
+	0.5MG; 1MG	N021355 002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG; 0.02MG	A078515 001	Mar 30, 2009
AB	WATSON LABS	3MG; 0.02MG	A078833 001	Nov 28, 2011
LORYNA				
AB	SANDOZ	3MG; 0.02MG	A079221 001	Mar 28, 2011
NIKKI				
AB	LUPIN LTD	3MG; 0.02MG	A201661 001	May 27, 2014
YAZ				
AB	+	BAYER HLTHCARE	3MG; 0.02MG	N021676 001 Mar 16, 2006

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG; 0.03MG	A077527 001	May 09, 2008
AB	LUPIN LTD	3MG; 0.03MG	A201663 001	Dec 18, 2012
AB	WATSON LABS	3MG; 0.03MG	A090081 001	Sep 07, 2010
SYEDA				
AB	SANDOZ	3MG; 0.03MG	A090114 001	Mar 28, 2011
YAELE				
AB	NOVAST LABS LTD	3MG; 0.03MG	A202015 001	Nov 19, 2014
YASMIN				
AB	+	BAYER HLTHCARE	3MG; 0.03MG	N021098 001 May 11, 2001

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

BAYER HLTHCARE	3MG, N/A; 0.02MG, N/A; 0.451MG, 0.451MG	N022532 001	Sep 24, 2010
SAFYRAL			
+	BAYER HLTHCARE	3MG, N/A; 0.03MG, N/A; 0.451MG, 0.451MG	N022574 001 Dec 16, 2010

DROXIDOPA

CAPSULE; ORAL

NORTHERA

LUNDBECK NA LTD	100MG	N203202 001	Feb 18, 2014
	200MG	N203202 002	Feb 18, 2014
+	300MG	N203202 003	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

AB	LILLY	EQ 20MG BASE	N021427 001	Aug 03, 2004
AB		EQ 30MG BASE	N021427 002	Aug 03, 2004
AB	+	EQ 60MG BASE	N021427 004	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A090776 001	Dec 17, 2013
AB		EQ 30MG BASE	A090776 002	Dec 17, 2013
AB		EQ 60MG BASE	A090776 003	Dec 17, 2013
AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949 001	Jun 09, 2014
AB		EQ 30MG BASE	A202949 002	Jun 09, 2014
AB		EQ 60MG BASE	A202949 003	Jun 09, 2014
AB	APOTEX INC	EQ 20MG BASE	A202045 001	Jun 11, 2014
AB		EQ 30MG BASE	A202045 002	Jun 11, 2014
AB		EQ 60MG BASE	A202045 003	Jun 11, 2014
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A090778 001	Dec 11, 2013
AB		EQ 30MG BASE	A090778 002	Dec 11, 2013
AB		EQ 60MG BASE	A090778 003	Dec 11, 2013
AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088 001	Jun 11, 2014
AB		EQ 30MG BASE	A203088 002	Jun 11, 2014
AB		EQ 60MG BASE	A203088 003	Jun 11, 2014
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A090723 001	Dec 11, 2013
AB		EQ 30MG BASE	A090723 002	Dec 11, 2013
AB		EQ 60MG BASE	A090723 003	Dec 11, 2013
AB	LUPIN LTD	EQ 20MG BASE	A090694 001	Dec 11, 2013
AB		EQ 30MG BASE	A090694 002	Dec 11, 2013
AB		EQ 60MG BASE	A090694 004	Dec 11, 2013
AB	SUN PHARMA GLOBAL	EQ 20MG BASE	A090745 001	Dec 11, 2013
AB		EQ 30MG BASE	A090745 002	Dec 11, 2013
AB		EQ 60MG BASE	A090745 003	Dec 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-127 (of 371)

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>EQ 20MG BASE</u>	<u>A090783 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090783 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090783 003</u>	Dec 11, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
	LUPIN LTD	EQ 40MG BASE	A090694 003	Dec 11, 2013

DUTASTERIDE

CAPSULE; ORAL

AVODART

<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.5MG</u>	<u>N021319 001</u>	Nov 20, 2001
		<u>DUTASTERIDE</u>			
<u>AB</u>		BARR	<u>0.5MG</u>	<u>A090095 001</u>	Dec 21, 2010

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

<u>AB</u>		ANCHEN PHARMS	<u>0.5MG; 0.4MG</u>	<u>A202509 001</u>	Feb 26, 2014
		<u>JALYN</u>			
<u>AB</u>	+	GLAXOSMITHKLINE	<u>0.5MG; 0.4MG</u>	<u>N022460 001</u>	Jun 14, 2010

DYPHYLLINE

TABLET; ORAL

LUFYLLIN

		MEDA PHARMS	200MG	A084566 001	
	+		400MG	A084566 002	

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

	+	WYETH PHARMS INC	0.125%	N011963 001	
--	---	------------------	--------	-------------	--

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

	+	VELDANA MEDICAL SA	1%	N205175 001	Oct 24, 2013
--	---	--------------------	----	-------------	--------------

CREAM; TOPICAL

ECONAZOLE NITRATE

<u>AB</u>	+	FOUGERA PHARMS	<u>1%</u>	<u>A076075 001</u>	Nov 26, 2002
<u>AB</u>		IGI LABS INC	<u>1%</u>	<u>A076574 001</u>	Dec 17, 2004
<u>AB</u>		PERRIGO NEW YORK	<u>1%</u>	<u>A076479 001</u>	Jun 23, 2004
<u>AB</u>		TARO	<u>1%</u>	<u>A076005 001</u>	Nov 26, 2002

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

	+	MEDICIS	200MG/ML	N008922 001	
--	---	---------	----------	-------------	--

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

<u>AP</u>		MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>A088873 001</u>	Aug 06, 1985
		<u>TENSILON</u>			
<u>AP</u>	+	VALEANT PHARMS	<u>10MG/ML</u>	<u>N007959 001</u>	
		<u>TENSILON PRESERVATIVE FREE</u>			
<u>AP</u>	+	VALEANT PHARMS	<u>10MG/ML</u>	<u>N007959 002</u>	

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

		BRISTOL MYERS SQUIBB	50MG	N020972 001	Sep 17, 1998
	+		200MG	N020972 003	Sep 17, 1998

TABLET; ORAL

SUSTIVA

	+	BRISTOL MYERS SQUIBB	600MG	N021360 002	Feb 01, 2002
--	---	----------------------	-------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-128 (of 371)

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

+ GILEAD

600MG; 200MG; 300MG

N021937 001 Jul 12, 2006

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

+ DOW PHARM

10%

N203567 001 Jun 06, 2014

EFLORNITHINE HYDROCHLORIDE

CREAM; TOPICAL

VANIQA

+ SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

RELPAK

PFIZER IRELAND

EQ 20MG BASE

N021016 001 Dec 26, 2002

+

EQ 40MG BASE

N021016 002 Dec 26, 2002

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA

+ GENZYME CORP

EQ 84MG BASE

N205494 001 Aug 19, 2014

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

GLAXOSMITHKLINE

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

EQ 25MG ACID

N022291 001 Nov 20, 2008

+

EQ 50MG ACID

N022291 002 Nov 20, 2008

EQ 75MG ACID

N022291 003 Sep 08, 2009

EQ 100MG ACID

N022291 005 Nov 16, 2012

ELVITEGRAVIR

TABLET; ORAL

VITEKTA

GILEAD SCIENCES INC

85MG

N203093 001 Sep 24, 2014

+

150MG

N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

+ ALCON

0.05%

N020706 001 Dec 29, 1997

EMPAGLIFLOZIN

TABLET; ORAL

JARDIANCE

BOEHRINGER INGELHEIM

10MG

N204629 001 Aug 01, 2014

+

25MG

N204629 002 Aug 01, 2014

EMTRICITABINE

CAPSULE; ORAL

EMTRIVA

+ GILEAD

200MG

N021500 001 Jul 02, 2003

SOLUTION; ORAL

EMTRIVA

+ GILEAD

10MG/ML

N021896 001 Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+ GILEAD SCIENCES INC

200MG; EQ 25MG BASE; 300MG

N202123 001 Aug 10, 2011

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TRUVADA

+ GILEAD

200MG; 300MG

N021752 001 Aug 02, 2004

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+ SILVERGATE PHARMS

1MG/ML

N204308 001 Aug 13, 2013

TABLET; ORAL

ENALAPRIL MALEATEAB APOTEX2.5MGA075178 002 Mar 23, 2001AB5MGA075178 001 Mar 23, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-129 (of 371)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>		<u>10MG</u>	<u>A075178</u>	<u>003</u>	Mar 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075178</u>	<u>004</u>	Mar 23, 2001
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A075480</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075480</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075480</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075480</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	TARO	<u>2.5MG</u>	<u>A075657</u>	<u>001</u>	Jan 23, 2001
<u>AB</u>		<u>5MG</u>	<u>A075657</u>	<u>002</u>	Jan 23, 2001
<u>AB</u>		<u>10MG</u>	<u>A075657</u>	<u>003</u>	Jan 23, 2001
<u>AB</u>		<u>20MG</u>	<u>A075657</u>	<u>004</u>	Jan 23, 2001
<u>AB</u>	TEVA	<u>2.5MG</u>	<u>A075479</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075479</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075479</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075479</u>	<u>004</u>	Aug 22, 2000
<u>AB</u>	WOCKHARDT USA	<u>2.5MG</u>	<u>A075483</u>	<u>001</u>	Aug 22, 2000
<u>AB</u>		<u>5MG</u>	<u>A075483</u>	<u>002</u>	Aug 22, 2000
<u>AB</u>		<u>10MG</u>	<u>A075483</u>	<u>003</u>	Aug 22, 2000
<u>AB</u>		<u>20MG</u>	<u>A075483</u>	<u>004</u>	Aug 22, 2000

VASOTEC

<u>AB</u>	VALEANT INTL	<u>2.5MG</u>	<u>N018998</u>	<u>005</u>	Jul 26, 1988
<u>AB</u>		<u>5MG</u>	<u>N018998</u>	<u>001</u>	Dec 24, 1985
<u>AB</u>		<u>10MG</u>	<u>N018998</u>	<u>002</u>	Dec 24, 1985
<u>AB</u>	+	<u>20MG</u>	<u>N018998</u>	<u>003</u>	Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>5MG;12.5MG</u>	<u>A076486</u>	<u>001</u>	Oct 27, 2004
<u>AB</u>		<u>10MG;25MG</u>	<u>A076486</u>	<u>002</u>	Oct 27, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909</u>	<u>001</u>	Oct 15, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u>	Oct 15, 2001
<u>AB</u>	MYLAN	<u>5MG;12.5MG</u>	<u>A075624</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075624</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u>	Sep 18, 2001
<u>AB</u>	TEVA	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u>	Sep 18, 2001
<u>AB</u>		<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u>	Sep 18, 2001

VASERETIC

<u>AB</u>	VALEANT INTL	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u>	Jul 12, 1995
<u>AB</u>	+	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u>	Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>	+	BEDFORD	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>	+	HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u>	Aug 22, 2000
<u>AP</u>		TEVA PHARMS USA	<u>1.25MG/ML</u>	<u>A075578</u>	<u>001</u>	Aug 22, 2000

ENFLURANE

LIQUID; INHALATION

ENFLURANE

<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074396</u>	<u>001</u>	Jul 29, 1994
<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017087</u>	<u>001</u>	

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+ ROCHE 90MG/VIAL

N021481 001 Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	LOVENOX				
<u>AB</u>	SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164</u>	<u>009</u>	Jan 23, 2003
	INJECTABLE; SUBCUTANEOUS				
	<u>ENOXAPARIN SODIUM (PRESERVATIVE FREE)</u>				
<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684</u>	<u>001</u>	Sep 19, 2011
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684</u>	<u>002</u>	Sep 19, 2011
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684</u>	<u>003</u>	Sep 19, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-130 (of 371)

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP		80MG/0.8ML (100MG/ML)	A076684	004	Sep 19, 2011
AP		100MG/ML (100MG/ML)	A076684	005	Sep 19, 2011
AP		120MG/0.8ML (150MG/ML)	A076684	006	Sep 19, 2011
AP		150MG/ML (150MG/ML)	A076684	007	Sep 19, 2011
AP	SANDOZ	30MG/0.3ML (100MG/ML)	A077857	002	Jul 23, 2010
AP		40MG/0.4ML (100MG/ML)	A077857	003	Jul 23, 2010
AP		60MG/0.6ML (100MG/ML)	A077857	004	Jul 23, 2010
AP		80MG/0.8ML (100MG/ML)	A077857	005	Jul 23, 2010
AP		100MG/ML (100MG/ML)	A077857	001	Jul 23, 2010
AP		120MG/0.8ML (150MG/ML)	A077857	006	Jul 23, 2010
AP		150MG/ML (150MG/ML)	A077857	007	Jul 23, 2010
AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014
AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014
AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014
AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014
AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014
AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014
AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014
<u>LOVENOX (PRESERVATIVE FREE)</u>					
AP	SANOFI AVENTIS US	30MG/0.3ML (100MG/ML)	N020164	001	Mar 29, 1993
AP		40MG/0.4ML (100MG/ML)	N020164	002	Jan 30, 1998
AP		60MG/0.6ML (100MG/ML)	N020164	003	Mar 27, 1998
AP		80MG/0.8ML (100MG/ML)	N020164	004	Mar 27, 1998
AP	+	100MG/ML (100MG/ML)	N020164	005	Mar 27, 1998
AP		120MG/0.8ML (150MG/ML)	N020164	007	Jun 02, 2000
AP		150MG/ML (150MG/ML)	N020164	008	Jun 02, 2000

ENTACAPONE

TABLET; ORAL

COMTAN

<u>AB</u>	+	ORION PHARMA	<u>200MG</u>	<u>N020796</u>	<u>001</u>	Oct 19, 1999
<u>ENTACAPONE</u>						
<u>AB</u>		MYLAN PHARMS INC	<u>200MG</u>	<u>A202394</u>	<u>001</u>	May 13, 2013
<u>AB</u>		SUN PHARMA GLOBAL	<u>200MG</u>	<u>A090690</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>		WOCKHARDT LTD	<u>200MG</u>	<u>A078941</u>	<u>001</u>	Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+ BRISTOL MYERS SQUIBB 0.05MG/ML

N021798 001 Mar 29, 2005

TABLET; ORAL

BARACLUDE

<u>AB</u>		BRISTOL MYERS SQUIBB	<u>0.5MG</u>	<u>N021797</u>	<u>001</u>	Mar 29, 2005
<u>AB</u>	+		<u>1MG</u>	<u>N021797</u>	<u>002</u>	Mar 29, 2005
<u>ENTECAVIR</u>						
<u>AB</u>		TEVA PHARMS USA	<u>0.5MG</u>	<u>A202122</u>	<u>001</u>	Aug 26, 2014
<u>AB</u>			<u>1MG</u>	<u>A202122</u>	<u>002</u>	Aug 26, 2014

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+ ASTELLAS 40MG

N203415 001 Aug 31, 2012

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003
<u>EPINASTINE HYDROCHLORIDE</u>						
AT		APOTEX	0.05%	A090919	001	Oct 31, 2011
AT		BRECKENRIDGE PHARM	0.05%	A090870	001	Mar 14, 2011
AT		GAVIS PHARMS LLC	0.05%	A090951	001	Oct 31, 2011
AT		SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALICK

BX	+	AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009
AUVI-Q						
BX	+	SANOFI AVENTIS US	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-131 (of 371)

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPIPEN

BX + MYLAN SPEC LT 0.3MG/DELIVERY N019430 001 Dec 22, 1987

EPIPEN JR.

BX + MYLAN SPEC LT 0.15MG/DELIVERY N019430 002 Dec 22, 1987

TWINJECT 0.15

BX + AMEDRA PHARMS EQ 0.15MG/DELIVERY N020800 002 May 28, 2004

TWINJECT 0.3

BX + AMEDRA PHARMS EQ 0.3MG/DELIVERY N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

+ DEPROCO

EQ 0.02MG BASE/ML; 2%

A088389 001 Jan 22, 1985

LIGNOSPAN STANDARD

+ DEPROCO

EQ 0.01MG BASE/ML; 2%

A088390 001 Jan 22, 1985

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP + DENTSPLY PHARM 0.005MG/ML; 4% N021383 001

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP SEPTODONT INC 0.005MG/ML; 4% A078959 001 Aug 30, 2011

EPINEPHRINE HYDROCHLORIDE

INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N204200 001 Dec 07, 2012

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML)

N204640 001 Dec 18, 2013

SOLUTION; IV (INFUSION)

EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N205029 001 Jul 29, 2014

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP EASTMAN KODAK 0.01MG/ML; 2% A040057 002 Feb 26, 1993

AP 0.02MG/ML; 2% A040057 001 Feb 26, 1993

AP HOSPIRA 0.005MG/ML; 0.5% A089635 001 Jun 21, 1988

AP 0.005MG/ML; 1.5% A088571 001 Sep 13, 1985

AP 0.005MG/ML; 1.5% A089645 001 Jun 21, 1988

AP 0.005MG/ML; 2% A089651 001 Jun 21, 1988

AP 0.01MG/ML; 1% A089644 001 Jun 21, 1988

AP 0.01MG/ML; 2% A078772 001 May 12, 2008

AP 0.01MG/ML; 2% A089646 001 Jun 21, 1988

AP 0.02MG/ML; 2% A078772 002 May 12, 2008

OCTOCAINE

AP + SEPTODONT 0.01MG/ML; 2% A084048 001

AP 0.02MG/ML; 2% A084048 002

XYLOCAINE W/ EPINEPHRINE

AP + FRESenius KABI USA 0.005MG/ML; 0.5% N006488 012

AP 0.005MG/ML; 1% N006488 018 Nov 13, 1986

AP 0.005MG/ML; 1.5% N006488 017

AP 0.005MG/ML; 2% N006488 019 Nov 13, 1986

AP 0.01MG/ML; 1% N006488 004

AP 0.02MG/ML; 2% N006488 005

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLEENCE

AP + PFIZER INC 200MG/100ML (2MG/ML) N050778 001 Sep 15, 1999

AP 50MG/25ML (2MG/ML) N050778 002 Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP ACTAVIS TOTOWA 10MG/5ML (2MG/ML) A065445 001 Sep 18, 2008

AP 50MG/25ML (2MG/ML) A065445 002 Sep 18, 2008

AP 200MG/100ML (2MG/ML) A065445 003 Sep 18, 2008

AP AKORN INC 50MG/25ML (2MG/ML) A090163 001 Jun 24, 2009

AP CIPLA LTD 50MG/25ML (2MG/ML) A065361 001 Oct 22, 2007

AP 200MG/100ML (2MG/ML) A065361 002 Oct 22, 2007

AP EUROHLTH INTL 50MG/25ML (2MG/ML) A065289 001 Jun 27, 2007

AP 200MG/100ML (2MG/ML) A065289 002 Jun 27, 2007

AP FRESenius KABI ONCOL 200MG/100ML (2MG/ML) A065411 001 Aug 20, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-132 (of 371)

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065411</u>	<u>002</u>	Aug 20, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/5ML (2MG/ML)</u>	<u>A065408</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/25ML (2MG/ML)</u>	<u>A065408</u>	<u>002</u>	Oct 15, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065408</u>	<u>003</u>	Oct 15, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065408</u>	<u>004</u>	Oct 15, 2007
<u>AP</u>	HISUN PHARM HANGZHOU	<u>50MG/25ML (2MG/ML)</u>	<u>A090075</u>	<u>001</u>	Mar 25, 2010
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A090075</u>	<u>002</u>	Mar 25, 2010
<u>AP</u>	HOSPIRA	<u>10MG/5ML (2MG/ML)</u>	<u>A065343</u>	<u>001</u>	Apr 19, 2007
<u>AP</u>		<u>150MG/75ML (2MG/ML)</u>	<u>A065343</u>	<u>003</u>	Apr 19, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065343</u>	<u>004</u>	Apr 19, 2007
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A091599</u>	<u>001</u>	Mar 12, 2012
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A091599</u>	<u>002</u>	Mar 12, 2012
<u>AP</u>	TEVA PHARMS USA	<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007
<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008
<u>AB</u>		<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008
<u>AB</u>		<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008
<u>INSPIRA</u>					
<u>AB</u>	GD SEARLE LLC	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002
<u>AB</u>	+	<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008
<u>AP</u>		<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008
<u>FLOLAN</u>					
<u>AP</u>	+	<u>GLAXOSMITHKLINE LLC</u>	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u> Sep 20, 1995
<u>AP</u>	+		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u> Sep 20, 1995
<u>VELETRI</u>					
	ACTELION PHARMS LTD	<u>EQ 0.5MG BASE/VIAL</u>	<u>N022260</u>	<u>002</u>	Jun 28, 2012
	+	<u>EQ 1.5MG BASE/VIAL</u>	<u>N022260</u>	<u>001</u>	Jun 27, 2008

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 400MG BASE</u>	<u>A202012</u>	<u>001</u>	Nov 16, 2011
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A202012</u>	<u>002</u>	Nov 16, 2011
<u>TEVETEN</u>					
<u>AB</u>	ABBVIE	<u>EQ 400MG BASE</u>	<u>N020738</u>	<u>005</u>	Dec 22, 1997
<u>AB</u>	+	<u>EQ 600MG BASE</u>	<u>N020738</u>	<u>006</u>	May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE

+

600MG; 12.5MG

600MG; 25MG

N021268 001 Nov 01, 2001N021268 002 Nov 01, 2001EPTIFIBATIDE

INJECTABLE; INJECTION

INTEGRILIN

+ SCHERING

2MG/ML

+

75MG/100ML

N020718 001 May 18, 1998N020718 002 May 18, 1998ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

<u>AA</u>	+	SANOFI AVENTIS US	<u>50,000 IU</u>	<u>N003444</u>	<u>001</u>
-----------	---	-------------------	------------------	----------------	------------

ERGOCALCIFEROL

<u>AA</u>	ORIT LABS LLC	<u>50,000 IU</u>	<u>A040833</u>	<u>001</u>	May 20, 2009
<u>AA</u>	SIGMAPHARM LABS LLC	<u>50,000 IU</u>	<u>A091004</u>	<u>001</u>	Jul 14, 2010
<u>AA</u>	STRIDES PHARMA	<u>50,000 IU</u>	<u>A090455</u>	<u>001</u>	Aug 03, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>50,000 IU</u>	<u>A040865</u>	<u>001</u>	Dec 29, 2009
<u>VITAMIN D</u>					
<u>AA</u>	BANNER PHARMACAPS	<u>50,000 IU</u>	<u>A080704</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-133 (of 371)

ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

AB	MUTUAL PHARM	1MG	A081113 001	Oct 31, 1991
-----------	--------------	------------	--------------------	--------------

HYDERGINE

AB	+ NOVARTIS	1MG	N017993 001	
-----------	------------	------------	--------------------	--

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

+ ROSEDALE THERAPEUTIC 2MG

A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+ EISAI INC 1MG/2ML (0.5MG/ML)

N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 25MG BASE	A091002 001	Jun 11, 2014
-----------	------------------	---------------------	--------------------	--------------

AB		EQ 100MG BASE	A091002 002	Jun 11, 2014
-----------	--	----------------------	--------------------	--------------

AB		EQ 150MG BASE	A091002 003	Jun 11, 2014
-----------	--	----------------------	--------------------	--------------

TARCEVA

AB	OSI PHARMS	EQ 25MG BASE	N021743 001	Nov 18, 2004
-----------	------------	---------------------	--------------------	--------------

AB		EQ 100MG BASE	N021743 002	Nov 18, 2004
-----------	--	----------------------	--------------------	--------------

AB	+	EQ 150MG BASE	N021743 003	Nov 18, 2004
-----------	---	----------------------	--------------------	--------------

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

INVANZ

+ MERCK SHARP DOHME EQ 1GM BASE/VIAL

N021337 001 Nov 21, 2001

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB	+	MAYNE PHARMA	250MG	N050536 001	
-----------	---	--------------	--------------	--------------------	--

ERYTHROMYCIN

AB	ARBOR PHARMS LLC	250MG	A062746 001	Dec 22, 1986
-----------	------------------	--------------	--------------------	--------------

GEL; TOPICAL

ERYGEL

AT	+	DELCOR ASSET CORP	2%	N050617 001	Oct 21, 1987
-----------	---	-------------------	-----------	--------------------	--------------

ERYTHROMYCIN

AT	FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997
-----------	----------------	-----------	--------------------	--------------

AT	PERRIGO	2%	A063211 001	Jan 29, 1993
-----------	---------	-----------	--------------------	--------------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	AKORN	0.5%	A064030 001	Jul 18, 1996
-----------	-------	-------------	--------------------	--------------

AT	BAUSCH AND LOMB	0.5%	A064067 001	Jul 29, 1994
-----------	-----------------	-------------	--------------------	--------------

AT	+	PERRIGO CO TENNESSEE	0.5%	A062447 001	Sep 26, 1983
-----------	---	----------------------	-------------	--------------------	--------------

OINTMENT; TOPICAL

AKNE-MYCIN

+ DOW PHARM 2%

N050584 001 Jan 10, 1985

SOLUTION; TOPICAL

C-SOLVE-2

AT	FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985
-----------	----------------	-----------	--------------------	--------------

ERYTHRA-DERM

AT	PADDOCK LLC	2%	A062687 001	Feb 05, 1988
-----------	-------------	-----------	--------------------	--------------

ERYTHRO-STATIN

AT	HI TECH PHARMA	2%	A064101 001	Oct 22, 1996
-----------	----------------	-----------	--------------------	--------------

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A064187 001	Sep 30, 1997
-----------	---	----------------	-----------	--------------------	--------------

AT	PERRIGO NEW YORK	2%	A063038 001	Jan 11, 1991
-----------	------------------	-----------	--------------------	--------------

AT	WOCKHARDT	2%	A062825 001	Oct 23, 1987
-----------	-----------	-----------	--------------------	--------------

SWAB; TOPICAL

ERYTHROMYCIN

AT	+	PERRIGO	2%	A064126 001	Jul 03, 1996
-----------	---	---------	-----------	--------------------	--------------

AT	VERSAPHARM	2%	A090215 001	May 12, 2010
-----------	------------	-----------	--------------------	--------------

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS LLC 250MG

A061621 001

+ 500MG

A061621 002

PRESCRIPTION DRUG PRODUCT LIST

3-134 (of 371)

ERYTHROMYCIN

TABLET, COATED PARTICLES;ORAL

PCE

ARBOR PHARMS LLC 333MG
+ 500MGN050611 001 Sep 09, 1986
N050611 002 Aug 22, 1990

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

ARBOR PHARMS LLC 250MG
333MG
+ 500MGA062298 001
A062298 003 Mar 29, 1982
A062298 002ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.AB ARBOR PHARMS LLC EQ 200MG BASE/5ML N050207 001ERYPEDAB ARBOR PHARMS LLC EQ 200MG BASE/5ML N050207 003 Mar 30, 1987
+ EQ 400MG BASE/5ML N050207 002

SUSPENSION;ORAL

E.E.S. 200AB ARBOR PHARMS LLC EQ 200MG BASE/5ML A061639 001E.E.S. 400AB + ARBOR PHARMS LLC EQ 400MG BASE/5ML A061639 002PEDIAMYCINAB ARBOR PHARMS LLC EQ 200MG BASE/5ML A062304 001PEDIAMYCIN 400AB ARBOR PHARMS LLC EQ 400MG BASE/5ML A062304 002

TABLET;ORAL

E.E.S. 400

BX + ARBOR PHARMS LLC EQ 400MG BASE A061905 002 Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX + ARBOR PHARMS LLC EQ 400MG BASE A061904 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

+ BARR EQ 200MG BASE/5ML;EQ 600MG BASE/5ML

A062759 001 May 20, 1988

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCINAP HOSPIRA EQ 500MG BASE/VIAL A062638 001 Oct 31, 1986AP + EQ 500MG BASE/VIAL N050609 001 Sep 24, 1986

+ EQ 1GM BASE/VIAL A062638 002 Oct 31, 1986

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

+ ARBOR PHARMS LLC EQ 250MG BASE

A060359 001

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATEAA AMNEAL PHARMS EQ 5MG BASE/5ML A202227 001 Mar 14, 2012AA AUROBINDO PHARMA LTD EQ 5MG BASE/5ML A079062 001 Apr 02, 2012AA HETERO LABS LTD III EQ 5MG BASE/5ML A202221 001 Jun 12, 2012AA SILARX PHARMS INC EQ 5MG BASE/5ML A090477 001 Jun 12, 2013AA TARO EQ 5MG BASE/5ML A079121 001 May 03, 2012LEXAPROAA + FOREST LABS EQ 5MG BASE/5ML N021365 001 Nov 27, 2002

TABLET;ORAL

ESCITALOPRAM OXALATEAB ACCORD HLTHCARE EQ 5MG BASE A202389 001 Sep 11, 2012AB EQ 10MG BASE A202389 002 Sep 11, 2012AB EQ 20MG BASE A202389 003 Sep 11, 2012AB APOTEX INC EQ 5MG BASE A078777 001 Sep 11, 2012AB EQ 10MG BASE A078777 002 Sep 11, 2012AB EQ 20MG BASE A078777 003 Sep 11, 2012AB AUROBINDO PHARMA LTD EQ 5MG BASE A090432 001 Sep 11, 2012AB EQ 10MG BASE A090432 002 Sep 11, 2012AB EQ 20MG BASE A090432 003 Sep 11, 2012AB HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012AB EQ 10MG BASE A078766 002 Sep 11, 2012AB EQ 20MG BASE A078766 003 Sep 11, 2012AB INVAGEN PHARMS EQ 5MG BASE A078604 001 Sep 11, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-135 (of 371)

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB		EQ 10MG BASE	A078604 002	Sep 11, 2012
AB		EQ 20MG BASE	A078604 003	Sep 11, 2012
AB	JUBILANT GENERICS	EQ 5MG BASE	A202280 001	Sep 12, 2012
AB		EQ 10MG BASE	A202280 002	Sep 12, 2012
AB		EQ 20MG BASE	A202280 003	Sep 12, 2012
AB	LUPIN LTD	EQ 5MG BASE	A078169 001	Sep 11, 2012
AB		EQ 10MG BASE	A078169 002	Sep 11, 2012
AB		EQ 20MG BASE	A078169 003	Sep 11, 2012
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012
AB		EQ 10MG BASE	A202210 002	Sep 11, 2012
AB		EQ 20MG BASE	A202210 003	Sep 11, 2012
AB	STI PHARMA LLC	EQ 5MG BASE	A077512 001	Sep 12, 2012
AB		EQ 10MG BASE	A077512 002	Sep 12, 2012
AB		EQ 20MG BASE	A077512 003	Sep 12, 2012
AB	TEVA PHARMS USA	EQ 5MG BASE	A076765 001	Mar 14, 2012
AB		EQ 10MG BASE	A076765 002	Mar 14, 2012
AB		EQ 20MG BASE	A076765 003	Mar 14, 2012
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939 001	Sep 11, 2012
AB		EQ 10MG BASE	A090939 002	Sep 11, 2012
AB		EQ 20MG BASE	A090939 003	Sep 11, 2012
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734 001	Sep 11, 2012
AB		EQ 10MG BASE	A077734 002	Sep 11, 2012
AB		EQ 20MG BASE	A077734 003	Sep 11, 2012

LEXAPRO

AB	FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002
AB		EQ 10MG BASE	N021323 002	Aug 14, 2002
AB	+	EQ 20MG BASE	N021323 003	Aug 14, 2002

ESLICARBAZEPINE ACETATE

TABLET; ORAL

APTIO

	SUNOVION PHARMS INC	200MG	N022416 001	Nov 08, 2013
		400MG	N022416 002	Nov 08, 2013
		600MG	N022416 003	Nov 08, 2013
	+	800MG	N022416 004	Nov 08, 2013

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

AP	+	BAXTER HLTHCARE	10MG/ML	N019386 006	Feb 25, 2003
ESMOLOL HYDROCHLORIDE					
AP		EUROHLTH INTL	10MG/ML	A076323 001	Aug 10, 2004
AP		FRESENIUS KABI USA	10MG/ML	A076573 001	May 02, 2005
AP		MYLAN INSTITUTIONAL	10MG/ML	A076474 001	May 02, 2005
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003
		BREVIBLOC IN PLASTIC CONTAINER			
	+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153 001	Feb 20, 2001
	+	EQ 40MG BASE	N021153 002	Feb 20, 2001

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957 003	Dec 15, 2011
		EQ 5MG BASE/PACKET	N021957 004	Dec 15, 2011
		EQ 10MG BASE/PACKET	N022101 001	Feb 27, 2008
		EQ 20MG BASE/PACKET	N021957 001	Oct 20, 2006
	+	EQ 40MG BASE/PACKET	N021957 002	Oct 20, 2006

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE; 375MG	A202461 001	Sep 27, 2013
AB		EQ 20MG BASE; 500MG	A202461 002	Sep 27, 2013
VIMOVO				
AB	HORIZON PHARMA	EQ 20MG BASE; 375MG	N022511 002	Apr 30, 2010
AB	+	EQ 20MG BASE; 500MG	N022511 001	Apr 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-136 (of 371)

ESOMEFRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEFRAZOLE SODIUM

<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 20MG BASE/VIAL</u>	<u>A200882</u>	<u>001</u>	Mar 18, 2013
<u>AP</u>		<u>EQ 40MG BASE/VIAL</u>	<u>A200882</u>	<u>002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+ ASTRAZENECA PHARMS	<u>EQ 20MG BASE/VIAL</u>	<u>N021689</u>	<u>001</u>	Mar 31, 2005
<u>AP</u>	+	<u>EQ 40MG BASE/VIAL</u>	<u>N021689</u>	<u>002</u>	Mar 31, 2005

ESOMEFRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEFRAZOLE STRONTIUM

	HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013
+		EQ 40MG BASE	N202342	002	Aug 06, 2013

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>	PAR PHARM	<u>1MG</u>	<u>A074826</u>	<u>001</u>	Jul 03, 1997
<u>AB</u>		<u>2MG</u>	<u>A074826</u>	<u>002</u>	Jul 03, 1997
<u>AB</u>	TEVA	<u>1MG</u>	<u>A074921</u>	<u>001</u>	Jul 10, 1997
<u>AB</u>	+	<u>2MG</u>	<u>A074921</u>	<u>002</u>	Jul 10, 1997
<u>AB</u>	WATSON LABS	<u>1MG</u>	<u>A074818</u>	<u>001</u>	Aug 19, 1997
<u>AB</u>		<u>2MG</u>	<u>A074818</u>	<u>002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069	001	Jan 31, 1984
---	--------------------	-------	---------	-----	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	BAYER HLTHCARE	<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB</u>		<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB</u>		<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006
<u>AB1</u>		<u>0.025MG/24HR</u>	<u>A201675</u>	<u>001</u>	Dec 19, 2014
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>A201675</u>	<u>002</u>	Dec 19, 2014
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>A201675</u>	<u>003</u>	Dec 19, 2014
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>A201675</u>	<u>004</u>	Dec 19, 2014
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>A201675</u>	<u>005</u>	Dec 19, 2014

VIVELLE

<u>AB1</u>	NOVARTIS	<u>0.05MG/24HR</u>	<u>N020323</u>	<u>002</u>	Oct 28, 1994
<u>AB1</u>		<u>0.1MG/24HR</u>	<u>N020323</u>	<u>004</u>	Oct 28, 1994

VIVELLE-DOT

<u>AB1</u>	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538</u>	<u>009</u>	May 03, 2002
<u>AB1</u>		<u>0.0375MG/24HR</u>	<u>N020538</u>	<u>005</u>	Jan 08, 1999
<u>AB1</u>		<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>		<u>0.075MG/24HR</u>	<u>N020538</u>	<u>007</u>	Jan 08, 1999
<u>AB1</u>	+	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

CLIMARA

<u>AB2</u>	BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+	<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000

ALORA

BX	WATSON LABS	0.025MG/24HR	N020655	004	Apr 05, 2002
BX		0.05MG/24HR	N020655	001	Dec 20, 1996
BX		0.075MG/24HR	N020655	002	Dec 20, 1996
BX		0.1MG/24HR	N020655	003	Dec 20, 1996

ESTRADERM

BX	NOVARTIS	0.05MG/24HR	N019081	002	Sep 10, 1986
BX	+	0.1MG/24HR	N019081	003	Sep 10, 1986

MENOSTAR

+	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004
---	----------------	--------------	---------	-----	--------------

MINIVELLE

NOVEN		0.0375MG/24HR	N203752	001	Oct 29, 2012
		0.05MG/24HR	N203752	003	Oct 29, 2012
		0.075MG/24HR	N203752	002	Oct 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-137 (of 371)

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

MINIVELLE

+

0.1MG/24HR

N203752 004 Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

VERTICAL PHARMS LLC

0.1% (0.25GM/PACKET)

N022038 001 Jun 04, 2007

0.1% (0.5GM/PACKET)

N022038 002 Jun 04, 2007

+

0.1% (1GM/PACKET)

N022038 003 Jun 04, 2007

GEL, METERED;TRANSDERMAL

ELESTRIN

+ MEDA PHARMS

0.06% (0.87GM/ACTIVATION)

N021813 001 Dec 15, 2006

ESTROGEL

+ ASCEND THERAPS US

0.06% (1.25GM/ACTIVATION)

N021166 002 Feb 09, 2004

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+ PHARMACIA AND UPJOHN

0.0075MG/24HR

N020472 001 Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

+ ELAN PHARMA INTL LTD

1.53MG/SPRAY

N022014 001 Jul 27, 2007

TABLET;ORAL

ESTRADIOL**AB** BARR LABS INC**0.5MG****A040197 001** Oct 22, 1997**AB****1MG****A040197 002** Oct 22, 1997**AB**

+

2MG**A040197 003** Oct 22, 1997**AB**

MYLAN

0.5MG**A040326 001** Apr 21, 1999**AB****1MG****A040326 002** Apr 21, 1999**AB****2MG****A040326 003** Apr 21, 1999**AB**

USL PHARMA

0.5MG**A040297 001** Apr 17, 2002**AB****1MG****A040297 002** Apr 17, 2002**AB****2MG****A040297 003** Apr 17, 2002**AB**

WATSON LABS

0.5MG**A040114 003** Mar 14, 1996**AB****1MG****A040114 001** Mar 14, 1996**AB****2MG****A040114 002** Mar 14, 1996

TABLET;VAGINAL

VAGIFEM

+ NOVO NORDISK INC

10MCG

N020908 002 Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

WARNER IRELAND

EQ 0.05MG BASE/24HR

N021367 001 Mar 20, 2003

+

EQ 0.1MG BASE/24HR

N021367 002 Mar 20, 2003

TABLET;ORAL

FEMTRACE

WARNER CHILCOTT LLC

0.45MG

N021633 001 Aug 20, 2004

0.9MG

N021633 002 Aug 20, 2004

+

1.8MG

N021633 003 Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

+ PHARMACIA AND UPJOHN

5MG/ML

A085470 003

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL

ESTRASORB

+ MEDICIS

0.25%

N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN**AO** + PAR STERILE PRODUCTS**20MG/ML****N009402 004****AO**

+

40MG/ML**N009402 003**ESTRADIOL VALERATE**AO** LUITPOLD**20MG/ML****A090920 001** Jan 19, 2010**AO****40MG/ML****A090920 002** Jan 19, 2010

DELESTROGEN

+ PAR STERILE PRODUCTS

10MG/ML

N009402 002

PRESCRIPTION DRUG PRODUCT LIST

3-138 (of 371)

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+ BAYER HLTHCARE 0.045MG/24HR; 0.015MG/24HR

N021258 001 Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

NOVEN PHARMS INC 0.05MG/24HR; 0.14MG/24HR

N020870 001 Aug 07, 1998

+ 0.05MG/24HR; 0.25MG/24HR

N020870 002 Aug 07, 1998

TABLET; ORAL

ACTIVELLA**AB** AMNEAL PHARMS LLC**0.5MG; 0.1MG****N020907 002** Dec 28, 2006**AB** +**1MG; 0.5MG****N020907 001** Nov 18, 1998ESTRADIOL AND NORETHINDRONE ACETATE**AB** BARR**1MG; 0.5MG****A079193 001** May 11, 2010**AB** BRECKENRIDGE PHARM**0.5MG; 0.1MG****A078324 002** Jun 09, 2011**AB****1MG; 0.5MG****A078324 001** Apr 17, 2008**AB** TEVA PHARMS USA**0.5MG; 0.1MG****A200747 001** Mar 08, 2012ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

+ BARR 1MG, 1MG; 1MG, 1MG; N/A, 0.09MG

A076812 001 Apr 29, 2005

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+ PHARMACIA AND UPJOHN EQ 140MG PHOSPHATE

N018045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+ WYETH PHARMS INC 0.625MG/GM

N020216 001

INJECTABLE; INJECTION

PREMARIN

+ WYETH PHARMS INC 25MG/VIAL

N010402 001

TABLET; ORAL

PREMARIN

WYETH PHARMS INC

0.3MG

N004782 003

0.45MG

N004782 006

+

0.625MG

N004782 004

+

0.9MG

N004782 005

+

1.25MG

N004782 001

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM

0.3MG

N020992 001 Jun 21, 2002

0.45MG

N020992 005 Feb 05, 2004

0.625MG

N020992 002 Mar 24, 1999

0.9MG

N020992 003 Mar 24, 1999

+

1.25MG

N020992 004 Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

TEVA WOMENS

0.3MG

N021443 001 Dec 20, 2004

0.45MG

N021443 002 Dec 20, 2004

0.625MG

N021443 003 May 10, 2004

0.9MG

N021443 005 Apr 27, 2007

+

1.25MG

N021443 004 May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+ WYETH PHARMS INC 0.625MG, 0.625MG; 0.625MG, 0.625MG; N/A, 5MG

N020527 002 Nov 17, 1995

PREMPRO

+ WYETH PHARMS INC

0.3MG; 1.5MG

N020527 005 Jun 04, 2003

+

0.45MG; 1.5MG

N020527 004 Mar 12, 2003

+

0.625MG; 0.625MG; 2.5MG; 2.5MG

N020527 001 Nov 17, 1995

+

0.625MG; 0.625MG; 5MG; 5MG

N020527 003 Jan 09, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-139 (of 371)

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS

0.3MG

A084951 001

0.625MG

A084948 001

1.25MG

A084950 001

+

2.5MG

A084949 001

ESTROPIPATE

TABLET; ORAL

ESTROPIPATEAB BARR0.75MGA040135 001 Nov 27, 1996AB1.5MGA040135 002 Nov 27, 1996AB3MGA040135 003 Nov 27, 1996AB MYLAN0.75MGA040359 001 Aug 26, 1999AB1.5MGA040359 002 Aug 26, 1999AB WATSON LABS0.75MGA081213 001 Sep 23, 1993AB1.5MGA081214 001 Sep 23, 1993AB3MGA081215 001 Sep 23, 1993OGEN .625AB PHARMACIA AND UPJOHN0.75MGA083220 001OGEN 1.25AB PHARMACIA AND UPJOHN1.5MGA083220 002OGEN 2.5AB + PHARMACIA AND UPJOHN3MGA083220 003

OGEN 5

PHARMACIA AND UPJOHN

6MG

A083220 004

ESZOPICLONE

TABLET; ORAL

ESZOPICLONEAB DR REDDYS LABS LTD1MGA091024 001 Apr 15, 2014AB2MGA091024 002 Apr 15, 2014AB3MGA091024 003 Apr 15, 2014AB GLENMARK GENERICS1MGA091166 001 Apr 15, 2014AB2MGA091166 002 Apr 15, 2014AB3MGA091166 003 Apr 15, 2014AB LUPIN LTD1MGA091124 001 Sep 13, 2011AB2MGA091124 002 Sep 13, 2011AB3MGA091124 003 Sep 13, 2011AB MYLAN PHARMS INC1MGA091151 001 Mar 26, 2013AB2MGA091151 002 Mar 26, 2013AB3MGA091151 003 Mar 26, 2013AB ORCHID HLTHCARE1MGA091113 001 Jun 10, 2014AB2MGA091113 002 Jun 10, 2014AB3MGA091113 003 Jun 10, 2014AB ROXANE1MGA091153 001 Apr 15, 2014AB2MGA091153 002 Apr 15, 2014AB3MGA091153 003 Apr 15, 2014AB SUN PHARMA GLOBAL1MGA091103 001 Apr 03, 2013AB2MGA091103 002 Apr 03, 2013AB3MGA091103 003 Apr 03, 2013AB TEVA1MGA091169 001 May 23, 2011AB2MGA091169 002 May 23, 2011AB3MGA091169 003 May 23, 2011LUNESTAAB SUNOVION PHARMS INC1MGN021476 001 Dec 15, 2004AB2MGN021476 002 Dec 15, 2004AB +3MGN021476 003 Dec 15, 2004ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

+ ATON

EQ 50MG BASE/VIAL

N016093 001

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

+ ATON

25MG

N016092 001

PRESCRIPTION DRUG PRODUCT LIST

3-140 (of 371)

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	BARR	<u>400MG</u>	<u>A076057</u>	<u>001</u>	Nov 26, 2001
AB	LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u>	Jun 17, 2009
AB		<u>400MG</u>	<u>A078939</u>	<u>002</u>	Jun 17, 2009

MYAMBUTOL

AB	STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>	
AB	+	<u>400MG</u>	<u>N016320</u>	<u>003</u>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988
---	-----------	---------	---------	-----	--------------

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR

AB	BARR	<u>0.035MG;1MG</u>	<u>A076785</u>	<u>001</u>	May 23, 2005
AB	WATSON LABS	<u>0.035MG;1MG</u>	<u>A072721</u>	<u>001</u>	Dec 30, 1991
	ZOVIA 1/50E-28				
	+	WATSON LABS	A072723	001	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001
---	-----------------	--------------------------	---------	-----	--------------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

DAYSEE

AB	LUPIN LTD	<u>0.03MG;0.01MG;0.15MG,N/A</u>	<u>A091467</u>	<u>001</u>	Apr 10, 2013
-----------	-----------	---------------------------------	----------------	------------	--------------

INTROVALE

AB	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079064</u>	<u>001</u>	Sep 27, 2010
-----------	--------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	<u>0.02MG;0.01MG;0.1MG,N/A</u>	<u>A091674</u>	<u>001</u>	Oct 26, 2011
AB		<u>0.03MG;0.15MG</u>	<u>A091440</u>	<u>001</u>	Oct 23, 2012
AB	WATSON LABS	<u>0.02MG;0.01MG;0.1MG,N/A</u>	<u>A200407</u>	<u>001</u>	Oct 25, 2011

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

AB	WATSON LABS	<u>0.03MG;0.01MG;0.15MG,N/A</u>	<u>A078834</u>	<u>001</u>	May 31, 2011
-----------	-------------	---------------------------------	----------------	------------	--------------

LOSEASONIQUE

AB	TEVA BRANDED PHARM	<u>0.01MG;0.02MG;0.1MG</u>	<u>N022262</u>	<u>001</u>	Oct 24, 2008
-----------	--------------------	----------------------------	----------------	------------	--------------

OUASENSE

AB	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101</u>	<u>001</u>	Sep 06, 2006
-----------	-------------	----------------------	----------------	------------	--------------

SEASONALE

AB	+	TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544</u>	<u>001</u>	Sep 05, 2003
-----------	---	--------------------	----------------------	----------------	------------	--------------

SEASONIQUE

AB	+	TEVA BRANDED PHARM	<u>0.03MG;0.01MG;0.03MG;0.01MG;0.15MG,N/A</u>	<u>N021840</u>	<u>001</u>	May 25, 2006
-----------	---	--------------------	---	----------------	------------	--------------

SETLAKIN

AB	NOVAST LABS LTD	<u>0.03MG;0.15MG</u>	<u>A090716</u>	<u>001</u>	Sep 15, 2014
-----------	-----------------	----------------------	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011
---	-------------	---------------	---------	-----	--------------

QUARTETTE

+	TEVA BRANDED PHARM	0.02MG;0.15MG	N204061	001	Mar 28, 2013
---	--------------------	---------------	---------	-----	--------------

TABLET; ORAL-28

ALTAVERA

AB	SANDOZ	<u>0.03MG;0.15MG</u>	<u>A079102</u>	<u>001</u>	Aug 03, 2010
-----------	--------	----------------------	----------------	------------	--------------

ENPRESSE-28

AB	DURAMED PHARMS BARR	<u>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</u>	<u>A075809</u>	<u>002</u>	Jul 16, 2001
-----------	---------------------	--	----------------	------------	--------------

KURVELO

AB	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408</u>	<u>001</u>	Oct 17, 2012
-----------	-----------	----------------------	----------------	------------	--------------

LEVONEST

AB	NOVAST LABS LTD	<u>0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.125MG</u>	<u>A090719</u>	<u>001</u>	Dec 29, 2010
-----------	-----------------	--	----------------	------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	<u>0.03MG;0.15MG</u>	<u>A091663</u>	<u>001</u>	Dec 21, 2012
-----------	---------------	----------------------	----------------	------------	--------------

AB	HAUPT PHARMA	<u>0.03MG;0.15MG</u>	<u>A201095</u>	<u>001</u>	Dec 08, 2014
-----------	--------------	----------------------	----------------	------------	--------------

LEVORA 0.15/30-28

AB	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A073594</u>	<u>001</u>	Dec 13, 1993
-----------	-------------	----------------------	----------------	------------	--------------

MARLISSA

AB	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452</u>	<u>001</u>	Feb 29, 2012
-----------	-------------------	----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-141 (of 371)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

MYZILRA

AB	VINTAGE PHARMS LLC	<u>0.03MG; 0.04MG; 0.03MG; 0.05MG; 0.075MG; 0.125MG</u>	A077502 001	Nov 23, 2011
-----------	--------------------	---	--------------------	--------------

NORDETTE-28

AB	+ TEVA BRANDED PHARM	<u>0.03MG; 0.15MG</u>	N018782 001	Jul 21, 1982
-----------	----------------------	-----------------------	--------------------	--------------

PORTIA-28

AB	BARR	<u>0.03MG; 0.15MG</u>	A075866 002	May 23, 2002
-----------	------	-----------------------	--------------------	--------------

TRIVORA-28

AB	+ WATSON LABS	<u>0.03MG; 0.03MG; 0.04MG; 0.05MG; 0.075MG; 0.125MG</u>	A074538 002	Dec 18, 1997
-----------	---------------	---	--------------------	--------------

AVIANE-28

AB1	DURAMED PHARMS BARR	<u>0.02MG; 0.1MG</u>	A075796 001	Apr 30, 2001
------------	---------------------	----------------------	--------------------	--------------

FALMINA

AB1	NOVAST LABS LTD	<u>0.02MG; 0.1MG</u>	A090721 001	Mar 28, 2012
------------	-----------------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	FAMY CARE LTD	<u>0.02MG; 0.1MG</u>	A200245 001	Oct 09, 2013
------------	---------------	----------------------	--------------------	--------------

AB1	HAUPT PHARMA	<u>0.02MG; 0.1MG</u>	A201108 001	Feb 05, 2014
------------	--------------	----------------------	--------------------	--------------

AB1	LUPIN LTD	<u>0.02MG; 0.1MG</u>	A091425 001	Jan 18, 2013
------------	-----------	----------------------	--------------------	--------------

AB1	+ WATSON LABS	<u>0.02MG; 0.1MG</u>	A076625 001	Nov 18, 2004
------------	---------------	----------------------	--------------------	--------------

ORSYTHIA

AB1	VINTAGE PHARMS LLC	<u>0.02MG; 0.1MG</u>	A077099 001	May 11, 2011
------------	--------------------	----------------------	--------------------	--------------

LESSINA-28

AB2	BARR	<u>0.02MG; 0.1MG</u>	A075803 002	Mar 20, 2002
------------	------	----------------------	--------------------	--------------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	FAMY CARE LTD	<u>0.02MG; 0.1MG</u>	A202247 001	Dec 08, 2014
------------	---------------	----------------------	--------------------	--------------

AB2	+ WATSON LABS	<u>0.02MG; 0.1MG</u>	A077681 001	May 31, 2006
------------	---------------	----------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

AB	+ JANSSEN PHARMS	<u>0.035MG/24HR; 0.15MG/24HR</u>	N021180 001	Nov 20, 2001
-----------	------------------	----------------------------------	--------------------	--------------

XULANE

AB	MYLAN TECHNOLOGIES	<u>0.035MG/24HR; 0.15MG/24HR</u>	A200910 001	Apr 16, 2014
-----------	--------------------	----------------------------------	--------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+35 21-DAY

AB	WATSON LABS	<u>0.035MG; 1MG</u>	N017565 001	
-----------	-------------	---------------------	--------------------	--

NORTREL 1/35-21

AB	BARR	<u>0.035MG; 1MG</u>	A072693 001	Feb 28, 1992
-----------	------	---------------------	--------------------	--------------

NORTREL 7/7/7

BARR	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG</u>	A075478 001	Aug 30, 2002
------	--	--------------------	--------------

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	<u>0.035MG; 1MG</u>	A091634 001	Jan 19, 2012
-----------	-------------------	---------------------	--------------------	--------------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG</u>	A091636 001	Jan 19, 2012
-----------	-------------------	--	--------------------	--------------

ARANELLE

AB	BARR	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.5MG; 1MG</u>	A076783 001	Sep 29, 2004
-----------	------	---	--------------------	--------------

BALZIVA-28

AB	BARR	<u>0.035MG; 0.4MG</u>	A076238 001	Apr 22, 2004
-----------	------	-----------------------	--------------------	--------------

BREVICON 28-DAY

AB	WATSON LABS	<u>0.035MG; 0.5MG</u>	N017743 001	
-----------	-------------	-----------------------	--------------------	--

BRIELLYN

AB	GLENMARK GENERICS	<u>0.035MG; 0.4MG</u>	A090538 001	Mar 22, 2011
-----------	-------------------	-----------------------	--------------------	--------------

CYCLAFEM 1/35

AB	VINTAGE PHARMS LLC	<u>0.035MG; 1MG</u>	A076337 001	Nov 12, 2010
-----------	--------------------	---------------------	--------------------	--------------

CYCLAFEM 7/7/7

AB	VINTAGE PHARMS LLC	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG</u>	A076338 001	Nov 16, 2010
-----------	--------------------	--	--------------------	--------------

DASETTA 1/35

AB	NOVAST LABS LTD	<u>0.035MG; 1MG</u>	A090948 001	Dec 22, 2011
-----------	-----------------	---------------------	--------------------	--------------

DASETTA 7/7/7

AB	NOVAST LABS LTD	<u>0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG</u>	A090946 001	Dec 22, 2011
-----------	-----------------	--	--------------------	--------------

GILDAGIA

AB	VINTAGE PHARMS	<u>0.035MG; 0.4MG</u>	A078376 001	Nov 06, 2012
-----------	----------------	-----------------------	--------------------	--------------

MODICON 28

AB	+ JANSSEN PHARMS	<u>0.035MG; 0.5MG</u>	N017735 001	
-----------	------------------	-----------------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-142 (of 371)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	+	FAMY CARE LTD	<u>0.05MG;1MG</u>	<u>A203006</u>	<u>001</u>	Aug 05, 2013
AB		WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010
AB			<u>0.035MG;0.5MG</u>	<u>A070686</u>	<u>001</u>	Jan 29, 1987
AB			<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987

NORINYL 1+35 28-DAY

AB		WATSON LABS	<u>0.035MG;1MG</u>	<u>N017565</u>	<u>002</u>	
-----------	--	--------------------	---------------------------	-----------------------	-------------------	--

NORTREL 0.5/35-28

AB		BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992
-----------	--	-------------	-----------------------------	-----------------------	-------------------	--------------

NORTREL 1/35-28

AB		BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992
-----------	--	-------------	---------------------------	-----------------------	-------------------	--------------

NORTREL 7/7/7

AB		BARR	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002
-----------	--	-------------	--	-----------------------	-------------------	--------------

ORTHO-NOVUM 1/35-28

AB	+	JANSSSEN PHARMS	<u>0.035MG;1MG</u>	<u>N017919</u>	<u>002</u>	
-----------	----------	------------------------	---------------------------	-----------------------	-------------------	--

ORTHO-NOVUM 7/7/7-28

AB	+	JANSSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.75MG;1MG</u>	<u>N018985</u>	<u>002</u>	Apr 04, 1984
-----------	----------	------------------------	--	-----------------------	-------------------	--------------

OVCON-35

AB	+	WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N017716</u>	<u>001</u>	
-----------	----------	----------------------------	-----------------------------	-----------------------	-------------------	--

PHILITH

AB		NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011
-----------	--	------------------------	-----------------------------	-----------------------	-------------------	--------------

PIRMELLA 1/35

AB		LUPIN LTD	<u>0.035MG;1MG</u>	<u>A201512</u>	<u>001</u>	Apr 24, 2013
-----------	--	------------------	---------------------------	-----------------------	-------------------	--------------

PIRMELLA 7/7/7

AB		LUPIN LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A201510</u>	<u>001</u>	Apr 24, 2013
-----------	--	------------------	--	-----------------------	-------------------	--------------

TRI-NORINYL 28-DAY

AB	+	WATSON LABS	<u>0.035MG;0.035MG;0.035MG;0.5MG;0.5MG;1MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984
-----------	----------	--------------------	---	-----------------------	-------------------	--------------

VYFEMLA

AB		LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013
-----------	--	------------------	-----------------------------	-----------------------	-------------------	--------------

WERA

AB		NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012
-----------	--	------------------------	-----------------------------	-----------------------	-------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

		WATSON LABS	<u>0.035MG;0.035MG;0.5MG;1MG</u>	<u>A071044</u>	<u>001</u>	Apr 01, 1988
--	--	--------------------	---	-----------------------	-------------------	--------------

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+	WARNER CHILCOTT LLC	<u>0.035MG;0.4MG</u>	<u>N021490</u>	<u>001</u>	Nov 14, 2003
-----------	----------	----------------------------	-----------------------------	-----------------------	-------------------	--------------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
-----------	--	----------------------	-----------------------------	-----------------------	-------------------	--------------

AB		BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
-----------	--	-------------	-----------------------------	-----------------------	-------------------	--------------

AB		FAMY CARE LTD	<u>0.025MG;0.8MG</u>	<u>A203371</u>	<u>001</u>	Apr 23, 2014
-----------	--	----------------------	-----------------------------	-----------------------	-------------------	--------------

AB	+	WARNER CHILCOTT	<u>0.025MG;0.8MG</u>	<u>N022573</u>	<u>001</u>	Dec 22, 2010
-----------	----------	------------------------	-----------------------------	-----------------------	-------------------	--------------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

GILDESS 24 FE

AB		VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293</u>	<u>001</u>	Dec 01, 2014
-----------	--	-----------------------	--------------------------	-----------------------	-------------------	--------------

LOESTRIN 24 FE

AB	+	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N021871</u>	<u>001</u>	Feb 17, 2006
-----------	----------	------------------------	--------------------------	-----------------------	-------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A078267</u>	<u>001</u>	Sep 01, 2009
-----------	--	----------------------	--------------------------	-----------------------	-------------------	--------------

AB		BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938</u>	<u>001</u>	Dec 01, 2014
-----------	--	----------------------	--------------------------	-----------------------	-------------------	--------------

AB		FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202742</u>	<u>001</u>	Oct 30, 2014
-----------	--	----------------------	--------------------------	-----------------------	-------------------	--------------

FEMHRT

		WARNER CHILCOTT LLC	<u>0.0025MG;0.5MG</u>	<u>N021065</u>	<u>001</u>	Jan 14, 2005
--	--	----------------------------	------------------------------	-----------------------	-------------------	--------------

LO LOESTRIN FE

	+	WARNER CHILCOTT LLC	<u>0.01MG,0.01MG;1MG,N/A</u>	<u>N022501</u>	<u>001</u>	Oct 21, 2010
--	----------	----------------------------	-------------------------------------	-----------------------	-------------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

	+	BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009
--	----------	----------------------	---------------------------	-----------------------	-------------------	--------------

TABLET; ORAL-21

GILDESS 1.5/30

AB		VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>002</u>	Jul 24, 2012
-----------	--	---------------------------	----------------------------	-----------------------	-------------------	--------------

GILDESS 1/20

AB		VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>002</u>	Jul 24, 2012
-----------	--	---------------------------	--------------------------	-----------------------	-------------------	--------------

JUNEL 1.5/30

AB		BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003
-----------	--	-------------	----------------------------	-----------------------	-------------------	--------------

JUNEL 1/20

AB		BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003
-----------	--	-------------	--------------------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-143 (of 371)

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

LARIN 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A202996</u>	<u>001</u>	Mar 20, 2014
-----------	-----------------	---------------------	----------------	------------	--------------

LARIN 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A202995</u>	<u>001</u>	Dec 04, 2013
-----------	-----------------	-------------------	----------------	------------	--------------

LOESTRIN 21 1.5/30

AB	WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017875</u>	<u>001</u>	
-----------	---------------------	---------------------	----------------	------------	--

LOESTRIN 21 1/20

AB	WARNER CHILCOTT LLC	<u>0.02MG;1MG</u>	<u>N017876</u>	<u>001</u>	
-----------	---------------------	-------------------	----------------	------------	--

MICROGESTIN 1.5/30

AB	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>002</u>	Jul 30, 2003
-----------	-------------	---------------------	----------------	------------	--------------

MICROGESTIN 1/20

AB	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>002</u>	Jul 30, 2003
-----------	-------------	-------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202771</u>	<u>001</u>	Nov 06, 2013
-----------	---------------	-------------------	----------------	------------	--------------

TRI-LEGEST 21

BARR

0.02MG;0.035MG;0.03MG;1MG;1MG;1MG

A076405 001 Oct 26, 2007

TABLET; ORAL-28

ESTROSTEP FE

AB	+ WARNER CHILCOTT LLC	<u>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</u>	<u>N020130</u>	<u>002</u>	Oct 09, 1996
-----------	-----------------------	--	----------------	------------	--------------

GILDESS FE 1.5/30

AB	VINTAGE PHARMS LLC	<u>0.03MG;1.5MG</u>	<u>A077075</u>	<u>001</u>	Apr 28, 2005
-----------	--------------------	---------------------	----------------	------------	--------------

GILDESS FE 1/20

AB	VINTAGE PHARMS LLC	<u>0.02MG;1MG</u>	<u>A077077</u>	<u>001</u>	May 20, 2005
-----------	--------------------	-------------------	----------------	------------	--------------

JUNEL FE 1.5/30

AB	BARR	<u>0.03MG;1.5MG</u>	<u>A076064</u>	<u>001</u>	Sep 18, 2003
-----------	------	---------------------	----------------	------------	--------------

JUNEL FE 1/20

AB	BARR	<u>0.02MG;1MG</u>	<u>A076081</u>	<u>001</u>	Sep 18, 2003
-----------	------	-------------------	----------------	------------	--------------

LARIN FE 1.5/30

AB	NOVAST LABS LTD	<u>0.03MG;1.5MG</u>	<u>A091453</u>	<u>001</u>	Aug 23, 2013
-----------	-----------------	---------------------	----------------	------------	--------------

LARIN FE 1/20

AB	NOVAST LABS LTD	<u>0.02MG;1MG</u>	<u>A091454</u>	<u>001</u>	Aug 26, 2013
-----------	-----------------	-------------------	----------------	------------	--------------

LOESTRIN FE 1.5/30

AB	+ WARNER CHILCOTT LLC	<u>0.03MG;1.5MG</u>	<u>N017355</u>	<u>001</u>	
-----------	-----------------------	---------------------	----------------	------------	--

LOESTRIN FE 1/20

AB	WARNER CHILCOTT	<u>0.02MG;1MG</u>	<u>N017354</u>	<u>001</u>	
-----------	-----------------	-------------------	----------------	------------	--

MICROGESTIN FE 1.5/30

AB	WATSON LABS	<u>0.03MG;1.5MG</u>	<u>A075548</u>	<u>001</u>	Feb 05, 2001
-----------	-------------	---------------------	----------------	------------	--------------

MICROGESTIN FE 1/20

AB	WATSON LABS	<u>0.02MG;1MG</u>	<u>A075647</u>	<u>001</u>	Feb 05, 2001
-----------	-------------	-------------------	----------------	------------	--------------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	<u>0.02MG;1MG</u>	<u>A202772</u>	<u>001</u>	Nov 14, 2013
-----------	---------------	-------------------	----------------	------------	--------------

AB	WATSON LABS	<u>0.02MG,0.03MG,0.035MG;1MG,1MG,1MG</u>	<u>A076629</u>	<u>001</u>	Mar 18, 2010
-----------	-------------	--	----------------	------------	--------------

TRI-LEGEST FE

AB	BARR	<u>0.02MG;0.035MG;0.03MG;1MG;1MG;1MG</u>	<u>A076105</u>	<u>001</u>	Oct 26, 2007
-----------	------	--	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

MINASTRIN 24 FE

+ WARNER CHILCOTT LLC 0.02MG;1MG

N203667 001 May 08, 2013

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

+ WARNER CHILCOTT 0.01MG,0.01MG,N/A;1MG,N/A,N/A

N204654 001 Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A200494</u>	<u>001</u>	Jun 17, 2011
-----------	-------------------	--	----------------	------------	--------------

TABLET; ORAL-28

ESTARYLLA

AB	SANDOZ	<u>0.035MG;0.25MG</u>	<u>A090794</u>	<u>001</u>	Jan 30, 2013
-----------	--------	-----------------------	----------------	------------	--------------

MONO-LINYAH

AB	NOVAST LABS LTD	<u>0.035MG;0.25MG</u>	<u>A090523</u>	<u>001</u>	May 23, 2012
-----------	-----------------	-----------------------	----------------	------------	--------------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	<u>0.035MG;0.25MG</u>	<u>A200538</u>	<u>001</u>	Apr 05, 2012
-----------	-------------------	-----------------------	----------------	------------	--------------

AB	LUPIN PHARMS	<u>0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG</u>	<u>A200541</u>	<u>001</u>	Jun 25, 2012
-----------	--------------	--	----------------	------------	--------------

ORTHO CYCLEN-28

AB	+ JANSSEN PHARMS	<u>0.035MG;0.25MG</u>	<u>N019653</u>	<u>002</u>	Dec 29, 1989
-----------	------------------	-----------------------	----------------	------------	--------------

ORTHO TRI-CYCLEN

AB	+ JANSSEN PHARMS	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>N019697</u>	<u>001</u>	Jul 03, 1992
-----------	------------------	--	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-144 (of 371)

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ORTHO TRI-CYCLEN LO

AB	+	JANSSEN PHARMS	<u>0.025MG;0.025MG;0.025MG;0.18MG;0.215MG;0.25MG</u>	<u>N021241</u>	<u>001</u>	Aug 22, 2002
-----------	----------	-----------------------	---	-----------------------	-------------------	--------------

PREVIFEM

AB		VINTAGE PHARMS LLC	<u>0.035MG;0.25MG</u>	<u>A076334</u>	<u>001</u>	Jan 09, 2004
-----------	--	---------------------------	------------------------------	-----------------------	-------------------	--------------

SPRINTEC

AB		BARR	<u>0.035MG;0.25MG</u>	<u>A075804</u>	<u>001</u>	Sep 25, 2002
-----------	--	-------------	------------------------------	-----------------------	-------------------	--------------

TRI-ESTARYLLA

AB		SANDOZ	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090793</u>	<u>001</u>	Jan 30, 2013
-----------	--	---------------	---	-----------------------	-------------------	--------------

TRI-LINYAH

AB		NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG</u>	<u>A090524</u>	<u>001</u>	May 30, 2012
-----------	--	------------------------	---	-----------------------	-------------------	--------------

TRI-PREVIFEM

AB		VINTAGE PHARMS LLC	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A076335</u>	<u>001</u>	Mar 26, 2004
-----------	--	---------------------------	---	-----------------------	-------------------	--------------

TRI-SPRINTEC

AB		BARR	<u>0.035MG;0.035MG;0.035MG;0.18MG;0.215MG;0.25MG</u>	<u>A075808</u>	<u>001</u>	Dec 29, 2003
-----------	--	-------------	---	-----------------------	-------------------	--------------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSELLE

AB		DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>001</u>	Nov 30, 2001
-----------	--	----------------------------	----------------------------	-----------------------	-------------------	--------------

TABLET; ORAL-28

CRYSELLE

AB		DURAMED PHARMS BARR	<u>0.03MG;0.3MG</u>	<u>A075840</u>	<u>002</u>	Nov 30, 2001
-----------	--	----------------------------	----------------------------	-----------------------	-------------------	--------------

ELINEST

AB		NOVAST LABS LTD	<u>0.03MG;0.3MG</u>	<u>A091105</u>	<u>001</u>	Mar 28, 2012
-----------	--	------------------------	----------------------------	-----------------------	-------------------	--------------

LO/OVRAL-28

AB		WYETH PHARMS	<u>0.03MG;0.3MG</u>	<u>N017802</u>	<u>001</u>	
		OGESTREL 0.5/50-28				
	+	WATSON LABS	0.05MG;0.5MG	A075406	002	Dec 15, 1999

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	GUERBET	99%	N009190	001	
----------	----------------	------------	----------------	------------	--

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+	WYETH PHARMS INC	250MG	N013026	002	
----------	-------------------------	--------------	----------------	------------	--

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB		BANNER PHARMACAPS	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002
-----------	--	--------------------------	---------------------	-----------------------	-------------------	--------------

AB		VERSAPHARM	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008
-----------	--	-------------------	---------------------	-----------------------	-------------------	--------------

AB		ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012
-----------	--	-----------------------------	---------------------	-----------------------	-------------------	--------------

ZARONTIN

AB	+	PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>	
-----------	----------	--------------------	---------------------	-----------------------	-------------------	--

SYRUP; ORAL

ETHOSUXIMIDE

AA		MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003
-----------	--	---------------	-------------------------	-----------------------	-------------------	--------------

AA		PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000
-----------	--	--------------------	-------------------------	-----------------------	-------------------	--------------

AA		TEVA PHARMS	<u>250MG/5ML</u>	<u>A081306</u>	<u>001</u>	Jul 30, 1993
-----------	--	--------------------	-------------------------	-----------------------	-------------------	--------------

ZARONTIN

AA	+	PARKE DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>	
-----------	----------	--------------------	-------------------------	-----------------------	-------------------	--

ETHOTOIN

TABLET; ORAL

PEGANONE

+	RECORDATI RARE	250MG	N010841	001	
----------	-----------------------	--------------	----------------	------------	--

ETIDRONATE DISODIUM

TABLET; ORAL

DIDRONEL

AB		PROCTER AND GAMBLE	<u>200MG</u>	<u>N017831</u>	<u>001</u>	
-----------	--	---------------------------	---------------------	-----------------------	-------------------	--

AB	+		<u>400MG</u>	<u>N017831</u>	<u>002</u>	
-----------	----------	--	---------------------	-----------------------	-------------------	--

ETIDRONATE DISODIUM

AB		MYLAN	<u>200MG</u>	<u>A075800</u>	<u>001</u>	Jan 24, 2003
-----------	--	--------------	---------------------	-----------------------	-------------------	--------------

AB			<u>400MG</u>	<u>A075800</u>	<u>002</u>	Jan 24, 2003
-----------	--	--	---------------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-145 (of 371)

ETODOLAC

CAPSULE; ORAL

ETODOLAC

<u>AB</u>	ANI PHARMS INC	<u>200MG</u>	<u>A075126</u>	<u>001</u>	Sep 16, 1999
<u>AB</u>		<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999
<u>AB</u>	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000
<u>AB</u>		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000
<u>AB</u>	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>	+	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002
<u>AB</u>		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002
<u>AB</u>	MYLAN	<u>400MG</u>	<u>A075104</u>	<u>001</u>	Feb 06, 1998
<u>AB</u>		<u>500MG</u>	<u>A075104</u>	<u>002</u>	Nov 20, 1998
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	+	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075009</u>	<u>001</u>	Nov 26, 1997
<u>AB</u>		<u>500MG</u>	<u>A075009</u>	<u>002</u>	Dec 28, 1999

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	+	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS USA INC	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982
-----------	---	---------	---------------	----------------	------------	--------------

ETOMIDATE

<u>AP</u>		AGILA SPECLTS	<u>2MG/ML</u>	<u>A078289</u>	<u>001</u>	Jan 02, 2009
<u>AP</u>		BEDFORD	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>		EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>		LUITPOLD	<u>2MG/ML</u>	<u>A078867</u>	<u>001</u>	Dec 22, 2009
<u>AP</u>		PAR STERILE PRODUCTS	<u>2MG/ML</u>	<u>A091297</u>	<u>001</u>	Jun 20, 2012
<u>AP</u>		ZYDUS PHARMS USA INC	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
---	-----------------	--------------	---------	-----	--------------

NEXPLANON

+	ORGANON USA INC	68MG/IMPLANT	N021529	002	May 31, 2011
---	-----------------	--------------	---------	-----	--------------

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

+	MYLAN	50MG	A075635	001	Sep 19, 2001
---	-------	------	---------	-----	--------------

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>		EUROHLTH INTL	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995
<u>AP</u>	+	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

+	BRISTOL MYERS SQUIBB	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996
---	----------------------	--------------------	---------	-----	--------------

ETRAVIRINE

TABLET; ORAL

INTELENCE

	JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012
		100MG	N022187	001	Jan 18, 2008
+		200MG	N022187	002	Dec 22, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-146 (of 371)

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

2.5MG

N022334 003 Jul 09, 2010

5MG

N022334 001 Mar 30, 2009

7.5MG

N022334 004 Mar 30, 2012

+

10MG

N022334 002 Mar 30, 2009

ZORTRESS

NOVARTIS

0.25MG

N021560 001 Apr 20, 2010

0.5MG

N021560 002 Apr 20, 2010

+

0.75MG

N021560 003 Apr 20, 2010

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM

2MG

N203985 001 Aug 29, 2012

3MG

N203985 002 Aug 29, 2012

+

5MG

N203985 003 Aug 29, 2012

EXEMESTANE

TABLET; ORAL

AROMASINAB + PHARMACIA AND UPJOHN 25MGN020753 001 Oct 21, 1999EXEMESTANEAB ALVOGEN INC 25MGA200898 001 Jul 28, 2014AB ROXANE 25MGA077431 001 Apr 01, 2011EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ ASTRAZENECA AB

2MG/VIAL

N022200 001 Jan 27, 2012

INJECTABLE; SUBCUTANEOUS

BYETTA

+ ASTRAZENECA AB

300MCG/1.2ML (250MCG/ML)

N021773 001 Apr 28, 2005

+

600MCG/2.4ML (250MCG/ML)

N021773 002 Apr 28, 2005

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG; 10MG

N021687 001 Jul 23, 2004

10MG; 20MG

N021687 002 Jul 23, 2004

10MG; 40MG

N021687 003 Jul 23, 2004

+

10MG; 80MG

N021687 004 Jul 23, 2004

EZOGBABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011

200MG

N022345 002 Jun 10, 2011

300MG

N022345 003 Jun 10, 2011

+

400MG

N022345 004 Jun 10, 2011

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIRAB APOTEX 125MGA091480 001 Jul 22, 2011AB 250MGA091480 002 Jul 22, 2011AB 500MGA091480 003 Jul 22, 2011AB AUROBINDO PHARMA LTD 125MGA091114 001 Mar 21, 2011AB 250MGA091114 002 Mar 21, 2011AB 500MGA091114 003 Mar 21, 2011AB CIPLA LTD 125MGA078278 001 Mar 21, 2011AB 250MGA078278 002 Mar 21, 2011AB 500MGA078278 003 Mar 21, 2011AB HETERO LABS LTD V 125MGA202438 001 Sep 10, 2014AB 250MGA202438 002 Sep 10, 2014AB 500MGA202438 003 Sep 10, 2014AB MACLEODS PHARMS LTD 125MGA201022 001 Jan 12, 2012AB 250MGA201022 002 Jan 12, 2012AB 500MGA201022 003 Jan 12, 2012AB MYLAN 125MGA201333 001 Mar 24, 2011AB 250MGA201333 002 Mar 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-147 (of 371)

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>		<u>500MG</u>	<u>A201333</u>	<u>003</u>	Mar 24, 2011
<u>AB</u>	ROXANE	<u>125MG</u>	<u>A090128</u>	<u>001</u>	Mar 21, 2011
<u>AB</u>		<u>250MG</u>	<u>A090128</u>	<u>002</u>	Mar 21, 2011
<u>AB</u>		<u>500MG</u>	<u>A090128</u>	<u>003</u>	Mar 21, 2011
<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007

FAMVIR

<u>AB</u>	NOVARTIS	<u>125MG</u>	<u>N020363</u>	<u>003</u>	Dec 11, 1995
<u>AB</u>		<u>250MG</u>	<u>N020363</u>	<u>001</u>	Apr 26, 1996
<u>AB</u>	+	<u>500MG</u>	<u>N020363</u>	<u>002</u>	Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	HI-TECH PHARMA CO	<u>40MG/5ML</u>	<u>A201995</u>	<u>001</u>	May 30, 2014
<u>AB</u>	LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010

PEPCID

<u>AB</u>	+	SALIX PHARMS	<u>40MG/5ML</u>	<u>N019527</u>	<u>001</u>	Feb 02, 1987
-----------	---	--------------	-----------------	----------------	------------	--------------

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	AGILA SPECLTS	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	+ HIKMA MAPLE	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	AGILA SPECLTS	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008
<u>AP</u>	BEDFORD	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	BEDFORD LABS	<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	+ HIKMA MAPLE	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>0.4MG/ML</u>	<u>A075591</u>	<u>001</u>	May 10, 2001
-----------	---	-----------------	-----------------	----------------	------------	--------------

SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012
-----------	----------------	-----------------	----------------	------------	--------------

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A075704</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075704</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	PERRIGO	<u>20MG</u>	<u>A077352</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>		<u>40MG</u>	<u>A077352</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>	TEVA	<u>20MG</u>	<u>A075311</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075311</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	WOCKHARDT	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001

PEPCID

<u>AB</u>	MARATHON PHARMS	<u>20MG</u>	<u>N019462</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>	+	<u>40MG</u>	<u>N019462</u>	<u>002</u>	Oct 15, 1986

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

+	HORIZON PHARMA	26.6MG; 800MG	N022519	001	Apr 23, 2011
---	----------------	---------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-148 (of 371)

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

40MG

N021856 001 Feb 13, 2009

+

80MG

N021856 002 Feb 13, 2009

FELBAMATE

SUSPENSION; ORAL

FELBAMATEAB AMNEAL PHARMS600MG/5MLA202385 001 Dec 16, 2011FELBATOLAB + MEDA PHARMS600MG/5MLN020189 003 Jul 29, 1993

TABLET; ORAL

FELBAMATEAB AMNEAL PHARMS400MGA201680 001 Sep 13, 2011AB600MGA201680 002 Sep 13, 2011FELBATOLAB MEDA PHARMS400MGN020189 001 Jul 29, 1993AB +600MGN020189 002 Jul 29, 1993FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINEAB AUROBINDO PHARMA LTD2.5MGA203417 001 Jan 17, 2013AB5MGA203417 002 Jan 17, 2013AB10MGA203417 003 Jan 17, 2013AB GLENMARK GENERICS2.5MGA090365 001 Dec 17, 2010AB5MGA090365 002 Dec 17, 2010AB10MGA090365 003 Dec 17, 2010AB HERITAGE PHARMS INC2.5MGA201964 001 Nov 08, 2013AB5MGA201964 002 Nov 08, 2013AB10MGA201964 003 Nov 08, 2013AB MUTUAL PHARM2.5MGA075896 001 Nov 02, 2004AB5MGA075896 002 Nov 02, 2004AB10MGA075896 003 Nov 02, 2004AB MYLAN2.5MGA078855 001 Apr 17, 2008AB5MGA078855 002 Apr 17, 2008AB +10MGA078855 003 Apr 17, 2008AB RANBAXY LABS LTD2.5MGA091200 001 Dec 13, 2013AB5MGA091200 002 Dec 13, 2013AB10MGA091200 003 Dec 13, 2013AB TORRENT PHARMS LTD2.5MGA202170 001 Nov 28, 2011AB5MGA202170 002 Nov 28, 2011AB10MGA202170 003 Nov 28, 2011AB VINTAGE PHARMS LLC2.5MGA200815 001 Oct 28, 2011AB5MGA200815 002 Oct 28, 2011AB10MGA200815 003 Oct 28, 2011PLENDILAB ASTRAZENECA2.5MGN019834 004 Sep 22, 1994AB5MGN019834 001 Jul 25, 1991AB10MGN019834 002 Jul 25, 1991FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)AB LUPIN ATLANTIS43MGN021695 001 Nov 30, 2004AB +130MGN021695 003 Nov 30, 2004FENOFIBRATEAB RANBAXY LABS LTD43MGA201748 001 Oct 31, 2014AB130MGA201748 002 Oct 31, 2014FENOFIBRATE (MICRONIZED)AB APOTEX INC43MGA202252 001 Jul 26, 2013AB130MGA202252 002 Jul 26, 2013AB DR REDDYS LABS SA43MGA090859 001 Mar 01, 2012AB130MGA090859 002 Mar 01, 2012AB IMPAX LABS67MGA075868 001 Oct 27, 2003AB134MGA075868 002 Oct 27, 2003AB200MGA075868 003 Oct 27, 2003AB MYLAN PHARMS INC43MGA202579 001 Jan 10, 2013AB67MGA202676 001 Oct 23, 2012AB130MGA202579 002 Jan 10, 2013AB134MGA202676 002 Oct 23, 2012AB200MGA202676 003 Oct 23, 2012AB TEVA67MGA075753 001 Sep 03, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-149 (of 371)

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB		134MG	A075753 002	Apr 09, 2002
AB	+	200MG	A075753 003	Apr 09, 2002
	ANTARA (MICRONIZED)			
	LUPIN ATLANTIS	30MG	N021695 004	Oct 18, 2013
		90MG	N021695 005	Oct 18, 2013
	LIPOFEN			
	CIPHER PHARMS INC	50MG	N021612 001	Jan 11, 2006
	+	150MG	N021612 003	Jan 11, 2006

TABLET; ORAL

FENOFIBRATE

AB	IMPAX LABS	54MG	A076509 001	Mar 26, 2008
AB		160MG	A076509 002	Mar 26, 2008
AB	LUPIN LTD	48MG	A090856 001	Dec 23, 2011
AB		145MG	A090856 002	Dec 23, 2011
AB	MYLAN	54MG	A076520 001	Oct 25, 2007
AB		160MG	A076520 003	Oct 25, 2007
AB	MYLAN PHARMS INC	48MG	A202856 001	Dec 07, 2012
AB		145MG	A202856 002	Dec 07, 2012
AB	RANBAXY	54MG	A076635 001	Oct 31, 2005
AB		160MG	A076635 003	Oct 31, 2005
AB	TEVA	54MG	A076433 001	May 13, 2005
AB	+	160MG	A076433 002	May 13, 2005
AB	VALEANT INTL	48MG	A090715 001	Apr 05, 2012
AB		145MG	A090715 002	Apr 05, 2012

TRICOR

AB	ABBVIE	48MG	N021656 001	Nov 05, 2004
AB	+	145MG	N021656 002	Nov 05, 2004
	TRIGLIDE			
BX	+	SKYEPHARMA AG	N021350 002	May 07, 2005
	FENOFIBRATE			
	RANBAXY	107MG	A076635 002	Oct 31, 2005
	FENOGLIDE			
	SANTARUS INC	40MG	N022118 001	Aug 10, 2007
	+	120MG	N022118 002	Aug 10, 2007

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

	MUTUAL PHARM CO INC	35MG	N022418 001	Aug 14, 2009
	+	105MG	N022418 002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP	+	HOSPIRA	EQ 10MG BASE/ML	N019922 001	Sep 23, 1997
-----------	---	---------	------------------------	--------------------	--------------

FENOLDOPAM MESYLATE

AP	EUROHLTH INTL	EQ 10MG BASE/ML	A076582 001	Oct 12, 2004
AP	SANDOZ	EQ 10MG BASE/ML	A077155 001	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

	+	XSPIRE	EQ 200MG BASE	N017604 003	
			EQ 400MG BASE	N017604 004	Jul 21, 2009

TABLET; ORAL

FENOPROFEN CALCIUM

	+	MYLAN PHARMS INC	EQ 600MG BASE	A072267 001	Aug 17, 1988
--	---	------------------	---------------	-------------	--------------

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC-100

AB	JANSSEN PHARMS	100MCG/HR	N019813 001	Aug 07, 1990
-----------	----------------	------------------	--------------------	--------------

DURAGESIC-12

AB	JANSSEN PHARMS	12.5MCG/HR	N019813 005	Feb 04, 2005
-----------	----------------	-------------------	--------------------	--------------

DURAGESIC-25

AB	+	JANSSEN PHARMS	25MCG/HR	N019813 004	Aug 07, 1990
-----------	---	----------------	-----------------	--------------------	--------------

DURAGESIC-50

AB	JANSSEN PHARMS	50MCG/HR	N019813 003	Aug 07, 1990
-----------	----------------	-----------------	--------------------	--------------

DURAGESIC-75

AB	JANSSEN PHARMS	75MCG/HR	N019813 002	Aug 07, 1990
-----------	----------------	-----------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-150 (of 371)

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

<u>AB</u>	AVEVA	<u>100MCG/HR</u>	<u>A077449</u>	<u>004</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>100MCG/HR</u>	<u>A077051</u>	<u>004</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>100MCG/HR</u>	<u>A077154</u>	<u>004</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>100MCG/HR</u>	<u>A077062</u>	<u>004</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>100MCG/HR</u>	<u>A076709</u>	<u>004</u>	Aug 20, 2007

FENTANYL-12

<u>AB</u>	MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007
-----------	--------------------	-------------------	----------------	------------	--------------

FENTANYL-25

<u>AB</u>	AVEVA	<u>25MCG/HR</u>	<u>A077449</u>	<u>001</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>25MCG/HR</u>	<u>A077051</u>	<u>001</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>25MCG/HR</u>	<u>A077154</u>	<u>001</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>25MCG/HR</u>	<u>A077062</u>	<u>001</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>25MCG/HR</u>	<u>A076709</u>	<u>001</u>	Aug 20, 2007

FENTANYL-50

<u>AB</u>	AVEVA	<u>50MCG/HR</u>	<u>A077449</u>	<u>002</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>50MCG/HR</u>	<u>A077051</u>	<u>002</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>50MCG/HR</u>	<u>A077154</u>	<u>002</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>50MCG/HR</u>	<u>A077062</u>	<u>002</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>50MCG/HR</u>	<u>A076709</u>	<u>002</u>	Aug 20, 2007

FENTANYL-75

<u>AB</u>	AVEVA	<u>75MCG/HR</u>	<u>A077449</u>	<u>003</u>	Oct 20, 2008
<u>AB</u>	LAVIPHARM LABS	<u>75MCG/HR</u>	<u>A077051</u>	<u>003</u>	Aug 04, 2006
<u>AB</u>	MALLINCKRODT INC	<u>75MCG/HR</u>	<u>A077154</u>	<u>003</u>	Feb 09, 2011
<u>AB</u>	MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005
<u>AB</u>	PAR PHARM INC	<u>75MCG/HR</u>	<u>A077062</u>	<u>003</u>	Aug 20, 2007
<u>AB</u>	WATSON LABS	<u>75MCG/HR</u>	<u>A076709</u>	<u>003</u>	Aug 20, 2007

FENTANYL-37

	MYLAN TECHNOLOGIES	37.5MCG/HR	A076258	006	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

FENTANYL-62

	MYLAN TECHNOLOGIES	62.5MCG/HR	A076258	007	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

FENTANYL-87

	MYLAN TECHNOLOGIES	87.5MCG/HR	A076258	008	Dec 29, 2014
--	--------------------	------------	---------	-----	--------------

SPRAY;SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012
		0.2MG	N202788	002	Jan 04, 2012
+		0.4MG	N202788	003	Jan 04, 2012
		0.6MG	N202788	004	Jan 04, 2012
		0.8MG	N202788	005	Jan 04, 2012
		1.2MG	N202788	006	Aug 30, 2012
		1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE

<u>AP</u>	HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985
-----------	---------	--------------------------	----------------	------------	--------------

FENTANYL CITRATE PRESERVATIVE FREE

<u>AP</u>	+	HIKMA MAPLE	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984
<u>AP</u>		HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991

SUBLIMAZE PRESERVATIVE FREE

<u>AP</u>	+	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	
-----------	---	-------	--------------------------	----------------	------------	--

SPRAY, METERED;NASAL

LAZANDA

	DEPOMED INC	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET;BUCCAL, SUBLINGUAL

FENTORA

	CEPHALON	EQ 0.1MG BASE	N021947	001	Sep 25, 2006
		EQ 0.2MG BASE	N021947	002	Sep 25, 2006
+		EQ 0.4MG BASE	N021947	003	Sep 25, 2006
		EQ 0.6MG BASE	N021947	004	Sep 25, 2006
		EQ 0.8MG BASE	N021947	005	Sep 25, 2006

TABLET;SUBLINGUAL

ABSTRAL

	GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011
		EQ 0.3MG BASE	N022510	003	Jan 07, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-151 (of 371)

FENTANYL CITRATE

TABLET;SUBLINGUAL

ABSTRAL

+

EQ 0.4MG BASE

N022510 004 Jan 07, 2011

EQ 0.6MG BASE

N022510 005 Jan 07, 2011

EQ 0.8MG BASE

N022510 006 Jan 07, 2011

TROCHE/LOZENGE;TRANSMUCOSAL

ACTIQAB CEPHALONEQ 0.2MG BASEN020747 001 Nov 04, 1998AB +EQ 0.4MG BASEN020747 002 Nov 04, 1998ABEQ 0.6MG BASEN020747 003 Nov 04, 1998ABEQ 0.8MG BASEN020747 004 Nov 04, 1998ABEQ 1.2MG BASEN020747 005 Nov 04, 1998ABEQ 1.6MG BASEN020747 006 Nov 04, 1998FENTANYL CITRATEAB MALLINCKRODTEQ 0.2MG BASEA078907 001 Oct 30, 2009ABEQ 0.4MG BASEA078907 002 Oct 30, 2009ABEQ 0.6MG BASEA078907 003 Oct 30, 2009ABEQ 0.8MG BASEA078907 004 Oct 30, 2009ABEQ 1.2MG BASEA078907 005 Oct 30, 2009ABEQ 1.6MG BASEA078907 006 Oct 30, 2009AB PAR PHARMEQ 0.2MG BASEA077312 001 Oct 30, 2009ABEQ 0.4MG BASEA077312 002 Oct 30, 2009ABEQ 0.6MG BASEA077312 003 Oct 30, 2009ABEQ 0.8MG BASEA077312 004 Oct 30, 2009ABEQ 1.2MG BASEA077312 005 Oct 30, 2009ABEQ 1.6MG BASEA077312 006 Oct 30, 2009FERRIC CARBOXYMALTOSE

INJECTABLE;INTRAVENOUS

INJECTAFER

+ LUITPOLD

750MG IRON/15ML (50MG IRON/ML)

N203565 001 Jul 25, 2013

FERRIC CITRATE

TABLET;ORAL

FERRIC CITRATE

+ KERYX BIOPHARMS

EQ 210MG IRON

N205874 001 Sep 05, 2014

FERRIC HEXACYANOFERRATE(II)

CAPSULE;ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+ HEYL CHEMISCH

500MG

N021626 001 Oct 02, 2003

FERUMOXYTOL

SOLUTION;INTRAVENOUS

FERAHEME

+ AMAG PHARMS INC

EQ 510MG IRON/17ML (EQ 30MG IRON/ML)

N022180 001 Jun 30, 2009

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

TOVIAZ

PFIZER

4MG

N022030 001 Oct 31, 2008

+

8MG

N022030 002 Oct 31, 2008

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

ALLEGRAAB + SANOFI AVENTIS US30MG/5MLN021963 001 Oct 16, 2006FEXOFENADINE HYDROCHLORIDEAB ACTAVIS MID ATLANTIC30MG/5MLA201311 001 Jul 25, 2012

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDEAB BARR30MGA076191 001 Aug 31, 2005AB60MGA076191 002 Aug 31, 2005AB180MGA076191 003 Aug 31, 2005AB DR REDDYS LABS LTD30MGA076502 001 Apr 11, 2006AB60MGA076502 002 Apr 11, 2006AB180MGA076502 003 Apr 11, 2006AB MYLAN30MGA077081 002 Apr 11, 2008AB60MGA077081 003 Apr 11, 2008AB180MGA077081 001 Apr 16, 2007AB TEVA30MGA076447 001 Sep 01, 2005AB60MGA076447 002 Sep 01, 2005AB180MGA076447 003 Sep 01, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-152 (of 371)

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AB	BARR	60MG;120MG	A076236 001	Apr 14, 2005
AB	IMPAX PHARMS	60MG;120MG	A076298 001	Nov 12, 2010

FIDAXOMICIN

TABLET; ORAL

DIFICID

+	CUBIST PHARMS	200MG	N201699 001	May 27, 2011
---	---------------	-------	-------------	--------------

FINAFLOXACIN

SUSPENSION/DROPS; OTIC

XTORO

+	ALCON RES LTD	0.3%	N206307 001	Dec 17, 2014
---	---------------	------	-------------	--------------

FINASTERIDE

TABLET; ORAL

FINASTERIDE

AB	ACCORD HLTHCARE	5MG	A090121 001	Feb 23, 2010
AB	ACCORD HLTHCARE INC	1MG	A091643 001	Nov 05, 2013
AB	ACTAVIS TOTOWA	1MG	A078371 001	Nov 05, 2013
AB		5MG	A077914 001	Mar 28, 2007
AB	AUROBINDO PHARMA	5MG	A078341 001	Oct 30, 2007
AB	AUROBINDO PHARMA LTD	1MG	A203687 001	Nov 05, 2013
AB	CIPLA LTD	1MG	A077335 001	Nov 20, 2014
AB	DR REDDYS LABS INC	1MG	A076436 001	Jul 28, 2006
AB	DR REDDYS LABS LTD	5MG	A076437 001	Feb 28, 2007
AB	GEDEON RICHTER USA	5MG	A077251 001	Dec 22, 2006
AB	HETERO LABS LTD III	1MG	A090060 001	Jul 01, 2013
AB		5MG	A090061 001	Jun 07, 2010
AB	MYLAN	5MG	A077578 001	Dec 18, 2006
AB	MYLAN PHARMS INC	1MG	A078161 001	Nov 05, 2013
AB	SUN PHARMA GLOBAL	1MG	A090508 001	Jul 01, 2013
AB		5MG	A090507 001	Aug 16, 2011
AB	TEVA	1MG	A076905 001	Nov 05, 2013
AB		5MG	A076511 001	Dec 15, 2006
AB	ZYDUS PHARMS USA INC	5MG	A078900 001	Dec 28, 2009

PROPECIA

AB	+	MERCK	1MG	N020788 001	Dec 19, 1997
-----------	---	-------	------------	--------------------	--------------

PROSCAR

AB	+	MERCK	5MG	N020180 001	Jun 19, 1992
-----------	---	-------	------------	--------------------	--------------

FINGOLIMOD

CAPSULE; ORAL

GILENYA

+	NOVARTIS	0.5MG	N022527 001	Sep 21, 2010
---	----------	-------	-------------	--------------

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

AB	EPIC PHARMA	100MG	A076835 001	Nov 30, 2005	
AB	IMPAX PHARMS	100MG	A076234 001	Aug 28, 2003	
AB	+	PADDOCK LLC	100MG	A076831 001	Dec 16, 2004

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	AMNEAL PHARM	50MG	A075442 001	Jul 31, 2001
AB		100MG	A075442 002	Jul 31, 2001
AB		150MG	A075442 003	Jul 31, 2001
AB	BARR	50MG	A075882 001	Oct 28, 2002
AB		100MG	A075882 002	Oct 28, 2002
AB		150MG	A075882 003	Oct 28, 2002
AB	RANBAXY	50MG	A076421 001	Mar 28, 2003
AB		100MG	A076421 002	Mar 28, 2003
AB		150MG	A076421 003	Mar 28, 2003
AB	ROXANE	50MG	A076278 001	Jan 14, 2003
AB		100MG	A076278 002	Jan 14, 2003
AB	+	150MG	A076278 003	Jan 14, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-153 (of 371)

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+ PIRAMAL IMAGING 30ML (1.4-135mCi/ML)

N204677 001 Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+ AVID RADIOPHARMS INC 10ML (13.5-51mCi/ML)

+ 10-30ML (13.5-51mCi/ML)

+ 10-50ML (13.5-51mCi/ML)

N202008 001 Apr 06, 2012

N202008 002 Apr 06, 2012

N202008 003 Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINEAP + EUROHLTH INTL 500MG/VIALA075387 001 Apr 16, 2000AP FRESENIUS KABI USA 500MG/VIALA075837 001 Feb 22, 2001FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCANAB PFIZER 50MG/5MLN020090 001 Dec 23, 1993AB + 200MG/5MLN020090 002 Dec 23, 1993FLUCONAZOLEAB AUROBINDO PHARM 50MG/5MLA079150 001 Sep 18, 2009AB 200MG/5MLA079150 002 Sep 18, 2009AB IVAX SUB TEVA PHARMS 50MG/5MLA077523 001 Sep 12, 2007AB 200MG/5MLA077523 002 Sep 12, 2007AB RANBAXY 50MG/5MLA076332 001 Jul 29, 2004AB 200MG/5MLA076332 002 Jul 29, 2004AB ROXANE 50MG/5MLA076246 001 Jul 29, 2004AB 200MG/5MLA076246 002 Jul 29, 2004

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINERAP + PFIZER 200MG/100ML (2MG/ML)N019950 003 Sep 29, 1992AP + 400MG/200ML (2MG/ML)N019950 005 Jul 08, 1994DIFLUCAN IN SODIUM CHLORIDE 0.9%AP + PFIZER 200MG/100ML (2MG/ML)N019950 001 Jan 29, 1990AP + 400MG/200ML (2MG/ML)N019950 006 Jan 29, 1990DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP + PFIZER 200MG/100ML (2MG/ML)N019950 002 Jan 29, 1990AP + 400MG/200ML (2MG/ML)N019950 004 Jan 29, 1990FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP ACS DOBFAR INFO SA 200MG/100ML (2MG/ML)A079104 001 Jul 30, 2009AP 400MG/200ML (2MG/ML)A079104 002 Jul 30, 2009FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINERAP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML)A077988 001 May 26, 2010AP 400MG/200ML (2MG/ML)A077988 002 May 26, 2010AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML)A078764 001 Jan 30, 2012AP 400MG/200ML (2MG/ML)A078764 002 Jan 30, 2012AP HOSPIRA 200MG/100ML (2MG/ML)A076304 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076304 002 Jul 29, 2004FLUCONAZOLE IN SODIUM CHLORIDE 0.9%AP BEDFORD 200MG/100ML (2MG/ML)A076087 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076087 003 Jul 29, 2004AP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML)A077947 001 May 26, 2010AP 400MG/200ML (2MG/ML)A077947 002 May 26, 2010AP FRESENIUS KABI USA 200MG/100ML (2MG/ML)A076145 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076145 002 Jul 29, 2004AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML)A076736 001 Aug 23, 2005AP TEVA PHARMS USA 200MG/100ML (2MG/ML)A076653 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076653 002 Jul 29, 2004FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP BAXTER HLTHCARE 200MG/100ML (2MG/ML)A076766 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076766 002 Jul 29, 2004AP BEDFORD LABS 200MG/100ML (2MG/ML)A078107 001 Jul 30, 2008AP 400MG/200ML (2MG/ML)A078107 002 Jul 30, 2008AP CLARIS LIFESCIENCES 200MG/100ML (2MG/ML)A077909 001 May 26, 2010AP 400MG/200ML (2MG/ML)A077909 002 May 26, 2010AP HIKMA FARMACEUTICA 200MG/100ML (2MG/ML)A078698 001 Jan 30, 2012AP 400MG/200ML (2MG/ML)A078698 002 Jan 30, 2012AP HOSPIRA 200MG/100ML (2MG/ML)A076303 001 Jul 29, 2004AP 400MG/200ML (2MG/ML)A076303 002 Jul 29, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-154 (of 371)

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

BEDFORD

100MG/50ML (2MG/ML)

A076087 002 Sep 26, 2008

TABLET; ORAL

DIFLUCANAB PFIZER50MGN019949 001 Jan 29, 1990AB100MGN019949 002 Jan 29, 1990AB150MGN019949 004 Jun 30, 1994AB +200MGN019949 003 Jan 29, 1990FLUCONAZOLEAB APOTEX50MGA076665 001 Jul 29, 2004AB100MGA076665 002 Jul 29, 2004AB150MGA076665 003 Jul 29, 2004AB200MGA076665 004 Jul 29, 2004AB AUROBINDO PHARMA50MGA077731 001 Oct 07, 2008AB100MGA077731 002 Oct 07, 2008AB150MGA077731 003 Oct 07, 2008AB200MGA077731 004 Oct 07, 2008AB DR REDDYS LABS INC50MGA076658 001 Jul 29, 2004AB100MGA076658 002 Jul 29, 2004AB150MGA076658 003 Jul 29, 2004AB200MGA076658 004 Jul 29, 2004AB GLENMARK GENERICS50MGA077253 001 Jan 25, 2006AB100MGA077253 002 Jan 25, 2006AB150MGA077253 003 Jan 25, 2006AB200MGA077253 004 Jan 25, 2006AB IVAX SUB TEVA PHARMS50MGA076077 001 Jul 29, 2004AB100MGA076077 002 Jul 29, 2004AB150MGA076077 003 Jul 29, 2004AB200MGA076077 004 Jul 29, 2004AB MYLAN50MGA076351 001 Jul 29, 2004AB100MGA076351 002 Jul 29, 2004AB150MGA076351 003 Jul 29, 2004AB200MGA076351 004 Jul 29, 2004AB TARO50MGA076507 001 Jul 29, 2004AB100MGA076507 002 Jul 29, 2004AB150MGA076507 003 Jul 29, 2004AB200MGA076507 004 Jul 29, 2004AB TEVA50MGA074681 001 Jul 29, 2004AB100MGA074681 002 Jul 29, 2004AB150MGA074681 003 Jul 29, 2004AB200MGA074681 004 Jul 29, 2004AB UNIQUE PHARM LABS50MGA076957 001 Sep 28, 2005AB100MGA076957 002 Sep 28, 2005AB200MGA076957 003 Sep 28, 2005FLUCYTOSINE

CAPSULE; ORAL

ANCOBONAB VALEANT250MGN017001 001AB +500MGN017001 002FLUCYTOSINEAB SIGMAPHARM LABS LLC250MGA201566 001 Jun 28, 2011AB500MGA201566 002 Jun 28, 2011FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATEAP ACTAVIS TOTOWA50MG/VIALA078610 001 Feb 11, 2009AP + FRESENIUS KABI USA50MG/2ML (25MG/ML)A078393 001 Oct 15, 2007AP50MG/VIALA078544 001 Oct 15, 2007AP + HOSPIRA50MG/VIALA077790 001 Apr 06, 2007AP MUSTAFA NEVZAT ILAC50MG/2ML (25MG/ML)A090724 001 Sep 27, 2010AP ONCO THERAPIES LTD50MG/2ML (25MG/ML)A200647 001 Dec 21, 2011AP50MG/VIALA200648 001 Oct 16, 2012AP + SANDOZ50MG/2ML (25MG/ML)N022137 001 Sep 21, 2007AP TEVA PHARMS USA50MG/VIALA076349 001 Aug 28, 2003AP50MG/2ML (25MG/ML)A076661 001 Apr 28, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-155 (of 371)

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	CPDC	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	+ FEINSTEIN	<u>20-200mCi/ML</u>	<u>N021870</u>	<u>001</u>	Aug 19, 2005
<u>AP</u>	+	<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	GLOBAL ISOTOPES LLC	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	+ HOUSTON CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	LANTHEUS MEDICAL	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	UCSF RODIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	WI MEDCL CYCLOTRON	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014
	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA PHARMS	<u>0.1MG</u>	<u>A091302</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	+ IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	AGILA SPECILTS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	+	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078595</u>	<u>002</u>	May 13, 2008
<u>AP</u>	BEDFORD LABS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	HIKMA MAPLE	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ MEDA PHARMS INC

0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	+ BAUSCH AND LOMB	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>	HI TECH PHARMA CO	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006
	+ APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>	FOUGERA	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>	G AND W LABS	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		<u>0.025%</u>	<u>A089525</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>	TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
	<u>SYNALAR</u>				
<u>AT</u>	+ MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+	<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-156 (of 371)

FLUOCINOLONE ACETONIDE

IMPLANT; INTRAVITREAL

ILUVIEN

+ ALIMERA SCIENCES INC 0.19MG

N201923 001 Sep 26, 2014

RETISERT

+ BAUSCH AND LOMB 0.59MG

N021737 001 Apr 08, 2005

OIL; TOPICAL

DERMA-SMOOTH/FS**AT** + HILL DERMAC 0.01%**N019452 001** Feb 03, 1988**AT** + 0.01%**N019452 002** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC 0.01%**A201759 001** Oct 17, 2011**AT** 0.01%**A201764 001** Oct 17, 2011**AT** PERRIGO ISRAEL 0.01%**A202847 001** Aug 09, 2013**AT** 0.01%**A202848 001** Aug 09, 2013

OIL/DROPS; OTIC

DERMOTIC**AT** + HILL DERMAC 0.01%**N019452 003** Nov 09, 2005FLUOCINOLONE ACETONIDE**AT** IDENTI PHARMS INC 0.01%**A091306 001** Oct 17, 2011

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA 0.025%**A088168 001** Dec 16, 1982**AT** G AND W LABS 0.025%**A089524 001** Jul 26, 1988**AT** TARO 0.025%**A040041 001** Sep 15, 1994SYNALAR**AT** + MEDIMETRIKS PHARMS 0.025%**N013960 001**

SHAMPOO; TOPICAL

CAPEX

+ GALDERMA LABS LP 0.01%

N020001 001 Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE**AT** FOUGERA 0.01%**A088167 001** Dec 16, 1982**AT** TARO 0.01%**A089124 001** Sep 11, 1985SYNALAR**AT** + MEDIMETRIKS PHARMS 0.01%**N015296 001**FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+ GALDERMA LABS LP 0.01%; 4%; 0.05%

N021112 001 Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

+ MEDIMETRIKS PHARMS 0.025%; EQ 3.5MG BASE/GM

A060700 001

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS INC 0.1%**A200735 001** Jul 14, 2014**AB** GLENMARK GENERICS 0.1%**A091282 001** Jul 14, 2014**AB** PERRIGO ISRAEL 0.1%**A090256 001** Jan 14, 2014**AB** TARO 0.1%**A200734 001** Jul 14, 2014VANOS**AB** + MEDICIS 0.1%**N021758 001** Feb 11, 2005FLUOCINONIDE**AB1** FOUGERA 0.05%**A073030 001** Oct 17, 1994**AB1** G AND W LABS INC 0.05%**A073085 001** Feb 14, 1992**AB1** + TARO 0.05%**N019117 001** Jun 26, 1984**AB1** TEVA 0.05%**A072488 001** Feb 06, 1989FLUOCINONIDE EMULSIFIED BASE**AB2** FOUGERA PHARMS 0.05%**A076586 001** Jun 23, 2004**AB2** + TARO 0.05%**A072494 001** Jan 19, 1989**AB2** TEVA 0.05%**A072490 001** Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE**AB** FOUGERA 0.05%**A072933 001** Dec 30, 1994**AB** + TARO 0.05%**A074935 001** Jul 29, 1997**AB** TEVA 0.05%**A072537 001** Feb 07, 1989

OINTMENT; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS 0.05%**A074905 001** Aug 26, 1997**AB** + TARO 0.05%**A075008 001** Jun 30, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-157 (of 371)

FLUOCINONIDE

OINTMENT; TOPICAL

FLUOCINONIDE

AB	TEVA	0.05%	A073481	001	Dec 27, 1991
-----------	------	--------------	----------------	------------	--------------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	FOUGERA	0.05%	A072934	001	Feb 27, 1995
-----------	---------	--------------	----------------	------------	--------------

AT	G AND W LABS INC	0.05%	A071535	001	Dec 02, 1988
-----------	------------------	--------------	----------------	------------	--------------

AT	+ TARO	0.05%	A074799	001	Dec 31, 1996
-----------	--------	--------------	----------------	------------	--------------

AT	TEVA	0.05%	A072511	001	Feb 07, 1989
-----------	------	--------------	----------------	------------	--------------

LIDEX

AT	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984
-----------	------------------	--------------	----------------	------------	--------------

FLUORESCHEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

AP	AKORN	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022186	001	Aug 08, 2008
-----------	-------	---	----------------	------------	--------------

FLUORESCITE

AP	+ ALCON PHARMS LTD	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006
-----------	--------------------	---	----------------	------------	--------------

AK-FLUOR 25%

	+ AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186	002	Aug 08, 2008
--	---------	--------------------------------------	---------	-----	--------------

FLUOROMETHOLONE

OINTMENT; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N017760	001	Sep 04, 1985
--	------------	------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

FML

	+ ALLERGAN	0.1%	N016851	002	Jul 28, 1982
--	------------	------	---------	-----	--------------

FML FORTE

	ALLERGAN	0.25%	N019216	001	Apr 23, 1986
--	----------	-------	---------	-----	--------------

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

	+ ALCON	0.1%	N019079	001	Feb 11, 1986
--	---------	------	---------	-----	--------------

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

AB	+ VALEANT PHARM INTL	5%	N016831	003	
-----------	----------------------	-----------	----------------	------------	--

FLUOROURACIL

AB	SPEAR PHARMS	5%	A077524	001	Apr 11, 2008
-----------	--------------	-----------	----------------	------------	--------------

AB	TARO	5%	A090368	001	Mar 05, 2010
-----------	------	-----------	----------------	------------	--------------

CARAC

	+ VALEANT BERMUDA	0.5%	N020985	001	Oct 27, 2000
--	-------------------	------	---------	-----	--------------

FLUOROPLEX

	+ AQUA PHARMS	1%	N016988	001	
--	---------------	----	---------	-----	--

INJECTABLE; INJECTION

FLUOROURACIL

AP	+ ACCORD HLTHCARE	1GM/20ML (50MG/ML)	A040743	001	Apr 26, 2007
-----------	-------------------	---------------------------	----------------	------------	--------------

AP		2.5GM/50ML (50MG/ML)	A040798	002	Apr 26, 2007
-----------	--	-----------------------------	----------------	------------	--------------

AP		5GM/100ML (50MG/ML)	A040798	001	Apr 26, 2007
-----------	--	----------------------------	----------------	------------	--------------

AP		500MG/10ML (50MG/ML)	A040743	002	Apr 26, 2007
-----------	--	-----------------------------	----------------	------------	--------------

AP	+ FRESENIUS KABI USA	1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998
-----------	----------------------	---------------------------	----------------	------------	--------------

AP		2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998
-----------	--	-----------------------------	----------------	------------	--------------

AP		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998
-----------	--	----------------------------	----------------	------------	--------------

AP		500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998
-----------	--	-----------------------------	----------------	------------	--------------

AP	ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012
-----------	--------------------	---------------------------	----------------	------------	--------------

AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012
-----------	--	-----------------------------	----------------	------------	--------------

AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012
-----------	--	----------------------------	----------------	------------	--------------

AP		500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012
-----------	--	-----------------------------	----------------	------------	--------------

AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011
-----------	--------	-----------------------------	----------------	------------	--------------

AP		5GM/100ML (50MG/ML)	A091299	002	May 02, 2011
-----------	--	----------------------------	----------------	------------	--------------

AP	+ TEVA PHARMS USA	2.5GM/50ML (50MG/ML)	A040334	001	Feb 25, 2000
-----------	-------------------	-----------------------------	----------------	------------	--------------

AP		5GM/100ML (50MG/ML)	A040334	002	Feb 25, 2000
-----------	--	----------------------------	----------------	------------	--------------

AP		500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000
-----------	--	-----------------------------	----------------	------------	--------------

SOLUTION; TOPICAL

EFUDEX

AT	+ VALEANT PHARM INTL	2%	N016831	001	
-----------	----------------------	-----------	----------------	------------	--

AT		5%	N016831	002	
-----------	--	-----------	----------------	------------	--

FLUOROURACIL

AT	TARO	2%	A076526	001	Nov 05, 2003
-----------	------	-----------	----------------	------------	--------------

AT		5%	A076526	002	Nov 05, 2003
-----------	--	-----------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-158 (of 371)

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 40MG BASE</u>	<u>A090223</u>	<u>003</u>	Mar 19, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 40MG BASE</u>	<u>A078619</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 40MG BASE</u>	<u>A075465</u>	<u>003</u>	Aug 02, 2001
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 40MG BASE</u>	<u>A201336</u>	<u>003</u>	Oct 01, 2012
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 40MG BASE</u>	<u>A075245</u>	<u>003</u>	Sep 28, 2004
<u>AB</u>	MYLAN	<u>EQ 40MG BASE</u>	<u>A075207</u>	<u>003</u>	May 25, 2007
<u>AB</u>	PAR PHARM	<u>EQ 40MG BASE</u>	<u>A076922</u>	<u>003</u>	Dec 16, 2004
<u>AB</u>	RANBAXY	<u>EQ 40MG BASE</u>	<u>A076990</u>	<u>001</u>	Dec 13, 2004
<u>AB</u>	SANDOZ	<u>EQ 40MG BASE</u>	<u>A075049</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>EQ 40MG BASE</u>	<u>A075452</u>	<u>003</u>	Jan 29, 2002

PROZAC

<u>AB</u>	+ ELI LILLY AND CO	<u>EQ 40MG BASE</u>	<u>N018936</u>	<u>003</u>	Jun 15, 1999
-----------	--------------------	---------------------	----------------	------------	--------------

FLUOXETINE HYDROCHLORIDE

<u>AB1</u>	ALEMBIC PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A090223</u>	<u>001</u>	Mar 19, 2009
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A090223</u>	<u>002</u>	Mar 19, 2009
<u>AB1</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078619</u>	<u>001</u>	Jan 31, 2008
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A078619</u>	<u>002</u>	Jan 31, 2008
<u>AB1</u>	BARR	<u>EQ 10MG BASE</u>	<u>A074803</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A074803</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A075465</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075465</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	HERITAGE PHARMS INC	<u>EQ 10MG BASE</u>	<u>A201336</u>	<u>001</u>	Oct 01, 2012
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A201336</u>	<u>002</u>	Oct 01, 2012
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A075245</u>	<u>002</u>	Jan 31, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075245</u>	<u>001</u>	Jan 31, 2002
<u>AB1</u>	LANDELA PHARM	<u>EQ 10MG BASE</u>	<u>A075464</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075464</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MALLINCKRODT	<u>EQ 10MG BASE</u>	<u>A075658</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075658</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075207</u>	<u>001</u>	Jan 30, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075207</u>	<u>002</u>	Jan 30, 2002
<u>AB1</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075577</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075577</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A075049</u>	<u>001</u>	Aug 02, 2001
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075049</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075452</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A075452</u>	<u>002</u>	Jan 29, 2002
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A076001</u>	<u>001</u>	Jan 29, 2002
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A076001</u>	<u>002</u>	Jan 29, 2002

PROZAC

<u>AB1</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>006</u>	Dec 23, 1992
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>001</u>	Dec 29, 1987

FLUOXETINE HYDROCHLORIDE

<u>AB2</u>	ANI PHARMS INC	<u>EQ 10MG BASE</u>	<u>A076287</u>	<u>001</u>	May 20, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A076287</u>	<u>002</u>	May 20, 2008
<u>AB2</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078045</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A078045</u>	<u>002</u>	Nov 17, 2008
<u>AB2</u>	SANDOZ	<u>EQ 10MG BASE</u>	<u>A077469</u>	<u>001</u>	Nov 17, 2008
<u>AB2</u>		<u>EQ 20MG BASE</u>	<u>A077469</u>	<u>002</u>	Nov 17, 2008

SARAFEM

<u>AB2</u>	ELI LILLY AND CO	<u>EQ 10MG BASE</u>	<u>N018936</u>	<u>007</u>	Jul 06, 2000
<u>AB2</u>	+	<u>EQ 20MG BASE</u>	<u>N018936</u>	<u>008</u>	Jul 06, 2000

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>EQ 90MG BASE</u>	<u>A076237</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 90MG BASE</u>	<u>A078572</u>	<u>001</u>	Mar 22, 2010

PROZAC WEEKLY

<u>AB</u>	+ LILLY	<u>EQ 90MG BASE</u>	<u>N021235</u>	<u>001</u>	Feb 26, 2001
-----------	---------	---------------------	----------------	------------	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AA</u>	AUROBINDO PHARM	<u>EQ 20MG BASE/5ML</u>	<u>A079209</u>	<u>001</u>	Mar 20, 2009
<u>AA</u>	LANNETT	<u>EQ 20MG BASE/5ML</u>	<u>A076458</u>	<u>001</u>	May 14, 2004
<u>AA</u>	MALLINCKRODT	<u>EQ 20MG BASE/5ML</u>	<u>A075920</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>	+ PHARM ASSOC	<u>EQ 20MG BASE/5ML</u>	<u>A076015</u>	<u>001</u>	Jan 30, 2002
<u>AA</u>	SILARX	<u>EQ 20MG BASE/5ML</u>	<u>A077849</u>	<u>001</u>	Feb 09, 2007
<u>AA</u>	TEVA	<u>EQ 20MG BASE/5ML</u>	<u>A075506</u>	<u>001</u>	Aug 02, 2001
<u>AA</u>	WOCKHARDT	<u>EQ 20MG BASE/5ML</u>	<u>A075514</u>	<u>001</u>	Aug 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-159 (of 371)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS INC	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A075755</u>	<u>001</u>	Aug 02, 2001
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
<u>SARAFEM</u>					
<u>AB1</u>	WARNER CHILCOTT LLC	<u>EQ 10MG BASE</u>	<u>N021860</u>	<u>001</u>	May 19, 2006
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>N021860</u>	<u>002</u>	May 19, 2006
<u>AB1</u>	+	<u>EQ 20MG BASE</u>	<u>N021860</u>	<u>003</u>	May 19, 2006
<u>SELFEMRA</u>					
<u>AB1</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A200151</u>	<u>001</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 15MG BASE</u>	<u>A200151</u>	<u>002</u>	Feb 03, 2014
<u>AB1</u>		<u>EQ 20MG BASE</u>	<u>A200151</u>	<u>003</u>	Feb 03, 2014
FLUOXETINE HYDROCHLORIDE					
	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011
	+	EQ 20MG BASE	A075755	002	Aug 02, 2001

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742</u>	<u>001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>005</u>	Nov 02, 2012
<u>AB</u>	SANDOZ	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901</u>	<u>005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>004</u>	Nov 16, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>004</u>	Jun 19, 2012
<u>SYMBYAX</u>					
<u>AB</u>	LILLY	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520</u>	<u>001</u>	Apr 09, 2007
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>002</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>004</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>003</u>	Dec 24, 2003
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>005</u>	Dec 24, 2003

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

+ USL PHARMA

10MG

A088342 001 Oct 21, 1983

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	EUROHLTH INTL	<u>25MG/ML</u>	<u>A074531</u>	<u>001</u>	Aug 30, 1996
<u>AO</u>	+	<u>25MG/ML</u>	<u>A071413</u>	<u>001</u>	Jul 14, 1987
<u>AO</u>	PAR STERILE PRODUCTS	<u>25MG/ML</u>	<u>A203732</u>	<u>001</u>	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

5MG/ML

A074725 001 Sep 16, 1996

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

+ PHARM ASSOC

2.5MG/5ML

A040146 001 Aug 21, 1996

INJECTABLE; INJECTION

FLUPHENAZINE HYDROCHLORIDE

+ FRESENIUS KABI USA

2.5MG/ML

A089556 001 Apr 16, 1987

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	LANNETT	<u>1MG</u>	<u>A089740</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089741</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>5MG</u>	<u>A089742</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A089804</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804</u>	<u>003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804</u>	<u>004</u>	Aug 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-160 (of 371)

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	+	10MG	A089804	001	Aug 12, 1988
AB	SANDOZ	1MG	A089583	001	Oct 16, 1987
AB		2.5MG	A089584	001	Oct 16, 1987
AB		5MG	A089585	001	Oct 16, 1987
AB		10MG	A089586	001	Oct 16, 1987

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+ AQUA PHARMS

0.025%

N012806 003

+

0.05%

N012806 002

LOTION; TOPICAL

CORDRAN

+ AQUA PHARMS

0.05%

N013790 001

TAPE; TOPICAL

CORDRAN

+ WATSON LABS INC

0.004MG/SQ CM

N016455 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC

15MG

A070345 002 Nov 27, 1985

+

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

ANSAID

AB	PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988
AB	+	100MG	N018766	003	Oct 31, 1988
AB	<u>FLURBIPROFEN</u>				
AB	MYLAN	50MG	A074358	001	Jun 20, 1994
AB		100MG	A074358	002	Jun 20, 1994
AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001
AB		100MG	A075058	002	Apr 27, 2001
AB	TEVA	100MG	A074431	001	May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

AT	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995
AT	<u>OCUFEN</u>				
AT	+	0.03%	N019404	001	Dec 31, 1986

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	ACTAVIS LABS FL INC	125MG	A075820	001	Sep 18, 2001
AB	+	125MG	A075780	001	Sep 19, 2001
AB	MYLAN	125MG	A076224	001	May 09, 2003
AB	PAR PHARM	125MG	A075298	001	Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+ GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013

+

121.5mCi/30ML (4.05mCi/ML)

N203137 002 Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

GLAXOSMITHKLINE

0.1MG/INH

N205625 001 Aug 20, 2014

+

0.2MG/INH

N205625 002 Aug 20, 2014

SPRAY, METERED; NASAL

VERAMYST

+ GLAXOSMITHKLINE

0.0275MG/INH

N022051 001 Apr 27, 2007

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+ GLAXO GRP LTD

0.1MG/INH; EQ 0.025MG BASE/INH

N204275 001 May 10, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-161 (of 371)

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+	GLAXO GRP LTD	0.044MG/INH
+		0.11MG/INH
+		0.22MG/INH

N021433	003	May 14, 2004
N021433	002	May 14, 2004
N021433	001	May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	<u>0.05%</u>	<u>A076451</u>	<u>001</u>	May 14, 2004
AB	G AND W LABS	<u>0.05%</u>	<u>A077055</u>	<u>001</u>	Jun 30, 2006
AB	PERRIGO NEW YORK	<u>0.05%</u>	<u>A076793</u>	<u>001</u>	May 14, 2004
AB	TOLMAR	<u>0.05%</u>	<u>A076633</u>	<u>001</u>	May 14, 2004

LOTION; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	<u>0.05%</u>	<u>N021152</u>	<u>001</u>	Mar 31, 2005
-----------	---	----------------	--------------	-----------------------	-------------------	--------------

FLUTICASONE PROPIONATE

AB	GLENMARK GENERICS	<u>0.05%</u>	<u>A090759</u>	<u>001</u>	May 02, 2011
AB	PERRIGO ISRAEL	<u>0.05%</u>	<u>A091553</u>	<u>001</u>	Jul 30, 2013

OINTMENT; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	<u>0.005%</u>	<u>N019957</u>	<u>001</u>	Dec 14, 1990
-----------	---	----------------	---------------	-----------------------	-------------------	--------------

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	<u>0.005%</u>	<u>A076300</u>	<u>001</u>	May 14, 2004
AB	G AND W LABS	<u>0.005%</u>	<u>A077168</u>	<u>001</u>	Mar 03, 2006
AB	PERRIGO NEW YORK	<u>0.005%</u>	<u>A076668</u>	<u>001</u>	May 14, 2004

POWDER; INHALATION

FLOVENT DISKUS 100

+	GLAXO GRP LTD	0.1MG/INH
---	---------------	-----------

N020833	002	Sep 29, 2000
---------	-----	--------------

FLOVENT DISKUS 250

+	GLAXO GRP LTD	0.25MG/INH
---	---------------	------------

N020833	003	Sep 29, 2000
---------	-----	--------------

FLOVENT DISKUS 50

+	GLAXO GRP LTD	0.05MG/INH
---	---------------	------------

N020833	001	Sep 29, 2000
---------	-----	--------------

SPRAY, METERED; NASAL

FLONASE

AB	+	GLAXOSMITHKLINE	<u>0.05MG/SPRAY</u>	<u>N020121</u>	<u>001</u>	Oct 19, 1994
-----------	---	-----------------	---------------------	-----------------------	-------------------	--------------

FLUTICASONE PROPIONATE

AB	APOTEX INC	<u>0.05MG/SPRAY</u>	<u>A077538</u>	<u>001</u>	Sep 12, 2007
AB	HI TECH PHARMA	<u>0.05MG/SPRAY</u>	<u>A077570</u>	<u>001</u>	Jan 16, 2008
AB	ROXANE	<u>0.05MG/SPRAY</u>	<u>A076504</u>	<u>001</u>	Feb 22, 2006
AB	WOCKHARDT	<u>0.05MG/SPRAY</u>	<u>A078492</u>	<u>001</u>	Jan 09, 2012

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+	GLAXO GRP LTD	0.045MG/INH;EQ 0.021MG BASE/INH
+		0.115MG/INH;EQ 0.021MG BASE/INH
+		0.23MG/INH;EQ 0.021MG BASE/INH

N021254	001	Jun 08, 2006
N021254	002	Jun 08, 2006
N021254	003	Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50

+	GLAXO GRP LTD	0.1MG/INH;EQ 0.05MG BASE/INH
---	---------------	------------------------------

N021077	001	Aug 24, 2000
---------	-----	--------------

ADVAIR DISKUS 250/50

+	GLAXO GRP LTD	0.25MG/INH;EQ 0.05MG BASE/INH
---	---------------	-------------------------------

N021077	002	Aug 24, 2000
---------	-----	--------------

ADVAIR DISKUS 500/50

+	GLAXO GRP LTD	0.5MG/INH;EQ 0.05MG BASE/INH
---	---------------	------------------------------

N021077	003	Aug 24, 2000
---------	-----	--------------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090595</u>	<u>001</u>	Apr 11, 2012
AB		<u>EQ 40MG BASE</u>	<u>A090595</u>	<u>002</u>	Apr 11, 2012
AB	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078407</u>	<u>001</u>	Jun 12, 2012
AB		<u>EQ 40MG BASE</u>	<u>A078407</u>	<u>002</u>	Jun 12, 2012

LESCOL

AB	NOVARTIS	<u>EQ 20MG BASE</u>	<u>N020261</u>	<u>001</u>	Dec 31, 1993
AB	+	<u>EQ 40MG BASE</u>	<u>N020261</u>	<u>002</u>	Dec 31, 1993

TABLET, EXTENDED RELEASE; ORAL

LESCOL XL

+	NOVARTIS	80MG
---	----------	------

N021192	001	Oct 06, 2000
---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-162 (of 371)

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091482</u>	<u>001</u>	Apr 23, 2013
<u>AB</u>		<u>150MG</u>	<u>A091482</u>	<u>002</u>	Nov 18, 2013
<u>AB</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091476</u>	<u>001</u>	Mar 13, 2013
<u>AB</u>		<u>150MG</u>	<u>A091476</u>	<u>002</u>	Mar 13, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>100MG</u>	<u>A203240</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>150MG</u>	<u>A203240</u>	<u>002</u>	Oct 31, 2014

LUVOX CR

<u>AB</u>	JAZZ PHARMS	<u>100MG</u>	<u>N022033</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	+	<u>150MG</u>	<u>N022033</u>	<u>002</u>	Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

<u>AB</u>	APOTEX	<u>25MG</u>	<u>A075902</u>	<u>001</u>	May 07, 2001
<u>AB</u>		<u>50MG</u>	<u>A075902</u>	<u>002</u>	May 07, 2001
<u>AB</u>		<u>100MG</u>	<u>A075902</u>	<u>003</u>	May 07, 2001
<u>AB</u>	BARR	<u>25MG</u>	<u>A075897</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>		<u>50MG</u>	<u>A075897</u>	<u>002</u>	Jan 25, 2001
<u>AB</u>		<u>100MG</u>	<u>A075897</u>	<u>003</u>	Jan 25, 2001
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A075889</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075889</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		<u>100MG</u>	<u>A075889</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A075888</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	+	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>AB</u>	TEVA	<u>25MG</u>	<u>A075893</u>	<u>001</u>	Sep 10, 2002
<u>AB</u>		<u>50MG</u>	<u>A075893</u>	<u>002</u>	Sep 10, 2002
<u>AB</u>		<u>100MG</u>	<u>A075893</u>	<u>003</u>	Sep 10, 2002

LUVOX

<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

+ FRESENIUS KABI USA

5MG/ML

A089202 001 Feb 18, 1986

TABLET;ORAL

FOLIC ACID

<u>AA</u>	+	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>		BICON PHARM	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>		CADILA PHARMS LTD	<u>1 MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>		CONTRACT PHARMACAL	<u>1MG</u>	<u>A085061</u>	<u>001</u>	
<u>AA</u>		EXCELLIUM	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>		HIKMA PHARMS LLC	<u>1MG</u>	<u>A080600</u>	<u>001</u>	
<u>AA</u>		INVAGEN PHARMS	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>		VINTAGE	<u>1MG</u>	<u>A040756</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS

FOLLISTIM AQ

+ ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005

+

150 IU/0.5ML

N021273 002 Aug 26, 2005

+

300 IU/0.36ML

N021211 001 Mar 23, 2004

+

600 IU/0.72ML

N021211 002 Mar 23, 2004

+

900 IU/1.08ML

N021211 004 Feb 11, 2005

GONAL-F

+ EMD SERONO

450 IU/VIAL

N020378 005 Mar 26, 2004

1,050 IU/VIAL

N020378 004 Feb 28, 2001

GONAL-F RFF

+ EMD SERONO

75 IU/VIAL

N021765 002 Mar 25, 2004

GONAL-F RFF REDI-JECT

+ EMD SERONO

300 IU/0.5ML

N021684 001 May 25, 2004

+

450 IU/0.75ML

N021684 002 May 25, 2004

+

900 IU/1.5ML

N021684 003 May 25, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-163 (of 371)

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

AP	+	PALADIN LABS	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>N020696</u>	<u>001</u>	Dec 04, 1997
-----------	----------	---------------------	------------------------------------	-----------------------	-------------------	--------------

FOMEPIZOLE

AP		LUITPOLD	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
-----------	--	-----------------	------------------------------------	-----------------------	-------------------	--------------

AP		MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
-----------	--	----------------------------	------------------------------------	-----------------------	-------------------	--------------

AP		NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008
-----------	--	--------------------	------------------------------------	-----------------------	-------------------	--------------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIIXTRA

AP	+	MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
-----------	----------	--------------------------	---------------------------	-----------------------	-------------------	--------------

AP	+		<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
-----------	----------	--	-------------------------	-----------------------	-------------------	--------------

AP	+		<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
-----------	----------	--	---------------------------	-----------------------	-------------------	--------------

AP	+		<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004
-----------	----------	--	--------------------------	-----------------------	-------------------	--------------

FONDAPARINUX SODIUM

AP		DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
-----------	--	---------------------------	---------------------------	-----------------------	-------------------	--------------

AP			<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
-----------	--	--	-------------------------	-----------------------	-------------------	--------------

AP			<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011
-----------	--	--	---------------------------	-----------------------	-------------------	--------------

AP			<u>10MG/0.8ML</u>	<u>A091316</u>	<u>004</u>	Jul 11, 2011
-----------	--	--	--------------------------	-----------------------	-------------------	--------------

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL

+	NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001
----------	-----------------	--------------------	----------------	------------	--------------

SOLUTION; INHALATION

PERFORMIST

+	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007
----------	---------------------	-------------------	----------------	------------	--------------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH; 0.1MG/INH	N022518	001	Jun 22, 2010
----------	--------------------------	-------------------------------	----------------	------------	--------------

+		0.005MG/INH; 0.2MG/INH	N022518	002	Jun 22, 2010
----------	--	-------------------------------	----------------	------------	--------------

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+	VIIIV HLTHCARE	EQ 50MG BASE/ML	N022116	001	Jun 14, 2007
----------	-----------------------	------------------------	----------------	------------	--------------

TABLET; ORAL

LEXIVA

+	VIIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003
----------	-----------------------	----------------------	----------------	------------	--------------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010
----------	-------------------------	---------------------------	----------------	------------	--------------

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP		HOSPIRA	<u>2.4GM/100ML</u>	<u>A077174</u>	<u>001</u>	May 31, 2005
-----------	--	----------------	---------------------------	-----------------------	-------------------	--------------

FOSCAVIR

AP	+	CLINIGEN HLTHCARE	<u>2.4GM/100ML</u>	<u>N020068</u>	<u>001</u>	Sep 27, 1991
-----------	----------	--------------------------	---------------------------	-----------------------	-------------------	--------------

FOSFOMYCIN TROMETHAMINE

FOR SUSPENSION; ORAL

MONUROL

+	ZAMBON SPA	EQ 3GM BASE/PACKET	N050717	001	Dec 19, 1996
----------	-------------------	---------------------------	----------------	------------	--------------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB		ACTAVIS LABS FL INC	<u>10MG</u>	<u>A076620</u>	<u>001</u>	Oct 15, 2004
-----------	--	----------------------------	--------------------	-----------------------	-------------------	--------------

AB			<u>20MG</u>	<u>A076620</u>	<u>002</u>	Oct 15, 2004
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB			<u>40MG</u>	<u>A076620</u>	<u>003</u>	Oct 15, 2004
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		APOTEX INC	<u>10MG</u>	<u>A076906</u>	<u>001</u>	May 17, 2005
-----------	--	-------------------	--------------------	-----------------------	-------------------	--------------

AB			<u>20MG</u>	<u>A076906</u>	<u>002</u>	May 17, 2005
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB			<u>40MG</u>	<u>A076906</u>	<u>003</u>	May 17, 2005
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A091163</u>	<u>001</u>	Mar 30, 2011
-----------	--	-----------------------------	--------------------	-----------------------	-------------------	--------------

AB			<u>20MG</u>	<u>A091163</u>	<u>002</u>	Mar 30, 2011
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB			<u>40MG</u>	<u>A091163</u>	<u>003</u>	Mar 30, 2011
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB		INVAGEN PHARMS	<u>10MG</u>	<u>A077222</u>	<u>001</u>	Apr 20, 2005
-----------	--	-----------------------	--------------------	-----------------------	-------------------	--------------

AB			<u>20MG</u>	<u>A077222</u>	<u>002</u>	Apr 20, 2005
-----------	--	--	--------------------	-----------------------	-------------------	--------------

AB			<u>40MG</u>	<u>A077222</u>	<u>003</u>	Apr 20, 2005
-----------	--	--	--------------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-164 (of 371)

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076483</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139</u>	<u>001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139</u>	<u>002</u>	Nov 25, 2003
<u>AB</u>	+	<u>40MG</u>	<u>A076139</u>	<u>003</u>	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>10MG;12.5MG</u>	<u>A076608</u>	<u>001</u>	Dec 03, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076608</u>	<u>002</u>	Dec 03, 2004
<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	EMCURE PHARMS INDIA	<u>10MG;12.5MG</u>	<u>A079025</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>	+	<u>20MG;12.5MG</u>	<u>A079025</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	RANBAXY	<u>10MG;12.5MG</u>	<u>A076739</u>	<u>001</u>	Dec 17, 2004
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076739</u>	<u>002</u>	Dec 17, 2004
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450</u>	<u>001</u>	Aug 05, 1996
-----------	-------------	--------------------------------	----------------	------------	--------------

FOSPHENYTOIN SODIUM

<u>AP</u>	AGILA SPECILTS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>	AMNEAL PHARMS CO	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078476</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	BEDFORD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	+	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>	HIKMA MAPLE	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	HOSPIRA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078158</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>	LUITPOLD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078277</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A090099</u>	<u>001</u>	May 13, 2010
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	+	<u>ENDO PHARMS</u>	<u>EQ 2.5MG BASE</u>	<u>N021006</u>	<u>001</u>	Nov 08, 2001
-----------	---	--------------------	----------------------	----------------	------------	--------------

FROVATRIPTAN SUCCINATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2.5MG BASE</u>	<u>A202931</u>	<u>001</u>	Aug 28, 2014
-----------	------------------	----------------------	----------------	------------	--------------

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

+	ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002
---	-------------	---------	---------	-----	--------------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>		CLARIS LIFESCIENCES	<u>10MG/ML</u>	<u>A202747</u>	<u>001</u>	Jan 27, 2014
<u>AP</u>		EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428</u>	<u>001</u>	Aug 26, 2014
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>		HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>			<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>	+	LUITPOLD	<u>10MG/ML</u>	<u>N018579</u>	<u>001</u>	Nov 30, 1983
<u>AP</u>		WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE

<u>AA</u>	+	ROXANE	<u>10MG/ML</u>	<u>A070434</u>	<u>001</u>	Apr 22, 1987
<u>AA</u>		WOCKHARDT	<u>10MG/ML</u>	<u>A070655</u>	<u>001</u>	Oct 02, 1987
		ROXANE	40MG/5ML	A070433	001	Apr 22, 1987

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	EXCELLIUM	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-165 (of 371)

FUROSEMIDE

TABLET; ORAL

FUROSEMIDE

<u>AB</u>	IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>		<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>		<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>N018413</u>	<u>001</u>	Nov 30, 1983
<u>AB</u>		<u>40MG</u>	<u>N018413</u>	<u>002</u>	Nov 30, 1983
<u>AB</u>	MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>		<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>		<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>	ROXANE	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>		<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>		<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>		<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>	SUN PHARM INDS INC	<u>20MG</u>	<u>A091258</u>	<u>001</u>	Apr 01, 2014
<u>AB</u>		<u>40MG</u>	<u>A091258</u>	<u>002</u>	Apr 01, 2014
<u>AB</u>		<u>80MG</u>	<u>A091258</u>	<u>003</u>	Apr 01, 2014
<u>AB</u>	VINTAGE PHARMS	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>		<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>		<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004

LASIX

<u>AB</u>	SANOFI AVENTIS US	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	+	<u>80MG</u>	<u>N016273</u>	<u>003</u>	

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	AUROBINDO PHARM	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	HIKMA	<u>100MG</u>	<u>A078150</u>	<u>001</u>	Sep 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078150</u>	<u>002</u>	Sep 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078150</u>	<u>003</u>	Sep 25, 2007
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A090158</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>300MG</u>	<u>A090158</u>	<u>002</u>	Feb 14, 2011
<u>AB</u>		<u>400MG</u>	<u>A090158</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	RANBAXY	<u>100MG</u>	<u>A076606</u>	<u>001</u>	Oct 07, 2005
<u>AB</u>		<u>300MG</u>	<u>A076606</u>	<u>002</u>	Oct 07, 2005
<u>AB</u>		<u>400MG</u>	<u>A076606</u>	<u>003</u>	Oct 07, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A075435</u>	<u>001</u>	Oct 08, 2004
<u>AB</u>		<u>300MG</u>	<u>A075435</u>	<u>002</u>	Oct 08, 2004
<u>AB</u>		<u>400MG</u>	<u>A075435</u>	<u>003</u>	Oct 08, 2004

NEURONTIN

<u>AB</u>	PFIZER PHARMS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>		<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-166 (of 371)

GABAPENTIN

CAPSULE; ORAL

NEURONTIN

AB	+	400MG	N020235	003	Dec 30, 1993
-----------	----------	--------------	----------------	------------	--------------

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403	001	May 01, 2012
AA	AMNEAL PHARMS	250MG/5ML	A202024	001	Mar 23, 2012
AA	HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011
AA	TARO	250MG/5ML	A076672	001	Jul 03, 2013

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000
-----------	----------	-------------	------------------	----------------	------------	--------------

TABLET; ORAL

GABAPENTIN

AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013
AB		800MG	A203244	001	Jul 12, 2013
AB	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004
AB		800MG	A075694	002	Oct 21, 2004
AB	APOTEX INC	100MG	A077894	001	Oct 10, 2006
AB		300MG	A077894	002	Oct 10, 2006
AB		400MG	A077894	003	Oct 10, 2006
AB		600MG	A077661	004	Sep 13, 2006
AB		800MG	A077661	005	Sep 13, 2006
AB	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011
AB		800MG	A200651	002	Oct 06, 2011
AB	GLENMARK GENERICS	600MG	A077662	001	Aug 18, 2006
AB		800MG	A077662	002	Aug 18, 2006
AB	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011
AB		800MG	A078782	002	Jul 21, 2011
AB	INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012
AB		800MG	A202764	002	Oct 16, 2012
AB	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004
AB		300MG	A076017	002	Apr 28, 2004
AB		400MG	A076017	003	Apr 28, 2004
AB		600MG	A076017	004	Apr 29, 2005
AB		800MG	A076017	005	Apr 29, 2005
AB	MYLAN PHARMS INC	600MG	A090335	001	Jun 01, 2010
AB		800MG	A090335	002	Jun 01, 2010
AB	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006
AB		800MG	A077525	002	Aug 24, 2006
AB	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011
AB		800MG	A078926	002	Feb 11, 2011

NEURONTIN

AB	PFIZER PHARMS	600MG	N020882	001	Oct 09, 1998
AB	+	800MG	N020882	002	Oct 09, 1998

GRALISE

BX	+	DEPOMED INC	300MG	N022544	001	Jan 28, 2011
BX	+		600MG	N022544	002	Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	XENOPORT INC	300MG	N022399	002	Dec 13, 2011
+		600MG	N022399	001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	BRACCO	2.645GM/5ML (529MG/ML)	N021357	001	Nov 23, 2004
+		5.29GM/10ML (529MG/ML)	N021357	002	Nov 23, 2004
+		7.935GM/15ML (529MG/ML)	N021357	003	Nov 23, 2004
+		10.58GM/20ML (529MG/ML)	N021357	004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	BRACCO	26.45GM/50ML (529MG/ML)	N021358	001	Nov 23, 2004
+		52.9GM/100ML (529MG/ML)	N021358	002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277	006	Dec 18, 2013
+		4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011
+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011
+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011
+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-167 (of 371)

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+

39.3068GM/65ML (604.72MG/ML)

N201277 005 Mar 14, 2011

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+ GE HEALTHCARE

28.7GM/100ML (287MG/ML)

N022066 002 Sep 05, 2007

+

287MG/ML

N020123 001 Jan 08, 1993

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL

2440MG/10ML (244MG/ML)

N021711 001 Dec 22, 2008

+

3660MG/15ML (244MG/ML)

N021711 002 Dec 22, 2008

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+ BAYER HLTHCARE

469.01MG/ML

N019596 001 Jun 02, 1988

+

469.01MG/ML

N021037 001 Mar 10, 2000

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

DOTAREM

+ GUERBET

3.769GM/10ML (376.9MG/ML)

N204781 002 Mar 20, 2013

+

5.6535GM/15ML (376.9MG/ML)

N204781 003 Mar 20, 2013

+

7.538GM/20ML (376.9MG/ML)

N204781 004 Mar 20, 2013

+

37.69GM/100ML (376.9MG/ML)

N204781 001 Mar 20, 2013

GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+ BRACCO

279.3MG/ML

N020131 001 Nov 16, 1992

PROHANCE MULTIPACK

+ BRACCO

279.3MG/ML

N021489 001 Oct 09, 2003

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+ MALLINCKRODT

16.545GM/50ML (330.9MG/ML)

N020975 001 Dec 08, 1999

+

1654.5MG/5ML (330.9MG/ML)

N020937 001 Dec 08, 1999

+

3309MG/10ML (330.9MG/ML)

N020937 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020937 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020937 004 Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+ MALLINCKRODT

3309MG/10ML (330.9MG/ML)

N020976 002 Dec 08, 1999

+

4963.5MG/15ML (330.9MG/ML)

N020976 003 Dec 08, 1999

+

6618MG/20ML (330.9MG/ML)

N020976 004 Dec 08, 1999

+

9927MG/30ML (330.9MG/ML)

N020976 001 Dec 08, 1999

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+ BAYER HLTHCARE

1.8143GM/10ML (181.43MG/ML)

N022090 001 Jul 03, 2008

2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDEAB BARREQ 8MG BASEA078189 001 Sep 15, 2008ABEQ 16MG BASEA078189 002 Sep 15, 2008ABEQ 24MG BASEA078189 003 Sep 15, 2008AB IMPAX LABSEQ 8MG BASEA078484 001 May 27, 2009ABEQ 16MG BASEA078484 002 May 27, 2009ABEQ 24MG BASEA078484 003 May 27, 2009AB MYLANEQ 8MG BASEA090900 001 Jan 24, 2011ABEQ 16MG BASEA090900 002 Jan 24, 2011ABEQ 24MG BASEA090900 003 Jan 24, 2011AB SUN PHARMA GLOBALEQ 8MG BASEA090178 001 Feb 02, 2011ABEQ 16MG BASEA090178 002 Feb 02, 2011ABEQ 24MG BASEA090178 003 Feb 02, 2011AB WATSON LABSEQ 8MG BASEA079028 001 Dec 15, 2008ABEQ 16MG BASEA079028 002 Dec 15, 2008ABEQ 24MG BASEA079028 003 Dec 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-168 (of 371)

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

RAZADYNE ER

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 8MG BASE</u>	<u>N021615</u>	<u>001</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 16MG BASE</u>	<u>N021615</u>	<u>002</u>	Apr 01, 2005
<u>AB</u>			<u>EQ 24MG BASE</u>	<u>N021615</u>	<u>003</u>	Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

<u>AA</u>		ROXANE	<u>4MG/ML</u>	<u>A078185</u>	<u>001</u>	Jan 30, 2009
-----------	--	--------	---------------	----------------	------------	--------------

RAZADYNE

<u>AA</u>	+	JANSSEN PHARMS	<u>4MG/ML</u>	<u>N021224</u>	<u>001</u>	Jun 22, 2001
-----------	---	----------------	---------------	----------------	------------	--------------

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

<u>AB</u>		APOTEX INC	<u>EQ 4MG BASE</u>	<u>A077781</u>	<u>001</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077781</u>	<u>002</u>	Sep 27, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077781</u>	<u>003</u>	Sep 27, 2011
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A090957</u>	<u>001</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A090957</u>	<u>002</u>	Mar 29, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A090957</u>	<u>003</u>	Mar 29, 2011
<u>AB</u>		BARR	<u>EQ 4MG BASE</u>	<u>A077605</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077605</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077605</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A077593</u>	<u>001</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077593</u>	<u>002</u>	Sep 11, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077593</u>	<u>003</u>	Sep 11, 2008
<u>AB</u>		MYLAN	<u>EQ 4MG BASE</u>	<u>A077590</u>	<u>001</u>	May 29, 2009
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A077603</u>	<u>001</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077590</u>	<u>002</u>	May 29, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077603</u>	<u>002</u>	Aug 28, 2008
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077590</u>	<u>003</u>	May 29, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077603</u>	<u>003</u>	Aug 28, 2008
<u>AB</u>		ROXANE	<u>EQ 4MG BASE</u>	<u>A077608</u>	<u>001</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077608</u>	<u>002</u>	Feb 11, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077608</u>	<u>003</u>	Feb 11, 2009
<u>AB</u>		SANDOZ	<u>EQ 4MG BASE</u>	<u>A077589</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077589</u>	<u>002</u>	Jun 22, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077589</u>	<u>003</u>	Jun 22, 2009
<u>AB</u>		TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A077587</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A077587</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A077587</u>	<u>003</u>	Jul 09, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 4MG BASE</u>	<u>A078898</u>	<u>001</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>A078898</u>	<u>002</u>	Feb 17, 2011
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>A078898</u>	<u>003</u>	Feb 17, 2011

RAZADYNE

<u>AB</u>	+	JANSSEN PHARMS	<u>EQ 4MG BASE</u>	<u>N021169</u>	<u>001</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 8MG BASE</u>	<u>N021169</u>	<u>002</u>	Feb 28, 2001
<u>AB</u>			<u>EQ 12MG BASE</u>	<u>N021169</u>	<u>003</u>	Feb 28, 2001

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS		LANTHEUS MEDCL	2mCi/ML	N017478	001	
BS		MALLINCKRODT	2mCi/ML	N018058	001	

GANCICLOVIR

GEL; OPHTHALMIC

ZIRGAN

+	BAUSCH AND LOMB	0.15%	N022211	001	Sep 15, 2009
---	-----------------	-------	---------	-----	--------------

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

<u>AP</u>	+	ROCHE PALO	<u>EQ 500MG BASE/VIAL</u>	<u>N019661</u>	<u>001</u>	Jun 23, 1989
-----------	---	------------	---------------------------	----------------	------------	--------------

GANCICLOVIR

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A090658</u>	<u>001</u>	Jun 21, 2010
<u>AP</u>		LUITPOLD	<u>EQ 500MG BASE/VIAL</u>	<u>A202624</u>	<u>001</u>	Sep 18, 2013

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

+	ORGANON USA INC	EQ 250MCG BASE/0.5ML	N021057	001	Jul 29, 1999
---	-----------------	----------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-169 (of 371)

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

<u>AT</u>	HI-TECH PHARMA CO	<u>0.5%</u>	<u>A203189</u>	<u>001</u>	Sep 03, 2014
<u>AT</u>	LUPIN LTD	<u>0.5%</u>	<u>A202653</u>	<u>001</u>	Aug 28, 2013
<u>ZYMAXID</u>					
<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N022548</u>	<u>001</u>	May 18, 2010
	ZYMAR				
	+ ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 1GM BASE/VIAL</u>	<u>A079160</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A079160</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	CIPLA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202997</u>	<u>001</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202063</u>	<u>002</u>	Sep 11, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202063</u>	<u>001</u>	Sep 11, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u>	May 16, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u>	May 16, 2011
<u>AP</u>	HAMELN RDS GMBH	<u>EQ 1GM BASE/VIAL</u>	<u>A090663</u>	<u>002</u>	Sep 10, 2012
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A090663</u>	<u>001</u>	Sep 10, 2012
<u>AP</u>	HOSPIRA	<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	+ HOSPIRA INC	<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u>	Nov 15, 2010
<u>AP</u>	JIANGSU HANSON PHARM	<u>EQ 1GM BASE/VIAL</u>	<u>A202485</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202485</u>	<u>001</u>	May 07, 2013
<u>AP</u>	LUITPOLD	<u>EQ 1GM BASE/VIAL</u>	<u>A202031</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A202031</u>	<u>001</u>	May 07, 2013
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A200145</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A200145</u>	<u>003</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A200145</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091597</u>	<u>002</u>	May 07, 2013
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A091597</u>	<u>001</u>	May 07, 2013
<u>AP</u>	SUN PHARMA GLOBAL	<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011
<u>AP</u>	TEVA PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A077983</u>	<u>001</u>	Jan 25, 2011
<u>AP</u>		<u>EQ 200MG BASE/VIAL</u>	<u>A077983</u>	<u>002</u>	Jan 25, 2011
<u>GEMZAR</u>					
<u>AP</u>	+ LILLY	<u>EQ 1GM BASE/VIAL</u>	<u>N020509</u>	<u>002</u>	May 15, 1996
<u>AP</u>	+	<u>EQ 200MG BASE/VIAL</u>	<u>N020509</u>	<u>001</u>	May 15, 1996
GEMCITABINE HYDROCHLORIDE					
	+ HOSPIRA INC	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011
	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011
	+	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

<u>AB</u>	APOTEX	<u>600MG</u>	<u>A075034</u>	<u>001</u>	Jul 20, 1998
<u>AB</u>	BLU CARIBE	<u>600MG</u>	<u>A078012</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>	DAVA PHARMS INC	<u>600MG</u>	<u>A074270</u>	<u>001</u>	Sep 27, 1993
<u>AB</u>	HIKMA PHARMS	<u>600MG</u>	<u>A078599</u>	<u>001</u>	Aug 16, 2010
<u>AB</u>	IMPAX PHARMS	<u>600MG</u>	<u>A078207</u>	<u>001</u>	Jun 01, 2007
<u>AB</u>	INVAGEN PHARMS	<u>600MG</u>	<u>A077836</u>	<u>001</u>	Jul 27, 2006
<u>AB</u>	NORTHSTAR HLTHCARE	<u>600MG</u>	<u>A079072</u>	<u>001</u>	Sep 13, 2010
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A079239</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>	TEVA	<u>600MG</u>	<u>A074256</u>	<u>001</u>	Oct 31, 1993
<u>LOPID</u>					
<u>AB</u>	+ PFIZER PHARMS	<u>600MG</u>	<u>N018422</u>	<u>003</u>	Nov 20, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-170 (of 371)

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

+ LG LIFE SCIENCES

EQ 320MG BASE

N021158 001 Apr 04, 2003

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATEAT + FOUGERAEQ 0.1% BASEA062531 001 Jul 05, 1984AT PERRIGO NEW YORKEQ 0.1% BASEA062307 001AT TAROEQ 0.1% BASEA062427 001 May 26, 1983

INJECTABLE; INJECTION

GENTAMICIN SULFATEAP FRESENIUS KABI USAEQ 10MG BASE/MLA062366 002 Feb 06, 1986AP +EQ 40MG BASE/MLA062366 001 Aug 04, 1983AP HOSPIRAEQ 10MG BASE/MLA062420 001 Aug 15, 1983APEQ 10MG BASE/MLA062612 004 Feb 20, 1986APEQ 40MG BASE/MLA062420 002 Aug 15, 1983GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERAP + B BRAUNEQ 0.8MG BASE/MLA062814 001 Aug 28, 1987AP +EQ 1.2MG BASE/MLA062814 002 Aug 28, 1987AP +EQ 1.4MG BASE/MLA062814 003 Aug 28, 1987AP +EQ 1.6MG BASE/MLA062814 004 Aug 28, 1987AP +EQ 1.8MG BASE/MLA062814 005 Aug 28, 1987AP +EQ 2MG BASE/MLA062814 006 Aug 28, 1987AP +EQ 2.4MG BASE/MLA062814 007 Aug 28, 1987AP +EQ 40MG BASE/100MLA062814 008 Aug 28, 1987AP +EQ 60MG BASE/100MLA062814 009 Aug 28, 1987AP +EQ 70MG BASE/100MLA062814 010 Aug 28, 1987AP +EQ 80MG BASE/100MLA062814 011 Aug 28, 1987AP +EQ 90MG BASE/100MLA062814 012 Aug 28, 1987AP +EQ 100MG BASE/100MLA062814 013 Aug 28, 1987AP +EQ 120MG BASE/100MLA062814 014 Aug 28, 1987AP HOSPIRAEQ 1.2MG BASE/MLA062414 001 Aug 15, 1983APEQ 1.4MG BASE/MLA062414 002 Aug 15, 1983APEQ 1.6MG BASE/MLA062414 003 Aug 15, 1983APEQ 1.8MG BASE/MLA062414 004 Aug 15, 1983APEQ 2MG BASE/MLA062414 005 Aug 15, 1983APEQ 60MG BASE/100MLA062414 006 Aug 15, 1983APEQ 70MG BASE/100MLA062414 007 Aug 15, 1983APEQ 80MG BASE/100MLA062414 008 Aug 15, 1983APEQ 90MG BASE/100MLA062414 009 Aug 15, 1983APEQ 100MG BASE/100MLA062414 010 Aug 15, 1983ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINERAP BAXTER HLTHCAREEQ 0.8MG BASE/MLA062373 001 Sep 07, 1982APEQ 1.2MG BASE/MLA062373 007 Sep 07, 1982APEQ 1.6MG BASE/MLA062373 008 Sep 07, 1982APEQ 2MG BASE/MLA062373 009 Sep 07, 1982APEQ 2.4MG BASE/MLA062373 010 Sep 07, 1982APEQ 40MG BASE/100MLA062373 003 Sep 07, 1982APEQ 60MG BASE/100MLA062373 004 Sep 07, 1982APEQ 80MG BASE/100MLA062373 002 Sep 07, 1982APEQ 100MG BASE/100MLA062373 005 Sep 07, 1982APEQ 120MG BASE/100MLA062373 006 Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATEAT + AKORNEQ 0.3% BASEA064093 001 Aug 31, 1995AT PERRIGO CO TENNESSEEEQ 0.3% BASEA065024 001 Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATEAT FOUGERAEQ 0.1% BASEA062533 001 Oct 05, 1984AT + PERRIGO NEW YORKEQ 0.1% BASEA062351 001 Feb 18, 1982AT TAROEQ 0.1% BASEA062477 001 Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTICAT ALLERGANEQ 0.3% BASEA062452 001 Oct 10, 1984GENTAKAT AKORNEQ 0.3% BASEA064163 001 Oct 12, 2001GENTAMICIN SULFATEAT AKORNEQ 0.3% BASEA062635 001 Jan 08, 1987AT ALCON RES LTDEQ 0.3% BASEA062196 001AT + BAUSCH AND LOMBEQ 0.3% BASEA064048 001 May 11, 1994AT PERRIGO CO TENNESSEEEQ 0.3% BASEA065121 001 Jan 30, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-171 (of 371)

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE;0.6%

N050612 001 Dec 01, 1989

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE;1%

N050586 001 Jun 10, 1988

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

+ TEVA PHARMS USA

20MG/ML

N020622 002 Feb 12, 2002

+

40MG/ML

N020622 003 Jan 28, 2014

GLIMEPIRIDE

TABLET;ORAL

AMARYL**AB** + SANOFI AVENTIS US**1MG****N020496 001** Nov 30, 1995**AB** **2MG****N020496 002** Nov 30, 1995**AB** **4MG****N020496 003** Nov 30, 1995GLIMEPIRIDE**AB** ACCORD HLTHCARE **1MG****A078181 001** Aug 23, 2007**AB** **2MG****A078181 002** Aug 23, 2007**AB** **4MG****A078181 003** Aug 23, 2007**AB** ACTAVIS LABS FL INC **1MG****A076995 001** Apr 27, 2010**AB** **2MG****A076995 002** Apr 27, 2010**AB** **4MG****A076995 003** Apr 27, 2010**AB** AUROBINDO PHARMA LTD **1MG****A202759 001** Jun 29, 2012**AB** **2MG****A202759 002** Jun 29, 2012**AB** **4MG****A202759 003** Jun 29, 2012**AB** CARLSBAD **1MG****A077911 001** Sep 22, 2009**AB** **2MG****A077911 002** Sep 22, 2009**AB** **4MG****A077911 003** Sep 22, 2009**AB** DR REDDYS LABS LTD **1MG****A077091 001** Oct 06, 2005**AB** **2MG****A077091 002** Oct 06, 2005**AB** **4MG****A077091 003** Oct 06, 2005**AB** HIKMA PHARMS **1MG****A078952 001** Aug 01, 2013**AB** **2MG****A078952 002** Aug 01, 2013**AB** **4MG****A078952 003** Aug 01, 2013**AB** INDOCO REMEDIES **1MG****A202112 001** Apr 17, 2013**AB** **2MG****A202112 002** Apr 17, 2013**AB** **4MG****A202112 003** Apr 17, 2013**AB** INVAGEN PHARMS **1MG****A077295 001** Oct 06, 2005**AB** **2MG****A077295 002** Oct 06, 2005**AB** **4MG****A077295 003** Oct 06, 2005**AB** MICRO LABS LTD INDIA **1MG****A091220 001** Jun 29, 2012**AB** **2MG****A091220 002** Jun 29, 2012**AB** **4MG****A091220 004** Jun 29, 2012**AB** **8MG****A091220 006** Jun 29, 2012**AB** MYLAN **1MG****A077624 001** Nov 28, 2005**AB** **2MG****A077624 002** Nov 28, 2005**AB** **4MG****A077624 003** Nov 28, 2005**AB** TEVA **1MG****A076802 001** Oct 06, 2005**AB** **2MG****A076802 002** Oct 06, 2005**AB** **4MG****A076802 003** Oct 06, 2005**AB** VINTAGE **1MG****A077370 001** Dec 23, 2005**AB** **2MG****A077370 002** Dec 23, 2005**AB** **4MG****A077370 003** Dec 23, 2005**AB** **8MG****A077370 004** Dec 23, 2005

MICRO LABS LTD INDIA 3MG

A091220 003 Jun 29, 2012

6MG

A091220 005 Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

DUETACT**AB** + TAKEDA PHARMS USA **2MG;30MG****N021925 001** Jul 28, 2006**AB** **4MG;30MG****N021925 002** Jul 28, 2006PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE**AB** SANDOZ **2MG;30MG****A201049 001** Jan 04, 2013**AB** **4MG;30MG****A201049 002** Jan 04, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-172 (of 371)

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDARYL

+ SB PHARMCO

1MG; 4MG

N021700 001 Nov 23, 2005

2MG; 4MG

N021700 002 Nov 23, 2005

2MG; 8MG

N021700 004 Mar 30, 2007

4MG; 4MG

N021700 003 Nov 23, 2005

4MG; 8MG

N021700 005 Mar 30, 2007

GLIPIZIDE

TABLET; ORAL

GLIPIZIDEAB ACCORD HLTHCARE5MGA074550 001 Sep 11, 1997AB APOTEX10MGA074550 002 Sep 11, 1997AB APOTEX5MGA075795 001 Jun 13, 2001AB IVAX SUB TEVA PHARMS10MGA075795 002 Jun 13, 2001AB IVAX SUB TEVA PHARMS5MGA074497 001 Aug 31, 1995AB MYLAN10MGA074497 002 Aug 31, 1995AB MYLAN5MGA074226 001 May 10, 1994AB MYLAN5MGA074438 001 Jun 20, 1995AB SANDOZ10MGA074226 002 May 10, 1994AB SANDOZ10MGA074438 002 Jun 20, 1995AB SANDOZ5MGA074305 001 Apr 07, 1995AB SANDOZ10MGA074305 002 Apr 07, 1995AB SUN PHARM INDS INC5MGA077820 001 Jul 11, 2006AB SUN PHARM INDS INC10MGA077820 002 Jul 11, 2006AB WATSON LABS5MGA074223 001 Feb 27, 1995AB WATSON LABS10MGA074223 002 Feb 27, 1995GLUCOTROLAB PFIZER5MGN017783 001 May 08, 1984AB +10MGN017783 002 May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDEAB PAR PHARM5MGA076159 002 Sep 20, 2013AB PAR PHARM10MGA076159 001 Sep 20, 2013AB WATSON LABS2.5MGA076467 003 Mar 27, 2006AB WATSON LABS5MGA076467 001 Sep 08, 2003AB WATSON LABS10MGA076467 002 Nov 07, 2003GLUCOTROL XLAB PFIZER2.5MGN020329 003 Aug 10, 1999AB PFIZER5MGN020329 001 Apr 26, 1994AB +10MGN020329 002 Apr 26, 1994GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDEAB COREPHARMA2.5MG; 250MGA077507 001 Oct 27, 2005AB COREPHARMA2.5MG; 500MGA077507 002 Oct 27, 2005AB COREPHARMA5MG; 500MGA077507 003 Oct 27, 2005AB HERITAGE PHARMS INC2.5MG; 250MGA078728 001 Jun 23, 2010AB HERITAGE PHARMS INC2.5MG; 500MGA078728 002 Jun 23, 2010AB HERITAGE PHARMS INC5MG; 500MGA078728 003 Jun 23, 2010AB MYLAN2.5MG; 250MGA078083 001 Apr 12, 2007AB MYLAN2.5MG; 500MGA078083 002 Apr 12, 2007AB MYLAN5MG; 500MGA078083 003 Apr 12, 2007AB SUN PHARM INDS INC2.5MG; 250MGA077620 001 Jan 11, 2008AB SUN PHARM INDS INC2.5MG; 500MGA077620 002 Jan 11, 2008AB SUN PHARM INDS INC5MG; 500MGA077620 003 Jan 11, 2008AB TEVA PHARMS2.5MG; 250MGA077270 001 Oct 28, 2005AB TEVA PHARMS2.5MG; 500MGA077270 002 Oct 28, 2005AB +5MG; 500MGA077270 003 Oct 28, 2005AB ZYDUS PHARMS USA INC2.5MG; 250MGA078905 001 Jan 31, 2011AB ZYDUS PHARMS USA INC2.5MG; 500MGA078905 002 Jan 31, 2011AB ZYDUS PHARMS USA INC5MG; 500MGA078905 003 Jan 31, 2011GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE; INJECTION

GLUCAGEN

+ NOVO NORDISK

EQ 1MG BASE/VIAL

N020918 001 Jun 22, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-173 (of 371)

GLUCAGON RECOMBINANT

INJECTABLE; INJECTION

GLUCAGON

+ LILLY

1MG/VIAL

N020928 001 Sep 11, 1998

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL

5GM/PACKET

N021667 001 Jun 10, 2004

GLYBURIDE

TABLET; ORAL

GLYBURIDE**AB** AUROBINDO PHARMA**1.25MG****A077537 001** Oct 18, 2007**AB****2.5MG****A077537 002** Oct 18, 2007**AB****5MG****A077537 003** Oct 18, 2007**AB** COREPHARMA**1.25MG****A076257 001** Jun 27, 2002**AB****2.5MG****A076257 002** Jun 27, 2002**AB****5MG****A076257 003** Jun 27, 2002**AB** HERITAGE PHARMS INC**1.25MG****A090937 001** Feb 28, 2011**AB****2.5MG****A090937 002** Feb 28, 2011**AB****5MG****A090937 003** Feb 28, 2011**AB** TEVA**1.25MG****A074388 001** Aug 29, 1995**AB****2.5MG****A074388 002** Aug 29, 1995**AB**

+

5MG**A074388 003** Aug 29, 1995GLYBURIDE (MICRONIZED)**AB** DAVA PHARMS INC**1.5MG****A074591 001** Dec 22, 1997**AB****3MG****A074591 002** Dec 22, 1997**AB****4.5MG****A074591 003** Dec 22, 1997**AB****6MG****A074591 004** Dec 22, 1997**AB** HIKMA**1.5MG****A075890 001** Jul 31, 2003**AB****3MG****A075890 002** Jul 31, 2003**AB****6MG****A075890 003** Jul 31, 2003**AB** MYLAN**1.5MG****A074792 001** Jun 26, 1998**AB****3MG****A074792 002** Jun 26, 1998**AB****6MG****A074792 003** Aug 17, 1999**AB** TEVA**1.5MG****A074686 001** Apr 20, 1999**AB****3MG****A074686 002** Apr 20, 1999**AB****4.5MG****A074686 003** Apr 20, 1999**AB****6MG****A074686 004** Apr 20, 1999GLYNASE**AB** PHARMACIA AND UPJOHN**1.5MG****N020051 001** Mar 04, 1992**AB****3MG****N020051 002** Mar 04, 1992**AB**

+

6MG**N020051 004** Sep 24, 1993

DIABETA

BX SANOFI AVENTIS US

1.25MG

N017532 001 May 01, 1984

BX

2.5MG

N017532 002 May 01, 1984

BX

+

5MG

N017532 003 May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOVANCE**AB** BRISTOL MYERS SQUIBB**1.25MG; 250MG****N021178 001** Jul 31, 2000**AB**

+

2.5MG; 500MG**N021178 002** Jul 31, 2000**AB****5MG; 500MG****N021178 003** Jul 31, 2000GLYBURIDE AND METFORMIN HYDROCHLORIDE**AB** ACTAVIS ELIZABETH**1.25MG; 250MG****A076716 001** Jun 28, 2005**AB****2.5MG; 500MG****A076716 002** Jun 28, 2005**AB****5MG; 500MG****A076716 003** Jun 28, 2005**AB** AUROBINDO PHARMA**1.25MG; 250MG****A077870 001** Nov 14, 2007**AB****2.5MG; 500MG****A077870 002** Nov 14, 2007**AB****5MG; 500MG****A077870 003** Nov 14, 2007**AB** COREPHARMA**1.25MG; 250MG****A076731 001** Nov 19, 2004**AB****2.5MG; 500MG****A076731 002** Nov 19, 2004**AB****5MG; 500MG****A076731 003** Nov 19, 2004**AB** HERITAGE PHARMS INC**1.25MG; 250MG****A079009 001** Jun 03, 2009**AB****2.5MG; 500MG****A079009 002** Jun 03, 2009**AB****5MG; 500MG****A079009 003** Jun 03, 2009**AB** IVAX SUB TEVA PHARMS**1.25MG; 250MG****A076345 001** Feb 18, 2004**AB****2.5MG; 500MG****A076345 002** Feb 18, 2004**AB****5MG; 500MG****A076345 003** Feb 18, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-174 (of 371)

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+ HYPERION THERAP INC 1.1GM/ML

N203284 001 Feb 01, 2013

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINERAT BAXTER HLTHCARE 1.5GM/100MLN017865 001GLYCINE 1.5% IN PLASTIC CONTAINERAT B BRAUN 1.5GM/100MLN016784 001AT HOSPIRA 1.5GM/100MLN018315 001GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATEAP HIKMA FARMACEUTICA 0.2MG/MLA090963 001 Sep 21, 2011AP LUITPOLD 0.2MG/MLA089335 001 Jul 23, 1986ROBINULAP + HIKMA MAPLE 0.2MG/MLN017558 001

SOLUTION; ORAL

CUVPOSA

+ MERZ PHARMS 1MG/5ML

N022571 001 Jul 28, 2010

TABLET; ORAL

GLYCOPYRROLATEAA AUROLIFE PHARMA LLC 1MGA202675 001 Apr 15, 2013AA DR REDDYS LABS LTD 1MGA040847 001 Mar 21, 2008AA 2MGA040847 002 Mar 21, 2008AA EXCELLIUM 1MGA090195 001 Sep 21, 2012AA 2MGA090195 002 Sep 21, 2012AA NEXGEN PHARMA 1.5MGA091522 001 Mar 12, 2012AA PAR PHARM 1MGA040653 001 Aug 31, 2006AA 2MGA040653 002 Aug 31, 2006AA RANBAXY 1MGA040844 001 Aug 18, 2009AA 2MGA040844 002 Aug 18, 2009AA STASON PHARMS 1MGA091182 001 Feb 03, 2014AA 2MGA091182 002 Feb 03, 2014AA VINTAGE 1MGA040821 001 Dec 29, 2008AA 2MGA040821 002 Dec 29, 2008AA VINTAGE PHARMS 1MGA090020 001 Oct 19, 2011AA 2MGA090020 002 Oct 19, 2011ROBINULAA + SHIONOGI INC 1MGN012827 001ROBINUL FORTEAA + SHIONOGI INC 2MGN012827 002GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPINAP + FERRING 10,000 UNITS/VIALN017016 007AP + FRESENIUS KABI USA 10,000 UNITS/VIALN017067 002PREGNLYLAP + ORGANON USA INC 10,000 UNITS/VIALN017692 001GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

+ ASTRAZENECA EQ 3.6MG BASE

N019726 001 Dec 29, 1989

+ EQ 10.8MG BASE

N020578 001 Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDINAT + BAUSCH AND LOMB 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA064047 001 Jan 31, 1996AT LUITPOLD 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA065187 001 Oct 28, 2005NEOSPORINAT + MONARCH PHARMS 0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/MLA060582 001

PRESCRIPTION DRUG PRODUCT LIST

3-175 (of 371)

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

+ PROSTRAKAN INC

3.1MG/24HR

N022198 001 Sep 12, 2008

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A079119</u>	<u>001</u>	Sep 10, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009
<u>AP</u>	BANNER PHARMACAPS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	BEDFORD LABS	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	CIPLA LTD	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	HIKMA MAPLE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	LUITPOLD	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091274</u>	<u>001</u>	Sep 22, 2010
<u>AP</u>	SAGENT AGILA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>	SAGENT STRIDES	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136</u>	<u>001</u>	Apr 09, 2010
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136</u>	<u>002</u>	Apr 09, 2010
<u>AP</u>	SANDOZ	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
<u>AP</u>	SANDOZ INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	+ TEVA PHARMS USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>	+	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077963</u>	<u>001</u>	Jan 03, 2008
<u>AP</u>	+	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078566</u>	<u>001</u>	Feb 29, 2008
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078564</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078565</u>	<u>001</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	BANNER PHARMACAPS	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>	+ FRESENIUS KABI USA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008

GRANISTERON HYDROCHLORIDE

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	CIPLA LTD	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	COREPHARMA	<u>EQ 1MG BASE</u>	<u>A078260</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A078725</u>	<u>001</u>	Jan 30, 2008
<u>AB</u>	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
<u>AB</u>	TARO	<u>EQ 1MG BASE</u>	<u>A090817</u>	<u>001</u>	May 28, 2010
<u>AB</u>	+ TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078080</u>	<u>001</u>	Dec 31, 2007

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRISEOFULVIN

<u>AB</u>	+ ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
<u>AB</u>	PERRIGO CO TENNESSEE	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005
<u>AB</u>	VINTAGE PHARMS	<u>125MG/5ML</u>	<u>A065438</u>	<u>001</u>	Oct 08, 2010

TABLET;ORAL

GRIFULVIN V

<u>AB</u>	+ VALEANT LUXEMBOURG	<u>500MG</u>	<u>A062279</u>	<u>003</u>	
-----------	----------------------	--------------	----------------	------------	--

GRISEOFULVIN

<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A091592</u>	<u>002</u>	Aug 07, 2013
<u>AB</u>	SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482</u>	<u>001</u>	Oct 22, 2012
	SANDOZ	250MG	A091592	001	Aug 07, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-176 (of 371)

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRIS-PEG

AB	VALEANT PHARMS INC	125MG	N050475 001	
AB	+	250MG	N050475 002	

GRISEOFULVIN, ULTRAMICROSIZED

AB	RICONPHARMA LLC	125MG	A204371 001	Jan 09, 2014
AB		250MG	A204371 002	Jan 09, 2014

GRISEOFULVIN, ULTRAMICROSIZED

AB	SIGMAPHARM LABS LLC	125MG	A202545 001	Oct 22, 2012
AB		250MG	A202545 002	Oct 22, 2012

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

OBREDON

+	SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML	N205474 001	Nov 14, 2014
---	------------------	----------------------	-------------	--------------

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149 001	Apr 07, 1995
+		EQ 8MG BASE	A074149 002	Apr 07, 1995

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	AMNEAL PHARM	EQ 1MG BASE	A075109 001	Nov 25, 1998
AB		EQ 2MG BASE	A075109 002	Nov 25, 1998
AB	EPIC PHARMA LLC	EQ 1MG BASE	A074673 001	Feb 28, 1997
AB		EQ 2MG BASE	A074673 002	Feb 28, 1997
AB	MYLAN	EQ 1MG BASE	A074796 001	Jan 27, 1997
AB		EQ 2MG BASE	A074796 002	Jan 27, 1997
AB	WATSON LABS	EQ 1MG BASE	A074145 001	Oct 17, 1995
AB		EQ 2MG BASE	A074145 002	Oct 17, 1995

TENEX

AB	PROMIUS PHARMA	EQ 1MG BASE	N019032 001	Oct 27, 1986
AB	+	EQ 2MG BASE	N019032 002	Nov 07, 1988

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881 001	Oct 05, 2012
AB		EQ 2MG BASE	A200881 002	Oct 05, 2012
AB		EQ 3MG BASE	A200881 003	Oct 05, 2012
AB		EQ 4MG BASE	A200881 004	Oct 05, 2012

INTUNIV

AB	SHIRE	EQ 1MG BASE	N022037 001	Sep 02, 2009
AB		EQ 2MG BASE	N022037 002	Sep 02, 2009
AB		EQ 3MG BASE	N022037 003	Sep 02, 2009
AB	+	EQ 4MG BASE	N022037 004	Sep 02, 2009

GUANIDINE HYDROCHLORIDE

TABLET; ORAL

GUANIDINE HYDROCHLORIDE

	MERCK SHARP DOHME	125MG	N001546 001	
--	-------------------	-------	-------------	--

HALCINONIDE

CREAM; TOPICAL

HALOG

+	RANBAXY	0.1%	N017556 001	
---	---------	------	-------------	--

OINTMENT; TOPICAL

HALOG

+	RANBAXY	0.1%	N017824 001	
---	---------	------	-------------	--

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004
AB	G AND W LABS	0.05%	A078162 001	Apr 24, 2007
AB	PERRIGO ISRAEL	0.05%	A077123 001	Dec 16, 2004
AB	TARO	0.05%	A077227 001	Aug 04, 2005

ULTRAVATE

AB	+	0.05%	N019967 001	Dec 27, 1990
-----------	---	--------------	--------------------	--------------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	G AND W LABS	0.05%	A077721 001	Sep 07, 2006
AB	PERRIGO	0.05%	A076872 001	Dec 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-177 (of 371)

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

<u>AB</u>	TARO	<u>0.05%</u>	<u>A076994</u>	<u>001</u>	Dec 16, 2004
-----------	------	--------------	----------------	------------	--------------

ULTRAVATE

<u>AB</u>	+ RANBAXY	<u>0.05%</u>	<u>N019968</u>	<u>001</u>	Dec 17, 1990
-----------	-----------	--------------	----------------	------------	--------------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

<u>AB</u>	MYLAN	<u>0.5MG</u>	<u>A070278</u>	<u>006</u>	Jun 10, 1986
<u>AB</u>		<u>1MG</u>	<u>A070278</u>	<u>004</u>	Jun 10, 1986
<u>AB</u>		<u>2MG</u>	<u>A070278</u>	<u>001</u>	Jun 10, 1986
<u>AB</u>		<u>5MG</u>	<u>A070278</u>	<u>005</u>	Jun 10, 1986
<u>AB</u>		<u>10MG</u>	<u>A070278</u>	<u>002</u>	Jul 16, 2009
<u>AB</u>		<u>20MG</u>	<u>A070278</u>	<u>003</u>	Jul 16, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071206</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>1MG</u>	<u>A071207</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>	+	<u>2MG</u>	<u>A071208</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>5MG</u>	<u>A071209</u>	<u>001</u>	Nov 17, 1986
<u>AB</u>		<u>10MG</u>	<u>A071210</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>		<u>20MG</u>	<u>A071211</u>	<u>001</u>	Mar 11, 1988
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077580</u>	<u>003</u>	Nov 29, 2007
<u>AB</u>		<u>10MG</u>	<u>A077580</u>	<u>004</u>	Nov 29, 2007
<u>AB</u>		<u>20MG</u>	<u>A077580</u>	<u>005</u>	Nov 29, 2007

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	+	JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>	AGILA SPECLTS	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>AO</u>	EUROHLTH INTL	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>	TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>		<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993	
<u>AA</u>	SILARX	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993	
<u>AA</u>	+	TEVA PHARMS	<u>EQ 2MG BASE/ML</u>	<u>A071617</u>	<u>001</u>	Dec 01, 1988

INJECTABLE; INJECTION

HALDOL

<u>AP</u>	+	JANSSEN PHARMS	<u>EQ 5MG BASE/ML</u>	<u>N015923</u>	<u>001</u>
-----------	---	----------------	-----------------------	----------------	------------

HALOPERIDOL

<u>AP</u>	AGILA SPECLTS	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>	EUROHLTH INTL	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>	SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A076035</u>	<u>001</u>	Aug 29, 2001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>	+	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>
<u>AP</u>	+		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>
<u>AP</u>	+	HIKMA MAPLE	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>
<u>AP</u>	+		<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>
<u>AP</u>	+		<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>
<u>AP</u>	HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>		<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>	SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-178 (of 371)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		10,000 UNITS/ML	A090808	003	Jun 30, 2010
AP		20,000 UNITS/ML	A090809	001	Jun 30, 2010
AP	SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011
AP		5,000 UNITS/ML	A091659	001	Jun 08, 2011
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014
AP		5,000 UNITS/ML	A202733	001	Jun 12, 2014
AP		5,000 UNITS/ML	A202957	002	Jun 12, 2014
AP		10,000 UNITS/ML	A203198	001	Jun 12, 2014
AP		20,000 UNITS/ML	A203198	002	Jun 12, 2014

HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	200 UNITS/100ML	N018609	001	Apr 28, 1982
----	-----------------	-----------------	---------	-----	--------------

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ B BRAUN	200 UNITS/100ML	N019953	001	Jul 20, 1992
AP	HOSPIRA	200 UNITS/100ML	N018916	010	Jun 23, 1989

HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HOSPIRA	10,000 UNITS/100ML	N019339	003	Mar 27, 1985
----	---------	--------------------	---------	-----	--------------

HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	200 UNITS/100ML	N018609	002	Apr 28, 1982
----	-----------------	-----------------	---------	-----	--------------

HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HOSPIRA	200 UNITS/100ML	N018916	011	Jun 23, 1989
----	---------	-----------------	---------	-----	--------------

HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992
AP	HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ B BRAUN	5,000 UNITS/100ML	N019952	004	Jul 20, 1992
AP	+	10,000 UNITS/100ML	N019952	005	Jul 20, 1992
AP	HOSPIRA	5,000 UNITS/100ML	N019339	004	Mar 27, 1985
AP		5,000 UNITS/100ML	N019805	002	Jan 25, 1989
AP		10,000 UNITS/100ML	N019339	002	Mar 27, 1985

HEPARIN SODIUM IN PLASTIC CONTAINER

AP	+ FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985
AP	+	5,000 UNITS/ML	N017029	014	Dec 05, 1985
AP	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985
AP	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985

HEPARIN SODIUM PRESERVATIVE FREE

AP	+ FRESENIUS KABI USA	1,000 UNITS/ML	N017029	010	Apr 28, 1986
AP	SAGENT PHARMS	1,000 UNITS/ML	A090810	001	Jun 30, 2010
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014

HEPARIN SODIUM

	+ FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	+ HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+ PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+	5,000 UNITS/ML	N201370	002	Jul 21, 2011
	+	10,000 UNITS/ML	N201370	003	Jul 21, 2011

HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
--	---------	-------------------	---------	-----	--------------

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
--	---------	-------------------	---------	-----	--------------

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
		10,000 UNITS/100ML	N018916	008	Jan 31, 1984

HEPARIN SODIUM PRESERVATIVE FREE

	+ FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010
	+ HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
	+ PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

EMULSION; TOPICAL

PHISOHEX

	+ SANOFI AVENTIS US	3%	N006882	001	
--	---------------------	----	---------	-----	--

SPONGE; TOPICAL

PRE-OP

AT	+ DAVIS AND GECK	480MG	N017433	001	
----	------------------	-------	---------	-----	--

PRE-OP II

AT	DAVIS AND GECK	480MG	N017433	002	
----	----------------	-------	---------	-----	--

PRESCRIPTION DRUG PRODUCT LIST

3-179 (of 371)

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL

N022555 001 May 28, 2010

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+ ENDO PHARM 50MG

N022058 001 May 03, 2007

VANTAS

+ ENDO PHARM 50MG

N021732 001 Oct 12, 2004

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE**AA** ACTAVIS MID ATLANTIC**1.5MG/5ML; 5MG/5ML****A088017 001** Jul 05, 1983**AA** + HI TECH PHARMA**1.5MG/5ML; 5MG/5ML****A040613 001** Feb 08, 2008**AA** WOCKHARDT**1.5MG/5ML; 5MG/5ML****A088008 001** Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE**AA** NOVEL LABS INC**1.5MG; 5MG****A091528 001** Apr 20, 2011TUSSIGON**AA** + KING PHARMS**1.5MG; 5MG****A088508 001** Jul 30, 1985HYALURONIDASE

INJECTABLE; INJECTION

AMPHADASE

+ AMPHASTAR PHARM 150 UNITS/ML

N021665 001 Oct 26, 2004

VITRASE

+ BAUSCH AND LOMB 200 UNITS/VIAL

N021640 002 Dec 02, 2004

HYALURONIDASE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HYLENEX RECOMBINANT

+ HALOZYME THERAP 150 UNITS/ML

N021859 001 Dec 02, 2005

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE**AP** AKORN**20MG/ML****A040730 001** Apr 21, 2009**AP** FRESENIUS KABI USA**20MG/ML****A040388 001** Mar 13, 2001**AP** + LUITPOLD**20MG/ML****A040136 001** Jun 30, 1997**AP** NAVINTA LLC**20MG/ML****A202938 001** Mar 28, 2013

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE**AA** ACTAVIS GRP PTC**10MG****A091679 001** Mar 04, 2013**AA****25MG****A091679 002** Mar 04, 2013**AA****50MG****A091679 003** Mar 04, 2013**AA****100MG****A091679 004** Mar 04, 2013**AA** ALKEM LABS LTD**10MG****A200737 001** Dec 07, 2012**AA****25MG****A200737 002** Dec 07, 2012**AA****50MG****A200737 003** Dec 07, 2012**AA****100MG****A200737 004** Dec 07, 2012**AA** CADILA PHARMS LTD**25MG****A203845 001** Sep 18, 2014**AA****50MG****A203845 002** Sep 18, 2014**AA****100MG****A203845 003** Sep 18, 2014**AA** GLENMARK PHARMS LTD**10MG****A090527 001** May 27, 2009**AA****25MG****A090527 002** May 27, 2009**AA****50MG****A090527 003** May 27, 2009**AA****100MG****A090527 004** May 27, 2009**AA** HERITAGE PHARMS INC**10MG****A086242 001** Feb 04, 2010**AA****25MG****A086242 003****AA****50MG****A086242 002****AA****100MG****A086242 004** Feb 04, 2010**AA** HETERO LABS LTD III**10MG****A040901 001** Sep 12, 2008**AA****25MG****A040901 002** Sep 12, 2008**AA****50MG****A040901 003** Sep 12, 2008**AA****100MG****A040901 004** Sep 12, 2008**AA** INVAGEN PHARMS**10MG****A090255 001** Dec 15, 2008**AA****25MG****A090255 002** Dec 15, 2008**AA****50MG****A090255 003** Dec 15, 2008**AA****100MG****A090255 004** Dec 15, 2008**AA** MYLAN**10MG****A090413 001** Dec 08, 2010**AA****25MG****A090413 002** Dec 08, 2010**AA****50MG****A090413 003** Dec 08, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-180 (of 371)

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

<u>AA</u>		<u>100MG</u>	<u>A090413</u>	<u>004</u>	Dec 08, 2010
<u>AA</u>	PAR PHARM	<u>10MG</u>	<u>A087836</u>	<u>001</u>	Oct 05, 1982
<u>AA</u>		<u>25MG</u>	<u>A086961</u>	<u>002</u>	
<u>AA</u>		<u>50MG</u>	<u>A086962</u>	<u>001</u>	
<u>AA</u>		<u>100MG</u>	<u>A088391</u>	<u>001</u>	Sep 27, 1983
<u>AA</u>	+	<u>10MG</u>	<u>A089097</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	+	<u>25MG</u>	<u>A088467</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>50MG</u>	<u>A088468</u>	<u>001</u>	May 01, 1984
<u>AA</u>	+	<u>100MG</u>	<u>A089098</u>	<u>001</u>	Dec 18, 1985
<u>AA</u>	STRIDES PHARMA	<u>25MG</u>	<u>A200770</u>	<u>001</u>	May 03, 2013
<u>AA</u>		<u>50MG</u>	<u>A200770</u>	<u>002</u>	May 03, 2013
<u>AA</u>		<u>100MG</u>	<u>A200770</u>	<u>003</u>	May 03, 2013

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

	PAR PHARM	25MG; 25MG	A088957	001	Oct 21, 1985
+		50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005
---	------------------	--------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG</u>	<u>A200645</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A078389</u>	<u>001</u>	May 16, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG</u>	<u>A078164</u>	<u>001</u>	Sep 18, 2007
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A079237</u>	<u>001</u>	Apr 02, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG</u>	<u>A077005</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A078391</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	LANNETT HOLDINGS INC	<u>12.5MG</u>	<u>A091662</u>	<u>001</u>	Jan 27, 2012
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A075640</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A090651</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>	UNICHEM	<u>12.5MG</u>	<u>A090510</u>	<u>001</u>	Jan 19, 2010
<u>AB</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A075907</u>	<u>001</u>	Sep 17, 2002

MICROZIDE

<u>AB</u>	+	WATSON LABS	<u>12.5MG</u>	<u>N020504</u>	<u>001</u>	Dec 27, 1996
-----------	---	-------------	---------------	----------------	------------	--------------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	ACCORD HLTHCARE	<u>12.5MG</u>	<u>A202556</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A202556</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A202556</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	ACTAVIS ELIZABETH	<u>12.5MG</u>	<u>A040707</u>	<u>001</u>	Feb 27, 2007
<u>AB</u>	APOTEX	<u>25MG</u>	<u>A040774</u>	<u>001</u>	Oct 03, 2007
<u>AB</u>		<u>50MG</u>	<u>A040774</u>	<u>002</u>	Oct 03, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A040780</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040780</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>	DAVA PHARMS INC	<u>25MG</u>	<u>A087059</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A087068</u>	<u>001</u>	
<u>AB</u>	EXCELLIUM	<u>25MG</u>	<u>A040702</u>	<u>001</u>	Mar 16, 2007
<u>AB</u>		<u>50MG</u>	<u>A040702</u>	<u>002</u>	Mar 16, 2007
<u>AB</u>	HERITAGE PHARMS INC	<u>25MG</u>	<u>A085182</u>	<u>002</u>	
<u>AB</u>		<u>50MG</u>	<u>A085182</u>	<u>001</u>	
<u>AB</u>	HIKMA PHARMS LLC	<u>50MG</u>	<u>A084878</u>	<u>001</u>	
<u>AB</u>	IPCA LABS LTD	<u>12.5MG</u>	<u>A040807</u>	<u>001</u>	Jul 20, 2007
<u>AB</u>		<u>25MG</u>	<u>A040807</u>	<u>002</u>	Jul 20, 2007
<u>AB</u>		<u>50MG</u>	<u>A040807</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>25MG</u>	<u>A083177</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A083177</u>	<u>002</u>	
<u>AB</u>	JUBILANT CADISTA	<u>25MG</u>	<u>A040809</u>	<u>001</u>	Sep 04, 2007
<u>AB</u>		<u>50MG</u>	<u>A040809</u>	<u>002</u>	Sep 04, 2007
<u>AB</u>	LANNETT	<u>25MG</u>	<u>A084325</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084324</u>	<u>001</u>	
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A040770</u>	<u>001</u>	Jan 23, 2007
<u>AB</u>		<u>25MG</u>	<u>A040735</u>	<u>002</u>	Jan 23, 2007
<u>AB</u>		<u>50MG</u>	<u>A040735</u>	<u>003</u>	Jan 23, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A203018</u>	<u>001</u>	Jul 23, 2014
<u>AB</u>		<u>50MG</u>	<u>A203018</u>	<u>002</u>	Jul 23, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-181 (of 371)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

<u>AB</u>	SUN PHARM INDS INC	<u>12.5MG</u>	<u>A040857</u>	<u>001</u>	May 30, 2008
<u>AB</u>		<u>25MG</u>	<u>A040810</u>	<u>001</u>	Mar 27, 2007
<u>AB</u>		<u>50MG</u>	<u>A040810</u>	<u>002</u>	Mar 27, 2007
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A040907</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>		<u>50MG</u>	<u>A040907</u>	<u>002</u>	Aug 15, 2008
<u>AB</u>	VINTAGE PHARMS	<u>25MG</u>	<u>A040412</u>	<u>001</u>	Mar 29, 2002
<u>AB</u>		<u>50MG</u>	<u>A040412</u>	<u>002</u>	Mar 29, 2002

ORETIC

<u>AB</u>	ABBVIE	<u>50MG</u>	<u>N011971</u>	<u>002</u>	
-----------	--------	-------------	----------------	------------	--

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

<u>AB</u>	+	SANOFI AVENTIS US	<u>12.5MG;150MG</u>	<u>N020758</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+		<u>12.5MG;300MG</u>	<u>N020758</u>	<u>003</u>	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC LTD	<u>12.5MG;150MG</u>	<u>A091370</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A091370</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>12.5MG;150MG</u>	<u>A201505</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201505</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>12.5MG;150MG</u>	<u>A203630</u>	<u>001</u>	Feb 22, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203630</u>	<u>002</u>	Feb 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>12.5MG;150MG</u>	<u>A203500</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203500</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG;150MG</u>	<u>A201524</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201524</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A202414</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>12.5MG;150MG</u>	<u>A077969</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077969</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG;150MG</u>	<u>A203072</u>	<u>001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203072</u>	<u>002</u>	May 09, 2014
<u>AB</u>	ROXANE	<u>12.5MG;150MG</u>	<u>A090351</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A090351</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077446</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG;150MG</u>	<u>A077369</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077369</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>12.5MG;150MG</u>	<u>A091539</u>	<u>001</u>	Oct 22, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A091539</u>	<u>002</u>	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX INC	<u>12.5MG;10MG</u>	<u>A076674</u>	<u>001</u>	Oct 05, 2004
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076674</u>	<u>002</u>	Oct 05, 2004
<u>AB</u>		<u>25MG;20MG</u>	<u>A076674</u>	<u>003</u>	Oct 05, 2004
<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u>	Mar 14, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>12.5MG;10MG</u>	<u>A076265</u>	<u>001</u>	Jul 08, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076265</u>	<u>002</u>	Jul 08, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076265</u>	<u>003</u>	Jul 08, 2002
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>12.5MG;10MG</u>	<u>A075776</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A075776</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A075776</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u>	Sep 27, 2006
<u>AB</u>	MYLAN	<u>12.5MG;10MG</u>	<u>A076113</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076113</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076113</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u>	Jul 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-182 (of 371)

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>25MG; 20MG</u>	<u>A076262</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG; 10MG</u>	<u>A076194</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A076194</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG; 20MG</u>	<u>A076194</u>	<u>002</u>	Jul 01, 2002
<u>PRINZIDE</u>					
<u>AB</u>	MERCK	<u>12.5MG; 10MG</u>	<u>N019778</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>N019778</u>	<u>001</u>	Feb 16, 1989
<u>ZESTORETIC</u>					
<u>AB</u>	ASTRAZENECA	<u>12.5MG; 10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+	<u>12.5MG; 20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+	<u>25MG; 20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>12.5MG; 50MG</u>	<u>N020387</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>N020387</u>	<u>003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG; 100MG</u>	<u>N020387</u>	<u>002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG; 50MG</u>	<u>A091617</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A091617</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG; 100MG</u>	<u>A091617</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>	APOTEX	<u>12.5MG; 50MG</u>	<u>A090150</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A090150</u>	<u>002</u>	Aug 11, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A090150</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG; 50MG</u>	<u>A091629</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A091629</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A091629</u>	<u>003</u>	Jan 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>12.5MG; 50MG</u>	<u>A201845</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A201845</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG; 100MG</u>	<u>A201845</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>12.5MG; 50MG</u>	<u>A201682</u>	<u>001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A201682</u>	<u>002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG; 100MG</u>	<u>A201682</u>	<u>003</u>	Mar 01, 2013
<u>AB</u>	LUPIN LTD	<u>12.5MG; 50MG</u>	<u>A078245</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A078245</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A078245</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG; 50MG</u>	<u>A202289</u>	<u>001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A202289</u>	<u>002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG; 100MG</u>	<u>A202289</u>	<u>003</u>	Aug 09, 2012
<u>AB</u>	MYLAN	<u>12.5MG; 50MG</u>	<u>A091652</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A091652</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A091652</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ROXANE	<u>12.5MG; 50MG</u>	<u>A077732</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A077732</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A077732</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>12.5MG; 50MG</u>	<u>A077948</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A077948</u>	<u>003</u>	Aug 19, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A077948</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG; 50MG</u>	<u>A077157</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A077157</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A077157</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>12.5MG; 50MG</u>	<u>A090528</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG; 100MG</u>	<u>A090528</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A090528</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG; 50MG</u>	<u>A078385</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG; 100MG</u>	<u>A078385</u>	<u>002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	MYLAN	15MG; 250MG	A070265	002	Jan 23, 1986
	+	25MG; 250MG	A070265	001	Jan 23, 1986

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	COVIS PHARMA SARL	12.5MG; EQ 25MG TARTRATE	N021956	001	Aug 28, 2006
		12.5MG; EQ 50MG TARTRATE	N021956	002	Aug 28, 2006
	+	12.5MG; EQ 100MG TARTRATE	N021956	003	Aug 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-183 (of 371)

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	US PHARMS HOLDINGS I	<u>25MG; 50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
<u>AB</u>	+	<u>25MG; 100MG</u>	<u>N018303</u>	<u>002</u>	Dec 31, 1984

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG; 50MG</u>	<u>A202870</u>	<u>001</u>	Nov 06, 2013
<u>AB</u>		<u>25MG; 100MG</u>	<u>A202870</u>	<u>002</u>	Nov 06, 2013
<u>AB</u>		<u>50MG; 100MG</u>	<u>A202870</u>	<u>003</u>	Nov 06, 2013
<u>AB</u>	MYLAN	<u>25MG; 50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>		<u>25MG; 100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
<u>AB</u>		<u>50MG; 100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004
<u>AB</u>	SUN PHARM INDS	<u>25MG; 50MG</u>	<u>A090654</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>		<u>25MG; 100MG</u>	<u>A090654</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>		<u>50MG; 100MG</u>	<u>A090654</u>	<u>003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	GLENMARK PHARMS	<u>12.5MG; 7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
<u>AB</u>		<u>25MG; 15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
<u>AB</u>	TEVA	<u>12.5MG; 7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>		<u>25MG; 15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>12.5MG; 7.5MG</u>	<u>A202150</u>	<u>001</u>	Mar 07, 2014
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>A202150</u>	<u>002</u>	Mar 07, 2014
<u>AB</u>		<u>25MG; 15MG</u>	<u>A202150</u>	<u>003</u>	Mar 07, 2014

UNIRETIC

<u>AB</u>	UCB INC	<u>12.5MG; 7.5MG</u>	<u>N020729</u>	<u>001</u>	Jun 27, 1997
<u>AB</u>		<u>12.5MG; 15MG</u>	<u>N020729</u>	<u>003</u>	Feb 14, 2002
<u>AB</u>	+	<u>25MG; 15MG</u>	<u>N020729</u>	<u>002</u>	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

	DAIICHI SANKYO	12.5MG; 20MG	N021532	002	Jun 05, 2003
		12.5MG; 40MG	N021532	003	Jun 05, 2003
	+	25MG; 40MG	N021532	005	Jun 05, 2003

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

<u>AB</u>	+	WYETH PHARMS INC	<u>25MG; 40MG</u>	<u>N018031</u>	<u>001</u>
<u>PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE</u>					
<u>AB</u>		MYLAN	<u>25MG; 40MG</u>	<u>A070947</u>	<u>002</u>
<u>AB</u>	+		<u>25MG; 80MG</u>	<u>A070947</u>	<u>001</u>
<u>AB</u>		PLIVA	<u>25MG; 40MG</u>	<u>A072042</u>	<u>001</u>
<u>AB</u>			<u>25MG; 80MG</u>	<u>A072043</u>	<u>001</u>

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCURETIC

<u>AB</u>	PFIZER PHARMS	<u>12.5MG; EQ 10MG BASE</u>	<u>N020125</u>	<u>001</u>	Dec 28, 1999
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>N020125</u>	<u>002</u>	Dec 28, 1999
<u>AB</u>	+	<u>25MG; EQ 20MG BASE</u>	<u>N020125</u>	<u>003</u>	Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	APOTEX CORP	<u>12.5MG; EQ 10MG BASE</u>	<u>A091524</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A091524</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A091524</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG; EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG; 10MG</u>	<u>A201356</u>	<u>001</u>	Apr 20, 2011
<u>AB</u>		<u>12.5MG; 20MG</u>	<u>A201356</u>	<u>002</u>	Apr 20, 2011
<u>AB</u>		<u>25MG; 20MG</u>	<u>A201356</u>	<u>003</u>	Apr 20, 2011
<u>AB</u>	MYLAN	<u>12.5MG; EQ 10MG BASE</u>	<u>A077093</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A077093</u>	<u>002</u>	Mar 28, 2005
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A077093</u>	<u>003</u>	Mar 28, 2005
<u>AB</u>	RANBAXY	<u>12.5MG; EQ 10MG BASE</u>	<u>A078211</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>12.5MG; EQ 20MG BASE</u>	<u>A078211</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>25MG; EQ 20MG BASE</u>	<u>A078211</u>	<u>003</u>	Mar 04, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-184 (of 371)

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINARETIC

AB	GAVIS PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A076374</u>	<u>001</u>	Mar 31, 2004
AB		<u>12.5MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>002</u>	Mar 31, 2004
AB		<u>25MG;EQ 20MG BASE</u>	<u>A076374</u>	<u>003</u>	Mar 31, 2004

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	GD SEARLE LLC	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>					
AB	MUTUAL PHARM	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
AB	MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
<u>ALDACTAZIDE</u>					
	+ GD SEARLE LLC	<u>50MG;50MG</u>	<u>N012616</u>	<u>005</u>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162</u>	<u>001</u>	Nov 17, 2000
AB		<u>12.5MG;80MG</u>	<u>N021162</u>	<u>002</u>	Nov 17, 2000
AB	+	<u>25MG;80MG</u>	<u>N021162</u>	<u>003</u>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	<u>12.5MG;40MG</u>	<u>A203010</u>	<u>001</u>	Feb 25, 2014
AB		<u>12.5MG;80MG</u>	<u>A203010</u>	<u>002</u>	Feb 25, 2014
AB		<u>25MG;80MG</u>	<u>A203010</u>	<u>003</u>	Feb 25, 2014
AB	LUPIN LTD	<u>12.5MG;40MG</u>	<u>A091351</u>	<u>001</u>	Aug 07, 2014
AB		<u>12.5MG;80MG</u>	<u>A091351</u>	<u>002</u>	Aug 07, 2014
AB		<u>25MG;80MG</u>	<u>A091351</u>	<u>003</u>	Aug 07, 2014
AB	MYLAN PHARMS INC	<u>12.5MG;40MG</u>	<u>A091648</u>	<u>001</u>	Feb 25, 2014
AB		<u>12.5MG;80MG</u>	<u>A091648</u>	<u>002</u>	Feb 25, 2014
AB		<u>25MG;80MG</u>	<u>A091648</u>	<u>003</u>	Feb 25, 2014
AB	TORRENT PHARMS LTD	<u>12.5MG;40MG</u>	<u>A201192</u>	<u>001</u>	Feb 25, 2014
AB		<u>12.5MG;80MG</u>	<u>A201192</u>	<u>002</u>	Feb 25, 2014
AB		<u>25MG;80MG</u>	<u>A201192</u>	<u>003</u>	Feb 25, 2014

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

AB	+ GLAXOSMITHKLINE LLC	<u>25MG;37.5MG</u>	<u>N016042</u>	<u>003</u>	Mar 03, 1994
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
AB	DURAMED PHARMS BARR	<u>25MG;37.5MG</u>	<u>A075052</u>	<u>001</u>	Jun 18, 1999
AB	IVAX SUB TEVA PHARMS	<u>25MG;50MG</u>	<u>A074259</u>	<u>001</u>	Mar 30, 1995
AB	LANNETT HOLDINGS INC	<u>25MG;37.5MG</u>	<u>A201407</u>	<u>001</u>	Dec 09, 2011
AB	MYLAN	<u>25MG;37.5MG</u>	<u>A074701</u>	<u>001</u>	Jun 07, 1996
AB	SANDOZ	<u>25MG;37.5MG</u>	<u>A074821</u>	<u>001</u>	Jun 05, 1997
AB	+	<u>25MG;50MG</u>	<u>A073191</u>	<u>001</u>	Jul 31, 1991

TABLET; ORAL

MAXZIDE

AB	+ MYLAN PHARMS INC	<u>50MG;75MG</u>	<u>N019129</u>	<u>001</u>	Oct 22, 1984
<u>MAXZIDE-25</u>					
AB	MYLAN PHARMS INC	<u>25MG;37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988
<u>TRIAMTERENE AND HYDROCHLOROTHIAZIDE</u>					
AB	APOTEX INC	<u>25MG;37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998
AB		<u>50MG;75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988
AB	PLIVA	<u>25MG;37.5MG</u>	<u>A074026</u>	<u>001</u>	Apr 26, 1996
AB		<u>50MG;75MG</u>	<u>A073467</u>	<u>001</u>	Jan 31, 1996
AB	SANDOZ	<u>25MG;37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992
AB		<u>50MG;75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988
AB	WATSON LABS	<u>25MG;37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993
AB		<u>50MG;75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

AB	NOVARTIS	<u>12.5MG;80MG</u>	<u>N020818</u>	<u>001</u>	Mar 06, 1998
AB		<u>12.5MG;160MG</u>	<u>N020818</u>	<u>002</u>	Mar 06, 1998
AB		<u>12.5MG;320MG</u>	<u>N020818</u>	<u>004</u>	Apr 28, 2006
AB		<u>25MG;160MG</u>	<u>N020818</u>	<u>003</u>	Jan 17, 2002
AB	+	<u>25MG;320MG</u>	<u>N020818</u>	<u>005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC LTD	<u>12.5MG;80MG</u>	<u>A201662</u>	<u>001</u>	Mar 21, 2013
AB		<u>12.5MG;160MG</u>	<u>A201662</u>	<u>002</u>	Mar 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-185 (of 371)

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		12.5MG;320MG	A201662	003	Mar 21, 2013
AB		25MG;160MG	A201662	004	Mar 21, 2013
AB		25MG;320MG	A201662	005	Mar 21, 2013
AB	APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013
AB		12.5MG;160MG	A203026	002	Mar 21, 2013
AB		12.5MG;320MG	A203026	003	Mar 21, 2013
AB		25MG;160MG	A203026	004	Mar 21, 2013
AB		25MG;320MG	A203026	005	Mar 21, 2013
AB	AUROBINDO PHARMA LTD	12.5MG;80MG	A202519	001	Mar 21, 2013
AB		12.5MG;160MG	A202519	002	Mar 21, 2013
AB		12.5MG;320MG	A202519	003	Mar 21, 2013
AB		25MG;160MG	A202519	004	Mar 21, 2013
AB		25MG;320MG	A202519	005	Mar 21, 2013
AB	LUPIN LTD	12.5MG;80MG	A078946	003	Mar 21, 2013
AB		12.5MG;160MG	A078946	004	Mar 21, 2013
AB		12.5MG;320MG	A078946	001	Mar 21, 2013
AB		25MG;160MG	A078946	005	Mar 21, 2013
AB		25MG;320MG	A078946	002	Mar 21, 2013
AB	MACLEODS PHARMS LTD	12.5MG;80MG	A203145	001	Apr 19, 2013
AB		12.5MG;160MG	A203145	002	Apr 19, 2013
AB		12.5MG;320MG	A203145	003	Apr 19, 2013
AB		25MG;160MG	A203145	004	Apr 19, 2013
AB		25MG;320MG	A203145	005	Apr 19, 2013
AB	MYLAN PHARMS INC	12.5MG;80MG	A078020	001	Sep 21, 2012
AB		12.5MG;160MG	A078020	002	Sep 21, 2012
AB		12.5MG;320MG	A078020	004	Sep 21, 2012
AB		25MG;160MG	A078020	003	Sep 21, 2012
AB		25MG;320MG	A078020	005	Sep 21, 2012
AB	WATSON LABS INC	12.5MG;80MG	A091519	001	Mar 21, 2013
AB		12.5MG;160MG	A091519	002	Mar 21, 2013
AB		12.5MG;320MG	A091519	003	Mar 21, 2013
AB		25MG;160MG	A091519	004	Mar 21, 2013
AB		25MG;320MG	A091519	005	Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+ ZOGENIX INC

10MG	N202880	001	Oct 25, 2013
15MG	N202880	002	Oct 25, 2013
20MG	N202880	003	Oct 25, 2013
30MG	N202880	004	Oct 25, 2013
40MG	N202880	005	Oct 25, 2013
50MG	N202880	006	Oct 25, 2013

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

PURDUE PHARMA LP

20MG	N206627	001	Nov 20, 2014
30MG	N206627	002	Nov 20, 2014
40MG	N206627	003	Nov 20, 2014
60MG	N206627	004	Nov 20, 2014
80MG	N206627	005	Nov 20, 2014
100MG	N206627	006	Nov 20, 2014
120MG	N206627	007	Nov 20, 2014

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010
AB		7.5MG;200MG	A076604	001	Dec 31, 2003
AB	AMNEAL PHARMS NY	5MG;200MG	A076642	002	Mar 18, 2004
AB		7.5MG;200MG	A076642	001	Oct 12, 2004
AB	SUN PHARM INDS INC	2.5MG;200MG	A091633	001	May 28, 2013
AB		5MG;200MG	A091633	002	May 28, 2013
AB		7.5MG;200MG	A091633	003	May 28, 2013
AB		10MG;200MG	A091633	004	May 28, 2013
AB	TEVA	7.5MG;200MG	A076023	001	Apr 11, 2003
AB	VINTAGE PHARMS	5MG;200MG	A077727	001	Nov 06, 2006
AB		7.5MG;200MG	A077723	001	Nov 06, 2006
AB		10MG;200MG	A077723	002	Nov 06, 2006

REPREXAIN

AB	AMNEAL PHARMS NY	2.5MG;200MG	A076642	003	Oct 19, 2007
----	------------------	-------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-186 (of 371)

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

REPREXAIN

<u>AB</u>		<u>10MG; 200MG</u>	<u>A076642</u>	<u>004</u>	Oct 19, 2007
-----------	--	--------------------	----------------	------------	--------------

VICOPROFEN

<u>AB</u>	+	ABBVIE	<u>7.5MG; 200MG</u>	<u>N020716</u>	<u>001</u>	Sep 23, 1997
-----------	---	--------	---------------------	----------------	------------	--------------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

<u>AA</u>	PADDOCK LLC	<u>5MG/5ML; 60MG/5ML</u>	<u>A204658</u>	<u>001</u>	Apr 29, 2014
-----------	-------------	--------------------------	----------------	------------	--------------

<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML; 60MG/5ML</u>	<u>A203839</u>	<u>001</u>	Oct 28, 2014
-----------	-----------------	--------------------------	----------------	------------	--------------

REZIRA

<u>AA</u>	+	CYPRESS PHARM	<u>5MG/5ML; 60MG/5ML</u>	<u>N022442</u>	<u>001</u>	Jun 08, 2011
-----------	---	---------------	--------------------------	----------------	------------	--------------

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

<u>AT</u>	CROWN LABS	<u>1%</u>	<u>A080706</u>	<u>006</u>	
-----------	------------	-----------	----------------	------------	--

ANUSOL HC

<u>AT</u>	SALIX PHARMS	<u>2.5%</u>	<u>A088250</u>	<u>001</u>	Jun 06, 1984
-----------	--------------	-------------	----------------	------------	--------------

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087795</u>	<u>001</u>	May 03, 1983
-----------	----------------------	-----------	----------------	------------	--------------

<u>AT</u>		<u>2.5%</u>	<u>A089682</u>	<u>001</u>	Mar 10, 1988
-----------	--	-------------	----------------	------------	--------------

<u>AT</u>	+	FOUGERA	<u>1%</u>	<u>A080693</u>	<u>003</u>
-----------	---	---------	-----------	----------------	------------

<u>AT</u>	+		<u>2.5%</u>	<u>A089414</u>	<u>001</u>	Dec 16, 1986
-----------	---	--	-------------	----------------	------------	--------------

<u>AT</u>	LYNE	<u>2.5%</u>	<u>A040879</u>	<u>001</u>	Aug 20, 2010
-----------	------	-------------	----------------	------------	--------------

<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085025</u>	<u>001</u>	
-----------	------------------	-------------	----------------	------------	--

<u>AT</u>	TARO	<u>2.5%</u>	<u>A088799</u>	<u>001</u>	Nov 09, 1984
-----------	------	-------------	----------------	------------	--------------

<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040503</u>	<u>001</u>	Mar 12, 2004
-----------	----------------	-------------	----------------	------------	--------------

SYNACORT

<u>AT</u>	MEDICIS	<u>1%</u>	<u>A087458</u>	<u>001</u>	
-----------	---------	-----------	----------------	------------	--

<u>AT</u>		<u>2.5%</u>	<u>A087457</u>	<u>001</u>	
-----------	--	-------------	----------------	------------	--

ENEMA; RECTAL

COLOCORT

<u>AB</u>	PADDOCK LLC	<u>100MG/60ML</u>	<u>A075172</u>	<u>001</u>	Dec 03, 1999
-----------	-------------	-------------------	----------------	------------	--------------

CORTENEMA

<u>AB</u>	+	ANI PHARMS	<u>100MG/60ML</u>	<u>N016199</u>	<u>001</u>
-----------	---	------------	-------------------	----------------	------------

HYDROCORTISONE

<u>AB</u>	TEVA PHARMS	<u>100MG/60ML</u>	<u>A074171</u>	<u>001</u>	May 27, 1994
-----------	-------------	-------------------	----------------	------------	--------------

LOTION; TOPICAL

HYDROCORTISONE

<u>AT</u>	+	FOUGERA PHARMS	<u>2.5%</u>	<u>A040351</u>	<u>001</u>	Jul 25, 2000
-----------	---	----------------	-------------	----------------	------------	--------------

<u>AT</u>	TARO	<u>2.5%</u>	<u>A040247</u>	<u>001</u>	Jul 23, 1999
-----------	------	-------------	----------------	------------	--------------

<u>AT</u>	VINTAGE PHARMS	<u>2.5%</u>	<u>A040417</u>	<u>001</u>	Jul 30, 2003
-----------	----------------	-------------	----------------	------------	--------------

NUTRACORT

<u>AT</u>	DOW PHARM	<u>2.5%</u>	<u>A087644</u>	<u>001</u>	Aug 24, 1982
-----------	-----------	-------------	----------------	------------	--------------

STIE-CORT

<u>AT</u>	PERRIGO	<u>2.5%</u>	<u>A089074</u>	<u>001</u>	Nov 26, 1985
-----------	---------	-------------	----------------	------------	--------------

ALA-SCALP

	CROWN LABS	<u>2%</u>	<u>A083231</u>	<u>001</u>	
--	------------	-----------	----------------	------------	--

OINTMENT; TOPICAL

HYDROCORTISONE

<u>AT</u>	ACTAVIS MID ATLANTIC	<u>1%</u>	<u>A087796</u>	<u>001</u>	Oct 13, 1982
-----------	----------------------	-----------	----------------	------------	--------------

<u>AT</u>	+	FOUGERA	<u>2.5%</u>	<u>A081203</u>	<u>001</u>	May 28, 1993
-----------	---	---------	-------------	----------------	------------	--------------

<u>AT</u>	+	FOUGERA PHARMS	<u>1%</u>	<u>A080692</u>	<u>001</u>
-----------	---	----------------	-----------	----------------	------------

<u>AT</u>	PERRIGO NEW YORK	<u>2.5%</u>	<u>A085027</u>	<u>001</u>	
-----------	------------------	-------------	----------------	------------	--

<u>AT</u>	TARO	<u>1%</u>	<u>A086257</u>	<u>001</u>	
-----------	------	-----------	----------------	------------	--

HYDROCORTISONE IN ABSORBASE

<u>AT</u>	CAROLINA MEDCL	<u>1%</u>	<u>A088138</u>	<u>001</u>	Sep 06, 1985
-----------	----------------	-----------	----------------	------------	--------------

POWDER; FOR RX COMPOUNDING

HYDRO-RX

	+	X GEN PHARMS	<u>100%</u>	<u>A085982</u>	<u>001</u>
--	---	--------------	-------------	----------------	------------

SOLUTION; TOPICAL

TEXACORT

	+	MISSION PHARMA	<u>2.5%</u>	<u>A081271</u>	<u>001</u>	Apr 17, 1992
--	---	----------------	-------------	----------------	------------	--------------

TABLET; ORAL

CORTEF

<u>AB</u>	PHARMACIA AND UPJOHN	<u>5MG</u>	<u>N008697</u>	<u>003</u>	
-----------	----------------------	------------	----------------	------------	--

<u>AB</u>		<u>10MG</u>	<u>N008697</u>	<u>001</u>	
-----------	--	-------------	----------------	------------	--

<u>AB</u>	+		<u>20MG</u>	<u>N008697</u>	<u>002</u>
-----------	---	--	-------------	----------------	------------

HYDROCORTISONE

<u>AB</u>	AMEDRA PHARMS	<u>5MG</u>	<u>A040646</u>	<u>001</u>	Mar 30, 2007
-----------	---------------	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-187 (of 371)

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

<u>AB</u>		<u>10MG</u>	<u>A040646</u>	<u>002</u>	Mar 30, 2007
<u>AB</u>		<u>20MG</u>	<u>A040646</u>	<u>003</u>	Mar 30, 2007
<u>AB</u>	VINTAGE	<u>5MG</u>	<u>A040761</u>	<u>001</u>	Jul 16, 2007
<u>AB</u>		<u>10MG</u>	<u>A040761</u>	<u>002</u>	Jul 16, 2007
<u>AB</u>		<u>20MG</u>	<u>A040761</u>	<u>003</u>	Jul 16, 2007

HYDROCORTISONE ACETATEAEROSOL, METERED; RECTAL
CORTIFOAM

+ MEDA PHARMS 10% N017351 001 Feb 10, 1982

CREAM; TOPICAL

HYDROCORTISONE ACETATE

+ FERNDAL LABS 2.5% A040259 001 Jul 29, 1999

MICORT-HC

+ SEBELA IRELAND LTD 2% A040398 001 Mar 29, 2002

2.5% A040396 001 Feb 27, 2001

POWDER; FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS 100% A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

CORTISPORIN

+ MONARCH PHARMS 0.5%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

EPIFOAM

BX MEDA PHARMS 1%; 1% A086457 001

PROCTOFOAM HC

BX MEDA PHARMS 1%; 1% A086195 001

CREAM; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%; 1% A083778 001

1%; 1% A085368 001

LOTION; TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%; 1% A085980 001

2.5%; 1% A085979 001

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

U-CORT

TARO 1%; 10% A089472 001 Jun 13, 1988

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATEAB1 TARO PHARM INDS 0.1% A076654 001 Aug 03, 2005LOCOIDAB1 + PRECISION DERMAT 0.1% N018514 001 Mar 31, 1982HYDROCORTISONE BUTYRATEAB2 GLENMARK GENERICS 0.1% A202145 001 Sep 27, 2013LOCOID LIPOCREAMAB2 + PRECISION DERMAT 0.1% N020769 001 Sep 08, 1997

LOTION; TOPICAL

LOCOID

+ PRECISION DERMAT 0.1% N022076 001 May 18, 2007

OINTMENT; TOPICAL

HYDROCORTISONE BUTYRATEAB TARO 0.1% A076842 001 Dec 27, 2004LOCOIDAB + PRECISION DERMAT 0.1% N018652 001 Oct 29, 1982

SOLUTION; TOPICAL

HYDROCORTISONE BUTYRATEAT TARO PHARM INDS 0.1% A076364 001 Jan 14, 2004LOCOIDAT + PRECISION DERMAT 0.1% N019116 001 Feb 25, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-188 (of 371)

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

+ FOUGERA PHARMS 0.1%

N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORTAP HOSPIRAEQ 100MG BASE/VIALA040666 001 Apr 06, 2006SOLU-CORTEFAP + PHARMACIA AND UPJOHNEQ 1GM BASE/VIALN009866 004AP +EQ 100MG BASE/VIALN009866 001AP +EQ 250MG BASE/VIALN009866 002AP +EQ 500MG BASE/VIALN009866 003HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATEAB PERRIGO NEW YORK0.2%A075666 001 May 24, 2000AB + TARO0.2%A075042 001 Aug 25, 1998

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

+ TARO 0.2%

A075043 001 Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORINAT + MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLN050479 001NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONEAT ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062423 001 Aug 25, 1983AT BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA064053 001 Dec 29, 1995AT LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA065216 001 Oct 31, 2005

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

+ ALCON PHARMS LTD 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062874 001 May 11, 1988

SUSPENSION/DROPS; OTIC

CORTISPORINAT + CITRON PHARMA LLC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA060613 001NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONEAT ALCON PHARMS LTD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062488 001 Nov 06, 1985AT LUITPOLD1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA065219 001 May 01, 2006OTICAIRAT BAUSCH AND LOMB1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA064065 001 Aug 28, 1996PEDIOTICAT MONARCH PHARMS1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLA062822 001 Sep 29, 1987HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURONAB + SHIRE LLC50MGN011949 001HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDIDAP + PURDUE PHARM PRODS1MG/MLN019034 003 Apr 30, 2009AP +2MG/MLN019034 004 Apr 30, 2009AP +4MG/MLN019034 005 Apr 30, 2009DILAUDID-HPAP + PURDUE PHARM PRODS10MG/MLN019034 001 Jan 11, 1984HYDROMORPHONE HYDROCHLORIDEAP AKORN10MG/MLA078228 001 Apr 14, 2010AP10MG/MLA078261 001 Apr 14, 2010AP BARR10MG/MLA076444 001 Apr 25, 2003AP HOSPIRA10MG/MLA074598 001 Jun 19, 1997AP HOSPIRA INC1MG/MLN200403 001 Dec 01, 2011AP2MG/MLN200403 002 Dec 01, 2011AP4MG/MLN200403 003 Dec 01, 2011AP10MG/MLA078591 001 Jun 17, 2008

DILAUDID-HP

+ PURDUE PHARM PRODS 250MG/VIAL

N019034 002 Aug 04, 1994

SOLUTION; ORAL

DILAUDIDAA + PURDUE PHARM PRODS5MG/5MLN019891 001 Dec 07, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-189 (of 371)

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

AA	ROXANE	5MG/5ML	A074653	001	Jul 29, 1998
-----------	--------	----------------	----------------	------------	--------------

TABLET; ORAL

DILAUDID

AB	PURDUE PHARM PRODS	2MG	N019892	003	Nov 09, 2007
AB		4MG	N019892	002	Nov 09, 2007
AB	+	8MG	N019892	001	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005
AB	LANNETT	2MG	A078439	001	Dec 09, 2009
AB		4MG	A078439	002	Dec 09, 2009
AB		8MG	A077471	001	Dec 09, 2009
AB	MALLINCKRODT	8MG	A076855	001	Dec 23, 2004
AB	MALLINCKRODT INC	2MG	A078273	001	Sep 19, 2007
AB		4MG	A078273	002	Sep 19, 2007
AB	ROXANE	4MG	A074597	003	May 29, 2009
AB		8MG	A074597	001	Jul 29, 1998

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010
AB		12MG	N021217	002	Mar 01, 2010
AB		16MG	N021217	003	Mar 01, 2010

HYDROMORPHONE HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014
AB		12MG	A202144	002	May 12, 2014
AB		16MG	A202144	003	May 12, 2014

EXALGO

+	MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012
---	------------------	------	---------	-----	--------------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+	MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011
---	-----------------	--------------------	---------	-----	--------------

HYDROXOCOBALAMIN

+	WATSON LABS	1MG/ML	A085998	001	
---	-------------	--------	---------	-----	--

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	1%; 0.25%	N019261	001	Jan 30, 1992
---	-------	-----------	---------	-----	--------------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	HIKMA PHARMS LLC	200MG	A040760	001	Aug 15, 2007
AB	IPCA LABS LTD	200MG	A040766	001	Jun 14, 2007
AB	MYLAN	200MG	A040274	001	May 29, 1998
AB	SANDOZ	200MG	A040104	001	Nov 30, 1995
AB	TEVA PHARMS	200MG	A040081	001	Sep 30, 1994
AB	ZYDUS PHARMS USA INC	200MG	A040657	001	Sep 21, 2007

PLAQUENIL

AB	+	SANOFI AVENTIS US	200MG	N009768	001
-----------	---	-------------------	--------------	----------------	------------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011
---	-------------------	-----------------------	---------	-----	--------------

HYDROXYPROPYL CELLULOSE

INSERT; OPHTHALMIC

LACRISERT

+	ATON	5MG	N018771	001	
---	------	-----	---------	-----	--

HYDROXYUREA

CAPSULE; ORAL

HYDREA

AB	+	BRISTOL MYERS SQUIBB	500MG	N016295	001
-----------	---	----------------------	--------------	----------------	------------

HYDROXYUREA

AB	BARR	500MG	A075143	001	Oct 16, 1998
AB	PAR PHARM	500MG	A075340	001	Feb 24, 1999

DROXIA

BRISTOL MYERS SQUIBB	200MG	N016295	002	Feb 25, 1998
	300MG	N016295	003	Feb 25, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-190 (of 371)

HYDROXYUREACAPSULE; ORAL
DROXIA

400MG

N016295 004 Feb 25, 1998

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HYDROCHLORIDE

AP + FRESenius KABI USA 25MG/ML
AP + 50MG/ML
AP LUITPOLD 25MG/ML
AP 50MG/ML

A087329 001
A087329 002
A087408 001
A087408 002

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

AA + HI TECH PHARMA 10MG/5ML
AA SILARX PHARMS INC 10MG/5ML
AA + VINTAGE PHARMS 10MG/5ML
AA + WOCKHARDT 10MG/5ML

A040010 001 Oct 28, 1994
A201674 001 Aug 21, 2013
A040391 001 Apr 10, 2002
A087294 001 Apr 12, 1982

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	10MG	<u>A040808 001</u>	Sep 24, 2008
<u>AB</u>		25MG	<u>A040808 002</u>	Sep 24, 2008
<u>AB</u>		50MG	<u>A040808 003</u>	Sep 24, 2008
<u>AB</u>	EMCURE PHARMS USA	10MG	<u>A204279 001</u>	Aug 20, 2014
<u>AB</u>		25MG	<u>A204279 002</u>	Aug 20, 2014
<u>AB</u>		50MG	<u>A204279 003</u>	Aug 20, 2014
<u>AB</u>	HERITAGE PHARMS INC	10MG	<u>A040804 001</u>	Jun 30, 2008
<u>AB</u>		25MG	<u>A040804 002</u>	Jun 30, 2008
<u>AB</u>		50MG	<u>A040804 003</u>	Jun 30, 2008
<u>AB</u>	HETERO LABS LTD III	10MG	<u>A040805 001</u>	May 29, 2008
<u>AB</u>		25MG	<u>A040805 002</u>	May 29, 2008
<u>AB</u>		50MG	<u>A040805 003</u>	May 29, 2008
<u>AB</u>	INVAGEN PHARMS	10MG	<u>A040812 001</u>	Mar 12, 2008
<u>AB</u>		25MG	<u>A040812 002</u>	Mar 12, 2008
<u>AB</u>		50MG	<u>A040812 003</u>	Mar 12, 2008
<u>AB</u>	KVK TECH	10MG	<u>A040786 001</u>	Mar 20, 2007
<u>AB</u>		25MG	<u>A040787 001</u>	Mar 20, 2007
<u>AB</u>		50MG	<u>A040788 001</u>	Mar 20, 2007
<u>AB</u>	MUTUAL PHARM	10MG	<u>A089381 001</u>	May 19, 1986
<u>AB</u>		25MG	<u>A089382 001</u>	May 19, 1986
<u>AB</u>		50MG	<u>A089383 001</u>	May 19, 1986
<u>AB</u>	MYLAN	10MG	<u>A091176 001</u>	Jun 07, 2010
<u>AB</u>		25MG	<u>A091176 002</u>	Jun 07, 2010
<u>AB</u>		50MG	<u>A091176 003</u>	Jun 07, 2010
<u>AB</u>	NORTHSTAR HLTHCARE	10MG	<u>A040841 001</u>	Mar 31, 2008
<u>AB</u>		25MG	<u>A040842 001</u>	Mar 31, 2008
<u>AB</u>		50MG	<u>A040840 001</u>	Mar 31, 2008
<u>AB</u>	+ PLIVA	10MG	<u>A088617 001</u>	Jan 10, 1986
<u>AB</u>	+	25MG	<u>A088618 001</u>	Jan 10, 1986
<u>AB</u>	+	50MG	<u>A088619 001</u>	Jan 10, 1986
<u>AB</u>	SUN PHARM INDS INC	10MG	<u>A040899 001</u>	Jun 10, 2008
<u>AB</u>		25MG	<u>A040899 002</u>	Jun 10, 2008
<u>AB</u>		50MG	<u>A040899 003</u>	Jun 10, 2008
<u>AB</u>	VINTAGE PHARMS	10MG	<u>A040579 001</u>	May 27, 2005
<u>AB</u>		25MG	<u>A040574 001</u>	May 27, 2005
<u>AB</u>		50MG	<u>A040580 001</u>	May 27, 2005
<u>AB</u>	WATSON LABS	10MG	<u>A088348 001</u>	Sep 15, 1983
<u>AB</u>		25MG	<u>A088349 001</u>	Sep 15, 1983
<u>AB</u>		50MG	<u>A088350 001</u>	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	EQ 25MG HCL	<u>A088496 001</u>	Jun 15, 1984
<u>AB</u>		EQ 50MG HCL	<u>A088487 001</u>	Jun 15, 1984
<u>AB</u>	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	<u>A201507 001</u>	Jun 03, 2013
<u>AB</u>		EQ 50MG HYDROCHLORIDE	<u>A201507 002</u>	Jun 03, 2013
<u>AB</u>	SANDOZ	EQ 25MG HCL	<u>A087479 001</u>	
<u>AB</u>		EQ 50MG HCL	<u>A086183 001</u>	
<u>AB</u>	WATSON LABS	EQ 25MG HCL	<u>A040156 001</u>	Jul 15, 1996
<u>AB</u>		EQ 50MG HCL	<u>A040156 002</u>	Jul 15, 1996

VISTARIL

<u>AB</u>	PFIZER	EQ 25MG HCL	<u>N011459 002</u>	
-----------	--------	-------------	--------------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-192 (of 371)

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N021903 001 Apr 13, 2006

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE AND IBUPROFEN**AB** ACTAVIS ELIZABETH 400MG; 5MG**A078769 001** Jan 04, 2008**AB** + BARR LABS INC 400MG; 5MG**A078316 001** Nov 29, 2007**AB** WATSON LABS 400MG; 5MG**A078394 001** Nov 26, 2007IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT**AP** + PHARMACIA AND UPJOHN 0.1MG/ML**N020491 001** Dec 28, 1995IBUTILIDE FUMARATE**AP** LUITPOLD 0.1MG/ML**A090240 001** Jan 11, 2010**AP** MYLAN INSTITUTIONAL 0.1MG/ML**A090643 001** Jan 11, 2010**AP** 0.1MG/ML**A090924 001** Jan 11, 2010ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

+ SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

N022150 001 Aug 25, 2011

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEOUS

+ BAXTER HLTHCARE 7.5GM/100ML

N021321 001 Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMS 1GM

N202057 001 Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS**AP** + PHARMACIA AND UPJOHN 1MG/ML**N050734 001** Feb 17, 1997IDARUBICIN HYDROCHLORIDE**AP** EUROHLTH INTL 1MG/ML**A065275 001** Dec 14, 2006**AP** 1MG/ML**A065288 001** May 15, 2007**AP** FRESENIUS KABI USA 1MG/ML**A065440 001** Aug 04, 2009**AP** ONCO THERAPIES LTD 1MG/ML**A200144 001** Oct 11, 2012IDARUBICIN HYDROCHLORIDE PFS**AP** TEVA PHARMS USA 1MG/ML**A065036 001** May 01, 2002IDELALISIB

TABLET; ORAL

ZYDELIG

+ GILEAD SCIENCES INC 100MG

N205858 001 Jul 23, 2014

+ 150MG

N205858 002 Jul 23, 2014

IDOXURIDINE

SOLUTION/DROPS; OPHTHALMIC

DENDRID**AT** + ALCON 0.1%**N014169 001**HERPLEX**AT** + ALLERGAN 0.1%**N013935 002**IFOSFAMIDE

INJECTABLE; INJECTION

IFEX**AP** BAXTER HLTHCARE 1GM/VIAL**N019763 001** Dec 30, 1988**AP** 3GM/VIAL**N019763 002** Dec 30, 1988IFOSFAMIDE**AP** EUROHLTH INTL 1GM/20ML (50MG/ML)**A076619 001** Jun 29, 2011**AP** 3GM/60ML (50MG/ML)**A076619 002** Jun 29, 2011**AP** + FRESENIUS KABI USA 1GM/VIAL**A076078 001** May 28, 2002**AP** 1GM/20ML (50MG/ML)**A090181 001** Sep 22, 2009**AP** + 3GM/VIAL**A076078 002** May 28, 2002**AP** 3GM/60ML (50MG/ML)**A090181 002** Sep 22, 2009**AP** ONCO THERAPIES LTD 1GM/20ML (50MG/ML)**A201689 001** Nov 26, 2012**AP** 3GM/60ML (50MG/ML)**A201689 002** Nov 26, 2012**AP** + TEVA PHARMS USA 1GM/20ML (50MG/ML)**A076657 001** Apr 04, 2007**AP** + 3GM/60ML (50MG/ML)**A076657 002** Apr 04, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-193 (of 371)

IFOSFAMIDE; MESNA

INJECTABLE; INTRAVENOUS

IFOSFAMIDE/MESNA KIT

+ TEVA PHARMS USA

1GM/20ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 001 Feb 26, 2002

+

3GM/60ML; 1GM/10ML (50MG/ML; 100MG/ML)

A075874 002 Feb 26, 2002

ILOPERIDONE

TABLET; ORAL

FANAPT

+ NOVARTIS

1MG

N022192 001 May 06, 2009

2MG

N022192 002 May 06, 2009

4MG

N022192 003 May 06, 2009

6MG

N022192 004 May 06, 2009

8MG

N022192 005 May 06, 2009

10MG

N022192 006 May 06, 2009

12MG

N022192 007 May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+ ACTELION PHARMS LTD

10MCG/ML (10MCG/ML)

N021779 002 Dec 08, 2005

+

20MCG/ML (20MCG/ML)

N021779 003 Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

NOVARTIS

EQ 100MG BASE

N021588 001 Apr 18, 2003

+

EQ 400MG BASE

N021588 002 Apr 18, 2003

IMIGLUCERASE

INJECTABLE; INJECTION

CEREZYME

GENZYME

200 UNITS/VIAL

N020367 001 May 23, 1994

+

400 UNITS/VIAL

N020367 002 Sep 22, 1999

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDEAB EXCELLIUM10MGA040903 001 Oct 24, 2012AB25MGA040903 002 Oct 24, 2012AB50MGA040903 003 Oct 24, 2012AB LUPIN LTD10MGA090443 001 Mar 11, 2010AB25MGA090442 001 Mar 11, 2010AB50MGA090441 001 Mar 11, 2010AB MUTUAL PHARM10MGA081048 001 Jun 05, 1990AB25MGA081049 001 Jun 05, 1990AB50MGA081050 001 Jun 05, 1990AB PAR PHARM10MGA088292 001 Oct 21, 1983AB10MGA089422 001 Jul 14, 1987AB25MGA088262 001 Oct 21, 1983AB50MGA088276 001 Oct 21, 1983AB SANDOZ10MGA084936 002AB25MGA083745 001AB50MGA084937 001TOFRANILAB MALLINCKRODT INC10MGA087844 001 May 22, 1984AB25MGA087845 001 May 22, 1984AB +50MGA087846 001 May 22, 1984IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATEAB LUPIN LTDEQ 75MG HCLA090444 001 Apr 16, 2010ABEQ 100MG HCLA090444 002 Apr 16, 2010ABEQ 125MG HCLA090444 003 Apr 16, 2010ABEQ 150MG HCLA090444 004 Apr 16, 2010AB MYLAN PHARMS INCEQ 75MG HCLA202338 001 Jun 28, 2013ABEQ 100MG HCLA202338 002 Jun 28, 2013ABEQ 125MG HCLA202338 003 Jun 28, 2013ABEQ 150MG HCLA202338 004 Jun 28, 2013AB ROXANEEQ 75MG HCLA091099 001 Apr 16, 2010ABEQ 100MG HCLA091099 002 Apr 16, 2010ABEQ 125MG HCLA091099 003 Apr 16, 2010ABEQ 150MG HCLA091099 004 Apr 16, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-194 (of 371)

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

<u>AB</u>	+	MALLINCKRODT INC	<u>EQ 75MG HCL</u>	<u>N017090</u>	<u>001</u>	
<u>AB</u>			<u>EQ 100MG HCL</u>	<u>N017090</u>	<u>004</u>	
<u>AB</u>			<u>EQ 125MG HCL</u>	<u>N017090</u>	<u>003</u>	
<u>AB</u>			<u>EQ 150MG HCL</u>	<u>N017090</u>	<u>002</u>	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+	MEDICIS	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997
-----------	---	---------	-----------	----------------	------------	--------------

IMIQUIMOD

<u>AB</u>		APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>		FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		GLENMARK GENERICS	<u>5%</u>	<u>A201994</u>	<u>001</u>	Mar 06, 2012
<u>AB</u>		PERRIGO ISRAEL	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010
<u>AB</u>		STRIDES PHARMA	<u>5%</u>	<u>A202002</u>	<u>001</u>	Jun 24, 2014
<u>AB</u>		TARO	<u>5%</u>	<u>A200173</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		TEVA PHARMS USA	<u>5%</u>	<u>A200481</u>	<u>001</u>	Apr 18, 2011
<u>AB</u>		TOLMAR	<u>5%</u>	<u>A091044</u>	<u>001</u>	Feb 28, 2011

ZYCLARA

+	MEDICIS	2.5%	N022483	002	Jul 15, 2011
+		3.75%	N022483	001	Mar 25, 2010

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

+	EUROHLTH INTL	EQ 5MG BASE/ML	A075513	001	May 09, 2000
---	---------------	----------------	---------	-----	--------------

INDACATEROL MALEATE

POWDER; INHALATION

ARCAPTA NEOHALER

+	NOVARTIS	EQ 75MCG BASE	N022383	001	Jul 01, 2011
---	----------	---------------	---------	-----	--------------

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>1.25MG</u>	<u>A074722</u>	<u>001</u>	Jun 17, 1996
<u>AB</u>			<u>2.5MG</u>	<u>A074722</u>	<u>002</u>	Jun 17, 1996
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>1.25MG</u>	<u>A074299</u>	<u>002</u>	Apr 29, 1996
<u>AB</u>			<u>2.5MG</u>	<u>A074299</u>	<u>001</u>	Jul 27, 1995
<u>AB</u>		MYLAN	<u>1.25MG</u>	<u>A074461</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>	+		<u>2.5MG</u>	<u>A074461</u>	<u>001</u>	Mar 27, 1996
<u>AB</u>		MYLAN PHARMS INC	<u>1.25MG</u>	<u>A075105</u>	<u>001</u>	Jul 23, 1998
<u>AB</u>			<u>2.5MG</u>	<u>A075105</u>	<u>002</u>	Jul 23, 1998

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

	MERCK SHARP DOHME	EQ 200MG BASE	N020685	003	Mar 13, 1996
+		EQ 400MG BASE	N020685	001	Mar 13, 1996

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992
---	---------------	------------	---------	-----	--------------

INDIUM IN 111 CHLORIDE

+	MALLINCKRODT	5mCi/0.5ML	N019841	001	Sep 27, 1994
---	--------------	------------	---------	-----	--------------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN-111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+	GE HEALTHCARE	1mCi/ML	N017707	001	Feb 18, 1982
---	---------------	---------	---------	-----	--------------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINCKRODT	3mCi/ML	N020314	001	Jun 02, 1994
---	--------------	---------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-195 (of 371)

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AP	+	AKORN	25MG/VIAL	N011525	001	
-----------	----------	--------------	------------------	----------------	------------	--

INDOCYANINE GREEN

AP		PULSION MEDCL	25MG/VIAL	A040811	001	Nov 21, 2007
-----------	--	----------------------	------------------	----------------	------------	--------------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB		GLENMARK GENERICS	25MG	A091276	001	Dec 22, 2010
AB			50MG	A091276	002	Dec 22, 2010
AB		HERITAGE PHARMS INC	25MG	N018851	001	May 18, 1984
AB			50MG	N018851	002	May 18, 1984
AB		HETERO LABS LTD III	25MG	A091240	001	Apr 12, 2011
AB			50MG	A091240	002	Apr 12, 2011
AB		IVAX SUB TEVA PHARMS	25MG	A070719	001	Feb 12, 1986
AB			50MG	A070756	001	Feb 12, 1986
AB		MYLAN	25MG	N018858	001	Apr 20, 1984
AB	+		50MG	A070624	001	Sep 04, 1985
AB		SANDOZ	25MG	A070673	001	Apr 29, 1987
AB			50MG	A070674	001	Apr 29, 1987
AB		SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013
AB			50MG	A091401	002	Mar 28, 2013
AB		ZYDUS PHARMS USA INC	25MG	A090403	001	Nov 15, 2010
AB			50MG	A090403	002	Nov 15, 2010

TIVORBEX

IROKO PHARMS LLC 20MG

N204768 001 Feb 24, 2014

+ 40MG

N204768 002 Feb 24, 2014

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB		AMNEAL PHARMS	75MG	A091549	001	Dec 01, 2010
AB		AVANTHI INC	75MG	A079175	001	Mar 06, 2009
AB		HETERO LABS LTD III	75MG	A201807	001	Sep 28, 2012
AB		MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014
AB		PADDOCK LLC	75MG	A200529	001	Nov 30, 2010
AB	+	SANDOZ	75MG	A074464	001	May 28, 1998
AB		WATSON LABS INC	75MG	A202572	001	Dec 09, 2013

INJECTABLE; INJECTION

INDOMETHACIN

+ FRESENIUS KABI USA EQ 1MG BASE/VIAL

N022536 001 Mar 17, 2010

SUPPOSITORY; RECTAL

INDOMETHACIN

+ G AND W LABS 50MG

A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+ IROKO PHARMS 25MG/5ML

N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	RECORDATI RARE	EQ 1MG BASE/VIAL	N018878	001	Jan 30, 1985
-----------	----------	-----------------------	-------------------------	----------------	------------	--------------

INDOMETHACIN SODIUM

AP		EUROHLTH INTL	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008
-----------	--	----------------------	-------------------------	----------------	------------	--------------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

LEO PHARMA AS 0.015%

N202833 001 Jan 23, 2012

+ 0.05%

N202833 002 Jan 23, 2012

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

+ NOVO NORDISK INC 700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML)

N021172 001 Nov 01, 2001

NOVOLOG MIX 70/30 FLEXPEN

+ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)

N021172 004 May 03, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-196 (of 371)

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N020986 001	Jun 07, 2000
NOVOLOG FLEXPEN			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 003	Jan 19, 2001
NOVOLOG FLEXTOUCH			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 005	Oct 31, 2013
NOVOLOG PENFILL			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986 002	Jun 07, 2000

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

+ NOVO NORDISK INC	1000 UNITS/10ML (100 UNITS/ML)	N021536 001	Jun 16, 2005
LEVEMIR FLEXPEN			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 002	Jun 16, 2005
LEVEMIR FLEXTOUCH			
+ NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536 005	Oct 31, 2013

INSULIN GLARGINE RECOMBINANT

INJECTABLE; INJECTION

LANTUS

+ SANOFI AVENTIS US	100 UNITS/ML	N021081 001	Apr 20, 2000
LANTUS SOLOSTAR			
+ SANOFI AVENTIS US	300 UNITS/3ML (100 UNITS/ML)	N021081 002	Apr 27, 2007

INSULIN GLULISINE RECOMBINANT

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N021629 001	Apr 16, 2004
	300 UNITS/3ML (100 UNITS/ML)	N021629 002	Dec 20, 2005

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

SANOFI AVENTIS US	300 UNITS/3ML	N021629 003	Feb 24, 2009
-------------------	---------------	-------------	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50

+ LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 001	Dec 22, 1999
HUMALOG MIX 50/50 KWIKPEN			
+ LILLY	50 UNITS/ML; 50 UNITS/ML	N021018 002	Sep 06, 2007
HUMALOG MIX 75/25			
+ LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 001	Dec 22, 1999
HUMALOG MIX 75/25 KWIKPEN			
+ LILLY	75 UNITS/ML; 25 UNITS/ML	N021017 002	Sep 06, 2007

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG

+ LILLY	100 UNITS/ML	N020563 001	Jun 14, 1996
HUMALOG KWIKPEN			
+ LILLY	100 UNITS/ML	N020563 003	Sep 06, 2007

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY	500 UNITS/ML	N018780 004	Mar 31, 1994
---------	--------------	-------------	--------------

POWDER; INHALATION

AFREZZA

SANOFI AVENTIS	4 UNITS/INH	N022472 001	Jun 27, 2014
	8 UNITS/INH	N022472 002	Jun 27, 2014

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+ GE HEALTHCARE	10mCi/5ML (2mCi/ML)	N022290 001	Sep 19, 2008
-----------------	---------------------	-------------	--------------

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

+ BRACCO	52%	N009321 003	
----------	-----	-------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-197 (of 371)

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

+ GE HEALTHCARE

55%

N020351 001 Mar 22, 1996

55%

N020808 001 Aug 29, 1997

VISIPAQUE 320

+ GE HEALTHCARE

65.2%

N020351 002 Mar 22, 1996

65.2%

N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+ GE HLTHCARE INC

5mCi/2.5ML (2mCi/ML)

N022454 001 Jan 14, 2011

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140

+ GE HEALTHCARE

30.2%

N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+ GE HEALTHCARE

75.5%

N018956 004 Dec 26, 1985

75.5%

N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+ GE HEALTHCARE

38.8%

N018956 001 Dec 26, 1985

OMNIPAQUE 240

+ GE HEALTHCARE

51.8%

N018956 002 Dec 26, 1985

51.8%

N020608 001 Oct 24, 1995

OMNIPAQUE 300

+ GE HEALTHCARE

64.7%

N018956 003 Dec 26, 1985

64.7%

N020608 002 Oct 24, 1995

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250AP FRESenius KABI USA51%A074679 001 Apr 02, 1997IOPAMIDOL-300AP FRESenius KABI USA61%A074679 002 Apr 02, 1997IOPAMIDOL-370AP FRESenius KABI USA76%A074679 003 Apr 02, 1997ISOVUE-200AP + BRACCO41%N018735 006 Jul 07, 1987ISOVUE-250AP + BRACCO51%N018735 007 Jul 06, 1992AP +51%N020327 002 Oct 12, 1994ISOVUE-300AP + BRACCO61%N018735 002 Dec 31, 1985AP +61%N020327 003 Oct 12, 1994ISOVUE-370AP + BRACCO76%N018735 003 Dec 31, 1985AP +76%N020327 004 Oct 12, 1994SCANLUX-300AP SANOChemia CORP USA61%A090394 001 Jun 18, 2010SCANLUX-370AP SANOChemia CORP USA76%A090394 002 Jun 18, 2010

ISOVUE-M 200

+ BRACCO

41%

N018735 001 Dec 31, 1985

ISOVUE-M 300

+ BRACCO

61%

N018735 004 Dec 31, 1985

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE

49.9%

N021425 003 Mar 12, 2004

+

62.3%

N021425 001 Sep 20, 2002

+

76.9%

N021425 002 Sep 20, 2002

ULTRAVIST 150

+ BAYER HLTHCARE

31.2%

N020220 004 May 10, 1995

ULTRAVIST 240

+ BAYER HLTHCARE

49.9%

N020220 003 May 10, 1995

ULTRAVIST 300

+ BAYER HLTHCARE

62.3%

N020220 002 May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+ BAYER HLTHCARE

62.3%

N020220 005 Nov 18, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-198 (of 371)

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST 370

+ BAYER HLTHCARE

76.9%

N020220 001 May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+ MALLINCKRODT

60%

N013295 001

CONRAY 30

+ MALLINCKRODT

30%

N016983 001

CONRAY 43

+ MALLINCKRODT

43%

N013295 002

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

MALLINCKRODT

17.2%

N017057 002

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX

250-300uCi/ML

N017279 001

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 240

+ MALLINCKRODT

51%

N019710 002 Dec 30, 1988

OPTIRAY 300

+ MALLINCKRODT

64%

N019710 004 Jan 22, 1992

+

64%

N020923 004 May 13, 1999

OPTIRAY 320

+ MALLINCKRODT

68%

N019710 001 Dec 30, 1988

OPTIRAY 350

+ MALLINCKRODT

74%

N019710 005 Jan 22, 1992

+

74%

N020923 003 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

+ GUERBET

39.3%; 19.6%

N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET

62%

N020316 001 Dec 21, 1995

OXILAN-350

GUERBET

73%

N020316 002 Dec 21, 1995

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+ BOEHRINGER INGELHEIM

0.021MG/INH

N021527 001 Nov 27, 2004

SOLUTION; INHALATION

IPRATROPIUM BROMIDE**AN** BAUSCH AND LOMB**0.02%****A075835 001** Oct 15, 2001**AN** LANDELA PHARM**0.02%****A077072 001** Jul 19, 2005**AN** + MYLAN SPECLT**0.02%****A074755 001** Jan 10, 1997**AN** NEPHRON**0.02%****A075562 001** Sep 27, 2001**AN** RITEDOSE CORP**0.02%****A075693 001** Jan 26, 2001**AN** WATSON LABS**0.02%****A076291 001** May 09, 2005

SPRAY, METERED; NASAL

ATROVENT**AB** + BOEHRINGER INGELHEIM**0.021MG/SPRAY****N020393 001** Oct 20, 1995**AB** +**0.042MG/SPRAY****N020394 001** Oct 20, 1995IPRATROPIUM BROMIDE**AB** BAUSCH AND LOMB**0.021MG/SPRAY****A076025 001** Mar 31, 2003**AB****0.042MG/SPRAY****A076103 001** Mar 31, 2003**AB** MYLAN SPECLT**0.021MG/SPRAY****A075552 001** Mar 31, 2003**AB****0.042MG/SPRAY****A075553 001** Mar 31, 2003**AB** ROXANE**0.021MG/SPRAY****A076664 001** Nov 05, 2003**AB****0.042MG/SPRAY****A076598 001** Nov 05, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-199 (of 371)

IRBESARTAN

TABLET; ORAL

AVAPRO

<u>AB</u>	SANOFI AVENTIS US	<u>75MG</u>	<u>N020757</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>		<u>150MG</u>	<u>N020757</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	<u>300MG</u>	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>	ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A091236</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A091236</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A200832</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A200832</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A200832</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	CIPLA LTD	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>		<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>		<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>75MG</u>	<u>A203161</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203161</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203161</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>75MG</u>	<u>A200461</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A200461</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A200461</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A203071</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	ROXANE	<u>75MG</u>	<u>A090201</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>150MG</u>	<u>A090201</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>		<u>300MG</u>	<u>A090201</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>	SANDOZ	<u>75MG</u>	<u>A077466</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A077466</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A077466</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>	TEVA PHARMS	<u>75MG</u>	<u>A077159</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>150MG</u>	<u>A077159</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>		<u>300MG</u>	<u>A077159</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>	WATSON LABS INC	<u>75MG</u>	<u>A090720</u>	<u>001</u>	Oct 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090720</u>	<u>002</u>	Oct 12, 2012
<u>AB</u>		<u>300MG</u>	<u>A090720</u>	<u>003</u>	Oct 12, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>150MG</u>	<u>A079213</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>		<u>300MG</u>	<u>A079213</u>	<u>003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

CAMPTOSAR

<u>AP</u>	+	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+		<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009
<u>AP</u>	BEDFORD LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	CIPLA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A077219</u>	<u>001</u>	Feb 20, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077219</u>	<u>002</u>	Feb 20, 2008
<u>AP</u>	DR REDDYS LABS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A078953</u>	<u>001</u>	Apr 15, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078953</u>	<u>002</u>	Apr 15, 2010
<u>AP</u>	EBEWE PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090137</u>	<u>001</u>	Nov 12, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090137</u>	<u>002</u>	Nov 12, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-200 (of 371)

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A200771</u>	<u>001</u>	Feb 14, 2012
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A200771</u>	<u>002</u>	Feb 14, 2012
<u>AP</u>	FRESENIUS KABI ONCOL	<u>40MG/2ML (20MG/ML)</u>	<u>A078188</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078188</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032</u>	<u>001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032</u>	<u>002</u>	Dec 20, 2010
<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	+	<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>	JIANGSU HENGRUI MED	<u>40MG/2ML (20MG/ML)</u>	<u>A090675</u>	<u>002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675</u>	<u>001</u>	Dec 16, 2011
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>40MG/2ML (20MG/ML)</u>	<u>A090393</u>	<u>002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393</u>	<u>003</u>	May 13, 2011
<u>AP</u>	PLIVA LACHEMA	<u>40MG/2ML (20MG/ML)</u>	<u>A078122</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078122</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	SUN PHARMA GLOBAL	<u>40MG/2ML (20MG/ML)</u>	<u>A078805</u>	<u>001</u>	Apr 21, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078805</u>	<u>002</u>	Apr 21, 2008
<u>AP</u>	TEVA PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A090101</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090101</u>	<u>003</u>	Feb 27, 2008
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
	CAMPTOSAR				
	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003 Aug 05, 2010

IRON DEXTRAN

INJECTABLE; INJECTION

DEXFERRUM

BP	LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996
	INFED				
BP	+	WATSON LABS (UTAH)	EQ 50MG IRON/ML	N017441	001
	PROFERDEX				
BP	NEW RIVER	EQ 50MG IRON/ML	N017807	001	

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

+

EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)
 EQ 100MG BASE/5ML (EQ 20MG BASE/ML)
 EQ 200MG BASE/10ML (EQ 20MG BASE/ML)

N021135 002 Mar 20, 2005
 N021135 001 Nov 06, 2000
 N021135 004 Feb 09, 2007

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+

VALIDUS PHARMS INC

10MG

N011961 001

ISOFLURANE

LIQUID; INHALATION

FORANE

<u>AN</u>	+	BAXTER HLTHCARE	<u>99.9%</u>	<u>N017624</u>	<u>001</u>
<u>AN</u>		HALOCARBON PRODS	<u>99.9%</u>	<u>A075225</u>	<u>001</u> Oct 20, 1999
<u>AN</u>		HOSPIRA	<u>99.9%</u>	<u>A074097</u>	<u>001</u> Jan 25, 1993
<u>AN</u>		PIRAMAL CRITICAL	<u>99.9%</u>	<u>A074416</u>	<u>001</u> Sep 30, 1994
<u>AN</u>		PIRAMAL ENT	<u>99.9%</u>	<u>A074502</u>	<u>001</u> Jun 27, 1995

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

+

SANDOZ

100MG/ML

A040648 001 Jul 05, 2005

SYRUP; ORAL

ISONIAZID

+

CAROLINA MEDCL

50MG/5ML

A088235 001 Nov 10, 1983

TABLET; ORAL

ISONIAZID

<u>AA</u>		BARR	<u>100MG</u>	<u>A080936</u>	<u>001</u>
<u>AA</u>			<u>300MG</u>	<u>A080937</u>	<u>002</u>
<u>AA</u>	+	SANDOZ	<u>100MG</u>	<u>N008678</u>	<u>002</u>
<u>AA</u>	+		<u>300MG</u>	<u>N008678</u>	<u>003</u>
<u>AA</u>		THEPHARMANETWORK LLC	<u>100MG</u>	<u>A202610</u>	<u>001</u> Oct 29, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-201 (of 371)

ISONIAZID

TABLET; ORAL

ISONIAZID

AA		300MG	A202610	002	Oct 29, 2014
-----------	--	--------------	----------------	------------	--------------

LANIAZID

AA	LANNETT	300MG	A089776	001	Jun 13, 1988
-----------	---------	--------------	----------------	------------	--------------

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET; ORAL

RIFATER

+	SANOFI AVENTIS US	50MG; 300MG; 120MG	N050705	001	May 31, 1994
---	-------------------	--------------------	---------	-----	--------------

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMATE

+	SANOFI AVENTIS US	150MG; 300MG	A061884	001	
---	-------------------	--------------	---------	-----	--

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISUPREL

+	HOSPIRA	0.2MG/ML	N010515	001	
---	---------	----------	---------	-----	--

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988
---	---------------------	------	---------	-----	--------------

TABLET; ORAL

ISORDIL

AB	VALEANT BERMUDA	5MG	N012093	007	Jul 29, 1988
-----------	-----------------	------------	----------------	------------	--------------

ISOSORBIDE DINITRATE

AB	HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987
-----------	-------------------	------------	----------------	------------	--------------

AB		10MG	A086066	001	Oct 29, 1987
-----------	--	-------------	----------------	------------	--------------

AB		20MG	A088088	001	Nov 02, 1987
-----------	--	-------------	----------------	------------	--------------

AB		30MG	A040591	001	Jan 10, 2007
-----------	--	-------------	----------------	------------	--------------

AB	PAR PHARM	5MG	A086923	001	Mar 12, 1987
-----------	-----------	------------	----------------	------------	--------------

AB		10MG	A086925	001	Mar 12, 1987
-----------	--	-------------	----------------	------------	--------------

AB		20MG	A087537	001	Oct 02, 1987
-----------	--	-------------	----------------	------------	--------------

AB	+	30MG	A087946	001	Jan 12, 1988
-----------	---	-------------	----------------	------------	--------------

AB	SANDOZ	5MG	A086221	001	Jan 07, 1988
-----------	--------	------------	----------------	------------	--------------

AB		10MG	A086223	001	Jan 07, 1988
-----------	--	-------------	----------------	------------	--------------

AB		20MG	A089367	001	Apr 07, 1988
-----------	--	-------------	----------------	------------	--------------

ISORDIL

+	VALEANT BERMUDA	40MG	N012093	001	Jul 29, 1988
---	-----------------	------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

AB	COREPHARMA	40MG	A040723	001	Mar 17, 2008
-----------	------------	-------------	----------------	------------	--------------

AB	+	SUN PHARM INDS INC	40MG	A040009	Dec 30, 1998
-----------	---	--------------------	-------------	----------------	--------------

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB	ACTAVIS ELIZABETH	10MG	A075037	002	Oct 30, 1998
-----------	-------------------	-------------	----------------	------------	--------------

AB		20MG	A075037	001	Oct 30, 1998
-----------	--	-------------	----------------	------------	--------------

AB	ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998
-----------	----------------	-------------	----------------	------------	--------------

AB	HIKMA PHARMS LLC	20MG	A075361	001	Oct 05, 2000
-----------	------------------	-------------	----------------	------------	--------------

MONOKET

AB	KREMERS URBAN PHARMS	10MG	N020215	002	Jun 30, 1993
-----------	----------------------	-------------	----------------	------------	--------------

AB	+	20MG	N020215	001	Jun 30, 1993
-----------	---	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	DEXCEL LTD	60MG	A075522	001	Apr 17, 2000
-----------	------------	-------------	----------------	------------	--------------

AB	HIKMA PHARMS	30MG	A076813	002	Mar 30, 2006
-----------	--------------	-------------	----------------	------------	--------------

AB		60MG	A076813	001	Jan 07, 2005
-----------	--	-------------	----------------	------------	--------------

AB	KREMERS URBAN PHARMS	30MG	A075155	002	Jan 13, 2000
-----------	----------------------	-------------	----------------	------------	--------------

AB		60MG	A075155	001	Oct 30, 1998
-----------	--	-------------	----------------	------------	--------------

AB	+	120MG	A075155	003	Aug 04, 2000
-----------	---	--------------	----------------	------------	--------------

AB	NESHER PHARMS	30MG	A075395	001	Mar 16, 2000
-----------	---------------	-------------	----------------	------------	--------------

AB		60MG	A075395	002	Mar 16, 2000
-----------	--	-------------	----------------	------------	--------------

AB		120MG	A075395	003	Mar 16, 2000
-----------	--	--------------	----------------	------------	--------------

AB	TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011
-----------	----------------	-------------	----------------	------------	--------------

AB		60MG	A200495	001	Jun 03, 2011
-----------	--	-------------	----------------	------------	--------------

AB		120MG	A200495	002	Jun 03, 2011
-----------	--	--------------	----------------	------------	--------------

AB	VINTAGE PHARMS	30MG	A090598	001	Aug 11, 2010
-----------	----------------	-------------	----------------	------------	--------------

AB		60MG	A090598	002	Aug 11, 2010
-----------	--	-------------	----------------	------------	--------------

AB		120MG	A090598	003	Aug 11, 2010
-----------	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-202 (of 371)

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

+ MYLAN INSTITUTIONAL 1%

A090874 001 Jul 20, 2010

ISOTRETINOIN

CAPSULE; ORAL

AMNESTEEMAB MYLAN PHARMS INC10MGA075945 001 Nov 08, 2002AB 20MGA075945 002 Nov 08, 2002AB 40MGA075945 003 Nov 08, 2002CLARAVISAB TEVA PHARMS USA10MGA076356 001 Apr 11, 2003AB 20MGA076135 002 Apr 11, 2003AB 30MGA076135 003 May 11, 2006AB + 40MGA076135 001 Apr 11, 2003MYORISANAB DOUGLAS PHARMS10MGA076485 001 Jan 19, 2012AB 20MGA076485 002 Jan 19, 2012AB 40MGA076485 003 Jan 19, 2012SOTRETAB RANBAXY10MGA076041 001 Dec 24, 2002AB 20MGA076041 002 Dec 24, 2002AB 30MGA076503 001 Jun 20, 2003AB 40MGA076041 003 Dec 24, 2002ZENATANEAB DR REDDYS LABS LTD10MGA202099 001 Mar 25, 2013AB 20MGA202099 002 Mar 25, 2013AB 40MGA202099 003 Mar 25, 2013

ABSORICA

BX RANBAXY

10MG

N021951 001 May 25, 2012

BX 20MG

N021951 002 May 25, 2012

BX 30MG

N021951 003 May 25, 2012

BX + 40MG

N021951 004 May 25, 2012

ISRADIPINE

CAPSULE; ORAL

ISRADIPINEAB MIKAH PHARMA2.5MGA077169 001 Apr 24, 2006AB 5MGA077169 002 Apr 24, 2006AB WATSON LABS 2.5MGA077317 001 Jan 05, 2006AB + 5MGA077317 002 Jan 05, 2006ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLEAB MYLAN PHARMS INC100MGA200463 001 Jul 20, 2012AB SANDOZ 100MGA076104 001 May 28, 2004SPORANOXAB + JANSSEN PHARMS100MGN020083 001 Sep 11, 1992

SOLUTION; ORAL

SPORANOX

+ JANSSEN PHARMS

10MG/ML

N020657 001 Feb 21, 1997

TABLET; ORAL

ONMEL

+ MERZ PHARMS

200MG

N022484 001 Apr 29, 2010

IVACAFTOR

TABLET; ORAL

KALYDECO

+ VERTEX PHARMS

150MG

N203188 001 Jan 31, 2012

IVERMECTIN

CREAM; TOPICAL

SOOLANTRA

+ GALDERMA LABS LP

1%

N206255 001 Dec 19, 2014

LOTION; TOPICAL

SKLICE

+ SANOFI PASTEUR INC

0.5%

N202736 001 Feb 07, 2012

TABLET; ORAL

IVERMECTINAB EDENBRIDGE PHARMS3MGA204154 001 Oct 24, 2014STROMECTOLAB + MERCK SHARP DOHME3MGN050742 002 Oct 08, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-203 (of 371)

IXABEPILONE

INJECTABLE; IV (INFUSION)

IXEMPRA KIT

+	BRISTOL MYERS SQUIBB	15MG/VIAL	N022065	001	Oct 16, 2007
+		45MG/VIAL	N022065	002	Oct 16, 2007

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

+	FRESENIUS KABI USA	EQ 1GM BASE/3ML	A065111	002	Dec 17, 2002
		EQ 500MG BASE/2ML	A065111	001	Dec 17, 2002

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>EQ 10MG BASE/ML</u>	<u>N016812</u>	<u>001</u>
<u>AP</u>	+		<u>EQ 50MG BASE/ML</u>	<u>N016812</u>	<u>002</u>
<u>AP</u>	+		<u>EQ 100MG BASE/ML</u>	<u>N016812</u>	<u>003</u>

KETAMINE HYDROCHLORIDE

<u>AP</u>		EUROHLTH INTL	<u>EQ 50MG BASE/ML</u>	<u>A074524</u>	<u>001</u>	Mar 22, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074524</u>	<u>002</u>	Mar 22, 1996
<u>AP</u>		HOSPIRA	<u>EQ 50MG BASE/ML</u>	<u>A074549</u>	<u>001</u>	Jun 27, 1996
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A074549</u>	<u>002</u>	Jun 27, 1996
<u>AP</u>		MYLAN INSTITUTIONAL	<u>EQ 10MG BASE/ML</u>	<u>A076092</u>	<u>001</u>	Sep 30, 2008
<u>AP</u>			<u>EQ 50MG BASE/ML</u>	<u>A076092</u>	<u>002</u>	Dec 28, 2001
<u>AP</u>			<u>EQ 100MG BASE/ML</u>	<u>A076092</u>	<u>003</u>	Oct 25, 2002

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

<u>AT</u>	+	DELCOR ASSET CORP	<u>2%</u>	<u>N021738</u>	<u>001</u>	Jun 12, 2007
-----------	---	-------------------	-----------	----------------	------------	--------------

KETOCONAZOLE

<u>AT</u>		PERRIGO ISRAEL	<u>2%</u>	<u>A091550</u>	<u>001</u>	Aug 25, 2011
-----------	--	----------------	-----------	----------------	------------	--------------

CREAM; TOPICAL

KETOCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A076294</u>	<u>001</u>	Apr 28, 2004
<u>AB</u>	+	TEVA	<u>2%</u>	<u>A075581</u>	<u>001</u>	Apr 25, 2000

KETOZOLE

<u>AB</u>		TARO	<u>2%</u>	<u>A075638</u>	<u>001</u>	Dec 18, 2002
-----------	--	------	-----------	----------------	------------	--------------

GEL; TOPICAL

XOLEGEL

+	AQUA PHARMS	2%	N021946	001	Jul 28, 2006
---	-------------	----	---------	-----	--------------

SHAMPOO; TOPICAL

KETOCONAZOLE

<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A076419</u>	<u>001</u>	Jan 07, 2004
<u>AB</u>		TOLMAR	<u>2%</u>	<u>A076942</u>	<u>001</u>	Apr 11, 2005

NIZORAL

<u>AB</u>	+	JANSSEN PHARMS	<u>2%</u>	<u>N019927</u>	<u>001</u>	Aug 31, 1990
-----------	---	----------------	-----------	----------------	------------	--------------

TABLET; ORAL

KETOCONAZOLE

<u>AB</u>		MYLAN	<u>200MG</u>	<u>A075597</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		TARO	<u>200MG</u>	<u>A075319</u>	<u>001</u>	Jun 15, 1999
<u>AB</u>	+	TEVA	<u>200MG</u>	<u>A075273</u>	<u>001</u>	Jun 15, 1999

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>		DORADO PHARMA	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>			<u>75MG</u>	<u>A074014</u>	<u>003</u>	Jan 29, 1993
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A074035</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>			<u>75MG</u>	<u>A074035</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>		TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
<u>AB</u>	+		<u>75MG</u>	<u>A073517</u>	<u>001</u>	Dec 22, 1992
		DORADO PHARMA	25MG	A074014	001	Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

<u>AB</u>		ACTAVIS LABS FL INC	<u>100MG</u>	<u>A075270</u>	<u>002</u>	Mar 24, 1999
<u>AB</u>			<u>150MG</u>	<u>A075270</u>	<u>003</u>	Mar 24, 1999
<u>AB</u>			<u>200MG</u>	<u>A075270</u>	<u>001</u>	Mar 24, 1999
<u>AB</u>		MYLAN	<u>100MG</u>	<u>A075679</u>	<u>003</u>	Feb 20, 2002
<u>AB</u>			<u>150MG</u>	<u>A075679</u>	<u>002</u>	Feb 20, 2002
<u>AB</u>	+		<u>200MG</u>	<u>A075679</u>	<u>001</u>	Feb 20, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-204 (of 371)

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	AGILA SPEC LTS	<u>15MG/ML</u>	<u>A078299</u>	<u>001</u>	Jul 16, 2007
<u>AP</u>		<u>15MG/ML</u>	<u>A201155</u>	<u>001</u>	Aug 04, 2014
<u>AP</u>		<u>30MG/ML</u>	<u>A078299</u>	<u>002</u>	Jul 16, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A201155</u>	<u>002</u>	Aug 04, 2014
<u>AP</u>	FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>	+ HOSPIRA	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>		<u>15MG/ML</u>	<u>A074993</u>	<u>001</u>	Jan 27, 1999
<u>AP</u>	+	<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>	SAGENT PHARMS	<u>15MG/ML</u>	<u>A091065</u>	<u>001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065</u>	<u>002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ	<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+ ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992
-----------	------------	-------------	----------------	------------	--------------

ACULAR LS

<u>AT</u>	+ ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003
-----------	------------	-------------	----------------	------------	--------------

ACUVAIL

<u>AT</u>	+ ALLERGAN	<u>0.45%</u>	<u>N022427</u>	<u>001</u>	Jul 22, 2009
-----------	------------	--------------	----------------	------------	--------------

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.4%</u>	<u>A078399</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	ALCON PHARMS LTD	<u>0.4%</u>	<u>A078721</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARMA GLOBAL	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009

SPRAY, METERED; NASAL

SPRIX

	+ LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010
--	------------	---------------	---------	-----	--------------

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	+ MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A075284</u>	<u>001</u>	Jun 23, 1999
<u>AB</u>	TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+ OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014
--	----------	---------------------------------------	---------	-----	--------------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

<u>AP</u>	AKORN INC	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>		<u>5MG/ML</u>	<u>A075524</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	EUROHLTH INTL	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
<u>AP</u>	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699</u>	<u>001</u>	Apr 03, 2012
<u>AP</u>	+ HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
<u>AP</u>	+	<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999

LABETALOL HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>5MG/ML</u>	<u>A079134</u>	<u>001</u>	Feb 03, 2010
-----------	----------------	---------------	----------------	------------	--------------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
<u>AB</u>	PAR FORM	<u>100MG</u>	<u>A200908</u>	<u>001</u>	Jul 10, 2012
<u>AB</u>		<u>200MG</u>	<u>A200908</u>	<u>002</u>	Jul 10, 2012
<u>AB</u>		<u>300MG</u>	<u>A200908</u>	<u>003</u>	Jul 10, 2012
<u>AB</u>	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
<u>AB</u>	+	<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
<u>AB</u>		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
<u>AB</u>		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
<u>AB</u>		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-205 (of 371)

LABETALOL HYDROCHLORIDE

TABLET; ORAL

TRANDATE

<u>AB</u>	CNTY LINE PHARMS	<u>100MG</u>	<u>N018716</u>	<u>001</u>	May 24, 1985
<u>AB</u>		<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984
<u>AB</u>		<u>300MG</u>	<u>N018716</u>	<u>003</u>	Aug 01, 1984

LACOSAMIDE

SOLUTION; INTRAVENOUS

VIMPAT

+ UCB INC

200MG/20ML (10MG/ML)

N022254 001 Oct 28, 2008

SOLUTION; ORAL

VIMPAT

+ UCB INC

10MG/ML

N022255 001 Apr 20, 2010

TABLET; ORAL

VIMPAT

UCB INC

50MG

N022253 001 Oct 28, 2008

100MG

N022253 002 Oct 28, 2008

150MG

N022253 003 Oct 28, 2008

+

200MG

N022253 004 Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+ CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997

+

20GM/PACKET

A074712 002 Dec 10, 1997

SOLUTION; ORAL

CONSTILAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071054</u>	<u>001</u>	Jul 26, 1988
-----------	------	------------------	----------------	------------	--------------

CONSTULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A070288</u>	<u>001</u>	Aug 15, 1988
-----------	------------------------	------------------	----------------	------------	--------------

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A078430</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	MORTON GROVE	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996
<u>AA</u>	PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>	ROXANE	<u>10GM/15ML</u>	<u>A073591</u>	<u>001</u>	May 29, 1992
<u>AA</u>	VINTAGE PHARMS	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>	VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992

SOLUTION; ORAL, RECTAL

CHOLAC

<u>AA</u>	ALRA	<u>10GM/15ML</u>	<u>A071331</u>	<u>001</u>	Jul 26, 1988
-----------	------	------------------	----------------	------------	--------------

ENULOSE

<u>AA</u>	+ ACTAVIS MID ATLANTIC	<u>10GM/15ML</u>	<u>A071548</u>	<u>001</u>	Aug 15, 1988
-----------	------------------------	------------------	----------------	------------	--------------

GENERLAC

<u>AA</u>	MORTON GROVE PHARMS	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996
-----------	---------------------	------------------	----------------	------------	--------------

LACTULOSE

<u>AA</u>	ANI PHARMS	<u>10GM/15ML</u>	<u>A090426</u>	<u>001</u>	Nov 21, 2008
<u>AA</u>	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>	HI TECH PHARMA	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995

LAMIVUDINE

SOLUTION; ORAL

EPIVIR

<u>AA</u>	+ VIIV HLTHCARE	<u>10MG/ML</u>	<u>N020596</u>	<u>001</u>	Nov 17, 1995
-----------	-----------------	----------------	----------------	------------	--------------

LAMIVUDINE

<u>AA</u>	SILARX PHARMS INC	<u>10MG/ML</u>	<u>A203564</u>	<u>001</u>	Oct 31, 2014
-----------	-------------------	----------------	----------------	------------	--------------

EPIVIR-HBV

+ GLAXOSMITHKLINE

5MG/ML

N021004 001 Dec 08, 1998

TABLET; ORAL

EPIVIR

<u>AB</u>	VIIV HLTHCARE	<u>150MG</u>	<u>N020564</u>	<u>001</u>	Nov 17, 1995
-----------	---------------	--------------	----------------	------------	--------------

<u>AB</u>	+	<u>300MG</u>	<u>N020564</u>	<u>003</u>	Jun 24, 2002
-----------	---	--------------	----------------	------------	--------------

EPIVIR-HBV

<u>AB</u>	+ GLAXOSMITHKLINE	<u>100MG</u>	<u>N021003</u>	<u>001</u>	Dec 08, 1998
-----------	-------------------	--------------	----------------	------------	--------------

LAMIVUDINE

<u>AB</u>	APOTEX	<u>150MG</u>	<u>A091606</u>	<u>001</u>	Dec 02, 2011
<u>AB</u>		<u>300MG</u>	<u>A091606</u>	<u>002</u>	Dec 02, 2011
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A202941</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG</u>	<u>A202032</u>	<u>001</u>	Nov 17, 2011
<u>AB</u>		<u>300MG</u>	<u>A202032</u>	<u>002</u>	Nov 17, 2011
<u>AB</u>	HETERO LABS LTD V	<u>100MG</u>	<u>A203260</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>		<u>150MG</u>	<u>A203277</u>	<u>001</u>	Jan 06, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-206 (of 371)

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

<u>AB</u>		<u>300MG</u>	<u>A203277</u>	<u>002</u>	Jan 06, 2014
<u>AB</u>	LUPIN LTD	<u>150MG</u>	<u>A205217</u>	<u>001</u>	Dec 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A205217</u>	<u>002</u>	Dec 18, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A204002</u>	<u>001</u>	Dec 31, 2014

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

COMBIVIR

<u>AB</u>	+ VIIIV HLTHCARE	<u>150MG;300MG</u>	<u>N020857</u>	<u>001</u>	Sep 26, 1997
-----------	------------------	--------------------	----------------	------------	--------------

LAMIVUDINE AND ZIDOVUDINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>150MG;300MG</u>	<u>A202418</u>	<u>001</u>	May 15, 2012
<u>AB</u>	HETERO LABS LTD V	<u>150MG;300MG</u>	<u>A203259</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	LUPIN LTD	<u>150MG;300MG</u>	<u>A090246</u>	<u>001</u>	May 15, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>150MG;300MG</u>	<u>A204005</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>	TEVA PHARMS	<u>150MG;300MG</u>	<u>A079081</u>	<u>001</u>	May 25, 2011

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N020241</u>	<u>005</u>	Dec 27, 1994
<u>AB</u>		<u>100MG</u>	<u>N020241</u>	<u>001</u>	Dec 27, 1994
<u>AB</u>		<u>150MG</u>	<u>N020241</u>	<u>002</u>	Dec 27, 1994
<u>AB</u>		<u>200MG</u>	<u>N020241</u>	<u>003</u>	Dec 27, 1994

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090607</u>	<u>001</u>	Jan 13, 2011
<u>AB</u>		<u>100MG</u>	<u>A090607</u>	<u>002</u>	Jan 13, 2011
<u>AB</u>		<u>150MG</u>	<u>A090607</u>	<u>003</u>	Jan 13, 2011
<u>AB</u>		<u>200MG</u>	<u>A090607</u>	<u>004</u>	Jan 13, 2011
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A200694</u>	<u>001</u>	Jun 14, 2013
<u>AB</u>		<u>100MG</u>	<u>A200694</u>	<u>002</u>	Jun 14, 2013
<u>AB</u>		<u>150MG</u>	<u>A200694</u>	<u>003</u>	Jun 14, 2013
<u>AB</u>		<u>200MG</u>	<u>A200694</u>	<u>004</u>	Jun 14, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A078625</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078625</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078625</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078625</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078956</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078956</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078956</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078956</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A079132</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079132</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A079132</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079132</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A077783</u>	<u>001</u>	Nov 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A077783</u>	<u>002</u>	Nov 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A077783</u>	<u>003</u>	Nov 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A077783</u>	<u>004</u>	Nov 01, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A076708</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076708</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A076708</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076708</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A090169</u>	<u>001</u>	May 12, 2012
<u>AB</u>		<u>100MG</u>	<u>A090169</u>	<u>002</u>	May 12, 2012
<u>AB</u>		<u>150MG</u>	<u>A090169</u>	<u>003</u>	May 12, 2012
<u>AB</u>		<u>200MG</u>	<u>A090169</u>	<u>004</u>	May 12, 2012
<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A078134</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>100MG</u>	<u>A078134</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>150MG</u>	<u>A078134</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>200MG</u>	<u>A078134</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078691</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078691</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>		<u>150MG</u>	<u>A078691</u>	<u>003</u>	Jun 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A078691</u>	<u>004</u>	Jun 01, 2010
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077420</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077420</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077420</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077420</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TARO PHARM INDS	<u>25MG</u>	<u>A078525</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078525</u>	<u>002</u>	Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-207 (of 371)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>		<u>150MG</u>	<u>A078525</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078525</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076388</u>	<u>001</u>	Aug 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A076388</u>	<u>002</u>	Aug 30, 2006
<u>AB</u>		<u>150MG</u>	<u>A076388</u>	<u>003</u>	Aug 30, 2006
<u>AB</u>		<u>200MG</u>	<u>A076388</u>	<u>004</u>	Aug 30, 2006
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A078947</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078947</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A078947</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078947</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090170</u>	<u>001</u>	Oct 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A090170</u>	<u>002</u>	Oct 06, 2011
<u>AB</u>		<u>150MG</u>	<u>A090170</u>	<u>003</u>	Oct 06, 2011
<u>AB</u>		<u>200MG</u>	<u>A090170</u>	<u>004</u>	Oct 06, 2011
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077633</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, CHEWABLE; ORAL

LAMICTAL CD

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000
<u>AB</u>		<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>5MG</u>	<u>A201168</u>	<u>001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168</u>	<u>002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200220</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>25MG</u>	<u>A200220</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076630</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076630</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076420</u>	<u>001</u>	Jun 21, 2006
<u>AB</u>		<u>25MG</u>	<u>A076420</u>	<u>002</u>	Jun 21, 2006
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115</u>	<u>001</u>	May 29, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022115</u>	<u>002</u>	May 29, 2009
<u>AB</u>		<u>100MG</u>	<u>N022115</u>	<u>003</u>	May 29, 2009
<u>AB</u>		<u>200MG</u>	<u>N022115</u>	<u>004</u>	May 29, 2009
<u>AB</u>		<u>250MG</u>	<u>N022115</u>	<u>006</u>	Jun 21, 2011
<u>AB</u>		<u>300MG</u>	<u>N022115</u>	<u>005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672</u>	<u>003</u>	Oct 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A200672</u>	<u>004</u>	Oct 17, 2013
<u>AB</u>		<u>25MG</u>	<u>A200672</u>	<u>001</u>	Oct 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A200672</u>	<u>002</u>	Oct 17, 2013
<u>AB</u>		<u>250MG</u>	<u>A203733</u>	<u>001</u>	Nov 13, 2013
<u>AB</u>		<u>300MG</u>	<u>A200672</u>	<u>005</u>	Oct 17, 2013
<u>AB</u>	ANCHEN PHARMS	<u>25MG</u>	<u>A201374</u>	<u>001</u>	Dec 26, 2012
<u>AB</u>		<u>50MG</u>	<u>A201374</u>	<u>002</u>	Dec 26, 2012
<u>AB</u>		<u>100MG</u>	<u>A201374</u>	<u>003</u>	Dec 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A201374</u>	<u>004</u>	Dec 26, 2012
<u>AB</u>		<u>250MG</u>	<u>A201374</u>	<u>005</u>	Dec 26, 2012
<u>AB</u>		<u>300MG</u>	<u>A201374</u>	<u>006</u>	Dec 26, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383</u>	<u>001</u>	Jun 19, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-208 (of 371)

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

<u>AB</u>		<u>50MG</u>	<u>A202383</u>	<u>002</u>	Jun 19, 2013
<u>AB</u>		<u>100MG</u>	<u>A202383</u>	<u>003</u>	Jun 19, 2013
<u>AB</u>		<u>200MG</u>	<u>A202383</u>	<u>004</u>	Jun 19, 2013
<u>AB</u>		<u>300MG</u>	<u>A202383</u>	<u>005</u>	Jun 19, 2013
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A201791</u>	<u>001</u>	Jan 18, 2013
<u>AB</u>		<u>50MG</u>	<u>A201791</u>	<u>002</u>	Jan 18, 2013
<u>AB</u>		<u>100MG</u>	<u>A201791</u>	<u>003</u>	Jan 18, 2013
<u>AB</u>		<u>200MG</u>	<u>A201791</u>	<u>004</u>	Jan 18, 2013
<u>AB</u>		<u>250MG</u>	<u>A201791</u>	<u>005</u>	Jan 18, 2013
<u>AB</u>		<u>300MG</u>	<u>A201791</u>	<u>006</u>	Jan 18, 2013
<u>AB</u>	TORRENT PHARMS LTD	<u>25MG</u>	<u>A203370</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>		<u>50MG</u>	<u>A203370</u>	<u>002</u>	Dec 23, 2013
<u>AB</u>		<u>100MG</u>	<u>A203370</u>	<u>003</u>	Dec 23, 2013
<u>AB</u>		<u>200MG</u>	<u>A203370</u>	<u>004</u>	Dec 23, 2013
<u>AB</u>	WILSHIRE PHARMS INC	<u>25MG</u>	<u>A202887</u>	<u>001</u>	Jun 17, 2013
<u>AB</u>		<u>50MG</u>	<u>A202887</u>	<u>002</u>	Jun 17, 2013
<u>AB</u>		<u>100MG</u>	<u>A202887</u>	<u>003</u>	Jun 17, 2013
<u>AB</u>		<u>200MG</u>	<u>A202887</u>	<u>004</u>	Jun 17, 2013
<u>AB</u>	WOCKHARDT LTD	<u>25MG</u>	<u>A202498</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>		<u>50MG</u>	<u>A202498</u>	<u>002</u>	Jan 04, 2013
<u>AB</u>		<u>100MG</u>	<u>A202498</u>	<u>003</u>	Jan 04, 2013
<u>AB</u>		<u>200MG</u>	<u>A202498</u>	<u>004</u>	Jan 04, 2013
<u>AB</u>		<u>300MG</u>	<u>A202498</u>	<u>005</u>	Jan 04, 2013

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251</u>	<u>001</u>	May 08, 2009
<u>AB</u>	+	<u>50MG</u>	<u>N022251</u>	<u>002</u>	May 08, 2009
<u>AB</u>		<u>100MG</u>	<u>N022251</u>	<u>003</u>	May 08, 2009
<u>AB</u>		<u>200MG</u>	<u>N022251</u>	<u>004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	IMPAX LABS INC	<u>25MG</u>	<u>A200828</u>	<u>001</u>	Jul 15, 2013
<u>AB</u>		<u>50MG</u>	<u>A200828</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>100MG</u>	<u>A200828</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>200MG</u>	<u>A200828</u>	<u>004</u>	Jul 15, 2013

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT USA	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366</u>	<u>001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366</u>	<u>002</u>	Aug 19, 2013

LANSOPRAZOLE

<u>AB</u>	KRKA TOVARNA ZDRAVIL	<u>15MG</u>	<u>A091212</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>		<u>30MG</u>	<u>A091212</u>	<u>002</u>	Sep 16, 2013

PREVACID

<u>AB</u>	TAKEDA PHARMS USA	<u>15MG</u>	<u>N020406</u>	<u>001</u>	May 10, 1995
<u>AB</u>	+	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-209 (of 371)

LANSOPRAZOLETABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL
PREVACIDTAKEDA PHARMS USA
+15MG
30MGN021428 001 Aug 30, 2002
N021428 002 Aug 30, 2002LANTHANUM CARBONATEPOWDER; ORAL
FOSRENOL

+ SHIRE DEV LLC

EQ 1GM BASE
EQ 750MG BASEN204734 002 Sep 24, 2014
N204734 001 Sep 24, 2014

TABLET, CHEWABLE; ORAL

FOSRENOL

+ SHIRE LLC

EQ 1GM BASE
EQ 500MG BASE
EQ 750MG BASEN021468 004 Nov 23, 2005
N021468 002 Oct 26, 2004
N021468 003 Nov 23, 2005LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+ SMITHKLINE BEECHAM

EQ 250MG BASE

N022059 001 Mar 13, 2007

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AKORN	0.005%
AT	ALCON RES	0.005%
AT	BAUSCH AND LOMB	0.005%
AT	DR REDDYS LABS LTD	0.005%
AT	LUITPOLD	0.005%
AT	MYLAN	0.005%

A090887	001	Jul 19, 2011
A091449	001	Mar 22, 2011
A201006	001	Mar 22, 2011
A202077	001	Feb 11, 2013
A200925	001	Mar 22, 2011
A201786	001	Mar 22, 2011

XALATAN**AT** + PHARMACIA AND UPJOHN **0.005%****N020597** **001** Jun 05, 1996LEDIPASVIR; SOFOSBUVIR

TABLET; ORAL

HARVONI

+ GILEAD SCIENCES INC

90MG; 400MG

N205834 001 Oct 10, 2014

LEFLUNOMIDE

TABLET; ORAL

ARAVA

AB	SANOFI AVENTIS US	10MG
AB	+	20MG

N020905	001	Sep 10, 1998
N020905	002	Sep 10, 1998

LEFLUNOMIDE

AB	ALEMBIC PHARMS LTD	10MG
AB		20MG
AB	APOTEX INC	10MG
AB		20MG
AB	BARR	10MG
AB		20MG
AB	HERITAGE PHARMS INC	10MG
AB		20MG
AB	TEVA PHARMS	10MG
AB		20MG

A091369	001	Nov 21, 2011
A091369	002	Nov 21, 2011
A077090	001	Sep 13, 2005
A077090	002	Sep 13, 2005
A077083	001	Sep 13, 2005
A077083	002	Sep 13, 2005
A077086	001	Sep 13, 2005
A077086	002	Sep 13, 2005
A077084	001	Sep 13, 2005
A077084	002	Sep 13, 2005

ARAVA

+ SANOFI AVENTIS US

100MG

N020905 003 Sep 10, 1998

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE

2.5MG
5MG
10MG
15MG
20MG
25MG

N021880	005	Dec 21, 2011
N021880	001	Dec 27, 2005
N021880	002	Dec 27, 2005
N021880	003	Jun 29, 2006
N021880	006	Jun 05, 2013
N021880	004	Jun 29, 2006

LETROZOLE

TABLET; ORAL

FEMARA**AB** + NOVARTIS PHARMS **2.5MG****N020726** **001** Jul 25, 1997LETROZOLE

AB	ACCORD HLTHCARE	2.5MG
AB	APOTEX INC	2.5MG
AB	DR REDDYS LABS LTD	2.5MG

A090934	001	Jun 03, 2011
A091303	001	Apr 19, 2012
A091191	001	Jun 03, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-210 (of 371)

LETROZOLE

TABLET; ORAL

LETROZOLE

<u>AB</u>	FRESENIUS KABI ONCOL	<u>2.5MG</u>	<u>A090491</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	INDICUS PHARMA	<u>2.5MG</u>	<u>A201804</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	JIANGSU HENGRUI MED	<u>2.5MG</u>	<u>A202716</u>	<u>001</u>	May 16, 2013
<u>AB</u>	KUDCO IRELAND	<u>2.5MG</u>	<u>A091098</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	LANNETT HOLDINGS INC	<u>2.5MG</u>	<u>A202048</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A078190</u>	<u>001</u>	Dec 24, 2008
<u>AB</u>	NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	ROXANE	<u>2.5MG</u>	<u>A090838</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091466</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A090289</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A090789</u>	<u>001</u>	Jun 03, 2011

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	+		<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>AP</u>		TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>	+	EUROHLTH INTL	<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>	+		<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>		SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 100MG BASE/VIAL</u>	<u>A200753</u>	<u>002</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A200753</u>	<u>003</u>	Sep 06, 2012
<u>AP</u>			<u>EQ 350MG BASE/VIAL</u>	<u>A200855</u>	<u>001</u>	Sep 06, 2012
	+	EUROHLTH INTL	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000
	+	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A040286	001	Feb 26, 1999

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>		BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>			<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>		ROXANE	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>			<u>EQ 15MG BASE</u>	<u>A072735</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
			EQ 10MG BASE	A072734	001	Feb 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

<u>AP</u>	+	SANDOZ	<u>1MG/0.2ML</u>	<u>A074728</u>	<u>001</u>	Aug 04, 1998
<u>AP</u>		SUN PHARMA GLOBAL	<u>1MG/0.2ML</u>	<u>A078885</u>	<u>001</u>	Mar 09, 2009
<u>AP</u>		TEVA PHARMS USA	<u>1MG/0.2ML</u>	<u>A075471</u>	<u>001</u>	Oct 25, 2000

LUPRON DEPOT

	+	ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995
	+		7.5MG/VIAL	N019732	001	Jan 26, 1989
	+		11.25MG/VIAL	N020708	001	Mar 07, 1997
	+		22.5MG/VIAL	N020517	001	Dec 22, 1995
	+		30MG/VIAL	N020517	002	May 30, 1997
			45MG/VIAL	N020517	003	Jun 17, 2011

LUPRON DEPOT-PED

	+	ABBVIE ENDOCRINE INC	7.5MG/VIAL	N020263	002	Apr 16, 1993
	+		11.25MG/VIAL	N020263	005	Jan 21, 1994
	+		11.25MG/VIAL	N020263	007	Aug 15, 2011
	+		15MG/VIAL	N020263	006	Jan 21, 1994
	+		30MG/VIAL	N020263	008	Aug 15, 2011

INJECTABLE; SUBCUTANEOUS

ELIGARD

	+	TOLMAR THERAP	7.5MG/VIAL	N021343	001	Jan 23, 2002
	+		22.5MG/VIAL	N021379	001	Jul 24, 2002
	+		30MG/VIAL	N021488	001	Feb 13, 2003
	+		45MG/VIAL	N021731	001	Dec 14, 2004

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

		ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012
	+		11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-211 (of 371)

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

<u>AN</u>	CIPLA LTD	<u>EQ 0.021% BASE</u>	<u>A078171</u>	<u>002</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A078171</u>	<u>003</u>	Dec 13, 2013
<u>AN</u>		<u>EQ 0.0103% BASE</u>	<u>A078171</u>	<u>001</u>	Dec 13, 2013
<u>AN</u>	MYLAN SPEC LT	<u>EQ 0.0103% BASE</u>	<u>A077800</u>	<u>001</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077800</u>	<u>002</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077800</u>	<u>003</u>	Mar 15, 2013
<u>AN</u>		<u>EQ 0.25% BASE</u>	<u>A078309</u>	<u>001</u>	Mar 20, 2009
<u>AN</u>	TEVA PARENTERAL	<u>EQ 0.25% BASE</u>	<u>A200875</u>	<u>001</u>	Sep 11, 2014
<u>AN</u>	TEVA PHARMS USA	<u>EQ 0.0103% BASE</u>	<u>A090297</u>	<u>001</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A090297</u>	<u>002</u>	Apr 26, 2013
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A090297</u>	<u>003</u>	Apr 26, 2013
<u>AN</u>	WATSON LABS INC	<u>EQ 0.0103% BASE</u>	<u>A077756</u>	<u>003</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.021% BASE</u>	<u>A077756</u>	<u>001</u>	Apr 09, 2008
<u>AN</u>		<u>EQ 0.042% BASE</u>	<u>A077756</u>	<u>002</u>	Apr 09, 2008
<u>XOPENEX</u>					
<u>AN</u>	+ OAK PHARMS INC	<u>EQ 0.0103% BASE</u>	<u>N020837</u>	<u>003</u>	Jan 30, 2002
<u>AN</u>	+	<u>EQ 0.021% BASE</u>	<u>N020837</u>	<u>001</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.042% BASE</u>	<u>N020837</u>	<u>002</u>	Mar 25, 1999
<u>AN</u>	+	<u>EQ 0.25% BASE</u>	<u>N020837</u>	<u>004</u>	Jul 18, 2003

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+ SUNOVION

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

KEPPRA

<u>AP</u>	+ UCB INC	<u>500MG/5ML (100MG/ML)</u>	<u>N021872</u>	<u>001</u>	Jul 31, 2006
<u>LEVETIRACETAM</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/5ML (100MG/ML)</u>	<u>A090813</u>	<u>001</u>	May 26, 2010
<u>AP</u>	HIKMA FARMACEUTICA	<u>500MG/5ML (100MG/ML)</u>	<u>A090981</u>	<u>001</u>	Oct 13, 2011
<u>AP</u>	HOSPIRA INC	<u>500MG/ML (100MG/ML)</u>	<u>A202869</u>	<u>001</u>	Apr 06, 2012
<u>AP</u>	LUITPOLD	<u>500MG/5ML (100MG/ML)</u>	<u>A202143</u>	<u>001</u>	Jan 31, 2012
<u>AP</u>	SAGENT PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091627</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	SUN PHARM INDS LTD	<u>500MG/5ML (100MG/ML)</u>	<u>A090754</u>	<u>001</u>	Jun 16, 2010
<u>AP</u>	X GEN PHARMS	<u>500MG/5ML (100MG/ML)</u>	<u>A091485</u>	<u>001</u>	Aug 05, 2011
LEVETIRACETAM IN SODIUM CHLORIDE					
	+ HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011
	+	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011
	+	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011

SOLUTION; ORAL

KEPPRA

<u>AA</u>	+ UCB INC	<u>100MG/ML</u>	<u>N021505</u>	<u>001</u>	Jul 15, 2003
<u>LEVETIRACETAM</u>					
<u>AA</u>	ACTAVIS MID ATLANTIC	<u>100MG/ML</u>	<u>A078976</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	AMNEAL PHARMS	<u>100MG/ML</u>	<u>A090992</u>	<u>001</u>	Oct 27, 2009
<u>AA</u>	AUROBINDO PHARM	<u>100MG/ML</u>	<u>A079063</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>100MG/ML</u>	<u>A079120</u>	<u>001</u>	Jan 16, 2009
<u>AA</u>	HETERO LABS LTD III	<u>100MG/ML</u>	<u>A203052</u>	<u>001</u>	Feb 28, 2013
<u>AA</u>	HI-TECH PHARMACAL	<u>100MG/ML</u>	<u>A090601</u>	<u>001</u>	Feb 28, 2012
<u>AA</u>	LUPIN LTD	<u>100MG/ML</u>	<u>A090893</u>	<u>001</u>	Oct 17, 2011
<u>AA</u>	ORIT LABS LLC	<u>100MG/ML</u>	<u>A203067</u>	<u>001</u>	May 09, 2013
<u>AA</u>	ROXANE	<u>100MG/ML</u>	<u>A078582</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	SILARX	<u>100MG/ML</u>	<u>A090263</u>	<u>001</u>	Apr 03, 2009
<u>AA</u>	TARO	<u>100MG/ML</u>	<u>A078774</u>	<u>001</u>	Feb 10, 2009
<u>AA</u>	TOLMAR	<u>100MG/ML</u>	<u>A079107</u>	<u>001</u>	Jan 15, 2009
<u>AA</u>	TRIS PHARMA INC	<u>100MG/ML</u>	<u>A090461</u>	<u>001</u>	Sep 30, 2010
<u>AA</u>	VINTAGE PHARMS	<u>100MG/ML</u>	<u>A090079</u>	<u>001</u>	Apr 11, 2012
<u>AA</u>	WOCKHARDT	<u>100MG/ML</u>	<u>A090028</u>	<u>001</u>	Mar 03, 2010

TABLET; ORAL

KEPPRA

<u>AB</u>	+ UCB INC	<u>1GM</u>	<u>N021035</u>	<u>004</u>	Jan 06, 2006
<u>AB</u>		<u>250MG</u>	<u>N021035</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>		<u>500MG</u>	<u>N021035</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		<u>750MG</u>	<u>N021035</u>	<u>003</u>	Nov 30, 1999
<u>LEVETIRACETAM</u>					
<u>AB</u>	ACCORD HLTHCARE	<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A090843</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A090843</u>	<u>002</u>	Feb 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-212 (of 371)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A090843</u>	<u>003</u>	Feb 14, 2011
<u>AB</u>	AJANTA PHARMA	<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>		<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>	APOTEX INC	<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>		<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009
<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	BRECKENRIDGE PHARM	<u>1GM</u>	<u>A090511</u>	<u>004</u>	Aug 18, 2011
<u>AB</u>		<u>250MG</u>	<u>A090511</u>	<u>001</u>	Aug 18, 2011
<u>AB</u>		<u>500MG</u>	<u>A090511</u>	<u>002</u>	Aug 18, 2011
<u>AB</u>		<u>750MG</u>	<u>A090511</u>	<u>003</u>	Aug 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LOTUS PHARM CO LTD	<u>500MG</u>	<u>A090906</u>	<u>001</u>	Nov 05, 2010
<u>AB</u>	LUPIN	<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	METHAPHARM	<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>		<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>		<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>		<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	PRINSTON INC	<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>		<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>	ROXANE	<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TARO	<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>	TEVA PHARMS	<u>1GM</u>	<u>A078101</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078101</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078101</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078101</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	VINTAGE PHARMS	<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-213 (of 371)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>	WOCKHARDT	<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>		<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009
<u>AB</u>		<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A091557</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091557</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MUTUAL PHARM CO INC	<u>500MG</u>	<u>A091285</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091285</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200475</u>	<u>001</u>	Dec 19, 2011
<u>AB</u>		<u>750MG</u>	<u>A200475</u>	<u>002</u>	Dec 19, 2011
<u>AB</u>	PAR PHARM	<u>500MG</u>	<u>A091291</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091291</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	ROUSES POINT PHARMS	<u>500MG</u>	<u>A202524</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>750MG</u>	<u>A202524</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013
<u>AB</u>	TEVA PHARMS	<u>500MG</u>	<u>A091430</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091430</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>500MG</u>	<u>A091338</u>	<u>001</u>	May 29, 2012
<u>AB</u>		<u>750MG</u>	<u>A091338</u>	<u>002</u>	May 29, 2012
<u>AB</u>	VINTAGE PHARMS	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	VINTAGE PHARMS LLC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKBETA

<u>AT</u>	AKORN	<u>0.25%</u>	<u>A074779</u>	<u>001</u>	Oct 29, 1996
<u>AT</u>		<u>0.5%</u>	<u>A074780</u>	<u>001</u>	Oct 29, 1996

BETAGAN

<u>AT</u>	+	ALLERGAN	<u>0.25%</u>	<u>N019814</u>	<u>001</u>	Jun 28, 1989
<u>AT</u>	+		<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>	ALCON RES LTD	<u>0.5%</u>	<u>A074850</u>	<u>001</u>	Oct 28, 1996
<u>AT</u>	BAUSCH AND LOMB	<u>0.25%</u>	<u>A074307</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>		<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994
<u>AT</u>	FALCON PHARMS	<u>0.25%</u>	<u>A074851</u>	<u>001</u>	Oct 28, 1996

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+	SIGMA TAU	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992
-----------	---	-----------	-----------------	----------------	------------	--------------

LEVOCARNITINE

<u>AP</u>	EUROHLTH INTL	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001
<u>AP</u>	LUITPOLD	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>	TEVA PHARMS USA	<u>200MG/ML</u>	<u>A075881</u>	<u>001</u>	Mar 29, 2001

SOLUTION; ORAL

CARNITOR

<u>AA</u>	+	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986
-----------	---	-----------	-----------------	----------------	------------	--------------

CARNITOR SF

<u>AA</u>	SIGMA TAU	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007
-----------	-----------	-----------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-214 (of 371)

LEVOCARNITINE

SOLUTION; ORAL

LEVOCARNITINE

<u>AA</u>	HI TECH PHARMA	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007
<u>AA</u>	LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

TABLET; ORAL

CARNITOR

<u>AB</u>	+ SIGMA TAU	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985
-----------	-------------	--------------	----------------	------------	--------------

LEVOCARNITINE

<u>AB</u>	COREPHARMA	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004
-----------	------------	--------------	----------------	------------	--------------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>	APOTEX INC	<u>2.5MG/5ML</u>	<u>A202915</u>	<u>001</u>	Aug 21, 2014
<u>AA</u>	L PERRIGO CO	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011
<u>AA</u>	TARO PHARM INDS	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

XYZAL

<u>AA</u>	+ UCB INC	<u>2.5MG/5ML</u>	<u>N022157</u>	<u>001</u>	Jan 28, 2008
-----------	-----------	------------------	----------------	------------	--------------

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013
<u>AB</u>	SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203646</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>	SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

XYZAL

<u>AB</u>	+ UCB INC	<u>5MG</u>	<u>N022064</u>	<u>001</u>	May 25, 2007
-----------	-----------	------------	----------------	------------	--------------

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>001</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>N020635</u>	<u>004</u>	Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+ JANSSEN PHARMS	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>002</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>003</u>	Dec 20, 1996
<u>AP</u>	+	<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>N020635</u>	<u>005</u>	Dec 20, 1996

LEVOFLOXACIN

<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202328</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436</u>	<u>001</u>	Jun 05, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>001</u>	Jan 24, 2013
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A202590</u>	<u>002</u>	Jan 24, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>001</u>	Jun 20, 2011
<u>AP</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A200560</u>	<u>002</u>	Jun 20, 2011

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011
<u>AP</u>	CLARIS LIFESCIENCES	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>001</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>002</u>	Aug 08, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>003</u>	Aug 08, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>001</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>002</u>	Jun 19, 2013
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>003</u>	Jun 19, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011
<u>AP</u>		<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011

SOLUTION; ORAL

LEVAQUIN

<u>AA</u>	+ JANSSEN PHARMS	<u>250MG/10ML</u>	<u>N021721</u>	<u>001</u>	Oct 21, 2004
-----------	------------------	-------------------	----------------	------------	--------------

LEVOFLOXACIN

<u>AA</u>	HI TECH PHARMA	<u>250MG/10ML</u>	<u>A091678</u>	<u>001</u>	Jun 20, 2011
-----------	----------------	-------------------	----------------	------------	--------------

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>	NEXUS PHARMS	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010
<u>AT</u>	WATSON LABS INC	<u>0.5%</u>	<u>A076826</u>	<u>001</u>	Feb 10, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-215 (of 371)

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

QUIXIN

AT	+	SANTEN	0.5%	N021199	001	Aug 18, 2000
TABLET;ORAL						

LEVAQUIN

AB	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996
AB		500MG	N020634	002	Dec 20, 1996
AB	+	750MG	N020634	003	Sep 08, 2000

LEVOFLOXACIN

AB	APOTEX INC	250MG	A090787	001	Sep 29, 2011
AB		500MG	A090787	002	Sep 29, 2011
AB		750MG	A090787	003	Sep 29, 2011
AB	AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011
AB		500MG	A201043	002	Jun 20, 2011
AB		750MG	A201043	003	Jun 20, 2011
AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012
AB		500MG	A076890	002	Mar 30, 2012
AB		750MG	A076890	003	Mar 30, 2012
AB	DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011
AB		500MG	A076710	002	Jun 20, 2011
AB		750MG	A076710	003	Jun 20, 2011
AB	GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011
AB		500MG	A200250	002	Jun 20, 2011
AB		750MG	A200250	003	Jun 20, 2011
AB	HETERO LABS LTD V	250MG	A202801	001	Jan 08, 2015
AB		500MG	A202801	002	Jan 08, 2015
AB		750MG	A202801	003	Jan 08, 2015
AB	LUPIN	250MG	A078424	001	Jun 20, 2011
AB		500MG	A078424	002	Jun 20, 2011
AB		750MG	A078424	003	Jun 20, 2011
AB	MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012
AB		500MG	A200839	002	Mar 22, 2012
AB		750MG	A200839	003	Mar 22, 2012
AB	MYLAN	250MG	A076276	001	Jun 20, 2011
AB		500MG	A076276	002	Jun 20, 2011
AB		750MG	A077097	001	Jun 20, 2011
AB	ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012
AB		500MG	A202200	002	Jan 30, 2012
AB		750MG	A202200	003	Jan 30, 2012
AB	SANDOZ	250MG	A077438	001	Jun 20, 2011
AB		500MG	A077438	002	Jun 20, 2011
AB		750MG	A077438	003	Jun 20, 2011
AB	TEVA	250MG	A076361	001	Jun 20, 2011
AB		500MG	A076361	002	Jun 20, 2011
AB		750MG	A076361	003	Jun 20, 2011
AB	TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011
AB		500MG	A090722	002	Jun 20, 2011
AB		750MG	A090722	003	Jun 20, 2011
AB	WOCKHARDT	250MG	A090367	001	Jun 20, 2011
AB		500MG	A090367	002	Jun 20, 2011
AB		750MG	A090367	003	Jun 20, 2011
AB	ZYDUS PHARMS USA INC	250MG	A077652	001	Sep 07, 2012
AB		500MG	A077652	002	Sep 07, 2012
AB		750MG	A077652	003	Sep 07, 2012

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008
---	-----------------	-------------------	---------	-----	--------------

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

FOREST LABS INC	EQ 20MG BASE	N204168	001	Jul 25, 2013
	EQ 40MG BASE	N204168	002	Jul 25, 2013
	EQ 80MG BASE	N204168	003	Jul 25, 2013
+	EQ 120MG BASE	N204168	004	Jul 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-216 (of 371)

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

+ DEPROCO

0.05MG/ML; 2%

A088388 001 Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

MIRENA

+ BAYER HLTHCARE

52MG

N021225 001 Dec 06, 2000

SKYLA

+ BAYER HLTHCARE

13.5MG

N203159 001 Jan 09, 2013

TABLET; ORAL

LEVONORGESTRELAB

NOVEL LABS INC

1.5MGA202508 001 Feb 22, 2013AB

PERRIGO R AND D

0.75MGA090740 001 Dec 30, 2010AB

+ WATSON LABS

0.75MGA078665 001 Aug 28, 2009AB

WATSON LABS INC

1.5MGA200670 001 Jul 12, 2012PLAN BAB

+ TEVA BRANDED PHARM

0.75MGN021045 002 Aug 24, 2006LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

+ ROXANE

2MG

A074278 001 Mar 31, 2000

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

TIROSINT

INST BIOCHIMIQUE

0.013MG

N022121 001 Aug 01, 2007

INSTITUT BIOCHIMIQUE

0.025MG

N021924 002 Oct 13, 2006

0.05MG

N021924 003 Oct 13, 2006

0.075MG

N021924 004 Oct 13, 2006

0.088MG

N021924 010 Oct 02, 2009

0.1MG

N021924 005 Oct 13, 2006

0.112MG

N021924 008 Oct 02, 2009

0.125MG

N021924 006 Oct 13, 2006

0.137MG

N021924 009 Oct 02, 2009

+

0.15MG

N021924 007 Oct 13, 2006

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

+ FRESENIUS KABI USA

100MCG/VIAL

N202231 001 Jun 24, 2011

+

200MCG/VIAL

N202231 002 Jun 24, 2011

+

500MCG/VIAL

N202231 003 Jun 24, 2011

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

SYNTHROID

-->

ABBVIE

--> AB1, AB20.025MG

N021402 001 Jul 24, 2002

-->

--> AB1, AB20.05MG

N021402 002 Jul 24, 2002

-->

--> AB1, AB20.075MG

N021402 003 Jul 24, 2002

-->

--> AB1, AB20.088MG

N021402 004 Jul 24, 2002

-->

--> AB1, AB20.1MG

N021402 005 Jul 24, 2002

-->

--> AB1, AB20.112MG

N021402 006 Jul 24, 2002

-->

--> AB1, AB20.125MG

N021402 007 Jul 24, 2002

-->

--> AB1, AB20.137MG

N021402 008 Jul 24, 2002

-->

--> AB1, AB20.15MG

N021402 009 Jul 24, 2002

-->

--> AB1, AB20.175MG

N021402 010 Jul 24, 2002

-->

--> AB1, AB20.2MG

N021402 012 Jul 24, 2002

-->

--> AB1, AB20.3MG

N021402 011 Jul 24, 2002

LEVO-T

-->

ALARA PHARM

--> AB1, AB2, AB30.025MG

N021342 001 Mar 01, 2002

-->

--> AB1, AB2, AB30.05MG

N021342 002 Mar 01, 2002

-->

--> AB1, AB2, AB30.075MG

N021342 003 Mar 01, 2002

-->

--> AB1, AB2, AB30.088MG

N021342 004 Mar 01, 2002

-->

--> AB1, AB2, AB30.1MG

N021342 005 Mar 01, 2002

-->

--> AB1, AB2, AB30.112MG

N021342 006 Mar 01, 2002

-->

--> AB1, AB2, AB30.125MG

N021342 007 Mar 01, 2002

-->

--> AB1, AB2,0.137MG

N021342 012 Dec 08, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-217 (of 371)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVO-T

	<u>AB3</u>	<u>0.137MG</u>	
-->	--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342 008 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342 009 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342 010 Mar 01, 2002
--> +	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342 011 Mar 01, 2002

UNITHROID

-->	STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210 006 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210 007 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210 012 Feb 08, 2008
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210 008 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210 009 Aug 21, 2000
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210 010 Aug 21, 2000
--> +		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210 011 Aug 21, 2000

LEVOTHYROXINE SODIUM

-->	MYLAN	-->	<u>0.025MG</u>	A076187 001 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.05MG</u>	A076187 002 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.075MG</u>	A076187 003 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.088MG</u>	A076187 004 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.1MG</u>	A076187 005 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.112MG</u>	A076187 006 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.125MG</u>	A076187 007 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.137MG</u>	A076187 012 Dec 13, 2006
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.15MG</u>	A076187 008 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.175MG</u>	A076187 009 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.2MG</u>	A076187 010 Jun 05, 2002
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		-->	<u>0.3MG</u>	A076187 011 Jun 05, 2002

LEVOXYL

-->	KING PHARMS R AND D	--> <u>AB1,AB3</u>	<u>0.025MG</u>	N021301 001 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.05MG</u>	N021301 002 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.075MG</u>	N021301 003 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.088MG</u>	N021301 004 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.1MG</u>	N021301 005 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.112MG</u>	N021301 006 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.125MG</u>	N021301 007 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.137MG</u>	N021301 008 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.15MG</u>	N021301 009 May 25, 2001
-->		--> <u>AB1,AB3</u>	<u>0.175MG</u>	N021301 010 May 25, 2001
--> +		--> <u>AB1,AB3</u>	<u>0.2MG</u>	N021301 011 May 25, 2001

LEVOTHROID

<u>AB4</u>	LLOYD	<u>0.025MG</u>	<u>N021116 001</u>	Oct 24, 2002
<u>AB4</u>		<u>0.05MG</u>	<u>N021116 002</u>	Oct 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-218 (of 371)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHROID

<u>AB4</u>	<u>0.075MG</u>	<u>N021116</u>	<u>003</u>	Oct 24, 2002
<u>AB4</u>	<u>0.088MG</u>	<u>N021116</u>	<u>010</u>	Oct 24, 2002
<u>AB4</u>	<u>0.1MG</u>	<u>N021116</u>	<u>004</u>	Oct 24, 2002
<u>AB4</u>	<u>0.112MG</u>	<u>N021116</u>	<u>011</u>	Oct 24, 2002
<u>AB4</u>	<u>0.125MG</u>	<u>N021116</u>	<u>005</u>	Oct 24, 2002
<u>AB4</u>	<u>0.137MG</u>	<u>N021116</u>	<u>012</u>	Dec 07, 2004
<u>AB4</u>	<u>0.15MG</u>	<u>N021116</u>	<u>006</u>	Oct 24, 2002
<u>AB4</u>	<u>0.175MG</u>	<u>N021116</u>	<u>007</u>	Oct 24, 2002
<u>AB4</u>	<u>0.2MG</u>	<u>N021116</u>	<u>008</u>	Oct 24, 2002
<u>AB4</u> +	<u>0.3MG</u>	<u>N021116</u>	<u>009</u>	Oct 24, 2002

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u> +	FOUGERA	<u>5%</u>	<u>A080198</u>	<u>001</u>	
<u>AT</u>	NOVOCOL INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>	TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	WATSON LABS INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
-----------	-----------------	-----------	----------------	------------	--------------

LIDODERM

<u>AB</u> +	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999
-------------	--------------------	-----------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

+ AKORN

3.5%

N022221 001 Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	AGILA SPECLTS	<u>0.5%</u>	<u>A091056</u>	<u>001</u>	Dec 08, 2010
<u>AP</u>		<u>0.5%</u>	<u>A091058</u>	<u>001</u>	Sep 30, 2010
<u>AP</u>		<u>1%</u>	<u>A091056</u>	<u>002</u>	Dec 08, 2010
<u>AP</u>		<u>1%</u>	<u>A091058</u>	<u>002</u>	Sep 30, 2010
<u>AP</u>		<u>2%</u>	<u>A202242</u>	<u>001</u>	Apr 11, 2014
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>		<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>20%</u>	<u>A083158</u>	<u>003</u>	
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>	LUITPOLD	<u>1%</u>	<u>A080850</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>400MG/100ML</u>	<u>N018388</u>	<u>002</u>	
-----------	---------	--------------------	----------------	------------	--

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>800MG/100ML</u>	<u>N018388</u>	<u>003</u>	Nov 05, 1982
-----------	---------	--------------------	----------------	------------	--------------

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	AGILA SPECLTS	<u>2%</u>	<u>A090665</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	AUROBINDO PHARMA LTD	<u>1%</u>	<u>A203040</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-219 (of 371)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP		2%	A080404	003	
AP		2%	N017584	001	
AP		4%	N017584	002	
AP	HOSPIRA	1%	A080408	001	
AP		1.5%	A080408	002	
AP		4%	A088295	001	May 17, 1984
AP	INTL MEDICATION	20%	N017702	001	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	HOSPIRA	1%	A040302	001	Sep 28, 1998
AP		2%	A040302	002	Sep 28, 1998

XYLOCAINE

AP	+ FRESENIUS KABI USA	0.5%	N006488	008	
AP	+	1%	N006488	007	
AP	+	1.5%	N006488	010	
AP	+	2%	N006488	002	

XYLOCAINE 4% PRESERVATIVE FREE

AP	+ FRESENIUS KABI USA	4%	N010417	001	
----	----------------------	----	---------	-----	--

XYLOCAINE PRESERVATIVE FREE

AP	+ FRESENIUS KABI USA	1%	N016801	005	Jan 19, 1988
AP	+	2%	N016801	001	
AP	+	4%	N016801	002	
AP	+	20%	N016801	004	

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

+	HOSPIRA	5%	A083914	001	
---	---------	----	---------	-----	--

JELLY; TOPICAL

GLYDO

AT	SAGENT PHARMS	2%	A201094	001	Apr 28, 2014
----	---------------	----	---------	-----	--------------

LIDOCAINE HYDROCHLORIDE

AT	AKORN	2%	A040433	001	Feb 12, 2003
AT	INTL MEDICATION	2%	A086283	001	
AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011

XYLOCAINE

AT	+ OAK PHARMS	2%	N008816	001	
----	--------------	----	---------	-----	--

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040014	001	Jul 10, 1995
AT	WOCKHARDT	2%	A087872	001	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

AT	VINTAGE	2%	A040708	001	Feb 27, 2007
----	---------	----	---------	-----	--------------

LIDOCAINE VISCOUS

AT	ROXANE	2%	A088802	001	Apr 26, 1985
----	--------	----	---------	-----	--------------

XYLOCAINE VISCOUS

AT	+ FRESENIUS KABI USA	2%	N009470	001	
----	----------------------	----	---------	-----	--

SOLUTION; TOPICAL

LARYNG-O-JET KIT

AT	INTL MEDICATION	4%	A086364	001	
----	-----------------	----	---------	-----	--

LIDOCAINE HYDROCHLORIDE

AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014
AT	ROXANE	4%	A088803	001	Apr 03, 1985
AT	VINTAGE	4%	A040710	001	Feb 27, 2007
AT	WOCKHARDT	4%	A087881	001	Nov 18, 1982

LTA II KIT

AT	HOSPIRA	4%	A080409	001	
----	---------	----	---------	-----	--

XYLOCAINE 4% PRESERVATIVE FREE

AT	+ FRESENIUS KABI USA	4%	N010417	002	
----	----------------------	----	---------	-----	--

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007
---------------	-------	---------	-----	--------------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB	+ WATSON LABS INC	2.5%; 2.5%	N019941	001	Dec 30, 1992
----	-------------------	------------	---------	-----	--------------

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%; 2.5%	A076453	001	Aug 18, 2003
AB	HI TECH PHARMA	2.5%; 2.5%	A076290	001	Sep 25, 2003
AB	TOLMAR	2.5%; 2.5%	A076320	001	Aug 27, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-220 (of 371)

LIDOCAINE; PRILOCAINE

GEL; PERIODONTAL

ORAQIX

+ DENTSPLY PHARM 2.5%; 2.5%

N021451 001 Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP 7%; 7%

N021717 001 Jun 29, 2006

PATCH; TOPICAL

SYNERA

+ GALEN SPECIALTY 70MG; 70MG

N021623 001 Jun 23, 2005

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS INC 145MCG

N202811 001 Aug 30, 2012

+ 290MCG

N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+ BOEHRINGER INGELHEIM 5MG

N201280 001 May 02, 2011

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

+ BOEHRINGER INGELHEIM 2.5MG; 1GM

N201281 003 Jan 30, 2012

2.5MG; 500MG

N201281 001 Jan 30, 2012

2.5MG; 850MG

N201281 002 Jan 30, 2012

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

+ PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

LINDANE

LOTION; TOPICAL

LINDANEAT OLTA PHARMS 1%A087313 001AT + WOCKHARDT 1%A088190 001 Aug 16, 1984

SHAMPOO; TOPICAL

LINDANEAT OLTA PHARMS 1%A087266 001AT + WOCKHARDT 1%A088191 001 Sep 18, 1984LINEZOLID

FOR SUSPENSION; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN 100MG/5ML

N021132 001 Apr 18, 2000

INJECTABLE; INJECTION

LINEZOLIDAP TEVA PHARMS 200MG/100MLA200222 001 Jun 27, 2012ZYVOXAP + PHARMACIA AND UPJOHN 200MG/100MLN021131 001 Apr 18, 2000

TABLET; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN 600MG

N021130 002 Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUMAP X GEN PHARMS EQ 0.01MG BASE/MLA076923 001 Aug 17, 2005TRIOSTATAP + PAR STERILE PRODUCTS EQ 0.01MG BASE/MLN020105 001 Dec 31, 1991

TABLET; ORAL

CYTOMELAB KING PHARMS R AND D EQ 0.005MG BASEN010379 001AB EQ 0.025MG BASEN010379 002AB + EQ 0.05MG BASEN010379 003LIOTHYRONINE SODIUMAB COASTAL PHARMS EQ 0.005MG BASEA090097 001 Mar 20, 2009AB EQ 0.025MG BASEA090097 002 Mar 20, 2009AB EQ 0.05MG BASEA090097 003 Mar 20, 2009AB MYLAN EQ 0.005MG BASEA090326 001 Jul 14, 2009AB EQ 0.025MG BASEA090326 002 Jul 14, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-221 (of 371)

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A090326</u>	<u>003</u>	Jul 14, 2009
<u>AB</u>	SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295</u>	<u>001</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.025MG BASE</u>	<u>A200295</u>	<u>002</u>	Nov 29, 2012
<u>AB</u>		<u>EQ 0.05MG BASE</u>	<u>A200295</u>	<u>003</u>	Nov 29, 2012

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

FOREST LABS

0.0031MG; 0.0125MG

N016807 001

THYROLAR-0.5

FOREST LABS

0.0063MG; 0.025MG

N016807 005

THYROLAR-1

FOREST LABS

0.0125MG; 0.05MG

N016807 004

THYROLAR-2

FOREST LABS

0.025MG; 0.1MG

N016807 002

THYROLAR-3

+ FOREST LABS

0.0375MG; 0.15MG

N016807 003

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

+ NOVO NORDISK INC

18MG/3ML (6MG/ML)

N206321 001 Dec 23, 2014

VICTOZA

+ NOVO NORDISK INC

18MG/3ML (6MG/ML)

N022341 001 Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

SHIRE DEVELOPMENT

10MG

N021977 007 Oct 30, 2014

20MG

N021977 004 Dec 10, 2007

30MG

N021977 001 Feb 23, 2007

40MG

N021977 005 Dec 10, 2007

50MG

N021977 002 Feb 23, 2007

60MG

N021977 006 Dec 10, 2007

+

70MG

N021977 003 Feb 23, 2007

LISINAPRIL

TABLET; ORAL

LISINAPRIL

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554</u>	<u>001</u>	Jul 30, 2013
<u>AB</u>		<u>5MG</u>	<u>A202554</u>	<u>002</u>	Jul 30, 2013
<u>AB</u>		<u>10MG</u>	<u>A202554</u>	<u>003</u>	Jul 30, 2013
<u>AB</u>		<u>20MG</u>	<u>A202554</u>	<u>004</u>	Jul 30, 2013
<u>AB</u>		<u>30MG</u>	<u>A202554</u>	<u>005</u>	Jul 30, 2013
<u>AB</u>		<u>40MG</u>	<u>A202554</u>	<u>006</u>	Jul 30, 2013
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A076102</u>	<u>001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102</u>	<u>002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102</u>	<u>003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102</u>	<u>004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102</u>	<u>005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102</u>	<u>006</u>	Sep 30, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622</u>	<u>001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622</u>	<u>002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622</u>	<u>003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622</u>	<u>004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622</u>	<u>005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622</u>	<u>006</u>	Feb 22, 2006
<u>AB</u>	HIKMA INTL PHARMS	<u>2.5MG</u>	<u>A076063</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076063</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076063</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076063</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076063</u>	<u>006</u>	Jun 27, 2003
<u>AB</u>		<u>40MG</u>	<u>A076063</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508</u>	<u>003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508</u>	<u>004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508</u>	<u>005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508</u>	<u>006</u>	Oct 29, 2013
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>2.5MG</u>	<u>A075752</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075752</u>	<u>002</u>	Jul 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-222 (of 371)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>10MG</u>	<u>A075752</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075752</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075752</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075752</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321</u>	<u>006</u>	Sep 09, 2005
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076071</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076071</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076071</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076071</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076071</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076071</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A076180</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076180</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076180</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	RANBAXY	<u>2.5MG</u>	<u>A075944</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944</u>	<u>006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	VINTAGE	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
<u>PRINIVIL</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019558</u>	<u>001</u>	Dec 29, 1987
<u>AB</u>		<u>10MG</u>	<u>N019558</u>	<u>002</u>	Dec 29, 1987
<u>AB</u>		<u>20MG</u>	<u>N019558</u>	<u>003</u>	Dec 29, 1987
<u>AB</u>		<u>40MG</u>	<u>N019558</u>	<u>004</u>	Oct 25, 1988
<u>ZESTRIL</u>					
<u>AB</u>	ASTRAZENECA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+	<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-223 (of 371)

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

AB	ALEMBIC LTD	150MG	A079159 001	Jan 12, 2009
AB		300MG	A079159 002	Jan 12, 2009
AB		600MG	A079159 003	Jan 12, 2009
AB	GLENMARK GENERICS	150MG	A079139 001	Feb 03, 2009
AB		300MG	A079139 002	Feb 03, 2009
AB		600MG	A079139 003	Feb 03, 2009
AB	HETERO LABS LTD III	150MG	A090702 001	Sep 25, 2009
AB		300MG	A090702 002	Sep 25, 2009
AB		600MG	A090702 003	Sep 25, 2009
AB	HIKMA INTL PHARMS	150MG	A076243 002	Feb 24, 2003
AB		300MG	A076243 001	Jun 27, 2002
AB	ROXANE	150MG	N017812 002	Jan 28, 1987
AB		300MG	N017812 001	
AB	+	600MG	N017812 003	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

AB	+	ROXANE	300MG	N018558 001	Jan 29, 1982
AB		SUN PHARM INDS INC	300MG	A091027 001	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	300MG	A091544 001	Dec 27, 2010
AB		450MG	A091616 001	Feb 14, 2011
AB	HIKMA INTL PHARMS	450MG	A076490 001	Jun 17, 2003
AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012
AB		450MG	A202219 001	Aug 08, 2012
AB	ROXANE	300MG	A076832 001	Oct 28, 2004
AB	+	450MG	A076691 001	Jan 05, 2004

LITHOBID

AB	+	ANI PHARMS INC	300MG	N018027 001	
-----------	---	----------------	--------------	--------------------	--

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

AA	+	ROXANE	EQ 300MG CARBONATE/5ML	N018421 001	
AA		WOCKHARDT	EQ 300MG CARBONATE/5ML	A070755 001	May 21, 1986

LODOXAMIDE TROMETHAMINESOLUTION/DROPS; OPHTHALMIC
ALOMIDE

+	ALCON	EQ 0.1% BASE	N020191 001	Sep 23, 1993
---	-------	--------------	--------------------	--------------

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

	AEGERION	EQ 5MG BASE	N203858 001	Dec 21, 2012
		EQ 10MG BASE	N203858 002	Dec 21, 2012
+		EQ 20MG BASE	N203858 003	Dec 21, 2012

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

	CORDEN PHARMA	10MG	N017588 001	
		40MG	N017588 002	
+		100MG	N017588 003	

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

IMODIUM

AB	+	MCNEIL CONS	2MG	N017694 001	
-----------	---	-------------	------------	--------------------	--

LOPERAMIDE HYDROCHLORIDE

AB	MYLAN	2MG	A072741 001	Sep 18, 1991
AB	TEVA	2MG	A073192 001	Apr 30, 1992

LOPINAVIR; RITONAVIR

CAPSULE; ORAL

KALETRA

+	ABBVIE	133.3MG; 33.3MG	N021226 001	Sep 15, 2000
---	--------	-----------------	--------------------	--------------

SOLUTION; ORAL

KALETRA

+	ABBVIE	80MG/ML; 20MG/ML	N021251 001	Sep 15, 2000
---	--------	------------------	--------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-224 (of 371)

LOPINAVIR; RITONAVIR

TABLET; ORAL

KALETRA

ABBVIE

100MG; 25MG

N021906 002 Nov 09, 2007

+

200MG; 50MG

N021906 001 Oct 28, 2005

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAMAA AMNEAL PHARMS2MG/MLA091383 001 Dec 23, 2009AA HI-TECH PHARMA CO2MG/MLA200169 001 Jan 30, 2012AA LUPIN LTD2MG/MLA091407 001 Feb 19, 2013AA PADDOCK LLC2MG/MLA079244 001 Apr 28, 2009AA PHARM ASSOC2MG/MLA090260 001 Jun 15, 2010LORAZEPAM INTENSOLAA + ROXANE2MG/MLA072755 001 Jun 28, 1991

INJECTABLE; INJECTION

ATIVANAP + HIKMA MAPLE2MG/MLN018140 001AP +4MG/MLN018140 002LORAZEPAMAP AKORN2MG/MLA075025 001 Jul 23, 1998AP HOSPIRA2MG/MLA074243 001 Apr 12, 1994AP2MG/MLA074282 001 May 27, 1994AP4MG/MLA074243 002 Apr 12, 1994AP4MG/MLA074282 002 May 27, 1994AP INTL MEDICATION SYS2MG/MLA076150 001 Nov 15, 2004LORAZEPAM PRESERVATIVE FREEAP BEDFORD LABS2MG/MLA077074 001 Jul 13, 2005AP4MG/MLA077074 002 Jul 13, 2005

TABLET; ORAL

ATIVANAB VALEANT INTL0.5MGN017794 001AB1MGN017794 002AB +2MGN017794 003LORAZEPAMAB AMNEAL PHARMS0.5MGA078826 001 Jun 23, 2010AB1MGA078826 002 Jun 23, 2010AB2MGA078826 003 Jun 23, 2010AB EXCELLIUM0.5MGA078203 001 Jul 30, 2007AB1MGA078203 002 Jul 30, 2007AB2MGA078203 003 Jul 30, 2007AB IVAX SUB TEVA PHARMS0.5MGA077396 001 Dec 13, 2006AB1MGA077396 002 Dec 13, 2006AB2MGA077396 003 Dec 13, 2006AB MYLAN0.5MGA071589 001 Oct 13, 1987AB0.5MGA077657 001 Mar 16, 2006AB1MGA071590 001 Oct 13, 1987AB1MGA077657 002 Mar 16, 2006AB2MGA071591 001 Oct 13, 1987AB2MGA077657 003 Mar 16, 2006AB RANBAXY0.5MGA076045 001 Aug 29, 2001AB1MGA076045 002 Aug 29, 2001AB2MGA076045 003 Aug 29, 2001AB SANDOZ0.5MGA071403 001 Apr 21, 1987AB1MGA071404 001 Apr 21, 1987AB2MGA071141 001 Apr 21, 1987AB VINTAGE PHARMS0.5MGA077754 001 May 10, 2006AB1MGA077754 002 May 10, 2006AB2MGA077754 003 May 10, 2006AB WATSON LABS0.5MGA072926 001 Oct 31, 1991AB1MGA072927 001 Oct 31, 1991AB2MGA072928 001 Oct 31, 1991LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+ EISAI INC

10MG

N022529 001 Jun 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-225 (of 371)

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

<u>AB</u>	MERCK SHARP DOHME	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	APOTEX CORP	<u>25MG</u>	<u>A090790</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090790</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090790</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	CADISTA PHARMS	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>		<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>		<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>		<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>		<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>	MICRO LABS LTD INDIA	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>		<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A091590</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A091590</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A091590</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>		<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>		<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>	ROXANE	<u>25MG</u>	<u>A077459</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077459</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077459</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076958</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A076958</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A076958</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A090467</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090467</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090467</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A090544</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090544</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090544</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	VIVIMED LABS	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>		<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB INC 0.5%

N202872 001 Sep 28, 2012

OINTMENT;OPHTHALMIC

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N200738 001 Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

ALREX

+ BAUSCH AND LOMB 0.2%

N020803 001 Mar 09, 1998

LOTEMAX

+ BAUSCH AND LOMB 0.5%

N020583 001 Mar 09, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-226 (of 371)

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

+ BAUSCH AND LOMB 0.5%;0.3%

N050804 001 Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB	ACTAVIS ELIZABETH	10MG	A075828 001	Dec 17, 2001
AB		20MG	A075828 002	Dec 17, 2001
AB		40MG	A075828 003	Dec 17, 2001
AB	APOTEX INC	10MG	A077748 001	Feb 28, 2007
AB		20MG	A077748 002	Feb 28, 2007
AB		40MG	A077748 003	Feb 28, 2007
AB	CARLSBAD	10MG	A075991 001	Jun 05, 2002
AB		20MG	A075991 002	Jun 05, 2002
AB	+	40MG	A075991 003	Jun 05, 2002
AB	LUPIN	10MG	A078296 001	Mar 14, 2008
AB		20MG	A078296 002	Nov 01, 2007
AB		40MG	A078296 003	Nov 01, 2007
AB	MUTUAL PHARM	10MG	A077520 001	Apr 14, 2006
AB		20MG	A077520 002	Apr 14, 2006
AB		40MG	A077520 003	Apr 14, 2006
AB	MYLAN	10MG	A075451 001	Dec 17, 2001
AB		10MG	A075935 001	Dec 17, 2001
AB		20MG	A075451 002	Dec 17, 2001
AB		20MG	A075935 002	Dec 17, 2001
AB		40MG	A075451 003	Dec 17, 2001
AB		40MG	A075935 003	Dec 17, 2001
AB	SANDOZ	10MG	A075300 001	Dec 17, 2001
AB		10MG	A075636 001	Dec 17, 2001
AB		20MG	A075300 002	Dec 17, 2001
AB		20MG	A075636 002	Dec 17, 2001
AB		40MG	A075300 003	Dec 17, 2001
AB		40MG	A075636 003	Dec 17, 2001
AB	TEVA	10MG	A075551 003	Dec 17, 2001
AB		20MG	A075551 002	Dec 17, 2001
AB		40MG	A075551 001	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

ANDRX LABS LLC 20MG

N021316 002 Jun 26, 2002

40MG

N021316 003 Jun 26, 2002

+ 60MG

N021316 004 Jun 26, 2002

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE;ORAL

ADVICOR

+ ABBVIE 20MG;1GM

N021249 003 Dec 17, 2001

+ 20MG;500MG

N021249 001 Dec 17, 2001

+ 20MG;750MG

N021249 002 Dec 17, 2001

+ 40MG;1GM

N021249 004 Apr 27, 2006

LOXAPINE

POWDER;INHALATION

ADASUVE

+ TEVA PHARMS USA INC 10MG

N022549 001 Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	LANNETT HOLDINGS INC	EQ 5MG BASE	A090695 001	Sep 26, 2011
AB		EQ 10MG BASE	A090695 002	Sep 26, 2011
AB		EQ 25MG BASE	A090695 003	Sep 26, 2011
AB		EQ 50MG BASE	A090695 004	Sep 26, 2011
AB	MIKAH PHARMA	EQ 5MG BASE	A076868 001	Aug 04, 2005
AB		EQ 10MG BASE	A076868 002	Aug 04, 2005
AB		EQ 25MG BASE	A076868 003	Aug 04, 2005
AB		EQ 50MG BASE	A076868 004	Aug 04, 2005
AB	MYLAN	EQ 5MG BASE	A076762 001	Nov 01, 2004
AB		EQ 10MG BASE	A076762 002	Nov 01, 2004
AB		EQ 25MG BASE	A076762 003	Nov 01, 2004
AB		EQ 50MG BASE	A076762 004	Nov 01, 2004
AB	WATSON LABS	EQ 5MG BASE	A072204 001	Jun 15, 1988
AB		EQ 10MG BASE	A072205 001	Jun 15, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-227 (of 371)

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	+	EQ 25MG BASE	A072206 001	Jun 15, 1988
AB		EQ 50MG BASE	A072062 001	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

SUCAMPO PHARMA LLC

8MCG

N021908 002 Apr 29, 2008

+

24MCG

N021908 001 Jan 31, 2006

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

+ DISCOVERY LABS

8.5ML

N021746 001 Mar 06, 2012

LULICONAZOLE

CREAM; TOPICAL

LUZU

+ MEDICIS

1%

N204153 001 Nov 14, 2013

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

SUNOVION PHARMS INC

20MG

N200603 003 Dec 07, 2011

+

40MG

N200603 001 Oct 28, 2010

60MG

N200603 005 Jul 12, 2013

80MG

N200603 002 Oct 28, 2010

120MG

N200603 004 Apr 26, 2012

MACITENTAN

TABLET; ORAL

OPSUMIT

+ ACTELION PHARMS LTD

10MG

N204410 001 Oct 18, 2013

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+ MYLAN INSTITUTIONAL

EQ 85MG BASE/GM

N016763 001

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

AT	PAR FORM	5%	A201511 001	Feb 12, 2013
-----------	----------	-----------	--------------------	--------------

SULFAMYLON

AT	+	MYLAN INSTITUTIONAL	5%	N019832 003	Jun 05, 1998
-----------	---	---------------------	-----------	--------------------	--------------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE

32MG/100ML; 128MG/100ML; 234MG/100ML

N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+ B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019696 001 Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378 001	
-----------	-----------------	--	--------------------	--

PLASMA-LYTE A IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378 002	Nov 22, 1982
-----------	-----------------	--	--------------------	--------------

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N019711 001 Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017586 001

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML

N019024 001 Jun 08, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-228 (of 371)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG
/100ML; 502MG/100ML

N017637 002 Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+ DIALYSIS SUPS

0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML

N021910 001 Jul 26, 2006

NORMOCARB HF 35

+ DIALYSIS SUPS

0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML

N021910 002 Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATEAP EXELA PHARMA SCS LLC500MG/MLA206039 001 Dec 18, 2014AP + FRESENIUS KABI USA500MG/MLN019316 001 Sep 08, 1986AP + HOSPIRA500MG/MLA075151 001 Apr 25, 2000

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ HOSPIRA

1GM/100ML

N020488 001 Jul 11, 1995

+

2GM/100ML

N020488 002 Jul 11, 1995

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA

2GM/50ML (40MG/ML)

N020309 003 Jan 26, 2007

+

4GM/100ML (40MG/ML)

N020309 001 Jun 24, 1994

+

4GM/50ML (80MG/ML)

N020309 002 Jun 24, 1994

20GM/500ML (40MG/ML)

N020309 004 Jan 18, 1995

40GM/1000ML (40MG/ML)

N020309 005 Jan 18, 1995

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL

SUPREP BOWEL PREP KIT

+ BRAINTREE LABS

1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT

N022372 001 Aug 05, 2010

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+ BRAINTREE LABS

1.6GM; 210GM; 0.74GM; 3.13GM; 2.86GM; 5.6GM;
17.5GM

N203595 001 Jan 18, 2013

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

TIS-U-SOLAT BAXTER HLTHCARE20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100MLN018508 001 Feb 19, 1982TIS-U-SOL IN PLASTIC CONTAINERAT BAXTER HLTHCARE20MG/100ML; 40MG/100ML; 6.25MG/100ML; 800MG/100ML; 8.75MG/100MLN018336 001MALATHION

LOTION; TOPICAL

MALATHIONAT SUVEN LIFE0.5%A091559 001 May 23, 2012OVIDEAT + TARO PHARMS NORTH0.5%N018613 001 Aug 02, 1982MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.1MG MANGANESE/ML

N018962 001 Jun 26, 1986

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%AP B BRAUN10GM/100MLN016080 002MANNITOL 10% IN PLASTIC CONTAINERAP B BRAUN10GM/100MLN020006 002 Jul 26, 1993AP HOSPIRA10GM/100MLN019603 002 Jan 08, 1987MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATERAP B BRAUN10GM/100MLN016080 006MANNITOL 15%AP B BRAUN15GM/100MLN016080 003MANNITOL 15% IN PLASTIC CONTAINERAP B BRAUN15GM/100MLN020006 003 Jul 26, 1993AP HOSPIRA15GM/100MLN019603 003 Jan 08, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-229 (of 371)

MANNITOL

INJECTABLE; INJECTION

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

AP	B BRAUN	15GM/100ML	N016080	005	
	<u>MANNITOL 20%</u>				
AP	B BRAUN	20GM/100ML	N016080	004	
	<u>MANNITOL 20% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	20GM/100ML	N020006	004	Jul 26, 1993
AP	HOSPIRA	20GM/100ML	N019603	004	Jan 08, 1990
	<u>MANNITOL 25%</u>				
AP	FRESENIUS KABI USA	12.5GM/50ML	A080677	001	
AP	HOSPIRA	12.5GM/50ML	N016269	006	Aug 25, 1994
AP	INTL MEDICATION	12.5GM/50ML	A083051	001	
AP	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982
	<u>MANNITOL 5%</u>				
AP	B BRAUN	5GM/100ML	N016080	001	
	<u>MANNITOL 5% IN PLASTIC CONTAINER</u>				
AP	B BRAUN	5GM/100ML	N020006	001	Jul 26, 1993
AP	HOSPIRA	5GM/100ML	N019603	001	Jan 08, 1987
	<u>MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%</u>				
AP	B BRAUN	5GM/100ML	N016080	007	
	<u>OSMITROL 10% IN WATER</u>				
AP	BAXTER HLTHCARE	10GM/100ML	N013684	002	
	<u>OSMITROL 10% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	10GM/100ML	N013684	006	
	<u>OSMITROL 15% IN WATER</u>				
AP	BAXTER HLTHCARE	15GM/100ML	N013684	004	
	<u>OSMITROL 15% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	15GM/100ML	N013684	008	
	<u>OSMITROL 20% IN WATER</u>				
AP	BAXTER HLTHCARE	20GM/100ML	N013684	003	
	<u>OSMITROL 20% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	20GM/100ML	N013684	007	
	<u>OSMITROL 5% IN WATER</u>				
AP	BAXTER HLTHCARE	5GM/100ML	N013684	001	
	<u>OSMITROL 5% IN WATER IN PLASTIC CONTAINER</u>				
AP	BAXTER HLTHCARE	5GM/100ML	N013684	005	

SOLUTION; IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

B BRAUN	5GM/100ML	N016772	002	
---------	-----------	---------	-----	--

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N018316	001	
---------	--------------------------	---------	-----	--

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

MAPROTILINE HYDROCHLORIDE

MYLAN	25MG	A072285	002	Oct 03, 1988
+	50MG	A072285	001	Oct 03, 1988
	75MG	A072285	003	Oct 03, 1988

MARAVIROC

TABLET; ORAL

SELZENTRY

VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007
+	300MG	N022128	002	Aug 06, 2007

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

MEBENDAZOLE

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995
---	-------------------	-------	---------	-----	--------------

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

NEXGEN PHARMA	2.5MG	A204054	001	Mar 19, 2013
---------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-230 (of 371)

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+ IPSEN INC

40MG/4ML (10MG/ML)

N021839 001 Aug 30, 2005

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+ ACTELION PHARMS LTD

EQ 0.016% BASE

N202317 001 Aug 23, 2013

INJECTABLE; INJECTION

MUSTARGEN

+ RECORDATI RARE

10MG/VIAL

N006695 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>12.5MG</u>	<u>A201451</u>	<u>001</u>	Feb 23, 2011
<u>AA</u>		<u>25MG</u>	<u>A201451</u>	<u>002</u>	Feb 23, 2011
<u>AA</u>	EPIC PHARMA LLC	<u>12.5MG</u>	<u>A200294</u>	<u>001</u>	Apr 13, 2012
<u>AA</u>		<u>25MG</u>	<u>A200294</u>	<u>002</u>	Apr 13, 2012
<u>AA</u>	JUBILANT CADISTA	<u>12.5MG</u>	<u>A040659</u>	<u>001</u>	Jun 04, 2010
<u>AA</u>		<u>25MG</u>	<u>A040659</u>	<u>002</u>	Jun 04, 2010
<u>AA</u>	MYLAN PHARMS INC	<u>12.5MG</u>	<u>A202640</u>	<u>001</u>	Sep 17, 2012
<u>AA</u>		<u>25MG</u>	<u>A202640</u>	<u>002</u>	Sep 17, 2012
<u>AA</u>	PAR PHARM	<u>12.5MG</u>	<u>A087127</u>	<u>001</u>	
<u>AA</u>		<u>25MG</u>	<u>A087128</u>	<u>001</u>	
<u>AA</u>	SANDOZ	<u>12.5MG</u>	<u>A084843</u>	<u>002</u>	May 22, 1989
<u>AA</u>		<u>25MG</u>	<u>A084092</u>	<u>003</u>	May 22, 1989
<u>AA</u>	VINTAGE PHARMS	<u>12.5MG</u>	<u>A040179</u>	<u>001</u>	Jan 30, 1997
<u>AA</u>		<u>25MG</u>	<u>A040179</u>	<u>002</u>	Jan 30, 1997

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

+

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

<u>AB</u>	+ PHARMACIA AND UPJOHN	<u>150MG/ML</u>	<u>N020246</u>	<u>001</u>	Oct 29, 1992
	<u>MEDROXYPROGESTERONE ACETATE</u>				
<u>AB</u>	SANDOZ	<u>150MG/ML</u>	<u>A078711</u>	<u>001</u>	May 20, 2009
<u>AB</u>	TEVA PHARMS USA	<u>150MG/ML</u>	<u>A076553</u>	<u>001</u>	Jul 28, 2004
	DEPO-PROVERA				
	+ PHARMACIA AND UPJOHN	400MG/ML			N012541 003
	INJECTABLE; SUBCUTANEOUS				
	DEPO-SUBQ PROVERA 104				
	+ PHARMACIA AND UPJOHN	104MG/0.65ML			N021583 001 Dec 17, 2004
	TABLET; ORAL				
	<u>MEDROXYPROGESTERONE ACETATE</u>				
<u>AB</u>	BARR	<u>2.5MG</u>	<u>A040159</u>	<u>001</u>	Aug 09, 1996
<u>AB</u>		<u>5MG</u>	<u>A040159</u>	<u>002</u>	Aug 09, 1996
<u>AB</u>		<u>10MG</u>	<u>A040159</u>	<u>003</u>	Aug 09, 1996
	<u>PROVERA</u>				
<u>AB</u>	PHARMACIA AND UPJOHN	<u>2.5MG</u>	<u>N011839</u>	<u>001</u>	
<u>AB</u>		<u>5MG</u>	<u>N011839</u>	<u>003</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N011839</u>	<u>004</u>	

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

<u>AB</u>	BRECKENRIDGE PHARM	<u>250MG</u>	<u>A090359</u>	<u>001</u>	Feb 05, 2013
<u>AB</u>	LUPIN LTD	<u>250MG</u>	<u>A091322</u>	<u>001</u>	Jul 22, 2011
<u>AB</u>	MICRO LABS LTD	<u>250MG</u>	<u>A090562</u>	<u>001</u>	Nov 19, 2010
<u>AB</u>	VINTAGE PHARMS LLC	<u>250MG</u>	<u>A091608</u>	<u>001</u>	Jun 02, 2014
	<u>PONSTEL</u>				
<u>AB</u>	+ SHIONOGI INC	<u>250MG</u>	<u>N015034</u>	<u>003</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-231 (of 371)

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

<u>AB</u>	BARR	<u>250MG</u>	<u>A076392</u>	<u>001</u>	Dec 29, 2003
<u>AB</u>	ROXANE	<u>250MG</u>	<u>A076523</u>	<u>001</u>	Oct 01, 2004
<u>AB</u>	+ SANDOZ	<u>250MG</u>	<u>A076175</u>	<u>001</u>	Feb 20, 2002

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>40MG/ML</u>	<u>N020264</u>	<u>001</u>	Sep 10, 1993
-----------	------------------------	----------------	----------------	------------	--------------

MEGACE ES

<u>AB</u>	+ PAR PHARM	<u>125MG/ML</u>	<u>N021778</u>	<u>001</u>	Jul 05, 2005
-----------	-------------	-----------------	----------------	------------	--------------

MEGESTROL ACETATE

<u>AB</u>	PAR PHARM	<u>40MG/ML</u>	<u>A075671</u>	<u>001</u>	Jul 25, 2001
<u>AB</u>	ROXANE	<u>40MG/ML</u>	<u>A075997</u>	<u>001</u>	Feb 15, 2002
<u>AB</u>	TEVA PHARMS	<u>40MG/ML</u>	<u>A075681</u>	<u>001</u>	May 05, 2003
<u>AB</u>	TWI PHARMS INC	<u>125MG/ML</u>	<u>A203139</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>	WOCKHARDT	<u>40MG/ML</u>	<u>A076721</u>	<u>001</u>	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

<u>AB</u>	BARR	<u>20MG</u>	<u>A074621</u>	<u>002</u>	Aug 16, 1996
<u>AB</u>		<u>40MG</u>	<u>A074621</u>	<u>001</u>	Nov 30, 1995
<u>AB</u>	PAR PHARM	<u>20MG</u>	<u>A072422</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	+	<u>40MG</u>	<u>A072423</u>	<u>001</u>	Aug 08, 1988
<u>AB</u>	ROXANE	<u>20MG</u>	<u>A074458</u>	<u>001</u>	Sep 29, 1995
<u>AB</u>		<u>40MG</u>	<u>A074458</u>	<u>002</u>	Sep 29, 1995

MELOXICAM

SUSPENSION; ORAL

MOBIC

	+ BOEHRINGER INGELHEIM	7.5MG/5ML	N021530	001	Jun 01, 2004
--	------------------------	-----------	---------	-----	--------------

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	BRECKENRIDGE PHARM	<u>7.5MG</u>	<u>A077920</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077920</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	CARLSBAD	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	CIPLA LTD	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	MYLAN	<u>7.5MG</u>	<u>A077923</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077923</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A077937</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077937</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	TEVA PHARMS	<u>7.5MG</u>	<u>A077936</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077936</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	BOEHRINGER INGELHEIM	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
<u>AB</u>	+	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-232 (of 371)

MELPHALAN

TABLET; ORAL

ALKERAN

+ GLAXOSMITHKLINE

2MG

N014691 002

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERANAP + GLAXOSMITHKLINEEQ 50MG BASE/VIALN020207 001 Nov 18, 1992MELPHALAN HYDROCHLORIDEAP EUROHLTH INTLEQ 50MG BASE/VIALA090303 001 Oct 28, 2010AP MYLAN INSTITUTIONALEQ 50MG BASE/VIALA090270 001 Jun 09, 2009MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMENDA XR

FOREST LABS

7MG

N022525 001 Jun 21, 2010

14MG

N022525 002 Jun 21, 2010

21MG

N022525 003 Jun 21, 2010

28MG

N022525 004 Jun 21, 2010

+

SOLUTION; ORAL

NAMENDA

+ FOREST LABS

2MG/ML

N021627 001 Apr 18, 2005

TABLET; ORAL

NAMENDAAB FOREST LABS5MGN021487 001 Oct 16, 2003AB +10MGN021487 002 Oct 16, 2003MENOTROPINS (FSH; LH)

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

+ FERRING

75 IU/VIAL; 75 IU/VIAL

N021047 001 Aug 27, 1999

INJECTABLE; SUBCUTANEOUS

MENOPUR

+ FERRING

75 IU/VIAL; 75 IU/VIAL

N021663 001 Oct 29, 2004

MEPENZOLATE BROMIDE

TABLET; ORAL

CANTIL

+ SANOFI AVENTIS US

25MG

N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROLAP + HOSPIRA25MG/MLN021171 001AP +50MG/MLN021171 002AP +75MG/MLN021171 003AP +100MG/MLN021171 004MEPERIDINE HYDROCHLORIDEAP HIKMA MAPLE25MG/MLA080445 001AP25MG/MLA080455 007AP50MG/MLA080445 002AP50MG/MLA080455 008AP75MG/MLA080445 003AP75MG/MLA080455 009AP100MG/MLA080445 004AP100MG/MLA080455 010MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREEAP HIKMA MAPLE10MG/MLA081002 001 Jul 30, 1993AP + HOSPIRA10MG/MLA088432 001 Aug 16, 1984

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

+ ROXANE

50MG/5ML

A088744 001 Jan 30, 1985

TABLET; ORAL

DEMEROLAA + SANOFI AVENTIS US50MGN005010 001AA +100MGN005010 004MEPERIDINE HYDROCHLORIDEAA BARR50MGA088639 001 Jul 02, 1984AA100MGA088640 001 Sep 19, 1984AA

EPIC PHARMA

50MGA040331 001 May 28, 1999AA100MGA040331 002 May 28, 1999AA

MALLINCKRODT

50MGA040352 001 Jun 13, 2000AA100MGA040352 002 Jun 13, 2000AA

MIKART

50MGA040893 001 Jun 24, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-233 (of 371)

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

<u>AA</u>		<u>100MG</u>	<u>A040893</u>	<u>003</u>	Jun 24, 2009
<u>AA</u>	ROXANE	<u>50MG</u>	<u>A040110</u>	<u>001</u>	Mar 12, 1997
<u>AA</u>		<u>100MG</u>	<u>A040110</u>	<u>002</u>	Mar 12, 1997
<u>AA</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A040446</u>	<u>001</u>	Aug 08, 2002
<u>AA</u>		<u>100MG</u>	<u>A040446</u>	<u>002</u>	Aug 08, 2002
<u>AA</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040191</u>	<u>001</u>	Dec 17, 1998
<u>AA</u>		<u>100MG</u>	<u>A040191</u>	<u>002</u>	Dec 17, 1998
	MIKART	75MG	A040893	002	Jun 24, 2009
		150MG	A040893	004	Jun 24, 2009

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+	HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>
<u>AP</u>	+		<u>1.5%</u>	<u>N012250</u>	<u>005</u>
<u>AP</u>	+		<u>2%</u>	<u>N012250</u>	<u>002</u>

ISOCAINE HYDROCHLORIDE

<u>AP</u>	+	NOVOCOL	<u>3%</u>	<u>A080925</u>	<u>001</u>
-----------	---	---------	-----------	----------------	------------

MEPIVACAINE HYDROCHLORIDE

<u>AP</u>		HOSPIRA INC	<u>3%</u>	<u>A040806</u>	<u>001</u>	Apr 28, 2008
-----------	--	-------------	-----------	----------------	------------	--------------

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	+	DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984
-----------	---	---------	-----------	----------------	------------	--------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>		ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>			<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008
<u>AA</u>	+	WATSON LABS	<u>200MG</u>	<u>A083304</u>	<u>001</u>	
<u>AA</u>	+		<u>400MG</u>	<u>A083308</u>	<u>001</u>	

MERCAPTOPURINE

SUSPENSION; ORAL

PURIXAN

	+	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014
--	---	---------------	---------	---------	-----	--------------

TABLET; ORAL

MERCAPTOPURINE

<u>AB</u>		MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		PROMETHEUS LABS	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	+	ROXANE	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>		ACS DOBFAR	<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>			<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>		HOSPIRA INC	<u>1GM/VIAL</u>	<u>A090940</u>	<u>002</u>	Jun 22, 2010
<u>AP</u>			<u>500MG/VIAL</u>	<u>A090940</u>	<u>001</u>	Jun 22, 2010
<u>AP</u>		SANDOZ	<u>1GM/VIAL</u>	<u>A091201</u>	<u>002</u>	Mar 29, 2011
<u>AP</u>			<u>500MG/VIAL</u>	<u>A091201</u>	<u>001</u>	Mar 29, 2011

MERREM

<u>AP</u>	+	ASTRAZENECA	<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996
<u>AP</u>	+		<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

	+	WARNER CHILCOTT LLC	400MG	N204412	001	Feb 01, 2013
--	---	---------------------	-------	---------	-----	--------------

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

	+	SALIX PHARMS	375MG	N022301	001	Oct 31, 2008
--	---	--------------	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-234 (of 371)

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

SHIRE

250MG

N020049 001 May 10, 1993

+

500MG

N020049 002 Jul 08, 2004

ENEMA; RECTAL

MESALAMINEAB PERRIGO ISRAEL4GM/60MLA076751 001 Sep 17, 2004AB TEVA4GM/60MLA076841 001 Sep 30, 2004ROWASAAB + MEDA PHARMS4GM/60MLN019618 001 Dec 24, 1987SFROWASAAB MEDA PHARMS4GM/60MLN019618 002 Jun 20, 2008

SUPPOSITORY; RECTAL

CANASA

+ FOREST LABS INC

1GM

N021252 002 Nov 05, 2004

TABLET, DELAYED RELEASE; ORAL

ASACOL

+ WARNER CHILCOTT LLC

400MG

N019651 001 Jan 31, 1992

ASACOL HD

+ WARNER CHILCOTT LLC

800MG

N021830 001 May 29, 2008

LIALDA

+ SHIRE

1.2GM

N022000 001 Jan 16, 2007

MESNA

INJECTABLE; INTRAVENOUS

MESNAAP AGILA SPECITS100MG/MLA203364 001 Jul 18, 2014AP EUROHLTH INTL100MG/MLA075739 001 Jan 09, 2004AP FRESINIUS KABI USA100MG/MLA075811 001 Apr 26, 2001AP MYLAN INSTITUTIONAL100MG/MLA076488 001 Mar 08, 2012AP SAGENT PHARMS100MG/MLA090913 001 Apr 13, 2010AP TEVA PHARMS USA100MG/MLA075764 001 Apr 27, 2001MESNEXAP + BAXTER HLTHCARE100MG/MLN019884 001 Dec 30, 1988

TABLET; ORAL

MESNEX

+ BAXTER HLTHCARE

400MG

N020855 001 Mar 21, 2002

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ WATSON LABS

0.05MG; 1MG

N016659 001

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATEAN + MYLAN SPECIT0.4%A071786 001 Aug 05, 1988AN +0.6%A070804 001 Aug 17, 1987AN WOCKHARDT0.4%A075586 001 May 30, 2002AN0.6%A075586 002 May 30, 2002

SYRUP; ORAL

METAPROTERENOL SULFATE

+ SILARX

10MG/5ML

A073632 001 Jul 22, 1992

TABLET; ORAL

METAPROTERENOL SULFATE

PAR PHARM

10MG

A072024 001 Jun 28, 1988

+

20MG

A072025 001 Jun 28, 1988

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

+ FRESINIUS KABI USA

EQ 10MG BASE/ML

A080722 001

METAXALONE

TABLET; ORAL

METAXALONEAB AMNEAL PHARMS800MGA203399 001 Jun 21, 2013AB SANDOZ800MGA040445 001 Mar 31, 2010SKELAXINAB + KING PHARMS800MGN013217 003 Aug 30, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-235 (of 371)

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+ RANBAXY

500MG/5ML

N021591 001 Sep 11, 2003

TABLET; ORAL

GLUCOPHAGEAB + BRISTOL MYERS SQUIBB1GMN020357 005 Nov 05, 1998AB500MGN020357 001 Mar 03, 1995AB850MGN020357 002 Mar 03, 1995METFORMIN HYDROCHLORIDEAB

ALKEM

1GMA091184 003 Nov 01, 2010AB500MGA091184 001 Nov 01, 2010AB850MGA091184 002 Nov 01, 2010AB

AMNEAL PHARMS NY

1GMA077880 003 Jun 05, 2006AB500MGA077880 001 Jun 05, 2006AB850MGA077880 002 Jun 05, 2006AB

APOTEX

1GMA075984 003 Apr 23, 2002AB1GMA090666 003 Dec 07, 2011AB500MGA075984 001 Apr 23, 2002AB500MGA090666 001 Dec 07, 2011AB850MGA075984 002 Apr 23, 2002AB850MGA090666 002 Dec 07, 2011AB

ATLAS PHARMS LLC

1GMA076033 003 Jan 24, 2002AB500MGA076033 001 Jan 24, 2002AB850MGA076033 002 Jan 24, 2002AB

AUROBINDO

1GMA077095 003 Jan 14, 2005AB500MGA077095 001 Jan 14, 2005AB850MGA077095 002 Jan 14, 2005AB

CHARTWELL LIFE SCI

1GMA075972 003 Jan 24, 2002AB500MGA075972 001 Jan 24, 2002AB850MGA075972 002 Jan 24, 2002AB

DR REDDYS LABS INC

1GMA077787 003 Aug 23, 2006AB500MGA077787 001 Aug 23, 2006AB850MGA077787 002 Aug 23, 2006AB

GLENMARK GENERICS

1GMA078170 003 May 23, 2008AB500MGA078170 001 May 23, 2008AB850MGA078170 002 May 23, 2008AB

GRANULES INDIA

1GMA090564 003 Apr 22, 2010AB500MGA090564 001 Apr 22, 2010AB850MGA090564 002 Apr 22, 2010AB

INDICUS PHARMA

1GMA079148 003 Nov 25, 2008AB500MGA079148 001 Nov 25, 2008AB850MGA079148 002 Nov 25, 2008AB

MARKSANS PHARMA

1GMA090888 003 Mar 12, 2012AB500MGA090888 001 Mar 12, 2012AB850MGA090888 002 Mar 12, 2012AB

MUTUAL PHARMA

1GMA076038 003 Feb 21, 2002AB500MGA076038 001 Feb 21, 2002AB850MGA076038 002 Feb 21, 2002AB

MYLAN

1GMA075973 003 Jan 25, 2002AB1GMA075976 003 Jan 24, 2002AB500MGA075973 001 Jan 25, 2002AB500MGA075976 001 Jan 24, 2002AB850MGA075973 002 Jan 25, 2002AB850MGA075976 002 Jan 24, 2002AB

MYLAN PHARMS INC

1GMA075969 003 Jan 29, 2002AB500MGA075969 001 Jan 29, 2002AB850MGA075969 002 Jan 29, 2002AB

PROVIDENT PHARM

1GMA077853 003 Jul 28, 2006AB500MGA077853 001 Jul 28, 2006AB850MGA077853 002 Jul 28, 2006AB

SANDOZ

1GMA075965 003 Jan 25, 2002AB1GMA075985 003 Jan 25, 2002AB500MGA075965 001 Jan 25, 2002AB500MGA075985 001 Jan 25, 2002AB850MGA075965 002 Jan 25, 2002AB850MGA075985 002 Jan 25, 2002AB

SCIEGEN PHARMS INC

500MGA203769 001 Sep 11, 2013AB850MGA203769 002 Sep 11, 2013AB1GMA203769 003 Sep 11, 2013AB

SUN PHARM INDS INC

1GMA075967 003 Jan 29, 2002AB500MGA075967 001 Jan 29, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-236 (of 371)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>	TEVA	<u>1GM</u>	<u>A075978</u>	<u>003</u>	Nov 05, 2002
<u>AB</u>		<u>500MG</u>	<u>A075978</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075978</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>	TORRENT PHARMS	<u>1GM</u>	<u>A077711</u>	<u>003</u>	Jan 24, 2007
<u>AB</u>		<u>500MG</u>	<u>A077711</u>	<u>001</u>	Jan 24, 2007
<u>AB</u>		<u>850MG</u>	<u>A077711</u>	<u>002</u>	Jan 24, 2007
<u>AB</u>	WATSON LABS FLORIDA	<u>1GM</u>	<u>A075961</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>		<u>500MG</u>	<u>A075961</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075961</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>		<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
<u>AB</u>		<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
	CHARTWELL LIFE SCI	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

GLUCOPHAGE XR

<u>AB</u>	+ BRISTOL MYERS SQUIBB	<u>750MG</u>	<u>N021202</u>	<u>004</u>	Apr 11, 2003
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	APOTEX	<u>750MG</u>	<u>A076706</u>	<u>002</u>	Dec 29, 2005
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BARR	<u>750MG</u>	<u>A076863</u>	<u>001</u>	Oct 14, 2004
<u>AB</u>	CSPC OUYI PHARM CO	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	IMPAX LABS	<u>750MG</u>	<u>A076985</u>	<u>001</u>	Sep 13, 2005
<u>AB</u>	MYLAN	<u>750MG</u>	<u>A077113</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005

GLUCOPHAGE XR

<u>AB1</u>	BRISTOL MYERS SQUIBB	<u>500MG</u>	<u>N021202</u>	<u>001</u>	Oct 13, 2000
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB1</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A076172</u>	<u>001</u>	Jun 16, 2004
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	APOTEX	<u>500MG</u>	<u>A076706</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	CSPC OUYI PHARM CO	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	IMPAX LABS	<u>500MG</u>	<u>A076249</u>	<u>001</u>	Jul 30, 2004
<u>AB1</u>	INVENTIA HLTHCARE	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MYLAN	<u>500MG</u>	<u>A076650</u>	<u>001</u>	Sep 13, 2005
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	TORRENT PHARM	<u>500MG</u>	<u>A090014</u>	<u>001</u>	Dec 30, 2009
<u>AB1</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

FORTAMET

<u>AB2</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004
<u>AB2</u>		<u>500MG</u>	<u>N021574</u>	<u>001</u>	Apr 27, 2004
	<u>METFORMIN HYDROCHLORIDE</u>				
<u>AB2</u>	LUPIN LTD	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>		<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB2</u>		<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB3</u>	LUPIN LTD	<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>		<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013

GLUMETZA

	+ SANTARUS INC	1GM	N021748	002	Jun 03, 2005
		500MG	N021748	001	Jun 03, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-237 (of 371)

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>001</u>	Aug 29, 2005
AB	+	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
AB	MYLAN	<u>500MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>001</u>	Feb 25, 2011
AB		<u>850MG;EQ 15MG BASE</u>	<u>A090406</u>	<u>002</u>	Feb 25, 2011
AB	SANDOZ	<u>500MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>001</u>	Apr 16, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A091273</u>	<u>002</u>	Apr 16, 2013
AB	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014
AB		<u>850MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>002</u>	Mar 10, 2014
AB	TORRENT PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>001</u>	Feb 13, 2013
AB		<u>850MG;EQ 15MG BASE</u>	<u>A202001</u>	<u>002</u>	Feb 13, 2013

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024	001	May 12, 2009
+		1GM;EQ 30MG BASE	N022024	002	May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008
+		500MG;2MG	N022386	002	Jun 23, 2008

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB	SB PHARMC0	<u>1GM;EQ 2MG BASE</u>	<u>N021410</u>	<u>004</u>	Aug 25, 2003
AB	+	<u>1GM;EQ 4MG BASE</u>	<u>N021410</u>	<u>005</u>	Aug 25, 2003
AB		<u>500MG;EQ 2MG BASE</u>	<u>N021410</u>	<u>002</u>	Oct 10, 2002
AB		<u>500MG;EQ 4MG BASE</u>	<u>N021410</u>	<u>003</u>	Oct 10, 2002

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB	TEVA	<u>1GM;EQ 4MG BASE</u>	<u>A077337</u>	<u>004</u>	May 07, 2014
AB		<u>1GM;EQ 2MG BASE</u>	<u>A077337</u>	<u>003</u>	May 07, 2014
AB		<u>500MG;EQ 2MG BASE</u>	<u>A077337</u>	<u>001</u>	May 07, 2014
AB		<u>500MG;EQ 4MG BASE</u>	<u>A077337</u>	<u>002</u>	May 07, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

+	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007
		500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012
		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986
---	------------	------------	---------	-----	--------------

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

AA	ROXANE	<u>10MG/ML</u>	<u>A040180</u>	<u>001</u>	Apr 30, 1998
AA	VISTAPHARM	<u>10MG/ML</u>	<u>A040088</u>	<u>001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

AA	ROXANE	<u>10MG/ML</u>	<u>A089897</u>	<u>001</u>	Sep 06, 1988
-----------	--------	----------------	----------------	------------	--------------

METHADOSE

AA	+	MALLINCKRODT	<u>10MG/ML</u>	<u>N017116</u>	<u>002</u>
-----------	---	--------------	----------------	----------------	------------

INJECTABLE; INJECTION

DOLOPHINE HYDROCHLORIDE

+	MYLAN INSTITUTIONAL	10MG/ML	N021624	001	
---	---------------------	---------	---------	-----	--

PRESCRIPTION DRUG PRODUCT LIST

3-238 (of 371)

METHADONE HYDROCHLORIDE

POWDER;FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT

50GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SOLUTION;ORAL

METHADONE HYDROCHLORIDEAA + ROXANE5MG/5MLA087393 001AA +10MG/5MLA087997 001

Aug 30, 1982

AA VISTAPHARM5MG/5MLA090707 001

Jun 30, 2010

AA10MG/5MLA090707 002

Jun 30, 2010

TABLET;ORAL

DOLOPHINE HYDROCHLORIDEAA + ROXANE5MGN006134 002AA +10MGN006134 010METHADONE HYDROCHLORIDEAA MALLINCKRODT5MGA040517 001

Apr 27, 2004

AA10MGA040517 002

Apr 27, 2004

AA SANDOZ10MGA040241 002

May 29, 1998

AA THE PHARMANETWORK10MGA090635 001

Nov 25, 2009

METHADOSEAA MALLINCKRODT5MGA040050 001

Apr 15, 1993

AA10MGA040050 002

Apr 15, 1993

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDEAA MALLINCKRODT INC40MGA077142 001

Jul 12, 2005

AA + ROXANE40MGN017058 001AA SANDOZ40MGA075082 001

Mar 25, 1998

METHADOSEAA MALLINCKRODT40MGA074184 001

Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYNAA + RECORDATI RARE5MGN005378 002METHAMPHETAMINE HYDROCHLORIDEAA COASTAL PHARMS5MGA091189 001

Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDEAB ANI PHARMS INC25MGA040001 001

Jun 30, 1993

AB50MGA040001 002

Jun 30, 1993

AB MIKART25MGA040062 001

Jan 27, 1994

AB +50MGA040062 002

Jan 27, 1994

AB SANDOZ25MGA040036 001

Jun 30, 1993

AB50MGA040036 002

Jun 30, 1993

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREXAB + SANOFI AVENTIS US1GMN017681 001METHENAMINE HIPPURATEAB COREPHARMA1GMA076411 001

Jun 20, 2003

UREXAB CNTY LINE PHARMS1GMN016151 001METHIMAZOLE

TABLET;ORAL

METHIMAZOLEAB CEDAR PHARMS5MGA040547 001

Feb 18, 2005

AB10MGA040547 002

Feb 18, 2005

AB EMCURE PHARMS USA5MGA040734 001

Dec 14, 2007

AB10MGA040734 002

Dec 14, 2007

AB MYLAN5MGA040350 001

Mar 29, 2000

AB +10MGA040350 002

Mar 29, 2000

AB SANDOZ5MGA040411 001

Mar 27, 2001

AB10MGA040411 002

Mar 27, 2001

AB SUN PHARM INDS INC5MGA040870 001

Sep 25, 2007

AB10MGA040870 002

Sep 25, 2007

AB VINTAGE PHARMS5MGA202068 001

Mar 07, 2012

AB10MGA202068 002

Mar 07, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-239 (of 371)

METHIMAZOLE

TABLET; ORAL

TAPAZOLEAB KING PHARMS5MGA040320 001 Mar 31, 2000AB10MGA040320 002 Mar 31, 2000METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOLAP MYLAN INSTITUTIONAL1GM/10ML (100MG/ML)A204404 001 Dec 05, 2014ROBAXINAP + HIKMA MAPLE1GM/10ML (100MG/ML)N011790 001

TABLET; ORAL

METHOCARBAMOLAA AUSTARPHARMA LLC500MGA200958 001 Oct 21, 2011AA750MGA200958 002 Oct 21, 2011AA HETERO LABS LTD III500MGA090200 001 Nov 06, 2009AA750MGA090200 002 Nov 06, 2009AA HIKMA INTL PHARMS500MGA085159 001AA750MGA085123 001AA LANNETT HOLDINGS INC500MGA084756 002 Mar 31, 2003AA750MGA084756 001AA PRINSTON INC500MGA086989 001AA750MGA086988 001AA SANDOZ500MGA084616 001AA750MGA084615 001AA VINTAGE PHARMS500MGA040489 001 Jan 29, 2003AA750MGA040489 002 Jan 29, 2003AA WATSON LABS500MGA084277 001AA750MGA084276 002ROBAXINAA + AUXILIUM PHARMS LLC500MGN011011 004ROBAXIN-750AA + AUXILIUM PHARMS LLC750MGN011011 006METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+ PAR STERILE PRODUCTS

2.5GM/VIAL

N011559 002

+

200MG/VIAL

N011559 004 Dec 21, 2012

+

500MG/VIAL

N011559 001

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

ANTARES PHARMA INC

7.5MG/0.4ML (7.5MG/0.4ML)

N204824 005 Nov 07, 2014

10MG/0.4ML (10MG/0.4ML)

N204824 001 Oct 11, 2013

15MG/0.4ML (15MG/0.4ML)

N204824 002 Oct 11, 2013

20MG/0.4ML (20MG/0.4ML)

N204824 003 Oct 11, 2013

25MG/0.4ML (25MG/0.4ML)

N204824 004 Oct 11, 2013

+

RASUVO

MEDAC PHARMA INC

7.5MG/0.15ML (7.5MG/0.15ML)

N205776 001 Jul 10, 2014

10MG/0.20ML (10MG/0.20ML)

N205776 002 Jul 10, 2014

12.5MG/0.25ML (12.5MG/0.25ML)

N205776 003 Jul 10, 2014

15MG/0.30ML (15MG/0.30ML)

N205776 004 Jul 10, 2014

17.5MG/0.35ML (17.5MG/0.35ML)

N205776 005 Jul 10, 2014

20MG/0.4ML (20MG/0.4ML)

N205776 006 Jul 10, 2014

22.5MG/0.45ML (22.5MG/0.45ML)

N205776 007 Jul 10, 2014

25MG/0.5ML (25MG/0.5ML)

N205776 008 Jul 10, 2014

27.5MG/0.55ML (27.5MG/0.55ML)

N205776 009 Jul 10, 2014

30MG/0.6ML (30MG/0.6ML)

N205776 010 Jul 10, 2014

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREEAP FRESENIUS KABI USAEQ 1GM BASE/VIALA040266 001 Feb 26, 1999AP PHARMACHEMIE BVEQ 100MG BASE/4ML (EQ 25MG BASE/ML)A200171 001 Feb 27, 2012METHOTREXATE SODIUMAP + EUROHLTH INTLEQ 100MG BASE/4ML (EQ 25MG BASE/ML)A089341 001 Sep 16, 1986AP + FRESENIUS KABI USAEQ 50MG BASE/2ML (EQ 25MG BASE/ML)A040263 001 Feb 26, 1999AP +EQ 250MG BASE/10ML (EQ 25MG BASE/ML)A040263 002 Feb 26, 1999AP + HOSPIRAEQ 50MG BASE/2ML (EQ 25MG BASE/ML)N011719 010 Dec 15, 2004METHOTREXATE SODIUM PRESERVATIVE FREEAP + ACCORD HLTHCAREEQ 1GM BASE/40ML (EQ 25MG BASE/ML)A040716 001 Apr 30, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-240 (of 371)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	+	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	EBEWE PHARMA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
<u>AP</u>	+	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+	<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A201530</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>		<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>001</u>	Mar 29, 2012
<u>AP</u>		<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>002</u>	Mar 29, 2012
<u>AP</u>		<u>EQ 200MG BASE/8ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>003</u>	Mar 29, 2012
<u>AP</u>		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A201529</u>	<u>004</u>	Mar 29, 2012
<u>AP</u>	PHARMACHEMIE BV	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040850</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		<u>EQ 250MG/10ML (EQ 25MG BASE/ML)</u>	<u>A040853</u>	<u>001</u>	Jan 11, 2010

METHOTREXATE SODIUM

+ EUROHLTH INTL EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

+ EUROHLTH INTL EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

TABLET; ORAL

METHOTREXATE SODIUM

<u>AB</u>	BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N008085</u>	<u>002</u>	
<u>AB</u>	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
<u>AB</u>	ROXANE	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
	TREXALL				
	BARR	EQ 5MG BASE	A040385	001	Mar 21, 2001
		EQ 7.5MG BASE	A040385	002	Mar 21, 2001
		EQ 10MG BASE	A040385	003	Mar 21, 2001
	+	EQ 15MG BASE	A040385	004	Mar 21, 2001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

<u>AB</u>	STRIDES PHARMA	<u>10MG</u>	<u>A202687</u>	<u>001</u>	Jun 05, 2014
	<u>OXSORALEN-ULTRA</u>				
<u>AB</u>	+	<u>10MG</u>	<u>N019600</u>	<u>001</u>	Oct 30, 1986
	8-MOP				
	+	10MG	N009048	001	
	INJECTABLE; INJECTION				
	UVADEX				
	+	0.02MG/ML	N020969	001	Feb 25, 1999
	LOTION; TOPICAL				
	OXSORALEN				
	+	1%	N009048	002	

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

<u>AA</u>	BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602</u>	<u>001</u>	Sep 24, 2012
<u>AA</u>		<u>5MG</u>	<u>A200602</u>	<u>002</u>	Sep 24, 2012
<u>AA</u>	BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642</u>	<u>001</u>	Dec 06, 2011
<u>AA</u>		<u>5MG</u>	<u>A040642</u>	<u>002</u>	Dec 06, 2011
<u>AA</u>	VINTAGE PHARMS	<u>2.5MG</u>	<u>A040624</u>	<u>001</u>	Dec 28, 2006
<u>AA</u>		<u>5MG</u>	<u>A040624</u>	<u>002</u>	Dec 28, 2006
	<u>PAMINE</u>				
<u>AA</u>	+	<u>2.5MG</u>	<u>N008848</u>	<u>001</u>	
	<u>PAMINE FORTE</u>				
<u>AA</u>	+	<u>5MG</u>	<u>N008848</u>	<u>002</u>	Mar 25, 2003

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

PARKE DAVIS

150MG

N010596 007

+

300MG

N010596 008

PRESCRIPTION DRUG PRODUCT LIST

3-241 (of 371)

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

+ MYLAN PHARMS INC 5MG

A087672 001 Aug 17, 1982

METHYLDOPA

TABLET; ORAL

METHYLDOPAAB ACCORD HLTHCARE 250MGA070084 001 Oct 15, 1985AB 500MGA070085 001 Oct 15, 1985AB IVAX SUB TEVA PHARMS 250MGA070098 001 Feb 20, 1986AB 500MGA070343 001 Feb 20, 1986AB MYLAN 250MGA070076 002 Apr 18, 1985AB + 500MGA070076 001 Apr 18, 1985AB WATSON LABS 500MGA070625 001 Jun 06, 1986METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDEAP + LUITPOLD 50MG/MLA071279 001 Oct 02, 1987METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINEAP + EDISON THERAPS LLC 0.2MG/MLN006035 004METHYLERGONOVINE MALEATEAP ERGOJECT 0.2MG/MLA040889 001 Sep 13, 2010AP LUITPOLD 0.2MG/MLA090193 001 Nov 24, 2008

TABLET; ORAL

METHERGINEAB + EDISON THERAPS LLC 0.2MGN006035 003METHYLERGONOVINE MALEATEAB NOVEL LABS INC 0.2MGA091577 001 May 02, 2011METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML (8MG/0.4ML)

N021964 002 Sep 27, 2010

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

NOVEN PHARMS INC

10MG/9HR (1.1MG/HR)

N021514 001 Apr 06, 2006

15MG/9HR (1.6MG/HR)

N021514 002 Apr 06, 2006

20MG/9HR (2.2MG/HR)

N021514 003 Apr 06, 2006

+

30MG/9HR (3.3MG/HR)

N021514 004 Apr 06, 2006

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDEAB1 BARR LABS INC 10MGA079031 004 Oct 15, 2014AB1 20MGA079031 001 Jul 13, 2012AB1 30MGA079031 002 Jul 13, 2012AB1 40MGA079031 003 Jul 13, 2012AB1 WATSON LABS INC 20MGA078458 001 Dec 01, 2011AB1 30MGA078458 002 Dec 01, 2011AB1 40MGA078458 003 Dec 01, 2011RITALIN LAAB1 NOVARTIS 10MGN021284 004 Apr 10, 2004AB1 20MGN021284 001 Jun 05, 2002AB1 30MGN021284 002 Jun 05, 2002AB1 + 40MGN021284 003 Jun 05, 2002METADATE CDAB2 UCB INC 10MGN021259 003 May 27, 2003AB2 20MGN021259 001 Apr 03, 2001AB2 30MGN021259 002 Jun 19, 2003AB2 40MGN021259 004 Feb 19, 2006AB2 50MGN021259 005 Feb 19, 2006AB2 + 60MGN021259 006 Feb 19, 2006METHYLPHENIDATE HYDROCHLORIDEAB2 TEVA PHARMS 10MGA077707 001 Jul 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-242 (of 371)

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>	<u>20MG</u>	<u>A077707</u>	<u>002</u>	Jul 19, 2012
<u>AB2</u>	<u>30MG</u>	<u>A077707</u>	<u>003</u>	Jul 19, 2012
<u>AB2</u>	<u>40MG</u>	<u>A078873</u>	<u>001</u>	Jul 19, 2012
<u>AB2</u>	<u>50MG</u>	<u>A078873</u>	<u>002</u>	Jul 19, 2012
<u>AB2</u>	<u>60MG</u>	<u>A078873</u>	<u>003</u>	Jul 19, 2012

RITALIN LA

NOVARTIS 60MG

N021284 005 Oct 27, 2014

FOR SUSPENSION, EXTENDED RELEASE;ORAL

QUILLIVANT XR

+ NEXTWAVE PHARMS 5MG/ML

N202100 001 Sep 27, 2012

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+ MALLINCKRODT	<u>5MG/5ML</u>	<u>N021419</u>	<u>001</u>	Dec 19, 2002
<u>AA</u>	+	<u>10MG/5ML</u>	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>	SUN PHARM INDS INC	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013
<u>AA</u>		<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013
<u>AA</u>	TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010
<u>AA</u>		<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>5MG</u>	<u>A040220</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>10MG</u>	<u>A040220</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>20MG</u>	<u>A040220</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A091159</u>	<u>001</u>	Mar 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A091159</u>	<u>002</u>	Mar 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A091159</u>	<u>003</u>	Mar 12, 2014
<u>AB</u>	MALLINCKRODT	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012
<u>AB</u>		<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012
<u>AB</u>	UCB INC	<u>5MG</u>	<u>A086429</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085799</u>	<u>001</u>	
<u>AB</u>		<u>20MG</u>	<u>A086428</u>	<u>001</u>	
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A202892</u>	<u>001</u>	Sep 23, 2014
<u>AB</u>		<u>10MG</u>	<u>A202892</u>	<u>002</u>	Sep 23, 2014
<u>AB</u>		<u>20MG</u>	<u>A202892</u>	<u>003</u>	Sep 23, 2014

RITALIN

<u>AB</u>	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>	
<u>AB</u>		<u>10MG</u>	<u>N010187</u>	<u>006</u>	
<u>AB</u>	+	<u>20MG</u>	<u>N010187</u>	<u>010</u>	

TABLET, CHEWABLE;ORAL

METHYLIN

	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003
		5MG	N021475	002	Apr 15, 2003
	+	10MG	N021475	003	Apr 15, 2003

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

<u>AB</u>	+	UCB INC	<u>20MG</u>	<u>A089601</u>	<u>001</u>	Jun 01, 1988
-----------	---	---------	-------------	----------------	------------	--------------

METHYLIN ER

<u>AB</u>	MALLINCKRODT INC	<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000
-----------	------------------	-------------	----------------	------------	--------------

RITALIN-SR

<u>AB</u>	NOVARTIS	<u>20MG</u>	<u>N018029</u>	<u>001</u>	Mar 30, 1982
-----------	----------	-------------	----------------	------------	--------------

METHYLPHENIDATE HYDROCHLORIDE

BX	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012

CONCERTA

	JANSSEN PHARMS	18MG	N021121	001	Aug 01, 2000
		27MG	N021121	004	Apr 01, 2002
		36MG	N021121	002	Aug 01, 2000
	+	54MG	N021121	003	Dec 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-243 (of 371)

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

METHYLIN ER

MALLINCKRODT INC 10MG

A075629 001 May 09, 2000

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL**AB** PHARMACIA AND UPJOHN**2MG****N011153 002****AB** **4MG****N011153 001****AB** **8MG****N011153 004****AB** **16MG****N011153 003****AB** + **32MG****N011153 006**METHYLPREDNISOLONE**AB** DURAMED PHARMS BARR**4MG****A088497 001** Feb 21, 1984**AB** JUBILANT CADISTA**4MG****A040189 001** Oct 31, 1997**AB** **8MG****A040189 002** Oct 31, 1997**AB** **16MG****A040189 003** Jul 20, 2007**AB** **32MG****A040189 004** Jul 20, 2007**AB** SANDOZ**4MG****A040194 001** Oct 31, 1997**AB** VINTAGE PHARMS**4MG****A040183 001** Dec 22, 1998**AB** WATSON LABS**4MG****A040232 001** Oct 16, 1997METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL**AB** + PHARMACIA AND UPJOHN**40MG/ML****N011757 001****AB** + **80MG/ML****N011757 004**METHYLPREDNISOLONE ACETATE**AB** SANDOZ**40MG/ML****A040719 001** Jan 29, 2009**AB** **40MG/ML****A040794 001** Mar 05, 2009**AB** **80MG/ML****A040719 002** Jan 29, 2009**AB** **80MG/ML****A040794 002** Mar 05, 2009**AB** TEVA PHARMS USA**40MG/ML****A040557 001** Feb 23, 2005**AB** **40MG/ML****A040620 001** Oct 27, 2006**AB** **80MG/ML****A040557 002** Feb 23, 2005**AB** **80MG/ML****A040620 002** Oct 27, 2006

DEPO-MEDROL

+ PHARMACIA AND UPJOHN 20MG/ML

N011757 002

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED**AP** HOSPIRA**EQ 40MG BASE/VIAL****A040664 001** Dec 20, 2005**AP** **EQ 125MG BASE/VIAL****A040665 001** Dec 20, 2005**AP** HOSPIRA INC**EQ 40MG BASE/VIAL****A040793 001** Nov 25, 2008**AP** **EQ 125MG BASE/VIAL****A040827 001** Nov 25, 2008METHYLPREDNISOLONE SODIUM SUCCINATE**AP** FRESENIUS KABI USA**EQ 1GM BASE/VIAL****A040612 001** Aug 12, 2004**AP** **EQ 40MG BASE/VIAL****A040583 001** Jul 30, 2004**AP** **EQ 125MG BASE/VIAL****A040583 002** Jul 30, 2004**AP** MUSTAFA NEVSAT**EQ 1GM BASE/VIAL****A040888 004** Jul 18, 2011**AP** **EQ 2GM BASE/VIAL****A040888 005** Jul 18, 2011**AP** **EQ 40MG BASE/VIAL****A040888 001** Jul 18, 2011**AP** **EQ 125MG BASE/VIAL****A040888 002** Jul 18, 2011**AP** **EQ 500MG BASE/VIAL****A040888 003** Jul 18, 2011SOLU-MEDROL**AP** + PHARMACIA AND UPJOHN**EQ 1GM BASE/VIAL****N011856 006****AP** + **EQ 2GM BASE/VIAL****N011856 007** Feb 27, 1985**AP** + **EQ 40MG BASE/VIAL****N011856 003****AP** + **EQ 125MG BASE/VIAL****N011856 004****AP** + **EQ 500MG BASE/VIAL****N011856 005**METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

+ VALEANT PHARM INTL 10MG

A083976 001

TABLET; ORAL

ANDROID 10

BP VALEANT PHARM INTL 10MG

A086450 001

ANDROID 25

BP VALEANT PHARM INTL 25MG

A087147 001

METHYLTESTOSTERONE

BP IMPAX LABS 10MG

A080767 002

PRESCRIPTION DRUG PRODUCT LIST

3-244 (of 371)

METHYLTESTOSTERONE

TABLET; ORAL

METHYLTESTOSTERONE

BP 25MG A084310 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

AT ALCON RES LTD 0.3% A075720 001 Aug 06, 2001

OPTIPRANOLOL

AT + BAUSCH AND LOMB 0.3% N019907 001 Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

AP EMCURE PHARMS LTD EQ 5MG BASE/ML A204756 001 Dec 20, 2013

METOCLOPRAMIDE HYDROCHLORIDE

AP BD RX EQ 5MG BASE/ML A091392 001 Apr 19, 2013

AP HOSPIRA EQ 5MG BASE/ML A073118 001 Jan 17, 1991

AP TEVA PHARMS USA EQ 5MG BASE/ML A073135 001 Nov 27, 1991

REGLAN

AP + BAXTER HLTHCARE CORP EQ 5MG BASE/ML N017862 001

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA ANI PHARMS EQ 5MG BASE/5ML A071402 001 Jun 25, 1993

AA PHARM ASSOC EQ 5MG BASE/5ML A072744 001 May 28, 1991

AA SILARX EQ 5MG BASE/5ML A073680 001 Oct 27, 1992

AA VISTAPHARM EQ 5MG BASE/5ML A075051 001 Jan 26, 2001

AA + WOCKHARDT EQ 5MG BASE/5ML A074703 001 Oct 31, 1997

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB IPCA LABS LTD EQ 5MG BASE A078807 001 Jun 12, 2008

AB EQ 10MG BASE A078807 002 Jun 12, 2008

AB MUTUAL PHARM EQ 5MG BASE A071536 002 Jan 16, 1997

AB NORTHSTAR HLTHCARE EQ 5MG BASE A078374 001 Nov 30, 2007

AB EQ 10MG BASE A078374 002 Nov 30, 2007

AB PAR PHARM INC EQ 10MG BASE A070581 001 Oct 17, 1985

AB TEVA EQ 5MG BASE A072801 001 Jun 15, 1993

AB EQ 10MG BASE A070184 001 Jul 29, 1985

AB VINTAGE PHARMS EQ 5MG BASE A077878 001 Aug 28, 2006

AB EQ 10MG BASE A077878 002 Aug 28, 2006

AB WATSON LABS EQ 5MG BASE A072750 001 Dec 28, 1995

AB EQ 10MG BASE A071250 001 Feb 03, 1988

REGLAN

AB ANI PHARMS EQ 5MG BASE N017854 002 May 05, 1987

AB + EQ 10MG BASE N017854 001

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB NOVEL LABS INC EQ 5MG BASE A202191 001 Aug 15, 2014

METOCLOPRAMIDE

AB + SALIX PHARMS EQ 5MG BASE N022246 001 Sep 04, 2009

METOCLOPRAMIDE HYDROCHLORIDE

NOVEL LABS INC EQ 10MG BASE A202191 002 Aug 15, 2014

METOLAZONE

TABLET; ORAL

METOLAZONE

AB MYLAN 2.5MG A076698 001 Dec 23, 2003

AB 5MG A076698 002 Oct 19, 2004

AB 10MG A076698 003 Oct 19, 2004

AB SANDOZ 2.5MG A076732 001 Dec 19, 2003

AB 5MG A076466 001 Dec 19, 2003

AB 10MG A076466 002 Dec 19, 2003

ZAROXOLYN

AB UCB INC 2.5MG N017386 001

AB + 5MG N017386 002

AB + 10MG N017386 003

PRESCRIPTION DRUG PRODUCT LIST

3-245 (of 371)

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 25MG TARTRATE</u>	<u>A077118</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A076862</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A077298</u>	<u>001</u>	Apr 15, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A077298</u>	<u>002</u>	Apr 15, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617</u>	<u>001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617</u>	<u>002</u>	Aug 01, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033</u>	<u>001</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A202033</u>	<u>002</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A202033</u>	<u>003</u>	Dec 15, 2011
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A202033</u>	<u>004</u>	Dec 15, 2011
<u>AB</u>	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889</u>	<u>001</u>	Aug 15, 2012
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A078889</u>	<u>002</u>	Aug 15, 2012
<u>AB</u>	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615</u>	<u>001</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090615</u>	<u>002</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A090615</u>	<u>003</u>	Jul 22, 2010
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A090615</u>	<u>004</u>	Jul 22, 2010

TOPROL-XL

<u>AB</u>	ASTRAZENECA PHARMS	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
<u>AB</u>	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
<u>AB</u>	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE;INJECTION

LOPRESSOR

<u>AP</u>	+	NOVARTIS	<u>1MG/ML</u>	<u>N018704</u>	<u>001</u>	Mar 30, 1984
-----------	---	----------	---------------	----------------	------------	--------------

METOPROLOL TARTRATE

<u>AP</u>		BEDFORD LABS	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
<u>AP</u>		CLARIS LIFESCIENCES	<u>1MG/ML</u>	<u>A078950</u>	<u>001</u>	Apr 29, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045</u>	<u>001</u>	Oct 25, 2010
<u>AP</u>		GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205</u>	<u>001</u>	Aug 27, 2014
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
<u>AP</u>			<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
<u>AP</u>			<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
<u>AP</u>		LUITPOLD	<u>1MG/ML</u>	<u>A090386</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>			<u>1MG/ML</u>	<u>A091307</u>	<u>001</u>	Dec 29, 2010
<u>AP</u>		SAGENT STRIDES	<u>1MG/ML</u>	<u>A090317</u>	<u>001</u>	Apr 19, 2010
<u>AP</u>		SANDOZ	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007

TABLET;ORAL

LOPRESSOR

<u>AB</u>	US PHARMS HOLDINGS I	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
<u>AB</u>		<u>100MG</u>	<u>N017963</u>	<u>002</u>	

METOPROLOL TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871</u>	<u>001</u>	May 28, 2013
<u>AB</u>		<u>50MG</u>	<u>A202871</u>	<u>002</u>	May 28, 2013
<u>AB</u>		<u>100MG</u>	<u>A202871</u>	<u>003</u>	May 28, 2013
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>		<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
<u>AB</u>		<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
<u>AB</u>		<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
<u>AB</u>	MUTUAL PHARM	<u>25MG</u>	<u>A073654</u>	<u>002</u>	Jul 15, 2009
<u>AB</u>		<u>50MG</u>	<u>A073653</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>100MG</u>	<u>A073654</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>		<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>	+	<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>	RUBICON RES PVT LTD	<u>25MG</u>	<u>A200981</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>		<u>50MG</u>	<u>A200981</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>		<u>100MG</u>	<u>A200981</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>	SANDOZ	<u>50MG</u>	<u>A073288</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>		<u>100MG</u>	<u>A073289</u>	<u>001</u>	Mar 25, 1994
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>	TEVA	<u>50MG</u>	<u>A074141</u>	<u>001</u>	Jan 31, 1995
<u>AB</u>		<u>100MG</u>	<u>A074141</u>	<u>002</u>	Jan 31, 1995
<u>AB</u>	WATSON LABS	<u>50MG</u>	<u>A074217</u>	<u>001</u>	May 27, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-246 (of 371)

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>		<u>100MG</u>	<u>A074217</u>	<u>002</u>	May 27, 1994
-----------	--	--------------	----------------	------------	--------------

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	GD SEARLE LLC	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995
-----------	---	---------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		ALEMBIC LTD	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>		PAR PHARM	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004
-----------	--	-----------	--------------	----------------	------------	--------------

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995
-----------	---	------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AB</u>		G AND W LABS	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007
-----------	--	--------------	--------------	----------------	------------	--------------

NORITATE

	+	VALEANT BERMUDA	1%	N020743	001	Sep 26, 1997
--	---	-----------------	----	---------	-----	--------------

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u>	Nov 22, 1988
-----------	---	------------------	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>1%</u>	<u>N021789</u>	<u>001</u>	Jun 30, 2005
-----------	---	--	-----------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018</u>	<u>001</u>	Jun 06, 2006
-----------	--	----------------	--------------	----------------	------------	--------------

<u>AB</u>		G AND W LABS INC	<u>0.75%</u>	<u>A078178</u>	<u>001</u>	Jan 19, 2011
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u>	Jul 18, 2006
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077547</u>	<u>001</u>	Jul 13, 2006
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>1%</u>	<u>A090903</u>	<u>001</u>	Jul 22, 2011
-----------	--	--	-----------	----------------	------------	--------------

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	MEDICIS	<u>0.75%</u>	<u>N020208</u>	<u>001</u>	Aug 17, 1992
-----------	---	---------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		TOLMAR	<u>0.75%</u>	<u>A077264</u>	<u>001</u>	Oct 31, 2006
-----------	--	--------	--------------	----------------	------------	--------------

VANDAZOLE

BX		TEVA PHARMS	0.75%	N021806	001	May 20, 2005
----	--	-------------	-------	---------	-----	--------------

METRONIDAZOLE

	+	WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014
--	---	-----------------	------	---------	-----	--------------

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657</u>	<u>001</u>	
-----------	---	-----------------	--------------------	----------------	------------	--

<u>AP</u>	+	PFIZER	<u>500MG/100ML</u>	<u>N018353</u>	<u>002</u>	
-----------	---	--------	--------------------	----------------	------------	--

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900</u>	<u>001</u>	Sep 29, 1983
-----------	---	---------	--------------------	----------------	------------	--------------

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>		CLARIS LIFESCIENCES	<u>500MG/100ML</u>	<u>A078084</u>	<u>001</u>	Mar 31, 2008
-----------	--	---------------------	--------------------	----------------	------------	--------------

<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890</u>	<u>002</u>	Nov 18, 1983
-----------	---	---------	--------------------	----------------	------------	--------------

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901</u>	<u>001</u>	Nov 24, 1998
-----------	---	------------------	--------------	----------------	------------	--------------

METRONIDAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077197</u>	<u>001</u>	May 24, 2006
-----------	--	----------------	--------------	----------------	------------	--------------

TABLET; ORAL

FLAGYL

<u>AB</u>		GD SEARLE LLC	<u>250MG</u>	<u>N012623</u>	<u>001</u>	
-----------	--	---------------	--------------	----------------	------------	--

<u>AB</u>	+		<u>500MG</u>	<u>N012623</u>	<u>003</u>	
-----------	---	--	--------------	----------------	------------	--

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS LTD	<u>250MG</u>	<u>A079067</u>	<u>001</u>	Mar 13, 2009
-----------	--	--------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A079067</u>	<u>002</u>	Mar 13, 2009
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		MUTUAL PHARM	<u>250MG</u>	<u>A070772</u>	<u>001</u>	Jul 16, 1986
-----------	--	--------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A070773</u>	<u>001</u>	Jul 16, 1986
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		PLIVA	<u>500MG</u>	<u>A070033</u>	<u>001</u>	Dec 06, 1984
-----------	--	-------	--------------	----------------	------------	--------------

<u>AB</u>		TEVA PHARMS USA	<u>250MG</u>	<u>A070027</u>	<u>001</u>	Nov 06, 1984
-----------	--	-----------------	--------------	----------------	------------	--------------

<u>AB</u>		UNICHEM LABS LTD	<u>250MG</u>	<u>A203458</u>	<u>001</u>	Jan 22, 2014
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A203458</u>	<u>002</u>	Jan 22, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A070035</u>	<u>001</u>	Dec 20, 1984
-----------	--	-------------	--------------	----------------	------------	--------------

<u>AB</u>		WATSON LABS INC	<u>500MG</u>	<u>A070044</u>	<u>001</u>	Feb 08, 1985
-----------	--	-----------------	--------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

<u>AB</u>	+	GD SEARLE LLC	<u>750MG</u>	<u>N020868</u>	<u>001</u>	Nov 26, 1997
-----------	---	---------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-247 (of 371)

METRONIDAZOLE

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

AB	ALEMBIC LTD	750MG	A090222	001	May 05, 2010
-----------	-------------	--------------	----------------	------------	--------------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+ HRA PHARMA

250MG

N012911 002 Aug 09, 1996

METYROSINE

CAPSULE; ORAL

DEMSEER

+ ATON PHARMA VPNA

250MG

N017871 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

TEVA

150MG

A074377 001 May 16, 1995

200MG

A074377 002 May 16, 1995

+

250MG

A074377 003 May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS

50MG/VIAL

N021506 002 Mar 16, 2005

+

100MG/VIAL

N021506 003 Jun 27, 2006

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ BIOALLIANCE PHARMA

50MG

N022404 001 Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

AB	ACTAVIS MID ATLANTIC	200MG	A073508	001	Nov 19, 1993
-----------	----------------------	--------------	----------------	------------	--------------

MONISTAT 3

AB	+ MEDTECH PRODUCTS	200MG	N018888	001	Aug 15, 1984
-----------	--------------------	--------------	----------------	------------	--------------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+ DELCOR ASSET

0.25%; 81.35%; 15%

N021026 001 Feb 16, 2006

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	AKORN INC	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000
-----------	-----------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP	BEDFORD	EQ 1MG BASE/ML	A075247	002	Jun 23, 2000
-----------	---------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075247	001	Jun 23, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP	BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000
-----------	--------------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP	FRESENIUS KABI USA	EQ 1MG BASE/ML	A075154	002	Jun 20, 2000
-----------	--------------------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075154	001	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696	001	Feb 29, 2012
-----------	------------------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A090850	001	Jan 25, 2012
-----------	--	-----------------------	----------------	------------	--------------

AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000
-----------	-------------	-----------------------	----------------	------------	--------------

AP		EQ 1MG BASE/ML	A075324	001	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075324	002	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP	+ HOSPIRA	EQ 1MG BASE/ML	A075293	001	Jun 20, 2000
-----------	-----------	-----------------------	----------------	------------	--------------

AP		EQ 1MG BASE/ML	A075856	001	Jun 13, 2002
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075293	002	Jun 20, 2000
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075856	002	Jun 13, 2002
-----------	--	-----------------------	----------------	------------	--------------

AP	WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008
-----------	-----------	-----------------------	----------------	------------	--------------

AP		EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A078141	002	May 30, 2008
-----------	--	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
-----------	--	-----------------------	----------------	------------	--------------

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

AP	BD RX	EQ 1MG BASE/ML	A203460	001	Aug 22, 2014
-----------	-------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A203460	002	Aug 22, 2014
-----------	--	-----------------------	----------------	------------	--------------

AP	+ HOSPIRA	EQ 1MG BASE/ML	A075857	001	Jul 22, 2002
-----------	-----------	-----------------------	----------------	------------	--------------

AP		EQ 5MG BASE/ML	A075857	002	Jul 22, 2002
-----------	--	-----------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-248 (of 371)

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090315</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090315</u>	<u>002</u>	Nov 29, 2010

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>	SAGENT STRIDES	<u>EQ 1MG BASE/ML</u>	<u>A090316</u>	<u>001</u>	May 04, 2011
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A090316</u>	<u>002</u>	May 04, 2011

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	HI TECH PHARMA	<u>EQ 2MG BASE/ML</u>	<u>A075958</u>	<u>001</u>	Sep 04, 2003
<u>AA</u>	PADDOCK LLC	<u>EQ 2MG BASE/ML</u>	<u>A076379</u>	<u>001</u>	May 02, 2005
<u>AA</u>	RANBAXY	<u>EQ 2MG BASE/ML</u>	<u>A076058</u>	<u>001</u>	Mar 15, 2002
<u>AA</u>	+ ROXANE	<u>EQ 2MG BASE/ML</u>	<u>A075873</u>	<u>001</u>	Apr 30, 2002

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A077746</u>	<u>001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746</u>	<u>002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746</u>	<u>003</u>	Sep 12, 2006
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449</u>	<u>001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449</u>	<u>002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577</u>	<u>001</u>	Sep 10, 2003
<u>AB</u>	+	<u>5MG</u>	<u>A076577</u>	<u>002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076514</u>	<u>001</u>	Sep 11, 2003
<u>AB</u>		<u>5MG</u>	<u>A076514</u>	<u>002</u>	Sep 11, 2003
<u>AB</u>		<u>10MG</u>	<u>A076514</u>	<u>003</u>	Jul 02, 2004

ORVATEN

<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>		<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004

MIFEPRISTONE

TABLET; ORAL

KORLYM

+ CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012
------------------	-------	---------	-----	--------------

MIFEPREX

+ DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000
------------------	-------	---------	-----	--------------

MIGLITOL

TABLET; ORAL

GLYSET

PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996
	50MG	N020682	002	Dec 18, 1996
+	100MG	N020682	003	Dec 18, 1996

MIGLUSTAT

CAPSULE; ORAL

ZAVESCA

+ ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003
-----------------------	-------	---------	-----	--------------

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009
	25MG	N022256	002	Jan 14, 2009
+	50MG	N022256	003	Jan 14, 2009
	100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

<u>AP</u>	+ BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A075660</u>	<u>001</u>	May 28, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A075936</u>	<u>001</u>	May 28, 2002
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A077190</u>	<u>001</u>	Oct 31, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML</u>	<u>A077966</u>	<u>001</u>	Dec 03, 2010
<u>AP</u>	HIKMA MAPLE	<u>EQ 1MG BASE/ML</u>	<u>A075530</u>	<u>001</u>	May 28, 2002
<u>AP</u>	HOSPIRA INC	<u>EQ 1MG BASE/ML</u>	<u>A203280</u>	<u>001</u>	Sep 03, 2014
<u>AP</u>	INTL MEDICATED	<u>EQ 1MG BASE/ML</u>	<u>A076013</u>	<u>001</u>	Aug 02, 2002

MILRINONE LACTATE IN DEXTROSE 5%

<u>AP</u>	APOTEX INC	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A077151</u>	<u>002</u>	Jul 20, 2005
-----------	------------	--	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-249 (of 371)

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A076414</u>	<u>001</u>	Aug 18, 2004
<u>AP</u>	+ BAXTER HLTHCARE	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>001</u>	May 28, 2002
<u>AP</u>	+ BEDFORD LABS	<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075834</u>	<u>002</u>	May 28, 2002
<u>AP</u>		<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>001</u>	May 21, 2008
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A078113</u>	<u>002</u>	May 21, 2008
<u>AP</u>	HOSPIRA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>001</u>	May 28, 2002
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A075885</u>	<u>002</u>	May 28, 2002

MILRINONE LACTATE IN PLASTIC CONTAINER

<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>001</u>	Jan 21, 2010
<u>AP</u>		<u>EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)</u>	<u>A090038</u>	<u>002</u>	Jan 21, 2010

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

	+ KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014
--	------------------	------	---------	-----	--------------

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

<u>AB</u>	CNTY LINE PHARMS	<u>EQ 75MG BASE</u>	<u>A063067</u>	<u>002</u>	Sep 15, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063067</u>	<u>001</u>	Jul 31, 1990

MINOCIN

<u>AB</u>	PRECISION DERMAT	<u>EQ 50MG BASE</u>	<u>N050649</u>	<u>001</u>	May 31, 1990
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>N050649</u>	<u>002</u>	May 31, 1990

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A065470</u>	<u>001</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065470</u>	<u>002</u>	Mar 11, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065470</u>	<u>003</u>	Mar 11, 2008
<u>AB</u>	IMPAX LABS	<u>EQ 50MG BASE</u>	<u>A065005</u>	<u>001</u>	Mar 23, 1999
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065005</u>	<u>003</u>	Apr 18, 2001
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065005</u>	<u>002</u>	Mar 23, 1999
<u>AB</u>	RANBAXY	<u>EQ 50MG BASE</u>	<u>A065062</u>	<u>001</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065062</u>	<u>002</u>	Nov 30, 2000
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065062</u>	<u>003</u>	Nov 30, 2000
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 50MG BASE</u>	<u>A090867</u>	<u>001</u>	May 13, 2013
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090867</u>	<u>002</u>	May 13, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090867</u>	<u>003</u>	May 13, 2013
<u>AB</u>	TEVA	<u>EQ 50MG BASE</u>	<u>A063011</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063009</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+ WATSON LABS	<u>EQ 100MG BASE</u>	<u>A063009</u>	<u>001</u>	Mar 02, 1992
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A063181</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A063065</u>	<u>002</u>	Jun 10, 1999
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A063065</u>	<u>001</u>	Dec 30, 1991

INJECTABLE; INJECTION

MINOCIN

	+ REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444	001	
--	---------------------	--------------------	---------	-----	--

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

	+ ORAPHARMA	EQ 1MG BASE	N050781	001	Feb 16, 2001
--	-------------	-------------	---------	-----	--------------

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 50MG BASE</u>	<u>A065436</u>	<u>001</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065436</u>	<u>002</u>	Dec 26, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065436</u>	<u>003</u>	Dec 26, 2007
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A065131</u>	<u>001</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065131</u>	<u>002</u>	Apr 16, 2003
<u>AB</u>	+ RANBAXY	<u>EQ 100MG BASE</u>	<u>A065131</u>	<u>003</u>	Apr 16, 2003
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A065156</u>	<u>001</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065156</u>	<u>002</u>	Jan 06, 2004
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065156</u>	<u>003</u>	Jan 06, 2004

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261</u>	<u>005</u>	Nov 19, 2012
<u>AB</u>	BARR LABS INC	<u>EQ 45MG BASE</u>	<u>A065485</u>	<u>001</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A065485</u>	<u>004</u>	May 18, 2012
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A065485</u>	<u>002</u>	Mar 17, 2009
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A065485</u>	<u>005</u>	May 18, 2012
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A065485</u>	<u>003</u>	Mar 17, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-250 (of 371)

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>EQ 45MG BASE</u>	<u>A090024 001</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090024 002</u>	Feb 03, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090024 003</u>	Feb 03, 2009
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 45MG BASE</u>	<u>A090911 001</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203443 002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090911 002</u>	Jul 20, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203443 003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090911 003</u>	Jul 20, 2010
<u>AB</u>	RANBAXY LABS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>SOLODYN</u>				
<u>AB</u>	MEDICIS	<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009
	+	EQ 55MG BASE	N050808 008	Aug 27, 2010

MINOXIDIL

TABLET;ORAL

MINOXIDIL

<u>AB</u>	MUTUAL PHARM	<u>2.5MG</u>	<u>A072708 001</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709 001</u>	Dec 14, 1995
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826 001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839 001</u>	Nov 14, 1988
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344 001</u>	Mar 03, 1987
<u>AB</u>	+	<u>10MG</u>	<u>A071345 001</u>	Mar 03, 1987

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

+ GENZYME CORP 200MG/ML (200MG/ML)

N203568 001 Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

APGDI 25MG

N202611 001 Jun 28, 2012

+ 50MG

N202611 002 Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076336 001</u>	Jun 20, 2003
<u>AB</u>		<u>30MG</u>	<u>A076336 002</u>	Jun 20, 2003
<u>AB</u>		<u>45MG</u>	<u>A076336 003</u>	Jun 20, 2003
<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666 001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666 002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666 003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921 001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921 002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921 003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921 004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122 003</u>	Jun 19, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A076176 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076176 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076176 003</u>	Jun 19, 2003
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A076219 001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219 002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219 003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541 004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541 001</u>	Apr 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-251 (of 371)

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	WATSON LABS	<u>15MG</u>	<u>A076312</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076312</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076312</u>	<u>003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>		<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996
<u>AB</u>		<u>45MG</u>	<u>N020415</u>	<u>003</u>	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>15MG</u>	<u>A076307</u>	<u>001</u>	Dec 17, 2003
<u>AB</u>		<u>30MG</u>	<u>A076307</u>	<u>002</u>	Dec 17, 2003
<u>AB</u>		<u>45MG</u>	<u>A076307</u>	<u>003</u>	Feb 28, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076901</u>	<u>001</u>	Jun 28, 2005
<u>AB</u>		<u>30MG</u>	<u>A076901</u>	<u>002</u>	Jun 28, 2005
<u>AB</u>		<u>45MG</u>	<u>A076901</u>	<u>003</u>	Jun 28, 2005

REMERON SOLTAB

<u>AB</u>	+ ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>		<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>		<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET; ORAL

CYTOTEC

<u>AB</u>	GD SEARLE LLC	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002
<u>AB</u>	NOVEL LABS INC	<u>0.1MG</u>	<u>A091667</u>	<u>001</u>	Jul 25, 2012
<u>AB</u>		<u>0.2MG</u>	<u>A091667</u>	<u>002</u>	Jul 25, 2012

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+ MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCIN

<u>AP</u>	+ ACCORD HLTHCARE	<u>5MG/VIAL</u>	<u>A064144</u>	<u>001</u>	Apr 30, 1998
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A064144</u>	<u>002</u>	Apr 30, 1998
<u>AP</u>	+	<u>40MG/VIAL</u>	<u>A064144</u>	<u>003</u>	Aug 11, 2009
<u>AP</u>	BEDFORD	<u>5MG/VIAL</u>	<u>A064117</u>	<u>001</u>	Apr 19, 1995
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064117</u>	<u>002</u>	Apr 19, 1995
<u>AP</u>	HIKMA MAPLE	<u>5MG/VIAL</u>	<u>A064180</u>	<u>001</u>	Dec 23, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A064180</u>	<u>002</u>	Dec 23, 1999

MITOTANE

TABLET; ORAL

LYSODREN

+ BRISTOL MYERS SQUIBB

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076611</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077496</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	+ HOSPIRA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>	+	<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A076871</u>	<u>003</u>	Apr 11, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>001</u>	Apr 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-252 (of 371)

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A078980</u>	<u>002</u>	Apr 13, 2009
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A201014</u>	<u>001</u>	Dec 11, 2012
<u>AP</u>	TEVA PHARMS USA	<u>EQ 20MG BASE/10ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>001</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>002</u>	Apr 11, 2006
<u>AP</u>		<u>EQ 30MG BASE/15ML (EQ 2MG BASE/ML)</u>	<u>A077356</u>	<u>003</u>	Apr 11, 2006

MODAFINIL

TABLET; ORAL

MODAFINIL

<u>AB</u>	ALEMBIC LTD	<u>100MG</u>	<u>A202700</u>	<u>001</u>	Oct 18, 2012
<u>AB</u>		<u>200MG</u>	<u>A202700</u>	<u>002</u>	Oct 18, 2012
<u>AB</u>	APOTEX INC	<u>100MG</u>	<u>A077667</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>		<u>200MG</u>	<u>A077667</u>	<u>002</u>	Feb 03, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A202566</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>200MG</u>	<u>A202566</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	CARLSBAD	<u>100MG</u>	<u>A076715</u>	<u>001</u>	Nov 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A076715</u>	<u>002</u>	Nov 01, 2012
<u>AB</u>	HIKMA PHARMS	<u>100MG</u>	<u>A090543</u>	<u>001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A090543</u>	<u>002</u>	Sep 26, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>100MG</u>	<u>A076594</u>	<u>001</u>	Jul 16, 2012
<u>AB</u>		<u>200MG</u>	<u>A076594</u>	<u>002</u>	Jul 16, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>100MG</u>	<u>A078963</u>	<u>001</u>	Sep 26, 2012
<u>AB</u>		<u>200MG</u>	<u>A078963</u>	<u>002</u>	Sep 26, 2012

PROVIGIL

<u>AB</u>	CEPHALON	<u>100MG</u>	<u>N020717</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N020717</u>	<u>002</u>	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A078454</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>15MG</u>	<u>A078454</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A090416</u>	<u>001</u>	Mar 30, 2010
<u>AB</u>		<u>15MG</u>	<u>A090416</u>	<u>002</u>	Mar 30, 2010
<u>AB</u>	PADDOCK LLC	<u>7.5MG</u>	<u>A077536</u>	<u>001</u>	Nov 30, 2006
<u>AB</u>		<u>15MG</u>	<u>A077536</u>	<u>002</u>	Nov 30, 2006
<u>AB</u>	TEVA	<u>7.5MG</u>	<u>A076204</u>	<u>001</u>	May 08, 2003
<u>AB</u>		<u>15MG</u>	<u>A076204</u>	<u>002</u>	May 08, 2003

UNIVASC

<u>AB</u>	UCB INC	<u>7.5MG</u>	<u>N020312</u>	<u>001</u>	Apr 19, 1995
<u>AB</u>	+	<u>15MG</u>	<u>N020312</u>	<u>002</u>	Apr 19, 1995

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

MERCK SHARP DOHME

0.10MG/INH

N205641 001 Apr 25, 2014

+

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019625</u>	<u>001</u>	May 06, 1987
<u>AB</u>			<u>0.1%</u>	<u>N019625</u>	<u>002</u>	Apr 19, 2013

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A076171</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077447</u>	<u>001</u>	May 22, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078541</u>	<u>001</u>	May 28, 2008
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076679</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076591</u>	<u>001</u>	Apr 18, 2007

LOTION; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019796</u>	<u>001</u>	Mar 30, 1989
-----------	---	-------------------	-------------	----------------	------------	--------------

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A075919</u>	<u>001</u>	Nov 29, 2007
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077678</u>	<u>001</u>	Nov 21, 2007
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A090506</u>	<u>001</u>	Aug 09, 2010
<u>AB</u>	PERRIGO	<u>0.1%</u>	<u>A077180</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>	TARO	<u>0.1%</u>	<u>A076788</u>	<u>001</u>	Mar 15, 2006
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076499</u>	<u>001</u>	Nov 21, 2007

OINTMENT; TOPICAL

ELOCON

<u>AB</u>	+	MERCK SHARP DOHME	<u>0.1%</u>	<u>N019543</u>	<u>001</u>	Apr 30, 1987
-----------	---	-------------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-253 (of 371)

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077061</u>	<u>001</u>	Mar 28, 2005
<u>AB</u>	G AND W LABS	<u>0.1%</u>	<u>A077401</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>	GLENMARK GENERICS	<u>0.1%</u>	<u>A078571</u>	<u>001</u>	May 28, 2008
<u>AB</u>	PERRIGO NEW YORK	<u>0.1%</u>	<u>A076067</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	TOLMAR	<u>0.1%</u>	<u>A076481</u>	<u>001</u>	Nov 14, 2003

POWDER; INHALATION

ASMANEX TWISTHALER

	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008
+		0.22MG/INH	N021067	001	Mar 30, 2005

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL

NASONEX

+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997
---	-------------------	----------------------	---------	-----	--------------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE/PACKET</u>	<u>A202776</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+	MERCK	<u>EQ 4MG BASE/PACKET</u>	<u>N021409</u>	<u>001</u>	Jul 26, 2002
-----------	---	-------	---------------------------	----------------	------------	--------------

TABLET; ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>	APOTEX CORP	<u>EQ 10MG BASE</u>	<u>A201294</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843</u>	<u>001</u>	Sep 10, 2014
<u>AB</u>	KUDCO IRELAND	<u>EQ 10MG BASE</u>	<u>A201522</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366</u>	<u>001</u>	Sep 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A079103</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 10MG BASE</u>	<u>A090655</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 10MG BASE</u>	<u>A091576</u>	<u>001</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	+	MERCK	<u>EQ 10MG BASE</u>	<u>N020829</u>	<u>002</u>	Feb 20, 1998
-----------	---	-------	---------------------	----------------	------------	--------------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

<u>AB</u>	APOTEX INC	<u>EQ 4MG BASE</u>	<u>A201508</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201508</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581</u>	<u>001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581</u>	<u>002</u>	Aug 06, 2012
<u>AB</u>	KUDCO IRELAND	<u>EQ 4MG BASE</u>	<u>A200405</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 4MG BASE</u>	<u>A079142</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079142</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	ROXANE	<u>EQ 4MG BASE</u>	<u>A091128</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091128</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984</u>	<u>002</u>	Aug 03, 2012
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037</u>	<u>001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037</u>	<u>002</u>	Oct 30, 2014
<u>AB</u>	VINTAGE PHARMS LLC	<u>EQ 4MG BASE</u>	<u>A091588</u>	<u>001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091588</u>	<u>002</u>	Aug 03, 2012

SINGULAIR

<u>AB</u>	MERCK	<u>EQ 4MG BASE</u>	<u>N020830</u>	<u>002</u>	Mar 03, 2000
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N020830</u>	<u>001</u>	Feb 20, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-254 (of 371)

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

<u>AB1</u>	+	WATSON LABS INC	<u>10MG</u>	<u>N020616</u>	<u>008</u>	Apr 20, 2007
<u>AB1</u>			<u>20MG</u>	<u>N020616</u>	<u>001</u>	Jul 03, 1996
<u>AB1</u>			<u>30MG</u>	<u>N020616</u>	<u>004</u>	Mar 09, 2001
<u>AB1</u>			<u>50MG</u>	<u>N020616</u>	<u>002</u>	Jul 03, 1996
<u>AB1</u>			<u>60MG</u>	<u>N020616</u>	<u>005</u>	Mar 09, 2001
<u>AB1</u>			<u>80MG</u>	<u>N020616</u>	<u>006</u>	Oct 27, 2006
<u>AB1</u>	+		<u>100MG</u>	<u>N020616</u>	<u>003</u>	Jul 03, 1996
<u>AB1</u>	+		<u>200MG</u>	<u>N020616</u>	<u>007</u>	Feb 27, 2007

MORPHINE SULFATE

<u>AB1</u>		PAR PHARM INC	<u>20MG</u>	<u>A200812</u>	<u>001</u>	Nov 10, 2011
<u>AB1</u>			<u>30MG</u>	<u>A200812</u>	<u>002</u>	Nov 10, 2011
<u>AB1</u>			<u>50MG</u>	<u>A200812</u>	<u>003</u>	Nov 10, 2011
<u>AB1</u>			<u>60MG</u>	<u>A200812</u>	<u>004</u>	Nov 10, 2011
<u>AB1</u>			<u>80MG</u>	<u>A200812</u>	<u>005</u>	Nov 10, 2011
<u>AB1</u>			<u>100MG</u>	<u>A200812</u>	<u>006</u>	Nov 10, 2011
<u>AB1</u>		TEVA PHARMS USA	<u>20MG</u>	<u>A202718</u>	<u>001</u>	Dec 29, 2014
<u>AB1</u>			<u>30MG</u>	<u>A202718</u>	<u>002</u>	Dec 29, 2014
<u>AB1</u>			<u>50MG</u>	<u>A202718</u>	<u>003</u>	Dec 29, 2014
<u>AB1</u>			<u>60MG</u>	<u>A202718</u>	<u>004</u>	Dec 29, 2014
<u>AB1</u>			<u>80MG</u>	<u>A202718</u>	<u>005</u>	Dec 29, 2014
<u>AB1</u>			<u>100MG</u>	<u>A202718</u>	<u>006</u>	Dec 29, 2014
<u>AB1</u>		UPSHER SMITH	<u>10MG</u>	<u>A202104</u>	<u>001</u>	Jun 03, 2013
<u>AB1</u>			<u>20MG</u>	<u>A202104</u>	<u>002</u>	Jun 03, 2013
<u>AB1</u>			<u>30MG</u>	<u>A202104</u>	<u>003</u>	Jun 03, 2013
<u>AB1</u>			<u>50MG</u>	<u>A202104</u>	<u>004</u>	Jun 03, 2013
<u>AB1</u>			<u>60MG</u>	<u>A202104</u>	<u>005</u>	Jun 03, 2013
<u>AB1</u>			<u>80MG</u>	<u>A202104</u>	<u>006</u>	Jun 03, 2013
<u>AB1</u>			<u>100MG</u>	<u>A202104</u>	<u>007</u>	Jun 03, 2013

AVINZA

<u>AB2</u>		KING PHARMS LLC	<u>30MG</u>	<u>N021260</u>	<u>001</u>	Mar 20, 2002
<u>AB2</u>			<u>45MG</u>	<u>N021260</u>	<u>005</u>	Dec 18, 2008
<u>AB2</u>			<u>60MG</u>	<u>N021260</u>	<u>002</u>	Mar 20, 2002
<u>AB2</u>			<u>75MG</u>	<u>N021260</u>	<u>006</u>	Dec 18, 2008
<u>AB2</u>			<u>90MG</u>	<u>N021260</u>	<u>003</u>	Mar 20, 2002
<u>AB2</u>	+		<u>120MG</u>	<u>N021260</u>	<u>004</u>	Mar 20, 2002

MORPHINE SULFATE

<u>AB2</u>		ACTAVIS ELIZABETH	<u>30MG</u>	<u>A079040</u>	<u>001</u>	Jan 16, 2013
<u>AB2</u>			<u>45MG</u>	<u>A079040</u>	<u>002</u>	Jan 16, 2013
<u>AB2</u>			<u>60MG</u>	<u>A079040</u>	<u>003</u>	Jan 16, 2013
<u>AB2</u>			<u>75MG</u>	<u>A079040</u>	<u>004</u>	Jan 16, 2013
<u>AB2</u>			<u>90MG</u>	<u>A079040</u>	<u>005</u>	Jan 16, 2013
<u>AB2</u>			<u>120MG</u>	<u>A079040</u>	<u>006</u>	Jan 16, 2013
		KADIAN				
		WATSON LABS INC	40MG	N020616	009	Jul 09, 2012
			70MG	N020616	010	Jul 09, 2012
			130MG	N020616	011	Jul 09, 2012
			150MG	N020616	012	Jul 09, 2012

INJECTABLE; INJECTION

ASTRAMORPH PF

<u>AP</u>		FRESENIUS KABI USA	<u>0.5MG/ML</u>	<u>A071050</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>0.5MG/ML</u>	<u>A071051</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>1MG/ML</u>	<u>A071052</u>	<u>001</u>	Oct 07, 1986
<u>AP</u>			<u>1MG/ML</u>	<u>A071053</u>	<u>001</u>	Oct 07, 1986

DURAMORPH PF

<u>AP</u>	+	HIKMA MAPLE	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
<u>AP</u>	+		<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984

MORPHINE SULFATE

<u>AP</u>		HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>			<u>1MG/ML</u>	<u>A071850</u>	<u>001</u>	May 11, 1988
<u>AP</u>			<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
<u>AP</u>	+		<u>1MG/ML</u>	<u>N019916</u>	<u>001</u>	Oct 30, 1992
		INFUMORPH				
	+	HIKMA MAPLE	10MG/ML	N018565	003	Jul 19, 1991
	+		25MG/ML	N018565	004	Jul 19, 1991
		MORPHINE SULFATE				
	+	HOSPIRA	5MG/ML	N019916	002	Oct 27, 2006
	+	HOSPIRA INC	2MG/ML	N202515	001	Nov 14, 2011
	+		4MG/ML	N202515	002	Nov 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-255 (of 371)

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

+	8MG/ML	N202515	003	Nov 14, 2011
+	10MG/ML	N202515	004	Nov 14, 2011
+	15MG/ML	N202515	005	Nov 14, 2011
+	MERIDIAN MEDCL TECHN 15MG/ML	N019999	001	Jul 12, 1990

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

+	BD RX	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
+		4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
+		5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
+		8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
+		10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

<u>AA</u>	MALLINCKRODT INC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
<u>AA</u>	PADDOCK LLC	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
<u>AA</u>	ROXANE	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
<u>AA</u>		<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
<u>AA</u>	SUN PHARM INDS INC	<u>10MG/5ML</u>	<u>A201011</u>	<u>001</u>	Feb 05, 2014
<u>AA</u>		<u>20MG/5ML</u>	<u>A201011</u>	<u>002</u>	Feb 05, 2014
<u>AA</u>	VISTAPHARM	<u>10MG/5ML</u>	<u>A201947</u>	<u>001</u>	Jan 05, 2012
<u>AA</u>		<u>20MG/5ML</u>	<u>A201947</u>	<u>002</u>	Jan 05, 2012
	LANNETT HOLDINGS INC	100MG/5ML	N201517	001	Jun 23, 2011

TABLET; ORAL

MORPHINE SULFATE

	ROXANE	15MG	N022207	001	Mar 17, 2008
+		30MG	N022207	002	Mar 17, 2008

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

<u>AB</u>	DAVA PHARMS INC	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MALLINCKRODT	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A200824</u>	<u>001</u>	Oct 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A200824</u>	<u>002</u>	Oct 18, 2011
<u>AB</u>		<u>60MG</u>	<u>A200824</u>	<u>003</u>	Oct 18, 2011
<u>AB</u>		<u>100MG</u>	<u>A200824</u>	<u>004</u>	Oct 18, 2011
<u>AB</u>		<u>200MG</u>	<u>A200824</u>	<u>005</u>	Oct 18, 2011
<u>AB</u>	NESHER PHARMS	<u>15MG</u>	<u>A076733</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>30MG</u>	<u>A076720</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>60MG</u>	<u>A076720</u>	<u>001</u>	May 19, 2004
<u>AB</u>		<u>100MG</u>	<u>A077855</u>	<u>001</u>	Sep 27, 2007
<u>AB</u>		<u>200MG</u>	<u>A077855</u>	<u>002</u>	Sep 27, 2007
<u>AB</u>	RANBAXY LABS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	VINTAGE PHARMS LLC	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000

MS CONTIN

<u>AB</u>	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u>	Sep 12, 1989
<u>AB</u>		<u>30MG</u>	<u>N019516</u>	<u>001</u>	May 29, 1987
<u>AB</u>		<u>60MG</u>	<u>N019516</u>	<u>002</u>	Apr 08, 1988
<u>AB</u>	+	<u>100MG</u>	<u>N019516</u>	<u>004</u>	Jan 16, 1990
<u>AB</u>		<u>200MG</u>	<u>N019516</u>	<u>005</u>	Nov 08, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-256 (of 371)

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EMBEDA

ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009
	30MG; 1.2MG	N022321	002	Aug 13, 2009
	50MG; 2MG	N022321	003	Aug 13, 2009
+	60MG; 2.4MG	N022321	004	Aug 13, 2009
	80MG; 3.2MG	N022321	005	Aug 13, 2009
	100MG; 4MG	N022321	006	Aug 13, 2009

MOXIFLOXACIN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+	BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001
---	----------------	-------------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<u>AT</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A202867</u>	<u>001</u>	Sep 04, 2014
	<u>VIGAMOX</u>				
<u>AT</u>	+ ALCON PHARMS LTD	<u>EQ 0.5% BASE</u>	<u>N021598</u>	<u>001</u>	Apr 15, 2003
	MOXEZA				
	+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010
	TABLET;ORAL				
	<u>AVELOX</u>				
<u>AB</u>	+ BAYER HLTHCARE	<u>EQ 400MG BASE</u>	<u>N021085</u>	<u>001</u>	Dec 10, 1999
	<u>MOXIFLOXACIN HYDROCHLORIDE</u>				
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 400MG BASE</u>	<u>A202632</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 400MG BASE</u>	<u>A076938</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>	TEVA PHARMS USA	<u>EQ 400MG BASE</u>	<u>A077437</u>	<u>001</u>	Feb 18, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 400MG BASE</u>	<u>A200160</u>	<u>001</u>	Apr 03, 2014

MUPIROCIN

OINTMENT; TOPICAL

BACTROBAN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>2%</u>	<u>N050591</u>	<u>001</u>	Dec 31, 1987
		<u>MUPIROCIN</u>				
<u>AB</u>		FOUGERA PHARMS	<u>2%</u>	<u>A065192</u>	<u>001</u>	Nov 30, 2005
<u>AB</u>		GLENMARK PHARMS	<u>2%</u>	<u>A090480</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>		PERRIGO NEW YORK	<u>2%</u>	<u>A065123</u>	<u>001</u>	Nov 07, 2003
<u>AB</u>		TARO	<u>2%</u>	<u>A065170</u>	<u>001</u>	Sep 23, 2005
<u>AB</u>		TEVA	<u>2%</u>	<u>A065085</u>	<u>001</u>	Nov 07, 2003
		CENTANY				
BX		PERRIGO NEW YORK	2%	N050788	001	Dec 04, 2002

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

<u>AB</u>	+	GLAXOSMITHKLINE	<u>EQ 2% BASE</u>	<u>N050746</u>	<u>001</u>	Dec 11, 1997
		<u>MUPIROCIN</u>				
<u>AB</u>		GLENMARK GENERICS	<u>EQ 2% BASE</u>	<u>A201587</u>	<u>001</u>	Jan 24, 2013
		OINTMENT;NASAL				
		BACTROBAN				
	+	GLAXOSMITHKLINE	EQ 2% BASE	N050703	001	Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

AB	+ ROCHE PALO	250MG	N050722	001	May 03, 1995
	MYCOPHENOLATE MOFETIL				
AB	ACCORD HLTHCARE	250MG	A090253	001	May 04, 2009
AB	ALKEM LABS LTD	250MG	A200197	001	Jun 13, 2013
AB	APOTEX CORP	250MG	A090419	001	Apr 22, 2009
AB	CADISTA PHARMS	250MG	A090762	001	Dec 15, 2014
AB	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011
AB	MYLAN	250MG	A065520	001	May 04, 2009
AB	ROXANE	250MG	A065410	001	Jul 29, 2008
AB	SANDOZ	250MG	A065379	001	Oct 15, 2008
AB	STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010
AB	TEVA PHARMS	250MG	A065491	001	May 06, 2009
AB	VINTAGE PHARMS LLC	250MG	A090111	001	Dec 22, 2009
	SUSPENSION;ORAL				
	CELLCEPT				
AB	+ ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998
	MYCOPHENOLATE MOFETIL				
AB	ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-257 (of 371)

MYCOPHENOLATE MOFETIL

TABLET; ORAL

CELLCEPT

AB	+	ROCHE PALO	500MG	<u>N050723</u>	<u>001</u>	Jun 19, 1997
-----------	----------	-------------------	--------------	-----------------------	-------------------	--------------

MYCOPHENOLATE MOFETIL

AB		ACCORD HLTHCARE	500MG	<u>A065416</u>	<u>001</u>	May 04, 2009
AB		ALKEM LABS LTD	500MG	<u>A091249</u>	<u>001</u>	Nov 04, 2011
AB		APOTEX	500MG	<u>A090499</u>	<u>001</u>	Apr 22, 2009
AB		CADISTA PHARMS	500MG	<u>A090661</u>	<u>001</u>	Dec 15, 2014
AB		MYLAN	500MG	<u>A065521</u>	<u>001</u>	May 04, 2009
AB		ROXANE	500MG	<u>A065413</u>	<u>001</u>	Jul 29, 2008
AB		SANDOZ	500MG	<u>A065451</u>	<u>001</u>	Oct 15, 2008
AB		STRIDES PHARMA	500MG	<u>A090456</u>	<u>001</u>	Jun 10, 2010
AB		TEVA PHARMS	500MG	<u>A065457</u>	<u>001</u>	May 04, 2009
AB		VINTAGE PHARMS LLC	500MG	<u>A090606</u>	<u>001</u>	Jul 16, 2010

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

+	ROCHE PALO	500MG/VIAL	<u>N050758</u>	<u>001</u>	Aug 12, 1998
----------	-------------------	-------------------	-----------------------	-------------------	--------------

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB		APOTEX INC	180MG	<u>A091558</u>	<u>001</u>	Aug 21, 2012
AB			360MG	<u>A091558</u>	<u>002</u>	Aug 19, 2014
AB		MYLAN PHARMS INC	180MG	<u>A091248</u>	<u>002</u>	Jan 08, 2014
AB			360MG	<u>A091248</u>	<u>001</u>	Jan 08, 2014
AB		TEVA PHARMS USA	180MG	<u>A202720</u>	<u>001</u>	Oct 30, 2014
AB			360MG	<u>A202720</u>	<u>002</u>	Oct 30, 2014

MYFORTIC

AB		NOVARTIS	180MG	<u>N050791</u>	<u>001</u>	Feb 27, 2004
AB	+		360MG	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

+	MEDA PHARMS	1MG	<u>N018677</u>	<u>001</u>	Dec 26, 1985
----------	--------------------	------------	-----------------------	-------------------	--------------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB		APOTEX INC	500MG	<u>A090427</u>	<u>001</u>	Dec 30, 2011
AB			750MG	<u>A090427</u>	<u>002</u>	Dec 30, 2011
AB		INVAGEN PHARMS	500MG	<u>A078671</u>	<u>001</u>	Mar 07, 2008
AB			750MG	<u>A078671</u>	<u>002</u>	Mar 07, 2008
AB		LUPIN LTD	500MG	<u>A090445</u>	<u>001</u>	Jan 12, 2011
AB			750MG	<u>A090445</u>	<u>002</u>	Jan 12, 2011
AB		MYLAN PHARMS INC	500MG	<u>A090516</u>	<u>001</u>	Jul 12, 2010
AB			750MG	<u>A090516</u>	<u>002</u>	Jul 12, 2010
AB		PAR PHARM	500MG	<u>A076009</u>	<u>001</u>	Jan 24, 2003
AB			750MG	<u>A076009</u>	<u>002</u>	Jan 24, 2003
AB		SANDOZ	500MG	<u>A075280</u>	<u>001</u>	Feb 25, 2002
AB			750MG	<u>A075280</u>	<u>002</u>	Feb 25, 2002
AB		TEVA	500MG	<u>A075189</u>	<u>001</u>	May 26, 2000
AB	+		750MG	<u>A075189</u>	<u>002</u>	Sep 24, 2001
AB		WATSON LABS	500MG	<u>A091083</u>	<u>001</u>	Jun 13, 2011
AB			750MG	<u>A091083</u>	<u>002</u>	Jun 13, 2011

NADOLOL

TABLET; ORAL

CORGARD

AB		KING PHARMS	20MG	<u>N018063</u>	<u>005</u>	Oct 28, 1986
AB			40MG	<u>N018063</u>	<u>001</u>	
AB	+		80MG	<u>N018063</u>	<u>002</u>	

NADOLOL

AB		IVAX SUB TEVA PHARMS	20MG	<u>A074229</u>	<u>001</u>	Aug 30, 1996
AB			40MG	<u>A074229</u>	<u>002</u>	Aug 30, 1996
AB			80MG	<u>A074255</u>	<u>001</u>	Jan 24, 1996
AB		MYLAN	20MG	<u>A074172</u>	<u>001</u>	Oct 31, 1993
AB			40MG	<u>A074172</u>	<u>002</u>	Oct 31, 1993
AB			80MG	<u>A074172</u>	<u>003</u>	Oct 31, 1993
AB		SANDOZ	20MG	<u>A074501</u>	<u>001</u>	Nov 09, 1995
AB			40MG	<u>A074501</u>	<u>002</u>	Nov 09, 1995
AB			80MG	<u>A074501</u>	<u>003</u>	Nov 09, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-258 (of 371)

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

+ GD SEARLE LLC

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUMAP AGILA SPECLTSEQ 1GM BASE/VIALA200002 001 Apr 07, 2014APEQ 2GM BASE/VIALA200002 002 Apr 07, 2014AP ANTIBIOTICEEQ 1GM BASE/VIALA090560 001 Oct 03, 2011APEQ 2GM BASE/VIALA090560 002 Oct 03, 2011AP AUROBINDO PHARMA LTDEQ 1GM BASE/VIALA091613 001 Dec 26, 2012APEQ 2GM BASE/VIALA091613 002 Dec 26, 2012APEQ 10GM BASE/VIALA091614 001 Dec 26, 2012AP ISTITUTO BIO ITA SPAEQ 1GM BASE/VIALA090002 001 Jun 30, 2011APEQ 2GM BASE/VIALA090002 002 Jun 30, 2011APEQ 10GM BASE/VIALA090005 001 Apr 20, 2011AP SAGENT PHARMSEQ 1GM BASE/VIALA090582 001 Aug 24, 2012APEQ 2GM BASE/VIALA090582 002 Aug 24, 2012APEQ 10GM BASE/VIALA090580 001 Aug 24, 2012AP + SANDOZEQ 1GM BASE/VIALA062527 002 Aug 02, 1984AP +EQ 1GM BASE/VIALA062732 001 Dec 23, 1986AP +EQ 2GM BASE/VIALA062527 003 Aug 02, 1984AP +EQ 2GM BASE/VIALA062732 002 Dec 23, 1986AP +EQ 10GM BASE/VIALA062527 004 Aug 02, 1984

NALLPEN IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 2GM BASE/100ML

N050655 002 Oct 31, 1989

+

EQ 20MG BASE/ML

N050655 001 Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019599 001 Feb 29, 1988

+

2%

N019599 002 Jan 13, 2012

GEL; TOPICAL

NAFTIN

+ MERZ PHARMS

1%

N019356 001 Jun 18, 1990

+

2%

N204286 001 Jun 27, 2013

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDEAP + HOSPIRA10MG/MLA070914 001 Feb 03, 1989AP +10MG/MLA070915 001 Feb 03, 1989AP +20MG/MLA070916 001 Feb 03, 1989AP +20MG/MLA070918 001 Feb 03, 1989NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

ASTRAZENECA PHARMS

EQ 12.5MG BASE

N204760 001 Sep 16, 2014

+

EQ 25MG BASE

N204760 002 Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDEAP + HOSPIRA0.4MG/MLA070172 001 Sep 24, 1986AP +0.4MG/MLA070254 001 Jan 07, 1987AP +0.4MG/MLA070256 001 Jan 07, 1987AP +0.4MG/MLA070257 001 Jan 07, 1987AP INTL MEDICATION0.4MG/MLA070639 001 Sep 24, 1986AP +1MG/MLA072076 001 Mar 24, 1988AP MYLAN INSTITUTIONAL0.4MG/MLA204997 001 Mar 06, 2014

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+ KALEO INC

0.4MG/0.4ML

N205787 001 Apr 03, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDEAB GAVIS PHARMSEQ 0.5MG BASE;EQ 50MG BASEA075735 001 Jul 11, 2001AB RANBAXYEQ 0.5MG BASE;EQ 50MG BASEA075523 001 Mar 17, 2000AB + WATSON LABSEQ 0.5MG BASE;EQ 50MG BASEA074736 001 Jan 21, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-259 (of 371)

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+ ALKERMES

380MG/VIAL

N021897 001 Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDEAB ACCORD HLTHCARE 50MGA091205 001 Aug 17, 2011AB BARR 50MGA074918 001 May 08, 1998AB ELITE LABS 50MGA075274 001 May 26, 1999AB MALLINCKRODT 50MGA076264 002 Mar 22, 2002AB SUN PHARMA GLOBAL 50MGA090356 001 Feb 24, 2012REVIAAB + TEVA WOMENS 50MGN018932 001 Nov 20, 1984

NALTREXONE HYDROCHLORIDE

MALLINCKRODT

25MG

A076264 001 Mar 22, 2002

100MG

A076264 003 Mar 22, 2002

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

+ PHARMAFORCE

200MG/ML

A091252 001 Aug 30, 2010

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE

+ AKORN INC

0.1%

A083590 001

NAPROXEN

SUSPENSION; ORAL

NAPROSYNAB + ROCHE PALO 25MG/MLN018965 001 Mar 23, 1987NAPROXENAB ROXANE 25MG/MLA074190 001 Mar 30, 1994

TABLET; ORAL

NAPROSYNAB ROCHE PALO 250MGN017581 002AB 375MGN017581 003AB + 500MGN017581 004 Apr 15, 1982NAPROXENAB AMNEAL PHARMS NY 250MGA075927 001 Dec 18, 2001AB 375MGA075927 002 Dec 18, 2001AB 500MGA075927 003 Dec 18, 2001AB AUROBINDO PHARMA USA 250MGA200429 001 Nov 08, 2011AB 375MGA200429 002 Nov 08, 2011AB 500MGA200429 003 Nov 08, 2011AB GLENMARK GENERICS 250MGA078250 001 Mar 28, 2007AB 375MGA078250 002 Mar 28, 2007AB 500MGA078250 003 Mar 28, 2007AB HIKMA INTL PHARMS 250MGA076494 001 Jan 14, 2004AB 375MGA076494 002 Jan 14, 2004AB 500MGA076494 003 Jan 14, 2004AB INVAGEN PHARMS 250MGA091305 001 Aug 24, 2011AB 375MGA091305 002 Aug 24, 2011AB 500MGA091305 003 Aug 24, 2011AB MARKSANS PHARMA 250MGA091416 001 Feb 14, 2011AB 375MGA091416 002 Feb 14, 2011AB 500MGA091416 003 Feb 14, 2011AB MYLAN 250MGA074121 001 Dec 21, 1993AB 375MGA074121 002 Dec 21, 1993AB 500MGA074121 003 Dec 21, 1993AB PERRIGO R AND D 250MGA077339 001 Apr 27, 2005AB 375MGA077339 002 Apr 27, 2005AB 500MGA077339 003 Apr 27, 2005AB SANDOZ 250MGA074140 001 Dec 21, 1993AB 375MGA074140 002 Dec 21, 1993AB 500MGA074140 003 Dec 21, 1993AB TEVA 250MGA074201 001 Dec 21, 1993AB 375MGA074201 002 Dec 21, 1993AB 500MGA074201 003 Dec 21, 1993AB ZYDUS PHARMS USA 250MGA078620 001 Jun 07, 2007AB 375MGA078620 002 Jun 07, 2007AB 500MGA078620 003 Jun 07, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-260 (of 371)

NAPROXEN

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

<u>AB</u>	+	ROCHE PALO	<u>375MG</u>	<u>N020067</u>	<u>002</u>	Oct 14, 1994
<u>AB</u>	+		<u>500MG</u>	<u>N020067</u>	<u>003</u>	Oct 14, 1994

NAPROXEN

<u>AB</u>	INVAGEN PHARMS	<u>375MG</u>	<u>A091432</u>	<u>001</u>	Sep 19, 2011
<u>AB</u>		<u>500MG</u>	<u>A091432</u>	<u>002</u>	Sep 19, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>375MG</u>	<u>A075390</u>	<u>001</u>	Apr 19, 2001
<u>AB</u>		<u>500MG</u>	<u>A075390</u>	<u>002</u>	Apr 19, 2001
<u>AB</u>	PLIVA	<u>375MG</u>	<u>A075337</u>	<u>001</u>	May 26, 1999
<u>AB</u>		<u>500MG</u>	<u>A075337</u>	<u>002</u>	May 26, 1999
<u>AB</u>	SANDOZ	<u>375MG</u>	<u>A075061</u>	<u>001</u>	Feb 18, 1998
<u>AB</u>		<u>500MG</u>	<u>A075061</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>	TEVA	<u>375MG</u>	<u>A075227</u>	<u>001</u>	Jun 30, 1998
<u>AB</u>		<u>500MG</u>	<u>A075227</u>	<u>002</u>	Jun 30, 1998

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

<u>AB</u>	HOFFMANN LA ROCHE	<u>EQ 250MG BASE</u>	<u>N018164</u>	<u>001</u>	
-----------	-------------------	----------------------	----------------	------------	--

ANAPROX DS

<u>AB</u>	+	HOFFMANN LA ROCHE	<u>EQ 500MG BASE</u>	<u>N018164</u>	<u>003</u>	Sep 30, 1987
-----------	---	-------------------	----------------------	----------------	------------	--------------

NAPROXEN SODIUM

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 250MG BASE</u>	<u>A078432</u>	<u>001</u>	Apr 25, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078432</u>	<u>002</u>	Apr 25, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629</u>	<u>001</u>	Oct 31, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629</u>	<u>002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486</u>	<u>001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486</u>	<u>002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078314</u>	<u>001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314</u>	<u>002</u>	Apr 27, 2007
<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A074480</u>	<u>002</u>	Feb 18, 1998
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074480</u>	<u>001</u>	May 14, 1996
<u>AB</u>	TEVA	<u>EQ 250MG BASE</u>	<u>A074198</u>	<u>001</u>	Dec 21, 1993
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A074198</u>	<u>002</u>	Dec 21, 1993

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

<u>AB</u>	ALMATICA PHARMA INC	<u>EQ 375MG BASE</u>	<u>N020353</u>	<u>001</u>	Jan 05, 1996
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N020353</u>	<u>002</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416</u>	<u>002</u>	Apr 23, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075416</u>	<u>001</u>	Aug 27, 2002

NAPRELAN

+	ALMATICA PHARMA INC	<u>EQ 750MG BASE</u>	<u>N020353</u>	<u>003</u>	Jan 05, 1996
---	---------------------	----------------------	----------------	------------	--------------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

+	PERNIX IRELAND LTD	<u>500MG;EQ 85MG BASE</u>	<u>N021926</u>	<u>001</u>	Apr 15, 2008
---	--------------------	---------------------------	----------------	------------	--------------

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

AMERGE

<u>AB</u>	GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763</u>	<u>002</u>	Feb 10, 1998
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N020763</u>	<u>001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	APOTEX CORP	<u>EQ 1MG BASE</u>	<u>A091373</u>	<u>001</u>	Apr 22, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091373</u>	<u>002</u>	Apr 22, 2011
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 1MG BASE</u>	<u>A200502</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1MG BASE</u>	<u>A202431</u>	<u>001</u>	May 31, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A202431</u>	<u>002</u>	May 31, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 1MG BASE</u>	<u>A091441</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>	PADDOCK LLC	<u>EQ 1MG BASE</u>	<u>A091326</u>	<u>001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326</u>	<u>002</u>	Jul 08, 2010
<u>AB</u>	ROXANE	<u>EQ 1MG BASE</u>	<u>A090381</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A090288</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090288</u>	<u>002</u>	Jul 07, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>	TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A078751</u>	<u>001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A078751</u>	<u>002</u>	Jul 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-261 (of 371)

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

+ ALCON

5%

N050514 001

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE**AB** DR REDDYS LABS LTD**60MG****A077461 001** Sep 09, 2009**AB** **120MG****A077461 002** Sep 09, 2009**AB** PAR PHARM**60MG****A077463 001** Sep 09, 2009**AB** **120MG****A077463 002** Sep 09, 2009**AB** WATSON LABS**60MG****A077462 001** Mar 30, 2011**AB** **120MG****A077462 002** Mar 30, 2011STARLIX**AB** NOVARTIS**60MG****N021204 001** Dec 22, 2000**AB** + **120MG****N021204 002** Dec 22, 2000NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

FOREST LABS

EQ 2.5MG BASE

N021742 002 Dec 17, 2007

EQ 5MG BASE

N021742 003 Dec 17, 2007

EQ 10MG BASE

N021742 004 Dec 17, 2007

+

EQ 20MG BASE

N021742 005 Oct 08, 2008

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALOCRIIL**AT** + ALLERGAN**2%****N021009 001** Dec 08, 1999NEDOCROMIL SODIUM**AT** AKORN**2%****A090638 001** Aug 22, 2012NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE**AB** RANBAXY**50MG****A076409 001** Sep 16, 2003**AB** **100MG****A076409 002** Sep 16, 2003**AB** **150MG****A076409 003** Sep 16, 2003**AB** **200MG****A076409 004** Sep 16, 2003**AB** **250MG****A076409 005** Sep 16, 2003**AB** TEVA**50MG****A076037 001** Sep 16, 2003**AB** **100MG****A076037 002** Sep 16, 2003**AB** **150MG****A076037 003** Sep 16, 2003**AB** **200MG****A076037 004** Sep 16, 2003**AB** + **250MG****A076037 005** Sep 16, 2003

BX DR REDDYS LABS INC

50MG

A076309 001 Sep 16, 2003

BX 100MG

A076309 002 Sep 16, 2003

BX 150MG

A076309 003 Sep 16, 2003

BX 200MG

A076309 004 Sep 16, 2003

BX 250MG

A076309 005 Sep 16, 2003

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+ SMITHKLINE BEECHAM

250MG/50ML (5MG/ML)

N021877 001 Oct 28, 2005

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

+ AGOURON

EQ 250MG BASE

N020779 001 Mar 14, 1997

+

EQ 625MG BASE

N021503 001 Apr 30, 2003

NEOMYCIN SULFATE

SOLUTION;ORAL

NEO-FRADIN

+ X GEN PHARMS

EQ 87.5MG BASE/5ML

A065010 001 May 23, 2002

TABLET;ORAL

NEOMYCIN SULFATE**AA** OMAN PHARM PRODUCTS**500MG****A065468 001** Mar 29, 2010**AA** + **500MG****A060304 001****AA** X GEN PHARMS**500MG****A065220 001** Jul 28, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-262 (of 371)

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT	WATSON LABS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A062664 001</u>	Apr 08, 1986
AT	X GEN PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065106 001</u>	Jan 31, 2006
AT		<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A065108 001</u>	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	+ MONARCH PHARMS	<u>EQ 40MG BASE/ML;200,000 UNITS/ML</u>	<u>A060707 001</u>	
-----------	------------------	--	---------------------------	--

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

	+ ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078 001	May 31, 2013
	+	10MG/10ML (1MG/ML)	N204078 002	May 31, 2013

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

	+ ALCON RES LTD	0.3%	N203491 001	Oct 16, 2012
--	-----------------	------	-------------	--------------

NEVANAC

	+ ALCON PHARMS LTD	0.1%	N021862 001	Aug 19, 2005
--	--------------------	------	-------------	--------------

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

	+ SCIOS LLC	1.5MG/VIAL	N020920 001	Aug 10, 2001
--	-------------	------------	-------------	--------------

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

	+ HELSINN HLTHCARE	300MG; EQ 0.5MG BASE	N205718 001	Oct 10, 2014
--	--------------------	----------------------	-------------	--------------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	AUROBINDO	<u>50MG/5ML</u>	<u>A077702 001</u>	May 22, 2012
-----------	-----------	------------------------	---------------------------	--------------

VIRAMUNE

AA	+ BOEHRINGER INGELHEIM	<u>50MG/5ML</u>	<u>N020933 001</u>	Sep 11, 1998
-----------	------------------------	------------------------	---------------------------	--------------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	<u>200MG</u>	<u>A203021 001</u>	May 22, 2012
AB	AUROBINDO	<u>200MG</u>	<u>A077521 001</u>	May 22, 2012
AB	CIPLA	<u>200MG</u>	<u>A077956 001</u>	May 22, 2012
AB	HETERO LABS LTD III	<u>200MG</u>	<u>A078584 001</u>	May 22, 2012
AB	MICRO LABS LTD	<u>200MG</u>	<u>A203080 001</u>	May 22, 2012
AB	MYLAN LABS	<u>200MG</u>	<u>A078864 001</u>	May 22, 2012
AB	MYLAN PHARMS INC	<u>200MG</u>	<u>A202523 001</u>	May 22, 2012
AB	PRINSTON INC	<u>200MG</u>	<u>A078644 001</u>	May 22, 2012
AB	SCIEGEN PHARMS INC	<u>200MG</u>	<u>A203176 001</u>	May 22, 2012
AB	STRIDES PHARMA	<u>200MG</u>	<u>A078195 001</u>	May 22, 2012

VIRAMUNE

AB	+ BOEHRINGER INGELHEIM	<u>200MG</u>	<u>N020636 001</u>	Jun 21, 1996
-----------	------------------------	---------------------	---------------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB	APOTEX INC	<u>400MG</u>	<u>A205258 001</u>	Apr 03, 2014
AB	MYLAN PHARMS INC	<u>400MG</u>	<u>A205651 001</u>	Oct 27, 2014
AB	SANDOZ	<u>400MG</u>	<u>A203411 001</u>	Apr 03, 2014

VIRAMUNE XR

AB	+ BOEHRINGER INGELHEIM	<u>400MG</u>	<u>N201152 001</u>	Mar 25, 2011
		100MG	N201152 002	Nov 08, 2012

NIACIN

TABLET; ORAL

NIACIN

AA	WOCKHARDT	<u>500MG</u>	<u>A081134 001</u>	Apr 28, 1992
-----------	-----------	---------------------	---------------------------	--------------

NIACOR

AA	+ UPSHER SMITH	<u>500MG</u>	<u>A040378 001</u>	May 03, 2000
-----------	----------------	---------------------	---------------------------	--------------

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	BARR	<u>1GM</u>	<u>A076250 001</u>	Apr 14, 2005
AB		<u>500MG</u>	<u>A076378 001</u>	Apr 26, 2005
AB		<u>750MG</u>	<u>A076378 002</u>	Apr 26, 2005
AB	LUPIN LTD	<u>1GM</u>	<u>A090446 001</u>	Mar 20, 2014
AB		<u>500MG</u>	<u>A090860 001</u>	Mar 20, 2014
AB		<u>750MG</u>	<u>A090892 001</u>	Mar 20, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-263 (of 371)

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

<u>AB</u>	SUN PHARMA GLOBAL	<u>1GM</u>	<u>A200484</u>	<u>002</u>	Apr 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A200484</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>		<u>750MG</u>	<u>A201273</u>	<u>001</u>	Apr 23, 2014

NIASPAN

<u>AB</u>	+ ABBVIE	<u>1GM</u>	<u>N020381</u>	<u>004</u>	Jul 28, 1997
<u>AB</u>		<u>500MG</u>	<u>N020381</u>	<u>002</u>	Jul 28, 1997
<u>AB</u>	+	<u>750MG</u>	<u>N020381</u>	<u>003</u>	Jul 28, 1997

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE;ORAL

SIMCOR

+	ABBVIE	1GM;20MG	N022078	003	Feb 15, 2008
+		1GM;40MG	N022078	005	Jul 28, 2010
+		500MG;20MG	N022078	001	Feb 15, 2008
+		500MG;40MG	N022078	004	Jul 28, 2010
+		750MG;20MG	N022078	002	Feb 15, 2008

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

<u>AB</u>	CHIESI USA INC	<u>20MG</u>	<u>N019488</u>	<u>001</u>	Dec 21, 1988
<u>AB</u>	+	<u>30MG</u>	<u>N019488</u>	<u>002</u>	Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS INC	<u>20MG</u>	<u>A074439</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>20MG</u>	<u>A074540</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>		<u>30MG</u>	<u>A074439</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>		<u>30MG</u>	<u>A074540</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
<u>AB</u>		<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A074642</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>		<u>30MG</u>	<u>A074642</u>	<u>002</u>	Jul 18, 1996

INJECTABLE;INJECTION

CARDENE

<u>AP</u>	+ CHIESI USA INC	<u>25MG/10ML (2.5MG/ML)</u>	<u>N019734</u>	<u>001</u>	Jan 30, 1992
-----------	------------------	-----------------------------	----------------	------------	--------------

NICARDIPINE HYDROCHLORIDE

<u>AP</u>	BEDFORD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A078714</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>	EXELA PHARMA SCIENCE	<u>25MG/10ML (2.5MG/ML)</u>	<u>N022276</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	LUITPOLD	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	MYLAN INSTITUTIONAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090664</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	NAVINTA LLC	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090125</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	SUN PHARMA GLOBAL	<u>25MG/10ML (2.5MG/ML)</u>	<u>N078405</u>	<u>001</u>	Nov 17, 2009
<u>AP</u>	WOCKHARDT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090671</u>	<u>001</u>	Nov 17, 2009

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008
---	----------------	-----------------------	---------	-----	--------------

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008
---	----------------	-----------------------	---------	-----	--------------

NICOTINE

INHALANT;ORAL

NICOTROL

+	PHARMACIA AND UPJOHN	4MG/CARTRIDGE	N020714	001	May 02, 1997
---	----------------------	---------------	---------	-----	--------------

SPRAY, METERED;NASAL

NICOTROL

+	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996
---	------------	-------------	---------	-----	--------------

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
<u>AB</u>		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	EMCURE PHARMS USA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	INTERGEL PHARM	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993

PROCARDIA

<u>AB</u>	+	PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>
-----------	---	--------	-------------	----------------	------------

PRESCRIPTION DRUG PRODUCT LIST

3-264 (of 371)

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

<u>AB1</u>	BAYER HLTHCARE	<u>30MG</u>	<u>N020198</u>	<u>001</u>	Apr 21, 1993
<u>AB1</u>	+	<u>60MG</u>	<u>N020198</u>	<u>002</u>	Apr 21, 1993
<u>AB1</u>	+	<u>90MG</u>	<u>N020198</u>	<u>003</u>	Apr 21, 1993

AFEDITAB CR

<u>AB1</u>	WATSON LABS	<u>30MG</u>	<u>A075128</u>	<u>001</u>	Mar 10, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075659</u>	<u>001</u>	Oct 26, 2001

NIFEDIPINE

<u>AB1</u>	MYLAN	<u>30MG</u>	<u>A201071</u>	<u>001</u>	Dec 03, 2010
<u>AB1</u>		<u>60MG</u>	<u>A201071</u>	<u>002</u>	Dec 03, 2010
<u>AB1</u>		<u>90MG</u>	<u>A201071</u>	<u>003</u>	Dec 03, 2010
<u>AB1</u>	PAR PHARM	<u>30MG</u>	<u>A077899</u>	<u>001</u>	Dec 13, 2006
<u>AB1</u>		<u>60MG</u>	<u>A077899</u>	<u>002</u>	Dec 13, 2006
<u>AB1</u>		<u>90MG</u>	<u>A077899</u>	<u>003</u>	May 25, 2012
<u>AB1</u>	VALEANT INTL	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
<u>AB1</u>		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
<u>AB1</u>		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
<u>AB2</u>	MATRIX LABS LTD	<u>30MG</u>	<u>A090602</u>	<u>001</u>	Sep 13, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090602</u>	<u>002</u>	Sep 13, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090602</u>	<u>003</u>	Sep 13, 2010
<u>AB2</u>	MYLAN	<u>30MG</u>	<u>A090649</u>	<u>001</u>	Jun 21, 2010
<u>AB2</u>		<u>60MG</u>	<u>A090649</u>	<u>002</u>	Jun 21, 2010
<u>AB2</u>		<u>90MG</u>	<u>A090649</u>	<u>003</u>	Jun 21, 2010
<u>AB2</u>	OSMOTICA PHARM	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
<u>AB2</u>		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005
<u>AB2</u>		<u>90MG</u>	<u>A077410</u>	<u>001</u>	Oct 03, 2007
<u>AB2</u>	TWI PHARMS INC	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014
<u>AB2</u>		<u>90MG</u>	<u>A203126</u>	<u>003</u>	Apr 03, 2014
<u>AB2</u>	VALEANT INTL	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000

PROCARDIA XL

<u>AB2</u>	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u>	+	<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

	NOVARTIS	EQ 150MG BASE	N022068	002	Jun 17, 2010
	+	EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

	+	COVIS PHARMA SARL	150MG	N020169	002	Apr 30, 1999
--	---	-------------------	-------	---------	-----	--------------

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<u>AB</u>	+	BANNER PHARMACAPS	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u>		BARR LABS INC	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>		SUN PHARM INDS INC	<u>30MG</u>	<u>A077067</u>	<u>001</u>	Apr 17, 2007
<u>AB</u>		THEPHARMANETWORK LLC	<u>30MG</u>	<u>A090103</u>	<u>001</u>	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

	+	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013
--	---	------------------	-----------	---------	-----	--------------

NINTEDANIB

CAPSULE;ORAL

OFEV

		BOEHRINGER INGELHEIM	100MG	N205832	001	Oct 15, 2014
	+		150MG	N205832	002	Oct 15, 2014

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<u>AB</u>	MYLAN	<u>8.5MG</u>	<u>A091001</u>	<u>001</u>	Jan 26, 2011
<u>AB</u>		<u>17MG</u>	<u>A091001</u>	<u>002</u>	Jan 26, 2011
<u>AB</u>		<u>34MG</u>	<u>A091001</u>	<u>004</u>	Jan 26, 2011

SULAR

<u>AB</u>	+	SHIONOGI INC	<u>8.5MG</u>	<u>N020356</u>	<u>008</u>	Jan 02, 2008
<u>AB</u>	+		<u>17MG</u>	<u>N020356</u>	<u>007</u>	Jan 02, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-265 (of 371)

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

AB	+	34MG	N020356	005	Jan 02, 2008
		NISOLDIPINE			
		MYLAN	20MG	A079051 001	Jul 25, 2008
			25.5MG	A091001 003	Jan 26, 2011
	+		30MG	A079051 002	Jul 25, 2008
	+		40MG	A079051 003	Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

	+	ROMARK	100MG/5ML	N021498 001	Nov 22, 2002
		TABLET; ORAL			
		ALINIA			
	+	ROMARK	500MG	N021497 001	Jul 21, 2004

NITISINONE

CAPSULE; ORAL

ORFADIN

		SWEDISH ORPHAN	2MG	N021232 001	Jan 18, 2002
			5MG	N021232 002	Jan 18, 2002
	+		10MG	N021232 003	Jan 18, 2002

NITRIC OXIDE

GAS; INHALATION

INOMAX

		INO	100PPM	N020845 002	Dec 23, 1999
	+		800PPM	N020845 003	Dec 23, 1999

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175	001
		NITROFURANTOIN			
AB		AMNEAL PHARMS	25MG/5ML	A201679	001 May 11, 2011
AB		NOVEL LABS INC	25MG/5ML	A201693	001 Sep 08, 2014
AB		SUN PHARM INDS INC	25MG/5ML	A201355	001 Aug 14, 2013

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB		ALVOGEN INC	50MG	N016620	001
AB	+		100MG	N016620	002
		NITROFURANTOIN			
AB		IVAX SUB TEVA PHARMS	50MG	A073671	001 Jan 28, 1993
AB			100MG	A073652	001 Jan 28, 1993
AB		MYLAN	50MG	A074967	001 Jul 09, 1997
AB			100MG	A077025	001 Aug 18, 2004
		MACRODANTIN			
		ALVOGEN INC	25MG	N016620 003	

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+	ALVOGEN INC	75MG; 25MG	N020064	001 Dec 24, 1991
		NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)			
AB		MYLAN	75MG; 25MG	A076648	001 Mar 22, 2004
AB		SANDOZ	75MG; 25MG	A077066	001 Apr 05, 2005

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST

	+	MIST PHARMS LLC	0.4MG/SPRAY	N021780 001	Nov 02, 2006
--	---	-----------------	-------------	-------------	--------------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1		MEDICIS	0.2MG/HR	A089772	001 Aug 30, 1996
AB1			0.4MG/HR	A089773	001 Aug 30, 1996
AB1		VALEANT PHARM NORTH	0.1MG/HR	A089771	001 Aug 30, 1996
AB1			0.6MG/HR	A089774	001 Aug 30, 1996

NITRO-DUR

AB1	+	MERCK SHARP DOHME	0.1MG/HR	N020145	001 Apr 04, 1995
AB1	+		0.2MG/HR	N020145	002 Apr 04, 1995
AB1	+		0.4MG/HR	N020145	004 Apr 04, 1995
AB1	+		0.6MG/HR	N020145	005 Apr 04, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-266 (of 371)

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

AB2	HERCON PHARM	<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998
AB2		<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998
AB2		<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998
AB2	+ MYLAN TECHNOLOGIES	<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
AB2	+	<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
AB2	+	<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996
	NITRO-DUR				
	+ MERCK SHARP DOHME	0.3MG/HR	N020145	003	Apr 04, 1995
	+	0.8MG/HR	N020145	006	Apr 04, 1995
	NITROGLYCERIN				
	+ MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998
	INJECTABLE; INJECTION				
	<u>NITROGLYCERIN IN DEXTROSE 5%</u>				
AP	+ BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
AP	+	<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
AP	+	<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989
AP	HOSPIRA	<u>10MG/100ML</u>	<u>A071846</u>	<u>001</u>	Aug 31, 1990
AP		<u>20MG/100ML</u>	<u>A071847</u>	<u>001</u>	Aug 31, 1990
AP		<u>40MG/100ML</u>	<u>A071848</u>	<u>001</u>	Aug 31, 1990
	NITROGLYCERIN				
	+ LUITPOLD	5MG/ML	A072034	001	May 24, 1988
	OINTMENT; INTRA-ANAL				
	RECTIV				
	+ FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011
	OINTMENT; TRANSDERMAL				
	NITROGLYCERIN				
	+ FOUGERA	2%	A087355	001	Jul 08, 1988
	SPRAY, METERED; SUBLINGUAL				
	<u>NITROGLYCERIN</u>				
AB	PERRIGO ISRAEL	<u>0.4MG/SPRAY</u>	<u>A091496</u>	<u>001</u>	Sep 20, 2013
	<u>NITROLINGUAL PUMPSPRAY</u>				
AB	+ POHL BOSKAMP	<u>0.4MG/SPRAY</u>	<u>N018705</u>	<u>002</u>	Jan 10, 1997
	TABLET; SUBLINGUAL				
	NITROSTAT				
	PFIZER PHARMS	0.3MG	N021134	001	May 01, 2000
		0.4MG	N021134	002	May 01, 2000
	+	0.6MG	N021134	003	May 01, 2000

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	ANI PHARMS INC	<u>150MG</u>	<u>A075668</u>	<u>001</u>	Sep 12, 2002
AB		<u>300MG</u>	<u>A075668</u>	<u>002</u>	Sep 12, 2002
AB	DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314</u>	<u>001</u>	Sep 15, 2005
AB		<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
AB	GLENMARK GENERICS	<u>150MG</u>	<u>A090618</u>	<u>001</u>	Jul 15, 2011
AB		<u>300MG</u>	<u>A090618</u>	<u>002</u>	Jul 15, 2011
AB	MYLAN PHARMS INC	<u>150MG</u>	<u>A075806</u>	<u>001</u>	Jul 05, 2002
AB	+	<u>300MG</u>	<u>A075806</u>	<u>002</u>	Jul 05, 2002
AB	SANDOZ	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
AB		<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
AB	WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
AB		<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

SOLUTION; ORAL

AXID

AA	+ BRAINTREE	<u>15MG/ML</u>	<u>N021494</u>	<u>001</u>	May 25, 2004
-----------	-------------	----------------	----------------	------------	--------------

NIZATIDINE

AA	AMNEAL PHARMS	<u>15MG/ML</u>	<u>A090576</u>	<u>001</u>	Nov 18, 2009
-----------	---------------	----------------	----------------	------------	--------------

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

LEVOPHED

AP	+ HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	
	<u>NOREPINEPHRINE BITARTRATE</u>				
AP	BEDFORD	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
AP	CLARIS LIFESCIENCES	<u>EQ 1MG BASE/ML</u>	<u>A040859</u>	<u>001</u>	Mar 27, 2012
AP	TEVA PHARMS USA	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-267 (of 371)

NORETHINDRONE

TABLET; ORAL-28

CAMILA

AB1	BARR	0.35MG	A076177	001	Oct 21, 2002
------------	------	---------------	----------------	------------	--------------

HEATHER

AB1	GLENMARK GENERICS	0.35MG	A090454	001	Apr 23, 2010
------------	-------------------	---------------	----------------	------------	--------------

NOR-OD

AB1	+ WATSON LABS (UTAH)	0.35MG	N017060	001	
------------	----------------------	---------------	----------------	------------	--

NORETHINDRONE

AB1	FAMY CARE LTD	0.35MG	A201483	001	Jun 24, 2013
------------	---------------	---------------	----------------	------------	--------------

AB1	HAUPT PHARMA	0.35MG	A202260	001	Aug 01, 2013
------------	--------------	---------------	----------------	------------	--------------

AB1	LUPIN LTD	0.35MG	A091325	001	Sep 19, 2011
------------	-----------	---------------	----------------	------------	--------------

AB1	NOVAST LABS LTD	0.35MG	A202014	001	Sep 13, 2013
------------	-----------------	---------------	----------------	------------	--------------

ERRIN

AB2	BARR	0.35MG	A076225	001	Oct 21, 2002
------------	------	---------------	----------------	------------	--------------

JENCYCLA

AB2	LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013
------------	-----------	---------------	----------------	------------	--------------

MICRONOR

AB2	+ JANSSEN PHARMS	0.35MG	N016954	001	
------------	------------------	---------------	----------------	------------	--

NORETHINDRONE

AB2	FAMY CARE LTD	0.35MG	A200980	001	Jun 12, 2013
------------	---------------	---------------	----------------	------------	--------------

AB2	GLENMARK GENERICS	0.35MG	A091209	001	Jul 21, 2010
------------	-------------------	---------------	----------------	------------	--------------

AB2	NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013
------------	-------------	---------------	----------------	------------	--------------

NORETHINDRONE ACETATE

TABLET; ORAL

AYGESTIN

AB	+ DURAMED RES	5MG	N018405	001	Apr 21, 1982
-----------	---------------	------------	----------------	------------	--------------

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012
-----------	---------------	------------	----------------	------------	--------------

AB	BARR	5MG	A075951	001	May 25, 2001
-----------	------	------------	----------------	------------	--------------

AB	GLENMARK GENERICS	5MG	A091090	001	Jul 21, 2010
-----------	-------------------	------------	----------------	------------	--------------

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB	MYLAN	EQ 10MG BASE	A074234	001	Jul 26, 1993
-----------	-------	---------------------	----------------	------------	--------------

AB		EQ 25MG BASE	A074234	002	Jul 26, 1993
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 50MG BASE	A074234	003	Jul 26, 1993
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 75MG BASE	A074234	004	Jul 26, 1993
-----------	--	---------------------	----------------	------------	--------------

AB	TARO	EQ 10MG BASE	A075520	004	May 08, 2000
-----------	------	---------------------	----------------	------------	--------------

AB		EQ 25MG BASE	A075520	003	May 08, 2000
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 50MG BASE	A075520	001	May 08, 2000
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 75MG BASE	A075520	002	May 08, 2000
-----------	--	---------------------	----------------	------------	--------------

AB	TEVA	EQ 10MG BASE	A074132	001	Mar 27, 1995
-----------	------	---------------------	----------------	------------	--------------

AB		EQ 25MG BASE	A074132	002	Mar 27, 1995
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 50MG BASE	A074132	003	Mar 27, 1995
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 75MG BASE	A074132	004	Mar 27, 1995
-----------	--	---------------------	----------------	------------	--------------

AB	WATSON LABS	EQ 10MG BASE	A073553	001	Mar 30, 1992
-----------	-------------	---------------------	----------------	------------	--------------

AB		EQ 25MG BASE	A073554	001	Mar 30, 1992
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 50MG BASE	A073555	001	Mar 30, 1992
-----------	--	---------------------	----------------	------------	--------------

AB		EQ 75MG BASE	A073556	001	Mar 30, 1992
-----------	--	---------------------	----------------	------------	--------------

PAMELOR

AB	MALLINCKRODT LLC	EQ 10MG BASE	N018013	001	
-----------	------------------	---------------------	----------------	------------	--

AB		EQ 25MG BASE	N018013	002	
-----------	--	---------------------	----------------	------------	--

AB		EQ 50MG BASE	N018013	004	
-----------	--	---------------------	----------------	------------	--

AB	+	EQ 75MG BASE	N018013	003	
-----------	---	---------------------	----------------	------------	--

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA	+ PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000
-----------	---------------	-------------------------	----------------	------------	--------------

AA	TARO	EQ 10MG BASE/5ML	A077965	001	Jun 20, 2006
-----------	------	-------------------------	----------------	------------	--------------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062949	001	Jun 13, 1988
-----------	----------------------	-------------------------	----------------	------------	--------------

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129	001	
-----------	----------------	-------------------------	----------------	------------	--

AT	PERRIGO NEW YORK	100,000 UNITS/GM	A062225	001	
-----------	------------------	-------------------------	----------------	------------	--

AT	+ TARO	100,000 UNITS/GM	A064022	001	Jan 29, 1993
-----------	--------	-------------------------	----------------	------------	--------------

AT	VINTAGE	100,000 UNITS/GM	A065315	001	May 31, 2006
-----------	---------	-------------------------	----------------	------------	--------------

OINTMENT; TOPICAL

NYSTATIN

AT	ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062840	001	Nov 13, 1987
-----------	----------------------	-------------------------	----------------	------------	--------------

AT	+ FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982
-----------	------------------	-------------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-268 (of 371)

NYSTATIN

OINTMENT; TOPICAL

NYSTATIN

AT	PERRIGO NEW YORK	<u>100,000 UNITS/GM</u>	<u>A062472</u>	<u>001</u>	Feb 13, 1984
-----------	------------------	-------------------------	----------------	------------	--------------

POWDER; TOPICAL

NYSTATIN

AT	+	COASTAL PHARMS	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
AT		GAVIS PHARMS	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
AT		UPSHER SMITH	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
AT		X GEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004

NYSTOP

AT		PADDOCK LLC	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996
-----------	--	-------------	-------------------------	----------------	------------	--------------

SUSPENSION; ORAL

NYSTATIN

AA		ACTAVIS MID ATLANTIC	<u>100,000 UNITS/ML</u>	<u>A062349</u>	<u>001</u>	Jul 14, 1982
AA		FOUGERA	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
AA		HI TECH PHARMA	<u>100,000 UNITS/ML</u>	<u>A064042</u>	<u>001</u>	Feb 28, 1994
AA		TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
AA		VINTAGE PHARMS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
AA		VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
AA			<u>100,000 UNITS/ML</u>	<u>A065422</u>	<u>001</u>	Mar 07, 2011
AA	+	WOCKHARDT	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

AA		HERITAGE PHARMS INC	<u>500,000 UNITS</u>	<u>A062474</u>	<u>001</u>	Dec 22, 1983
AA		MUTUAL PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
AA	+	TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

TABLET; VAGINAL

NYSTATIN

+	ODYSSEY PHARMS	<u>100,000 UNITS</u>	<u>A062615</u>	<u>001</u>	Oct 17, 1985
---	----------------	----------------------	----------------	------------	--------------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
AT	+	TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987

OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		FOUGERA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
AT	+	TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	+	EUROHLTH INTL	<u>EQ 0.2MG BASE/ML</u>	<u>A076330</u>	<u>001</u>	Apr 08, 2005
AP	+		<u>EQ 1MG BASE/ML</u>	<u>A076330</u>	<u>002</u>	Apr 08, 2005
AP		FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450</u>	<u>001</u>	Feb 10, 2006
AP			<u>EQ 1MG BASE/ML</u>	<u>A077450</u>	<u>002</u>	Feb 10, 2006
AP		SAGENT PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A091041</u>	<u>001</u>	Nov 12, 2013
AP			<u>EQ 1MG BASE/ML</u>	<u>A091041</u>	<u>002</u>	Nov 12, 2013
AP		SUN PHARM INDS	<u>EQ 0.05MG BASE/ML</u>	<u>A077329</u>	<u>001</u>	Mar 04, 2008
AP			<u>EQ 0.05MG BASE/ML</u>	<u>A077372</u>	<u>001</u>	Aug 14, 2007
AP			<u>EQ 0.1MG BASE/ML</u>	<u>A077329</u>	<u>002</u>	Mar 04, 2008
AP			<u>EQ 0.1MG BASE/ML</u>	<u>A077372</u>	<u>002</u>	Aug 14, 2007
AP			<u>EQ 0.2MG BASE/ML</u>	<u>A077330</u>	<u>001</u>	Mar 04, 2008
AP			<u>EQ 0.2MG BASE/ML</u>	<u>A077373</u>	<u>001</u>	Aug 14, 2007
AP			<u>EQ 0.5MG BASE/ML</u>	<u>A077329</u>	<u>003</u>	Mar 04, 2008
AP			<u>EQ 0.5MG BASE/ML</u>	<u>A077372</u>	<u>003</u>	Aug 14, 2007
AP			<u>EQ 1MG BASE/ML</u>	<u>A077331</u>	<u>001</u>	Mar 04, 2008
AP			<u>EQ 1MG BASE/ML</u>	<u>A077373</u>	<u>002</u>	Aug 14, 2007
AP		TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957</u>	<u>001</u>	Oct 03, 2005
AP			<u>EQ 0.1MG BASE/ML</u>	<u>A075957</u>	<u>002</u>	Oct 03, 2005
AP			<u>EQ 0.2MG BASE/ML</u>	<u>A075959</u>	<u>001</u>	Nov 21, 2005
AP			<u>EQ 0.5MG BASE/ML</u>	<u>A075957</u>	<u>003</u>	Oct 03, 2005
AP			<u>EQ 1MG BASE/ML</u>	<u>A075959</u>	<u>002</u>	Nov 21, 2005
AP		WOCKHARDT USA	<u>EQ 0.2MG BASE/ML</u>	<u>A090986</u>	<u>001</u>	May 11, 2011
AP			<u>EQ 1MG BASE/ML</u>	<u>A090986</u>	<u>002</u>	May 11, 2011

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	+	EUROHLTH INTL	<u>EQ 0.05MG BASE/ML</u>	<u>A076313</u>	<u>001</u>	Mar 28, 2005
AP	+		<u>EQ 0.1MG BASE/ML</u>	<u>A076313</u>	<u>003</u>	Mar 28, 2005
AP	+		<u>EQ 0.5MG BASE/ML</u>	<u>A076313</u>	<u>002</u>	Mar 28, 2005
AP		FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457</u>	<u>001</u>	Feb 10, 2006
AP			<u>EQ 0.1MG BASE/ML</u>	<u>A077457</u>	<u>002</u>	Feb 10, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-269 (of 371)

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457</u>	<u>003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198</u>	<u>001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198</u>	<u>002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198</u>	<u>003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A090834</u>	<u>001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834</u>	<u>002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834</u>	<u>003</u>	Nov 12, 2013
<u>AP</u>	WOCKHARDT USA	<u>EQ 0.05MG BASE/ML</u>	<u>A090985</u>	<u>001</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090985</u>	<u>002</u>	May 11, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090985</u>	<u>003</u>	May 11, 2011

SANDOSTATIN

<u>AP</u>	+	NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667</u>	<u>001</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.1MG BASE/ML</u>	<u>N019667</u>	<u>002</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 0.2MG BASE/ML</u>	<u>N019667</u>	<u>004</u>	Jun 12, 1991
<u>AP</u>	+		<u>EQ 0.5MG BASE/ML</u>	<u>N019667</u>	<u>003</u>	Oct 21, 1988
<u>AP</u>	+		<u>EQ 1MG BASE/ML</u>	<u>N019667</u>	<u>005</u>	Jun 12, 1991
		SANDOSTATIN LAR				
		NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998
			EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998
	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

<u>AT</u>	+	ALLERGAN	<u>0.3%</u>	<u>N019921</u>	<u>001</u>	Jul 30, 1993
		<u>OFLOXACIN</u>				
<u>AT</u>		AKORN	<u>0.3%</u>	<u>A076407</u>	<u>001</u>	Apr 15, 2008
<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A076231</u>	<u>001</u>	May 14, 2004
<u>AT</u>		ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692</u>	<u>001</u>	Apr 29, 2013
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622</u>	<u>001</u>	May 14, 2004
<u>AT</u>		FDC LTD	<u>0.3%</u>	<u>A078559</u>	<u>001</u>	Feb 25, 2009
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A076830</u>	<u>001</u>	Aug 31, 2004
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076615</u>	<u>001</u>	May 14, 2004

SOLUTION/DROPS; OTIC

FLOXIN OTIC

<u>AT</u>	+	DAIICHI	<u>0.3%</u>	<u>N020799</u>	<u>001</u>	Dec 16, 1997
		<u>OFLOXACIN</u>				
<u>AT</u>		ALCON PHARMS LTD	<u>0.3%</u>	<u>A078222</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>		APOTEX INC	<u>0.3%</u>	<u>A076527</u>	<u>001</u>	Sep 28, 2007
<u>AT</u>		BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128</u>	<u>001</u>	Mar 17, 2008
<u>AT</u>		FERA PHARMS	<u>0.3%</u>	<u>A090395</u>	<u>001</u>	Aug 11, 2009
<u>AT</u>		HI TECH PHARMA	<u>0.3%</u>	<u>A076616</u>	<u>001</u>	Mar 17, 2008

TABLET; ORAL

OFLOXACIN

<u>AB</u>		CADILA PHARMS LTD	<u>200MG</u>	<u>A091656</u>	<u>001</u>	Sep 18, 2014
<u>AB</u>			<u>300MG</u>	<u>A091656</u>	<u>002</u>	Sep 18, 2014
<u>AB</u>			<u>400MG</u>	<u>A091656</u>	<u>003</u>	Sep 18, 2014
<u>AB</u>		DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>			<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>			<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>		TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>			<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	+		<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>		LUITPOLD	<u>10MG/VIAL</u>	<u>A201741</u>	<u>001</u>	Mar 20, 2012
<u>AP</u>		SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588</u>	<u>001</u>	Oct 24, 2011
		<u>ZYPREXA</u>				
<u>AP</u>	+	LILLY	<u>10MG/VIAL</u>	<u>N021253</u>	<u>001</u>	Mar 29, 2004

TABLET; ORAL

OLANZAPINE

<u>AB</u>		APOTEX INC	<u>2.5MG</u>	<u>A090798</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>			<u>5MG</u>	<u>A090798</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>			<u>7.5MG</u>	<u>A090798</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>			<u>10MG</u>	<u>A090798</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>			<u>15MG</u>	<u>A090798</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>			<u>20MG</u>	<u>A090798</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050</u>	<u>001</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-270 (of 371)

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>		<u>5MG</u>	<u>A202050</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862</u>	<u>001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862</u>	<u>002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862</u>	<u>003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862</u>	<u>004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862</u>	<u>005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862</u>	<u>006</u>	Aug 15, 2014
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076866</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076866</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076866</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076866</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076866</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076866</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ORCHID HLTHCARE	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A076000</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>5MG</u>	<u>A076000</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A076000</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076000</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076000</u>	<u>005</u>	Oct 24, 2011
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A091434</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091434</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091434</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091434</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091434</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091434</u>	<u>006</u>	Apr 23, 2012

ZYPREXA

<u>AB</u>	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708</u>	<u>001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708</u>	<u>002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708</u>	<u>003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708</u>	<u>004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-271 (of 371)

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A078109</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A078109</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A090881</u>	<u>001</u>	Feb 28, 2012
<u>AB</u>		<u>10MG</u>	<u>A090881</u>	<u>002</u>	Feb 28, 2012
<u>AB</u>		<u>15MG</u>	<u>A090881</u>	<u>003</u>	Feb 28, 2012
<u>AB</u>		<u>20MG</u>	<u>A090881</u>	<u>004</u>	Feb 28, 2012
<u>AB</u>	TORRENT PHARMS LLC	<u>5MG</u>	<u>A091415</u>	<u>001</u>	Oct 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A091415</u>	<u>002</u>	Oct 25, 2011
<u>AB</u>		<u>15MG</u>	<u>A091415</u>	<u>003</u>	Oct 25, 2011
<u>AB</u>		<u>20MG</u>	<u>A091415</u>	<u>004</u>	Oct 25, 2011
<u>ZYPREXA ZYDIS</u>					
<u>AB</u>	+ LILLY	<u>5MG</u>	<u>N021086</u>	<u>001</u>	Apr 06, 2000
<u>AB</u>		<u>10MG</u>	<u>N021086</u>	<u>002</u>	Apr 06, 2000
<u>AB</u>		<u>15MG</u>	<u>N021086</u>	<u>003</u>	Apr 06, 2000
<u>AB</u>		<u>20MG</u>	<u>N021086</u>	<u>004</u>	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ZYPREXA RELPREVV

ELI LILLY CO

EQ 210MG BASE/VIAL

N022173 001 Dec 11, 2009

EQ 300MG BASE/VIAL

N022173 002 Dec 11, 2009

+

EQ 405MG BASE/VIAL

N022173 003 Dec 11, 2009

OLAPARIB

CAPSULE; ORAL

OLAPARIB

ASTRAZENECA PHARMS

50MG

N206162 001 Dec 19, 2014

OLIVE OIL; SOYBEAN OIL

INJECTABLE; INJECTION

CLINOLIPID 20%

+ BAXTER HLTHCARE

16% (160GM/1000ML); 4% (40GM/1000ML)

N204508 001 Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

DAIICHI SANKYO

5MG

N021286 001 Apr 25, 2002

20MG

N021286 003 Apr 25, 2002

+

40MG

N021286 004 Apr 25, 2002

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+ BOEHRINGER INGELHEIM

EQ 0.0025MG BASE/INH

N203108 001 Jul 31, 2014

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PATADAY

+ ALCON PHARMS LTD

EQ 0.2% BASE

N021545 001 Dec 22, 2004

PATANOL

+ ALCON

EQ 0.1% BASE

N020688 001 Dec 18, 1996

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>0.665MG/SPRAY</u>	<u>A091572</u>	<u>001</u>	Oct 08, 2014
<u>AB</u>	+ ALCON PHARMS LTD	<u>0.665MG/SPRAY</u>	<u>N021861</u>	<u>001</u>	Apr 15, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-272 (of 371)

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+ MEDA PHARMS

250MG

N019715 001 Jul 31, 1990

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+ IVAX INTL

3.5MG/VIAL

N203585 001 Oct 26, 2012

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZAAB + SMITHKLINE BEECHAM1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSN021654 001 Nov 10, 2004OMEGA-3-ACID ETHYL ESTERSAB APOTEX INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA090973 001 Sep 30, 2014AB PAR PHARM INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091018 001 Jun 24, 2014AB TEVA PHARMS USA1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091028 001 Apr 07, 2014

OMTRYG

+ TRYGG

1.2GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977 001 Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE; ORAL

EPANOVA

+ ASTRAZENECA PHARMS

1GM CONTAINS AT LEAST 850MG OF
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLEAB ACTAVIS LABS FL INC10MGA075347 001 May 30, 2008AB20MGA075347 002 May 30, 2008AB40MGA075347 003 May 30, 2008AB APOTEX10MGA076048 001 Oct 22, 2007AB20MGA076048 002 Oct 22, 2007AB40MGA076048 003 Jan 21, 2009AB DR REDDYS LABS LTD10MGA075576 003 Oct 22, 2007AB10MGA078490 002 Mar 16, 2009AB20MGA075576 002 Oct 22, 2007AB20MGA078490 003 Mar 16, 2009AB40MGA075576 001 Jan 21, 2009AB40MGA078490 001 Apr 17, 2009AB GLENMARK GENERICS10MGA091672 001 Oct 31, 2014AB20MGA091672 002 Oct 31, 2014AB40MGA091672 003 Oct 31, 2014AB IMPAX LABS10MGA075785 001 Oct 22, 2007AB20MGA075785 002 Oct 22, 2007AB40MGA075785 003 Jan 21, 2009AB KREMERS URBAN PHARMS10MGA075410 001 Nov 01, 2002AB20MGA075410 002 Nov 01, 2002AB40MGA075410 003 Jan 23, 2009AB MYLAN10MGA075876 001 May 29, 2003AB20MGA075876 002 May 29, 2003AB40MGA075876 003 Jan 21, 2009AB SANDOZ10MGA075757 001 Jan 28, 2003AB20MGA075757 002 Jan 28, 2003AB40MGA076515 001 Jan 21, 2009AB ZYDUS PHARMS USA INC10MGA091352 001 Nov 19, 2012AB20MGA091352 002 Nov 19, 2012AB40MGA091352 003 Nov 19, 2012PRILOSECAB ASTRAZENECA PHARMS10MGN019810 003 Oct 05, 1995AB

+

20MGN019810 001 Sep 14, 1989AB

+

40MGN019810 002 Jan 15, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-273 (of 371)

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PRILOSEC

ASTRAZENECA PHARMS EQ 2.5MG BASE/PACKET
 + EQ 10MG BASE/PACKET

N022056 001 Mar 20, 2008
 N022056 002 Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB PAR PHARM **20MG;1.1GM**
AB **40MG;1.1GM**

A078966 001 May 25, 2010
A078966 002 May 25, 2010

ZEGERID

AB SANTARUS INC **20MG;1.1GM**
AB + **40MG;1.1GM**

N021849 001 Feb 27, 2006
N021849 002 Feb 27, 2006

FOR SUSPENSION; ORAL

ZEGERID

SANTARUS INC 20MG/PACKET;1.68GM/PACKET
 + 40MG/PACKET;1.68GM/PACKET

N021636 001 Jun 15, 2004
 N021636 002 Dec 21, 2004

ONDANSETRON

FILM; ORAL

ZUPLENZ

GALENA BIOPHARMA INC 4MG
 + 8MG

N022524 001 Jul 02, 2010
 N022524 002 Jul 02, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB AUROBINDO PHARMA **4MG**
AB **8MG**
AB BARR **4MG**
AB **8MG**
AB GLENMARK GENERICS **4MG**
AB **8MG**
AB MYLAN **4MG**
AB **8MG**
AB RANBAXY **4MG**
AB **8MG**
AB SANDOZ **4MG**
AB **8MG**
AB SUN PHARM INDS **4MG**
AB **8MG**
AB TEVA **4MG**
AB **8MG**

A090469 001 Apr 12, 2010
A090469 002 Apr 12, 2010
A076693 001 Jun 25, 2007
A076693 002 Jun 25, 2007
A078152 001 Jun 27, 2007
A078152 002 Jun 27, 2007
A078139 001 Jun 25, 2007
A078139 002 Jun 25, 2007
A078602 001 Feb 24, 2011
A078602 002 Feb 24, 2011
A078050 001 Aug 13, 2007
A078050 002 Aug 13, 2007
A077557 001 Aug 02, 2007
A077557 002 Aug 02, 2007
A076810 001 Jun 25, 2007
A076810 002 Jun 25, 2007

ZOFRAN ODT

AB GLAXOSMITHKLINE **4MG**
AB + **8MG**

N020781 001 Jan 27, 1999
N020781 002 Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP AGILA SPECLTS **EQ 2MG BASE/ML**
AP AUROBINDO PHARMA LTD **EQ 2MG BASE/ML**
AP BEDFORD **EQ 2MG BASE/ML**
AP CLARIS LIFESCIENCES **EQ 2MG BASE/ML**
AP EMCURE PHARMS **EQ 2MG BASE/ML**
AP FRESENIUS KABI USA **EQ 2MG BASE/ML**
AP GLAND PHARMA LTD **EQ 2MG BASE/ML**
AP **EQ 2MG BASE/ML**
AP HIKMA FARMACEUTICA **EQ 2MG BASE/ML**
AP HIKMA MAPLE **EQ 2MG BASE/ML**
AP HOSPIRA **EQ 2MG BASE/ML**
AP **EQ 2MG BASE/ML**
AP LANNETT **EQ 2MG BASE/ML**
AP LUITPOLD **EQ 2MG BASE/ML**
AP QILU PHARM CO LTD **EQ 2MG BASE/ML**
AP SANDOZ **EQ 2MG BASE/ML**
AP SUN PHARM INDS (IN) **EQ 2MG BASE/ML**
AP TEVA **EQ 2MG BASE/ML**
AP WOCKHARDT **EQ 2MG BASE/ML**

A078257 001 Apr 23, 2008
A202599 001 Dec 21, 2012
A076967 001 Dec 26, 2006
A078288 001 Feb 22, 2013
A090424 001 Apr 16, 2010
A076974 001 Dec 26, 2006
A079224 001 Sep 25, 2009
A090648 001 Jun 15, 2012
A076781 001 Dec 26, 2006
A077365 001 Dec 26, 2006
A077473 001 Dec 26, 2006
A077840 001 Jan 19, 2007
A090883 001 Aug 05, 2010
A079039 001 Nov 18, 2008
A203711 001 Sep 08, 2014
A077430 001 Jun 27, 2007
A077172 001 Dec 26, 2006
A076876 001 Nov 22, 2006
A077577 001 Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP AGILA SPECLTS **EQ 2MG BASE/ML**
AP AUROBINDO PHARMA LTD **EQ 2MG BASE/ML**
AP BD RX **EQ 2MG BASE/ML**
AP BEDFORD LABS **EQ 2MG BASE/ML**
AP CLARIS LIFESCIENCES **EQ 2MG BASE/ML**

A078244 001 Apr 23, 2008
A202600 001 Dec 21, 2012
A202253 001 Jul 19, 2013
A077011 001 Dec 26, 2006
A078287 001 Feb 22, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-274 (of 371)

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 2MG BASE/ML</u>	<u>A078945</u>	<u>001</u>	Jan 03, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076780</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA MAPLE	<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	LUITPOLD	<u>EQ 2MG BASE/ML</u>	<u>A079032</u>	<u>001</u>	Nov 18, 2008
<u>AP</u>	SANDOZ	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 2MG BASE/ML</u>	<u>A077173</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	TARO PHARMS IRELAND	<u>EQ 2MG BASE/ML</u>	<u>A078014</u>	<u>001</u>	Mar 21, 2008
<u>AP</u>	TEVA	<u>EQ 2MG BASE/ML</u>	<u>A076759</u>	<u>001</u>	Nov 22, 2006
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

ZOFRAN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>001</u>	Jan 04, 1991
-----------	-------------------	-----------------------	----------------	------------	--------------

ZOFRAN PRESERVATIVE FREE

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 2MG BASE/ML</u>	<u>N020007</u>	<u>003</u>	Dec 10, 1993
-----------	-------------------	-----------------------	----------------	------------	--------------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	APOTEX	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	ROXANE	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	SILARX	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

ZOFRAN

<u>AA</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/5ML</u>	<u>N020605</u>	<u>001</u>	Jan 24, 1997
-----------	-------------------	------------------------	----------------	------------	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A078539</u>	<u>003</u>	Jul 31, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076183</u>	<u>001</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077535</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>	MYLAN	<u>EQ 4MG BASE</u>	<u>A076930</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076930</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076930</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	PLIVA HRVATSKA DOO	<u>EQ 4MG BASE</u>	<u>A077112</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077112</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077112</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A077517</u>	<u>003</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	TEVA	<u>EQ 4MG BASE</u>	<u>A076252</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076252</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 24MG BASE</u>	<u>A076252</u>	<u>003</u>	Jun 25, 2007

ZOFRAN

<u>AB</u>	GLAXOSMITHKLINE	<u>EQ 4MG BASE</u>	<u>N020103</u>	<u>001</u>	Dec 31, 1992
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N020103</u>	<u>002</u>	Dec 31, 1992
<u>AB</u>	+ ONDANSETRON HYDROCHLORIDE	<u>EQ 24MG BASE</u>	<u>N020103</u>	<u>003</u>	Aug 27, 1999
	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006

ORITAVANCIN DIPHOSPHATE

POWDER; IV (INFUSION)

ORBACTIV

	+ MEDICINES CO	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014
--	----------------	--------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-275 (of 371)

ORLISTAT

CAPSULE; ORAL

XENICAL

+ HOFFMANN LA ROCHE

120MG

N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEXAP + MEDICIS30MG/MLN013055 001ORPHENADRINE CITRATEAP AKORN30MG/MLA040484 001 May 24, 2006AP EUROHLTH INTL30MG/MLA040463 001 Mar 04, 2003AP SAGENT PHARMS30MG/MLA090585 001 Aug 30, 2011AP WATSON LABS30MG/MLA084779 001 Mar 15, 1982

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATEAB GAVIS PHARMS100MGA040284 001 Jun 19, 1998AB IMPAX PHARMS100MGA040368 001 Jun 23, 2000AB INVAGEN PHARMS100MGA091158 001 Jul 27, 2012AB + SANDOZ100MGA040327 001 Feb 15, 2000AB TEDOR PHARMA INC100MGA040249 001 Jan 29, 1999OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

TAMIFLU

ROCHE

EQ 30MG BASE

N021087 003 Jul 02, 2007

EQ 45MG BASE

N021087 002 Jul 02, 2007

+

EQ 75MG BASE

N021087 001 Oct 27, 1999

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE

EQ 6MG BASE/ML

N021246 002 Mar 21, 2011

OSPEMIFENE

TABLET; ORAL

OSPHEA

+ SHIONOGI INC

60MG

N203505 001 Feb 26, 2013

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUMAP AGILA SPECLTSEQ 1GM BASE/VIALA091486 001 Aug 25, 2014APEQ 2GM BASE/VIALA091486 002 Aug 25, 2014AP AUROBINDO PHARMA LTDEQ 1GM BASE/VIALA201539 001 Jan 18, 2013APEQ 2GM BASE/VIALA201539 002 Jan 18, 2013APEQ 10GM BASE/VIALA201538 001 Jan 18, 2013AP SAGENT PHARMSEQ 1GM BASE/VIALA091246 001 Mar 30, 2012APEQ 2GM BASE/VIALA091246 002 Mar 30, 2012APEQ 10GM BASE/VIALA091245 001 Mar 30, 2012AP + SANDOZEQ 1GM BASE/VIALA061490 003AP +EQ 2GM BASE/VIALA061490 004AP +EQ 10GM BASE/VIALA061490 006 May 09, 1991

BACTOCILL IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

EQ 20MG BASE/ML

N050640 001 Oct 26, 1989

+

EQ 40MG BASE/ML

N050640 002 Oct 26, 1989

POWDER; INTRAVENOUS

OXACILLIN SODIUMAP + SANDOZEQ 1GM BASE/VIALA062737 001 Dec 23, 1986AP +EQ 2GM BASE/VIALA062737 002 Dec 23, 1986OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATINAP + SANOFI AVENTIS US50MG/10ML (5MG/ML)N021759 001 Jan 31, 2005AP +100MG/20ML (5MG/ML)N021759 002 Jan 31, 2005OXALIPLATINAP ACTAVIS TOTOWA50MG/VIALA078803 001 Aug 08, 2012AP100MG/VIALA078803 002 Aug 08, 2012AP EBEWE PHARMA50MG/10ML (5MG/ML)A078812 001 Aug 07, 2009AP100MG/20ML (5MG/ML)A078812 002 Aug 07, 2009AP FRESENIUS KABI ONCOL50MG/10ML (5MG/ML)A078811 001 Jun 10, 2010AP100MG/20ML (5MG/ML)A078811 002 Jun 10, 2010AP50MG/VIALA078810 001 Aug 07, 2009AP100MG/VIALA078810 002 Aug 07, 2009AP FRESENIUS KABI USA50MG/VIALA078819 001 Jun 02, 2010AP100MG/VIALA078819 002 Jun 02, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-276 (of 371)

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

<u>AP</u>	HOSPIRA INC	<u>50MG/VIAL</u>	<u>A078815</u>	<u>001</u>	Sep 30, 2009
<u>AP</u>		<u>100MG/VIAL</u>	<u>A078815</u>	<u>002</u>	Sep 30, 2009
<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	JIANGSU HENGRUI MED	<u>50MG/10ML (5MG/ML)</u>	<u>A203869</u>	<u>001</u>	Jun 18, 2014
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A203869</u>	<u>002</u>	Jun 18, 2014
<u>AP</u>	ONCO THERAPIES LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358</u>	<u>001</u>	Aug 07, 2012
<u>AP</u>		<u>50MG/VIAL</u>	<u>A200979</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358</u>	<u>002</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/VIAL</u>	<u>A200979</u>	<u>002</u>	Aug 08, 2012
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817</u>	<u>001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817</u>	<u>002</u>	Jan 24, 2011
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>50MG/VIAL</u>	<u>A078818</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>50MG/10ML (5MG/ML)</u>	<u>A202922</u>	<u>001</u>	Apr 08, 2014
<u>AP</u>	+	<u>100MG/VIAL</u>	<u>A078818</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A202922</u>	<u>002</u>	Apr 08, 2014
<u>AP</u>	+ TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+	<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	ELOXATIN				
	+ SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006

OXANDROLONE

TABLET; ORAL

OXANDRIN

<u>AB</u>	CREALTA PHARMS LLC	<u>2.5MG</u>	<u>N013718</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N013718</u>	<u>002</u>	Nov 05, 2001
	<u>OXANDROLONE</u>				
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+ GD SEARLE	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992
	<u>OXAPROZIN</u>				
<u>AB</u>	APOTEX INC	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>600MG</u>	<u>A075846</u>	<u>001</u>	May 13, 2002
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	SUN PHARM INDS INC	<u>600MG</u>	<u>A075844</u>	<u>001</u>	Jan 03, 2002
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072251</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072252</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	+	<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	RANBAXY	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
<u>AB</u>	ROXANE	<u>300MG/5ML</u>	<u>A201193</u>	<u>001</u>	Oct 03, 2012
	<u>TRILEPTAL</u>				
<u>AB</u>	+ NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	APOTEX INC	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	CADISTA PHARMS	<u>150MG</u>	<u>A090239</u>	<u>001</u>	Jan 25, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-277 (of 371)

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		<u>300MG</u>	<u>A090239</u>	<u>002</u>	Jan 25, 2010
<u>AB</u>		<u>600MG</u>	<u>A090239</u>	<u>003</u>	Jan 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	ROXANE	<u>150MG</u>	<u>A077795</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077795</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077795</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007

TRILEPTAL

<u>AB</u>	NOVARTIS	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>		<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000
TABLET, EXTENDED RELEASE; ORAL					
OXTELLAR XR					
	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
		300MG	N202810	002	Oct 19, 2012
	+	600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+ FOUGERA PHARMS EQ 1% BASE

N019828 001 Dec 30, 1988

LOTION; TOPICAL

OXISTAT

+ FOUGERA PHARMS EQ 1% BASE

N020209 001 Sep 30, 1992

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+ WARNER CHILCOTT LLC 400MG

A087863 001 May 24, 1983

+ 600MG

A086742 001

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYBUTYNIN

<u>AB</u>	BARR LABS DIV TEVA	<u>3.9MG/24HR</u>	<u>A090526</u>	<u>001</u>	Mar 04, 2014
<u>OXYTROL</u>					
<u>AB</u>	+ WATSON LABS (UTAH)	<u>3.9MG/24HR</u>	<u>N021351</u>	<u>002</u>	Feb 26, 2003
GEL, METERED; TRANSDERMAL					
GELNIQUE 3%					
	+ WATSON LABS INC	3%	N202513	001	Dec 07, 2011

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+ WATSON LABS 10% (100MG/PACKET)

N022204 001 Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998
<u>AA</u>	SILARK	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>	VINTAGE PHARMS	<u>5MG/5ML</u>	<u>A076682</u>	<u>001</u>	Dec 28, 2004
<u>AA</u>	+ WOCKHARDT	<u>5MG/5ML</u>	<u>A074868</u>	<u>001</u>	Feb 12, 1997

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	USL PHARMA	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
<u>AB</u>	+ VINTAGE PHARMS	<u>5MG</u>	<u>A075079</u>	<u>001</u>	Oct 31, 1997

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998
<u>AB</u>	+	<u>15MG</u>	<u>N020897</u>	<u>003</u>	Jun 22, 1999

OXYBUTYNIN CHLORIDE

<u>AB</u>	IMPAX PHARMS	<u>5MG</u>	<u>A076745</u>	<u>002</u>	May 09, 2007
<u>AB</u>		<u>10MG</u>	<u>A076745</u>	<u>003</u>	May 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-278 (of 371)

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A076745</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A076702</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A076644</u>	<u>001</u>	Nov 09, 2006
<u>AB</u>		<u>15MG</u>	<u>A076644</u>	<u>002</u>	May 10, 2007
<u>AB</u>	OSMOTICA PHARM	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	LANNETT HOLDINGS INC	<u>5MG</u>	<u>A203823</u>	<u>001</u>	Aug 01, 2014
<u>AB</u>	+ LEHIGH VALLEY	<u>5MG</u>	<u>N200534</u>	<u>001</u>	Oct 20, 2010

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	COASTAL PHARMS	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014
<u>AA</u>	LANNETT HOLDINGS INC	<u>100MG/5ML</u>	<u>A204085</u>	<u>001</u>	Sep 09, 2014
<u>AA</u>	LEHIGH VALLEY	<u>5MG/5ML</u>	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+	<u>100MG/5ML</u>	<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	ROXANE	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>100MG/5ML</u>	<u>A203208</u>	<u>001</u>	Jul 12, 2013
<u>AA</u>	+ VISTAPHARM	<u>5MG/5ML</u>	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A076636</u>	<u>001</u>	Feb 06, 2004
<u>AB</u>		<u>30MG</u>	<u>A076636</u>	<u>002</u>	Feb 06, 2004
<u>AB</u>	ALVOGEN INC	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>		<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	COASTAL PHARMS	<u>5MG</u>	<u>A091313</u>	<u>001</u>	Feb 18, 2011
<u>AB</u>		<u>15MG</u>	<u>A091313</u>	<u>002</u>	Feb 18, 2011
<u>AB</u>		<u>30MG</u>	<u>A091313</u>	<u>003</u>	Feb 18, 2011
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>	MALLINCKRODT INC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	NESHER PHARMS	<u>5MG</u>	<u>A077290</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>10MG</u>	<u>A077290</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>15MG</u>	<u>A077290</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>20MG</u>	<u>A077290</u>	<u>004</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077290</u>	<u>005</u>	Dec 08, 2005
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A077712</u>	<u>003</u>	Mar 02, 2009
<u>AB</u>		<u>15MG</u>	<u>A077712</u>	<u>001</u>	Jan 31, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-279 (of 371)

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		30MG	A077712 002	Jan 31, 2007
	<u>ROXICODONE</u>			
AB	MALLINCKRODT INC	5MG	N021011 003	May 15, 2009
AB	+	15MG	N021011 001	Aug 31, 2000
AB		30MG	N021011 002	Aug 31, 2000
	<u>OXYCTA</u>			
	ACURA PHARMS INC	5MG	N202080 001	Jun 17, 2011
		7.5MG	N202080 002	Jun 17, 2011
	<u>TABLET, EXTENDED RELEASE; ORAL</u>			
	<u>OXYCONTIN</u>			
	PURDUE PHARMA LP	10MG	N022272 001	Apr 05, 2010
		15MG	N022272 002	Apr 05, 2010
		20MG	N022272 003	Apr 05, 2010
		30MG	N022272 004	Apr 05, 2010
	+	40MG	N022272 005	Apr 05, 2010
		60MG	N022272 006	Apr 05, 2010
		80MG	N022272 007	Apr 05, 2010

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+	MEDA PHARMS	50MG	N016848 001	
---	-------------	------	-------------	--

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

+	ENDO PHARMS	1MG/ML	N011707 002	
---	-------------	--------	-------------	--

TABLET; ORAL

OPANA

AB	ENDO PHARMS	5MG	N021611 001	Jun 22, 2006
AB	+	10MG	N021611 002	Jun 22, 2006
	<u>OXYMORPHONE HYDROCHLORIDE</u>			
AB	AVANTHI INC	5MG	A203601 001	Jan 30, 2013
AB		10MG	A203601 002	Jan 30, 2013
AB	COREPHARMA	5MG	A201187 001	Dec 15, 2014
AB		10MG	A201187 002	Dec 15, 2014
AB	MALLINCKRODT INC	5MG	A202321 001	Apr 25, 2013
AB		10MG	A202321 002	Apr 25, 2013
AB	ROXANE	5MG	A090964 001	Sep 27, 2010
AB		10MG	A090964 002	Sep 27, 2010
AB	TEVA	5MG	A091443 002	Feb 15, 2011
AB		10MG	A091443 001	Feb 15, 2011

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	5MG	A079046 003	Jul 11, 2013
AB		7.5MG	A079046 001	Dec 13, 2010
AB		10MG	A079046 004	Jul 11, 2013
AB		15MG	A079046 002	Dec 13, 2010
AB		20MG	A079046 005	Jul 11, 2013
AB		30MG	A079046 006	Jul 11, 2013
AB		40MG	A079046 007	Jul 11, 2013
AB	IMPAX LABS	5MG	A079087 001	Jun 14, 2010
AB		7.5MG	A079087 002	Dec 21, 2010
AB		10MG	A079087 003	Jun 14, 2010
AB		15MG	A079087 004	Dec 21, 2010
AB		20MG	A079087 005	Jun 14, 2010
AB		30MG	A079087 006	Jul 22, 2010
AB		40MG	A079087 007	Jun 14, 2010
AB	MALLINCKRODT INC	5MG	A202946 001	Jun 27, 2014
AB		7.5MG	A202946 002	Jun 27, 2014
AB		10MG	A202946 003	Jun 27, 2014
AB		15MG	A202946 004	Jun 27, 2014
AB		20MG	A202946 005	Jun 27, 2014
AB		30MG	A202946 006	Jun 27, 2014
AB		40MG	A202946 007	Jun 27, 2014
AB	PAR PHARM	5MG	A200792 001	Oct 24, 2014
AB		7.5MG	A200792 002	Oct 24, 2014
AB		10MG	A200792 003	Oct 24, 2014
AB		15MG	A200792 004	Oct 24, 2014
AB		20MG	A200792 005	Oct 24, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-280 (of 371)

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A200792</u>	<u>006</u>	Oct 24, 2014
<u>AB</u>		<u>40MG</u>	<u>A200792</u>	<u>007</u>	Oct 24, 2014
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A200822</u>	<u>002</u>	Jul 15, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200822</u>	<u>003</u>	Jul 15, 2013
<u>AB</u>		<u>10MG</u>	<u>A200822</u>	<u>004</u>	Jul 15, 2013
<u>AB</u>		<u>15MG</u>	<u>A200822</u>	<u>005</u>	Jul 15, 2013
<u>AB</u>		<u>20MG</u>	<u>A200822</u>	<u>006</u>	Jul 15, 2013
<u>AB</u>		<u>30MG</u>	<u>A200822</u>	<u>007</u>	Jul 15, 2013
<u>AB</u>		<u>40MG</u>	<u>A200822</u>	<u>001</u>	Jul 15, 2013
	OPANA ER				
	ENDO PHARMS	5MG	N201655	001	Dec 09, 2011
		7.5MG	N201655	002	Dec 09, 2011
		10MG	N201655	003	Dec 09, 2011
		15MG	N201655	004	Dec 09, 2011
		20MG	N201655	005	Dec 09, 2011
		30MG	N201655	006	Dec 09, 2011
	+	40MG	N201655	007	Dec 09, 2011

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

+	PFIZER	EQ 5MG BASE/GM;10,000 UNITS/GM	A061015	001	
---	--------	--------------------------------	---------	-----	--

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

<u>AP</u>	+	FRESENIUS KABI USA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018248</u>	<u>002</u>	
<u>AP</u>		HIKMA FARMACEUTICA	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A200219</u>	<u>001</u>	Feb 13, 2013
<u>AP</u>	+	HIKMA MAPLE	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>001</u>	
<u>AP</u>	+		<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018243</u>	<u>002</u>	Jan 10, 2007
<u>AP</u>		SAGENT PHARMS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>A091676</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>A091676</u>	<u>002</u>	Oct 29, 2014

PITOCIN

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>10USP UNITS/ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>001</u>	
<u>AP</u>			<u>100USP UNITS/10ML (10USP UNITS/ML)</u>	<u>N018261</u>	<u>002</u>	Jul 27, 2007
		OXYTOCIN				
	+	FRESENIUS KABI USA	300USP UNITS/30ML (10USP UNITS/ML)	N018248	003	Jul 27, 2007
		PITOCIN				
		PAR STERILE PRODUCTS	500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012

PACLITAXEL

FOR SUSPENSION;IV (INFUSION)

ABRAXANE

+	ABRAXIS BIOSCIENCE	100MG/VIAL	N021660	001	Jan 07, 2005
---	--------------------	------------	---------	-----	--------------

INJECTABLE;INJECTION

PACLITAXEL

<u>AP</u>		ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130</u>	<u>001</u>	Dec 09, 2009
<u>AP</u>		EBEWE PHARMA	<u>6MG/ML</u>	<u>A078167</u>	<u>001</u>	Dec 26, 2007
<u>AP</u>		EUROHLTH INTL	<u>6MG/ML</u>	<u>A075190</u>	<u>001</u>	Jan 28, 2002
<u>AP</u>		FRESENIUS KABI ONCOL	<u>6MG/ML</u>	<u>A077574</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	+	HOSPIRA	<u>6MG/ML</u>	<u>A076131</u>	<u>001</u>	May 08, 2002
<u>AP</u>		ONCO THERAPIES LTD	<u>6MG/ML</u>	<u>A091540</u>	<u>001</u>	Sep 29, 2011
<u>AP</u>		TEVA PHARMS	<u>6MG/ML</u>	<u>A075184</u>	<u>001</u>	Jan 25, 2002

TAXOL

<u>AP</u>		HQ SPCLT PHARMA	<u>6MG/ML</u>	<u>N020262</u>	<u>001</u>	Dec 29, 1992
-----------	--	-----------------	---------------	----------------	------------	--------------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008
		3MG	N021999	001	Dec 19, 2006
+		6MG	N021999	002	Dec 19, 2006
		9MG	N021999	003	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-281 (of 371)

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

234MG/1.5ML (156MG/ML)

N022264 005 Jul 31, 2009

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

+ HELSINN HLTHCARE

EQ 0.075MG BASE/1.5ML (EQ 0.05MG
BASE/ML)

N021372 002 Feb 29, 2008

+

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N021372 001 Jul 25, 2003

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUMAP AGILA SPECILTS30MG/10ML (3MG/ML)A078520 001 Oct 31, 2008AP90MG/10ML (9MG/ML)A078520 002 Oct 31, 2008AP AREVA PHARMS30MG/VIALA077433 001 Nov 26, 2008AP60MG/VIALA077433 002 Nov 26, 2008AP90MG/VIALA077433 003 Nov 26, 2008AP EUROHLTH INTL30MG/VIALA075290 001 Apr 30, 2001AP +30MG/10ML (3MG/ML)N021113 001 Mar 04, 2002AP90MG/VIALA075290 003 Apr 30, 2001AP +90MG/10ML (9MG/ML)N021113 002 Mar 04, 2002AP FRESENIUS KABI USA30MG/VIALA075773 001 May 06, 2002AP30MG/10ML (3MG/ML)A076207 001 May 17, 2002AP90MG/VIALA075773 002 May 06, 2002AP90MG/10ML (9MG/ML)A076207 002 May 17, 2002AP + HOSPIRA30MG/10ML (3MG/ML)A075841 001 Jun 27, 2002AP +60MG/10ML (6MG/ML)A075841 002 Jun 27, 2002AP +90MG/10ML (9MG/ML)A075841 003 Jun 27, 2002AP LUITPOLD30MG/10ML (3MG/ML)A078942 001 Jul 25, 2008AP90MG/10ML (9MG/ML)A078942 002 Jul 25, 2008AP MUSTAFA NEVZAT30MG/10ML (3MG/ML)A078373 001 Dec 23, 2008AP90MG/10ML (9MG/ML)A078373 002 Dec 23, 2008AP PLIVA LACHEMA30MG/10ML (3MG/ML)A078156 001 Aug 19, 2008AP60MG/10ML (6MG/ML)A078156 002 Aug 19, 2008AP90MG/10ML (9MG/ML)A078156 003 Aug 19, 2008AP SUN PHARMA GLOBAL30MG/VIALA077703 001 Dec 24, 2008AP90MG/VIALA077703 002 Dec 24, 2008AP TEVA PHARMS USA30MG/10ML (3MG/ML)A076153 001 Mar 27, 2002AP90MG/10ML (9MG/ML)A076153 002 Mar 27, 2002PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBVIE

12,000USP UNITS\; 38,000USP

N020725 002 Apr 30, 2009

UNITS\; 60,000USP UNITS\

15,000USP UNITS\; 3,000USP

N020725 004 Jul 12, 2011

UNITS\; 9,500USP UNITS\

19,000USP UNITS\; 30,000USP

N020725 001 Apr 30, 2009

UNITS\; 6,000USP UNITS\

114,000USP UNITS; 180,000USP

N020725 005 Mar 14, 2013

UNITS; 36,000USP UNITS

+

120,000USP UNITS\; 24,000USP

N020725 003 Apr 30, 2009

UNITS\; 76,000USP UNITS\

PANCREAZE

JANSSEN PHARMS

10,850USP UNITS; 2,600USP UNITS; 6,200USP

N022523 005 Mar 07, 2014

UNITS

17,500USP UNITS; 4,200USP

N022523 001 Apr 12, 2010

UNITS; 10,000USP UNITS

43,750USP UNITS; 10,500USP

N022523 002 Apr 12, 2010

UNITS; 25,000USP UNITS

+

61,000USP UNITS; 21,000USP

N022523 003 Apr 12, 2010

UNITS; 37,000USP UNITS

70,000USP UNITS; 16,800USP

N022523 004 Apr 12, 2010

UNITS; 40,000USP UNITS

PERTZY

DIGESTIVE CARE INC

30,250USP UNITS; 8,000USP

N022175 001 May 17, 2012

UNITS; 28,750USP UNITS

+

60,500USP UNITS; 16,000USP

N022175 002 May 17, 2012

UNITS; 57,500USP UNITS

ULTRESA

FOREST LABS INC

13,800USP UNITS; 27,600USP

N022222 001 Mar 01, 2012

UNITS; 27,600USP UNITS

20,700USP UNITS; 41,400USP

N022222 002 Mar 01, 2012

UNITS; 41,400USP UNITS

PRESCRIPTION DRUG PRODUCT LIST

3-282 (of 371)

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

ULTRESA

+

23,000USP UNITS;46,000USP
UNITS;46,000USP UNITS

N022222 003 Mar 01, 2012

ZENPEP

FOREST LABS INC

218,000USP UNITS; 40,00USP UNITS;
136,000 USP UNITS

N022210 007 Mar 25, 2014

10,000USP UNITS;16,000USP
UNITS;3,000USP UNITS

N022210 005 Jun 15, 2011

10,000USP UNITS;34,000USP
UNITS;55,000USP UNITS

N022210 002 Aug 27, 2009

15,000USP UNITS;51,000USP
UNITS;82,000USP UNITS

N022210 003 Aug 27, 2009

17,000USP UNITS;27,000USP
UNITS;5,000USP UNITS

N022210 001 Aug 27, 2009

109,000USP UNITS;20,000USP
UNITS;68,000USP UNITS

N022210 004 Aug 27, 2009

+

136,000USP UNITS;25,000USP
UNITS;85,000USP UNITS

N022210 006 Jul 13, 2011

TABLET;ORAL

VIOKACE

FOREST LABS INC

10440USPU;39150USPU;39150USPU

N022542 001 Mar 01, 2012

+

20880USPU;78300USPU;78300USPU

N022542 002 Mar 01, 2012

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDEAP HOSPIRA1MG/MLA072320 001 Jan 19, 1989AP + TEVA PHARMS USA1MG/MLA072759 001 Jul 31, 1990AP +2MG/MLA072760 001 Jul 31, 1990PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PROTONIX

+ WYETH PHARMS INC

EQ 40MG BASE

N022020 001 Nov 14, 2007

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUMAP AKORN INCEQ 40MG BASE/VIALA079197 001 Nov 08, 2012PROTONIX IVAP + WYETH PHARMS INCEQ 40MG BASE/VIALN020988 001 Mar 22, 2001

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUMAB ACTAVIS TOTOWAEQ 20MG BASEA090797 001 Feb 07, 2011ABEQ 40MG BASEA090797 002 Feb 07, 2011AB APOTEX INCEQ 20MG BASEA090807 001 May 02, 2012ABEQ 40MG BASEA090807 002 May 02, 2012AB AUROBINDO PHARMA LTDEQ 20MG BASEA202038 001 Sep 28, 2012ABEQ 40MG BASEA202038 002 Sep 28, 2012AB DR REDDYS LABS LTDEQ 20MG BASEA077619 001 Jan 19, 2011ABEQ 40MG BASEA077619 002 Jan 19, 2011AB HETERO LABS LTD VEQ 20MG BASEA202882 001 Sep 10, 2014ABEQ 40MG BASEA202882 002 Sep 10, 2014AB JUBILANT GENERICSEQ 20MG BASEA090901 001 Aug 30, 2011ABEQ 40MG BASEA090901 002 Aug 30, 2011AB KUDCO IRELANDEQ 20MG BASEA078281 001 Jan 20, 2011ABEQ 40MG BASEA078281 002 Jan 20, 2011AB MACLEODS PHARMS LTDEQ 20MG BASEA200821 001 Feb 16, 2012ABEQ 40MG BASEA200821 002 Feb 16, 2012AB MYLAN PHARMS INCEQ 20MG BASEA090970 001 Jan 19, 2011ABEQ 40MG BASEA090970 002 Jan 19, 2011AB ORCHID HLTHCAREEQ 20MG BASEA202052 001 Dec 02, 2014ABEQ 40MG BASEA202052 002 Dec 02, 2014AB PERRIGO R AND DEQ 20MG BASEA203024 001 May 07, 2014ABEQ 20MG BASEA200794 001 May 02, 2012AB RANBAXY LABS LTDEQ 20MG BASEA200794 002 May 02, 2012ABEQ 40MG BASEA077058 001 Sep 10, 2007AB SUN PHARMA GLOBALEQ 20MG BASEA077058 002 Sep 10, 2007ABEQ 20MG BASEA077056 001 Aug 02, 2007AB TEVAEQ 40MG BASEA077056 002 Aug 02, 2007ABEQ 20MG BASEA090074 001 Jan 19, 2011AB TORRENT PHARMSEQ 40MG BASEA090074 002 Jan 19, 2011ABEQ 20MG BASEA091231 001 Jan 19, 2011AB WOCKHARDTEQ 40MG BASEA091231 002 Jan 19, 2011AB

PRESCRIPTION DRUG PRODUCT LIST

3-283 (of 371)

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PROTONIX

<u>AB</u>	WYETH PHARMS INC	<u>EQ 20MG BASE</u>	<u>N020987 002</u>	Jun 12, 2001
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020987 001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>	BANNER PHARMACAPS	<u>1MCG</u>	<u>A202539 001</u>	Mar 27, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202539 002</u>	Mar 27, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202539 003</u>	Mar 27, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>1MCG</u>	<u>A091412 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A091412 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412 003</u>	Jun 24, 2014
<u>AB</u>	RISING PHARMS INC	<u>1MCG</u>	<u>A202124 001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124 002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124 003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829 001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829 002</u>	Sep 27, 2013
<u>AB</u>		<u>4MCG</u>	<u>A090829 003</u>	Sep 27, 2013

ZEMPLAR

<u>AB</u>	ABBVIE	<u>1MCG</u>	<u>N021606 001</u>	May 26, 2005
<u>AB</u>		<u>2MCG</u>	<u>N021606 002</u>	May 26, 2005
<u>AB</u>	+	<u>4MCG</u>	<u>N021606 003</u>	May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917 001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917 002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917 003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657 001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657 002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657 003</u>	Oct 21, 2014
<u>AP</u>	SANDOZ CANADA INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108 001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108 002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108 003</u>	Jul 27, 2011

ZEMPLAR

<u>AP</u>	+	ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819 002</u>	Feb 01, 2000
<u>AP</u>	+		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819 001</u>	Apr 17, 1998
<u>AP</u>	+		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819 003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS INC	<u>EQ 250MG BASE</u>	<u>A065173 001</u>	Dec 14, 2007	
<u>AA</u>	+	SUN PHARM INDS INC	<u>EQ 250MG BASE</u>	<u>A064171 001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAXIL

<u>AB</u>	+	APOTEX TECHNOLOGIES	<u>EQ 10MG BASE/5ML</u>	<u>N020710 001</u>	Jun 25, 1997
-----------	---	---------------------	-------------------------	--------------------	--------------

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854 001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854 002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854 003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854 004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356 001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356 002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356 003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356 004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406 001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406 002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406 003</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A075716 001</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075716 002</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075716 003</u>	Mar 08, 2004
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075716 004</u>	Mar 08, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-284 (of 371)

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010
AB	SUN PHARM INDS INC	EQ 10MG BASE	A078194 001	Jun 29, 2007
AB		EQ 20MG BASE	A078194 002	Jun 29, 2007
AB		EQ 30MG BASE	A078194 003	Jun 29, 2007
AB		EQ 40MG BASE	A078194 004	Jun 29, 2007
AB	TEVA	EQ 10MG BASE	A076618 001	Aug 15, 2005
AB		EQ 20MG BASE	A076618 002	Aug 15, 2005
AB		EQ 30MG BASE	A076618 003	Aug 15, 2005
AB		EQ 40MG BASE	A076618 004	Aug 15, 2005
AB	ZYDUS PHARMS USA	EQ 10MG BASE	A077584 001	Mar 07, 2007
AB		EQ 20MG BASE	A077584 002	Mar 07, 2007
AB		EQ 30MG BASE	A077584 003	Mar 07, 2007
AB		EQ 40MG BASE	A077584 004	Mar 07, 2007

PAXIL

AB	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031 001	Dec 29, 1992
AB		EQ 20MG BASE	N020031 002	Dec 29, 1992
AB		EQ 30MG BASE	N020031 003	Dec 29, 1992
AB	+	EQ 40MG BASE	N020031 005	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	MYLAN	EQ 12.5MG BASE	A077873 001	Jun 29, 2007
AB		EQ 25MG BASE	A077873 002	Jun 29, 2007
AB		EQ 37.5MG BASE	A091427 001	Apr 14, 2011

PAXIL CR

AB	APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936 001	Feb 16, 1999
AB		EQ 25MG BASE	N020936 002	Feb 16, 1999
AB	+	EQ 37.5MG BASE	N020936 003	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

+ NOVEN THERAP

EQ 7.5MG BASE

N204516 001 Jun 28, 2013

TABLET; ORAL

PEXEVA

NOVEN THERAP

EQ 10MG BASE

N021299 001 Jul 03, 2003

EQ 20MG BASE

N021299 002 Jul 03, 2003

EQ 30MG BASE

N021299 003 Jul 03, 2003

+

EQ 40MG BASE

N021299 004 Jul 03, 2003

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

NOVARTIS

EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)

N200677 001 Dec 14, 2012

EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)

N200677 002 Dec 14, 2012

+

EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)

N200677 003 Dec 14, 2012

PASIREOTIDE PAMOATE

POWDER; INTRAMUSCULAR

SIGNIFOR LAR

NOVARTIS PHARMS CORP

EQ 20MG BASE/VIAL

N203255 001 Dec 15, 2014

EQ 40MG BASE/VIAL

N203255 002 Dec 15, 2014

+

EQ 60MG BASE/VIAL

N203255 003 Dec 15, 2014

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+ GLAXOSMITHKLINE

EQ 200MG BASE

N022465 001 Oct 19, 2009

EQ 400MG BASE

N022465 002 Oct 19, 2009

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

+ SIGMA TAU

250 UNITS/ML

N019818 001 Mar 21, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-285 (of 371)

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+ VALEANT PHARMS LLC EQ 0.3MG ACID/0.09ML

N021756 001 Dec 17, 2004

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS

SOMAVERT

+ PHARMACIA AND UPJOHN 10MG/VIAL

N021106 001 Mar 25, 2003

+ 15MG/VIAL

N021106 002 Mar 25, 2003

+ 20MG/VIAL

N021106 003 Mar 25, 2003

+ 25MG/VIAL

N021106 004 Jul 31, 2014

+ 30MG/VIAL

N021106 005 Jul 31, 2014

PEMETREXED DISODIUM

INJECTABLE; IV (INFUSION)

ALIMTA

+ LILLY EQ 100MG BASE/VIAL

N021462 002 Sep 07, 2007

+ EQ 500MG BASE/VIAL

N021462 001 Feb 04, 2004

PENCICLOVIR SODIUM

CREAM; TOPICAL

DENA VIR

+ DENCO ASSET 1%

N020629 001 Sep 24, 1996

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

+ ATON 250MG

N019853 001

TABLET; ORAL

DEPEN

+ MEDA PHARMS 250MG

N019854 001

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC + KING PHARMS 600,000 UNITS/ML

N050141 001

PERMAPEN

BC PFIZER 600,000 UNITS/ML

A060014 001

BICILLIN L-A

+ KING PHARMS 300,000 UNITS/ML

N050141 003

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+ KING PHARMS 150,000 UNITS/ML; 150,000 UNITS/ML

N050138 002

+ 300,000 UNITS/ML; 300,000 UNITS/ML

N050138 001

BICILLIN C-R 900/300

+ KING PHARMS 900,000 UNITS/2ML; 300,000 UNITS/2ML

N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUMAP HANFORD GC 5,000,000 UNITS/VIALA065149 002 Jul 23, 2009AP 20,000,000 UNITS/VIALA065149 003 Jul 23, 2009AP ISTITUTO BIO ITA SPA 5,000,000 UNITS/VIALA065448 001 Aug 18, 2009AP 20,000,000 UNITS/VIALA065448 002 Aug 18, 2009AP SANDOZ 5,000,000 UNITS/VIALA065079 002 Aug 30, 2002AP 20,000,000 UNITS/VIALA065079 003 Aug 30, 2002PFIZERPENAP + PFIZER 5,000,000 UNITS/VIALA060657 002AP + 20,000,000 UNITS/VIALA060657 003

PENICILLIN G POTASSIUM

HANFORD GC 1,000,000 UNITS/VIAL

A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+ BAXTER HLTHCARE 20,000 UNITS/ML

N050638 001 Jun 25, 1990

+ 40,000 UNITS/ML

N050638 002 Jun 25, 1990

+ 60,000 UNITS/ML

N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

+ KING PHARMS 300,000 UNITS/ML

A060101 002

+ 600,000 UNITS/ML

A060101 001

PRESCRIPTION DRUG PRODUCT LIST

3-286 (of 371)

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

+ SANDOZ

5,000,000 UNITS/VIAL

A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUMAA DAVA PHARMS INCEQ 125MG BASE/5MLA062981 001 Feb 10, 1989AAEQ 250MG BASE/5MLA062981 002 Feb 10, 1989PENICILLIN-VKAA TEVAEQ 125MG BASE/5MLA060456 001AA +EQ 250MG BASE/5MLA060456 002

TABLET; ORAL

PENICILLIN V POTASSIUMAB AUROBINDO PHARMAEQ 250MG BASEA065435 001 Apr 29, 2008ABEQ 500MG BASEA065435 002 Apr 29, 2008AB DAVA PHARMS INCEQ 250MG BASEA062936 001 Nov 25, 1988ABEQ 500MG BASEA062935 001 Nov 23, 1988AB HIKMA PHARMSEQ 250MG BASEA090549 001 Oct 11, 2013ABEQ 500MG BASEA090549 002 Oct 11, 2013AB SANDOZEQ 250MG BASEA064071 001 Nov 30, 1995AB +EQ 500MG BASEA064071 002 Nov 30, 1995PENICILLIN-VKAB TEVAEQ 250MG BASEA060711 002ABEQ 500MG BASEA060711 003PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

+ FRESENIUS KABI USA

300MG/VIAL

N019887 001 Jun 15, 1989

INJECTABLE; INJECTION

PENTAM

+ FRESENIUS KABI USA

300MG/VIAL

N019264 001 Oct 16, 1984

PENTAZOCINE LACTATE

INJECTABLE; INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N016194 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+ OAK PHARMS

50MG/ML

A083246 001

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+ JANSSEN PHARMS

100MG

N020193 001 Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENTAP + HOSPIRA INC10MG/VIALN020122 001 Oct 11, 1991PENTOSTATINAP EUROHLTH INTL10MG/VIALA077841 001 Aug 07, 2007AP MYLAN INSTITUTIONAL10MG/VIALA203554 001 Sep 19, 2014PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINEAB APOTEX400MGA075191 001 Jun 09, 1999AB IMPAX LABS400MGA075093 001 Aug 10, 1999AB MYLAN400MGA074425 001 Jul 08, 1997AB PLIVA400MGA074874 001 May 25, 1999AB VALEANT BERMUDA400MGA075028 001 Jul 20, 1998PENTOXILAB UPSHER SMITH400MGA074962 001 Mar 31, 1999PERAMIVIR

SOLUTION; IV (INFUSION)

RAPIVAB

+ BIOCRYST

200MG/20ML (10MG/ML)

N206426 001 Dec 19, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-287 (of 371)

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

2MG

N202834 001 Oct 22, 2012

4MG

N202834 002 Oct 22, 2012

6MG

N202834 003 Oct 22, 2012

8MG

N202834 004 Oct 22, 2012

10MG

N202834 005 Oct 22, 2012

+

12MG

N202834 006 Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+ LANTHEUS MEDCL

6.52MG/ML

N021064 001 Jul 31, 2001

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEONAB SYMPLMED PHARMS LLC2MGN020184 001 Dec 30, 1993AB 4MGN020184 002 Dec 30, 1993AB + 8MGN020184 003 Dec 30, 1993PERINDOPRIL ERBUMINEAB ANI PHARMS INC2MGA078138 001 Nov 10, 2009AB 4MGA078138 002 Nov 10, 2009AB 8MGA078138 003 Nov 10, 2009AB APOTEX 2MGA090463 001 Aug 30, 2010AB 4MGA090463 002 Aug 30, 2010AB 8MGA090463 003 Aug 30, 2010AB AUROBINDO PHARMA 2MGA079070 001 Nov 10, 2009AB 4MGA079070 002 Nov 10, 2009AB 8MGA079070 003 Nov 10, 2009AB LUPIN LTD 2MGA078263 001 Jan 27, 2010AB 4MGA078263 002 Jan 27, 2010AB 8MGA078263 003 Jan 27, 2010AB ROXANE 2MGA090072 001 Nov 10, 2009AB 4MGA090072 002 Nov 10, 2009AB 8MGA090072 003 Nov 10, 2009PERMETHRIN

CREAM; TOPICAL

ELIMITEAB + RENAISSANCE PHARMA 5%N019855 001 Aug 25, 1989PERMETHRINAB ACTAVIS MID ATLANTIC 5%A074806 001 Jan 23, 1998AB PERRIGO NEW YORK 5%A076369 001 Apr 21, 2003PERPHENAZINE

TABLET; ORAL

PERPHENAZINEAB SANDOZ 2MGA089683 001 Dec 08, 1988AB 4MGA089684 001 Dec 08, 1988AB 8MGA089685 001 Dec 08, 1988AB + 16MGA089686 001 Dec 08, 1988AB VINTAGE PHARMS 2MGA040226 001 Dec 31, 1998AB 4MGA040226 002 Dec 31, 1998AB 8MGA040226 003 Dec 31, 1998AB 16MGA040226 004 Dec 31, 1998PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

BC VALEANT 105MG

A088021 001 Sep 21, 1982

PHENDIMETRAZINE TARTRATE

BC + SANDOZ 105MG

N018074 001

TABLET; ORAL

BONTRIL PDMAA + VALEANT 35MGA085272 001PHENDIMETRAZINE TARTRATEAA ELITE LABS INC 35MGA040762 001 Jan 28, 2008AA KVK TECH 35MGA091042 001 Aug 31, 2010AA MIKART 35MGA089452 001 Oct 30, 1991AA SANDOZ 35MGA085588 001

PRESCRIPTION DRUG PRODUCT LIST

3-288 (of 371)

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

<u>AB</u>	+ PARKE DAVIS	<u>EQ 15MG BASE</u>	<u>N011909</u>	<u>002</u>	
-----------	---------------	---------------------	----------------	------------	--

PHENELZINE SULFATE

<u>AB</u>	NOVEL LABS INC	<u>EQ 15MG BASE</u>	<u>A200181</u>	<u>001</u>	Dec 08, 2010
-----------	----------------	---------------------	----------------	------------	--------------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

<u>AB</u>	+ COVIS PHARMA SARL	<u>10MG</u>	<u>N008708</u>	<u>001</u>	
-----------	---------------------	-------------	----------------	------------	--

PHENOXYBENZAMINE HYDROCHLORIDE

<u>AB</u>	ROXANE	<u>10MG</u>	<u>A201050</u>	<u>001</u>	Jul 16, 2012
-----------	--------	-------------	----------------	------------	--------------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

<u>AA</u>	+ TEVA	<u>37.5MG</u>	<u>A088023</u>	<u>001</u>	Aug 02, 1983
-----------	--------	---------------	----------------	------------	--------------

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	BARR	<u>15MG</u>	<u>A090591</u>	<u>001</u>	Mar 18, 2010
-----------	------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A090591</u>	<u>002</u>	Mar 18, 2010
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>	ELITE LABS	<u>15MG</u>	<u>A202248</u>	<u>001</u>	Sep 28, 2012
-----------	------------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A202248</u>	<u>002</u>	Sep 28, 2012
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>	INVAGEN PHARMS	<u>15MG</u>	<u>A202858</u>	<u>001</u>	Feb 14, 2014
-----------	----------------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A202858</u>	<u>002</u>	Feb 14, 2014
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A204414</u>	<u>001</u>	May 05, 2014
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>37.5MG</u>	<u>A202846</u>	<u>001</u>	Feb 05, 2014
-----------	--	---------------	----------------	------------	--------------

<u>AA</u>	KEN LIFESCIENCE	<u>15MG</u>	<u>A205019</u>	<u>001</u>	Dec 05, 2014
-----------	-----------------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A205019</u>	<u>002</u>	Dec 05, 2014
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>37.5MG</u>	<u>A205017</u>	<u>001</u>	Sep 25, 2014
-----------	--	---------------	----------------	------------	--------------

<u>AA</u>	KVK TECH	<u>15MG</u>	<u>A040886</u>	<u>002</u>	Mar 31, 2008
-----------	----------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A040875</u>	<u>001</u>	Mar 21, 2008
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A040886</u>	<u>001</u>	Mar 31, 2008
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>37.5MG</u>	<u>A040887</u>	<u>001</u>	Apr 24, 2008
-----------	--	---------------	----------------	------------	--------------

<u>AA</u>	LANNETT	<u>15MG</u>	<u>A087022</u>	<u>002</u>	Jan 20, 2012
-----------	---------	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A087022</u>	<u>001</u>	Feb 03, 1983
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>		<u>30MG</u>	<u>A091359</u>	<u>001</u>	Jul 16, 2010
-----------	--	-------------	----------------	------------	--------------

<u>AA</u>	LANNETT HOLDINGS INC	<u>37.5MG</u>	<u>A201961</u>	<u>001</u>	Jul 20, 2011
-----------	----------------------	---------------	----------------	------------	--------------

<u>AA</u>	MUTUAL PHARM	<u>30MG</u>	<u>A040525</u>	<u>001</u>	Oct 23, 2003
-----------	--------------	-------------	----------------	------------	--------------

<u>AA</u>	+ SANDOZ	<u>15MG</u>	<u>A087190</u>	<u>002</u>	
-----------	----------	-------------	----------------	------------	--

<u>AA</u>	+	<u>30MG</u>	<u>A086945</u>	<u>001</u>	Jul 20, 1983
-----------	---	-------------	----------------	------------	--------------

<u>AA</u>	+	<u>30MG</u>	<u>A087190</u>	<u>001</u>	
-----------	---	-------------	----------------	------------	--

TABLET; ORAL

ADIPEX-P

<u>AA</u>	+ TEVA	<u>37.5MG</u>	<u>A085128</u>	<u>001</u>	
-----------	--------	---------------	----------------	------------	--

PHENTERMINE HYDROCHLORIDE

<u>AA</u>	AUROLIFE PHARMA LLC	<u>37.5MG</u>	<u>A203068</u>	<u>001</u>	Aug 06, 2014
-----------	---------------------	---------------	----------------	------------	--------------

<u>AA</u>	BARR	<u>37.5MG</u>	<u>A090470</u>	<u>001</u>	Aug 31, 2009
-----------	------	---------------	----------------	------------	--------------

<u>AA</u>	ELITE LABS	<u>37.5MG</u>	<u>A200272</u>	<u>001</u>	Jan 31, 2011
-----------	------------	---------------	----------------	------------	--------------

<u>AA</u>	INVAGEN PHARMS	<u>37.5MG</u>	<u>A202942</u>	<u>001</u>	Feb 05, 2014
-----------	----------------	---------------	----------------	------------	--------------

<u>AA</u>	KEN LIFESCIENCE	<u>37.5MG</u>	<u>A205008</u>	<u>001</u>	Sep 25, 2014
-----------	-----------------	---------------	----------------	------------	--------------

<u>AA</u>	KVK TECH	<u>37.5MG</u>	<u>A040876</u>	<u>001</u>	Mar 31, 2008
-----------	----------	---------------	----------------	------------	--------------

<u>AA</u>	LANNETT	<u>37.5MG</u>	<u>A040555</u>	<u>001</u>	Apr 15, 2005
-----------	---------	---------------	----------------	------------	--------------

<u>AA</u>	MIKAH PHARMA	<u>37.5MG</u>	<u>A040190</u>	<u>001</u>	May 30, 1997
-----------	--------------	---------------	----------------	------------	--------------

<u>AA</u>	MIRROR PHARMS	<u>37.5MG</u>	<u>A091451</u>	<u>001</u>	Sep 21, 2012
-----------	---------------	---------------	----------------	------------	--------------

<u>AA</u>	MUTUAL PHARM	<u>37.5MG</u>	<u>A040526</u>	<u>001</u>	Oct 23, 2003
-----------	--------------	---------------	----------------	------------	--------------

<u>AA</u>	SUN PHARM INDS INC	<u>37.5MG</u>	<u>A040790</u>	<u>001</u>	Aug 21, 2007
-----------	--------------------	---------------	----------------	------------	--------------

<u>AA</u>	VINTAGE PHARMS	<u>37.5MG</u>	<u>A040377</u>	<u>001</u>	Jan 04, 2002
-----------	----------------	---------------	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011
--	---------------	------	---------	-----	--------------

		30MG	N202088	002	Jun 13, 2011
--	--	------	---------	-----	--------------

+		37.5MG	N202088	003	Mar 27, 2012
---	--	--------	---------	-----	--------------

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

	VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
--	-------	----------------------	---------	-----	--------------

		EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
--	--	---------------------	---------	-----	--------------

		EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
--	--	-----------------------	---------	-----	--------------

+		EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012
---	--	--------------------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-289 (of 371)

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+ LANNETT HOLDINGS INC EQ 15MG BASE
 + EQ 30MG BASE

A040872 001 Jul 28, 2011
 A040872 002 Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE**AP** EUROHLTH INTL **5MG/VIAL****A040235 001** Mar 11, 1998REGITINE**AP** + NOVARTIS **5MG/VIAL****N008278 003**

ORAVERSE

+ SEPTODONT HOLDING 0.4MG/1.7ML

N022159 001 May 09, 2008

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

+ WEST WARD PHARM CORP 10MG/ML (10MG/ML)

N203826 001 Dec 20, 2012

VAZCULEP

ECLAT PHARMS LLC 10MG/ML (10MG/ML)

N204300 001 Jun 27, 2014

50MG/5ML (10MG/ML)

N204300 002 Jun 27, 2014

+ 100MG/10ML (10MG/ML)

N204300 003 Jun 27, 2014

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

PARAGON BIOTECK 2.5%

N203510 001 Mar 21, 2013

+ 10%

N203510 002 Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE**AA** HI-TECH PHARMACAL **5MG/5ML; 6.25MG/5ML****A040675 001** Dec 23, 2014**AA** VINTAGE **5MG/5ML; 6.25MG/5ML****A040654 001** Dec 07, 2006PROMETH VC PLAIN**AA** + ACTAVIS MID ATLANTIC **5MG/5ML; 6.25MG/5ML****A088761 001** Nov 08, 1984PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE**AA** AMNEAL PHARMS **5MG/5ML; 6.25MG/5ML****A040902 001** Aug 25, 2009PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125**AB** + PARKE DAVIS **125MG/5ML****N008762 001**PHENYTOIN**AB** TARO **125MG/5ML****A040521 001** Mar 08, 2004**AB** VISTAPHARM **125MG/5ML****A040342 001** Jan 31, 2001**AB** **125MG/5ML****A040610 001** Aug 18, 2005**AB** WOCKHARDT **125MG/5ML****A040420 001** Apr 19, 2002

TABLET, CHEWABLE; ORAL

DILANTIN**AB** + PFIZER PHARMS **50MG****A084427 001**PHENYTOIN**AB** COREPHARMA **50MG****A040884 001** Nov 28, 2014**AB** MYLAN PHARMS INC **50MG****A200691 001** Dec 26, 2012**AB** TARO **50MG****A200565 001** Apr 17, 2014PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN**AB** + PARKE DAVIS **30MG EXTENDED****A084349 001****AB** + **100MG EXTENDED****A084349 002**EXTENDED PHENYTOIN SODIUM**AB** AMNEAL PHARMS NY **100MG EXTENDED****A040765 001** Nov 12, 2008**AB** MYLAN **100MG EXTENDED****A040298 001** Dec 28, 1998**AB** SUN PHARM INDS **200MG EXTENDED****A040731 001** Jun 30, 2008**AB** **300MG EXTENDED****A040731 002** Jun 30, 2008**AB** SUN PHARM INDS (IN) **100MG EXTENDED****A040621 001** Dec 11, 2006**AB** TARO **100MG EXTENDED****A040684 001** Sep 05, 2006**AB** WOCKHARDT **30MG EXTENDED****A040759 001** Dec 18, 2007**AB** WOCKHARDT USA **100MG EXTENDED****A040732 001** Jan 30, 2008PHENYTEK**AB** MYLAN **200MG EXTENDED****A040298 002** Dec 06, 2001**AB** + **300MG EXTENDED****A040298 003** Dec 06, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-290 (of 371)

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	<u>A084307</u>	<u>001</u>	
AP		HOSPIRA	50MG/ML	<u>A089521</u>	<u>001</u>	Mar 17, 1987
AP		LUITPOLD	50MG/ML	<u>A040781</u>	<u>001</u>	Dec 04, 2007
AP		X-GEN PHARMS	50MG/ML	<u>A040573</u>	<u>001</u>	Sep 13, 2006

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001	
		VITAMIN K1				
BP	+	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983
	+		10MG/ML	A087955	001	Jul 25, 1983

TABLET; ORAL

MEPHYTON

+	VALEANT PHARMS	5MG	N010104	003	
---	----------------	-----	---------	-----	--

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

+	ALCON	4%	N018796	001	Oct 01, 1984
---	-------	----	---------	-----	--------------

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

	ALCON RES	1%	N200890	001	Jun 22, 2010
--	-----------	----	---------	-----	--------------

		2%	N200890	002	Jun 22, 2010
--	--	----	---------	-----	--------------

+		4%	N200890	003	Jun 22, 2010
---	--	----	---------	-----	--------------

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB		COREPHARMA	5MG	<u>A076746</u>	<u>001</u>	Nov 16, 2004
AB		IMPAX LABS	5MG	<u>A077248</u>	<u>001</u>	Mar 31, 2006
AB			7.5MG	<u>A077248</u>	<u>002</u>	Mar 31, 2006
AB		LANNETT	5MG	<u>A077220</u>	<u>001</u>	Oct 14, 2005
AB			7.5MG	<u>A077220</u>	<u>002</u>	May 06, 2009
AB		ROXANE	5MG	<u>A076963</u>	<u>001</u>	Dec 22, 2004
AB			7.5MG	<u>A076963</u>	<u>002</u>	Feb 27, 2007

SALAGEN

AB		EISAI INC	5MG	<u>N020237</u>	<u>001</u>	Mar 22, 1994
AB	+		7.5MG	<u>N020237</u>	<u>002</u>	Apr 18, 2003

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+	VALEANT BERMUDA	1%	N021302	001	Dec 13, 2001
---	-----------------	----	---------	-----	--------------

PIMOZIDE

TABLET; ORAL

ORAP

	TEVA	1MG	N017473	003	Aug 27, 1997
+		2MG	N017473	001	Jul 31, 1984

PINDOLOL

TABLET; ORAL

PINDOLOL

AB		MUTUAL PHARM	5MG	<u>A074063</u>	<u>001</u>	Jan 27, 1994
AB			10MG	<u>A074063</u>	<u>002</u>	Jan 27, 1994
AB		MYLAN PHARMS INC	5MG	<u>A074019</u>	<u>001</u>	Sep 03, 1992
AB	+		10MG	<u>A074019</u>	<u>002</u>	Sep 03, 1992

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB		TAKEDA PHARMS USA	EQ 15MG BASE	<u>N021073</u>	<u>001</u>	Jul 15, 1999
AB			EQ 30MG BASE	<u>N021073</u>	<u>002</u>	Jul 15, 1999
AB	+		EQ 45MG BASE	<u>N021073</u>	<u>003</u>	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 15MG BASE	<u>A200044</u>	<u>001</u>	Feb 13, 2013
AB			EQ 30MG BASE	<u>A200044</u>	<u>002</u>	Feb 13, 2013
AB			EQ 45MG BASE	<u>A200044</u>	<u>003</u>	Feb 13, 2013
AB		AUROBINDO PHARMA LTD	EQ 15MG BASE	<u>A200268</u>	<u>001</u>	Feb 13, 2013
AB			EQ 30MG BASE	<u>A200268</u>	<u>002</u>	Feb 13, 2013
AB			EQ 45MG BASE	<u>A200268</u>	<u>003</u>	Feb 13, 2013
AB		BRECKENRIDGE PHARM	EQ 15MG BASE	<u>A078472</u>	<u>001</u>	Feb 13, 2013
AB			EQ 30MG BASE	<u>A078472</u>	<u>002</u>	Feb 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-291 (of 371)

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078472</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 15MG BASE</u>	<u>A078383</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078383</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078383</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 15MG BASE</u>	<u>A204133</u>	<u>001</u>	Apr 07, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A204133</u>	<u>002</u>	Apr 07, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A204133</u>	<u>003</u>	Apr 07, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467</u>	<u>001</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202467</u>	<u>002</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202467</u>	<u>003</u>	Feb 06, 2013
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 15MG BASE</u>	<u>A076801</u>	<u>001</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076801</u>	<u>002</u>	Aug 17, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076801</u>	<u>003</u>	Aug 17, 2012
<u>AB</u>	SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078670</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078670</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210</u>	<u>001</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077210</u>	<u>002</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A077210</u>	<u>003</u>	Jan 10, 2014
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A091298</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A091298</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A091298</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	WATSON LABS	<u>EQ 15MG BASE</u>	<u>A076798</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076798</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076798</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202456</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202456</u>	<u>003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	AGILA SPECLTS	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458</u>	<u>001</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458</u>	<u>002</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458</u>	<u>003</u>	Aug 15, 2014
<u>AP</u>	AUROBINDO PHARMA LTD	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498</u>	<u>001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498</u>	<u>002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498</u>	<u>003</u>	May 23, 2011
<u>AP</u>	HOSPIRA INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065386</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065386</u>	<u>002</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065386</u>	<u>003</u>	Sep 15, 2009
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A065446</u>	<u>001</u>	Sep 15, 2009
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523</u>	<u>001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523</u>	<u>002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523</u>	<u>003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498</u>	<u>001</u>	May 31, 2011
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010

ZOSYN

<u>AP</u>	+	WYETH PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>N050684</u>	<u>001</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>N050684</u>	<u>002</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050684</u>	<u>003</u>	Oct 22, 1993
<u>AP</u>	+		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>N050684</u>	<u>004</u>	Oct 22, 1993
ZOSYN IN PLASTIC CONTAINER						
	+	WYETH PHARMS INC	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998
	+		EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+		EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-292 (of 371)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

SANDOZ

EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL

A203557 001 Oct 29, 2014

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

+ MEDICIS

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+ INTERMUNE INC

267MG

N022535 001 Oct 15, 2014

PIROXICAM

CAPSULE; ORAL

FELDENE**AB** PFIZER**10MG****N018147 002** Apr 06, 1982**AB** +**20MG****N018147 003** Apr 06, 1982**PIROXICAM****AB** MUTUAL PHARM**10MG****A073535 001** Mar 12, 1993**AB** MYLAN**10MG****A074102 001** Jul 31, 1992**AB****20MG****A074102 002** Jul 31, 1992**AB** NOSTRUM LABS**10MG****A074116 001** Jun 15, 1993**AB****20MG****A074118 001** Jun 15, 1993**AB** TEVA**10MG****A074131 001** Dec 11, 1992**AB****20MG****A074131 002** Dec 11, 1992PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

KOWA CO

EQ 1MG BASE

N022363 001 Aug 03, 2009

EQ 2MG BASE

N022363 002 Aug 03, 2009

+

EQ 4MG BASE

N022363 003 Aug 03, 2009

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

+ GENZYME

24MG/1.2ML (20MG/ML)

N022311 001 Dec 15, 2008

PODOFILOX

GEL; TOPICAL

CONDYLOX

+ WATSON PHARMS

0.5%

N020529 001 Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOX**AT** + WATSON PHARMS**0.5%****N019795 001** Dec 13, 1990**PODOFILOX****AT** PADDOCK LLC**0.5%****A075600 001** Jan 29, 2002**AT** PRECISION DERMAT**0.5%****A090184 001** Jul 21, 2010POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

CHEMISCH FBRK KRSSLR

10MG/2ML (5MG/ML)

N021201 001 Mar 30, 2010

+

20MG/2ML (10MG/ML)

N021201 002 Mar 30, 2010

VARITHENA

+ PROVENISIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX**AA** KREMERS URBAN PHARMS**17GM/SCOOPFUL****A076652 001** Jul 02, 2004**POLYETHYLENE GLYCOL 3350****AA** BRECKENRIDGE PHARM**17GM/SCOOPFUL****A077736 001** May 26, 2006**AA** NEXGEN PHARMA INC**17GM/SCOOPFUL****A077706 001** Sep 27, 2006**AA** PADDOCK LLC**17GM/SCOOPFUL****A077893 001** May 26, 2006POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS**AA** PADDOCK LLC**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****A079232 001** Feb 25, 2010**NULYTELY****AA** + BRAINTREE**420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT****N019797 001** Apr 22, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-293 (of 371)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY-FLAVORED

AA	+	BRAINTREE	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>N019797 002</u>	Nov 18, 1994
-----------	---	-----------	--	--------------------	--------------

PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

AA		MYLAN	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A090409 001</u>	Apr 02, 2010
-----------	--	-------	--	--------------------	--------------

AA		NOVEL LABS INC	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A090019 001</u>	May 27, 2009
-----------	--	----------------	--	--------------------	--------------

TRILYTE

AA		MEDA PHARMS	<u>420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT</u>	<u>A076491 001</u>	Feb 05, 2004
-----------	--	-------------	--	--------------------	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

AA	+	BRAINTREE	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	<u>N019011 001</u>	Jul 13, 1984
-----------	---	-----------	---	--------------------	--------------

PEG 3350 AND ELECTROLYTES

AA		MYLAN	<u>236GM; 2.97GM; 6.74GM; 5.86GM; 22.74GM</u>	<u>A090928 001</u>	Jan 28, 2010
-----------	--	-------	---	--------------------	--------------

AA		NOVEL LABS INC	<u>236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT</u>	<u>A090231 001</u>	Jun 01, 2009
-----------	--	----------------	---	--------------------	--------------

AA			<u>240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT</u>	<u>A090186 001</u>	Jun 01, 2009
-----------	--	--	---	--------------------	--------------

COLYTE

		MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983 010	Jan 31, 1989
--	--	-------------	---	-------------	--------------

COLYTE WITH FLAVOR PACKS

		MEDA PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983 012	Oct 08, 1998
--	--	-------------	--	-------------	--------------

GOLYTELY

	+	BRAINTREE	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N019011 002	Jun 02, 1992
--	---	-----------	--	-------------	--------------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

AP		SAGENT STRIDES	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A090110 001</u>	Jun 29, 2011
-----------	--	----------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE

AP	+	EUROHLTH INTL	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A060716 001</u>	
-----------	---	---------------	-----------------------------------	--------------------	--

AP		FRESENIUS KABI USA	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A065372 001</u>	Jan 10, 2008
-----------	--	--------------------	-----------------------------------	--------------------	--------------

AP		X GEN PHARMS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A063000 001</u>	Sep 30, 1994
-----------	--	--------------	-----------------------------------	--------------------	--------------

AP		XELLIA PHARMS APS	<u>EQ 500,000 UNITS BASE/VIAL</u>	<u>A202766 001</u>	Jan 15, 2014
-----------	--	-------------------	-----------------------------------	--------------------	--------------

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM

AT	+	ALLERGAN	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>N050567 001</u>	Oct 20, 1988
-----------	---	----------	--	--------------------	--------------

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT		AKORN INC	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A065006 001</u>	Dec 17, 1998
-----------	--	-----------	--	--------------------	--------------

AT		BAUSCH AND LOMB	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A064120 001</u>	Feb 14, 1997
-----------	--	-----------------	--	--------------------	--------------

AT		FALCON PHARMS	<u>10,000 UNITS/ML; EQ 1MG BASE/ML</u>	<u>A064211 001</u>	Apr 13, 1998
-----------	--	---------------	--	--------------------	--------------

POMALIDOMIDE

CAPSULE; ORAL

POMALYST

		CELGENE	1MG	N204026 001	Feb 08, 2013
--	--	---------	-----	-------------	--------------

			2MG	N204026 002	Feb 08, 2013
--	--	--	-----	-------------	--------------

			3MG	N204026 003	Feb 08, 2013
--	--	--	-----	-------------	--------------

+			4MG	N204026 004	Feb 08, 2013
---	--	--	-----	-------------	--------------

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

		ARIAD	EQ 15MG BASE	N203469 001	Dec 14, 2012
--	--	-------	--------------	-------------	--------------

+			EQ 45MG BASE	N203469 002	Dec 14, 2012
---	--	--	--------------	-------------	--------------

PORACTANT ALFA

SUSPENSION; INTRATRACHEAL

CUROSURF

+		CHIESI USA INC	80MG/ML	N020744 001	Nov 18, 1999
---	--	----------------	---------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-294 (of 371)

PORFIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

CONCORDIA LABS INC

75MG/VIAL

N020451 001 Dec 27, 1995

POSACONAZOLE

SOLUTION; IV (INFUSION)

NOXAFIL

+ MERCK SHARP DOHME

300MG/16.7ML (18MG/ML)

N205596 001 Mar 13, 2014

SUSPENSION; ORAL

NOXAFIL

+ SCHERING

40MG/ML

N022003 001 Sep 15, 2006

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

+ MERCK SHARP DOHME

100MG

N205053 001 Nov 25, 2013

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE IN PLASTIC CONTAINER

+ HOSPIRA

2MEQ/ML

N018896 001 Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-KAB NESHER PHARMS8MEQN018238 001MICRO-K 10AB NESHER PHARMS10MEQN018238 002 May 14, 1984POTASSIUM CHLORIDEAB ACTAVIS LABS FL INC8MEQA077419 001 Jun 02, 2008AB +10MEQA077419 002 Jun 02, 2008AB AMNEAL PHARMS10MEQA202128 001 Feb 22, 2013AB ANCHEN PHARMS8MEQA202886 001 Dec 26, 2013AB10MEQA202886 002 Dec 26, 2013AB PADDOCK LLC8MEQA200185 001 May 18, 2011AB10MEQA200185 002 May 18, 2011

INJECTABLE; INJECTION

POTASSIUM CHLORIDEAP B BRAUN2MEQ/MLA085870 001AP BAXTER HLTHCARE2MEQ/MLA085499 001AP FRESenius KABI USA2MEQ/MLA080225 001AP + HOSPIRA2MEQ/MLA080205 001POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE14.9MG/MLN019904 001 Dec 26, 1989AP +746MG/100MLN019904 005 Dec 17, 1990AP HOSPIRA14.9MG/MLN020161 005 Nov 30, 1992AP745MG/100MLN020161 001 Nov 30, 1992POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE1.49GM/100MLN019904 006 Dec 17, 1990AP +29.8MG/MLN019904 002 Dec 26, 1989AP HOSPIRA1.49GM/100MLN020161 002 Nov 30, 1992AP +29.8MG/MLN020161 006 Aug 11, 1998POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.24GM/100MLN019904 003 Dec 26, 1989AP + HOSPIRA2.24GM/100MLN020161 003 Aug 11, 1998POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINERAP + BAXTER HLTHCARE2.98GM/100MLN019904 004 Dec 26, 1989AP + HOSPIRA2.98GM/100MLN020161 004 Aug 11, 1998POTASSIUM CHLORIDE IN PLASTIC CONTAINERAP FRESenius KABI USA2MEQ/MLA088901 001 Jan 25, 1985AP2MEQ/MLA088908 001 Jan 25, 1985

POTASSIUM CHLORIDE

+ FRESenius KABI USA

3MEQ/ML

A080225 003

SOLUTION; ORAL

POTASSIUM CHLORIDE

PHARMA-MED INC

20MEQ/15ML

N206814 001 Dec 22, 2014

+

40MEQ/15ML

N206814 002 Dec 22, 2014

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10AB1 UPSHER SMITH LABS10MEQA074726 002 Aug 09, 2000KLOR-CON M20AB1 + UPSHER SMITH LABS20MEQA074726 001 Nov 20, 1998POTASSIUM CHLORIDEAB1 ACTAVIS LABS FL INC10MEQA075604 001 Apr 10, 2002AB120MEQA075604 002 Apr 10, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-295 (of 371)

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1	EURAND	20MEQ	A076368	001	Aug 18, 2004
	KLOR-CON				
AB2	UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986
AB2	+	10MEQ	N019123	002	Apr 17, 1986
	POTASSIUM CHLORIDE				
AB2	MYLAN PHARMS INC	8.0MEQ	A204662	001	Aug 21, 2014
AB2		10.0MEQ	A204662	002	Aug 21, 2014
	K-TAB				
BC	ABBVIE	8MEQ	N018279	002	Aug 01, 1988
BC		10MEQ	N018279	001	
BC	+	20MEQ	N018279	003	Nov 25, 2013
	KLOR-CON M15				
	UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	HOSPIRA	149MG/100ML; 450MG/100ML	A078446	001	Sep 10, 2008
	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER				
AP	+	BAXTER HLTHCARE 150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002
	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	B BRAUN	150MG/100ML; 900MG/100ML	N019708	004	Sep 29, 1989
AP	BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001	
	POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002	
	POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	149MG/100ML; 900MG/100ML	N019686	001	Oct 17, 1988
	POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
AP	HOSPIRA	298MG/100ML; 900MG/100ML	N019686	002	Oct 17, 1988
	POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%				
	BAXTER HLTHCARE	224MG/100ML; 900MG/100ML	N017648	003	

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB	COREPHARMA	5MEQ	A077440	001	Jun 09, 2006
AB		10MEQ	A077440	002	Jun 09, 2006
AB	ZYDUS PHARMS USA INC	5MEQ	A203546	001	Aug 06, 2014
AB		10MEQ	A203546	002	Aug 06, 2014
AB		15MEQ	A203546	003	Aug 06, 2014
	UROCIT-K				
AB	MISSION PHARMA	5MEQ	N019071	001	Aug 30, 1985
AB		10MEQ	N019071	002	Aug 31, 1992
AB	+	15MEQ	N019071	003	Dec 30, 2009

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

+	ALCON PHARMS LTD	5%	N018634	001	Dec 17, 1986
---	------------------	----	---------	-----	--------------

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

	ALLOS	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009
+		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

+	MERIDIAN MEDCL TECHN	300MG/ML	N018986	001	Apr 26, 1983
---	----------------------	----------	---------	-----	--------------

PROTOPAM CHLORIDE

+	BAXTER HLTHCARE CORP	1GM/VIAL	N014134	001	
---	----------------------	----------	---------	-----	--

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

AB	BOEHRINGER INGELHEIM	0.125MG	N020667	001	Jul 01, 1997
AB	+	0.25MG	N020667	002	Jul 01, 1997
AB		0.5MG	N020667	006	Feb 12, 1998
AB		0.75MG	N020667	007	Jul 30, 2007
AB		1MG	N020667	003	Jul 01, 1997
AB		1.5MG	N020667	005	Jul 01, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-296 (of 371)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS GRP PTC	<u>0.125MG</u>	<u>A091254</u>	<u>001</u>	Nov 30, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091254</u>	<u>002</u>	Nov 30, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091254</u>	<u>003</u>	Nov 30, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A091254</u>	<u>004</u>	Nov 30, 2010
<u>AB</u>		<u>1MG</u>	<u>A091254</u>	<u>005</u>	Nov 30, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091254</u>	<u>006</u>	Nov 30, 2010
<u>AB</u>	ALEMBIC LTD	<u>0.125MG</u>	<u>A078894</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078894</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078894</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A078894</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078894</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	APOTEX INC	<u>0.125MG</u>	<u>A090151</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151</u>	<u>003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151</u>	<u>006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151</u>	<u>004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151</u>	<u>005</u>	Apr 30, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633</u>	<u>004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633</u>	<u>005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633</u>	<u>006</u>	Oct 26, 2012
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077724</u>	<u>001</u>	Feb 19, 2008
<u>AB</u>		<u>0.25MG</u>	<u>A077724</u>	<u>002</u>	Feb 19, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077724</u>	<u>003</u>	Feb 19, 2008
<u>AB</u>		<u>1MG</u>	<u>A077724</u>	<u>004</u>	Feb 19, 2008
<u>AB</u>		<u>1.5MG</u>	<u>A077724</u>	<u>005</u>	Feb 19, 2008
<u>AB</u>	BRECKENRIDGE PHARM	<u>0.125MG</u>	<u>A091450</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A091450</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A091450</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A091450</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A091450</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090781</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090781</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.125MG</u>	<u>A202164</u>	<u>001</u>	Sep 20, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202164</u>	<u>002</u>	Sep 20, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202164</u>	<u>003</u>	Sep 20, 2012
<u>AB</u>		<u>1MG</u>	<u>A202164</u>	<u>004</u>	Sep 20, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202164</u>	<u>005</u>	Sep 20, 2012
<u>AB</u>	MYLAN	<u>0.125MG</u>	<u>A077854</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A077854</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A077854</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090764</u>	<u>001</u>	Apr 09, 2010
<u>AB</u>		<u>1MG</u>	<u>A077854</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A077854</u>	<u>005</u>	Oct 08, 2010
<u>AB</u>	SANDOZ	<u>0.125MG</u>	<u>A090190</u>	<u>001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090190</u>	<u>002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090190</u>	<u>003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090190</u>	<u>006</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090190</u>	<u>004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090190</u>	<u>005</u>	Jul 06, 2010
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855</u>	<u>004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855</u>	<u>005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855</u>	<u>006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702</u>	<u>006</u>	Jun 03, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A091683</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>		<u>0.25MG</u>	<u>A091683</u>	<u>002</u>	Mar 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-297 (of 371)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB		0.5MG	A091683	003	Mar 27, 2013
AB		0.75MG	A091683	004	Mar 27, 2013
AB		1MG	A091683	005	Mar 27, 2013
AB		1.5MG	A091683	006	Mar 27, 2013
AB	TEVA PHARMS	0.125MG	A090241	001	Oct 08, 2010
AB		0.25MG	A090241	002	Oct 08, 2010
AB		0.5MG	A090241	003	Oct 08, 2010
AB		0.75MG	A090241	004	Oct 08, 2010
AB		1MG	A090241	005	Oct 08, 2010
AB		1.5MG	A090241	006	Oct 08, 2010
AB	TORRENT PHARMS	0.125MG	A090865	001	Oct 08, 2010
AB		0.25MG	A090865	002	Oct 08, 2010
AB		0.5MG	A090865	003	Oct 08, 2010
AB		0.75MG	A090865	004	Oct 08, 2010
AB		1MG	A090865	005	Oct 08, 2010
AB		1.5MG	A090865	006	Oct 08, 2010
AB	ZYDUS PHARMS USA INC	0.125MG	A078920	001	Jul 06, 2010
AB		0.25MG	A078920	002	Jul 06, 2010
AB		0.5MG	A078920	003	Jul 06, 2010
AB		1MG	A078920	004	Jul 06, 2010
AB		1.5MG	A078920	005	Jul 06, 2010

TABLET, DELAYED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	SANDOZ	0.375MG	A202353	001	Dec 04, 2014
AB		0.75MG	A202353	002	Dec 04, 2014
AB		1.5MG	A202353	003	Dec 04, 2014
AB		3MG	A202353	004	Dec 04, 2014
AB		4.5MG	A202353	005	Dec 04, 2014

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010
AB		0.75MG	N022421	002	Feb 19, 2010
AB		1.5MG	N022421	003	Feb 19, 2010
AB		2.25MG	N022421	006	Jun 17, 2011
AB		3MG	N022421	004	Feb 19, 2010
AB		3.75MG	N022421	007	Jun 17, 2011
AB		4.5MG	N022421	005	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014
AB		0.75MG	A202206	002	Feb 06, 2014
AB		1.5MG	A202206	003	Feb 06, 2014
AB		2.25MG	A202206	004	Feb 06, 2014
AB		3MG	A202206	005	Feb 06, 2014
AB		3.75MG	A202206	006	Feb 06, 2014
AB		4.5MG	A202206	007	Feb 06, 2014

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007
+	EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

ELI LILLY AND CO	EQ 5MG BASE	N022307	001	Jul 10, 2009
+	EQ 10MG BASE	N022307	002	Jul 10, 2009

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

AB	BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991
AB		40MG	N019898	004	Mar 22, 1993
AB	+	80MG	N019898	008	Dec 18, 2001

PRAVASTATIN SODIUM

AB	APOTEX	10MG	A076341	001	Oct 23, 2006
AB		20MG	A076341	002	Oct 23, 2006
AB		40MG	A076341	003	Oct 23, 2006
AB		80MG	A076341	004	Dec 28, 2007
AB	CIPLA LTD	10MG	A077904	001	Oct 23, 2006
AB		20MG	A077904	002	Oct 23, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-298 (of 371)

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A077013</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077013</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077013</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077013</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A079187</u>	<u>001</u>	May 27, 2010
<u>AB</u>		<u>20MG</u>	<u>A079187</u>	<u>002</u>	May 27, 2010
<u>AB</u>		<u>40MG</u>	<u>A079187</u>	<u>003</u>	May 27, 2010
<u>AB</u>		<u>80MG</u>	<u>A079187</u>	<u>004</u>	May 27, 2010
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A076397</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076397</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076397</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A077751</u>	<u>001</u>	Apr 30, 2008
<u>AB</u>		<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008

PRAZIOUANTEL

TABLET; ORAL

BILTRICIDE

+ BAYER HLTHCARE

600MG

N018714 001 Dec 29, 1982

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071994</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989
<u>AB</u>	TEVA PHARMS	<u>EQ 2MG BASE</u>	<u>A071995</u>	<u>001</u>	Sep 12, 1988
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N020279</u>	<u>001</u>	Oct 29, 1993
-----------	---	-----------------	-------------	----------------	------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077287</u>	<u>001</u>	Sep 19, 2006
-----------	----------------	-------------	----------------	------------	--------------

OINTMENT; TOPICAL

DERMATOP

<u>AB</u>	+	VALEANT BERMUDA	<u>0.1%</u>	<u>N019568</u>	<u>001</u>	Sep 23, 1991
-----------	---	-----------------	-------------	----------------	------------	--------------

PREDNICARBATE

<u>AB</u>	FOUGERA PHARMS	<u>0.1%</u>	<u>A077236</u>	<u>001</u>	Mar 09, 2007
-----------	----------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-299 (of 371)

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	ALPHARMA	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
AA	+ HI TECH PHARMA CO	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
AA	PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
AA	VINTAGE	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
AA	WOCKHARDT	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003

PRELONE

AA	TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986
-----------	------	-----------------	-----------------------	-------------------	--------------

TABLET; ORAL

PREDNISOLONE

+ WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION; ORAL

FLO-PRED

+ TARO

EQ 15MG BASE/5ML

N022067 002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

AB	ALCON	<u>1%</u>	<u>N017469</u>	<u>001</u>	
-----------	-------	-----------	-----------------------	-------------------	--

PRED FORTE

AB	+ ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>	
-----------	------------	-----------	-----------------------	-------------------	--

PRED MILD

+ ALLERGAN

0.12%

N017100 001

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPHAMIDE S.O.P.

+ ALLERGAN

0.2%;10%

A087748 001 Dec 03, 1986

SUSPENSION; OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN

0.2%;10%

N012813 002

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

ORAPRED

AA	+ CONCORDIA PHARMS INC	<u>EQ 15MG BASE/5ML</u>	<u>A075117</u>	<u>001</u>	Dec 14, 2000
-----------	------------------------	-------------------------	-----------------------	-------------------	--------------

PEDIAAPRED

AA	+ SETON PHARM	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986
-----------	---------------	------------------------	-----------------------	-------------------	--------------

PREDNISOLONE SODIUM PHOSPHATE

AA	AMNEAL PHARMS	<u>EQ 15MG BASE/5ML</u>	<u>A078345</u>	<u>001</u>	Mar 10, 2009
AA	HI TECH PHARMA	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003
AA	PADDOCK LLC	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004
AA	PHARM ASSOC	<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
AA	VINTAGE	<u>EQ 15MG BASE/5ML</u>	<u>A079010</u>	<u>001</u>	May 26, 2009
AA	WOCKHARDT	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
AA		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004
	+ MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010
	+ PHARM ASSOC	EQ 10MG BASE/5ML	A078465	001	Mar 07, 2008
		EQ 20MG BASE/5ML	A078988	001	Jun 09, 2008

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

+ BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

TABLET, ORALLY DISINTEGRATING; ORAL

ORAPRED ODT

AB	CONCORDIA PHARMS INC	<u>EQ 10MG BASE</u>	<u>N021959</u>	<u>001</u>	Jun 01, 2006
AB		<u>EQ 15MG BASE</u>	<u>N021959</u>	<u>002</u>	Jun 01, 2006
AB		<u>EQ 30MG BASE</u>	<u>N021959</u>	<u>003</u>	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE

AB	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A202179</u>	<u>001</u>	Apr 10, 2013
AB		<u>EQ 15MG BASE</u>	<u>A202179</u>	<u>002</u>	Apr 10, 2013
AB		<u>EQ 30MG BASE</u>	<u>A202179</u>	<u>003</u>	Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	ALCON PHARMS LTD	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A073630</u>	<u>001</u>	May 27, 1993
AT	+ BAUSCH AND LOMB	<u>EQ 0.23% PHOSPHATE;10%</u>	<u>A074449</u>	<u>001</u>	Dec 29, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-300 (of 371)

PREDNISON

SOLUTION;ORAL

PREDNISON

+ ROXANE

5MG/5ML

A088703 001 Nov 08, 1984

PREDNISON INTENSOL

+ ROXANE

5MG/ML

A088810 001 Feb 20, 1985

TABLET;ORAL

PREDNISONAB CONTRACT PHARMACAL5MGA080209 001AB HIKMA PHARMS1MGA040890 001

Nov 01, 2010

AB 2.5MGA040538 001

Jan 08, 2004

AB 5MGA080292 001AB 10MGA088832 001

Dec 04, 1985

AB 20MGA083677 001AB 50MGA088465 001

Jun 01, 1984

AB JUBILANT CADISTA1MGA040611 001

Jun 06, 2005

AB 5MGA040362 002

Aug 29, 2001

AB 10MGA040362 001

Aug 29, 2001

AB 20MGA040362 003

Jun 29, 2005

AB MUTUAL PHARM5MGA089245 001

Dec 04, 1985

AB 10MGA089246 001

Dec 04, 1985

AB 20MGA089247 001

Dec 04, 1985

AB + ROXANE1MGA087800 001

Apr 22, 1982

AB + 2.5MGA087801 001

Apr 22, 1982

AB + 5MGA080352 001AB + 10MGA084122 001AB + 20MGA087342 001AB + 50MGA084283 001AB VINTAGE PHARMS1MGA040584 001

Dec 21, 2004

AB 2.5MGA040581 001

Dec 21, 2004

AB 5MGA040256 001

Jul 12, 2002

AB 10MGA040256 002

Jul 12, 2002

AB 20MGA040392 001

Feb 12, 2003

AB WATSON LABS5MGA080356 001AB 10MGA085162 001AB 20MGA085161 001

TABLET, DELAYED RELEASE;ORAL

RAYOS

HORIZON PHARMA

1MG

N202020 001 Jul 26, 2012

+ 2MG

N202020 002 Jul 26, 2012

+ 5MG

N202020 003 Jul 26, 2012

PREGABALIN

CAPSULE;ORAL

LYRICAAB PF PRISM CV25MGN021446 001

Dec 30, 2004

AB 50MGN021446 002

Dec 30, 2004

AB 75MGN021446 003

Dec 30, 2004

AB 100MGN021446 004

Dec 30, 2004

AB 150MGN021446 005

Dec 30, 2004

AB 200MGN021446 006

Dec 30, 2004

AB 225MGN021446 007

Dec 30, 2004

AB + 300MGN021446 008

Dec 30, 2004

PREGABALINAB LUPIN LTD25MGA091040 001

Jul 03, 2012

AB 50MGA091040 002

Jul 03, 2012

AB 75MGA091040 003

Jul 03, 2012

AB 100MGA091040 004

Jul 03, 2012

AB 150MGA091040 005

Jul 03, 2012

AB 200MGA091040 006

Jul 03, 2012

AB 225MGA091040 007

Jul 03, 2012

AB 300MGA091040 008

Jul 03, 2012

AB TEVA PHARMS25MGA091219 001

Jul 03, 2012

AB 50MGA091219 002

Jul 03, 2012

AB 75MGA091224 001

Jul 03, 2012

AB 100MGA091224 002

Jul 03, 2012

AB 150MGA091224 003

Jul 03, 2012

AB 200MGA091224 004

Jul 03, 2012

AB 225MGA091224 005

Jul 03, 2012

AB 300MGA091224 006

Jul 03, 2012

AB WATSON LABS INC25MGA091221 001

Jul 03, 2012

AB 50MGA091221 002

Jul 03, 2012

AB 75MGA091221 003

Jul 03, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-301 (of 371)

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>100MG</u>	<u>A091221</u>	<u>004</u>	Jul 03, 2012
<u>AB</u>		<u>150MG</u>	<u>A091221</u>	<u>005</u>	Jul 03, 2012
<u>AB</u>		<u>200MG</u>	<u>A091221</u>	<u>006</u>	Jul 03, 2012
<u>AB</u>		<u>225MG</u>	<u>A091221</u>	<u>007</u>	Jul 03, 2012
<u>AB</u>		<u>300MG</u>	<u>A091221</u>	<u>008</u>	Jul 03, 2012

SOLUTION; ORAL

LYRICA

+ PF PRISM CV

20MG/ML

N022488 001 Jan 04, 2010

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRILOCAINE HYDROCHLORIDE

+ SEPTODONT INC

4%

A079235 001 Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE

<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316</u>	<u>001</u>	
-----------	---------------------	---------------------	----------------	------------	--

PRIMAQUINE PHOSPHATE

<u>AB</u>	ALVOGEN INC	<u>EQ 15MG BASE</u>	<u>A203924</u>	<u>001</u>	Feb 03, 2014
<u>AB</u>	BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476</u>	<u>001</u>	Feb 25, 2014

PRIMIDONE

TABLET; ORAL

MYSOLINE

<u>AB</u>	+ VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>	
<u>AB</u>		<u>250MG</u>	<u>N009170</u>	<u>002</u>	

PRIMIDONE

<u>AB</u>	AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u>	Apr 23, 2008
<u>AB</u>		<u>250MG</u>	<u>A040866</u>	<u>002</u>	Apr 23, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>250MG</u>	<u>A040667</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>	IMPAX LABS	<u>50MG</u>	<u>A040717</u>	<u>001</u>	Feb 12, 2008
<u>AB</u>		<u>250MG</u>	<u>A040717</u>	<u>002</u>	Feb 12, 2008
<u>AB</u>	LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u>	May 24, 2001
<u>AB</u>		<u>250MG</u>	<u>A084903</u>	<u>001</u>	
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A040626</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>250MG</u>	<u>A040626</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	VINTAGE PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u>	Feb 24, 2005
<u>AB</u>		<u>250MG</u>	<u>A040586</u>	<u>002</u>	Feb 24, 2005
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>	

PROBENECID

TABLET; ORAL

PROBALAN

<u>AB</u>	LANNETT	<u>500MG</u>	<u>A080966</u>	<u>001</u>	
-----------	---------	--------------	----------------	------------	--

PROBENECID

<u>AB</u>	+ MYLAN	<u>500MG</u>	<u>A084211</u>	<u>002</u>	
<u>AB</u>	WATSON LABS	<u>500MG</u>	<u>A084442</u>	<u>004</u>	Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

+ HOSPIRA

100MG/ML

A089069 001 Feb 12, 1986

+

500MG/ML

A089070 001 Feb 12, 1986

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+ SIGMA TAU

EQ 50MG BASE

N016785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPRO

<u>AB</u>	PADDOCK LLC	<u>25MG</u>	<u>A040246</u>	<u>001</u>	Jun 28, 2000
-----------	-------------	-------------	----------------	------------	--------------

PROCHLORPERAZINE

<u>AB</u>	+ G AND W LABS	<u>25MG</u>	<u>A040058</u>	<u>001</u>	Nov 24, 1993
-----------	----------------	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-302 (of 371)

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

<u>AP</u>	BEDFORD	<u>EQ 5MG BASE/ML</u>	<u>A040540</u>	<u>001</u>	May 28, 2004
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204147</u>	<u>001</u>	Oct 15, 2013
<u>AP</u>	+ HIKMA MAPLE	<u>EQ 5MG BASE/ML</u>	<u>A089903</u>	<u>001</u>	Aug 29, 1989

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A040185</u>	<u>002</u>	Oct 28, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040185</u>	<u>001</u>	Oct 28, 1996
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A040101</u>	<u>001</u>	Jul 19, 1996
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>A040101</u>	<u>002</u>	Jul 19, 1996
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A040120</u>	<u>001</u>	Jul 11, 1996
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040120</u>	<u>002</u>	Jul 11, 1996
<u>PROCOMP</u>					
<u>AB</u>	JUBILANT CADISTA	<u>EQ 5MG BASE</u>	<u>A040268</u>	<u>001</u>	Feb 27, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A040268</u>	<u>002</u>	Feb 27, 1998

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

<u>AB</u>	BANNER PHARMACAPS	<u>100MG</u>	<u>A200900</u>	<u>001</u>	Aug 16, 2013
<u>AB</u>		<u>200MG</u>	<u>A200900</u>	<u>002</u>	Aug 16, 2013
<u>AB</u>	SOFGEN PHARMS	<u>100MG</u>	<u>A200456</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>200MG</u>	<u>A200456</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>	TEVA PHARMS	<u>100MG</u>	<u>A202121</u>	<u>001</u>	Feb 29, 2012
<u>AB</u>		<u>200MG</u>	<u>A202121</u>	<u>002</u>	Feb 29, 2012

PROMETRIUM

<u>AB</u>	ABBVIE INC	<u>100MG</u>	<u>N019781</u>	<u>001</u>	May 14, 1998
<u>AB</u>	+	<u>200MG</u>	<u>N019781</u>	<u>002</u>	Oct 15, 1999

GEL; VAGINAL

CRINONE

	WATSON LABS	4%	N020701	001	Jul 31, 1997
	+	8%	N020701	002	Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONE

<u>AO</u>	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075906</u>	<u>001</u>	Apr 25, 2001
<u>AO</u>	HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A091033</u>	<u>001</u>	Oct 28, 2010
<u>AO</u>	LUITPOLD	<u>50MG/ML</u>	<u>A090845</u>	<u>001</u>	Jun 22, 2009
<u>AO</u>	+ WATSON LABS (UTAH)	<u>50MG/ML</u>	<u>N017362</u>	<u>002</u>	

INSERT; VAGINAL

ENDOMETRIN

	+ FERRING	100MG	N022057	001	Jun 21, 2007
--	-----------	-------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	+ HIKMA MAPLE	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
<u>AP</u>	+	<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>	X-GEN PHARMS	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>		<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>	G AND W LABS	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	+	<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>	PERRIGO NEW YORK	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>		<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>	TARO	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>		<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
<u>AB</u>	WATSON LABS INC	<u>12.5MG</u>	<u>A040479</u>	<u>001</u>	Jun 24, 2003
<u>AB</u>		<u>25MG</u>	<u>A040479</u>	<u>002</u>	Jun 24, 2003

PROMETHEGAN

	+ G AND W LABS	50MG	A087165	001	Aug 14, 1987
--	----------------	------	---------	-----	--------------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>	HI TECH PHARMA	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>	SUN PHARM INDS INC	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>	TARO	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>	TRIS PHARMA INC	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012
<u>AA</u>	VINTAGE	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-303 (of 371)

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE PLAIN

AA	+	WOCKHARDT	6.25MG/5ML	A087953	001	Nov 15, 1982
-----------	---	-----------	-------------------	----------------	------------	--------------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB		AMNEAL PHARMS NY	12.5MG	A091179	001	Dec 13, 2010
AB			25MG	A091179	002	Dec 13, 2010
AB			50MG	A091179	003	Dec 13, 2010
AB		EMCURE PHARMS USA	12.5MG	A040673	001	Mar 05, 2008
AB			25MG	A040673	002	Mar 05, 2008
AB			50MG	A040673	003	Mar 05, 2008
AB		IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008
AB			25MG	A040724	002	Feb 12, 2008
AB			50MG	A040791	001	May 20, 2008
AB		KVK TECH	12.5MG	A040712	002	May 04, 2007
AB			25MG	A040712	001	Jul 31, 2006
AB			50MG	A040713	001	Jul 31, 2006
AB		MYLAN	12.5MG	A091054	001	Aug 30, 2011
AB			25MG	A091054	002	Aug 30, 2011
AB			50MG	A091054	003	Aug 30, 2011
AB		SANDOZ	25MG	A084176	003	
AB	+		50MG	A084176	001	
AB		SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008
AB			25MG	A040863	002	Dec 30, 2008
AB			50MG	A040863	003	Dec 30, 2008
AB		VINTAGE PHARMS	12.5MG	A040622	001	Jul 18, 2006
AB			25MG	A040622	002	Jul 18, 2006
AB			50MG	A040622	003	Jul 18, 2006
AB		WATSON LABS	25MG	A083426	001	
AB			50MG	A083711	001	
AB		ZYDUS PHARMS USA	12.5MG	A040596	001	Nov 18, 2005
AB			25MG	A040596	002	Nov 18, 2005
AB			50MG	A040596	003	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

AB		PAR PHARM	225MG	A078540	001	Oct 18, 2010
AB			325MG	A078540	002	Oct 18, 2010
AB			425MG	A078540	003	Oct 18, 2010
		RYTHMOL SR				
AB		GLAXOSMITHKLINE LLC	225MG	N021416	001	Sep 04, 2003
AB			325MG	N021416	002	Sep 04, 2003
AB	+		425MG	N021416	003	Sep 04, 2003

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004
AB			225MG	A076550	002	Apr 23, 2004
AB			300MG	A076550	003	Apr 23, 2004
AB		MUTUAL PHARM	150MG	A075998	001	Nov 29, 2001
AB			225MG	A075998	002	Nov 29, 2001
AB			300MG	A075998	003	Nov 29, 2001
AB		VINTAGE PHARMS	150MG	A075938	001	Oct 17, 2002
AB			225MG	A075938	002	Oct 17, 2002
AB			300MG	A075938	003	Oct 17, 2002
AB		WATSON LABS	150MG	A075203	001	Oct 24, 2000
AB			225MG	A075203	002	Oct 24, 2000
		RYTHMOL				
AB		GLAXOSMITHKLINE LLC	150MG	N019151	001	Nov 27, 1989
AB			225MG	N019151	003	Nov 20, 1992
AB	+		300MG	N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927	002	
---	--------	------	---------	-----	--

PRESCRIPTION DRUG PRODUCT LIST

3-304 (of 371)

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALCAINE

AT	+	ALCON	0.5%	<u>A080027</u>	<u>001</u>	
<u>PROPARACAINE HYDROCHLORIDE</u>						
AT		AKORN INC	0.5%	<u>A040277</u>	<u>001</u>	Mar 16, 2000
AT		BAUSCH AND LOMB	0.5%	<u>A040074</u>	<u>001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE;INJECTION

DIPRIVAN

AB	+	FRESENIUS KABI USA	10MG/ML	<u>N019627</u>	<u>002</u>	Jun 11, 1996
<u>PROPOFOL</u>						
AB		HOSPIRA	10MG/ML	<u>A077908</u>	<u>001</u>	Mar 17, 2006
AB		TEVA PHARMS USA	10MG/ML	<u>A075102</u>	<u>001</u>	Jan 04, 1999

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

PROPOXYPHENE HYDROCHLORIDE

PVT FORM

32MG

A083464 001

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERAL LA

AB		CRANFORD PHARMS LLC	60MG	<u>N018553</u>	<u>004</u>	Mar 18, 1987
AB			80MG	<u>N018553</u>	<u>002</u>	Apr 19, 1983
AB			120MG	<u>N018553</u>	<u>003</u>	Apr 19, 1983
AB	+		160MG	<u>N018553</u>	<u>001</u>	Apr 19, 1983
<u>PROPRANOLOL HYDROCHLORIDE</u>						
AB		ACTAVIS ELIZABETH	60MG	<u>A078494</u>	<u>001</u>	Aug 10, 2007
AB			80MG	<u>A078494</u>	<u>002</u>	Aug 10, 2007
AB			120MG	<u>A078494</u>	<u>003</u>	Aug 10, 2007
AB			160MG	<u>A078494</u>	<u>004</u>	Aug 10, 2007
AB		APTALIS PHARMATECH	60MG	<u>A078703</u>	<u>001</u>	Jul 15, 2011
AB			80MG	<u>A078703</u>	<u>002</u>	Jul 15, 2011
AB			120MG	<u>A078703</u>	<u>003</u>	Jul 15, 2011
AB			160MG	<u>A078703</u>	<u>004</u>	Jul 15, 2011
AB		MYLAN	60MG	<u>A078022</u>	<u>001</u>	Feb 15, 2007
AB			80MG	<u>A078022</u>	<u>002</u>	Feb 15, 2007
AB			120MG	<u>A078022</u>	<u>003</u>	Feb 15, 2007
AB			160MG	<u>A078022</u>	<u>004</u>	Feb 15, 2007
AB		NORTEC DEV ASSOC	60MG	<u>A078065</u>	<u>001</u>	Jan 26, 2007
AB			80MG	<u>A078065</u>	<u>002</u>	Jan 26, 2007
AB			120MG	<u>A078065</u>	<u>003</u>	Jan 26, 2007
AB			160MG	<u>A078065</u>	<u>004</u>	Jan 26, 2007
AB		UPSHER SMITH	60MG	<u>A078311</u>	<u>001</u>	Mar 06, 2009
AB			80MG	<u>A078311</u>	<u>002</u>	Mar 06, 2009
AB			120MG	<u>A078311</u>	<u>003</u>	Mar 06, 2009
AB			160MG	<u>A078311</u>	<u>004</u>	Mar 06, 2009
AB		ZYDUS PHARMS USA INC	60MG	<u>A090321</u>	<u>001</u>	Mar 25, 2011
AB			80MG	<u>A090321</u>	<u>002</u>	Mar 25, 2011
AB			120MG	<u>A090321</u>	<u>003</u>	Mar 25, 2011
AB			160MG	<u>A090321</u>	<u>004</u>	Mar 25, 2011

INNOPRAN XL

BX		GLAXOSMITHKLINE LLC	80MG	<u>N021438</u>	<u>001</u>	Mar 12, 2003
BX			120MG	<u>N021438</u>	<u>002</u>	Mar 12, 2003

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

AP	+	BAXTER HLTHCARE CORP	1MG/ML	<u>N016419</u>	<u>001</u>	
AP		BEDFORD	1MG/ML	<u>A075792</u>	<u>001</u>	Aug 29, 2000
AP		FRESENIUS KABI USA	1MG/ML	<u>A075826</u>	<u>001</u>	Aug 31, 2001
AP		HIKMA FARMACEUTICA	1MG/ML	<u>A077760</u>	<u>001</u>	Jan 31, 2008
AP		SANDOZ	1MG/ML	<u>A076400</u>	<u>001</u>	Feb 26, 2003

SOLUTION;ORAL

HEMANGEOL

+ PIERRE FABRE DERMA

4.28MG/ML

N205410 001 Mar 14, 2014

PROPRANOLOL HYDROCHLORIDE

+ ROXANE

20MG/5ML

A070979 001 May 15, 1987

+

40MG/5ML

A070690 001 May 15, 1987

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB		IPCA LABS LTD	10MG	<u>A078955</u>	<u>001</u>	Jun 02, 2008
AB			20MG	<u>A078955</u>	<u>002</u>	Jun 02, 2008
AB			40MG	<u>A078955</u>	<u>003</u>	Jun 02, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-305 (of 371)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>		<u>60MG</u>	<u>A070213</u>	<u>005</u>	Apr 08, 2011
<u>AB</u>		<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>	PLIVA	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>20MG</u>	<u>A071973</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>40MG</u>	<u>A071974</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>60MG</u>	<u>A071975</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	+	<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070217</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070218</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070219</u>	<u>001</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070220</u>	<u>001</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+	DAVA PHARMS INC	N006188	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

+	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987
---	--------------------	---------	---------	-----	--------------

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A202220</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>10MG</u>	<u>A202220</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A078913</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>10MG</u>	<u>A078913</u>	<u>002</u>	Sep 16, 2008
<u>AB</u>	SIGMAPHARM LABS LLC	<u>5MG</u>	<u>A090462</u>	<u>001</u>	May 03, 2010
<u>AB</u>		<u>10MG</u>	<u>A090462</u>	<u>002</u>	May 03, 2010

VIVACTIL

<u>AB</u>	ODYSSEY PHARMS	<u>5MG</u>	<u>A073644</u>	<u>001</u>	Aug 24, 1995
<u>AB</u>	+	<u>10MG</u>	<u>A073645</u>	<u>001</u>	Aug 24, 1995

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

<u>AB</u>	+	DAVA PHARMS INC	<u>A080157</u>	<u>001</u>	
<u>AB</u>		MIKART	<u>A081319</u>	<u>001</u>	Jun 30, 1992

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

<u>AP</u>	+	VALEANT PHARM INTL	<u>N009830</u>	<u>001</u>	
-----------	---	--------------------	----------------	------------	--

REGONOL

<u>AP</u>		SANDOZ	<u>N017398</u>	<u>001</u>	
-----------	--	--------	----------------	------------	--

SYRUP; ORAL

MESTINON

+	VALEANT PHARM NORTH	60MG/5ML	N015193	001	
---	---------------------	----------	---------	-----	--

TABLET; ORAL

MESTINON

<u>AB</u>	+	VALEANT PHARMS LLC	<u>N009829</u>	<u>002</u>	
-----------	---	--------------------	----------------	------------	--

PYRIDOSTIGMINE BROMIDE

<u>AB</u>		IMPAX LABS	<u>A040502</u>	<u>001</u>	Apr 24, 2003
-----------	--	------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-306 (of 371)

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

MESTINON

+ VALEANT PHARMS LLC

180MG

N011665 001

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

+ FRESENIUS KABI USA

100MG/ML

A080618 001

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+ AMEDRA PHARMS

25MG

N008578 001

QUAZEPAM

TABLET;ORAL

DORAL

+ SCIECURE PHARMA INC

15MG

N018708 001 Dec 27, 1985

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG BASE</u>	<u>A202152 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202152 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202152 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A202152 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202152 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A202152 006</u>	Mar 27, 2012
<u>AB</u>	ACTAVIS GRP PTC	<u>EQ 25MG BASE</u>	<u>A201762 001</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201762 002</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201762 003</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201762 004</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201762 005</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201762 006</u>	Feb 27, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201762 007</u>	Feb 27, 2013
<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A203390 001</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203390 002</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203390 003</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A203390 004</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A203390 005</u>	Oct 28, 2014
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A203390 006</u>	Oct 28, 2014
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG BASE</u>	<u>A201504 001</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201504 002</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201504 003</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A201504 004</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201504 005</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A201504 006</u>	Feb 12, 2013
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A201504 007</u>	Feb 12, 2013
<u>AB</u>	APOTEX INC	<u>EQ 25MG BASE</u>	<u>A090960 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090960 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090960 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090960 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090960 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090960 006</u>	Mar 27, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A091388 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091388 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091388 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091388 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091388 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091388 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A091388 007</u>	Mar 27, 2012
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A077380 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077380 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077380 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A077380 004</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A077380 005</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077380 006</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A077380 007</u>	Mar 27, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 25MG BASE</u>	<u>A203150 001</u>	Nov 26, 2013
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A201109 001</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201109 002</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201109 003</u>	Mar 27, 2012
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A201109 004</u>	Mar 27, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-307 (of 371)

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		<u>EQ 300MG BASE</u>	<u>A201109</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A201109</u>	<u>006</u>	Mar 27, 2012
AB	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A090323</u>	<u>001</u>	Mar 27, 2012
AB	ROXANE	<u>EQ 25MG BASE</u>	<u>A090120</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A090749</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A090749</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A090749</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A090749</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A090749</u>	<u>005</u>	Mar 27, 2012
AB	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679</u>	<u>001</u>	Dec 14, 2012
AB		<u>EQ 50MG BASE</u>	<u>A078679</u>	<u>002</u>	Dec 14, 2012
AB		<u>EQ 100MG BASE</u>	<u>A078679</u>	<u>003</u>	Dec 14, 2012
AB		<u>EQ 150MG BASE</u>	<u>A078679</u>	<u>004</u>	Dec 14, 2012
AB		<u>EQ 200MG BASE</u>	<u>A078679</u>	<u>005</u>	Dec 14, 2012
AB		<u>EQ 300MG BASE</u>	<u>A078679</u>	<u>006</u>	Dec 14, 2012
AB		<u>EQ 400MG BASE</u>	<u>A078679</u>	<u>007</u>	Dec 14, 2012
AB	SUN PHARMA GLOBAL	<u>EQ 25MG BASE</u>	<u>A201190</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A201190</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A201190</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A201190</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A201190</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A201190</u>	<u>006</u>	Mar 27, 2012
AB	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A077745</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A077745</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 150MG BASE</u>	<u>A077745</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A077745</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A077745</u>	<u>006</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A077745</u>	<u>007</u>	Mar 27, 2012
AB	TORRENT PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A200363</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A200363</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A200363</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A200363</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A200363</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A200363</u>	<u>006</u>	Mar 27, 2012
<u>SEROQUEL</u>					
AB	+ ASTRAZENECA	<u>EQ 25MG BASE</u>	<u>N020639</u>	<u>001</u>	Sep 26, 1997
AB		<u>EQ 50MG BASE</u>	<u>N020639</u>	<u>007</u>	Oct 04, 2005
AB		<u>EQ 100MG BASE</u>	<u>N020639</u>	<u>002</u>	Sep 26, 1997
AB		<u>EQ 200MG BASE</u>	<u>N020639</u>	<u>003</u>	Sep 26, 1997
AB	+	<u>EQ 300MG BASE</u>	<u>N020639</u>	<u>005</u>	Jul 26, 2000
AB		<u>EQ 400MG BASE</u>	<u>N020639</u>	<u>006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

SEROQUEL XR

ASTRAZENECA

+

EQ 50MG BASE
EQ 150MG BASE
EQ 200MG BASE
EQ 300MG BASE
EQ 400MG BASE

N022047 001 May 17, 2007
N022047 005 Aug 11, 2008
N022047 002 May 17, 2007
N022047 003 May 17, 2007
N022047 004 May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

ACCUPRIL

AB	PFIZER PHARMS	<u>EQ 5MG BASE</u>	<u>N019885</u>	<u>001</u>	Nov 19, 1991
AB		<u>EQ 10MG BASE</u>	<u>N019885</u>	<u>002</u>	Nov 19, 1991
AB		<u>EQ 20MG BASE</u>	<u>N019885</u>	<u>003</u>	Nov 19, 1991
AB	+	<u>EQ 40MG BASE</u>	<u>N019885</u>	<u>004</u>	Nov 19, 1991
<u>QUINAPRIL HYDROCHLORIDE</u>					
AB	ACTAVIS LABS FL INC	<u>EQ 5MG BASE</u>	<u>A076049</u>	<u>001</u>	Jan 14, 2005
AB		<u>EQ 10MG BASE</u>	<u>A076049</u>	<u>002</u>	Jan 14, 2005
AB		<u>EQ 20MG BASE</u>	<u>A076049</u>	<u>003</u>	Jan 14, 2005
AB		<u>EQ 40MG BASE</u>	<u>A076049</u>	<u>004</u>	Jan 14, 2005
AB	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725</u>	<u>001</u>	Apr 29, 2013
AB		<u>EQ 10MG BASE</u>	<u>A202725</u>	<u>002</u>	Apr 29, 2013
AB		<u>EQ 20MG BASE</u>	<u>A202725</u>	<u>003</u>	Apr 29, 2013
AB		<u>EQ 40MG BASE</u>	<u>A202725</u>	<u>004</u>	Apr 29, 2013
AB	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457</u>	<u>001</u>	Aug 24, 2007
AB		<u>EQ 10MG BASE</u>	<u>A078457</u>	<u>002</u>	Aug 24, 2007
AB		<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
AB		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-308 (of 371)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690 001</u>	Jun 20, 2006
AB		<u>EQ 10MG BASE</u>	<u>A077690 002</u>	Jun 20, 2006
AB		<u>EQ 20MG BASE</u>	<u>A077690 003</u>	Jun 20, 2006
AB		<u>EQ 40MG BASE</u>	<u>A077690 004</u>	Jun 20, 2006
AB	MYLAN	<u>EQ 5MG BASE</u>	<u>A076694 001</u>	Dec 23, 2004
AB		<u>EQ 10MG BASE</u>	<u>A076694 002</u>	Dec 23, 2004
AB		<u>EQ 20MG BASE</u>	<u>A076694 003</u>	Dec 23, 2004
AB		<u>EQ 40MG BASE</u>	<u>A076694 004</u>	Dec 23, 2004
AB	RANBAXY	<u>EQ 5MG BASE</u>	<u>A076607 001</u>	Dec 15, 2004
AB		<u>EQ 10MG BASE</u>	<u>A076607 002</u>	Dec 15, 2004
AB		<u>EQ 20MG BASE</u>	<u>A076607 003</u>	Dec 15, 2004
AB		<u>EQ 40MG BASE</u>	<u>A076607 004</u>	Dec 15, 2004
AB	SUN PHARM INDS LTD	<u>EQ 5MG BASE</u>	<u>A090800 001</u>	Jun 18, 2009
AB		<u>EQ 10MG BASE</u>	<u>A090800 002</u>	Jun 18, 2009
AB		<u>EQ 20MG BASE</u>	<u>A090800 003</u>	Jun 18, 2009
AB		<u>EQ 40MG BASE</u>	<u>A090800 004</u>	Jun 18, 2009
AB	TEVA	<u>EQ 5MG BASE</u>	<u>A075504 001</u>	Aug 24, 2007
AB		<u>EQ 10MG BASE</u>	<u>A075504 002</u>	Aug 24, 2007
AB		<u>EQ 20MG BASE</u>	<u>A075504 003</u>	Aug 24, 2007
AB		<u>EQ 40MG BASE</u>	<u>A075504 004</u>	Aug 24, 2007

QUINIDINE GLUCONATE

INJECTABLE; INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX + MUTUAL PHARM

324MG

A089338 001 Feb 11, 1987

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE**AB** MUTUAL PHARM**200MG****A081030 001** Apr 14, 1989**AB****300MG****A081031 001** Apr 14, 1989**AB** SANDOZ**200MG****A088072 002****AB****300MG****A088072 001** Sep 26, 1983**AB** + WATSON LABS**200MG****A083288 001****AB** +**300MG****A085583 001**

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+ TEVA PHARMS

300MG

A040045 001 Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN**AB** + MUTUAL PHARM CO INC**324MG****N021799 001** Aug 12, 2005QUININE SULFATE**AB** MYLAN PHARMS INC**324MG****A202581 001** Dec 14, 2012**AB** TEVA PHARMS**324MG****A091661 001** Sep 28, 2012RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

EISAI INC

5MG

N204736 001 Mar 26, 2013

+

10MG

N204736 002 Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX**AB** + EISAI INC**20MG****N020973 002** Aug 19, 1999RABEPRAZOLE SODIUM**AB** DR REDDYS LABS LTD**20MG****A076824 001** Nov 08, 2013**AB** KREMERS URBAN DEV**20MG****A090678 001** Nov 08, 2013**AB** LUPIN LTD**20MG****A078964 001** Nov 08, 2013**AB** MYLAN PHARMS INC**20MG****A076885 001** Nov 08, 2013**AB** TEVA PHARMS USA**20MG****A076822 001** Nov 08, 2013**AB** TORRENT PHARMS LTD**20MG****A202376 001** Nov 08, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-309 (of 371)

RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+ BAYER HLTHCARE 162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTAAB + LILLY60MGN020815 001 Dec 09, 1997RALOXIFENE HYDROCHLORIDEAB INVAGEN PHARMS60MGA090842 001 Sep 24, 2014AB TEVA PHARMS USA60MGA078193 001 Mar 04, 2014RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+ MERCK SHARP DOHME EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+ MERCK SHARP DOHME EQ 400MG BASE

N022145 001 Oct 12, 2007

TABLET, CHEWABLE; ORAL

ISENTRESS

MERCK SHARP DOHME EQ 25MG BASE

N203045 001 Dec 21, 2011

+ EQ 100MG BASE

N203045 002 Dec 21, 2011

RAMELTEON

TABLET; ORAL

RAMELTEONAB TEVA PHARMS USA8MGA091693 001 Jul 26, 2013ROZEREMAB + TAKEDA PHARMS USA8MGN021782 001 Jul 22, 2005RAMIPRIL

CAPSULE; ORAL

ALTACEAB KING PHARMS1.25MGN019901 001 Jan 28, 1991AB2.5MGN019901 002 Jan 28, 1991AB5MGN019901 003 Jan 28, 1991AB +10MGN019901 004 Jan 28, 1991RAMIPRILAB ACCORD HLTHCARE INC1.25MGA202392 001 Apr 15, 2014AB2.5MGA202392 002 Apr 15, 2014AB5MGA202392 003 Apr 15, 2014AB10MGA202392 004 Apr 15, 2014AB APOTEX1.25MGA079116 001 Jun 20, 2008AB2.5MGA079116 002 Jun 20, 2008AB5MGA079116 003 Jun 20, 2008AB10MGA079116 004 Jun 20, 2008AB AUROBINDO PHARMA LTD1.25MGA091604 001 Jun 08, 2011AB2.5MGA091604 002 Jun 08, 2011AB5MGA091604 003 Jun 08, 2011AB10MGA091604 004 Jun 08, 2011AB DR REDDYS LABS LTD1.25MGA078191 001 Jun 18, 2008AB2.5MGA078191 002 Jun 18, 2008AB5MGA078191 003 Jun 18, 2008AB10MGA078191 004 Jun 18, 2008AB INVAGEN PHARMS1.25MGA078745 001 Jun 18, 2008AB2.5MGA078745 002 Jun 18, 2008AB5MGA078745 003 Jun 18, 2008AB10MGA078745 004 Jun 18, 2008AB LUPIN1.25MGA077626 001 Jun 09, 2008AB2.5MGA077626 002 Jun 09, 2008AB5MGA077626 003 Jun 09, 2008AB10MGA077626 004 Jun 09, 2008AB ROXANE1.25MGA077900 001 Jun 18, 2008AB2.5MGA077900 002 Jun 18, 2008AB5MGA077900 003 Jun 18, 2008AB10MGA077900 004 Jun 18, 2008AB SANDOZ1.25MGA077514 001 Jun 18, 2008AB2.5MGA077514 002 Jun 18, 2008AB5MGA077514 003 Jun 18, 2008AB10MGA077514 004 Jun 18, 2008AB TEVA PHARMS1.25MGA077470 001 Jun 18, 2008AB2.5MGA077470 002 Jun 18, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-310 (of 371)

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

<u>AB</u>		<u>5MG</u>	<u>A077470</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>		<u>10MG</u>	<u>A077470</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>	WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>		<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>		<u>5MG</u>	<u>A076549</u>	<u>003</u>	Oct 24, 2005
<u>AB</u>		<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>		<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>		<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>		<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

TABLET;ORAL

RAMIPRIL

<u>AB</u>	MYLAN PHARMS INC	<u>1.25MG</u>	<u>A090650</u>	<u>001</u>	Jun 30, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090650</u>	<u>002</u>	Jun 30, 2011
<u>AB</u>		<u>5MG</u>	<u>A090650</u>	<u>003</u>	Jun 30, 2011
<u>AB</u>		<u>10MG</u>	<u>A090650</u>	<u>004</u>	Jun 30, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>1.25MG</u>	<u>A090697</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>2.5MG</u>	<u>A090697</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A090697</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>10MG</u>	<u>A090697</u>	<u>004</u>	Sep 24, 2009

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE;INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>	EUROHLTH INTL	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>		<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>	ZYDUS PHARMS USA INC	<u>25MG/ML</u>	<u>A091534</u>	<u>001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	+	COVIS INJECTABLES	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984
-----------	---	-------------------	------------------------	----------------	------------	--------------

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>	ACTAVIS MID ATLANTIC	<u>EQ 15MG BASE/ML</u>	<u>A076124</u>	<u>001</u>	Feb 21, 2007
<u>AA</u>	AMNEAL PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078312</u>	<u>001</u>	Sep 02, 2008
<u>AA</u>	AUROBINDO PHARM	<u>EQ 15MG BASE/ML</u>	<u>A090623</u>	<u>001</u>	Jul 28, 2010
<u>AA</u>	BIO PHARM INC	<u>EQ 15MG BASE/ML</u>	<u>A090102</u>	<u>001</u>	May 26, 2009
<u>AA</u>	BRECKENRIDGE PHARM	<u>EQ 15MG BASE/ML</u>	<u>A078684</u>	<u>001</u>	Aug 27, 2009
<u>AA</u>	CARACO	<u>EQ 15MG BASE/ML</u>	<u>A091091</u>	<u>001</u>	Sep 20, 2011
<u>AA</u>	HI TECH PHARMA	<u>EQ 15MG BASE/ML</u>	<u>A091078</u>	<u>001</u>	Mar 22, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>	SILARX	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	TARO	<u>EQ 15MG BASE/ML</u>	<u>A077476</u>	<u>001</u>	Jun 13, 2011
<u>AA</u>	TOLMAR	<u>EQ 15MG BASE/ML</u>	<u>A090054</u>	<u>001</u>	Nov 15, 2010
<u>AA</u>	VINTAGE PHARMS	<u>EQ 15MG BASE/ML</u>	<u>A078890</u>	<u>001</u>	Jul 01, 2010
<u>AA</u>	WOCKHARDT	<u>EQ 15MG BASE/ML</u>	<u>A079211</u>	<u>001</u>	May 26, 2009
<u>AA</u>		<u>EQ 15MG BASE/ML</u>	<u>A079212</u>	<u>001</u>	Feb 23, 2009

ZANTAC

<u>AA</u>	+	GLAXO GRP LTD	<u>EQ 15MG BASE/ML</u>	<u>N019675</u>	<u>001</u>	Dec 30, 1988
-----------	---	---------------	------------------------	----------------	------------	--------------

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 150MG BASE</u>	<u>A077824</u>	<u>001</u>	Oct 13, 2006
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A077824</u>	<u>002</u>	Oct 13, 2006
<u>AB</u>	APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK GENERICS	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 150MG BASE</u>	<u>A075165</u>	<u>001</u>	Sep 30, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075165</u>	<u>002</u>	Sep 30, 1998
<u>AB</u>	MYLAN	<u>EQ 150MG BASE</u>	<u>A074023</u>	<u>001</u>	Aug 22, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074023</u>	<u>002</u>	Aug 22, 1997
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-311 (of 371)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467 002</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>EQ 150MG BASE</u>	<u>A074488 001</u>	Jul 31, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074488 002</u>	Jul 31, 1997
<u>AB</u>	WOCKHARDT	<u>EQ 150MG BASE</u>	<u>A075208 001</u>	Dec 17, 1998
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075208 002</u>	Dec 17, 1998
<u>ZANTAC 150</u>				
<u>AB</u>	GLAXO GRP LTD	<u>EQ 150MG BASE</u>	<u>N018703 001</u>	Jun 09, 1983
<u>ZANTAC 300</u>				
<u>AB</u>	+ GLAXO GRP LTD	<u>EQ 300MG BASE</u>	<u>N018703 002</u>	Dec 09, 1985

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+ GILEAD	<u>1GM</u>	<u>N021526 001</u>	Feb 12, 2007
<u>AB</u>		<u>500MG</u>	<u>N021526 002</u>	Jan 27, 2006
<u>RANOLAZINE</u>				
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046 001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046 002</u>	Jul 29, 2013

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641 001</u>	May 16, 2006
<u>AB</u>	+	<u>EQ 1MG BASE</u>	<u>N021641 002</u>	May 16, 2006
<u>RASAGILINE MESYLATE</u>				
<u>AB</u>	APOTEX INC	<u>EQ 0.5MG BASE</u>	<u>A201950 001</u>	Sep 12, 2013
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201950 002</u>	Sep 12, 2013

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

+ ASTELLAS

0.4MG/5ML (0.08MG/ML)

N022161 001 Apr 10, 2008

REGORAFENIB

TABLET; ORAL

STIVARGA

+ BAYER HLTHCARE

40MG

N203085 001 Sep 27, 2012

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ULTIVA

MYLAN INSTITUTIONAL

EQ 1MG BASE/VIAL

N020630 001 Jul 12, 1996

EQ 2MG BASE/VIAL

N020630 002 Jul 12, 1996

+

EQ 5MG BASE/VIAL

N020630 003 Jul 12, 1996

REPAGLINIDE

TABLET; ORAL

PRANDIN

<u>AB</u>	NOVO NORDISK INC	<u>0.5MG</u>	<u>N020741 001</u>	Dec 22, 1997
<u>AB</u>		<u>1MG</u>	<u>N020741 002</u>	Dec 22, 1997
<u>AB</u>	+	<u>2MG</u>	<u>N020741 003</u>	Dec 22, 1997
<u>REPAGLINIDE</u>				
<u>AB</u>	ACTAVIS TOTOWA	<u>0.5MG</u>	<u>A090008 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A090008 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090008 003</u>	Jan 22, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820 001</u>	Jan 22, 2014
<u>AB</u>		<u>1MG</u>	<u>A203820 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A203820 003</u>	Jan 22, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>0.5MG</u>	<u>A090252 001</u>	Aug 23, 2013
<u>AB</u>		<u>1MG</u>	<u>A090252 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A090252 003</u>	Jan 22, 2014
<u>AB</u>	PADDOCK LLC	<u>0.5MG</u>	<u>A201189 001</u>	Jul 17, 2013
<u>AB</u>		<u>1MG</u>	<u>A201189 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A201189 003</u>	Jan 22, 2014
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078555 001</u>	Nov 22, 2013
<u>AB</u>		<u>1MG</u>	<u>A078555 002</u>	Jan 22, 2014
<u>AB</u>		<u>2MG</u>	<u>A078555 003</u>	Jan 22, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>1MG</u>	<u>A077571 002</u>	Jul 11, 2013
<u>AB</u>		<u>2MG</u>	<u>A077571 003</u>	Jul 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-312 (of 371)

RESERPINE

TABLET; ORAL

RESERPINE

BP	SANDOZ	0.1MG	N009838	001	
BP	+	0.25MG	N009838	002	

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+	GLAXO GRP LTD	1%	N022055	001	Apr 12, 2007
---	---------------	----	---------	-----	--------------

RIBAVIRIN

CAPSULE; ORAL

REBETOL

<u>AB</u>	+	MERCK SHARP DOHME	<u>200MG</u>	<u>N020903</u>	<u>002</u>	Jul 25, 2001
-----------	---	-------------------	--------------	----------------	------------	--------------

RIBASPHERE

<u>AB</u>		THREE RIVERS PHARMS	<u>200MG</u>	<u>A076203</u>	<u>001</u>	Apr 06, 2004
-----------	--	---------------------	--------------	----------------	------------	--------------

RIBAVARIN

<u>AB</u>		AUROBINDO PHARMA	<u>200MG</u>	<u>A079117</u>	<u>001</u>	Sep 17, 2009
-----------	--	------------------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A076192</u>	<u>001</u>	Apr 06, 2004
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>200MG</u>	<u>A076277</u>	<u>001</u>	Oct 04, 2004
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>200MG</u>	<u>A077224</u>	<u>001</u>	Oct 28, 2005
-----------	--	------------------	--------------	----------------	------------	--------------

REBETOL

+	MERCK SHARP DOHME	200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetrone Combination Therapy**	N020903	001	Jun 03, 1998
---	-------------------	---	---------	-----	--------------

FOR SOLUTION; INHALATION

VIRAZOLE

+	VALEANT PHARM INTL	6GM/VIAL	N018859	001	Dec 31, 1985
---	--------------------	----------	---------	-----	--------------

SOLUTION; ORAL

REBETOL

+	SCHERING	40MG/ML	N021546	001	Jul 29, 2003
---	----------	---------	---------	-----	--------------

TABLET; ORAL

COPEGUS

<u>AB</u>		ROCHE	<u>200MG</u>	<u>N021511</u>	<u>001</u>	Dec 03, 2002
-----------	--	-------	--------------	----------------	------------	--------------

RIBAVIRIN

<u>AB</u>		AUROBINDO PHARMA	<u>200MG</u>	<u>A079111</u>	<u>001</u>	Sep 17, 2009
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>200MG</u>	<u>A077743</u>	<u>001</u>	Oct 03, 2006
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>200MG</u>	<u>A202546</u>	<u>001</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A202546</u>	<u>002</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A202546</u>	<u>003</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>600MG</u>	<u>A202546</u>	<u>004</u>	Aug 12, 2014
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		TEVA	<u>200MG</u>	<u>A077053</u>	<u>001</u>	Dec 05, 2005
-----------	--	------	--------------	----------------	------------	--------------

<u>AB</u>		THREE RIVERS PHARMS	<u>200MG</u>	<u>A077456</u>	<u>001</u>	Dec 05, 2005
-----------	--	---------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A077456</u>	<u>002</u>	Dec 05, 2005
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>	+		<u>600MG</u>	<u>A077456</u>	<u>003</u>	Dec 05, 2005
-----------	---	--	--------------	----------------	------------	--------------

<u>AB</u>		ZYDUS PHARMS USA	<u>200MG</u>	<u>A077094</u>	<u>001</u>	Dec 05, 2005
-----------	--	------------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>400MG</u>	<u>A077094</u>	<u>002</u>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>500MG</u>	<u>A077094</u>	<u>004</u>	Apr 18, 2008
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>			<u>600MG</u>	<u>A077094</u>	<u>003</u>	Mar 16, 2007
-----------	--	--	--------------	----------------	------------	--------------

RIFABUTIN

CAPSULE; ORAL

MYCOBUTIN

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>150MG</u>	<u>N050689</u>	<u>001</u>	Dec 23, 1992
-----------	---	----------------------	--------------	----------------	------------	--------------

RIFABUTIN

<u>AB</u>		LUPIN LTD	<u>150MG</u>	<u>A090033</u>	<u>001</u>	Feb 24, 2014
-----------	--	-----------	--------------	----------------	------------	--------------

RIFAMPIN

CAPSULE; ORAL

RIFADIN

<u>AB</u>		SANOFI AVENTIS US	<u>150MG</u>	<u>A062303</u>	<u>001</u>	
-----------	--	-------------------	--------------	----------------	------------	--

<u>AB</u>	+		<u>300MG</u>	<u>N050420</u>	<u>001</u>	
-----------	---	--	--------------	----------------	------------	--

RIFAMPIN

<u>AB</u>		LANNETT	<u>150MG</u>	<u>A065390</u>	<u>001</u>	Mar 28, 2008
-----------	--	---------	--------------	----------------	------------	--------------

<u>AB</u>			<u>300MG</u>	<u>A065390</u>	<u>002</u>	Mar 28, 2008
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		LUPIN PHARMS	<u>150MG</u>	<u>A090034</u>	<u>001</u>	Aug 21, 2013
-----------	--	--------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>300MG</u>	<u>A090034</u>	<u>002</u>	Aug 21, 2013
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		SANDOZ	<u>150MG</u>	<u>A064150</u>	<u>002</u>	Jan 02, 1998
-----------	--	--------	--------------	----------------	------------	--------------

<u>AB</u>			<u>300MG</u>	<u>A064150</u>	<u>001</u>	May 28, 1997
-----------	--	--	--------------	----------------	------------	--------------

<u>AB</u>		VERSAPHARM	<u>150MG</u>	<u>A065028</u>	<u>001</u>	Mar 14, 2001
-----------	--	------------	--------------	----------------	------------	--------------

<u>AB</u>			<u>300MG</u>	<u>A065028</u>	<u>002</u>	Mar 14, 2001
-----------	--	--	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-313 (of 371)

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB	PROSAM LABS	300MG	N050429	001	
-----------	-------------	--------------	----------------	------------	--

INJECTABLE; INJECTION

RIFADIN

AP	+	SANOFI AVENTIS US	600MG/VIAL	N050627	001	May 25, 1989
-----------	---	-------------------	-------------------	----------------	------------	--------------

RIFAMPIN

AP		AGILA SPECLTS	600MG/VIAL	A065421	001	May 22, 2008
AP		BEDFORD	600MG/VIAL	A064217	001	Oct 29, 1999
AP		EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014
AP		FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014
AP		VERSAPHARM INC	600MG/VIAL	A065502	001	Sep 21, 2010

RIFAPENTINE

TABLET; ORAL

PRIFTIN

+	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998
---	-------------------	-------	---------	-----	--------------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	200MG	N021361	001	May 25, 2004
+		550MG	N022554	001	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011
---	---------------	--------------	---------	-----	--------------

RILUZOLE

TABLET; ORAL

RILUTEK

AB	+	COVIS PHARMA SARL	50MG	N020599	001	Dec 12, 1995
-----------	---	-------------------	-------------	----------------	------------	--------------

RILUZOLE

AB		APOTEX CORP	50MG	A091300	001	Jun 18, 2013
AB		GLENMARK GENERICS	50MG	A091394	001	Jun 18, 2013
AB		IMPAX LABS	50MG	A076173	001	Jan 29, 2003
AB		MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013
AB		SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

AB	+	CARACO	100MG	N019649	001	Sep 17, 1993
-----------	---	--------	--------------	----------------	------------	--------------

RIMANTADINE HYDROCHLORIDE

AB		IMPAX LABS	100MG	A076132	001	Aug 30, 2002
-----------	--	------------	--------------	----------------	------------	--------------

RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

+	ALCON	1%	N020474	001	Dec 30, 1994
---	-------	----	---------	-----	--------------

RIOCIGUAT

TABLET; ORAL

ADEMPAS

	BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013
		1MG	N204819	002	Oct 08, 2013
		1.5MG	N204819	003	Oct 08, 2013
		2MG	N204819	004	Oct 08, 2013
+		2.5MG	N204819	005	Oct 08, 2013

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB		WARNER CHILCOTT LLC	5MG	N020835	002	Apr 14, 2000
AB			30MG	N020835	001	Mar 27, 1998
AB	+		35MG	N020835	003	May 25, 2002
AB	+		150MG	N020835	005	Apr 22, 2008

RISEDRONATE SODIUM

AB		APOTEX INC	75MG	A090877	002	Jun 10, 2014
AB			150MG	A090877	003	Jun 10, 2014
AB		MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014
AB			150MG	A200477	005	Jun 10, 2014
AB		SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014
AB			150MG	A090886	005	Jun 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-314 (of 371)

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007
<u>AB</u>		<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>		<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
<u>AB</u>	TEVA PHARMS USA	<u>150MG</u>	<u>A079215</u>	<u>001</u>	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010
---	---------------------	------	---------	-----	--------------

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
--	----------------	-------------	---------	-----	--------------

+		25MG/VIAL	N021346	001	Oct 29, 2003
---	--	-----------	---------	-----	--------------

		37.5MG/VIAL	N021346	002	Oct 29, 2003
--	--	-------------	---------	-----	--------------

		50MG/VIAL	N021346	003	Oct 29, 2003
--	--	-----------	---------	-----	--------------

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	+	JANSSEN PHARMS	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996
-----------	---	----------------	---------------	----------------	------------	--------------

RISPERIDONE

<u>AA</u>	AMNEAL PHARMS	<u>1MG/ML</u>	<u>A091384</u>	<u>001</u>	May 25, 2011
<u>AA</u>	ANI PHARMS INC	<u>1MG/ML</u>	<u>A076440</u>	<u>001</u>	Jan 30, 2009
<u>AA</u>	APOTEX INC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u>	BIO PHARM INC	<u>1MG/ML</u>	<u>A078909</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	PRECISION DOSE	<u>1MG/ML</u>	<u>A076797</u>	<u>001</u>	Jun 28, 2010
<u>AA</u>	ROXANE	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>	SILARX PHARMS INC	<u>1MG/ML</u>	<u>A202386</u>	<u>001</u>	Jan 12, 2015
<u>AA</u>	TARO	<u>1MG/ML</u>	<u>A090347</u>	<u>001</u>	Feb 07, 2011
<u>AA</u>	TRIS PHARMA INC	<u>1MG/ML</u>	<u>A079059</u>	<u>001</u>	Dec 12, 2012
<u>AA</u>	VINTAGE	<u>1MG/ML</u>	<u>A079158</u>	<u>001</u>	Dec 03, 2010
<u>AA</u>	WOCKHARDT	<u>1MG/ML</u>	<u>A078744</u>	<u>001</u>	Oct 08, 2009

TABLET; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>		<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>	+	<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>		<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>		<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>		<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>	AJANTA PHARMA LTD	<u>0.25MG</u>	<u>A201003</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A201003</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>		<u>1MG</u>	<u>A201003</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>		<u>2MG</u>	<u>A201003</u>	<u>004</u>	Aug 24, 2011
<u>AB</u>		<u>3MG</u>	<u>A201003</u>	<u>005</u>	Aug 24, 2011
<u>AB</u>		<u>4MG</u>	<u>A201003</u>	<u>006</u>	Aug 24, 2011
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	CIPLA	<u>0.25MG</u>	<u>A077543</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077543</u>	<u>002</u>	May 18, 2011
<u>AB</u>		<u>1MG</u>	<u>A077543</u>	<u>003</u>	May 18, 2011
<u>AB</u>		<u>2MG</u>	<u>A077543</u>	<u>004</u>	May 18, 2011
<u>AB</u>		<u>3MG</u>	<u>A077543</u>	<u>005</u>	May 18, 2011
<u>AB</u>		<u>4MG</u>	<u>A077543</u>	<u>006</u>	May 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-315 (of 371)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>	MYLAN	<u>0.25MG</u>	<u>A076288</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076288</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A076288</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A076288</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A076288</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A076288</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	PLIVA HRVATSKA DOO	<u>0.25MG</u>	<u>A077769</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077769</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A077769</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A077769</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A077769</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A077769</u>	<u>006</u>	Oct 16, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	PROSAM LABS	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>0.25MG</u>	<u>A078036</u>	<u>001</u>	Mar 10, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078036</u>	<u>002</u>	Mar 10, 2014
<u>AB</u>		<u>1MG</u>	<u>A078036</u>	<u>003</u>	Mar 10, 2014
<u>AB</u>		<u>2MG</u>	<u>A078036</u>	<u>004</u>	Mar 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A078036</u>	<u>005</u>	Mar 10, 2014
<u>AB</u>		<u>4MG</u>	<u>A078036</u>	<u>006</u>	Mar 10, 2014
<u>AB</u>	TEVA	<u>0.25MG</u>	<u>A076228</u>	<u>001</u>	Jun 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076228</u>	<u>002</u>	Jun 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A076228</u>	<u>003</u>	Jun 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A076228</u>	<u>004</u>	Jun 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A076228</u>	<u>005</u>	Jun 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A076228</u>	<u>006</u>	Jun 30, 2008
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	VINTAGE	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	WOCKHARDT	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

<u>AB</u>	JANSSEN PHARMS	<u>0.5MG</u>	<u>N021444</u>	<u>001</u>	Apr 02, 2003
-----------	----------------	--------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-316 (of 371)

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERDAL

<u>AB</u>	+	<u>1MG</u>	<u>N021444</u>	<u>002</u>	Apr 02, 2003
<u>AB</u>		<u>2MG</u>	<u>N021444</u>	<u>003</u>	Apr 02, 2003
<u>AB</u>		<u>3MG</u>	<u>N021444</u>	<u>004</u>	Dec 23, 2004
<u>AB</u>		<u>4MG</u>	<u>N021444</u>	<u>005</u>	Dec 23, 2004

RISPERIDONE

<u>AB</u>	ACTAVIS LABS FL INC	<u>0.5MG</u>	<u>A076996</u>	<u>001</u>	Apr 19, 2011
<u>AB</u>		<u>1MG</u>	<u>A076996</u>	<u>002</u>	Apr 19, 2011
<u>AB</u>		<u>2MG</u>	<u>A076996</u>	<u>003</u>	Apr 19, 2011
<u>AB</u>		<u>3MG</u>	<u>A076996</u>	<u>004</u>	Apr 19, 2011
<u>AB</u>		<u>4MG</u>	<u>A076996</u>	<u>005</u>	Apr 19, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>		<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>0.25MG</u>	<u>A091537</u>	<u>006</u>	Feb 12, 2013
<u>AB</u>		<u>0.5MG</u>	<u>A091537</u>	<u>001</u>	Mar 30, 2011
<u>AB</u>		<u>1MG</u>	<u>A091537</u>	<u>002</u>	Mar 30, 2011
<u>AB</u>		<u>2MG</u>	<u>A091537</u>	<u>003</u>	Mar 30, 2011
<u>AB</u>		<u>3MG</u>	<u>A091537</u>	<u>004</u>	Mar 30, 2011
<u>AB</u>		<u>4MG</u>	<u>A091537</u>	<u>005</u>	Mar 30, 2011
<u>AB</u>	PAR PHARM	<u>0.25MG</u>	<u>A077494</u>	<u>001</u>	Apr 30, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	RANBAXY	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A076908</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>1MG</u>	<u>A076908</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>2MG</u>	<u>A076908</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009

RITONAVIR

CAPSULE;ORAL

NORVIR

+ ABBVIE

100MG

N020945 001 Jun 29, 1999

SOLUTION;ORAL

NORVIR

+ ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIRAB + ABBVIE100MGN022417 001 Feb 10, 2010RITONAVIRAB ROXANE100MGA202573 001 Jan 15, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-317 (of 371)

RIVAROXABAN

TABLET; ORAL

XARELTO

+ JANSSEN PHARMS

10MG

N022406 001 Jul 01, 2011

15MG

N022406 002 Nov 04, 2011

+

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS

4.6MG/24HR

N022083 001 Jul 06, 2007

+

9.5MG/24HR

N022083 002 Jul 06, 2007

13.3MG/24HR

N022083 005 Aug 31, 2012

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELONAB + NOVARTISEQ 1.5MG BASEN020823 003 Apr 21, 2000ABEQ 3MG BASEN020823 004 Apr 21, 2000ABEQ 4.5MG BASEN020823 005 Apr 21, 2000ABEQ 6MG BASEN020823 006 Apr 21, 2000RIVASTIGMINE TARTRATEAB ALEMBIC PHARMS LTDEQ 1.5MG BASEA091689 001 Jun 12, 2012ABEQ 3MG BASEA091689 002 Jun 12, 2012ABEQ 4.5MG BASEA091689 003 Jun 12, 2012ABEQ 6MG BASEA091689 004 Jun 12, 2012AB

APOTEX INC

EQ 1.5MG BASEA091072 001 May 16, 2013ABEQ 3MG BASEA091072 002 May 16, 2013ABEQ 4.5MG BASEA091072 003 May 16, 2013ABEQ 6MG BASEA091072 004 May 16, 2013AB

DR REDDYS LABS INC

EQ 1.5MG BASEA077130 001 Oct 31, 2007ABEQ 3MG BASEA077130 002 Oct 31, 2007ABEQ 4.5MG BASEA077130 003 Oct 31, 2007ABEQ 6MG BASEA077130 004 Oct 31, 2007AB

MACLEODS PHARMS LTD

EQ 1.5MG BASEA203148 001 Aug 22, 2014ABEQ 3MG BASEA203148 002 Aug 22, 2014ABEQ 4.5MG BASEA203148 003 Aug 22, 2014ABEQ 6MG BASEA203148 004 Aug 22, 2014AB

SUN PHARM INDS

EQ 1.5MG BASEA077131 001 Oct 22, 2007ABEQ 3MG BASEA077131 002 Oct 22, 2007ABEQ 4.5MG BASEA077131 003 Oct 22, 2007ABEQ 6MG BASEA077131 004 Oct 22, 2007AB

WATSON LABS

EQ 1.5MG BASEA077129 001 Jan 08, 2008ABEQ 3MG BASEA077129 002 Jan 08, 2008ABEQ 4.5MG BASEA077129 003 Jan 08, 2008ABEQ 6MG BASEA077129 004 Jan 08, 2008RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALTAB MERCKEQ 5MG BASEN020864 001 Jun 29, 1998AB

+

EQ 10MG BASEN020864 002 Jun 29, 1998RIZATRIPTAN BENZOATEAB APOTEX INCEQ 5MG BASEA202244 001 Dec 31, 2012ABEQ 10MG BASEA202244 002 Dec 31, 2012AB

AUROBINDO PHARMA LTD

EQ 5MG BASEA202490 001 Dec 31, 2012ABEQ 10MG BASEA202490 002 Dec 31, 2012AB

CIPLA LTD

EQ 5MG BASEA077526 001 Mar 26, 2013ABEQ 10MG BASEA077526 002 Mar 26, 2013AB

EMCURE PHARMS LTD

EQ 5MG BASEA204090 001 Nov 26, 2013ABEQ 10MG BASEA204090 002 Nov 26, 2013AB

GLENMARK GENERICS

EQ 5MG BASEA201967 001 Dec 31, 2012ABEQ 10MG BASEA201967 002 Dec 31, 2012AB

INVAGEN PHARMS

EQ 5MG BASEA204339 001 Jul 01, 2013ABEQ 10MG BASEA204339 002 Jul 01, 2013AB

JUBILANT GENERICS

EQ 5MG BASEA203252 001 Dec 31, 2014ABEQ 10MG BASEA203252 002 Dec 31, 2014AB

MACLEODS PHARMS LTD

EQ 5MG BASEA203147 001 Feb 11, 2014ABEQ 10MG BASEA203147 002 Feb 11, 2014AB

MYLAN PHARMS INC

EQ 5MG BASEA201993 001 Dec 31, 2012ABEQ 10MG BASEA201993 002 Dec 31, 2012AB

NATCO PHARMA LTD

EQ 5MG BASEA200482 001 Dec 31, 2012ABEQ 10MG BASEA200482 002 Dec 31, 2012AB

SANDOZ

EQ 5MG BASEA079230 001 Dec 31, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-318 (of 371)

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079230</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 5MG BASE</u>	<u>A202047</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263</u>	<u>002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	MERCK	<u>EQ 5MG BASE</u>	<u>N020865</u>	<u>001</u>	Jun 29, 1998
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020865</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	APOTEX INC	<u>EQ 5MG BASE</u>	<u>A202477</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202477</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201914</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146</u>	<u>001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146</u>	<u>002</u>	Sep 19, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A078173</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078173</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	SANDOZ	<u>EQ 5MG BASE</u>	<u>A078739</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078739</u>	<u>002</u>	Jul 01, 2013

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	SAGENT STRIDES	<u>50MG/5ML (10MG/ML)</u>	<u>A091458</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008
<u>AP</u>	+	<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115</u>	<u>001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115</u>	<u>002</u>	Aug 27, 2012
<u>AP</u>	TEVA PHARMS	<u>50MG/5ML (10MG/ML)</u>	<u>A078717</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078717</u>	<u>002</u>	Nov 26, 2008

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011
---	---------------------	--------	---------	-----	--------------

ROMIDEPSIN

POWDER; IV (INFUSION)

ISTODAX

+	CELGENE	10MG/VIAL	N022393	001	Nov 05, 2009
---	---------	-----------	---------	-----	--------------

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

<u>AB</u>	+	<u>GLAXOSMITHKLINE LLC</u>	<u>EQ 0.25MG BASE</u>	<u>N020658</u>	<u>001</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 0.5MG BASE</u>	<u>N020658</u>	<u>002</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 1MG BASE</u>	<u>N020658</u>	<u>003</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>N020658</u>	<u>004</u>	Sep 19, 1997
<u>AB</u>			<u>EQ 3MG BASE</u>	<u>N020658</u>	<u>006</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>N020658</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>N020658</u>	<u>005</u>	Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-319 (of 371)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 0.25MG BASE</u>	<u>A079165 001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165 002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165 003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165 004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165 005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165 006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165 007</u>	Feb 07, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135 001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135 002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135 003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135 004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135 005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135 006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135 007</u>	Feb 25, 2010
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881 007</u>	May 19, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A079229 001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229 002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229 003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229 004</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229 005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229 006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229 007</u>	Nov 28, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 0.25MG BASE</u>	<u>A078110 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110 007</u>	Jul 11, 2008
<u>AB</u>	ROXANE	<u>EQ 0.25MG BASE</u>	<u>A077852 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077852 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077852 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077852 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077852 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077852 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077852 007</u>	May 19, 2008
<u>AB</u>	TEVA	<u>EQ 0.25MG BASE</u>	<u>A077460 001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A077460 002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A077460 003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A077460 004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077460 005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A077460 006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A077460 007</u>	May 19, 2008
<u>AB</u>	WOCKHARDT	<u>EQ 0.25MG BASE</u>	<u>A079050 001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050 002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050 003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050 004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050 005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050 006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050 007</u>	May 29, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 0.25MG BASE</u>	<u>A090411 001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411 002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411 003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411 004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411 005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411 006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411 007</u>	Jun 01, 2009
TABLET, EXTENDED RELEASE; ORAL				
<u>REQUIP XL</u>				
<u>AB</u>	+ GLAXOSMITHKLINE LLC	<u>EQ 2MG BASE</u>	<u>N022008 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N022008 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>N022008 006</u>	Apr 10, 2009
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>N022008 004</u>	Jun 13, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-320 (of 371)

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

<u>AB</u>		<u>EQ 12MG BASE</u>	<u>N022008</u>	<u>005</u>	Oct 31, 2008
	<u>ROPINIROLE HYDROCHLORIDE</u>				
<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090869</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869</u>	<u>002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869</u>	<u>003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869</u>	<u>004</u>	May 17, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869</u>	<u>005</u>	May 17, 2012
<u>AB</u>	ALEMBIC LTD	<u>EQ 2MG BASE</u>	<u>A202786</u>	<u>001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786</u>	<u>002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786</u>	<u>003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786</u>	<u>004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786</u>	<u>005</u>	Apr 22, 2013
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 2MG BASE</u>	<u>A201576</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 2MG BASE</u>	<u>A200462</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200462</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200462</u>	<u>004</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200462</u>	<u>005</u>	Oct 15, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200462</u>	<u>006</u>	Oct 15, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 2MG BASE</u>	<u>A201047</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047</u>	<u>006</u>	Jun 06, 2012
<u>AB</u>	WATSON LABS INC	<u>EQ 2MG BASE</u>	<u>A200431</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200431</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A200431</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A200431</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A200431</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 2MG BASE</u>	<u>A091395</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395</u>	<u>003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395</u>	<u>004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395</u>	<u>005</u>	Aug 27, 2012
	MYLAN PHARMS INC	EQ 3MG BASE	A200462	002	Oct 15, 2012

ROPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NAROPIN

<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>N020533</u>	<u>001</u>	Sep 24, 1996
<u>AP</u>		<u>5MG/ML</u>	<u>N020533</u>	<u>003</u>	Sep 24, 1996
<u>AP</u>		<u>7.5MG/ML</u>	<u>N020533</u>	<u>004</u>	Sep 24, 1996
<u>AP</u>	+	<u>10MG/ML</u>	<u>N020533</u>	<u>005</u>	Sep 24, 1996

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>	HOSPIRA	<u>2MG/ML</u>	<u>A090194</u>	<u>001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090194</u>	<u>002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090194</u>	<u>003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090194</u>	<u>004</u>	Sep 23, 2014
<u>AP</u>	NAVINTA LLC	<u>5MG/ML</u>	<u>A078601</u>	<u>002</u>	Jul 17, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A078601</u>	<u>003</u>	Jul 17, 2014
<u>AP</u>	SAGENT STRIDES	<u>2MG/ML</u>	<u>A090318</u>	<u>001</u>	Sep 23, 2014
<u>AP</u>		<u>5MG/ML</u>	<u>A090318</u>	<u>002</u>	Sep 23, 2014
<u>AP</u>		<u>7.5MG/ML</u>	<u>A090318</u>	<u>003</u>	Sep 23, 2014
<u>AP</u>		<u>10MG/ML</u>	<u>A090318</u>	<u>004</u>	Sep 23, 2014

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

<u>AB</u>	SB PHARMC0	<u>EQ 2MG BASE</u>	<u>N021071</u>	<u>002</u>	May 25, 1999
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>N021071</u>	<u>003</u>	May 25, 1999
<u>AB</u>	+	<u>EQ 8MG BASE</u>	<u>N021071</u>	<u>004</u>	May 25, 1999
	<u>ROSIGLITAZONE MALEATE</u>				
<u>AB</u>	TEVA	<u>EQ 2MG BASE</u>	<u>A076747</u>	<u>001</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076747</u>	<u>002</u>	Jan 25, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076747</u>	<u>003</u>	Jan 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-321 (of 371)

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

IPR

5MG

N021366 002 Aug 12, 2003

10MG

N021366 003 Aug 12, 2003

20MG

N021366 004 Aug 12, 2003

+

40MG

N021366 005 Aug 12, 2003

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

1MG/24HR

N021829 004 Apr 02, 2012

+

2MG/24HR

N021829 001 May 09, 2007

3MG/24HR

N021829 005 Apr 02, 2012

4MG/24HR

N021829 002 May 09, 2007

6MG/24HR

N021829 003 May 09, 2007

8MG/24HR

N021829 006 Apr 02, 2012

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011

TABLET; ORAL

BANZEL

EISAI INC

200MG

N021911 002 Nov 14, 2008

+

400MG

N021911 003 Nov 14, 2008

RUXOLITINIB PHOSPHATE

TABLET; ORAL

JAKAFI

INCYTE CORP

EQ 5MG BASE

N202192 001 Nov 16, 2011

EQ 10MG BASE

N202192 002 Nov 16, 2011

EQ 15MG BASE

N202192 003 Nov 16, 2011

EQ 20MG BASE

N202192 004 Nov 16, 2011

+

EQ 25MG BASE

N202192 005 Nov 16, 2011

SACROSIDASE

SOLUTION; ORAL

SUCRAID

+ QOL MEDCL

8,500 IU/ML

N020772 001 Apr 09, 1998

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+ GLAXOSMITHKLINE

EQ 0.05MG BASE/INH

N020692 001 Sep 19, 1997

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+ LANTHEUS MEDICAL

50mCi/ML

N020570 001 Mar 28, 1997

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

+ BIOMARIN PHARM

100MG/PACKET

N205065 001 Dec 19, 2013

TABLET; ORAL

KUVAN

+ BIOMARIN PHARM

100MG

N022181 001 Dec 13, 2007

SAQUINAVIR MESYLATE

CAPSULE; ORAL

INVIRASE

+ HOFFMANN LA ROCHE

EQ 200MG BASE

N020628 001 Dec 06, 1995

TABLET; ORAL

INVIRASE

+ HOFFMAN LA ROCHE

EQ 500MG BASE

N021785 001 Dec 17, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-322 (of 371)

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+	EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

TRANSDERM SCOP

NOVARTIS	1MG/72HR	N017874 001	
----------	----------	-------------	--

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983
+	100MG	A086101 002	Oct 03, 1983

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

CHIRHOCLIN	16MCG/VIAL	N021256 001	Apr 09, 2004
	40MCG/VIAL	N021256 002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
	9MG/24HR	N021336 002	Feb 27, 2006
	12MG/24HR	N021336 003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

ELDEPRYL

AB	+	SOMERSET	5MG	<u>N020647</u>	<u>001</u>	May 15, 1996
----	---	----------	-----	----------------	------------	--------------

SELEGILINE HYDROCHLORIDE

AB		APOTEX	5MG	<u>A075321</u>	<u>001</u>	Dec 04, 1998
----	--	--------	-----	----------------	------------	--------------

AB		DAVA PHARMS INC	5MG	<u>A075352</u>	<u>001</u>	Nov 30, 1998
----	--	-----------------	-----	----------------	------------	--------------

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	+	APOTEX INC	5MG	<u>A074871</u>	<u>001</u>	Jun 06, 1997
----	---	------------	-----	----------------	------------	--------------

AB		MYLAN	5MG	<u>A074866</u>	<u>001</u>	Nov 26, 1997
----	--	-------	-----	----------------	------------	--------------

AB		STASON	5MG	<u>A074912</u>	<u>001</u>	Apr 30, 1998
----	--	--------	-----	----------------	------------	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+	VALEANT PHARM INTL	1.25MG	N021479 001	Jun 14, 2006
---	--------------------	--------	-------------	--------------

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

AT		PERRIGO NEW YORK	2.5%	<u>A089996</u>	<u>001</u>	Jan 10, 1991
----	--	------------------	------	----------------	------------	--------------

AT		WOCKHARDT	2.5%	<u>A088228</u>	<u>001</u>	Sep 01, 1983
----	--	-----------	------	----------------	------------	--------------

SELSUN

AT	+	CHATTEM	2.5%	<u>N007936</u>	<u>001</u>	
----	---	---------	------	----------------	------------	--

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT LUXEMBOURG	2%	N021385 001	Dec 10, 2003
---	--------------------	----	-------------	--------------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

AA		AUROBINDO PHARMA	EQ 20MG BASE/ML	<u>A078861</u>	<u>001</u>	Oct 31, 2008
----	--	------------------	-----------------	----------------	------------	--------------

ZOLOFT

AA	+	PFIZER	EQ 20MG BASE/ML	<u>N020990</u>	<u>001</u>	Dec 07, 1999
----	---	--------	-----------------	----------------	------------	--------------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		ACCORD HLTHCARE	EQ 25MG BASE	<u>A202825</u>	<u>001</u>	Nov 07, 2014
----	--	-----------------	--------------	----------------	------------	--------------

AB			EQ 50MG BASE	<u>A202825</u>	<u>002</u>	Nov 07, 2014
----	--	--	--------------	----------------	------------	--------------

AB			EQ 100MG BASE	<u>A202825</u>	<u>003</u>	Nov 07, 2014
----	--	--	---------------	----------------	------------	--------------

AB		APOTEX INC	EQ 25MG BASE	<u>A076882</u>	<u>001</u>	Feb 06, 2007
----	--	------------	--------------	----------------	------------	--------------

AB			EQ 50MG BASE	<u>A076882</u>	<u>002</u>	Feb 06, 2007
----	--	--	--------------	----------------	------------	--------------

AB			EQ 100MG BASE	<u>A076882</u>	<u>003</u>	Feb 06, 2007
----	--	--	---------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	EQ 25MG BASE	<u>A077206</u>	<u>001</u>	Feb 06, 2007
----	--	------------------	--------------	----------------	------------	--------------

AB			EQ 50MG BASE	<u>A077206</u>	<u>002</u>	Feb 06, 2007
----	--	--	--------------	----------------	------------	--------------

AB			EQ 100MG BASE	<u>A077206</u>	<u>003</u>	Feb 06, 2007
----	--	--	---------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-323 (of 371)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

<u>AB</u>	AUSTARPHARMA LLC	<u>EQ 25MG BASE</u>	<u>A078677</u>	<u>001</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078677</u>	<u>002</u>	Mar 04, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078677</u>	<u>003</u>	Mar 04, 2009
<u>AB</u>	HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A077864</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077864</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077864</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	INVAGEN PHARMS	<u>EQ 25MG BASE</u>	<u>A077397</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077397</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077397</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	LUPIN	<u>EQ 25MG BASE</u>	<u>A077670</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077670</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077670</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A076671</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076671</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076671</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078626</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078626</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078626</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	PROSAM LABS	<u>EQ 25MG BASE</u>	<u>A078175</u>	<u>001</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078175</u>	<u>002</u>	Jul 21, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078175</u>	<u>003</u>	Jul 21, 2010
<u>AB</u>	RANBAXY	<u>EQ 25MG BASE</u>	<u>A077977</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077977</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077977</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 25MG BASE</u>	<u>A078108</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078108</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078108</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076465</u>	<u>001</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A076465</u>	<u>002</u>	Aug 11, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076465</u>	<u>003</u>	Aug 11, 2006
<u>AB</u>	TORRENT PHARMS	<u>EQ 25MG BASE</u>	<u>A077765</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077765</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077765</u>	<u>003</u>	Feb 06, 2007
<u>AB</u>	WOCKHARDT	<u>EQ 25MG BASE</u>	<u>A078403</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078403</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078403</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077106</u>	<u>001</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077106</u>	<u>002</u>	Feb 06, 2007
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077106</u>	<u>003</u>	Feb 06, 2007
<u>ZOLOFT</u>					
<u>AB</u>	PFIZER	<u>EQ 25MG BASE</u>	<u>N019839</u>	<u>005</u>	Mar 06, 1996
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>N019839</u>	<u>001</u>	Dec 30, 1991
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N019839</u>	<u>002</u>	Dec 30, 1991
	SERTRALINE HYDROCHLORIDE				
	RANBAXY	EQ 150MG BASE	A077977	004	Feb 06, 2007
		EQ 200MG BASE	A077977	005	Feb 06, 2007

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

REVELA

+ GENZYME

2.4GM/PACKET
800MG/PACKETN022318 002 Feb 18, 2009
N022318 001 Aug 12, 2009

TABLET; ORAL

REVELA

+ GENZYME

800MG

N022127 001 Oct 19, 2007

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

+ GENZYME

400MG

N021179 001 Jul 12, 2000

+ 800MG

N021179 002 Jul 12, 2000

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

<u>AN</u>	BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>	HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
<u>SOJOURN</u>					
<u>AN</u>	PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-324 (of 371)

SEVOFLURANE

LIQUID; INHALATION

ULTANE

AN	+	ABBVIE	100%	N020478	001	Jun 07, 1995
-----------	----------	---------------	-------------	----------------	------------	--------------

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER

EQ 10MG BASE/ML

N203109 001 Aug 30, 2012

SOLUTION; INTRAVENOUS

REVATIO

+ PFIZER

EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)

N022473 001 Nov 18, 2009

TABLET; ORAL

REVATIO

AB	+	PFIZER	EQ 20MG BASE	N021845	001	Jun 03, 2005
-----------	----------	---------------	---------------------	----------------	------------	--------------

SILDENAFIL CITRATE

AB		ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013
-----------	--	------------------------	---------------------	----------------	------------	--------------

AB		AMNEAL PHARMS	EQ 20MG BASE	A202025	001	Feb 28, 2013
-----------	--	----------------------	---------------------	----------------	------------	--------------

AB		APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012
-----------	--	--------------------	---------------------	----------------	------------	--------------

AB		DR REDDYS LABS LTD	EQ 20MG BASE	A202598	001	Nov 06, 2012
-----------	--	---------------------------	---------------------	----------------	------------	--------------

AB		HETERO LABS LTD V	EQ 20MG BASE	A203623	001	Nov 26, 2014
-----------	--	--------------------------	---------------------	----------------	------------	--------------

AB		MACLEODS PHARMS LTD	EQ 20MG BASE	A203814	001	Dec 17, 2013
-----------	--	----------------------------	---------------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012
-----------	--	-------------------------	---------------------	----------------	------------	--------------

AB		TEVA PHARMS	EQ 20MG BASE	A078380	001	Jan 07, 2013
-----------	--	--------------------	---------------------	----------------	------------	--------------

AB		TORRENT PHARMS LTD	EQ 20MG BASE	A091479	001	Nov 06, 2012
-----------	--	---------------------------	---------------------	----------------	------------	--------------

AB		WATSON LABS INC	EQ 20MG BASE	A202503	001	Nov 06, 2012
-----------	--	------------------------	---------------------	----------------	------------	--------------

VIAGRA

PFIZER IRELAND

EQ 25MG BASE

N020895 001 Mar 27, 1998

EQ 50MG BASE

N020895 002 Mar 27, 1998

+

EQ 100MG BASE

N020895 003 Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ WATSON LABS

4MG

N022206 001 Oct 08, 2008

8MG

N022206 002 Oct 08, 2008

SILVER SULFADIAZINE

CREAM; TOPICAL

SILVADENE

AB	+	KING PHARMS	1%	N017381	001	
-----------	----------	--------------------	-----------	----------------	------------	--

SSD

AB		DR REDDYS LA	1%	N018578	001	Feb 25, 1982
-----------	--	---------------------	-----------	----------------	------------	--------------

THERMAZENE

AB		THEPHARMANETWORK LLC	1%	N018810	001	Dec 23, 1985
-----------	--	-----------------------------	-----------	----------------	------------	--------------

SSD AF

BX		DR REDDYS LA	1%	N018578	003	Jul 11, 1990
-----------	--	---------------------	-----------	----------------	------------	--------------

SIMEPREVIR SODIUM

CAPSULE; ORAL

OLYSIO

+ JANSSEN PRODS

EQ 150MG BASE

N205123 001 Nov 22, 2013

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB		ACCORD HLTHCARE	5MG	A078155	005	Apr 05, 2013
-----------	--	------------------------	------------	----------------	------------	--------------

AB			10MG	A078155	002	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB			20MG	A078155	003	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB			40MG	A078155	004	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB			80MG	A078155	001	Feb 26, 2008
-----------	--	--	-------------	----------------	------------	--------------

AB		AUROBINDO PHARMA	5MG	A077691	001	Dec 20, 2006
-----------	--	-------------------------	------------	----------------	------------	--------------

AB			10MG	A077691	002	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			20MG	A077691	003	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			40MG	A077691	004	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			80MG	A077691	005	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB		BLU CARIBE	5MG	A078034	001	Dec 20, 2006
-----------	--	-------------------	------------	----------------	------------	--------------

AB			10MG	A078034	002	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			20MG	A078034	003	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			40MG	A078034	004	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			80MG	A078034	005	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB		DR REDDYS LABS INC	5MG	A077752	005	Jan 23, 2008
-----------	--	---------------------------	------------	----------------	------------	--------------

AB			10MG	A077752	001	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			20MG	A077752	002	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

AB			40MG	A077752	003	Dec 20, 2006
-----------	--	--	-------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-325 (of 371)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
<u>AB</u>		<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
<u>AB</u>		<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
<u>AB</u>		<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>5MG</u>	<u>A076052</u>	<u>001</u>	Jun 23, 2006
<u>AB</u>		<u>10MG</u>	<u>A076052</u>	<u>002</u>	Jun 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076052</u>	<u>003</u>	Jun 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076052</u>	<u>004</u>	Jun 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076052</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS LTD	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011
<u>AB</u>	MYLAN PHARMS INC	<u>5MG</u>	<u>A090868</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>		<u>10MG</u>	<u>A090868</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>		<u>20MG</u>	<u>A090868</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		<u>40MG</u>	<u>A090868</u>	<u>004</u>	Jun 08, 2010
<u>AB</u>		<u>80MG</u>	<u>A090868</u>	<u>005</u>	Jun 08, 2010
<u>AB</u>	PROSAM LABS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	RANBAXY	<u>5MG</u>	<u>A076285</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076285</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076285</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076285</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076285</u>	<u>005</u>	Jun 23, 2006
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006
<u>ZOCOR</u>					
<u>AB</u>	MERCK	<u>5MG</u>	<u>N019766</u>	<u>001</u>	Dec 23, 1991
<u>AB</u>		<u>10MG</u>	<u>N019766</u>	<u>002</u>	Dec 23, 1991
<u>AB</u>		<u>20MG</u>	<u>N019766</u>	<u>003</u>	Dec 23, 1991
<u>AB</u>		<u>40MG</u>	<u>N019766</u>	<u>004</u>	Dec 23, 1991
<u>AB</u>	+	<u>80MG</u>	<u>N019766</u>	<u>005</u>	Jul 10, 1998

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+ BRACCO

0.005MG/VIAL

N017697 001

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+ MEDIGENE AG

15%

N021902 001 Oct 31, 2006

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

+ PF PRISM CV

1MG/ML

N021083 001 Sep 15, 1999

TABLET; ORAL

RAPAMUNE

<u>AB</u>	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u>	Jan 25, 2010
<u>AB</u>		<u>1MG</u>	<u>N021110</u>	<u>001</u>	Aug 25, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-326 (of 371)

SIROLIMUS

TABLET; ORAL

RAPAMUNE

AB	+	2MG	N021110	002	Aug 22, 2002
-----------	---	------------	----------------	------------	--------------

SIROLIMUS

AB	DR REDDYS LABS LTD	1MG	A201578	001	Oct 27, 2014
-----------	--------------------	------------	----------------	------------	--------------

AB		2MG	A201578	002	Oct 27, 2014
-----------	--	------------	----------------	------------	--------------

AB	ZYDUS PHARMS USA INC	0.5MG	A201676	003	Jan 08, 2014
-----------	----------------------	--------------	----------------	------------	--------------

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
--	-------------------	--------------	---------	-----	--------------

		EQ 50MG BASE	N021995	002	Oct 16, 2006
--	--	--------------	---------	-----	--------------

+		EQ 100MG BASE	N021995	003	Oct 16, 2006
---	--	---------------	---------	-----	--------------

SODIUM ACETATE ANHYDROUS

INJECTABLE; INJECTION

SODIUM ACETATE IN PLASTIC CONTAINER

+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983
---	---------	---------	---------	-----	--------------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; IV (INFUSION)

AMMONUL

+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005
---	---------	-----------------------------	---------	-----	--------------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

+	HOSPIRA	0.9MEQ/ML	A077394	001	Nov 09, 2005
---	---------	-----------	---------	-----	--------------

+		1MEQ/ML	A077394	002	Nov 09, 2005
---	--	---------	---------	-----	--------------

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985
-----------	--------------------	---------------	----------------	------------	--------------

AP	+	9MG/ML	N018800	001	Oct 29, 1982
-----------	---	---------------	----------------	------------	--------------

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	450MG/100ML	N019635	001	Mar 09, 1988
-----------	---------	--------------------	----------------	------------	--------------

AP	BAXTER HLTHCARE	450MG/100ML	N018016	001	
-----------	-----------------	--------------------	----------------	------------	--

AP	HOSPIRA	450MG/100ML	N018090	001	
-----------	---------	--------------------	----------------	------------	--

AP		450MG/100ML	N019759	001	Jun 08, 1988
-----------	--	--------------------	----------------	------------	--------------

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850	001	Jan 20, 2012
-----------	---------------	---------------	----------------	------------	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	900MG/100ML	N017464	001	
-----------	---	--------------------	----------------	------------	--

AP	+	900MG/100ML	N019635	002	Mar 09, 1988
-----------	---	--------------------	----------------	------------	--------------

AP	+	9MG/ML	N016677	004	Oct 30, 1985
-----------	---	---------------	----------------	------------	--------------

AP		9MG/ML	N020178	002	Dec 07, 1992
-----------	--	---------------	----------------	------------	--------------

AP	+	900MG/100ML	N016677	001	
-----------	---	--------------------	----------------	------------	--

AP	+	900MG/100ML	N020178	001	Dec 07, 1992
-----------	---	--------------------	----------------	------------	--------------

AP	+	9MG/ML	A088912	001	Jan 10, 1985
-----------	---	---------------	----------------	------------	--------------

AP	FRESENIUS KABI USA	900MG/100ML	A078177	001	Apr 12, 2007
-----------	--------------------	--------------------	----------------	------------	--------------

AP	FRESENIUS MEDCL	900MG/100ML	A076316	001	Oct 27, 2004
-----------	-----------------	--------------------	----------------	------------	--------------

AP	HAEMONETICS	900MG/100ML	N018803	001	Oct 29, 1982
-----------	-------------	--------------------	----------------	------------	--------------

AP	+	9MG/ML	N019217	001	Jul 13, 1984
-----------	---	---------------	----------------	------------	--------------

AP	+	9MG/ML	N019465	002	Jul 15, 1985
-----------	---	---------------	----------------	------------	--------------

AP	+	900MG/100ML	N016366	001	
-----------	---	--------------------	----------------	------------	--

AP	+	900MG/100ML	N019465	001	Jul 15, 1985
-----------	---	--------------------	----------------	------------	--------------

AP	+	900MG/100ML	N019480	001	Sep 17, 1985
-----------	---	--------------------	----------------	------------	--------------

AP	+	9MG/ML	A077407	001	Aug 11, 2006
-----------	---	---------------	----------------	------------	--------------

SODIUM CHLORIDE 0.9%

	MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
--	-------------	--------------------	---------	-----	--------------

SODIUM CHLORIDE 0.9%

	HIKMA MAPLE	9MG/ML	A201833	001	Sep 24, 2013
--	-------------	--------	---------	-----	--------------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	MALLINCKRODT	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006
---	--------------	--------------------	---------	-----	--------------

		112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006
--	--	------------------------	---------	-----	--------------

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	3GM/100ML	N019022	001	Nov 01, 1983
--	-----------------	-----------	---------	-----	--------------

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

	BAXTER HLTHCARE	5GM/100ML	N019022	002	Nov 01, 1983
--	-----------------	-----------	---------	-----	--------------

SODIUM CHLORIDE IN PLASTIC CONTAINER

	HOSPIRA	2.5MEQ/ML	N018897	001	Jul 20, 1984
--	---------	-----------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-327 (of 371)

SODIUM CHLORIDE

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	
AT	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	
AT		<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	
AT	HOSPIRA	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	
AT		<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	<u>62.5MG/5ML</u>	<u>N020955</u>	<u>001</u>	Feb 18, 1999
<u>SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE</u>						
AB		HIKMA PHARMS	<u>62.5MG/5ML</u>	<u>A078215</u>	<u>001</u>	Mar 31, 2011

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP		BIOMEDCL RES FDN	<u>10-200mCi/ML</u>	<u>A204351</u>	<u>001</u>	Jan 09, 2015
AP		ESSENTIAL ISOTOPES	<u>10-200mCi/ML</u>	<u>A204541</u>	<u>001</u>	Oct 29, 2014
AP		GLOBAL ISOTOPES LLC	<u>10-200mCi/ML</u>	<u>A204464</u>	<u>001</u>	Oct 21, 2014
AP	+	HOUSTON CYCLOTRON	<u>10-200mCi/ML</u>	<u>A203544</u>	<u>001</u>	Dec 26, 2012
AP		NCM USA BRONX LLC	<u>10-200mCi/ML</u>	<u>A204513</u>	<u>001</u>	Nov 28, 2014
AP		SHERTECH LABS LLC	<u>10-200mCi/ML</u>	<u>A204315</u>	<u>001</u>	Sep 22, 2014
AP		UCSF RODIOPHARM	<u>10-200mCi/ML</u>	<u>A204437</u>	<u>001</u>	Mar 13, 2014
AP		UNIV TX MD ANDERSON	<u>10-200mCi/ML</u>	<u>A203247</u>	<u>001</u>	Dec 23, 2013
	+	MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
		THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HLTH 414	<u>100uCi</u>	<u>N018671</u>	<u>001</u>	May 27, 1982
AA	+		<u>200uCi</u>	<u>N018671</u>	<u>002</u>	May 27, 1982
AA		MALLINCKRODT	<u>100uCi</u>	<u>A071909</u>	<u>001</u>	Feb 28, 1989
AA			<u>200uCi</u>	<u>A071910</u>	<u>001</u>	Feb 28, 1989

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ MALLINCKRODT 0.8-100mCi

N016517 001

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE 0.009-0.1mCi

N021305 006 May 19, 2005

SOLUTION; ORAL

HICON

+ JUBILANT DRAXIMAGE 250-1000mCi

N021305 007 Dec 05, 2011

SODIUM IODIDE I 131

+ MALLINCKRODT 3.5-150mCi/VIAL

N016515 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	<u>1.87GM/100ML</u>	<u>N016692</u>	<u>001</u>	
-----------	--	-----------------	---------------------	----------------	------------	--

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

AP		B BRAUN	<u>1.87GM/100ML</u>	<u>N020004</u>	<u>001</u>	Apr 21, 1992
SODIUM LACTATE IN PLASTIC CONTAINER						
	+	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS 300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODE

+ HOPE PHARMS 300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML (250MG/ML)

N201444 001 Jan 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-328 (of 371)

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NITROPRESS

+ HOSPIRA

25MG/ML

A071961 001 Aug 01, 1988

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+ JAZZ PHARMS

500MG/ML

N021196 001 Jul 17, 2002

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYLAB + HYPERION THERAPS INC3GM/TEASPOONFULN020573 001 Apr 30, 1996SODIUM PHENYLBUTYRATEAB SIGMAPHARM LABS LLC3GM/TEASPOONFULA202819 001 Mar 22, 2013

TABLET; ORAL

BUPHENYLAB + HYPERION THERAPS INC500MGN020572 001 May 13, 1996SODIUM PHENYLBUTYRATEAB AMPOLGEN500MGA090910 001 Nov 18, 2011SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

OSMOPREP

+ SALIX PHARMS

0.398GM; 1.102GM

N021892 001 Mar 16, 2006

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

+ HOSPIRA

142MG/ML; 276MG/ML

N018892 001 May 10, 1983

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATEAA KVK TECH454GM/BOTA040905 001 Mar 30, 2009KAYEXALATEAA + COVIS PHARMA SARL453.6GM/BOTN011287 001KIONEXAA PADDOCK LLC454GM/BOTA040029 001 Feb 06, 1998SODIUM POLYSTYRENE SULFONATEAA CAROLINA MEDCL454GM/BOTA089910 001 Jan 19, 1989AA CEDAR PHARMS453.6GM/BOTA090313 001 Dec 21, 2011AA EPIC PHARMA LLC453.6GM/BOTA202333 001 Mar 19, 2014AA NUVO PHARM INC454GM/BOTA204071 001 Nov 28, 2014

15GM/BOT

A204071 002 Nov 28, 2014

SUSPENSION; ORAL, RECTAL

KIONEXAA PADDOCK LLC15GM/60MLA040028 001 Sep 17, 2007SODIUM POLYSTYRENE SULFONATEAA PADDOCK LLC15GM/60MLA090590 001 May 13, 2011AA ROXANE15GM/60MLA089049 001 Nov 17, 1986SPSAA + CAROLINA MEDCL15GM/60MLA087859 001 Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

MYLAN INSTITUTIONAL

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

+

60MG/2ML (30MG/ML)

A040541 002 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012

SOFOSBUVIR

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC

400MG

N204671 001 Dec 06, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-329 (of 371)

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	TEVA PHARMS USA	5MG	A091464 001	Apr 02, 2014
AB		10MG	A091464 002	Apr 02, 2014

VESICARE

AB	ASTELLAS	5MG	N021518 001	Nov 19, 2004
AB	+	10MG	N021518 002	Nov 19, 2004

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280 006	Aug 24, 1995
----	---	----------------------	------------	-------------	--------------

GENOTROPIN PRESERVATIVE FREE

BX		PHARMACIA AND UPJOHN	1.5MG/VIAL	N020280 004	Aug 24, 1995
----	--	----------------------	------------	-------------	--------------

HUMATROPE

BX	+	LILLY	5MG/VIAL	N019640 004	Mar 08, 1987
----	---	-------	----------	-------------	--------------

BX			6MG/VIAL	N019640 005	Feb 04, 1999
----	--	--	----------	-------------	--------------

NORDITROPIN FLEXPRO

BX		NOVO NORDISK INC	5MG/1.5ML	N021148 008	Mar 01, 2010
----	--	------------------	-----------	-------------	--------------

BX			10MG/1.5ML	N021148 009	Mar 01, 2010
----	--	--	------------	-------------	--------------

NUTROPIN

BX		GENENTECH	5MG/VIAL	N020168 001	Nov 17, 1993
----	--	-----------	----------	-------------	--------------

OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426 002	May 30, 2006
----	--	--------	------------	-------------	--------------

BX			5MG/1.5ML	N021426 003	Jan 16, 2008
----	--	--	-----------	-------------	--------------

BX			5.8MG/VIAL	N021426 001	May 30, 2006
----	--	--	------------	-------------	--------------

BX			10MG/1.5ML	N021426 004	Aug 25, 2008
----	--	--	------------	-------------	--------------

SAIZEN

BX		EMD SERONO	5MG/VIAL	N019764 002	Oct 08, 1996
----	--	------------	----------	-------------	--------------

SEROSTIM

BX		EMD SERONO	4MG/VIAL	N020604 003	Jul 25, 1997
----	--	------------	----------	-------------	--------------

BX			5MG/VIAL	N020604 002	Aug 23, 1996
----	--	--	----------	-------------	--------------

BX			6MG/VIAL	N020604 001	Aug 23, 1996
----	--	--	----------	-------------	--------------

TEV-TROPIN

BX	+	FERRING	5MG/VIAL	N019774 002	Jan 04, 2002
----	---	---------	----------	-------------	--------------

VALTROPIN

BX		LG LIFE	5MG/VIAL	N021905 001	Apr 19, 2007
----	--	---------	----------	-------------	--------------

GENOTROPIN

	+	PHARMACIA AND UPJOHN	13.8MG/VIAL	N020280 007	Oct 23, 1996
--	---	----------------------	-------------	-------------	--------------

GENOTROPIN PRESERVATIVE FREE

		PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280 001	Jan 27, 1998
--	--	----------------------	------------	-------------	--------------

			0.4MG/VIAL	N020280 002	Jan 27, 1998
--	--	--	------------	-------------	--------------

			0.6MG/VIAL	N020280 003	Jan 27, 1998
--	--	--	------------	-------------	--------------

			0.8MG/VIAL	N020280 005	Jan 27, 1998
--	--	--	------------	-------------	--------------

			1MG/VIAL	N020280 008	Jan 27, 1998
--	--	--	----------	-------------	--------------

			1.2MG/VIAL	N020280 009	Jan 27, 1998
--	--	--	------------	-------------	--------------

			1.4MG/VIAL	N020280 010	Jan 27, 1998
--	--	--	------------	-------------	--------------

			1.6MG/VIAL	N020280 011	Jan 27, 1998
--	--	--	------------	-------------	--------------

			1.8MG/VIAL	N020280 012	Jan 27, 1998
--	--	--	------------	-------------	--------------

	+		2MG/VIAL	N020280 013	Jan 27, 1998
--	---	--	----------	-------------	--------------

HUMATROPE

	+	LILLY	12MG/VIAL	N019640 006	Feb 04, 1999
--	---	-------	-----------	-------------	--------------

	+		24MG/VIAL	N019640 007	Feb 04, 1999
--	---	--	-----------	-------------	--------------

NORDITROPIN FLEXPRO

		NOVO NORDISK INC	15MG/1.5ML	N021148 010	Mar 01, 2010
--	--	------------------	------------	-------------	--------------

NORDITROPIN NORDIFLEX

		NOVO NORDISK INC	30MG/3ML	N021148 007	Mar 10, 2009
--	--	------------------	----------	-------------	--------------

NUTROPIN

	+	GENENTECH	10MG/VIAL	N020168 002	Nov 17, 1993
--	---	-----------	-----------	-------------	--------------

NUTROPIN AQ

	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522 003	Jan 03, 2008
--	---	-----------	--------------------	-------------	--------------

	+		10MG/2ML (5MG/ML)	N020522 001	Dec 29, 1995
--	---	--	-------------------	-------------	--------------

	+		20MG/2ML (10MG/ML)	N020522 004	Jan 03, 2008
--	---	--	--------------------	-------------	--------------

NUTROPIN AQ PEN

	+	GENENTECH	10MG/2ML (5MG/ML)	N020522 002	Apr 22, 2002
--	---	-----------	-------------------	-------------	--------------

SAIZEN

	+	EMD SERONO	8.8MG/VIAL	N019764 003	Aug 29, 2000
--	---	------------	------------	-------------	--------------

ZORBTIVE

	+	EMD SERONO	8.8MG/VIAL	N021597 004	Dec 01, 2003
--	---	------------	------------	-------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-330 (of 371)

SORAFENIB TOSYLATE

TABLET;ORAL

NEXAVAR

+ BAYER HLTHCARE EQ 200MG BASE

N021923 001 Dec 20, 2005

SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

SOTALOL HYDROCHLORIDE

+ ACADEMIC PHARMS 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

SOLUTION;ORAL

SOTYLIZE

+ ARBOR PHARMS LLC 5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014

TABLET;ORAL

BETAPACEAB1 BAYER HLTHCARE80MGN019865 001 Oct 30, 1992AB1 120MGN019865 005 Apr 20, 1994AB1 + 160MGN019865 002 Oct 30, 1992AB1 240MGN019865 003 Oct 30, 1992SORINEAB1 UPSHER SMITH80MGA075500 001 Apr 27, 2001AB1 120MGA075500 004 Apr 27, 2001AB1 160MGA075500 002 Apr 27, 2001AB1 240MGA075500 003 Apr 27, 2001SOTALOL HYDROCHLORIDEAB1 APOTEX INC80MGA076140 001 Sep 26, 2002AB1 120MGA076140 002 Sep 26, 2002AB1 160MGA076140 003 Sep 26, 2002AB1 240MGA076140 004 Sep 26, 2002AB1 IMPAX PHARMS80MGA075663 001 Nov 07, 2000AB1 120MGA075663 002 Nov 07, 2000AB1 160MGA075663 003 Nov 07, 2000AB1 240MGA075663 004 Nov 07, 2000AB1 MYLAN80MGA075237 001 May 01, 2000AB1 80MGA075725 001 Dec 19, 2000AB1 120MGA075237 002 May 01, 2000AB1 120MGA075725 002 Dec 19, 2000AB1 160MGA075237 003 May 01, 2000AB1 160MGA075725 003 Dec 19, 2000AB1 240MGA075237 004 May 01, 2000AB1 240MGA075725 004 Dec 19, 2000AB1 SANDOZ80MGA075366 001 May 01, 2000AB1 120MGA075366 002 May 01, 2000AB1 160MGA075366 003 May 01, 2000AB1 240MGA075366 004 May 01, 2000AB1 TEVA80MGA075429 001 May 01, 2000AB1 120MGA075429 002 May 01, 2000AB1 160MGA075429 003 May 01, 2000AB1 240MGA075429 004 May 01, 2000AB1 VINTAGE PHARMS80MGA075563 001 Nov 07, 2003AB1 120MGA075563 002 Nov 07, 2003AB1 160MGA075563 003 Nov 07, 2003AB1 240MGA075563 004 Nov 07, 2003BETAPACE AFAB2 COVIS PHARMA SARL80MGN021151 001 Feb 22, 2000AB2 120MGN021151 002 Feb 22, 2000AB2 + 160MGN021151 003 Feb 22, 2000SOTALOL HYDROCHLORIDEAB2 APOTEX80MGA076214 001 Aug 27, 2003AB2 120MGA076214 002 Aug 27, 2003AB2 160MGA076214 003 Aug 27, 2003AB2 EPIC PHARMA INC80MGA077070 001 Nov 04, 2005AB2 120MGA077070 002 Nov 04, 2005AB2 160MGA077070 003 Nov 04, 2005AB2 MYLAN80MGA077616 001 Feb 07, 2007AB2 120MGA077616 002 Feb 07, 2007AB2 160MGA077616 003 Feb 07, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-331 (of 371)

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

<u>AB2</u>	TEVA	<u>80MG</u>	<u>A076883</u>	<u>001</u>	Jul 26, 2004
<u>AB2</u>		<u>120MG</u>	<u>A076883</u>	<u>002</u>	Jul 26, 2004
<u>AB2</u>		<u>160MG</u>	<u>A076883</u>	<u>003</u>	Jul 26, 2004

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

<u>AP</u>	+	FRESENIUS	<u>10%</u>	<u>N017643</u>	<u>001</u>	
-----------	---	-----------	------------	----------------	------------	--

INTRALIPID 20%

<u>AP</u>	+	FRESENIUS	<u>20%</u>	<u>N018449</u>	<u>001</u>	
-----------	---	-----------	------------	----------------	------------	--

<u>AP</u>	+		<u>20%</u>	<u>N020248</u>	<u>001</u>	Aug 07, 1996
-----------	---	--	------------	----------------	------------	--------------

INTRALIPID 30%

<u>AP</u>	+	FRESENIUS	<u>30%</u>	<u>N019942</u>	<u>001</u>	Dec 30, 1993
-----------	---	-----------	------------	----------------	------------	--------------

NUTRILIPID 10%

<u>AP</u>	+	B BRAUN	<u>10%</u>	<u>N019531</u>	<u>001</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

NUTRILIPID 20%

<u>AP</u>	+	B BRAUN	<u>20%</u>	<u>N019531</u>	<u>002</u>	May 28, 1993
-----------	---	---------	------------	----------------	------------	--------------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	<u>N022408</u>	<u>001</u>	Jan 18, 2011
---	-------------	------	----------------	------------	--------------

SPIRONOLACTONE

TABLET; ORAL

ALDACTONE

<u>AB</u>		GD SEARLE LLC	<u>25MG</u>	<u>N012151</u>	<u>009</u>	Dec 30, 1983
<u>AB</u>			<u>50MG</u>	<u>N012151</u>	<u>008</u>	Dec 30, 1982
<u>AB</u>	+		<u>100MG</u>	<u>N012151</u>	<u>010</u>	Dec 30, 1983

SPIRONOLACTONE

<u>AB</u>		ACTAVIS ELIZABETH	<u>25MG</u>	<u>A040353</u>	<u>003</u>	Mar 15, 2006
<u>AB</u>			<u>50MG</u>	<u>A040353</u>	<u>001</u>	Jul 29, 1999
<u>AB</u>			<u>100MG</u>	<u>A040353</u>	<u>002</u>	Jul 29, 1999
<u>AB</u>		AMNEAL PHARMS	<u>25MG</u>	<u>A091426</u>	<u>001</u>	Jun 08, 2010
<u>AB</u>			<u>50MG</u>	<u>A091426</u>	<u>002</u>	Jun 08, 2010
<u>AB</u>			<u>100MG</u>	<u>A091426</u>	<u>003</u>	Jun 08, 2010
<u>AB</u>		JUBILANT GENERICS	<u>25MG</u>	<u>A203253</u>	<u>001</u>	Apr 23, 2014
<u>AB</u>			<u>50MG</u>	<u>A203253</u>	<u>002</u>	Apr 23, 2014
<u>AB</u>			<u>100MG</u>	<u>A203253</u>	<u>003</u>	Apr 23, 2014
<u>AB</u>		MUTUAL PHARM	<u>25MG</u>	<u>A089424</u>	<u>001</u>	Jul 23, 1986
<u>AB</u>			<u>50MG</u>	<u>A089424</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>			<u>100MG</u>	<u>A089424</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>		MYLAN	<u>25MG</u>	<u>A040424</u>	<u>001</u>	Aug 20, 2001
<u>AB</u>			<u>50MG</u>	<u>A040424</u>	<u>002</u>	Aug 20, 2001
<u>AB</u>			<u>100MG</u>	<u>A040424</u>	<u>003</u>	Aug 20, 2001
<u>AB</u>		ORION CORP ORION	<u>25MG</u>	<u>A202187</u>	<u>001</u>	Mar 06, 2014
<u>AB</u>			<u>50MG</u>	<u>A202187</u>	<u>002</u>	Mar 06, 2014
<u>AB</u>			<u>100MG</u>	<u>A202187</u>	<u>003</u>	Mar 06, 2014
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A086809</u>	<u>001</u>	
<u>AB</u>		VINTAGE	<u>25MG</u>	<u>A040750</u>	<u>001</u>	Aug 29, 2006
<u>AB</u>			<u>50MG</u>	<u>A040750</u>	<u>002</u>	Aug 29, 2006
<u>AB</u>			<u>100MG</u>	<u>A040750</u>	<u>003</u>	Aug 29, 2006

STAVUDINE

CAPSULE; ORAL

STAVUDINE

<u>AB</u>		AUROBINDO PHARMA	<u>15MG</u>	<u>A077672</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>			<u>20MG</u>	<u>A077672</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>			<u>30MG</u>	<u>A077672</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>			<u>40MG</u>	<u>A077672</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		HETERO LABS LTD III	<u>15MG</u>	<u>A078957</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>			<u>20MG</u>	<u>A078957</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>			<u>30MG</u>	<u>A078957</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>			<u>40MG</u>	<u>A078957</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		MATRIX LABS LTD	<u>30MG</u>	<u>A078775</u>	<u>001</u>	Jan 05, 2009
<u>AB</u>			<u>40MG</u>	<u>A078775</u>	<u>002</u>	Jan 05, 2009
<u>AB</u>		MYLAN	<u>15MG</u>	<u>A079069</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>			<u>20MG</u>	<u>A079069</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>			<u>30MG</u>	<u>A079069</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>			<u>40MG</u>	<u>A079069</u>	<u>004</u>	Dec 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-332 (of 371)

STAVUDINE

CAPSULE; ORAL

ZERIT

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>15MG</u>	<u>N020412</u>	<u>002</u>	Jun 24, 1994
<u>AB</u>		<u>20MG</u>	<u>N020412</u>	<u>003</u>	Jun 24, 1994
<u>AB</u>		<u>30MG</u>	<u>N020412</u>	<u>004</u>	Jun 24, 1994
<u>AB</u>	+	<u>40MG</u>	<u>N020412</u>	<u>005</u>	Jun 24, 1994

FOR SOLUTION; ORAL

STAVUDINE

<u>AA</u>	AUROBINDO PHARMA	<u>1MG/ML</u>	<u>A077774</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>	CIPLA LTD	<u>1MG/ML</u>	<u>A078030</u>	<u>001</u>	Mar 20, 2009

ZERIT

<u>AA</u>	+	BRISTOL MYERS SQUIBB	<u>1MG/ML</u>	<u>N020413</u>	<u>001</u>	Sep 06, 1996
-----------	---	----------------------	---------------	----------------	------------	--------------

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018802</u>	<u>001</u>	Oct 27, 1982
-----------	---	---------	-------------	----------------	------------	--------------

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>100%</u>	<u>N019633</u>	<u>001</u>	Feb 29, 1988
<u>AP</u>	+	BAXTER HLTHCARE	<u>100%</u>	<u>N018632</u>	<u>001</u>	Jun 30, 1982
<u>AP</u>	+		<u>100%</u>	<u>N018632</u>	<u>002</u>	Apr 19, 1988
<u>AP</u>		FRESENIUS KABI USA	<u>100%</u>	<u>A088400</u>	<u>001</u>	Jan 16, 1984
<u>AP</u>	+	HOSPIRA	<u>100%</u>	<u>N018233</u>	<u>001</u>	
<u>AP</u>	+		<u>100%</u>	<u>N018801</u>	<u>001</u>	Oct 27, 1982
<u>AP</u>	+		<u>100%</u>	<u>N019869</u>	<u>001</u>	Dec 26, 1989
<u>AP</u>		TARO PHARMS IRELAND	<u>100%</u>	<u>A077393</u>	<u>001</u>	Aug 11, 2006

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER

<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017428</u>	<u>001</u>	
-----------	--	-----------------	-------------	----------------	------------	--

STERILE WATER IN PLASTIC CONTAINER

<u>AT</u>		B BRAUN	<u>100%</u>	<u>N016734</u>	<u>001</u>	
<u>AT</u>		BAXTER HLTHCARE	<u>100%</u>	<u>N017866</u>	<u>001</u>	
<u>AT</u>		HOSPIRA	<u>100%</u>	<u>N017513</u>	<u>001</u>	
<u>AT</u>			<u>100%</u>	<u>N018313</u>	<u>001</u>	

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

	+	X GEN PHARMS	EQ 1GM BASE/VIAL	A064210	001	Jun 30, 1998
--	---	--------------	------------------	---------	-----	--------------

STREPTOZOCIN

INJECTABLE; INJECTION

ZANOSAR

	+	TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982
--	---	-----------------	----------	---------	-----	--------------

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

<u>AP</u>	+	GE HEALTHCARE	<u>1mCi/ML</u>	<u>N020134</u>	<u>001</u>	Jun 18, 1993
-----------	---	---------------	----------------	----------------	------------	--------------

STRONTIUM CHLORIDE SR-89

<u>AP</u>		BIO NUCLEONICS	<u>1mCi/ML</u>	<u>A075941</u>	<u>001</u>	Jan 06, 2003
-----------	--	----------------	----------------	----------------	------------	--------------

SUCCIMER

CAPSULE; ORAL

CHEMET

	+	RECORDATI RARE	100MG	N019998	002	Jan 30, 1991
--	---	----------------	-------	---------	-----	--------------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

<u>AP</u>	+	SANDOZ	<u>20MG/ML</u>	<u>N008453</u>	<u>002</u>	
-----------	---	--------	----------------	----------------	------------	--

QUELICIN

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>006</u>	
-----------	---	---------	----------------	----------------	------------	--

QUELICIN PRESERVATIVE FREE

<u>AP</u>	+	HOSPIRA	<u>20MG/ML</u>	<u>N008845</u>	<u>001</u>	
	+		100MG/ML	N008845	004	

PRESCRIPTION DRUG PRODUCT LIST

3-333 (of 371)

SUCRALFATE

SUSPENSION; ORAL

CARAFATE

+ FOREST LABS INC

1GM/10ML

N019183 001 Dec 16, 1993

TABLET; ORAL

CARAFATEAB + FOREST LABS INC1GMN018333 001SUCRALFATEAB NOSTRUM LABS1GMA074415 001 Jun 08, 1998AB TEVA1GMA070848 001 Mar 29, 1996SUCROFERRIC OXYHYDROXIDE

TABLET, CHEWABLE; ORAL

VELPHORO

+ VIFOR FRESENIUS

500MG

N205109 001 Nov 27, 2013

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTA PRESERVATIVE FREEAP + AKORNEQ 0.05MG BASE/MLN019050 001 May 04, 1984SUFENTANIL CITRATEAP HIKMA MAPLEEQ 0.05MG BASE/MLA074413 001 Dec 15, 1995AP HOSPIRAEQ 0.05MG BASE/MLA074534 001 Dec 11, 1996SULCONAZOLE NITRATE

CREAM; TOPICAL

EXELDERM

+ RANBAXY

1%

N018737 001 Feb 28, 1989

SOLUTION; TOPICAL

EXELDERM

+ RANBAXY

1%

N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION; TOPICAL

KLARONAB + VALEANT BERMUDA10%N019931 001 Dec 23, 1996SULFACETAMIDE SODIUMAB FOUGERA PHARMS10%A077015 001 Nov 17, 2006AB PERRIGO CO TENNESSEE10%A078649 001 Mar 23, 2009AB TARO10%A078668 001 May 20, 2009

OINTMENT; OPHTHALMIC

CETAMIDEAT + ALCON10%A080021 001SULFACETAMIDE SODIUMAT PERRIGO CO TENNESSEE10%A080029 001

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10AT + ALLERGAN10%A080028 001SULFACETAMIDE SODIUMAT ALCON PHARMS LTD10%A089560 001 Oct 18, 1988AT BAUSCH AND LOMB10%A040066 001 Dec 28, 1994SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

+ SANDOZ

500MG

A040091 001 Jul 29, 1994

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

+ TEVA PHARMS USA

80MG/ML; 16MG/ML

A073303 001 Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIMAB AUROBINDO PHARMA200MG/5ML; 40MG/5MLA091348 001 Jun 08, 2010AB + HI TECH PHARMA200MG/5ML; 40MG/5MLA074650 001 Dec 29, 1997AB VINTAGE200MG/5ML; 40MG/5MLA077785 001 Jan 24, 2007SULFATRIM PEDIATRICAB STI PHARMA LLC200MG/5ML; 40MG/5MLN018615 001 Jan 07, 1983

TABLET; ORAL

BACTRIMAB MUTUAL PHARM400MG; 80MGN017377 001BACTRIM DSAB + MUTUAL PHARM800MG; 160MGN017377 002SEPTRAAB MONARCH PHARMS400MG; 80MGN017376 001

PRESCRIPTION DRUG PRODUCT LIST

3-334 (of 371)

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SEPTRA DS

AB	MONARCH PHARMS	800MG;160MG	N017376 002	
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM</u>				
AB	AMNEAL PHARMS NY	400MG;80MG	A076899 001	Jan 27, 2005
AB		800MG;160MG	A076899 002	Jan 27, 2005
AB	AUROBINDO PHARMA	400MG;80MG	A090624 001	Feb 16, 2010
AB		800MG;160MG	A090624 002	Feb 16, 2010
AB	GLENMARK GENERICS	400MG;80MG	A090828 002	Dec 22, 2010
AB		800MG;160MG	A090828 001	Dec 22, 2010
AB	MUTUAL PHARM	800MG;160MG	A071017 001	Aug 25, 1986
AB	VINTAGE	400MG;80MG	A078060 002	Jan 25, 2007
AB		800MG;160MG	A078060 001	Jan 25, 2007
AB	VISTA PHARMS	400MG;80MG	A076817 001	Oct 07, 2005
AB		800MG;160MG	A076817 002	Oct 07, 2005
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH</u>				
AB	TEVA	800MG;160MG	A070037 001	Jun 02, 1987
<u>SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH</u>				
AB	TEVA PHARMS	400MG;80MG	A070030 001	Jun 02, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MEDA PHARMS	15%	N006530 003	Jan 27, 1987
---	-------------	-----	-------------	--------------

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

+	PHARMACIA AND UPJOHN	250MG/5ML	A086983 001	
---	----------------------	-----------	-------------	--

TABLET; ORAL

AZULFIDINE

<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>001</u>	
<u>SULFASALAZINE</u>						
<u>AB</u>		VINTAGE PHARMS	<u>500MG</u>	<u>A040349</u>	<u>001</u>	Jan 11, 2002
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A085828</u>	<u>001</u>	
TABLET, DELAYED RELEASE;ORAL						
<u>AZULFIDINE EN-TABS</u>						
<u>AB</u>	+	PHARMACIA AND UPJOHN	<u>500MG</u>	<u>N007073</u>	<u>002</u>	Apr 06, 1983
<u>SULFASALAZINE</u>						
<u>AB</u>		VINTAGE PHARMS	<u>500MG</u>	<u>A075339</u>	<u>001</u>	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+	BRACCO	60.7MG/25MG	N203684 001	Oct 15, 2014
---	--------	-------------	-------------	--------------

SULINDAC

TABLET; ORAL

CLINORIL

<u>AB</u>	<u>+</u>	<u>MERCK</u>	<u>200MG</u>	<u>N017911</u>	<u>002</u>	
<u>SULINDAC</u>						
<u>AB</u>		<u>EPIC PHARMA</u>	<u>150MG</u>	<u>A072710</u>	<u>001</u>	<u>Mar 25, 1991</u>
<u>AB</u>			<u>200MG</u>	<u>A072711</u>	<u>001</u>	<u>Mar 25, 1991</u>
<u>AB</u>		<u>HERITAGE PHARMS INC</u>	<u>150MG</u>	<u>A073262</u>	<u>002</u>	<u>Sep 06, 1991</u>
<u>AB</u>			<u>200MG</u>	<u>A073262</u>	<u>001</u>	<u>Sep 06, 1991</u>
<u>AB</u>		<u>MUTUAL PHARM</u>	<u>150MG</u>	<u>A072050</u>	<u>001</u>	<u>Apr 17, 1991</u>
<u>AB</u>			<u>200MG</u>	<u>A072051</u>	<u>001</u>	<u>Apr 17, 1991</u>
<u>AB</u>		<u>MYLAN</u>	<u>150MG</u>	<u>A073039</u>	<u>002</u>	<u>Jun 22, 1993</u>
<u>AB</u>			<u>200MG</u>	<u>A073039</u>	<u>001</u>	<u>Jun 22, 1993</u>
<u>AB</u>		<u>WATSON LABS</u>	<u>150MG</u>	<u>A071891</u>	<u>001</u>	<u>Apr 03, 1990</u>
<u>AB</u>			<u>200MG</u>	<u>A071795</u>	<u>001</u>	<u>Apr 03, 1990</u>

SUMATRIPTAN

SPRAY; NASAL

IMITREX

+	GLAXOSMITHKLINE	5MG/SPRAY	N020626 001	Aug 26, 1997
+		20MG/SPRAY	N020626 003	Aug 26, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-335 (of 371)

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

AB	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 003</u>	Dec 23, 1996
-----------	----------	-----------------	---	---------------------------	--------------

SUMATRIPTAN SUCCINATE

AB		DR REDDYS LABS INC	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495 001</u>	Jan 29, 2014
-----------	--	--------------------	---	---------------------------	--------------

AB		SUN PHARMA GLOBAL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358 001</u>	Jun 21, 2011
-----------	--	-------------------	---	---------------------------	--------------

IMITREX

AP	+	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080 001</u>	Dec 28, 1992
-----------	----------	-----------------	---	---------------------------	--------------

SUMATRIPTAN SUCCINATE

AP		AGILA SPECLTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A203322 001</u>	Apr 14, 2014
-----------	--	---------------	---	---------------------------	--------------

AP		AUROBINDO PHARMA LTD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758 001</u>	Apr 23, 2013
-----------	--	----------------------	---	---------------------------	--------------

AP		BEDFORD	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123 001</u>	Feb 06, 2009
-----------	--	---------	---	---------------------------	--------------

AP		FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242 001</u>	Mar 02, 2009
-----------	--	--------------------	---	---------------------------	--------------

AP		HIKMA FARMACEUTICA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183 001</u>	Sep 16, 2013
-----------	--	--------------------	---	---------------------------	--------------

AP		INJECTALIA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090310 001</u>	Aug 11, 2010
-----------	--	------------	---	---------------------------	--------------

AP		PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332 001</u>	Oct 09, 2009
-----------	--	-----------	---	---------------------------	--------------

AP		PAR STERILE PRODUCTS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077871 001</u>	Jul 09, 2009
-----------	--	----------------------	---	---------------------------	--------------

AP		SAGENT AGILA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090641 001</u>	Jul 28, 2010
-----------	--	--------------	---	---------------------------	--------------

AP		SAGENT STRIDES	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090314 001</u>	Jun 10, 2010
-----------	--	----------------	---	---------------------------	--------------

AP		TEVA PHARMS USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077907 001</u>	Feb 06, 2009
-----------	--	-----------------	---	---------------------------	--------------

AP		WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593 001</u>	Feb 06, 2009
-----------	--	-----------	---	---------------------------	--------------

ALSUMA

BX		MERIDIAN MEDCL	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N022377 001</u>	Jun 29, 2010
-----------	--	----------------	---	---------------------------	--------------

IMITREX STATDOSE

BX	+	GLAXOSMITHKLINE	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>N020080 002</u>	Feb 01, 2006
-----------	----------	-----------------	--	---------------------------	--------------

SUMAVEL DOSEPRO

BX	+	ENDO VENTURES LTD	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>N022239 002</u>	Nov 26, 2013
-----------	----------	-------------------	--	---------------------------	--------------

BX	+		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N022239 001</u>	Jul 15, 2009
-----------	----------	--	---	---------------------------	--------------

SYSTEM; IONTOPHORESIS

ZECUITY

+ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR**N202278 001** Jan 17, 2013

TABLET; ORAL

IMITREX

AB		GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132 002</u>	Jun 01, 1995
-----------	--	-----------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>N020132 003</u>	Jun 01, 1995
-----------	--	--	----------------------------	---------------------------	--------------

AB	+		<u>EQ 100MG BASE</u>	<u>N020132 001</u>	Jun 01, 1995
-----------	----------	--	-----------------------------	---------------------------	--------------

SUMATRIPTAN SUCCINATE

AB		APOTEX INC	<u>EQ 25MG BASE</u>	<u>A200263 001</u>	Jun 19, 2012
-----------	--	------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A200263 002</u>	Jun 19, 2012
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A200263 003</u>	Jun 19, 2012
-----------	--	--	-----------------------------	---------------------------	--------------

AB		AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327 001</u>	Aug 10, 2009
-----------	--	------------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A078327 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A078327 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847 001</u>	Aug 10, 2009
-----------	--	--------------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A076847 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A076847 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		HIKMA PHARMS	<u>EQ 25MG BASE</u>	<u>A078298 001</u>	May 21, 2013
-----------	--	--------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A078298 002</u>	May 21, 2013
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A078298 003</u>	May 21, 2013
-----------	--	--	-----------------------------	---------------------------	--------------

AB		MYLAN	<u>EQ 25MG BASE</u>	<u>A077744 001</u>	Aug 10, 2009
-----------	--	-------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A077744 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A077744 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		ORCHID HLTHCARE	<u>EQ 25MG BASE</u>	<u>A078284 001</u>	Aug 10, 2009
-----------	--	-----------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A078284 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A078284 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		RANBAXY	<u>EQ 25MG BASE</u>	<u>A076554 001</u>	Aug 10, 2009
-----------	--	---------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A076554 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A076572 001</u>	Feb 09, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		SANDOZ	<u>EQ 25MG BASE</u>	<u>A076976 001</u>	Aug 10, 2009
-----------	--	--------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A076976 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A076976 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295 001</u>	Aug 10, 2009
-----------	--	----------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A078295 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A078295 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

AB		WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933 001</u>	Aug 10, 2009
-----------	--	-------------	----------------------------	---------------------------	--------------

AB			<u>EQ 50MG BASE</u>	<u>A076933 002</u>	Aug 10, 2009
-----------	--	--	----------------------------	---------------------------	--------------

AB			<u>EQ 100MG BASE</u>	<u>A076933 003</u>	Aug 10, 2009
-----------	--	--	-----------------------------	---------------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-336 (of 371)

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

<u>AB</u>	MYLAN PHARMS INC	<u>EQ 12.5MG BASE</u>	<u>A201275</u>	<u>001</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A201275</u>	<u>002</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A201275</u>	<u>003</u>	Jan 30, 2014
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201275</u>	<u>004</u>	Jan 30, 2014

SUTENT

<u>AB</u>	CPPI CV	<u>EQ 12.5MG BASE</u>	<u>N021938</u>	<u>001</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>N021938</u>	<u>002</u>	Jan 26, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>N021938</u>	<u>004</u>	Mar 31, 2009
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N021938</u>	<u>003</u>	Jan 26, 2006

SUVOREXANT

TABLET; ORAL

BELSOMRA

	MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014
		10MG	N204569	002	Aug 13, 2014
		15MG	N204569	003	Aug 13, 2014
	+	20MG	N204569	004	Aug 13, 2014

TACROLIMUS

CAPSULE; ORAL

PROGRAF

<u>AB</u>	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708</u>	<u>003</u>	Aug 24, 1998
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>N050708</u>	<u>001</u>	Apr 08, 1994
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N050708</u>	<u>002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195</u>	<u>001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195</u>	<u>002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195</u>	<u>003</u>	Aug 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509</u>	<u>001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509</u>	<u>002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509</u>	<u>003</u>	May 12, 2010
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596</u>	<u>001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596</u>	<u>002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596</u>	<u>003</u>	Sep 17, 2010
<u>AB</u>	PANACEA BIOTEC LTD	<u>EQ 0.5MG BASE</u>	<u>A090802</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802</u>	<u>003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687</u>	<u>001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687</u>	<u>002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687</u>	<u>003</u>	Jul 22, 2014

CAPSULE, EXTENDED RELEASE; ORAL

ASTAGRAF XL

	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
		EQ 1MG BASE	N204096	002	Jul 19, 2013
	+	EQ 5MG BASE	N204096	003	Jul 19, 2013

INJECTABLE; INJECTION

PROGRAF

	+	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994
--	---	----------	----------------	---------	-----	--------------

OINTMENT; TOPICAL

PROTOPIC

<u>AB</u>	+	ASTELLAS	<u>0.03%</u>	<u>N050777</u>	<u>001</u>	Dec 08, 2000
<u>AB</u>	+		<u>0.1%</u>	<u>N050777</u>	<u>002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>	FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>		<u>0.1%</u>	<u>A200744</u>	<u>002</u>	Sep 09, 2014

TADALAFIL

TABLET; ORAL

ADCIRCA

	+	ELI LILLY CO	20MG	N022332	001	May 22, 2009
--	---	--------------	------	---------	-----	--------------

CIALIS

	LILLY	2.5MG	N021368	004	Jan 07, 2008
		5MG	N021368	001	Nov 21, 2003
		10MG	N021368	002	Nov 21, 2003
	+	20MG	N021368	003	Nov 21, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-337 (of 371)

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

ZIOPTAN

+ OAK PHARMS INC 0.0015%

N202514 001 Feb 10, 2012

TALC

AEROSOL, METERED;INTRAPLEURAL

SCLEROSOL

+ BRYAN 400MG/SPRAY

N020587 001 Dec 24, 1997

POWDER;INTRAPLEURAL

TALC

+ BRYAN 5GM/BOT

N021388 001 Dec 15, 2003

TALIGLUCERASE ALFA

POWDER;IV (INFUSION)

ELELYSO

+ PFIZER 200 UNITS/VIAL

N022458 001 May 01, 2012

TAMOXIFEN CITRATE

SOLUTION;ORAL

SOLTAMOX

DARA BIOSCIENCES EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005

TABLET;ORAL

TAMOXIFEN CITRATEAB ACTAVIS LABS FL INCEQ 10MG BASEA070929 001 Feb 20, 2003ABEQ 10MG BASEA076179 001 Feb 20, 2003ABEQ 20MG BASEA070929 002 Feb 20, 2003ABEQ 20MG BASEA076179 002 Feb 20, 2003AB APOTEXEQ 10MG BASEA090878 001 Sep 23, 2011ABEQ 20MG BASEA090878 002 Sep 23, 2011AB MYLANEQ 10MG BASEA074732 002 Feb 20, 2003ABEQ 20MG BASEA074732 001 Feb 20, 2003AB TEVAEQ 10MG BASEA075797 001 Feb 20, 2003AB + TEVA PHARMSEQ 20MG BASEA074858 001 Feb 20, 2003TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

FLOMAXAB + BOEHRINGER INGELHEIM0.4MGN020579 001 Apr 15, 1997TAMSULOSIN HYDROCHLORIDEAB ANCHEN PHARMS0.4MGA202010 001 Jan 04, 2013AB AUROBINDO PHARMA LTD0.4MGA202433 001 Apr 30, 2013AB IMPAX LABS0.4MGA090377 001 Mar 02, 2010AB MYLAN0.4MGA090408 001 Apr 27, 2010AB SANDOZ0.4MGA078015 001 Apr 27, 2010AB SUN PHARM INDS LTD0.4MGA090931 001 Jul 15, 2010AB SYNTHON PHARMS0.4MGA078801 001 Apr 27, 2010AB TEVA PHARMS0.4MGA077630 001 Apr 27, 2010AB WOCKHARDT0.4MGA078938 001 Apr 27, 2010AB ZYDUS PHARMS USA INC0.4MGA078225 001 Apr 27, 2010TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+ JANSSEN PHARMS EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TABLET;ORAL

NUCYNTA

JANSSEN PHARMS EQ 50MG BASE

N022304 001 Nov 20, 2008

EQ 75MG BASE

N022304 002 Nov 20, 2008

+ EQ 100MG BASE

N022304 003 Nov 20, 2008

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

JANSSEN PHARMS EQ 50MG BASE

N200533 001 Aug 25, 2011

EQ 100MG BASE

N200533 002 Aug 25, 2011

EQ 150MG BASE

N200533 003 Aug 25, 2011

EQ 200MG BASE

N200533 004 Aug 25, 2011

+ EQ 250MG BASE

N200533 005 Aug 25, 2011

TASIMELTEON

CAPSULE;ORAL

HETLIOZ

+ VANDA PHARMS INC 20MG

N205677 001 Jan 31, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-338 (of 371)

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

+ ANACOR PHARMS INC 5%

N204427 001 Jul 07, 2014

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+ STIEFEL LABS INC 0.1%

N202428 001 May 11, 2012

CREAM; TOPICAL

AVAGE

+ ALLERGAN 0.1%

N021184 003 Sep 30, 2002

TAZORAC

+ ALLERGAN 0.05%

N021184 001 Sep 29, 2000

+ 0.1%

N021184 002 Sep 29, 2000

GEL; TOPICAL

TAZORAC

+ ALLERGAN 0.05%

N020600 001 Jun 13, 1997

+ 0.1%

N020600 002 Jun 13, 1997

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

PULMOLITE

BS JUBILANT DRAXIMAGE N/A

N017776 001

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

BS DRAXIMAGE N/A

N017881 001 Dec 30, 1987

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

LANTHEUS MEDCL N/A

N020256 001 Nov 23, 1994

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

PHARMALUCENCE N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+ GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC**AP + BRACCO N/A****N018963 001** Jan 21, 1987**TECHNETIUM TC-99M MEBROFENIN****AP PHARMALUCENCE N/A****A078242 001** Jan 29, 2008TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+ JUBILANT DRAXIMAGE N/A

N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP**AP PHARMALUCENCE N/A****N018124 001****MDP-BRACCO****AP BRACCO N/A****N018107 001**TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3

+ MALLINCKRODT N/A

N019882 001 Jun 15, 1990

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+ MALLINCKRODT N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA**AP JUBILANT DRAXIMAGE N/A****N017714 001****DTPA****AP DRAXIMAGE N/A****N018511 001** Dec 29, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-339 (of 371)

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO

AP	PHARMALUCENCE	N/A	N019039	001	Jun 30, 1987
-----------	---------------	------------	----------------	------------	--------------

TECHNESCAN PYP KIT

AP	MALLINCKRODT	N/A	N017538	001	
-----------	--------------	------------	----------------	------------	--

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

MALLINCKRODT N/A

N019981 001 Jun 10, 1991

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

AP	+ LANTHEUS MEDCL	N/A	N019785	001	Dec 21, 1990
-----------	------------------	------------	----------------	------------	--------------

TECHNETIUM TC 99M SESTAMIBI

AP	CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009
-----------	---------------------	------------	----------------	------------	--------------

AP	DRAXIMAGE	N/A	A078806	001	Apr 29, 2009
-----------	-----------	------------	----------------	------------	--------------

AP	PHARMALUCENCE	10-30mCi	A079157	001	Jul 10, 2009
-----------	---------------	-----------------	----------------	------------	--------------

TECHNETIUM TC-99M SESTAMIBI

AP	MALLINCKRODT	N/A	A078098	001	Sep 22, 2008
-----------	--------------	------------	----------------	------------	--------------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

+ LANTHEUS MEDCL 1-20 CI/GENERATOR

N017771 002 Feb 12, 2014

ULTRA-TECHNEKOW FM

+ MALLINCKRODT 1-19 CI/GENERATOR

N017243 003 Feb 18, 2014

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+ GE HEALTHCARE 68-2703mCi/GENERATOR

N017693 002 Dec 13, 2013

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

GE HEALTHCARE N/A

N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+ PHARMALUCENCE N/A

N017858 001

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE

+ GE HEALTHCARE N/A

N020372 001 Feb 09, 1996

MYOVUE 30ML

+ GE HEALTHCARE N/A

N020372 002 Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+ NAVIDEA BIOPHARMS N/A

N020207 001 Mar 13, 2013

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+ CUBIST PHARMS INC 200MG/VIAL

N205436 001 Jun 20, 2014

TABLET; ORAL

SIVEXTRO

+ CUBIST PHARMS INC 200MG

N205435 001 Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+ NPS PHARMS INC 5MG/VIAL

N203441 001 Dec 21, 2012

TELAPREVIR

TABLET; ORAL

INCIVEK

+ VERTEX PHARMS 375MG

N201917 001 May 23, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-340 (of 371)

TELAVANCIN HYDROCHLORIDE

POWDER; IV (INFUSION)

VIBATIV

THERAVANCE BIOPHARMA EQ 250MG BASE/VIAL
+ EQ 750MG BASE/VIALN022110 001 Sep 11, 2009
N022110 002 Sep 11, 2009TELBIVUDINE

TABLET; ORAL

TYZEKA

+ NOVARTIS 600MG

N022011 001 Oct 25, 2006

TELITHROMYCIN

TABLET; ORAL

KETEK

SANOFI AVENTIS US 300MG
+ 400MGN021144 002 Feb 09, 2005
N021144 001 Apr 01, 2004TELMISARTAN

TABLET; ORAL

MICARDISAB BOEHRINGER INGELHEIM20MGN020850 003 Apr 04, 2000AB 40MGN020850 001 Nov 10, 1998AB + 80MGN020850 002 Nov 10, 1998TELMISARTANAB ALEMBIC PHARMS LTD20MGA202130 001 Jul 07, 2014AB 40MGA202130 002 Jul 07, 2014AB 80MGA202130 003 Jul 07, 2014AB GLENMARK GENERICS20MGA090032 001 Jul 07, 2014AB 40MGA090032 002 Jul 07, 2014AB 80MGA090032 003 Jul 07, 2014AB MYLAN PHARMS INC20MGA202397 001 Jul 07, 2014AB 40MGA202397 002 Jul 07, 2014AB 80MGA202397 003 Jul 07, 2014AB SANDOZ20MGA203867 001 Nov 03, 2014AB 40MGA203867 002 Nov 03, 2014AB 80MGA203867 003 Nov 03, 2014AB TORRENT PHARMS LTD20MGA203171 001 Jul 07, 2014AB 40MGA203171 002 Jul 07, 2014AB 80MGA203171 003 Jul 07, 2014AB WATSON LABS20MGA078710 001 Jan 08, 2014AB 40MGA078710 002 Jan 08, 2014AB 80MGA078710 003 Jan 08, 2014AB ZYDUS PHARMS USA INC20MGA203325 001 Aug 26, 2014AB 40MGA203325 002 Aug 26, 2014AB 80MGA203325 003 Aug 26, 2014TEMAZEPAM

CAPSULE; ORAL

RESTORILAB MALLINCKRODT INC7.5MGN018163 003 Oct 25, 1991AB 15MGN018163 001AB 22.5MGN018163 004 Nov 02, 2004AB + 30MGN018163 002TEMAZEPAMAB ACTAVIS ELIZABETH15MGA071638 001 Aug 07, 1987AB 30MGA071620 001 Aug 07, 1987AB MUTUAL PHARM7.5MGA078581 001 Sep 08, 2009AB 22.5MGA071175 002 Sep 14, 2009AB MYLAN7.5MGA070920 002 May 21, 2010AB 15MGA070920 004 Jul 07, 1986AB 22.5MGA070920 003 Jun 12, 2009AB 30MGA070920 001 Jul 10, 1986AB NOVEL LABS INC7.5MGA071457 002 Jun 22, 2012AB 15MGA071456 001 Apr 21, 1987AB 22.5MGA071457 003 Jun 22, 2012AB 30MGA071457 001 Apr 21, 1987AB SANDOZ15MGA071427 001 Jan 12, 1988AB 30MGA071428 001 Jan 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-341 (of 371)

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

<u>AB</u>	MERCK SHARP DOHME	<u>5MG</u>	<u>N021029</u>	<u>001</u>	Aug 11, 1999
<u>AB</u>		<u>20MG</u>	<u>N021029</u>	<u>002</u>	Aug 11, 1999
<u>AB</u>		<u>100MG</u>	<u>N021029</u>	<u>003</u>	Aug 11, 1999
<u>AB</u>		<u>140MG</u>	<u>N021029</u>	<u>005</u>	Oct 19, 2006
<u>AB</u>		<u>180MG</u>	<u>N021029</u>	<u>006</u>	Oct 19, 2006
<u>AB</u>	+	<u>250MG</u>	<u>N021029</u>	<u>004</u>	Aug 11, 1999

TEMOZOLOMIDE

<u>AB</u>	BARR	<u>5MG</u>	<u>A078879</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879</u>	<u>005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879</u>	<u>006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879</u>	<u>004</u>	Mar 01, 2010
<u>AB</u>	SUN PHARMA GLOBAL	<u>5MG</u>	<u>A201742</u>	<u>001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742</u>	<u>002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742</u>	<u>003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742</u>	<u>004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742</u>	<u>005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742</u>	<u>006</u>	Feb 12, 2014

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277	001	Feb 27, 2009
---	-------------------	------------	---------	-----	--------------

TEMESIROLIMUS

SOLUTION; INTRAVENOUS

TORISEL

+	PF PRISM CV	25MG/ML (25MG/ML)	N022088	001	May 30, 2007
---	-------------	-------------------	---------	-----	--------------

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+	HQ SPECLT PHARMA	10MG/ML	N020119	001	Jul 14, 1992
---	------------------	---------	---------	-----	--------------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577	001	Jan 18, 2012
---	---------------------	---------------	---------	-----	--------------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012
		200MG	N021356	003	Jan 18, 2012
		250MG	N021356	004	Jan 18, 2012
+		300MG	N021356	001	Oct 26, 2001

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A075498</u>	<u>001</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075498</u>	<u>002</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075498</u>	<u>003</u>	Apr 12, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075498</u>	<u>004</u>	Apr 12, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A075614</u>	<u>002</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075614</u>	<u>001</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075614</u>	<u>003</u>	Jan 30, 2001
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075614</u>	<u>004</u>	Jan 30, 2001
<u>AB</u>	JUBILANT CADISTA	<u>EQ 1MG BASE</u>	<u>A075317</u>	<u>001</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075317</u>	<u>002</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075317</u>	<u>003</u>	Dec 20, 2004
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075317</u>	<u>004</u>	Dec 20, 2004
<u>AB</u>	MYLAN	<u>EQ 1MG BASE</u>	<u>A075140</u>	<u>002</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A075140</u>	<u>003</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A075140</u>	<u>001</u>	Feb 11, 2000
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A075140</u>	<u>004</u>	Feb 11, 2000
<u>AB</u>	SANDOZ	<u>EQ 1MG BASE</u>	<u>A074823</u>	<u>001</u>	Mar 30, 1998
<u>AB</u>	+	<u>EQ 2MG BASE</u>	<u>A074823</u>	<u>002</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A074823</u>	<u>003</u>	Mar 30, 1998
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A074823</u>	<u>004</u>	Mar 30, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-342 (of 371)

TERBINAFINE HYDROCHLORIDE

GRANULE; ORAL

LAMISIL

NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

TABLET; ORAL

LAMISILAB + NOVARTISEQ 250MG BASEN020539 001 May 10, 1996TERBINAFINE HYDROCHLORIDEAB APOTEXEQ 250MG BASEA078199 001 Jul 02, 2007AB AUROBINDO PHARMAEQ 250MG BASEA078297 001 Jul 02, 2007AB BRECKENRIDGE PHARMEQ 250MG BASEA077714 001 Jun 04, 2010AB CIPLA LTDEQ 250MG BASEA077137 001 Jul 02, 2007AB DR REDDYS LABS INCEQ 250MG BASEA076390 001 Jul 02, 2007AB GLENMARK GENERICSEQ 250MG BASEA078157 001 Jul 02, 2007AB HARRIS PHARMEQ 250MG BASEA077919 001 Jul 02, 2007AB INVAGEN PHARMSEQ 250MG BASEA077533 001 Jul 02, 2007AB MYLANEQ 250MG BASEA077195 001 Jul 02, 2007AB ORCHID HLTHCAREEQ 250MG BASEA078163 001 Jul 02, 2007AB TEVAEQ 250MG BASEA076377 001 Jul 02, 2007AB WOCKHARDTEQ 250MG BASEA078229 001 Jul 02, 2007TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATEAP AKORN1MG/MLA078151 001 Jan 07, 2008AP + BEDFORD1MG/MLA076770 001 Apr 23, 2004AP FRESENIUS KABI USA1MG/MLA076887 001 May 26, 2004AP HIKMA FARMACEUTICA1MG/MLA078630 001 May 20, 2009AP UNITED BIOMEDCL1MG/MLA200122 001 Nov 08, 2013

TABLET; ORAL

TERBUTALINE SULFATEAB IMPAX LABS2.5MGA075877 001 Jun 26, 2001AB +5MGA075877 002 Jun 26, 2001AB LANNETT2.5MGA077152 001 Mar 25, 2005AB5MGA077152 002 Mar 25, 2005TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3AB + JANSSEN PHARMS0.8%N019964 001 Feb 21, 1991TERAZOL 7AB + JANSSEN PHARMS0.4%N019579 001 Dec 31, 1987TERCONAZOLEAB FOUGERA PHARMS0.4%A076712 001 Feb 18, 2005AB TARO0.4%A076043 001 Jan 19, 2005AB0.8%A075953 001 Apr 06, 2004

BX + NYCOMED US

0.8%

N021735 001 Oct 01, 2004

SUPPOSITORY; VAGINAL

TERAZOL 3AB + JANSSEN PHARMS80MGN019641 001 May 24, 1988TERCONAZOLEAB PERRIGO NEW YORK80MGA077149 001 Mar 17, 2006TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

SANOFI AVENTIS US

7MG

N202992 001 Sep 12, 2012

+

14MG

N202992 002 Sep 12, 2012

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

+ LILLY

0.6MG/2.4ML (0.25MG/ML)

N021318 002 Jun 25, 2008

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

+ THERATECHNOLOGIES

EQ 1MG BASE/VIAL

N022505 001 Nov 10, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-343 (of 371)

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

+ ACTAVIS LABS UT INC

2MG/24HR

N020489 003 Oct 20, 2011

+

4MG/24HR

N020489 004 Oct 20, 2011

GEL;TRANSDERMAL

ANDROGELAB ABBVIE25MG/2.5GM PACKETN021015 001 Feb 28, 2000AB +50MG/5GM PACKETN021015 002 Feb 28, 2000TESTOSTERONEAB PERRIGO ISRAEL25MG/2.5GM PACKETN203098 002 Jan 31, 2013AB50MG/5GM PACKETN203098 003 Jan 31, 2013

TESTIM

BX + AUXILIUM PHARMS

1% (50MG/5GM PACKET)

N021454 001 Oct 31, 2002

TESTOSTERONE

BX TEVA PHARMS

25MG/2.5GM PACKET

N202763 001 Feb 14, 2012

BX

50MG/5GM PACKET

N202763 002 Feb 14, 2012

ANDROGEL

ABBVIE

1.62% (20.25MG/1.25GM PACKET)

N022309 002 Sep 07, 2012

+

1.62% (40.5MG/2.5GM PACKET)

N022309 003 Sep 07, 2012

VOGELXO

UPSHER SMITH

50MG/5GM PACKET

N204399 002 Jun 04, 2014

GEL, METERED;NASAL

NATESTO

ENDO VENTURES LTD

5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014

GEL, METERED;TRANSDERMAL

ANDROGELAB + ABBVIE12.5MG/1.25GM ACTUATIONN021015 003 Sep 26, 2003TESTOSTERONEAB PERRIGO ISRAEL12.5MG/1.25GM ACTUATIONN203098 001 Jan 31, 2013

VOGELXO

BX UPSHER SMITH

12.5MG/1.25GM ACTUATION

N204399 003 Jun 04, 2014

ANDROGEL

+ ABBVIE

1.62% (20.25MG/1.25GM ACTUATION)

N022309 001 Apr 29, 2011

FORTESTA

+ ENDO PHARMS

10MG/0.5GM ACTUATION

N021463 001 Dec 29, 2010

PELLET;IMPLANTATION

TESTOPEL

+ ACTIENT PHARMS

75MG

A080911 001

SOLUTION, METERED;TRANSDERMAL

AXIRON

+ ELI LILLY AND CO

30MG/1.5ML ACTUATION

N022504 001 Nov 23, 2010

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+ AUXILIUM PHARMS LLC

30MG

N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONEAO + PHARMACIA AND UPJOHN100MG/MLA085635 002AO +200MG/MLA085635 003TESTOSTERONE CYPIONATEAO BEDFORD100MG/MLA090387 001 Jul 15, 2010AO200MG/MLA090387 002 Jul 15, 2010AO HIKMA FARMACEUTICA200MG/MLA091244 001 May 01, 2012AO MYLAN INSTITUTIONAL200MG/MLA040652 001 Dec 11, 2006AO PADDOCK LLC200MG/MLA040530 001 Jan 31, 2005AO SANDOZ100MG/MLA040615 001 Aug 10, 2006AO200MG/MLA040615 002 Aug 10, 2006AO SUN PHARM INDS LTD100MG/MLA201720 001 Jun 03, 2013AO200MG/MLA201720 002 Jun 03, 2013AO WATSON LABS200MG/MLA086030 001TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYLAO + ENDO PHARMS200MG/MLN009165 003TESTOSTERONE ENANTHATEAO HIKMA FARMACEUTICA200MG/MLA091120 001 Sep 18, 2012AO MYLAN INSTITUTIONAL200MG/MLA040647 001 Oct 05, 2009AO PADDOCK LLC200MG/MLA040575 001 Jun 14, 2006AO WATSON LABS200MG/MLA085598 001

PRESCRIPTION DRUG PRODUCT LIST

3-344 (of 371)

TESTOSTERONE UNDECANOATE

INJECTABLE; INTRAMUSCULAR

AVEED

+ ENDO PHARMS INC 750MG/3ML (250MG/ML)

N022219 001 Mar 04, 2014

TETRABENAZINE

TABLET; ORAL

XENAZINE

VALEANT BERMUDA 12.5MG

N021894 001 Aug 15, 2008

+ 25MG

N021894 002 Aug 15, 2008

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN VAB HERITAGE PHARMS INC250MGN050278 003AB500MGN050278 001TETRACYCLINE HYDROCHLORIDEAB IMPAX LABS250MGA060469 001AB500MGA060469 003AB IVAX SUB TEVA PHARMS250MGA060704 001AB +500MGA060704 002AB WATSON LABS250MGA061837 001AB500MGA061837 002

IMPAX LABS 100MG

A060469 002

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+ FOUGERA PHARMS 0.05%

A086576 002

0.1%

A086576 001

SPRAY; NASAL

TYZINE

+ FOUGERA PHARMS 0.1%

A086576 003

THALIDOMIDE

CAPSULE; ORAL

THALOMID

CELGENE 50MG

N020785 001 Jul 16, 1998

100MG

N020785 002 Jan 17, 2003

150MG

N020785 004 Jan 10, 2007

+ 200MG

N020785 003 Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201AP + GE HEALTHCARE 1mCi/MLN018110 002 Feb 27, 1996AP + LANTHEUS MEDCL 1mCi/MLN017806 001AP + MALLINCKRODT 1mCi/MLN018150 001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201AP + LANTHEUS MEDCL 2mCi/MLN017806 002 Oct 09, 1998THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

ACTIENT PHARMS 100MG

A087942 001 Aug 22, 1983

200MG

A087943 001 Aug 22, 1983

300MG

A087944 001 Aug 22, 1983

+ 400MG

A081034 001 Feb 28, 1992

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN 40MG/100MLN019826 001 Aug 14, 1992THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN 80MG/100MLN019826 002 Aug 14, 1992THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN 160MG/100MLN019826 003 Aug 14, 1992THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINERAP + B BRAUN 320MG/100MLN019826 006 Aug 14, 1992THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINERAP + HOSPIRA INC 4MG/MLN019211 007 Dec 14, 1984AP + 40MG/100MLN019211 001 Dec 14, 1984AP + 160MG/100MLN019211 003 Dec 14, 1984AP + 320MG/100MLN019211 006 Jan 20, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-345 (of 371)

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

AA	+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011
AA		TRIS PHARMA INC	80MG/15ML	A091586	001	Jun 15, 2012
		SOLUTION, ELIXIR; ORAL				
		ELIXOPHYLLIN				
	+	SUN PHARM INDS INC	80MG/15ML	A085186	001	
		TABLET; ORAL				
		THEOLAIR				
	+	MEDICIS	125MG	A086399	001	
	+		250MG	A086399	002	
		TABLET, EXTENDED RELEASE; ORAL				

THEOCHRON

AB		SUN PHARM INDS INC	100MG	A088320	001	Feb 21, 1985
AB			200MG	A088321	001	Feb 21, 1985

THEOPHYLLINE

AB		ALEMBIC LTD	300MG	A090430	001	Oct 27, 2010
AB			450MG	A090430	002	Oct 27, 2010
AB		GLENMARK GENERICS	400MG	A090355	001	Jul 13, 2010
AB			600MG	A090355	002	Jul 13, 2010
AB		NOSTRUM	400MG	A040595	001	Apr 21, 2006
AB	+		600MG	A040560	002	Apr 21, 2006
AB	+	PLIVA	100MG	A089807	001	Apr 30, 1990
AB	+		200MG	A089808	001	Apr 30, 1990
AB			300MG	A089763	001	Apr 30, 1990
AB		RHODES PHARMS	600MG	A040086	001	Apr 15, 1996
AB	+	TEVA PHARMS	450MG	A081236	001	Nov 09, 1992

UNIPHYL

AB		RHODES PHARMS	400MG	A087571	001	Sep 01, 1982
-----------	--	---------------	--------------	----------------	------------	--------------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	+	FRESENIUS KABI USA	100MG/ML	A080556	001	
AP		MYLAN INSTITUTIONAL	100MG/ML	A091623	001	Jun 25, 2012

THIOGUANINE

TABLET; ORAL

THIOGUANINE

	+	ASPEN GLOBAL INC	40MG	N012429	001	
--	---	------------------	------	---------	-----	--

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

AB		MUTUAL PHARM	10MG	A089953	004	Aug 01, 1986
AB			25MG	A089953	003	Aug 01, 1986
AB			50MG	A089953	002	Aug 01, 1986
AB			100MG	A089953	001	Oct 07, 1988
AB		MYLAN	10MG	A088004	002	Mar 15, 1983
AB			25MG	A088004	003	Mar 15, 1983
AB			50MG	A088004	004	Mar 15, 1983
AB	+		100MG	A088004	001	Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

		EUROHLTH INTL	15MG/VIAL	A075547	001	Apr 02, 2001
--	--	---------------	-----------	---------	-----	--------------

THIOTHIXENE

CAPSULE; ORAL

NAVANE

AB		PFIZER	1MG	N016584	001	
AB			2MG	N016584	002	
AB	+		5MG	N016584	003	
AB			10MG	N016584	004	

THIOTHIXENE

AB		MYLAN	1MG	A071093	002	Jun 23, 1987
AB			2MG	A071093	003	Jun 23, 1987
AB			5MG	A071093	004	Jun 23, 1987
AB			10MG	A071093	001	Jun 23, 1987
AB		SANDOZ	1MG	A071610	001	Jun 24, 1987
AB			2MG	A071570	001	Jun 24, 1987
AB			5MG	A071529	001	Jun 24, 1987
AB			10MG	A071530	001	Jun 24, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-346 (of 371)

THYROTROPIN ALFA

INJECTABLE; INJECTION

THYROGEN

+ GENZYME

1.1MG/VIAL

N020898 001 Nov 30, 1998

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRILAB CEPHALON2MGN020646 005 Apr 16, 1999AB +4MGN020646 001 Sep 30, 1997TIAGABINE HYDROCHLORIDEAB SUN PHARM INDS2MGA077555 001 Nov 04, 2011AB4MGA077555 002 Nov 04, 2011

GABITRIL

CEPHALON

12MG

N020646 002 Sep 30, 1997

16MG

N020646 003 Sep 30, 1997

TICAGRELOL

TABLET; ORAL

BRILINTA

+ ASTRAZENECA LP

90MG

N022433 001 Jul 20, 2011

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDEAB APOTEX250MGA075089 001 Jul 01, 1999AB SUN PHARM INDS INC250MGA075526 001 Sep 26, 2002AB + TEVA250MGA075149 001 Aug 20, 1999TIGECYCLINE

INJECTABLE; IV (INFUSION)

TYGACIL

+ PF PRISM CV

50MG/VIAL

N021821 001 Jun 15, 2005

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

+ OAK PHARMS INC

EQ 0.25% BASE

N020439 001 Mar 31, 1995

+

EQ 0.5% BASE

N020439 002 Mar 31, 1995

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATEAB ALCON RES LTDEQ 0.25% BASEN020963 001 Oct 21, 1998ABEQ 0.5% BASEN020963 002 Oct 21, 1998TIMOPTIC-XEAB + VALEANT PHARMS LLCEQ 0.25% BASEN020330 001 Nov 04, 1993AB +EQ 0.5% BASEN020330 002 Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATEAT AKORNEQ 0.5% BASEA074466 001 Mar 25, 1997ATEQ 0.5% BASEA074516 001 Mar 25, 1997AT ALCON RES LTDEQ 0.25% BASEA074261 001 Apr 28, 1995ATEQ 0.5% BASEA074262 001 Apr 28, 1995AT BAUSCH AND LOMBEQ 0.25% BASEA074778 001 Mar 25, 1997ATEQ 0.5% BASEA074776 001 Mar 25, 1997AT FDC LTDEQ 0.25% BASEA077259 001 Apr 30, 2008ATEQ 0.5% BASEA077259 002 Apr 30, 2008AT HI TECH PHARMAEQ 0.5% BASEA075163 001 Sep 10, 2002AT PACIFIC PHARMAEQ 0.25% BASEA074746 001 Mar 25, 1997ATEQ 0.5% BASEA074747 001 Mar 25, 1997AT WOCKHARDTEQ 0.25% BASEA078771 001 Sep 28, 2009ATEQ 0.5% BASEA078771 002 Sep 28, 2009TIMOPTICAT + ATONEQ 0.25% BASEN018086 001AT +EQ 0.5% BASEN018086 002

ISTALOL

BT + BAUSCH AND LOMB

EQ 0.5% BASE

N021516 001 Jun 04, 2004

TIMOPTIC IN OCUDOSE

+ ATON

EQ 0.25% BASE

N019463 001 Nov 05, 1986

+

EQ 0.5% BASE

N019463 002 Nov 05, 1986

TABLET; ORAL

TIMOLOL MALEATE

MYLAN

5MG

A072668 002 Jun 08, 1990

10MG

A072668 003 Jun 08, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-347 (of 371)

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

+

20MG

A072668 001 Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAXAB MISSION PHARMA250MGN021618 001 May 17, 2004AB +500MGN021618 002 May 17, 2004TINIDAZOLEAB NOVEL LABS INC250MGA202044 001 Apr 30, 2012AB500MGA202044 002 Apr 30, 2012AB ROXANE250MGA201172 001 Apr 30, 2012AB500MGA201172 002 Apr 30, 2012AB UNIQUE PHARM LABS250MGA202489 001 Oct 09, 2013AB500MGA202489 002 Oct 09, 2013TIOPRONIN

TABLET; ORAL

THIOLA

+ MISSION PHARMA

100MG

N019569 001 Aug 11, 1988

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

+ BOEHRINGER INGELHEIM

EQ 0.018MG BASE/INH

N021395 001 Jan 30, 2004

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

+ BOEHRINGER INGELHEIM

EQ 0.0025MG BASE/INH

N021936 001 Sep 24, 2014

TIPRANAVIR

CAPSULE; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

250MG

N021814 001 Jun 22, 2005

SOLUTION; ORAL

APTIVUS

+ BOEHRINGER INGELHEIM

100MG/ML

N022292 001 Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)

N020913 002 May 17, 2002

+

EQ 12.5MG BASE/250ML (EQ 0.05MG
BASE/ML)

N020913 003 Apr 20, 2000

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEX INCEQ 2MG BASEA078868 001 Feb 03, 2012ABEQ 4MG BASEA078868 002 Feb 03, 2012ABEQ 6MG BASEA078868 003 Feb 03, 2012AB MYLAN PHARMS INCEQ 2MG BASEA091502 001 Nov 09, 2012ABEQ 4MG BASEA091502 002 Nov 09, 2012ABEQ 6MG BASEA091502 003 Nov 09, 2012ZANAFLEXAB ACORDAEQ 2MG BASEN021447 001 Aug 29, 2002ABEQ 4MG BASEN021447 002 Aug 29, 2002AB +EQ 6MG BASEN021447 003 Aug 29, 2002

TABLET; ORAL

TIZANIDINE HYDROCHLORIDEAB APOTEXEQ 2MG BASEA076533 001 Jan 16, 2004ABEQ 4MG BASEA076533 002 Jan 16, 2004AB COREPHARMAEQ 2MG BASEA076347 001 Oct 11, 2002ABEQ 4MG BASEA076347 002 Oct 11, 2002AB DR REDDYS LABS INCEQ 2MG BASEA076286 001 Jul 03, 2002ABEQ 4MG BASEA076286 002 Jul 03, 2002AB MYLANEQ 2MG BASEA076354 001 Mar 28, 2003ABEQ 4MG BASEA076354 002 Mar 28, 2003AB PROSAM LABSEQ 2MG BASEA076281 001 Oct 20, 2003ABEQ 4MG BASEA076281 002 Oct 20, 2003AB SANDOZ INCEQ 2MG BASEA076280 001 Nov 26, 2002ABEQ 4MG BASEA076280 002 Jun 27, 2002AB SUN PHARM INDS INCEQ 2MG BASEA076416 001 Sep 29, 2003ABEQ 4MG BASEA076416 002 Sep 29, 2003AB TEVAEQ 2MG BASEA076284 001 Jul 03, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-348 (of 371)

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A076284</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>	UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091283</u>	<u>002</u>	Nov 28, 2012

ZANAFLEX

<u>AB</u>	+ ACORDA	<u>EQ 4MG BASE</u>	<u>N020397</u>	<u>001</u>	Nov 27, 1996
-----------	----------	--------------------	----------------	------------	--------------

TOBRAMYCIN

OINTMENT; OPHTHALMIC

TOBREX

+	ALCON	0.3%	N050555	001	
---	-------	------	---------	-----	--

POWDER; INHALATION

TOBI PODHALER

+	NOVARTIS	28MG	N201688	001	Mar 22, 2013
---	----------	------	---------	-----	--------------

SOLUTION; INHALATION

TOBI

<u>AN</u>	+ NOVARTIS PHARMS	<u>300MG/5ML</u>	<u>N050753</u>	<u>001</u>	Dec 22, 1997
-----------	-------------------	------------------	----------------	------------	--------------

TOBRAMYCIN

<u>AN</u>	AKORN INC	<u>300MG/5ML</u>	<u>A201422</u>	<u>001</u>	May 28, 2014
-----------	-----------	------------------	----------------	------------	--------------

<u>AN</u>	TEVA PHARMS USA	<u>300MG/5ML</u>	<u>A091589</u>	<u>001</u>	Oct 10, 2013
-----------	-----------------	------------------	----------------	------------	--------------

BETHKIS

CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012
----------------	-----------	---------	-----	--------------

KITABIS PAK

+	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014
---	---------------	-----------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

AKTOB

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A064096</u>	<u>001</u>	Jan 31, 1996
-----------	-------	-------------	----------------	------------	--------------

TOBRAMYCIN

<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A064052</u>	<u>001</u>	Nov 29, 1993
-----------	-----------------	-------------	----------------	------------	--------------

<u>AT</u>	FERA PHARMS	<u>0.3%</u>	<u>A065026</u>	<u>001</u>	Sep 11, 2001
-----------	-------------	-------------	----------------	------------	--------------

TOBREX

<u>AT</u>	ALCON	<u>0.3%</u>	<u>A062535</u>	<u>001</u>	Dec 13, 1984
-----------	-------	-------------	----------------	------------	--------------

<u>AT</u>	+ FALCON PHARMS	<u>0.3%</u>	<u>N050541</u>	<u>001</u>	
-----------	-----------------	-------------	----------------	------------	--

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

<u>AP</u>	AGILA SPECLTS	<u>EQ 40MG BASE/ML</u>	<u>A065407</u>	<u>001</u>	Mar 11, 2008
-----------	---------------	------------------------	----------------	------------	--------------

<u>AP</u>	AKORN	<u>EQ 40MG BASE/ML</u>	<u>A205179</u>	<u>001</u>	Sep 16, 2014
-----------	-------	------------------------	----------------	------------	--------------

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1.2GM BASE/VIAL</u>	<u>N050789</u>	<u>001</u>	Jul 13, 2004
-----------	--------------------	---------------------------	----------------	------------	--------------

<u>AP</u>		<u>EQ 10MG BASE/ML</u>	<u>A065122</u>	<u>001</u>	Nov 29, 2002
-----------	--	------------------------	----------------	------------	--------------

<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A065122</u>	<u>002</u>	Nov 29, 2002
-----------	---	------------------------	----------------	------------	--------------

<u>AP</u>	HIKMA MAPLE	<u>EQ 40MG BASE/ML</u>	<u>A063117</u>	<u>001</u>	Apr 26, 1991
-----------	-------------	------------------------	----------------	------------	--------------

<u>AP</u>	+ HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>A063112</u>	<u>001</u>	Apr 30, 1991
-----------	-----------	------------------------	----------------	------------	--------------

<u>AP</u>		<u>EQ 40MG BASE/ML</u>	<u>A063111</u>	<u>001</u>	Apr 30, 1991
-----------	--	------------------------	----------------	------------	--------------

<u>AP</u>	+	<u>EQ 40MG BASE/ML</u>	<u>A063116</u>	<u>001</u>	May 18, 1992
-----------	---	------------------------	----------------	------------	--------------

<u>AP</u>	TEVA PHARMS USA	<u>EQ 40MG BASE/ML</u>	<u>A063100</u>	<u>001</u>	Jan 30, 1992
-----------	-----------------	------------------------	----------------	------------	--------------

<u>AP</u>	+ X GEN PHARMS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A065013</u>	<u>001</u>	Aug 17, 2001
-----------	----------------	---------------------------	----------------	------------	--------------

<u>AP</u>	XELLIA PHARMS APS	<u>EQ 1.2GM BASE/VIAL</u>	<u>A205685</u>	<u>001</u>	Sep 16, 2014
-----------	-------------------	---------------------------	----------------	------------	--------------

TOBRAMYCIN SULFATE (PHARMACY BULK)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/ML</u>	<u>A065120</u>	<u>001</u>	Nov 29, 2002
-----------	--------------------	------------------------	----------------	------------	--------------

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1.2MG BASE/ML	A063081	003	Jul 31, 1990
---	---------	------------------	---------	-----	--------------

+		EQ 1.6MG BASE/ML	A063081	006	Jun 02, 1993
---	--	------------------	---------	-----	--------------

+		EQ 80MG BASE/100ML	A063081	001	Jul 31, 1990
---	--	--------------------	---------	-----	--------------

TOFACITINIB CITRATE

TABLET; ORAL

XELJANZ

+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012
---	-------------	-------------	---------	-----	--------------

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

MYLAN PHARMS INC	250MG	A070259	001	Jan 02, 1986
------------------	-------	---------	-----	--------------

+		500MG	A070259	003	Mar 17, 1986
---	--	-------	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-349 (of 371)

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+ MYLAN PHARMS INC

500MG

A086445 001

TOLCAPONE

TABLET; ORAL

TASMAR

+ VALEANT PHARMS LLC

100MG

N020697 001 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUMAB MYLANEQ 400MG BASEA073393 001 May 27, 1993AB + TEVAEQ 400MG BASEA073290 001 Nov 27, 1991

TABLET; ORAL

TOLMETIN SODIUMAB MUTUAL PHARMEQ 200MG BASEA073310 001 Nov 27, 1991AB + MYLANEQ 600MG BASEA074473 001 Aug 30, 1994TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

DETROL LAAB PHARMACIA AND UPJOHN2MGN021228 001 Dec 22, 2000AB +4MGN021228 002 Dec 22, 2000TOLTERODINE TARTRATEAB MYLAN PHARMS INC2MGA201486 001 Oct 31, 2013AB4MGA201486 002 Oct 31, 2013

TABLET; ORAL

DETROLAB PHARMACIA AND UPJOHN1MGN020771 001 Mar 25, 1998AB +2MGN020771 002 Mar 25, 1998TOLTERODINE TARTRATEAB APOTEX CORP1MGA200164 001 Sep 25, 2012AB2MGA200164 002 Sep 25, 2012AB MYLAN PHARMS INC1MGA202641 001 Nov 27, 2012AB2MGA202641 002 Nov 27, 2012TOLVAPTAN

TABLET; ORAL

SAMSCA

+ OTSUKA AMERICA PHARM

15MG

N022275 001 May 19, 2009

+

30MG

N022275 002 May 19, 2009

TOPIRAMATE

CAPSULE; ORAL

TOPAMAXAB JANSSEN PHARMS15MGN020844 001 Oct 26, 1998AB +25MGN020844 002 Oct 26, 1998TOPIRAMATEAB MYLAN15MGA078418 001 Oct 14, 2009AB25MGA078418 002 Oct 14, 2009AB TEVA15MGA076575 001 Apr 17, 2009AB25MGA076575 002 Apr 17, 2009AB WATSON LABS15MGA077868 001 Apr 15, 2009AB25MGA077868 002 Apr 15, 2009AB ZYDUS PHARMS USA INC15MGA078877 001 Oct 14, 2009AB25MGA078877 002 Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

QUDEXY XR

+ UPSHER SMITH

25MG

N205122 001 Mar 11, 2014

50MG

N205122 002 Mar 11, 2014

100MG

N205122 003 Mar 11, 2014

150MG

N205122 004 Mar 11, 2014

+

200MG

N205122 005 Mar 11, 2014

TROKENDI XR

+ SUPERNUS PHARMS

25MG

N201635 001 Aug 16, 2013

50MG

N201635 002 Aug 16, 2013

100MG

N201635 003 Aug 16, 2013

+

200MG

N201635 004 Aug 16, 2013

TABLET; ORAL

TOPAMAXAB JANSSEN PHARMS25MGN020505 004 Dec 24, 1996AB50MGN020505 005 Dec 24, 1996AB +100MGN020505 001 Dec 24, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-350 (of 371)

TOPIRAMATE

TABLET; ORAL

TOPAMAX

<u>AB</u>		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996
<u>AB</u>	<u>TOPIRAMATE</u>				
<u>AB</u>	ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	ACTIVIS TOTOWA LLC	<u>25MG</u>	<u>A078637</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>50MG</u>	<u>A078637</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>		<u>100MG</u>	<u>A078637</u>	<u>003</u>	Feb 27, 2013
<u>AB</u>		<u>200MG</u>	<u>A078637</u>	<u>004</u>	Feb 27, 2013
<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	LUPIN	<u>25MG</u>	<u>A078410</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>50MG</u>	<u>A078410</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>100MG</u>	<u>A078410</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>		<u>200MG</u>	<u>A078410</u>	<u>004</u>	Sep 11, 2013
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A076314</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076314</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076314</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076314</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	RANBAXY	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	SUN PHARMA GLOBAL	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	TORRENT PHARMS	<u>25MG</u>	<u>A079153</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A079153</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079153</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079153</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	UPSHER SMITH	<u>25MG</u>	<u>A078499</u>	<u>001</u>	Jan 07, 2010
<u>AB</u>		<u>50MG</u>	<u>A078499</u>	<u>002</u>	Jan 07, 2010
<u>AB</u>		<u>100MG</u>	<u>A078499</u>	<u>003</u>	Jan 07, 2010
<u>AB</u>		<u>200MG</u>	<u>A078499</u>	<u>004</u>	Jan 07, 2010
<u>AB</u>	WOCKHARDT USA	<u>25MG</u>	<u>A090353</u>	<u>001</u>	Sep 01, 2010
<u>AB</u>		<u>50MG</u>	<u>A090353</u>	<u>002</u>	Sep 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A090353</u>	<u>003</u>	Sep 01, 2010
<u>AB</u>		<u>200MG</u>	<u>A090353</u>	<u>004</u>	Sep 01, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-351 (of 371)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>	HIKMA PHARMS	<u>25MG</u>	<u>A091185</u>	<u>001</u>	Nov 25, 2013
<u>AB</u>		<u>50MG</u>	<u>A091185</u>	<u>002</u>	Nov 25, 2013
<u>AB</u>		<u>100MG</u>	<u>A091185</u>	<u>003</u>	Nov 25, 2013
<u>AB</u>		<u>200MG</u>	<u>A091185</u>	<u>004</u>	Nov 25, 2013

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

GLAXO WELLCOME

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCANTIN

<u>AP</u>	+ GLAXOSMITHKLINE	<u>EQ 4MG BASE/VIAL</u>	<u>N020671</u>	<u>001</u>	May 28, 1996
-----------	-------------------	-------------------------	----------------	------------	--------------

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	CIPLA LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	INNOPHARMA LICENSING	<u>EQ 4MG BASE/VIAL</u>	<u>A201166</u>	<u>001</u>	Aug 08, 2012
<u>AP</u>	ONCO THERAPIES LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A091542</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A202203</u>	<u>001</u>	Aug 29, 2013

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	+ HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012

TOREMIFENE CITRATE

TABLET; ORAL

FARESTON

+ PROSTRAKAN INC

EQ 60MG BASE

N020497 001 May 29, 1997

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

<u>AP</u>	+ EUROHLTH INTL	<u>20MG/2ML (10MG/ML)</u>	<u>A078007</u>	<u>001</u>	Jun 11, 2008
<u>AP</u>	+	<u>50MG/5ML (10MG/ML)</u>	<u>A078007</u>	<u>002</u>	Jun 11, 2008
<u>AP</u>	LUITPOLD	<u>20MG/2ML (10MG/ML)</u>	<u>A090656</u>	<u>001</u>	Apr 21, 2010
<u>AP</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A090656</u>	<u>002</u>	Apr 21, 2010

TABLET; ORAL

DEMADEX

<u>AB</u>	MEDA PHARMS	<u>5MG</u>	<u>N020136</u>	<u>001</u>	Aug 23, 1993
<u>AB</u>		<u>10MG</u>	<u>N020136</u>	<u>002</u>	Aug 23, 1993
<u>AB</u>	+	<u>20MG</u>	<u>N020136</u>	<u>003</u>	Aug 23, 1993
<u>AB</u>		<u>100MG</u>	<u>N020136</u>	<u>004</u>	Aug 23, 1993

TORSEMIDE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009
<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	PAR PHARM	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>		<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	SUN PHARM INDS	<u>5MG</u>	<u>A078478</u>	<u>001</u>	Feb 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-352 (of 371)

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>		<u>10MG</u>	<u>A078478</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078478</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>100MG</u>	<u>A078478</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
<u>AB</u>	VINTAGE PHARMS	<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011

TRAMADOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
CONZIP

+	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
		150MG	N022370	004	Aug 01, 2011
		200MG	N022370	002	May 07, 2010
		300MG	N022370	003	May 07, 2010

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE INC	<u>50MG</u>	<u>A202390</u>	<u>001</u>	May 16, 2013
<u>AB</u>	ALLIED PHARMA INC	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MALLINCKRODT	<u>50MG</u>	<u>A075983</u>	<u>001</u>	Jun 25, 2002
<u>AB</u>	MUTUAL PHARM	<u>50MG</u>	<u>A076100</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A075986</u>	<u>001</u>	Jun 21, 2002
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A075980</u>	<u>001</u>	Nov 21, 2002
<u>AB</u>	NORTHSTAR HLTHCARE	<u>50MG</u>	<u>A078935</u>	<u>001</u>	May 26, 2010
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011

ULTRAM

<u>AB</u>	+	JANSSEN PHARMS	<u>50MG</u>	<u>N020281</u>	<u>002</u>	Mar 03, 1995
-----------	---	----------------	-------------	----------------	------------	--------------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>		<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>		<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>	PAR PHARM INC	<u>100MG</u>	<u>A078783</u>	<u>001</u>	Nov 13, 2009
<u>AB1</u>		<u>200MG</u>	<u>A078783</u>	<u>002</u>	Nov 13, 2009
<u>AB1</u>		<u>300MG</u>	<u>A078783</u>	<u>003</u>	Sep 20, 2011
<u>AB1</u>	SUN PHARMA GLOBAL	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>		<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>		<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011

ULTRAM ER

<u>AB1</u>	+	VALEANT INTL	<u>100MG</u>	<u>N021692</u>	<u>001</u>	Sep 08, 2005
<u>AB1</u>			<u>200MG</u>	<u>N021692</u>	<u>002</u>	Sep 08, 2005
<u>AB1</u>			<u>300MG</u>	<u>N021692</u>	<u>003</u>	Sep 08, 2005

TRAMADOL HYDROCHLORIDE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A200491</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>		<u>200MG</u>	<u>A200491</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>		<u>300MG</u>	<u>A200491</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	+ SUN PHARMA GLOBAL	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>		<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011
<u>AB2</u>		<u>300MG</u>	<u>A091607</u>	<u>003</u>	Dec 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-353 (of 371)

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

GLAXOSMITHKLINE LLC

EQ 0.5MG NON-SOLVATED PARENT

N204114 001 May 29, 2013

EQ 1MG NON-SOLVATED PARENT

N204114 002 May 29, 2013

+ EQ 2MG NON-SOLVATED PARENT

N204114 003 May 29, 2013

TRANDOLAPRIL

TABLET; ORAL

MAVIKAB ABBVIE1MGN020528 001 Apr 26, 1996AB2MGN020528 002 Apr 26, 1996AB +4MGN020528 003 Apr 26, 1996TRANDOLAPRILAB AUROBINDO PHARMA1MGA078438 001 Jun 12, 2007AB 2MGA078438 002 Jun 12, 2007AB 4MGA078438 003 Jun 12, 2007AB EPIC PHARMA1MGA078508 003 Jun 18, 2008AB 2MGA078508 001 Jun 18, 2008AB 4MGA078508 002 Jun 18, 2008AB INVAGEN PHARMS1MGA078320 001 Jun 12, 2007AB 2MGA078320 002 Jun 12, 2007AB 4MGA078320 003 Jun 12, 2007AB LUPIN1MGA077522 001 Jun 12, 2007AB 2MGA077522 002 Jun 12, 2007AB 4MGA077522 003 Jun 12, 2007AB MYLAN1MGA078346 001 Apr 28, 2008AB 2MGA078346 002 Apr 28, 2008AB 4MGA078346 003 Apr 28, 2008AB TEVA PHARMS1MGA077489 001 Dec 12, 2006AB 2MGA077489 002 Dec 12, 2006AB 4MGA077489 003 Dec 12, 2006AB WATSON LABS1MGA077805 001 Jun 12, 2007AB 2MGA077805 002 Jun 12, 2007AB 4MGA077805 003 Jun 12, 2007TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARKAAB ABBVIE1MG;240MGN020591 003 Oct 22, 1996AB 2MG;180MGN020591 001 Oct 22, 1996AB 2MG;240MGN020591 004 Oct 22, 1996AB + 4MG;240MGN020591 002 Oct 22, 1996TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDEAB GLENMARK GENERICS1MG;240MGA079135 004 Aug 30, 2010AB 2MG;180MGA079135 001 May 26, 2010AB 2MG;240MGA079135 002 May 26, 2010AB 4MG;240MGA079135 003 May 05, 2010TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRONAP + PHARMACIA AND UPJOHN100MG/MLN019281 001 Dec 30, 1986TRANEXAMIC ACIDAP ACIC FINE CHEMS100MG/MLA202436 001 Feb 11, 2014AP EMCURE PHARMS LTD100MG/MLA203521 001 Aug 12, 2014AP LUITPOLD100MG/MLA201885 001 Aug 10, 2011AP MYLAN INSTITUTIONAL100MG/MLA091657 001 Nov 03, 2011AP VERSAPHARM INC100MG/MLA202373 001 Nov 17, 2011AP X-GEN PHARMS INC100MG/MLA201580 001 Jun 14, 2013

TABLET; ORAL

LYSTEDAAB + FERRING PHARMS AS650MGN022430 001 Nov 13, 2009TRANEXAMIC ACIDAB ACTAVIS LABS FL INC650MGA202093 001 Dec 27, 2012AB APOTEX INC650MGA202286 001 Jan 27, 2014TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATEAB + COVIS PHARMAEQ 10MG BASEN012342 003 Aug 16, 1985TRANLYCYPROMINE SULFATEAB PAR PHARMEQ 10MG BASEA040640 001 Jun 29, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-354 (of 371)

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ ALCON LABS INC 0.003%

N204822 001 May 15, 2014

TRAVATAN Z

+ ALCON PHARMS LTD 0.004%

N021994 001 Sep 21, 2006

TRAVOPROST

+ PAR PHARM 0.004%

A091340 001 Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE**AB** ALVOGEN**50MG****A071636 001** Apr 18, 1988**AB****100MG****A071514 001** Apr 18, 1988**AB** APOTEX**50MG****A071258 001** Mar 25, 1987**AB** + APOTEX INC**100MG****A071196 001** Mar 25, 1987**AB****150MG****A071196 002** Apr 26, 1999**AB****300MG****A071196 003** Apr 26, 1999**AB** MUTUAL PHARM**50MG****A073137 002** Mar 24, 1993**AB****100MG****A073137 001** Mar 24, 1993**AB****150MG****A073137 003** Dec 22, 1995**AB** MYLAN PHARMS INC**50MG****A090514 001** Jun 02, 2009**AB****100MG****A090514 002** Jun 02, 2009**AB****150MG****A090514 003** Jun 02, 2009**AB****300MG****A090514 004** Jun 02, 2009**AB** PLIVA**150MG****A071525 001** Mar 09, 1988**AB** TEVA PHARMS USA**50MG****A071523 001** Dec 11, 1987**AB****100MG****A071524 001** Dec 11, 1987**AB** TORRENT PHARMS LTD**50MG****A202180 001** Nov 27, 2013**AB****100MG****A202180 002** Nov 27, 2013**AB****150MG****A202180 003** Nov 27, 2013**AB****300MG****A202180 004** Nov 27, 2013**AB** VINTAGE**50MG****A072192 001** Feb 02, 1989**AB****100MG****A072193 001** Feb 02, 1989

TABLET, EXTENDED RELEASE;ORAL

OLEPTRO

+ ANGELINI PHARMA 150MG

N022411 001 Feb 02, 2010

300MG

N022411 002 Feb 02, 2010

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

UNITED THERAP

1MG/ML

N021272 001 May 21, 2002

2.5MG/ML

N021272 002 May 21, 2002

5MG/ML

N021272 003 May 21, 2002

+

10MG/ML

N021272 004 May 21, 2002

SOLUTION;INHALATION

TYVASO

+ UNITED THERAP

0.6MG/ML

N022387 001 Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

UNITED THERAP

EQ 0.125MG BASE

N203496 001 Dec 20, 2013

EQ 0.25MG BASE

N203496 002 Dec 20, 2013

EQ 1MG BASE

N203496 003 Dec 20, 2013

+

EQ 2.5MG BASE

N203496 004 Dec 20, 2013

TRETINOIN

CAPSULE;ORAL

TRETINOIN**AB** ANCHEN PHARMS**10MG****A201687 001** Oct 24, 2012**AB** + BARR LABS INC**10MG****A077684 001** Jun 22, 2007

CREAM;TOPICAL

AVITA**AB** MYLAN PHARMS INC**0.025%****N020404 003** Jan 14, 1997RETIN-A**AB** + VALEANT BERMUDA**0.025%****N019049 001** Sep 16, 1988**AB** +**0.1%****N017340 001**TRETINOIN**AB** MATAWAN PHARMS**0.025%****A075264 001** Dec 24, 1998**AB****0.1%****A075213 001** Dec 24, 1998RETIN-A**AB1** + VALEANT BERMUDA**0.05%****N017522 001**

PRESCRIPTION DRUG PRODUCT LIST

3-355 (of 371)

TRETINOIN

CREAM; TOPICAL

TRETINOIN

AB1	MATAWAN PHARMS	0.05%	A075265	001	Dec 24, 1998
------------	----------------	--------------	----------------	------------	--------------

RENOVA

AB2	+ VALEANT INTL	0.05%	N019963	001	Dec 29, 1995
------------	----------------	--------------	----------------	------------	--------------

TRETINOIN

AB2	SUNEVA MEDCL	0.05%	A076498	001	Sep 15, 2005
------------	--------------	--------------	----------------	------------	--------------

RENOVA

	+ VALEANT INTL	0.02%	N021108	001	Aug 31, 2000
--	----------------	-------	---------	-----	--------------

TRETINOIN

	+ WATSON LABS INC	0.0375%	A090098	001	Mar 22, 2010
--	-------------------	---------	---------	-----	--------------

0.075%

A202209 001 Oct 11, 2012

GEL; TOPICAL

RETIN-A

AB	+ VALEANT INTL	0.01%	N017955	001	
-----------	----------------	--------------	----------------	------------	--

AB	+	0.025%	N017579	002	
-----------	---	---------------	----------------	------------	--

RETIN-A MICRO

AB	+ VALEANT INTL	0.04%	N020475	002	May 10, 2002
-----------	----------------	--------------	----------------	------------	--------------

AB	+	0.1%	N020475	001	Feb 07, 1997
-----------	---	-------------	----------------	------------	--------------

TRETINOIN

AB	MATAWAN PHARMS	0.01%	A075589	001	Jun 11, 2002
-----------	----------------	--------------	----------------	------------	--------------

AB		0.025%	A075529	001	Feb 22, 2000
-----------	--	---------------	----------------	------------	--------------

AB	SPEAR PHARMS INC	0.04%	A202567	001	Jul 17, 2013
-----------	------------------	--------------	----------------	------------	--------------

AB		0.1%	A202026	001	Jul 17, 2013
-----------	--	-------------	----------------	------------	--------------

AVITA

BT	MYLAN	0.025%	N020400	001	Jan 29, 1998
----	-------	--------	---------	-----	--------------

ATRALIN

	+ DOW PHARM	0.05%	N022070	001	Jul 26, 2007
--	-------------	-------	---------	-----	--------------

RETIN-A-MICRO

	+ VALEANT INTL	0.08%	N020475	003	Jan 28, 2014
--	----------------	-------	---------	-----	--------------

SOLUTION; TOPICAL

RETIN-A

	+ VALEANT INTL	0.05%	N016921	001	
--	----------------	-------	---------	-----	--

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	+ FOUGERA PHARMS	0.025%	A085692	001	
-----------	------------------	---------------	----------------	------------	--

AT	+	0.1%	A085692	003	
-----------	---	-------------	----------------	------------	--

AT	+	0.5%	A085692	002	
-----------	---	-------------	----------------	------------	--

AT	PERRIGO NEW YORK	0.025%	A086415	001	
-----------	------------------	---------------	----------------	------------	--

AT		0.1%	A086414	001	
-----------	--	-------------	----------------	------------	--

AT		0.5%	A086413	001	
-----------	--	-------------	----------------	------------	--

AT	TARO	0.1%	A040039	001	Nov 26, 1997
-----------	------	-------------	----------------	------------	--------------

AT	VINTAGE	0.025%	A040671	001	Jun 09, 2006
-----------	---------	---------------	----------------	------------	--------------

AT		0.1%	A040671	002	Jun 09, 2006
-----------	--	-------------	----------------	------------	--------------

TRIDERM

AT	CROWN LABS	0.1%	A088042	001	Mar 19, 1984
-----------	------------	-------------	----------------	------------	--------------

INJECTABLE; INJECTION

KENALOG-10

	APOTHECON	10MG/ML	N012041	001	
--	-----------	---------	---------	-----	--

KENALOG-40

	+ APOTHECON	40MG/ML	N014901	001	
--	-------------	---------	---------	-----	--

INJECTABLE; INTRAVITREAL

TRIESENCE

	+ ALCON	40MG/ML (40MG/ML)	N022048	001	Nov 29, 2007
--	---------	-------------------	---------	-----	--------------

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003
-----------	----------------	---------------	----------------	------------	--------------

AT		0.1%	A040467	002	Apr 21, 2003
-----------	--	-------------	----------------	------------	--------------

AT	VERSAPHARM INC	0.025%	A202374	001	May 08, 2013
-----------	----------------	---------------	----------------	------------	--------------

AT		0.1%	A202374	002	May 08, 2013
-----------	--	-------------	----------------	------------	--------------

AT	VINTAGE	0.1%	A040672	002	Dec 13, 2006
-----------	---------	-------------	----------------	------------	--------------

AT	+ WOCKHARDT	0.1%	A088451	001	Apr 03, 1985
-----------	-------------	-------------	----------------	------------	--------------

AT	+ WOCKHARDT EU OPERATN	0.025%	A088450	001	Apr 01, 1985
-----------	------------------------	---------------	----------------	------------	--------------

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691	001	
-----------	----------------	---------------	----------------	------------	--

AT		0.1%	A085691	003	
-----------	--	-------------	----------------	------------	--

AT		0.5%	A085691	002	
-----------	--	-------------	----------------	------------	--

AT	+ PERRIGO NEW YORK	0.025%	A087356	001	
-----------	--------------------	---------------	----------------	------------	--

AT	+	0.1%	A087357	001	
-----------	---	-------------	----------------	------------	--

PRESCRIPTION DRUG PRODUCT LIST

3-356 (of 371)

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	+	0.5%	A087385	001	
AT	TARO	0.1%	A040037	001	Sep 30, 1994
	TRIAMCINOLONE ACETONIDE IN ABSORBASE				
	+ CAROLINA MEDCL	0.05%	A089595	001	Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

AT	LYNE	0.1%	A040771	001	Jul 01, 2010
AT	+	0.1%	A070730	001	Oct 01, 1986
	SPRAY; TOPICAL				
	KENALOG				
	+ RANBAXY	0.147MG/GM	N012104	001	
	SPRAY, METERED; NASAL				
	TRIAMCINOLONE ACETONIDE				
	TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+	SANDOZ	5MG/ML	N016466	001	
+		20MG/ML	N016466	002	

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

	COVIS PHARMA SARL	50MG	N013174	001	
+		100MG	N013174	002	

TRIAZOLAM

TABLET; ORAL

HALCION

AB	PHARMACIA AND UPJOHN	0.125MG	N017892	003	Apr 26, 1985
AB	+	0.25MG	N017892	001	Nov 15, 1982
	<u>TRIAZOLAM</u>				
AB	MYLAN PHARMS INC	0.125MG	A074031	001	Mar 25, 1994
AB		0.25MG	A074031	002	Mar 25, 1994
AB	ROXANE	0.125MG	A074224	001	Jun 01, 1994
AB		0.25MG	A074224	002	Jun 01, 1994

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

+	ATON	250MG	N019194	001	Nov 08, 1985
---	------	-------	---------	-----	--------------

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB	MYLAN	EQ 1MG BASE	A040209	001	Jul 07, 1997
AB		EQ 2MG BASE	A040209	002	Jul 07, 1997
AB		EQ 5MG BASE	A040209	003	Jul 07, 1997
AB	+	EQ 10MG BASE	A040209	004	Jul 07, 1997
AB	SANDOZ	EQ 1MG BASE	A085785	001	
AB		EQ 2MG BASE	A085786	001	
AB		EQ 5MG BASE	A085789	001	
AB		EQ 10MG BASE	A085788	001	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT	ALCON PHARMS LTD	1%	A074311	001	Oct 06, 1995
	<u>VIROPTIC</u>				
AT	+	1%	N018299	001	

TRIHXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

AA	MIKART	2MG/5ML	A040251	001	Sep 27, 1999
AA	+	2MG/5ML	A040177	001	Apr 17, 1997
	TABLET; ORAL				

TRIHXYPHENIDYL HYDROCHLORIDE

AA	NATCO PHARMA LTD	2MG	A091630	001	Nov 17, 2010
AA		5MG	A091630	002	Nov 17, 2010
AA	VINTAGE PHARMS	2MG	A040254	001	Dec 24, 1998
AA		5MG	A040254	002	Dec 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-357 (of 371)

TRIHXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHXYPHENIDYL HYDROCHLORIDE

<u>AA</u>	+	WATSON LABS	<u>2MG</u>	<u>A084363</u>	<u>001</u>	
<u>AA</u>	+		<u>5MG</u>	<u>A084364</u>	<u>001</u>	

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

+	ABBVIE	150MG		N005856	009	
---	--------	-------	--	---------	-----	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

<u>AB</u>	+	KING PHARMS	<u>300MG</u>	<u>N017531</u>	<u>006</u>	Dec 13, 2001
-----------	---	-------------	--------------	----------------	------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

<u>AB</u>		GAVIS PHARMS	<u>300MG</u>	<u>A076546</u>	<u>001</u>	Aug 20, 2003
<u>AB</u>		MUTUAL PHARMA	<u>300MG</u>	<u>A076570</u>	<u>001</u>	Aug 28, 2003

INJECTABLE; INJECTION

TIGAN

<u>AP</u>	+	PAR STERILE PRODUCTS	<u>100MG/ML</u>	<u>N017530</u>	<u>001</u>	
-----------	---	----------------------	-----------------	----------------	------------	--

TRIMETHOBENZAMIDE HYDROCHLORIDE

<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A091330</u>	<u>001</u>	Mar 08, 2011
-----------	--	----------	-----------------	----------------	------------	--------------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		LUITPOLD	<u>100MG/ML</u>	<u>A091329</u>	<u>001</u>	Mar 08, 2011
-----------	--	----------	-----------------	----------------	------------	--------------

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

<u>AB</u>		NOVEL LABS INC	<u>100MG</u>	<u>A091437</u>	<u>001</u>	Jun 15, 2011
<u>AB</u>	+	TEVA	<u>100MG</u>	<u>N018679</u>	<u>001</u>	Jul 30, 1982
<u>AB</u>		WATSON LABS	<u>100MG</u>	<u>A070049</u>	<u>001</u>	Jun 06, 1985

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

+	FSC	EQ 50MG BASE/5ML		N074973	001	Jan 24, 2000
---	-----	------------------	--	---------	-----	--------------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

<u>AB</u>		ODYSSEY PHARMS	<u>EQ 25MG BASE</u>	<u>N016792</u>	<u>001</u>	
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>N016792</u>	<u>002</u>	
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N016792</u>	<u>003</u>	Sep 15, 1982

TRIMIPRAMINE MALEATE

<u>AB</u>		MIKAH PHARMA	<u>EQ 25MG BASE</u>	<u>A077361</u>	<u>001</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077361</u>	<u>002</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077361</u>	<u>003</u>	Aug 02, 2006

TRIPTORELIN PAMOATE

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+	WATSON LABS	EQ 3.75MG BASE/VIAL		N020715	001	Jun 15, 2000
+		EQ 11.25MG BASE/VIAL		N021288	001	Jun 29, 2001
+		EQ 22.5MG BASE/VIAL		N022437	001	Mar 10, 2010

TROMETHAMINE

INJECTABLE; INJECTION

THAM

+	HOSPIRA	3.6GM/100ML		N013025	002	
---	---------	-------------	--	---------	-----	--

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

<u>AT</u>	+	ALCON	<u>0.5%</u>	<u>A084305</u>	<u>001</u>	
<u>AT</u>	+		<u>1%</u>	<u>A084306</u>	<u>001</u>	

TROPICACYL

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A040314</u>	<u>001</u>	Sep 29, 2000
<u>AT</u>			<u>1%</u>	<u>A040315</u>	<u>001</u>	Sep 29, 2000

TROPICAMIDE

<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040067</u>	<u>001</u>	Jul 27, 1994
<u>AT</u>			<u>1%</u>	<u>A040064</u>	<u>001</u>	Jul 27, 1994

PRESCRIPTION DRUG PRODUCT LIST

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

AB	+	ALLERGAN	60MG	<u>N022103</u>	<u>001</u>	Aug 03, 2007
-----------	----------	-----------------	-------------	-----------------------	-------------------	--------------

TROSPIUM CHLORIDE

AB		ACTAVIS LABS FL INC	60MG	<u>A091289</u>	<u>001</u>	Oct 12, 2012
-----------	--	---------------------	-------------	-----------------------	-------------------	--------------

AB		PADDOCK LLC	60MG	<u>A201291</u>	<u>001</u>	May 24, 2013
-----------	--	-------------	-------------	-----------------------	-------------------	--------------

TABLET; ORAL

SANCTURA

AB	+	ALLERGAN	20MG	<u>N021595</u>	<u>001</u>	May 28, 2004
-----------	----------	-----------------	-------------	-----------------------	-------------------	--------------

TROSPIUM CHLORIDE

AB		APOTEX	20MG	<u>A091513</u>	<u>001</u>	Dec 06, 2011
-----------	--	--------	-------------	-----------------------	-------------------	--------------

AB		GLENMARK GENERICS	20MG	<u>A091575</u>	<u>001</u>	Aug 13, 2010
-----------	--	-------------------	-------------	-----------------------	-------------------	--------------

AB		PADDOCK LLC	20MG	<u>A091573</u>	<u>001</u>	Nov 17, 2010
-----------	--	-------------	-------------	-----------------------	-------------------	--------------

TRYPAN BLUE

SOLUTION; OPHTHALMIC

MEMBRANE BLUE

+	DORC	0.15%	N022278	001	Feb 20, 2009
----------	-------------	--------------	----------------	------------	--------------

VISION BLUE

+	DORC	0.06%	N021670	001	Dec 16, 2004
----------	-------------	--------------	----------------	------------	--------------

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA

+	LAB HRA PHARMA	30MG	N022474	001	Aug 13, 2010
----------	-----------------------	-------------	----------------	------------	--------------

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+	GLAXO GRP ENGLAND	EQ 62.5MCG BASE/INH	N205382	001	Apr 30, 2014
----------	--------------------------	----------------------------	----------------	------------	--------------

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013
----------	------------------------	--	----------------	------------	--------------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC

RESCULA

+	SUCAMPO PHARMS	0.15%	N021214	001	Aug 03, 2000
----------	-----------------------	--------------	----------------	------------	--------------

UREA, C-14

CAPSULE; ORAL

PYTEST

+	AVENT	1uCi	N020617	001	May 09, 1997
----------	--------------	-------------	----------------	------------	--------------

PYTEST KIT

+	AVENT	1uCi	N020617	002	May 09, 1997
----------	--------------	-------------	----------------	------------	--------------

UROFOLLITROPIN

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

BRAVELLE

+	FERRING	75 IU/VIAL	N021289	001	May 06, 2002
----------	----------------	-------------------	----------------	------------	--------------

URSODIOL

CAPSULE; ORAL

ACTIGALL

AB	+	WATSON PHARMS	300MG	<u>N019594</u>	<u>002</u>	Dec 31, 1987
-----------	----------	----------------------	--------------	-----------------------	-------------------	--------------

URSODIOL

AB		COREPHARMA	300MG	<u>A077895</u>	<u>001</u>	Jul 27, 2006
-----------	--	------------	--------------	-----------------------	-------------------	--------------

AB		EPIC PHARMA	300MG	<u>A075517</u>	<u>001</u>	Mar 14, 2000
-----------	--	-------------	--------------	-----------------------	-------------------	--------------

AB		LANNETT	300MG	<u>A079082</u>	<u>001</u>	Dec 15, 2008
-----------	--	---------	--------------	-----------------------	-------------------	--------------

AB		MYLAN	300MG	<u>A090530</u>	<u>001</u>	Feb 17, 2010
-----------	--	-------	--------------	-----------------------	-------------------	--------------

AB		TEVA PHARMS	300MG	<u>A075592</u>	<u>001</u>	May 25, 2000
-----------	--	-------------	--------------	-----------------------	-------------------	--------------

TABLET; ORAL

URSO 250

AB		FOREST LABS INC	250MG	<u>N020675</u>	<u>001</u>	Dec 10, 1997
-----------	--	-----------------	--------------	-----------------------	-------------------	--------------

URSO FORTE

AB	+	FOREST LABS INC	500MG	<u>N020675</u>	<u>002</u>	Jul 21, 2004
-----------	----------	------------------------	--------------	-----------------------	-------------------	--------------

URSODIOL

AB		GLENMARK GENERICS	250MG	<u>A090801</u>	<u>001</u>	Jul 12, 2011
-----------	--	-------------------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A090801</u>	<u>002</u>	Jul 12, 2011
-----------	--	--	--------------	-----------------------	-------------------	--------------

AB		IMPAX LABS INC	250MG	<u>A200826</u>	<u>001</u>	Dec 23, 2011
-----------	--	----------------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A200826</u>	<u>002</u>	Dec 23, 2011
-----------	--	--	--------------	-----------------------	-------------------	--------------

AB		PAR PHARM	250MG	<u>A202540</u>	<u>001</u>	Feb 14, 2013
-----------	--	-----------	--------------	-----------------------	-------------------	--------------

AB			500MG	<u>A202540</u>	<u>002</u>	Feb 14, 2013
-----------	--	--	--------------	-----------------------	-------------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-359 (of 371)

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>EQ 1GM BASE</u>	<u>A090500</u>	<u>002</u>	Apr 04, 2014
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090500</u>	<u>001</u>	Apr 04, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 1GM BASE</u>	<u>A090682</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090682</u>	<u>001</u>	May 24, 2010
<u>AB</u>	CIPLA LTD	<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 1GM BASE</u>	<u>A079012</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A079012</u>	<u>001</u>	May 24, 2010
<u>AB</u>	JUBILANT GENERICS	<u>EQ 1GM BASE</u>	<u>A201506</u>	<u>002</u>	Apr 03, 2012
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A201506</u>	<u>001</u>	Apr 03, 2012
<u>AB</u>	MYLAN	<u>EQ 1GM BASE</u>	<u>A078070</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078070</u>	<u>001</u>	May 24, 2010
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 1GM BASE</u>	<u>A078518</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078518</u>	<u>001</u>	May 24, 2010
<u>AB</u>	RANBAXY	<u>EQ 1GM BASE</u>	<u>A076588</u>	<u>002</u>	Jan 31, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A076588</u>	<u>001</u>	Jan 31, 2007
<u>AB</u>	ROXANE	<u>EQ 1GM BASE</u>	<u>A078656</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078656</u>	<u>001</u>	May 24, 2010
<u>AB</u>	SANDOZ	<u>EQ 1GM BASE</u>	<u>A077478</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
<u>AB</u>	TEVA PHARMS	<u>EQ 1GM BASE</u>	<u>A077655</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A077655</u>	<u>001</u>	May 24, 2010
<u>AB</u>	WATSON LABS INC	<u>EQ 1GM BASE</u>	<u>A090370</u>	<u>002</u>	Mar 16, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090370</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010
<u>VALTREX</u>					
<u>AB</u>	+ GLAXOSMITHKLINE	<u>EQ 1GM BASE</u>	<u>N020487</u>	<u>002</u>	Jun 23, 1995
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>N020487</u>	<u>001</u>	Jun 23, 1995

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+ HOFFMANN LA ROCHE 50MG/ML

N022257 001 Aug 28, 2009

TABLET; ORAL

VALCYTE

<u>AB</u>	+ HOFFMANN LA ROCHE	<u>EQ 450MG BASE</u>	<u>N021304</u>	<u>001</u>	Mar 29, 2001
-----------	---------------------	----------------------	----------------	------------	--------------

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 450MG BASE</u>	<u>A203511</u>	<u>001</u>	Nov 04, 2014
<u>AB</u>	ENDO PHARMS INC	<u>EQ 450MG BASE</u>	<u>A200790</u>	<u>001</u>	Nov 04, 2014

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPAACON

<u>AP</u>	+ ABBVIE	<u>EQ 100MG BASE/ML</u>	<u>N020593</u>	<u>001</u>	Dec 30, 1996
-----------	----------	-------------------------	----------------	------------	--------------

VALPROATE SODIUM

<u>AP</u>	BEDFORD	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

DEPAKENE

<u>AB</u>	+ ABBVIE	<u>250MG</u>	<u>N018081</u>	<u>001</u>	
-----------	----------	--------------	----------------	------------	--

VALPROIC ACID

<u>AB</u>	BANNER PHARMACAPS	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>	CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
<u>AB</u>	SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037</u>	<u>001</u>	Feb 22, 2013

SYRUP; ORAL

DEPAKENE

<u>AA</u>	+ ABBVIE	<u>250MG/5ML</u>	<u>N018082</u>	<u>001</u>	
-----------	----------	------------------	----------------	------------	--

VALPROIC ACID

<u>AA</u>	ALPHARMA	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>	ANI PHARMS INC	<u>250MG/5ML</u>	<u>A073178</u>	<u>001</u>	Aug 25, 1992
<u>AA</u>	HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>	PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000
<u>AA</u>	SUN PHARM INDS INC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>	VINTAGE	<u>250MG/5ML</u>	<u>A077960</u>	<u>001</u>	Oct 13, 2006
<u>AA</u>	WOCKHARDT	<u>250MG/5ML</u>	<u>A070868</u>	<u>001</u>	Jul 01, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-360 (of 371)

VALRUBICIN

SOLUTION;INTRAVESICAL

VALSTAR PRESERVATIVE FREE

+ ENDO PHARM

40MG/ML

N020892 001 Sep 25, 1998

VALSARTAN

TABLET;ORAL

DIOVANAB NOVARTIS40MGN021283 004 Aug 14, 2002AB80MGN021283 001 Jul 18, 2001AB160MGN021283 002 Jul 18, 2001AB

+

320MGN021283 003 Jul 18, 2001VALSARTANAB ALEMBIC PHARMS LTD40MGA091367 001 Jan 05, 2015AB80MGA091367 002 Jan 05, 2015AB160MGA091367 003 Jan 05, 2015AB320MGA091367 004 Jan 05, 2015AB AUROBINDO PHARMA LTD40MGA202223 001 Jan 05, 2015AB80MGA202223 002 Jan 05, 2015AB160MGA202223 003 Jan 05, 2015AB320MGA202223 004 Jan 05, 2015AB HETERO LABS LTD V40MGA203311 001 Jan 05, 2015AB80MGA203311 002 Jan 05, 2015AB160MGA203311 003 Jan 05, 2015AB320MGA203311 004 Jan 05, 2015AB IVAX PHARMS40MGA077530 001 Jan 05, 2015AB80MGA077530 002 Jan 05, 2015AB160MGA077530 003 Jan 05, 2015AB320MGA077530 004 Jan 05, 2015AB JUBILANT GENERICS40MGA203536 001 Jan 05, 2015AB80MGA203536 002 Jan 05, 2015AB160MGA203536 003 Jan 05, 2015AB320MGA203536 004 Jan 05, 2015AB LUPIN LTD40MGA201677 001 Jan 05, 2015AB80MGA201677 002 Jan 05, 2015AB160MGA201677 003 Jan 05, 2015AB320MGA201677 004 Jan 05, 2015AB MYLAN LABS LTD40MGA090866 001 Jan 05, 2015AB80MGA090866 002 Jan 05, 2015AB160MGA090866 003 Jan 05, 2015AB320MGA090866 004 Jan 05, 2015AB OHM LABS INC40MGA077492 001 Jun 26, 2014AB80MGA077492 002 Jun 26, 2014AB160MGA077492 003 Jun 26, 2014AB320MGA077492 004 Jun 26, 2014AB TORRENT PHARMS LTD40MGA202728 001 Jan 05, 2015AB80MGA202728 002 Jan 05, 2015AB160MGA202728 003 Jan 05, 2015AB320MGA202728 004 Jan 05, 2015AB WATSON LABS INC40MGA090642 001 Jan 05, 2015AB80MGA090642 002 Jan 05, 2015AB160MGA090642 003 Jan 05, 2015AB320MGA090642 004 Jan 05, 2015VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOCIN HYDROCHLORIDEAB ANI PHARMS INCEQ 125MG BASEN050606 001 Apr 15, 1986AB

+

EQ 250MG BASEN050606 002 Apr 15, 1986VANCOMYCIN HYDROCHLORIDEAB AKORNEQ 125MG BASEA065478 001 Apr 09, 2012ABEQ 250MG BASEA065478 002 Apr 09, 2012AB FRESENIUS KABI USAEQ 125MG BASEA065453 001 Jun 18, 2012ABEQ 250MG BASEA065453 002 Jun 18, 2012AB STRIDES PHARMAEQ 125MG BASEA065490 001 Apr 09, 2012ABEQ 250MG BASEA065490 002 Apr 09, 2012AB WATSON LABSEQ 125MG BASEA065510 001 Apr 09, 2012ABEQ 250MG BASEA065510 002 Apr 09, 2012

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDEAP AGILA SPECLTSEQ 1GM BASE/VIALA065397 002 Dec 30, 2008APEQ 5GM BASE/VIALA065432 001 Dec 30, 2008APEQ 10GM BASE/VIALA091469 001 Jul 01, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-361 (of 371)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A202275</u>	<u>002</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A202464</u>	<u>001</u>	Oct 09, 2013
<u>AP</u>		<u>EQ 5GM BASE/VIAL</u>	<u>A202274</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A202275</u>	<u>001</u>	Oct 31, 2013
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	+	<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
<u>AP</u>	+	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
<u>AP</u>	+	<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
<u>AP</u>	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
<u>AP</u>	MUSTAFA NEVZAT ILAC	<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
<u>AP</u>	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A200837</u>	<u>002</u>	Sep 02, 2014
<u>AP</u>	SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A090250</u>	<u>002</u>	Apr 27, 2010
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090250</u>	<u>001</u>	Apr 27, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048</u>	<u>001</u>	Aug 10, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A201048</u>	<u>002</u>	Aug 10, 2012
	VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER				
	+	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
	+	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010

VANDETANIB

TABLET; ORAL

CAPRELSA

IPR PHARMS INC

+

100MG

300MG

N022405 001 Apr 06, 2011

N022405 002 Apr 06, 2011

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

<u>AB</u>	BAYER HLTHCARE	<u>2.5MG</u>	<u>N021400</u>	<u>003</u>	Aug 19, 2003
<u>AB</u>		<u>5MG</u>	<u>N021400</u>	<u>001</u>	Aug 19, 2003
<u>AB</u>		<u>10MG</u>	<u>N021400</u>	<u>002</u>	Aug 19, 2003
<u>AB</u>	+	<u>20MG</u>	<u>N021400</u>	<u>004</u>	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

<u>AB</u>	TEVA PHARMS	<u>2.5MG</u>	<u>A091347</u>	<u>001</u>	May 03, 2012
<u>AB</u>		<u>5MG</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
<u>AB</u>		<u>10MG</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
<u>AB</u>		<u>20MG</u>	<u>A091347</u>	<u>004</u>	May 03, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

+ BAYER HLTHCARE | 10MG | N200179 | 001 | Jun 17, 2010 |VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

PFIZER INC

+

EQ 0.5MG BASE

EQ 1MG BASE

N021928 001 May 10, 2006

N021928 002 May 10, 2006

VASOPRESSIN

SOLUTION; IV (INFUSION)

VASOSTRICT

+ PAR STERILE PRODUCTS | 20UNITS/ML (20UNITS/ML) | N204485 | 001 | Apr 17, 2014 |VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	AGILA SPECLTS	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
<u>AP</u>		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
<u>AP</u>	BEDFORD	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
<u>AP</u>	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-362 (of 371)

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	MUSTAFA NEVZAT	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>	+	<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>	TEVA PHARMS USA	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>		<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999

VELAGLUCERASE ALFA

INJECTABLE; IV (INFUSION)

VPRIV

	SHIRE HUMAN GENETIC	400 UNITS/VIAL	N022575	001	Feb 26, 2010
--	---------------------	----------------	---------	-----	--------------

VEMURAFENIB

TABLET; ORAL

ZELBORAF

	+ HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011
--	---------------------	-------	---------	-----	--------------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	WYETH PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>N020699</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N020699</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N020699</u>	<u>004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 37.5MG BASE</u>	<u>A078087</u>	<u>001</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078087</u>	<u>002</u>	Mar 16, 2012
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078087</u>	<u>003</u>	Mar 16, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A200834</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A200834</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421</u>	<u>001</u>	May 06, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078421</u>	<u>002</u>	May 06, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078421</u>	<u>003</u>	May 06, 2011
<u>AB</u>	MYLAN	<u>EQ 37.5MG BASE</u>	<u>A078789</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078789</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078789</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	ORCHID HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A091123</u>	<u>001</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091123</u>	<u>002</u>	Jul 11, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091123</u>	<u>003</u>	Jul 11, 2011
<u>AB</u>	TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076565</u>	<u>002</u>	Jun 28, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A076565</u>	<u>003</u>	Jun 28, 2010
<u>AB</u>	TORRENT PHARMS LLC	<u>EQ 37.5MG BASE</u>	<u>A090899</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090899</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090899</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>	VALEANT BERMUDA	<u>EQ 37.5MG BASE</u>	<u>A090071</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090071</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090071</u>	<u>003</u>	Apr 15, 2011
<u>AB</u>	WOCKHARDT	<u>EQ 37.5MG BASE</u>	<u>A078865</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078865</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A078865</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090174</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090174</u>	<u>003</u>	Apr 14, 2011

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932</u>	<u>005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098</u>	<u>001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098</u>	<u>002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098</u>	<u>003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098</u>	<u>004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098</u>	<u>005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555</u>	<u>004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555</u>	<u>005</u>	Apr 07, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-363 (of 371)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301 005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS INC	<u>EQ 25MG BASE</u>	<u>A078554 001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554 002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554 003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554 004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554 005</u>	Jan 09, 2009
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A077166 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077166 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077166 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077166 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077166 005</u>	Jun 13, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627 005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690 001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690 002</u>	Aug 03, 2006
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>A076690 003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690 004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690 005</u>	Aug 03, 2006
<u>AB</u>	VINTAGE	<u>EQ 25MG BASE</u>	<u>A090027 001</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090027 002</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090027 003</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090027 004</u>	Aug 04, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090027 005</u>	Aug 04, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653 001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653 002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653 003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653 004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653 005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	OSMOTICA PHARM	<u>EQ 37.5MG BASE</u>	<u>N022104 001</u>	May 20, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>N022104 002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104 003</u>	May 20, 2008
<u>AB</u>	SUN PHARMA GLOBAL	<u>EQ 37.5MG BASE</u>	<u>A091272 001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272 002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272 003</u>	Aug 18, 2010
	OSMOTICA PHARM	EQ 225MG BASE	N022104 004	May 20, 2008

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	MYLAN	<u>100MG</u>	<u>A078306 001</u>	Aug 09, 2007
<u>AB</u>		<u>120MG</u>	<u>A075138 001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138 002</u>	Apr 20, 1999
<u>AB</u>		<u>200MG</u>	<u>A078306 002</u>	Aug 09, 2007
<u>AB</u>		<u>240MG</u>	<u>A075138 003</u>	Apr 20, 1999
<u>AB</u>		<u>300MG</u>	<u>A078306 003</u>	Aug 09, 2007

VERELAN

<u>AB</u>	ALKERMES GAINESVILLE	<u>120MG</u>	<u>N019614 001</u>	May 29, 1990
<u>AB</u>		<u>180MG</u>	<u>N019614 003</u>	Jan 09, 1992
<u>AB</u>		<u>240MG</u>	<u>N019614 002</u>	May 29, 1990

VERELAN PM

<u>AB</u>	ALKERMES GAINESVILLE	<u>100MG</u>	<u>N020943 001</u>	Nov 25, 1998
<u>AB</u>		<u>200MG</u>	<u>N020943 002</u>	Nov 25, 1998
<u>AB</u>	+	<u>300MG</u>	<u>N020943 003</u>	Nov 25, 1998

VERELAN

+	ALKERMES GAINESVILLE	360MG	N019614 004	May 10, 1996
---	----------------------	-------	-------------	--------------

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>	+	<u>HOSPIRA</u>	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070738 001</u>	May 06, 1987
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136 001</u>	Oct 20, 1998
<u>AP</u>	+		<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737 001</u>	May 06, 1987
<u>AP</u>	+		<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737 002</u>	May 06, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-364 (of 371)

VERAPAMIL HYDROCHLORIDE

TABLET; ORAL

CALAN

<u>AB</u>	GD SEARLE LLC	<u>40MG</u>	<u>N018817</u>	<u>003</u>	Feb 23, 1988
<u>AB</u>		<u>80MG</u>	<u>N018817</u>	<u>001</u>	Sep 10, 1984
<u>AB</u>	+	<u>120MG</u>	<u>N018817</u>	<u>002</u>	Sep 10, 1984

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	HERITAGE PHARMS INC	<u>80MG</u>	<u>A071880</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>120MG</u>	<u>A071881</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	MYLAN	<u>80MG</u>	<u>A071483</u>	<u>002</u>	Feb 15, 1989
<u>AB</u>		<u>120MG</u>	<u>A071483</u>	<u>001</u>	Feb 15, 1989
<u>AB</u>	WATSON LABS	<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

<u>AB</u>	+	PFIZER	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
<u>AB</u>	+		<u>180MG</u>	<u>N019152</u>	<u>002</u>	Dec 15, 1989
<u>AB</u>	+		<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>	APOTEX CORP	<u>120MG</u>	<u>A200878</u>	<u>001</u>	Apr 20, 2012
<u>AB</u>		<u>180MG</u>	<u>A200878</u>	<u>002</u>	Apr 20, 2012
<u>AB</u>		<u>240MG</u>	<u>A200878</u>	<u>003</u>	Apr 20, 2012
<u>AB</u>	GLENMARK GENERICS	<u>120MG</u>	<u>A090700</u>	<u>001</u>	Aug 03, 2011
<u>AB</u>		<u>180MG</u>	<u>A090700</u>	<u>002</u>	Aug 03, 2011
<u>AB</u>		<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
<u>AB</u>		<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
<u>AB</u>		<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>	MYLAN	<u>120MG</u>	<u>A074587</u>	<u>002</u>	Feb 21, 1997
<u>AB</u>		<u>180MG</u>	<u>A074587</u>	<u>003</u>	Sep 09, 1997
<u>AB</u>		<u>240MG</u>	<u>A074587</u>	<u>001</u>	Mar 23, 1996
<u>AB</u>	PAR PHARM	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
<u>AB</u>		<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
<u>AB</u>	SUN PHARM INDS INC	<u>120MG</u>	<u>A090529</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>180MG</u>	<u>A090529</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>240MG</u>	<u>A090529</u>	<u>003</u>	Dec 30, 2011

COVERA-HS

BC	+	GD SEARLE LLC	180MG	N020552	001	Feb 26, 1996
BC	+		240MG	N020552	002	Feb 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

VISUDYNE

+	VALEANT PHARMS INC	15MG/VIAL	N021119	001	Apr 12, 2000
---	--------------------	-----------	---------	-----	--------------

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006	001	Aug 21, 2009
---	--------------	--------------	---------	-----	--------------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009
---	--------------	-------	---------	-----	--------------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567	001	Jan 21, 2011
		20MG	N022567	002	Jan 21, 2011
		40MG	N022567	003	Jan 21, 2011

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

+	EUROHLTH INTL	10MG/VIAL	A089395	001	Apr 09, 1987
+	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE PFS

<u>AP</u>	+	HOSPIRA	<u>1MG/ML</u>	<u>A071484</u>	<u>001</u>	Apr 19, 1988
<u>AP</u>		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A075493</u>	<u>001</u>	Sep 01, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-365 (of 371)

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ TALON THERAP

5MG/5ML (1MG/ML)

N202497 001 Aug 09, 2012

VINORELBINE

INJECTABLE; INJECTION

VINORELBINEAP ONCO THERAPIES LTDEQ 10MG BASE/MLA200148 001 Aug 31, 2012VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINEAP + PIERRE FABREEQ 10MG BASE/MLN020388 001 Dec 23, 1994VINORELBINE TARTRATEAP ACTAVIS TOTOWAEQ 10MG BASE/MLA078011 001 Jul 22, 2009AP BEDFORDEQ 10MG BASE/MLA076461 001 Dec 11, 2003AP DR REDDYS LABS LTDEQ 10MG BASE/MLA202017 001 Sep 12, 2013AP FRESENIUS KABI USAEQ 10MG BASE/MLA076849 001 Apr 18, 2005AP HIKMA MAPLEEQ 10MG BASE/MLA075992 001 Jun 10, 2003AP HOSPIRAEQ 10MG BASE/MLA076827 001 Jun 02, 2005AP JIANGSU HANSOH PHARMEQ 10MG BASE/MLA091106 001 Sep 26, 2012AP TEVA PHARMS USAEQ 10MG BASE/MLA076028 001 Feb 03, 2003VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+ GENENTECH

150MG

N203388 001 Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+ HOSPIRA

EQ 50,000 UNITS BASE/ML

N006823 001

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+ MERCK SHARP DOHME

EQ 2.08MG BASE

N204886 001 May 08, 2014

VORICONAZOLE

FOR SUSPENSION; ORAL

VFENDAB + PF PRISM CV200MG/5MLN021630 001 Dec 19, 2003VORICONAZOLEAB MYLAN PHARMS INC200MG/5MLA202361 001 May 28, 2013

INJECTABLE; IV (INFUSION)

VFENDAP + PF PRISM CV200MG/VIALN021267 001 May 24, 2002VORICONAZOLEAP SANDOZ INC200MG/VIALA090862 001 May 30, 2012

TABLET; ORAL

VFENDAB PF PRISM CV50MGN021266 001 May 24, 2002AB +200MGN021266 002 May 24, 2002VORICONAZOLEAB MYLAN PHARMS INC50MGA090547 001 Apr 22, 2010AB200MGA090547 002 Apr 22, 2010AB SANDOZ INC50MGA200265 001 Dec 12, 2011AB200MGA200265 002 Dec 12, 2011AB TEVA PHARMS50MGA091658 001 Apr 06, 2012AB200MGA091658 002 Apr 06, 2012VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+ MERCK

100MG

N021991 001 Oct 06, 2006

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

BRINTELLIX

TAKEDA PHARMS USA

EQ 5MG BASE

N204447 001 Sep 30, 2013

EQ 10MG BASE

N204447 002 Sep 30, 2013

EQ 15MG BASE

N204447 003 Sep 30, 2013

+

EQ 20MG BASE

N204447 004 Sep 30, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-366 (of 371)

WARFARIN SODIUM

TABLET; ORAL

COUMADIN

<u>AB</u>	BRISTOL MYERS SQUIBB	<u>1MG</u>	<u>N009218</u>	<u>022</u>	Mar 01, 1990
<u>AB</u>		<u>2MG</u>	<u>N009218</u>	<u>013</u>	
<u>AB</u>		<u>2.5MG</u>	<u>N009218</u>	<u>018</u>	
<u>AB</u>		<u>3MG</u>	<u>N009218</u>	<u>025</u>	Nov 18, 1996
<u>AB</u>		<u>4MG</u>	<u>N009218</u>	<u>023</u>	Aug 24, 1993
<u>AB</u>		<u>5MG</u>	<u>N009218</u>	<u>007</u>	
<u>AB</u>		<u>6MG</u>	<u>N009218</u>	<u>026</u>	Nov 18, 1996
<u>AB</u>		<u>7.5MG</u>	<u>N009218</u>	<u>016</u>	
<u>AB</u>	+	<u>10MG</u>	<u>N009218</u>	<u>005</u>	

JANTOVEN

<u>AB</u>	USL PHARMA	<u>1MG</u>	<u>A040416</u>	<u>001</u>	Oct 02, 2003
<u>AB</u>		<u>2MG</u>	<u>A040416</u>	<u>002</u>	Oct 02, 2003
<u>AB</u>		<u>2.5MG</u>	<u>A040416</u>	<u>003</u>	Oct 02, 2003
<u>AB</u>		<u>3MG</u>	<u>A040416</u>	<u>004</u>	Oct 02, 2003
<u>AB</u>		<u>4MG</u>	<u>A040416</u>	<u>005</u>	Oct 02, 2003
<u>AB</u>		<u>5MG</u>	<u>A040416</u>	<u>006</u>	Oct 02, 2003
<u>AB</u>		<u>6MG</u>	<u>A040416</u>	<u>007</u>	Oct 02, 2003
<u>AB</u>		<u>7.5MG</u>	<u>A040416</u>	<u>008</u>	Oct 02, 2003
<u>AB</u>		<u>10MG</u>	<u>A040416</u>	<u>009</u>	Oct 02, 2003

WARFARIN SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>1MG</u>	<u>A202202</u>	<u>001</u>	Mar 04, 2013
<u>AB</u>		<u>2MG</u>	<u>A202202</u>	<u>002</u>	Mar 04, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A202202</u>	<u>003</u>	Mar 04, 2013
<u>AB</u>		<u>3MG</u>	<u>A202202</u>	<u>004</u>	Mar 04, 2013
<u>AB</u>		<u>4MG</u>	<u>A202202</u>	<u>005</u>	Mar 04, 2013
<u>AB</u>		<u>5MG</u>	<u>A202202</u>	<u>006</u>	Mar 04, 2013
<u>AB</u>		<u>6MG</u>	<u>A202202</u>	<u>007</u>	Mar 04, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A202202</u>	<u>008</u>	Mar 04, 2013
<u>AB</u>		<u>10MG</u>	<u>A202202</u>	<u>009</u>	Mar 04, 2013
<u>AB</u>	BARR	<u>1MG</u>	<u>A040145</u>	<u>001</u>	Mar 26, 1997
<u>AB</u>		<u>2MG</u>	<u>A040145</u>	<u>002</u>	Mar 26, 1997
<u>AB</u>		<u>2.5MG</u>	<u>A040145</u>	<u>003</u>	Mar 26, 1997
<u>AB</u>		<u>3MG</u>	<u>A040145</u>	<u>008</u>	Nov 05, 1998
<u>AB</u>		<u>4MG</u>	<u>A040145</u>	<u>004</u>	Mar 26, 1997
<u>AB</u>		<u>5MG</u>	<u>A040145</u>	<u>005</u>	Mar 26, 1997
<u>AB</u>		<u>6MG</u>	<u>A040145</u>	<u>009</u>	Nov 05, 1998
<u>AB</u>		<u>7.5MG</u>	<u>A040145</u>	<u>006</u>	Mar 26, 1997
<u>AB</u>		<u>10MG</u>	<u>A040145</u>	<u>007</u>	Mar 26, 1997
<u>AB</u>	INVAGEN PHARMS	<u>1MG</u>	<u>A090935</u>	<u>001</u>	May 25, 2011
<u>AB</u>		<u>2MG</u>	<u>A090935</u>	<u>002</u>	May 25, 2011
<u>AB</u>		<u>2.5MG</u>	<u>A090935</u>	<u>003</u>	May 25, 2011
<u>AB</u>		<u>3MG</u>	<u>A090935</u>	<u>004</u>	May 25, 2011
<u>AB</u>		<u>4MG</u>	<u>A090935</u>	<u>005</u>	May 25, 2011
<u>AB</u>		<u>5MG</u>	<u>A090935</u>	<u>006</u>	May 25, 2011
<u>AB</u>		<u>6MG</u>	<u>A090935</u>	<u>007</u>	May 25, 2011
<u>AB</u>		<u>7.5MG</u>	<u>A090935</u>	<u>008</u>	May 25, 2011
<u>AB</u>		<u>10MG</u>	<u>A090935</u>	<u>009</u>	May 25, 2011
<u>AB</u>	IPCA LABS LTD	<u>1MG</u>	<u>A200104</u>	<u>001</u>	Jun 27, 2013
<u>AB</u>		<u>2MG</u>	<u>A200104</u>	<u>002</u>	Jun 27, 2013
<u>AB</u>		<u>2.5MG</u>	<u>A200104</u>	<u>003</u>	Jun 27, 2013
<u>AB</u>		<u>3MG</u>	<u>A200104</u>	<u>004</u>	Jun 27, 2013
<u>AB</u>		<u>4MG</u>	<u>A200104</u>	<u>005</u>	Jun 27, 2013
<u>AB</u>		<u>5MG</u>	<u>A200104</u>	<u>006</u>	Jun 27, 2013
<u>AB</u>		<u>6MG</u>	<u>A200104</u>	<u>007</u>	Jun 27, 2013
<u>AB</u>		<u>7.5MG</u>	<u>A200104</u>	<u>008</u>	Jun 27, 2013
<u>AB</u>		<u>10MG</u>	<u>A200104</u>	<u>009</u>	Jun 27, 2013
<u>AB</u>	MYLAN	<u>1MG</u>	<u>A040415</u>	<u>001</u>	Sep 27, 2004
<u>AB</u>		<u>2MG</u>	<u>A040415</u>	<u>002</u>	Sep 27, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040415</u>	<u>003</u>	Sep 29, 2004
<u>AB</u>		<u>3MG</u>	<u>A040415</u>	<u>004</u>	Sep 27, 2004
<u>AB</u>		<u>4MG</u>	<u>A040415</u>	<u>005</u>	Sep 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A040415</u>	<u>006</u>	Sep 27, 2004
<u>AB</u>		<u>6MG</u>	<u>A040415</u>	<u>007</u>	Sep 27, 2004
<u>AB</u>		<u>7.5MG</u>	<u>A040415</u>	<u>008</u>	Sep 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A040415</u>	<u>009</u>	Sep 27, 2004
<u>AB</u>	PLIVA	<u>1MG</u>	<u>A040616</u>	<u>009</u>	Jul 05, 2006
<u>AB</u>		<u>2MG</u>	<u>A040616</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040616</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>3MG</u>	<u>A040616</u>	<u>003</u>	Jul 05, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-367 (of 371)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>4MG</u>	<u>A040616</u>	<u>004</u>	Jul 05, 2006
<u>AB</u>		<u>5MG</u>	<u>A040616</u>	<u>005</u>	Jul 05, 2006
<u>AB</u>		<u>6MG</u>	<u>A040616</u>	<u>006</u>	Jul 05, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040616</u>	<u>007</u>	Jul 05, 2006
<u>AB</u>		<u>10MG</u>	<u>A040616</u>	<u>008</u>	Jul 05, 2006
<u>AB</u>	TARO	<u>1MG</u>	<u>A040301</u>	<u>002</u>	Jul 15, 1999
<u>AB</u>		<u>2MG</u>	<u>A040301</u>	<u>003</u>	Jul 15, 1999
<u>AB</u>		<u>2.5MG</u>	<u>A040301</u>	<u>004</u>	Jul 15, 1999
<u>AB</u>		<u>3MG</u>	<u>A040301</u>	<u>005</u>	Jul 15, 1999
<u>AB</u>		<u>4MG</u>	<u>A040301</u>	<u>006</u>	Jul 15, 1999
<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

<u>AA</u>	LANTHEUS MEDCL	<u>20mCi/VIAL</u>	<u>N017284</u>	<u>002</u>	
		10mCi/VIAL	N017284	001	

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	ASTRAZENECA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996
	<u>ZAFIRLUKAST</u>				
<u>AB</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>		<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999
	<u>ZALEPLON</u>				
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	CIPLA LTD	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>		<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>	HIKMA PHARMS LLC	<u>5MG</u>	<u>A078147</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>10MG</u>	<u>A078147</u>	<u>002</u>	Nov 25, 2008
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A077238</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077238</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	ORCHID HLTHCARE	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>	ROXANE	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	TEVA PHARMS	<u>5MG</u>	<u>A077239</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A077239</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>	UPSHER SMITH	<u>5MG</u>	<u>A078706</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>		<u>10MG</u>	<u>A078706</u>	<u>002</u>	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+	GLAXOSMITHKLINE	5MG	N021036	001	Jul 26, 1999
---	-----------------	-----	---------	-----	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-368 (of 371)

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+	VIIV HLTHCARE	100MG	N019655	001	Mar 19, 1987
-----------	---	---------------	--------------	----------------	------------	--------------

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	100MG	A078128	001	Mar 27, 2006
-----------	--	----------------------	--------------	----------------	------------	--------------

AB		CIPLA LTD	100MG	A078349	001	May 23, 2007
-----------	--	-----------	--------------	----------------	------------	--------------

INJECTABLE; INJECTION

RETROVIR

AP	+	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990
-----------	---	---------------	----------------	----------------	------------	--------------

ZIDOVUDINE

AP		LUITPOLD	10MG/ML	A091457	001	May 06, 2010
-----------	--	----------	----------------	----------------	------------	--------------

SYRUP; ORAL

RETROVIR

AA	+	VIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989
-----------	---	---------------	-----------------	----------------	------------	--------------

ZIDOVUDINE

AA		AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005
-----------	--	-----------	-----------------	----------------	------------	--------------

AA		CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008
-----------	--	-----------	-----------------	----------------	------------	--------------

TABLET; ORAL

ZIDOVUDINE

AB		AUROBINDO	300MG	A077267	001	Sep 19, 2005
-----------	--	-----------	--------------	----------------	------------	--------------

AB		CIPLA	300MG	A090561	001	Oct 27, 2010
-----------	--	-------	--------------	----------------	------------	--------------

AB	+	HETERO LABS LTD III	300MG	A090092	001	Apr 25, 2008
-----------	---	---------------------	--------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008
-----------	--	------------------	--------------	----------------	------------	--------------

AB		ROXANE	300MG	A076844	001	Sep 19, 2005
-----------	--	--------	--------------	----------------	------------	--------------

AB		SUNSHINE LAKE	300MG	A202058	001	Oct 07, 2011
-----------	--	---------------	--------------	----------------	------------	--------------

ZILEUTON

TABLET; ORAL

ZYFLO

+	CHIESI USA INC	600MG	N020471	003	Dec 09, 1996
---	----------------	-------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

ZYFLO CR

+	CHIESI USA INC	600MG	N022052	001	May 30, 2007
---	----------------	-------	---------	-----	--------------

ZINC ACETATE

CAPSULE; ORAL

GALZIN

	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997
--	------	--------------	---------	-----	--------------

+		EQ 50MG ZINC	N020458	002	Jan 28, 1997
---	--	--------------	---------	-----	--------------

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986
---	---------	----------------	---------	-----	--------------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001
-----------	---	--------	---------------------	----------------	------------	--------------

AB			EQ 40MG BASE	N020825	002	Feb 05, 2001
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 60MG BASE	N020825	003	Feb 05, 2001
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 80MG BASE	N020825	004	Feb 05, 2001
-----------	--	--	---------------------	----------------	------------	--------------

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012
-----------	--	-------------	---------------------	----------------	------------	--------------

AB			EQ 40MG BASE	A077561	002	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 60MG BASE	A077561	003	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 80MG BASE	A077561	004	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012
-----------	--	--------------------	---------------------	----------------	------------	--------------

AB			EQ 40MG BASE	A077565	002	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 60MG BASE	A077565	003	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 80MG BASE	A077565	004	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012
-----------	--	--------------	---------------------	----------------	------------	--------------

AB			EQ 40MG BASE	A077560	002	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 60MG BASE	A077560	003	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB			EQ 80MG BASE	A077560	004	Mar 02, 2012
-----------	--	--	---------------------	----------------	------------	--------------

AB		MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013
-----------	--	------------------	---------------------	----------------	------------	--------------

AB			EQ 40MG BASE	A202395	002	Oct 10, 2013
-----------	--	--	---------------------	----------------	------------	--------------

PRESCRIPTION DRUG PRODUCT LIST

3-369 (of 371)

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A202395</u>	<u>003</u>	Oct 10, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202395</u>	<u>004</u>	Oct 10, 2013
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562</u>	<u>003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562</u>	<u>004</u>	Jun 01, 2012
<u>AB</u>	WOCKHARDT LTD	<u>EQ 20MG BASE</u>	<u>A090348</u>	<u>001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348</u>	<u>002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348</u>	<u>003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348</u>	<u>004</u>	Sep 05, 2012
SUSPENSION; ORAL					
GEODON					
	+ PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006

ZIPRASIDONE MESYLATE

INJECTABLE; INTRAMUSCULAR

GEODON

+ PFIZER

EQ 20MG BASE/ML

N020919 001 Jun 21, 2002

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

RECLAST

<u>AP</u>	+ NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817</u>	<u>001</u>	Apr 16, 2007
<u>ZOLEDRONIC ACID</u>					
<u>AP</u>	ACS DOBFAR INFO SA	<u>EQ 4MG BASE/100ML</u>	<u>N203231</u>	<u>001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828</u>	<u>001</u>	Sep 23, 2013
<u>AP</u>	ACTAVIS INC	<u>EQ 4MG BASE/5ML</u>	<u>A202472</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>	AGILA SPECLTS	<u>EQ 4MG BASE/5ML</u>	<u>A202650</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>	AKORN	<u>EQ 5MG BASE/100ML</u>	<u>A200918</u>	<u>001</u>	Aug 21, 2014
<u>AP</u>	AKORN INC	<u>EQ 4MG BASE/5ML</u>	<u>A202548</u>	<u>001</u>	May 22, 2014
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363</u>	<u>001</u>	Mar 29, 2013
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A201783</u>	<u>001</u>	Mar 12, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A201801</u>	<u>001</u>	Mar 29, 2013
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182</u>	<u>001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA INC	<u>EQ 5MG BASE/100ML</u>	<u>A202837</u>	<u>001</u>	Apr 05, 2013
<u>AP</u>	PHARMACEUTICS	<u>EQ 4MG BASE/5ML</u>	<u>A091170</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A202571</u>	<u>001</u>	May 07, 2013
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091493</u>	<u>001</u>	Nov 24, 2014
<u>AP</u>	+ SUN PHARMA GLOBAL	<u>EQ 4MG BASE/VIAL</u>	<u>A090018</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202746</u>	<u>001</u>	Mar 04, 2013
<u>AP</u>	USV NORTH AMERICA	<u>EQ 4MG BASE/VIAL</u>	<u>A202923</u>	<u>001</u>	Sep 04, 2014
<u>ZOMETA</u>					
<u>AP</u>	+ NOVARTIS	<u>EQ 4MG BASE/5ML</u>	<u>N021223</u>	<u>002</u>	Mar 07, 2003
<u>AP</u>	+	<u>EQ 4MG BASE/100ML</u>	<u>N021223</u>	<u>003</u>	Jun 17, 2011

ZOLMITRIPTAN

SPRAY; NASAL

ZOMIG

ASTRAZENECA

2.5MG/SPRAY

N021450 003 Sep 16, 2013

+

5MG/SPRAY

N021450 004 Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A202078</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202078</u>	<u>002</u>	May 14, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779</u>	<u>002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284</u>	<u>001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284</u>	<u>002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279</u>	<u>002</u>	Nov 20, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A203186</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A203186</u>	<u>002</u>	May 14, 2013
<u>AB</u>	SUN PHARMA GLOBAL	<u>2.5MG</u>	<u>A203476</u>	<u>001</u>	Nov 13, 2014
<u>AB</u>		<u>5MG</u>	<u>A203476</u>	<u>002</u>	Nov 13, 2014
<u>AB</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090861</u>	<u>001</u>	Mar 04, 2014
<u>AB</u>		<u>5MG</u>	<u>A090861</u>	<u>002</u>	Mar 04, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-370 (of 371)

ZOLMITRIPTAN

TABLET; ORAL

ZOMIGAB IPR 2.5MGN020768 001 Nov 25, 1997AB + 5MGN020768 002 Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTANAB APOTEX INC 2.5MGA202476 001 May 14, 2013AB 5MGA202476 002 May 14, 2013AB GLENMARK GENERICS 2.5MGA202560 001 May 14, 2013AB 5MGA202560 002 May 14, 2013AB ZYDUS PHARMS USA INC 2.5MGA202890 001 May 15, 2013AB 5MGA202890 002 May 15, 2013ZOMIG-ZMTAB ASTRAZENECA 2.5MGN021231 001 Feb 13, 2001AB + 5MGN021231 002 Sep 17, 2001ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ NOVADEL

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

AMBIENAB SANOFI AVENTIS US 5MGN019908 001 Dec 16, 1992AB + 10MGN019908 002 Dec 16, 1992ZOLPIDEM TARTRATEAB APOTEX INC 5MGA077884 001 Apr 23, 2007AB 10MGA077884 002 Apr 23, 2007AB AUROBINDO PHARMA 5MGA078413 001 May 04, 2007AB 10MGA078413 002 May 04, 2007AB CARLSBAD 5MGA077990 001 Apr 23, 2007AB 10MGA077990 002 Apr 23, 2007AB CIPLA LTD 5MGA077388 001 Jul 30, 2012AB 10MGA077388 002 Jul 30, 2012AB HIKMA 5MGA078129 001 Apr 30, 2008AB 10MGA078129 002 Apr 30, 2008AB INVAGEN PHARMS 5MGA078184 001 Sep 07, 2007AB 10MGA078184 002 Sep 07, 2007AB LEK PHARMS DD 5MGA077322 001 Apr 23, 2007AB 10MGA077322 002 Apr 23, 2007AB MYLAN 5MGA076578 001 Apr 23, 2007AB 10MGA076578 002 Apr 23, 2007AB RANBAXY 5MGA078055 001 Apr 23, 2007AB 10MGA078055 002 Apr 23, 2007AB ROXANE 5MGA077214 001 Apr 23, 2007AB 10MGA077214 002 Apr 23, 2007AB SUN PHARM INDS INC 5MGA077359 001 Apr 23, 2007AB 10MGA077359 002 Apr 23, 2007AB TEVA 5MGA076410 001 Apr 23, 2007AB 10MGA076410 002 Apr 23, 2007AB TORRENT PHARMS 5MGA077903 001 Aug 17, 2007AB 10MGA077903 002 Aug 17, 2007AB VINTAGE 5MGA078616 001 Nov 21, 2008AB 10MGA078616 002 Nov 21, 2008AB WOCKHARDT 5MGA078426 001 May 15, 2007AB 10MGA078426 002 May 15, 2007

TABLET; SUBLINGUAL

EDLUAR

MEDA PHARMS

5MG

N021997 001 Mar 13, 2009

+

10MG

N021997 002 Mar 13, 2009

INTERMEZZO

PURDUE PHARMA

1.75MG

N022328 001 Nov 23, 2011

+

3.5MG

N022328 002 Nov 23, 2011

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CRAB SANOFI AVENTIS US 6.25MGN021774 002 Sep 02, 2005AB + 12.5MGN021774 001 Sep 02, 2005ZOLPIDEM TARTRATEAB ACTAVIS ELIZABETH 6.25MGA078179 002 Oct 13, 2010AB 12.5MGA078179 001 Jun 06, 2011AB ACTAVIS LABS FL INC 6.25MGA090153 001 Mar 25, 2013AB 12.5MGA090153 002 Mar 25, 2013AB ANCHEN PHARMS 6.25MGA078148 002 Apr 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-371 (of 371)

ZOLPIDEM TARTRATE

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

<u>AB</u>		<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>	APOTEX INC	<u>6.25MG</u>	<u>A200266</u>	<u>001</u>	Sep 10, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A200266</u>	<u>002</u>	Sep 10, 2013
<u>AB</u>	LUPIN LTD	<u>6.25MG</u>	<u>A078970</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>12.5MG</u>	<u>A078970</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>	SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>	SYNTHON PHARMS	<u>6.25MG</u>	<u>A078483</u>	<u>001</u>	Apr 12, 2011
<u>AB</u>		<u>12.5MG</u>	<u>A078483</u>	<u>002</u>	Jun 06, 2011

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

<u>AB</u>	EISAI INC	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>		<u>50MG</u>	<u>N020789</u>	<u>002</u>	Aug 22, 2003
<u>AB</u>	+	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>	APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	BANNER PHARMACAPS	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>	GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>		<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>		<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A077637</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077637</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077637</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>25MG</u>	<u>A077647</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		<u>50MG</u>	<u>A077647</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>		<u>100MG</u>	<u>A077647</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	WOCKHARDT	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>		<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>		<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006

OTC DRUG PRODUCT LIST

4-1 (of 17)

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

N018060 001

325MG

A072344 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

A072237 001 Mar 27, 1992

650MG

N018060 002

ACETAMINOPHEN

PERRIGO NEW YORK

120MG

A070607 001 Apr 06, 1987

650MG

A070608 001 Dec 01, 1986

TARO PHARMS NORTH

120MG

N018337 003 Sep 12, 1983

325MG

N018337 002

+

650MG

N018337 001

INFANTS' FEVERALL

TARO PHARMS NORTH

80MG

N018337 004 Aug 26, 1992

NEOPAP

POLYMEDICA

120MG

N016401 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

OHM LABS

650MG

A076200 001 Mar 19, 2002

PERRIGO

650MG

A075077 001 Feb 25, 2000

RANBAXY LABS LTD

650MG

A078569 001 Dec 14, 2011

TYLENOL

+ MCNEIL CONS

650MG

N019872 001 Jun 08, 1994

+

650MG

N019872 002 Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

PERRIGO

250MG; 250MG; 65MG

A075794 001 Nov 26, 2001

EXCEDRIN (MIGRAINE)

+ NOVARTIS

250MG; 250MG; 65MG

N020802 001 Jan 14, 1998

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+ 3M

61%; 1%

N021074 001 Jun 07, 2001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

FOAMCOAT

GUARDIAN DRUG

80MG; 20MG

A071793 001 Sep 04, 1987

GAVISCON

SANOFI AVENTIS US

80MG; 20MG

N018685 001 Dec 09, 1983

+

160MG; 40MG

N018685 002 Dec 09, 1983

ASPIRIN

CAPSULE; ORAL

ASPIRIN

+ PLX PHARMA

325MG

N203697 001 Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+ LOREAL USA

2%; 2%; 10%

N021502 001 Jul 21, 2006

CAPITAL SOLEIL 15

+ LOREAL USA

2%; 3%; 10%

N021501 001 Oct 02, 2006

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+ LOREAL USA

2%; 2%; 10%; 2%

N021471 001 Oct 05, 2006

ANTHELIOS 40

+ LOREAL USA

2%; 3%; 10%; 5%

N022009 001 Mar 31, 2008

+

2%; 3%; 10%; 5%

N022009 002 Oct 29, 2009

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ SCHERING PLOUGH

3%; 7.5%; 3%

N020045 001 Dec 07, 1992

OTC DRUG PRODUCT LIST

4-2 (of 17)

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+ STAND HOMEOPATH

5%

N020532 001 Aug 26, 1996

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

LOTRIMIN ULTRA

+ SCHERING PLOUGH

1%

N021307 001 Dec 07, 2001

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT 3

+ BAYER

2%

N020421 001 Dec 21, 1995

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE

PERRIGO R AND D

800MG; 10MG; 165MG

A077355 001 Feb 06, 2008

PEPCID COMPLETE

+ MCNEIL CONS

800MG; 10MG; 165MG

N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER PHARMACAPS

5MG

N022429 001 Jul 23, 2009

+

10MG

N022429 004 Jul 23, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER PHARMACAPS

5MG

N022429 003 Jul 23, 2009

+

10MG

N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS

5MG/5ML

A090765 002 Oct 07, 2009

AUROBINDO PHARMA

5MG/5ML

A090750 002 Feb 02, 2010

BIO PHARM INC

5MG/5ML

A090474 002 Mar 30, 2009

CYPRESS PHARM

5MG/5ML

A090300 001 Oct 10, 2008

PERRIGO R AND D

5MG/5ML

A204226 001 Sep 09, 2013

5MG/5ML

A090254 002 Apr 09, 2008

SILARX

5MG/5ML

A091130 001 Apr 22, 2011

SUN PHARM INDS INC

5MG/5ML

A091327 001 Oct 17, 2011

TARO

5MG/5ML

A090182 002 Apr 22, 2008

5MG/5ML

A201546 001 May 20, 2011

TRIS PHARMA INC

5MG/5ML

A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS

5MG/5ML

A090765 001 Oct 07, 2009

AUROBINDO PHARMA

5MG/5ML

A090750 001 Feb 02, 2010

BIO PHARM INC

5MG/5ML

A090474 001 Mar 30, 2009

CYPRESS PHARM

5MG/5ML

A090300 002 Oct 10, 2008

PERRIGO R AND D

5MG/5ML

A090254 001 Apr 09, 2008

SILARX

5MG/5ML

A091130 002 Apr 22, 2011

SUN PHARM INDS INC

5MG/5ML

A091327 002 Oct 17, 2011

TARO

5MG/5ML

A090182 001 Apr 22, 2008

5MG/5ML

A201546 002 May 20, 2011

TRIS PHARMA INC

5MG/5ML

A090572 002 Nov 16, 2012

CHILDREN'S ZYRTEC ALLERGY

+ MCNEIL CONSUMER

5MG/5ML

N022155 002 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ MCNEIL CONSUMER

5MG/5ML

N022155 001 Nov 16, 2007

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY

5MG

A078780 001 Jan 21, 2010

10MG

A078780 004 Jan 21, 2010

APOTEX INC

5MG

A078317 001 Dec 27, 2007

10MG

A078317 002 Dec 27, 2007

CADISTA PHARMS

5MG

A078933 001 Jun 15, 2010

10MG

A078933 002 Jun 15, 2010

CIPLA LTD

5MG

A077318 001 Jul 25, 2013

10MG

A077318 002 Jul 25, 2013

CONTRACT PHARMACAL

5MG

A076047 001 Dec 27, 2007

10MG

A076047 002 Dec 27, 2007

DR REDDYS LABS LTD

5MG

A078343 004 Jan 15, 2008

10MG

A078343 003 Jan 15, 2008

IPCA LABS LTD

5MG

A202277 002 Mar 11, 2014

10MG

A202277 004 Mar 11, 2014

OTC DRUG PRODUCT LIST

4-3 (of 17)

CETIRIZINE HYDROCHLORIDE

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
RANBAXY	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
SANDOZ	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007
	10MG	A077499	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	001	Apr 15, 2010
	10MG	A079191	004	Apr 15, 2010
UNICHEM	5MG	A078680	003	Jun 26, 2009
	10MG	A078680	004	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009
WOCKHARDT	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007

CETIRIZINE HYDROCHLORIDE HIVES

CADISTA PHARMS	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORCHID HLTHCARE	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
RANBAXY	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007
	10MG	A077499	004	Dec 27, 2007
UNICHEM	5MG	A078680	001	Jun 26, 2009
	10MG	A078680	002	Jun 26, 2009
UNIQUE PHARM LABS	5MG	A077829	003	Aug 26, 2009
	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
TARO	10MG	A078072	002	Jul 22, 2009
	10MG	A078072	004	Jul 22, 2009
TORRENT PHARMS LLC	5MG	A079191	003	Apr 15, 2010
	10MG	A079191	002	Apr 15, 2010

ZYRTEC ALLERGY

MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007
+	10MG	N019835	004	Nov 16, 2007

ZYRTEC HIVES RELIEF

MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007
+	10MG	N019835	006	Nov 16, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SANDOZ	5MG	A078692	001	Feb 14, 2008
+	10MG	A078692	002	Feb 14, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARMA GLOBAL	5MG	A090142	001	Aug 30, 2011
	10MG	A090142	002	Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARMA GLOBAL	5MG	A090142	003	Aug 30, 2011
	10MG	A090142	004	Aug 30, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

ZYRTEC ALLERGY

+	MCNEIL CONSUMER	10MG	N022578	001	Sep 03, 2010
---	-----------------	------	---------	-----	--------------

OTC DRUG PRODUCT LIST

4-4 (of 17)

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	5MG;120MG	A077170	001	Feb 25, 2008
SANDOZ	5MG;120MG	A077991	001	Mar 05, 2008
SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012
ZYRTEC-D 12 HOUR				
+ MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+ XTTRIUM	4%	N019127	001	Dec 24, 1984
-----------	----	---------	-----	--------------

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+ SAGE PRODS	2%	N021669	001	Apr 25, 2005
--------------	----	---------	-----	--------------

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO	4%	A071419	001	Dec 17, 1987
--------	----	---------	-----	--------------

CHG SCRUB

ECOLAB	4%	N019258	002	Jul 22, 1986
--------	----	---------	-----	--------------

CIDA-STAT

ECOLAB	2%	N019258	001	Jul 22, 1986
--------	----	---------	-----	--------------

DYNA-HEX

BAJAJ MEDICAL LLC	0.75%	N020111	001	Sep 11, 1997
-------------------	-------	---------	-----	--------------

EXIDINE

+ XTTRIUM	2%	N019422	001	Dec 17, 1985
	4%	N019125	001	Dec 24, 1984

HIBICLENS

+ MOLNLYCKE HLTH	4%	N017768	001	
------------------	----	---------	-----	--

HIBISTAT

+ MOLNLYCKE HLTH	0.5%	N018300	001	
------------------	------	---------	-----	--

SPONGE;TOPICAL

BIOSCRUB

GRIFFEN	4%	N019822	001	Mar 31, 1989
---------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE

BECTON DICKINSON	4%	A072525	001	Oct 24, 1989
------------------	----	---------	-----	--------------

PHARMASEAL SCRUB CARE

+ CAREFUSION	4%	N019793	001	Dec 02, 1988
--------------	----	---------	-----	--------------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+ CAREFUSION	2%;70% (3ML)	N020832	001	Jul 14, 2000
	2%;70% (10.5ML)	N020832	004	Aug 20, 2003
	2%;70% (26ML)	N020832	006	Nov 21, 2006

CHLORAPREP ONE-STEP FREPP

+ CAREFUSION	2%;70% (1.5ML)	N020832	003	Apr 26, 2002
--------------	----------------	---------	-----	--------------

CHLORAPREP WITH TINT

+ CAREFUSION	2%;70% (26ML)	N020832	002	May 03, 2005
	2%;70% (10.5ML)	N020832	005	Apr 03, 2006
	2%;70% (3ML)	N020832	007	Oct 10, 2006

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002
--------------	-----------------	---------	-----	--------------

CHLORAPREP SINGLE SWABSTICK

+ CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005
--------------	-----------------	---------	-----	--------------

CHLORAPREP TRIPLE SWABSTICK

+ CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009
--------------	-----------------	---------	-----	--------------

PREVANTICS MAXI SWABSTICK

+ PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005
--------------	-------------------	---------	-----	--------------

PREVANTICS SWAB

+ PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005
--------------	-----------------	---------	-----	--------------

PREVANTICS SWABSTICK

+ PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005
--------------	-------------------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH	12MG	N007638	002	
-------------------	------	---------	-----	--

CHLORPHENIRAMINE MALEATE

AVANTHI INC	12MG	A040829	001	May 13, 2009
-------------	------	---------	-----	--------------

OTC DRUG PRODUCT LIST

4-5 (of 17)

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+ PFIZER 4MG;200MG;10MG

N022113 001 Dec 21, 2011

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+ PFIZER 1MG/5ML;100MG/5ML;15MG/5ML

N021587 001 Feb 24, 2004

TABLET;ORAL

ADVIL ALLERGY SINUS

+ PFIZER 2MG;200MG;30MG

N021441 001 Dec 19, 2002

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ SCHERING PLOUGH 8MG;120MG

N018397 001

CIMETIDINE

TABLET;ORAL

CIMETIDINE

APOTEX 100MG

A074948 001 Jun 19, 1998

200MG

A074948 002 Jul 26, 2002

CONTRACT PHARMACAL 200MG

A074961 001 Jun 19, 1998

200MG

A074963 001 Jun 19, 1998

IVAX SUB TEVA PHARMS 200MG

A075345 001 Jun 16, 1999

PERRIGO 200MG

A075285 001 Oct 29, 1998

TAGAMET HB

+ MEDTECH PRODUCTS 200MG

N020238 002 Aug 21, 1996

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PERRIGO 1.34MG

A074512 001 Nov 22, 1995

SANDOZ 1.34MG

A073458 001 Oct 31, 1993

TAVIST-1

+ NOVARTIS 1.34MG

N020925 001 Aug 21, 1992

CLOTRIMAZOLE

CREAM;VAGINAL

CLOTRIMAZOLE

ACTAVIS MID ATLANTIC 1%

A074165 001 Jul 16, 1993

TARO 1%

A072641 001 Dec 04, 1995

GYNE-LOTRIMIN

+ SCHERING PLOUGH 1%

N018052 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ SCHERING PLOUGH 2%

N020574 001 Nov 24, 1998

MYCELEX-7

BAYER HEALTHCARE LLC 1%

N018230 002 Dec 26, 1991

TRIVAGIZOLE 3

TARO 2%

N021143 001 Apr 12, 2000

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 200MG;200MG

N020526 002 Jul 29, 1996

GYNE-LOTRIMIN COMBINATION PACK

+ SCHERING PLOUGH 100MG;100MG

N020289 002 Apr 26, 1993

MYCELEX-7 COMBINATION PACK

BAYER HEALTHCARE LLC 1%;100MG

N020389 002 Jun 23, 1994

TABLET;VAGINAL

GYNE-LOTRIMIN

+ SCHERING PLOUGH 100MG

N017717 002 Nov 30, 1990

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996

MYCELEX-7

BAYER HEALTHCARE LLC 100MG

N018182 002 Dec 26, 1991

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

+ BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

PERRIGO 5.2MG/SPRAY

A075427 001 Dec 12, 2001

OTC DRUG PRODUCT LIST

4-6 (of 17)

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC

6MG;120MG

A078648 001 Feb 27, 2013

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

MUCINEX DM

RECKITT BENCKISER

30MG;600MG

N021620 002 Apr 29, 2004

+

60MG;1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+ RECKITT BENCKISER

EQ 30MG HBR/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC

EQ 30MG HBR/5ML

A091135 001 May 25, 2012

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET; ORAL

ADVIL PM

+ PFIZER

38MG;200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

DR REDDYS LABS LTD

38MG;200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D

38MG;200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

ADVIL PM

+ PFIZER

25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER PHARMACAPS

25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A090397 001 Nov 22, 2010

STRIDES PHARMA

25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

A200888 001 Mar 05, 2012

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

ALEVE PM

+ BAYER HLTHCARE

25MG;220MG

N205352 001 Jan 17, 2014

DOCOSANOL

CREAM; TOPICAL

ABREVA

+ GLAXOSMITHKLINE

10%

N020941 001 Jul 25, 2000

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK

25MG

A040564 001 Aug 27, 2004

PERRIGO

25MG

A040167 001 Sep 18, 1996

UNISOM

+ CHATTEM

25MG

N018066 001

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

NEXIUM 24HR

+ ASTRAZENECA LP

EQ 20MG BASE

N204655 001 Mar 28, 2014

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

DR REDDYS LABS LTD

10MG

A075758 001 Aug 17, 2001

20MG

A077367 001 Sep 25, 2006

IVAX SUB TEVA PHARMS

10MG

A075512 001 Jul 26, 2001

MYLAN

10MG

A075674 001 Dec 21, 2001

PERRIGO

10MG

A075400 001 Mar 18, 2005

20MG

A077351 001 Sep 25, 2006

RANBAXY

10MG

A090283 001 Nov 17, 2009

20MG

A090283 002 Nov 17, 2009

TEVA

10MG

A075312 001 May 31, 2001

WOCKHARDT

10MG

A077146 001 Mar 07, 2005

20MG

A090837 001 Aug 04, 2010

PEPCID AC

MCNEIL CONS

10MG

N020325 001 Apr 28, 1995

+

20MG

N020325 002 Sep 23, 2003

OTC DRUG PRODUCT LIST

4-7 (of 17)

FAMOTIDINE

TABLET;ORAL

PEPCID AC

MCNEIL CONS

10MG

N020902 001 Aug 05, 1999

TABLET, CHEWABLE;ORAL

FAMOTIDINE

PERRIGO

10MG

A075715 001 Aug 22, 2003

PEPCID AC

+ MCNEIL CONS

20MG

N020801 002 Dec 17, 2007

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US

30MG/5ML

N201373 001 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US

30MG/5ML

N201373 002 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC

30MG/5ML

A203330 001 Nov 18, 2014

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC

30MG/5ML

A203330 002 Nov 18, 2014

TABLET;ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US

60MG

N020872 007 Jan 24, 2011

+

180MG

N020872 010 Jan 24, 2011

ALLEGRA HIVES

SANOFI AVENTIS US

60MG

N020872 008 Jan 24, 2011

+

180MG

N020872 009 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US

30MG

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US

30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC

30MG

A202039 001 Nov 19, 2014

DR REDDYS LABS LTD

30MG

A076502 004 Apr 12, 2011

MYLAN

30MG

A077081 004 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 002 Feb 06, 2012

TEVA

30MG

A076447 004 Apr 13, 2011

WOCKHARDT LTD

30MG

A079112 002 Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD

30MG

A076502 005 Apr 12, 2011

MYLAN

30MG

A077081 005 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 001 Feb 06, 2012

TEVA

30MG

A076447 005 Apr 13, 2011

WOCKHARDT LTD

30MG

A079112 001 Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC

60MG

A202039 002 Nov 19, 2014

180MG

A202039 003 Nov 19, 2014

DR REDDYS LABS LTD

60MG

A076502 006 Apr 12, 2011

180MG

A076502 008 Apr 12, 2011

MYLAN

60MG

A077081 006 Jul 21, 2011

180MG

A077081 008 Jul 21, 2011

SUN PHARM INDS

60MG

A091567 004 Feb 06, 2012

180MG

A091567 006 Feb 06, 2012

TEVA

60MG

A076447 006 Apr 13, 2011

180MG

A076447 008 Apr 13, 2011

WOCKHARDT LTD

60MG

A079112 004 Feb 08, 2012

180MG

A079112 006 Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD

60MG

A076502 007 Apr 12, 2011

180MG

A076502 009 Apr 12, 2011

MYLAN

60MG

A077081 007 Jul 21, 2011

180MG

A077081 009 Jul 21, 2011

SUN PHARM INDS

60MG

A091567 003 Feb 06, 2012

180MG

A091567 005 Feb 06, 2012

TEVA

60MG

A076447 007 Apr 13, 2011

180MG

A076447 009 Apr 13, 2011

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012

180MG

A079112 005 Feb 08, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US

30MG

N021909 002 Jan 24, 2011

OTC DRUG PRODUCT LIST

4-8 (of 17)

FEXOFENADINE HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US 30MG

N021909 003 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD 30MG

A202978 001 Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD 30MG

A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 60MG;120MG

N020786 002 Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US 180MG;240MG

N021704 002 Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD 60MG;120MG

A076667 001 Nov 18, 2014

180MG;240MG

A079043 002 Jun 22, 2011

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

PERRIGO R AND D 600MG

A078912 001 Nov 23, 2011

MUCINEX

+ RECKITT BENCKISER 1.2GM

N021282 002 Dec 18, 2002

600MG

N021282 001 Jul 12, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MUCINEX D

+ RECKITT BENCKISER 1.2GM;120MG

N021585 002 Jun 22, 2004

600MG;60MG

N021585 001 Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

BANNER PHARMACAPS EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

+ CONTRACT PHARMACAL 200MG

A074782 001 Jul 06, 1998

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

P AND L DEV LLC EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

MIDOL LIQUID GELS

+ BANNER PHARMACAPS 200MG

N021472 001 Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

PFIZER 100MG/5ML

N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

PFIZER 100MG/5ML

N020589 002 Nov 07, 1997

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML

A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+ MCNEIL 100MG/5ML

N020516 001 Jun 16, 1995

IBUPROFEN

ACTAVIS MID ATLANTIC 100MG/5ML

A074916 001 Apr 30, 1999

AMNEAL PHARMS 100MG/5ML

A200457 001 Aug 18, 2011

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+ MCNEIL CONS 40MG/ML

N020603 001 Jun 10, 1996

IBUPROFEN

PERRIGO 40MG/ML

A075217 001 Dec 16, 1998

TRIS PHARMA INC 40MG/ML

A079058 001 Aug 31, 2009

PEDIATRIC ADVIL

+ PFIZER 100MG/2.5ML

N020812 001 Jan 30, 1998

OTC DRUG PRODUCT LIST

4-9 (of 17)

IBUPROFEN

TABLET;ORAL

ADVIL

PFIZER	200MG	N018989	001	May 18, 1984
IBU-TAB 200				
ALRA	200MG	A071057	001	Aug 11, 1988
IBUPROFEN				
AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014
AMNEAL PHARMS NY	200MG	A071333	001	Feb 17, 1987
	200MG	A072199	001	May 23, 1988
AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003
CONTRACT PHARMACAL	200MG	A071732	001	Sep 10, 1987
	200MG	A071735	001	Sep 10, 1987
	200MG	A072299	001	Jul 01, 1988
	200MG	A074931	001	Jul 20, 1998
DR REDDYS LA	200MG	A075661	001	Dec 12, 2001
DR REDDYS LABS INC	100MG	A076117	001	Nov 20, 2001
GRANULES INDIA	200MG	A079174	001	Dec 10, 2010
LNK	100MG	A076741	001	Jun 17, 2004
	200MG	A075010	001	Mar 01, 1999
	200MG	A075139	001	Mar 01, 1999
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011
	200MG	A091239	001	Feb 01, 2011
MCNEIL	200MG	A073019	001	Mar 30, 1994
MERRO PHARM	200MG	A070985	001	Oct 02, 1987
OHM	200MG	A071163	001	Jul 15, 1986
PAR PHARM	200MG	A070481	001	Sep 24, 1986
PERRIGO	200MG	A072096	001	Dec 08, 1987
	200MG	A075995	001	Mar 14, 2002
PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011
	200MG	A091355	001	Apr 04, 2011
VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987
	200MG	A071639	001	Feb 02, 1988
IBUPROHM				
OHM LABS	200MG	A071214	001	Dec 01, 1986
JUNIOR STRENGTH ADVIL				
PFIZER	100MG	N020267	002	Dec 13, 1996
JUNIOR STRENGTH IBUPROFEN				
PERRIGO	100MG	A075367	001	Apr 22, 1999
JUNIOR STRENGTH MOTRIN				
MCNEIL CONS	100MG	N020602	001	Jun 10, 1996
MOTRIN IB				
+ MCNEIL	200MG	N019012	003	Dec 17, 1990
MOTRIN MIGRAINE PAIN				
+ MCNEIL	200MG	N019012	004	Feb 25, 2000
PROFEN				
CONTRACT PHARMACAL	200MG	A071265	001	Oct 15, 1986
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987
TABLET, CHEWABLE;ORAL				
CHILDREN'S ADVIL				
PFIZER	50MG	N020944	001	Dec 18, 1998
CHILDREN'S MOTRIN				
MCNEIL CONS	50MG	N020601	001	Nov 15, 1996
IBUPROFEN				
PERRIGO	50MG	A076359	001	Jan 16, 2004
	100MG	A076359	002	Jan 16, 2004
JUNIOR STRENGTH ADVIL				
PFIZER	100MG	N020944	002	Dec 18, 1998
JUNIOR STRENGTH MOTRIN				
+ MCNEIL CONS	100MG	N020601	003	Nov 15, 1996

IBUPROFEN SODIUM

TABLET;ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012
------------------------	---------------	---------	-----	--------------

OTC DRUG PRODUCT LIST

4-10 (of 17)

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+ PFIZER 200MG; 10MG N022565 001 May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D 200MG; 10MG A203200 001 Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+ PFIZER EQ 200MG FREE ACID AND POTASSIUM SALT; 30MG N021374 001 May 30, 2002

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

PFIZER 100MG/5ML; 15MG/5ML N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+ MCNEIL CONS 100MG/5ML; 15MG/5ML N021128 001 Aug 01, 2000

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 100MG/5ML; 15MG/5ML A076478 001 Nov 05, 2003

TABLET; ORAL

ADVIL COLD AND SINUS

+ PFIZER 200MG; 30MG N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

CONTRACT PHARMACAL 200MG; 30MG A075588 001 Apr 08, 2002

DR REDDYS LABS LTD 200MG; 30MG A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS 200MG; 30MG A074567 001 Apr 17, 2001

SINE-AID IB

MCNEIL CONS 200MG; 30MG N019899 001 Dec 31, 1992

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN R

+ LILLY 100 UNITS/ML N018780 001 Oct 28, 1982

HUMULIN R PEN

+ LILLY 100 UNITS/ML N018780 005 Aug 06, 1998

NOVOLIN R

+ NOVO NORDISK INC 100 UNITS/ML N019938 001 Jun 25, 1991

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 70/30

+ LILLY 30 UNITS/ML; 70 UNITS/ML N019717 001 Apr 25, 1989

HUMULIN 70/30 PEN

+ LILLY 30 UNITS/ML; 70 UNITS/ML N019717 002 Aug 06, 1998

NOVOLIN 70/30

+ NOVO NORDISK INC 30 UNITS/ML; 70 UNITS/ML N019991 001 Jun 25, 1991

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN N

+ LILLY 100 UNITS/ML N018781 001 Oct 28, 1982

NOVOLIN N

+ NOVO NORDISK INC 100 UNITS/ML N019959 001 Jul 01, 1991

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+ 3M EQ 0.7% IODINE; 74% (6ML) N021586 001 Sep 29, 2006

+ EQ 0.7% IODINE; 74% (26ML) N021586 002 Sep 29, 2006

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ JOHNSON AND JOHNSON 1% N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+ BAUSCH AND LOMB EQ 0.025% BASE N021996 001 Dec 01, 2006

KETOTIFEN FUMARATE

AKORN EQ 0.025% BASE A077958 001 Jul 26, 2007

ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008

ZADITOR

+ ALCON PHARMA EQ 0.025% BASE N021066 002 Oct 19, 2006

OTC DRUG PRODUCT LIST

4-11 (of 17)

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012
PERRIGO R AND D	15MG	A202319	001	May 18, 2012
WOCKHARDT LTD	15MG	A202727	001	May 18, 2012
PREVACID 24 HR				
+ NOVARTIS	15MG	N022327	001	May 18, 2009

LEVONORGESTREL

TABLET; ORAL

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014
LEVONORGESTREL				
FAMY CARE LTD	1.5MG	A202739	001	Oct 31, 2014
NOVEL LABS INC	1.5MG	A202508	001	Feb 22, 2013
PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010
	1.5MG	A202334	001	Aug 20, 2014
+ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009
WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012
OPCICON ONE-STEP				
SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014
PLAN B				
+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006
PLAN B ONE-STEP				
+ TEVA BRANDED PHARM	1.5MG	N021998	001	Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER PHARMACAPS	1MG	N021855	001	Aug 04, 2005
+	2MG	N021855	002	Aug 04, 2005

SOLUTION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988
LOPERAMIDE HYDROCHLORIDE				
HI TECH PHARMA	1MG/5ML	A074352	001	Nov 17, 1995
PERRIGO	1MG/5ML	A073243	001	Jan 21, 1992
ROXANE	1MG/5ML	A073079	001	Apr 30, 1992
WOCKHARDT	1MG/5ML	A074730	001	Aug 28, 1997

SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004
LOPERAMIDE HYDROCHLORIDE				
PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011

TABLET; ORAL

IMODIUM A-D

+ MCNEIL CONS	2MG	N019860	001	Nov 22, 1989
LOPERAMIDE HYDROCHLORIDE				
CONTRACT PHARMACAL	2MG	A073254	001	Jul 30, 1993
LNK	2MG	A076497	001	Jun 10, 2003
OHM LABS	2MG	A074091	001	Dec 10, 1992
PERRIGO	2MG	A075232	001	Jan 06, 2000

TABLET, CHEWABLE; ORAL

IMODIUM A-D EZ CHEWS

+ MCNEIL	2MG	N020448	001	Jul 24, 1997
----------	-----	---------	-----	--------------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL CONS	2MG; 125MG	N021140	001	Nov 30, 2000
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
RANBAXY	2MG; 125MG	A077500	001	Sep 06, 2006

TABLET, CHEWABLE; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ MCNEIL	2MG; 125MG	N020606	001	Jun 26, 1996
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE				
PERRIGO	2MG; 125MG	A076029	001	Aug 30, 2002

OTC DRUG PRODUCT LIST

4-12 (of 17)

LORATADINE

CAPSULE; ORAL

CLARITIN

+ SCHERING PLOUGH 10MG N021952 001 Jun 16, 2008

SUSPENSION; ORAL

LORATADINE

+ TARO 1MG/ML N021734 001 Oct 04, 2005

SYRUP; ORAL

CLARITIN

+ SCHERING PLOUGH 1MG/ML N020641 002 Nov 27, 2002

LORATADINE

PERRIGO

1MG/ML A075728 001 Aug 20, 2004

SILARX

1MG/ML A077421 001 Jun 29, 2006

TARO

1MG/ML A076805 001 Aug 20, 2004

TEVA

1MG/ML A075505 001 Nov 07, 2003

WOCKHARDT

1MG/ML A075815 001 Aug 20, 2004

TABLET; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 10MG N019658 003 Nov 19, 2003

LORATADINE

APOTEX INC

10MG A076471 001 Feb 14, 2006

MYLAN

10MG A075790 001 Nov 07, 2008

10MG A076154 001 Aug 20, 2003

10MG A078447 001 Aug 12, 2011

PERRIGO

10MG A076301 001 Jun 25, 2004

RANBAXY

10MG A076134 001 Aug 18, 2003

SANDOZ

10MG A075209 001 Jan 21, 2003

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+ SCHERING PLOUGH 5MG N021891 001 Aug 23, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

PFIZER

10MG N021375 001 Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+ BAYER HEALTHCARE LLC 10MG N020704 003 Nov 19, 2003

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 10MG N020704 002 Nov 27, 2002

+ SCHERING PLOUGH 5MG N021993 001 Dec 12, 2006

LORATADINE

ACTAVIS LABS FL INC

10MG A075990 001 Nov 03, 2003

IMPAX LABS

10MG A076011 001 Sep 29, 2003

PFIZER

10MG A075822 001 Feb 10, 2003

LORATADINE REDIDOSE

RANBAXY

10MG A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARITIN-D

+ SCHERING PLOUGH 5MG; 120MG N019670 002 Nov 27, 2002

CLARITIN-D 24 HOUR

+ SCHERING PLOUGH 10MG; 240MG N020470 002 Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC

10MG; 240MG A075706 001 Feb 21, 2003

IMPAX LABS

5MG; 120MG A076050 001 Jan 30, 2003

10MG; 240MG A075989 001 Mar 04, 2004

RANBAXY

10MG; 240MG A076557 001 Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

+ HISAMITSU PHARM CO 3%; 10% N022029 001 Feb 20, 2008

3%; 10% N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM; TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO

2%; 4% A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS

2%; 4% N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS

2%; 4% N021261 001 Feb 02, 2001

OTC DRUG PRODUCT LIST

4-13 (of 17)

MICONAZOLE NITRATE

CREAM;VAGINAL

MICONAZOLE 3

TARO 4%

A076773 001 Mar 02, 2005

MICONAZOLE 7

ACTAVIS MID ATLANTIC 2%

A074164 001 Mar 29, 1996

MICONAZOLE NITRATE

G AND W LABS INC 2%

A074366 001 Feb 22, 1996

PERRIGO 2%

A074760 001 May 15, 1997

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010

TARO 2%

A074444 001 Jan 13, 1997

MONISTAT 3

+ MEDTECH PRODUCTS 4%

N020827 001 Mar 30, 1998

MONISTAT 7

+ MEDTECH PRODUCTS 2%

N017450 002 Feb 15, 1991

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

ACTAVIS MID ATLANTIC 2%;200MG

A074926 001 Apr 16, 1999

MICONAZOLE 7 COMBINATION PACK

G AND W LABS 100MG;2%

A076585 001 Mar 26, 2004

MICONAZOLE NITRATE

PERRIGO R AND D 1.2GM;2%

A079114 001 Jun 02, 2010

MICONAZOLE NITRATE COMBINATION PACK

PERRIGO 200MG;200MG

A075329 001 Apr 20, 1999

MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS 1.2GM;2%

N021308 001 Jun 29, 2001

MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS 100MG;2%

N020288 002 Apr 26, 1993

MONISTAT-3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%;200MG

N020670 002 Apr 16, 1996

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

ACTAVIS MID ATLANTIC 100MG

A073507 001 Nov 19, 1993

G AND W LABS 100MG

A074414 001 Apr 30, 1997

+ PERRIGO 100MG

A074395 001 Mar 20, 1997

MONISTAT 7

+ MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO ISRAEL 5%

A091344 001 Apr 28, 2011

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

ACTAVIS MID ATLANTIC 2%

A074588 001 Apr 05, 1996

HI TECH PHARMA 2%

A074731 001 Dec 24, 1996

PERRIGO 2%

A075357 001 Jul 30, 1999

WOCKHARDT 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

HI TECH PHARMA 2%

A074731 002 May 11, 2005

PERRIGO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

ACTAVIS MID ATLANTIC 5%

A075518 001 Nov 17, 2000

AVACOR PRODS 5%

A075619 001 Nov 17, 2000

PERRIGO 5%

A075598 001 Jun 13, 2001

PERRIGO NEW YORK 5%

A075737 001 Mar 15, 2002

WOCKHARDT 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+ JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+ JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+ JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

EI INC 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

OTC DRUG PRODUCT LIST

4-14 (of 17)

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN INC	0.025%;0.3%	A202795	001	Jan 24, 2013
ALTAIRE PHARMS INC	0.02675%;0.315%	A078208	001	Sep 27, 2010
NAPHCN-A				
+ ALCON	0.025%;0.3%	N020226	001	Jun 08, 1994
OPCN-A				
+ BAUSCH AND LOMB	0.02675%;0.315%	N020065	001	Jun 08, 1994
VISINE-A				
+ JOHNSON AND JOHNSON	0.025%;0.3%	N020485	001	Jan 31, 1996

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS	EQ 200MG BASE	N021920	001	Feb 17, 2006
---------------------	---------------	---------	-----	--------------

TABLET;ORAL

ALEVE

+ BAYER	EQ 200MG BASE	N020204	002	Jan 11, 1994
---------	---------------	---------	-----	--------------

NAPROXEN SODIUM

AMNEAL PHARMS NY	EQ 200MG BASE	A079096	001	Dec 16, 2008
CONTRACT PHARMACAL	EQ 200MG BASE	A074635	001	Jan 13, 1997
	EQ 200MG BASE	A074789	001	Feb 27, 1997
DR REDDYS LABS INC	EQ 200MG BASE	A075168	001	Jul 28, 1998
GRANULES INDIA	EQ 200MG BASE	A091353	001	Sep 20, 2011
MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011
PERRIGO	EQ 200MG BASE	A074661	001	Jan 13, 1997
RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ BAYER	200MG;120MG	N021076	001	Nov 29, 1999
---------	-------------	---------	-----	--------------

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	EQ 220MG BASE;120MG	A077381	001	Sep 27, 2006
PERRIGO	EQ 200MG BASE;120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

HABITROL

+ DR REDDYS LABS INC	7MG/24HR	N020076	004	Nov 12, 1999
	14MG/24HR	N020076	005	Nov 12, 1999
	21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+ SANOFI AVENTIS US	7MG/24HR	N020165	006	Aug 02, 1996
	14MG/24HR	N020165	005	Aug 02, 1996
	21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
	14MG/24HR	A074612	003	Oct 20, 1997
	21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICORETTE

+ GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
	EQ 2MG BASE	N018612	004	Sep 25, 2000
	EQ 4MG BASE	N020066	002	Feb 09, 1996
	EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
	EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

ACTAVIS LABS NY INC	EQ 2MG BASE	A074507	001	Mar 15, 1999
	EQ 2MG BASE	A076569	001	Jul 29, 2004
	EQ 2MG BASE	A078699	001	Dec 29, 2008
	EQ 2MG BASE	A079216	001	Jul 08, 2009
	EQ 4MG BASE	A074707	001	Mar 19, 1999
	EQ 4MG BASE	A076568	002	Jul 29, 2004
	EQ 4MG BASE	A078697	001	Dec 29, 2008
	EQ 4MG BASE	A079038	001	Jul 08, 2009
	EQ 4MG BASE	A079219	001	Jul 08, 2009
IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009
	EQ 4MG BASE	A077850	001	Feb 18, 2009

OTC DRUG PRODUCT LIST

4-15 (of 17)

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

PERRIGO

EQ 2MG BASE

A076775 001 Sep 16, 2004

EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 2MG BASE

A076777 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

EQ 4MG BASE

A076779 001 Sep 16, 2004

EQ 4MG BASE

A076789 001 Sep 16, 2004

PERRIGO R AND D

EQ 2MG BASE

A078325 001 Oct 30, 2006

EQ 2MG BASE

A078547 001 May 24, 2007

EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 2MG BASE

A091349 001 Jul 20, 2011

EQ 4MG BASE

A078326 001 Oct 30, 2006

EQ 4MG BASE

A078546 001 May 24, 2007

EQ 4MG BASE

A078968 001 Apr 23, 2008

EQ 4MG BASE

A091354 001 Jul 20, 2011

WATSON LABS

EQ 2MG BASE

A079044 001 Jul 08, 2009

THRIVE

NOVARTIS

EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

TROCHE/LOZENGE;ORAL

COMMIT

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N021330 001 Oct 31, 2002

+

EQ 4MG BASE

N021330 002 Oct 31, 2002

NICORETTE

GLAXOSMITHKLINE CONS

EQ 2MG BASE

N022360 001 May 18, 2009

+

EQ 4MG BASE

N022360 002 May 18, 2009

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A077007 001 Jan 31, 2006

EQ 2MG BASE

A090711 001 Jul 10, 2009

EQ 2MG BASE

A090821 001 Jul 10, 2009

EQ 2MG BASE

A203690 001 Oct 09, 2012

EQ 4MG BASE

A077007 002 Jan 31, 2006

EQ 4MG BASE

A090711 002 Jul 10, 2009

EQ 4MG BASE

A090821 002 Jul 10, 2009

EQ 4MG BASE

A203690 002 Oct 09, 2012

NIZATIDINE

TABLET;ORAL

AXID AR

+ PFIZER

75MG

N020555 001 May 09, 1996

NONOXYNOL-9

SPONGE;VAGINAL

TODAY

+ MAYER LABS INC

1GM

N018683 001 Apr 01, 1983

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

+ DEXCEL PHARMA

20MG

N022032 001 Dec 04, 2007

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

+ DR REDDYS LABS LTD

EQ 20MG BASE

A078878 001 Jun 05, 2009

TABLET, DELAYED RELEASE;ORAL

PRILOSEC OTC

+ ASTRAZENECA PHARMS

EQ 20MG BASE

N021229 001 Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG;1.1GM

N022281 001 Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+ MSD CONSUMER

20MG/PACKET;1.68GM/PACKET

N022283 001 Jun 17, 2013

OTC DRUG PRODUCT LIST

4-16 (of 17)

ORLISTAT

CAPSULE;ORAL

ALLI

+ GLAXOSMITHKLINE CONS 60MG

N021887 001 Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ BAYER HEALTHCARE LLC 3.9MG/24HR

N202211 001 Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

SCHERING PLOUGH 0.025%

N018471 001 May 30, 1986

VISINE L.R.

+ JOHNSON AND JOHNSON 0.025%

N019407 001 Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+ MEDTECH PRODUCTS 1%

N019918 001 May 02, 1990

PERMETHRIN

ACTAVIS MID ATLANTIC 1%

A075014 001 Mar 28, 2000

PERRIGO NEW YORK 1%

A076090 001 Dec 20, 2001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

KREMERS URBAN PHARMS 17GM/PACKET
17GM/SCOOPFUL

A090600 001 Oct 06, 2009

A090600 002 Oct 06, 2009

MIRALAX

+ SCHERING PLOUGH 17GM/SCOOPFUL

N022015 001 Oct 06, 2006

POLYETHYLENE GLYCOL 3350

EMCURE PHARMS USA 17GM/SCOOPFUL

A202071 001 Dec 28, 2012

MYLAN 17GM/PACKET

A078915 001 Oct 06, 2009

17GM/SCOOPFUL

A078915 002 Oct 06, 2009

NEXGEN PHARMA 17GM/SCOOPFUL

A090812 001 Oct 07, 2009

NOVEL LABS INC 17GM/SCOOPFUL

A091077 001 Oct 06, 2009

PAR PHARM 17GM/SCOOPFUL

A079214 001 Jan 31, 2013

PERRIGO R AND D 17GM/PACKET

A090685 001 Oct 06, 2009

17GM/SCOOPFUL

A090685 002 Oct 06, 2009

POTASSIUM IODIDE

SOLUTION;ORAL

THYROSHIELD

+ ARCO PHARMS LLC 65MG/ML

A077218 001 Jan 12, 2005

TABLET;ORAL

IOSAT

ANBEX 65MG

N018664 002 May 12, 2011

+ 130MG

N018664 001 Oct 14, 1982

THYROSAFE

+ RECIP 65MG

A076350 001 Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+ ALLEGIANCE HLTHCARE 1%

N019522 001 Mar 31, 1989

SPONGE;TOPICAL

E-Z SCRUB 201

+ BECTON DICKINSON 20%

N019240 001 Nov 29, 1985

E-Z SCRUB 241

+ BECTON DICKINSON 10%

N019476 001 Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

PERRIGO 120MG

A075153 001 Feb 26, 1999

RANBAXY 120MG

A077442 001 Sep 28, 2005

SUDAFED 12 HOUR

+ MCNEIL CONS 120MG

A073585 001 Oct 31, 1991

SUDAFED 24 HOUR

+ MCNEIL CONS 240MG

N020021 002 Dec 15, 1992

OTC DRUG PRODUCT LIST

4-17 (of 17)

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

AFRINOL

+ SCHERING PLOUGH 120MG N018191 001

PURIFIED WATER

SOLUTION; OPHTHALMIC

PUR-WASH

+ NIAGARA PHARMS 98.3% N022305 001 Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 150MG BASE

A200172 001 May 31, 2012

CONTRACT PHARMACAL

EQ 75MG BASE

A075094 001 Jun 21, 1999

DR REDDYS LABS LTD

EQ 75MG BASE

A075294 001 Mar 28, 2000

EQ 150MG BASE

A078192 001 Aug 31, 2007

IVAX SUB TEVA PHARMS

EQ 75MG BASE

A075296 001 Jan 14, 2000

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000

PERRIGO

EQ 75MG BASE

A076195 001 Aug 30, 2002

PERRIGO R AND D

EQ 150MG BASE

A091429 001 May 11, 2011

EQ 150MG BASE

A091429 002 May 11, 2011

SHASUN CHEMS

EQ 75MG BASE

A201745 001 Feb 29, 2012

SVADS HOLDINGS SA

EQ 150MG BASE

A200536 001 Jun 28, 2011

TORPHARM

EQ 75MG BASE

A075167 001 May 04, 2000

WOCKHARDT

EQ 75MG BASE

A076760 001 Feb 24, 2006

EQ 75MG BASE

A078884 001 Jul 31, 2008

ZANTAC 150

+ BOEHRINGER INGELHEIM

EQ 150MG BASE

N021698 001 Aug 31, 2004

EQ 150MG BASE

N021698 002 Mar 13, 2007

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE

N020520 001 Dec 19, 1995

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX 0.9%

N019912 001 Sep 03, 1992

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%; 0.3%

N020231 001 Jul 11, 1997

TERBINAFINE

GEL; TOPICAL

LAMISIL AT

+ NOVARTIS 1%

N021958 001 Jul 24, 2006

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+ NOVARTIS 1%

N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO 1%

A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+ NOVARTIS 1%

N021124 001 Mar 17, 2000

SPRAY; TOPICAL

LAMISIL AT

+ NOVARTIS 1%

N021124 002 Mar 17, 2000

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

PERRIGO 6.5%

A075915 001 Nov 21, 2001

VAGISTAT-1

+ NOVARTIS 6.5%

N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US 0.055MG/SPRAY

N020468 002 Oct 11, 2013

35TH EDITION - 2015 - APPROVED DRUG PRODUCT LIST

5 - 1 of 4

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N760305

Jun 30, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

ANDA

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

ANDA

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

NONE

HAEMONETICS

MANUFACTURING INC

A710497

ANDA

Nov 06, 1987

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

ARTERIOCYTE MEDICAL
SYSTEMS, INC

A110057

May 11, 2012

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

35TH EDITION - 2015 - APPROVED DRUG PRODUCT LIST

5 - 2 of 4

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION		
ADSOL IN PLASTIC CONTAINER		
FENWAL INC	N900223	Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION		
CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER		
FENWAL INC	N900224	Dec 27, 1991
MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB		
MACOPRODUCTIONS SAS	N040083	Nov 21, 2005
NONE		
TERUMO BCT INC	A070025	Jan 06, 2008

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION		
NONE		
FENWAL INC	N170401	Dec 06, 1977
	N811012	Jun 28, 1983
HAEMONETICS	N800222	Aug 23, 1982
MANUFACTURING INC		
TERUMO MEDICAL CORP	N781211	Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION		
FENWAL INC	N811104	May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION		
OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION		
TERUMO MEDICAL CORP	N880217	Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-3 NUTRICEL ADDITIVE SYSTEM		
HAEMONETICS	0.042GM/100ML;0.276GM/100ML;	N820915
MANUFACTURING INC	0.410GM/100ML;0.30GM/100ML;	
	1.10GM/100ML;0.588GM/100ML	Oct 19, 1984

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION		
AS-2 NUTRICEL ADDITIVE SYSTEM		
MEDSEP CORP	0.042GM/100ML;0.285GM/100ML;	N820915
	0.718GM/100ML;0.017GM/100ML;	
	0.396GM/100ML;0.588GM/100ML	Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION		
NONE		
HAEMONETICS	N980123	Mar 03, 2000
CORPORATION		

35TH EDITION - 2015 - APPROVED DRUG PRODUCT LIST

5 - 3 of 4

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CYTOSOL

LABORATORIES INC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N770923

Jan 20, 1978

TERUMO MEDICAL CORP

N781214

Feb 08, 1980

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC

10GM/100ML;5GM/100ML

A720563

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC

10GM/100ML;5GM/100ML

N160767

Apr 06, 1970

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC

10GM/100ML;0.9GM/100ML

A720562

ANDA

Oct 30, 1992

NONE

B BRAUN MEDICAL INC

10GM/100ML;0.9GM/100ML

N160767

Apr 06, 1970

DEXTRAN 70, 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

B BRAUN MEDICAL INC

6GM/100ML;0.9 GM/100ML

N090024

Aug 18, 1969

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952

Mar 31, 1999

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC

6GM/100ML;0.9GM/100ML

A740193

ANDA

Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC

6GM/100ML;0.9GM/100ML

N890105

Apr 04, 1991

NONE

B BRAUN MEDICAL INC

6GM/100ML;0.9GM/100ML

A740283

ANDA

Oct 21, 1998

TEVA PARENTERAL

6GM/100ML;0.9GM/100ML

A740592

ANDA

Nov 12, 1998

MEDICINES INC

35TH EDITION - 2015 - APPROVED DRUG PRODUCT LIST

5 - 4 of 4

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

NONE

B. BRAUN MEDICAL

A110013 ANDA Jan 09, 2015

VOLUVEN

FRESENIUS KABI

6GM/100ML; 0.9GM/100ML

N070012 NDA Dec 27, 2007

DEUTSCHLAND GMBH

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

INJECTABLE; INJECTION

ISOPLATE SOLUTION

HAEMONETICS CORP

N90067 Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HAEMONETICS CORP

N110059 Apr 25, 2013

PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

PENTASPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 10GM/100ML; 0.9GM/100ML

N890104 Apr 04, 1991

RED BLOOD CELL PROCESSING SOLUTION

INJECTABLE; INJECTION

REJUVESOL

CITRA LABS LLC

N950522 Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

INJECTABLE; INJECTION

INTERSOL SOLUTION

FENWAL INC.

2.26G/500ML; 2.21G/500ML; 1.59G/500ML;
1.53G/500ML; 0.465G/500ML

N080041 Dec 09, 2009

DISCONTINUED DRUG PRODUCT LIST

6-1 (of 337)

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN 100MG/VIAL

N021320 001 Nov 25, 2003

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

WATSON LABS

EQ 200MG BASE

A074007 001 Oct 18, 1995

EQ 400MG BASE

A074007 002 Oct 18, 1995

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM

100MG/ML

N017785 001 Mar 07, 1986

SUPPOSITORY; RECTAL

ACEPHEN

G AND W LABS

120MG

A072218 001 Mar 27, 1992

ACETAMINOPHEN

ABLE

120MG

A073106 001 Feb 27, 1995

325MG

A073107 001 Feb 27, 1995

650MG

A073108 001 Feb 27, 1995

ROXANE

120MG

A071010 001 May 12, 1987

650MG

A071011 001 May 12, 1987

TYLENOL

MCNEIL CONS

120MG

N017756 002

650MG

N017756 001

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

RANBAXY

650MG

A090205 001 Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART

150MG; 180MG; 15MG

A081095 001 Oct 26, 1990

150MG; 180MG; 30MG

A081096 001 Oct 26, 1990

150MG; 180MG; 60MG

A081097 001 Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

SCHERER LABS

150MG; 180MG; 15MG

A085640 001

CODEINE, ASPIRIN, APAP FORMULA NO. 3

SCHERER LABS

150MG; 180MG; 30MG

A085639 001

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS

150MG; 180MG; 60MG

A085638 001

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BANCAP

FOREST PHARMS

325MG; 50MG

A088889 001 Jan 16, 1986

BUCET

MALLINCKRODT

650MG; 50MG

A088991 001 Jun 28, 1985

PHRENILIN FORTE

VALEANT

650MG; 50MG

A088831 001 Jun 19, 1985

TENCON

MALLINCKRODT

650MG; 50MG

A089405 001 May 15, 1990

TRIAPRIN

DUNHALL

325MG; 50MG

A089268 001 Jul 02, 1987

TABLET; ORAL

BUTALBITAL AND ACETAMINOPHEN

HALSEY

325MG; 50MG

A089568 001 Oct 05, 1988

WATSON LABS

325MG; 50MG

A087550 001 Oct 19, 1984

BUTAPAP

MIKART

650MG; 50MG

A089988 001 Oct 26, 1992

PHRENILIN

VALEANT

325MG; 50MG

A087811 001 Jun 19, 1985

SEDAPAP

MAYRAND

650MG; 50MG

A088944 001 Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

SHIRE

325MG; 50MG; 40MG

A087628 001 Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GRAHAM DM

325MG; 50MG; 40MG

A088743 001 Jul 18, 1985

325MG; 50MG; 40MG

A088765 001 Mar 27, 1985

325MG; 50MG; 40MG

A089067 001 Apr 19, 1985

DISCONTINUED DRUG PRODUCT LIST

6-2 (of 337)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

HIKMA PHARMS LLC	500MG;50MG;40MG	A040261	001	Oct 28, 1998
MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

GILBERT LABS	325MG;50MG;40MG	A088825	001	Dec 05, 1984
--------------	-----------------	---------	-----	--------------

ESGIC-PLUS

MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996
--------	-----------------	---------	-----	--------------

FEMCET

MALLINCKRODT	325MG;50MG;40MG	A089102	001	Jun 19, 1985
--------------	-----------------	---------	-----	--------------

MEDIGESIC PLUS

US CHEM	325MG;50MG;40MG	A089115	001	Jan 14, 1986
---------	-----------------	---------	-----	--------------

TRIAD

MALLINCKRODT	325MG;50MG;40MG	A089023	001	Jun 19, 1985
--------------	-----------------	---------	-----	--------------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE	325MG;50MG;40MG	A040390	001	Jul 23, 2001
	500MG;50MG;40MG	A040394	001	Jul 23, 2001

GILBERT LABS	325MG;50MG;40MG	A087629	001	Nov 13, 1984
--------------	-----------------	---------	-----	--------------

HIKMA PHARMS LLC	500MG;50MG;40MG	A040336	001	Aug 18, 1999
------------------	-----------------	---------	-----	--------------

MIKART	750MG;50MG;40MG	A040496	001	Dec 23, 2003
--------	-----------------	---------	-----	--------------

MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008
---------------	-----------------	---------	-----	--------------

MIRROR PHARMS LLC	500MG;50MG;40MG	A040883	001	Dec 23, 2008
-------------------	-----------------	---------	-----	--------------

MUTUAL PHARM	325MG;50MG;40MG	A040601	001	Jul 29, 2005
--------------	-----------------	---------	-----	--------------

VINTAGE PHARMS	500MG;50MG;40MG	A040513	001	Aug 25, 2003
----------------	-----------------	---------	-----	--------------

WATSON LABS	325MG;50MG;40MG	A089536	001	Feb 16, 1988
-------------	-----------------	---------	-----	--------------

	500MG;50MG;40MG	A040267	001	Jul 30, 1998
--	-----------------	---------	-----	--------------

ESGIC

FOREST PHARMS	325MG;50MG;40MG	A089660	001	Dec 23, 1988
---------------	-----------------	---------	-----	--------------

ESGIC-PLUS

MIKART	500MG;50MG;40MG	A089451	001	May 23, 1988
--------	-----------------	---------	-----	--------------

FIORICET

WATSON PHARMS	325MG;50MG;40MG	A088616	001	Nov 09, 1984
---------------	-----------------	---------	-----	--------------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE	325MG;50MG;40MG;30MG	A076528	001	Aug 21, 2003
------	----------------------	---------	-----	--------------

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT	325MG;50MG;40MG;30MG	A074911	001	Aug 22, 2001
---------	----------------------	---------	-----	--------------

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART	356.4MG;30MG;16MG	A040109	001	Aug 26, 1997
--------	-------------------	---------	-----	--------------

WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007
-------------------	-------------------	---------	-----	--------------

DHC PLUS

PHARM RES ASSOC	356.4MG;30MG;16MG	A088584	001	Mar 04, 1986
-----------------	-------------------	---------	-----	--------------

SYNALGOS-DC-A

LEITNER PHARMS	356.4MG;30MG;16MG	A089166	001	May 14, 1986
----------------	-------------------	---------	-----	--------------

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC	712.8MG;60MG;32MG	A040701	001	Apr 03, 2007
-----------------	-------------------	---------	-----	--------------

MIKART	712.8MG;60MG;32MG	A040316	001	Apr 28, 1999
--------	-------------------	---------	-----	--------------

WEST-WARD PHARM CORP	712.8MG;60MG;32MG	A040637	001	Sep 22, 2006
----------------------	-------------------	---------	-----	--------------

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N021082	001	Mar 01, 2001
----------	---------------------------	---------	-----	--------------

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA	300MG;15MG	A088537	001	Jun 04, 1984
------	------------	---------	-----	--------------

	300MG;30MG	A088324	001	Dec 29, 1983
--	------------	---------	-----	--------------

	300MG;60MG	A088599	001	Jun 01, 1984
--	------------	---------	-----	--------------

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH	325MG;15MG	A084444	001	
-----------	------------	---------	-----	--

PHENAPHEN W/ CODEINE NO. 3

ROBINS AH	325MG;30MG	A084445	001	
-----------	------------	---------	-----	--

PHENAPHEN W/ CODEINE NO. 4

ROBINS AH	325MG;60MG	A084446	001	
-----------	------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-3 (of 337)

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

PROVAL #3

SOLVAY	325MG;30MG	A085685	001
TYLENOL W/ CODEINE NO. 3			
ORTHO MCNEIL PHARM	300MG;30MG	A087422	001
TYLENOL W/ CODEINE NO. 4			
ORTHO MCNEIL PHARM	300MG;60MG	A087421	001

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	
DAVA PHARMS INC	120MG/5ML;12MG/5ML	A040098	001	Sep 20, 1996
ROXANE	120MG/5ML;12MG/5ML	A086366	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	

SUSPENSION; ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085883	001
----------------------	--------------------	---------	-----

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE	300MG;30MG	A040452	001	Aug 01, 2002
	300MG;60MG	A040459	001	Aug 01, 2002
AM THERAP	300MG;15MG	A089478	001	Mar 03, 1987
	300MG;15MG	A089481	001	Mar 03, 1987
	300MG;30MG	A089479	001	Mar 03, 1987
	300MG;30MG	A089482	001	Mar 03, 1987
	300MG;60MG	A089480	001	Mar 03, 1987
	300MG;60MG	A089483	001	Mar 03, 1987
DURAMED PHARMS BARR	300MG;15MG	A040223	001	Nov 18, 1997
	300MG;15MG	A088353	001	Feb 06, 1984
	300MG;30MG	A040223	002	Nov 18, 1997
	300MG;30MG	A088354	001	Feb 06, 1984
	300MG;60MG	A040223	003	Nov 18, 1997
	300MG;60MG	A088355	001	Feb 06, 1984
EVERYLIFE	325MG;30MG	A085217	001	
HALSEY	300MG;15MG	A083871	001	
	300MG;30MG	A083872	001	
	300MG;60MG	A086549	001	
KV PHARM	300MG;30MG	A085288	001	
	300MG;60MG	A085365	001	
	325MG;15MG	A085364	001	
	325MG;45MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A085363	001	
LEDERLE	300MG;30MG	A087141	001	
MIKART	300MG;30MG	A089238	001	Feb 25, 1986
	300MG;60MG	A089244	001	Feb 25, 1986
	650MG;30MG	A089231	001	Mar 03, 1986
	650MG;60MG	A089363	001	Sep 09, 1991
MUTUAL PHARM	300MG;15MG	A085795	001	
	300MG;15MG	A089671	001	Feb 10, 1988
	300MG;30MG	A085794	001	
	300MG;30MG	A089672	001	Feb 10, 1988
	300MG;60MG	A087653	001	Apr 13, 1982
	300MG;60MG	A089673	001	Feb 10, 1988
PURACAP PHARM	300MG;30MG	A087762	001	Dec 10, 1982
PUREPAC PHARM	300MG;30MG	A086681	001	
	300MG;30MG	A089080	001	Jul 17, 1986
	300MG;60MG	A086683	001	
ROXANE	300MG;15MG	A084659	001	
	300MG;30MG	A084656	001	
	300MG;60MG	A084667	001	
	500MG;15MG	A089511	001	Apr 25, 1989
	500MG;30MG	A089512	001	Apr 25, 1989
	500MG;60MG	A089513	001	Apr 25, 1989
SANDOZ	300MG;15MG	A087433	001	
	300MG;30MG	A081250	001	Jul 16, 1992
	300MG;30MG	A085291	002	
	300MG;30MG	A085917	001	
	300MG;60MG	A081249	001	Jul 16, 1992
	300MG;60MG	A085964	001	
	300MG;60MG	A087423	001	

DISCONTINUED DRUG PRODUCT LIST

6-4 (of 337)

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

SUPERPHARM	300MG; 15MG	A089183	001	Oct 18, 1985
	300MG; 30MG	A089184	001	Oct 18, 1985
	300MG; 30MG	A089253	001	May 19, 1986
	300MG; 60MG	A089185	001	Oct 18, 1985
	300MG; 60MG	A089254	001	May 19, 1986
USL PHARMA	300MG; 30MG	A087919	001	Jun 22, 1982
	300MG; 60MG	A087920	001	Jun 22, 1982
VALEANT PHARM INTL	300MG; 30MG	A085896	001	
VITARINE	300MG; 30MG	A085676	001	
WARNER CHILCOTT	300MG; 15MG	A085992	001	
	300MG; 30MG	A085218	002	
	300MG; 60MG	A087306	001	
WATSON LABS	300MG; 15MG	A087277	001	May 26, 1982
	300MG; 15MG	A089997	001	Dec 28, 1994
	300MG; 30MG	A087276	001	May 26, 1982
	300MG; 30MG	A089998	001	Dec 28, 1994
	300MG; 60MG	A087275	001	May 26, 1982
	300MG; 60MG	A089999	001	Dec 28, 1994
WATSON LABS FLORIDA	300MG; 15MG	A040443	001	Jan 22, 2003
	300MG; 30MG	A040443	002	Jan 22, 2003
	300MG; 60MG	A040443	003	Jan 22, 2003
WHITEWORTH TOWN PLSN	300MG; 30MG	A084360	001	
	300MG; 60MG	A085607	001	
CAPITAL AND CODEINE				
CARNRICK	325MG; 30MG	A083643	001	
CODRIX				
WATSON LABS FLORIDA	500MG; 15MG	A040447	001	Feb 26, 2003
	500MG; 30MG	A040441	001	Mar 27, 2003
	500MG; 60MG	A040488	001	Mar 28, 2003
EMPRACET W/ CODEINE PHOSPHATE #3				
GLAXOSMITHKLINE	300MG; 30MG	A083951	001	
EMPRACET W/ CODEINE PHOSPHATE #4				
GLAXOSMITHKLINE	300MG; 60MG	A083951	002	
PAPA-DEINE #3				
VANGARD	300MG; 30MG	A088037	001	Mar 20, 1984
PAPA-DEINE #4				
VANGARD	300MG; 60MG	A088715	001	Mar 20, 1984
PHENAPHEN-650 W/ CODEINE				
ROBINS AH	650MG; 30MG	A085856	001	
TYLENOL W/ CODEINE				
ORTHO MCNEIL PHARM	325MG; 7.5MG	A085056	001	
	325MG; 15MG	A085056	002	
	325MG; 30MG	A085056	003	
	325MG; 60MG	A085056	004	
TYLENOL W/ CODEINE NO. 1				
JANSSEN PHARMS	300MG; 7.5MG	A085055	001	
TYLENOL W/ CODEINE NO. 2				
JANSSEN PHARMS	300MG; 15MG	A085055	002	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

SCHERING PLOUGH	500MG; 3MG; 60MG	N019453	001	May 22, 1987
-----------------	------------------	---------	-----	--------------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG; 5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG; 5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG; 5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG; 5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG; 5MG	A088956	001	Jul 19, 1985
	500MG; 5MG	A089006	001	Aug 09, 1985
MIKART	500MG; 5MG	A081067	001	Nov 30, 1989
	500MG; 5MG	A081068	001	Nov 30, 1989
	500MG; 5MG	A081069	001	Nov 30, 1989

DISCONTINUED DRUG PRODUCT LIST

6-5 (of 337)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

500MG; 5MG

A081070 001 Nov 30, 1989

500MG; 5MG

A089008 001 Feb 21, 1986

LORCET-HD

MALLINCKRODT

500MG; 5MG

A087336 001 Jul 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT

500MG/15ML; 7.5MG/15ML

A040418 001 Jun 27, 2001

MALLINCKRODT INC

500MG/15ML; 10MG/15ML

A040508 001 Aug 29, 2003

MIKART

500MG/15ML; 5MG/15ML

A081226 001 Oct 27, 1992

500MG/15ML; 5MG/15ML

A089557 001 Apr 29, 1992

500MG/15ML; 7.5MG/15ML

A081051 001 Aug 28, 1992

NESHER PHARMS

500MG/15ML; 7.5MG/15ML

A040366 001 Jan 23, 2002

PHARM ASSOC

500MG/15ML; 7.5MG/15ML

A040182 001 Mar 13, 1998

VINTAGE PHARMS

500MG/15ML; 7.5MG/15ML

A040520 001 Oct 30, 2003

TABLET; ORAL

ANEXSIA

MALLINCKRODT

500MG; 5MG

A089160 001 Apr 23, 1987

750MG; 10MG

A040468 001 Oct 31, 2002

ANEXSIA 7.5/650

MALLINCKRODT

650MG; 7.5MG

A089725 001 Sep 30, 1987

CO-GESIC

UCB INC

500MG; 5MG

A087757 001 May 03, 1982

DURADYNE DHC

FOREST PHARMS

500MG; 5MG

A087809 001 Mar 17, 1983

HY-PHEN

ASCHER

500MG; 5MG

A087677 001 May 03, 1982

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

ABLE

325MG; 5MG

A040478 001 Nov 08, 2002

325MG; 7.5MG

A040464 001 Oct 23, 2002

325MG; 10MG

A040464 002 Oct 23, 2002

500MG; 5MG

A040477 001 Nov 06, 2002

500MG; 7.5MG

A040490 001 May 21, 2003

500MG; 10MG

A040473 001 Nov 06, 2002

650MG; 7.5MG

A040474 001 Jan 02, 2003

650MG; 10MG

A040476 001 Oct 23, 2002

750MG; 7.5MG

A040469 001 Oct 25, 2002

ACTAVIS LABS FL INC

500MG; 10MG

A040148 002 Feb 14, 1997

AMNEAL PHARMS NY

500MG; 5MG

A040729 001 Aug 25, 2006

500MG; 7.5MG

A040748 001 Aug 25, 2006

500MG; 10MG

A040813 001 Feb 23, 2007

650MG; 7.5MG

A040754 001 Aug 25, 2006

650MG; 10MG

A040757 001 Aug 25, 2006

750MG; 7.5MG

A040769 001 Aug 28, 2006

BARR

500MG; 2.5MG

A040307 001 Jul 26, 2000

500MG; 5MG

A040308 001 Jul 26, 2000

500MG; 5MG

A088577 001 Dec 21, 1984

500MG; 7.5MG

A040307 002 Jul 26, 2000

500MG; 10MG

A040309 001 Jul 26, 2000

650MG; 7.5MG

A040307 003 Jul 26, 2000

650MG; 10MG

A040307 004 Jul 26, 2000

750MG; 7.5MG

A040308 002 Jul 26, 2000

CARACO

500MG; 5MG

A090265 001 Dec 23, 2008

500MG; 7.5MG

A090265 002 Dec 23, 2008

500MG; 10MG

A090265 003 Dec 23, 2008

650MG; 7.5MG

A090380 001 Dec 23, 2008

650MG; 10MG

A090380 002 Dec 23, 2008

660MG; 10MG

A090380 003 Dec 23, 2008

750MG; 7.5MG

A090380 004 Dec 23, 2008

HALSEY

500MG; 5MG

A089554 001 Jun 12, 1987

IVAX PHARMS

500MG; 5MG

A089696 001 Apr 21, 1988

MALLINCKRODT

500MG; 5MG

A040084 002 Jun 01, 1995

500MG; 7.5MG

A040201 001 Feb 27, 1998

500MG; 10MG

A040201 002 Feb 27, 1998

650MG; 10MG

A040084 004 Oct 16, 1996

660MG; 10MG

A040084 003 Jul 29, 1996

750MG; 7.5MG

A040084 001 Jun 01, 1995

MIKART

500MG; 2.5MG

A089698 001 Aug 25, 1989

500MG; 5MG

A089271 001 Jul 16, 1986

500MG; 5MG

A089697 001 Jan 28, 1992

DISCONTINUED DRUG PRODUCT LIST

6-6 (of 337)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	500MG; 7.5MG	A089699 001	Aug 25, 1989
	650MG; 5MG	A040849 001	Jun 09, 2010
	650MG; 7.5MG	A089689 001	Jun 29, 1988
	650MG; 10MG	A081223 001	May 29, 1992
MUTUAL PHARM	500MG; 5MG	A040236 001	Sep 25, 1997
	650MG; 7.5MG	A040240 002	Nov 26, 1997
	650MG; 10MG	A040240 001	Nov 26, 1997
	750MG; 7.5MG	A040236 002	Sep 25, 1997
RANBAXY	500MG; 5MG	A040825 001	Aug 16, 2007
	500MG; 10MG	A040824 001	Aug 16, 2007
RANBAXY LABS LTD	325MG; 10MG	A040826 001	Aug 16, 2007
	750MG; 7.5MG	A040822 001	Aug 16, 2007
SANDOZ	500MG; 5MG	A040149 001	Jan 27, 1997
	750MG; 7.5MG	A040149 002	Jan 27, 1997
UCB INC	500MG; 10MG	A040210 001	Aug 13, 1997
	650MG; 7.5MG	A040134 001	Nov 21, 1996
USL PHARMA	500MG; 5MG	A089290 001	May 29, 1987
	500MG; 5MG	A089291 001	May 29, 1987
VINTAGE PHARMS	500MG; 2.5MG	A040144 002	Apr 25, 1997
	500MG; 5MG	A089831 001	Sep 07, 1988
	500MG; 5MG	A089971 001	Dec 02, 1988
	500MG; 7.5MG	A040144 001	Feb 22, 1996
	500MG; 10MG	A040356 001	May 31, 2000
	650MG; 7.5MG	A040155 001	Apr 14, 1997
	650MG; 10MG	A040143 001	Feb 22, 1996
	660MG; 10MG	A040358 001	May 31, 2000
	750MG; 7.5MG	A040157 001	Apr 12, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040281 001	Sep 30, 1998
	500MG; 7.5MG	A040280 001	Sep 30, 1998
	650MG; 7.5MG	A040280 002	Sep 30, 1998
	650MG; 10MG	A040280 003	Sep 30, 1998
	750MG; 7.5MG	A040281 002	Sep 30, 1998
WATSON LABS	325MG; 7.5MG	A040248 001	Apr 28, 2000
	325MG; 10MG	A040248 002	Apr 28, 2000
	500MG; 2.5MG	A040123 003	Mar 04, 1996
	500MG; 2.5MG	A081079 001	Aug 30, 1991
	500MG; 5MG	A040122 001	Mar 04, 1996
	500MG; 5MG	A089883 001	Dec 01, 1988
	500MG; 7.5MG	A040123 004	Mar 04, 1996
	500MG; 7.5MG	A081080 001	Aug 30, 1991
	650MG; 7.5MG	A040094 001	Sep 29, 1995
	650MG; 7.5MG	A040123 001	Mar 04, 1996
	650MG; 10MG	A040094 002	Sep 29, 1995
	650MG; 10MG	A040123 002	Mar 04, 1996
	660MG; 10MG	A040094 003	Aug 08, 2000
	750MG; 7.5MG	A040122 002	Mar 04, 1996
	750MG; 7.5MG	A081083 001	Aug 30, 1991
	750MG; 10MG	A040094 004	Mar 22, 1999
WATSON LABS FLORIDA	500MG; 5MG	A040493 001	May 28, 2003
	660MG; 10MG	A040495 001	May 28, 2003
	750MG; 7.5MG	A040494 001	May 28, 2003
LORTAB			
UCB INC	500MG; 5MG	A087722 001	Jul 09, 1982
	500MG; 10MG	A040100 001	Jan 26, 1996
NORCET			
ABANA	500MG; 5MG	A088871 001	May 15, 1986
TYCOLET			
ORTHO MCNEIL PHARM	500MG; 5MG	A089385 001	Aug 27, 1986
VICODIN			
ABBOTT	500MG; 5MG	A085667 001	
ABBVIE	500MG; 5MG	A088058 001	Jan 07, 1983
VICODIN ES			
ABBVIE	750MG; 7.5MG	A089736 001	Dec 09, 1988
VICODIN HP			
ABBVIE	660MG; 10MG	A040117 001	Sep 23, 1996
ZYDONE			
VINTAGE PHARMS LLC	400MG; 5MG	A040288 001	Nov 27, 1998
	400MG; 7.5MG	A040288 002	Nov 27, 1998
	400MG; 10MG	A040288 003	Nov 27, 1998

DISCONTINUED DRUG PRODUCT LIST

6-7 (of 337)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998
BARR	500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY	500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997

ROXILOX

ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995
--------	------------	---------	-----	--------------

TYLOX

JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984
----------------	------------	---------	-----	--------------

TYLOX-325

ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001	Nov 08, 1984
--------------------	------------	---------	-----	--------------

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006
------------------	--------------------	---------	-----	--------------

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001	
----------------------	--------------	---------	-----	--

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001	
----------------------	------------	---------	-----	--

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999
	325MG; 7.5MG	A040800	001	Apr 03, 2012
	325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007
	650MG; 10MG	A040789	002	Nov 27, 2007
BARR	325MG; 5MG	A087406	001	
COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008
	650MG; 10MG	A090177	006	Oct 20, 2008
DURAMED PHARMS BARR	325MG; 5MG	A040272	001	Jun 30, 1998
MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004
	650MG; 10MG	A040550	002	Jun 30, 2004
MIKART	400MG; 2.5MG	A040679	001	May 16, 2006
	400MG; 5MG	A040687	001	Apr 27, 2006
	400MG; 7.5MG	A040698	001	Apr 27, 2006
	400MG; 10MG	A040692	001	Apr 27, 2006
	500MG; 10MG	A040676	001	Apr 19, 2006
WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000
	650MG; 10MG	A040371	002	Dec 29, 2000

PERCOCET

VINTAGE PHARMS LLC	325MG; 5MG	A085106	002	
	500MG; 7.5MG	A040341	001	Jul 26, 1999
	650MG; 10MG	A040341	002	Jul 26, 1999

ROXICET 5/500

ROXANE	500MG; 5MG	A089775	001	Jan 12, 1989
--------	------------	---------	-----	--------------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE; ORAL

TYLOX

ORTHO MCNEIL PHARM	500MG; 4.5MG; 0.38MG	A085375	001	
--------------------	----------------------	---------	-----	--

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002
WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000

TALACEN

SANOFI AVENTIS US	650MG; EQ 25MG BASE	N018458	001	Sep 23, 1982
-------------------	---------------------	---------	-----	--------------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

DARVOCET

AAIPHARMA LLC	325MG; 32.5MG	N016844	001	
---------------	---------------	---------	-----	--

DOLENE AP-65

LEDERLE	650MG; 65MG	A085100	001	
---------	-------------	---------	-----	--

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN	650MG; 65MG	A083978	001	
SANDOZ	650MG; 65MG	A089959	001	Jul 18, 1989

DISCONTINUED DRUG PRODUCT LIST

6-8 (of 337)

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

VINTAGE PHARMS	650MG; 65MG	A040507	001	Jul 30, 2003
WATSON LABS	650MG; 65MG	A040139	001	Dec 16, 1996
WYGESIC				
CARACO	650MG; 65MG	A084999	001	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET A500

XANODYNE PHARM	500MG; 100MG	A076429	001	Sep 10, 2003
----------------	--------------	---------	-----	--------------

DARVOCET-N 100

XANODYNE PHARM	650MG; 100MG	N017122	002	
----------------	--------------	---------	-----	--

DARVOCET-N 50

XANODYNE PHARM	325MG; 50MG	N017122	001	
----------------	-------------	---------	-----	--

PROPACET 100

TEVA	650MG; 100MG	A070107	001	Jun 12, 1985
------	--------------	---------	-----	--------------

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE	650MG; 100MG	A075838	001	Jul 11, 2001
------	--------------	---------	-----	--------------

ACTAVIS ELIZABETH	650MG; 100MG	A070910	001	Jan 02, 1987
-------------------	--------------	---------	-----	--------------

CORNERSTONE	325MG; 100MG	A076743	001	May 07, 2004
-------------	--------------	---------	-----	--------------

	500MG; 100MG	A076750	001	Jun 28, 2004
--	--------------	---------	-----	--------------

HALSEY	325MG; 50MG	A072105	001	May 13, 1988
--------	-------------	---------	-----	--------------

	650MG; 100MG	A072106	001	May 13, 1988
--	--------------	---------	-----	--------------

IVAX SUB TEVA PHARMS	650MG; 100MG	A070146	001	Aug 02, 1985
----------------------	--------------	---------	-----	--------------

MALLINCKRODT	650MG; 100MG	A075738	001	Feb 02, 2001
--------------	--------------	---------	-----	--------------

MIRROR PHARMS	650MG; 100MG	A077821	001	Feb 11, 2008
---------------	--------------	---------	-----	--------------

MUTUAL PHARM	325MG; 50MG	A070115	001	Jun 12, 1985
--------------	-------------	---------	-----	--------------

	650MG; 100MG	A070116	001	Jun 12, 1985
--	--------------	---------	-----	--------------

	650MG; 100MG	A070615	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070771	001	Mar 21, 1986
--	--------------	---------	-----	--------------

	650MG; 100MG	A070775	001	Mar 21, 1986
--	--------------	---------	-----	--------------

MYLAN	650MG; 100MG	A072195	001	Feb 16, 1988
-------	--------------	---------	-----	--------------

MYLAN PHARMS INC	650MG; 100MG	A070145	001	Jun 12, 1985
------------------	--------------	---------	-----	--------------

SANDOZ	650MG; 100MG	A070443	001	Jan 23, 1986
--------	--------------	---------	-----	--------------

SUPERPHARM	650MG; 100MG	A071319	001	Jan 06, 1987
------------	--------------	---------	-----	--------------

TEVA	650MG; 100MG	A070732	001	Jan 03, 1986
------	--------------	---------	-----	--------------

	650MG; 100MG	A074119	001	Dec 19, 1994
--	--------------	---------	-----	--------------

VINTAGE PHARMS	325MG; 50MG	A074843	002	Feb 15, 2001
----------------	-------------	---------	-----	--------------

	650MG; 100MG	A074843	001	Feb 12, 1997
--	--------------	---------	-----	--------------

WATSON LABS	325MG; 50MG	A070398	001	Dec 18, 1986
-------------	-------------	---------	-----	--------------

	650MG; 100MG	A070399	001	Dec 18, 1986
--	--------------	---------	-----	--------------

WATSON LABS FLORIDA	500MG; 100MG	A077196	001	Jun 28, 2005
---------------------	--------------	---------	-----	--------------

	650MG; 100MG	A076609	001	Nov 16, 2004
--	--------------	---------	-----	--------------

WOCKHARDT LTD	325MG; 50MG	A077677	001	Mar 16, 2007
---------------	-------------	---------	-----	--------------

	650MG; 100MG	A077677	002	Mar 16, 2007
--	--------------	---------	-----	--------------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006
-------------	---------------	---------	-----	--------------

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
------	-------	---------	-----	--

ASCOT	250MG	A087686	001	Oct 20, 1982
-------	-------	---------	-----	--------------

MUTUAL PHARM	250MG	A089753	001	Jun 22, 1988
--------------	-------	---------	-----	--------------

VANGARD	250MG	A087654	001	Feb 05, 1982
---------	-------	---------	-----	--------------

WATSON LABS	250MG	A084498	002	
-------------	-------	---------	-----	--

	250MG	A088882	001	Oct 22, 1985
--	-------	---------	-----	--------------

DIAMOX

TEVA BRANDED PHARM	125MG **Federal Register determination	N008943	001	
--------------------	--	---------	-----	--

	that product was not discontinued or			
	withdrawn for safety or efficacy			
	reasons**			

	250MG **Federal Register determination	N008943	002	
--	--	---------	-----	--

	that product was not discontinued or			
	withdrawn for safety or efficacy			
	reasons**			

DISCONTINUED DRUG PRODUCT LIST

6-9 (of 337)

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA

EQ 500MG BASE/VIAL

A040108 001 Oct 30, 1995

DIAMOX

TEVA WOMENS

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N009388 001 Dec 05, 1990

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETASOL

ACTAVIS MID ATLANTIC

2%

A087146 001

ACETIC ACID

KV PHARM

2%

A085493 001

ORLEX

WARNER CHILCOTT

2%

A086845 001

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

BOROFAIR

PHARMAFAIR

2%; 0.79%

A088606 001 Aug 21, 1985

DOMEBORO

BAYER PHARMS

2%; 0.79%

A084476 001

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON

BAYER PHARMS

2%; 0.05%

N017914 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETIC ACID W/ HYDROCORTISONE

KV PHARM

2%; 1%

A085492 001

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB

2%; 1%

A040097 001 Oct 31, 1994

WOCKHARDT

2%; 1%

A040168 001 Aug 30, 1996

ORLEX HC

WARNER CHILCOTT

2%; 1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS; OTIC

NEO-CORT-DOME

BAYER PHARMS

2%; 1%; EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

BARR

250MG

A070869 001 Feb 09, 1987

500MG

A070870 001 Feb 09, 1987

USL PHARMA

250MG

A070753 001 Nov 03, 1986

500MG

A070754 001 Nov 03, 1986

WATSON LABS

250MG

A071893 001 Nov 25, 1987

500MG

A071894 001 Nov 25, 1987

DYMELOR

LILLY

250MG

N013378 002

500MG

N013378 001

ACETOPHENAZINE MALEATE

TABLET; ORAL

TINDAL

SCHERING

20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION; INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM

53%

N009008 001

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL

NOVARTIS

20MG/VIAL

N016211 001

DISCONTINUED DRUG PRODUCT LIST

6-10 (of 337)

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA	10%	A071364	001	May 01, 1989
	20%	A071365	001	May 01, 1989
ROXANE	10%	A072323	001	Apr 30, 1992
	10%	A072621	001	Sep 30, 1992
	20%	A072324	001	Apr 30, 1992
	20%	A072622	001	Sep 30, 1992
MUCOMYST				
APOTHECON	10%	N013601	002	
	20%	N013601	001	
MUCOSIL-10				
DEY	10%	A070575	001	Oct 14, 1986
MUCOSIL-20				
DEY	20%	A070576	001	Oct 14, 1986

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON	10%; 0.05%	N017366	001	
--------------	------------	---------	-----	--

ACETYLDIGITOXIN

TABLET; ORAL

ACYLANID

NOVARTIS	0.1MG	N009436	001	
----------	-------	---------	-----	--

ACRISORCIN

CREAM; TOPICAL

AKRINOL

SCHERING	2MG/GM	N012470	001	
----------	--------	---------	-----	--

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	200MG	A074906	001	Aug 26, 1997
DAVA PHARMS INC	200MG	A074872	001	Apr 22, 1997
HERITAGE PHARMS INC	200MG	A074889	001	Oct 31, 1997
IVAX SUB TEVA PHARMS	200MG	A074674	001	Apr 22, 1997
LEK PHARM	200MG	A074750	001	Apr 22, 1997
MYLAN	200MG	A074977	001	Apr 13, 1998
ROXANE	200MG	A074570	002	Apr 22, 1997
TEVA	200MG	A074828	001	Apr 22, 1997
TEVA PHARMS	200MG	A074914	001	Nov 26, 1997
WATSON LABS	200MG	A075101	001	Apr 15, 1998

TABLET; ORAL

ACYCLOVIR

ACTAVIS ELIZABETH	400MG	A074870	001	Jun 05, 1997
	800MG	A074870	002	Jun 05, 1997
DAVA PHARMS INC	400MG	A074834	001	Apr 24, 1997
	800MG	A074834	002	Apr 24, 1997
HERITAGE PHARMS INC	400MG	A074891	001	Oct 31, 1997
	800MG	A074891	002	Oct 31, 1997
IVAX SUB TEVA PHARMS	400MG	A074836	001	Apr 22, 1997
	800MG	A074836	002	Apr 22, 1997
LEK PHARM	400MG	A074658	001	Apr 22, 1997
	800MG	A074658	002	Apr 22, 1997
MYLAN	400MG	A074976	001	Apr 13, 1998
	800MG	A074976	002	Apr 13, 1998
TEVA	200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A074556	001	Apr 22, 1997
TEVA PHARMS	400MG	A075021	001	Mar 18, 1998
	800MG	A075021	002	Mar 18, 1998

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE

EQ 50MG BASE/ML	A075114	001	Jul 26, 1999
-----------------	---------	-----	--------------

ACYCLOVIR SODIUM

APOTHECON

EQ 1GM BASE/VIAL	A074897	002	Feb 27, 1998
------------------	---------	-----	--------------

EQ 500MG BASE/VIAL

A074897	001	Feb 27, 1998
---------	-----	--------------

EQ 1GM BASE/VIAL

A074913	002	Oct 15, 1997
---------	-----	--------------

EQ 500MG BASE/VIAL

A074913	001	Oct 15, 1997
---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-11 (of 337)

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

HOSPIRA

EQ 1GM BASE/VIAL

A074663 002 Apr 22, 1997

EQ 1GM BASE/VIAL

A074758 002 Apr 22, 1997

EQ 25MG BASE/ML

A074720 001 Apr 22, 1997

EQ 50MG BASE/ML

A075065 001 Feb 25, 1999

EQ 500MG BASE/VIAL

A074663 001 Apr 22, 1997

EQ 500MG BASE/VIAL

A074758 001 Apr 22, 1997

TEVA PARENTERAL

EQ 1GM BASE/VIAL

A074969 002 Aug 26, 1997

EQ 50MG BASE/ML

A075627 001 Mar 28, 2001

EQ 500MG BASE/VIAL

A074969 001 Aug 26, 1997

ZOVIRAX

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018603 002 Jun 29, 1989

EQ 250MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018603 003 Aug 30, 1983

EQ 500MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018603 001 Oct 22, 1982

ADAPALENE

SOLUTION; TOPICAL

DIFFERIN

GALDERMA LABS LP

0.1%

N020338 001 May 31, 1996

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

HIKMA MAPLE

3MG/ML

A076501 001 Jun 16, 2004

TEVA PHARMS USA

3MG/ML

A076564 001 Jun 16, 2004

3MG/ML

A078676 001 Jul 31, 2008

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER

EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBUMIN CHROMATED CR-51 SERUM

INJECTABLE; INJECTION

CHROMALBIN

ISO TEX

100uCi/VIAL

N017835 001

250uCi/VIAL

N017835 002

500uCi/VIAL

N017835 003

ALBUMIN IODINATED I-125 SERUM

INJECTABLE; INJECTION

RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)

BAYER PHARMS

2.5uCi/AMP

N017846 001

RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125

MALLINCKRODT

6.67uCi/ML

N017844 003

10uCi/ML

N017844 001

100uCi/ML

N017844 002

ALBUMIN IODINATED I-131 SERUM

INJECTABLE; INJECTION

MEGATOPE

ISO TEX

2mCi/VIAL

N017837 003

5uCi/AMP

N017837 004

20uCi/AMP

N017837 005

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS

0.09MG/INH

A072273 001 Aug 14, 1996

GENPHARM

0.09MG/INH

A073045 001 Aug 19, 1997

IVAX SUB TEVA PHARMS

0.09MG/INH

A073272 001 Dec 28, 1995

PLIVA

0.09MG/INH

A074072 001 Aug 01, 1996

PROVENTIL

SCHERING

0.09MG/INH

N017559 001

DISCONTINUED DRUG PRODUCT LIST

6-12 (of 337)

ALBUTEROL

AEROSOL, METERED; INHALATION

VENTOLIN

GLAXOSMITHKLINE

0.09MG/INH

N018473 001

ALBUTEROL SULFATE

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE

EQ 0.2MG BASE

N019489 001 May 04, 1988

SOLUTION; INHALATION

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC

EQ 0.083% BASE

A073533 001 Sep 26, 1995

APOTEX INC

EQ 0.021% BASE

A078623 001 Apr 05, 2010

EQ 0.042% BASE

A078623 002 Apr 05, 2010

EQ 0.083% BASE

A075717 001 Feb 02, 2007

EQ 0.5% BASE

A076391 001 Apr 01, 2003

BAUSCH AND LOMB

EQ 0.083% BASE

A075358 001 Mar 29, 2000

COPLEY PHARM

EQ 0.083% BASE

A073495 001 May 28, 1993

EQ 0.5% BASE

A073307 001 Nov 27, 1991

ROXANE

EQ 0.083% BASE

A075129 001 Feb 13, 2001

WOCKHARDT EU OPERATN

EQ 0.083% BASE

A075394 001 Nov 22, 1999

PROVENTIL

SCHERING

EQ 0.083% BASE

N019243 002 Jan 14, 1987

EQ 0.5% BASE

N019243 001 Jan 14, 1987

VENTOLIN

GLAXOSMITHKLINE

EQ 0.083% BASE

N019773 001 Apr 23, 1992

EQ 0.5% BASE

N019269 002 Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC

EQ 2MG BASE/5ML

A075262 001 Mar 30, 1999

MOVA

EQ 2MG BASE/5ML

A074302 001 Sep 30, 1994

WATSON LABS

EQ 2MG BASE/5ML

A073165 001 Apr 29, 1993

PROVENTIL

SCHERING

EQ 2MG BASE/5ML

N018062 001 Jan 19, 1983

VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE/5ML

N019621 001 Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP

EQ 2MG BASE

A072449 001 Dec 05, 1989

EQ 4MG BASE

A072450 001 Dec 05, 1989

COPLEY PHARM

EQ 2MG BASE

A072966 001 Nov 22, 1991

EQ 4MG BASE

A072967 001 Nov 22, 1991

DAVA PHARMS INC

EQ 2MG BASE

A072859 001 Dec 20, 1989

EQ 4MG BASE

A072860 001 Dec 20, 1989

PLIVA

EQ 2MG BASE

A072316 001 Dec 05, 1989

EQ 4MG BASE

A072317 001 Dec 05, 1989

SANDOZ

EQ 2MG BASE

A072151 001 Dec 05, 1989

EQ 4MG BASE

A072152 001 Dec 05, 1989

TEVA

EQ 2MG BASE

A072619 001 Dec 05, 1989

EQ 2MG BASE

A072779 001 Jun 25, 1993

EQ 2MG BASE

A072938 001 Mar 30, 1990

EQ 4MG BASE

A072620 001 Dec 05, 1989

EQ 4MG BASE

A072780 001 Jun 25, 1993

EQ 4MG BASE

A072939 001 Mar 30, 1990

UCB INC

EQ 2MG BASE

A073120 001 Sep 29, 1992

EQ 4MG BASE

A073121 001 Sep 29, 1992

WARNER CHILCOTT

EQ 2MG BASE

A072817 001 Jan 09, 1990

EQ 4MG BASE

A072818 001 Jan 09, 1990

WATSON LABS

EQ 2MG BASE

A072629 001 Jan 31, 1991

EQ 2MG BASE

A072764 001 Aug 28, 1991

EQ 4MG BASE

A072630 001 Jan 31, 1991

EQ 4MG BASE

A072765 001 Aug 28, 1991

PROVENTIL

SCHERING

EQ 2MG BASE

N017853 001 May 07, 1982

EQ 4MG BASE

N017853 002 May 07, 1982

VENTOLIN

GLAXOSMITHKLINE

EQ 2MG BASE

N019112 001 Jul 10, 1986

EQ 4MG BASE

N019112 002 Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

SCHERING

EQ 4MG BASE

N019383 001 Jul 13, 1987

DISCONTINUED DRUG PRODUCT LIST

6-13 (of 337)

ALBUTEROL SULFATE

TABLET, EXTENDED RELEASE; ORAL

VOLMAX

MURO

EQ 4MG BASE

N019604 002 Dec 23, 1992

EQ 8MG BASE

N019604 001 Dec 23, 1992

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC

EQ 0.083% BASE; 0.017%

A077117 001 Dec 31, 2007

SANDOZ INC

EQ 0.083% BASE; 0.017%

A076867 001 Dec 21, 2006

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05%

N018707 001 Dec 14, 1982

OINTMENT; TOPICAL

ACLOVATE

FOUGERA PHARMS

0.05%

N018702 001 Dec 14, 1982

ALCOHOL

INJECTABLE; INJECTION

ALCOHOL 5% IN DEXTROSE 5%

MILES

5ML/100ML

A083483 001

ALCOHOL; DEXTROSE

INJECTABLE; INJECTION

ALCOHOL 5% IN D5-W

HOSPIRA

5ML/100ML; 5GM/100ML

A083263 001

ALCOHOL 5% IN DEXTROSE 5% IN WATER

BAXTER HLTHCARE

5ML/100ML; 5GM/100ML

A083256 001

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

MYLAN

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

SANDOZ

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

FOSAMAX

MERCK AND CO INC

EQ 5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020560 003 Apr 25, 1997

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020560 001 Sep 29, 1995

EQ 35MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020560 004 Oct 20, 2000

EQ 40MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020560 002 Sep 29, 1995

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

GENZYME

10 UNITS/ML

N020057 004 May 08, 1992

80 UNITS/ML

N020057 003 Apr 05, 1991

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009

DISCONTINUED DRUG PRODUCT LIST

6-14 (of 337)

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

MUTUAL PHARM

100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM

100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

PUREPAC PHARM

100MG

A070579 001 Apr 14, 1986

300MG

A070580 001 Apr 14, 1986

SANDOZ

100MG

A070268 001 Dec 31, 1985

300MG

A070269 001 Dec 31, 1985

SUPERPHARM

100MG

A070950 001 Nov 30, 1988

300MG

A070951 001 Nov 30, 1988

WATSON LABS

100MG

N018241 001 Nov 16, 1984

100MG

N018785 001 Sep 28, 1984

300MG

N018241 002 Nov 16, 1984

300MG

N018785 002 Sep 28, 1984

LOPURIN

ABBOTT

100MG

N018297 001

300MG

N018297 002

ALPRAZOLAM

SOLUTION; ORAL

ALPRAZOLAM

ROXANE

0.5MG/5ML

A074314 001 Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

IVAX SUB TEVA PHARMS

0.25MG

A074294 001 Jul 29, 1994

0.5MG

A074294 002 Jul 29, 1994

1MG

A074294 003 Jul 29, 1994

2MG

A074294 004 Jul 29, 1994

ROXANE

0.25MG

A074199 001 Oct 19, 1993

0.5MG

A074199 002 Oct 19, 1993

1MG

A074199 003 Oct 19, 1993

TEVA

0.25MG

A074085 001 Feb 16, 1994

0.5MG

A074085 002 Feb 16, 1994

1MG

A074085 003 Feb 16, 1994

2MG

A074085 004 Feb 26, 1996

WATSON LABS

0.25MG

A074456 001 Aug 31, 1995

0.25MG

A074479 001 Jan 21, 1997

0.5MG

A074456 002 Aug 31, 1995

0.5MG

A074479 002 Jan 21, 1997

1MG

A074456 003 Aug 31, 1995

1MG

A074479 003 Jan 21, 1997

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

ANI PHARMS INC

0.5MG

A077979 001 Feb 28, 2007

1MG

A077979 002 Feb 28, 2007

2MG

A077979 003 Feb 28, 2007

3MG

A077979 004 Feb 28, 2007

SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006

1MG

A077777 002 Jun 30, 2006

2MG

A077777 003 Jun 30, 2006

3MG

A077777 004 Jun 30, 2006

VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007

1MG

A078442 002 Oct 15, 2007

2MG

A078442 003 Oct 15, 2007

3MG

A078442 004 Oct 15, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

UCB INC

0.25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 001 Jan 19, 2005

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 002 Jan 19, 2005

DISCONTINUED DRUG PRODUCT LIST

6-15 (of 337)

ALPRAZOLAMTABLET, ORALLY DISINTEGRATING; ORAL
NIRAVAM1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 003 Jan 19, 2005

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021726 004 Jan 19, 2005

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

PFIZER

0.005MG/ML

N020755 001 Oct 31, 1997

0.01MG/ML

N020755 002 Oct 01, 1997

0.02MG/ML

N020755 003 Oct 01, 1997

EDEX

AUXILIUM PHARMS LLC

0.005MG/VIAL

N020649 001 Jun 12, 1997

ALSEROXYLON

TABLET; ORAL

RAUTENSIN

NOVARTIS

2MG

N009215 001

RAUWILOID

3M

2MG

N008867 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX

80MG; 20MG

A089449 001 Nov 27, 1987

FOAMICON

NOVARTIS

80MG; 20MG

A072687 001 Jun 28, 1989

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A077659 001 Feb 23, 2006

WATSON LABS

100MG

A071382 001 Jan 21, 1987

SYMADINE

SOLVAY

100MG

A071000 001 Sep 04, 1986

SYMMETREL

ENDO PHARMS

100MG

N016020 001

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

50MG/5ML

A072655 001 Oct 30, 1990

TEVA PHARMS

50MG/5ML

A073115 001 Aug 23, 1991

SYMMETREL

ENDO PHARMS

50MG/5ML

N016023 002

TABLET; ORAL

SYMMETREL

ENDO PHARMS

100MG

N018101 001

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US

10MG

N010155 002

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

ASTELLAS

0.025%

N018116 001

0.1%

N018116 002

LOTION; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N019729 001 Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

ASTELLAS

0.1%

N018498 001

DISCONTINUED DRUG PRODUCT LIST

6-16 (of 337)

AMDINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE

1GM/VIAL
250MG/VIAL
500MG/VIALN050565 003 Dec 21, 1984
N050565 001 Dec 21, 1984
N050565 002 Dec 21, 1984AMIFOSTINE

INJECTABLE; INJECTION

ETHYOL

CLINIGEN HLTHCARE

375MG/VIAL

N020221 002 Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT

EQ 250MG BASE/ML
EQ 250MG BASE/MLA063265 001 Nov 30, 1994
A063266 001 Oct 31, 1994

ASTRAZENECA

EQ 50MG BASE/ML
EQ 250MG BASE/MLA063167 001 Dec 14, 1995
A063169 001 Dec 14, 1995

HIKMA MAPLE

EQ 50MG BASE/ML
EQ 250MG BASE/MLA063274 001 May 18, 1992
A063275 001 May 18, 1992

HOSPIRA

EQ 50MG BASE/ML
EQ 50MG BASE/MLA063263 001 Nov 30, 1994
A063350 001 Jul 30, 1993

EQ 62.5MG BASE/ML

A063283 001 Oct 31, 1994

EQ 250MG BASE/ML

A063264 001 Nov 30, 1994

EQ 250MG BASE/ML

A063350 002 Jul 30, 1993

EQ 250MG BASE/ML

A064098 001 Jun 26, 1995

EQ 250MG BASE/ML

A064099 001 Jun 20, 1995

EQ 50MG BASE/ML

A064045 001 Sep 28, 1993

TEVA PHARMS USA

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 500MG BASE/100ML

A064146 001 Apr 02, 1997

AMIKIN

APOTHECON

EQ 50MG BASE/ML

A062311 001

EQ 50MG BASE/ML

A062562 001 Sep 20, 1984

EQ 50MG BASE/ML

N050495 001

EQ 250MG BASE/ML

A062311 002

EQ 250MG BASE/ML

A062562 002 Sep 20, 1984

EQ 250MG BASE/ML

N050495 002

AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

APOTHECON

EQ 5MG BASE/ML

N050618 002 Nov 30, 1987

EQ 10MG BASE/ML

N050618 001 Nov 30, 1987

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SANDOZ

EQ 5MG ANHYDROUS; 50MG

A073357 001 Nov 27, 1991

TEVA

EQ 5MG ANHYDROUS; 50MG

A070795 001 Apr 17, 1988

WATSON LABS

EQ 5MG ANHYDROUS; 50MG

A073334 001 Jul 19, 1991

HYDRO-RIDE

PAR PHARM

EQ 5MG ANHYDROUS; 50MG

A070347 001 Dec 25, 1990

MODURETIC 5-50

MERCK

EQ 5MG ANHYDROUS; 50MG

N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA

5.2% (5.2GM/100ML)

N018901 001 Apr 06, 1984

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N018804 001 May 15, 1984

3.5% (3.5GM/100ML)

N018875 001 Aug 08, 1984

AMINOSYN II 3.5%

HOSPIRA

3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N019491 001 Oct 10, 1986

AMINOSYN II 5%

HOSPIRA

5% (5GM/100ML)

N019438 002 Apr 03, 1986

AMINOSYN-HBC 7% IN PLASTIC CONTAINER

ABBOTT

7% (7GM/100ML)

N019400 001 Jul 23, 1986

BRANCHAMIN 4%

BAXTER HLTHCARE

4% (4GM/100ML)

N018678 001 Sep 28, 1984

FREAMINE 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 001

FREAMINE II 8.5%

B BRAUN

8.5% (8.5GM/100ML)

N016822 002

DISCONTINUED DRUG PRODUCT LIST

6-17 (of 337)

AMINO ACIDS

INJECTABLE; INJECTION

HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	003	Sep 12, 1988
HOSPIRA INC	5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML; 2.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	004	Nov 07, 1988

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019118	001	Oct 11, 1984
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019120	001	Oct 11, 1984
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 25GM/100ML	N019119	001	Oct 11, 1984
AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 25GM/100ML	N019505	002	Nov 07, 1986
HOSPIRA	3.5%; 25GM/100ML	N019713	006	Sep 09, 1988
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBOTT	3.5%; 5GM/100ML	N019506	001	Nov 07, 1986
HOSPIRA	3.5%; 5GM/100ML	N019713	002	Sep 09, 1988
AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 10GM/100ML	N019713	001	Sep 09, 1988
HOSPIRA	4.25%; 10GM/100ML	N019681	004	Nov 01, 1988
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER				
ABBOTT	4.25%; 20GM/100ML	N019713	004	Sep 09, 1988
HOSPIRA	4.25%; 20GM/100ML	N019681	005	Nov 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6-18 (of 337)

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%; 25GM/100ML	N019504	002	Nov 07, 1986
	4.25%; 25GM/100ML	N019713	005	Sep 09, 1988
HOSPIRA	4.25%; 25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%; 25GM/100ML	N019565	001	Dec 17, 1986
	5%; 25GM/100ML	N019713	003	Sep 09, 1988
HOSPIRA	5%; 25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 10GM/100ML	N019520	002	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 15GM/100ML	N019520	003	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 20GM/100ML	N019520	004	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 25GM/100ML	N019520	005	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 5GM/100ML	N019520	001	Sep 23, 1988
-----------------	------------------	---------	-----	--------------

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 10GM/100ML	N019520	007	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 15GM/100ML	N019520	008	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 20GM/100ML	N019520	009	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 25GM/100ML	N019520	010	Sep 23, 1988
-----------------	-------------------	---------	-----	--------------

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 5GM/100ML	N019520	006	Sep 23, 1988
-----------------	------------------	---------	-----	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%; 10GM/100ML; 51MG/100ML; 176.5MG/100ML; 22.4MG/100ML; 104.5MG/100ML; 205MG/100ML	N019712	002	Sep 08, 1988
HOSPIRA INC	4.25%; 10GM/100ML; 51MG/100ML; 176.5MG/100ML; 22.4MG/100ML; 104.5MG/100ML; 205MG/100ML	N019682	003	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019564	002	Dec 16, 1986
--------	--	---------	-----	--------------

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%; 25GM/100ML; 51MG/100ML; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019564	004	Dec 16, 1986
--------	---	---------	-----	--------------

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC; HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019564	001	Dec 16, 1986
	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019712	001	Sep 08, 1988
HOSPIRA INC	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019682	001	Nov 01, 1988

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%; 10GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019564	003	Dec 16, 1986
HOSPIRA INC	4.25%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 120MG/100ML; 49.3MG/100ML	N019682	002	Nov 01, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 10GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147	002	Oct 23, 1995
-----------------	--	---------	-----	--------------

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 15GM/100ML; 51MG/100ML; 261MG/100ML; 216MG/100ML; 112MG/100ML	N020147	003	Oct 23, 1995
-----------------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-19 (of 337)

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020147 004	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%; 25GM/100ML; 51MG/100ML; 261MG/100ML	N020147 005	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		
TRAVASOL 2.75% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	2.75%; 5GM/100ML; 51MG/100ML; 261MG/100ML;	N020147 001	Oct 23, 1995
	216MG/100ML; 112MG/100ML		
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%; 10GM/100ML; 51MG/100ML; 261MG/100ML	N020147 007	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%; 15GM/100ML; 51MG/100ML; 261MG/100ML	N020147 008	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020147 009	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%; 25GM/100ML; 51MG/100ML; 261MG/100ML	N020147 010	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		
TRAVASOL 4.25% SULFITE FREE	W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER		
BAXTER HLTHCARE	4.25%; 5GM/100ML; 51MG/100ML; 261MG/100ML;	N020147 006	Oct 23, 1995
	297MG/100ML; 77MG/100ML		

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M IN PLASTIC CONTAINER			
ABBOTT	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML;	N018804 002	May 15, 1984
	234MG/100ML		
	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML;	N018875 002	Aug 08, 1984
	234MG/100ML		

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M			
HOSPIRA	3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017789 005	

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER			
ABBOTT	3.5%; 32MG/100ML; 128MG/100ML; 222MG/100ML	N019493 001	Oct 16, 1986
	; 49MG/100ML		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%			
HOSPIRA INC	8%; 61MG/100ML; 211MG/100ML; 56MG/100ML; 38	N017957 001	
	8MG/100ML		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 7% W/ ELECTROLYTES			
HOSPIRA	7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 4	N019437 006	Apr 03, 1986
	10MG/100ML		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M			
HOSPIRA	3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML;	N019437 007	Apr 03, 1986
	49MG/100ML		

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML	N017493 003	
	; 35MG/100ML		
TRAVASOL 5.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	5.5%; 102MG/100ML; 522MG/100ML; 431MG/100M	N017493 001	
	L; 224MG/100ML		
TRAVASOL 8.5% W/ ELECTROLYTES			
BAXTER HLTHCARE	8.5%; 102MG/100ML; 522MG/100ML; 594MG/100M	N017493 002	
	L; 154MG/100ML		

DISCONTINUED DRUG PRODUCT LIST

6-20 (of 337)

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

CLOVER PHARMS

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM

250MG/ML

A070522 001 Jun 17, 1986

BAXTER HLTHCARE

250MG/ML

N018590 001 Oct 29, 1982

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK

20%

N005619 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001 Jul 23, 1982

INTL MEDICATION

25MG/ML

A087209 001 Feb 01, 1982

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

LYPHOMED

25MG/ML

A087431 001

PHARMA SERVE NY

25MG/ML

A087387 001 Jun 03, 1983

25MG/ML

A087392 001 Dec 15, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001 May 30, 1985

25MG/ML

A088749 001 May 30, 1985

TEVA PARENTERAL

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

G AND W LABS

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

DISCONTINUED DRUG PRODUCT LIST

6-21 (of 337)

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLIN

200MG

N002386 003

AMINOPHYLLINE

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

BARR

100MG

A088297 001 Aug 19, 1983

200MG

A088298 001 Aug 19, 1983

DURAMED PHARMS BARR

100MG

A088182 001 Mar 31, 1983

200MG

A088183 001 Mar 31, 1983

HALSEY

100MG

A084674 001

HIKMA INTL PHARMS

100MG

A084540 001

200MG

A085003 001

IMPAX LABS

100MG

A084574 001

200MG

A084576 001

KV PHARM

100MG

A085284 001

200MG

A085289 001

LANNETT

100MG

A084588 001

200MG

A084588 002

PAL PAK

100MG

A084533 001

PANRAY

100MG

A084552 001

200MG

A084552 002

PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

ROXANE

100MG

A087500 001 Feb 09, 1982

200MG

A087501 001 Feb 09, 1982

SANDOZ

100MG

A085261 003

100MG

A085262 002

200MG

A085261 002

VALEANT PHARM INTL

200MG

A084563 001

VANGARD

100MG

A088314 001 Oct 03, 1983

200MG

A088319 001 Oct 03, 1983

VINTAGE PHARMS

100MG

A085409 001

200MG

A085410 001

WATSON LABS

100MG

A085567 001

200MG

A085564 001

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS

100MG

A084577 001

200MG

A084575 001

TABLICAPS

100MG

A084632 002

VALE

100MG

A084531 001

200MG

A084530 001

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC

225MG

A086760 001

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS

4GM/PACKET

A080947 001

SODIUM AMINOSALICYLATE

HEXCEL

100%

A080097 001

TABLET; ORAL

PARASAL SODIUM

PANRAY

1GM

N006811 011

500MG

N006811 006

SODIUM P.A.S.

LANNETT

500MG

A080138 002

TEEBACIN

CONSOLIDATED MIDLAND

500MG

N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC

846MG; 112MG

A080059 002

DISCONTINUED DRUG PRODUCT LIST

6-22 (of 337)

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY

1GM

N006811 002

500MG

N006811 001

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB

EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

BEDFORD

50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS

50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE

50MG/ML

A076088 001 Oct 15, 2002

HOSPIRA

50MG/ML

A076108 001 Oct 15, 2002

INTL MEDICATION SYS

50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS

50MG/ML

A076394 001 Apr 25, 2003

TEVA PHARMS USA

50MG/ML

A076163 001 Sep 05, 2003

CORDARONE

WYETH PHARMS INC

50MG/ML

N020377 001 Aug 03, 1995

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

TEVA

200MG

A074895 001 Apr 16, 1999

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

ROCHE

40MG/ML

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A085594 001

ELAVIL

ASTRAZENECA

10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB

10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT

10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

AMITRIPTYLINE HYDROCHLORIDE

AM THERAP

25MG

A088672 001 Nov 20, 1984

50MG

A088673 001 Nov 20, 1984

75MG

A088674 001 Nov 20, 1984

100MG

A088675 001 Nov 20, 1984

COPLEY PHARM

10MG

A088421 001 Apr 30, 1984

25MG

A088422 001 Apr 30, 1984

50MG

A088423 001 Apr 30, 1984

75MG

A088424 001 Apr 30, 1984

100MG

A088425 001 Apr 30, 1984

150MG

A088426 001 Apr 30, 1984

HALSEY

10MG

A085923 001

25MG

A085922 001

50MG

A085925 001

50MG

A087557 001 Mar 05, 1982

75MG

A085926 001 May 20, 1983

100MG

A085927 001 May 20, 1983

LEDERLE

10MG

A086744 001

10MG

A087366 001 Jan 04, 1982

25MG

A086746 001

25MG

A087367 001 May 03, 1982

50MG

A086743 001

50MG

A087181 001 Jan 04, 1982

75MG

A086745 001

DISCONTINUED DRUG PRODUCT LIST

6-23 (of 337)

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A087369	001	Jan 04, 1982
	100MG	A086747	001	
	100MG	A087368	001	May 03, 1982
	150MG	A087370	001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744	001	
	25MG	A085627	001	
	50MG	A085745	001	
	75MG	A085743	001	
	100MG	A085742	002	May 11, 1982
	150MG	A089423	001	Feb 17, 1987
PAR PHARM	10MG	A088697	001	Sep 25, 1984
	25MG	A088698	001	Sep 25, 1984
	50MG	A088699	001	Sep 25, 1984
	75MG	A088700	001	Sep 25, 1984
	100MG	A088701	001	Sep 25, 1984
	150MG	A088702	001	Sep 25, 1984
PLIVA	10MG	A088883	001	Sep 26, 1984
	25MG	A088884	001	Sep 26, 1984
	50MG	A088885	001	Sep 26, 1984
	75MG	A088886	001	Sep 26, 1984
	100MG	A088887	001	Sep 26, 1984
	150MG	A088888	001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075	001	Sep 16, 1983
	10MG	A088084	001	Jul 18, 1983
	25MG	A088076	001	May 20, 1983
	25MG	A088085	001	Jul 18, 1983
	50MG	A088077	001	Sep 16, 1983
	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A084910	003	
	10MG	A086610	001	
	25MG	A085031	001	
	25MG	A086859	001	
	50MG	A085032	001	
	50MG	A086857	001	
	75MG	A085030	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982

DISCONTINUED DRUG PRODUCT LIST

6-24 (of 337)

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	75MG	A087617 001	Feb 05, 1982
	100MG	A087639 001	Feb 08, 1982
WATSON LABS	10MG	A085816 001	
	10MG	A088620 001	Mar 02, 1984
	25MG	A085817 001	
	25MG	A088621 001	Mar 02, 1984
	50MG	A085815 001	
	50MG	A088622 001	Mar 02, 1984
	75MG	A085819 001	
	75MG	A088633 001	Mar 02, 1984
	100MG	A085820 001	
	100MG	A088634 001	Mar 02, 1984
	150MG	A085821 001	
	150MG	A088635 001	Mar 02, 1984
WEST WARD	10MG	A087647 001	Mar 05, 1982
	25MG	A087278 001	
ELAVIL			
ASTRAZENECA	10MG	N012703 001	
	25MG	N012703 003	
	50MG	N012703 004	
	75MG	N012703 005	
	100MG	N012703 006	
	150MG	N012703 007	
ENDEP			
ROCHE	10MG	A083639 001	
	25MG	A083639 002	
	50MG	A083639 003	
	75MG	A083639 004	
	100MG	A083639 005	
	150MG	A085303 001	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MUTUAL PHARM	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
PAR PHARM	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988
WATSON LABS	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
LIMBITROL			
VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001	
LIMBITROL DS			
VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10			
SCHERING	10MG;2MG	N014713 007	
ETRAFON 2-25			
SCHERING	25MG;2MG	N014713 004	
ETRAFON-A			
SCHERING	10MG;4MG	N014713 002	
ETRAFON-FORTE			
SCHERING	25MG;4MG	N014713 006	
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE			
IVAX SUB TEVA PHARMS	10MG;2MG	A070935 001	Sep 11, 1986
	10MG;4MG	A070937 001	Sep 11, 1986
	25MG;2MG	A070936 001	Sep 11, 1986
	25MG;4MG	A070938 001	Sep 11, 1986
	50MG;4MG	A070939 001	Sep 12, 1986
MUTUAL PHARM	10MG;2MG	A071077 001	Nov 12, 1986
	10MG;4MG	A071078 001	Nov 12, 1986
	25MG;2MG	A070297 001	Nov 12, 1986
	25MG;4MG	A071079 001	Nov 12, 1986
PAR PHARM	10MG;2MG	A070565 001	Sep 11, 1986
	10MG;4MG	A070620 001	Sep 11, 1986
	25MG;2MG	A070621 001	Sep 11, 1986

DISCONTINUED DRUG PRODUCT LIST

6-25 (of 337)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	25MG; 4MG	A070595	001	Sep 11, 1986
	50MG; 4MG	A070574	001	Sep 11, 1986
SANDOZ	10MG; 2MG	A071062	001	Nov 27, 1987
	10MG; 4MG	A071862	001	Dec 21, 1987
	25MG; 2MG	A071063	001	Nov 27, 1987
	25MG; 4MG	A071064	001	Nov 27, 1987
	50MG; 4MG	A071863	001	Dec 21, 1987
WATSON LABS	10MG; 2MG	A070373	001	Aug 25, 1986
	10MG; 2MG	A072539	001	Feb 15, 1989
	10MG; 2MG	A073007	001	Oct 17, 1991
	10MG; 4MG	A070375	001	Aug 25, 1986
	10MG; 4MG	A072540	001	Feb 15, 1989
	10MG; 4MG	A073009	001	Oct 17, 1991
	25MG; 2MG	A070374	001	Aug 25, 1986
	25MG; 2MG	A072541	001	Feb 15, 1989
	25MG; 2MG	A073008	001	Oct 17, 1991
	25MG; 4MG	A070376	001	Aug 25, 1986
	25MG; 4MG	A072134	001	Feb 15, 1989
	25MG; 4MG	A073010	001	Oct 17, 1991
	50MG; 4MG	A070377	001	Nov 04, 1986
	50MG; 4MG	A071558	001	Mar 02, 1987
	50MG; 4MG	A072135	001	Feb 15, 1989
TRIAVIL 2-10				
NEW RIVER	10MG; 2MG	N014715	004	
TRIAVIL 2-25				
NEW RIVER	25MG; 2MG	N014715	002	
TRIAVIL 4-10				
NEW RIVER	10MG; 4MG	N014715	003	
TRIAVIL 4-25				
NEW RIVER	25MG; 4MG	N014715	005	
TRIAVIL 4-50				
NEW RIVER	50MG; 4MG	N014715	006	

AMLEXANOX

PASTE; DENTAL

APHTHASOL

ULURU

5%

N020511 001 Dec 17, 1996

PATCH; TOPICAL

AMLEXANOX

ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

MUTUAL PHARMA

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

EQ 10MG BASE

A078081 003 Jan 31, 2008

PURACAP PHARM

EQ 2.5MG BASE

A078131 001 Sep 04, 2007

EQ 5MG BASE

A078131 002 Sep 04, 2007

EQ 10MG BASE

A078131 003 Sep 04, 2007

SANDOZ

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

SYNTHON PHARMS

EQ 2.5MG BASE

A077080 001 Jun 27, 2007

EQ 5MG BASE

A077080 002 Jun 27, 2007

EQ 10MG BASE

A077080 003 Jun 27, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

AMLODIPINE BESYLATE

SYNTHON PHARMS

EQ 2.5MG BASE

N022026 001 Sep 27, 2007

EQ 5MG BASE

N022026 002 Sep 27, 2007

EQ 10MG BASE

N022026 003 Sep 27, 2007

DISCONTINUED DRUG PRODUCT LIST

6-26 (of 337)

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC

2.5MG

N021435 001 Oct 31, 2003

5MG

N021435 002 Oct 31, 2003

10MG

N021435 003 Oct 31, 2003

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT

5MEQ/ML

A083130 001

GD SEARLE LLC

3MEQ/ML

A086205 001

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

MCGAW

900MG/100ML

N006580 001

AMMONIUM CHLORIDE 2.14%

B BRAUN

40MEQ/100ML

A085734 001

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS

EQ 200MG BASE

N006441 001

AMOXAPINE

TABLET; ORAL

AMOXAPINE

SANDOZ

25MG

A072943 001 Jun 28, 1991

50MG

A072944 001 Jun 28, 1991

100MG

A072878 001 Jun 28, 1991

150MG

A072879 001 Jun 28, 1991

WATSON LABS

25MG

A072418 001 May 11, 1989

50MG

A072419 001 May 11, 1989

100MG

A072420 001 May 11, 1989

150MG

A072421 001 May 11, 1989

ASENDIN

LEDERLE

25MG

N018021 001

50MG

N018021 002

100MG

N018021 003

150MG

N018021 004

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL

250MG

A062528 001 Aug 07, 1985

500MG

A062528 002 Aug 07, 1985

MYLAN

250MG

A062067 001

500MG

A062067 002

TEVA

250MG

A062853 001 Dec 22, 1987

250MG

A063030 001 Feb 28, 1989

500MG

A062854 001 Dec 22, 1987

500MG

A063031 001 Feb 28, 1989

AMOXIL

GLAXOSMITHKLINE

250MG

N050459 001

500MG

N050459 002

TRIMOX

APOTHECON

250MG

A061885 001

250MG

A062098 001

250MG

A062152 001

250MG

A063099 001 Mar 20, 1992

500MG

A061885 002

500MG

A062098 002

500MG

A062152 002

500MG

A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS

250MG

A062107 001

500MG

A062107 002

WYMOX

WYETH AYERST

250MG

A062120 001

500MG

A062120 002

FOR SUSPENSION; ORAL

AMOXICILLIN

AM ANTIBIOTICS

125MG/5ML

A062059 001

250MG/5ML

A062059 002

MYLAN

125MG/5ML

A062090 001

250MG/5ML

A062090 002

DISCONTINUED DRUG PRODUCT LIST

6-27 (of 337)

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

RANBAXY

200MG/5ML

A065113 001 Nov 29, 2002

400MG/5ML

A065113 002 Nov 29, 2002

TEVA

125MG/5ML

A062946 001 Nov 01, 1988

250MG/5ML

A063001 001 Jan 06, 1989

AMOXIL

GLAXOSMITHKLINE

50MG/ML

N050460 005

125MG/5ML

N050460 001

250MG/5ML

N050460 002

LAROTID

GLAXOSMITHKLINE

50MG/ML

N050460 006

POLYMOX

APOTHECON

125MG/5ML

A061851 001

125MG/5ML

A062323 001

250MG/5ML

A061851 002

250MG/5ML

A062323 002

TRIMOX

APOTHECON

50MG/ML

A061886 001

125MG/5ML

A061886 002

125MG/5ML

A062099 001

125MG/5ML

A062154 001

125MG/5ML

A062885 001 Mar 08, 1988

250MG/5ML

A061886 003

250MG/5ML

A062099 002

250MG/5ML

A062154 002

250MG/5ML

A062885 002 Mar 08, 1988

UTIMOX

PARKE DAVIS

125MG/5ML

A062127 001

250MG/5ML

A062127 002

WYMOX

WYETH AYERST

125MG/5ML

A062131 001

250MG/5ML

A062131 002

TABLET; ORAL

AMOXICILLIN

DAVA PHARMS INC

875MG

A065344 001 Jan 15, 2009

TABLET, CHEWABLE; ORAL

AMOXICILLIN

APOTHECON

125MG

A064131 001 May 06, 1996

250MG

A064131 002 May 06, 1996

DAVA PHARMS INC

125MG

A064139 001 Jan 29, 1996

250MG

A064139 002 Jan 29, 1996

RANBAXY

200MG

A065060 001 Nov 29, 2000

400MG

A065060 002 Nov 29, 2000

TEVA

125MG

A064031 001 Dec 19, 1996

250MG

A064031 002 Dec 19, 1996

AMOXIL

DR REDDYS LABS INC

200MG

N050761 001 Apr 15, 1999

400MG

N050761 002 Apr 15, 1999

TABLET, FOR SUSPENSION; ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD

200MG

A065324 001 Jan 17, 2007

400MG

A065324 002 Jan 17, 2007

DISPERMOX

RANBAXY LABS LTD

200MG

A065080 002 Aug 11, 2003

400MG

A065080 001 Aug 11, 2003

600MG

A065159 001 Dec 04, 2003

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC

250MG;EQ 125MG BASE

A065333 001 Feb 24, 2009

500MG;EQ 125MG BASE

A065333 002 Feb 24, 2009

875MG;EQ 125MG BASE

A065317 003 Oct 20, 2008

RANBAXY LABS

500MG;EQ 125MG BASE

A065109 001 Nov 04, 2002

DISCONTINUED DRUG PRODUCT LIST

6-28 (of 337)

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCOBESSE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG **Federal	A083564	001
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
2.5MG;2.5MG;2.5MG;2.5MG **Federal	A083564	002
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
3.75MG;3.75MG;3.75MG;3.75MG **Federal	A083564	003
Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**		
5MG;5MG;5MG;5MG **Federal Register	A083564	004
determination that product was not discontinued or withdrawn for safety or efficacy reasons**		

TABLET; ORAL

DELCOBESSE

TEVA

1.25MG;1.25MG;1.25MG;1.25MG	A083563	004
2.5MG;2.5MG;2.5MG;2.5MG	A083563	003
3.75MG;3.75MG;3.75MG;3.75MG	A083563	002
5MG;5MG;5MG;5MG	A083563	001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

ADDERALL 10

TEVA WOMENS

2.5MG;2.5MG;2.5MG;2.5MG

N011522 007 Feb 13, 1996

ADDERALL 12.5

TEVA WOMENS

3.125MG;3.125MG;3.125MG;3.125MG

N011522 012 Aug 31, 2000

ADDERALL 15

TEVA WOMENS

3.75MG;3.75MG;3.75MG;3.75MG

N011522 013 Aug 31, 2000

ADDERALL 20

TEVA WOMENS

5MG;5MG;5MG;5MG

N011522 008 Feb 13, 1996

ADDERALL 30

TEVA WOMENS

7.5MG;7.5MG;7.5MG;7.5MG

N011522 010 May 12, 1997

ADDERALL 5

TEVA WOMENS

1.25MG;1.25MG;1.25MG;1.25MG

N011522 009 May 12, 1997

ADDERALL 7.5

TEVA WOMENS

1.875MG;1.875MG;1.875MG;1.875MG

N011522 011 Aug 31, 2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS

1.25MG;1.25MG;1.25MG;1.25MG

A040472 001 Sep 30, 2003

2.5MG;2.5MG;2.5MG;2.5MG

A040472 002 Sep 30, 2003

5MG;5MG;5MG;5MG

A040472 003 Sep 30, 2003

7.5MG;7.5MG;7.5MG;7.5MG

A040472 004 Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5

UCB INC

EQ 6.25MG BASE;EQ 6.25MG BASE

N010093 007

BIPHETAMINE 20

UCB INC

EQ 10MG BASE;EQ 10MG BASE

N010093 003

BIPHETAMINE 7.5

UCB INC

EQ 3.75MG BASE;EQ 3.75MG BASE

N010093 009

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

LANNETT

5MG

A083901 001 Aug 31, 1984

10MG

A083901 002 Aug 31, 1984

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

APOTHECON

3%

N050314 001

INJECTABLE; INJECTION

AMPHOTERICIN B

ABBOTT

50MG/VIAL

A064141 001 Dec 23, 1996

ABRAXIS PHARM

50MG/VIAL

A062728 001 Apr 13, 1987

TEVA PARENTERAL

50MG/VIAL

A064062 001 Mar 31, 1995

FUNGIZONE

APOTHECON

50MG/VIAL

A060517 001

DISCONTINUED DRUG PRODUCT LIST

6-29 (of 337)

AMPHOTERICIN B

LOTION; TOPICAL

FUNGIZONE

APOTHECON

3%

A060570 001

OINTMENT; TOPICAL

FUNGIZONE

APOTHECON

3%

N050313 001

SUSPENSION; ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB

100MG/ML

N050341 003

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A062860 004 Feb 05, 1988

EQ 2GM BASE/VIAL

A062860 005 Feb 05, 1988

EQ 125MG BASE/VIAL

A062860 001 Feb 05, 1988

EQ 250MG BASE/VIAL

A062860 002 Feb 05, 1988

EQ 500MG BASE/VIAL

A062860 003 Feb 05, 1988

CONSOLIDATED PHARM

EQ 1GM BASE/VIAL

A061936 003

EQ 2GM BASE/VIAL

A061936 004

EQ 125MG BASE/VIAL

A061936 005

EQ 250MG BASE/VIAL

A061936 001

EQ 500MG BASE/VIAL

A061936 002

HANFORD GC

EQ 1GM BASE/VIAL

A063139 001 Apr 15, 1993

EQ 2GM BASE/VIAL

A063141 001 Apr 15, 1993

EQ 125MG BASE/VIAL

A063143 001 Apr 15, 1993

EQ 500MG BASE/VIAL

A063147 001 Apr 15, 1993

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062692 004 Jun 24, 1986

EQ 2GM BASE/VIAL

A062692 005 Jun 24, 1986

EQ 10GM BASE/VIAL

A062692 006 Jun 24, 1986

EQ 125MG BASE/VIAL

A062692 001 Jun 24, 1986

EQ 250MG BASE/VIAL

A062692 002 Jun 24, 1986

EQ 500MG BASE/VIAL

A062692 003 Jun 24, 1986

INTL MEDICATION

EQ 1GM BASE/VIAL

A062634 002 Jan 09, 1987

EQ 2GM BASE/VIAL

A062634 003 Jan 09, 1987

LILLY

EQ 1GM BASE/VIAL

A062565 002 Apr 04, 1985

EQ 2GM BASE/VIAL

A062565 003 Jun 24, 1986

EQ 500MG BASE/VIAL

A062565 001 Apr 04, 1985

WATSON LABS INC

EQ 1GM BASE/VIAL

A062816 004 Oct 24, 1988

EQ 2GM BASE/VIAL

A062816 005 Oct 24, 1988

EQ 10GM BASE/VIAL

A062994 001 Sep 15, 1988

EQ 125MG BASE/VIAL

A062816 001 Oct 24, 1988

EQ 250MG BASE/VIAL

A062816 002 Oct 24, 1988

EQ 500MG BASE/VIAL

A062816 003 Oct 24, 1988

OMNIPEN-N

WYETH AYERST

EQ 1GM BASE/VIAL

A060626 004

EQ 1GM BASE/VIAL

A062718 004 Dec 16, 1986

EQ 2GM BASE/VIAL

A060626 005

EQ 2GM BASE/VIAL

A062718 005 Dec 16, 1986

EQ 125MG BASE/VIAL

A060626 001

EQ 125MG BASE/VIAL

A062718 001 Dec 16, 1986

EQ 250MG BASE/VIAL

A060626 002

EQ 250MG BASE/VIAL

A062718 002 Dec 16, 1986

EQ 500MG BASE/VIAL

A060626 003

EQ 500MG BASE/VIAL

A062718 003 Dec 16, 1986

PENBRITIN-S

WYETH AYERST

EQ 1GM BASE/VIAL

N050072 004

EQ 2GM BASE/VIAL

N050072 005

EQ 4GM BASE/VIAL

N050072 006

EQ 125MG BASE/VIAL

N050072 001

EQ 250MG BASE/VIAL

N050072 002

EQ 500MG BASE/VIAL

N050072 003

POLYCILLIN-N

BRISTOL

EQ 1GM BASE/VIAL

N050309 004

EQ 2GM BASE/VIAL

N050309 005

EQ 125MG BASE/VIAL

N050309 001

EQ 250MG BASE/VIAL

N050309 002

EQ 500MG BASE/VIAL

N050309 003

TOTACILLIN-N

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A060677 004

EQ 1GM BASE/VIAL

A062727 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A060677 005

DISCONTINUED DRUG PRODUCT LIST

6-30 (of 337)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

TOTACILLIN-N

EQ 2GM BASE/VIAL	A062727	002	Dec 19, 1986
EQ 10GM BASE/VIAL	A060677	006	
EQ 125MG BASE/VIAL	A060677	001	
EQ 250MG BASE/VIAL	A060677	002	
EQ 500MG BASE/VIAL	A060677	003	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

UNASYN

PFIZER

EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N050608	003	Dec 31, 1986
--	---------	-----	--------------

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS

EQ 250MG BASE	A062041	001	
EQ 500MG BASE	A062041	002	

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 250MG BASE	A061602	001	
EQ 500MG BASE	A061602	002	

IVAX SUB TEVA PHARMS

EQ 250MG BASE	A060765	001	
EQ 500MG BASE	A060765	002	

LEDERLE

EQ 250MG BASE	A062208	001	
EQ 500MG BASE	A062208	002	

MYLAN

EQ 250MG BASE	A061755	001	
EQ 500MG BASE	A061755	002	

PUREPAC PHARM

EQ 250MG BASE	A061853	001	
EQ 500MG BASE	A061853	002	

TEVA

EQ 250MG BASE	A061502	001	
EQ 500MG BASE	A061502	002	

VITARINE

EQ 250MG BASE	A061387	001	
EQ 500MG BASE	A061387	003	

OMNIPEN (AMPICILLIN)

WYETH AYERST

250MG	A060624	001	
500MG	A060624	002	

PENBRITIN

WYETH AYERST

EQ 250MG BASE	A060908	001	
EQ 500MG BASE	A060908	002	

PFIZERPEN-A

PFIZER

EQ 250MG BASE	A062050	001	
EQ 500MG BASE	A062050	002	

POLYCILLIN

BRISTOL

EQ 250MG BASE	N050310	001	
EQ 500MG BASE	N050310	002	

PRINCIPEN

APOTHECON

EQ 250MG BASE	A062888	001	Mar 04, 1988
EQ 500MG BASE	A062888	002	Mar 04, 1988

BRISTOL MYERS SQUIBB

EQ 250MG BASE	A061392	001	
EQ 500MG BASE	A061392	002	

PRINCIPEN '250'

APOTHECON

EQ 250MG BASE	A062157	002	
EQ 250MG BASE	N050056	001	

PRINCIPEN '500'

APOTHECON

EQ 500MG BASE	A062157	001	
EQ 500MG BASE	N050056	002	

TOTACILLIN

GLAXOSMITHKLINE

EQ 250MG BASE	A060060	001	
EQ 250MG BASE	A062212	001	
EQ 500MG BASE	A060060	002	
EQ 500MG BASE	A062212	002	

FOR SUSPENSION; ORAL

AMCILL

PARKE DAVIS

EQ 125MG BASE/5ML	A062030	001	
EQ 250MG BASE/5ML	A062030	002	

AMPICILLIN TRIHYDRATE

AM ANTIBIOTICS

EQ 125MG BASE/5ML	A061601	001	
EQ 250MG BASE/5ML	A061601	002	

MYLAN

EQ 125MG BASE/5ML	A061829	002	
EQ 250MG BASE/5ML	A061829	001	

PUREPAC PHARM

EQ 125MG BASE/5ML	A061980	001	
EQ 250MG BASE/5ML	A061980	002	

DISCONTINUED DRUG PRODUCT LIST

6-31 (of 337)

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

TEVA	EQ 125MG BASE/5ML	A061370 001
	EQ 250MG BASE/5ML	A061370 002
OMNIPEN (AMPICILLIN)		
WYETH AYERST	100MG/ML	A060625 001
	125MG/5ML	A060625 002
	250MG/5ML	A060625 003
	500MG/5ML	A060625 004
PENBRITIN		
WYETH AYERST	EQ 100MG BASE/ML	N050019 001
	EQ 125MG BASE/5ML	N050019 002
	EQ 250MG BASE/5ML	N050019 003
PFIZERPEN-A		
PFIZER	EQ 125MG BASE/5ML	A062049 001
	EQ 250MG BASE/5ML	A062049 002
POLYCILLIN		
APOTHECON	EQ 125MG BASE/5ML	A062297 001
	EQ 250MG BASE/5ML	A062297 002
BRISTOL	EQ 100MG BASE/ML	N050308 004
	EQ 125MG BASE/5ML	N050308 001
	EQ 250MG BASE/5ML	N050308 002
	EQ 500MG BASE/5ML	N050308 003
PRINCIPEN		
APOTHECON	EQ 100MG BASE/ML	A061394 001
	EQ 125MG BASE/5ML	A061394 002
	EQ 250MG BASE/5ML	A061394 003
PRINCIPEN '125'		
APOTHECON	EQ 125MG BASE/5ML	A060127 002
	EQ 125MG BASE/5ML	A062151 001
PRINCIPEN '250'		
APOTHECON	EQ 250MG BASE/5ML	A060127 001
	EQ 250MG BASE/5ML	A062151 002
TOTACILLIN		
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666 001
	EQ 125MG BASE/5ML	A062223 001
	EQ 250MG BASE/5ML	A060666 002
	EQ 250MG BASE/5ML	A062223 002
TABLET, CHEWABLE;ORAL		
POLYCILLIN		
BRISTOL	EQ 125MG BASE	N050093 001

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150 001
	EQ 389MG BASE;111MG	N050488 001

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898 001
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457 001
PROBAMPACIN		
TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	A061741 001

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N021007 001	Apr 15, 1999
	150MG	N021007 002	Apr 15, 1999

SOLUTION;ORAL

AGENERASE

GLAXOSMITHKLINE	15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021039 001	Apr 15, 1999
-----------------	--	-------------	--------------

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

AGRYLIN

SHIRE LLC	EQ 1MG BASE	N020333 002	Mar 14, 1997
ANAGRELIDE HYDROCHLORIDE			
ROXANE	EQ 0.5MG BASE	A076489 001	Apr 18, 2005
	EQ 1MG BASE	A076489 002	Apr 18, 2005

DISCONTINUED DRUG PRODUCT LIST

6-32 (of 337)

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

SANDOZ INC

EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

WATSON LABS

EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

IMPAX LABS INC

1MG

A091242 001 May 31, 2012

KUDCO IRELAND

1MG

A091331 001 Jan 05, 2011

SYNTHON PHARMS

1MG

A078322 001 Jun 28, 2010

WATSON LABS

1MG

A078984 001 Jun 28, 2010

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK

EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK

25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING

50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS

50MG

A086046 001

VALPIN 50

ENDO PHARMS

50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS

0.5%; 0.05%

N018746 002 Jul 11, 1994

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

US WORLDMEDS

20MG/2ML (10MG/ML)

N021264 001 Apr 20, 2004

APROTININ

INJECTABLE; INJECTION

TRASYLOL

BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS

0.05MG/ML

N020420 001 Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

PHARMACIA AND UPJOHN

5,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 002 May 23, 1997

10,000 UNITS/0.5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020227 001 May 23, 1997

ARGATROBAN

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

SANDOZ

125MG/125ML (1MG/ML)

N201743 001 May 09, 2011

DISCONTINUED DRUG PRODUCT LIST

6-33 (of 337)

ARIPRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

OTSUKA

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 004 Jun 07, 2006

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012

150MG

A200043 002 Jun 01, 2012

250MG

A200043 003 Jun 01, 2012

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012

200MG

A200156 004 Aug 29, 2012

NUVIGIL

CEPHALON

100MG

N021875 002 Mar 26, 2009

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A
PALMITATE; VITAMIN E

INJECTABLE; INJECTION

BEROCCA PN

ROCHE

50MG/ML; 0.03MG/ML; 0.0025MG/ML; 7.5MG/ML;
100
IU/ML; 0.2MG/ML; 20MG/ML; 2MG/ML; 1.8MG/ML;

N006071 003 Oct 10, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A;
VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018440 002 Aug 08, 1985

M.V.I.-12

HOSPIRA

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N008809 004 Aug 08, 1985

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

N018439 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0
IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

N008809 005 Apr 22, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE;
PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

ASTRAZENECA

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4
MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID;
PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001
MG/VIAL; 400
IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI
AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/
VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ
2,300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

DISCONTINUED DRUG PRODUCT LIST

6-34 (of 337)

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREP

NOVEL LABS INC 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM A090145 001 Jan 25, 2012

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER 500MG N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER 650MG N016030 001

MEASURIN

BAYER 650MG N016030 002

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS 650MG;50MG A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

MUTUAL PHARM 325MG;50MG;40MG A078149 001 Jun 13, 2007

WATSON LABS 325MG;50MG;40MG A086231 002 Feb 12, 1985

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH 325MG;50MG;40MG A086710 002 Aug 23, 1983

HALSEY 325MG;50MG;40MG A089448 001 Dec 01, 1986

IVAX PHARMS 325MG;50MG;40MG A085441 002 Oct 31, 1984

PURACAP PHARM 325MG;50MG;40MG A087048 002 Dec 09, 1983

QUANTUM PHARMICS 325MG;50MG;40MG A088972 001 Jun 18, 1985

SANDOZ 325MG;50MG;40MG A086398 002 Apr 06, 1984

WATSON LABS 325MG;50MG;40MG A086237 002 Mar 23, 1984

FIORINAL

WATSON LABS INC 325MG;50MG;40MG N017534 003 Apr 16, 1986

LANORINAL

LANNETT 325MG;50MG;40MG A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

VINTAGE PHARMS LLC 325MG;50MG;40MG;30MG A075351 001 Mar 05, 1999

WATSON LABS 325MG;50MG;40MG;30MG A074359 001 Aug 31, 1995

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ 385MG;30MG;25MG A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ 770MG;60MG;50MG A074817 002 Nov 27, 1996

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

STEVENS J 385MG;30MG;25MG A074988 001 Apr 30, 1999

770MG;60MG;50MG A074988 002 Apr 30, 1999

ORPHENGESIC

PRINSTON INC 385MG;30MG;25MG A075141 001 May 29, 1998

ORPHENGESIC FORTE

PRINSTON INC 770MG;60MG;50MG A075141 002 May 29, 1998

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA 389MG;32.4MG;65MG A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM 389MG;32.4MG;32MG N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM 389MG;32.4MG;65MG N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS 389MG;32.4MG;65MG A083077 002 Dec 07, 1984

SANDOZ 389MG;32.4MG;65MG A080044 002 Sep 16, 1983

TEVA 389MG;32.4MG;65MG A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ 389MG;32.4MG;65MG A083101 002 Jun 24, 1985

DISCONTINUED DRUG PRODUCT LIST

6-35 (of 337)

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS

389MG; 32.4MG; 65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL COMPOUND

WATSON LABS

325MG; 200MG

A088809 001 Oct 03, 1985

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

MIRROR PHARMS

325MG; 200MG; 16MG

A040860 001 Jan 07, 2010

PROSAM LABS

325MG; 200MG; 16MG

A040283 001 Dec 29, 1998

ASPIRIN; HYDROCODONE BITARTRATE

TABLET; ORAL

AZDONE

SCHWARZ PHARMA

500MG; 5MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT

500MG; 5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET; ORAL

EQUAGESIC

CARACO

325MG; 200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ

325MG; 200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM

325MG; 200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC

325MG; 200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS

325MG; 200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS

325MG; 400MG

A087211 001 Dec 22, 1982

MCNEIL

325MG; 400MG

A089193 001 Feb 12, 1986

PAR PHARM

325MG; 400MG

A089657 001 Nov 04, 1988

ROBAXISAL

ROBINS AH

325MG; 400MG

N012281 001

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY

325MG; 4.5MG; 0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

MUTUAL PHARM

325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982

WATSON LABS

325MG; 4.5MG; 0.38MG

A040255 001 Feb 27, 1998

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE

325MG; 2.25MG; 0.19MG

A087742 001 Jun 04, 1982

PERCODAN

ENDO PHARMS

325MG; 4.5MG; 0.38MG

N007337 006

PERCODAN-DEMI

ENDO PHARMS

325MG; 2.25MG; 0.19MG

N007337 005

ROXIPRIN

ROXANE

325MG; 4.5MG; 0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

SANOFI AVENTIS US

325MG; EQ 12.5MG BASE

N016891 001

ASPIRIN; PRAVASTATIN SODIUM

TABLET, TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB

325MG, N/A; N/A, 80MG

N021387 006 Jun 24, 2003

DISCONTINUED DRUG PRODUCT LIST

6-36 (of 337)

ASPIRIN; PRAVASTATIN SODIUMTABLET, TABLET, TABLET; ORAL
PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB	81MG, N/A; N/A, 20MG	N021387 001	Jun 24, 2003
	81MG, N/A; N/A, 40MG	N021387 002	Jun 24, 2003
	81MG, N/A; N/A, 80MG	N021387 003	Jun 24, 2003
	325MG, N/A; N/A, 20MG	N021387 004	Jun 24, 2003
	325MG, N/A; N/A, 40MG	N021387 005	Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM	325MG; 65MG	N010996 005
----------------	-------------	-------------

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016829 001
---------------	--------------	-------------

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC	325MG; 100MG	N016863 001
---------------	--------------	-------------

ATAZANAVIR SULFATE

CAPSULE; ORAL

REYATAZ

BRISTOL MYERS SQUIBB	EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021567 001	Jun 20, 2003
----------------------	--	-------------	--------------

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

ASTRAZENECA	0.5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019058 001	Sep 13, 1989
-------------	---	-------------	--------------

TABLET; ORAL

ATENOLOL

ABLE	25MG	A076907 001	Jul 30, 2004
	50MG	A076907 002	Jul 30, 2004
	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
MYLAN	25MG	A074126 003	Aug 26, 1998
	50MG	A074126 001	Mar 23, 1994
	100MG	A074126 002	Mar 23, 1994
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SANDOZ	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

NOSTRUM LABS	50MG; 25MG	A074404 001	May 14, 1998
	100MG; 25MG	A074404 002	May 14, 1998
PLIVA	50MG; 25MG	A074107 001	Sep 24, 1997
	100MG; 25MG	A074107 002	Sep 24, 1997

DISCONTINUED DRUG PRODUCT LIST

6-37 (of 337)

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

ZYDUS PHARMS USA INC

18MG

A079017 001 Sep 17, 2010

25MG

A079017 002 Sep 17, 2010

40MG

A079017 003 Sep 17, 2010

60MG

A079017 004 Sep 17, 2010

80MG

A079017 005 Sep 17, 2010

100MG

A079017 006 Sep 17, 2010

STRATTERA

LILLY

5MG

N021411 001 Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

TEVA PHARMS

EQ 10MG BASE

A078773 001 May 29, 2012

EQ 20MG BASE

A078773 002 May 29, 2012

EQ 40MG BASE

A078773 003 May 29, 2012

EQ 80MG BASE

A078773 004 May 29, 2012

ATOVAQUONE

TABLET; ORAL

MEPRON

GLAXOSMITHKLINE LLC

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

WATSON LABS INC

10MG/ML

A074945 001 Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

WATSON LABS INC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

HOSPIRA

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

HOSPIRA

10MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018831 001 Nov 23, 1983

ATROPINE

INJECTABLE; INJECTION

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

VALEANT

0.025MG; 0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG; 2.5MG

A086440 001

SOLUTION; ORAL

COLONAIID

MEDPOINTE PHARM HLC

0.025MG/5ML; 2.5MG/5ML

A085735 001

DISCONTINUED DRUG PRODUCT LIST

6-38 (of 337)

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

LOMANATE

ALPHARMA US PHARMS 0.025MG/5ML; 2.5MG/5ML A085746 001

LOMOTIL

GD SEARLE LLC 0.025MG/5ML; 2.5MG/5ML N012699 001

TABLET; ORAL

COLONAL

MEDPOINTE PHARM HLC 0.025MG; 2.5MG A085737 001

DI-ATRO

MD PHARM 0.025MG; 2.5MG A085266 001

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE 0.025MG; 2.5MG A040395 001 Nov 27, 2000

ASCOT 0.025MG; 2.5MG A087934 001 Jul 19, 1983

HEATHER 0.025MG; 2.5MG A086798 001

HIKMA PHARMS LLC 0.025MG; 2.5MG A087765 001 Mar 15, 1982

INWOOD LABS 0.025MG; 2.5MG A085509 001

IVAX PHARMS 0.025MG; 2.5MG A086727 001

KV PHARM 0.025MG; 2.5MG A085659 001

LEDERLE 0.025MG; 2.5MG A086950 001

MUTUAL PHARM 0.025MG; 2.5MG A085506 001

PARKE DAVIS 0.025MG; 2.5MG A087131 001

PVT FORM 0.025MG; 2.5MG A085766 001

R AND S PHARMA 0.025MG; 2.5MG A085035 001

ROXANE 0.025MG; 2.5MG A086057 001

SANDOZ 0.025MG; 2.5MG A086173 001

USL PHARMA 0.025MG; 2.5MG A087842 001 Mar 29, 1982

VALEANT PHARM INTL 0.025MG; 2.5MG A087195 001 Feb 16, 1982

WATSON LABS 0.025MG; 2.5MG A085876 001

LO-TROL

VANGARD 0.025MG; 2.5MG A088009 001 Mar 25, 1983

LOGEN

SUPERPHARM 0.025MG; 2.5MG A088962 001 May 10, 1985

LOW-QUEL

HALSEY 0.025MG; 2.5MG A085211 001

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

MYLAN INSTITUTIONAL 0.14MG/ML; 10MG/ML N019677 001 Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE 0.4MG/ML; 50MG/ML A087853 001 Nov 26, 1982

0.4MG/ML; 75MG/ML A087847 001 Nov 26, 1982

0.4MG/ML; 100MG/ML A087848 001 Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST 0.4MG/ML; 50MG/ML A085121 001

0.4MG/ML; 75MG/ML A085121 002

0.4MG/ML; 100MG/ML A085121 003

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY 2.1MG/0.7ML; 600MG/0.7ML; 600MG/0.7ML N021175 001 Jan 17, 2002

AZATADINE MALEATE

TABLET; ORAL

OPTIMINE

SCHERING 1MG N017601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

TRINALIN

SCHERING 1MG; 120MG N018506 001 Mar 23, 1982

AZATHIOPRINE

TABLET; ORAL

IMURAN

PROMETHEUS LABS 25MG N016324 002

DISCONTINUED DRUG PRODUCT LIST

6-39 (of 337)

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

PROMETHEUS LABS

EQ 100MG BASE/VIAL

N017391 001

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

MEDA PHARMS

EQ 0.125MG BASE/SPRAY

N022203 001 Oct 15, 2008

AZITHROMYCIN

CAPSULE; ORAL

ZITHROMAX

PFIZER

EQ 250MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050670 001 Nov 01, 1991

FOR SUSPENSION; ORAL

AZITHROMYCIN

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

INJECTABLE; INJECTION

AZITHROMYCIN

PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

TEVA PARENTERAL

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB

500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB

10MG/ML

N050632 003 May 24, 1989

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

PFIZER

50,000 UNITS/VIAL

A060282 001

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN

500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

DISCONTINUED DRUG PRODUCT LIST

6-40 (of 337)

BACITRACIN

POWDER;FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

CITRON PHARMA LLC

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050416 002

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT;TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062167 001

NEO-POLYCIN

DOW PHARM

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060647 001

NEOSPORIN

CITRON PHARMA LLC

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050417 001

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM;10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A061048 001

DISCONTINUED DRUG PRODUCT LIST

6-41 (of 337)

BACITRACIN; POLYMYXIN B SULFATE

DISC; TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM; 5,000 UNITS/GM

N050598 001 Sep 22, 1986

BACLOFEN

TABLET; ORAL

BACLOFEN

TEVA

10MG

A073043 001 Feb 27, 1992

20MG

A073044 001 Feb 27, 1992

USL PHARMA

10MG

A071260 001 May 06, 1988

20MG

A071261 001 May 06, 1988

WATSON LABS

10MG

A073092 001 Jan 28, 1994

10MG

A074698 001 Aug 20, 1996

20MG

A073093 001 Jan 28, 1994

20MG

A074698 002 Aug 20, 1996

LIORESAL

NOVARTIS

10MG

N017851 001

20MG

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

UCB INC

10MG

N021589 001 Oct 30, 2003

20MG

N021589 002 Oct 30, 2003

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

BECLOVENT

GLAXOSMITHKLINE

0.042MG/INH

N018153 001

VANCERIL

SCHERING

0.042MG/INH

N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING

0.084MG/INH

N020486 001 Dec 24, 1996

AEROSOL, METERED; NASAL

BECONASE

GLAXOSMITHKLINE

0.042MG/INH

N018584 001

VANCENASE

SCHERING

0.042MG/INH

N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

VANCENASE AQ

SCHERING

EQ 0.042MG DIPROP/SPRAY

N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY

N020469 001 Jun 26, 1996

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MYLAN PHARMS INC

5MG; 6.25MG

A076612 001 Feb 11, 2004

10MG; 12.5MG

A076612 002 Feb 11, 2004

20MG; 12.5MG

A076612 003 Feb 11, 2004

20MG; 25MG

A076612 004 Feb 11, 2004

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON

10MG

N012164 003

NATURETIN-2.5

APOTHECON

2.5MG

N012164 001

NATURETIN-5

APOTHECON

5MG

N012164 002

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND

0.4%

A084149 001

DISCONTINUED DRUG PRODUCT LIST

6-42 (of 337)

BENTIROMIDE

SOLUTION; ORAL

CHYMEX

SAVAGE LABS

500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE; ORAL

BENZONATATE

NESHER PHARMS

100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

TESSALON

PFIZER

200MG

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZAACLIN

VALEANT BERMUDA

5%; EQ 1% BASE

N050756 002 Apr 20, 2007

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

COREPHARMA

50MG

A040714 001 Oct 29, 2007

DIDREX

PHARMACIA AND UPJOHN

25MG

N012427 003

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

EMETE-CON

PFIZER

EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY; RECTAL

EMETE-CON

ROERIG

EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET; ORAL

AQUATAG

SOLVAY

25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM

50MG

A083206 001

EXNA

AH ROBINS INC

50MG

N012489 001

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

LANNETT HOLDINGS INC

0.5MG

A088877 001 Apr 11, 1985

1MG

A088894 001 Apr 11, 1985

2MG

A088895 001 Apr 11, 1985

MUTUAL PHARM

1MG

A081264 001 Jan 23, 1992

2MG

A081265 001 Jan 23, 1992

PROSAM LABS

0.5MG

A040699 001 Feb 14, 2008

1MG

A040705 001 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

MERCK

0.5MG

N009193 004

1MG

N009193 003

2MG

N009193 002

BENZYL BENZOATE

EMULSION; TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

DISCONTINUED DRUG PRODUCT LIST

6-43 (of 337)

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE; ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM; TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP; ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET; ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

BETAMETHASONE BENZOATE

CREAM; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT; TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

PERRIGO NEW YORK

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 001 Jan 31, 1986

DISC; TOPICAL

DIPROSONE

SCHERING

EQ 0.1% BASE

N017829 001

GEL, AUGMENTED; TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION; TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ALPHARMA US PHARMS

EQ 0.05% BASE

A071085 001 Feb 03, 1987

PHARMADERM

EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO

EQ 0.05% BASE

A072276 001 Aug 24, 1988

EQ 0.05% BASE

A074272 001 Sep 30, 1994

TEVA PHARMS

EQ 0.05% BASE

A071882 001 Jun 06, 1988

DIPROSONE

SCHERING

EQ 0.05% BASE

N017781 001

DISCONTINUED DRUG PRODUCT LIST

6-44 (of 337)

BETAMETHASONE DIPROPIONATE

OINTMENT; TOPICAL

ALPHATREX

SAVAGE LABS EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING EQ 0.05% BASE

N017691 001

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS EQ 3MG BASE/ML

A085738 001

CELESTONE

SCHERING EQ 3MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017561 001

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETADERM

ROACO EQ 0.1% BASE

N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070485 001 May 29, 1987

TARO EQ 0.1% BASE

A070062 001 May 14, 1985

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018862 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

LOTION; TOPICAL

BETAMETHASONE VALERATE

PHARMADERM EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS EQ 0.1% BASE

A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018867 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETA-VAL

TEVA EQ 0.1% BASE

A070069 001 Dec 19, 1985

BETAMETHASONE VALERATE

PERRIGO NEW YORK EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR EQ 0.1% BASE

A070486 001 May 29, 1987

BETATREX

SAVAGE LABS EQ 0.1% BASE

N018863 001 Aug 31, 1983

VALISONE

SCHERING EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC EQ 0.5% BASE

A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US 10MG

N019507 001 Oct 27, 1989

20MG

N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US 5MG; 12.5MG

N019807 001 Oct 30, 1992

10MG; 12.5MG

N019807 002 Oct 30, 1992

DISCONTINUED DRUG PRODUCT LIST

6-45 (of 337)

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE;1.75%

N020619 001 Apr 17, 1997

BETAZOLE HYDROCHLORIDE

INJECTABLE;INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE;INJECTION

URECHOLINE

ODYSSEY PHARMS

5MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N006536 001

TABLET;ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001 Jul 27, 2004

10MG

A040483 001 Jul 27, 2004

25MG

A040485 001 Jul 27, 2004

50MG

A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH

5MG

A040552 001 Oct 28, 2004

10MG

A040553 001 Oct 28, 2004

25MG

A040554 001 Oct 28, 2004

50MG

A040551 001 Oct 28, 2004

ASCOT

10MG

A088288 001 Jun 08, 1983

25MG

A088289 001 Jun 08, 1983

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

LANNETT HOLDINGS INC

5MG

A040703 001 Mar 27, 2008

50MG

A040677 001 Mar 27, 2008

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

WATSON LABS

5MG

A084402 001

5MG

A085230 002

5MG

A085841 001

10MG

A084408 001

10MG

A085228 001

10MG

A085842 001

25MG

A084441 001

25MG

A085229 001

25MG

A085839 001

50MG

A087397 001

50MG

A087444 001

DUVOID

WELLSPRING PHARM

10MG

A086262 001

25MG

A086263 001

50MG

A085882 003

MYOTONACHOL

GLENWOOD

5MG

A084188 001

10MG

A084188 003

25MG

A084188 004

URECHOLINE

ODYSSEY PHARMS

5MG

N006536 003

10MG

N006536 002

25MG

N006536 004

50MG

N006536 005

BETHANIDINE SULFATE

TABLET;ORAL

TENATHAN

ROBINS AH

10MG

N017675 001

25MG

N017675 002

DISCONTINUED DRUG PRODUCT LIST

6-46 (of 337)

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

BANNER PHARMACAPS

75MG

A203174 001 Aug 12, 2014

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

KUDCO IRELAND

50MG

A077995 001 Jul 06, 2009

ROXANE

50MG

A078285 001 Mar 24, 2011

SYNTHON PHARMS

50MG

A077973 001 Jul 06, 2009

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

ALLERGAN

0.03% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021275 001 Mar 16, 2001

BIPERIDEN LACTATE

INJECTABLE; INJECTION

AKINETON

ABBVIE

5MG/ML

N012418 002

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTEL

BRAINTREE

5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM
; N/A, 5.6GM

N021551 003 Jul 16, 2010

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

PROMETHEUS LABS

262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 5
00MG

N050719 001 Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MUTUAL PHARM

5MG

A075474 001 Oct 25, 2002

10MG

A075474 002 Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

2.5MG; 6.25MG

A075672 001 Sep 25, 2000

5MG; 6.25MG

A075672 002 Sep 25, 2000

10MG; 6.25MG

A075672 003 Sep 25, 2000

APOTHECON

2.5MG; 6.25MG

A075642 002 Dec 27, 2000

5MG; 6.25MG

A075642 001 Dec 27, 2000

10MG; 6.25MG

A075642 003 Dec 27, 2000

IVAX SUB TEVA PHARMS

2.5MG; 6.25MG

A075632 001 Sep 27, 2000

5MG; 6.25MG

A075632 002 Sep 27, 2000

10MG; 6.25MG

A075632 003 Sep 27, 2000

SANDOZ

2.5MG; 6.25MG

A075527 001 Sep 25, 2000

5MG; 6.25MG

A075527 003 Sep 25, 2000

10MG; 6.25MG

A075527 002 Sep 25, 2000

TEVA

2.5MG; 6.25MG

A075686 001 Jan 19, 2001

5MG; 6.25MG

A075686 002 Jan 19, 2001

10MG; 6.25MG

A075686 003 Jan 19, 2001

WATSON LABS

2.5MG; 6.25MG

A075469 001 Sep 25, 2000

5MG; 6.25MG

A075469 002 Sep 25, 2000

10MG; 6.25MG

A075469 003 Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US

0.37MG/INH

N018770 001 Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US

0.2%

N019548 001 Feb 19, 1992

DISCONTINUED DRUG PRODUCT LIST

6-47 (of 337)

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

BRISTOL MYERS SQUIBB EQ 15 UNITS BASE/VIAL
EQ 30 UNITS BASE/VIAL

N050443 001
N050443 002 Sep 07, 1995

BLEOMYCIN SULFATE

PHARMACHEMIE BV EQ 15 UNITS BASE/VIAL
TEVA PARENTERAL EQ 15 UNITS BASE/VIAL
EQ 30 UNITS BASE/VIAL

A065201 001 Dec 13, 2007
A064084 001 Jun 01, 1996
A064084 002 Jun 01, 1996

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM 50MG/ML
100MG/ML

A070134 001 Apr 29, 1986
A071298 001 Feb 13, 1987

ASTRAZENECA 50MG/ML
50MG/ML
50MG/ML

A071151 001 Aug 10, 1987
A071152 001 Aug 10, 1987
A071153 001 Aug 10, 1987

HIKMA MAPLE 50MG/ML
50MG/ML

A070545 001 May 14, 1986
A070546 001 May 14, 1986

HOSPIRA 50MG/ML
50MG/ML

N019030 001 Apr 29, 1986
N019033 001 Apr 29, 1986

INTL MEDICATION 50MG/ML
LUITPOLD 50MG/ML

A070119 001 Apr 29, 1986
A070891 001 Jul 26, 1988

BRETYLIUM TOSYLATE IN DEXTROSE 5%

ABBOTT 200MG/100ML
400MG/100ML
800MG/100ML

N019005 002 Apr 29, 1986
N019005 003 Apr 29, 1986
N019005 001 Apr 29, 1986

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 200MG/100ML
400MG/100ML

N019837 002 Apr 12, 1989
N019837 001 Apr 12, 1989

HOSPIRA INC 200MG/100ML
400MG/100ML
800MG/100ML

N019008 002 Apr 29, 1986
N019008 003 Apr 29, 1986
N019008 001 Apr 29, 1986

BRETYLOL

HOSPIRA 50MG/ML

N017954 001

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

ALLERGAN 0.2%
0.5%

N020613 001 Sep 06, 1996
N020490 001 Mar 13, 1997

BRIMONIDINE TARTRATE

TEVA PARENTERAL 0.2%

A076372 001 Sep 10, 2004

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

XIBROM

BAUSCH AND LOMB INC EQ 0.09% ACID

N021664 001 Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM EQ 5MG BASE

A075100 001 Dec 10, 1998

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS 25MG

N007984 001

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS 12.5MG/5ML; 10MG/5ML

N009319 006 Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS 12.5MG/5ML; 10MG/5ML

A088343 001 Aug 15, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE
WOCKHARDT 12.5MG/5ML; 10MG/5ML

A088626 001 Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS 2MG/5ML
KV PHARM 2MG/5ML
PHARM ASSOC 2MG/5ML
USL PHARMA 2MG/5ML

A086936 001
A085466 001
A087517 001
A087964 001 Jan 25, 1983

DISCONTINUED DRUG PRODUCT LIST

6-48 (of 337)

BROMPHENIRAMINE MALEATE

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS

10MG/ML

A083821 001

100MG/ML

A083820 001

DIMETANE-TEN

WYETH AYERST

10MG/ML

N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR

4MG

A084468 001

IVAX SUB TEVA PHARMS

4MG

A084351 001

NEWTRON PHARMS

4MG

A086987 001

NEXGEN PHARMA INC

4MG

A086187 001

PAR PHARM

4MG

A087009 001

PIONEER PHARMS

4MG

A088604 001 Jul 13, 1984

SANDOZ

4MG

A083215 001

VITARINE

4MG

A085850 001

WATSON LABS

4MG

A083123 001

4MG

A085769 001

DIMETANE

WYETH CONS

4MG

N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS

8MG

N010799 010 Jun 10, 1983

12MG

N010799 011 Jun 10, 1983

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS

2MG/5ML; 10MG/5ML; 30MG/5ML

A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT

2MG/5ML; 10MG/5ML; 30MG/5ML

A089681 001 Dec 22, 1988

DIMETANE-DX

ROBINS AH

2MG/5ML; 10MG/5ML; 30MG/5ML

N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA

16MG; 240MG

N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS

50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA

0.032MG/INH

N020233 001 Feb 14, 1994

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA

0.16MG/INH

N020441 002 Jun 24, 1997

0.32MG/INH

N020441 003 Jun 24, 1997

SPRAY, METERED; NASAL

RHINOCORT

ASTRAZENECA PHARMS

0.064MG/INH

N020746 002 Oct 01, 1999

SUSPENSION; INHALATION

BUDESONIDE

APOTEX INC

0.25MG/2ML

A078202 001 Mar 30, 2009

0.5MG/2ML

A078202 002 Mar 30, 2009

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA

0.25MG/ML

A074160 001 Oct 30, 1997

TEVA PARENTERAL

0.25MG/ML

A074613 001 Nov 18, 1997

BUMEX

VALIDUS PHARMS INC

0.25MG/ML

N018226 001 Feb 28, 1983

TABLET; ORAL

BUMEX

VALIDUS PHARMS INC

0.5MG

N018225 002 Feb 28, 1983

1MG

N018225 001 Feb 28, 1983

2MG

N018225 003 Jun 14, 1985

DISCONTINUED DRUG PRODUCT LIST

6-49 (of 337)

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

PACIRA PHARMS INC 133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

HOSPIRA 0.75%

A070587 001 Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA 0.075%

N019978 001 Sep 03, 1992

0.114%

N019978 002 Sep 03, 1992

0.23%

N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED 0.25%

A076012 001 Jan 09, 2002

0.5%

A076012 002 Jan 09, 2002

0.75%

A076012 003 Jan 09, 2002

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA 0.25%; 0.005MG/ML

A071166 001 Jun 16, 1988

0.5%; 0.005MG/ML

A071169 001 Jun 16, 1988

0.75%; 0.005MG/ML

A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)

N021496 001 May 23, 2003

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBUTEX

RECKITT BENCKISER EQ 2MG BASE

N020732 002 Oct 08, 2002

EQ 8MG BASE

N020732 003 Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER EQ 2MG BASE; EQ 0.5MG BASE

N020733 001 Oct 08, 2002

EQ 8MG BASE; EQ 2MG BASE

N020733 002 Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

SANDOZ 75MG

A075613 002 Oct 10, 2000

100MG

A075613 001 Oct 10, 2000

TEVA 75MG

A075310 001 Nov 29, 1999

100MG

A075310 002 Nov 29, 1999

WELLBUTRIN

GLAXOSMITHKLINE 50MG

N018644 001 Dec 30, 1985

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC 300MG

A077715 002 Jun 13, 2007

IMPAX LABS 300MG

A077415 002 Dec 15, 2006

SANDOZ 100MG

A076845 001 Jul 14, 2005

150MG

A076834 001 Jul 14, 2005

150MG

A076845 002 Jul 14, 2005

WELLBUTRIN SR

GLAXOSMITHKLINE 50MG

N020358 001 Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE 100MG

N020711 002 May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL

BUSPAR

BRISTOL MYERS SQUIBB 5MG

N021190 001 Dec 20, 2000

7.5MG

N021190 002 Dec 20, 2000

10MG

N021190 003 Dec 20, 2000

15MG

N021190 004 Dec 20, 2000

TABLET; ORAL

BUSPAR

BRISTOL MYERS SQUIBB 5MG

N018731 001 Sep 29, 1986

10MG

N018731 002 Sep 29, 1986

15MG

N018731 003 Apr 22, 1996

DISCONTINUED DRUG PRODUCT LIST

6-50 (of 337)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPAR

30MG

N018731 004 Apr 22, 1996

BUSPIRONE HYDROCHLORIDE

APOTEX

5MG

A075521 001 Apr 05, 2002

10MG

A075521 002 Apr 05, 2002

15MG

A075521 003 Apr 05, 2002

EGIS

5MG

A075119 001 Mar 14, 2002

10MG

A075119 002 Mar 14, 2002

15MG

A075119 003 Jan 23, 2003

IVAX SUB TEVA PHARMS

5MG

A075385 001 Mar 01, 2002

10MG

A075385 002 Mar 01, 2002

15MG

A075385 003 Mar 01, 2002

NESHER PHARMS

5MG

A075572 001 Feb 27, 2002

10MG

A075572 002 Feb 27, 2002

15MG

A075572 003 Feb 27, 2002

PROSAM LABS

5MG

A075388 001 May 09, 2002

10MG

A075388 002 May 09, 2002

15MG

A075388 003 May 09, 2002

SANDOZ

5MG

A075413 001 Mar 19, 2002

10MG

A075413 002 Mar 19, 2002

15MG

A075413 003 Mar 19, 2002

BUTABARBITAL SODIUM

CAPSULE; ORAL

BUTICAPS

MEDPOINTE PHARM HLC

15MG

A085381 001

30MG

A085381 002

50MG

A085381 003

100MG

A085381 004

ELIXIR; ORAL

BUTABARB

ALPHARMA US PHARMS

30MG/5ML

A085873 001

BUTABARBITAL SODIUM

WOCKHARDT

30MG/5ML

A085383 001

BUTALAN

LANNETT

33.3MG/5ML

A085880 001

SARISOL

HALSEY

30MG/5ML

A084723 001

TABLET; ORAL

BUTABARBITAL

BUNDY

30MG

A085550 001

BUTABARBITAL SODIUM

SANDOZ

15MG

A084292 003 Feb 09, 1982

15MG

A085938 001

30MG

A084272 002

30MG

A085934 001

SOLVAY

16.2MG

A083606 001

32.4MG

A083898 001

48.6MG

A083897 001

97.2MG

A083896 001

TEVA

15MG

A088632 001 May 18, 1985

30MG

A088631 001 May 01, 1985

WATSON LABS

15MG

A085764 001

30MG

A085772 001

WHITEWORTH TOWN PLSN

15MG

A083325 002

30MG

A083337 001

BUTISOL SODIUM

MEDA PHARMS

15MG

N000793 002

100MG

N000793 005

SARISOL NO. 1

HALSEY

15MG

A084719 001

SARISOL NO. 2

HALSEY

30MG

A084719 002

SODIUM BUTABARBITAL

HIKMA PHARMS LLC

15MG

A085418 001

30MG

A085432 001

IVAX SUB TEVA PHARMS

15MG

A083484 001

30MG

A084040 001

LANNETT

15MG

A085849 001

30MG

A085866 001

100MG

A085881 001

DISCONTINUED DRUG PRODUCT LIST

6-51 (of 337)

BUTABARBITAL SODIUM

TABLET; ORAL

SODIUM BUTABARBITAL

MARSHALL PHARMA

16.2MG

A083524 001

32.4MG

A083858 001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN

1%

N021408 001 Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

FEMSTAT

ROCHE PALO

2%

N019215 001 Nov 25, 1985

GYNAZOLE-1

ELAN PHARMA INTL LTD

2%

N019881 001 Feb 07, 1997

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO

100MG

N019359 001 Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

APOTEX INC

2MG/ML

A075697 001 Oct 23, 2001

HIKMA FARMACEUTICA

2MG/ML

A078247 001 Apr 29, 2009

HOSPIRA

1MG/ML

A075342 001 Nov 04, 1999

1MG/ML

A075559 001 Mar 20, 2000

2MG/ML

A075342 002 Nov 04, 1999

2MG/ML

A075559 002 Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

APOTEX INC

1MG/ML

A075695 001 Oct 23, 2001

2MG/ML

A075695 002 Oct 23, 2001

HOSPIRA

1MG/ML

A074620 001 Jan 22, 1997

1MG/ML

A075170 001 Sep 28, 1998

2MG/ML

A074620 002 Jan 22, 1997

2MG/ML

A075170 002 Sep 28, 1998

STADOL

APOTHECON

2MG/ML

N017857 004

STADOL PRESERVATIVE FREE

APOTHECON

1MG/ML

N017857 001

2MG/ML

N017857 002

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB

1MG/SPRAY

N019890 001 Dec 12, 1991

CABERGOLINE

TABLET; ORAL

DOSTINEX

PHARMACIA AND UPJOHN

0.5MG

N020664 001 Dec 23, 1996

CAFFEINE, ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

NOVARTIS

100MG; 2MG

N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS

100MG; 1MG

N006620 001

WIGRAINE

ORGANON USA INC

100MG; 1MG

A086562 001

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

OINTMENT; TOPICAL

DOVONEX

LEO PHARMA AS

0.005%

N020273 001 Dec 29, 1993

SOLUTION; TOPICAL

DOVONEX

LEO PHARM

0.005% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy

N020611 001 Mar 03, 1997

DISCONTINUED DRUG PRODUCT LIST

6-52 (of 337)

CALCIPOTRIENESOLUTION; TOPICAL
DOVONEX

reasons**

CALCITONIN HUMANINJECTABLE; INJECTION
CIBACALCIN
NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMONINJECTABLE; INJECTION
CALCIMAR

SANOFI AVENTIS US

200 IU/ML

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

ASTRAZENECA

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

SEBELA IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

CALCITRIOLINJECTABLE; INJECTION
CALCITRIOL

HOSPIRA

0.001MG/ML

A075816 001 Jan 16, 2004

0.002MG/ML

A075816 002 Jan 16, 2004

TEVA PARENTERAL

0.001MG/ML

A075823 001 Mar 31, 2003

0.002MG/ML

A075823 002 Mar 31, 2003

CALCIUM ACETATECAPSULE; ORAL
PHOSLO

FRESENIUS MEDCL

EQ 84.5MG CALCIUM

N021160 001 Apr 02, 2001

EQ 169MG CALCIUM

N021160 002 Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

ROXANE

EQ 169MG CALCIUM

A077693 001 Jan 30, 2008

PHOSLO

FRESENIUS MEDCL

EQ 169MG CALCIUM

N019976 001 Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET, TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

WARNER CHILCOTT

EQ 500MG BASE, N/A; N/A, 35MG **Federal
Register determination that product was
not discontinued or withdrawn for
safety or efficacy reasons**

N021823 001 Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML;
7.07GM/1000ML

N021703 012 Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 005 Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML;
2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML;
6.46GM/1000ML

N021703 008 Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 007 Oct 25, 2006

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

GAMBRO RENAL PRODS

3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML;
0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML

N021703 009 Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML;
330MG/100ML; 88MG/100ML

N018271 001

DISCONTINUED DRUG PRODUCT LIST

6-53 (of 337)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993
---------	---	-------------	--------------

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269 002	Jan 17, 1983
---------	---	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 006	Jan 29, 1986
---------	---	-------------	--------------

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 001	
---------	---	-------------	--

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 003	
---------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 002	
---------	---	-------------	--

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460 008	Jan 29, 1986
---------	--	-------------	--------------

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460 004	
---------	--	-------------	--

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 001	Jun 13, 1994
-----------	---	-------------	--------------

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 002	Jun 13, 1994
-----------	---	-------------	--------------

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 003	Jun 13, 1994
-----------	---	-------------	--------------

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374 004	Jun 13, 1994
-----------	--	-------------	--------------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256 001	
---------	--	-------------	--

BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N016695 001	
-----------------	--	-------------	--

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634 002	Feb 24, 1988
---------	--	-------------	--------------

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510 001	
---------	---	-------------	--

MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499 001	
-------	---	-------------	--

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005	Oct 17, 1988
---------	--	-------------	--------------

	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006	Oct 17, 1988
--	--	-------------	--------------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007	Oct 17, 1988
---------	--	-------------	--------------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003	Oct 17, 1988
---------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

6-54 (of 337)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

HOSPIRA

20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/
100ML; 310MG/100ML

N019685 001 Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 44
8MG/100ML

N019395 001 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 44
8MG/100ML

N019395 002 Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL

25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 4
48MG/100ML

N019395 003 Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT

16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML;
16.1MG/ML

N019399 001 Jun 16, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/
100ML; 500MG/100ML; 74MG/100ML

N018899 001 Oct 31, 1983

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG
/100ML

N018725 001 Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN

33MG/100ML; 30MG/100ML; 860MG/100ML

N018721 001 Nov 09, 1982

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT

33MG/100ML; 30MG/100ML; 860MG/100ML

N018462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N019485 001 Oct 24, 1985

B BRAUN

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018023 001

MILES

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018417 001

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

ABBOTT

EQ 90MG CALCIUM/5ML

A080001 001

EQ 90MG CALCIUM/5ML

A083159 001

ABRAXIS PHARM

EQ 90MG CALCIUM/5ML

A089373 001 Apr 30, 1987

LILLY

EQ 90MG CALCIUM/5ML

N006470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE

0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML

N016847 001

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE

0.35MG/ML; 140.1MG/ML; 461.8MG/ML

N017506 001

CANDICIDIN

OINTMENT; VAGINAL

VANOBIID

SANOFI AVENTIS US

0.6MG/GM

A061596 001

DISCONTINUED DRUG PRODUCT LIST

6-55 (of 337)

CANDICIDIN

TABLET;VAGINAL

VANOBID

SANOFI AVENTIS US

3MG

A061613 001

CAPTOPRIL

TABLET;ORAL

CAPOTEN

PAR PHARM

37.5MG

N018343 006 Sep 17, 1986

75MG

N018343 007 Jun 13, 1995

150MG

N018343 004 Jun 13, 1995

CAPTOPRIL

APOTHECON

12.5MG

A074472 001 Mar 31, 1995

25MG

A074472 002 Mar 31, 1995

50MG

A074472 003 Mar 31, 1995

100MG

A074472 004 Mar 31, 1995

DAVA PHARMS INC

12.5MG

A074423 001 Feb 13, 1996

25MG

A074423 002 Feb 13, 1996

50MG

A074423 003 Feb 13, 1996

100MG

A074423 004 Feb 13, 1996

EGIS PHARMS

12.5MG

A074748 004 May 29, 1997

25MG

A074748 002 May 29, 1997

50MG

A074748 001 May 29, 1997

100MG

A074748 003 May 29, 1997

IVAX SUB TEVA PHARMS

12.5MG

A074590 004 Aug 30, 1996

25MG

A074590 002 Aug 30, 1996

50MG

A074590 001 Aug 30, 1996

100MG

A074590 003 Aug 30, 1996

PAR PHARM

12.5MG

A074493 001 Feb 13, 1996

25MG

A074493 002 Feb 13, 1996

50MG

A074493 003 Feb 13, 1996

100MG

A074493 004 Feb 13, 1996

PRINSTON INC

12.5MG

A074477 001 Feb 13, 1996

25MG

A074477 002 Feb 13, 1996

50MG

A074477 003 Feb 13, 1996

100MG

A074477 004 Feb 13, 1996

PUREPAC PHARM

12.5MG

A074640 001 Mar 31, 1997

25MG

A074640 002 Mar 31, 1997

50MG

A074640 003 Mar 31, 1997

100MG

A074640 004 Mar 31, 1997

SANDOZ

12.5MG

A074481 001 Feb 13, 1996

12.5MG

A074519 001 Feb 13, 1996

25MG

A074481 002 Feb 13, 1996

25MG

A074519 002 Feb 13, 1996

50MG

A074481 003 Feb 13, 1996

50MG

A074519 003 Feb 13, 1996

100MG

A074481 004 Feb 13, 1996

100MG

A074519 004 Feb 13, 1996

TEVA

12.5MG

A074433 001 Feb 13, 1996

12.5MG

A074483 001 Feb 13, 1996

25MG

A074433 002 Feb 13, 1996

25MG

A074483 002 Feb 13, 1996

50MG

A074433 003 Feb 13, 1996

50MG

A074483 003 Feb 13, 1996

100MG

A074433 004 Feb 13, 1996

100MG

A074483 004 Feb 13, 1996

TEVA PHARMS

12.5MG

A074462 001 Feb 13, 1996

25MG

A074462 002 Feb 13, 1996

50MG

A074462 003 Feb 13, 1996

100MG

A074462 004 Feb 13, 1996

VINTAGE PHARMS LLC

12.5MG

A074418 001 Feb 13, 1996

25MG

A074418 002 Feb 13, 1996

50MG

A074418 003 Feb 13, 1996

100MG

A074418 004 Feb 13, 1996

WATSON LABS

12.5MG

A074451 001 Feb 13, 1996

12.5MG

A074576 001 Apr 23, 1996

25MG

A074451 002 Feb 13, 1996

25MG

A074576 002 Apr 23, 1996

50MG

A074451 003 Feb 13, 1996

50MG

A074576 003 Apr 23, 1996

100MG

A074451 004 Feb 13, 1996

100MG

A074576 004 Apr 23, 1996

DISCONTINUED DRUG PRODUCT LIST

6-56 (of 337)

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

APOTHECON

25MG;15MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018709 001 Oct 12, 1984

CAPOZIDE 25/25

APOTHECON

25MG;25MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018709 002 Oct 12, 1984

CAPOZIDE 50/15

APOTHECON

50MG;15MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018709 004 Oct 12, 1984

CAPOZIDE 50/25

APOTHECON

50MG;25MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018709 003 Oct 12, 1984

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

25MG;15MG

A075055 001 Jun 18, 1998

25MG;25MG

A075055 002 Jun 18, 1998

50MG;15MG

A075055 004 Jun 18, 1998

50MG;25MG

A075055 003 Jun 18, 1998

VINTAGE PHARMS LLC

25MG;15MG

A074788 001 Dec 29, 1997

25MG;25MG

A074788 002 Dec 29, 1997

50MG;15MG

A074788 004 Dec 29, 1997

50MG;25MG

A074788 003 Dec 29, 1997

WATSON LABS

50MG;25MG

A074832 001 Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR

0.01%

A070292 001 May 21, 1986

CARBASTAT

NOVARTIS

0.01%

A073677 001 Apr 28, 1995

CARBAMAZEPINE

SUSPENSION; ORAL

CARBAMAZEPINE

TARO

100MG/5ML

A075875 001 Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH

200MG

A071696 001 Nov 09, 1987

INWOOD LABS

200MG

A070231 001 Aug 14, 1986

PLIVA

200MG

A071479 001 Jul 24, 1987

USL PHARMA

200MG

A070300 001 May 15, 1986

WARNER CHILCOTT

200MG

A070429 001 Jan 02, 1987

TERIL

TARO

200MG

A076525 001 Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG

EQ 1GM BASE/VIAL

N050306 001

EQ 2GM BASE/VIAL

N050306 004

EQ 5GM BASE/VIAL

N050306 002

EQ 10GM BASE/VIAL

N050306 006

EQ 30GM BASE/VIAL

N050306 007

PYOPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050298 001

EQ 2GM BASE/VIAL

N050298 002

EQ 5GM BASE/VIAL

N050298 003

EQ 10GM BASE/VIAL

N050298 006

EQ 20GM BASE/VIAL

N050298 007

DISCONTINUED DRUG PRODUCT LIST

6-57 (of 337)

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER

EQ 382MG BASE

N050435 001

CARBDOPA; LEVODOPA

TABLET; ORAL

CARBDOPA AND LEVODOPA

SANDOZ

10MG; 100MG

A073586 001 Jun 29, 1995

25MG; 100MG

A073587 001 Jun 29, 1995

25MG; 250MG

A073620 001 Jun 29, 1995

SCS

10MG; 100MG

A074080 001 Mar 25, 1994

25MG; 100MG

A074080 002 Mar 25, 1994

25MG; 250MG

A074080 003 Mar 25, 1994

WATSON LABS

10MG; 100MG

A073381 001 Sep 28, 1993

25MG; 100MG

A073382 001 Sep 28, 1993

25MG; 250MG

A073383 001 Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBDOPA AND LEVODOPA

KV PHARM

50MG; 200MG

A076663 001 Jun 24, 2004

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY

10MG; 100MG

A076643 001 Jun 10, 2005

25MG; 100MG

A076643 002 Jun 10, 2005

25MG; 250MG

A076643 003 Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBDOPA AND LEVODOPA

IMPAX LABS

10MG; 100MG

A090631 001 Jun 08, 2010

25MG; 100MG

A090631 002 Jun 08, 2010

25MG; 250MG

A090631 003 Jun 08, 2010

PARCOPA

UCB INC

10MG; 100MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A076699 001 Aug 27, 2004

25MG; 100MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A076699 002 Aug 27, 2004

25MG; 250MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

A076699 003 Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

MCNEIL

4MG/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N008955 001

TABLET; ORAL

CLISTIN

ORTHO MCNEIL PHARM

4MG

N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL

A077383 001 Jan 27, 2006

150MG/VIAL

A077383 002 Jan 27, 2006

450MG/VIAL

A077383 003 Jan 27, 2006

EUROHLTH INTL

50MG/VIAL

A076099 001 Oct 14, 2004

150MG/VIAL

A076099 002 Oct 14, 2004

450MG/VIAL

A076099 003 Oct 14, 2004

FRESENIUS KABI USA

50MG/VIAL

A076235 001 Oct 14, 2004

150MG/VIAL

A076235 002 Oct 14, 2004

450MG/VIAL

A076235 003 Oct 14, 2004

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

ONCO THERAPIES LTD

50MG/VIAL

A091510 001 May 29, 2012

150MG/VIAL

A091510 002 May 29, 2012

450MG/VIAL

A091510 003 May 29, 2012

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

DISCONTINUED DRUG PRODUCT LIST

6-58 (of 337)

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	450MG/VIAL	A076602	003	Nov 16, 2004
SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005
	150MG/VIAL	A076959	002	Mar 18, 2005
	450MG/VIAL	A076959	003	Mar 18, 2005
WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004
	150MG/VIAL	A076162	002	Oct 14, 2004
	450MG/VIAL	A076162	003	Oct 14, 2004
PARAPLATIN				
CORDEN PHARMA	50MG/VIAL	N019880	001	Mar 03, 1989
	150MG/VIAL	N019880	002	Mar 03, 1989
	450MG/VIAL	N019880	003	Mar 03, 1989

INJECTABLE; IV (INFUSION)

CARBOPLATIN

FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004
	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006
	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004
	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006
PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009
	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009
	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009
TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
PARAPLATIN				
CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003
	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003
	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003
	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004

CARISOPRODOL

CAPSULE; ORAL

SOMA

MEDA PHARMS	250MG	N011792	003	
-------------	-------	---------	-----	--

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421	001	Jun 21, 2001
COREPHARMA	350MG	A040397	001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
PROSAM LABS	350MG	A040188	001	Mar 07, 1997
SANDOZ	350MG	A081025	001	Apr 13, 1989
	350MG	A089566	001	Aug 30, 1988
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
	350MG	A086179	001	
RELA				
SCHERING	350MG	N012155	001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173	001	
--------------	---------	---------	-----	--

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

CARPROFEN

TABLET; ORAL

RIMADYL

ROCHE	100MG	N018550	002	Dec 31, 1987
	150MG	N018550	003	Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC	1%	A076097	001	Feb 06, 2002
------------	----	---------	-----	--------------

TABLET; ORAL

CARTROL

ABBVIE	2.5MG	N019204	001	Dec 28, 1988
--------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-59 (of 337)

CARTEOLOL HYDROCHLORIDE

TABLET; ORAL

CARTROL

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET; ORAL

CARVEDILOL

WOCKHARDT LTD

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

CEFACLOL

CAPSULE; ORAL

CECLOR

LILLY

EQ 250MG BASE

N050521 001

EQ 500MG BASE

N050521 002

CEFACLOL

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

WATSON LABS INC

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

FOR SUSPENSION; ORAL

CECLOR

LILLY

EQ 125MG BASE/5ML

N050522 001

EQ 250MG BASE/5ML

N050522 002

CEFACLOL

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

WATSON LABS INC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

EQ 375MG BASE/5ML

A064207 001 Feb 18, 1998

TABLET, CHEWABLE; ORAL

RANICLOL

RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003

EQ 187MG BASE

A065092 002 Dec 22, 2003

EQ 250MG BASE

A065092 003 Dec 22, 2003

EQ 375MG BASE

A065092 004 Dec 22, 2003

TABLET, EXTENDED RELEASE; ORAL

CECLOR CD

LILLY

EQ 375MG BASE

N050673 001 Jun 28, 1996

EQ 500MG BASE

N050673 002 Jun 28, 1996

CEFACLOL

WORLD GEN

EQ 500MG BASE

A065057 001 Jan 05, 2001

DISCONTINUED DRUG PRODUCT LIST

6-60 (of 337)

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

IVAX SUB TEVA PHARMS	EQ 500MG BASE	A062766 001	Mar 03, 1987
PUREPAC PHARM	EQ 500MG BASE	A063017 001	Jan 05, 1989
RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999
TEVA	EQ 500MG BASE	A062695 001	Feb 10, 1989

DURICEF

WARNER CHILCOTT	EQ 250MG BASE	N050512 002	
	EQ 500MG BASE	N050512 001	

ULTRACEF

BRISTOL	EQ 500MG BASE	A062378 001	Mar 16, 1982
---------	---------------	-------------	--------------

FOR SUSPENSION; ORAL

CEFADROXIL

ANI PHARMS INC	EQ 125MG BASE/5ML	A062698 001	Mar 01, 1989
	EQ 250MG BASE/5ML	A062698 002	Mar 01, 1989
	EQ 250MG BASE/5ML	A065278 001	Jan 20, 2006
	EQ 500MG BASE/5ML	A062698 003	Mar 01, 1989
	EQ 500MG BASE/5ML	A065278 002	Jan 20, 2006
APOTHECON	EQ 125MG BASE/5ML	A062334 001	
	EQ 250MG BASE/5ML	A062334 002	
	EQ 500MG BASE/5ML	A062334 003	

DURICEF

WARNER CHILCOTT	EQ 125MG BASE/5ML	N050527 002	
	EQ 250MG BASE/5ML	N050527 003	
	EQ 500MG BASE/5ML	N050527 001	

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376 001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376 002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376 003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999
---------	-------------	-------------	--------------

DURICEF

WARNER CHILCOTT	EQ 1GM BASE	N050528 001	
-----------------	-------------	-------------	--

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390 001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408 001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY	EQ 1GM BASE/VIAL	A062560 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504 002	
	EQ 2GM BASE/VIAL	A062560 002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504 003	
	EQ 10GM BASE/VIAL	N050504 004	
	EQ 500MG BASE/VIAL	N050504 001	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050461 003	
	EQ 5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 004	
	EQ 10GM BASE/VIAL	N050461 005	
	EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N050461 001	
	EQ 500MG BASE/VIAL	N050461 002	

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 003	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 004	Jun 08, 1983

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566 001	Jun 08, 1983
	EQ 20MG BASE/ML	N050566 002	Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779 001	Jul 27, 2000
---------	--------------------	-------------	--------------

CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 1GM BASE/VIAL	A062688 003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688 004	Nov 17, 1986

DISCONTINUED DRUG PRODUCT LIST

6-61 (of 337)

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

	EQ 20GM BASE/VIAL	A062688 005	Aug 03, 1987
	EQ 500MG BASE/VIAL	A062688 002	Nov 17, 1986
AUROBINDO PHARMA	EQ 1GM BASE/VIAL	A065395 002	Aug 08, 2008
	EQ 500MG BASE/VIAL	A065395 001	Aug 08, 2008
BEDFORD	EQ 1GM BASE/VIAL	A062894 003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894 004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894 005	Jul 21, 1988
	EQ 250MG BASE/VIAL	A062894 001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894 002	Jul 21, 1988
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009
	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
	EQ 500MG BASE/VIAL	A064169 001	Aug 14, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
HIKMA MAPLE	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
STERI PHARMA	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
TEVA PHARMS	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
WATSON LABS INC	EQ 1GM BASE/VIAL	A062988 003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989 001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989 002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989 003	Dec 29, 1989
	EQ 250MG BASE/VIAL	A062988 001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988 002	Dec 29, 1989
KEFZOL			
ACS DOBFAR	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
	EQ 250MG BASE/VIAL	A061773 001	
LILLY	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985
	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

FOR SUSPENSION; ORAL

OMNICEF

ABBVIE

300MG N050739 001 Dec 04, 1997

ABBVIE

125MG/5ML

N050749 001 Dec 04, 1997

250MG/5ML

N050749 002 Jul 29, 2004

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

SANDOZ

EQ 1GM BASE/VIAL

A090291 002 Dec 21, 2010

EQ 2GM BASE/VIAL

A090291 003 Dec 21, 2010

EQ 500MG BASE/VIAL

A090291 001 Dec 21, 2010

CEFIXIME

FOR SUSPENSION; ORAL

SUPRAX

LEDERLE

100MG/5ML

N050622 001 Apr 28, 1989

TABLET; ORAL

SUPRAX

LEDERLE

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N050621 001 Apr 28, 1989

400MG

N050621 002 Apr 28, 1989

DISCONTINUED DRUG PRODUCT LIST

6-62 (of 337)

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N050637 001 Dec 11, 1989

EQ 2GM BASE/VIAL

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

PHARMACIA AND UPJOHN

EQ 20MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050683 001 Dec 29, 1992

EQ 40MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

EQ 40MG BASE/ML

N050613 001 Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

1GM/VIAL

A062579 002 Nov 26, 1984

2GM/VIAL

A062579 003 Nov 26, 1984

10GM/VIAL

A062579 004 Nov 26, 1984

20GM/VIAL

A062579 005 Nov 26, 1984

500MG/VIAL

A062579 001 Nov 26, 1984

BRISTOL

1GM/VIAL

N050554 002 May 24, 1984

2GM/VIAL

N050554 003 May 24, 1984

10GM/VIAL

N050554 004 May 24, 1984

20GM/VIAL

N050554 005 May 24, 1984

500MG/VIAL

N050554 001 May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A064200 002 Mar 24, 2000

EQ 2GM BASE/VIAL

A064200 003 Mar 24, 2000

EQ 10GM BASE/VIAL

A064201 001 Mar 24, 2000

EQ 20GM BASE/VIAL

A064201 002 Mar 24, 2000

EQ 500MG BASE/VIAL

A064200 001 Mar 24, 2000

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

B BRAUN

EQ 2GM BASE

N050792 001 Jul 29, 2004

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

B BRAUN

EQ 1GM BASE

N050792 002 Jul 29, 2004

CEFOTAXIME SODIUM

AUROBINDO PHARMA

EQ 1GM BASE/VIAL

A065517 002 Nov 06, 2009

EQ 2GM BASE/VIAL

A065517 003 Nov 06, 2009

EQ 500MG BASE/VIAL

A065517 001 Nov 06, 2009

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065516 001 Nov 06, 2009

CEPHAZONE PHARMA

EQ 10GM BASE/VIAL

A065348 001 Jan 25, 2010

DISCONTINUED DRUG PRODUCT LIST

6-63 (of 337)

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 20MG BASE/ML

N050596 001 May 20, 1985

EQ 40MG BASE/ML

N050596 003 May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

ASTRAZENECA

EQ 1GM BASE/VIAL

A063293 001 Apr 29, 1993

EQ 1GM BASE/VIAL

N050588 001 Dec 27, 1985

EQ 2GM BASE/VIAL

A063293 002 Apr 29, 1993

EQ 2GM BASE/VIAL

N050588 002 Dec 27, 1985

EQ 10GM BASE/VIAL

N050588 003 Apr 25, 1988

CEFOTAN IN PLASTIC CONTAINER

ASTRAZENECA

EQ 20MG BASE/ML

N050694 002 Jul 30, 1993

EQ 40MG BASE/ML

N050694 001 Jul 30, 1993

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA

EQ 1GM BASE/VIAL

N050601 001 Dec 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

FRESENIUS KABI USA

EQ 1GM BASE/VIAL

A065012 001 Jul 03, 2000

EQ 2GM BASE/VIAL

A065012 002 Jul 03, 2000

EQ 10GM BASE/VIAL

A065011 001 Jul 03, 2000

MEFOXIN

MYLAN INSTITUTIONAL

EQ 1GM BASE/VIAL

A062757 001 Jan 08, 1987

EQ 1GM BASE/VIAL

N050517 001

EQ 2GM BASE/VIAL

A062757 002 Jan 08, 1987

EQ 2GM BASE/VIAL

N050517 002

EQ 10GM BASE/VIAL

N050517 003

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

MERCK

EQ 20MG BASE/ML

N050581 003 Sep 20, 1984

EQ 40MG BASE/ML

N050581 004 Sep 20, 1984

MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MERCK

EQ 20MG BASE/ML

N050581 002 Sep 20, 1984

EQ 40MG BASE/ML

N050581 001 Sep 20, 1984

CEFPYRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPYRAMIDE SODIUM

WYETH AYERST

EQ 1GM BASE/VIAL

N050633 002 Jan 31, 1989

EQ 2GM BASE/VIAL

N050633 003 Jan 31, 1989

EQ 10GM BASE/VIAL

N050633 005 Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO

EQ 50MG BASE/5ML

N050688 002 Aug 07, 1992

EQ 100MG BASE/5ML

N050688 001 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 50MG BASE/5ML

N050675 001 Aug 07, 1992

EQ 100MG BASE/5ML

N050675 002 Aug 07, 1992

TABLET; ORAL

BANAN

SANKYO

EQ 100MG BASE

N050687 001 Aug 07, 1992

EQ 200MG BASE

N050687 002 Aug 07, 1992

VANTIN

PHARMACIA AND UPJOHN

EQ 100MG BASE

N050674 001 Aug 07, 1992

EQ 200MG BASE

N050674 002 Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

RANBAXY LABS LTD

125MG/5ML

A065202 001 Jun 30, 2006

250MG/5ML

A065202 002 Jun 30, 2006

CEFZIL

CORDEN PHARMA

125MG/5ML

N050665 001 Dec 23, 1991

250MG/5ML

N050665 002 Dec 23, 1991

DISCONTINUED DRUG PRODUCT LIST

6-64 (of 337)

CEFPROZIL

TABLET; ORAL

CEFPROZIL

RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006

500MG

A065198 002 Dec 13, 2006

CEFZIL

CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991

500MG

N050664 002 Dec 23, 1991

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

AUROBINDO PHARMA LTD

1GM/VIAL

A065481 002 May 28, 2010

2GM/VIAL

A065481 003 May 28, 2010

6GM/VIAL

A065482 001 May 28, 2010

500MG/VIAL

A065481 001 May 28, 2010

CEPTAZ

GLAXOSMITHKLINE

1GM/VIAL

N050646 002 Sep 27, 1990

2GM/VIAL

N050646 003 Sep 27, 1990

10GM/VIAL

N050646 004 Sep 27, 1990

500MG/VIAL

N050646 001 Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE

1GM/VIAL

A063322 001 Nov 07, 1995

1GM/VIAL

A064006 001 Mar 31, 1992

2GM/VIAL

A063322 002 Nov 07, 1995

2GM/VIAL

A064006 002 Mar 31, 1992

6GM/VIAL

A064008 001 Mar 31, 1992

10GM/VIAL

A064008 002 Mar 31, 1992

TAZIDIME

LILLY

1GM/VIAL

A062655 001 Nov 20, 1985

2GM/VIAL

A062655 002 Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY

1GM/VIAL

A062739 001 Jul 10, 1986

2GM/VIAL

A062739 002 Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 10MG BASE/ML

A063221 001 Apr 29, 1993

EQ 20MG BASE/ML

A063221 002 Apr 29, 1993

EQ 40MG BASE/ML

A063221 003 Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

COVIS INJECTABLES

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS

EQ 1GM BASE/VIAL

A063294 002 Mar 31, 1994

EQ 1GM BASE/VIAL

N050560 002 Sep 15, 1983

EQ 2GM BASE/VIAL

A063294 003 Mar 31, 1994

EQ 2GM BASE/VIAL

N050560 003 Sep 15, 1983

EQ 10GM BASE/VIAL

N050560 005 Mar 19, 1993

EQ 500MG BASE/VIAL

N050560 001 Sep 15, 1983

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML

N050589 001 Oct 03, 1984

EQ 40MG BASE/ML

N050589 002 Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML

N050589 003 Apr 13, 1995

EQ 40MG BASE/ML

N050589 004 Apr 13, 1995

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS

EQ 10GM BASE/VIAL

A091068 001 Jan 07, 2013

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008

FRESENIUS KABI USA

EQ 10GM BASE/VIAL

A065252 001 Feb 15, 2006

TEVA

EQ 10GM BASE/VIAL

A065274 001 May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE

EQ 1GM BASE/VIAL

A062654 002 Apr 30, 1987

EQ 2GM BASE/VIAL

A062654 003 Apr 30, 1987

EQ 10GM BASE/VIAL

N050585 005 Dec 21, 1984

EQ 250MG BASE/VIAL

A063239 001 Aug 13, 1993

EQ 500MG BASE/VIAL

A062654 001 Apr 30, 1987

ROCHE

EQ 1GM BASE/VIAL

A062510 003 Mar 12, 1985

DISCONTINUED DRUG PRODUCT LIST

6-65 (of 337)

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN

	EQ 250MG BASE/VIAL	A062510 001	Mar 12, 1985
	EQ 500MG BASE/VIAL	A062510 002	Mar 12, 1985
ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER			
HOFFMANN LA ROCHE	EQ 10MG BASE/ML	N050624 001	Feb 11, 1987
	EQ 20MG BASE/ML	N050624 002	Feb 11, 1987
	EQ 40MG BASE/ML	N050624 003	Feb 11, 1987
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS			
CEFTRIAXONE			
AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A065505 003	Jul 31, 2008
	EQ 2GM BASE/VIAL	A065505 004	Jul 31, 2008
	EQ 250MG BASE/VIAL	A065505 001	Jul 31, 2008
	EQ 500MG BASE/VIAL	A065505 002	Jul 31, 2008
CEPHAZONE PHARMA	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007
	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007
	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007
	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007
FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065245 003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245 004	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245 002	Feb 15, 2006
STERI PHARMA	EQ 1GM BASE/VIAL	A065268 001	Feb 28, 2007
	EQ 2GM BASE/VIAL	A065268 002	Feb 28, 2007
TEVA	EQ 1GM BASE/VIAL	A065262 001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262 002	Jun 29, 2006
TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007
	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007
ROCEPHIN			
HOFFMANN LA ROCHE	EQ 1GM BASE/VIAL	N050585 003	Dec 21, 1984
	EQ 2GM BASE/VIAL	N050585 004	Dec 21, 1984
	EQ 250MG BASE/VIAL	N050585 001	Dec 21, 1984
	EQ 500MG BASE/VIAL	N050585 002	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 1GM BASE/VIAL, N/A; N/A, 1%	N050585 006	May 08, 1996
	EQ 500MG BASE/VIAL, N/A; N/A, 1%	N050585 007	May 08, 1996

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002
	EQ 250MG BASE	A065043 002	Feb 15, 2002
	EQ 500MG BASE	A065043 001	Feb 15, 2002
SANDOZ	EQ 250MG BASE	A065126 001	Oct 28, 2003
	EQ 500MG BASE	A065126 002	Oct 28, 2003

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001 002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002 001	Sep 28, 1998
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035 002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036 001	Feb 26, 1993
CEFUROXIME SODIUM IN PLASTIC CONTAINER			
SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251 001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251 002	Dec 30, 2009
KEFUROX			
ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591 002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591 003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592 002	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER			
LILLY	EQ 1.5GM BASE/VIAL	A062590 002	Jan 10, 1986
ZINACEF IN PLASTIC CONTAINER			
COVIS INJECTABLES	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS			
CEFUROXIME SODIUM			
FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001 001	May 30, 2001
TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998

DISCONTINUED DRUG PRODUCT LIST

6-66 (of 337)

CEFUROXIME SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035 001	Feb 26, 1993
KEFUROX			
ACS DOBFAR	EQ 750MG BASE/VIAL	A062591 001	Jan 10, 1986
INJECTABLE; INTRAVENOUS			
KEFUROX			
LILLY	EQ 750MG BASE/VIAL	A062592 001	Jan 10, 1986
KEFUROX IN PLASTIC CONTAINER			
LILLY	EQ 750MG BASE/VIAL	A062590 001	Jan 10, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757 002	Dec 28, 1982
	300GM/BOT	N018757 003	Oct 16, 1984

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973 001	Nov 08, 1988
	EQ 250MG BASE	A063063 001	Sep 29, 1989
	EQ 250MG BASE	A063186 001	Dec 30, 1994
	EQ 500MG BASE	A062974 001	Nov 23, 1988
	EQ 500MG BASE	A063063 002	Sep 29, 1989
	EQ 500MG BASE	A063186 002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773 001	Jun 26, 1987
	EQ 500MG BASE	A062775 001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118 001	
	EQ 500MG BASE	A062118 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969 001	
	EQ 500MG BASE	A061969 002	
PUREPAC PHARM	EQ 250MG BASE	A062809 001	Apr 22, 1987
	EQ 500MG BASE	A062809 002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870 001	Mar 17, 1988
	EQ 500MG BASE	A062869 001	Mar 17, 1988
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988
KEFLEX			
SHIONOGI INC	EQ 333MG BASE	N050405 004	May 12, 2006
FOR SUSPENSION; ORAL			
CEPHALEXIN			
APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
FACTA FARMA	EQ 100MG BASE/ML	A062117 001	
	EQ 125MG BASE/5ML	A062117 002	
	EQ 250MG BASE/5ML	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
RANBAXY	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987
YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336 001	Jul 25, 2007
	EQ 250MG BASE/5ML	A065336 002	Jul 25, 2007
KEFLEX			
SHIONOGI INC	EQ 100MG BASE/ML	N050406 003	
	EQ 125MG BASE/5ML	N050406 001	
	EQ 250MG BASE/5ML	N050406 002	

DISCONTINUED DRUG PRODUCT LIST

6-67 (of 337)

CEPHALEXIN

TABLET; ORAL

CEPHALEXIN

BARR

EQ 250MG BASE

A062826 001 Aug 17, 1987

EQ 500MG BASE

A062827 001 Aug 17, 1987

VITARINE

EQ 1GM BASE

A062863 003 Aug 11, 1988

EQ 250MG BASE

A062863 001 Aug 11, 1988

EQ 500MG BASE

A062863 002 Aug 11, 1988

KEFLET

LILLY

EQ 1GM BASE

N050440 002

EQ 250MG BASE

A062745 001 Dec 01, 1986

EQ 250MG BASE

N050440 003 Feb 26, 1987

EQ 500MG BASE

A062745 002 Dec 01, 1986

EQ 500MG BASE

N050440 001

TABLET, FOR SUSPENSION; ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD

EQ 125MG BASE

A065100 002 Sep 11, 2003

EQ 250MG BASE

A065100 001 Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET; ORAL

KEFTAB

LILLY

EQ 250MG BASE

N050614 001 Oct 29, 1987

EQ 333MG BASE

N050614 003 May 16, 1988

EQ 500MG BASE

N050614 002 Oct 29, 1987

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

DISCONTINUED DRUG PRODUCT LIST

6-68 (of 337)

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 1GM BASE/VIAL	A061769	001	
EQ 1GM BASE/VIAL	A062724	001	Dec 23, 1986
EQ 1GM BASE/VIAL	A062961	002	Sep 20, 1988
EQ 1GM BASE/VIAL	N050446	001	
EQ 2GM BASE/VIAL	A061769	002	
EQ 2GM BASE/VIAL	A062724	002	Dec 23, 1986
EQ 2GM BASE/VIAL	A062961	003	Sep 20, 1988
EQ 2GM BASE/VIAL	N050446	002	
EQ 4GM BASE/VIAL	A061769	003	
EQ 4GM BASE/VIAL	A062961	004	Sep 20, 1988
EQ 4GM BASE/VIAL	N050446	003	
EQ 20GM BASE/VIAL	N050446	004	
EQ 500MG BASE/VIAL	A062961	001	Sep 20, 1988
EQ 500MG BASE/VIAL	N050446	005	

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 1GM BASE/VIAL	A062723	002	Nov 17, 1986
EQ 2GM BASE/VIAL	A062723	003	Nov 17, 1986
EQ 4GM BASE/VIAL	A062723	004	Nov 17, 1986
EQ 20GM BASE/VIAL	A062723	005	Nov 17, 1986
EQ 500MG BASE/VIAL	A062723	001	Nov 17, 1986

HIKMA MAPLE

EQ 1GM BASE/VIAL	A062720	002	Jul 02, 1987
EQ 2GM BASE/VIAL	A062720	003	Jul 02, 1987
EQ 20GM BASE/VIAL	A062720	004	Jul 02, 1987
EQ 500MG BASE/VIAL	A062720	001	Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG	A061859	001	
500MG	A061859	002	

CEPHRADINE

BARR

250MG	A062850	001	Apr 22, 1988
500MG	A062851	001	Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG	A062762	001	Mar 06, 1987
500MG	A062762	002	Mar 06, 1987

TEVA

250MG	A062683	001	Jan 09, 1987
500MG	A062683	002	Jan 09, 1987

VITARINE

250MG	A062813	001	Feb 25, 1988
500MG	A062813	002	Feb 25, 1988

VELOSEF

APOTHECON

250MG	A061764	001	
500MG	A061764	002	

VELOSEF '250'

ERSANA

250MG	N050548	001	
-------	---------	-----	--

VELOSEF '500'

ERSANA

500MG	N050548	002	
-------	---------	-----	--

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML	A061866	001	
250MG/5ML	A061866	002	

CEPHRADINE

BARR

125MG/5ML	A062858	001	May 19, 1988
250MG/5ML	A062859	001	May 19, 1988

TEVA

125MG/5ML	A062693	001	Jan 09, 1987
250MG/5ML	A062693	002	Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML	A061763	001	
-----------	---------	-----	--

VELOSEF '250'

APOTHECON

250MG/5ML	A061763	002	
-----------	---------	-----	--

INJECTABLE; INJECTION

VELOSEF

APOTHECON

1GM/VIAL	A061976	004	
2GM/VIAL	A061976	003	
4GM/VIAL	A061976	005	
250MG/VIAL	A061976	001	
500MG/VIAL	A061976	002	

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB

1GM	N050530	001	
-----	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-69 (of 337)

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

0.8MG

N020740 006 Jul 24, 2000

CERULETIDE DIETHYLAMINE

INJECTABLE; INJECTION

TYMTRAN

PHARMACIA AND UPJOHN

0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

5MG/5ML

A078617 001 Feb 02, 2010

APOTEX INC

5MG/5ML

A078412 001 Jun 18, 2008

AUROBINDO PHARMA LTD

5MG/5ML

A090751 001 Dec 16, 2009

RANBAXY LABS LTD

5MG/5ML

A077472 001 Jun 18, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC

5MG/5ML

A090378 002 May 09, 2008

APOTEX INC

5MG/5ML

A090188 002 Apr 22, 2008

RANBAXY LABS LTD

5MG/5ML

A090183 002 Apr 24, 2008

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ACTAVIS MID ATLANTIC

5MG/5ML

A090378 001 May 09, 2008

APOTEX INC

5MG/5ML

A090188 001 Apr 22, 2008

RANBAXY LABS LTD

5MG/5ML

A090183 001 Apr 24, 2008

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

ACTAVIS ELIZABETH

5MG

A078615 003 Dec 28, 2007

10MG

A078615 004 Dec 28, 2007

TABLET, CHEWABLE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC

5MG

A077631 004 Jan 11, 2008

10MG

A077631 003 Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC

5MG

A077631 001 Jan 11, 2008

10MG

A077631 002 Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021621 003 Nov 16, 2007

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021621 004 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

MCNEIL CONS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021621 005 Nov 16, 2007

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021621 006 Nov 16, 2007

CETRORELIX

INJECTABLE; INJECTION

CETROTIDE

EMD SERONO INC

EQ 3MG BASE/ML

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSKERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION; INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE

12MG/VIAL; 108MG/VIAL; 8MG/VIAL

N020044 001 Aug 02, 1990

DISCONTINUED DRUG PRODUCT LIST

6-70 (of 337)

CHENODIOL

TABLET; ORAL

CHENIX

SIGMA TAU

250MG

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP; ORAL

ULO

3M

25MG/5ML

N012126 001

CHLORAMPHENICOL

CAPSULE; ORAL

AMPHICOL

FERRANTE

100MG

A060058 001

CHLOROMYCETIN

PARKEDALE

50MG

A060591 001

100MG

A060591 003

CREAM; TOPICAL

CHLOROMYCETIN

PARKE DAVIS

1%

N050183 001

FOR SOLUTION; OPHTHALMIC

CHLOROMYCETIN

PARKEDALE

25MG/VIAL

N050143 001

INJECTABLE; INJECTION

CHLOROMYCETIN

PARKE DAVIS

250MG/ML

N050153 001

OINTMENT; OPHTHALMIC

CHLORAMPHENICOL

ALTANA

1%

A060133 001

CHLOROFAIR

PHARMAFAIR

1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE

1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN

1%

A061187 001

ECONOCHLOR

ALCON

1%

A061648 001

SOLUTION/DROPS; OPHTHALMIC

CHLORAMPHENICOL

AKORN

0.5%

A062042 001

ALCON

0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR

0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN

0.5%

N050091 001

ECONOCHLOR

ALCON

0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE

0.5%

A061220 001

OPTOMYCIN

OPTOPICS

0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS; OTIC

CHLOROMYCETIN

PARKEDALE

0.5%

N050205 001

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

CHLOROMYCETIN PALMITATE

PARKE DAVIS

EQ 150MG BASE/5ML

A062301 001

EQ 150MG BASE/5ML

N050152 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL

ELKINS SINN

EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT

EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

PARKEDALE

EQ 1GM BASE/VIAL

N050155 001

MYCHEL-S

ANGUS

EQ 1GM BASE/VIAL

A060132 001

DISCONTINUED DRUG PRODUCT LIST

6-71 (of 337)

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

PARKE DAVIS

10MG/GM; 666 UNITS/GM; 1 UNITS/GM

N050294 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE

12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE

10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCIN

PARKE DAVIS

1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN

1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL

30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL

5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT

5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE

5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT

5MG

A087525 001 Jan 07, 1982

10MG

A087524 001 Jan 07, 1982

25MG

A087512 001 Jan 07, 1982

FERRANTE

5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY

5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

HIKMA PHARMS LLC

5MG

A085014 001

10MG

A085000 001

25MG

A085294 001

IMPAX LABS

5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS

5MG

A083741 001

10MG

A083742 001

25MG

A083570 001

LEDERLE

5MG

A086892 001

5MG

A087234 001

10MG

A086876 001

10MG

A087037 001

25MG

A086893 001

25MG

A087231 001

MAST MM

10MG

A086217 001

MYLAN

5MG

A084886 001

DISCONTINUED DRUG PRODUCT LIST

6-72 (of 337)

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SANDOZ	5MG	A084678	001	
	5MG	A084919	001	
	10MG	A084041	001	
	10MG	A084920	001	
	25MG	A084679	002	
	25MG	A084823	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
USL PHARMA	5MG	A084644	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
LIBRIUM				
VALEANT PHARM INTL	5MG	N012249	002	
	10MG	N012249	001	
	25MG	N012249	003	
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	
INJECTABLE; INJECTION				
LIBRIUM				
VALEANT PHARMS LLC	100MG/AMP	N012301	001	

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE	10MG; 0.4MG	N014740	006	
MENRIUM 5-2				
ROCHE	5MG; 0.2MG	N014740	002	
MENRIUM 5-4				
ROCHE	5MG; 0.4MG	N014740	004	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

APOTEX INC	0.12%	A075561	001	Nov 14, 2000
------------	-------	---------	-----	--------------

SOLUTION; TOPICAL

EXIDINE

XTTRIUM	2.5%	N019421	001	Dec 17, 1985
MICRODERM				
J AND J	4%	A072255	001	Apr 15, 1991
PREVACARE R				
J AND J	0.5%	A072292	001	Jan 28, 1992
STERI-STAT				
MATRIX MEDCL	4%	A070104	001	Jul 24, 1986

DISCONTINUED DRUG PRODUCT LIST

6-73 (of 337)

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL

4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON

4%

A073416 001 Mar 14, 2000

HIBICLENS

MOLNLYCKE HLTH

4% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018423 001

MICRODERM

J AND J

4%

A072295 001 Feb 28, 1991

CHLORMERODRIN HG-197

INJECTABLE; INJECTION

CHLORMERODRIN HG 197

BRACCO

0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET; ORAL

TRANCOPAL

SANOFI AVENTIS US

100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NESACAINE-MPF

FRESENIUS KABI USA

2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US

EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

MD PHARM

EQ 150MG BASE

A087228 001

PUREPAC PHARM

EQ 150MG BASE

A080886 001

TEVA

EQ 150MG BASE

A087504 001

Jan 13, 1982

WATSON LABS

EQ 150MG BASE

A087979 001

Dec 21, 1982

EQ 300MG BASE

A088030 001

Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET; ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US

EQ 300MG BASE; EQ 45MG BASE

N014860 002

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

ABC HOLDING

250MG

A085569 001

HIKMA INTL PHARMS

250MG

A086028 001

Jul 14, 1982

500MG

A087736 001

Jul 14, 1982

LEDERLE

250MG

A086940 001

500MG

A086938 001

SANDOZ

250MG

A085485 001

WATSON LABS

250MG

A085165 001

250MG

A085173 001

250MG

A086795 001

Aug 15, 1983

500MG

A084026 001

Sep 01, 1982

500MG

A086796 001

Aug 15, 1983

DIURIL

OAK PHARMS AKORN

250MG

N011145 004

500MG

N011145 002

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDOCLOR-150

MERCK

150MG; 250MG

N016016 001

ALDOCLOR-250

MERCK

250MG; 250MG

N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM

150MG; 250MG

A070783 001

Nov 06, 1987

250MG; 250MG

A070654 001

Nov 06, 1987

DISCONTINUED DRUG PRODUCT LIST

6-74 (of 337)

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA PHARMS LLC 250MG;0.125MG
500MG;0.125MG

A088557 001 Dec 22, 1983
A088365 001 Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 250MG;0.125MG
500MG;0.125MG

A084853 001
A088151 001 Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN 250MG;0.125MG
500MG;0.125MG

A087744 001 May 06, 1982
A087745 001 May 06, 1982

DIUPRES-250

MERCK 250MG;0.125MG

N011635 003 Aug 26, 1987

DIUPRES-500

MERCK 500MG;0.125MG

N011635 006 Aug 26, 1987

CHLOROTRIANISENE

CAPSULE; ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS 12MG

A084652 001

TACE

SANOFI AVENTIS US 12MG
25MG
72MG

N008102 004
N011444 001
N016235 001

CHLOROXINE

SHAMPOO; TOPICAL

CAPITROL

WESTWOOD SQUIBB 2%

N017594 001

CHLORPHENESIN CARBAMATE

TABLET; ORAL

MAOLATE

PHARMACIA AND UPJOHN 400MG

N014217 002

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

SANDOZ 12MG

A070797 001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE 8MG
12MG

N017369 001
N017369 002

INJECTABLE; INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH 10MG/ML
100MG/ML

N008826 001
N008794 001

CHLORPHENIRAMINE MALEATE

BEL MAR 10MG/ML
ELKINS SINN 10MG/ML
WATSON LABS 10MG/ML
10MG/ML
100MG/ML

A080821 001
A080797 001
A083593 001
A086096 001
A086095 001

PYRIDAMAL 100

BEL MAR 100MG/ML

A083733 001

SYRUP; ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML

N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML

A087520 001 Feb 10, 1982

TABLET; ORAL

ANTAGONATE

BAYER PHARMS 4MG

A083381 001

CHLOR-TRIMETON

SCHERING 4MG

N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG
BELL PHARMA 4MG
ELKINS SINN 4MG
IMPAX LABS 4MG
IVAX SUB TEVA PHARMS 4MG
KV PHARM 4MG
LEDERLE 4MG
MUTUAL PHARM 4MG
NEWTRON PHARMS 4MG

A083078 001
A083062 001
A080938 001
A080809 001
A080779 001
A087164 001
A086941 001
A080700 001
A086519 001

DISCONTINUED DRUG PRODUCT LIST

6-75 (of 337)

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

PANRAY	4MG	A083243	001	
PHARMAVITE	4MG	A085104	001	
PHARMERAL	4MG	A083753	001	
PIONEER PHARMS	4MG	A088556	001	Jul 13, 1984
PUREPAC PHARM	4MG	A086306	001	
PVT FORM	4MG	A080786	001	
ROXANE	4MG	A080626	001	
SANDOZ	4MG	A080961	001	
VITARINE	4MG	A085837	001	
WATSON LABS	4MG	A080696	001	
	4MG	A080791	001	
	4MG	A085139	001	
	4MG	A083787	001	

WEST WARD

KLOROMIN

HALSEY	4MG	A083629	001	
--------	-----	---------	-----	--

PHENETRON

LANNETT	4MG	A080846	001	
---------	-----	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

SCHERING PLOUGH	8MG	N007638	001	
-----------------	-----	---------	-----	--

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA	16MG	N019746	002	Nov 18, 1994
------	------	---------	-----	--------------

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

GRAHAM DM	12MG; 75MG	N018793	001	Apr 25, 1985
-----------	------------	---------	-----	--------------

COLD CAPSULE V

GRAHAM DM	8MG; 75MG	N018794	001	Apr 23, 1985
-----------	-----------	---------	-----	--------------

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12

NOVARTIS	12MG; 75MG	N018115	001	
----------	------------	---------	-----	--

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA	12MG; 120MG	N018935	001	Apr 15, 1985
----------------	-------------	---------	-----	--------------

ISOCIOR

FISONS	8MG; 120MG	N018747	001	Mar 06, 1986
--------	------------	---------	-----	--------------

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS	8MG; 120MG	N019428	001	Aug 02, 1988
-------------	------------	---------	-----	--------------

GRAHAM DM	8MG; 120MG	N018844	001	Mar 20, 1985
-----------	------------	---------	-----	--------------

	12MG; 120MG	N018843	001	Mar 18, 1985
--	-------------	---------	-----	--------------

KV PHARM	12MG; 120MG	A071455	001	Mar 01, 1989
----------	-------------	---------	-----	--------------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

UCB INC	EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML	N021369	001	Jun 21, 2004
---------	--------------------------------------	---------	-----	--------------

PENNTUSS

FISONS	EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML	N018928	001	Aug 14, 1985
--------	--------------------------------------	---------	-----	--------------

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS	EQ 65MG BASE	N014696	001	
-------------	--------------	---------	-----	--

CHLORPROMAZINE

SUPPOSITORY; RECTAL

THORAZINE

GLAXOSMITHKLINE	25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	024	
-----------------	---	---------	-----	--

	100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	033	
--	--	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-76 (of 337)

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120	016
	75MG	N011120	017
	150MG	N011120	018
	200MG	N011120	019
	300MG	N011120	020

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001
PHARM ASSOC	30MG/ML	A040231	001 Dec 30, 1999
	100MG/ML	A040224	001 Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001 Jul 08, 1982
	100MG/ML	A087053	001

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

ROXANE	30MG/ML	A088157	001 Apr 27, 1983
	100MG/ML	A088158	001 Apr 27, 1983

SONAZINE

SANDOZ	30MG/ML	A080983	004
	100MG/ML	A080983	005

THORAZINE

GLAXOSMITHKLINE	30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	032
	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	043

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001
MARSAM PHARMS LLC	25MG/ML	A089563	001 Apr 15, 1988
WATSON LABS	25MG/ML	A080365	001
	25MG/ML	A085591	001
WYETH AYERST	25MG/ML	A080370	001

THORAZINE

GLAXOSMITHKLINE	25MG/ML	N009149	011
-----------------	---------	---------	-----

SYRUP; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001
--------------------	----------	---------	-----

SONAZINE

SANDOZ	10MG/5ML	A083040	001
--------	----------	---------	-----

THORAZINE

GLAXOSMITHKLINE	10MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N009149	022
-----------------	--	---------	-----

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001
	25MG	A084415	001
	50MG	A084411	001
	100MG	A084412	001
	200MG	A084413	001
IVAX SUB TEVA PHARMS	10MG	A083549	001
	25MG	A083549	002
	50MG	A083549	003
	100MG	A083574	001
	200MG	A083575	001
KV PHARM	10MG	A085750	002 Jan 04, 1982
	25MG	A085751	001
	50MG	A085484	001
	100MG	A085752	001
	200MG	A085748	002 Jan 04, 1982
LEDERLE	10MG	A084803	001
	25MG	A084801	001
	50MG	A084800	001
	100MG	A084789	001
	200MG	A084802	001
PUREPAC PHARM	10MG	A080403	004
	25MG	A080403	001
	50MG	A080403	002

DISCONTINUED DRUG PRODUCT LIST

6-77 (of 337)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
ROXANE	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG	N009149	002	
	25MG	N009149	007	
	50MG	N009149	013	
	100MG	N009149	018	
	200MG	N009149	020	

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984
	100MG	A088812	001	Oct 19, 1984
	100MG	A088840	001	Oct 25, 1984
	100MG	A088918	001	Oct 16, 1984
	100MG	A089446	001	Nov 17, 1986
	250MG	A088813	001	Oct 19, 1984
	250MG	A088919	001	Oct 16, 1984
	250MG	A089447	001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
PAR PHARM	100MG	A088175	001	Feb 27, 1984
	250MG	A088176	001	Feb 27, 1984
SANDOZ	100MG	A088725	001	Aug 31, 1984
	250MG	A084669	001	
	250MG	A088726	001	Aug 31, 1984
SUPERPHARM	100MG	A088694	001	Sep 17, 1984
	250MG	A088695	001	Sep 17, 1984
TEVA PHARMS USA	250MG	A087353	001	
USL PHARMA	100MG	A088708	001	Aug 30, 1984
	250MG	A088709	001	Aug 30, 1984
WATSON LABS	100MG	A086865	001	Sep 24, 1984
	100MG	A088608	001	Apr 12, 1984
	250MG	A086866	001	
	250MG	A088568	001	Apr 12, 1984
WATSON LABS INC	100MG	A088852	001	Sep 26, 1984
	250MG	A088826	001	Sep 26, 1984
GLUCAMIDE				
TEVA PHARMS USA	250MG	A088641	001	Oct 11, 1984

DISCONTINUED DRUG PRODUCT LIST

6-78 (of 337)

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE

100MG/5ML

N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE

12.5MG/ML

N012487 001

TABLET; ORAL

TARACTAN

ROCHE

10MG

N012486 005

25MG

N012486 004

50MG

N012486 003

100MG

N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE

1%

N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT

25MG

A087364 001

50MG

A087384 001

ASCOT

25MG

A087698 001

Oct 20, 1982

50MG

A087699 001

Oct 20, 1982

BARR LABS INC

25MG

A088902 001

Sep 19, 1985

50MG

A088903 001

Sep 19, 1985

DAVA PHARMS INC

25MG

A087451 001

50MG

A087450 001

IVAX PHARMS

25MG

A087555 001

25MG

A088164 001

Jan 09, 1984

50MG

A087176 001

50MG

A087947 001

Feb 27, 1984

KV PHARM

25MG

A087311 001

50MG

A087312 001

MUTUAL PHARM

25MG

A087292 001

25MG

A089285 001

Jul 21, 1986

25MG

A089738 001

Sep 19, 1988

50MG

A087293 001

50MG

A089286 001

Jul 21, 1986

50MG

A089739 001

Sep 19, 1988

PIONEER PHARMS

50MG

A089591 001

Jul 21, 1988

PUREPAC PHARM

25MG

A088139 001

Jul 16, 1986

50MG

A088140 001

Aug 11, 1983

SANDOZ

25MG

A087380 001

50MG

A087118 001

50MG

A087381 001

SUPERPHARM

25MG

A087473 001

Feb 09, 1983

50MG

A087247 001

Feb 09, 1983

TEVA

50MG

A088651 001

May 30, 1985

USL PHARMA

25MG

A089051 001

Jun 01, 1987

50MG

A089052 001

Jun 01, 1987

VANGARD

25MG

A088012 001

Jul 14, 1982

50MG

A088073 001

Mar 25, 1983

WARNER CHILCOTT

25MG

A087515 001

Jan 24, 1983

50MG

A087516 001

Feb 09, 1983

WATSON LABS

25MG

A087050 001

25MG

A087100 001

25MG

A087296 001

25MG

A087706 001

50MG

A087029 001

50MG

A087082 001

50MG

A087521 001

50MG

A087689 001

HYGROTON

SANOFI AVENTIS US

25MG

N012283 004

50MG

N012283 003

THALITONE

CITRON PHARMA LLC

25MG

N019574 002

Feb 12, 1992

MONARCH PHARMS

25MG

A088051 001

Nov 12, 1982

DISCONTINUED DRUG PRODUCT LIST

6-79 (of 337)

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM

15MG; 0.1MG

A071179 001 Dec 16, 1987

15MG; 0.2MG

A071178 001 Dec 16, 1987

15MG; 0.3MG

A071142 001 Dec 16, 1987

COMBIPRES

BOEHRINGER INGELHEIM

15MG; 0.1MG

N017503 001

15MG; 0.2MG

N017503 002

15MG; 0.3MG

N017503 003 Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS

25MG; 100MG

N019451 001 Dec 31, 1987

25MG; 200MG

N019451 002 Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US

25MG; 0.125MG

N015103 002

REGROTON

SANOFI AVENTIS US

50MG; 0.25MG

N015103 001

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH

250MG

A088928 001 May 08, 1987

500MG

A040113 001 Sep 29, 1995

MUTUAL PHARM

500MG

A089970 001 Sep 27, 1990

OHM LABS

250MG

A081298 001 Dec 29, 1993

500MG

A081299 001 Dec 29, 1993

PAR PHARM

250MG

A087981 001 Sep 20, 1983

PIONEER PHARMS

250MG

A089592 001 Jan 06, 1989

500MG

A089948 001 Jan 06, 1989

SANDOZ

250MG

A089852 001 May 04, 1988

500MG

A089853 001 May 04, 1988

WATSON LABS

250MG

A086901 001

250MG

A086948 001 Aug 09, 1982

500MG

A040137 001 Aug 09, 1996

500MG

A081019 001 Jul 29, 1991

500MG

A081040 001 Aug 22, 1989

PARAFLEX

ORTHO MCNEIL PHARM

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011300 003

STRIFON FORTE DSC

FERNDAL LABS

500MG

A081008 001 Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS

EQ 4GM RESIN/BAR

A071621 001 May 26, 1988

EQ 4GM RESIN/BAR

A071739 001 May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS

EQ 4GM RESIN/PACKET

A074771 001 Jul 09, 1997

EQ 4GM RESIN/SCOOPFUL

A074771 002 Jul 09, 1997

TEVA

EQ 4GM RESIN/PACKET

A074347 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074347 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996

EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996

CHOLESTYRAMINE LIGHT

TEVA

EQ 4GM RESIN/PACKET

A074348 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074348 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

LOCHOLEST

SANDOZ

EQ 4GM RESIN/PACKET

A074561 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074561 002 Aug 15, 1996

LOCHOLEST LIGHT

SANDOZ

EQ 4GM RESIN/PACKET

A074562 001 Aug 15, 1996

EQ 4GM RESIN/SCOOPFUL

A074562 002 Aug 15, 1996

DISCONTINUED DRUG PRODUCT LIST

6-80 (of 337)

CHOLESTYRAMINE

POWDER; ORAL

QUESTRAN

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N016640 001

EQ 4GM RESIN/SCOOPFUL

N016640 003

QUESTRAN LIGHT

BRISTOL MYERS

EQ 4GM RESIN/PACKET

N019669 001 Dec 05, 1988

EQ 4GM RESIN/SCOOPFUL

N019669 003 Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 1GM RESIN

A073403 001 Apr 28, 1994

EQ 800MG RESIN

A073403 002 Dec 27, 1999

CHORIOGONADOTROPIN ALFA

INJECTABLE; INJECTION

OVIDREL

EMD SERONO

0.25MG/VIAL

N021149 001 Sep 20, 2000

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM

EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

MALLINCKRODT

5mCi/ML

N017084 001

CHYMOPAPAIN

INJECTABLE; INJECTION

CHYMODIACTIN

CHART MEDCL

4,000 UNITS/VIAL

N018663 002 Aug 21, 1984

10,000 UNITS/VIAL **Federal Register

N018663 001 Nov 10, 1982

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

DISCASE

ABBOTT

12,500 UNITS/VIAL

N018625 001 Jan 18, 1984

CHYMOTRYPSIN

FOR SOLUTION; OPHTHALMIC

ALPHA CHYMAR

SOLA BARNES HIND

750 UNITS/VIAL

N011837 001

CATARASE

CIBA

300 UNITS/VIAL

N016938 001

NOVARTIS

150 UNITS/VIAL

N018121 001

ZOLYSE

ALCON

750 UNITS/VIAL

N011903 001

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

APOTEX INC

8%

A078172 001 Sep 18, 2007

MYLAN PHARMS INC

8%

A078567 001 Sep 18, 2007

TEVA PHARMS

8%

A078079 001 Sep 18, 2007

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK

EQ 250MG BASE/VIAL; 250MG/VIAL

A062756 001 Jan 08, 1987

EQ 500MG BASE/VIAL; 500MG/VIAL

A062756 002 Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK

EQ 750MG BASE/VIAL; 750MG/VIAL

N050630 002 Dec 14, 1990

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH

100MG

A077028 002 Nov 26, 2004

COREPHARMA

50MG

A077150 001 Mar 11, 2005

100MG

A077022 001 Nov 23, 2004

IVAX SUB TEVA PHARMS

100MG

A077020 002 Mar 01, 2005

MUTUAL PHARM

50MG

A077208 002 Mar 29, 2006

100MG

A077208 001 Mar 29, 2006

DISCONTINUED DRUG PRODUCT LIST

6-81 (of 337)

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE

200MG/20ML

N020951 001 Jul 09, 1999

TABLET; ORAL

CIMETIDINE

CYCLE PHARMS LTD

300MG

A074361 001 Dec 23, 1994

400MG

A074361 002 Dec 23, 1994

800MG

A074371 001 Dec 23, 1994

DAVA PHARMS INC

300MG

A074340 001 Jun 23, 1995

400MG

A074340 002 Jun 23, 1995

800MG

A074339 001 Jun 23, 1995

IVAX SUB TEVA PHARMS

200MG

A074401 001 May 30, 1995

200MG

A074424 001 Jul 28, 1995

300MG

A074401 002 May 30, 1995

300MG

A074424 002 Jul 28, 1995

400MG

A074401 003 May 30, 1995

400MG

A074424 003 Jul 28, 1995

800MG

A074402 001 May 30, 1995

800MG

A074424 004 Jul 28, 1995

LEK PHARMS

100MG

A075122 001 Jun 19, 1998

200MG

A074250 001 Jun 29, 1995

200MG

A075122 002 Jun 19, 1998

300MG

A074250 002 Jun 29, 1995

400MG

A074250 003 Jun 29, 1995

800MG

A074250 004 Jun 29, 1995

PERRIGO

100MG

A074972 001 Jun 19, 1998

PLIVA

200MG

A074568 001 Feb 27, 1997

300MG

A074568 002 Feb 27, 1997

400MG

A074568 003 Feb 27, 1997

SANDOZ

200MG

A074100 001 Jan 31, 1995

200MG

A074506 001 Jan 24, 1996

300MG

A074100 002 Jan 31, 1995

300MG

A074506 002 Jan 24, 1996

400MG

A074100 003 Jan 31, 1995

400MG

A074506 003 Jan 24, 1996

800MG

A074100 004 Jan 31, 1995

800MG

A074506 004 Jan 24, 1996

TEVA

200MG

A074365 001 Feb 28, 1995

300MG

A074365 002 Feb 28, 1995

400MG

A074365 003 Feb 28, 1995

800MG

A074365 004 Feb 28, 1995

VINTAGE PHARMS LLC

200MG

A074281 001 May 17, 1994

300MG

A074281 002 May 17, 1994

400MG

A074281 003 May 17, 1994

800MG

A074329 001 May 17, 1994

WATSON LABS

200MG

A075425 001 Jul 29, 1999

WATSON LABS INC

200MG

A074349 001 Aug 30, 1996

300MG

A074349 002 Aug 30, 1996

400MG

A074349 003 Aug 30, 1996

800MG

A074316 001 Feb 28, 1996

TAGAMET

GLAXOSMITHKLINE

200MG

N017920 002

300MG

N017920 003

400MG

N017920 004 Dec 14, 1983

800MG

N017920 005 Apr 30, 1986

TAGAMET HB

MEDTECH PRODUCTS

100MG

N020238 001 Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

HOSPIRA

EQ 300MG BASE/2ML

A074296 001 Mar 28, 1997

EQ 300MG BASE/2ML

A074344 001 Jan 31, 1995

EQ 300MG BASE/2ML

A074345 001 Jan 31, 1995

EQ 300MG BASE/2ML

A074412 001 Mar 28, 1997

EQ 300MG BASE/2ML

A074422 001 Jan 31, 1995

LUITPOLD

EQ 300MG BASE/2ML

A074353 001 Dec 20, 1994

TEVA PARENTERAL

EQ 300MG BASE/2ML

A074252 001 Nov 26, 1997

VINTAGE PHARMS LLC

EQ 300MG BASE/2ML

A074005 001 Aug 31, 1994

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA

EQ 6MG BASE/ML

A074269 001 Dec 27, 1994

EQ 90MG BASE/100ML

A074468 005 Dec 29, 1994

DISCONTINUED DRUG PRODUCT LIST

6-82 (of 337)

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/2ML	N017939	002
-----------------	-------------------	---------	-----

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 6MG BASE/ML	N019434	001 Oct 31, 1985
-----------------	----------------	---------	------------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 300MG BASE/5ML	A074176	001 Jun 01, 1994
ANI PHARMS INC	EQ 300MG BASE/5ML	A074859	001 Jul 09, 1998
	EQ 300MG BASE/5ML	A075110	001 Jun 18, 1998
APOTEX INC	EQ 300MG BASE/5ML	A075560	001 Mar 15, 2000
CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001 Aug 05, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251	001 Dec 22, 1994

TAGAMET

GLAXOSMITHKLINE	EQ 300MG BASE/5ML	N017924	001
-----------------	-------------------	---------	-----

CINOXACIN

CAPSULE; ORAL

CINOXACIN

LILLY	250MG	N018067	001
	500MG	N018067	002

CINOXACIN

TEVA	250MG	A073005	001 Feb 28, 1992
	500MG	A073006	001 Feb 28, 1992

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPRO

BAYER HLTHCARE	1200MG/120ML (10MG/ML)	N019847	003 Dec 26, 1990
----------------	------------------------	---------	------------------

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS	200MG/100ML	N019858	001 Dec 26, 1990
--------------	-------------	---------	------------------

CIPROFLOXACIN

BEDFORD LABS	200MG/20ML (10MG/ML)	A076992	001 Aug 28, 2006
	400MG/40ML (10MG/ML)	A076992	002 Aug 28, 2006
	1200MG/120ML (10MG/ML)	A076993	001 Aug 28, 2006
FRESENIUS KABI USA	200MG/20ML (10MG/ML)	A076484	001 Aug 28, 2006
	400MG/40ML (10MG/ML)	A076484	002 Aug 28, 2006
TEVA PHARMS USA	200MG/20ML (10MG/ML)	A077782	001 Aug 28, 2006
	400MG/40ML (10MG/ML)	A077782	002 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA	200MG/100ML	A076757	001 Apr 21, 2008
--------------------	-------------	---------	------------------

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	200MG/100ML	A077888	001 Mar 18, 2008
	400MG/200ML	A077888	002 Mar 18, 2008
BEDFORD	200MG/100ML	A078114	001 Mar 18, 2008
	400MG/200ML	A078114	002 Mar 18, 2008
TEVA PHARMS	200MG/100ML	A077138	001 Mar 18, 2008
	400MG/200ML	A077138	002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

APOTEX INC	EQ 0.3% BASE	A075928	001 Jun 09, 2004
------------	--------------	---------	------------------

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

BARR	EQ 250MG BASE	A074124	001 Jun 09, 2004
	EQ 500MG BASE	A074124	002 Jun 09, 2004
	EQ 750MG BASE	A074124	003 Jun 09, 2004
NOSTRUM LABS	EQ 250MG BASE	A076138	001 Jun 09, 2004
	EQ 500MG BASE	A076138	002 Jun 09, 2004
	EQ 750MG BASE	A076138	003 Jun 09, 2004
PLIVA	EQ 100MG BASE	A076426	001 Jun 15, 2005
	EQ 250MG BASE	A076426	002 Jun 15, 2005
	EQ 500MG BASE	A076426	003 Jun 15, 2005
	EQ 750MG BASE	A076426	004 Jun 15, 2005
SANDOZ	EQ 100MG BASE	A075939	001 Mar 03, 2005
	EQ 250MG BASE	A075939	002 Jun 09, 2004

DISCONTINUED DRUG PRODUCT LIST

6-83 (of 337)

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

	EQ 250MG BASE	A076593	002	Jun 09, 2004
	EQ 500MG BASE	A075939	003	Jun 09, 2004
	EQ 500MG BASE	A076593	003	Jun 09, 2004
	EQ 750MG BASE	A075939	004	Jun 09, 2004
	EQ 750MG BASE	A076593	004	Jun 09, 2004
TEVA	EQ 250MG BASE	A076136	001	Jun 09, 2004
	EQ 500MG BASE	A076136	002	Jun 09, 2004
	EQ 750MG BASE	A076136	003	Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005
-------------	---------------	---------	-----	--------------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE	212.6MG; EQ 287.5MG BASE	N021473	001	Dec 13, 2002
	425.2MG; EQ 574.9MG BASE	N021473	002	Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

DR REDDYS LABS LTD	212.6MG; EQ 287.5MG BASE	A077701	002	Oct 31, 2007
SANDOZ	212.6MG; EQ 287.5MG BASE	A078712	001	Dec 11, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS	EQ 1MG BASE/ML	N020398	001	Sep 15, 1995
----------------	----------------	---------	-----	--------------

TABLET; ORAL

PROPULSID

JANSSEN PHARMS	EQ 10MG BASE	N020210	001	Jul 29, 1993
	EQ 20MG BASE	N020210	002	Dec 23, 1993

TABLET, ORALLY DISINTEGRATING; ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA	EQ 20MG BASE	N020767	001	Nov 07, 1997
----------------	--------------	---------	-----	--------------

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

BEDFORD	10MG/VIAL	A074713	001	Nov 14, 2000
	50MG/VIAL	A074713	002	Nov 14, 2000
TEVA PHARMS USA	1MG/ML	A074814	001	May 16, 2000

PLATINOL

HQ SPCLT PHARMA	10MG/VIAL	N018057	001	
	50MG/VIAL	N018057	002	

PLATINOL-AQ

HQ SPCLT PHARMA	0.5MG/ML	N018057	003	Jul 18, 1984
-----------------	----------	---------	-----	--------------

CITALOPRAM HYDROBROMIDE

SOLUTION; ORAL

CELEXA

FOREST LABS	EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021046	001	Dec 22, 1999
-------------	---	---------	-----	--------------

CITALOPRAM HYDROBROMIDE

APOTEX INC	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005
------------	------------------	---------	-----	--------------

TABLET; ORAL

CELEXA

FOREST LABS	EQ 60MG BASE	N020822	004	Jul 17, 1998
-------------	--------------	---------	-----	--------------

CITALOPRAM HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 10MG BASE	A077033	001	Oct 28, 2004
	EQ 20MG BASE	A077033	002	Oct 28, 2004
	EQ 40MG BASE	A077033	003	Oct 28, 2004
COREPHARMA	EQ 10MG BASE	A077036	001	Oct 28, 2004
	EQ 20MG BASE	A077036	002	Oct 28, 2004
	EQ 40MG BASE	A077036	003	Oct 28, 2004
MUTUAL PHARM	EQ 10MG BASE	A077052	001	Jul 03, 2006
	EQ 20MG BASE	A077052	002	Jul 03, 2006
	EQ 40MG BASE	A077052	003	Jul 03, 2006
NATCO PHARMA LTD	EQ 20MG BASE	A077141	002	Apr 10, 2008
	EQ 40MG BASE	A077141	001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041	001	Nov 23, 2004
	EQ 20MG BASE	A077041	002	Nov 23, 2004
	EQ 40MG BASE	A077041	003	Nov 23, 2004

DISCONTINUED DRUG PRODUCT LIST

6-84 (of 337)

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

SANDOZ

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

TARO

EQ 10MG BASE

A077278 001 Mar 22, 2006

EQ 20MG BASE

A077278 002 Mar 22, 2006

EQ 40MG BASE

A077278 003 Mar 22, 2006

TEVA PHARMS

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 40MG BASE

A077213 003 Mar 31, 2006

WATSON LABS

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 40MG BASE

A077034 003 Jun 30, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

BIOVAIL LABS INTL

EQ 10MG BASE

N021763 001 Dec 20, 2005

EQ 20MG BASE

N021763 002 Dec 20, 2005

EQ 40MG BASE

N021763 003 Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018519 001 Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA

3.24GM/100ML; 380MG/100ML; 430MG/100ML

N018904 001 May 27, 1983

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

JANSSEN PHARMS

1MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020229 001 Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

ABBVIE

187MG/5ML

N050698 003 Sep 30, 1998

TABLET; ORAL

CLARITHROMYCIN

IVAX SUB TEVA PHARMS

250MG

A065137 001 May 31, 2005

500MG

A065137 002 May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

RANBAXY

1GM

A065210 001 Jan 26, 2005

SANDOZ

500MG

A065250 001 Aug 25, 2005

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC

EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993

APOTEX INC

EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000

SILARX

EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997

TEVA PHARMS

EQ 0.5MG BASE/5ML

A073095 001 Apr 21, 1992

TAVIST

NOVARTIS

EQ 0.5MG BASE/5ML

N018675 001 Jun 28, 1985

TABLET; ORAL

CLEMASTINE FUMARATE

TEVA

1.34MG

A073282 001 Jan 31, 1992

1.34MG

A073282 002 Dec 03, 1992

TAVIST

NOVARTIS

2.68MG

N017661 001

TAVIST-1

NOVARTIS

1.34MG

N017661 002

1.34MG

N017661 003 Aug 21, 1992

DISCONTINUED DRUG PRODUCT LIST

6-85 (of 337)

CLIDINIUM BROMIDE

CAPSULE; ORAL

QUARZAN

ROCHE

2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

TEVA

EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS

EQ 75MG BASE

A063082 001 Jul 31, 1991

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 75MG BASE/5ML

A061827 001

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLEOCIN

PHARMACIA AND UPJOHN

EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN

EQ 150MG BASE/ML

A061839 001

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

ASTRAZENECA

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

HIKMA MAPLE

EQ 150MG BASE/ML

A062806 001 Oct 15, 1987

EQ 150MG BASE/ML

A062953 001 Apr 21, 1988

EQ 150MG BASE/ML

A063068 001 Aug 28, 1989

LOCH

EQ 150MG BASE/ML

A062905 001 May 09, 1988

MARSAM PHARMS LLC

EQ 150MG BASE/ML

A062913 001 Oct 20, 1988

SOLOPAK

EQ 150MG BASE/ML

A062819 001 Mar 15, 1988

EQ 150MG BASE/ML

A062852 001 Mar 17, 1988

TEVA PARENTERAL

EQ 150MG BASE/ML

A063041 001 Dec 29, 1989

EQ 150MG BASE/ML

A063282 001 May 29, 1992

WATSON LABS

EQ 150MG BASE/ML

A062900 001 Jun 08, 1988

EQ 150MG BASE/ML

A063079 001 Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM

EQ 12MG BASE/ML

N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE

EQ 6MG BASE/ML

A065027 001 Jun 29, 2001

EQ 12MG BASE/ML

A065027 002 Jun 29, 2001

EQ 18MG BASE/ML

A065027 003 Jun 29, 2001

BAXTER HLTHCARE

EQ 6MG BASE/ML

N050648 001 Dec 29, 1989

EQ 12MG BASE/ML

N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML

N050648 003 Dec 29, 1989

SOLUTION; TOPICAL

CLEOCIN T

PHARMACIA AND UPJOHN

EQ 1% BASE

A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

COPLEY PHARM

EQ 1% BASE

A062944 001 Jan 11, 1989

RENAISSANCE PHARMA

EQ 1% BASE

A064108 001 Sep 27, 1996

VINTAGE PHARMS

EQ 1% BASE

A062930 001 Jun 28, 1989

CLIOQUINOL; NYSTATIN

OINTMENT; TOPICAL

NYSTAFORM

BAYER PHARMS

10MG/GM; 100,000 UNITS/GM

N050235 001

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC

5MG

N202067 001 Oct 21, 2011

DISCONTINUED DRUG PRODUCT LIST

6-86 (of 337)

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

RENAISSANCE PHARMA 0.05%

A075338 001 Feb 09, 2001

TEVA PHARMS USA 0.05%

A074087 001 Feb 16, 1994

CLOBETASOL PROPIONATE (EMOLLIENT)

RENAISSANCE PHARMA 0.05%

A075733 001 Aug 22, 2001

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC 0.05%

A074128 001 Aug 03, 1994

RENAISSANCE PHARMA 0.05%

A075057 001 Aug 12, 1998

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

G AND W LABS INC 0.05%

A074331 001 Dec 15, 1995

TEMOVATE

FOUGERA PHARMS 0.05% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019966 001 Feb 22, 1990

CLOFAZIMINE

CAPSULE; ORAL

LAMPRENE

NOVARTIS

100MG

N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE; ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET; ORAL

MILOPHENE

MILEX

50MG

A072196 001 Dec 20, 1988

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

SANDOZ

25MG

A074953 001 Jun 25, 1997

50MG

A074953 002 Jun 25, 1997

75MG

A074953 003 Jun 25, 1997

TEVA

25MG

A074849 001 Apr 04, 1997

50MG

A074849 002 Apr 04, 1997

75MG

A074849 003 Apr 04, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

APOTEX INC

0.5MG

A075468 001 Oct 06, 2000

1MG

A075468 002 Oct 06, 2000

2MG

A075468 003 Oct 06, 2000

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

KLONOPIN

ROCHE

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

KLONOPIN RAPIDLY DISINTEGRATING

ROCHE

0.125MG **Federal Register

N020813 001 Dec 23, 1997

DISCONTINUED DRUG PRODUCT LIST

6-87 (of 337)

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

KLONOPIN RAPIDLY DISINTEGRATING

determination that product was not discontinued or withdrawn for safety or efficacy reasons**

0.25MG **Federal Register determination N020813 002 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons**

0.5MG **Federal Register determination N020813 003 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons**

1MG **Federal Register determination N020813 004 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons**

2MG **Federal Register determination N020813 005 Dec 23, 1997

that product was not discontinued or withdrawn for safety or efficacy reasons**

CLONIDINE

SUSPENSION, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE

TRIS PHARMA INC EQ 0.17MG BASE

N022500 001 Dec 03, 2009

EQ 0.26MG BASE

N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AM THERAP

0.1MG

A070881 001 Jul 08, 1986

0.2MG

A070882 001 Jul 08, 1986

0.3MG

A070883 001 Jul 08, 1986

DURAMED PHARMS BARR

0.1MG

A071103 001 Aug 14, 1986

0.2MG

A071102 001 Aug 14, 1986

0.3MG

A071101 001 Aug 14, 1986

INTERPHARM

0.1MG

A071252 001 Oct 01, 1986

0.2MG

A071253 001 Oct 01, 1986

0.3MG

A071254 001 Oct 01, 1986

PAR PHARM

0.1MG

A070461 001 Jul 08, 1986

0.2MG

A070460 001 Jul 08, 1986

0.3MG

A070459 001 Jul 08, 1986

SANDOZ

0.1MG

A070887 001 Aug 31, 1988

0.2MG

A070886 001 Aug 31, 1988

0.3MG

A071294 001 Aug 31, 1988

TEVA

0.1MG

A070747 001 Jul 08, 1986

0.2MG

A070702 001 Jul 08, 1986

0.3MG

A070659 001 Jul 08, 1986

WARNER CHILCOTT

0.1MG

A072138 001 Jun 13, 1988

0.2MG

A072139 001 Jun 13, 1988

0.3MG

A072140 001 Jun 13, 1988

WATSON LABS

0.1MG

A070395 001 Mar 23, 1987

0.1MG

A070965 001 Jul 08, 1986

0.2MG

A070396 001 Mar 23, 1987

0.2MG

A070964 001 Jul 08, 1986

0.3MG

A070397 001 Mar 23, 1987

0.3MG

A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

JENLOGA

CONCORDIA PHARMS INC 0.1MG

N022331 001 Sep 30, 2009

0.2MG

N022331 002 May 25, 2010

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE

3.75MG

A071777 001 Jul 14, 1987

7.5MG

A071778 001 Jul 14, 1987

15MG

A071779 001 Jul 14, 1987

AM THERAP

3.75MG

A071429 001 Jun 23, 1987

7.5MG

A071430 001 Jun 23, 1987

15MG

A071431 001 Jun 23, 1987

DISCONTINUED DRUG PRODUCT LIST

6-88 (of 337)

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

DAVA PHARMS INC	3.75MG	A071742	001	Dec 14, 1987
	7.5MG	A071743	001	Dec 14, 1987
	15MG	A071744	001	Dec 14, 1987
GD SEARLE LLC	3.75MG	A071727	001	Dec 18, 1987
	7.5MG	A071728	001	Dec 18, 1987
	15MG	A071729	001	Dec 18, 1987
MYLAN	3.75MG	A071509	001	Oct 19, 1987
	7.5MG	A071510	001	Oct 19, 1987
	15MG	A071511	001	Oct 19, 1987
PUREPAC PHARM	3.75MG	A071924	001	Apr 25, 1988
	7.5MG	A071925	001	Apr 25, 1988
	15MG	A071926	001	Apr 25, 1988
QUANTUM PHARMICS	3.75MG	A071549	001	Sep 12, 1988
	7.5MG	A071550	001	Sep 12, 1988
	15MG	A071522	001	Sep 12, 1988
SANDOZ	3.75MG	A072219	001	Aug 26, 1988
	7.5MG	A072220	001	Aug 26, 1988
	15MG	A072112	001	Aug 26, 1988
USL PHARMA	3.75MG	A071242	001	Jun 23, 1987
	7.5MG	A071243	001	Jun 23, 1987
	15MG	A071244	001	Jun 23, 1987
WARNER CHILCOTT	3.75MG	A071774	001	Mar 01, 1988
	7.5MG	A071775	001	Mar 01, 1988
	15MG	A071776	001	Mar 01, 1988
WATSON LABS	3.75MG	A071878	001	Mar 15, 1988
	7.5MG	A071879	001	Mar 15, 1988
	15MG	A071860	001	Mar 15, 1988
TRANXENE				
RECORDATI RARE	3.75MG	N017105	001	
	7.5MG	N017105	002	
	15MG	N017105	003	

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

ABLE	3.75MG	A071780	001	Jun 26, 1987
	7.5MG	A071781	001	Jun 26, 1987
	15MG	A071782	001	Jun 26, 1987
AM THERAP	3.75MG	A071747	001	Jun 23, 1987
	7.5MG	A071748	001	Jun 23, 1987
	15MG	A071749	001	Jun 23, 1987
LEDERLE	3.75MG	A072013	001	Dec 15, 1987
	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SANDOZ	3.75MG	A072512	001	May 11, 1990
	7.5MG	A072513	001	May 11, 1990
	15MG	A072514	001	May 11, 1990
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988
TRANXENE SD				
RECORDATI RARE	11.25MG	N017105	005	
	22.5MG	N017105	004	

CLOTRIMAZOLE

CREAM; TOPICAL

LOTTRIMIN

SCHERING PLOUGH	1%	N017619	001	
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183	001	

DISCONTINUED DRUG PRODUCT LIST

6-89 (of 337)

CLOTRIMAZOLE

LOTION; TOPICAL

LOTRIMIN

SCHERING

1%

N018813 001 Feb 17, 1984

SOLUTION; TOPICAL

LOTRIMIN

SCHERING PLOUGH

1%

N017613 001

MYCELEX

BAYER HLTHCARE

1%

N018181 001

TABLET; VAGINAL

GYNIX

TEVA PHARMS

100MG

A073249 001 Feb 13, 1998

MYCELEX-G

BAYER PHARMS

500MG

N019069 001 Apr 19, 1985

TROCHE/LOZENGE; ORAL

MYCELEX

BAYER HLTHCARE

10MG

N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE; ORAL

CLOXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061452 001

EQ 500MG BASE

A061452 002

TEVA

EQ 250MG BASE

A062240 001

EQ 500MG BASE

A062240 002

CLOXAPEN

GLAXOSMITHKLINE

EQ 250MG BASE

A061806 001

EQ 250MG BASE

A062233 001

EQ 500MG BASE

A061806 002

EQ 500MG BASE

A062233 002

FOR SOLUTION; ORAL

CLOXACILLIN SODIUM

TEVA

EQ 125MG BASE/5ML

A062268 001

EQ 125MG BASE/5ML

A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON

EQ 125MG BASE/5ML

A061453 001

EQ 125MG BASE/5ML

N050192 001

CLOZAPINE

TABLET; ORAL

CLOZAPINE

PAR PHARM

25MG

A075162 001 Apr 26, 2005

100MG

A075162 002 Apr 26, 2005

SANDOZ

25MG

A074546 001 Aug 30, 1996

100MG

A074546 002 Aug 30, 1996

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ PHARMS III

50MG

N021590 003 Jun 03, 2005

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-57 KIT

BRACCO

N/A; N/A; N/A; N/A

N016089 001

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A; N/A

RUBRATOPE-60 KIT

BRACCO

N/A; N/A; N/A; N/A

N016090 001

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC W/ CODEINE

ANI PHARMS

10MG/5ML; 5MG/5ML; 6.25MG/5ML

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML; 5MG/5ML; 6.25MG/5ML

A088896 001 Jan 04, 1985

DISCONTINUED DRUG PRODUCT LIST

6-90 (of 337)

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN W/ CODEINE			
ANI PHARMS	10MG/5ML; 6.25MG/5ML	N008306 004	Apr 02, 1984
PERAZINE W/ CODEINE			
HALSEY	10MG/5ML; 6.25MG/5ML	A088739 001	Dec 23, 1988
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE			
PHARM ASSOC	10MG/5ML; 6.25MG/5ML	A089647 001	Dec 22, 1988
PROMETHAZINE W/ CODEINE			
CENCI	10MG/5ML; 6.25MG/5ML	A088814 001	Nov 22, 1985

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE			
GLAXOSMITHKLINE	10MG/5ML; 30MG/5ML; 1.25MG/5ML	N012575 003	Apr 04, 1984
TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE			
CENCI	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A089018 001	Jul 23, 1986
TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE			
WOCKHARDT	10MG/5ML; 30MG/5ML; 1.25MG/5ML	A088833 001	Nov 16, 1984

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID			
MERCK	0.5MG; 500MG	N012383 001	
PROBEN-C			
WATSON LABS	0.5MG; 500MG	A085552 001	
PROBENECID AND COLCHICINE			
BEECHAM	0.5MG; 500MG	A084321 001	
IMPAX LABS	0.5MG; 500MG	A083720 002	
IVAX SUB TEVA PHARMS	0.5MG; 500MG	A083734 001	
SANDOZ	0.5MG; 500MG	A086130 001	
PROBENECID W/ COLCHICINE			
LEDERLE	0.5MG; 500MG	A086954 001	
WATSON LABS	0.5MG; 500MG	A083221 001	

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL

WELCHOL			
DAIICHI SANKYO	375MG	N021141 001	May 26, 2000

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S			
PARKE DAVIS	EQ 25MG BASE/5ML	N050355 001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL			
CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697 001	Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7			
GD SEARLE LLC	89MG	N017408 001	
TATUM-T			
GD SEARLE LLC	120MG	N018205 001	

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH			
PARKEDALE	25 UNITS/VIAL	N008317 002	
	40 UNITS/VIAL	N008317 004	
ACTHAR			
SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002	
	40 UNITS/VIAL	N007504 003	
CORTICOTROPIN			
ORGANICS LAGRANGE	40 UNITS/ML	N010831 001	
	80 UNITS/ML	N010831 002	
WATSON LABS	40 UNITS/VIAL	A088772 001	Nov 21, 1984
H.P. ACTHAR GEL			
QUESTCOR PHARMS	40 UNITS/ML	N008372 006	
PURIFIED CORTROPHIN GEL			
ORGANON USA INC	40 UNITS/ML	N008975 001	
	80 UNITS/ML	N008975 002	

DISCONTINUED DRUG PRODUCT LIST

6-91 (of 337)

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ORGANON USA INC

40 UNITS/ML

N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN

25MG/ML

N008126 002

WATSON LABS

25MG/ML

A083147 003

25MG/ML

A085677 001

50MG/ML

A083147 004

50MG/ML

A085677 002

CORTONE

MERCK

25MG/ML

N007110 002

50MG/ML

N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR

25MG

A083471 001

ELKINS SINN

25MG

A080836 001

EVERYLIFE

25MG

A084246 001

HEATHER

25MG

A085736 001

IMPAX LABS

25MG

N009458 001

INWOOD LABS

25MG

A080731 001

IVAX SUB TEVA PHARMS

25MG

A080630 001

25MG

A083536 001

LANNETT

25MG

A080694 001

PANRAY

5MG

N008284 002

25MG

N008284 001

PHARMACIA AND UPJOHN

5MG

N008126 003

10MG

N008126 004

25MG

N008126 001

PUREPAC PHARM

25MG

A080493 001

VITARINE

25MG

A080333 001

WATSON LABS

25MG

A085884 001

WHITEWORTH TOWN PLSN

25MG

A080341 001

CORTONE

MERCK

25MG

N007750 003

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ

0.25MG/ML (0.25MG/ML)

N022028 001 Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PFIZER

0.8MG/INH

N018887 001 Dec 05, 1985

CAPSULE; INHALATION

INTAL

SANOFI AVENTIS US

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC

100MG

N019188 001 Dec 22, 1989

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS

100MG/5ML

A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

10MG/ML

A075067 001 Jul 19, 1999

APOTEX INC

10MG/ML

A075333 001 Apr 30, 2002

PHARMASCIENCE INC

10MG/ML

A075437 001 Apr 21, 2000

ROXANE

10MG/ML

A075175 001 Sep 30, 1999

WATSON LABS

10MG/ML

A076469 001 Jun 17, 2005

INTAL

KING PHARMS

10MG/ML

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

APOTEX INC

4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS

4%

A075088 001 Apr 27, 1999

DISCONTINUED DRUG PRODUCT LIST

6-92 (of 337)

CROMOLYN SODIUM

SOLUTION/DROPS;OPHTHALMIC

OPTICROM

ALLERGAN

4%

N018155 001 Oct 03, 1984

SPRAY, METERED;NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

NASALCROM

BLACKSMITH BRANDS

5.2MG/SPRAY **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020463 001 Jan 03, 1997

CRYPTENAMINE ACETATES

INJECTABLE;INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET;ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE;INJECTION

CUPRIC SULFATE

ABRAXIS PHARM

EQ 0.4MG COPPER/ML

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED;NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE;INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

BETALIN 12

LILLY

0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS

0.1MG/ML

A083013 001

1MG/ML

A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM

0.03MG/ML

A080510 003

0.1MG/ML

A080510 001

1MG/ML

A080510 002

AKORN

1MG/ML

A087969 001 Nov 10, 1983

DELL LABS

0.03MG/ML

A080689 001

0.1MG/ML

A080689 002

1MG/ML

A080689 003

FRESENIUS KABI USA

0.1MG/ML

A080557 002

HIKMA MAPLE

1MG/ML

A080515 002

LUITPOLD

0.03MG/ML

A080668 001

LYPHOMED

1MG/ML

A083075 001

MYLAN INSTITUTIONAL

1MG/ML

A040451 001 Sep 23, 2003

SANOFI AVENTIS US

1MG/ML

A080564 001

SOLOPAK

1MG/ML

A087551 001 Feb 29, 1984

WARNER CHILCOTT

1MG/ML

N007085 002

WATSON LABS

0.1MG/ML

A080573 002

0.1MG/ML

A083120 001

1MG/ML

A080573 001

1MG/ML

A083120 002

WYETH AYERST

0.1MG/ML

A080554 001

1MG/ML

A080554 002

REDISOL

MERCK

1MG/ML

N006668 010

RUBIVITE

BEL MAR

0.03MG/ML

N010791 004

0.05MG/ML

N010791 001

0.1MG/ML

N010791 002

0.12MG/ML

N010791 005

1MG/ML

N010791 003

RUBRAMIN PC

BRISTOL MYERS SQUIBB

0.1MG/ML

N006799 002

1MG/ML

N006799 004

DISCONTINUED DRUG PRODUCT LIST

6-93 (of 337)

CYANOCOBALAMIN

INJECTABLE; INJECTION

RUBRAMIN PC

1MG/ML

N006799 010 Apr 28, 1988

RUVITE

SAVAGE LABS

1MG/ML

A080570 002

VI-TWEL

BAYER HLTHCARE

1MG/ML

N007012 002

SPRAY, METERED; NASAL

CALOMIST

PAR PHARM

25MCG/SPRAY

N022102 001 Jul 27, 2007

TABLET; ORAL

CYANOCOBALAMIN

WEST WARD

1MG

A084264 001

CYANOCOBALAMIN CO-57

CAPSULE; ORAL

RUBRATOPE-57

BRACCO

0.5-1uCi

N016089 002

CYANOCOBALAMIN CO-60

CAPSULE; ORAL

RUBRATOPE-60

BRACCO

0.5-1uCi

N016090 002

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE

N/A; N/A; N/A

N017406 001

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A; N/A

CYANOCOBALAMIN CO 57 SCHILLING TEST KIT

MALLINCKRODT

0.1MG; 0.5uCi; 60MG

N016635 001

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM

0.5MG/ML; 2.3MG/ML; 1MG/ML

N011208 001

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST

125MG/5ML

N050508 001

250MG/5ML

N050508 002

500MG/5ML

N050508 003

TABLET; ORAL

CYCLACILLIN

TEVA

250MG

A062895 001 Aug 04, 1988

500MG

A062895 002 Aug 04, 1988

CYCLAPEN-W

WYETH AYERST

250MG

N050509 001

500MG

N050509 002

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE

50MG/ML

N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

PROSAM LABS

5MG

A077291 001 Feb 03, 2006

SANDOZ

5MG

A072854 002 Feb 03, 2006

10MG

A072854 001 Nov 19, 1991

10MG

A073683 001 Feb 26, 1993

WATSON LABS

10MG

A073143 001 Nov 27, 1991

10MG

A074436 001 Nov 30, 1994

FLEXERIL

JANSSEN RES AND DEV

5MG

N017821 001

10MG

N017821 002

DISCONTINUED DRUG PRODUCT LIST

6-94 (of 337)

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AK-PENTOLATE

AKORN 1%

A085555 001

AKPENTOLATE

AKORN 2%

A040165 001 Jan 13, 1997

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD 1%

A089162 001 Jan 24, 1991

SOLA BARNES HIND 1%

A084150 001

1%

A084863 001

PENTOLAIR

PHARMAFAIR 0.5%

A088643 001 Feb 09, 1987

1%

A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE 1GM/VIAL

A088374 001 Sep 24, 1986

100MG/VIAL

A088371 001 Jul 03, 1986

200MG/VIAL

A088372 001 Jul 03, 1986

500MG/VIAL

A088373 001 Jul 03, 1986

CYTOXAN

BAXTER HLTHCARE 100MG/VIAL

N012142 001

200MG/VIAL

N012142 002

CYTOXAN (LYOPHILIZED)

BAXTER HLTHCARE 1GM/VIAL

N012142 010 Sep 24, 1985

2GM/VIAL

N012142 009 Dec 10, 1985

500MG/VIAL

N012142 008 Jan 04, 1984

LYOPHILIZED CYTOXAN

BAXTER HLTHCARE 100MG/VIAL

N012142 006 Dec 05, 1985

200MG/VIAL

N012142 007 Dec 10, 1985

NEOSAR

BEDFORD 1GM/VIAL

A087442 004 Jul 08, 1983

2GM/VIAL

A087442 005 Mar 30, 1989

100MG/VIAL

A087442 001 Feb 16, 1982

200MG/VIAL

A087442 002 Feb 16, 1982

500MG/VIAL

A087442 003 Feb 16, 1982

TEVA PARENTERAL 1GM/VIAL

A040015 004 Apr 29, 1993

2GM/VIAL

A040015 005 Apr 29, 1993

100MG/VIAL

A040015 001 Apr 29, 1993

200MG/VIAL

A040015 002 Apr 29, 1993

500MG/VIAL

A040015 003 Apr 29, 1993

TABLET; ORAL

CYTOXAN

BAXTER HLTHCARE 25MG

N012141 002

50MG

N012141 001

CYCLOSPORINE

CAPSULE; ORAL

NEORAL

NOVARTIS 50MG

N050715 003 Jul 14, 1995

SOLUTION; ORAL

CYCLOSPORINE

APOTEX INC 100MG/ML

A065167 001 Jan 05, 2005

CYCLOTHIAZIDE

TABLET; ORAL

ANHYDRON

LILLY 2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN 2MG

N018173 001

CYCRIMINE HYDROCHLORIDE

TABLET; ORAL

PAGITANE

LILLY 1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 2MG/5ML

A086833 001

HALSEY 2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE 2MG/5ML

A087001 001 Nov 04, 1982

NASKA 2MG/5ML

A089021 001 Dec 21, 1987

DISCONTINUED DRUG PRODUCT LIST

6-95 (of 337)

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

PERIACTIN

MERCK

2MG/5ML

N013220 002

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

SANDOZ

4MG

A086808 001

SUPERPHARM

4MG

A087405 001

TG UNITED LABS

4MG

A088212 001 May 26, 1983

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

MERCK

4MG

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE; INJECTION

CYSTEINE HYDROCHLORIDE

HOSPIRA

7.25% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019523 001 Oct 22, 1986

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

TEVA PARENTERAL

1GM/VIAL

N016793 003 Dec 21, 1987

2GM/VIAL

N016793 004 Dec 21, 1987

100MG/VIAL

N016793 001

500MG/VIAL

N016793 002

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM

100MG/VIAL

A070962 001 Aug 28, 1986

200MG/VIAL

A070990 001 Aug 28, 1986

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; IV (INFUSION)

SYNERCID

KING PHARMS

420MG/VIAL; 180MG/VIAL

N050748 002 Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

EISAI INC

7,500 IU/0.75ML

N020287 008 Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

EISAI INC

10,000IU/0.4ML (25,000IU/ML)

N020287 002 May 01, 2007

95,000IU/9.5ML (10,000IU/ML)

N020287 007 Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

AGI

750 UNITS/0.6ML

N020430 001 Dec 24, 1996

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG

N017557 003

100MG

N017557 004

200MG

N017557 002

DISCONTINUED DRUG PRODUCT LIST

6-96 (of 337)

DAPIPIRAZOLE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DAPIPIRAZOLE HYDROCHLORIDE

FERA PHARMS

0.5%

N019849 001 Dec 31, 1990

DAPTOMYCIN

INJECTABLE;IV (INFUSION)

CUBICIN

CUBIST

250MG/VIAL

N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZISTA

JANSSEN PRODS

EQ 300MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021976 001 Jun 23, 2006

EQ 400MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021976 003 Oct 21, 2008

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL

N050484 001

DAUNORUBICIN HYDROCHLORIDE

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE;INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

DEFEROXAMINE MESYLATE

WATSON LABS

2GM/VIAL

A076806 002 Mar 31, 2006

500MG/VIAL

A076806 001 Mar 31, 2006

DEMECARIUM BROMIDE

SOLUTION/DROPS;OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOXYCLINE HYDROCHLORIDE

CAPSULE;ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP;ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET;ORAL

DECLOMYCIN

COREPHARMA

75MG

N050261 001

150MG

N050261 002

300MG

N050261 003

DESERPIDINE

TABLET;ORAL

HARMONYL

ABBVIE

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ORETICYL 25

ABBVIE

0.125MG;25MG

N012148 001

ORETICYL 50

ABBVIE

0.125MG;50MG

N012148 003

ORETICYL FORTE

ABBVIE

0.25MG;25MG

N012148 002

DISCONTINUED DRUG PRODUCT LIST

6-97 (of 337)

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS

0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US

25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS INC

25MG

A071800 001 Dec 08, 1987

50MG

A071801 001 Dec 08, 1987

75MG

A071802 001 Dec 08, 1987

100MG

A071803 001 May 29, 1997

150MG

A071804 001 May 29, 1997

USL PHARMA

25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC

0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD

0.004MG/ML

A074575 001 Feb 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD

0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING

0.01%

N019776 001 Dec 26, 1990

SPRAY, METERED; NASAL

DDAVP

FERRING PHARMS INC

0.01MG/SPRAY

N017922 002 Feb 06, 1989

STIMATE

CSL BEHRING

0.15MG/SPRAY

N020355 001 Mar 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGEN

ORGANON USA INC

0.15MG; 0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR

0.15MG; 0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

JANSSEN PHARMS

0.15MG; 0.03MG

N020301 001 Dec 14, 1992

TABLET; ORAL-28

MIRCETTE

TEVA BRANDED PHARM

0.15MG, N/A; 0.02MG, 0.01MG; 0.02MG, 0.01MG

N020713 001 Apr 22, 1998

**Federal Register determination that
product was not discontinued or
withdrawn for safety or efficacy
reasons**

DESONIDE

CREAM; TOPICAL

DESONIDE

TEVA PHARMS

0.05%

A074027 001 Sep 28, 1992

DISCONTINUED DRUG PRODUCT LIST

6-98 (of 337)

DESOXIMETASONE

CREAM; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.25% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017856 001

TOPICORT LP

TARO PHARMS NORTH

0.05%

N018309 001

GEL; TOPICAL

TOPICORT

TARO PHARMS NORTH

0.05%

N018586 001 Mar 29, 1982

OINTMENT; TOPICAL

DESOXIMETASONE

ALTANA

0.25%

A073440 001 Apr 01, 1998

TOPICORT

TARO PHARMS NORTH

0.25%

N018763 001 Sep 30, 1983

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC

5MG/ML

N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS

125MG

N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

TEVA PHARMS USA

EQ 50MG BASE

N205208 001 Oct 11, 2013

EQ 100MG BASE

N205208 002 Oct 11, 2013

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A083296 002

DECASPRAY

MERCK

0.04% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

HEXADROL

ORGANON USA INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

MERCK

0.25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 004

0.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 001

0.75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011664 002

1.5MG

N011664 003

DISCONTINUED DRUG PRODUCT LIST

6-99 (of 337)

DEXAMETHASONE

TABLET; ORAL

DECADRON

4MG

N011664 005

6MG

N011664 006 Jul 30, 1982

DEXAMETHASONE

IMPAX LABS

0.75MG

A085376 001

MUTUAL PHARM

0.25MG

A084013 001

0.25MG

A084764 001

0.5MG

A084084 001

0.5MG

A084766 001

0.75MG

A084081 001

0.75MG

A084765 001

1.5MG

A084086 001

1.5MG

A084763 001

PAR PHARM

0.25MG

A088149 001 Apr 28, 1983

PHOENIX LABS NY

0.75MG

A083806 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

SANDOZ

0.75MG

A080399 001

UPSHER SMITH

0.75MG

A087534 001

1.5MG

A087533 001

WATSON LABS

0.25MG

A085455 001

0.5MG

A085458 001

0.75MG

A080968 001

0.75MG

A084457 001

0.75MG

A085818 001

1.5MG

A085456 001

1.5MG

A085840 001

WHITEWORTH TOWN PLSN

0.75MG

A084327 001

DEXONE 0.5

SOLVAY

0.5MG

A084991 001

DEXONE 0.75

SOLVAY

0.75MG

A084993 001

DEXONE 1.5

SOLVAY

1.5MG

A084990 001

DEXONE 4

SOLVAY

4MG

A084992 001

HEXADROL

ORGANON USA INC

0.5MG

N012675 004

0.75MG

N012675 007

1.5MG

N012675 009

4MG

N012675 010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

MERCK

EQ 8MG BASE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016675 001

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML

A084315 001

EQ 16MG BASE/ML

A087711 001 May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N013413 001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011983 002

INJECTABLE; INJECTION

DECADRON

MERCK

EQ 4MG PHOSPHATE/ML

N012071 002

EQ 24MG PHOSPHATE/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML

A084342 001

DISCONTINUED DRUG PRODUCT LIST

6-100 (of 337)

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

ABRAXIS PHARM	EQ 4MG PHOSPHATE/ML	A088448	001	Jan 25, 1984
FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A088469	001	Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 4MG PHOSPHATE/ML	A084493	001	
BEL MAR	EQ 4MG PHOSPHATE/ML	A084752	001	
DELL LABS	EQ 4MG PHOSPHATE/ML	A083161	001	
HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282	001	
INTL MEDICATION	EQ 20MG PHOSPHATE/ML	A088522	001	Feb 17, 1984
LYPHOMED	EQ 4MG PHOSPHATE/ML	A087065	001	
TEVA PARENTERAL	EQ 4MG PHOSPHATE/ML	A081125	001	Aug 31, 1990
	EQ 10MG PHOSPHATE/ML	A081126	001	Aug 31, 1990
WATSON LABS	EQ 4MG PHOSPHATE/ML	A083702	001	
	EQ 4MG PHOSPHATE/ML	A084355	001	
	EQ 4MG PHOSPHATE/ML	A089169	001	Apr 09, 1986
	EQ 10MG PHOSPHATE/ML	A087668	001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606	001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641	001	

HEXADROL

ORGANON USA INC	EQ 4MG PHOSPHATE/ML	N014694	002	
	EQ 10MG PHOSPHATE/ML	N014694	003	
	EQ 20MG PHOSPHATE/ML	N014694	004	

OINTMENT; OPHTHALMIC

DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977	001	
-------	--------------------	---------	-----	--

DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071	001	Dec 28, 1982
------------	--------------------	---------	-----	--------------

MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342	001	
-------	--------------------	---------	-----	--

SOLUTION/DROPS; OPHTHALMIC

DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433	001	Dec 15, 1983
------------	-------------------	---------	-----	--------------

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170	001	
	EQ 0.1% PHOSPHATE	A084173	001	

SOLUTION/DROPS; OPHTHALMIC, OTIC

DECADRON

MERCK	EQ 0.1% PHOSPHATE	N011984	001	
-------	-------------------	---------	-----	--

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855	001	
-------	-------------------	---------	-----	--

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML; 10MG/ML	N013334	002	
-------	------------------------------	---------	-----	--

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEODECADRON

MERCK	EQ 0.05% PHOSPHATE; EQ 3.5MG BASE/GM	N050324	001	
-------	--------------------------------------	---------	-----	--

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

MERCK	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N050322	001	
-------	-------------------------------------	---------	-----	--

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A064055	001	Oct 30, 1995
-----------------	-------------------------------------	---------	-----	--------------

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062714	001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	A062539	001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062566	001	Feb 22, 1985
----------	---	---------	-----	--------------

DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	A062411	001	May 16, 1983
------------	---	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062544	001	Oct 29, 1984
----------	---	---------	-----	--------------

DEXASPORIN

PHARMAFAIR	0.1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062428	001	May 18, 1983
------------	---	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-101 (of 337)

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062721 001 Nov 17, 1986

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING 2MG/5ML N011814 002

TABLET;ORAL

DISOMER

SCHERING 2MG N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING 2MG;60MG N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM 6MG;120MG A089116 001 Jan 22, 1987

DISOBROM

SANDOZ 6MG;120MG A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982

DRIXORAL

SCHERING PLOUGH 6MG;120MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS 6MG;120MG A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLARAMINE

SCHERING 2MG/5ML A086837 001 Jul 19, 1982

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS INC 2MG A088682 001 Jan 17, 1986

POLARAMINE

SCHERING 2MG A086835 001

DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DEXAMPEX

TEVA 15MG A085355 001

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

ABLE 5MG A076814 001 Aug 25, 2004
10MG A076814 002 Aug 25, 2004
15MG A076814 003 Aug 25, 2004

ELIXIR;ORAL

DEXEDRINE

GLAXOSMITHKLINE 5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** A083902 001

TABLET;ORAL

DEXAMPEX

TEVA 5MG A083735 001
10MG A083735 002

DEXEDRINE

GLAXOSMITHKLINE 5MG A084935 001

DEXTROAMPHETAMINE SULFATE

HALSEY 10MG A083930 001

LANNETT 5MG A083903 001

10MG A083903 003

15MG A085652 001

MAST MM 5MG A086521 001

NESHER PHARMS 5MG A040365 001 Oct 31, 2002

10MG A040367 001 Oct 31, 2002

PUREPAC PHARM 5MG A084125 001

SANDOZ 5MG A085370 001

10MG A085371 001

VINTAGE PHARMS LLC 5MG A040299 001 May 13, 1999

DISCONTINUED DRUG PRODUCT LIST

6-102 (of 337)

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

VITARINE	5MG	A084986	001
	10MG	A085892	001

DEXTROSTAT

SHIRE	5MG	A084051	001
	10MG	A084051	002

FERNDEX

FERNDAL LABS	5MG	A084001	001
--------------	-----	---------	-----

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY	15MG/5ML; 6.25MG/5ML	A088913	001	Mar 02, 1987
--------	----------------------	---------	-----	--------------

PROMETH W/ DEXTROMETHORPHAN

ACTAVIS MID ATLANTIC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984
----------------------	----------------------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

ANI PHARMS	15MG/5ML; 6.25MG/5ML	N011265	002	Apr 02, 1984
------------	----------------------	---------	-----	--------------

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011
---------------	----------------------	---------	-----	--------------

TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012
-----------------	----------------------	---------	-----	--------------

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML	N018046	001
---------	------------	---------	-----

MILES	10GM/100ML	N018504	001
-------	------------	---------	-----

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML	N018358	001
---------	-------------	---------	-----

	2.5GM/100ML	N019626	001	Feb 02, 1988
--	-------------	---------	-----	--------------

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT	38.5GM/100ML	N018923	001	Sep 19, 1984
--------	--------------	---------	-----	--------------

DEXTROSE 5% IN PLASTIC CONTAINER

DHL	5GM/100ML	N019971	001	Sep 28, 1995
-----	-----------	---------	-----	--------------

DEXTROSE 60%

B BRAUN	60GM/100ML	N017995	002	Sep 22, 1982
---------	------------	---------	-----	--------------

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN	60GM/100ML	N017995	001
---------	------------	---------	-----

BAXTER HLTHCARE	60GM/100ML	N020047	002	Jul 02, 1991
-----------------	------------	---------	-----	--------------

HOSPIRA	60GM/100ML	N019346	001	Jan 25, 1985
---------	------------	---------	-----	--------------

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN	7.7GM/100ML	N019626	003	Feb 02, 1988
---------	-------------	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019025	001	Dec 27, 1984
---------	---	---------	-----	--------------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML	N018273	001
---------	---	---------	-----

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274	001
---------	--	---------	-----

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 37MG/100ML	N019699	001	Sep 29, 1989
---------	-----------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML	N019699	002	Sep 29, 1989
---------	-----------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N019699	003	Sep 29, 1989
---------	------------------------	---------	-----	--------------

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML	N018744	003	Nov 09, 1982
---------	------------------------	---------	-----	--------------

	5GM/100ML; 220MG/100ML	N019699	005	Sep 29, 1989
--	------------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-103 (of 337)

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG	N019514 001	May 08, 1986
	/100ML; 207MG/100ML		

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG	N018270 001
	/100ML; 91MG/100ML	

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009
---------	------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
---------	------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268 014	Jan 18, 1986
---------	-------------------------------------	-------------	--------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%

B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268 010
---------	------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268 001
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268 002
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268 003
---------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008 003
-----------------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008 001
-----------------	-------------------------------------	-------------

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008 002
-----------------	------------------------------------	-------------

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 200MG/100ML	N018386 001
---------	-------------------------	-------------

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 450MG/100ML	N018229 001
---------	-------------------------	-------------

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 900MG/100ML	N018047 001
---------	-------------------------	-------------

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 450MG/100ML	N018030 001
---------	--------------------------	-------------

HOSPIRA	2.5GM/100ML; 450MG/100ML	N018096 001
---------	--------------------------	-------------

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 900MG/100ML	N018376 001
---------	--------------------------	-------------

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML; 300MG/100ML	N018055 001
--------	--------------------------	-------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N018030 005
---------	------------------------	-------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 200MG/100ML	N018030 004
---------	------------------------	-------------

MILES	5GM/100ML; 200MG/100ML	N018399 001
-------	------------------------	-------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 225MG/100ML	N019482 001	Oct 04, 1985
--------	------------------------	-------------	--------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 300MG/100ML	N019486 001	Oct 04, 1985
--------	------------------------	-------------	--------------

MILES	5GM/100ML; 300MG/100ML	N018501 001
-------	------------------------	-------------

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 330MG/100ML	N018030 003
---------	------------------------	-------------

DISCONTINUED DRUG PRODUCT LIST

6-104 (of 337)

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT 5GM/100ML; 450MG/100ML

N019484 001 Oct 04, 1985

B BRAUN 5GM/100ML; 450MG/100ML

N018030 002

MILES 5GM/100ML; 450MG/100ML

N018400 001

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT 5GM/100ML; 900MG/100ML

N019483 001 Oct 04, 1985

B BRAUN 5GM/100ML; 900MG/100ML

N018026 001

MILES 5GM/100ML; 900MG/100ML

N018500 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBVIE

1MG

N012302 005

2MG

N012302 002

4MG

N012302 004

6MG

N012302 006

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA

5MG/ML

N019082 001 Dec 29, 1989

10MG/ML

N019082 002 Dec 29, 1989

15MG/ML

N019082 003 Dec 29, 1989

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282

BAYER HLTHCARE

60%

A087726 001 Sep 23, 1982

CARDIOGRAFIN

BRACCO

85%

N011620 002

DIATRIZOATE MEGLUMINE

BRACCO

76%

N010040 017

HYPAQUE

GE HEALTHCARE

30%

N016403 002

60%

N016403 001

RENO-60

BRACCO

60%

N010040 016

RENO-DIP

BRACCO

30%

N010040 012

UROVIST MEGLUMINE DIU/CT

BAYER HLTHCARE

30%

A087739 001 Sep 23, 1982

SOLUTION; URETERAL

RENO-30

BRACCO

30%

N010040 021

UROVIST CYSTO

BAYER HLTHCARE

30%

A087729 001 Sep 23, 1982

UROVIST CYSTO PEDIATRIC

BAYER HLTHCARE

30%

A087731 001 Sep 23, 1982

SOLUTION; URETHRAL

HYPAQUE-CYSTO

GE HEALTHCARE

30%

N016403 003

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292

BAYER HLTHCARE

52%; 8%

A087724 001 Sep 23, 1982

ANGIOVIST 370

BAYER HLTHCARE

66%; 10%

A087723 001 Sep 23, 1982

DIATRIZOATE-60

INTL MEDICATION

52%; 8%

A088166 001 Jun 17, 1983

HYPAQUE-76

GE HEALTHCARE

66%; 10%

A086505 001

HYPAQUE-M, 75%

GE HEALTHCARE

50%; 25%

N010220 003

HYPAQUE-M, 90%

GE HEALTHCARE

60%; 30%

N010220 002

MD-60

MALLINCKRODT

52%; 8%

A087074 001

MD-76

MALLINCKRODT

66%; 10%

A087073 001

RENOCAL-76

BRACCO

66%; 10%

A089347 001 Jun 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6-105 (of 337)

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

RENOGRAFIN-60

BRACCO

52%; 8%

N010040 006

RENOVIST

BRACCO

34.3%; 35%

N010040 020

RENOVIST II

BRACCO

28.5%; 29.1%

N010040 019

SOLUTION; ORAL, RECTAL

GASTROVIST

BAYER HLTHCARE

66%; 10%

A087728 001 Sep 23, 1982

DIATRIZOATE SODIUM

FOR SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

100%

N011386 001

INJECTABLE; INJECTION

HYPAQUE

GE HEALTHCARE

25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT

50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE

50%

A087725 001 Sep 23, 1982

SOLUTION; ORAL, RECTAL

HYPAQUE

GE HEALTHCARE

40%

N011386 003

SOLUTION; URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE

20%

N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

VALRELEASE

ROCHE

15MG

N018179 001

GEL; RECTAL

DIASTAT

VALEANT PHARMS NORTH

5MG/ML (5MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020648 002 Jul 29, 1997

10MG/2ML (5MG/ML)

N020648 003 Jul 29, 1997

15MG/3ML (5MG/ML)

N020648 004 Jul 29, 1997

20MG/4ML (5MG/ML)

N020648 005 Jul 29, 1997

INJECTABLE; INJECTION

DIAZEPAM

ABRAXIS PHARM

5MG/ML

A070662 001 Jun 25, 1986

HIKMA MAPLE

5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A070313 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

HOSPIRA

5MG/ML

A071584 001 Oct 13, 1987

MARSAM PHARMS LLC

5MG/ML

A072371 001 Jan 29, 1993

PARENTA PHARMS

5MG/ML

A076815 001 Apr 15, 2004

US ARMY

5MG/ML

N020124 001 Dec 05, 1990

WARNER CHILCOTT

5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS

5MG/ML

A070296 001 Feb 12, 1986

5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

WATSON LABS INC

5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

DIZAC

PHARMACIA AND UPJOHN

5MG/ML

N019287 001 Jun 18, 1993

VALIUM

ROCHE

5MG/ML

N016087 001

TABLET; ORAL

DIAZEPAM

ACTAVIS ELIZABETH

2MG

A070781 001 Mar 19, 1986

5MG

A070706 001 Mar 19, 1986

10MG

A070707 001 Mar 19, 1986

DISCONTINUED DRUG PRODUCT LIST

6-106 (of 337)

DIAZEPAM

TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC	2MG	A070226 001	Sep 26, 1985
	5MG	A070227 001	Sep 26, 1985
	10MG	A070228 001	Sep 26, 1985
DURAMED PHARMS BARR	2MG	A070894 001	Aug 27, 1986
	5MG	A070895 001	Aug 27, 1986
	10MG	A070896 001	Aug 27, 1986
FERNDAL LABS	2MG	A070903 001	Apr 01, 1987
	5MG	A070904 001	Apr 01, 1987
	10MG	A070905 001	Apr 01, 1987
HALSEY	2MG	A070987 001	Aug 15, 1986
	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
PAR PHARM	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
SANDOZ	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985
Q-PAM			
QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001
	100MG	N017425 002

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987
HYPERSTAT			
SCHERING	15MG/ML	N016996 001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCAINE

NOVARTIS	2.5MG/ML	N006203 001
----------	----------	-------------

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

TARO	50MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N011366 001
------	---	-------------

DISCONTINUED DRUG PRODUCT LIST

6-107 (of 337)

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

NOVARTIS

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020142 001 Nov 24, 1993

DICLOFENAC POTASSIUM

MUTUAL PHARM

50MG

A075470 001 Feb 21, 2002

SANDOZ

50MG

A075582 001 Feb 23, 2001

WATSON LABS

50MG

A075152 001 Nov 27, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

APOTEX INC

0.1%

A077600 001 Nov 13, 2008

FALCON PHARMS

0.1%

N020809 001 May 04, 1998

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

NOSTRUM LABS

50MG

A074986 001 Feb 26, 1999

75MG

A074986 002 Feb 26, 1999

PLIVA

50MG

A074432 002 Jul 29, 1999

75MG

A074432 003 Jul 29, 1999

ROXANE

25MG

A074391 001 Jun 29, 1995

50MG

A074391 002 Jun 29, 1995

75MG

A074391 003 Jun 29, 1995

TEVA

50MG

A074723 001 Mar 30, 1999

75MG

A074390 001 Aug 15, 1996

TEVA PHARMS

25MG

A074459 001 Jun 25, 1997

50MG

A074459 002 Jun 25, 1997

75MG

A074459 003 Jun 25, 1997

VOLTAREN

NOVARTIS

25MG

N019201 001 Jul 28, 1988

50MG

N019201 002 Jul 28, 1988

75MG

N019201 003 Jul 28, 1988

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

PATHOCIL

WYETH AYERST

EQ 250MG BASE

N050011 002

EQ 500MG BASE

N050011 003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET; ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

10MG

A040204 001 Feb 28, 1997

MUTUAL PHARM

10MG

A084505 001 Oct 21, 1986

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

WATSON LABS

10MG

A083179 001 Feb 12, 1986

DISCONTINUED DRUG PRODUCT LIST

6-108 (of 337)

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

WATSON LABS

10MG/ML

A080614 001 Feb 11, 1986

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

HIKMA PHARMS LLC

20MG

A040161 001 Oct 01, 1996

MUTUAL PHARM

20MG

A084600 001 Jul 29, 1985

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

FOR SOLUTION; ORAL

VIDEX

BRISTOL MYERS SQUIBB

100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE; ORAL

VIDEX

BRISTOL MYERS SQUIBB

25MG

N020154 002 Oct 09, 1991

50MG

N020154 003 Oct 09, 1991

100MG

N020154 004 Oct 09, 1991

150MG

N020154 005 Oct 09, 1991

200MG

N020154 006 Oct 28, 1999

DIENESTROL

CREAM; VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM

0.01%

N006110 005

DV

SANOFI AVENTIS US

0.01%

A083518 001

ESTRAGUARD

SOLVAY

0.01%

A084436 001

SUPPOSITORY; VAGINAL

DV

SANOFI AVENTIS US

0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET; ORAL

HETRAZAN

LEDERLE

50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

SANDOZ

25MG

A085916 001

TEVA

25MG

A088642 001 Sep 20, 1984

TG UNITED LABS

25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

UCB INC

25MG

A085544 001

WATSON LABS

25MG

A085741 001

TENUATE

SANOFI AVENTIS US

25MG

N017668 001

TEPANIL

3M

25MG

N011673 001

TABLET, EXTENDED RELEASE; ORAL

TENUATE

SANOFI AVENTIS US

75MG

N017669 001

TEPANIL TEN-TAB

3M

75MG

N017956 001

DIETHYLSTILBESTROL

INJECTABLE; INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB

0.2MG/ML

N004056 003

0.5MG/ML

N004056 004

1MG/ML

N004056 005

5MG/ML

N004056 006

DISCONTINUED DRUG PRODUCT LIST

6-109 (of 337)

DIETHYLSTILBESTROL

SUPPOSITORY; VAGINAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004040 001

0.5MG

N004040 002

STILBESTROL

BRISTOL MYERS SQUIBB

0.1MG

N004056 001

0.5MG

N004056 002

TABLET; ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004041 002

0.5MG

N004041 003

1MG

N004041 004

5MG

N004041 005

STILBESTROL

TABLICAPS

0.5MG

A083004 001

1MG

A083002 001

5MG

A083006 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG

N004056 007

0.25MG

N004056 017

0.5MG

N004056 008

1MG

N004056 009

5MG

N004056 010

TABLET, DELAYED RELEASE; ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004039 002

0.25MG

N004039 005

0.5MG

N004039 003

1MG

N004039 004

5MG

N004039 006

STILBESTROL

TABLICAPS

0.5MG

A083003 001

1MG

A083005 001

5MG

A083007 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG

N004056 011

0.5MG

N004056 012

1MG

N004056 013

5MG

N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS

250MG/5ML

N010010 001

TABLET; ORAL

STILPHOSTROL

BAYER PHARMS

50MG

N010010 002

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS

0.05%

A075187 001 Mar 30, 1998

FLORONE

PHARMACIA AND UPJOHN

0.05%

N017741 001

FLORONE E

PHARMACIA AND UPJOHN

0.05%

N019259 001 Aug 28, 1985

PSORCON

TARO PHARMS NORTH

0.05%

N020205 001 Nov 20, 1992

OINTMENT; TOPICAL

PSORCON

PHARMACIA AND UPJOHN

0.05%

N019260 001 Aug 28, 1985

PSORCON E

PHARMACIA AND UPJOHN

0.05%

N017994 001

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

PUREPAC PHARM

250MG

A074285 001 May 07, 1996

500MG

A074285 002 May 07, 1996

ROXANE

250MG

A073562 001 Nov 27, 1992

500MG

A073563 001 Nov 27, 1992

SANDOZ

500MG

A074604 001 Jun 10, 1996

TEVA

250MG

A073679 001 Jul 31, 1992

DISCONTINUED DRUG PRODUCT LIST

6-110 (of 337)

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

WATSON LABS

250MG

A074400 001 Jul 17, 1997

500MG

A074400 002 Jul 17, 1997

DOLOBID

MERCK

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018445 001 Apr 19, 1982

500MG

N018445 002 Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY

0.2MG/ML

A084100 005

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC

0.05MG

N018118 002 Jul 26, 1982

0.1MG

N018118 003 Jul 26, 1982

0.15MG

N018118 004 Sep 24, 1984

0.2MG

N018118 001 Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM

0.25MG/ML

A083217 001

HOSPIRA

0.25MG/ML

A040093 001 May 16, 1996

0.25MG/ML

A040206 001 Aug 28, 1998

WYETH AYERST

0.25MG/ML

A084386 001

DIGOXIN PEDIATRIC

HOSPIRA

0.1MG/ML

A040092 001 Apr 25, 1996

TABLET; ORAL

DIGOXIN

SUN PHARM INDS INC

0.125MG

A076363 001 Jan 31, 2003

0.25MG

A076363 002 Jan 31, 2003

LANOXIN

COVIS PHARMA

0.375MG

N020405 005 Sep 30, 1997

0.5MG

N020405 006 Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS

0.5MG/0.5ML; 2,500
UNITS/0.5ML; 5.33MG/0.5ML
0.5MG/0.7ML; 5,000
UNITS/0.7ML; 7.46MG/0.7ML

N018885 001 Nov 30, 1984

N018885 002 Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

BIOVAIL

60MG

N019471 001 Jan 23, 1989

90MG

N019471 002 Jan 23, 1989

120MG

N019471 003 Jan 23, 1989

180MG

N019471 004 Jan 23, 1989

DILTIAZEM HYDROCHLORIDE

BIOVAIL

60MG

A074845 001 Sep 15, 1999

90MG

A074845 002 Sep 15, 1999

120MG

A074845 003 Sep 15, 1999

120MG

N020939 001 Jan 28, 2000

180MG

N020939 002 Jan 28, 2000

240MG

N020939 003 Jan 28, 2000

300MG

N020939 004 Jan 28, 2000

360MG

N020939 005 Sep 14, 2001

420MG

N020939 006 Sep 14, 2001

NESHER PHARMS

120MG

A076563 002 Sep 12, 2006

180MG

A076563 003 Sep 12, 2006

240MG

A076563 004 Sep 12, 2006

300MG

A076563 005 Sep 12, 2006

360MG

A076563 006 Sep 12, 2006

420MG

A076563 001 Sep 12, 2006

TEVA

60MG

A074079 001 Nov 30, 1993

90MG

A074079 002 Nov 30, 1993

120MG

A074079 003 Nov 30, 1993

DISCONTINUED DRUG PRODUCT LIST

6-111 (of 337)

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

CARDIZEM

BIOVAIL	100MG/VIAL	N020792 001	Sep 05, 1997
BIOVAIL LABS INTL	5MG/ML	N020027 001	Oct 24, 1991
	25MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020027 003	Aug 18, 1995

DILTIAZEM HYDROCHLORIDE

AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999
HOSPIRA	5MG/ML	A075004 001	Feb 16, 2000
	5MG/ML	A075106 001	Apr 29, 1999
TEVA PHARMS USA	5MG/ML	A074894 001	Aug 26, 1997

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

APOTHECON	30MG	A074051 001	Mar 31, 1993
	60MG	A074051 002	Mar 31, 1993
	90MG	A074051 003	Mar 31, 1993
	120MG	A074051 004	Mar 31, 1993
DAVA PHARMS INC	30MG	A074093 001	Nov 05, 1992
	60MG	A074093 002	Nov 05, 1992
	90MG	A074093 003	Nov 05, 1992
	120MG	A074093 004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168 001	Mar 03, 1995
	60MG	A074168 002	Mar 03, 1995
	90MG	A074168 003	Mar 03, 1995
	120MG	A074168 004	Mar 03, 1995
TEVA	30MG	A074084 001	Feb 25, 1994
	60MG	A074084 002	Feb 25, 1994
TEVA PHARMS	30MG	A074067 001	Nov 05, 1992
	60MG	A074067 002	Nov 05, 1992
	90MG	A074067 003	Nov 05, 1992
	120MG	A074067 004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HCL	N020506 001	Oct 04, 1996
	EQ 180MG HCL	N020506 002	Oct 04, 1996
	EQ 240MG HCL	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HCL; 5MG	N020507 001	Oct 04, 1996
---------	-------------------	-------------	--------------

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001
WATSON LABS	50MG/ML	A080615 001
	50MG/ML	A083531 001
WYETH AYERST	50MG/ML	A084316 001

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001
------	------------	-------------

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001
NEXGEN PHARMA INC	50MG	A085985 001
WATSON LABS	50MG	A085166 001

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

IMCOR PHARMS CO	0.92MG/VIAL; 0.092MG/VIAL	N021191 001	May 31, 2002
-----------------	---------------------------	-------------	--------------

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001
----------------------	----------------	-------------

DISCONTINUED DRUG PRODUCT LIST

6-112 (of 337)

DIPHEMANIL METHYLSULFATE

TABLET; ORAL

PRANTAL

SCHERING

100MG

N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

BENADRYL

MCNEIL CONS

25MG

N005845 007

50MG

N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA

25MG

A080519 004

50MG

A080519 003

ANABOLIC

50MG

A083275 001

ELKINS SINN

25MG

A085701 001

50MG

A085701 002

HALSEY

50MG

A087914 001

Jun 04, 1984

HEATHER

25MG

A084524 001

50MG

A083953 001

HIKMA PHARMS LLC

50MG

A083567 001

IMPAX LABS

25MG

A080807 001

50MG

A080807 002

IVAX SUB TEVA PHARMS

25MG

A080762 001

50MG

A080762 002

LANNETT

25MG

A080868 001

50MG

A080868 002

LEDERLE

25MG

A086874 001

50MG

A086875 001

LNK

25MG

A087977 001

Jan 27, 1983

50MG

A087978 001

Jan 27, 1983

MK LABS

25MG

A083087 001

50MG

A083087 002

MUTUAL PHARM

25MG

A084506 001

25MG

A089488 001

Jan 02, 1987

50MG

A089489 001

Jan 02, 1987

NEWTRON PHARMS

25MG

A086543 001

50MG

A086544 001

NEXGEN PHARMA INC

25MG

A083634 001

PERRIGO

25MG

A083061 001

50MG

A083061 002

PIONEER PHARMS

25MG

A089101 001

Dec 20, 1985

50MG

A088880 001

Dec 20, 1985

PUREPAC PHARM

25MG

A085156 001

50MG

A085150 001

PVT FORM

25MG

A083027 001

50MG

A083027 002

ROXANE

50MG

A080635 001

SANDOZ

25MG

A080832 001

25MG

A080845 002

50MG

A080832 002

50MG

A080845 001

SUPERPHARM

25MG

A089040 001

May 15, 1985

50MG

A089041 001

May 15, 1985

TEVA

25MG

A085874 001

50MG

A085874 002

VALEANT PHARM INTL

25MG

A080596 001

50MG

A080592 001

VANGARD

25MG

A088034 001

Oct 27, 1982

50MG

A087630 001

WATSON LABS

25MG

A080728 001

25MG

A083797 001

25MG

A085138 001

50MG

A080727 001

50MG

A083797 002

50MG

A085083 001

WHITEWORTH TOWN PLSN

25MG

A083441 001

50MG

A080800 001

ELIXIR; ORAL

BELIX

HALSEY

12.5MG/5ML

A086586 001

Oct 03, 1983

BENADRYL

MCNEIL CONS

12.5MG/5ML

N005845 004

DISCONTINUED DRUG PRODUCT LIST

6-113 (of 337)

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIBENIL

CENCI 12.5MG/5ML A088304 001 Dec 16, 1983

DIPHEN

USL PHARMA 12.5MG/5ML A084640 001

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY 12.5MG/5ML A083674 001

CENCI 12.5MG/5ML A087941 001 Dec 17, 1982

KV PHARM 12.5MG/5ML A085621 001

LANNETT 12.5MG/5ML A080939 002

LEDERLE 12.5MG/5ML A086937 001

MK LABS 12.5MG/5ML A083088 002

NASKA 12.5MG/5ML A088680 001 May 31, 1985

PERRIGO 12.5MG/5ML A083063 001

PUREPAC PHARM 12.5MG/5ML A083237 001 Jan 25, 1982

PVT FORM 12.5MG/5ML A085287 001

ROXANE 12.5MG/5ML A080643 001

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A080763 002

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS 10MG/ML N006146 001

50MG/ML N006146 002

BENADRYL PRESERVATIVE FREE

MCNEIL CONS 50MG/ML N009486 001

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR 10MG/ML A080822 001

HIKMA MAPLE 50MG/ML A083183 001

LYPHOMED 10MG/ML A087066 001

WATSON LABS 10MG/ML A083533 001

WATSON LABS INC 10MG/ML A080873 001

50MG/ML A080873 002

WYETH AYERST 50MG/ML A080577 001

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM 50MG/ML A080586 002

INTL MEDICATION 50MG/ML A084094 001

WATSON LABS INC 50MG/ML A080873 003

SYRUP; ORAL

ANTITUSSIVE

PERRIGO 12.5MG/5ML A071292 001 Apr 10, 1987

BELDIN

HALSEY 12.5MG/5ML A089179 001 Jun 05, 1986

BENYLIN

PARKE DAVIS 12.5MG/5ML N006514 004

DIPHEN

MORTON GROVE 12.5MG/5ML A070118 001 Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

ALPHARMA US PHARMS 12.5MG/5ML A070497 001 Apr 25, 1989

CUMBERLAND SWAN 12.5MG/5ML A073611 001 Aug 20, 1992

HI TECH PHARMA 12.5MG/5ML A072416 001 Sep 28, 1990

HYDRAMINE

ALPHARMA US PHARMS 12.5MG/5ML A070205 001 Jan 28, 1986

SILPHEN

SILARX 12.5MG/5ML A072646 001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT 12.5MG/5ML A070524 001 Jan 14, 1987

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

BENYLIN

PARKE DAVIS 12.5MG/5ML; 30MG/5ML N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET; ORAL

VONTROL

GLAXOSMITHKLINE EQ 25MG BASE N016033 001

DISCONTINUED DRUG PRODUCT LIST

6-114 (of 337)

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

HISPRIL

GLAXOSMITHKLINE 5MG

N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

AKORN 0.1%

A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB 0.1%

A074188 001 May 19, 1995

FALCON PHARMS 0.1%

A073636 001 Jun 30, 1994

PROPINE

ALLERGAN 0.1%

N018239 001

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AGILA SPECILTS 5MG/ML

A075769 001 Nov 27, 2002

HOSPIRA 5MG/ML

A074601 001 Dec 19, 1997

TEVA PHARMS USA 5MG/ML

A074952 001 Nov 26, 1997

IV PERSANTINE

BOEHRINGER INGELHEIM 5MG/ML

N019817 001 Dec 13, 1990

TABLET; ORAL

DIPYRIDAMOLE

GLENMARK GENERICS 25MG

A088999 001 Feb 05, 1991

50MG

A089000 001 Feb 05, 1991

75MG

A089001 001 Feb 05, 1991

PROSAM LABS 25MG

A040542 001 Apr 21, 2006

50MG

A040542 002 Apr 21, 2006

75MG

A040542 003 Apr 21, 2006

PUREPAC PHARM 50MG

A089426 001 Jul 12, 1990

75MG

A089427 001 Jul 12, 1990

SANDOZ 25MG

A086944 002 Apr 16, 1991

50MG

A087562 001 Feb 25, 1992

75MG

A087561 001 Feb 25, 1992

WATSON LABS 50MG

A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE; ORAL

DYNABAC

LILLY RES LABS 250MG

N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM EQ 100MG BASE

A071190 001 Jan 15, 1987

EQ 150MG BASE

A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS EQ 100MG BASE

A070186 001 Nov 18, 1985

EQ 150MG BASE

A070187 001 Nov 18, 1985

MUTUAL PHARM EQ 100MG BASE

A070351 001 Dec 17, 1985

EQ 150MG BASE

A070352 001 Dec 17, 1985

MYLAN EQ 100MG BASE

A070138 001 Jun 14, 1985

EQ 150MG BASE

A070139 001 Jun 14, 1985

SANDOZ EQ 100MG BASE

A070470 001 Dec 10, 1985

EQ 150MG BASE

A070471 001 Dec 10, 1985

SUPERPHARM EQ 100MG BASE

A070940 001 Feb 09, 1987

EQ 150MG BASE

A070941 001 Feb 09, 1987

WATSON LABS EQ 100MG BASE

A070240 001 Feb 02, 1986

EQ 150MG BASE

A070241 001 Feb 02, 1986

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS EQ 150MG BASE

A071200 001 Dec 15, 1987

DISULFIRAM

TABLET; ORAL

ANTABUSE

TEVA WOMENS 250MG

N007883 003

500MG

N007883 002

DISULFIRAM

PAR PHARM 250MG

A088792 001 Aug 14, 1984

500MG

A088793 001 Aug 14, 1984

WATSON LABS 250MG

A086889 001

250MG

A087973 001 Aug 05, 1983

500MG

A086890 001

DISCONTINUED DRUG PRODUCT LIST

6-115 (of 337)

DISULFIRAMTABLET; ORAL
DISULFIRAM

500MG

A087974 001 Aug 05, 1983

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP

ABBOTT

EQ 250MG BASE

N019794 001 Jul 11, 1990

EQ 500MG BASE

N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

MYLAN

EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008

EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008

EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

TEVA PHARMS USA

EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

ASTRAZENECA

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995

BAXTER HLTHCARE

EQ 12.5MG BASE/ML

A074381 001 Sep 26, 1996

HOSPIRA

EQ 1.25GM BASE/100ML

A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML

A074545 001 Jun 25, 1998

TEVA PARENTERAL

EQ 12.5MG BASE/ML

A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML

A074279 001 Feb 18, 1998

EQ 12.5MG BASE/ML

A074995 001 Mar 31, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993

DOBUTREX

LILLY

EQ 12.5MG BASE/ML

N017820 002

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012

TAXOTERE

SANOFI AVENTIS US

40MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020449 001 May 14, 1996

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

EISAI INC

5MG/5ML

N021719 001 Oct 18, 2004

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

ACCORD HLTHCARE

5MG

A201335 001 Aug 29, 2011

10MG

A201335 002 Aug 29, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

MUTUAL PHARM

5MG

A077975 002 Dec 11, 2009

10MG

A077975 001 Dec 11, 2009

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT

40MG/ML

A070656 001 Jan 24, 1989

80MG/ML

A070657 001 Jan 24, 1989

ABRAXIS PHARM

40MG/ML

A070012 001 Jun 12, 1985

40MG/ML

A070058 001 Mar 20, 1985

80MG/ML

A070013 001 Jun 12, 1985

80MG/ML

A070059 001 Mar 20, 1985

160MG/ML

A070364 001 Dec 04, 1985

ASTRAZENECA

40MG/ML

A070087 001 Oct 23, 1985

40MG/ML

N018656 001 Jun 28, 1983

80MG/ML

A070089 001 Oct 23, 1985

80MG/ML

A070090 001 Oct 23, 1985

80MG/ML

A070091 001 Oct 23, 1985

DISCONTINUED DRUG PRODUCT LIST

6-116 (of 337)

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995
INTROPIN				
HOSPIRA	40MG/ML	N017395	001	
	80MG/ML	N017395	002	
	160MG/ML	N017395	003	

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

APOTEX INC EQ 2% BASE

A078395 001 Oct 28, 2008

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

APOTEX INC EQ 2% BASE; EQ 0.5% BASE

A078201 001 Oct 28, 2008

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE EQ 1MG BASE/ML

N019946 001 Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS 20MG/ML

A073529 001 Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH	EQ 1MG BASE	A075574	001	Oct 18, 2000
	EQ 2MG BASE	A075574	002	Oct 18, 2000
	EQ 4MG BASE	A075574	003	Oct 18, 2000
	EQ 8MG BASE	A075574	004	Oct 18, 2000
GENPHARM	EQ 1MG BASE	A075466	001	Oct 18, 2000
	EQ 2MG BASE	A075466	002	Oct 18, 2000
	EQ 4MG BASE	A075466	003	Oct 18, 2000
	EQ 8MG BASE	A075466	004	Oct 18, 2000
IVAX SUB TEVA PHARMS	EQ 1MG BASE	A075453	001	Oct 18, 2000
	EQ 2MG BASE	A075453	002	Oct 18, 2000
	EQ 4MG BASE	A075453	003	Oct 18, 2000
	EQ 8MG BASE	A075453	004	Oct 18, 2000
NESHER PHARMS	EQ 1MG BASE	A075609	001	Oct 18, 2000
	EQ 2MG BASE	A075609	002	Oct 18, 2000
	EQ 4MG BASE	A075609	003	Oct 18, 2000
	EQ 8MG BASE	A075609	004	Oct 18, 2000
SANDOZ	EQ 1MG BASE	A075432	001	Oct 18, 2000
	EQ 1MG BASE	A075646	001	Oct 18, 2000
	EQ 2MG BASE	A075432	002	Oct 18, 2000
	EQ 2MG BASE	A075646	002	Oct 18, 2000
	EQ 4MG BASE	A075432	003	Oct 18, 2000
	EQ 4MG BASE	A075646	003	Oct 18, 2000
	EQ 8MG BASE	A075432	004	Oct 18, 2000
	EQ 8MG BASE	A075646	004	Oct 18, 2000
TEVA	EQ 1MG BASE	A075353	001	Jan 12, 2001
	EQ 2MG BASE	A075353	002	Jan 12, 2001

DISCONTINUED DRUG PRODUCT LIST

6-117 (of 337)

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000

DOXEPIH HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
MUTUAL PHARM	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071697 001	Nov 09, 1987
	EQ 25MG BASE	A071437 001	Nov 09, 1987
	EQ 50MG BASE	A071595 001	Nov 09, 1987
	EQ 75MG BASE	A071608 001	Nov 09, 1987
	EQ 100MG BASE	A071422 001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 50MG BASE	A072987 001	Mar 29, 1991
	EQ 75MG BASE	A071326 001	Apr 30, 1987
	EQ 75MG BASE	A071763 001	Feb 09, 1988
	EQ 100MG BASE	A070955 001	May 15, 1986
	EQ 100MG BASE	A071239 001	Apr 30, 1987
	EQ 150MG BASE	A071764 001	Feb 09, 1988

SINEQUAN

PFIZER

EQ 10MG BASE	N016798 003
EQ 25MG BASE	N016798 001
EQ 50MG BASE	N016798 002
EQ 75MG BASE	N016798 006
EQ 100MG BASE	N016798 005
EQ 150MG BASE	N016798 007

DISCONTINUED DRUG PRODUCT LIST

6-118 (of 337)

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004

SINEQUAN

PFIZER

EQ 10MG BASE/ML

N017516 001

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PHARMACIA AND UPJOHN

2MG/ML

A063165 001 Jan 30, 1991

2MG/ML

N050629 001 Dec 23, 1987

200MG/100ML

A063165 002 Jan 30, 1991

200MG/100ML

N050629 002 May 03, 1988

ADRIAMYCIN RDF

PHARMACIA AND UPJOHN

10MG/VIAL

N050467 001

20MG/VIAL

N050467 003 May 20, 1985

50MG/VIAL

N050467 002

150MG/VIAL

N050467 004 Jul 22, 1987

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL

A062926 001 Apr 13, 1989

50MG/VIAL

A062926 002 Apr 13, 1989

100MG/VIAL

A062926 003 Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

PAR PHARM

EQ 75MG BASE

A065055 004 Apr 18, 2005

SANDOZ INC

EQ 50MG BASE

A065032 001 Jun 30, 2000

EQ 100MG BASE

A065032 002 Jun 30, 2000

WATSON LABS

EQ 50MG BASE

A065041 001 Apr 28, 2000

EQ 100MG BASE

A065041 002 Apr 28, 2000

FOR SUSPENSION; ORAL

DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML

A061720 001

TABLET; ORAL

DOXYCYCLINE

MUTUAL PHARM

EQ 50MG BASE

A065471 001 Apr 17, 2009

EQ 75MG BASE

A065471 002 Apr 17, 2009

EQ 100MG BASE

A065471 003 Apr 17, 2009

SANDOZ INC

EQ 50MG BASE

A065353 001 Nov 27, 2006

EQ 75MG BASE

A065353 002 Nov 27, 2006

EQ 100MG BASE

A065353 003 Nov 27, 2006

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXY-LEMMON

TEVA

EQ 50MG BASE

A062497 001 Aug 23, 1984

EQ 100MG BASE

A062497 002 Jun 15, 1984

DOXYCYCLINE HYCLATE

HALSEY

EQ 50MG BASE

A062119 002 May 24, 1985

EQ 100MG BASE

A062119 001 May 24, 1985

HEATHER

EQ 50MG BASE

A062463 001 Dec 07, 1983

EQ 100MG BASE

A062463 002 Dec 07, 1983

INTERPHARM

EQ 50MG BASE

A062763 001 Sep 02, 1988

EQ 100MG BASE

A062763 002 Sep 02, 1988

MUTUAL PHARM

EQ 50MG BASE

A062418 001 Jan 28, 1983

EQ 100MG BASE

A062418 002 Jan 28, 1983

PAR PHARM

EQ 50MG BASE

A062434 001 Oct 19, 1984

EQ 100MG BASE

A062442 001 Dec 22, 1983

PVT FORM

EQ 50MG BASE

A062631 001 Jul 24, 1986

EQ 100MG BASE

A062631 002 Jul 24, 1986

RANBAXY

EQ 50MG BASE

A062479 001 Dec 23, 1983

EQ 100MG BASE

A062479 002 Dec 23, 1983

SUPERPHARM

EQ 50MG BASE

A062469 001 Oct 31, 1984

EQ 100MG BASE

A062469 002 Oct 31, 1984

WARNER CHILCOTT

EQ 50MG BASE

A062594 001 Dec 05, 1985

EQ 100MG BASE

A062594 002 Dec 05, 1985

WATSON LABS

EQ 50MG BASE

A061717 001

EQ 50MG BASE

A062142 001

EQ 100MG BASE

A061717 002

EQ 100MG BASE

A062142 002

DISCONTINUED DRUG PRODUCT LIST

6-119 (of 337)

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

PERIOSTAT

COLLAGENEX

EQ 20MG BASE

N050744 001 Sep 30, 1998

CAPSULE, COATED PELLETS; ORAL

DOXYCYCLINE HYCLATE

PLIVA

EQ 100MG BASE

A063187 001 Jun 30, 1992

CAPSULE, DELAYED RELEASE; ORAL

DORYX

MAYNE PHARMA INTL

EQ 75MG BASE

N050582 002 Aug 13, 2001

EQ 100MG BASE

N050582 001 Jul 22, 1985

WARNER CHILCOTT

EQ 100MG BASE

A062653 001 Oct 30, 1985

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE

EQ 100MG BASE/VIAL

A061953 001

DOXYCYCLINE

EUROHLTH INTL

EQ 200MG BASE/VIAL

A062569 002 Mar 09, 1988

HIKMA MAPLE

EQ 100MG BASE/VIAL

A062450 001 Oct 27, 1983

EQ 200MG BASE/VIAL

A062450 002 Oct 27, 1983

DOXYCYCLINE HYCLATE

HIKMA MAPLE

EQ 100MG BASE/VIAL

A062992 001 Feb 16, 1989

EQ 200MG BASE/VIAL

A062992 002 Feb 16, 1989

VIBRAMYCIN

PFIZER

EQ 100MG BASE/VIAL

N050442 002

EQ 200MG BASE/VIAL

N050442 001

TABLET; ORAL

DOXY-LEMMON

TEVA

EQ 100MG BASE

A062581 001 Mar 15, 1985

DOXYCYCLINE HYCLATE

BLU CARIBE INC

EQ 50MG BASE

A062269 003

HEATHER

EQ 100MG BASE

A062462 001 May 11, 1983

INTERPHARM

EQ 100MG BASE

A062764 001 Sep 02, 1988

MUTUAL PHARM

EQ 100MG BASE

A062391 001 Sep 30, 1982

SUPERPHARM

EQ 100MG BASE

A062494 001 Feb 20, 1985

WARNER CHILCOTT

EQ 100MG BASE

A062593 001 Aug 28, 1985

WATSON LABS

EQ 50MG BASE

A062392 001 Mar 31, 1983

EQ 100MG BASE

A062392 002 Mar 31, 1983

PERIOSTAT

GALDERMA LABS LP

EQ 20MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050783 001 Feb 02, 2001

VIBRA-TABS

PFIZER

EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N050533 001

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG

N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG

N006412 015

25MG

N006412 014

DOXY-SLEEP-AID

PAR PHARM

25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG

A088900 002 Feb 12, 1988

QUANTUM PHARMICS

25MG

A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG; 10MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010598 002

DISCONTINUED DRUG PRODUCT LIST

6-120 (of 337)

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM

2.5MG/ML

A070992 001 Nov 17, 1986

2.5MG/ML

A070993 001 Nov 17, 1986

ASTRAZENECA

2.5MG/ML

A072018 001 Oct 20, 1988

2.5MG/ML

A072019 001 Oct 19, 1988

2.5MG/ML

A072020 001 Oct 19, 1988

2.5MG/ML

A072021 001 Oct 19, 1988

HOSPIRA

2.5MG/ML

A071645 001 Apr 07, 1988

2.5MG/ML

A072272 001 Aug 31, 1995

LUITPOLD

2.5MG/ML

A072335 001 Oct 24, 1988

SMITH AND NEPHEW

2.5MG/ML

A071750 001 Sep 06, 1988

SOLOPAK

2.5MG/ML

A071754 001 Sep 06, 1988

2.5MG/ML

A071755 001 Sep 06, 1988

WATSON LABS

2.5MG/ML

A073520 001 Nov 27, 1991

2.5MG/ML

A073521 001 Nov 27, 1991

2.5MG/ML

A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA

2.5MG/ML;EQ 0.05MG BASE/ML

A072026 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML

A072027 001 Apr 13, 1989

2.5MG/ML;EQ 0.05MG BASE/ML

A072028 001 Apr 13, 1989

HOSPIRA

2.5MG/ML;EQ 0.05MG BASE/ML

A071982 001 May 04, 1988

INNOVAR

AKORN MFG

2.5MG/ML;EQ 0.05MG BASE/ML

N016049 001

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLONE

ASTRAZENECA

0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 002

1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N009925 001

DYDROGESTERONE

TABLET; ORAL

GYNOREST

SOLVAY

5MG

N017388 001

10MG

N017388 002

DYPHYLLINE

ELIXIR; ORAL

NEOTHYLLINE

TEVA

160MG/15ML

N007794 003

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA

250MG/ML

N009088 001

TABLET; ORAL

DILOR

SAVAGE LABS

200MG

A084514 001

DILOR-400

SAVAGE LABS

400MG

A084751 001

NEOTHYLLINE

TEVA

200MG

N007794 001

400MG

N007794 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

WYETH PHARMS INC

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

DISCONTINUED DRUG PRODUCT LIST

6-121 (of 337)

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE

MERZ PHARMS LLC

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET; ORAL

CALCIUM DISODIUM VERSENATE

MEDICIS

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

EFAVIRENZ

CAPSULE; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

100MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020972 002 Sep 17, 1998

TABLET; ORAL

SUSTIVA

BRISTOL MYERS SQUIBB

300MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021360 001 Feb 01, 2002

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US

200MG/ML

N019879 002 Nov 28, 1990

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

APOTHECON

2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

IVAX SUB TEVA PHARMS

2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

10MG

A075482 003 Aug 22, 2000

20MG

A075482 004 Aug 22, 2000

KRKA DD NOVO MESTO

2.5MG

A075370 001 Aug 22, 2000

5MG

A075370 002 Aug 22, 2000

10MG

A075369 001 Aug 22, 2000

20MG

A075369 002 Aug 22, 2000

MYLAN

2.5MG

A075472 001 Aug 22, 2000

5MG

A075472 002 Aug 22, 2000

10MG

A075472 003 Aug 22, 2000

20MG

A075472 004 Aug 22, 2000

RANBAXY

2.5MG

A075556 001 Aug 22, 2000

5MG

A075556 002 Aug 22, 2000

10MG

A075556 003 Aug 22, 2000

20MG

A075556 004 Aug 22, 2000

SANDOZ

2.5MG

A075048 001 Aug 22, 2000

5MG

A075048 002 Aug 22, 2000

10MG

A075048 003 Aug 22, 2000

20MG

A075048 004 Aug 22, 2000

SANDOZ INC

2.5MG

A075496 001 Aug 22, 2000

2.5MG

A075621 001 Aug 22, 2000

5MG

A075496 002 Aug 22, 2000

5MG

A075621 002 Aug 22, 2000

10MG

A075459 001 Aug 22, 2000

10MG

A075621 003 Aug 22, 2000

20MG

A075459 002 Aug 22, 2000

20MG

A075621 004 Aug 22, 2000

WATSON LABS

2.5MG

A075501 001 Aug 22, 2000

5MG

A075501 002 Aug 22, 2000

DISCONTINUED DRUG PRODUCT LIST

6-122 (of 337)

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

10MG

A075501 003 Aug 22, 2000

20MG

A075501 004 Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXXEL

ASTRAZENECA

5MG; 2.5MG

N020668 002 Oct 28, 1998

5MG; 5MG

N020668 001 Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

IVAX SUB TEVA PHARMS

5MG; 12.5MG

A075736 001 Mar 25, 2003

10MG; 25MG

A075736 002 Mar 25, 2003

SANDOZ INC

5MG; 12.5MG

A076116 001 Sep 19, 2001

10MG; 25MG

A076116 002 Sep 19, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

HOSPIRA

1.25MG/ML

A075456 001 Aug 22, 2000

1.25MG/ML

A075571 001 Aug 22, 2000

VASOTEC

BIOVAIL LABS INTL

1.25MG/ML

N019309 001 Feb 09, 1988

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT

99.9%

A070803 001 Sep 08, 1987

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG

N019616 004 Dec 31, 1991

400MG

N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

SANOFI AVENTIS US

90MG/0.6ML (150MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020164 006 Jun 02, 2000

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING

0.25MG/INH

N016803 001

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS

0.2MG/INH

N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE-FREE

FOREST LABS

1.5MG/AMP

N007942 003 Feb 05, 1999

5MG/ML

N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPEC LT

0.15MG/DELIVERY

N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPEC LT

0.3MG/DELIVERY

N019430 003 Aug 03, 1995

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

DISCONTINUED DRUG PRODUCT LIST

6-123 (of 337)

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML; 1%	N017751	006
	0.005MG/ML; 1.5%	N017751	007
DENTSPLY PHARM	0.005MG/ML; 1.5%	N021384	001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA	0.005MG/ML; 4%	N014763	008
-------------	----------------	---------	-----

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA	0.005MG/ML; 0.5%	N017751	004
-------------	------------------	---------	-----

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE	0.01MG/ML; 2%	A084720	001
	0.02MG/ML; 2%	A084732	001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

GRAHAM CHEM	0.01MG/ML; 2%	A080504	004	Oct 19, 1983
	0.02MG/ML; 2%	A080504	005	Oct 19, 1983
HIKMA MAPLE	0.01MG/ML; 1%	A080406	001	
	0.01MG/ML; 2%	A080406	002	
HOSPIRA	0.005MG/ML; 1%	A089649	001	Jun 21, 1988
	0.005MG/ML; 1.5%	A089650	001	Jun 21, 1988

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT	0.01MG/ML; 1%	A083154	001
BEL MAR	0.01MG/ML; 1%	A080820	001
	0.01MG/ML; 2%	A080757	001
DELL LABS	0.01MG/ML; 1%	A083389	001
	0.01MG/ML; 2%	A083390	001
INTL MEDICATION	0.01MG/ML; 1%	A086402	001
WATSON LABS	0.01MG/ML; 1%	A080377	003
	0.01MG/ML; 1%	A085463	001
	0.01MG/ML; 2%	A080377	004

LIDOCATON

PHARMATON	0.01MG/ML; 2%	A084729	001	Aug 17, 1983
	0.02MG/ML; 2%	A084728	001	Aug 17, 1983

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM	0.01MG/ML; 2%	N021381	001
	0.02MG/ML; 2%	N021381	002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA	0.005MG/ML; 1%	N010418	006
	0.005MG/ML; 1.5%	N010418	010
	0.005MG/ML; 2%	N010418	008
FRESENIUS KABI USA	0.01MG/ML; 2%	N006488	003

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS	1.05MG/PATCH; 100MG/PATCH	N021504	001	May 06, 2004
---------	---------------------------	---------	-----	--------------

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED	0.01MG/ML; 2%	N020530	001	Dec 21, 1995
-------	---------------	---------	-----	--------------

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI	0.01MG/ML; 2%	N021486	001	Oct 26, 2004
------	---------------	---------	-----	--------------

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR	0.02MG/ML; 1%	A080758	001
	0.02MG/ML; 2%	A080759	001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009
	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009
HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007
MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011
	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011
MYLAN INSTITUTIONAL	50MG/25ML (2MG/ML)	A065371	001	Nov 28, 2007

DISCONTINUED DRUG PRODUCT LIST

6-124 (of 337)

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

200MG/100ML (2MG/ML)

A065371 002 Nov 28, 2007

INJECTABLE; IV (INFUSION)

EPIRUBICIN HYDROCHLORIDE

HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPRA

GD SEARLE LLC

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

TEVETEN

ABBVIE

EQ 300MG BASE

N020738 004 Dec 22, 1997

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY

50,000 IU

A080884 001

VITAMIN D

CHASE CHEM

50,000 IU

A080747 001

EVERYLIFE

50,000 IU

A080956 001

IMPAX LABS

50,000 IU

A080951 001

LANNETT

50,000 IU

A080825 001

VITARINE

50,000 IU

A084053 001

WEST WARD

50,000 IU

A083102 001

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS

1MG

N018706 001 Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS

1MG/ML

N018418 001

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM

1MG

A088891 001 Nov 01, 1985

WATSON LABS

1MG

A086433 001 May 27, 1982

1MG

A087244 001 Aug 16, 1982

GERIMAL

WATSON LABS

1MG

A088207 001 Mar 22, 1984

HYDERGINE

NOVARTIS

0.5MG

N017993 003

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ

0.5MG

A085153 001

1MG

A087417 001

CIRCANOL

3M

0.5MG

A084868 001

1MG

A085809 001

DEAPRIL-ST

BRISTOL MYERS SQUIBB

1MG

A085020 002

ERGOLOID MESYLATES

KV PHARM

0.5MG

A085899 001

0.5MG

A086265 001

1MG

A085900 001

1MG

A086264 001

LEDERLE

0.5MG

A086984 001

1MG

A086985 001

MUTUAL PHARM

0.5MG

A087407 001

1MG

A087552 001

SUPERPHARM

0.5MG

A089233 001 Sep 23, 1986

1MG

A089234 001 Sep 23, 1986

VANGARD

0.5MG

A088013 001 Sep 20, 1982

1MG

A088014 001 Sep 20, 1982

WATSON LABS

0.5MG

A084930 001

0.5MG

A087233 001

1MG

A085177 001

1MG

A087183 001

DISCONTINUED DRUG PRODUCT LIST

6-125 (of 337)

ERGOLOID MESYLATES

TABLET;SUBLINGUAL

GERIMAL

WATSON LABS

0.5MG

A086189 001

1MG

A086188 001

HYDERGINE

NOVARTIS

0.5MG

N009087 002

1MG

N009087 001

HYDROGENATED ERGOT ALKALOIDS

IVAX PHARMS

0.5MG

A087186 001

1MG

A087185 001

ERGOTAMINE TARTRATE

AEROSOL, METERED; INHALATION

MEDIHALER ERGOTAMINE

3M

0.36MG/INH

N012102 001

TABLET;SUBLINGUAL

ERGOSTAT

PARKE DAVIS

2MG

A088337 001

Jun 08, 1984

WIGRETTES

ORGANON USA INC

2MG

A086750 001

Jul 29, 1982

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

PARKE DAVIS

250MG

A062546 001

Jul 25, 1985

250MG

A062618 001

Sep 25, 1985

WARNER CHILCOTT LLC

250MG

A062338 001

ERYC 125

PARKE DAVIS

125MG

A062648 001

Oct 24, 1985

ERYC SPRINKLES

HOSPIRA

125MG

N050593 001

Jul 22, 1985

ERYTHROMYCIN

BARR

250MG

A063098 001

May 04, 1989

GEL; TOPICAL

E-GLADES

RENAISSANCE PHARMA

2%

A065009 001

Mar 18, 2002

EMGEL

ALTANA

2%

A063107 001

Aug 23, 1991

LOTION; TOPICAL

E-SOLVE 2

SYOSSET

2%

A062467 001

Jul 03, 1985

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

PHARMADERM

5MG/GM

A062446 001

Sep 26, 1983

PHARMAFAIR

5MG/GM

A062481 001

Apr 05, 1984

ILOTYCIN

DISTA

0.5%

N050368 001

POWDER; FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC

100%

N050610 001

Nov 07, 1986

SOLUTION; TOPICAL

A/T/S

TARO PHARMS NORTH

2%

A062405 001

Nov 18, 1982

ERYDERM

ARBOR PHARMS INC

2%

A062290 001

ERYMAX

MERZ PHARMS

2%

A062508 002

Jul 11, 1985

ERYTHROMYCIN

ALPHARMA US PHARMS

1.5%

A062328 001

Apr 19, 1982

2%

A062326 001

Apr 19, 1982

2%

A062327 001

Apr 19, 1982

2%

A062342 001

Feb 25, 1982

2%

A062957 001

Jul 21, 1988

BAUSCH AND LOMB

2%

A064039 001

Jan 27, 1994

LILLY

2%

N050532 001

PHARMAFAIR

1.5%

A062485 001

Jul 11, 1984

2%

A062616 001

Jul 25, 1985

RENAISSANCE PHARMA

2%

A064127 001

Feb 14, 1997

SANSAC

DOW PHARM

2%

A062522 001

Jan 24, 1985

STATICIN

WESTWOOD SQUIBB

1.5%

N050526 001

DISCONTINUED DRUG PRODUCT LIST

6-126 (of 337)

ERYTHROMYCIN

SOLUTION; TOPICAL

T-STAT

WESTWOOD SQUIBB 2% A062436 001 Mar 09, 1983

SWAB; TOPICAL

C-SOLVE-2

IVAX SUB TEVA PHARMS 2% A062751 001 Jul 30, 1993

ERYCETTE

JOHNSON AND JOHNSON 2% N050594 001 Feb 15, 1985

ERYTHROMYCIN

FOUGERA PHARMS 2% A065320 001 Jul 25, 2006

RENAISSANCE PHARMA 2% A064128 001 Jul 03, 1996

T-STAT

WESTWOOD SQUIBB 2% A062748 001 Jul 23, 1987

TABLET, DELAYED RELEASE; ORAL

E-BASE

BARR 333MG A063028 001 May 15, 1990

333MG A063086 001 May 15, 1990

500MG A062999 001 Nov 25, 1988

E-MYCIN

ARBOR PHARMS INC 250MG A060272 001

333MG A060272 002

ILOTYCIN

DISTA 250MG A061910 001

R-P MYCIN

SOLVAY 250MG A061659 001

ROBIMYCIN

ROBINS AH 250MG A061633 001

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR EQ 125MG BASE A062162 001

EQ 250MG BASE A062162 002

IVAX SUB TEVA PHARMS EQ 250MG BASE A062237 001

WATSON LABS EQ 250MG BASE A062087 001

ILOSONE

LILLY EQ 125MG BASE A061897 001

EQ 250MG BASE A061897 002

FOR SUSPENSION; ORAL

ILOSONE

DISTA EQ 125MG BASE/5ML A061893 001

SUSPENSION; ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS EQ 125MG BASE/5ML A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML A062409 001 Dec 16, 1982

BARR EQ 125MG BASE/5ML A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML A062169 002 Oct 17, 1990

LIFE LABS EQ 250MG BASE/5ML A062362 001 Dec 17, 1982

ILOSONE

LILLY EQ 125MG BASE/5ML A061894 001

EQ 125MG BASE/5ML N050010 001

EQ 250MG BASE/5ML A061894 002

EQ 250MG BASE/5ML N050010 002

SUSPENSION/DROPS; ORAL

ILOSONE

LILLY EQ 100MG BASE/ML A061894 003

TABLET; ORAL

ILOSONE

LILLY EQ 500MG BASE A061896 001

TABLET, CHEWABLE; ORAL

ILOSONE

DISTA EQ 125MG BASE A061895 001

EQ 250MG BASE A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION; ORAL

ILOSONE SULFA

LILLY EQ 125MG BASE/5ML; EQ 600MG BASE/5ML N050599 001 Sep 29, 1989

DISCONTINUED DRUG PRODUCT LIST

6-127 (of 337)

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 200MG BASE/5ML A062055 001

PEDIAMYCIN

ROSS LABS EQ 200MG BASE/5ML A062305 001

SUSPENSION; ORAL

E-MYCIN E

PHARMACIA AND UPJOHN EQ 200MG BASE/5ML A062198 001

EQ 400MG BASE/5ML A062198 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS EQ 200MG BASE/5ML A062200 001

EQ 400MG BASE/5ML A062200 002

DISTA EQ 200MG BASE/5ML A062177 001

EQ 400MG BASE/5ML A062177 002

NASKA EQ 400MG BASE/5ML A062674 001 Mar 10, 1987

PARKE DAVIS EQ 200MG BASE/5ML A062231 001

EQ 400MG BASE/5ML A062231 002

PHARMAFAIR EQ 200MG BASE/5ML A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML A062558 001 Mar 15, 1985

WYAMYCIN E

WYETH AYERST EQ 200MG BASE/5ML A062123 002

EQ 400MG BASE/5ML A062123 001

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

ROSS LABS EQ 100MG BASE/2.5ML A062305 002

TABLET; ORAL

E.E.S. 400

ARBOR PHARMS LLC EQ 400MG BASE A061905 001

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

TABLET, CHEWABLE; ORAL

E.E.S.

ARBOR PHARMS INC EQ 200MG BASE N050297 002

ERYPED

ARBOR PHARMS INC EQ 200MG BASE N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYZOLE

ALRA EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML; EQ 600MG BASE/5ML N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 1GM BASE/VIAL N050370 003

EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

HOSPIRA EQ 1GM BASE/VIAL N050182 003

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

EQ 500MG BASE/VIAL N050182 002

ERYTHROMYCIN

ELKINS SINN EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

BAXTER HLTHCARE EQ 1GM BASE/VIAL A062993 002 May 09, 1989

EQ 500MG BASE/VIAL A062993 001 May 09, 1989

TEVA PARENTERAL EQ 1GM BASE/VIAL A063253 002 Jul 30, 1993

EQ 500MG BASE/VIAL A063253 001 Jul 30, 1993

DISCONTINUED DRUG PRODUCT LIST

6-128 (of 337)

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL

EQ 250MG BASE

A061304 001

EQ 250MG BASE

A061887 001

ERYPAR

PARKE DAVIS

EQ 250MG BASE

A062032 001

EQ 500MG BASE

A062032 002

WARNER CHILCOTT

EQ 250MG BASE

A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC

EQ 125MG BASE

A060359 002

EQ 500MG BASE

A060359 003

ERYTHROMYCIN STEARATE

ANI PHARMS INC

EQ 250MG BASE

A061461 001

EQ 250MG BASE

A061591 001

EQ 500MG BASE

A061461 002

EQ 500MG BASE

A063179 001

May 15, 1990

LEDERLE

EQ 250MG BASE

A062089 001

EQ 500MG BASE

A062089 002

MYLAN

EQ 250MG BASE

A061505 001

EQ 500MG BASE

A061505 002

PUREPAC PHARM

EQ 250MG BASE

A061743 001

WATSON LABS

EQ 250MG BASE

A062121 002

EQ 500MG BASE

A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB

EQ 250MG BASE

A061605 001

ETHRIL 500

BRISTOL MYERS SQUIBB

EQ 500MG BASE

A061605 002

PFIZER-E

PFIZER

EQ 250MG BASE

A061791 001

EQ 500MG BASE

A061791 002

WYAMYCIN S

WYETH AYERST

EQ 250MG BASE

A061675 001

EQ 500MG BASE

A061675 002

ESCITALOPRAM OXALATE

CAPSULE; ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC

EQ 5MG BASE

A077660 001

Jul 31, 2007

EQ 10MG BASE

A077660 002

Jul 31, 2007

EQ 20MG BASE

A077660 003

Jul 31, 2007

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

BAXTER HLTHCARE

10MG/ML

N019386 003

Aug 15, 1988

20MG/ML

N019386 007

May 28, 2003

ESTAZOLAM

TABLET; ORAL

PROSOM

ABBOTT

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019080 001

Dec 26, 1990

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019080 002

Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE

0.025MG/24HR

N020847 001

Aug 04, 1998

0.0375MG/24HR

N020847 002

Aug 04, 1998

0.05MG/24HR

N020847 003

Aug 04, 1998

0.075MG/24HR

N020847 004

Aug 04, 1998

0.1MG/24HR

N020847 005

Aug 04, 1998

ESTRADIOL

ORTHO MCNEIL PHARM

0.05MG/24HR

N021048 001

Sep 20, 1999

0.075MG/24HR

N021048 002

Sep 20, 1999

0.1MG/24HR

N021048 003

Sep 20, 1999

FEMPATCH

PARKE DAVIS

0.025MG/24HR

N020417 001

Dec 03, 1996

DISCONTINUED DRUG PRODUCT LIST

6-129 (of 337)

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

VIVELLE

NOVARTIS

0.025MG/24HR
0.0375MG/24HR
0.075MG/24HRN020323 005 Aug 16, 2000
N020323 001 Oct 28, 1994
N020323 003 Oct 28, 1994

GEL;TOPICAL

ESTROGEL

ASCEND THERAPS US

0.06%

N021166 001 Feb 09, 2004

TABLET;ORAL

ESTRACE

BRISTOL MYERS SQUIBB

0.5MG
1MG
2MGA081295 001 Jun 30, 1993
A084499 001
A084500 001

ESTRADIOL

HERITAGE PHARMS INC

0.5MG
1MG
2MGA040275 001 Dec 29, 1998
A040275 002 Dec 29, 1998
A040275 003 Dec 29, 1998

LANNETT HOLDINGS INC

0.5MG
1MG
2MGA040138 001 Jan 30, 1998
A040138 002 Jan 30, 1998
A040138 003 Jan 30, 1998

GYNODIOL

DURAMED PHARMS BARR

0.5MG
1MG
1.5MG
2MGA040212 001 Dec 29, 1997
A040212 002 Dec 29, 1997
A040212 003 Dec 29, 1997
A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC

0.5MG
1MG
2MGA040312 001 Nov 19, 1999
A040312 002 Nov 19, 1999
A040312 003 Nov 19, 1999

TABLET;VAGINAL

VAGIFEM

NOVO NORDISK INC

25MCG

N020908 001 Mar 26, 1999

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

PHARMACIA AND UPJOHN

1MG/ML
3MG/MLA085470 001
A085470 002

ESTRADIOL CYPIONATE

WATSON LABS

5MG/ML

A085620 001

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE;INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN 5MG/0.5ML;25MG/0.5ML

N020874 001 Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN

2MG/ML;50MG/ML

N017968 001

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS

2MG/ML;50MG/ML

A085603 001 Mar 13, 1986

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

SANDOZ

10MG/ML
20MG/ML
40MG/MLA040628 001 Oct 04, 2007
A040628 002 Oct 04, 2007
A040628 003 Oct 04, 2007

WATSON LABS

10MG/ML

A083546 001

40MG/ML

A083714 001

WATSON LABS INC

20MG/ML

A083547 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DITATE-DS

SAVAGE LABS

8MG/ML;180MG/ML

A086423 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS

4MG/ML;90MG/ML

A085865 001

8MG/ML;180MG/ML

A085860 001

DISCONTINUED DRUG PRODUCT LIST

6-130 (of 337)

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

PREFEST

TEVA WOMENS

1MG, 1MG; 1MG, 1MG; N/A, 0.09MG **Federal
Register determination that product was
not discontinued or withdrawn for
safety or efficacy reasons**

N021040 001 Oct 22, 1999

ESTROGENS, CONJUGATED

TABLET; ORAL

PREMARIN

WYETH PHARMS INC

2.5MG

N004782 002

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM; VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS

0.625MG/GM

N021788 001 Nov 28, 2008

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE (PREMARIN; CYCRIN 14/14)

WYETH PHARMS INC

0.625MG; 0.625MG; N/A, 5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN; CYCRIN)

WYETH PHARMS INC

0.625MG; 0.625MG; 2.5MG; 2.5MG

N020303 001 Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET; ORAL

MILPREM-200

MEDPOINTE PHARM HLC

0.45MG; 200MG

N011045 002

MILPREM-400

MEDPOINTE PHARM HLC

0.45MG; 400MG

N011045 001

PMB 200

WYETH AYERST

0.45MG; 200MG

N010971 005

PMB 400

WYETH AYERST

0.45MG; 400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET; ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB

0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM

0.625MG

A083414 001

1.25MG

A083765 001

2.5MG

A085907 001

SANDOZ

1.25MG

A085302 001

ESTRATAB

SOLVAY

0.3MG

A086715 001

0.625MG

A083209 001

1.25MG

A083856 001

2.5MG

A083857 001

EVEX

ROCHE PALO

0.625MG

A084215 001

1.25MG

A083376 002

FEMOGEN

PVT FORM

0.625MG

A085076 001

1.25MG

A085008 001

2.5MG

A085007 001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST

2MG/ML

A083488 001

ESTRONE

WATSON LABS

2MG/ML

A083397 001

5MG/ML

A085239 001

NATURAL ESTROGENIC SUBSTANCE-ESTRONE

WATSON LABS

2MG/ML

A085237 001 Nov 23, 1982

THEELIN

PARKEDALE

1MG/ML

N003977 001

2MG/ML

N003977 002

5MG/ML

N003977 003

DISCONTINUED DRUG PRODUCT LIST

6-131 (of 337)

ESTROPIPATECREAM; VAGINAL
OGEN

PHARMACIA AND UPJOHN 1.5MG/GM

A084710 001

TABLET; ORAL

ESTROPIPATE

DURAMED PHARMS BARR 0.75MG

A040296 001 Nov 01, 1999

1.5MG

A040296 002 Nov 01, 1999

3MG

A040296 003 Nov 01, 1999

MYLAN

3MG

A040359 003 Aug 26, 1999

WATSON LABS

6MG

A081216 001 Sep 23, 1993

ORTHO-EST

SUN PHARM INDS INC 0.75MG

A089567 001 Feb 27, 1991

1.5MG

A089582 001 Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

WOCKHARDT LTD 1MG

A091165 001 Jul 14, 2011

2MG

A091165 002 Jul 14, 2011

3MG

A091165 003 Jul 14, 2011

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

ATON 50MG

N016092 002

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

VERSAPHARM INC 100MG

A075095 001 Nov 30, 1999

400MG

A075095 002 Nov 30, 1999

MYAMBUTOL

STI PHARMA LLC 200MG

N016320 002

500MG

N016320 004

ETHCHLORVYNOL

CAPSULE; ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS 100MG

A084463 001

200MG

A084463 002

500MG

A084463 003

750MG

A084463 004

PLACIDYL

ABBVIE 100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATE

CAPSULE; ORAL

VALMID

DISTA 500MG

N009750 001

ETHINYL ESTRADIOL

TABLET; ORAL

ESTINYL

SCHERING 0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN 0.05MG

N016649 001

LYNORAL

ORGANON USA INC 0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC 0.035MG; 1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC 0.05MG; 1MG

N016927 001

DISCONTINUED DRUG PRODUCT LIST

6-132 (of 337)

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

ZOVIA 1/35E-21

WATSON LABS

0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001 Dec 30, 1991

TABLET; ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG

N016936 001

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET; ORAL-28

NORQUEST FE

GD SEARLE LLC

0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET; ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS

0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS

0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LYBREL

WYETH PHARMS INC

0.02MG;0.09MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM

0.05MG;0.25MG

N020946 001 Sep 01, 1998

TABLET; ORAL-21

ALESSE

WYETH PHARMS

0.02MG;0.1MG **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR

0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1
25MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR

0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVILITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS

0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM

0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR

0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

WYETH PHARMS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1
25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019192 001 Nov 01, 1984

TRIVORA-21

WATSON LABS

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1
25MG

A074538 001 Dec 18, 1997

TABLET; ORAL-28

ALESSE

WYETH PHARMS

0.02MG;0.1MG

N020683 002 Mar 27, 1997

LEVILITE

BAYER HLTHCARE

0.02MG;0.1MG

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR

0.02MG;0.1MG

A075862 002 Apr 29, 2003

TRIPHASIL-28

WYETH PHARMS INC

0.03MG;0.03MG;0.04MG;0.05MG;0.075MG;0.1
25MG

N019190 001 Nov 01, 1984

DISCONTINUED DRUG PRODUCT LIST

6-133 (of 337)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR

0.035MG; 0.4MG

A076198 001 Apr 22, 2004

BREVICON 21-DAY

WATSON LABS

0.035MG; 0.5MG

N017566 001

GENCEPT 10/11-21

BARR

0.035MG; 0.035MG; 0.5MG; 1MG

A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM

0.035MG; 0.5MG

N017488 001

N.E.E. 1/35 21

LPI

0.035MG; 1MG

A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071545 001 Feb 09, 1989

NORETHIN 1/35E-21

WATSON LABS

0.035MG; 1MG

A071480 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG; 0.4MG

A078379 001 Feb 23, 2010

0.035MG; 0.5MG

A070684 001 Jan 29, 1987

0.035MG; 1MG

A070685 001 Jan 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS

0.035MG; 0.035MG; 0.5MG; 1MG

A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS

0.035MG; 0.035MG; 0.5MG; 1MG

A071041 001 Sep 24, 1991

NORTREL 0.5/35-21

BARR

0.035MG; 0.5MG

A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM

0.035MG; 1MG

N017489 002

ORTHO-NOVUM 10/11-21

ORTHO MCNEIL JANSSEN

0.035MG; 0.035MG; 0.5MG; 1MG

N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM

0.035MG; 0.035MG; 0.5MG; 1MG

N019004 001 Apr 04, 1984

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS

0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG

N018985 001 Apr 04, 1984

OVCON-35

WARNER CHILCOTT

0.035MG; 0.4MG

N018127 001

OVCON-50

WARNER CHILCOTT

0.05MG; 1MG

N018128 001

TRI-NORINYL 21-DAY

WATSON LABS

0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.5MG; 1MG

N018977 001 Apr 13, 1984

TABLET; ORAL-28

GENCEPT 10/11-28

BARR

0.035MG; 0.035MG; 0.5MG; 1MG

A072697 001 Feb 28, 1992

N.E.E. 1/35 28

LPI

0.035MG; 1MG

A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM

0.035MG; 1MG

A071546 001 Feb 09, 1989

NORETHIN 1/35E-28

WATSON LABS

0.035MG; 1MG

A071481 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS

0.035MG; 0.035MG; 0.035MG; 0.5MG; 0.75MG; 1MG

A076393 001 Feb 04, 2010

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS

0.035MG; 0.035MG; 0.035MG; 0.035MG; 0.5MG; 1MG; 0.5MG, 1MG

A071042 001 Sep 24, 1991

ORTHO-NOVUM 10/11-28

ORTHO MCNEIL JANSSEN

0.035MG; 0.035MG; 0.5MG; 1MG

N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM

0.035MG; 0.035MG; 0.5MG; 1MG

N019004 002 Apr 04, 1984

OVCON-50

WARNER CHILCOTT LLC

0.05MG; 1MG

N017576 001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

WARNER CHILCOTT

0.02MG; 1MG

N204426 001 Apr 19, 2013

TABLET; ORAL

FEMHRT

WARNER CHILCOTT LLC

0.005MG; 1MG

N021065 002 Oct 15, 1999

TABLET; ORAL-21

ESTROSTEP 21

WARNER CHILCOTT LLC

0.02MG; 0.035MG; 0.03MG; 1MG; 1MG; 1MG

N020130 001 Oct 09, 1996

DISCONTINUED DRUG PRODUCT LIST

6-134 (of 337)

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

NORLESTRIN 21 1/50

PARKE DAVIS

0.05MG; 1MG

N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS

0.05MG; 2.5MG

N016852 001

TABLET; ORAL-28

NORLESTRIN 28 1/50

PARKE DAVIS

0.05MG; 1MG

N016723 001

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-21

ORTHO CYCLEN-21

JANSSEN PHARMS

0.035MG; 0.25MG

N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

JANSSEN PHARMS

0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG;
0.25MG

N019697 002 Jul 03, 1992

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

WATSON LABS

0.025MG; 0.025MG; 0.025MG; 0.18MG; 0.215MG;
0.25MG

A090479 001 Mar 09, 2011

0.035MG; 0.035MG; 0.035MG; 0.18MG; 0.215MG;
0.25MG

A076626 001 Aug 17, 2006

0.035MG; 0.25MG

A076627 001 Aug 17, 2006

TRI LO SPRINTC

BARR LABS INC

0.025MG; 0.025MG; 0.025MG; 0.18MG; 0.215MG;
0.25MG

A076784 001 Jun 29, 2009

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

WYETH PHARMS INC

0.03MG; 0.3MG

N017612 001

LOW-OGESTREL-21

WATSON LABS

0.03MG; 0.3MG

A075288 001 Jul 28, 1999

OGESTREL 0.5/50-21

WATSON LABS

0.05MG; 0.5MG

A075406 001 Dec 15, 1999

OVRAL

WYETH PHARMS

0.05MG; 0.5MG

N016672 001

TABLET; ORAL-28

LOW-OGESTREL-28

WATSON LABS

0.03MG; 0.3MG

A075288 002 Jul 28, 1999

OVRAL-28

WYETH PHARMS

0.05MG; 0.5MG

N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS

10MG

N009078 003

50MG

N009078 006

100MG

N009078 008

ETHOTOIN

TABLET; ORAL

PEGANONE

RECORDATI RARE

500MG

N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN

62.5MG

N011047 002

125MG

N011047 001

ETHAMIDE

ALLERGAN

125MG

N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC

2MG/5ML

N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC

2MG

N014005 002

DISCONTINUED DRUG PRODUCT LIST

6-135 (of 337)

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC

1MG; 0.1MG

N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC

1MG; 0.1MG

N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC

1MG; 0.1MG

N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

ASTRAZENECA

0.5%

N017751 003

1%

N017751 005

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AAIPHARMA LLC

300MG

A074929 001 Jan 30, 1998

ANI PHARMS INC

200MG

A074899 001 Jul 08, 1997

300MG

A074899 002 Jul 08, 1997

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074840 001 Aug 29, 1997

200MG

A074942 001 Sep 30, 1997

300MG

A074840 002 Aug 29, 1997

300MG

A074942 002 Sep 30, 1997

VINTAGE PHARMS LLC

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

WATSON LABS

200MG

A074844 001 Dec 23, 1997

300MG

A074844 002 Dec 23, 1997

LODINE

WYETH PHARMS INC

200MG

N018922 002 Jan 31, 1991

300MG

N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

AAIPHARMA LLC

400MG

A074927 001 Oct 30, 1997

IVAX SUB TEVA PHARMS

400MG

A074883 001 Feb 28, 1997

500MG

A074883 002 Nov 20, 1998

MYLAN

400MG

A075012 001 Sep 30, 1998

500MG

A075012 002 Sep 30, 1998

PROSAM LABS

400MG

A074819 001 Feb 28, 1997

500MG

A074819 002 Apr 28, 1998

RANBAXY LABS LTD

400MG

A075226 001 Nov 24, 1998

500MG

A075226 002 Nov 24, 1998

SANDOZ

400MG

A074839 001 Jul 11, 1997

400MG

A074846 001 Feb 28, 1997

TEVA

400MG

A074847 001 Apr 23, 1999

500MG

A074847 002 Apr 23, 1999

VINTAGE PHARMS LLC

400MG

A074841 001 Jun 27, 1997

WATSON LABS

400MG

A074892 001 Apr 16, 1997

400MG

A075069 001 Apr 16, 1998

500MG

A074892 002 Oct 29, 1998

LODINE

WYETH PHARMS INC

400MG

N018922 004 Jul 29, 1993

500MG

N018922 005 Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH

400MG

A075696 001 Jul 31, 2000

SANDOZ

400MG

A075943 001 Jul 26, 2002

500MG

A075943 002 Jul 26, 2002

600MG

A075943 003 Jul 26, 2002

WATSON LABS FLORIDA

400MG

A075829 001 Nov 30, 2001

500MG

A075829 002 Nov 30, 2001

DISCONTINUED DRUG PRODUCT LIST

6-136 (of 337)

ETODOLAC

TABLET, EXTENDED RELEASE; ORAL

LODINE XL

WYETH PHARMS INC

400MG

N020584 001 Oct 25, 1996

500MG

N020584 003 Jan 20, 1998

600MG

N020584 002 Oct 25, 1996

ETOPOSIDE

CAPSULE; ORAL

VEPESID

DAVA PHARMS INC

50MG

N019557 001 Dec 30, 1986

100MG

N019557 002 Dec 30, 1986

INJECTABLE; INJECTION

ETOPOSIDE

HOSPIRA

20MG/ML

A074320 001 Aug 30, 1995

20MG/ML

A074351 001 Aug 30, 1995

PHARMACHEMIE BV

20MG/ML

A074227 001 Feb 22, 1996

PIERRE FABRE

20MG/ML

A074813 001 Jul 09, 1997

TEVA PARENTERAL

20MG/ML

A074510 001 Jun 29, 1995

TEVA PHARMS USA

20MG/ML

A074284 001 Feb 10, 1994

WATSON LABS

20MG/ML

A074228 001 Oct 15, 1996

WATSON LABS INC

20MG/ML

A074968 001 Jan 09, 1998

TOPOSAR

TEVA PARENTERAL

20MG/ML

A074166 001 Feb 27, 1995

VEPESID

CORDEN PHARMA

20MG/ML

N018768 001 Nov 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB

EQ 1GM BASE/VIAL

N020906 002 Feb 27, 1998

EQ 500MG BASE/VIAL

N020906 001 Feb 27, 1998

ETRETINATE

CAPSULE; ORAL

TEGISON

ROCHE

10MG

N019369 001 Sep 30, 1986

25MG

N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE; INJECTION

EVANS BLUE

PARKE DAVIS

0.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N008041 001

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

APOTEX INC

10MG/ML

A075942 001 Aug 02, 2002

APOTHECON

10MG/ML

A075707 001 Apr 16, 2001

HIKMA MAPLE

10MG/ML

A075799 001 Apr 30, 2002

HOSPIRA

10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075870 001 Nov 23, 2001

10MG/ML

A075905 001 Nov 23, 2001

FAMOTIDINE PRESERVATIVE FREE

APOTEX INC

10MG/ML

A076324 001 Nov 27, 2002

APOTHECON

10MG/ML

A075708 001 Apr 16, 2001

HIKMA MAPLE

10MG/ML

A075789 001 Apr 30, 2002

HOSPIRA

10MG/ML

A075669 001 Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

APOTEX INC

10MG/ML

A076322 001 Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE

0.4MG/ML

A075729 001 Dec 17, 2001

PEPCID

MERCK

10MG/ML

N019510 001 Nov 04, 1986

PEPCID PRESERVATIVE FREE

MERCK

10MG/ML

N019510 004 Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

MERCK SHARP DOHME

0.4MG/ML

N020249 001 Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH

20MG

A075650 001 Sep 14, 2001

40MG

A075650 002 Sep 14, 2001

DISCONTINUED DRUG PRODUCT LIST

6-137 (of 337)

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

APOTEX	10MG	A075610	001	Mar 12, 2002
MUTUAL PHARM	20MG	A075639	002	Dec 12, 2001
	40MG	A075639	001	Dec 12, 2001
MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
	40MG	A075457	002	Apr 18, 2001
SANDOZ	10MG	A076101	001	Oct 21, 2002
	20MG	A075302	001	Apr 16, 2001
	20MG	A075607	001	May 10, 2001
	20MG	A075793	001	Apr 16, 2001
	40MG	A075302	002	Apr 16, 2001
	40MG	A075607	002	May 10, 2001
	40MG	A075793	002	Apr 16, 2001
WATSON LABS	10MG	A075404	001	Nov 28, 2001
	20MG	A075062	002	Apr 16, 2001
	40MG	A075062	001	Apr 16, 2001

TABLET, CHEWABLE; ORAL

PEPCID AC

MCNEIL CONS	10MG	N020801	001	Sep 24, 1998
-------------	------	---------	-----	--------------

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC	20MG	N021712	001	Sep 24, 2004
	40MG	N021712	002	Sep 24, 2004
PEPCID RPD				
MERCK	20MG	N020752	001	May 28, 1998
	40MG	N020752	002	May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012
	5MG	A091484	002	Aug 15, 2012
	10MG	A091484	003	Aug 15, 2012

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

LUPIN ATLANTIS	87MG	N021695	002	Nov 30, 2004
----------------	------	---------	-----	--------------

LIPIDIL

ABBVIE	100MG	N019304	001	Dec 31, 1993
--------	-------	---------	-----	--------------

LIPOFEN

CIPHER PHARMS INC	100MG	N021612	002	Jan 11, 2006
-------------------	-------	---------	-----	--------------

TRICOR (MICRONIZED)

ABBVIE	67MG	N019304	002	Feb 09, 1998
	134MG	N019304	003	Jun 30, 1999
	200MG	N019304	004	Jun 30, 1999

TABLET; ORAL

FENOFIBRATE

MYLAN	107MG	A076520	002	Dec 29, 2005
-------	-------	---------	-----	--------------

TRICOR

ABBOTT	54MG	N021203	001	Sep 04, 2001
	160MG	N021203	003	Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG	50MG	N021350	001	May 07, 2005
---------------	------	---------	-----	--------------

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656	001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826	001	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307	001	Aug 22, 1988
	EQ 300MG BASE	A072308	001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355	001	Aug 17, 1988
	EQ 300MG BASE	A072356	001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437	001	Aug 22, 1988
	EQ 300MG BASE	A072438	001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214	001	Aug 17, 1988
	EQ 300MG BASE	A071738	001	Aug 17, 1988

DISCONTINUED DRUG PRODUCT LIST

6-138 (of 337)

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

SANDOZ

EQ 200MG BASE

A072394 001 Oct 17, 1988

EQ 300MG BASE

A072395 001 Oct 17, 1988

WARNER CHILCOTT

EQ 200MG BASE

A072946 001 Apr 30, 1991

EQ 300MG BASE

A072472 001 Apr 30, 1991

WATSON LABS

EQ 200MG BASE

A072294 001 Aug 17, 1988

EQ 200MG BASE

A072981 001 Aug 19, 1991

EQ 300MG BASE

A072293 001 Aug 17, 1988

EQ 300MG BASE

A072982 001 Aug 19, 1991

NALFON

XSPIRE

EQ 300MG BASE

N017604 002

TABLET;ORAL

FENOPROFEN CALCIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A072274 001 May 02, 1988

AM THERAP

EQ 600MG BASE

A072309 001 Aug 17, 1988

DAVA PHARMS INC

EQ 600MG BASE

A072326 001 Aug 17, 1988

HALSEY

EQ 600MG BASE

A072357 001 Aug 17, 1988

IVAX SUB TEVA PHARMS

EQ 600MG BASE

A072557 001 Aug 29, 1988

MUTUAL PHARM

EQ 600MG BASE

A072902 001 Dec 21, 1990

PAR PHARM

EQ 600MG BASE

A072429 001 Aug 17, 1988

QUANTUM PHARMICS

EQ 600MG BASE

A072194 001 Aug 17, 1988

SANDOZ

EQ 600MG BASE

A072396 001 Oct 17, 1988

USL PHARMA

EQ 600MG BASE

A072362 001 Aug 17, 1988

WATSON LABS

EQ 600MG BASE

A072165 001 Aug 17, 1988

EQ 600MG BASE

A072407 001 Aug 17, 1988

EQ 600MG BASE

A072602 001 Oct 11, 1988

NALFON

DISTA

EQ 600MG BASE

N017710 001

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

NOVEN

100MCG/HR

A077775 004 Oct 16, 2009

FENTANYL-25

NOVEN

25MCG/HR

A077775 001 Oct 16, 2009

FENTANYL-50

NOVEN

50MCG/HR

A077775 002 Oct 16, 2009

FENTANYL-75

NOVEN

75MCG/HR

A077775 003 Oct 16, 2009

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

MEDA PHARMS

EQ 0.2MG BASE

N022266 001 Jul 16, 2009

EQ 0.4MG BASE

N022266 002 Jul 16, 2009

EQ 0.6MG BASE

N022266 003 Jul 16, 2009

EQ 0.8MG BASE

N022266 004 Jul 16, 2009

EQ 1.2MG BASE

N022266 005 Jul 16, 2009

INJECTABLE;INJECTION

FENTANYL CITRATE

ABBOTT

EQ 0.05MG BASE/ML

A070636 001 Apr 30, 1990

EQ 0.05MG BASE/ML

A070637 001 Apr 30, 1990

WATSON LABS

EQ 0.05MG BASE/ML

A073488 001 Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

WATSON LABS INC

EQ 0.05MG BASE/ML

A074917 001 Feb 03, 1998

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

WATSON LABS

EQ 0.1MG BASE

A079075 001 Jan 07, 2011

EQ 0.2MG BASE

A079075 002 Jan 07, 2011

EQ 0.4MG BASE

A079075 003 Jan 07, 2011

EQ 0.6MG BASE

A079075 004 Jan 07, 2011

EQ 0.8MG BASE

A079075 005 Jan 07, 2011

FENTORA

CEPHALON

EQ 0.3MG BASE

N021947 006 Mar 02, 2007

TROCHE/LOZENGE;ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

DISCONTINUED DRUG PRODUCT LIST

6-139 (of 337)

FENTANYL HYDROCHLORIDESYSTEM; IONTOPHORESIS, TRANSDERMAL
IONSYS

INCLINE THERAP 10.8MCG

N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION; ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERROUS CITRATE, FE-59

INJECTABLE; INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE; ORAL

FOLVRON

LEDERLE

182MG; 0.33MG

N006012 003

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

FERUMOXIL

SUSPENSION; ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

SANOFI AVENTIS US

60MG

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001 Jul 13, 2005

FIBRINOGEN, I-125

INJECTABLE; INJECTION

IBRIN

GE HEALTHCARE

154uCi/VIAL

N017879 001

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

ABBOTT

140uCi/ML

N017787 001

FINASTERIDE

TABLET; ORAL

FINASTERIDE

IVAX SUB TEVA PHARMS

5MG

A076340 001 Jun 19, 2006

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

URISPAS

ORTHO MCNEIL JANSSEN

100MG

N016769 001

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

APOTEX INC

50MG

A079164 001 Jul 09, 2009

100MG

A079164 002 Jul 09, 2009

150MG

A079164 003 Jul 09, 2009

SANDOZ

50MG

A076030 001 Oct 28, 2002

100MG

A076030 002 Oct 28, 2002

150MG

A076030 003 Oct 28, 2002

TAMBOCOR

CNTY LINE PHARMS

50MG

N018830 004 Aug 23, 1988

100MG

N018830 001 Oct 31, 1985

150MG

N018830 003 Jun 03, 1988

200MG

N018830 002 Oct 31, 1985

FLOXURIDINE

INJECTABLE; INJECTION

FUDR

HOSPIRA

500MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016929 001

DISCONTINUED DRUG PRODUCT LIST

6-140 (of 337)

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

TARO PHARM INDS	50MG/5ML	A076918 001	Dec 18, 2006
	200MG/5ML	A076918 002	Dec 18, 2006

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617 001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617 002	Jul 29, 2004
TEVA PHARMS	200MG/100ML (2MG/ML)	A076837 001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837 002	Jan 13, 2005

TABLET; ORAL

FLUCONAZOLE

GEDEON RICHTER USA	50MG	A076432 001	Jul 29, 2004
	100MG	A076432 002	Jul 29, 2004
	150MG	A076432 003	Jul 29, 2004
	200MG	A076432 004	Jul 29, 2004
HARRIS PHARM	50MG	A078423 001	Mar 07, 2011
	100MG	A078423 002	Mar 07, 2011
	150MG	A078423 003	Mar 07, 2011
	200MG	A078423 004	Mar 07, 2011
MYLAN PHARMS INC	50MG	A076042 001	Jul 29, 2004
	100MG	A076042 002	Jul 29, 2004
	150MG	A076042 003	Jul 29, 2004
	200MG	A076042 004	Jul 29, 2004
PLIVA	50MG	A076424 001	Jul 29, 2004
	100MG	A076424 002	Jul 29, 2004
	150MG	A076424 003	Jul 29, 2004
	200MG	A076424 004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004
	100MG	A076386 002	Jul 29, 2004
	150MG	A076386 003	Jul 29, 2004
	200MG	A076386 004	Jul 29, 2004
ROXANE	50MG	A076213 001	Jul 29, 2004
	100MG	A076213 002	Jul 29, 2004
	150MG	A076213 003	Jul 29, 2004
	200MG	A076213 004	Jul 29, 2004
SANDOZ	50MG	A076086 001	Jul 29, 2004
	100MG	A076086 002	Jul 29, 2004
	150MG	A076086 003	Jul 29, 2004
	200MG	A076086 004	Jul 29, 2004

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991
--------------	-----------	-------------	--------------

TABLET; ORAL

OFORTA

SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008
-------------------	------	-------------	--------------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F 18

DOWNSTATE CLINCL	4-40mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306 001	Aug 19, 1994
	4-90mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020306 002	Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

WEILL MEDCL COLL	10-100mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021768 001	Aug 05, 2004
------------------	---	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

6-141 (of 337)

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

CITRON PHARMA LLC

0.1MG

N010060 001

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

APOTEX INC

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004

TEVA PHARMS USA

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

ROMAZICON

HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020073 001 Dec 20, 1991

0.5MG/5ML (0.1MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

SPRAY, METERED; NASAL

NASALIDE

IVAX RES

0.025MG/SPRAY

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMADERM

0.01%

A088047 001 Dec 16, 1982

0.025%

A088045 001 Dec 16, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

SYNALAR-HP

MEDIMETRIKS PHARMS

0.2%

N016161 002

GEL; TOPICAL

FLUONID

ALLERGAN HERBERT

0.025%

A087300 001 May 27, 1982

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM

0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR

0.025%

A088507 001 Feb 27, 1984

USL PHARMA

0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.025%

A088172 001 Mar 09, 1983

DISCONTINUED DRUG PRODUCT LIST

6-142 (of 337)

FLUOCINOLONE ACETONIDE

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.01%	A087159	001	Jun 16, 1982
BAUSCH AND LOMB	0.01%	A040059	001	Dec 20, 1993
MORTON GROVE	0.01%	A088312	001	Jan 27, 1984
PHARMADERM	0.01%	A088048	001	Dec 16, 1982
PHARMAFAIR	0.01%	A088449	001	Feb 08, 1984

FLUONID

ALLERGAN HERBERT	0.01%	A087158	001	Mar 17, 1983
------------------	-------	---------	-----	--------------

FLUOTREX

SAVAGE LABS	0.01%	A088171	001	Mar 09, 1983
-------------	-------	---------	-----	--------------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

PERRIGO NEW YORK	0.05%	A071790	001	Jul 13, 1988
TARO	0.05%	A071500	001	Jun 10, 1987

FLUOCINONIDE EMULSIFIED BASE

G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995
------------------	-------	---------	-----	--------------

LIDEX

CNTY LINE PHARMS	0.05%	N016908	002	
------------------	-------	---------	-----	--

LIDEX-E

CNTY LINE PHARMS	0.05%	N016908	003	
------------------	-------	---------	-----	--

GEL; TOPICAL

LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017373	001	
------------------	--	---------	-----	--

OINTMENT; TOPICAL

LIDEX

CNTY LINE PHARMS	0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016909	002	
------------------	--	---------	-----	--

SOLUTION; TOPICAL

FLUOCINONIDE

TARO	0.05%	A072857	001	Aug 02, 1989
TEVA PHARMS	0.05%	A072522	001	Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE; INJECTION

FUNDUSCEIN-25

NOVARTIS	25%	N017869	001	
----------	-----	---------	-----	--

FLUOROMETHOLONE

CREAM; TOPICAL

OXYLONE

PHARMACIA AND UPJOHN	0.025%	N011748	001	
----------------------	--------	---------	-----	--

SUSPENSION/DROPS; OPHTHALMIC

FLUOR-OP

NOVARTIS	0.1%	A070185	001	Feb 27, 1986
----------	------	---------	-----	--------------

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRASONE

ALCON	0.1%; 0.3%	N050628	001	Jul 21, 1989
-------	------------	---------	-----	--------------

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS; OPHTHALMIC

FML-S

ALLERGAN	0.1%; 10%	N019525	001	Sep 29, 1989
----------	-----------	---------	-----	--------------

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN	50MG/ML	A081222	001	Jun 28, 1991
	50MG/ML	N017959	001	
TEVA PARENTERAL	50MG/ML	A040023	001	Oct 18, 1991
	50MG/ML	A081225	001	Aug 28, 1991

FLUOROURACIL

ABIC	50MG/ML	A088929	001	Mar 04, 1986
ABRAXIS PHARM	50MG/ML	A089152	001	Mar 21, 1986
	50MG/ML	A089428	001	Jan 12, 1987
	50MG/ML	A089519	001	Mar 12, 1987

DISCONTINUED DRUG PRODUCT LIST

6-143 (of 337)

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

BEDFORD	50MG/ML	A089508	001	Jan 26, 1988
EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008
FRESENIUS KABI USA	50MG/ML	A040291	001	Mar 24, 1999
	50MG/ML	A040379	001	Nov 15, 2000
MARCHAR	50MG/ML	A087791	001	Jan 18, 1983
SMITH AND NEPHEW	50MG/ML	A088766	001	Dec 28, 1984
	50MG/ML	A088767	001	Dec 28, 1984
	50MG/ML	A089434	001	Mar 26, 1987
SPECTRUM PHARMS	50MG/ML	A087792	001	Oct 13, 1982
VALEANT	500MG/10ML (50MG/ML)	N012209	001	

SOLUTION; TOPICAL

FLUOROPLEX

ELORAC	1%	N016765	001	
--------	----	---------	-----	--

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE

MUTUAL PHARMA	EQ 10MG BASE	A075787	001	Jan 29, 2002
	EQ 20MG BASE	A075787	002	Jan 29, 2002
WATSON LABS	EQ 10MG BASE	A075662	001	Jan 29, 2002
	EQ 20MG BASE	A075662	002	Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

BARR	EQ 40MG BASE	A076251	001	May 18, 2005
CARLSBAD	EQ 10MG BASE	A076022	001	Jan 30, 2002
	EQ 20MG BASE	A076022	002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165	001	Feb 01, 2002
	EQ 20MG BASE	A076165	002	Feb 01, 2002
PAR PHARM	EQ 10MG BASE	A076922	001	Dec 16, 2004
	EQ 20MG BASE	A076922	002	Dec 16, 2004
SANDOZ	EQ 10MG BASE	A075807	001	Jan 29, 2002
	EQ 20MG BASE	A075807	002	Jan 29, 2002
WOCKHARDT LTD	EQ 10MG BASE	A078143	001	Jan 16, 2008
	EQ 20MG BASE	A078143	002	Jan 16, 2008
	EQ 40MG BASE	A078143	003	Jan 16, 2008

PROZAC

ELI LILLY AND CO	EQ 60MG BASE	N018936	004	Jun 15, 1999
------------------	--------------	---------	-----	--------------

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690	001	Jan 31, 2002
APOTEX INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002
HI TECH PHARMA	EQ 20MG BASE/5ML	A075525	001	Jun 27, 2002

PROZAC

LILLY	EQ 20MG BASE/5ML	N020101	001	Apr 24, 1991
-------	------------------	---------	-----	--------------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

BARR	EQ 10MG BASE	A075810	001	Feb 01, 2002
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865	001	Feb 28, 2002
	EQ 40MG BASE	A075865	003	Aug 30, 2004
SANDOZ	EQ 10MG BASE	A076024	001	Jan 29, 2002

PROZAC

LILLY	EQ 10MG BASE	N020974	001	Mar 09, 1999
	EQ 20MG BASE	N020974	002	Mar 09, 1999

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL	10MG	A087196	001	
--------------------	------	---------	-----	--

FLUOXYMESTERONE

VALEANT PHARM INTL	10MG	A088221	001	May 05, 1983
WATSON LABS	2MG	A088260	001	Dec 06, 1983
	5MG	A088265	001	Dec 06, 1983
	10MG	A088309	001	Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN	2MG	N010611	002	
	5MG	N010611	006	
	10MG	N010611	010	

ORA-TESTRYL

BRISTOL MYERS SQUIBB	2MG	N011359	001	
	5MG	N011359	002	

DISCONTINUED DRUG PRODUCT LIST

6-144 (of 337)

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AGILA SPECCLTS 25MG/ML

A075918 001 Aug 17, 2001

HOSPIRA 25MG/ML

A074966 001 Apr 16, 1998

TEVA PARENTERAL 25MG/ML

A074795 001 Sep 10, 1996

PROLIXIN DECANOATE

BRISTOL MYERS SQUIBB 25MG/ML

N016727 001

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON 25MG/ML

N016110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

TEVA PHARMS 5MG/ML

A073058 001 Aug 30, 1991

PERMITIL

SCHERING 5MG/ML

N016008 001

PROLIXIN

APOTHECON 5MG/ML

A070533 001 Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS INC 2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

APOTHECON 2.5MG/5ML

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON 2.5MG/ML

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

WATSON LABS 1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING 0.25MG

N012034 001

2.5MG

N012034 004

5MG

N012034 005

10MG

N012034 006

PROLIXIN

APOTHECON 1MG

N011751 004

2.5MG

N011751 001

5MG

N011751 003

10MG

N011751 002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING 1MG

N012419 004

FLUPREDNISOLONE

TABLET; ORAL

ALPHADROL

PHARMACIA AND UPJOHN 1.5MG

N012259 002

FLURANDRENOLIDE

LOTION; TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05%

A087203 001 Apr 29, 1982

OINTMENT; TOPICAL

CORDRAN

AQUA PHARMS 0.025% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N012806 004

0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N012806 001

DISCONTINUED DRUG PRODUCT LIST

6-145 (of 337)

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT; TOPICAL

CORDRAN-N

LILLY

0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

DALMANE

VALEANT PHARM INTL

15MG

N016721 001

30MG

N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

HIKMA PHARMS LLC

15MG

A071107 001 Dec 08, 1986

30MG

A071108 001 Dec 08, 1986

MUTUAL PHARM

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

PAR PHARM

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

SANDOZ

15MG

A071716 001 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

WATSON LABS

15MG

A071205 001 Nov 25, 1986

15MG

A072368 001 Mar 30, 1989

30MG

A071068 001 Nov 25, 1986

30MG

A072369 001 Mar 30, 1989

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

IVAX SUB TEVA PHARMS

50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

PLIVA

50MG

A074647 001 Apr 01, 1997

100MG

A074647 002 Apr 01, 1997

SANDOZ

50MG

A074448 001 Jul 28, 1995

100MG

A074448 002 Jul 28, 1995

TEVA

50MG

A074405 002 May 24, 1995

100MG

A074405 001 May 24, 1995

THERAGEN

100MG

A074560 002 May 16, 1997

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

SCHERING

125MG

N018554 001 Jan 27, 1989

FLUTAMIDE

SANDOZ

125MG

A075818 001 Sep 18, 2001

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020548 001 Mar 27, 1996

0.11MG/INH

N020548 002 Mar 27, 1996

0.22MG/INH

N020548 003 Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

FOUGERA PHARMS

0.05% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

DISCONTINUED DRUG PRODUCT LIST

6-146 (of 337)

FLUTICASONE PROPIONATE

POWDER; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

IVAX SUB TEVA PHARMS

25MG

A075898 001 Mar 12, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075898 003 Mar 12, 2001

MUTUAL PHARM

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

MYLAN

50MG

A075950 001 Oct 15, 2001

100MG

A075950 002 Oct 15, 2001

SANDOZ

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

SUN PHARM INDS INC

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

WATSON LABS

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

LUVOX

SOLVAY

25MG

N020243 001 Dec 05, 1994

50MG

N020243 002 Dec 05, 1994

100MG

N020243 003 Dec 05, 1994

150MG

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

HIKMA (MAPLE)

5MG/ML

N005897 008

TABLET; ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

IMPAX LABS

1MG

A080686 001

IVAX SUB TEVA PHARMS

1MG

A083000 001

JUBILANT CADISTA

1MG

A040514 001 Jun 14, 2005

LANNETT

1MG

A080816 001

LILLY

1MG

N006135 003

MK LABS

1MG

A083526 001

MUTUAL PHARM

1MG

A040582 001 Jul 18, 2005

NEXGEN PHARMA INC

1MG

A084915 001

PHARMERAL

1MG

A084158 001

PIONEER PHARMS

1MG

A088949 001 Sep 13, 1985

PUREPAC PHARM

1MG

A080784 001

SANDOZ

1MG

A084472 001

TABLICAPS

1MG

A083133 002

UDL

1MG

A088199 001 Mar 29, 1983

USL PHARMA

1MG

A087828 001 May 13, 1982

VALEANT PHARM INTL

1MG

A080903 001

VANGARD

1MG

A088730 001 Mar 23, 1984

VINTAGE PHARMS

1MG

A086296 001

WATSON LABS

1MG

A083141 001

1MG

A085141 002

WHITEWORTH TOWN PLSN

1MG

A080691 002

FOLICET

MISSION PHARMA

1MG

A087438 001

DISCONTINUED DRUG PRODUCT LIST

6-147 (of 337)

FOLIC ACID

TABLET; ORAL

FOLVITE

HIKMA (MAPLE)

1MG

N005897 004

FOLLITROPIN ALFA/BETA

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

FOLLISTIM

ORGANON USA INC

75 IU/VIAL

N020582 001 Sep 29, 1997

150 IU/VIAL

N020582 002 Sep 29, 1997

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

ORGANON USA INC

150 IU/0.18ML

N021211 003 Feb 11, 2004

GONAL-F

EMD SERONO

37.5 IU/VIAL

N020378 003 May 25, 2000

37.5 IU/VIAL

N021765 001 Mar 25, 2004

75 IU/VIAL

N020378 001 Sep 29, 1997

150 IU/VIAL

N020378 002 Sep 29, 1997

150 IU/VIAL

N021765 003 Mar 25, 2004

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

MYLAN INSTITUTIONAL

1.5GM/1.5ML (1GM/ML)

A079033 001 Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE; INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS

6.6MG/ML

N020961 001 Aug 26, 1998

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

NOVARTIS

0.0085MG/INH

N021592 001 Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND

MERCK AND CO INC

EQ 115MG BASE/VIAL

N022023 001 Jan 25, 2008

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

RANBAXY LABS LTD

10MG

A076580 001 Apr 23, 2004

20MG

A076580 002 Apr 23, 2004

40MG

A076580 003 Apr 23, 2004

SANDOZ

10MG

A076188 001 Oct 08, 2004

20MG

A076188 002 Oct 08, 2004

40MG

A076188 003 Oct 08, 2004

WATSON LABS

10MG

A076987 001 Dec 23, 2004

10MG

A077531 001 Aug 31, 2006

20MG

A076987 002 Dec 23, 2004

20MG

A077531 002 Aug 31, 2006

40MG

A076987 003 Dec 23, 2004

40MG

A077531 003 Aug 31, 2006

MONOPRIL

BRISTOL MYERS SQUIBB

10MG

N019915 002 May 16, 1991

20MG

N019915 003 May 16, 1991

40MG

N019915 004 Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

MYLAN

10MG; 12.5MG

A077705 001 Aug 14, 2006

20MG; 12.5MG

A077705 002 Aug 14, 2006

TEVA

10MG; 12.5MG

A076945 001 Jul 05, 2006

20MG; 12.5MG

A076945 002 Jul 05, 2006

WATSON LABS

10MG; 12.5MG

A077144 001 Aug 16, 2005

20MG; 12.5MG

A077144 002 Aug 16, 2005

MONOPRIL-HCT

BRISTOL MYERS SQUIBB

10MG; 12.5MG

N020286 002 Nov 30, 1994

20MG; 12.5MG

N020286 001 Nov 30, 1994

DISCONTINUED DRUG PRODUCT LIST

6-148 (of 337)

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

APOTEX INC

EQ 50MG PHENYTOIN NA/ML

A078126 001 Aug 06, 2007

TEVA PHARMS USA

EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC

1050MG/30ML (35MG/ML)

N022244 001 Dec 12, 2008

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001 Jul 30, 1982

10MG/ML

N019036 001 Aug 13, 1984

ASTRAZENECA

10MG/ML

A070014 001 Sep 09, 1985

10MG/ML

A070095 001 Sep 09, 1985

10MG/ML

A070096 001 Sep 09, 1985

HIKMA MAPLE

10MG/ML

A071439 001 Sep 14, 1990

10MG/ML

N018267 001

HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987

10MG/ML

A072080 001 Aug 13, 1991

10MG/ML

A074337 001 Oct 31, 1994

INTL MEDICATION

10MG/ML

N018025 001

MARSAM PHARMS LLC

10MG/ML

A074017 001 Jun 30, 1994

ORGANON USA INC

10MG/ML

A070017 001 Dec 15, 1986

SMITH AND NEPHEW

10MG/ML

A070023 001 Feb 05, 1986

10MG/ML

A070078 001 Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001 Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001 Sep 22, 1986

10MG/ML

A070604 001 Jan 02, 1987

WYETH AYERST

10MG/ML

N018670 001 Jul 20, 1982

LASIX

SANOFI AVENTIS US

10MG/ML

N016363 001

SOLUTION; ORAL

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

DAVA PHARMS INC

20MG

N018415 001 Jul 27, 1982

40MG

N018415 002 Jul 27, 1982

80MG

N018415 003 Nov 26, 1984

INTL MEDICATION

20MG

N018753 001 Feb 28, 1984

40MG

N018753 002 Feb 28, 1984

KALAPHARM

20MG

N018868 001 Jun 28, 1983

40MG

N018868 002 Jun 28, 1983

MUTUAL PHARM

20MG

A070043 001 Sep 26, 1985

40MG

N018790 001 Nov 29, 1983

80MG

A070100 001 Jan 26, 1988

SANDOZ

40MG

N018750 002 Jul 30, 1984

SUPERPHARM

20MG

N018370 002 Jun 26, 1984

40MG

N018370 001 Feb 10, 1983

WARNER CHILCOTT

20MG

N018419 001 Jan 31, 1983

40MG

N018419 002 Jan 31, 1983

80MG

N018419 003 Nov 13, 1984

WATSON LABS

20MG

A070412 001 Feb 26, 1986

20MG

A070449 001 Nov 22, 1985

20MG

A071379 001 Jan 02, 1987

20MG

N018369 001 May 14, 1982

40MG

A070413 001 Feb 26, 1986

40MG

A070450 001 Nov 22, 1985

40MG

N018369 002 May 14, 1982

80MG

A070528 001 Jan 07, 1986

80MG

A071594 001 Feb 09, 1988

DISCONTINUED DRUG PRODUCT LIST

6-149 (of 337)

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

IVAX SUB TEVA PHARMS	100MG	A075477 001	Mar 23, 2005
	300MG	A075477 002	Mar 23, 2005
	400MG	A075477 003	Mar 23, 2005
MUTUAL PHARM	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

TABLET; ORAL

GABAPENTIN

RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	600MG	A076877 001	Jul 06, 2006
	800MG	A076120 002	Jan 27, 2006
	800MG	A076877 002	Jul 06, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007
---------------	-------------------------	-------------	--------------

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

ACTAVIS ELIZABETH	EQ 4MG BASE	A077585 001	Sep 15, 2009
	EQ 8MG BASE	A077585 002	Sep 15, 2009
	EQ 12MG BASE	A077585 003	Sep 15, 2009
YABAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
	EQ 8MG BASE	A077604 002	Feb 06, 2009
	EQ 12MG BASE	A077604 003	Feb 06, 2009

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK	20MG/ML	N007842 001	
	100MG/ML	N007842 002	

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE	1mCi/ML	N017700 001	
NEOSCAN			
GE HEALTHCARE	2mCi/ML	N017655 001	

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE	25MG/ML	N019961 002	Jan 17, 1991
-------------------	---------	-------------	--------------

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

ROCHE PALO	250MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 001	Dec 22, 1994
	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020460 002	Dec 12, 1997

GANCICLOVIR

RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003
	500MG	A076457 002	Jun 27, 2003

DISCONTINUED DRUG PRODUCT LIST

6-150 (of 337)

GANCICLOVIR

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB

4.5MG

N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

EUROHLTH INTL

EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMFIBROZIL

CAPSULE; ORAL

GEMFIBROZIL

MYLAN

300MG

A073466 001 Jan 25, 1993

PUREPAC PHARM

300MG

A072929 001 Jan 29, 1993

LOPID

PFIZER PHARMS

200MG

N018422 001

300MG

N018422 002

TABLET; ORAL

GEMFIBROZIL

MYLAN

600MG

A074452 001 Feb 16, 1995

PUREPAC PHARM

600MG

A074360 001 Aug 31, 1994

SANDOZ

600MG

A074615 001 Sep 29, 1995

WATSON LABS

600MG

A074156 001 Oct 24, 1994

600MG

A074442 001 Apr 28, 1995

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION

MYLOTARG

WYETH PHARMS INC

5MG/VIAL

N021174 001 May 17, 2000

GENTAMICIN SULFATE

CREAM; TOPICAL

GARAMYCIN

SCHERING

EQ 0.1% BASE

A060462 001

GENTAFAIR

PHARMAFAIR

EQ 0.1% BASE

A062458 001 Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS

EQ 0.1% BASE

A062471 001 Sep 27, 1983

G AND W LABS INC

EQ 0.1% BASE

A064056 001 Apr 29, 1994

PHARMADERM

EQ 1MG BASE/GM

A062530 001 Jul 05, 1984

INJECTABLE; INJECTION

APOGEN

KING PHARMS

EQ 10MG BASE/ML

A062289 001

EQ 40MG BASE/ML

A062289 002

BRISTAGEN

BRISTOL

EQ 40MG BASE/ML

A062288 001

GARAMYCIN

SCHERING

EQ 1MG BASE/ML

A061716 002

EQ 10MG BASE/ML

A061739 001

EQ 40MG BASE/ML

A061716 001

GENTAFAIR

PHARMAFAIR

EQ 40MG BASE/ML

A062493 001 Aug 28, 1985

GENTAMICIN

INTL MEDICATION

EQ 1MG BASE/ML

A062325 003 Jun 23, 1982

EQ 40MG BASE/ML

A062325 001

EQ 100MG BASE/100ML

A062325 004 Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT

EQ 1.2MG BASE/ML

A062413 001 Aug 11, 1983

EQ 1.4MG BASE/ML

A062413 002 Aug 11, 1983

EQ 1.6MG BASE/ML

A062413 003 Aug 11, 1983

EQ 1.8MG BASE/ML

A062413 004 Aug 11, 1983

EQ 2MG BASE/ML

A062413 005 Aug 11, 1983

EQ 60MG BASE/100ML

A062413 006 Aug 11, 1983

EQ 70MG BASE/100ML

A062413 007 Aug 11, 1983

DISCONTINUED DRUG PRODUCT LIST

6-151 (of 337)

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HIKMA MAPLE	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
KALAPHARM	EQ 40MG BASE/ML	A062354	001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340	001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507	001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507	002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149	001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106	002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318	002	
	EQ 40MG BASE/ML	A062318	001	
WYETH AYERST	EQ 10MG BASE/ML	A062264	001	
	EQ 40MG BASE/ML	A062264	002	
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 1.2MG BASE/ML	A062588	001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062588	002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588	003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062588	004	Jan 06, 1986
	EQ 2MG BASE/ML	A062588	005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062588	006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062588	007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588	008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062588	009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588	010	Jan 06, 1986
U-GENCIN				
PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248	001	
	EQ 40MG BASE/ML	A062248	002	
INJECTABLE; INTRATHECAL				
GARAMYCIN				
SCHERING	EQ 2MG BASE/ML	N050505	001	
OINTMENT; OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050425	001	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062501	001	Jul 26, 1984
GENTAFAIR				
PHARMAFAIR	EQ 3MG BASE/GM	A062443	001	May 26, 1983
OINTMENT; TOPICAL				
GARAMYCIN				
SCHERING	EQ 0.1% BASE	A060463	001	
GENTAFAIR				
PHARMAFAIR	EQ 0.1% BASE	A062444	001	May 26, 1983
GENTAMICIN SULFATE				
ALPHARMA US PHARMS	EQ 0.1% BASE	A062496	001	Mar 14, 1984
G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994
PHARMADERM	EQ 0.1% BASE	A062534	001	Oct 10, 1984
SOLUTION/DROPS; OPHTHALMIC				
GARAMYCIN				
SCHERING	EQ 0.3% BASE	N050039	002	
GENTACIDIN				
NOVARTIS	EQ 0.3% BASE	A062480	001	Mar 30, 1984
GENTAFAIR				
PHARMAFAIR	EQ 0.3% BASE	A062440	001	May 03, 1983
GENTAMICIN SULFATE				
ALCON PHARMS LTD	EQ 0.3% BASE	A062523	001	Nov 25, 1985
PACO	EQ 3MG BASE/ML	A062932	001	Nov 07, 1988

GENTIAN VIOLET

SUPPOSITORY; VAGINAL

GVS

SAVAGE LABS	0.4%	A083513	001	
TAMPON; VAGINAL				
GENAPAX				
KEY PHARMS	5MG	A085017	001	

DISCONTINUED DRUG PRODUCT LIST

6-152 (of 337)

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA

20MG/VIAL

N020622 001 Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

COREPHARMA

1MG

A077274 001 Oct 06, 2005

2MG

A077274 002 Oct 06, 2005

4MG

A077274 003 Oct 06, 2005

MYLAN

1MG

A077486 001 Feb 10, 2006

2MG

A077486 002 Feb 10, 2006

4MG

A077486 003 Feb 10, 2006

RANBAXY

3MG

A077366 001 Oct 06, 2005

6MG

A077366 002 Oct 06, 2005

RANBAXY LABS LTD

1MG

A076875 001 Oct 06, 2005

2MG

A076875 002 Oct 06, 2005

4MG

A076875 003 Oct 06, 2005

8MG

A076875 004 Oct 06, 2005

WATSON LABS

1MG

A077280 001 Feb 03, 2006

2MG

A077280 002 Feb 03, 2006

4MG

A077280 003 Feb 03, 2006

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

BARR LABS INC

5MG

A074619 001 Apr 04, 1997

10MG

A074619 002 Apr 04, 1997

SANDOZ

5MG

A074542 001 Jun 20, 1995

10MG

A074542 002 Jun 20, 1995

TEVA

5MG

A074387 001 Mar 04, 1996

10MG

A074387 002 Mar 04, 1996

VINTAGE PHARMS LLC

5MG

A074378 001 Nov 28, 1994

10MG

A074378 002 Nov 28, 1994

WATSON LABS

5MG

A074370 001 Nov 22, 1994

10MG

A074370 002 Nov 22, 1994

GLUCOTROL

PFIZER

2.5MG

N017783 003 May 11, 1993

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

METAGLIP

BRISTOL MYERS SQUIBB

2.5MG;250MG

N021460 001 Oct 21, 2002

2.5MG;500MG

N021460 002 Oct 21, 2002

5MG;500MG

N021460 003 Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGON

LILLY

EQ 1MG BASE/VIAL

N012122 001

EQ 10MG BASE/VIAL

N012122 002

GLUTETHIMIDE

CAPSULE;ORAL

DORIDEN

SANOFI AVENTIS US

500MG

N009519 008

TABLET;ORAL

DORIDEN

SANOFI AVENTIS US

250MG

N009519 002

500MG

N009519 005

GLUTETHIMIDE

HALSEY

250MG

A089458 001 Oct 10, 1986

500MG

A089459 001 Oct 10, 1986

LANNETT

250MG

A083475 001

500MG

A085571 001

SANDOZ

500MG

A083234 002

UCB INC

500MG

A085171 001

VITARINE

500MG

A087297 001

WATSON LABS

500MG

A084362 001

500MG

A085763 001

DISCONTINUED DRUG PRODUCT LIST

6-153 (of 337)

GLYBURIDE

TABLET; ORAL

GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947 001	Nov 14, 2002
	3MG	A075947 002	Nov 14, 2002
	6MG	A075947 003	Nov 14, 2002

GLYBURIDE (MICRONIZED)

SANDOZ	1.5MG	A075174 001	Jun 22, 1998
	3MG	A075174 002	Jun 22, 1998
SANOFI AVENTIS US	1.5MG	N020055 001	Apr 17, 1992
	3MG	N020055 002	Apr 17, 1992
	6MG	N020055 003	Mar 08, 2000

GLYNASE

PHARMACIA AND UPJOHN	4.5MG	N020051 003	Sep 24, 1993
----------------------	-------	-------------	--------------

MICRONASE

PHARMACIA AND UPJOHN	1.25MG	N017498 001	May 01, 1984
	2.5MG	N017498 002	May 01, 1984
	5MG	N017498 003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

TEVA	1.25MG; 250MG	A076821 001	Jan 27, 2005
	2.5MG; 500MG	A076821 002	Jan 27, 2005
	5MG; 500MG	A076821 003	Jan 27, 2005

GLYCINE

SOLUTION; IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522 001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633 001	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475 001	Jun 12, 1984
HOSPIRA	0.2MG/ML	A089393 001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169 001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947 001	Jun 24, 1983

ROBINUL

ROBINS AH	0.2MG/ML	N014764 001	
-----------	----------	-------------	--

TABLET; ORAL

GLYCOPYRROLATE

COREPHARMA	1MG	A040568 001	Dec 22, 2004
	2MG	A040568 002	Dec 22, 2004
HIKMA PHARMS LLC	1MG	A040836 001	Mar 05, 2009
	2MG	A040836 002	Mar 05, 2009
WATSON LABS	1MG	A085562 001	
	1MG	A086902 001	
	2MG	A085563 001	
	2MG	A086178 001	
	2MG	A086900 001	

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687 001	Oct 10, 1989
	3.2MG/VIAL	N019687 002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA (MAPLE)	EQ 0.1MG BASE/VIAL	N018123 001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123 002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123 003	Sep 30, 1982

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

A.P.L.

FERRING	5,000 UNITS/VIAL	N017055 001	
	10,000 UNITS/VIAL	N017055 002	
	20,000 UNITS/VIAL	N017055 003	

CHORIONIC GONADOTROPIN

BEL MAR	5,000 UNITS/VIAL	N017054 001	
	10,000 UNITS/VIAL	N017054 002	

DISCONTINUED DRUG PRODUCT LIST

6-154 (of 337)

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

FERRING	2,000 UNITS/VIAL	N017016 009	Dec 27, 1984
	2,000 UNITS/VIAL	N017016 011	Feb 16, 1990
	5,000 UNITS/VIAL	N017016 006	
	15,000 UNITS/VIAL	N017016 010	Feb 15, 1985
	20,000 UNITS/VIAL	N017016 004	
FRESENIUS KABI USA	5,000 UNITS/VIAL	N017067 001	
	15,000 UNITS/VIAL	N017067 004	
	20,000 UNITS/VIAL	N017067 003	

FOLLUTEIN

BRISTOL MYERS SQUIBB	10,000 UNITS/VIAL	N017056 001	
----------------------	-------------------	-------------	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427 001	
-----------	--	-------------	--

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818 001	Oct 11, 1988
--------	--	-------------	--------------

WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788 001	Jun 11, 1987
-------------	--	-------------	--------------

NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN

PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383 001	Aug 31, 1982
------------	--	-------------	--------------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

APOTEX INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197 001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198 002	Jun 30, 2008
SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007
-----------------	---------------------------------	-------------	--------------

KYTRIL

ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020239 003	Sep 17, 2004
-------	-------------------------------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N020239 004	Mar 11, 1994
---------------------------------	-------------	--------------

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020239 001	Dec 29, 1993
---	-------------	--------------

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	N020239 002	Mar 11, 1994
--	-------------	--------------

SOLUTION; ORAL

GRANISOL

PEDIATRAX	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008
-----------	------------------	-------------	--------------

KYTRIL

ROCHE	EQ 2MG BASE/10ML	N021238 001	Jun 27, 2001
-------	------------------	-------------	--------------

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
------	-------------	-------------	--------------

KYTRIL

ROCHE	EQ 1MG BASE	N020305 001	Mar 16, 1995
-------	-------------	-------------	--------------

EQ 2MG BASE	N020305 002	Jun 15, 1998
-------------	-------------	--------------

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
--------	---------------	-------------	--------------

EQ 400MG BASE	N020695 002	May 14, 1998
---------------	-------------	--------------

EQ 600MG BASE	N020695 003	May 14, 1998
---------------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

6-155 (of 337)

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE;ORAL

GRISACTIN

WYETH AYERST

125MG

N050051 002

250MG

N050051 001

SUSPENSION;ORAL

GRIFULVIN V

JOHNSON AND JOHNSON

125MG/5ML

N050448 001

TABLET;ORAL

FULVICIN-U/F

ELORAC

250MG

A060569 002

500MG

A060569 001

GRIFULVIN V

J AND J

125MG

A060618 001

250MG

A060618 002

500MG

A060618 003

VALEANT LUXEMBOURG

125MG

A062279 001

250MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A062279 002

GRISACTIN

WYETH AYERST

500MG

A060212 001

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

VALEANT LUXEMBOURG

125MG/5ML

A062483 001 Jan 26, 1984

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

FULVICIN P/G

ELORAC

125MG

A061996 001

250MG

A061996 002

FULVICIN P/G 165

ELORAC

165MG

A061996 003 Apr 06, 1982

FULVICIN P/G 330

ELORAC

330MG

A061996 004 Apr 06, 1982

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS INC

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074267 002 Jun 01, 1994

SANDOZ

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

DISCONTINUED DRUG PRODUCT LIST

6-156 (of 337)

GUANETHIDINE MONOSULFATE

TABLET; ORAL

ISMELIN

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ESIMIL

NOVARTIS

10MG; 25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

PROMIUS PHARMA

EQ 3MG BASE

N019032 003 Nov 07, 1988

HALAZEPAM

TABLET; ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM; TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

RANBAXY

0.1%

N018234 001

OINTMENT; TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

SOLUTION; TOPICAL

HALOG

RANBAXY

0.1%

N017823 001

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

G AND W LABS INC

0.05%

A077109 001 Jun 14, 2005

HALOFANTRINE HYDROCHLORIDE

TABLET; ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET; ORAL

HALDOL

ORTHO MCNEIL

0.5MG

N015921 001

1MG

N015921 002

2MG

N015921 003

5MG

N015921 004

10MG

N015921 005

20MG

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

2MG

A071218 001 Dec 04, 1986

5MG

A071219 001 Dec 04, 1986

10MG

A071220 001 Jul 07, 1987

20MG

A071221 001 Jul 07, 1987

LEDERLE

0.5MG

A072727 001 Sep 19, 1989

1MG

A072728 001 Sep 19, 1989

2MG

A072729 001 Sep 19, 1989

5MG

A072730 001 Sep 19, 1989

10MG

A072731 001 Sep 19, 1989

20MG

A072732 001 Sep 19, 1989

MUTUAL PHARM

0.5MG

A071156 001 Jan 02, 1987

1MG

A071157 001 Jan 02, 1987

2MG

A071172 001 Jan 02, 1987

5MG

A071212 001 Jan 07, 1988

DISCONTINUED DRUG PRODUCT LIST

6-157 (of 337)

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	10MG	A071173	001	Jan 07, 1988
	20MG	A071177	001	Jan 07, 1988
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROXANE	0.5MG	A071128	001	Feb 17, 1987
	1MG	A071129	001	Feb 17, 1987
	2MG	A071130	001	Feb 17, 1987
	5MG	A071131	001	Feb 17, 1987
	10MG	A071132	001	May 12, 1987
	20MG	A071133	001	May 12, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
VINTAGE	0.5MG	A071233	001	Nov 03, 1986
	1MG	A071234	001	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071236	001	Nov 03, 1986
	10MG	A071237	001	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

ORTHO MCNEIL	EQ 2MG BASE/ML	N015922	001	
HALOPERIDOL				
ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986
SCS	EQ 2MG BASE/ML	A070726	001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015	001	Aug 25, 1987
HALOPERIDOL INTENSOL				
ROXANE	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988

DISCONTINUED DRUG PRODUCT LIST

6-158 (of 337)

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187	001	Jan 20, 1987
APOTEX INC	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828	001	Aug 25, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516	001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517	001	Feb 25, 1993
SANDOZ	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802	001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801	001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864	001	Dec 14, 1987
WATSON LABS	EQ 5MG BASE/ML	A070713	001	May 17, 1988
	EQ 5MG BASE/ML	A070714	001	May 17, 1988
	EQ 5MG BASE/ML	A070744	001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536	001	Nov 02, 1995
----------------------	----------------	---------	-----	--------------

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942	001	
-----------------	----	---------	-----	--

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943	001	
-----------------	----	---------	-----	--

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST	99.99%	N011338	001	
--------------	--------	---------	-----	--

HALOTHANE

BH	99.99%	A084977	001	
HALOCARBON	99.99%	A080810	001	
HOSPIRA	99.99%	A083254	001	

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US	25,000 UNITS/ML	N018237	001	
-------------------	-----------------	---------	-----	--

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264	010	
INTL MEDICATION	10 UNITS/ML	A086357	001	
	500 UNITS/ML	A086357	002	
LUITPOLD	10 UNITS/ML	A089063	001	Oct 09, 1985
	100 UNITS/ML	A089064	001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346	006	
SMITH AND NEPHEW	10 UNITS/ML	A087904	001	Apr 20, 1983
	10 UNITS/ML	A087958	001	Apr 20, 1983
	10 UNITS/ML	A088458	001	Jul 26, 1984
	10 UNITS/ML	A088580	001	Oct 25, 1984
	100 UNITS/ML	A087906	001	Apr 20, 1983
	100 UNITS/ML	A087959	001	Apr 20, 1983
	100 UNITS/ML	A088460	001	Jul 26, 1984
	100 UNITS/ML	A088581	001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903	001	Apr 20, 1983
	10 UNITS/ML	A088457	001	Oct 25, 1984
	100 UNITS/ML	A087905	001	Apr 20, 1983
	100 UNITS/ML	A088459	001	Jul 26, 1984

HEPARIN SODIUM

ABRAXIS PHARM	1,000 UNITS/ML	N017033	001	
	1,000 UNITS/ML	N017979	001	
	5,000 UNITS/ML	N017979	003	
	10,000 UNITS/ML	N017979	002	
AKORN	1,000 UNITS/ML	N017486	001	
	5,000 UNITS/ML	N017486	002	
	10,000 UNITS/ML	N017486	003	
	20,000 UNITS/ML	N017486	004	
	40,000 UNITS/ML	N017486	005	
BAXTER HLTHCARE CORP	1,000 UNITS/ML	N017007	001	

DISCONTINUED DRUG PRODUCT LIST

6-159 (of 337)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	2,500 UNITS/ML	N017007	007	
	5,000 UNITS/ML	N017007	002	
	5,000 UNITS/0.5ML	N017007	010	
	7,500 UNITS/ML	N017007	003	
	10,000 UNITS/ML	N017007	004	
	15,000 UNITS/ML	N017007	005	
	20,000 UNITS/ML	N017007	006	
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
HIKMA MAPLE	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
PHARM SPEC	1,000 UNITS/ML	N017780	001	
	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	
	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
WATSON LABS INC	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	A040008	001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985

DISCONTINUED DRUG PRODUCT LIST

6-160 (of 337)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
WATSON LABS INC	1,000 UNITS/ML	A089464	001	Jun 03, 1986
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	

DISCONTINUED DRUG PRODUCT LIST

6-161 (of 337)

HEPARIN SODIUM

INJECTABLE; INJECTION

LIQUAEMIN SODIUM

20,000 UNITS/ML

N000552 001

40,000 UNITS/ML

N000552 002

LIQUAEMIN SODIUM PRESERVATIVE FREE

ORGANON USA INC

1,000 UNITS/ML

N000552 011 Apr 11, 1986

5,000 UNITS/ML

N000552 012 Apr 11, 1986

10,000 UNITS/ML

N000552 013 Apr 11, 1986

PANHEPRIN

HOSPIRA

1,000 UNITS/ML

N005264 004

5,000 UNITS/ML

N005264 006

10,000 UNITS/ML

N005264 007

20,000 UNITS/ML

N005264 008

40,000 UNITS/ML

N005264 009

SODIUM HEPARIN

ABRAXIS PHARM

5,000 UNITS/ML

N017033 002

10,000 UNITS/ML

N017033 003

20,000 UNITS/ML

N017033 004

BAXTER HLTHCARE

1,000 UNITS/ML

N017036 001 Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN

BRISTOL

EQ 112.5MG AMPICIL/ML

A061398 001

EQ 112.5MG AMPICIL/5ML

N050060 001

EQ 112.5MG AMPICIL/ML

N050060 003

EQ 225MG AMPICIL/5ML

A061398 002

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K

BRISTOL

EQ 225MG AMPICIL

A061396 001

EQ 450MG AMPICIL

A061396 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL

VESTAL LABS

0.23%

N017424 001

TURGEX

XTTRIUM

3%

N018375 001

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

DISCONTINUED DRUG PRODUCT LIST

6-162 (of 337)

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINA

MERCK

5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

HISTRELIN ACETATE

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA

10MG

A086308 001

HOMAPIN-5

MISSION PHARMA

5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA

3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODAN

ENDO PHARMS

1.5MG/5ML; 5MG/5ML

N005213 002 Jul 26, 1988

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS

1.5MG/5ML; 5MG/5ML

A040285 001 Jul 19, 1999

HYDROPANE

HALSEY

1.5MG/5ML; 5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH

1.5MG; 5MG

A040295 001 Dec 01, 2000

HYCODAN

ENDO PHARMS

1.5MG; 5MG

N005213 001 Jul 26, 1988

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

AKORN INC

150 UNITS/ML

N021716 001 Oct 25, 2005

VITRASE

BAUSCH AND LOMB

6,200 UNITS/VIAL

N021640 001 May 05, 2004

WYDASE

BAXTER HLTHCARE

150 UNITS/ML

N006343 002

150 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N006343 006

1,500 UNITS/VIAL **Federal Register

N006343 005

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

NOVARTIS

20MG/ML

N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM

20MG/ML

A089532 001 Aug 11, 1987

SMITH AND NEPHEW

20MG/ML

A088518 001 Apr 20, 1984

DISCONTINUED DRUG PRODUCT LIST

6-163 (of 337)

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

SOLOPAK	20MG/ML	A088517	001	Aug 22, 1985
TEVA PARENTERAL	20MG/ML	A040373	001	Feb 23, 2000

TABLET; ORAL

APRESOLINE

NOVARTIS	10MG	N008303	004	
	25MG	N008303	001	
	50MG	N008303	002	
	100MG	N008303	005	

DRALZINE

TEVA	25MG	A084301	001	
------	------	---------	-----	--

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH	25MG	A088560	001	Oct 04, 1984
	50MG	A088649	001	Oct 18, 1984
ASCOT	25MG	A088310	001	Dec 19, 1984
	50MG	A088311	001	Dec 19, 1984
HALSEY	10MG	A089218	001	Jan 22, 1986
	25MG	A089130	001	Jan 15, 1986
	50MG	A089222	001	Jan 22, 1986
	100MG	A089178	001	Jan 15, 1986
IMPAX LABS	25MG	A084922	001	
	50MG	A084923	001	
IVAX SUB TEVA PHARMS	10MG	A084443	001	
	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	10MG	A089359	001	Jul 25, 1986
	25MG	A084106	002	
	25MG	A089258	001	May 05, 1986
	50MG	A084107	002	
	50MG	A089259	001	May 05, 1986
	100MG	A088729	001	Apr 11, 1985
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
SANDOZ	10MG	A083241	001	
	25MG	A083560	001	
	50MG	A083561	001	
	50MG	A085088	001	
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
TG UNITED LABS	10MG	A088846	001	Feb 26, 1985
	25MG	A088847	001	Feb 26, 1985
	50MG	A088848	001	Feb 26, 1985
	100MG	A088849	001	Feb 26, 1985
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983
ZYDUS PHARMS USA	10MG	A040858	001	Feb 26, 2010
	25MG	A040858	002	Feb 26, 2010
	50MG	A040858	003	Feb 26, 2010
	100MG	A040858	004	Feb 26, 2010

DISCONTINUED DRUG PRODUCT LIST

6-164 (of 337)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

NOVARTIS	25MG; 25MG	A084735	001
	50MG; 50MG	A084810	001
	100MG; 50MG	A084811	001

HYDRA-ZIDE

PAR PHARM	100MG; 50MG	A088961	001 Oct 21, 1985
-----------	-------------	---------	------------------

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY	25MG; 25MG	A087608	001 Feb 08, 1982
	50MG; 50MG	A087213	001 Feb 08, 1982
	100MG; 50MG	A087609	001 Feb 08, 1982
SUPERPHARM	25MG; 25MG	A089200	001 Feb 09, 1987
	50MG; 50MG	A089201	001 Feb 09, 1987
WATSON LABS	25MG; 25MG	A085457	001 Mar 04, 1982
	50MG; 50MG	A085446	001 Mar 04, 1982
	100MG; 50MG	A085440	001 Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS	100MG; 50MG	A088358	001 Apr 10, 1984
-------------	-------------	---------	------------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS	25MG; 25MG	A088356	001 Apr 10, 1984
-------------	------------	---------	------------------

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS	50MG; 50MG	A088357	001 Apr 10, 1984
-------------	------------	---------	------------------

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS	25MG; 15MG	N012026	002
----------	------------	---------	-----

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS	25MG; 15MG	A085827	001
-------------	------------	---------	-----

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS	25MG; 15MG	A085373	001
-------------	------------	---------	-----

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

TG UNITED LABS	25MG; 15MG; 0.1MG	A084897	001
----------------	-------------------	---------	-----

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A084291	001
----------------------	-------------------	---------	-----

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN	25MG; 15MG; 0.1MG	A087085	001
-------	-------------------	---------	-----

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS	25MG; 15MG; 0.1MG	A085771	001
-------------	-------------------	---------	-----

HYDRAP-ES

SANDOZ	25MG; 15MG; 0.1MG	A084876	001
--------	-------------------	---------	-----

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS	25MG; 15MG; 0.1MG	A083770	001
-------------	-------------------	---------	-----

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS	25MG; 15MG; 0.1MG	A083877	001
----------------------	-------------------	---------	-----

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

MUTUAL PHARM	25MG; 15MG; 0.1MG	A088570	001 Apr 10, 1984
SOLVAY	25MG; 15MG; 0.1MG	A088376	001 Oct 28, 1983
WATSON LABS	25MG; 15MG; 0.1MG	A085549	001
	25MG; 15MG; 0.1MG	A087556	001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE	25MG; 15MG; 0.1MG	A087709	001 May 13, 1982
---------	-------------------	---------	------------------

SER-A-GEN

SOLVAY	25MG; 15MG; 0.1MG	A087210	001
--------	-------------------	---------	-----

SER-AP-ES

NOVARTIS	25MG; 15MG; 0.1MG	N012193	005
----------	-------------------	---------	-----

UNIPRES

SOLVAY	25MG; 15MG; 0.1MG	A085893	001
	25MG; 15MG; 0.1MG	A086298	001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ	25MG; 0.1MG	A084617	001
--------	-------------	---------	-----

SERPASIL-APRESOLINE

NOVARTIS	25MG; 0.1MG	N009296	004
	50MG; 0.2MG	N009296	002

DISCONTINUED DRUG PRODUCT LIST

6-165 (of 337)

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

HIKMA INTL PHARMS

12.5MG

A077885 001 Nov 26, 2007

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE

50MG/5ML

A089661 001 Jun 20, 1988

ROXANE

50MG/5ML

A088587 001 Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE

100MG/ML

A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS

25MG

N011793 005

50MG

N011793 008

100MG

N011793 009

HYDRO-D

HALSEY

25MG

A086504 001

50MG

A083891 002

HYDROCHLOROTHIAZIDE

ABC HOLDING

50MG

A085672 001

ACTAVIS ELIZABETH

25MG

A085054 002

50MG

A085208 001

ALRA

25MG

A086369 001

50MG

A083554 001

ASCOT

25MG

A087539 001 Feb 03, 1982

50MG

A087540 001 Feb 03, 1982

BARR

50MG

A084771 001

DAVA PHARMS INC

100MG

A087060 001

ELKINS SINN

50MG

A085152 002

HEATHER

50MG

A084135 001

HIKMA PHARMS LLC

25MG

A084878 002 Jul 12, 2006

IMPAX LABS

25MG

A084029 001

50MG

A083607 002

100MG

A085098 001

INWOOD LABS

25MG

A084776 001

25MG

A085067 001

50MG

A084776 002

IVAX SUB TEVA PHARMS

50MG

A084658 001

100MG

A085022 001

MAST MM

25MG

A086192 001

50MG

A086192 002

MUTUAL PHARM

25MG

A083972 001

50MG

A083972 002

100MG

A083972 003

MYLAN

25MG

A084880 001

50MG

A085112 001

PVT FORM

50MG

A086597 001

ROXANE

25MG

A085004 001

50MG

A084536 002

50MG

A085005 001

SANDOZ

25MG

A083899 001

25MG

A087565 001 Mar 09, 1982

50MG

A084912 001

50MG

A085219 001

SOLVAY

25MG

A085323 001

SUPERPHARM

25MG

A088827 001 Dec 28, 1984

50MG

A088828 001 Dec 28, 1984

100MG

A088829 001 Dec 28, 1984

TEVA

25MG

A088924 001 Feb 07, 1985

50MG

A088923 001 Feb 07, 1985

TG UNITED LABS

25MG

A085683 001

50MG

A083965 001

USL PHARMA

25MG

A087827 001 Apr 19, 1982

50MG

A087752 001 Apr 19, 1982

VANGARD

25MG

A087638 001

50MG

A087610 001

WARNER CHILCOTT

25MG

A087586 001 May 03, 1982

50MG

A087587 001 May 03, 1982

WATSON LABS

25MG

A081189 001 Jan 24, 1992

25MG

A083458 001

25MG

A085232 002

50MG

A083232 001

DISCONTINUED DRUG PRODUCT LIST

6-166 (of 337)

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

50MG	A083456	001	
50MG	A085233	001	
50MG	A086087	001	
50MG	A086594	001	
100MG	A081190	001	Jan 24, 1992
100MG	A085099	001	
100MG	A087002	001	
WEST WARD 25MG	A084899	001	
WHITEWORTH TOWN PLSN 25MG	A083809	002	
50MG	A083809	001	
100MG	A085347	001	
HYDRODIURIL			
MERCK 25MG	N011835	003	
50MG	N011835	006	
100MG	N011835	007	
ORETIC			
ABBVIE 25MG	N011971	001	
ZIDE			
SOLVAY 50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

SANOFI AVENTIS US 12.5MG;75MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	001	Sep 30, 1997
25MG;300MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

TEVA 25MG;300MG	A077369	003	Mar 30, 2012
-----------------	---------	-----	--------------

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING 25MG;100MG	N019046	001	Apr 06, 1987
25MG;200MG	N019046	002	Apr 06, 1987
25MG;300MG	N019046	003	Apr 06, 1987
25MG;400MG	N019046	004	Apr 06, 1987
TRANDATE HCT			
GLAXOSMITHKLINE 25MG;100MG	N019174	001	Apr 10, 1987
25MG;200MG	N019174	002	Apr 10, 1987
25MG;300MG	N019174	003	Apr 10, 1987
25MG;400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

SANDOZ 12.5MG;10MG	A075926	001	Jul 01, 2002
12.5MG;20MG	A075926	002	Jul 01, 2002
25MG;20MG	A075926	003	Jul 01, 2002
TEVA 12.5MG;10MG	A075869	001	Jul 01, 2002
12.5MG;20MG	A075869	002	Jul 01, 2002
25MG;20MG	A075869	003	Jul 01, 2002
PRINZIDE			
MERCK 25MG;20MG	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

WATSON LABS 12.5MG;50MG	A200180	001	Jan 12, 2011
12.5MG;100MG	A200180	002	Jan 12, 2011
25MG;100MG	A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK 15MG;250MG	N013402	001
------------------	---------	-----

ALDORIL 25

MERCK 25MG;250MG	N013402	002
------------------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

6-167 (of 337)

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL D30

MERCK

30MG; 500MG

N013402 003

ALDORIL D50

MERCK

50MG; 500MG

N013402 004

METHYLDOPA AND HYDROCHLOROTHIAZIDE

DAVA PHARMS INC

15MG; 250MG

A072507 001 Jun 02, 1989

25MG; 250MG

A072508 001 Jun 02, 1989

30MG; 500MG

A072509 001 Jun 02, 1989

50MG; 500MG

A072510 001 Jun 02, 1989

IVAX SUB TEVA PHARMS

15MG; 250MG

A071458 001 Mar 08, 1988

25MG; 250MG

A071459 001 Mar 08, 1988

30MG; 500MG

A071460 001 Mar 08, 1988

50MG; 500MG

A071461 001 Mar 08, 1988

PAR PHARM

15MG; 250MG

A070616 001 Feb 02, 1987

25MG; 250MG

A070612 001 Feb 02, 1987

30MG; 500MG

A070613 001 Feb 02, 1987

50MG; 500MG

A070614 001 Feb 02, 1987

PARKE DAVIS

15MG; 250MG

A071897 001 Nov 23, 1987

25MG; 250MG

A071898 001 Nov 23, 1987

30MG; 500MG

A071899 001 Nov 23, 1987

50MG; 500MG

A071900 001 Nov 23, 1987

PUREPAC PHARM

15MG; 250MG

A070853 001 Oct 08, 1986

25MG; 250MG

A070688 001 Apr 24, 1986

30MG; 500MG

A070854 001 Oct 08, 1986

50MG; 500MG

A070689 001 Apr 24, 1986

SANDOZ

15MG; 250MG

A070182 001 Jan 15, 1986

15MG; 250MG

A070829 001 Mar 09, 1987

25MG; 250MG

A070183 001 Jan 15, 1986

25MG; 250MG

A070830 001 Mar 09, 1987

30MG; 500MG

A070543 001 Jan 15, 1986

50MG; 500MG

A070544 001 Jan 15, 1986

TEVA

15MG; 250MG

A071819 001 Apr 08, 1988

25MG; 250MG

A071820 001 Apr 08, 1988

30MG; 500MG

A071821 001 Apr 08, 1988

50MG; 500MG

A071822 001 Apr 08, 1988

WATSON LABS

15MG; 250MG

A070365 001 Mar 19, 1986

15MG; 250MG

A070958 001 Feb 06, 1989

15MG; 250MG

A071920 001 Aug 29, 1988

25MG; 250MG

A070366 001 Apr 16, 1986

25MG; 250MG

A070959 001 Jan 19, 1989

25MG; 250MG

A071921 001 Aug 29, 1988

30MG; 500MG

A070367 001 Mar 19, 1986

30MG; 500MG

A071069 001 Jan 19, 1989

30MG; 500MG

A071922 001 Aug 29, 1988

50MG; 500MG

A070368 001 Apr 16, 1986

50MG; 500MG

A070960 001 Feb 06, 1989

50MG; 500MG

A071923 001 Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

US PHARMS HOLDINGS I

50MG; 100MG

N018303 003 Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

PADDOCK LLC

12.5MG; 7.5MG

A090096 001 Sep 25, 2008

12.5MG; 15MG

A090096 002 Sep 25, 2008

25MG; 15MG

A090096 003 Sep 25, 2008

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS

25MG; 5MG

N018872 001 Jul 22, 1987

25MG; 10MG

N018872 002 Jul 22, 1987

DISCONTINUED DRUG PRODUCT LIST

6-168 (of 337)

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50				
WYETH AYERST	50MG;120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50				
WYETH AYERST	50MG;160MG	N019059	003	Jul 03, 1985
INDERIDE LA 80/50				
WYETH AYERST	50MG;80MG	N019059	001	Jul 03, 1985

TABLET; ORAL

INDERIDE-80/25				
WYETH PHARMS INC	25MG;80MG	N018031	002	
PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE				
DURAMED PHARMS BARR	25MG;40MG	A071126	001	Mar 02, 1987
	25MG;80MG	A071127	001	Mar 02, 1987
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE				
ACTAVIS ELIZABETH	25MG;40MG	A070851	001	May 15, 1986
	25MG;80MG	A070852	001	May 15, 1986
BARR	25MG;40MG	A070704	001	Oct 01, 1986
	25MG;80MG	A070705	001	Oct 01, 1986
IVAX SUB TEVA PHARMS	25MG;40MG	A071552	001	Dec 01, 1988
	25MG;80MG	A071553	001	Dec 01, 1988
SANDOZ	25MG;40MG	A071060	001	Aug 26, 1987
	25MG;80MG	A071061	001	Aug 26, 1987
WARNER CHILCOTT	25MG;40MG	A071771	001	Jan 26, 1988
	25MG;80MG	A071772	001	Jan 26, 1988
WATSON LABS	25MG;40MG	A070301	001	Apr 18, 1986
	25MG;40MG	A071498	001	Dec 18, 1991
	25MG;80MG	A070305	001	Apr 18, 1986
	25MG;80MG	A071501	001	Dec 18, 1991

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

H.R.-50				
WHITEWORTH TOWN PLSN	50MG;0.125MG	A085338	001	
HYDRO-RESERP				
ABC HOLDING	50MG;0.125MG	A084714	002	Jun 29, 1982
HYDRO-SERP "25"				
SANDOZ	25MG;0.125MG	A084827	001	
HYDRO-SERP "50"				
SANDOZ	50MG;0.125MG	A085213	001	
HYDROCHLOROTHIAZIDE W/ RESERPINE				
IVAX SUB TEVA PHARMS	25MG;0.1MG	A083572	001	
	25MG;0.125MG	A083571	001	
	50MG;0.1MG	A083568	001	
	50MG;0.125MG	A083573	001	
PHARMERAL	25MG;0.125MG	A085421	001	
	50MG;0.125MG	A085420	001	
ROXANE	50MG;0.125MG	A084603	001	
WATSON LABS	25MG;0.125MG	A084466	001	
	25MG;0.125MG	A085317	001	
	25MG;0.125MG	A086330	002	
	50MG;0.125MG	A083666	001	
	50MG;0.125MG	A084467	001	
	50MG;0.125MG	A086331	001	
HYDROPRES 25				
MERCK	25MG;0.125MG	N011958	002	
HYDROPRES 50				
MERCK	50MG;0.125MG	N011958	003	
RESERPINE AND HYDROCHLOROTHIAZIDE				
BARR	25MG;0.125MG	A084580	001	
	50MG;0.125MG	A084579	001	
SANDOZ	50MG;0.125MG	A088200	001	Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50				
WEST WARD	50MG;0.125MG	A088189	001	May 10, 1984
SERPASIL-ESIDRIX #1				
NOVARTIS	25MG;0.1MG	N011878	003	
SERPASIL-ESIDRIX #2				
NOVARTIS	50MG;0.1MG	N011878	005	

DISCONTINUED DRUG PRODUCT LIST

6-169 (of 337)

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG	A088025	001	Nov 23, 1984
MUTUAL PHARM	25MG; 25MG	A087267	001	
PUREPAC PHARM	25MG; 25MG	A087999	001	Nov 06, 1985
SANDOZ	25MG; 25MG	A086881	001	
SUPERPHARM	25MG; 25MG	A089137	001	Aug 26, 1985
WATSON LABS	25MG; 25MG	A087398	001	

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

IVAX PHARMS	25MG; 25MG	A087004	002	May 24, 1982
LEDERLE	25MG; 25MG	A087511	001	
PARKE DAVIS	25MG; 25MG	A087948	001	Feb 22, 1983
PUREPAC PHARM	25MG; 25MG	A088054	001	Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553	001	
USL PHARMA	25MG; 25MG	A087651	001	
VANGARD	25MG; 25MG	A087655	001	
WATSON LABS	25MG; 25MG	A085974	001	
	25MG; 25MG	A086026	001	

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061	001	
-------	------------	---------	-----	--

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

GLAXOSMITHKLINE LLC	25MG; 50MG	N016042	002	
---------------------	------------	---------	-----	--

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

BARR	25MG; 37.5MG	A074970	001	Jan 06, 1998
NOVARTIS	25MG; 37.5MG	A074857	001	Sep 09, 1997
VITARINE	25MG; 50MG	A071737	001	Feb 12, 1988

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP	50MG; 75MG	A072022	001	Apr 17, 1988
QUANTUM PHARMICS	50MG; 75MG	A071980	001	Apr 17, 1988
WATSON LABS	50MG; 75MG	A071969	001	Apr 17, 1988

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

CODAMINE

ALPHARMA US PHARMS	5MG/5ML; 25MG/5ML	A075103	001	Sep 29, 2000
--------------------	-------------------	---------	-----	--------------

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT; TOPICAL

MAGNACORT

PFIZER	0.5%	N010554	001	
--------	------	---------	-----	--

HYDROCORTISONE

AEROSOL; TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	
------------------	------	---------	-----	--

CREAM; TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

DERMACORT

MONARCH PHARMS	1%	A083011	002	
----------------	----	---------	-----	--

ELDECORT

VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	

FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

H-CORT

PHARM ASSOC	0.5%	A086823	001	
-------------	------	---------	-----	--

HC #1

BAYER PHARMS	0.5%	A080438	001	
--------------	------	---------	-----	--

HC #4

BAYER PHARMS	1%	A080438	002	
--------------	----	---------	-----	--

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	

DISCONTINUED DRUG PRODUCT LIST

6-170 (of 337)

HYDROCORTISONE

CREAM; TOPICAL

HI-COR

C AND M PHARMA 2.5% A080483 001

HYDROCORTISONE

ALPHARMA US PHARMS 2.5% A089754 001 Feb 01, 1989

ALTANA 0.5% A080848 002

1% A080848 003

AMBIX 1% A086080 001

2.5% A086271 001

EVERYLIFE 0.5% A080452 001

1% A080452 002

G AND W LABS 1% A084059 001

INGRAM PHARM 0.5% A080456 002

1% A080456 003

IVAX PHARMS 1% A085733 001

NASKA 1% A089706 001 Mar 10, 1988

PERRIGO NEW YORK 0.5% A084970 002

1% A085026 001

PHARMADERM 1% A088845 001 Feb 27, 1986

2.5% A089413 001 Dec 16, 1986

PHARMAFAIR 1% A087838 001 Jul 28, 1982

STIEFEL 1% A086170 001

SYOSSET 0.5% A085527 001

TARO 0.5% A086154 001

1% A086155 001

TEVA 0.5% A080400 002

1% A080400 003

1% A085191 001

2.5% A080400 004

TOPIDERM 1% A089273 001 Feb 17, 1989

USL PHARMA 1% A088027 001 Sep 27, 1983

2.5% A088029 001 Sep 27, 1983

WHITEWORTH TOWN PLSN 1% A080496 002

HYTONE

VALEANT INTL 1% A080472 003

2.5% A080472 004

NOGENIC HC

IVAX PHARMS 1% A087427 001 Apr 04, 1988

NUTRACORT

DOW PHARM 0.5% A080442 002

1% A080442 003

PENECORT

ALLERGAN HERBERT 1% A088216 001 Jun 06, 1984

PROCTOCORT

MONARCH PHARMS 1% A083011 001

SYNACORT

MEDICIS 0.5% A087459 001

GEL; TOPICAL

NUTRACORT

HEALTHPOINT 1% A084698 001

PENECORT

ALLERGAN HERBERT 1% A088215 001 Jun 06, 1984

INJECTABLE; INJECTION

CORTEF

PHARMACIA AND UPJOHN 50MG/ML N009864 001

LOTION; TOPICAL

ACTICORT

BAKER NORTON 1% A086535 001

ALA-CORT

CROWN LABS 1% A083201 001

BALNEOL-HC

SOLVAY 1% A088041 001 Dec 03, 1982

BETA-HC

BETA DERMAC 1% A089495 001 Jan 25, 1988

CETACORT

DOW PHARM 0.5% A080426 002

1% A080426 001

CORT-DOME

BAYER PHARMS 0.5% N009895 003

1% N009895 001

DISCONTINUED DRUG PRODUCT LIST

6-171 (of 337)

HYDROCORTISONE

LOTION; TOPICAL

DERMACORT

SOLVAY

0.5%

A084573 002

1%

A086462 001

EPICORT

BLULINE

0.5%

A083219 002

GLYCORT

HERAN

1%

A087489 001 Oct 03, 1983

H-CORT

PHARM ASSOC

0.5%

A086824 001

HYDROCORTISONE

ALPHARMA US PHARMS

0.5%

A087317 001 Jun 07, 1982

1%

A087315 001 Jun 07, 1982

MERICON

0.5%

A085282 001

1%

A085282 002 Feb 26, 1987

NASKA

1%

A089705 001 Apr 25, 1988

PERRIGO NEW YORK

0.5%

A085662 001

1%

A085663 001

TARO

1%

A089024 001 Feb 12, 1986

HYTONE

VALEANT INTL

1%

A080473 003

2.5%

A080473 004 Nov 30, 1982

NUTRACORT

DOW PHARM

0.5%

A080443 002

1%

A080443 003

STIE-CORT

PERRIGO CO

1%

A089066 001 Nov 25, 1985

OINTMENT; TOPICAL

CORTRIL

PFIZER GLOBAL

1%

N009176 001

2.5%

N009176 002

HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080481 001

1%

A080481 002

HYDROCORTISONE

ALTANA

0.5%

A080489 002

1%

A080489 003

AMBIX

1%

A086079 001

2.5%

A086272 001

NASKA

1%

A089704 001 Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084969 003

1%

A085028 001

PHARMADERM

1%

A088842 001 Feb 09, 1987

TARO

0.5%

A086256 001

2.5%

A040310 001 Dec 29, 2000

USL PHARMA

1%

A088061 001 Sep 27, 1983

2.5%

A088039 001 Sep 27, 1983

HYTONE

DERMIK LABS

1%

A080474 003

2.5%

A080474 004

PENECORT

ALLERGAN HERBERT

2.5%

A088217 001 Jun 06, 1984

POWDER; FOR RX COMPOUNDING

H-CORT

TORCH

100%

A087834 001 Mar 29, 1982

HYDROCORTISONE

PADDOCK LLC

100%

A088082 001 Apr 08, 1983

SOLUTION; TOPICAL

PENECORT

ALLERGAN HERBERT

1%

A088214 001 Jun 06, 1984

TEXACORT

MISSION PHARMA

1%

A080425 001

TABLET; ORAL

CORTRIL

PFIZER

10MG

N009127 005

20MG

N009127 003

HYDROCORTISONE

BARR

20MG

A083999 001

ELKINS SINN

20MG

A080624 001

FERRANTE

10MG

A080568 001

20MG

A080568 002

DISCONTINUED DRUG PRODUCT LIST

6-172 (of 337)

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

HIKMA INTL PHARMS	20MG	A083365	001	
IMPAX LABS	20MG	A080781	001	
INWOOD LABS	20MG	A080732	001	
LANNETT	20MG	A085070	001	
NEXGEN PHARMA INC	20MG	A083140	001	
PANRAY	10MG	N009659	001	
	20MG	N009659	002	
PARKE DAVIS	20MG	A084243	001	
PUREPAC PHARM	10MG	A084247	003	Aug 31, 1982
	20MG	A080395	001	
	20MG	A084247	002	
ROXANE	10MG	A088539	001	Mar 21, 1984
SANDOZ	20MG	A080642	002	
WATSON LABS	20MG	A080355	001	
WHITEWORTH TOWN PLSN	10MG	A080344	001	
	20MG	A080344	002	
HYDROCORTONE				
MERCK	10MG	N008506	007	
	20MG	N008506	011	

TABLET; VAGINAL

CORTRIL

PFIPHARMECS	10MG	N009796	001	
-------------	------	---------	-----	--

HYDROCORTISONE ACETATE

CREAM; TOPICAL

HEMSOL-HC

ABLE	1%	A081274	001	Jun 19, 1992
------	----	---------	-----	--------------

HYDROCORTISONE ACETATE

CENCI	1%	A080419	001	Jan 25, 1982
PARKE DAVIS	1%	A089914	001	Jan 03, 1989
PUREPAC PHARM	0.5%	A086050	001	
	1%	A086052	001	

INJECTABLE; INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378	002	
----------------------	---------	---------	-----	--

CORTRIL

PFIZER	25MG/ML	N009164	001	
--------	---------	---------	-----	--

HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637	001	
	50MG/ML	N009637	002	
BEL MAR	25MG/ML	A083739	001	
	50MG/ML	A083739	002	
WATSON LABS	25MG/ML	A083128	001	
	25MG/ML	A083759	001	
	50MG/ML	A083759	002	
	50MG/ML	A085214	001	

HYDROCORTONE

MERCK	25MG/ML	N008228	001	
	50MG/ML	N008228	004	

LOTION; TOPICAL

DRICORT

INGRAM PHARM	0.5%	A086207	001	
--------------	------	---------	-----	--

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828	001	
-------------	------	---------	-----	--

OINTMENT; OPHTHALMIC, OTIC

HYDROCORTONE

MERCK	1.5%	N009018	003	
-------	------	---------	-----	--

OINTMENT; TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917	002	
	2.5% **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008917	001	

PASTE; TOPICAL

ORABASE HCA

COLGATE	0.5%	A083205	001	
---------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-173 (of 337)

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	A061049 001
	2.5%;EQ 3.5MG BASE/GM	A061049 002

OINTMENT; OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060610 001
	1.5%;EQ 3.5MG BASE/GM	A060610 002

OINTMENT; TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/GM	A060751 001
	1%;EQ 3.5MG BASE/GM	A060751 002
	2.5%;EQ 3.5MG BASE/GM	A060751 003

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

AKORN	1.5%;EQ 3.5MG BASE/ML	A060188 001
-------	-----------------------	-------------

NEO-CORTEF

PHARMACIA AND UPJOHN	0.5%;EQ 3.5MG BASE/ML	A060612 002
	1.5%;EQ 3.5MG BASE/ML	A060612 001

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC

TERRA-CORTIL

PFIZER	1.5%;EQ 5MG BASE/ML	A061016 001
--------	---------------------	-------------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

VINTAGE PHARMS	1%;1%	A089440 001	May 17, 1988
----------------	-------	-------------	--------------

LOTION; TOPICAL

PRAMOSONE

FERNDAL LABS	0.5%;1%	A083213 002
--------------	---------	-------------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

FOUGERA PHARMS	1%;10%	A080505 001
----------------	--------	-------------

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N018795 001	Jan 07, 1983
------------	------	-------------	--------------

OINTMENT; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019106 001	Jul 03, 1984
------------	------	-------------	--------------

SOLUTION; TOPICAL

LOCOID

YAMANOUCHI	0.1%	N019819 001	Sep 15, 1988
------------	------	-------------	--------------

HYDROCORTISONE CYPIONATE

SUSPENSION; ORAL

CORTEF

PHARMACIA AND UPJOHN	EQ 10MG BASE/5ML	N009900 001
----------------------	------------------	-------------

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

MERCK	EQ 50MG BASE/ML	N012052 001
-------	-----------------	-------------

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 1GM BASE/VIAL	A089580 001	Apr 11, 1989
EQ 100MG BASE/VIAL	A085928 001	
EQ 100MG BASE/VIAL	A089577 001	Apr 11, 1989
EQ 250MG BASE/VIAL	A089578 001	Apr 11, 1989
EQ 500MG BASE/VIAL	A089579 001	Apr 11, 1989

HOSPIRA

EQ 1GM BASE/VIAL	A085932 001
EQ 100MG BASE/VIAL	A085929 001
EQ 250MG BASE/VIAL	A085930 001
EQ 500MG BASE/VIAL	A085931 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 1GM BASE/VIAL	A088670 001	Jun 08, 1984
EQ 100MG BASE/VIAL	A088667 001	Jun 08, 1984
EQ 100MG BASE/VIAL	A088712 001	Jun 08, 1984

DISCONTINUED DRUG PRODUCT LIST

6-174 (of 337)

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

HYDROCORTISONE SODIUM SUCCINATE

	EQ 250MG BASE/VIAL	A088668	001	Jun 08, 1984
	EQ 500MG BASE/VIAL	A088669	001	Jun 08, 1984
BAXTER HLTHCARE	EQ 1GM BASE/VIAL	A087569	001	
	EQ 100MG BASE/VIAL	A086619	001	
	EQ 250MG BASE/VIAL	A087567	001	
	EQ 500MG BASE/VIAL	A087568	001	
INTL MEDICATION	EQ 100MG BASE/VIAL	A087532	001	Mar 19, 1982
WATSON LABS	EQ 1GM BASE/VIAL	A084748	001	
	EQ 100MG BASE/VIAL	A084737	002	
	EQ 100MG BASE/VIAL	A084738	001	
	EQ 250MG BASE/VIAL	A084737	001	
	EQ 500MG BASE/VIAL	A084747	001	

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

TEVA PHARMS	0.2%	A074489	001	Aug 12, 1998
WESTCORT				
RANBAXY	0.2%	N017950	001	
ointment; TOPICAL				
HYDROCORTISONE VALERATE				
FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001
WESTCORT				
RANBAXY	0.2%	N018726	001	Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS	0.5%; EQ 3.5MG BASE/GM	N050237	006	Jun 05, 1984
	1%; EQ 3.5MG BASE/GM	N050237	005	Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062394	001	Sep 29, 1982
OTOCORT				
WATSON LABS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A060730	002	
SUSPENSION/DROPS; OPHTHALMIC				
CORTISPORIN				
MONARCH PHARMS	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N050169	001	
NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE				
PHARMAFAIR	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062623	001	Sep 24, 1985
SUSPENSION/DROPS; OTIC				
NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE				
PHARMAFAIR	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062617	001	Sep 18, 1985
OTICAIR				
PHARMAFAIR	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062399	001	Nov 18, 1982
OTOBIONE				
SCHERING	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A061816	001	
OTOCORT				
ACTAVIS LABS FL INC	1%; EQ 3.5MG BASE/ML; 10,000 UNITS/ML	A062521	001	Jul 11, 1985

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

OTOBiotic

SCHERING	5MG/ML; EQ 10,000 UNITS BASE/ML	A062302	001	
PYOCIDIN				
FOREST LABS	5MG/ML; EQ 10,000 UNITS BASE/ML	A061606	001	

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

ointment; OPHTHALMIC

ACHROMYCIN

LEDERLE	1.5%; 1%	N050272	001	
---------	----------	---------	-----	--

HYDROCORTISONE; UREA

CREAM; TOPICAL

ALPHADERM

BIOGLAN	1%; 10%	A086008	001	
CALMURID HC				
PHARMACIA AND UPJOHN	1%; 10%	A083947	001	

DISCONTINUED DRUG PRODUCT LIST

6-175 (of 337)

HYDROFLUMETHIAZIDE

TABLET; ORAL

DIUCARDIN

WYETH AYERST

50MG

A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM

50MG

A088850 001 May 31, 1985

WATSON LABS

50MG

A088031 001 Apr 06, 1983

50MG

A088528 001 Aug 15, 1984

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA

50MG; 0.125MG

A088195 001 Oct 26, 1983

WATSON LABS

25MG; 0.125MG

A088127 001 Mar 22, 1983

50MG; 0.125MG

A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS

50MG; 0.125MG

A088932 001 Jan 11, 1985

PAR PHARM

50MG; 0.125MG

A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE

50MG; 0.125MG

N012359 003

SALUTENSIN-DEMI

SHIRE

25MG; 0.125MG

N012359 004

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PALLADONE

PURDUE PHARMA LP

12MG

N021044 001 Sep 24, 2004

16MG

N021044 002 Sep 24, 2004

24MG

N021044 003 Sep 24, 2004

32MG

N021044 004 Sep 24, 2004

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

WATSON LABS

10MG/ML

A074317 001 Aug 23, 1995

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

NESHER PHARMS

2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK

1MG/ML

A080778 001

CYANOKIT

MERCK SANTE SAS

2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM

1MG/ML

A084921 001

WATSON LABS

1MG/ML

A085528 001

HYDROXOMIN

BEL MAR

1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

PHARMICS

1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

SANDOZ

200MG

A040150 001 Jan 27, 1996

WATSON LABS

200MG

A040133 001 Nov 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

BRISTOL MYERS SQUIBB

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N010347 004

125MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N016911 001

250MG/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or

N010347 002

DISCONTINUED DRUG PRODUCT LIST

6-176 (of 337)

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

DELALUTIN

efficacy reasons**

250MG/ML **Federal Register

N016911 002

determination that product was not

discontinued or withdrawn for safety or

efficacy reasons**

HYDROXYPROGESTERONE CAPROATE

AKORN

125MG/ML

N018004 001

WATSON LABS

125MG/ML

N017439 001

250MG/ML

N017439 002

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US

225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR

250MG

A075143 002 Sep 21, 2000

BARR LABS INC

250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE

500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR

1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE

50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA

25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE

25MG/ML

A085551 001

FRESENIUS KABI USA

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA

25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR

25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW

25MG/ML

A087592 001

SOLOPAK

25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS

25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A085779 001

50MG/ML

A087274 002

WYETH AYERST

25MG/ML

A086258 001

50MG/ML

A086258 002

ORGATRAK

ORGANON USA INC

25MG/ML

A087014 001

50MG/ML

A087014 002

VISTARIL

PFIZER

25MG/ML

N011111 001

50MG/ML

N011111 002

SYRUP; ORAL

ATARAX

ROERIG

10MG/5ML

N010485 001

HYDROXYZINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A088785 001 Feb 03, 1988

KV PHARM

10MG/5ML

A087730 001 Jul 01, 1982

STI PHARMA LLC

10MG/5ML

A086880 001

DISCONTINUED DRUG PRODUCT LIST

6-177 (of 337)

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

ATARAX

PFIZER	10MG	N010392	001
	25MG	N010392	004
	50MG	N010392	006
	100MG	N010392	005

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004
	25MG	A040602	001	Dec 28, 2004
	50MG	A040604	001	Dec 28, 2004
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
	100MG	A087862	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
SANDOZ	10MG	A087246	002	
	10MG	A087869	001	Dec 20, 1982
	25MG	A085247	001	
	25MG	A087870	001	Dec 20, 1982
	50MG	A087245	001	
	50MG	A087871	001	Dec 20, 1982
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
VINTAGE	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HCL	A088713	001	Mar 04, 1985
------	-------------	---------	-----	--------------

HYDROXYZINE PAMOATE

DURAMED PHARMS BARR	EQ 25MG HCL	A088593	001	Feb 29, 1984
	EQ 50MG HCL	A088594	001	Feb 29, 1984
	EQ 100MG HCL	A088595	001	Feb 29, 1984
IVAX SUB TEVA PHARMS	EQ 25MG HCL	A087761	001	Mar 05, 1982
	EQ 50MG HCL	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HCL	A087656	001	Jun 11, 1982
	EQ 25MG HCL	A089145	001	Mar 17, 1986
	EQ 50MG HCL	A087657	001	Jun 11, 1982

DISCONTINUED DRUG PRODUCT LIST

6-178 (of 337)

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

	EQ 50MG HCL	A089146	001	Mar 17, 1986
	EQ 100MG HCL	A087658	001	Jun 11, 1982
SANDOZ	EQ 25MG HCL	A081127	001	Jun 28, 1991
	EQ 50MG HCL	A081128	001	Jun 28, 1991
	EQ 100MG HCL	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HCL	A089031	001	Jan 02, 1987
	EQ 50MG HCL	A089032	001	Jan 02, 1987
	EQ 100MG HCL	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HCL	A088392	001	Sep 19, 1983
	EQ 50MG HCL	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HCL	A086698	001	
	EQ 25MG HCL	A086840	001	Jul 01, 1982
	EQ 50MG HCL	A086695	001	
	EQ 50MG HCL	A086705	001	Jul 01, 1982
	EQ 50MG HCL	A087767	001	Aug 16, 1982
	EQ 100MG HCL	A086697	001	
	EQ 100MG HCL	A086728	001	Oct 05, 1982
	EQ 100MG HCL	A087790	001	Aug 16, 1982
VISTARIL				
PFIZER	EQ 100MG HCL	N011459	006	
SUSPENSION;ORAL				
VISTARIL				
PFIZER	EQ 25MG HCL/5ML	N011795	001	

IBANDRONATE SODIUM

TABLET;ORAL

BONIVA

HOFFMANN LA ROCHE

EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021455 001 May 16, 2003

IBUPROFEN

CAPSULE;ORAL

MIDOL

BAYER

200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A070626 001 Sep 02, 1987

200MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A071002 001 Sep 02, 1987

SOLUTION;INTRAVENOUS

CALDOLOR

CUMBERLAND PHARMS

400MG/4ML (100MG/ML)

N022348 001 Jun 11, 2009

SUSPENSION;ORAL

CHILDREN'S ADVIL

WYETH CONS

100MG/5ML

N019833 002 Sep 19, 1989

IBU

ABBOTT

100MG/5ML

N019784 001 Dec 18, 1989

MOTRIN

MCNEIL CONSUMER

100MG/5ML

N019842 001 Sep 19, 1989

SUSPENSION/DROPS;ORAL

MOTRIN

MCNEIL

40MG/ML

N020476 001 May 25, 1995

TABLET;ORAL

ACHES-N-PAIN

LEDERLE

200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO

200MG

A072097 001 Dec 08, 1987

IBU

BASF

400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA

800MG

A071965 001 Aug 11, 1988

DISCONTINUED DRUG PRODUCT LIST

6-179 (of 337)

IBUPROFEN

TABLET; ORAL

IBUPRIN

PLIVA

200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT

600MG

A070556 001 Jun 14, 1985

800MG

A071264 001 Jul 25, 1986

CONTRACT PHARMACAL

200MG

A073691 001 Feb 25, 1994

HALSEY

200MG

A071027 001 Sep 29, 1987

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS

200MG

A071144 001 Jan 20, 1987

200MG

A071154 001 Oct 27, 1987

200MG

A072040 001 Apr 29, 1988

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

LEDERLE

400MG

A070629 001 Sep 19, 1986

600MG

A070630 001 Sep 19, 1986

LEINER

300MG

A071266 001 Oct 15, 1986

MCNEIL

400MG

A070081 001 Jun 16, 1986

600MG

A070476 001 Jun 16, 1986

MUTUAL PHARM

200MG

A070493 001 Dec 24, 1985

200MG

A070908 001 Sep 26, 1986

200MG

A071462 001 Oct 02, 1986

400MG

A070079 001 Jul 24, 1985

600MG

A070080 001 Jul 24, 1985

800MG

A071448 001 Feb 18, 1987

MYLAN

200MG

A071870 001 May 05, 1988

400MG

A070045 001 Sep 24, 1985

600MG

A070057 001 Sep 24, 1985

800MG

A071999 001 Dec 03, 1987

NORTHSTAR HLTHCARE

400MG

A078132 001 Sep 10, 2007

600MG

A078132 002 Sep 10, 2007

800MG

A078132 003 Sep 10, 2007

OHM LABS

400MG

A070818 001 Dec 26, 1985

PAR PHARM

200MG

A071575 001 May 08, 1987

300MG

A070328 001 Aug 06, 1985

400MG

A070329 001 Aug 06, 1985

600MG

A070330 001 Aug 06, 1985

800MG

A070986 001 Jul 25, 1986

PERRIGO

200MG

A072098 001 Dec 08, 1987

PLIVA

400MG

A071666 001 Jun 18, 1987

600MG

A071667 001 Jun 18, 1987

800MG

A071668 001 Jun 18, 1987

PUREPAC PHARM

200MG

A071122 001 Oct 03, 1986

200MG

A071664 001 Feb 03, 1987

300MG

A071123 001 Sep 19, 1986

400MG

A071124 001 Sep 19, 1986

600MG

A071125 001 Sep 19, 1986

800MG

A071964 001 Feb 01, 1988

SANDOZ

200MG

A070733 001 Sep 19, 1986

200MG

A071807 001 Feb 25, 1988

200MG

A074525 001 Dec 15, 1995

200MG

A074533 001 Dec 15, 1995

300MG

A070734 001 Jun 12, 1986

400MG

A070735 001 Jun 12, 1986

400MG

A072064 001 Jan 14, 1988

600MG

A070736 001 Jun 12, 1986

600MG

A072065 001 Jan 14, 1988

800MG

A071938 001 Jan 14, 1988

800MG

A072169 001 Dec 11, 1987

SUPERPHARM

600MG

A070709 001 Apr 25, 1986

TEVA

200MG

A073141 001 May 29, 1992

400MG

A073343 001 Jun 30, 1992

600MG

A073344 001 Jun 30, 1992

800MG

A073345 001 Jun 30, 1992

VINTAGE PHARMS

200MG

A072249 001 Jan 10, 1989

DISCONTINUED DRUG PRODUCT LIST

6-180 (of 337)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

WATSON LABS

200MG

A070435 001 Mar 05, 1986

200MG

A071765 001 Sep 04, 1987

200MG

A071905 001 Mar 08, 1988

300MG

A071338 001 Dec 01, 1986

400MG

A070038 001 Sep 06, 1985

400MG

A070436 001 Aug 21, 1985

600MG

A070041 001 Sep 06, 1985

600MG

A070437 001 Aug 21, 1985

800MG

A071547 001 Jul 02, 1987

800MG

A071911 001 Oct 13, 1987

IBUPROHM

OHM LABS

400MG

A070469 001 Aug 29, 1985

MEDIPREN

MCNEIL

200MG

A070475 001 Feb 06, 1986

200MG

A071215 001 Jun 26, 1986

MIDOL

BAYER

200MG

A070591 001 Sep 02, 1987

200MG

A071001 001 Sep 02, 1987

MOTRIN

MCNEIL CONSUMER

300MG

N017463 003

400MG

N017463 002

600MG

N017463 004

800MG

N017463 005 May 22, 1985

MCNEIL PED

100MG

N020418 001 Nov 16, 1994

NUPRIN

BRISTOL MYERS

200MG

A072035 001 Feb 16, 1988

200MG

A072036 001 Feb 16, 1988

MCNEIL

200MG

N019012 001 May 18, 1984

200MG

N019012 002 Jul 29, 1987

RUFEN

BASF

600MG

N018197 002 Mar 05, 1984

TABLET, CHEWABLE; ORAL

MOTRIN

MCNEIL PED

50MG

N020135 001 Nov 16, 1994

100MG

N020135 002 Nov 16, 1994

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

COMBUNOX

FOREST LABS

400MG; 5MG

N021378 001 Nov 26, 2004

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN

PHARMACIA AND UPJOHN

5MG/VIAL

N050661 002 Sep 27, 1990

10MG/VIAL

N050661 001 Sep 27, 1990

20MG/VIAL

N050661 003 Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

SANDOZ

1MG/ML

A091293 001 Mar 29, 2011

TEVA PARENTERAL

5MG/VIAL

A065037 003 May 01, 2002

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

IDOXURIDINE

OINTMENT; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%

N015868 001

SOLUTION/DROPS; OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.1%

N013934 001

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL; 100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL; 100MG/ML

N019763 004 Oct 10, 1992

DISCONTINUED DRUG PRODUCT LIST

6-181 (of 337)

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS

EQ 50MG BASE

N021335 001 May 10, 2001

EQ 100MG BASE

N021335 002 May 10, 2001

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

25MG

A089497 001 Jul 14, 1987

PROSAM LABS

10MG

A040753 001 Feb 28, 2008

25MG

A040752 001 Feb 28, 2008

50MG

A040751 001 Feb 28, 2008

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001 May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001 Jul 31, 1984

DISCONTINUED DRUG PRODUCT LIST

6-182 (of 337)

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AMERIGEN PHARMS LTD	1.25MG	A075201 001	Dec 04, 1998
	2.5MG	A075201 002	Dec 04, 1998
SANDOZ	1.25MG	A074594 001	May 23, 1996
	2.5MG	A074594 002	May 23, 1996
TEVA	1.25MG	A074498 002	Feb 12, 1998
	1.25MG	A074665 001	Apr 04, 1997
	2.5MG	A074498 001	Oct 31, 1996
	2.5MG	A074665 002	Apr 04, 1997
WATSON LABS	1.25MG	A074585 001	Sep 26, 1996
	2.5MG	A074585 002	Sep 26, 1996

LOZOL

SANOFI AVENTIS US	1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 002	Apr 29, 1993
	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018538 001	Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

DECABID

LILLY	EQ 50MG BASE	N019693 001	Dec 29, 1989
	EQ 75MG BASE	N019693 002	Dec 29, 1989
	EQ 100MG BASE	N019693 003	Dec 29, 1989

INDINAVIR SULFATE

CAPSULE; ORAL

CRIXIVAN

MERCK SHARP DOHME	EQ 100MG BASE	N020685 006	Apr 19, 2000
	EQ 333MG BASE	N020685 005	Dec 17, 1998

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN	10MG/VIAL	N011525 003
	40MG/VIAL	N011525 004
	50MG/VIAL	N011525 002

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA	25MG	A070266 001	Nov 07, 1985
	50MG	A070267 001	Nov 07, 1985

INDOCIN

IROKO PHARMS LLC	25MG	N016059 001
	50MG	N016059 002

INDOMETHACIN

ABLE	25MG	A076666 001	Dec 17, 2003
	50MG	A076666 002	Dec 17, 2003
CYCLE PHARMS LTD	25MG	A070353 001	Jun 18, 1985
	50MG	A070354 001	Jun 18, 1985
DURAMED PHARMS BARR	25MG	A070326 001	Oct 18, 1985
	50MG	A070327 001	Oct 18, 1985
HALSEY	25MG	A070782 001	Jun 03, 1987
	50MG	A070635 001	Jun 03, 1987
IVAX SUB TEVA PHARMS	25MG	N018730 001	May 04, 1984
	50MG	N018730 002	May 04, 1984
MUTUAL PHARM	25MG	A070067 001	Oct 03, 1986
	25MG	A070899 001	Feb 09, 1987
	50MG	A070068 001	Oct 03, 1986
	50MG	A070900 001	Feb 09, 1987
MYLAN	50MG	N018858 002	Apr 20, 1984
PARKE DAVIS	25MG	N018806 001	Nov 23, 1984
	50MG	N018806 002	Nov 23, 1984
PIONEER PHARMS	25MG	A070813 001	Aug 11, 1986
	50MG	A070592 001	Aug 11, 1986
PLIVA	25MG	A071148 001	Mar 18, 1987
	50MG	A071149 001	Mar 18, 1987
SUPERPHARM	25MG	A070487 001	Oct 10, 1986
	50MG	A070488 001	Oct 10, 1986

DISCONTINUED DRUG PRODUCT LIST

6-183 (of 337)

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

TEVA	25MG	A071342	001	Apr 18, 1988
	50MG	A071343	001	Apr 18, 1988
VINTAGE	25MG	N018829	002	Aug 06, 1984
	50MG	A070651	001	Mar 05, 1986
	50MG	N018829	001	Aug 06, 1984
WATSON LABS	25MG	A070529	001	Oct 18, 1985
	25MG	A070784	001	Aug 20, 1986
	25MG	A072996	001	Jul 31, 1991
	25MG	N018690	001	Jul 31, 1984
	50MG	A070530	001	Oct 18, 1985
	50MG	A070785	001	Aug 20, 1986
	50MG	A071635	001	May 18, 1987
	50MG	A072997	001	Jul 31, 1991
	50MG	N018690	002	Jul 31, 1984

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

IROKO PHARMS	75MG	N018185	001	Feb 23, 1982
--------------	------	---------	-----	--------------

INDOMETHACIN

ABLE	75MG	A076114	001	Feb 06, 2002
INWOOD LABS	75MG	A072410	001	Mar 15, 1989

SUPPOSITORY; RECTAL

INDOCIN

IROKO PHARMS	50MG	N017814	001	Aug 13, 1984
--------------	------	---------	-----	--------------

SUSPENSION; ORAL

INDOMETHACIN

CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987
------------------	----------	---------	-----	--------------

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 50/50

NOVO NORDISK INC	50 UNITS/ML; 50 UNITS/ML	N021810	001	Aug 26, 2008
------------------	--------------------------	---------	-----	--------------

NOVOLOG MIX 70/30 PENFILL

NOVO NORDISK INC	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	002	Nov 01, 2001
	210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML)	N021172	003	Nov 01, 2001

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	004	Apr 23, 2004
------------------	------------------------------	---------	-----	--------------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR INNOLET

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	003	Jun 16, 2005
------------------	------------------------------	---------	-----	--------------

LEVEMIR PENFILL

NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	004	Jun 16, 2005
------------------	------------------------------	---------	-----	--------------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

LILLY	50 UNITS/ML; 50 UNITS/ML	N021018	003	Dec 22, 1999
-------	--------------------------	---------	-----	--------------

HUMALOG MIX 75/25 PEN

LILLY	75 UNITS/ML; 25 UNITS/ML	N021017	003	Dec 22, 1999
-------	--------------------------	---------	-----	--------------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

LILLY	100 UNITS/ML	N020563	002	Aug 06, 1998
-------	--------------	---------	-----	--------------

INSULIN PORK

INJECTABLE; INJECTION

ILETIN I

LILLY	500 UNITS/ML	N017931	001	
-------	--------------	---------	-----	--

INSULIN

NOVO NORDISK INC	40 UNITS/ML	N017926	001	
------------------	-------------	---------	-----	--

REGULAR INSULIN

NOVO NORDISK INC	100 UNITS/ML	N017926	003	
------------------	--------------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-184 (of 337)

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION

REGULAR ILETIN II

LILLY

100 UNITS/ML

N018478 001

INSULIN PURIFIED PORK

INJECTABLE; INJECTION

ILETIN II

LILLY

500 UNITS/ML

N018344 002

REGULAR ILETIN II (PORK)

LILLY

100 UNITS/ML

N018344 001

REGULAR PURIFIED PORK INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018381 001

VELOSULIN

NOVO NORDISK INC

100 UNITS/ML

N018193 001

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN NORDISK MIXTARD (PORK)

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N018195 001

INSULIN RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN BR

LILLY

100 UNITS/ML

N019529 001 Apr 28, 1986

VELOSULIN BR

NOVO NORDISK INC

100 UNITS/ML

N021028 001 Jul 19, 1999

POWDER; INHALATION

EXUBERA

PFIZER

1MG/INH

N021868 001 Jan 27, 2006

3MG/INH

N021868 002 Jan 27, 2006

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

LILLY

50 UNITS/ML; 50 UNITS/ML

N020100 001 Apr 29, 1992

INSULIN RECOMBINANT PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN R

NOVO NORDISK INC

100 UNITS/ML

N018778 001 Aug 30, 1983

VELOSULIN BR HUMAN

NOVO NORDISK INC

100 UNITS/ML

N019450 001 May 30, 1986

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

MIXTARD HUMAN 70/30

BAYER PHARMS

30 UNITS/ML; 70 UNITS/ML

N019585 001 Mar 11, 1988

NOVOLIN 70/30

NOVO NORDISK INC

30 UNITS/ML; 70 UNITS/ML

N019441 001 Jul 11, 1986

INSULIN SUSP ISOPHANE BEEF

INJECTABLE; INJECTION

NPH INSULIN

NOVO NORDISK INC

40 UNITS/ML

N017929 001

100 UNITS/ML

N017929 003

INSULIN SUSP ISOPHANE BEEF/PORK

INJECTABLE; INJECTION

NPH ILETIN I (BEEF-PORK)

LILLY

40 UNITS/ML

N017936 001

100 UNITS/ML

N017936 002

INSULIN SUSP ISOPHANE PURIFIED BEEF

INJECTABLE; INJECTION

NPH ILETIN II

LILLY

100 UNITS/ML

N018479 001

INSULIN SUSP ISOPHANE PURIFIED PORK

INJECTABLE; INJECTION

INSULIN INSULATARD NPH NORDISK

NOVO NORDISK INC

100 UNITS/ML

N018194 001

NPH ILETIN II (PORK)

LILLY

100 UNITS/ML

N018345 001

NPH PURIFIED PORK ISOPHANE INSULIN

NOVO NORDISK INC

100 UNITS/ML

N018623 001

DISCONTINUED DRUG PRODUCT LIST

6-185 (of 337)

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

INSULATARD NPH HUMAN

NOVO NORDISK INC 100 UNITS/ML

N019449 001 May 30, 1986

NOVOLIN N

NOVO NORDISK INC 100 UNITS/ML

N019065 001 Jan 23, 1985

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

INJECTABLE; INJECTION

PROTAMINE ZINC & ILETIN I (BEEF-PORK)

LILLY 40 UNITS/ML

N017932 001

100 UNITS/ML

N017932 002

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II

LILLY 100 UNITS/ML

N018476 001

PROTAMINE ZINC INSULIN

BRISTOL MYERS SQUIBB 40 UNITS/ML

N017928 001

100 UNITS/ML

N017928 003

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

INJECTABLE; INJECTION

PROTAMINE ZINC AND ILETIN II (PORK)

LILLY 100 UNITS/ML

N018346 001

INSULIN ZINC SUSP BEEF

INJECTABLE; INJECTION

LENTE INSULIN

NOVO NORDISK INC 40 UNITS/ML

N017998 001

100 UNITS/ML

N017998 003

INSULIN ZINC SUSP EXTENDED BEEF

INJECTABLE; INJECTION

ULTRALENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017997 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION

ULTRALENTE

NOVO NORDISK INC 100 UNITS/ML

N018385 001

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN U

LILLY 40 UNITS/ML

N019571 001 Jun 10, 1987

100 UNITS/ML

N019571 002 Jun 10, 1987

INSULIN ZINC SUSP PROMPT BEEF

INJECTABLE; INJECTION

SEMILENTE INSULIN

NOVO NORDISK INC 100 UNITS/ML

N017996 003

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION

SEMILENTE

NOVO NORDISK INC 100 UNITS/ML

N018382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION

LENTE ILETIN II

LILLY 100 UNITS/ML

N018477 001

INSULIN ZINC SUSP PURIFIED BEEF/PORK

INJECTABLE; INJECTION

LENTARD

NOVO NORDISK INC 100 UNITS/ML

N018384 001

INSULIN ZINC SUSP PURIFIED PORK

INJECTABLE; INJECTION

LENTE

NOVO NORDISK INC 100 UNITS/ML

N018383 001

LENTE ILETIN II (PORK)

LILLY 100 UNITS/ML

N018347 001

DISCONTINUED DRUG PRODUCT LIST

6-186 (of 337)

INSULIN ZINC SUSP RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN L

LILLY

100 UNITS/ML

N019377 002 Sep 30, 1985

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION

NOVOLIN L

NOVO NORDISK INC

100 UNITS/ML

N018777 001 Aug 30, 1983

INULIN

INJECTABLE; INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX

100MG/ML

N002282 001

INVERT SUGAR

INJECTABLE; INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE

10GM/100ML

N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE; INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE

2.3mCi/ML

N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET; ORAL

CHOLEBRINE

MALLINCKRODT

750MG

N017129 001

IODAMIDE MEGLUMINE

INJECTABLE; INJECTION

RENOVUE-65

BRACCO

65%

N017902 001

RENOVUE-DIP

BRACCO

24%

N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE; INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO

10.3%

N009321 007

IODIPAMIDE SODIUM

INJECTABLE; INJECTION

CHOLOGRAFIN SODIUM

BRACCO

20%

N009321 001

ODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

ODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIP PURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

ODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

ODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

DISCONTINUED DRUG PRODUCT LIST

6-187 (of 337)

IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA

61%

A074636 003 Dec 30, 1997

61%

A074637 001 Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING

76%

A074881 004 Jul 28, 2000

HOSPIRA

76%

A074898 004 Dec 30, 1997

76%

A075005 003 Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA

76%

A074636 004 Dec 30, 1997

ISOVUE-128

BRACCO

26%

N018735 005 Oct 21, 1986

ISOVUE-200

BRACCO

41%

N020327 001 Oct 12, 1994

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE

500MG

N008032 001

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON

100%

N005319 001

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT

52%; 26%

N016783 001

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT

80%

N013319 001

CONRAY 325

MALLINCKRODT

54.3%

N017685 001

CONRAY 400

MALLINCKRODT

66.8%

N014295 001

DISCONTINUED DRUG PRODUCT LIST

6-188 (of 337)

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE

40.6%

N019580 001 Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE

51.3%

N019580 002 Dec 07, 1989

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

MALLINCKRODT

34%

N019710 003 Dec 30, 1988

OPTIRAY 240

MALLINCKRODT

51%

N020923 001 May 28, 1998

OPTIRAY 320

MALLINCKRODT

68%

N020923 002 May 29, 1998

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO

3GM/PACKET

N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE

500MG

A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO

500MG

N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

BOEHRINGER INGELHEIM

0.02%

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC

0.02%

A075111 001 Apr 22, 1999

APOTEX INC

0.02%

A075441 001 Mar 28, 2001

PHARMASCIENCE INC

0.02%

A075507 001 Jan 19, 2001

ROXANE

0.02%

A075867 001 Jul 22, 2002

TEVA PHARMS USA

0.02%

A075313 001 Feb 07, 2000

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE

APOTEX INC

0.021MG/SPRAY

A076156 001 Apr 18, 2003

0.042MG/SPRAY

A076155 001 Apr 18, 2003

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

SANDOZ

40MG/2ML (20MG/ML)

A077994 001 Feb 27, 2008

100MG/5ML (20MG/ML)

A077994 002 Feb 27, 2008

IRON DEXTRAN

INJECTABLE; INJECTION

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)

N021135 005 Mar 29, 2013

EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)

N021135 003 Mar 29, 2005

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON

1%

A086711 001

BRONKOSOL

SANOFI AVENTIS US

0.25%

N012339 009

1%

N012339 008

ISOETHARINE HYDROCHLORIDE

ALPHARMA US PHARMS

1%

A087101 001

ASTRAZENECA

0.062%

A087937 001 Nov 15, 1982

0.062%

A089614 001 Jun 13, 1991

0.125%

A087938 001 Nov 15, 1982

0.125%

A089615 001 Jun 13, 1991

DISCONTINUED DRUG PRODUCT LIST

6-189 (of 337)

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

	0.167%	A088470 001	Mar 14, 1984
	0.167%	A089616 001	Jun 13, 1991
	0.2%	A088471 001	Mar 14, 1984
	0.2%	A089617 001	Jun 13, 1991
	0.25%	A088472 001	Mar 14, 1984
	0.25%	A089618 001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144 001	Jul 29, 1983
	0.14%	A088145 001	Mar 26, 1984
	0.25%	A088146 001	Aug 01, 1983
DEY	0.08%	A088187 001	Dec 03, 1982
	0.1%	A087389 001	
	0.17%	A087390 001	
	0.25%	A088188 001	Dec 03, 1982
	1%	A086763 001	
INTL MEDICATION	0.077%	A086651 001	
	0.08%	A086651 002	
	0.1%	A086651 003	
	0.143%	A086651 004	
	0.167%	A086651 005	
	0.2%	A086651 006	
	0.25%	A086651 007	
	1%	A086651 008	
PARKE DAVIS	0.5%	A085997 001	
	1%	A085889 001	
ROXANE	0.1%	A087396 001	
	0.125%	A087025 001	
	0.167%	A088226 001	Sep 16, 1983
	0.2%	A087324 001	
	0.25%	A088275 001	Jun 03, 1983
	1%	A086899 001	
ISOETHARINE HYDROCHLORIDE S/F			
DEY	0.08%	A089817 001	Nov 22, 1988
	0.1%	A089818 001	Nov 22, 1988
	0.17%	A089819 001	Nov 22, 1988
	0.25%	A089820 001	Nov 22, 1988
	1%	A089252 001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339 007	
ISOETHARINE MESYLATE			
ALPHARMA US PHARMS	0.34MG/INH	A087858 001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

WATSON LABS INC	99.9%	A074393 001	May 12, 1995
-----------------	-------	-------------	--------------

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656 001	
-------	--------	-------------	--

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML	N008662 001	
--------	----------	-------------	--

RIMIFON

ROCHE	25MG/ML	N008420 002	
	100MG/ML	N008420 003	

SYRUP; ORAL

ISONIAZID

MIKART	50MG/5ML	A081118 001	Jul 21, 1997
--------	----------	-------------	--------------

LANIAZID

LANNETT	50MG/5ML	A089243 001	Feb 03, 1986
---------	----------	-------------	--------------

RIMIFON

ROCHE	50MG/5ML	N008420 001	
-------	----------	-------------	--

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330 002	
-----------	-------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

6-190 (of 337)

ISONIAZID

TABLET; ORAL

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003
	300MG	A080134	004

INH

NOVARTIS	300MG	A080935	001
----------	-------	---------	-----

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	
MIKART	100MG	A040090	001	Jun 26, 1997
	300MG	A040090	002	Jun 26, 1997
MK LABS	100MG	A080941	001	
MUTUAL PHARM	100MG	A080136	001	
	300MG	A083633	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID				
LANNETT	50MG	A080140	001	
	100MG	A080140	002	
NYDRAZID				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

HIKMA INTL PHARMS	150MG; 300MG	A065221	001	Jul 29, 2005
-------------------	--------------	---------	-----	--------------

ISOPROPAMIDE IODIDE

TABLET; ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001
-----------------	-------------	---------	-----

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004
ALPHARMA US PHARMS	0.12MG/INH	A085904	001

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001
-------------------	-------------	---------	-----

DISC; INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001
--------	-------	---------	-----

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001
BAXTER HLTHCARE	0.2MG/ML	A083486	001

DISCONTINUED DRUG PRODUCT LIST

6-191 (of 337)

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

HOSPIRA	0.02MG/ML	A083283	001
	0.2MG/ML	A083346	001
INTL MEDICATION	0.2MG/ML	A083724	001

SOLUTION; INHALATION

AEROLONE

LILLY	0.25%	N007245	001
-------	-------	---------	-----

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM	0.031%	A087935	001	Nov 18, 1982
	0.062%	A087936	001	Nov 18, 1982
DEY	0.5%	A086764	001	Jan 04, 1982
PARKE DAVIS	0.25%	A085994	001	
	0.5%	A085540	001	

ISUPREL

SANOFI AVENTIS US	0.5%	N006327	002
	1%	N006327	003

VAPO-ISO

FISONS	0.5%	N016813	001
--------	------	---------	-----

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US	10MG	N006328	001
	15MG	N006328	002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M	0.16MG/INH; 0.24MG/INH	N013296	001
----	------------------------	---------	-----

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M	0.08MG/INH	N010375	003
----	------------	---------	-----

POWDER; INHALATION

NORISODRINE

ABBVIE	10%	N006905	003
	25%	N006905	002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON	100GM/220ML	N017063	001
-------	-------------	---------	-----

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

ISORDIL

WYETH AYERST	40MG	N012882	002	Jul 29, 1988
--------------	------	---------	-----	--------------

TABLET; ORAL

ISORDIL

VALEANT BERMUDA	10MG	N012093	002	Jul 29, 1988
	20MG	N012093	006	Jul 29, 1988
	30MG	N012093	005	Jul 29, 1988

ISOSORBIDE DINITRATE

MUTUAL PHARM

	5MG	A086166	002	Sep 19, 1986
	10MG	A086169	001	Sep 19, 1986
	20MG	A086167	001	Sep 19, 1986
	30MG	A087564	001	Sep 18, 1986

SUPERPHARM

	5MG	A089190	001	Feb 17, 1987
	10MG	A089191	001	Feb 17, 1987
	20MG	A089192	001	Feb 17, 1987
WATSON LABS	5MG	A086034	001	Jan 06, 1988
	10MG	A086032	001	Jan 07, 1988

SORBITRATE

ASTRAZENECA

	5MG	N016192	001	Apr 01, 1996
	10MG	N016192	002	Apr 01, 1996
	20MG	A086405	002	Aug 21, 1990
	30MG	A088124	001	Aug 21, 1990
	40MG	A088125	001	Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

BIOVAIL	2.5MG	N012940	004	Jul 29, 1988
	5MG	N012940	003	Jul 29, 1988
	10MG **Federal Register determination	N012940	005	Jul 29, 1988

DISCONTINUED DRUG PRODUCT LIST

6-192 (of 337)

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISORDIL

that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS

2.5MG

A086054 001 Oct 29, 1987

5MG

A086055 001 Nov 02, 1987

MUTUAL PHARM

2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

WATSON LABS

2.5MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

A086033 001 Feb 26, 1988

5MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

A086031 001 Sep 29, 1987

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA

5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST

40MG

N012882 001 Jul 29, 1988

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA

20MG

N019091 001 Dec 30, 1991

TABLET, EXTENDED RELEASE;ORAL

IMDUR

SCHERING PLOUGH

30MG

N020225 001 Aug 12, 1993

60MG

N020225 002 Aug 12, 1993

120MG

N020225 003 Mar 30, 1995

ISOSORBIDE MONONITRATE

ACTAVIS ELIZABETH

30MG

A075306 001 Dec 31, 1998

60MG

A075306 002 Dec 31, 1998

ALKERMES GAINESVILLE

60MG

A075041 001 Sep 22, 1998

IVAX SUB TEVA PHARMS

30MG

A075448 002 Aug 07, 2001

60MG

A075448 001 Jun 19, 2000

120MG

A075448 003 Aug 07, 2001

SKYEPHARMA AG

60MG

A075166 001 Oct 07, 1999

ISOSULFAN BLUE

INJECTABLE;INJECTION

LYMPHAZURIN

COVIDIEN

1% **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy
 reasons**

N018310 001

ISOTRETINOIN

CAPSULE;ORAL

ACCUTANE

HOFFMANN LA ROCHE

10MG

N018662 002 May 07, 1982

20MG

N018662 004 Mar 28, 1983

40MG

N018662 003 May 07, 1982

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

SMITHKLINE BEECHAM

2.5MG

N019546 001 Dec 20, 1990

5MG

N019546 002 Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

GLAXOSMITHKLINE LLC

5MG **Federal Register determination
 that product was not discontinued or
 withdrawn for safety or efficacy

N020336 001 Jun 01, 1994

DISCONTINUED DRUG PRODUCT LIST

6-193 (of 337)

ISRADIPINE

TABLET, EXTENDED RELEASE;ORAL
DYNACIRC CR

reasons**

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020336 002 Jun 01, 1994

ITRACONAZOLE

INJECTABLE;INJECTION
SPORANOX
JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

IVERMECTIN

TABLET;ORAL
STROMEKTOL
MERCK SHARP DOHME

6MG

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE;ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE;INJECTION

KANAMYCIN

HIKMA MAPLE

EQ 1GM BASE/3ML

A062324 003

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

KANAMYCIN SULFATE

ABRAXIS PHARM

EQ 1GM BASE/3ML

A062504 003 Apr 05, 1984

EQ 75MG BASE/2ML

A062504 001 Apr 05, 1984

EQ 500MG BASE/2ML

A062504 002 Apr 05, 1984

INTL MEDICATION

EQ 1GM BASE/3ML

A062466 002 Sep 30, 1983

EQ 500MG BASE/2ML

A062466 001 Sep 30, 1983

LOCH

EQ 1GM BASE/3ML

A063025 001 Jul 31, 1992

EQ 75MG BASE/2ML

A063021 001 Jul 31, 1992

EQ 500MG BASE/2ML

A063022 001 Jul 31, 1992

PHARMAFAIR

EQ 1GM BASE/3ML

A062669 001 May 07, 1987

EQ 75MG BASE/2ML

A062668 001 May 07, 1987

EQ 500MG BASE/2ML

A062672 001 May 07, 1987

SOLOPAK

EQ 1GM BASE/3ML

A062605 002 Feb 26, 1986

EQ 75MG BASE/2ML

A062605 003 Feb 26, 1986

EQ 500MG BASE/2ML

A062605 001 Feb 26, 1986

WARNER CHILCOTT

EQ 1GM BASE/3ML

A063092 001 Oct 11, 1989

WATSON LABS

EQ 1GM BASE/3ML

A062520 003 May 09, 1985

KANTREX

APOTHECON

EQ 1GM BASE/3ML

A061655 002

EQ 1GM BASE/3ML

A061901 002

EQ 1GM BASE/3ML

A062564 003 Sep 21, 1984

EQ 75MG BASE/2ML

A061655 003

EQ 75MG BASE/2ML

A061901 003

EQ 75MG BASE/2ML

A062564 001 Sep 21, 1984

EQ 500MG BASE/2ML

A061655 001

EQ 500MG BASE/2ML

A061901 001

EQ 500MG BASE/2ML

A062564 002 Sep 21, 1984

KLEBCIL

KING PHARMS

EQ 1GM BASE/3ML

A062170 003

EQ 75MG BASE/2ML

A062170 001

EQ 500MG BASE/2ML

A062170 002

KETOCONAZOLE

CREAM;TOPICAL

NIZORAL

JANSSEN PHARMA

2%

N019084 001 Dec 31, 1985

SUSPENSION;ORAL

NIZORAL

JANSSEN PHARMA

100MG/5ML

A070767 001 Nov 07, 1986

TABLET;ORAL

KETOCONAZOLE

AAIPHARMA LLC

200MG

A075341 001 Jul 27, 1999

APOTEX

200MG

A075912 001 Jan 10, 2002

MUTUAL PHARMA

200MG

A075314 001 Jun 15, 1999

PLIVA

200MG

A075362 001 Jun 15, 1999

DISCONTINUED DRUG PRODUCT LIST

6-194 (of 337)

KETOCONAZOLE

TABLET; ORAL

KETOCONAZOLE

TEVA

200MG

A074971 001 Jun 15, 1999

NIZORAL

JANSSEN PHARMS

200MG

N018533 001

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

SANDOZ

50MG

A074024 001 Dec 29, 1995

75MG

A074024 002 Dec 29, 1995

TEVA

25MG

A073515 001 Dec 22, 1992

ORUDIS

WYETH AYERST

25MG

N018754 001 Jul 31, 1987

50MG

N018754 002 Jan 09, 1986

75MG

N018754 003 Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ALKERMES GAINESVILLE

200MG

A074879 001 Dec 10, 1997

ORUVAIL

WYETH PHARMS INC

100MG

N019816 003 Feb 08, 1995

150MG

N019816 002 Feb 08, 1995

200MG

N019816 001 Sep 24, 1993

FILM; ORAL

NEXCEDE

NOVARTIS

12.5MG

N022470 001 Nov 25, 2009

TABLET; ORAL

ACTRON

BAYER

12.5MG

N020499 001 Oct 06, 1995

KETOPROFEN

PERRIGO

12.5MG

A075364 001 Feb 07, 2002

ORUDIS KT

WYETH CONS

12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020429 001 Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM

15MG/ML

A076209 001 Jul 21, 2004

30MG/ML

A076209 002 Jul 21, 2004

APOTEX INC

15MG/ML

A075631 002 Jun 29, 2001

30MG/ML

A075626 001 Jul 24, 2001

30MG/ML

A075631 001 Jun 29, 2001

30MG/ML

A077201 001 Oct 14, 2005

APOTHECON

15MG/ML

A075348 001 Nov 28, 2000

30MG/ML

A075348 002 Nov 28, 2000

BEDFORD

15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A075222 001 Apr 26, 1999

15MG/ML

A075230 002 Oct 25, 1999

30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A075222 002 Apr 26, 1999

30MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

A075228 001 Apr 26, 1999

30MG/ML

A075230 001 Oct 25, 1999

GLAND PHARMA LTD

15MG/ML

A076722 001 Jul 27, 2004

30MG/ML

A076722 002 Jul 27, 2004

HIKMA MAPLE

15MG/ML

A075299 001 Nov 03, 1999

15MG/ML

A075772 001 Jul 21, 2004

30MG/ML

A075299 002 Nov 03, 1999

30MG/ML

A075772 002 Jul 21, 2004

HOSPIRA

15MG/ML

A074801 001 Jun 05, 1997

30MG/ML

A074801 002 Jun 05, 1997

LUITPOLD

15MG/ML

A078145 001 Jan 14, 2008

30MG/ML

A078145 002 Jan 14, 2008

SANDOZ

15MG/ML

A076271 001 Oct 06, 2004

SUN PHARMA GLOBAL

15MG/ML

A078737 001 Oct 06, 2008

DISCONTINUED DRUG PRODUCT LIST

6-195 (of 337)

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

30MG/ML

A078737 002 Oct 06, 2008

WOCKHARDT

30MG/ML

A077943 001 Mar 27, 2007

TORADOL

ROCHE PALO

15MG/ML

N019698 001 Nov 30, 1989

30MG/ML

N019698 002 Nov 30, 1989

SOLUTION/DROPS; OPHTHALMIC

ACULAR PRESERVATIVE FREE

ALLERGAN

0.5%

N020811 001 Nov 03, 1997

KETOROLAC TROMETHAMINE

AKORN

0.45%

A203376 001 Feb 10, 2014

TABLET; ORAL

KETOROLAC TROMETHAMINE

CYCLE PHARMS LTD

10MG

A074790 001 Jun 26, 1997

WATSON LABS

10MG

A074955 001 Sep 19, 1997

TORADOL

ROCHE PALO

10MG

N019645 001 Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

KETOTIFEN FUMARATE

APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006

KRYPTON, KR-81M

GAS; INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE

N/A

N018088 001

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

APOTEX INC

5MG/ML

A076051 001 Jul 05, 2002

APOTHECON

5MG/ML

A075355 001 Nov 29, 1999

HOSPIRA

5MG/ML

A075242 001 Sep 30, 1999

NORMODYNE

SCHERING

5MG/ML

N018686 001 Aug 01, 1984

TRANDATE

PROMETHEUS LABS

5MG/ML

N019425 001 Dec 31, 1985

TABLET; ORAL

LABETALOL HYDROCHLORIDE

APOTHECON

100MG

A075223 001 Nov 20, 1998

200MG

A075223 002 Nov 20, 1998

300MG

A075223 003 Nov 20, 1998

MUTUAL PHARM

100MG

A075215 001 Jul 29, 1999

200MG

A075215 002 Jul 29, 1999

300MG

A075215 003 Jul 29, 1999

TEVA

100MG

A074989 001 Sep 30, 1998

200MG

A074989 002 Sep 30, 1998

300MG

A074989 003 Sep 30, 1998

NORMODYNE

SCHERING

100MG

N018687 001 Aug 31, 1987

200MG

N018687 002 Aug 01, 1984

300MG

N018687 003 Aug 01, 1984

400MG

N018687 004 Aug 01, 1984

TRANDATE

CNTY LINE PHARMS

400MG

N018716 004 Aug 01, 1984

LACTULOSE

SOLUTION; ORAL

CHRONULAC

SANOFI AVENTIS US

10GM/15ML

N017884 001

DUPHALAC

SOLVAY

10GM/15ML

A072372 001 Mar 22, 1989

EVALOSE

TEVA PHARMS

10GM/15ML

A073497 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A075911 001 Feb 21, 2002

MORTON GROVE

10GM/15ML

A071841 001 Sep 22, 1988

PACO

10GM/15ML

A073160 001 Aug 25, 1992

LAXILOSE

NOSTRUM LABS

10GM/15ML

A073686 001 May 28, 1993

DISCONTINUED DRUG PRODUCT LIST

6-196 (of 337)

LACTULOSE

SOLUTION;ORAL, RECTAL

ACILAC

NOSTRUM LABS

10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

SANOFI AVENTIS US

10GM/15ML

N017657 001

GENERLAC

MORTON GROVE

10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS

10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

APOTEX INC

10GM/15ML

A076645 001 Jul 28, 2003

PACO

10GM/15ML

A072029 001 Aug 25, 1992

ROXANE

10GM/15ML

A073590 001 May 29, 1992

SOLVAY

10GM/15ML

N017906 001

PORTALAC

SOLVAY

10GM/15ML

A072374 001 Mar 22, 1989

LAMOTRIGINE

TABLET;ORAL

LAMICTAL

GLAXOSMITHKLINE LLC

50MG

N020241 006 Dec 27, 1994

250MG

N020241 004 Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA

25MG

A078669 001 Apr 08, 2011

100MG

A078669 002 Apr 08, 2011

150MG

A078669 003 Apr 08, 2011

200MG

A078669 004 Apr 08, 2011

MATRIX LABS LTD

25MG

A078443 001 Feb 11, 2009

100MG

A078443 002 Feb 11, 2009

150MG

A078443 003 Feb 11, 2009

200MG

A078443 004 Feb 11, 2009

MYLAN

25MG

A077428 001 Jan 27, 2009

100MG

A077428 002 Jan 27, 2009

150MG

A077428 003 Jan 27, 2009

200MG

A077428 004 Jan 27, 2009

PHARMASCIENCE INC

25MG

A078310 001 Feb 04, 2009

100MG

A078310 002 Feb 04, 2009

150MG

A078310 003 Feb 04, 2009

200MG

A078310 004 Feb 04, 2009

ROXANE

25MG

A077392 001 Jan 27, 2009

100MG

A077392 002 Jan 27, 2009

150MG

A077392 003 Jan 27, 2009

200MG

A077392 004 Jan 27, 2009

SANDOZ

25MG

A078645 001 Jan 27, 2009

100MG

A078645 002 Jan 27, 2009

150MG

A078645 003 Jan 27, 2009

200MG

A078645 004 Jan 27, 2009

WOCKHARDT

25MG

A078982 001 Jan 27, 2009

100MG

A078982 002 Jan 27, 2009

150MG

A078982 003 Jan 27, 2009

200MG

A078982 004 Jan 27, 2009

TABLET, CHEWABLE;ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC

100MG

N020764 003 Aug 24, 1998

LAMOTRIGINE

SANDOZ

5MG

A078409 002 Jan 22, 2009

25MG

A078409 003 Jan 22, 2009

LANSOPRAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA

15MG/PACKET

N021281 001 May 03, 2001

30MG/PACKET

N021281 002 May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

TAKEDA PHARMS NA

30MG/VIAL

N021566 001 May 27, 2004

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL

LANSOPRAZOLE

ANI PHARMS INC

15MG

A078730 001 Oct 15, 2010

30MG

A078730 002 Oct 15, 2010

DISCONTINUED DRUG PRODUCT LIST

6-197 (of 337)

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 250MG	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021507	002	Nov 14, 2003
------------------	-----------------------	--	---------	-----	--------------

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 375MG		N021507	003	Nov 14, 2003
------------------	-----------------------	--	---------	-----	--------------

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA	15MG, N/A; N/A, 500MG		N021507	004	Nov 14, 2003
------------------	-----------------------	--	---------	-----	--------------

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

SHIRE LLC	EQ 250MG BASE		N021468	001	Oct 26, 2004
-----------	---------------	--	---------	-----	--------------

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION; TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%; 1.8%		N011914	001	
-------------------	------------	--	---------	-----	--

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%		A077697	001	Mar 22, 2011
------------	--------	--	---------	-----	--------------

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

SANDOZ	10MG		A077085	001	Sep 13, 2005
	10MG		A077087	001	Sep 13, 2005
	20MG		A077085	002	Sep 13, 2005
	20MG		A077087	002	Sep 13, 2005

LEPIRUDIN RECOMBINANT

INJECTABLE; INJECTION

REFLUDAN

BAYER HLTHCARE	50MG/VIAL		N020807	001	Mar 06, 1998
----------------	-----------	--	---------	-----	--------------

LETROZOLE

TABLET; ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG		A090292	001	Jul 13, 2011
IMPAX LABS	2.5MG		A091638	001	Jun 03, 2011
SYNTHON PHARMS	2.5MG		A090196	001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION; ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL		N008107	003	Jan 30, 1987
---------	-------------------	--	---------	-----	--------------

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML		A089352	001	Jun 01, 1988
	EQ 50MG BASE/VIAL		A089353	001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL		A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL		A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL		A081224	001	Jun 03, 1994
HOSPIRA	EQ 3MG BASE/ML		N008107	001	
	EQ 50MG BASE/VIAL		N008107	002	
	EQ 100MG BASE/VIAL		N008107	004	May 23, 1988
	EQ 350MG BASE/VIAL		N008107	005	Apr 05, 1989
PHARMACHEMIE	EQ 350MG BASE/VIAL		A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL		A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL		A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL		A081278	001	Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

HOSPIRA	EQ 10MG BASE/ML	**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A040147	001	Jun 25, 1997
---------	-----------------	--	---------	-----	--------------

LUITPOLD	EQ 50MG BASE/VIAL		A040338	001	Jan 31, 2001
----------	-------------------	--	---------	-----	--------------

TEVA PARENTERAL	EQ 10MG BASE/ML		A040332	001	Jun 28, 1999
-----------------	-----------------	--	---------	-----	--------------

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML		A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL		A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL		A089465	001	Jan 23, 1989

DISCONTINUED DRUG PRODUCT LIST

6-198 (of 337)

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

WELLCOVORIN

EQ 100MG BASE/VIAL

A089834 001 Jan 23, 1989

TABLET; ORAL

LEUCOVORIN CALCIUM

COREPHARMA

EQ 5MG BASE

A074544 001 Aug 28, 1997

EQ 25MG BASE

A074544 002 Aug 28, 1997

PAR PHARM

EQ 5MG BASE

A071600 001 Oct 14, 1987

EQ 25MG BASE

A071598 001 Oct 14, 1987

PHARMACHEMIE

EQ 5MG BASE

A073099 001 Mar 28, 1997

EQ 25MG BASE

A073101 001 Mar 28, 1997

SANDOZ

EQ 15MG BASE

A075327 001 Mar 24, 1999

XANODYNE PHARM

EQ 5MG BASE

N018459 001 Jan 30, 1986

EQ 10MG BASE

A071962 001 Nov 19, 1987

EQ 15MG BASE

A071104 001 Mar 04, 1987

WELLCOVORIN

GLAXOSMITHKLINE

EQ 5MG BASE

N018342 001 Jul 08, 1983

EQ 25MG BASE

N018342 002 Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN

EQ 65MG BASE

N021088 001 Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME

1MG/0.2ML

A075721 001 Nov 29, 2001

LUPRON

ABBVIE ENDOCRINE INC

1MG/0.2ML

N019010 001 Apr 09, 1985

LUPRON DEPOT

ABBVIE ENDOCRINE INC

3.75MG/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020011 001 Oct 22, 1990

LUPRON DEPOT-PED

ABBVIE ENDOCRINE INC

3.75MG/VIAL, 7.5MG/VIAL; 3.75MG/VIAL, 7.5M
G/VIAL **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020263 003 Apr 16, 1993

7.5MG/VIAL, 7.5MG/VIAL; 7.5MG/VIAL, 7.5MG/
VIAL **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020263 004 Apr 16, 1993

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE

1MG/ML

N010423 001

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA

EQ 50MG BASE

N020035 001 Jun 18, 1990

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

APOTEX INC

100MG/ML

A090187 001 Aug 05, 2011

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC

250MG

A077408 001 Mar 02, 2009

500MG

A077408 002 Mar 02, 2009

750MG

A077408 003 Mar 02, 2009

MYLAN

1GM

A078731 004 Feb 10, 2009

250MG

A078731 001 Feb 10, 2009

500MG

A078731 002 Feb 10, 2009

750MG

A078731 003 Feb 10, 2009

SANDOZ

1GM

A077324 004 Jan 15, 2009

250MG

A077324 001 Jan 15, 2009

500MG

A077324 002 Jan 15, 2009

750MG

A077324 003 Jan 15, 2009

WATSON LABS INC

1GM

A078797 001 Jan 15, 2009

250MG

A078797 002 Jan 15, 2009

500MG

A078797 003 Jan 15, 2009

DISCONTINUED DRUG PRODUCT LIST

6-199 (of 337)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

750MG

A078797 004 Jan 15, 2009

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

SANDOZ

500MG

A091668 001 Nov 01, 2012

750MG

A091668 002 Nov 01, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

ALCON PHARMS LTD

EQ 0.5% BASE

N021114 001 Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

LEVOBUNOLOL HYDROCHLORIDE

APOTEX INC

0.25%

A075473 001 Aug 03, 2000

0.5%

A075475 001 Aug 03, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML

N020997 001 Aug 05, 1999

EQ 5MG BASE/ML

N020997 002 Aug 05, 1999

EQ 7.5MG BASE/ML

N020997 003 Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001 Nov 10, 1993

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

SIGMA TAU

1GM/10ML

N018948 002 Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

SANDOZ

5MG

A090486 001 Mar 26, 2013

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL

100MG

N016948 003

250MG

N016948 001

500MG

N016948 002

DOPAR

SHIRE

100MG

N016913 003

250MG

N016913 001

500MG

N016913 002

LARODOPA

ROCHE

100MG

N016912 002

250MG

N016912 001

500MG

N016912 006

TABLET; ORAL

DOPAR

SHIRE

250MG

N016913 004

500MG

N016913 005

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AKORN

EQ 500MG/20ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011

EQ 750MG/30ML (EQ 25MG/ML)

A091644 002 Jun 20, 2011

SOLUTION/DROPS; OPHTHALMIC

IQUIX

SANTEN

1.5% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021571 001 Mar 01, 2004

DISCONTINUED DRUG PRODUCT LIST

6-200 (of 337)

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

APOTEX INC

0.5%

A078282 001 Dec 20, 2010

TABLET;ORAL

LEVOFLOXACIN

WATSON LABS INC

250MG

A201484 001 Nov 22, 2013

500MG

A201484 002 Nov 22, 2013

750MG

A201484 003 Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

FUSILEV

SPECTRUM PHARMS

EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)

N020140 002 Apr 29, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 003 Apr 29, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons

LEVOMEPRMAZINE

INJECTABLE;INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE;ORAL

ORLAAM

ROXANE

10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020315 001 Jul 09, 1993

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY

0.05MG/ML;2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

NOVOCOL

0.05MG/ML;2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

GRAHAM CHEM

0.05MG/ML;2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM

0.05MG/ML;2%

A089517 001 Apr 14, 1988

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML;2%;0.4%

N008592 007

LEVONORGESTREL

IMPLANT;IMPLANTATION

JADELLE

POPULATION COUNCIL

75MG/IMPLANT **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET;ORAL

LEVONORGESTREL

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013

WATSON LABS

0.75MG

A078666 001 Jun 24, 2009

PLAN B

TEVA BRANDED PHARM

0.75MG

N021045 001 Jul 28, 1999

DISCONTINUED DRUG PRODUCT LIST

6-201 (of 337)

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

VALEANT PHARM INTL

2MG

N008720 001 Dec 19, 1991

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOLET

VINTAGE

0.025MG

N021137 001 Jun 06, 2003

0.05MG

N021137 002 Jun 06, 2003

0.075MG

N021137 003 Jun 06, 2003

0.088MG

N021137 004 Jun 06, 2003

0.1MG

N021137 005 Jun 06, 2003

0.112MG

N021137 006 Jun 06, 2003

0.125MG

N021137 007 Jun 06, 2003

0.137MG

N021137 008 Jun 06, 2003

0.15MG

N021137 009 Jun 06, 2003

0.175MG

N021137 010 Jun 06, 2003

0.2MG

N021137 011 Jun 06, 2003

0.3MG

N021137 012 Jun 06, 2003

LEVOTHYROXINE SODIUM

MERCK KGAA

0.025MG

A076752 001 Jun 16, 2005

0.05MG

A076752 002 Jun 16, 2005

0.075MG

A076752 003 Jun 16, 2005

0.088MG

A076752 004 Jun 16, 2005

0.1MG

A076752 005 Jun 16, 2005

0.112MG

A076752 006 Jun 16, 2005

0.125MG

A076752 007 Jun 16, 2005

0.15MG

A076752 008 Jun 16, 2005

0.175MG

A076752 009 Jun 16, 2005

0.2MG

A076752 010 Jun 16, 2005

0.3MG

A076752 011 Jun 16, 2005

LEVOXYL

KING PHARMS R AND D

0.3MG

N021301 012 May 25, 2001

NOVOTHYROX

MERCK KGAA

0.025MG

N021292 001 May 31, 2002

0.05MG

N021292 002 May 31, 2002

0.075MG

N021292 003 May 31, 2002

0.088MG

N021292 004 May 31, 2002

0.1MG

N021292 005 May 31, 2002

0.112MG

N021292 006 May 31, 2002

0.125MG

N021292 007 May 31, 2002

0.137MG

N021292 008 May 31, 2002

0.15MG

N021292 009 May 31, 2002

0.175MG

N021292 010 May 31, 2002

0.2MG

N021292 011 May 31, 2002

0.3MG

N021292 012 May 31, 2002

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

5%

A084947 001

DISCONTINUED DRUG PRODUCT LIST

6-202 (of 337)

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

GRAHAM CHEM

5%

A080210 001

XYLOCAINE

ASTRAZENECA

5%

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%

N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG

N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE

2%

A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT

10%

A087980 001 Feb 02, 1983

20%

A089362 001 May 25, 1988

ABRAXIS PHARM

1%

A080420 001

1%

A086761 001

1.5%

A080420 005

2%

A080420 002

2%

A080420 004

2%

A086761 002

2%

N017508 001

4%

N017508 002

20%

N017508 004

AKORN

1%

A085037 001

2%

A085037 002

BEL MAR

1%

A080710 001

2%

A080760 001

DELL LABS

1%

A083387 001

2%

A083388 001

ELKINS SINN

0.5%

A085131 001

4%

A084626 001

GD SEARLE LLC

1%

A083135 001

2%

A083135 002

GRAHAM CHEM

2%

A080504 001

HIKMA MAPLE

1%

A080407 001

2%

A080407 002

HOSPIRA

1%

A040013 001 Jun 23, 1995

1.5%

A088330 001 May 17, 1984

2%

A088331 001 May 17, 1984

INTL MEDICATION

1%

N017701 002

1GM/VIAL

N018543 001

2%

N017701 001

2GM/VIAL

N018543 002

LUITPOLD

2%

A083198 001

LYPHOMED

1%

A080390 001

2%

A080390 002

MILES

1%

A080414 001

2%

A080414 002

WATSON LABS

1%

A080377 001

1%

A083627 001

2%

A080377 002

2%

A083627 002

WYETH AYERST

1%

A083083 001

2%

A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

100MG/100ML

N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

200MG/100ML

N018967 001 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA

200MG/100ML

A083158 005

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT

200MG/100ML

N018954 001 Jul 09, 1985

HOSPIRA

200MG/100ML

N018388 001

DISCONTINUED DRUG PRODUCT LIST

6-203 (of 337)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	400MG/100ML	N018967 002	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%			
HOSPIRA	400MG/100ML	A083158 006	
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	800MG/100ML	N018967 003	Mar 30, 1984
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER			
HOSPIRA	1.5%	A088326 001	Jul 31, 1984
	10%	A088367 001	Jul 31, 1984
	20%	A088368 001	Jul 31, 1984
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE			
HIKMA MAPLE	1%	A084625 001	
	2%	A084625 002	
INTL MEDICATION	4%	N017702 002	
LIDOCATON			
PHARMATON	2%	A084727 001	Aug 17, 1983
LIDOPEN			
MERIDIAN MEDCL TECHN	10%	N017549 001	
XYLOCAINE			
ASTRAZENECA	1%	N010418 005	
	1.5%	N010418 009	
	2%	N010418 007	
XYLOCAINE DENTAL			
DENTSPLY PHARM	2%	N021380 001	
XYLOCAINE PRESERVATIVE FREE			
FRESENIUS KABI USA	10%	N016801 003	
INJECTABLE; SPINAL			
XYLOCAINE 1.5% W/ DEXTROSE 7.5%			
FRESENIUS KABI USA	1.5%	N016297 001	
XYLOCAINE 5% W/ GLUCOSE 7.5%			
ASTRAZENECA	5%	N010496 002	Jul 07, 1982
JELLY; TOPICAL			
ANESTACON			
BANNER PHARMACAPS	2%	A080429 001	
LIDOCAINE HYDROCHLORIDE			
TEVA PHARMS USA	2%	A081318 001	Apr 29, 1993
SOLUTION; ORAL			
LIDOCAINE HYDROCHLORIDE VISCOUS			
ACTAVIS MID ATLANTIC	2%	A086578 001	
INTL MEDICATION	2%	A086389 001	Feb 02, 1982
SOLUTION; TOPICAL			
LARYNGOTRACHEAL ANESTHESIA KIT			
KENDALL IL	4%	A087931 001	Jun 10, 1983
LIDOCAINE HYDROCHLORIDE			
PACO	4%	A089688 001	Jun 30, 1989
LTA II KIT			
HOSPIRA	4%	A088542 001	Jul 31, 1984
PEDIATRIC LTA KIT			
ABBOTT	2%	A088572 001	Jul 31, 1984
HOSPIRA	2%	A085995 001	

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE; INJECTION

TERRAMYCIN			
PFIZER	2%; 50MG/ML	A060567 001	
	2%; 125MG/ML	A060567 002	

LIDOCAINE; PRILOCAINE

DISC; TOPICAL

EMLA			
ASTRAZENECA	2.5%; 2.5%	N020962 001	Feb 04, 1998

LINCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

LINCOCIN			
PHARMACIA AND UPJOHN	EQ 250MG BASE	N050316 001	
	EQ 500MG BASE	N050316 002	

INJECTABLE; INJECTION

LINCOMYCIN HYDROCHLORIDE			
WATSON LABS	EQ 300MG BASE/ML	A063180 001	Apr 16, 1991

DISCONTINUED DRUG PRODUCT LIST

6-204 (of 337)

LINDANE

CREAM; TOPICAL

KWELL

REED AND CARNRICK

1%

A084218 001

1%

N006309 001

LOTION; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084989 001

KWELL

REED AND CARNRICK

1%

A084218 002

1%

N006309 003

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4; T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.0075MG; 0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.015MG; 0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.03MG; 0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.045MG; 0.045MG

N016680 004

THYROLAR-5

FOREST LABS

0.0625MG; 0.25MG

N016807 006

LISINAPRIL

TABLET; ORAL

LISINAPRIL

SANDOZ

2.5MG

A075903 001 Jul 01, 2002

2.5MG

A075999 001 Jul 01, 2002

5MG

A075903 002 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075903 003 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075903 004 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

30MG

A075903 005 Jul 01, 2002

30MG

A075999 005 Jul 01, 2002

40MG

A075903 006 Jul 01, 2002

40MG

A075999 006 Jul 01, 2002

TEVA

2.5MG

A075783 001 Jul 01, 2002

5MG

A075783 002 Jul 01, 2002

10MG

A075783 003 Jul 01, 2002

20MG

A075783 004 Jul 01, 2002

30MG

A075783 005 Jul 01, 2002

40MG

A075783 006 Jul 01, 2002

PRINIVIL

MERCK

2.5MG

N019558 006 Jan 28, 1994

DISCONTINUED DRUG PRODUCT LIST

6-205 (of 337)

LITHIUM CARBONATE

CAPSULE;ORAL

ESKALITH

NOVEN THERAP

300MG

N016860 001

LITHIUM CARBONATE

ABLE

150MG

A076823 001 Jun 29, 2004

300MG

A076121 001 Sep 27, 2001

300MG

A076823 002 Jun 29, 2004

600MG

A076823 003 Jun 29, 2004

APOTEX INC

300MG

A076795 001 Nov 22, 2004

HIKMA PHARMS LLC

600MG

A078763 001 Apr 15, 2008

USL PHARMA

300MG

A072542 001 Feb 01, 1989

WATSON LABS

300MG

A070407 001 Mar 19, 1987

LITHONATE

SOLVAY

300MG

N016782 001

TABLET;ORAL

ESKALITH

JDS PHARMS

300MG

N017971 001

LITHANE

BAYER PHARMS

300MG

N018833 001 Jul 18, 1985

LITHIUM CARBONATE

HIKMA INTL PHARMS

300MG

A078715 001 Dec 28, 2010

PFIZER

300MG

N016834 001

LITHOTABS

SOLVAY

300MG

N016980 001

TABLET, EXTENDED RELEASE;ORAL

ESKALITH CR

JDS PHARMS

450MG

N018152 001 Mar 29, 1982

LITHIUM CARBONATE

ABLE

300MG

A076382 001 Apr 21, 2003

BARR

300MG

A076170 001 Jun 10, 2002

450MG

A076366 001 Aug 21, 2003

LITHIUM CITRATE

SYRUP;ORAL

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

MCNEIL PED

2MG

N017690 001

LOPERAMIDE HYDROCHLORIDE

ROXANE

2MG

A073080 001 Nov 27, 1991

SANDOZ

2MG

A072993 001 Aug 28, 1992

TEVA

2MG

A073122 001 Aug 30, 1991

SOLUTION;ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

PERRIGO

2MG

A074194 001 Oct 30, 1992

LORACARBEF

CAPSULE;ORAL

LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

FOR SUSPENSION;ORAL

LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

DISCONTINUED DRUG PRODUCT LIST

6-206 (of 337)

LORATADINE

SYRUP; ORAL

CLARITIN HIVES RELIEF

SCHERING PLOUGH

1MG/ML **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020641 003 Nov 19, 2003

LORATADINE

APOTEX INC

1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD

1MG/ML

A076529 001 Aug 20, 2004

TABLET; ORAL

LORATADINE

PERRIGO

10MG

N021512 001 Jun 24, 2004

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

ACTAVIS LABS FL INC

5MG; 120MG

A076208 001 Jan 28, 2004

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AKORN

2MG/ML

A074974 001 Jul 23, 1998

BEDFORD

2MG/ML

A077076 001 Jul 13, 2005

4MG/ML

A077076 002 Jul 13, 2005

DAVA PHARMS INC

2MG/ML

A074793 001 Mar 16, 2000

4MG/ML

A074793 002 Mar 16, 2000

HIKMA MAPLE

2MG/ML

A074496 001 Sep 28, 1998

4MG/ML

A074496 002 Sep 28, 1998

HOSPIRA

2MG/ML

A074280 001 May 27, 1994

2MG/ML

A074300 001 Apr 12, 1994

4MG/ML

A074280 002 May 27, 1994

4MG/ML

A074300 003 Mar 19, 1997

WATSON LABS

2MG/ML

A074276 001 Apr 15, 1994

4MG/ML

A074276 002 Apr 15, 1994

WATSON LABS INC

1MG/0.5ML

A074551 003 Sep 12, 1996

2MG/ML

A074535 001 Sep 12, 1996

2MG/ML

A074551 001 Sep 12, 1996

4MG/ML

A074535 002 Sep 12, 1996

4MG/ML

A074551 002 Sep 12, 1996

SOLUTION; ORAL

LORAZEPAM

ROXANE

0.5MG/5ML

A074648 001 Mar 18, 1997

TABLET; ORAL

LORAZ

QUANTUM PHARMICS

0.5MG

A070200 001 Aug 09, 1985

1MG

A070201 001 Aug 09, 1985

2MG

A070202 001 Aug 09, 1985

LORAZEPAM

AM THERAP

0.5MG

A070727 001 Mar 07, 1986

1MG

A070728 001 Mar 07, 1986

2MG

A070729 001 Mar 07, 1986

HALSEY

0.5MG

A071434 001 Sep 01, 1987

1MG

A071435 001 Sep 01, 1987

2MG

A071436 001 Sep 01, 1987

MUTUAL PHARM

0.5MG

A070472 001 Dec 10, 1985

0.5MG

A072553 001 Mar 29, 1991

1MG

A070473 001 Dec 10, 1985

1MG

A072554 001 Mar 29, 1991

2MG

A070474 001 Dec 10, 1985

2MG

A072555 001 Mar 29, 1991

PAR PHARM

0.5MG

A070675 001 Dec 01, 1986

1MG

A070676 001 Dec 01, 1986

2MG

A070677 001 Dec 01, 1986

SANDOZ

0.5MG

A071193 001 Apr 15, 1988

1MG

A071194 001 Apr 15, 1988

2MG

A071195 001 Apr 15, 1988

SUPERPHARM

0.5MG

A071245 001 Feb 09, 1987

1MG

A071246 001 Feb 09, 1987

2MG

A071247 001 Feb 09, 1987

USL PHARMA

1MG

A070539 001 Dec 22, 1986

2MG

A070540 001 Dec 22, 1986

WARNER CHILCOTT

1MG

A071038 001 Jan 12, 1988

2MG

A071039 001 Jan 12, 1988

DISCONTINUED DRUG PRODUCT LIST

6-207 (of 337)

LORAZEPAM

TABLET; ORAL

LORAZEPAM

WATSON LABS

0.5MG

A071086 001 Mar 23, 1987

0.5MG

A071117 001 Jul 24, 1986

1MG

A071087 001 Mar 23, 1987

1MG

A071118 001 Jul 24, 1986

2MG

A071088 001 Mar 23, 1987

2MG

A071110 001 Jul 24, 1986

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

WATSON LABS

25MG

A091129 001 Oct 06, 2010

50MG

A091129 002 Oct 06, 2010

100MG

A091129 003 Oct 06, 2010

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS; OPHTHALMIC

LOTEMAX

PHARMOS

0.5%

N020841 001 Mar 09, 1998

LOVASTATIN

TABLET; ORAL

MEVACOR

MERCK

10MG

N019643 002 Mar 28, 1991

20MG

N019643 003 Aug 31, 1987

40MG

N019643 004 Dec 14, 1988

TABLET, EXTENDED RELEASE; ORAL

ALTOPREV

ANDRX LABS LLC

10MG

N021316 001 Jun 26, 2002

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL

LOXITANE C

WATSON LABS

EQ 25MG BASE/ML

N017658 001

INJECTABLE; INJECTION

LOXITANE IM

WATSON LABS

EQ 50MG BASE/ML

N018039 001

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXITANE

WATSON LABS

EQ 5MG BASE

N017525 001

EQ 10MG BASE

N017525 002

EQ 25MG BASE

N017525 003

EQ 50MG BASE

N017525 004

TABLET; ORAL

LOXITANE

WATSON LABS

EQ 10MG BASE

N017525 006

EQ 25MG BASE

N017525 007

EQ 50MG BASE

N017525 008

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

EMD SERONO

75 IU/VIAL

N021322 001 Oct 08, 2004

LYPRESSIN

SOLUTION; NASAL

DIAPID

NOVARTIS

0.185MG/ML

N016755 001

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN

30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML

N019006 001 Apr 04, 1984

DISCONTINUED DRUG PRODUCT LIST

6-208 (of 337)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N018252 001	
---------	---	-------------	--

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 001	
-------------	---	-------------	--

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 002	Jul 08, 1982
-------------	---	-------------	--------------

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG /100ML; 502MG/100ML	N019326 001	Jan 25, 1985
-----------------	---	-------------	--------------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001	Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002	Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001	Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002	Mar 24, 2006

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009
------------------	------	-------------	--------------

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

GE HEALTHCARE	37.9MG/ML	N020652 001	Nov 26, 1997
---------------	-----------	-------------	--------------

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001	Dec 19, 1997
--------	-----------	-------------	--------------

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML	N019228 001	May 05, 1987
---------------	-----------------------	-------------	--------------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

HOSPIRA	10GM/100ML	N016269 002	
MILES	10GM/100ML	N016472 002	

MANNITOL 15%

HOSPIRA	15GM/100ML	N016269 003	
MILES	15GM/100ML	N016472 005	

MANNITOL 20%

B BRAUN	20GM/100ML	N014738 001	
HOSPIRA	20GM/100ML	N016269 004	
MILES	20GM/100ML	N016472 004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754 001	
ASTRAZENECA	12.5GM/50ML	A089239 001	May 06, 1987
	12.5GM/50ML	A089240 001	May 06, 1987
HOSPIRA	12.5GM/50ML	N016269 005	
MERCK	12.5GM/50ML	N005620 001	
WATSON LABS	12.5GM/50ML	A087460 001	Jun 27, 1983

MANNITOL 5%

HOSPIRA	5GM/100ML	N016269 001	
---------	-----------	-------------	--

POWDER; INHALATION

ARIDOL KIT

PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010
---------------	----------------------------	-------------	--------------

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704 002	
---------	-----------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

6-209 (of 337)

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA

540MG/100ML; 2.7GM/100ML

A080224 001

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA

540MG/100ML; 2.7GM/100ML

N017636 001

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS

25MG

N017543 001

50MG

N017543 002

75MG

N017543 003 Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP

25MG

A072129 001 Jan 14, 1988

50MG

A072130 001 Jan 14, 1988

75MG

A072131 001 Jan 14, 1988

WATSON LABS

25MG

A071943 001 Dec 30, 1987

25MG

A072162 001 Jun 01, 1988

50MG

A071944 001 Dec 30, 1987

50MG

A072163 001 Jun 01, 1988

75MG

A071945 001 Dec 30, 1987

75MG

A072164 001 Jun 01, 1988

MASOPROCOL

CREAM; TOPICAL

ACTINEX

UNIV AZ CANCER CTR

10%

N019940 001 Sep 04, 1992

MAZINDOL

TABLET; ORAL

MAZANOR

WYETH AYERST

1MG

N017980 002

2MG

N017980 001

SANOREX

NOVARTIS

1MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017247 001

2MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017247 002

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

JANSSEN PHARMS

100MG

N017481 001

MEBUTAMATE

TABLET; ORAL

DORMATE

MEDPOINTE PHARM HLC

600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

INVERSINE

TARGACEPT

2.5MG

N010251 001

MECASERMIN RINFABATE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

IPLEX

INSMED

36MG/0.6ML

N021884 001 Dec 12, 2005

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

CITRON PHARMA LLC

12.5MG

N010721 006

25MG

N010721 004

50MG

N010721 001 Jan 20, 1982

MECLIZINE HYDROCHLORIDE

ABC HOLDING

12.5MG

A085253 001

25MG

A085252 001

AMNEAL PHARMS

50MG

A201451 003 Feb 23, 2011

ANABOLIC

25MG

A085891 001

BUNDY

12.5MG

A084382 001

25MG

A084872 001

DISCONTINUED DRUG PRODUCT LIST

6-210 (of 337)

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	12.5MG	A083784	001	
	12.5MG	A084975	001	
	25MG	A084657	001	
KV PHARM	12.5MG	A085524	001	
	25MG	A085523	001	
MYLAN PHARMS INC	50MG	A202640	003	Sep 17, 2012
PAR PHARM	50MG	A089674	001	Mar 31, 1988
PLIVA	12.5MG	A088732	001	Dec 11, 1985
	25MG	A088734	001	Dec 11, 1985
SUPERPHARM	12.5MG	A089113	001	Aug 20, 1985
	25MG	A089114	001	Aug 20, 1985
UDL	12.5MG	A088256	001	Jun 13, 1983
	25MG	A088257	001	Jun 13, 1983
VANGARD	12.5MG	A087877	001	Apr 20, 1982
	25MG	A087620	001	Jan 04, 1982
WATSON LABS	12.5MG	A085195	001	
	12.5MG	A085269	001	
	25MG	A085740	001	

TABLET, CHEWABLE; ORAL

ANTIVERT

CITRON PHARMA LLC	25MG	N010721	005	
MECLIZINE HYDROCHLORIDE				
IVAX SUB TEVA PHARMS	25MG	A084976	001	
NEXGEN PHARMA INC	25MG	A086392	001	
PLIVA	25MG	A088733	001	Dec 11, 1985

MECLOCYCLINE SULFOSALICYLATE

CREAM; TOPICAL

MECLAN

JOHNSON AND JOHNSON	1%	N050518	001	
---------------------	----	---------	-----	--

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLODIUM

QUANTUM PHARMICS	EQ 50MG BASE	A071380	001	Jul 14, 1987
	EQ 100MG BASE	A071381	001	Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP	EQ 50MG BASE	A071362	001	Feb 10, 1987
	EQ 100MG BASE	A071363	001	Feb 10, 1987
BARR	EQ 50MG BASE	A072848	001	Mar 20, 1989
	EQ 100MG BASE	A072809	001	Mar 20, 1989
PAR PHARM	EQ 50MG BASE	A072077	001	Mar 10, 1988
	EQ 100MG BASE	A072078	001	Mar 10, 1988
SANDOZ	EQ 50MG BASE	A072262	001	Nov 29, 1988
	EQ 100MG BASE	A072263	001	Nov 29, 1988
USL PHARMA	EQ 50MG BASE	A071007	001	Mar 25, 1988
	EQ 100MG BASE	A071008	001	Mar 25, 1988
VITARINE	EQ 50MG BASE	A071710	001	Jun 15, 1988
	EQ 100MG BASE	A071684	001	Jun 15, 1988
WATSON LABS	EQ 50MG BASE	A070400	001	Nov 25, 1986
	EQ 100MG BASE	A071468	001	Apr 15, 1987
	EQ 50MG BASE	A071640	001	Aug 11, 1987
	EQ 100MG BASE	A070401	001	Nov 25, 1986
	EQ 100MG BASE	A071469	001	Apr 15, 1987
	EQ 100MG BASE	A071641	001	Aug 11, 1987

MECLOMEN

PARKE DAVIS	EQ 50MG BASE	N018006	001	
	EQ 100MG BASE	N018006	002	

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

PHARMACIA AND UPJOHN	100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012541	002	
----------------------	---	---------	-----	--

MEDROXYPROGESTERONE ACETATE

TEVA PHARMS USA	150MG/ML	A076552	001	Oct 27, 2004
-----------------	----------	---------	-----	--------------

TABLET; ORAL

AMEN

AMARIN PHARMS	10MG	A083242	001	
---------------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-211 (of 337)

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

USL PHARMA

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION; OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

LARIAM

ROCHE

250MG

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA PHARMS LLC

250MG

A077699 001 Apr 21, 2010

US ARMY WALTER REED

250MG

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

APOTEX INC

40MG/ML

A077404 001 Feb 16, 2006

TABLET; ORAL

MEGACE

BRISTOL MYERS SQUIBB

20MG

N016979 001

40MG

N016979 002

MEGESTROL ACETATE

TEVA

40MG

A074745 001 Feb 27, 1998

USL PHARMA

20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

TABLET; ORAL

MELOXICAM

COREPHARMA

7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

CR DOUBLE CRANE

7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

MUTUAL PHARM

7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

MYLAN

7.5MG

A077934 001 Jul 20, 2006

15MG

A077934 002 Jul 20, 2006

ROXANE

7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

YABAO PHARM

7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL

EQ 50MG BASE/VIAL

A090299 001 Oct 27, 2009

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

SUN PHARMA GLOBAL

5MG

A090058 001 May 05, 2010

10MG

A090058 002 May 05, 2010

MEMANTINE HYDROCHLORIDE

DR REDDYS LABS LTD

5MG

A090048 001 Apr 14, 2010

10MG

A090048 002 Apr 14, 2010

ORCHID HLTHCARE

5MG

A090044 001 Mar 12, 2012

10MG

A090044 002 Mar 12, 2012

TEVA PHARMS

5MG

A090052 001 Oct 25, 2011

10MG

A090052 002 Oct 25, 2011

DISCONTINUED DRUG PRODUCT LIST

6-212 (of 337)

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY

10MG/ML

N005725 001

SYNKAYVITE

ROCHE

5MG/ML

N003718 004

10MG/ML

N003718 006

37.5MG/ML

N003718 008

TABLET; ORAL

SYNKAYVITE

ROCHE

5MG

N003718 010

MENADIONE

TABLET; ORAL

MENADIONE

LILLY

5MG

N002139 003

MENOTROPINS (FSH; LH)

INJECTABLE; INJECTION

HUMEGON

ORGANON USA INC

75 IU/VIAL; 75 IU/VIAL

N020328 001 Sep 01, 1994

150 IU/VIAL; 150 IU/VIAL

N020328 002 Sep 01, 1994

MENOTROPINS

FERRING

75 IU/VIAL; 75 IU/VIAL

A073598 001 Jan 30, 1997

150 IU/VIAL; 150 IU/VIAL

A073599 001 Jan 30, 1997

PERGONAL

SERONO

75 IU/AMP; 75 IU/AMP

N017646 001

150 IU/AMP; 150 IU/AMP

N017646 002 May 20, 1985

REPRONEX

FERRING

150 IU/VIAL; 150 IU/VIAL

N021047 002 Aug 27, 1999

MEPENZOLATE BROMIDE

SOLUTION; ORAL

CANTIL

SANOFI AVENTIS US

25MG/5ML

N010679 004

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

SANOFI AVENTIS US

25MG/ML

N005010 007

50MG/ML

N005010 002

75MG/ML

N005010 009

100MG/ML

N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML

A080388 001

50MG/ML

A080385 001

50MG/ML

A080387 001

75MG/ML

A080389 001

100MG/ML

A080386 001

ASTRAZENECA

25MG/ML

A089781 001 Mar 31, 1989

50MG/ML

A089782 001 Mar 31, 1989

50MG/ML

A089783 001 Mar 31, 1989

50MG/ML

A089784 001 Mar 31, 1989

75MG/ML

A089785 001 Mar 31, 1989

100MG/ML

A089786 001 Mar 31, 1989

100MG/ML

A089787 001 Mar 31, 1989

100MG/ML

A089788 001 Mar 31, 1989

BAXTER HLTHCARE

25MG/ML

A088279 001 Jun 15, 1984

50MG/ML

A088280 001 Jun 15, 1984

75MG/ML

A088281 001 Jun 15, 1984

100MG/ML

A088282 001 Jun 15, 1984

INTL MEDICATION

10MG/ML

A086332 001

PARKE DAVIS

50MG/ML

A080364 002

75MG/ML

A080364 003

100MG/ML

A080364 001

WATSON LABS

50MG/ML

A073444 001 Mar 17, 1992

100MG/ML

A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML

A040305 001 Mar 10, 1999

INTL MEDICATION

10MG/ML

A081309 001 Aug 30, 1993

MALLINCKRODT

10MG/ML

A040163 001 May 12, 1997

WATSON LABS

10MG/ML

A073443 001 Mar 17, 1992

DISCONTINUED DRUG PRODUCT LIST

6-213 (of 337)

MEPERIDINE HYDROCHLORIDE

SYRUP; ORAL

DEMEROL

SANOFI AVENTIS US

50MG/5ML

N005010 005

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

DURAMED PHARMS BARR

50MG

A040318 001 Oct 05, 1999

100MG

A040318 002 Oct 05, 1999

MUTUAL PHARM

50MG

A080448 001

100MG

A080448 002

WATSON LABS

50MG

A040186 001 Jun 30, 1997

100MG

A040186 002 Jun 30, 1997

WYETH AYERST

50MG

A080454 001

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

BAXTER HLTHCARE CORP

25MG/ML; 25MG/ML

N011730 001

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP

EQ 15MG BASE/ML

N008248 002

EQ 30MG BASE/ML

N008248 001

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

NOVARTIS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N006008 001

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY

3%

A084777 002 Apr 18, 1982

CARBOCAINE

EASTMAN KODAK

3%

N012125 003

MEPIVACAINE HYDROCHLORIDE

GRAHAM CHEM

3%

A083559 001

INTL MEDICATION

1%

A087509 001 Oct 05, 1982

WATSON LABS

1%

A088769 001 Nov 20, 1984

2%

A088770 001 Nov 20, 1984

POLOCAINE

DENTSPLY PHARM

3%

A088653 001 Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING

4MG

N016053 002

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST

400MG

N012455 002

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC

200MG

N011284 001

400MG

N011284 002

TABLET; ORAL

AMOSENE

FERNDAL LABS

400MG

A084030 001

BAMATE

ALRA

200MG

A080380 001

400MG

A080380 002

EQUANIL

WYETH AYERST

200MG

N010028 005

400MG

N010028 004

MEPRIAM

TEVA

400MG

N016069 001

MEPROBAMATE

BARR

600MG

A084230 001

ELKINS SINN

200MG

N015426 002

400MG

N015426 001

HEATHER

400MG

N016928 003

DISCONTINUED DRUG PRODUCT LIST

6-214 (of 337)

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

	600MG	A084329	001	
IMPAX LABS	200MG	N014322	002	
	400MG	N014322	001	
IVAX SUB TEVA PHARMS	200MG	N015438	001	
	400MG	N015438	002	
	600MG	A084181	001	
IVC INDS	400MG	A084153	001	
LANNETT	200MG	N014882	002	
	400MG	N014882	001	
LEDERLE	400MG	A086299	001	
LEE KM	400MG	A089538	001	Nov 25, 1987
MALLARD	400MG	N015072	002	
MK LABS	200MG	N014368	004	
	400MG	N014368	002	
MUTUAL PHARM	200MG	A080699	001	
	400MG	A080699	002	
MYLAN	400MG	A083618	001	
NEXGEN PHARMA INC	200MG	A084220	001	
	400MG	A084589	001	
PARKE DAVIS	200MG	A084744	001	
	400MG	A084744	002	
PERRIGO	200MG	A084546	001	
	400MG	A084547	001	
PHARMAVITE	400MG	A084438	001	
PUREPAC PHARM	200MG	A084804	001	
	400MG	A084804	002	
PVT FORM	400MG	N014601	001	
ROXANE	600MG	A084332	001	
SANDOZ	200MG	N014547	002	
	400MG	A080655	001	
	400MG	N014547	001	
SCHERER LABS	400MG	A083343	001	
SOLVAY	200MG	A084435	001	
STANLABS PHARM	200MG	N014474	002	
	400MG	N014474	004	
TABLICAPS	400MG	A083494	001	
TARO	200MG	A200998	001	May 23, 2011
	400MG	A200998	002	May 23, 2011
USL PHARMA	200MG	A087825	001	Mar 18, 1982
	400MG	A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG	N015139	006	
	400MG	N015139	005	
VANGARD	400MG	A088011	001	Jul 14, 1982
WATSON LABS	200MG	A085720	001	
	400MG	A085721	001	
	600MG	A084274	001	
	600MG	A085719	001	
WEST WARD	200MG	N015417	003	
	400MG	N015417	002	
WHITEWORTH TOWN PLSN	200MG	A083830	001	
	400MG	A083442	001	
MILTOWN				
MEDPOINTE PHARM HLC	200MG	N009698	004	
	400MG	N009698	002	
	600MG	A083919	001	
NEURAMATE				
HALSEY	200MG	N014359	002	
	400MG	N014359	001	
TRANMEP				
SOLVAY	400MG	A084369	001	
	400MG	N016249	001	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999
-------------	----------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-215 (of 337)

MERCAPTOPURINE

TABLET; ORAL
PURINETHOL
TEVA

50MG

N009053 002

MERSALYL SODIUM; THEOPHYLLINE

INJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE
WATSON LABS

100MG/ML; 50MG/ML

A084875 001

MESALAMINE

SUPPOSITORY; RECTAL
CANASA
FOREST LABS INC
ROWASA
MEDA PHARMS

500MG

N021252 001 Jan 05, 2001

500MG

N019919 001 Dec 18, 1990

MESORIDAZINE BESYLATE

CONCENTRATE; ORAL
SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016997 001

INJECTABLE; INJECTION

SERENTIL

NOVARTIS

EQ 25MG BASE/ML

N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS

EQ 10MG BASE

N016774 001

EQ 25MG BASE

N016774 002

EQ 50MG BASE

N016774 003

EQ 100MG BASE

N016774 004

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

WATSON LABS

0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

WATSON LABS

0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

WATSON LABS

0.05MG; 1MG

N013625 002

NORINYL 1+80 21-DAY

GD SEARLE LLC

0.08MG; 1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM

0.05MG; 1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM

0.08MG; 1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM

0.06MG; 10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM

0.1MG; 2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

WATSON LABS

0.05MG; 1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG; 1MG

A070759 001 Jul 01, 1988

NORINYL 1+80 28-DAY

GD SEARLE LLC

0.08MG; 1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN

0.05MG; 1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM

0.08MG; 1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL
ENOVID

GD SEARLE LLC

0.075MG; 5MG

N010976 008

0.15MG; 9.85MG

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC

0.075MG; 5MG

N010976 004

ENOVID-E

GD SEARLE LLC

0.1MG; 2.5MG

N010976 006

DISCONTINUED DRUG PRODUCT LIST

6-216 (of 337)

MESTRANOL; NORETHYNODREL

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG; 2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

APOTEX INC

0.4%

A075402 001 Feb 28, 2001

0.6%

A075403 001 Feb 28, 2001

ASTRAZENECA

0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY

0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

NEPHRON

0.4%

A071855 001 Jul 14, 1988

0.6%

A071726 001 Jul 14, 1988

WOCKHARDT

5%

A072190 001 Jun 07, 1988

PROMETA

MURO

5%

A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML

N017571 001

METAPROTERENOL SULFATE

APOTEX INC

10MG/5ML

A075235 001 Jan 27, 2000

MORTON GROVE

10MG/5ML

A071656 001 Oct 13, 1987

TEVA

10MG/5ML

A072761 001 Feb 27, 1992

TEVA PHARMS

10MG/5ML

A073034 001 Aug 30, 1991

WOCKHARDT

10MG/5ML

A074702 001 Mar 24, 1997

PROMETA

MURO

10MG/5ML

A072023 001 Sep 15, 1988

TABLET; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG

N015874 002

20MG

N015874 001

METAPROTERENOL SULFATE

AM THERAP

10MG

A072054 001 Jun 23, 1988

20MG

A072055 001 Jun 23, 1988

TEVA

10MG

A072519 001 Mar 30, 1990

20MG

A072520 001 Mar 30, 1990

USL PHARMA

10MG

A071013 001 Jan 25, 1988

20MG

A071014 001 Jan 25, 1988

WATSON LABS

10MG

A073013 001 Jan 31, 1991

20MG

A072795 001 Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

ARAMINE

MERCK

EQ 10MG BASE/ML

N009509 002 Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM

EQ 10MG BASE/ML

A080431 001

ELKINS SINN

EQ 10MG BASE/ML

A083363 001

GD SEARLE LLC

EQ 10MG BASE/ML

A086418 001

EQ 20MG BASE/ML

A086418 002

METAXALONE

TABLET; ORAL

SKELAXIN

KING PHARMS

400MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N013217 001

DISCONTINUED DRUG PRODUCT LIST

6-217 (of 337)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE

BRISTOL MYERS SQUIBB	625MG	N020357	003	Nov 05, 1998
	750MG	N020357	004	Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR	1GM	A075971	003	Jan 25, 2002
	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
IPCA LABS LTD	1GM	A078422	003	Aug 06, 2007
	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007
IVAX SUB TEVA PHARMS	1GM	A075975	003	Jan 24, 2002
	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
TEVA	1GM	A076328	003	Dec 16, 2002
	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
WATSON LABS	1GM	A075979	003	Jan 24, 2002
	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
	750MG	A076878	001	Apr 13, 2005
BARR	500MG	A076496	001	Nov 25, 2005
IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
MUTUAL PHARM	500MG	A077124	001	Dec 21, 2005
RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004
TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010
WATSON LABS INC	500MG	A076818	001	Dec 14, 2004

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

SB PHARMCO	500MG; EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N021410	001	Oct 10, 2002
------------	---	---------	-----	--------------

METHACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 140MG BASE	A060641	001	
	EQ 280MG BASE	A060641	002	

SYRUP; ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC	EQ 70MG BASE/5ML	A060641	003	
---------------------	------------------	---------	-----	--

METHADONE HYDROCHLORIDE

SYRUP; ORAL

DOLOPHINE HYDROCHLORIDE

ROXANE	10MG/30ML	N006134	004	
--------	-----------	---------	-----	--

TABLET; ORAL

METHADONE HYDROCHLORIDE

ROXANE	5MG	A088108	001	Mar 08, 1983
	10MG	A088109	001	Mar 08, 1983
	40MG	A074081	001	Apr 28, 1995
SANDOZ	5MG	A040241	001	May 29, 1998

TABLET, DISPERSIBLE; ORAL

WESTADONE

SANDOZ	2.5MG	N017108	001	
--------	-------	---------	-----	--

TABLET, EFFERVESCENT; ORAL

WESTADONE

SANDOZ	5MG	N017108	002	
	10MG	N017108	003	
	40MG	N017108	004	

DISCONTINUED DRUG PRODUCT LIST

6-218 (of 337)

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPEX

TEVA 10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE 5MG

A040529 001 Feb 25, 2004

REXAR 5MG

A084931 001

10MG

A084931 002

TEVA 5MG

A086359 001

TABLET, EXTENDED RELEASE; ORAL

DESOXYN

RECORDATI RARE 5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

SHIRE 50MG

N007390 001

METHARBITAL

TABLET; ORAL

GEMONIL

ABBVIE 100MG

N008322 001

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

APPLIED ANAL 25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

SANDOZ 25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

NEPTAZANE

LEDERLE 25MG

N011721 002 Nov 25, 1991

50MG

N011721 001

METHDILAZINE

TABLET, CHEWABLE; ORAL

TACARYL

WESTWOOD SQUIBB 3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP; ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS 4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB 4MG/5ML

N011950 007

TABLET; ORAL

TACARYL

WESTWOOD SQUIBB 8MG

N011950 006

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

CEDAR PHARMS 15MG

A040619 003 Jul 12, 2005

20MG

A040547 004 Feb 18, 2005

MYLAN 20MG

A040350 003 Jun 07, 2001

TAPAZOLE

KING PHARMS 5MG

N007517 002

10MG

N007517 004

DISCONTINUED DRUG PRODUCT LIST

6-219 (of 337)

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS

1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

MARSAM PHARMS LLC

100MG/ML

A089849 001 Dec 27, 1991

WATSON LABS

100MG/ML

A086459 001

TABLET; ORAL

DELAXIN

FERNDAL LABS

500MG

A085454 001

FORBAXIN

FOREST LABS

750MG

A085136 001

METHOCARBAMOL

ABLE

500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987

ASCOT

500MG

A087660 001 Oct 27, 1982

750MG

A087661 001 Oct 27, 1982

CLONMEL HLTHCARE

500MG

A085961 001

750MG

A085963 001

HEATHER

500MG

A084675 001

750MG

A084924 001

IMPAX LABS

500MG

A084927 001

750MG

A084928 001

INWOOD LABS

500MG

A085137 001

IVAX SUB TEVA PHARMS

500MG

A084648 001

750MG

A084649 001

KV PHARM

500MG

A085660 001

750MG

A085658 001

MUTUAL PHARM

500MG

A084488 001

750MG

A084486 001

MYLAN

500MG

A084259 001

750MG

A084323 001

NYLOS

750MG

A085033 001

PIONEER PHARMS

500MG

A088731 001 Dec 13, 1985

750MG

A089082 001 Dec 13, 1985

PURACAP PHARM

500MG

A084231 002

750MG

A084471 001

PUREPAC PHARM

500MG

A085718 001

750MG

A085718 002

ROXANE

500MG

A088646 001 Feb 29, 1984

750MG

A088647 001 Feb 29, 1984

SANDOZ

500MG

A087283 001

750MG

A087282 001

SOLVAY

500MG

A084448 001

750MG

A084449 001

SUPERPHARM

500MG

A087589 001 Jan 22, 1982

750MG

A087590 001 Jan 22, 1982

TABLICAPS

500MG

A084846 001

UPSHER SMITH

500MG

A087453 001

750MG

A087454 001

WATSON LABS

500MG

A083605 001

500MG

A085180 001

750MG

A083605 002

750MG

A085192 001

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS

5GM/VIAL

N011559 003

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML

A089161 001 Mar 10, 1987

EQ 50MG BASE/VIAL

A089354 001 Jul 17, 1987

EQ 100MG BASE/VIAL

A089355 001 Jul 17, 1987

EQ 250MG BASE/VIAL

A089356 001 Jul 17, 1987

DISCONTINUED DRUG PRODUCT LIST

6-220 (of 337)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX

PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695 002	Apr 08, 1983
	EQ 100MG BASE/VIAL	A087695 003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954 001	Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242 001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180 001	Jan 03, 1986

METHOTREXATE LPF

HOSPIRA	EQ 25MG BASE/ML	N011719 007	Mar 31, 1982
---------	-----------------	-------------	--------------

METHOTREXATE PRESERVATIVE FREE

FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265 001	Feb 26, 1999
HOSPIRA	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719 011	Apr 13, 2005
	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719 014	Apr 13, 2005
	EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N011719 013	Apr 13, 2005
	Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons		

METHOTREXATE SODIUM

ABRAXIS PHARM	EQ 2.5MG BASE/ML	A089323 001	Jun 13, 1986
	EQ 20MG BASE/VIAL	A088935 001	Oct 11, 1985
	EQ 25MG BASE/ML	A089263 001	Jun 13, 1986
	EQ 25MG BASE/ML	A089322 001	Jun 13, 1986
	EQ 50MG BASE/VIAL	A088936 001	Oct 11, 1985
	EQ 100MG BASE/VIAL	A088937 001	Oct 11, 1985

HOSPIRA

EQ 2.5MG BASE/ML	N011719 004
EQ 20MG BASE/VIAL	N011719 001
EQ 25MG BASE/ML	N011719 005
EQ 50MG BASE/VIAL	N011719 003
EQ 100MG BASE/VIAL	N011719 006

NORBROOK

EQ 25MG BASE/ML	A088648 001	May 09, 1986
-----------------	-------------	--------------

PHARMACHEMIE USA

EQ 25MG BASE/ML	A089158 001	Jul 08, 1988
-----------------	-------------	--------------

METHOTREXATE SODIUM PRESERVATIVE FREE

HOSPIRA	EQ 1GM BASE/VIAL	N011719 009	Apr 07, 1988
---------	------------------	-------------	--------------

MEXATE

BRISTOL	EQ 20MG BASE/VIAL	A086358 001
	EQ 50MG BASE/VIAL	A086358 002
	EQ 100MG BASE/VIAL	A086358 003
	EQ 250MG BASE/VIAL	A086358 004

MEXATE-AQ

BRISTOL MYERS	EQ 25MG BASE/ML	A088760 001	Feb 14, 1985
---------------	-----------------	-------------	--------------

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887 001	Apr 14, 1989
----------------------	-----------------	-------------	--------------

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233 001	Jun 17, 1999
---------------------	---------------	-------------	--------------

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772 002
	20MG/ML	N006772 001

METHOXSALEN

CAPSULE; ORAL

METHOXSALEN

SANDOZ	10MG	A087781 001	Jun 08, 1982
--------	------	-------------	--------------

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM	2.5MG	A080970 001
----------	-------	-------------

METHYCLOTHIAZIDE

TABLET; ORAL

AQUATENSEN

MEDPOINTE PHARM HLC	5MG	N017364 001
---------------------	-----	-------------

ENDURON

ABBVIE	2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N012524 001
--------	--	-------------

DISCONTINUED DRUG PRODUCT LIST

6-221 (of 337)

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

	5MG	N012524	004	
METHYCLOTHIAZIDE				
IVAX PHARMS	2.5MG	A087913	001	Jun 03, 1982
	5MG	A087786	001	May 18, 1982
MYLAN	2.5MG	A087671	001	Aug 17, 1982
PAR PHARM	2.5MG	A089135	001	Feb 12, 1986
	5MG	A089136	001	Feb 12, 1986
SANDOZ	2.5MG	A089835	001	Aug 18, 1988
	5MG	A089837	001	Aug 18, 1988
USL PHARMA	5MG	A088745	001	Mar 21, 1985
WATSON LABS	2.5MG	A085487	001	Mar 11, 1982
	2.5MG	A088750	001	Sep 06, 1984
	5MG	A085476	001	Mar 11, 1982
	5MG	A088724	001	Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTRON

ABBOTT	5MG; 25MG	N016047	001
--------	-----------	---------	-----

METHYCLOTHIAZIDE; RESERPINE

TABLET; ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC	2.5MG; 0.1MG	N012708	005
---------------------	--------------	---------	-----

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM; TOPICAL

METVIXIA

GALDERMA LABS LP	EQ 16.8% BASE	N021415	001	Jul 27, 2004
------------------	---------------	---------	-----	--------------

METHYLDOPA

SUSPENSION; ORAL

ALDOMET

MERCK	250MG/5ML	N018389	001
-------	-----------	---------	-----

TABLET; ORAL

ALDOMET

MERCK	125MG	N013400	003
	250MG	N013400	001
	500MG	N013400	002

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
MUTUAL PHARM	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
PAR PHARM	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
SANDOZ	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986

DISCONTINUED DRUG PRODUCT LIST

6-222 (of 337)

METHYLDOPA

TABLET; ORAL

METHYLDOPA

	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

MERCK	50MG/ML	N013401	001	
METHYLDOPATE HYDROCHLORIDE				
ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE	5MG	A040404	001	Mar 29, 2001
	10MG	A040404	002	Mar 29, 2001
	20MG	A040404	003	Mar 29, 2001
ACTAVIS ELIZABETH	5MG	A040321	001	Feb 05, 2002
	10MG	A040321	002	Feb 05, 2002
	20MG	A040321	003	Feb 05, 2002

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

UCB INC	10MG	A040306	001	Oct 20, 1999
METHYLPHENIDATE HYDROCHLORIDE				
ABLE	20MG	A076032	001	May 09, 2001
ACTAVIS ELIZABETH	20MG	A075450	001	Dec 21, 2001
WATSON LABS	20MG	A040410	001	Feb 09, 2001

METHYLPREDNISOLONE

TABLET; ORAL

MEDROL

PHARMACIA AND UPJOHN	24MG	N011153	005	
METHYLPREDNISOLONE				
HEATHER	4MG	A085650	001	
PAR PHARM	16MG	A089207	001	Apr 25, 1988
	24MG	A089208	001	Apr 25, 1988
	32MG	A089209	001	Apr 25, 1988
SANDOZ	4MG	A087341	001	
WATSON LABS	4MG	A086161	001	Feb 09, 1982
	16MG	A086159	001	Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA; RECTAL

MEDROL

PHARMACIA AND UPJOHN	40MG/BOT	N018102	001	
----------------------	----------	---------	-----	--

INJECTABLE; INJECTION

M-PREDROL

BEL MAR	40MG/ML	A086666	001	
	80MG/ML	A087135	001	

METHYLPREDNISOLONE ACETATE

AKORN	40MG/ML	A086903	001	Oct 20, 1982
	80MG/ML	A086903	002	Oct 20, 1982
WATSON LABS	20MG/ML	A085597	001	
	20MG/ML	A087248	001	
	40MG/ML	A085374	001	
	40MG/ML	A085600	001	
	80MG/ML	A085595	001	
	80MG/ML	A086507	001	

DISCONTINUED DRUG PRODUCT LIST

6-223 (of 337)

METHYLPREDNISOLONE ACETATE

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN

0.25%

N012421 001

1%

N012421 002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN

0.25%; EQ 3.5MG BASE/GM

A060611 002

1%; EQ 3.5MG BASE/GM

A060611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT

EQ 1GM BASE/VIAL

A089576 001 Feb 22, 1991

EQ 40MG BASE/VIAL

A089573 001 Feb 22, 1991

EQ 125MG BASE/VIAL

A089574 001 Feb 22, 1991

EQ 500MG BASE/VIAL

A089575 001 Feb 22, 1991

HOSPIRA

EQ 1GM BASE/VIAL

A085852 001

EQ 1GM BASE/VIAL

A089174 001 Aug 18, 1987

EQ 40MG BASE/VIAL

A085853 001

EQ 125MG BASE/VIAL

A085855 001

EQ 500MG BASE/VIAL

A085854 001

EQ 500MG BASE/VIAL

A089173 001 Aug 18, 1987

METHYLPREDNISOLONE

ELKINS SINN

EQ 1GM BASE/VIAL

A086906 004

EQ 125MG BASE/VIAL

A086906 002

EQ 500MG BASE/VIAL

A086906 003

ORGANON USA INC

EQ 1GM BASE/VIAL

A087535 002 Jun 25, 1982

EQ 500MG BASE/VIAL

A087535 001 Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A088679 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A089188 001 Mar 28, 1986

EQ 1GM BASE/VIAL

A089189 001 Mar 28, 1986

EQ 40MG BASE/VIAL

A088676 001 Jun 08, 1984

EQ 40MG BASE/VIAL

A089143 001 Mar 28, 1986

EQ 125MG BASE/VIAL

A088677 001 Jun 08, 1984

EQ 125MG BASE/VIAL

A089144 001 Mar 28, 1986

EQ 500MG BASE/VIAL

A088678 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A089186 001 Mar 28, 1986

EQ 500MG BASE/VIAL

A089187 001 Mar 28, 1986

BEDFORD LABS

EQ 1GM BASE/VIAL

A040641 004 Feb 21, 2007

EQ 1GM BASE/VIAL

A040709 002 Feb 21, 2007

EQ 40MG BASE/VIAL

A040662 001 Feb 21, 2007

EQ 125MG BASE/VIAL

A040641 002 Feb 21, 2007

EQ 500MG BASE/VIAL

A040641 003 Feb 21, 2007

EQ 500MG BASE/VIAL

A040709 001 Feb 21, 2007

ELKINS SINN

EQ 40MG BASE/VIAL

A086906 001

INTL MEDICATION

EQ 1GM BASE/VIAL

A087852 001 Feb 09, 1983

EQ 40MG BASE/VIAL

A087812 001 Feb 09, 1983

EQ 125MG BASE/VIAL

A087813 001 Feb 09, 1983

EQ 500MG BASE/VIAL

A087851 001 Feb 09, 1983

TEVA PARENTERAL

EQ 1GM BASE/VIAL

A081268 001 Nov 30, 1992

EQ 125MG BASE/VIAL

A081266 001 Nov 30, 1992

EQ 500MG BASE/VIAL

A081267 001 Nov 30, 1992

WATSON LABS

EQ 1GM BASE/VIAL

A088524 001 Jul 24, 1984

EQ 40MG BASE/VIAL

A086953 001 Jul 22, 1982

EQ 125MG BASE/VIAL

A087030 001 Jul 22, 1982

EQ 500MG BASE/VIAL

A088523 001 Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN

0.1%; EQ 3.5MG BASE/GM

A060645 001

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER

10MG

A084967 001

VIRILON

STAR PHARMS FL

10MG

A087750 001 Nov 24, 1982

DISCONTINUED DRUG PRODUCT LIST

6-224 (of 337)

METHYLTESTOSTERONE

TABLET;BUCCAL

ANDROID 5

VALEANT PHARM INTL

5MG

A087222 001

ORETON

SCHERING

10MG

A080281 001

TABLET;BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS

5MG

N003240 004

10MG

N003240 001

10MG

N003240 005

25MG

N003240 003

METHYLTESTOSTERONE

IMPAX LABS

10MG

A084287 001

LILLY

10MG

A080256 001

25MG

A080256 002

PUREPAC PHARM

10MG

A080308 001

10MG

A080475 001

10MG

A080475 002

25MG

A080475 003

PVT FORM

5MG

A083836 001

TABLICAPS

10MG

A085125 001

USL PHARMA

10MG

A080271 001

TABLET;ORAL

METHYLTESTOSTERONE

INWOOD LABS

10MG

A080839 001

25MG

A080973 001

KV PHARM

10MG

A084312 001

LANNETT

10MG

A087092 001

Nov 05, 1982

25MG

A087111 001

Jan 27, 1983

PARKE DAVIS

10MG

A084244 001

25MG

A084241 001

PUREPAC PHARM

10MG

A080309 001

25MG

A080310 001

PVT FORM

5MG

A080214 001

10MG

A080214 002

25MG

A080214 003

TABLICAPS

10MG

A080313 001

25MG

A085270 001

WATSON LABS

10MG

A080933 001

25MG

A080931 001

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

METHYPRYLON

CAPSULE;ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR;ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

TABLET;ORAL

NOLUDAR

ROCHE

50MG

N009660 002

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET;ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE;ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001

Jan 30, 1992

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001

Mar 30, 1992

EQ 5MG BASE/ML

A072244 001

Mar 30, 1992

EQ 5MG BASE/ML

A072247 001

May 18, 1992

DISCONTINUED DRUG PRODUCT LIST

6-225 (of 337)

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

HOSPIRA	EQ 5MG BASE/ML	A070505	001	Jun 23, 1989
	EQ 5MG BASE/ML	A070506	001	Jun 22, 1989
	EQ 5MG BASE/ML	A070847	001	Nov 07, 1988
	EQ 5MG BASE/ML	A071291	001	Mar 03, 1989
	EQ 5MG BASE/ML	A071990	001	Jan 18, 1989
	EQ 5MG BASE/ML	A073117	001	Jan 17, 1991
	EQ 5MG BASE/ML	A074147	001	Aug 02, 1996
LYPHOMED	EQ 10MG BASE/2ML	A070293	001	Jan 24, 1986
NORBROOK	EQ 10MG BASE/2ML	A070892	001	Aug 26, 1988
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070623	001	Mar 02, 1987
	EQ 10MG BASE/2ML	A070622	001	Mar 02, 1987

REGLAN

BAXTER HLTHCARE CORP	EQ 10MG BASE/ML	N017862	004	May 28, 1987
----------------------	-----------------	---------	-----	--------------

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 5MG BASE/5ML	A071340	001	Aug 18, 1988
MORTON GROVE	EQ 5MG BASE/5ML	A070949	001	Mar 06, 1987
PACO	EQ 5MG BASE/5ML	A071665	001	Dec 05, 1988
ROXANE	EQ 5MG BASE/5ML	A072038	001	Dec 05, 1988
TEVA	EQ 5MG BASE/5ML	A070819	001	Jul 10, 1987
	EQ 5MG BASE/5ML	A071315	001	Jun 30, 1993

REGLAN

ROBINS AH	EQ 5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N018821	001	Mar 25, 1983
-----------	--	---------	-----	--------------

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS	EQ 5MG BASE	A072384	001	Jun 02, 1988
	EQ 10MG BASE	A070294	001	Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS	EQ 10MG BASE	A070632	001	Oct 28, 1985
------------------	--------------	---------	-----	--------------

MAXOLON

KING PHARMS	EQ 10MG BASE	A070106	001	Mar 04, 1986
-------------	--------------	---------	-----	--------------

METOCLOPRAMIDE HYDROCHLORIDE

CLONMEL	EQ 10MG BASE	A072639	001	May 09, 1991
HALSEY	EQ 10MG BASE	A070906	001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213	001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660	001	Feb 10, 1987
	EQ 10MG BASE	A071536	001	Apr 28, 1993
PAR PHARM	EQ 10MG BASE	A070342	001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436	001	Jun 22, 1989
	EQ 5MG BASE	A074478	001	Oct 05, 1995
	EQ 10MG BASE	A070850	001	Feb 03, 1987
	EQ 10MG BASE	A072215	001	Jan 30, 1990
	EQ 10MG BASE	A074478	002	Oct 05, 1995
SCHERING	EQ 10MG BASE	A070598	001	Feb 02, 1987
SUPERPHARM	EQ 10MG BASE	A070926	001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339	001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363	001	Mar 02, 1987
	EQ 10MG BASE	A070453	001	Jun 06, 1986
	EQ 10MG BASE	A070511	001	Jan 22, 1986
	EQ 10MG BASE	A070645	001	May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

SALIX PHARMS	EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N022246	002	Sep 04, 2009
--------------	---	---------	-----	--------------

REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793	001	Jun 10, 2005
	EQ 10MG BASE	N021793	002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632	003	
-------	--------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-226 (of 337)

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC

2.5MG

N018535 001

5MG

N018535 002

10MG

N018535 003

METOLAZONE

ROXANE

10MG

A076482 002 Apr 29, 2004

TEVA

2.5MG

A076600 001 Jan 06, 2004

5MG

A076833 001 Mar 01, 2004

10MG

A075543 003 Dec 24, 2003

WATSON LABS

10MG

A076891 001 Jul 21, 2004

MYKROX

UCB INC

0.5MG

N019532 001 Oct 30, 1987

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS

EQ 100MG TARTRATE

N019786 001 Dec 27, 1989

EQ 200MG TARTRATE

N019786 002 Dec 27, 1989

EQ 300MG TARTRATE

N019786 003 Dec 27, 1989

EQ 400MG TARTRATE

N019786 004 Dec 27, 1989

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

NESHER PHARMS

EQ 25MG TARTRATE

A077779 001 Mar 20, 2008

EQ 50MG TARTRATE

A077176 001 May 14, 2008

EQ 100MG TARTRATE

A076640 002 May 18, 2007

EQ 200MG TARTRATE

A076640 001 May 18, 2007

SANDOZ

EQ 25MG TARTRATE

A076969 001 Jul 31, 2006

EQ 50MG TARTRATE

A076969 002 May 18, 2007

EQ 100MG TARTRATE

A076969 003 Mar 20, 2008

EQ 200MG TARTRATE

A076969 004 Mar 20, 2008

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

WATSON LABS

1MG/ML

A074032 001 Dec 21, 1993

TABLET; ORAL

METOPROLOL TARTRATE

APOTHECON

50MG

A074258 001 Jan 27, 1994

100MG

A074258 002 Jan 27, 1994

MYLAN

50MG

A073666 001 Dec 21, 1993

100MG

A073666 002 Dec 21, 1993

PRINSTON INC

50MG

A074453 001 Apr 27, 1995

100MG

A074453 002 Apr 27, 1995

PUREPAC PHARM

50MG

A074380 001 Jul 29, 1994

100MG

A074380 002 Jul 29, 1994

TEVA

50MG

A074143 001 Sep 30, 1994

100MG

A074143 002 Sep 30, 1994

TEVA PHARMS

50MG

A074333 001 Jan 27, 1994

100MG

A074333 002 Jan 27, 1994

METRIZAMIDE

INJECTABLE; INJECTION

AMIPAQUE

GE HEALTHCARE

2.5GM/VIAL

N017982 003 Sep 12, 1983

3.75GM/VIAL

N017982 001

6.75GM/VIAL

N017982 002

13.5GM/VIAL

N017982 004 Sep 12, 1983

METRONIDAZOLE

CAPSULE; ORAL

METRONIDAZOLE

ABLE

375MG

A076505 001 Nov 13, 2003

INJECTABLE; INJECTION

METRO I.V.

B BRAUN

500MG/100ML

N018674 001 Aug 31, 1982

METRONIDAZOLE

ABBOTT

500MG/100ML

N018889 001 Nov 18, 1983

ABRAXIS PHARM

500MG/100ML

A070071 001 Dec 03, 1984

HIKMA MAPLE

500MG/100ML

N018907 001 Mar 30, 1984

INTL MEDICATION

500MG/100ML

A070004 001 May 08, 1985

WATSON LABS

500MG/100ML

A070042 001 Dec 20, 1984

DISCONTINUED DRUG PRODUCT LIST

6-227 (of 337)

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE

500MG/100ML

A070170 001 Apr 01, 1986

TABLET; ORAL

METROMIDOL

LABS AF

250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE

250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

HALSEY

250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS

250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK

250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM

250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

PAR PHARM

250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

SANDOZ

250MG

N018620 001 Mar 04, 1982

500MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

SUPERPHARM

250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

VIVIMED LABS

250MG

A070040 001 Jan 29, 1985

500MG

A070039 001 Jan 29, 1985

WATSON LABS

250MG

N018599 001 Sep 17, 1982

250MG

N018764 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

500MG

N018764 002 Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM

250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS

250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

METRONIDAZOLE

ABLE

750MG

A076462 001 Jun 25, 2003

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER

EQ 500MG BASE/VIAL

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYRAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA

250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

SANDOZ

150MG

A074450 001 May 16, 1996

200MG

A074450 002 May 16, 1996

250MG

A074450 003 May 16, 1996

WATSON LABS

150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

MEXITIL

BOEHRINGER INGELHEIM

150MG

N018873 002 Dec 30, 1985

200MG

N018873 003 Dec 30, 1985

250MG

N018873 004 Dec 30, 1985

DISCONTINUED DRUG PRODUCT LIST

6-228 (of 337)

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS

EQ 1GM BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 1GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 2GM BASE/VIAL
 EQ 3GM BASE/VIAL
 EQ 3GM BASE/VIAL
 EQ 3GM BASE/VIAL
 EQ 3GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 4GM BASE/VIAL
 EQ 20GM BASE/VIAL
 EQ 20GM BASE/VIAL

A062333 001
 A062372 005 Jan 13, 1983
 N050549 001
 A062333 002
 A062372 001 May 13, 1982
 N050549 002
 A062333 003
 A062372 002 May 13, 1982
 A062697 001 Jan 22, 1987
 N050549 003
 A062333 004
 A062372 003 May 13, 1982
 A062697 002 Jan 22, 1987
 N050549 004
 A062372 004 Mar 02, 1988
 N050549 005 Mar 02, 1988

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA

10MG/ML

N018040 001

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017494 001

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA

2%

A074136 001 Jan 04, 1995

TEVA PHARMS

2%

A074030 001 Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC

2%, 100MG

A074586 001 Jul 17, 1997

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS

2%

N017739 001

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS

100MG

N018592 001 Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 1MG BASE/ML

A075637 001 Oct 31, 2000

EQ 5MG BASE/ML

A075637 002 Oct 31, 2000

APOTHECON

EQ 1MG BASE/ML

A075620 001 Nov 01, 2000

EQ 5MG BASE/ML

A075620 002 Nov 01, 2000

EQ 5MG BASE/ML

A075641 001 Oct 19, 2000

ASTRAZENECA

EQ 5MG BASE/ML

A075263 001 Jun 26, 2000

BEDFORD

EQ 5MG BASE/ML

A075249 001 Jun 23, 2000

BEN VENUE

EQ 5MG BASE/ML

A075455 001 Jun 20, 2000

HOSPIRA

EQ 1MG BASE/ML

A075396 001 Jun 20, 2000

EQ 5MG BASE/ML

A075396 002 Jun 20, 2000

EQ 5MG BASE/ML

A075484 001 Jun 20, 2000

HOSPIRA INC

EQ 1MG BASE/ML

A075409 002 Jun 20, 2000

EQ 5MG BASE/ML

A075409 001 Jun 20, 2000

INTL MEDICATED

EQ 1MG BASE/ML

A076144 001 Jan 26, 2005

EQ 5MG BASE/ML

A076144 002 Jan 26, 2005

INTL MEDICATION

EQ 1MG BASE/ML

A076020 001 Jul 16, 2004

EQ 5MG BASE/ML

A076020 002 Jul 16, 2004

VERSED

HLR

EQ 1MG BASE/ML

N018654 002 May 26, 1987

EQ 5MG BASE/ML

N018654 001 Dec 20, 1985

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077115 001 Sep 09, 2005

VERSED

ROCHE

EQ 2MG BASE/ML

N020942 001 Oct 15, 1998

DISCONTINUED DRUG PRODUCT LIST

6-229 (of 337)

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

SHIRE LLC

2.5MG

N019815 001 Sep 06, 1996

5MG

N019815 002 Sep 06, 1996

10MG

N019815 003 Mar 20, 2002

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

APOTEX INC

EQ 1MG BASE/ML

A076427 001 Sep 21, 2004

HIKMA MAPLE

EQ 1MG BASE/ML

A075852 001 May 28, 2002

HOSPIRA

EQ 1MG BASE/ML

A075830 001 May 28, 2002

EQ 1MG BASE/ML

A075884 001 May 28, 2002

MYLAN INSTITUTIONAL

EQ 1MG BASE/ML

A076428 001 Jun 16, 2003

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

APOTEX INC

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A077151 001 Jul 20, 2005

BAXTER HLTHCARE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A076259 001 Aug 08, 2002

HIKMA MAPLE

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

A075510 001 May 28, 2002

PRIMACOR

SANOFI AVENTIS US

EQ 1MG BASE/ML

N019436 001 Dec 31, 1987

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

SANOFI AVENTIS US

EQ 10MG BASE/100ML

N020343 001 Aug 09, 1994

EQ 15MG BASE/100ML

N020343 002 Aug 09, 1994

EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)

N020343 003 Aug 09, 1994

EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)

N020343 004 Aug 09, 1994

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

CNTY LINE PHARMS

EQ 50MG BASE

A063066 001 Aug 14, 1990

MINOCIN

PRECISION DERMAT

EQ 75MG BASE

N050649 003 Feb 12, 2001

TRIAx PHARMS

EQ 50MG BASE

N050315 002

EQ 100MG BASE

N050315 001

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

RANBAXY LABS LTD

EQ 45MG BASE

N201922 001 Jul 11, 2012

EQ 67.5MG BASE

N201922 002 Jul 11, 2012

EQ 90MG BASE

N201922 003 Jul 11, 2012

EQ 112.5MG BASE

N201922 004 Jul 11, 2012

EQ 135MG BASE

N201922 005 Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN

LEDERLE

EQ 100MG BASE/VIAL

A062139 001

SUSPENSION; ORAL

MINOCIN

PRECISION DERMAT

EQ 50MG BASE/5ML

N050445 001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE

TRIAx PHARMS

EQ 50MG BASE

N050451 003 Aug 10, 1982

EQ 100MG BASE

N050451 002 Aug 10, 1982

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

LUPIN LTD

EQ 55MG BASE

A091424 002 Nov 30, 2011

SOLODYN

MEDICIS

EQ 45MG BASE

N050808 001 May 08, 2006

EQ 90MG BASE

N050808 002 May 08, 2006

EQ 135MG BASE

N050808 003 May 08, 2006

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)

APOTEX INC

2%

A074924 001 Apr 29, 1998

BAUSCH AND LOMB

2%

A074643 001 Apr 09, 1996

COPLEY PHARM

2%

A074500 001 May 23, 1996

SIGHT PHARMS

2%

A074743 002 Oct 18, 1996

TEVA

2%

A074589 001 Apr 05, 1996

MINOXIDIL (FOR WOMEN)

APOTEX INC

2%

A074924 002 Apr 29, 1998

SIGHT PHARMS

2%

A074743 001 Oct 18, 1996

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC

5%

A075839 001 Oct 01, 2001

DISCONTINUED DRUG PRODUCT LIST

6-230 (of 337)

MINOXIDIL

TABLET; ORAL

LONITEN

PHARMACIA AND UPJOHN	2.5MG	N018154	001	
	10MG	N018154	003	
MINODYL				
QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987
MINOXIDIL				
ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
SANDOZ	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HOSPIRA	20MG/VIAL	A064106	001	Nov 29, 1995
MITOZYTREX				
SUPERGEN	5MG/VIAL	N050763	001	Nov 14, 2002
MUTAMYCIN				
BRISTOL	5MG/VIAL	N050450	001	
	20MG/VIAL	N050450	002	
BRISTOL MYERS	5MG/VIAL	A062336	001	
	20MG/VIAL	A062336	002	
	40MG/VIAL	A062336	003	Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606	001	May 14, 2008
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606	002	May 14, 2008
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606	003	May 14, 2008
NOVANTRONE				
EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987
	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	N019297	002	Dec 23, 1987
	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N019297	003	Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON

ABBVIE	EQ 2MG BASE/ML	N020098	001	Jan 22, 1992
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER				
ABBVIE	EQ 0.5MG BASE/ML	N020098	002	Jan 22, 1992
	EQ 50MG BASE/100ML	N020098	003	Jan 22, 1992
MIVACURIUM CHLORIDE				
AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009

DISCONTINUED DRUG PRODUCT LIST

6-231 (of 337)

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

ENDO PHARMS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 001

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 002

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS

20MG/ML

N017938 001

TABLET; ORAL

MOBAN

ENDO PHARMS

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 004

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 005

25MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 006

50MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 007

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017111 008

MOMETASONE FUROATE

OINTMENT; TOPICAL

MOMETASONE FUROATE

TARO

0.1%

A076624 001 Dec 03, 2004

MONOBENZONE

CREAM; TOPICAL

BENOQUIN

VALEANT PHARM INTL

20%

N008173 003

MONOCTANOIN

LIQUID; PERFUSION, BILIARY

MOCTANIN

ETHITEK

100%

N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

HOSPIRA

0.5MG/ML

N019917 001 Oct 30, 1992

MALLINCKRODT

1MG/ML

N020631 001 Jul 03, 1996

2MG/ML

N020631 002 Jul 03, 1996

WATSON LABS

0.5MG/ML

A073373 001 Sep 30, 1991

0.5MG/ML

A073375 001 Sep 30, 1991

1MG/ML

A073374 001 Sep 30, 1991

1MG/ML

A073376 001 Sep 30, 1991

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

PACIRA PHARMS INC

10MG/ML (10MG/ML)

N021671 001 May 18, 2004

15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004

20MG/2ML (10MG/ML)

N021671 003 May 18, 2004

DISCONTINUED DRUG PRODUCT LIST

6-232 (of 337)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

WATSON LABS

100MG

A075656 001 Jan 30, 2001

ORAMORPH SR

XANODYNE PHARMS INC

15MG

N019977 004 Nov 23, 1994

30MG

N019977 001 Aug 15, 1991

60MG

N019977 002 Aug 15, 1991

100MG

N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY

EQ 1GM BASE/VIAL

N050550 003

EQ 2GM BASE/VIAL

N050550 004

EQ 10GM BASE/VIAL

N050550 008

EQ 250MG BASE/VIAL

N050550 001

EQ 500MG BASE/VIAL

N050550 002

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

ZYDUS PHARMS USA INC

250MG

A065433 001 May 04, 2009

TABLET;ORAL

MYCOPHENOLATE MOFETIL

DR REDDYS LABS LTD

500MG

A090464 001 Sep 13, 2010

ZYDUS PHARMS USA INC

500MG

A065477 001 May 04, 2009

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM

750MG

A075179 001 Jun 06, 2000

DR REDDYS LABS LTD

500MG

A078420 001 Sep 24, 2008

750MG

A078420 002 Sep 24, 2008

PROSAM LABS

500MG

A079093 001 Feb 27, 2009

750MG

A079093 002 Feb 27, 2009

SANDOZ

500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

RELAFEN

SMITHKLINE BEECHAM

500MG

N019583 001 Dec 24, 1991

750MG

N019583 002 Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

KING PHARMS

120MG

N018063 003

160MG

N018063 004

NADOLOL

IVAX SUB TEVA PHARMS

120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

TEVA PHARMS

80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE

N050111 001

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST

EQ 250MG BASE/5ML

N050199 001

INJECTABLE; INJECTION

NAFCILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

EQ 500MG BASE/VIAL

A061984 001

SANDOZ

EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

WATSON LABS INC

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

DISCONTINUED DRUG PRODUCT LIST

6-233 (of 337)

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NALLPEN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A061999 002

EQ 1GM BASE/VIAL

A062755 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061999 003

EQ 2GM BASE/VIAL

A062755 002 Dec 19, 1986

EQ 10GM BASE/VIAL

A061999 004

EQ 500MG BASE/VIAL

A061999 001

UNIPEN

WYETH AYERST

EQ 1GM BASE/VIAL

A062717 002 Dec 16, 1986

EQ 2GM BASE/VIAL

A062717 004 Dec 16, 1986

EQ 2GM BASE/VIAL

N050320 003

EQ 4GM BASE/VIAL

N050320 004

EQ 10GM BASE/VIAL

N050320 005

EQ 20GM BASE/VIAL

N050320 006

EQ 500MG BASE/VIAL

A062717 001 Dec 16, 1986

EQ 500MG BASE/VIAL

N050320 001

UNIPEN IN PLASTIC CONTAINER

WYETH AYERST

EQ 1GM BASE/VIAL

N050320 002

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE

N050462 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML

A070751 001 Jul 02, 1986

20MG/ML

A070752 001 Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

20MG/ML

A070917 001 Feb 03, 1989

ABBVIE

1.5MG/ML

N020200 001 Mar 12, 1993

ASTRAZENECA

10MG/ML

A072070 001 Apr 10, 1989

10MG/ML

A072071 001 Apr 10, 1989

10MG/ML

A072072 001 Apr 10, 1989

20MG/ML

A072073 001 Apr 10, 1989

20MG/ML

A072074 001 Apr 10, 1989

20MG/ML

A072075 001 Apr 10, 1989

BARR

10MG/ML

A074471 001 Mar 19, 1998

20MG/ML

A074471 002 Mar 19, 1998

NUBAIN

ENDO PHARMS

10MG/ML

N018024 001

20MG/ML

N018024 002 May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML

N017430 001

TABLET; ORAL

NALIDIXIC ACID

MUTUAL PHARM

1GM

A070272 001 Jun 29, 1988

250MG

A070270 001 Jun 29, 1988

500MG

A070271 001 Jun 29, 1988

WATSON LABS

1GM

A071919 001 Jun 29, 1988

250MG

A071936 001 Jun 29, 1988

500MG

A072061 001 Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US

1GM

N014214 005

250MG

N014214 002

500MG

N014214 004

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION

REVEX

BAXTER HLTHCARE CORP

EQ 0.1MG BASE/ML

N020459 001 Apr 17, 1995

EQ 1MG BASE/ML

N020459 002 Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

HIKMA MAPLE

0.4MG/ML

A070298 001 Sep 24, 1986

0.4MG/ML

A070299 001 Sep 24, 1986

0.4MG/ML

A070496 001 Sep 24, 1986

WYETH AYERST

0.02MG/ML

A070188 001 Sep 24, 1986

DISCONTINUED DRUG PRODUCT LIST

6-234 (of 337)

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

0.02MG/ML	A070189	001	Sep 24, 1986
0.4MG/ML	A070190	001	Sep 24, 1986
0.4MG/ML	A070191	001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM

0.02MG/ML	A070648	001	Nov 17, 1986
0.02MG/ML	A070661	001	Nov 17, 1986
0.4MG/ML	A070649	001	Nov 17, 1986
1MG/ML	A071604	001	Dec 16, 1988

ASTRAZENECA

0.02MG/ML	A072081	001	Apr 11, 1989
0.02MG/ML	A072082	001	Apr 11, 1989
0.02MG/ML	A072083	001	Apr 11, 1989
0.02MG/ML	A072084	001	Apr 11, 1989
0.02MG/ML	A072085	001	Apr 11, 1989
0.4MG/ML	A072086	001	Apr 11, 1989
0.4MG/ML	A072087	001	Apr 11, 1989
0.4MG/ML	A072088	001	Apr 11, 1989
0.4MG/ML	A072089	001	Apr 11, 1989
0.4MG/ML	A072090	001	Apr 11, 1989
1MG/ML	A072091	001	Apr 11, 1989
1MG/ML	A072092	001	Apr 11, 1989
1MG/ML	A072093	001	Apr 11, 1989

HIKMA MAPLE

0.02MG/ML	A071272	001	May 24, 1988
1MG/ML	A071273	001	May 24, 1988
1MG/ML	A071274	001	May 24, 1988
1MG/ML	A071287	001	May 24, 1988

HOSPIRA

0.02MG/ML	A070171	001	Sep 24, 1986
0.02MG/ML	A070252	001	Jan 16, 1987
0.02MG/ML	A070253	001	Jan 16, 1987
0.4MG/ML	A070255	001	Jan 07, 1987

INTL MEDICATION

0.4MG/ML	A070417	001	Sep 24, 1986
1MG/ML	A072115	001	Apr 27, 1988

MARSAM PHARMS LLC

0.4MG/ML	A071811	001	Jul 19, 1988
----------	---------	-----	--------------

SMITH AND NEPHEW

0.02MG/ML	A071671	001	Nov 17, 1987
0.4MG/ML	A071681	001	Nov 17, 1987
0.4MG/ML	A071682	001	Nov 17, 1987

SOLOPAK

0.02MG/ML	A071672	001	Nov 17, 1987
0.4MG/ML	A071683	001	Nov 17, 1987

WATSON LABS

0.4MG/ML	A071339	001	Nov 18, 1987
----------	---------	-----	--------------

NARCAN

BRISTOL MYERS SQUIBB

0.4MG/ML	A071083	001	Jul 28, 1988
1MG/ML	A071084	001	Jul 28, 1988
1MG/ML	A071311	001	Jul 28, 1988

ENDO PHARMS

0.02MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	002	
0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	001	
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N016636	003	Jun 14, 1982

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TARGINIQ

PURDUE PHARMA LP

5MG; 10MG	N205777	001	Jul 23, 2014
10MG; 20MG	N205777	002	Jul 23, 2014
20MG; 40MG	N205777	003	Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN NX

SANOFI AVENTIS US

EQ 0.5MG BASE; EQ 50MG BASE	N018733	001	Dec 16, 1982
-----------------------------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-235 (of 337)

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

SANDOZ

50MG

A075434 001 Mar 08, 2000

NANDROLONE DECANOATE

INJECTABLE; INJECTION

DECA-DURABOLIN

AGI

50MG/ML

N013132 001 Jun 12, 1986

100MG/ML

N013132 002 Jun 12, 1986

200MG/ML

N013132 003 Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM

100MG/ML

A088290 001 Oct 03, 1983

200MG/ML

A088317 001 Oct 14, 1983

AKORN

100MG/ML

A087519 001 Sep 28, 1983

WATSON LABS

50MG/ML

A086385 001 Jan 13, 1984

50MG/ML

A087598 001 Oct 06, 1983

50MG/ML

A088554 001 Feb 10, 1986

100MG/ML

A086598 001 Jan 13, 1984

100MG/ML

A087599 001 Oct 06, 1983

200MG/ML

A088128 001 Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE; INJECTION

DURABOLIN

ORGANON USA INC

25MG/ML

N011891 001

50MG/ML

N011891 002

NANDROLONE PHENPROPIONATE

WATSON LABS

25MG/ML

A086386 001 Jun 17, 1983

50MG/ML

A087488 001 Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

ALLERGAN

0.1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

A080248 001

NAFAZAIR

BAUSCH AND LOMB

0.1%

A040073 001 May 25, 1994

PHARMAFAIR

0.1%

A088101 001 Apr 15, 1983

NAPHCN FORTE

ALCON

0.1%

A080229 001

OPCON

BAUSCH AND LOMB

0.1%

A087506 001

VASOCON

NOVARTIS

0.1%

A080235 002 Mar 24, 1983

NAPROXEN

TABLET; ORAL

NAPROXEN

DAVA PHARMS INC

250MG

A074105 001 Dec 21, 1993

250MG

A074410 001 Apr 28, 1995

375MG

A074105 002 Dec 21, 1993

375MG

A074410 002 Apr 28, 1995

500MG

A074105 003 Dec 21, 1993

500MG

A074410 003 Apr 28, 1995

HAMILTON PHARMS

250MG

A074110 001 Oct 30, 1992

375MG

A074110 002 Oct 30, 1992

500MG

A074110 003 Oct 30, 1992

IVAX SUB TEVA PHARMS

250MG

A074111 001 Feb 28, 1995

375MG

A074111 002 Feb 28, 1995

500MG

A074111 003 Feb 28, 1995

PLIVA

250MG

A074182 001 Jun 27, 1996

375MG

A074182 002 Jun 27, 1996

500MG

A074182 003 Jun 27, 1996

PUREPAC PHARM

250MG

A074263 001 Dec 21, 1993

375MG

A074263 002 Dec 21, 1993

500MG

A074263 003 Dec 21, 1993

ROXANE

250MG

A074211 001 Feb 28, 1994

375MG

A074211 002 Feb 28, 1994

500MG

A074211 003 Feb 28, 1994

TEVA

250MG

A074129 001 Dec 21, 1993

250MG

A074216 001 Apr 11, 1996

375MG

A074129 002 Dec 21, 1993

DISCONTINUED DRUG PRODUCT LIST

6-236 (of 337)

NAPROXEN

TABLET; ORAL

NAPROXEN

	375MG	A074216 002	Apr 11, 1996
	500MG	A074129 003	Dec 21, 1993
	500MG	A074216 003	Apr 11, 1996
TEVA PHARMS	250MG	A074207 001	Dec 21, 1993
	375MG	A074207 002	Dec 21, 1993
	500MG	A074207 003	Dec 21, 1993
WATSON LABS	250MG	A074163 001	Feb 10, 1995
	250MG	A074457 001	May 31, 1995
	375MG	A074163 002	Feb 10, 1995
	375MG	A074457 002	May 31, 1995
	500MG	A074163 003	Feb 10, 1995
	500MG	A074457 003	May 31, 1995
TABLET, DELAYED RELEASE; ORAL			
NAPROXEN			
ACTAVIS ELIZABETH	375MG	A074936 001	Feb 24, 1998
	500MG	A074936 002	Feb 24, 1998

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

ABLE	EQ 250MG BASE	A076544 001	Aug 22, 2003
	EQ 500MG BASE	A076544 002	Aug 22, 2003
HAMILTON PHARMS	EQ 250MG BASE	A074106 001	Aug 31, 1993
	EQ 500MG BASE	A074106 002	Aug 31, 1993
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A074230 001	Mar 14, 1995
	EQ 500MG BASE	A074230 002	Mar 14, 1995
MYLAN	EQ 250MG BASE	A074367 001	Aug 31, 1994
	EQ 500MG BASE	A074367 002	Aug 31, 1994
PLIVA	EQ 250MG BASE	A074242 001	Jun 20, 1996
	EQ 500MG BASE	A074242 002	Jun 20, 1996
PUREPAC PHARM	EQ 250MG BASE	A074319 001	Mar 20, 1995
	EQ 500MG BASE	A074319 002	Mar 20, 1995
ROXANE	EQ 250MG BASE	A074257 001	Dec 21, 1993
	EQ 500MG BASE	A074257 002	Dec 21, 1993
SANDOZ	EQ 200MG BASE	A074646 001	Jan 13, 1997
	EQ 250MG BASE	A074162 001	Dec 21, 1993
	EQ 250MG BASE	A074495 001	Dec 05, 1994
	EQ 500MG BASE	A074162 002	Dec 21, 1993
	EQ 500MG BASE	A074495 002	Dec 05, 1994
TEVA	EQ 250MG BASE	A074142 001	Dec 21, 1993
	EQ 500MG BASE	A074142 002	Dec 21, 1993
TEVA PHARMS	EQ 250MG BASE	A074289 001	Jan 27, 1994
	EQ 500MG BASE	A074289 002	Jan 27, 1994
WATSON LABS	EQ 250MG BASE	A074195 001	Dec 21, 1993
	EQ 250MG BASE	A074455 001	May 31, 1995
	EQ 500MG BASE	A074195 002	Dec 21, 1993
	EQ 500MG BASE	A074455 002	May 31, 1995

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

TEVA PHARMS	60MG	A077467 001	Sep 09, 2009
	120MG	A077467 002	Sep 09, 2009

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

TILADE

KING PHARMS	1.75MG/INH	N019660 001	Dec 30, 1992
SOLUTION; INHALATION			
TILADE			
SANOFI AVENTIS US	0.5%	N020750 001	Oct 01, 1997

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

IVAX SUB TEVA PHARMS	50MG	A075763 001	Sep 16, 2003
	100MG	A075763 002	Sep 16, 2003
	150MG	A075763 003	Sep 16, 2003
	200MG	A075763 004	Sep 16, 2003
	250MG	A075763 005	Sep 16, 2003
MYLAN	100MG	A076129 002	Sep 16, 2003

DISCONTINUED DRUG PRODUCT LIST

6-237 (of 337)

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SANDOZ	50MG	A076072 001	Sep 16, 2003
	50MG	A076302 001	Sep 16, 2003
	100MG	A076072 002	Sep 16, 2003
	100MG	A076302 002	Sep 16, 2003
	150MG	A076072 003	Sep 16, 2003
	150MG	A076302 003	Sep 16, 2003
	200MG	A076072 004	Sep 16, 2003
	200MG	A076302 004	Sep 16, 2003
	250MG	A076072 005	Sep 16, 2003
	250MG	A076302 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
BRISTOL MYERS SQUIBB	50MG	N020152 001	Dec 22, 1994
	100MG	N020152 002	Dec 22, 1994
	150MG	N020152 003	Dec 22, 1994
	200MG	N020152 004	Dec 22, 1994
	250MG	N020152 005	Dec 22, 1994
	300MG	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER; ORAL

VIRACEPT

AGOURON

EQ 50MG BASE/SCOOPFUL

N020778 001 Mar 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING

NEO-RX

X GEN PHARMS

100%

A061579 001

SOLUTION; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 87.5MG BASE/5ML

N050285 001

TABLET; ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN

EQ 350MG BASE

A060520 001

NEOBIOTIC

PFIZER

EQ 350MG BASE

A060475 001

NEOMYCIN SULFATE

BRISTOL MYERS SQUIBB

500MG

A060365 001

LANNETT

500MG

A060607 001

LILLY

500MG

A060385 001

ROXANE

500MG

A062173 001

SANDOZ

500MG

A061586 001

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

NEOSPORIN

GLAXOSMITHKLINE

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050176 002 Jan 14, 1985

OINTMENT; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/GM; 10,000 UNITS/GM

N050344 002

SOLUTION/DROPS; OPHTHALMIC

STATROL

ALCON

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

A062339 001 Nov 30, 1984

EQ 3.5MG BASE/ML; 16,250 UNITS/ML

N050456 001

DISCONTINUED DRUG PRODUCT LIST

6-238 (of 337)

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

POLY-PRED

ALLERGAN

EQ 0.35% BASE;10,000 UNITS/ML;0.5%

N050081 002

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/GM;0.25%

A061039 002

EQ 3.5MG BASE/GM;0.5%

A061039 001

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/ML;0.25%

A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK

EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTREX A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062600 001 Jul 21, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTREX A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062608 001 May 23, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062607 001 May 23, 1986

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

SCHERING

EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

NIACIN

CAPSULE;ORAL

WAMPOCAP

MEDPOINTE PHARM HLC

500MG

N011073 003

TABLET;ORAL

NIACIN

EVERYLIFE

500MG

A083203 001

HALSEY

500MG

A083453 001

HIKMA PHARMS LLC

500MG

A083718 001

IMPAX LABS

500MG

A083115 001

IVAX SUB TEVA PHARMS

500MG

A083180 001

MK LABS

500MG

A083525 001

PUREPAC PHARM

500MG

A083271 001

SANDOZ

500MG

A083306 001

TABLICAPS

500MG

A084237 001

WATSON LABS

500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

NICOLAR

SANOFI AVENTIS US

500MG

A083823 001

TABLET, EXTENDED RELEASE;ORAL

NIASPAN

ABBVIE

375MG

N020381 001 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE

375MG

N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL

TPN

INTL MINERALS

15MG/5ML;3.75MG/5ML;600MG/5ML

N008378 003

DISCONTINUED DRUG PRODUCT LIST

6-239 (of 337)

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

WATSON LABS

20MG

A074670 001 Oct 28, 1996

30MG

A074670 002 Oct 28, 1996

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

CHIESI USA INC

30MG

N020005 001 Feb 21, 1992

45MG

N020005 002 Feb 21, 1992

60MG

N020005 003 Feb 21, 1992

NICLOSAMIDE

TABLET, CHEWABLE;ORAL

NICLOCIDE

BAYER PHARMS

500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NICOTROL

MCNEIL CONS

15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA

11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC

EQ 2MG BASE

A076568 001 Jul 29, 2004

EQ 4MG BASE

A076569 002 Jul 29, 2004

NIFEDIPINE

CAPSULE;ORAL

ADALAT

BAYER PHARMS

10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CATALENT

10MG

A073250 001 Oct 08, 1991

20MG

A074045 001 Apr 30, 1992

CHASE LABS NJ

10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA

10MG

A072651 001 Feb 19, 1992

PROCARDIA

PFIZER

20MG

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

MARTEC USA LLC

90MG

A075414 003 Mar 23, 2004

MYLAN

30MG

A075108 001 Dec 17, 1999

NILUTAMIDE

TABLET;ORAL

NILANDRON

COVIS PHARMA SARL

50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE;ORAL

NIMOTOP

BAYER PHARMS

30MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018869 001 Dec 28, 1988

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

SULAR

SHIONOGI INC

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 001 Feb 02, 1995

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 002 Feb 02, 1995

25.5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 006 Jan 02, 2008

30MG **Federal Register determination
that product was not discontinued or

N020356 003 Feb 02, 1995

DISCONTINUED DRUG PRODUCT LIST

6-240 (of 337)

NISOLDIPINETABLET, EXTENDED RELEASE;ORAL
SULARwithdrawn for safety or efficacy
reasons**40MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020356 004 Feb 02, 1995

NITROFURANTOIN

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

100MG

A084326 002

TABLET;ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

100MG

A080017 002

NITROFURANTOIN

ELKINS SINN

50MG

A080003 001

100MG

A080003 002

IVAX SUB TEVA PHARMS

50MG

A080078 002

100MG

A080078 001

SANDOZ

50MG

A080043 001

100MG

A080043 002

WATSON LABS

50MG

A080447 001

50MG

A085797 001

100MG

A080447 002

100MG

A085796 001

WHITEWORTH TOWN PLSN

100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE;INJECTION

IVADANTIN

PROCTER AND GAMBLE

EQ 180MG BASE/VIAL

N012402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

MYLAN

100MG

A074967 002 Jul 09, 1997

SANDOZ

25MG

A074336 001 Jan 25, 1995

50MG

A074336 002 Jan 25, 1995

100MG

A074336 003 Jan 25, 1995

WATSON LABS

25MG

A073696 001 Dec 31, 1992

50MG

A073696 002 Dec 31, 1992

100MG

A073696 003 Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS

50MG

A070248 001 Jun 24, 1988

100MG

A070249 001 Jun 24, 1988

NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

RANBAXY LABS LTD

75MG;25MG

A076951 001 Mar 30, 2005

NITROFURAZONE

CREAM;TOPICAL

FURACIN

SHIRE

0.2%

A083789 001

DRESSING;TOPICAL

ACTIN-N

SHERWOOD MEDCL

0.2%

N017343 001

OINTMENT;TOPICAL

FURACIN

SHIRE

0.2%

N005795 001

NITROFURAZONE

AMBIX

0.2%

A086077 001

LANNETT

0.2%

A084393 001

PERRIGO NEW YORK

0.2%

A084968 001

TARO

0.2%

A086156 001

WENDT

0.2%

A086766 001

DISCONTINUED DRUG PRODUCT LIST

6-241 (of 337)

NITROFURAZONE

POWDER; TOPICAL

FURACIN

SHIRE

0.2%

A083791 001

SOLUTION; TOPICAL

NITROFURAZONE

PERRIGO NEW YORK

0.2%

A085130 001

WENDT

0.2%

A087081 001

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP

0.4MG/SPRAY

N018705 001 Oct 31, 1985

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

KREMERS URBAN PHARMS

0.2MG/HR

A075115 001 Aug 10, 2004

0.4MG/HR

A075115 002 Aug 10, 2004

MYLAN TECHNOLOGIES

0.1MG/HR

A074992 004 Nov 12, 1999

0.2MG/HR

A074992 003 Nov 12, 1999

0.4MG/HR

A074992 002 Nov 12, 1999

0.6MG/HR

A074992 001 Nov 12, 1999

TRANSDERM-NITRO

NOVARTIS

0.1MG/HR

N020144 001 Feb 27, 1996

0.2MG/HR

N020144 002 Feb 27, 1996

0.4MG/HR

N020144 003 Feb 27, 1996

0.6MG/HR

N020144 004 Feb 27, 1996

0.8MG/HR

N020144 005 Feb 27, 1996

INJECTABLE; INJECTION

NITRO IV

POHL BOSKAMP

5MG/ML

N018672 002 Aug 30, 1983

NITRO-BID

SANOFI AVENTIS US

5MG/ML

N018621 001 Jan 05, 1982

10MG/ML

A071159 001 Feb 28, 1990

NITROGLYCERIN

ABRAXIS PHARM

5MG/ML

A070077 001 Dec 13, 1985

5MG/ML

A071203 001 May 08, 1987

HOSPIRA

5MG/ML

N018531 001

INTL MEDICATION

5MG/ML

A070026 001 Sep 10, 1985

LUITPOLD

5MG/ML

A071492 001 May 24, 1988

SMITH AND NEPHEW

5MG/ML

A070633 001 Jun 19, 1986

5MG/ML

A070634 001 Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA

0.1MG/ML

A074083 001 Oct 26, 1994

NITROL

RORER

0.8MG/ML

N018774 001 Jan 19, 1983

NITRONAL

POHL BOSKAMP

1MG/ML

N018672 001 Aug 30, 1983

NITROSTAT

PARKE DAVIS

0.8MG/ML

N018588 001

5MG/ML

A070863 001 Jan 08, 1987

5MG/ML

N018588 002 Dec 23, 1983

10MG/ML

A070871 001 Jan 08, 1987

10MG/ML

A070872 001 Jan 08, 1987

TRIDIL

HOSPIRA

0.5MG/ML

N018537 002 Jun 16, 1983

5MG/ML

N018537 001

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM

150MG

N019508 001 Apr 12, 1988

300MG

N019508 002 Apr 12, 1988

NIZATIDINE

ANI PHARMS INC

150MG

A075461 001 Jul 08, 2002

300MG

A075461 002 Jul 08, 2002

APOTEX INC

150MG

A076383 001 Jan 23, 2003

300MG

A076383 002 Jan 23, 2003

MYLAN PHARMS INC

150MG

A075934 001 Jul 09, 2002

300MG

A075934 002 Jul 09, 2002

DISCONTINUED DRUG PRODUCT LIST

6-242 (of 337)

NONOXYNOL-9

AEROSOL; VAGINAL

DELFIN

PERSONAL PRODS

12.5%

N014349 002

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM

EQ 1MG BASE/ML

A040522 001 Sep 30, 2004

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK

EQ 0.033MG BASE/ML; 2%; 0.4%

N008592 003

NORETHINDRONE

TABLET; ORAL

NORLUTIN

PARKE DAVIS

5MG

N010895 002

NORETHINDRONE ACETATE

TABLET; ORAL

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

TABLET; ORAL

NOROXIN

MERCK

400MG

N019384 002 Oct 31, 1986

NORGESTREL

TABLET; ORAL

OVRETTE

WYETH PHARMS

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074054 004 Dec 31, 1992

EQ 75MG BASE

A074835 004 Jun 30, 1997

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

SOLUTION; ORAL

AVENTYL

RANBAXY

EQ 10MG BASE/5ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N014685 001

PAMELOR

MALLINCKRODT INC

EQ 10MG BASE/5ML

N018012 001

NYSTATIN

CREAM; TOPICAL

CANDEX

BAYER PHARMS

100,000 UNITS/GM

A061810 001

MYCOSTATIN

DELCOR ASSET CORP

100,000 UNITS/GM

A060575 001

MYKINAC

ALPHARMA US PHARMS

100,000 UNITS/GM

A062387 001 Jul 29, 1982

NILSTAT

LEDERLE

100,000 UNITS/GM

A061445 001

DISCONTINUED DRUG PRODUCT LIST

6-243 (of 337)

NYSTATIN

CREAM; TOPICAL

NYSTATIN

G AND W LABS INC	100,000 UNITS/GM	A061966 001	
TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983

LOTION; TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233 001	
--------------	------------------	-------------	--

OINTMENT; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM	A060571 001	
-------------------	------------------	-------------	--

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986
--------------------	------------------	-------------	--------------

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444 001	
---------	------------------	-------------	--

PASTILLE; ORAL

MYCOSTATIN

BRISTOL MYERS SQUIBB	200,000 UNITS	N050619 001	Apr 09, 1987
----------------------	---------------	-------------	--------------

POWDER; ORAL

BARSTATIN 100

BARLAN	100%	A062489 001	Apr 27, 1988
--------	------	-------------	--------------

NILSTAT

DAVA PHARMS INC	100%	N050576 001	Dec 22, 1983
-----------------	------	-------------	--------------

NYSTATIN

PADDOCK LLC	100%	A062613 001	Nov 26, 1985
-------------	------	-------------	--------------

POWDER; TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM	A060578 001	
-------------------	------------------	-------------	--

NYSTATIN

NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006
---------------	------------------	-------------	--------------

SUPPOSITORY; VAGINAL

NYSERT

WARNER CHILCOTT	100,000 UNITS	N050478 001	
-----------------	---------------	-------------	--

SUSPENSION; ORAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/ML	A061533 001	
-------------------	------------------	-------------	--

NILSTAT

GLENMARK GENERICS	100,000 UNITS/ML	N050299 001	
-------------------	------------------	-------------	--

NYSTATIN

ALPHARMA US PHARMS	100,000 UNITS/ML	A062571 001	Oct 29, 1985
--------------------	------------------	-------------	--------------

MORTON GROVE	100,000 UNITS/ML	A062835 001	Nov 19, 1987
--------------	------------------	-------------	--------------

PHARMADERM	100,000 UNITS/ML	A062518 001	Jul 06, 1984
------------	------------------	-------------	--------------

PHARMAFAIR	100,000 UNITS/ML	A062541 001	Jan 16, 1985
------------	------------------	-------------	--------------

ROXANE	100,000 UNITS/ML	A062832 001	Dec 27, 1991
--------	------------------	-------------	--------------

TEVA	100,000 UNITS/ML	A062670 001	Jun 18, 1987
------	------------------	-------------	--------------

	100,000 UNITS/ML	A062776 001	Dec 17, 1987
--	------------------	-------------	--------------

NYSTEX

SAVAGE LABS	100,000 UNITS/ML	A062519 001	Jul 06, 1984
-------------	------------------	-------------	--------------

TABLET; ORAL

MYCOSTATIN

DELCOR ASSET CORP	500,000 UNITS	A060574 001	
-------------------	---------------	-------------	--

NILSTAT

LEDERLE	500,000 UNITS	A061151 001	
---------	---------------	-------------	--

NYSTATIN

QUANTUM PHARMICS	500,000 UNITS	A062525 001	Oct 29, 1984
------------------	---------------	-------------	--------------

SANDOZ	500,000 UNITS	A062065 001	
--------	---------------	-------------	--

USL PHARMA	500,000 UNITS	A062524 001	Nov 26, 1985
------------	---------------	-------------	--------------

WATSON LABS	500,000 UNITS	A062402 001	Dec 16, 1982
-------------	---------------	-------------	--------------

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718 001	
----------------	---------------	-------------	--

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS	A060577 001	
-------------------	---------------	-------------	--

NILSTAT

LEDERLE	100,000 UNITS	A061325 001	
---------	---------------	-------------	--

NYSTATIN

FOUGERA	100,000 UNITS	A062459 001	Nov 09, 1983
---------	---------------	-------------	--------------

PHARMADERM	100,000 UNITS	A062460 001	Nov 09, 1983
------------	---------------	-------------	--------------

QUANTUM PHARMICS	100,000 UNITS	A062509 001	Apr 03, 1984
------------------	---------------	-------------	--------------

SANDOZ	100,000 UNITS	A061965 001	
--------	---------------	-------------	--

TEVA	100,000 UNITS	A062502 001	Dec 23, 1983
------	---------------	-------------	--------------

WATSON LABS	100,000 UNITS	A062176 001	
-------------	---------------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

6-244 (of 337)

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A061954	002	Sep 20, 1985
------	-----------------------	---------	-----	--------------

MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060576	002	May 01, 1985
	100,000 UNITS/GM;0.1%	A062606	001	May 15, 1985

MYKACET

G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985
------------------	-----------------------	---------	-----	--------------

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062597	001	Oct 08, 1985
-------------	-----------------------	---------	-----	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM;0.1%	A063010	001	Dec 20, 1988
PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062186	002	Jun 06, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062657	001	Jul 30, 1986
TARO	100,000 UNITS/GM;0.1%	A062347	001	Mar 30, 1987

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062596	001	Oct 08, 1985
------------	-----------------------	---------	-----	--------------

OINTMENT; TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM;0.1%	A062045	002	Nov 26, 1985
------	-----------------------	---------	-----	--------------

MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985
-------------------	-----------------------	---------	-----	--------------

MYKACET

G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987
------------------	-----------------------	---------	-----	--------------

MYTREX F

SAVAGE LABS	100,000 UNITS/GM;0.1%	A062601	001	Oct 09, 1985
-------------	-----------------------	---------	-----	--------------

NYSTATIN AND TRIAMCINOLONE ACETONIDE

PERRIGO NEW YORK	100,000 UNITS/GM;0.1%	A062280	002	Oct 10, 1985
PHARMAFAIR	100,000 UNITS/GM;0.1%	A062656	001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM;0.1%	A062603	001	Oct 09, 1985
------------	-----------------------	---------	-----	--------------

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992

FLOXIN IN DEXTROSE 5%

ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
--------------------	-------------	---------	-----	--------------

FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992

OFLOXACIN

BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
---------	---------	---------	-----	--------------

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

APOTEX INC	0.3%	A076513	001	May 14, 2004
SANDOZ	0.3%	A076848	001	Nov 25, 2008

TABLET; ORAL

FLOXIN

JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990
	300MG	N019735	002	Dec 28, 1990
	400MG	N019735	003	Dec 28, 1990

OFLOXACIN

LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
	400MG	A076093	003	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
	300MG	A076220	002	Sep 02, 2003
	400MG	A076220	003	Sep 02, 2003

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION; ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013
	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013

DISCONTINUED DRUG PRODUCT LIST

6-245 (of 337)

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

NESHER PHARMS	4MG	A077717	001	Jun 25, 2007
	8MG	A077717	002	Jun 25, 2007
PAR PHARM	4MG	A076506	001	Dec 26, 2006
	8MG	A076506	002	Dec 26, 2006
	16MG	A077406	001	Dec 26, 2006
	24MG	A077406	002	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC	EQ 2MG BASE/ML	A077368	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076695	001	Dec 26, 2006
LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010
LUITPOLD	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006
PLIVA HRVATSKA DOO	EQ 2MG BASE/ML	A077544	001	Dec 26, 2006
SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

BEDFORD LABS	EQ 0.64MG BASE/ML	A078291	001	Apr 13, 2009
CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	A078308	001	Mar 17, 2008
HOSPIRA	EQ 0.64MG BASE/ML	A076978	001	Feb 26, 2007
	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007
TEVA PHARMS	EQ 0.64MG BASE/ML	A077480	001	Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915	002	Dec 27, 2006
-----------------	-------------------	---------	-----	--------------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

APOTEX INC	EQ 2MG BASE/ML	A077343	001	Dec 26, 2006
HOSPIRA	EQ 2MG BASE/ML	A076696	001	Dec 26, 2006
LUITPOLD	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006

ZOFTRAN AND DEXTROSE IN PLASTIC CONTAINER

GLAXOSMITHKLINE	EQ 0.64MG BASE/ML	N020403	001	Jan 31, 1995
-----------------	-------------------	---------	-----	--------------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

HIKMA PHARMS LLC	EQ 4MG BASE	A077545	001	Sep 06, 2007
	EQ 8MG BASE	A077545	002	Sep 06, 2007
	EQ 24MG BASE	A077545	003	Sep 06, 2007
PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007
	EQ 8MG BASE	A077303	002	Jun 25, 2007
	EQ 24MG BASE	A077303	004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011
	EQ 8MG BASE	A077729	002	Mar 28, 2011
	EQ 24MG BASE	A077729	003	Mar 28, 2011

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATE

WATSON LABS	30MG/ML	A087062	001	
-------------	---------	---------	-----	--

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

MEDICIS	100MG	N012157	001	
---------	-------	---------	-----	--

ORPHENADRINE CITRATE

ASCOT	100MG	A088067	001	Apr 06, 1983
SANDOZ	100MG	A085046	001	
WATSON LABS	100MG	A084303	001	

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

3M	50MG	N010653	001	
----	------	---------	-----	--

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

ROCHE	EQ 12MG BASE/ML	N021246	001	Dec 14, 2000
-------	-----------------	---------	-----	--------------

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

GLAXOSMITHKLINE	EQ 250MG BASE	A061336	001	
	EQ 250MG BASE	A062241	001	
	EQ 500MG BASE	A061336	002	
	EQ 500MG BASE	A062241	002	

DISCONTINUED DRUG PRODUCT LIST

6-246 (of 337)

OXACILLIN SODIUM

CAPSULE; ORAL

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061450 002

EQ 500MG BASE

A061450 001

TEVA

EQ 250MG BASE

A062222 001

EQ 500MG BASE

A062222 002

PROSTAPHLIN

APOTHECON

EQ 500MG BASE

N050118 002

FOR SOLUTION; ORAL

BACTOCILL

GLAXOSMITHKLINE

EQ 250MG BASE/5ML

A062321 001

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE; INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL

A061334 010

EQ 500MG BASE/VIAL

A061334 009 Mar 26, 1982

OXACILLIN SODIUM

APOTHECON

EQ 1GM BASE/VIAL

N050195 003

EQ 2GM BASE/VIAL

N050195 004

EQ 4GM BASE/VIAL

N050195 005

EQ 250MG BASE/VIAL

N050195 001

EQ 500MG BASE/VIAL

N050195 002

ELKINS SINN

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

ISTITUTO BIO ITA SPA

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

WATSON LABS INC

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

OXALIPLATIN

INJECTABLE; IV (INFUSION)

ELOXATIN

SANOFI AVENTIS US

50MG/VIAL

N021492 001 Aug 09, 2002

100MG/VIAL

N021492 002 Aug 09, 2002

OXALIPLATIN

SANDOZ

50MG/VIAL

A090849 001 Apr 28, 2011

100MG/VIAL

A090849 002 Apr 28, 2011

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER

250MG

N018069 001

OXANDROLONE

TABLET; ORAL

OXANDROLONE

ROXANE

2.5MG

A077249 001 Jul 10, 2007

10MG

A077249 002 Jul 10, 2007

SANDOZ

2.5MG

A076897 001 Dec 01, 2006

10MG

A076897 002 Dec 01, 2006

DISCONTINUED DRUG PRODUCT LIST

6-247 (of 337)

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843	001	Oct 03, 2001
MYLAN	600MG	A075851	001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847	001	Feb 28, 2001
SANDOZ	600MG	A075842	001	Apr 12, 2001
	600MG	A075850	001	Apr 27, 2001
WATSON LABS	600MG	A075848	001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

GD SEARLE	600MG	N020776	001	Oct 17, 2002
-----------	-------	---------	-----	--------------

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955	001	Mar 03, 1988
	15MG	A071956	001	Mar 03, 1988
	30MG	A071957	001	Mar 03, 1988
IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987
	15MG	A070944	001	Aug 03, 1987
	30MG	A070945	001	Aug 03, 1987
MUTUAL PHARM	10MG	A071026	002	Aug 10, 1987
	15MG	A071026	003	Aug 10, 1987
	30MG	A071026	001	Aug 10, 1987
MYLAN	10MG	A071713	001	Oct 20, 1987
	15MG	A071714	001	Oct 20, 1987
	30MG	A071715	001	Oct 20, 1987
WATSON LABS	10MG	A072952	001	Sep 28, 1990
	15MG	A072953	001	Sep 28, 1990
	30MG	A072954	001	Sep 28, 1990

SERAX

ALPHARMA US PHARMS	10MG	N015539	002	
	15MG	N015539	004	
	30MG	N015539	006	

ZAXOPAM

QUANTUM PHARMICS	10MG	A070650	001	Mar 01, 1988
	15MG	A070640	001	Mar 01, 1988
	30MG	A070641	001	Mar 01, 1988

TABLET; ORAL

OXAZEPAM

MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987
PARKE DAVIS	15MG	A071508	001	Feb 02, 1987
WATSON LABS	15MG	A071494	001	Apr 21, 1987

SERAX

ALPHARMA US PHARMS	15MG	N015539	008	
--------------------	------	---------	-----	--

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007
	300MG	A078005	002	Dec 11, 2007
	600MG	A078005	003	Dec 11, 2007

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS	20MG	N018166	001	Dec 28, 1983
	40MG	N018166	002	Dec 28, 1983
	80MG	N018166	003	Dec 28, 1983
	160MG	N018166	004	Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS	100MG/5ML	N009268	012	Nov 27, 1984
-------------	-----------	---------	-----	--------------

OXTRIPHYLLINE

MORTON GROVE	100MG/5ML	A088243	001	Dec 05, 1983
--------------	-----------	---------	-----	--------------

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS	50MG/5ML	N009268	011	
-------------	----------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-248 (of 337)

OXTRIPHYLLINE

SYRUP; ORAL

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

DITROPAN

ORTHO MCNEIL JANSSEN

5MG/5ML

N018211 001

OXYBUTYNIN CHLORIDE

APOTEX INC

5MG/5ML

A074997 001 Oct 15, 1997

MIKART

5MG/5ML

A075039 001 Jan 29, 1999

TABLET; ORAL

DITROPAN

JANSSEN PHARMS

5MG

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

OXYMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

OPANA

ENDO PHARMS

1.5MG/ML

N011707 001

SUPPOSITORY; RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

ENDO PHARMS

5MG

N021610 001 Jun 22, 2006

7.5MG

N021610 005 Feb 29, 2008

10MG

N021610 002 Jun 22, 2006

15MG

N021610 006 Feb 29, 2008

20MG

N021610 003 Jun 22, 2006

30MG

N021610 007 Feb 29, 2008

40MG

N021610 004 Jun 22, 2006

OXYPHENBUTAZONE

TABLET; ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET; ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET; ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET; ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

DISCONTINUED DRUG PRODUCT LIST

6-249 (of 337)

OXYTETRACYCLINE CALCIUM

SYRUP; ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA PHARMS LLC

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

INJECTABLE; INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM; 10,000 UNITS/GM

A061841 001

TABLET; VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE; 100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

TEVA PHARMS USA

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML

N019185 004 Mar 29, 1985

2USP UNITS/100ML

N019185 003 Mar 29, 1985

OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

ABBOTT

2USP UNITS/100ML

N019185 002 Mar 29, 1985

OXYTOCIN 5 USP UNITS IN DEXTROSE 5%

ABBOTT

1USP UNITS/100ML

N019185 001 Mar 29, 1985

SYNTOCINON

NOVARTIS

10USP UNITS/ML

N018245 001

SOLUTION; NASAL

SYNTOCINON

RETROPHIN INC

40USP UNITS/ML

N012285 001

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

ACCORD HLTHCARE

6MG/ML

A075436 001 Nov 12, 2004

HOSPIRA

6MG/ML

A076233 001 Aug 01, 2002

MYLAN

6MG/ML

A075278 001 Jan 25, 2002

PLIVA LACHEMA

6MG/ML

A077413 001 Mar 12, 2008

TEVA PHARMS USA

6MG/ML

A075297 001 Jan 25, 2002

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

JANSSEN PHARMS

12MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N021999 004 Dec 19, 2006

PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

ALOXI

HELSINN HLTHCARE

EQ 0.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N022233 001 Aug 22, 2008

DISCONTINUED DRUG PRODUCT LIST

6-250 (of 337)

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009

90MG/VIAL

A078300 002 Mar 10, 2009

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE; ORAL

COTAZYM

ORGANON USA INC

30000USPU; 30000USPU; 8000USPU

N020580 001 Dec 09, 1996

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ASTRAZENECA

1MG/ML

A072210 001 Mar 31, 1988

2MG/ML

A072211 001 Mar 31, 1988

2MG/ML

A072212 001 Mar 31, 1988

2MG/ML

A072213 001 Mar 31, 1988

ELKINS SINN

1MG/ML

A072058 001 Mar 23, 1988

2MG/ML

A072059 001 Mar 23, 1988

2MG/ML

A072060 001 Mar 23, 1988

HOSPIRA

2MG/ML

A072321 001 Jan 19, 1989

PAVULON

ORGANON USA INC

1MG/ML

N017015 002

2MG/ML

N017015 001

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

150MG

N006800 003

300MG

N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE

300MG/ML

N006800 002

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

1MG

N012772 005

2MG

N012772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

APOTEX TECHNOLOGIES

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 001 Oct 09, 1998

EQ 20MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 002 Oct 09, 1998

EQ 30MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or

N020885 003 Oct 09, 1998

DISCONTINUED DRUG PRODUCT LIST

6-251 (of 337)

PAROXETINE HYDROCHLORIDE

CAPSULE;ORAL

PAXIL

efficacy reasons**

EQ 40MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020885 004 Oct 09, 1998

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

ROXANE

EQ 10MG BASE

A078026 001 Jun 29, 2007

EQ 20MG BASE

A078026 002 Jun 29, 2007

EQ 30MG BASE

A078026 003 Jun 29, 2007

EQ 40MG BASE

A078026 004 Jun 29, 2007

SANDOZ

EQ 10MG BASE

A075566 001 Mar 08, 2004

EQ 20MG BASE

A075566 002 Mar 08, 2004

EQ 30MG BASE

A075566 003 Mar 08, 2004

EQ 40MG BASE

A075566 004 Mar 08, 2004

TEVA PHARMS

EQ 10MG BASE

A077082 001 Jun 29, 2007

EQ 20MG BASE

A077082 002 Jun 29, 2007

EQ 30MG BASE

A077082 003 Jun 29, 2007

EQ 40MG BASE

A077082 004 Jun 29, 2007

PAXIL

APOTEX TECHNOLOGIES

EQ 50MG BASE

N020031 004 Dec 29, 1992

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA

EQ 10MG BASE/ML (EQ 10MG BASE/ML)

N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA

EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)

N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)

N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)

N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)

N202799 005 Mar 27, 2012

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)

N202799 006 Mar 27, 2012

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN

0.1%

N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT

18.75MG

N016832 001

37.5MG

N016832 002

75MG

N016832 003

PEMOLINE

ACTAVIS ELIZABETH

18.75MG

A075595 001 Feb 28, 2000

37.5MG

A075595 002 Feb 28, 2000

75MG

A075595 003 Feb 28, 2000

MALLINCKRODT

18.75MG

A075726 003 Mar 30, 2001

37.5MG

A075726 002 Mar 30, 2001

75MG

A075726 001 Mar 30, 2001

SANDOZ

18.75MG

A075286 001 Dec 27, 1999

37.5MG

A075286 002 Jun 30, 1999

75MG

A075286 003 Jun 30, 1999

TEVA PHARMS

18.75MG

A075030 003 Feb 22, 2000

37.5MG

A075030 001 Jan 29, 1999

75MG

A075030 002 Jan 29, 1999

VINTAGE PHARMS

18.75MG

A075328 001 Apr 19, 2000

37.5MG

A075328 002 Apr 19, 2000

75MG

A075328 003 Apr 19, 2000

WATSON LABS

18.75MG

A075287 001 Jun 13, 2001

37.5MG

A075287 002 Sep 18, 2000

75MG

A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT

37.5MG

N017703 001

DISCONTINUED DRUG PRODUCT LIST

6-252 (of 337)

PEMOLINE

TABLET, CHEWABLE;ORAL

PEMOLINE

ACTAVIS ELIZABETH

37.5MG

A075678 001 Jul 26, 2000

TEVA PHARMS

37.5MG

A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

AUXILIUM PHARMS LLC

10MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018976 001 Dec 30, 1987

20MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

ATON

125MG

N019853 002

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

WYETH AYERST

300,000 UNITS/ML

N050131 001

SUSPENSION;ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET;ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

APOTHECON

1,000,000 UNITS/VIAL

A060362 001

5,000,000 UNITS/VIAL

A060362 003

10,000,000 UNITS/VIAL

A060362 004

20,000,000 UNITS/VIAL

A060362 002

CONSOLIDATED PHARM

500,000 UNITS/VIAL

A060806 001

1,000,000 UNITS/VIAL

A060806 002

5,000,000 UNITS/VIAL

A060806 003

10,000,000 UNITS/VIAL

A060806 004

LILLY

200,000 UNITS/VIAL

A060384 004

500,000 UNITS/VIAL

A060384 003

1,000,000 UNITS/VIAL

A060384 002

5,000,000 UNITS/VIAL

A060384 001

20,000,000 UNITS/VIAL

A060384 005

20,000,000 UNITS/VIAL

A060601 001

PARKE DAVIS

1,000,000 UNITS/VIAL

A062003 001

5,000,000 UNITS/VIAL

A062003 002

PFIZER

20,000,000 UNITS/VIAL

A060074 003

SANDOZ

1,000,000 UNITS/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or

A065079 001 Aug 30, 2002

DISCONTINUED DRUG PRODUCT LIST

6-253 (of 337)

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

	efficacy reasons**	
WATSON LABS INC	1,000,000 UNITS/VIAL	A062991 001 Sep 13, 1988
	5,000,000 UNITS/VIAL	A062991 002 Sep 13, 1988
	10,000,000 UNITS/VIAL	A062991 003 Sep 13, 1988
	20,000,000 UNITS/VIAL	A062991 004 Sep 13, 1988
PFIZERPEN		
PFIZER	1,000,000 UNITS/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	A060657 001

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON	250,000 UNITS	A060392 003
IVAX SUB TEVA PHARMS	400,000 UNITS	A060073 004
LILLY	250,000 UNITS	A060403 001
MYLAN	200,000 UNITS	A060781 001
	250,000 UNITS	A060781 002
	400,000 UNITS	A060781 003
	500,000 UNITS	A060781 005
	800,000 UNITS	A060781 004
PUREPAC PHARM	200,000 UNITS	A061588 001
	250,000 UNITS	A061588 002
	400,000 UNITS	A061588 003
TEVA	200,000 UNITS	A060306 001
	250,000 UNITS	A060306 002
	400,000 UNITS	A060306 003
	500,000 UNITS	A060306 004
WYETH AYERST	200,000 UNITS	A060413 001
	250,000 UNITS	A060413 002
	400,000 UNITS	A060413 003
PENTIDS '200'		
APOTHECON	200,000 UNITS	A062155 001
PENTIDS '250'		
APOTHECON	250,000 UNITS	A062155 002
PENTIDS '400'		
APOTHECON	400,000 UNITS	A060392 004
	400,000 UNITS	A062155 003
PENTIDS '800'		
APOTHECON	800,000 UNITS	A060392 005
	800,000 UNITS	A062155 004
PFIZERPEN G		
PFIZER	50,000 UNITS	A060075 001
	100,000 UNITS	A060075 002
	200,000 UNITS	A060075 003
	250,000 UNITS	A060075 004
	400,000 UNITS	A060075 005
	800,000 UNITS	A060075 006

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY	300,000 UNITS/ML	A060093 001
PENICILLIN G PROCAINE		
CONSOLIDATED PHARM	300,000 UNITS/ML	A060800 001
	600,000 UNITS/1.2ML	A060800 002
PARKE DAVIS	300,000 UNITS/ML	A062029 001
PFIZER	300,000 UNITS/VIAL	A060099 001
	1,500,000 UNITS/VIAL	A060099 002
PFIZERPEN-AS		
PFIZER	300,000 UNITS/ML	A060286 001
	600,000 UNITS/ML	A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB	5,000,000 UNITS/VIAL	A061935 001
COPANOS	5,000,000 UNITS/VIAL	A061051 001
PHARMACIA AND UPJOHN	1,000,000 UNITS/VIAL	A061046 001

DISCONTINUED DRUG PRODUCT LIST

6-254 (of 337)

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC

5,000,000 UNITS/VIAL

A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY

125MG/0.6ML

A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A062270 001

EQ 250MG BASE/5ML

A062270 002

BETAPEN-VK

APOTHECON

EQ 125MG BASE/5ML

A061149 001

EQ 250MG BASE/5ML

A061149 002

LEDERCILLIN VK

LEDERLE

EQ 125MG BASE/5ML

A060136 001

EQ 250MG BASE/5ML

A060136 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE/5ML

A060007 001

EQ 250MG BASE/5ML

A060007 002

PENAPAR-VK

PARKE DAVIS

EQ 125MG BASE/5ML

A062002 001

EQ 250MG BASE/5ML

A062002 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 125MG BASE/5ML

A061529 001

EQ 250MG BASE/5ML

A061529 002

MYLAN

EQ 125MG BASE/5ML

A061624 002

EQ 250MG BASE/5ML

A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061758 001

EQ 250MG BASE/5ML

A061758 002

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

A061815 001

EQ 250MG BASE/5ML

A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 250MG BASE

A062273 001

EQ 500MG BASE

A062273 002

BETAPEN-VK

BRISTOL

EQ 250MG BASE

A061150 001

EQ 500MG BASE

A061150 002

LEDERCILLIN VK

LEDERLE

EQ 250MG BASE

A060134 001

EQ 500MG BASE

A060134 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE

A060006 001

EQ 250MG BASE

A060006 002

EQ 500MG BASE

A060006 003

PENAPAR-VK

PARKE DAVIS

EQ 250MG BASE

A062001 001

EQ 500MG BASE

A062001 002

PENICILLIN V POTASSIUM

AM ANTIBIOTICS

EQ 250MG BASE

A061528 001

EQ 500MG BASE

A061528 002

IVAX SUB TEVA PHARMS

EQ 125MG BASE

A060518 001

EQ 250MG BASE

A060518 002

EQ 500MG BASE

A060518 003

MYLAN

EQ 250MG BASE

A061530 001

DISCONTINUED DRUG PRODUCT LIST

6-255 (of 337)

PENICILLIN V POTASSIUM

TABLET; ORAL

PENICILLIN V POTASSIUM

	EQ 500MG BASE	A061530 002
PUREPAC PHARM	EQ 125MG BASE	A061571 001
	EQ 250MG BASE	A061571 002
	EQ 500MG BASE	A061571 003
PFIZERPEN VK		
PFIZER	EQ 250MG BASE	A061836 001
	EQ 500MG BASE	A061836 002
UTICILLIN VK		
PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001
	EQ 500MG BASE	A061651 002
V-CILLIN K		
LILLY	EQ 125MG BASE	A060003 001
	EQ 250MG BASE	A060003 002
	EQ 500MG BASE	A060003 003
VEETIDS		
APOTHECON	EQ 250MG BASE	A061411 001
	EQ 500MG BASE	A061411 002
VEETIDS '250'		
APOTHECON	EQ 250MG BASE	A061164 001
	EQ 250MG BASE	A062156 002
VEETIDS '500'		
APOTHECON	EQ 500MG BASE	A061164 002
	EQ 500MG BASE	A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

WYETH AYERST	0.25MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N017048 001
--------------	--	-------------

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996
INJECTABLE; INJECTION			
PENTACARINAT			
ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994
PENTAMIDINE ISETHIONATE			
BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN 50

SANOFI AVENTIS US	EQ 50MG BASE	N016732 001
-------------------	--------------	-------------

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021749 001	Aug 11, 2004
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons			

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE; INJECTION

YTTERBIUM YB 169 DTPA

3M	2mCi/ML	N017518 001
----	---------	-------------

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

HAMELN PHARMS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)	N021751 001	Aug 11, 2004
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons			

DISCONTINUED DRUG PRODUCT LIST

6-256 (of 337)

PENTOBARBITAL

ELIXIR; ORAL

NEMBUTAL

OAK PHARMS 18.2MG/5ML A083244 001

PENTOBARBITAL SODIUM

CAPSULE; ORAL

NEMBUTAL SODIUM

OAK PHARMS 30MG A084095 001
50MG A084093 001
100MG A083245 001

PENTOBARBITAL SODIUM

LANNETT 50MG A085937 001

100MG A085915 001

VITARINE 100MG A083284 001

WHITEWORTH TOWN PLSN 100MG A083338 001

SODIUM PENTOBARBITAL

ANABOLIC 100MG A084590 001

ELKINS SINN 100MG A083368 001

EVERYLIFE 100MG A083259 001

HALSEY 100MG A084677 001

IVAX SUB TEVA PHARMS 50MG A083461 001

100MG A083461 002

PARKE DAVIS 100MG A084156 001

PERRIGO 100MG A084560 001

PUREPAC PHARM 100MG A083301 001

VALEANT PHARM INTL 100MG A083264 001

WATSON LABS 100MG A085791 001

WYETH AYERST 100MG A083239 001

INJECTABLE; INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN 50MG/ML A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST 50MG/ML A083261 001

SUPPOSITORY; RECTAL

NEMBUTAL

OAK PHARMS 30MG A083247 001 Jan 25, 1982
60MG A083247 002 Jan 25, 1982
120MG A083247 003 Jan 25, 1982
200MG A083247 004 Jan 25, 1982

TABLET; ORAL

PENTOBARBITAL SODIUM

VITARINE 100MG A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC 100MG A084238 001

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST 10MG/ML N009372 001

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ACTAVIS ELIZABETH 400MG A074878 001 Jul 09, 1997

HERITAGE PHARMS INC 400MG A074877 001 Jul 08, 1997

TEVA 400MG A075199 001 Sep 03, 1999

WATSON LABS 400MG A075107 001 Sep 04, 1998

TRENTAL

SANOFI AVENTIS US 400MG N018631 001 Aug 30, 1984

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM 100% N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY 50%; 50% N021084 001 Feb 17, 2000

DISCONTINUED DRUG PRODUCT LIST

6-257 (of 337)

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS	EQ 0.05MG BASE	A076094 001	Sep 04, 2003
	EQ 0.25MG BASE	A076094 002	Sep 04, 2003
	EQ 1MG BASE	A076094 003	Sep 04, 2003
PAR PHARM	EQ 0.05MG BASE	A076061 001	Nov 27, 2002
	EQ 0.25MG BASE	A076061 002	Nov 27, 2002
	EQ 1MG BASE	A076061 003	Nov 27, 2002
PERMAX			
VALEANT PHARM INTL	EQ 0.05MG BASE	N019385 001	Dec 30, 1988
	EQ 0.25MG BASE	N019385 002	Dec 30, 1988
	EQ 1MG BASE	N019385 003	Dec 30, 1988

PERMETHRIN

LOTION; TOPICAL

NIX

GLAXOSMITHKLINE	1%	N019435 001	Mar 31, 1986
-----------------	----	-------------	--------------

PERPHENAZINE

CONCENTRATE; ORAL

PERPHENAZINE

PHARM ASSOC	16MG/5ML	A040360 001	May 25, 2001
-------------	----------	-------------	--------------

TRILAFON

SCHERING	16MG/5ML	N011557 001	
----------	----------	-------------	--

INJECTABLE; INJECTION

TRILAFON

SCHERING	5MG/ML	N011213 002	
----------	--------	-------------	--

SYRUP; ORAL

TRILAFON

SCHERING	2MG/5ML	N011294 002	
----------	---------	-------------	--

TABLET; ORAL

PERPHENAZINE

ANI PHARMS INC	8MG	A089456 001	Sep 10, 1987
----------------	-----	-------------	--------------

TEVA PHARMS USA	2MG	A089707 001	Sep 10, 1987
-----------------	-----	-------------	--------------

	4MG	A089708 001	Sep 10, 1987
--	-----	-------------	--------------

	16MG	A089457 001	Sep 10, 1987
--	------	-------------	--------------

TRILAFON

SCHERING	2MG	N010775 001	
----------	-----	-------------	--

	4MG	N010775 002	
--	-----	-------------	--

	8MG	N010775 003	
--	-----	-------------	--

	16MG	N010775 004	
--	------	-------------	--

TABLET, EXTENDED RELEASE; ORAL

TRILAFON

SCHERING	8MG	N011361 002	
----------	-----	-------------	--

PHENACEMIDE

TABLET; ORAL

PHENURONE

ABBVIE	500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N007707 001	
--------	--	-------------	--

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET; ORAL

AZO GANTANOL

ROCHE	100MG; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N013294 001	Sep 10, 1987
-------	---	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HYDROCHLORIDE

ABLE	200MG; 800MG; 160MG	N021105 001	Jun 26, 2001
------	---------------------	-------------	--------------

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

ROCHE	50MG; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N019358 001	Aug 31, 1990
-------	--	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

6-258 (of 337)

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085695 001

35MG

A085702 001

VITARINE

35MG

A085634 001

35MG

A085645 001

35MG

A085670 001

35MG

A086403 001

35MG

A086408 001

35MG

A086410 001

35MG

A087424 001

SPRX-3

SOLVAY

35MG

A085897 001

STATOBEX

TEVA

35MG

A085507 001

X-TROZINE

SHIRE RICHWOOD

35MG

A087394 001 Sep 22, 1982

CAPSULE, EXTENDED RELEASE; ORAL

MELFIAT-105

NUMARK

105MG

A087487 001 Oct 13, 1982

PHENDIMETRAZINE TARTRATE

GRAHAM DM

105MG

A087214 001 May 26, 1982

105MG

A088020 001 Aug 16, 1982

105MG

A088028 001 Aug 16, 1982

105MG

A088062 001 Sep 13, 1982

105MG

A088063 001 Sep 10, 1982

105MG

A088111 001 Oct 18, 1982

SANDOZ

105MG

A087378 001

SPRX-105

NUMARK

105MG

A088024 001 Dec 22, 1982

X-TROZINE L.A.

SHIRE RICHWOOD

105MG

A087371 001 Aug 24, 1982

TABLET; ORAL

ADPHEN

FERNDAL LABS

35MG

A083655 001

ALPHAZINE

SANDOZ

35MG

A085034 001

CAM-METRAZINE

ABC HOLDING

35MG

A085511 001

CAMALL

35MG

A085756 001

TG UNITED LABS

35MG

A083922 001

35MG

A085318 001

35MG

A085320 001

35MG

A085321 001

DI-METREX

PVT FORM

35MG

A085698 001

MELFIAT

NUMARK

35MG

A083790 002

METRA

FOREST PHARMS

35MG

A083754 001

PHENAZINE

MAST MM

35MG

A087305 001

PHENAZINE-35

ABC HOLDING

35MG

A085512 001

PHENDIMETRAZINE TARTRATE

BARR

35MG

A083644 001

35MG

A083684 001

35MG

A083686 001

35MG

A083687 001

35MG

A084831 001

35MG

A084834 001

35MG

A084835 001

FERNDAL LABS

35MG

A086834 001 Sep 15, 1983

INWOOD LABS

35MG

A084740 001

35MG

A084741 001

DISCONTINUED DRUG PRODUCT LIST

6-259 (of 337)

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A084742	001
	35MG	A084743	001
IVAX PHARMS	35MG	A085611	001
	35MG	A085612	001
IVAX SUB TEVA PHARMS	35MG	A083682	001
KV PHARM	35MG	A084138	001
	35MG	A084141	001
	35MG	A085525	001
MFG CHEMISTS	35MG	A085914	001
NEXGEN PHARMA INC	35MG	A086020	001
NUMARK	35MG	A083790	001
PVT FORM	35MG	A085199	001
	35MG	A085697	001
SANDOZ	35MG	A085402	001
	35MG	A085497	001
	35MG	A085830	001
	35MG	A086365	001
	35MG	A086370	001
SOLVAY	35MG	A083993	001
TG UNITED LABS	35MG	A085761	001
	35MG	A085941	001 Jun 27, 1983
USL PHARMA	35MG	A083805	001
	35MG	A084398	001
	35MG	A084399	001
VITARINE	35MG	A085519	001
	35MG	A086005	001
	35MG	A086106	001
WATSON LABS	35MG	A085767	001
	35MG	A085768	001
	35MG	A085770	001
	35MG	A085773	001
PLEGINE			
WYETH AYERST	35MG	N012248	001
STATOBEX			
TEVA	35MG	A086013	001
STATOBEX-G			
TEVA	35MG	A085095	001
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550	001
	35MG	A086551	001
	35MG	A086552	001
	35MG	A086553	001
	35MG	A086554	001

PHENINDIONE

TABLET; ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767	002
-------------------	------	---------	-----

PHENMETRAZINE HYDROCHLORIDE

TABLET; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460	005
----------------------	------	---------	-----

TABLET, EXTENDED RELEASE; ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752	004
	75MG	N011752	003

PHENPROCOUMON

TABLET; ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228	001
-----------------	-----	---------	-----

PHENSUXIMIDE

CAPSULE; ORAL

MILONTIN

PARKE DAVIS	500MG	N008855	004
-------------	-------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

6-260 (of 337)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

FASTIN

GLAXOSMITHKLINE	30MG	N017352	001	
OBESTIN-30				
FERNDAL LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
IVAX PHARMS	30MG	A086329	001	
MIKAH PHARMA	15MG	A040460	001	Jan 14, 2003
	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
	37.5MG	A040228	001	Jun 19, 1997
MUTUAL PHARM	37.5MG	A040527	001	Oct 23, 2003
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
TG UNITED LABS	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
USL PHARMA	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985

TABLET; ORAL

ONA-MAST

MAST MM	8MG	A086260	001	
---------	-----	---------	-----	--

PHENTERMINE HYDROCHLORIDE

ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
IVAX PHARMS	8MG	A085553	001	
SANDOZ	8MG	A085671	001	
	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
TG UNITED LABS	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	

DISCONTINUED DRUG PRODUCT LIST

6-261 (of 337)

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

TORA

SOLVAY

8MG

A084035 001

WILPO

SANDOZ

8MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N012737 001

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN

UCB INC

EQ 15MG BASE

N011613 004

EQ 30MG BASE

N011613 002

PHENTERMINE RESIN 30

QUANTUM PHARMICS

EQ 30MG BASE

A089120 001 Feb 04, 1988

PHENYL AMINOSALICYLATE

POWDER; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

50%

N011695 002

TABLET; ORAL

PHENY-PAS-TEBAMIN

PHARM RES ASSOC

500MG

N011695 003

PHENYLBUTAZONE

CAPSULE; ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087260 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 009

PHENYLBUTAZONE

IVAX PHARMS

100MG

A088218 001 Jun 24, 1983

MUTUAL PHARM

100MG

A088994 001 Dec 04, 1985

SANDOZ

100MG

A087774 001 Jun 16, 1982

WATSON LABS

100MG

A087756 001 Dec 17, 1982

TABLET; ORAL

AZOLID

SANOFI AVENTIS US

100MG

A087091 001

BUTAZOLIDIN

NOVARTIS

100MG

N008319 008

PHENYLBUTAZONE

MUTUAL PHARM

100MG

A088863 001 Dec 04, 1985

SANDOZ

100MG

A084339 001

WATSON LABS

100MG

A086151 001

100MG

A087674 001 Apr 21, 1982

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENERGAN VC

ANI PHARMS

5MG/5ML; 6.25MG/5ML

N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY

5MG/5ML; 6.25MG/5ML

A088868 001 Mar 02, 1987

PROMETHAZINE VC PLAIN

CENCI

5MG/5ML; 6.25MG/5ML

A088815 001 Nov 22, 1985

WOCKHARDT

5MG/5ML; 6.25MG/5ML

A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

PREFRIN-A

ALLERGAN

0.12%; 0.1%

N007953 001

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-30

PARKE DAVIS

30MG/5ML

N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC

125MG/5ML

A089892 001 Sep 25, 1992

DISCONTINUED DRUG PRODUCT LIST

6-262 (of 337)

PHENYTOIN SODIUM

CAPSULE; ORAL

DIPHENYLAN SODIUM

LANNETT

30MG PROMPT

A080857 001

100MG PROMPT

A080857 002

EXTENDED PHENYTOIN SODIUM

ANI PHARMS INC

100MG EXTENDED

A040435 001 Jun 20, 2003

100MG EXTENDED

A089441 001 Dec 18, 1986

PHENYTEX

WATSON LABS

100MG EXTENDED

A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL

100MG PROMPT

A085435 001

WATSON LABS

100MG PROMPT

A085894 001

PROMPT PHENYTOIN SODIUM

ANI PHARMS INC

100MG PROMPT

A080259 001

WATSON LABS

100MG PROMPT

A080905 001

INJECTABLE; INJECTION

DILANTIN

PARKE DAVIS

50MG/ML

N010151 001

PHENYTOIN SODIUM

FRESENIUS KABI USA

50MG/ML

A089003 001 May 31, 1985

HOSPIRA

50MG/ML

A089744 001 Dec 18, 1987

MARSAM PHARMS LLC

50MG/ML

A089501 001 Oct 13, 1987

50MG/ML

A089779 001 Nov 27, 1992

SMITH AND NEPHEW

50MG/ML

A088519 001 Dec 19, 1984

50MG/ML

A088521 001 Dec 18, 1984

SOLOPAK

50MG/ML

A088520 001 Dec 17, 1984

WARNER CHILCOTT

50MG/ML

A089900 001 Mar 30, 1990

WATSON LABS

50MG/ML

A085434 001

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

BIOVAIL TECHNOLOGIES

1MG/0.5ML

N012223 002

10MG/ML

N012223 001

KONAKION

ROCHE

1MG/0.5ML

N011745 001

10MG/ML

N011745 003

PHYTONADIONE

GLAXOSMITHKLINE

1MG/0.5ML

A084060 001

10MG/ML

A084060 002

VITAMIN K1

HOSPIRA

10MG/ML

A087956 001 Jul 25, 1983

PILOCARPINE

INSERT, EXTENDED RELEASE; OPHTHALMIC

OCUSERT PILO-20

AKORN

5MG

N017431 001

OCUSERT PILO-40

AKORN

11MG

N017548 001

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM

12.5MG

N019456 001 Dec 28, 1989

25MG

N019456 002 Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

IVAX SUB TEVA PHARMS

5MG

A073687 001 Feb 26, 1993

10MG

A073687 002 Feb 26, 1993

MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992

10MG

A074018 001 Sep 24, 1992

NOSTRUM LABS

5MG

A074474 001 Oct 28, 1996

10MG

A074474 002 Oct 28, 1996

PUREPAC PHARM

5MG

A074125 001 Apr 28, 1993

10MG

A074125 002 Apr 28, 1993

SANDOZ

5MG

A073608 001 Mar 29, 1993

10MG

A073609 001 Mar 29, 1993

TEVA

5MG

A073661 001 Oct 31, 1993

5MG

A074123 001 Apr 17, 1997

10MG

A073661 002 Oct 31, 1993

10MG

A074123 002 Apr 17, 1997

DISCONTINUED DRUG PRODUCT LIST

6-263 (of 337)

PINDOLOL

TABLET; ORAL

PINDOLOL

WATSON LABS

5MG

A074437 001 Feb 27, 1995

10MG

A074437 002 Feb 27, 1995

VISKEN

NOVARTIS

5MG

N018285 001 Sep 03, 1982

10MG

N018285 002 Sep 03, 1982

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON USA INC

10MG/VIAL

N019638 001 Jun 26, 1990

PIPERACETAZINE

TABLET; ORAL

QUIDE

DOW PHARM

10MG

N013615 001

25MG

N013615 002

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPRACIL

WYETH PHARMS INC

EQ 2GM BASE/VIAL

A062750 001 Oct 13, 1987

EQ 2GM BASE/VIAL

N050545 002

EQ 3GM BASE/VIAL

A062750 002 Oct 13, 1987

EQ 3GM BASE/VIAL

N050545 003

EQ 4GM BASE/VIAL

A062750 003 Oct 13, 1987

EQ 4GM BASE/VIAL

N050545 004

EQ 40GM BASE/VIAL

N050545 006 Sep 30, 1985

PIPERAZINE CITRATE

SYRUP; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE/5ML

N009102 001

BRYREL

SANOFI AVENTIS US

EQ 500MG BASE/5ML

N017796 001

MULTIFUGE

BLULINE

EQ 500MG BASE/5ML

N009452 001

PIPERAZINE CITRATE

ALPHARMA US PHARMS

EQ 500MG BASE/5ML

A080774 001

LANNETT

EQ 500MG BASE/5ML

A080963 001

LUITPOLD

EQ 500MG BASE/5ML

A080671 001

VERMIDOL

SOLVAY

EQ 500MG BASE/5ML

A080992 001

TABLET; ORAL

ANTEPAR

GLAXOSMITHKLINE

EQ 500MG BASE

N009102 003

PIPERAZINE CITRATE

IMPAX LABS

EQ 250MG BASE

A080874 001

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC

4%; EQ 0.33% BASE

N021043 001 Mar 07, 2000

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

VALEANT PHARM NORTH

EQ 0.2MG BASE/INH

N019009 001 Dec 30, 1986

PIROXICAM

CAPSULE; ORAL

PIROXICAM

CYCLE PHARMS LTD

10MG

A073651 001 Feb 26, 1993

20MG

A073651 002 Feb 26, 1993

EGIS

10MG

A074808 001 Jul 08, 1997

20MG

A074808 002 Jul 08, 1997

IVAX SUB TEVA PHARMS

10MG

A074148 001 Jun 03, 1996

20MG

A074148 002 Jun 03, 1996

DISCONTINUED DRUG PRODUCT LIST

6-264 (of 337)

PIROXICAM

CAPSULE; ORAL

PIROXICAM

MUTUAL PHARM	20MG	A073536	001	Mar 12, 1993
MYLAN	10MG	A074043	001	Sep 22, 1992
	20MG	A074043	002	Sep 22, 1992
SCS	10MG	A074036	001	May 29, 1992
	20MG	A074036	002	May 29, 1992
TEVA	10MG	A073637	001	Jan 28, 1994
	20MG	A073638	001	Jan 28, 1994
TEVA PHARMS	10MG	A074103	001	Aug 28, 1992
	20MG	A074103	002	Aug 28, 1992
WATSON LABS	10MG	A074287	001	May 16, 1996
	10MG	A074460	001	Sep 29, 1995
	20MG	A074287	002	May 16, 1996
	20MG	A074460	002	Sep 29, 1995

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER	2.5MG/VIAL	N050109	001	
--------	------------	---------	-----	--

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST	40MG/AMP	N010753	001	
--------------	----------	---------	-----	--

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

PADDOCK LLC	17GM/SCOOPFUL	A090567	001	Oct 15, 2009
TEVA PHARMS	17GM/SCOOPFUL	A077445	001	May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A090769	001	Jun 07, 2010
-------------	--	---------	-----	--------------

SOLUTION; ORAL

OCL

HOSPIRA	6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML	N019284	001	Apr 30, 1986
---------	---	---------	-----	--------------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MEDA PHARMS	120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET	N018983	005	Oct 26, 1984
	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	N018983	004	Oct 26, 1984
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	007	Jun 12, 1987
	360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET	N018983	006	Oct 26, 1984

COLYTE-FLAVORED

MEDA PHARMS	227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT	N018983	008	Nov 14, 1991
	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	N018983	009	Nov 14, 1991

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A090712	001	Feb 25, 2010
-------------	--	---------	-----	--------------

FOR SUSPENSION; ORAL

CO-LAV

VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A073428	001	Jan 28, 1992
----------------	--	---------	-----	--------------

COLOVAGE

DYNAPHARM	227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET	A071320	001	Apr 20, 1988
-----------	--	---------	-----	--------------

E-Z-EM PREP LYTE

E Z EM	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A071278	001	Nov 21, 1988
--------	--	---------	-----	--------------

GLYCOPREP

GOLDLINE	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A072319	001	Dec 23, 1988
----------	--	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-265 (of 337)

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION; ORAL

GO-EVAC

VINTAGE PHARMS

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 U BASE/VIAL

A062036 001

POWDER; FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET; ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIZIDE

PFIZER

0.5MG; EQ 1MG BASE

N017986 001

0.5MG; EQ 2MG BASE

N017986 002

0.5MG; EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET; ORAL

RENESE-R

PFIZER

2MG; 0.25MG

N013636 001

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD

500MG

N009395 004

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL

100%

A080098 001

TABLET; ORAL

PASKALIUM

GLENWOOD

1GM

N009395 003

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS

8MEQ

A073398 001 Jan 28, 1992

10MEQ

A072427 001 Mar 28, 1990

POTASSIUM CHLORIDE

NESHER PHARMS

10MEQ

A070980 001 Feb 17, 1987

TEVA

8MEQ

A073531 001 Apr 26, 1996

10MEQ

A073532 001 Apr 26, 1996

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

KV PHARM

20MEQ/PACKET

N019561 003 Aug 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

ABRAXIS PHARM

2MEQ/ML

A080204 001

2MEQ/ML

A084290 001

2MEQ/ML

A086713 001

2MEQ/ML

A086714 001

2MEQ/ML

A087787 001 Apr 20, 1982

2MEQ/ML

A087885 001 Feb 03, 1983

AKORN

2MEQ/ML

A088286 001 Sep 05, 1985

BAXTER HLTHCARE

2MEQ/ML

A080203 001

FRESENIUS KABI USA

2MEQ/ML

A087817 001 Oct 20, 1982

GD SEARLE LLC

1MEQ/ML

A086219 001

2MEQ/ML

A086219 002

2MEQ/ML

A086220 002

DISCONTINUED DRUG PRODUCT LIST

6-266 (of 337)

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	
TABLET, EXTENDED RELEASE; ORAL				
K+10				
FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10				
SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX				
APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE				
COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
SCHERING	10MEQ	N019439	002	Jun 13, 1986
	20MEQ	N019439	001	Jun 13, 1986
SLOW-K				
NOVARTIS	8MEQ	N017476	002	
TEN-K				
NOVARTIS	10MEQ	N019381	001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 900MG/100ML	N019708	001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N019708	002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	110MG/100ML; 900MG/100ML	N019708	003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N019708	005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N019708	006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER				
B BRAUN	75MG/100ML; 900MG/100ML	N018722	001	Nov 09, 1982
BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER				
B BRAUN	150MG/100ML; 900MG/100ML	N018722	002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER				
B BRAUN	220MG/100ML; 900MG/100ML	N018722	003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER				
B BRAUN	300MG/100ML; 900MG/100ML	N018722	004	Nov 09, 1982

DISCONTINUED DRUG PRODUCT LIST

6-267 (of 337)

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE; INJECTION

THAM-E

HOSPIRA

370MG/VIAL; 1.75GM/VIAL; 36GM/VIAL

N013025 001

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

UT SW MEDCTR

10MEQ/PACKET **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019647 002 Oct 13, 1988

20MEQ/PACKET **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N019647 001 Oct 13, 1988

POTASSIUM IODIDE

SOLUTION; ORAL

POTASSIUM IODIDE

ROXANE

1GM/ML

N018551 001 Feb 19, 1982

TABLET; ORAL

THYRO-BLOCK

MEDPOINTE PHARM HLC

130MG

N018307 001

POTASSIUM PERCHLORATE

CAPSULE; ORAL

PERCHLORACAP

MALLINCKRODT

200MG

N017551 001

POVIDONE-IODINE

SOLUTION; TOPICAL

E-Z PREP

CLINIPAD

10%

N019382 001 Jul 25, 1989

SPONGE; TOPICAL

E-Z PREP

CLINIPAD

5%

N019382 002 Jul 25, 1989

E-Z PREP 220

CLINIPAD

5%

N019382 003 Jul 25, 1989

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP

300MG/ML

N018799 001 Dec 13, 1982

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST

500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

BOEHRINGER INGELHEIM

1.25MG

N020667 004 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

WATSON LABS

0.125MG

A078551 001 Oct 08, 2010

0.25MG

A078551 002 Oct 08, 2010

0.5MG

A078551 003 Oct 08, 2010

1MG

A078551 004 Oct 08, 2010

1.5MG

A078551 005 Oct 08, 2010

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB

EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)

N021332 001 Mar 16, 2005

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

BRISTOL MYERS SQUIBB

10MG

N019898 002 Oct 31, 1991

PRAVASTATIN SODIUM

PLIVA HRVATSKA DOO

10MG

A077730 001 Nov 21, 2006

20MG

A077730 002 Nov 21, 2006

30MG

A077730 003 Nov 21, 2006

40MG

A077730 005 Nov 21, 2006

RANBAXY LABS LTD

10MG

A076445 001 Apr 23, 2007

20MG

A076445 002 Apr 23, 2007

40MG

A076445 003 Apr 23, 2007

80MG

A076445 004 Apr 23, 2007

DISCONTINUED DRUG PRODUCT LIST

6-268 (of 337)

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001 May 16, 1989

EQ 2MG BASE

A072783 001 May 16, 1989

EQ 5MG BASE

A072784 001 May 16, 1989

DAVA PHARMS INC

EQ 1MG BASE

A072705 001 May 16, 1989

EQ 2MG BASE

A072706 001 May 16, 1989

EQ 5MG BASE

A072707 001 May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001 May 16, 1989

EQ 2MG BASE

A072921 001 May 16, 1989

EQ 5MG BASE

A072992 001 May 16, 1989

SANDOZ

EQ 1MG BASE

A072576 001 May 16, 1989

EQ 2MG BASE

A072577 001 May 16, 1989

EQ 5MG BASE

A072578 001 May 16, 1989

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

0.5%

N010209 002

SYRUP; ORAL

PREDNISOLONE

APOTEX INC

5MG/5ML

A040570 001 Aug 25, 2005

15MG/5ML

A040571 001 Aug 25, 2005

IVAX SUB TEVA PHARMS

15MG/5ML

A040287 001 May 28, 1999

NESHER PHARMS

5MG/5ML

A040423 001 Oct 22, 2001

15MG/5ML

A040364 001 Apr 10, 2002

TEVA PHARMS

15MG/5ML

A040322 001 Jan 19, 2000

WE PHARMS

15MG/5ML

A040192 001 May 28, 1998

PRELONE

MURO

5MG/5ML

A089654 001 Jan 17, 1989

TABLET; ORAL

CORTALONE

HALSEY

1MG

A080304 003

2.5MG

A080304 002

5MG

A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN

5MG

N009987 004

FERNISOLONE-P

FERNDAL LABS

5MG

A083941 001

PREDNISOLONE

BARR

5MG

A084426 002

BUNDY

5MG

A083675 001

ELKINS SINN

5MG

A080625 001

EVERYLIFE

1MG

A084439 001

2.5MG

A084439 002

5MG

A084439 003

FERRANTE

2.5MG

A080562 001

5MG

A080562 002

HEATHER

5MG

A080326 001

IMPAX LABS

5MG

A080780 001

INWOOD LABS

5MG

A080748 001

IVAX SUB TEVA PHARMS

5MG

A080378 001

DISCONTINUED DRUG PRODUCT LIST

6-269 (of 337)

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

LANNETT	5MG	A080531	002	
MARSHALL PHARMA	5MG	A080307	001	
PANRAY	1MG	A080351	001	
	5MG	A080351	002	
PERRIGO	5MG	A084542	001	
PHOENIX LABS NY	5MG	A080322	001	
PUREPAC PHARM	5MG	A080325	001	
PVT FORM	5MG	A080211	001	
ROXANE	5MG	A080327	002	
SANDOZ	5MG	A080339	001	
	5MG	A084773	001	
SPERTI	1MG	A080358	001	
	2.5MG	A080358	002	
	5MG	A080358	003	
SUPERPHARM	5MG	A088892	001	Feb 26, 1985
TABLICAPS	5MG	A085170	001	
TEVA	5MG	A080398	001	
UDL	5MG	A087987	001	Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001	
VITARINE	5MG	A080534	001	
WATSON LABS	5MG	A085085	002	
	5MG	A085415	001	
	5MG	A085416	001	
WEST WARD	5MG	A080324	001	
WHITEWORTH TOWN PLSN	5MG	A080342	001	
STERANE				
PFIZER	5MG	N009996	001	

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255	002	
----------	---------	---------	-----	--

PREDNISOLONE ACETATE

AKORN	25MG/ML	A083032	001	
	50MG/ML	A084492	001	
BEL MAR	25MG/ML	A083738	001	
	50MG/ML	A083738	002	
CENT PHARMS	25MG/ML	A084717	001	
	50MG/ML	A084717	002	
WATSON LABS	25MG/ML	A083398	001	
	25MG/ML	A083654	001	
	40MG/ML	A083767	001	
	50MG/ML	A083764	001	
	50MG/ML	A085781	001	

STERANE

PFIZER	25MG/ML	N011446	001	
--------	---------	---------	-----	--

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008
------	-----------------	---------	-----	--------------

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

ALCON	0.125%	N017468	001	
-------	--------	---------	-----	--

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

CETAPRED

ALCON	0.25%;10%	A087771	001	Aug 06, 1993
-------	-----------	---------	-----	--------------

METIMYD

SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
----------	----------	---------	-----	--------------

PREDSULFAIR

PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
------------	----------	---------	-----	--------------

VASOCIDIN

NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984
----------	----------	---------	-----	--------------

SUSPENSION; OPHTHALMIC

ISOPTO CETAPRED

ALCON	0.25%;10%	A087547	001	
-------	-----------	---------	-----	--

SUSPENSION/DROPS; OPHTHALMIC

METIMYD

SCHERING	0.5%;10%	N010210	001	
----------	----------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-270 (of 337)

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS;OPHTHALMIC

PREDAMIDE

AKORN	0.5%;10%	A088059	001	Jul 29, 1983
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
PREDSULFAIR II				
PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
SULPHRIN				
BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDELTRASOL

MERCK	EQ 20MG PHOSPHATE/ML	N011583	002	
PREDNISOLONE SODIUM PHOSPHATE				
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001	

OINTMENT;OPHTHALMIC, OTIC

HYDELTRASOL

MERCK	EQ 0.25% PHOSPHATE	N011028	001	
-------	--------------------	---------	-----	--

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005
	EQ 15MG BASE/5ML	A076988	001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002	
----------	-------------------	---------	-----	--

INFLAMASE MILD

NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001	
----------	--------------------	---------	-----	--

METRETON

SCHERING	EQ 0.5% PHOSPHATE	A083834	001	
----------	-------------------	---------	-----	--

PREDAIR

PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984
------------	--------------------	---------	-----	--------------

PREDAIR FORTE

PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983
------------	-------------------	---------	-----	--------------

PREDNISOLONE SODIUM PHOSPHATE

AKORN	EQ 0.11% PHOSPHATE	A083358	001	
	EQ 0.9% PHOSPHATE	A083358	002	
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	
	EQ 0.9% PHOSPHATE	A084168	001	
	EQ 0.9% PHOSPHATE	A084169	001	
	EQ 0.9% PHOSPHATE	A084172	001	

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULSTER

AKORN	EQ 0.23% PHOSPHATE;10%	A074511	001	Jul 30, 1996
-------	------------------------	---------	-----	--------------

VASOCIDIN

NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988
----------	------------------------	---------	-----	--------------

PREDNISOLONE TEBUTATE

INJECTABLE; INJECTION

HYDELTRA-TBA

MERCK	20MG/ML	N010562	001	
-------	---------	---------	-----	--

PREDNISOLONE TEBUTATE

WATSON LABS	20MG/ML	A083362	001	Feb 17, 1984
-------------	---------	---------	-----	--------------

PREDNISON

SOLUTION;ORAL

PREDNISON

WOCKHARDT	5MG/5ML	A089726	001	Aug 02, 1988
-----------	---------	---------	-----	--------------

SYRUP;ORAL

LIQUID PRED

MURO	5MG/5ML	A087611	002	Sep 07, 1982
------	---------	---------	-----	--------------

TABLET;ORAL

CORTAN

HALSEY	20MG	A087480	001	
--------	------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-271 (of 337)

PREDNISONE

TABLET; ORAL

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

PHARMACIA AND UPJOHN

2.5MG

N009986 005

5MG

N009986 002

10MG

N009986 006

20MG

N009986 007

50MG

N009986 008

FERNISONE

FERNDAL LABS

5MG

A083364 001

METICORTEN

SCHERING

1MG

N009766 002

5MG

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISONE

AM THERAP

5MG

A089387 001 Nov 06, 1986

10MG

A089388 001 Nov 06, 1986

20MG

A089389 001 Nov 06, 1986

AMNEAL PHARMS NY

5MG

A089597 001 Oct 05, 1987

10MG

A089598 001 Oct 05, 1987

20MG

A089599 001 Oct 05, 1987

BUNDY

5MG

A083676 001

DURAMED PHARMS BARR

5MG

A088394 001 Oct 04, 1983

10MG

A088395 001 Oct 04, 1983

20MG

A088396 001 Oct 04, 1983

ELKINS SINN

5MG

A080491 001

20MG

A085811 001

EVERYLIFE

1MG

A084440 001

2.5MG

A084440 002

5MG

A084440 003

FERRANTE

2.5MG

A080563 001

5MG

A080563 002

HALSEY

5MG

A080300 001

HEATHER

5MG

A080320 001

10MG

A084341 001

20MG

A084417 001

20MG

A085543 001

50MG

A086946 001

IMPAX LABS

5MG

A080782 001

INWOOD LABS

1MG

A080328 001

2.5MG

A080306 001

5MG

A080279 001

IVAX SUB TEVA PHARMS

5MG

A080283 001

10MG

A084133 001

20MG

A084134 001

KV PHARM

5MG

A084236 001

LANNETT

5MG

A080514 001

20MG

A084275 001

LEDERLE

5MG

A086968 001

MARSHALL PHARMA

5MG

A080301 001

MUTUAL PHARM

5MG

A080701 001

10MG

A086595 001

20MG

A084634 001

50MG

A086596 001

NYLOS

5MG

A085115 001

PANRAY

1MG

A080350 001

2.5MG

A080350 002

5MG

A080350 003

PERRIGO

5MG

A083059 001

PHARMAVITE

5MG

A084662 002

PHOENIX LABS NY

5MG

A080321 001

DISCONTINUED DRUG PRODUCT LIST

6-272 (of 337)

PREDNISONE

TABLET; ORAL

PREDNISONE

	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
ROXANE	20MG	N017109	001	
	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	
VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

ASTRAZENECA	1%	N014763	004	
	2%	N014763	005	
	3%	N014763	003	
CITANEST PLAIN				
ASTRAZENECA	4%	N014763	007	
CITANEST PLAIN DENTAL				
DENTSPLY PHARM	4%	N021382	001	

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

NURO PHARMA	250MG/5ML	N010401	001	
-------------	-----------	---------	-----	--

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008
HIKMA PHARMS LLC	50MG	A040667	001	Jul 27, 2006
WATSON LABS	250MG	A085052	001	

DISCONTINUED DRUG PRODUCT LIST

6-273 (of 337)

PROBENECID

TABLET; ORAL

BENEMID

MERCK

500MG

N007898 004

PROBENECID

IVAX SUB TEVA PHARMS

500MG

A083740 001 May 09, 1984

LEDERLE

500MG

A086917 001

WATSON LABS

500MG

A086150 002 Apr 23, 1982

PROBUCOL

TABLET; ORAL

LORELCO

SANOFI AVENTIS US

250MG

N017535 001

500MG

N017535 002 Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ASCOT

250MG

A087542 001 Jan 08, 1982

375MG

A087697 001 Mar 01, 1983

500MG

A087543 001 Jan 08, 1982

IVAX SUB TEVA PHARMS

250MG

A084604 001

375MG

A084595 001

500MG

A084606 001

LANNETT

250MG

A083693 001

500MG

A084696 001

LEDERLE

250MG

A086942 001

375MG

A086952 001

500MG

A086943 001

ROXANE

250MG

A088989 001 Apr 26, 1985

500MG

A088990 001 Apr 26, 1985

SANDOZ

250MG

A089219 001 Jul 01, 1986

375MG

A089220 001 Jul 01, 1986

500MG

A089221 001 Jul 01, 1986

VANGARD

250MG

A087643 001 Jun 01, 1982

500MG

A087875 001 Jun 01, 1982

WATSON LABS

250MG

A083287 001

250MG

A083795 001

250MG

A085167 001

375MG

A084403 001

375MG

A087020 001

500MG

A084280 001

500MG

A084357 001

500MG

A087021 001

PROCAN

PARKE DAVIS

250MG

A085804 001

375MG

A087502 001

500MG

A085079 001

PROCAPAN

PANRAY

250MG

A083553 002

PRONESTYL

APOTHECON

250MG

N007335 001

375MG

N007335 004

500MG

N007335 003

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A089415 001 Nov 17, 1986

500MG/ML

A089416 001 Nov 17, 1986

HIKMA MAPLE

100MG/ML

A089029 001 Apr 17, 1986

500MG/ML

A089030 001 Apr 17, 1986

HOSPIRA

500MG/ML

A089537 001 Aug 25, 1987

INTL MEDICATION

100MG/ML

A088636 001 Jul 31, 1984

500MG/ML

A088637 001 Jul 31, 1984

PHARMAFAIR

100MG/ML

A088824 001 Nov 20, 1985

500MG/ML

A088830 001 Nov 20, 1985

SMITH AND NEPHEW

100MG/ML

A088530 001 Mar 04, 1985

500MG/ML

A088531 001 Mar 04, 1985

SOLOPAK

500MG/ML

A088532 001 Mar 04, 1985

WARNER CHILCOTT

100MG/ML

A089528 001 May 03, 1988

500MG/ML

A089529 001 May 03, 1988

WATSON LABS

100MG/ML

A087079 001

500MG/ML

A087080 001

DISCONTINUED DRUG PRODUCT LIST

6-274 (of 337)

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PRONESTYL

APOTHECON

100MG/ML

N007335 002

500MG/ML

N007335 005

TABLET; ORAL

PRONESTYL

APOTHECON

250MG

N017371 001

375MG

N017371 002

500MG

N017371 003

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS INC

1GM

A040111 001 Dec 13, 1996

250MG

A088958 001 Dec 02, 1985

500MG

A088959 001 Dec 02, 1985

500MG

A088974 001 Jul 22, 1985

750MG

A089438 001 Mar 23, 1987

INWOOD LABS

500MG

A089840 001 Mar 06, 1989

SANDOZ

250MG

A089369 001 Aug 14, 1987

500MG

A089284 001 Jun 23, 1986

500MG

A089370 001 Jan 09, 1987

750MG

A089371 001 Aug 14, 1987

WATSON LABS

1GM

A089520 001 Jan 15, 1987

250MG

A088533 001 Dec 03, 1984

250MG

A089026 001 Oct 22, 1985

500MG

A088534 001 Dec 03, 1984

500MG

A089027 001 Oct 22, 1985

750MG

A088535 001 Nov 03, 1984

750MG

A089042 001 Oct 22, 1985

PROCAN SR

PARKE DAVIS

250MG

A086468 001

PARKEDALE

1GM

A088489 001 Jan 16, 1985

500MG

A086065 001

750MG

A087510 001 Apr 01, 1982

PROCANBID

KING PHARMS

1GM

N020545 002 Jan 31, 1996

500MG

N020545 001 Jan 31, 1996

PRONESTYL-SR

APOTHECON

500MG

A087361 001

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA

1%

A085362 003

2%

A085362 004

10%

A086797 001

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM

1%

A080384 002

1%

A080421 001

2%

A080384 003

2%

A080421 002

BEL MAR

1%

A080711 001

2%

A080756 001

ELKINS SINN

1%

A083315 001

2%

A083315 002

GD SEARLE LLC

1%

A086202 001

2%

A086202 002

HOSPIRA

1%

A080416 001

2%

A080416 002

MILES

1%

A080415 001

2%

A080415 002

WATSON LABS

1%

A080658 001

1%

A083535 001

2%

A080658 002

2%

A083535 002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE

40MG/VIAL; 100MG/VIAL

N050276 001

40MG/VIAL; 250MG/VIAL

N050276 003

TETRACYN

PFIZER

40MG/VIAL; 100MG/VIAL

A060285 002

DISCONTINUED DRUG PRODUCT LIST

6-275 (of 337)

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

TETRACYN

40MG/VIAL; 250MG/VIAL

A060285 003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG

N011127 003

5MG

N011127 001

25MG

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001 Jul 11, 2001

5MG

A040407 002 Jul 11, 2001

25MG

A040407 003 Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001 Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001 Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/ML

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001 Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HIKMA MAPLE

EQ 5MG BASE/ML

A089523 001 May 03, 1988

HOSPIRA

EQ 5MG BASE/ML

A089703 001 Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001 Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001 Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001 May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001 Jul 08, 1987

EQ 5MG BASE/ML

A089605 001 Jul 08, 1987

EQ 5MG BASE/ML

A089606 001 Jul 08, 1987

EQ 5MG BASE/ML

A086348 001

WYETH AYERST

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001 Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002 Oct 06, 1999

EQ 30MG BASE

N011000 003

EQ 75MG BASE

N011000 004

TABLET; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE

N010571 001

EQ 10MG BASE

N010571 002

EQ 25MG BASE

N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE

A085580 001

EQ 10MG BASE

A085178 001

EQ 25MG BASE

A085579 001

PROCHLORPERAZINE MALEATE

DURAMED PHARMS BARR

EQ 5MG BASE

A040207 001 May 01, 1997

EQ 5MG BASE

A089484 001 Jan 20, 1987

EQ 10MG BASE

A040207 002 May 01, 1997

EQ 10MG BASE

A089485 001 Jan 20, 1987

DISCONTINUED DRUG PRODUCT LIST

6-276 (of 337)

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATE

	EQ 25MG BASE	A089486 001	Jan 20, 1987
IVAX SUB TEVA PHARMS	EQ 5MG BASE	A040162 001	Jan 20, 1998
	EQ 10MG BASE	A040162 002	Jan 20, 1998
SANDOZ	EQ 25MG BASE	A040101 003	Jul 19, 1996

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

MONARCH PHARMS

2MG

N009818 005

5MG

N009818 003

PROGESTERONE

CAPSULE; ORAL

PROMETRIUM

ABBVIE INC

300MG

N019781 003 Oct 15, 1999

INJECTABLE; INJECTION

PROGESTERONE

LILLY

25MG/ML

N009238 002

50MG/ML

N009238 001

INSERT, EXTENDED RELEASE; INTRAUTERINE

PROGESTASERT

ALZA

38MG

N017553 001

PROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SPARINE

WYETH AYERST

30MG/ML

N010942 001

100MG/ML

N010942 004

INJECTABLE; INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML

A084510 001

50MG/ML

A084517 001

SPARINE

BAXTER HLTHCARE CORP

25MG/ML

N010349 008

50MG/ML

N010349 006

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG

N010348 006

25MG

N010348 001

50MG

N010348 002

100MG

N010348 003

200MG

N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML

N008857 002

50MG/ML

N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML

A084223 001

50MG/ML

A084222 001

AKORN

25MG/ML

A083955 002

50MG/ML

A083955 001

BEDFORD LABS

25MG/ML

A040524 001 Mar 17, 2004

50MG/ML

A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML

A040372 001 Jun 08, 2000

50MG/ML

A040372 002 Jun 08, 2000

50MG/ML

A083838 002

LUITPOLD

25MG/ML

A040515 001 Mar 19, 2003

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

50MG/ML

A089477 001 May 02, 1988

MYLAN INSTITUTIONAL

25MG/ML

A040471 001 Nov 21, 2002

SANDOZ

25MG/ML

A040593 001 Nov 08, 2006

50MG/ML

A040593 002 Nov 08, 2006

TEVA PHARMS USA

25MG/ML

A040454 001 Aug 22, 2002

50MG/ML

A040454 002 Aug 22, 2002

WATSON LABS

25MG/ML

A083532 001

25MG/ML

A084591 001

DISCONTINUED DRUG PRODUCT LIST

6-277 (of 337)

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

50MG/ML

A080629 002

50MG/ML

A083532 002

WOCKHARDT

25MG/ML

A040785 001 Sep 26, 2008

50MG/ML

A040785 002 Sep 26, 2008

ZIPAN-25

ALTANA

25MG/ML

A083997 001

ZIPAN-50

ALTANA

50MG/ML

A083997 002

SUPPOSITORY; RECTAL

PHENERGAN

DELCOR ASSET CORP

50MG

N011689 001

SHIONOGI INC

12.5MG

N010926 002

25MG

N010926 001

PROMETHACON

POLYMEDICA

25MG

A084901 001

50MG

A084902 001

PROMETHAZINE HYDROCHLORIDE

ABLE

12.5MG

A040504 001 Apr 11, 2003

25MG

A040504 002 Apr 11, 2003

50MG

A040449 001 Feb 27, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA

25MG/5ML

A087996 001 Jan 18, 1983

PROMETH FORTIS

ALPHARMA US PHARMS

25MG/5ML

A084772 001

PROMETH PLAIN

ACTAVIS MID ATLANTIC

6.25MG/5ML

A085953 001

PROMETHAZINE

CENCI

6.25MG/5ML

A089013 001 Sep 20, 1985

PROMETHAZINE HYDROCHLORIDE

KV PHARM

6.25MG/5ML

A085388 001

25MG/5ML

A085385 001

PHARM ASSOC

6.25MG/5ML

A087518 001

WHITEWORTH TOWN PLSN

6.25MG/5ML

A086395 001

PROMETHAZINE HYDROCHLORIDE PLAIN

ANI PHARMS

6.25MG/5ML

N008381 004 Apr 18, 1984

25MG/5ML **Federal Register

N008381 003

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

TABLET; ORAL

PHENERGAN

DELCOR ASSET CORP

12.5MG

N007935 002

25MG

N007935 003

50MG

N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT

12.5MG

A084160 001

25MG

A084166 001

50MG

A084539 001

ABLE

12.5MG

A040558 001 Jul 01, 2004

25MG

A040558 002 Jul 01, 2004

50MG

A040558 003 Jul 01, 2004

IMPAX LABS

25MG

A084214 002 Jul 07, 1982

IVAX SUB TEVA PHARMS

12.5MG

A083604 001

25MG

A083603 001

50MG

A083613 001

LANNETT

12.5MG

A080949 001

25MG

A080949 002

50MG

A080949 003

MUTUAL PHARM

12.5MG

A084555 001

25MG

A084554 001

50MG

A084557 001

PVT FORM

12.5MG

A083214 001

25MG

A083658 001

SANDOZ

12.5MG

A084176 002 May 22, 2009

12.5MG

A084233 001

25MG

A085146 001

50MG

A085146 002

TABLICAPS

12.5MG

A084080 001

25MG

A084027 001

DISCONTINUED DRUG PRODUCT LIST

6-278 (of 337)

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

TEVA	25MG	A089109 001	Sep 10, 1985
WATSON LABS	12.5MG	A083401 001	
	12.5MG	A083712 001	
	12.5MG	A085986 001	
	25MG	A083204 001	
	25MG	A085684 001	
	50MG	A083403 001	
	50MG	A085664 001	
REMSD			
BRISTOL MYERS SQUIBB	25MG	A083176 002	
	50MG	A083176 001	

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS	150MG	A076193 001	Feb 07, 2002
	225MG	A076193 002	Feb 07, 2002
	300MG	A076193 003	Feb 07, 2002

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC	30MG/VIAL	N008843 001	
---------------	-----------	-------------	--

TABLET; ORAL

PRO-BANTHINE

SHIRE	7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**	N008732 003	
	15MG	N008732 002	

PROPANTHELINE BROMIDE

ASCOT	15MG	A087663 001	Oct 25, 1982
HEATHER	15MG	A085780 001	
IMPAX LABS	15MG	A084541 002	
MYLAN	15MG	A083706 001	
PAR PHARM	15MG	A088377 001	Dec 08, 1983
PVT FORM	15MG	A080977 001	
ROXANE	7.5MG	A080927 001	
SANDOZ	15MG	A080928 001	
TABLICAPS	15MG	A084428 001	
WATSON LABS	15MG	A083029 002	
	15MG	A083151 001	

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR	0.5%	A088087 001	Jun 07, 1983
------------	------	-------------	--------------

OPHTHAINE

APOTHECON	0.5%	N008883 001	
-----------	------	-------------	--

OPHTHETIC

ALLERGAN	0.5%	N012583 001	
----------	------	-------------	--

PARACAINE

OPTOPICS	0.5%	A087681 001	Aug 05, 1982
----------	------	-------------	--------------

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND	0.5%	A084144 001	
	0.5%	A084151 001	

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS	N/A	N011657 001	
-------------	-----	-------------	--

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

HIKMA MAPLE	20MG/ML	N012382 002	
-------------	---------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

6-279 (of 337)

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

FRESENIUS KABI USA 10MG/ML N019627 001 Oct 02, 1989

PROPOFOL

EUROHLTH INTL 10MG/ML A074848 001 Apr 19, 2005

TEVA PARENTERAL 10MG/ML A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM 32MG N010997 001

65MG N010997 003

DOLENE

HERITAGE PHARMS INC 65MG A080530 001

KESSO-GESIC

MK LABS 65MG A083544 001

PROPHENE 65

HALSEY 65MG A083538 002

PROPOXYPHENE HYDROCHLORIDE

ALRA 65MG A083184 001

IMPAX LABS 65MG A083317 001

IVAX SUB TEVA PHARMS 32MG A083597 001

MUTUAL PHARM 65MG A083186 001

MYLAN 32MG A083528 001

65MG A040569 001 Dec 16, 2004

65MG A083299 001

NEXGEN PHARMA INC 65MG A083185 001

PAR PHARM 65MG A080269 001

PUREPAC PHARM 65MG A083278 001

PVT FORM 65MG A083113 001

ROXANE 32MG A083089 001

65MG A083089 002

SANDOZ 32MG A084014 001

65MG A083125 002

65MG A083688 001

65MG A083870 002

65MG A086495 001

TEVA 65MG A088615 001 Oct 22, 1984

VALEANT PHARM INTL 65MG A080783 001

VINTAGE PHARMS 65MG A040908 001 Jul 17, 2009

WATSON LABS 65MG A080908 002

65MG A085190 001

WEST WARD 65MG A083501 001

WHITEWORTH TOWN PLSN 65MG A084551 001

PROPOXYPHENE HYDROCHLORIDE 65

WARNER CHILCOTT 65MG A083786 001

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC 50MG/5ML N016861 001

TABLET; ORAL

DARVON-N

XANODYNE PHARM 100MG N016862 002

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS 60MG A072499 001 Apr 11, 1989

80MG A072500 001 Apr 11, 1989

120MG A072501 001 Apr 11, 1989

160MG A072502 001 Apr 11, 1989

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE 80MG/ML A071388 001 May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

SMITH AND NEPHEW 1MG/ML A070135 001 Apr 15, 1986

1MG/ML A070137 001 Apr 15, 1986

SOLOPAK 1MG/ML A070136 001 Apr 15, 1986

DISCONTINUED DRUG PRODUCT LIST

6-280 (of 337)

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

MORTON GROVE

20MG/5ML

A071984 001 Mar 03, 1989

40MG/5ML

A071985 001 Mar 03, 1989

SUSPENSION; ORAL

INDERAL

WYETH AYERST

10MG/ML

N019536 001 Dec 12, 1986

TABLET; ORAL

INDERAL

WYETH PHARMS INC

10MG

N016418 001

20MG

N016418 003

40MG

N016418 002

60MG

N016418 009 Oct 18, 1982

80MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016418 004

90MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N016418 010 Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS INC

90MG

A071977 001 Apr 06, 1988

DAVA PHARMS INC

10MG

A070125 001 Jul 30, 1985

20MG

A070126 001 Jul 30, 1985

40MG

A070127 001 Jul 30, 1985

60MG

A071495 001 Dec 31, 1987

80MG

A070128 001 Jul 30, 1985

90MG

A071496 001 Dec 31, 1987

DURAMED PHARMS BARR

10MG

A070306 001 Sep 09, 1985

20MG

A070307 001 Sep 09, 1985

40MG

A070308 001 Sep 09, 1985

60MG

A070309 001 Oct 01, 1986

80MG

A070310 001 Sep 09, 1985

90MG

A071327 001 Oct 01, 1986

INTERPHARM

10MG

A071368 001 May 05, 1987

20MG

A071369 001 May 05, 1987

40MG

A071370 001 May 05, 1987

80MG

A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS

10MG

A072063 001 Jul 29, 1988

20MG

A072066 001 Jul 29, 1988

40MG

A072067 001 Jul 29, 1988

60MG

A072068 001 Jul 29, 1988

80MG

A072069 001 Jul 29, 1988

LEDERLE

10MG

A072117 001 Jun 23, 1988

20MG

A072118 001 Jun 23, 1988

40MG

A072119 001 Jun 23, 1988

80MG

A072120 001 Jun 23, 1988

MUTUAL PHARM

10MG

A070319 001 Oct 22, 1985

20MG

A070320 001 Oct 22, 1985

40MG

A070103 001 Oct 22, 1985

60MG

A070321 001 Sep 24, 1986

80MG

A070322 001 Aug 04, 1986

MYLAN

60MG

A072275 001 Jun 09, 1989

PAR PHARM

90MG

A071288 001 Oct 22, 1986

PUREPAC PHARM

10MG

A070814 001 Nov 03, 1986

20MG

A070815 001 Nov 03, 1986

40MG

A070816 001 Nov 03, 1986

60MG

A070817 001 Nov 03, 1986

80MG

A070757 001 Nov 03, 1986

ROXANE

10MG

A070516 001 Jul 07, 1986

20MG

A070517 001 Jul 07, 1986

40MG

A070518 001 Jul 07, 1986

60MG

A070519 001 Sep 24, 1986

80MG

A070520 001 Jul 07, 1986

90MG

A070521 001 Sep 24, 1986

SANDOZ

10MG

A070663 001 Jun 13, 1986

10MG

A071658 001 Jul 05, 1988

20MG

A070664 001 Jun 13, 1986

20MG

A071687 001 Jul 05, 1988

40MG

A070665 001 Jun 13, 1986

40MG

A071688 001 Jul 05, 1988

DISCONTINUED DRUG PRODUCT LIST

6-281 (of 337)

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

60MG	A070666	001	Oct 10, 1986
60MG	A072197	001	Jul 05, 1988
80MG	A070667	001	Jun 13, 1986
80MG	A071689	001	Jul 05, 1988
90MG	A072198	001	Jul 05, 1988
SCHERING	10MG	A070120	001 Aug 06, 1985
	20MG	A070121	001 Aug 06, 1985
	40MG	A070122	001 Aug 06, 1985
	60MG	A070123	001 Oct 29, 1986
	80MG	A070124	001 Aug 06, 1985
SUPERPHARM	10MG	A071515	001 Jun 08, 1988
	20MG	A071516	001 Jun 08, 1988
	40MG	A071517	001 Jun 08, 1988
	80MG	A071518	001 Jun 08, 1988
TEVA	10MG	A070232	001 Oct 07, 1987
	20MG	A070233	001 Jun 23, 1986
	40MG	A070234	001 Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001 Sep 15, 1986
	20MG	A070439	001 Sep 15, 1986
	40MG	A070440	001 Sep 15, 1986
	60MG	A070441	001 Sep 24, 1986
	80MG	A070442	001 Sep 15, 1986
WATSON LABS	10MG	A070140	001 Jul 30, 1985
	10MG	A070378	001 Mar 19, 1987
	10MG	A070548	001 Jul 10, 1986
	20MG	A070141	001 Jul 30, 1985
	20MG	A070379	001 Mar 19, 1987
	20MG	A070549	001 Apr 11, 1986
	40MG	A070142	001 Jul 30, 1985
	40MG	A070380	001 Mar 19, 1987
	40MG	A070550	001 Apr 11, 1986
	60MG	A070143	001 Jan 15, 1987
	60MG	A070381	001 Mar 19, 1987
	60MG	A071098	001 Oct 06, 1986
	60MG	A071791	001 Jul 15, 1987
	80MG	A070144	001 Jul 30, 1985
	80MG	A070382	001 Mar 19, 1987
	80MG	A070551	001 Jul 10, 1986
	90MG	A071183	001 Oct 06, 1986
	90MG	A071792	001 Jul 15, 1987

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309	001
-----------------	-----	---------	-----

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309	002
-----------------	-----	---------	-----

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS INC	50MG	A080215	001
HALSEY	50MG	A080015	001
HIKMA PHARMS LLC	50MG	A080154	001
IMPAX LABS	50MG	A080159	001
LANNETT	50MG	A080016	001
LILLY	50MG	N006213	001
MUTUAL PHARM	50MG	A083982	001
PERRIGO	50MG	A084543	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

DISCONTINUED DRUG PRODUCT LIST

6-282 (of 337)

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

HIKMA MAPLE

10MG/ML

A089474 001 Nov 05, 1986

10MG/ML

A089475 001 Nov 05, 1986

LILLY

10MG/ML

N006460 002

PHARMACIA AND UPJOHN

50MG/VIAL

N007413 001

250MG/VIAL

N007413 002 Aug 02, 1984

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE

5%

N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN

5%

N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT

0.5MG/ML

N017638 001

THYREL TRH

FERRING

0.5MG/ML

N018087 001

PROTOKYLQOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US

2MG

A083459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

TEVA WOMENS

5MG

N016012 001

10MG

N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US

120MG

N017603 001

SUDAFED 12 HOUR

GLAXOSMITHKLINE

120MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N017941 002

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE

120MG; 5MG

N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG; 5MG

A071798 001 Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI

30MG/5ML; 1.25MG/5ML

A088344 001 Feb 09, 1984

HISTAFED

CENCI

30MG/5ML; 1.25MG/5ML

A088283 001 Apr 20, 1984

MYFED

USL PHARMA

30MG/5ML; 1.25MG/5ML

A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS

30MG/5ML; 1.25MG/5ML

A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM

60MG; 2.5MG

A088860 001 Jan 31, 1985

CORPHED

SANDOZ

60MG; 2.5MG

A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ

60MG; 2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS

60MG; 2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA

60MG; 2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS

60MG; 2.5MG

A088318 002 Jan 13, 1984

WEST WARD

60MG; 2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

60MG; 2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM

60MG; 2.5MG

A088578 001 Feb 21, 1985

DISCONTINUED DRUG PRODUCT LIST

6-283 (of 337)

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG; 5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

PSEUDO-12

UCB INC

EQ 60MG HCL/5ML

N019401 001 Jun 19, 1987

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

BARR

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

COREPHARMA

60MG

A040457 001 Dec 26, 2002

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

WATSON LABS

100MG/ML

A080572 001

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET; ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET; ORAL

FANSIDAR

ROCHE

25MG; 500MG

N018557 001

PYRITHIONE ZINC

LOTION; TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET; ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET; ORAL

DORAL

SCIECURE PHARMA INC

7.5MG

N018708 003 Feb 26, 1987

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

ASTRAZENECA

EQ 150MG BASE

N020639 004 Dec 20, 1998

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

DISCONTINUED DRUG PRODUCT LIST

6-284 (of 337)

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 40MG BASE	A076240 004	Jan 26, 2006
MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005
	EQ 10MG BASE	A076036 002	Jan 28, 2005
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 40MG BASE	A076036 004	Jan 28, 2005
SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005
	EQ 10MG BASE	A076803 002	Mar 02, 2005
	EQ 20MG BASE	A076803 003	Mar 02, 2005
	EQ 40MG BASE	A076803 004	Mar 02, 2005

QUINESTROL

TABLET; ORAL

ESTROVIS

PARKE DAVIS

0.1MG	N016768 002
0.2MG	N016768 003

QUINETHAZONE

TABLET; ORAL

HYDROMOX

LEDERLE

50MG	N013264 001
------	-------------

QUINETHAZONE; RESERPINE

TABLET; ORAL

HYDROMOX R

LEDERLE

50MG; 0.125MG	N013927 001
---------------	-------------

QUINIDINE GLUCONATE

TABLET; ORAL

QUINACT

BAYER HLTHCARE

266MG	A085978 001
400MG	A086099 001

TABLET, EXTENDED RELEASE; ORAL

DURAQUIN

WARNER CHILCOTT

330MG	N017917 001
-------	-------------

QUINAGLUTE

BAYER HLTHCARE

324MG	N016647 001
-------	-------------

QUINALAN

LANNETT

324MG	A088081 001	Feb 10, 1986
-------	-------------	--------------

QUINATIME

WATSON LABS

324MG	A087448 001
-------	-------------

QUINIDINE GLUCONATE

ASCOT

324MG	A088582 001	Jun 17, 1985
-------	-------------	--------------

HALSEY

324MG	A089476 001	Apr 10, 1987
-------	-------------	--------------

ROXANE

324MG	A088431 001	Jan 06, 1984
-------	-------------	--------------

SANDOZ

324MG	A089894 001	Dec 15, 1988
-------	-------------	--------------

SUPERPHARM

324MG	A089164 001	Nov 21, 1985
-------	-------------	--------------

WATSON LABS

324MG	A087785 001	Jan 24, 1983
-------	-------------	--------------

324MG	A087810 001	Sep 29, 1982
-------	-------------	--------------

QUINIDINE POLYGALACTURONATE

TABLET; ORAL

CARDIOQUIN

PHARM RES ASSOC

275MG	N011642 002
-------	-------------

QUINIDINE SULFATE

CAPSULE; ORAL

CIN-QUIN

SOLVAY

200MG	A085296 001
300MG	A085297 001

QUINIDINE SULFATE

LILLY

200MG	A085103 001
-------	-------------

TABLET; ORAL

CIN-QUIN

SOLVAY

100MG	A085299 001
200MG	A084932 001
300MG	A085298 001

QUINIDINE SULFATE

BARR

200MG	A084177 001
-------	-------------

CONTRACT PHARMACAL

200MG	A083808 001
-------	-------------

DAVA PHARMS INC

200MG	A087011 001
-------	-------------

ELKINS SINN

200MG	A083622 001
-------	-------------

EVERYLIFE

200MG	A083439 001
-------	-------------

DISCONTINUED DRUG PRODUCT LIST

6-285 (of 337)

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

HALSEY	200MG	A083583	001	
HIKMA PHARMS LLC	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LANNETT	200MG	A083743	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
ROXANE	200MG	A083640	001	
	300MG	A085632	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A085140	002	
WHITEWORTH TOWN PLSN	200MG	A085444	001	
QUINORA				
KEY PHARMS	200MG	A083576	001	
SCHERING	300MG	A085222	001	

TABLET, EXTENDED RELEASE;ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	
------------------	-------	---------	-----	--

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

EISAI INC	10MG	N020973	001	May 29, 2002
Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons				

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513	001	Jun 18, 2008
	2.5MG	A077513	002	Jun 18, 2008
	5MG	A077513	003	Jun 18, 2008
	10MG	A077513	004	Jun 18, 2008
CIPLA	1.25MG	A077004	001	Aug 07, 2008
	2.5MG	A077004	002	Aug 07, 2008
	5MG	A077004	003	Aug 07, 2008
	10MG	A077004	004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849	001	Mar 06, 2009
	10MG	A078849	002	Mar 06, 2009

TABLET;ORAL

ALTACE

KING PFIZER	1.25MG	N022021	001	Feb 27, 2007
	2.5MG	N022021	002	Feb 27, 2007
	5MG	N022021	003	Feb 27, 2007
	10MG	N022021	004	Feb 27, 2007

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559	001	Aug 08, 1996
-----------------	-------	---------	-----	--------------

DISCONTINUED DRUG PRODUCT LIST

6-286 (of 337)

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 150MG BASE

A075564 001 Oct 27, 2000

EQ 300MG BASE

A075564 002 Oct 27, 2000

TEVA

EQ 150MG BASE

A075557 001 Oct 31, 2003

EQ 300MG BASE

A075557 002 Oct 31, 2003

ZANTAC 150

GLAXOSMITHKLINE

EQ 150MG BASE

N020095 001 Mar 08, 1994

ZANTAC 300

GLAXOSMITHKLINE

EQ 300MG BASE

N020095 002 Mar 08, 1994

GRANULE, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE/PACKET

N020251 002 Mar 31, 1994

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD

EQ 25MG BASE/ML

A074764 001 Nov 19, 2004

ZANTAC IN PLASTIC CONTAINER

COVIS INJECTABLES

EQ 1MG BASE/ML

N019593 002 Sep 27, 1991

EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 15MG BASE/ML

A077602 001 Sep 17, 2007

RANBAXY

EQ 15MG BASE/ML

A078448 001 Dec 13, 2007

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

BOEHRINGER INGELHEIM

EQ 150MG BASE

A074662 001 Aug 29, 1997

EQ 300MG BASE

A074662 002 Aug 29, 1997

MYLAN

EQ 150MG BASE

A074552 001 Jul 30, 1998

EQ 300MG BASE

A074552 002 Jul 30, 1998

RANBAXY

EQ 75MG BASE

A075132 001 Jan 14, 2000

EQ 75MG BASE

A075254 001 Jan 14, 2000

EQ 150MG BASE

A075000 001 Jan 30, 1998

EQ 150MG BASE

A075439 001 Apr 19, 2000

EQ 300MG BASE

A075000 002 Jan 30, 1998

EQ 300MG BASE

A075439 002 Apr 19, 2000

SANDOZ

EQ 75MG BASE

A075519 001 Sep 26, 2002

WATSON LABS

EQ 75MG BASE

A075212 001 Jan 14, 2000

EQ 150MG BASE

A074864 001 Oct 20, 1997

EQ 300MG BASE

A074864 002 Oct 20, 1997

WATSON LABS INC

EQ 150MG BASE

A077426 001 Dec 19, 2005

EQ 300MG BASE

A077426 002 Dec 19, 2005

WOCKHARDT

EQ 150MG BASE

A078653 001 Nov 26, 2007

EQ 150MG BASE

A078701 001 Nov 12, 2009

EQ 300MG BASE

A078701 002 Dec 11, 2009

TABLET, EFFERVESCENT; ORAL

ZANTAC 150

GLAXO GRP LTD

EQ 150MG BASE

N020251 001 Mar 31, 1994

ZANTAC 25

GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004

ZANTAC 75

BOEHRINGER INGELHEIM

EQ 75MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020745 001 Feb 26, 1998

RAPACURONIUM BROMIDE

INJECTABLE; INJECTION

RAPLON

ORGANON USA INC

100MG/VIAL

N020984 001 Aug 18, 1999

200MG/VIAL

N020984 002 Aug 18, 1999

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

WATSON LABS INC

EQ 0.5MG BASE

A201823 001 Jul 01, 2013

EQ 1MG BASE

A201823 002 Jul 01, 2013

DISCONTINUED DRUG PRODUCT LIST

6-287 (of 337)

RAUWOLFIA SERPENTINA ROOT

TABLET; ORAL

HIWOLFIA

BOWMAN PHARMS

50MG

N009276 003

50MG

N009276 005

100MG

N009276 004

HYSERPIN

PHYS PRODS VA

50MG

N010581 001

KOGLUCCOID

PANRAY

50MG

N009278 001

100MG

N009278 002

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDAL LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

RESCINNAMINE

CAPSULE; ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET; ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

RESERPINE

ELIXIR; ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE; INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET; ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

RAU-SED

BRISTOL MYERS SQUIBB

0.1MG

N009357 001

0.25MG

N009357 004

0.5MG

N009357 006

1MG

N009357 008

DISCONTINUED DRUG PRODUCT LIST

6-288 (of 337)

RESERPINE

TABLET; ORAL

RESERPINE

BARR	0.25MG	A080721	002	
BELL PHARMA	0.1MG	A083058	001	
	0.25MG	A083058	002	
BUNDY	0.1MG	N009663	001	
	0.25MG	N009663	003	
CYCLE PHARMS LTD	0.1MG	N009859	001	
	0.25MG	N009859	002	
ELKINS SINN	0.1MG	A083145	001	
	0.25MG	A083145	002	
EVERYLIFE	0.1MG	N010441	001	
	0.25MG	N010441	002	
	0.5MG	N010441	003	
	1MG	N010441	004	
HALSEY	0.1MG	A080457	002	
	0.25MG	A080457	001	
	1MG	A080457	003	
HIKMA PHARMS LLC	0.1MG	A080975	001	
	0.25MG	A080975	002	
	1MG	A080975	003	
IMPAX LABS	0.1MG	N009627	001	
	0.25MG	N009627	002	
IVAX SUB TEVA PHARMS	0.1MG	N011185	001	
	0.25MG	N011185	002	
MARSHALL PHARMA	0.1MG	A080492	001	
	0.25MG	A080492	002	
MK LABS	0.1MG	A080525	002	
	0.25MG	A080525	001	
MYLAN	1MG	A084974	001	
PHARMAVITE	0.25MG	A084663	001	
PUREPAC PHARM	0.1MG	A080753	002	
	0.25MG	A080753	001	
PVT FORM	0.1MG	A086117	001	
	0.25MG	A080582	001	
	0.25MG	A085775	001	
	1MG	A080582	002	
REXALL	0.25MG	A080637	001	
SOLVAY	0.25MG	A080446	001	
TABLICAPS	0.25MG	A085207	001	
TEVA	0.1MG	A089020	001	Mar 07, 1985
	0.25MG	A089019	001	Mar 07, 1985
VALEANT PHARM INTL	0.1MG	N009667	001	
	0.25MG	N009667	002	
WATSON LABS	0.1MG	A080679	001	
	0.25MG	A080393	001	
	0.25MG	A085401	001	
	1MG	A080749	001	
WHITEWORTH TOWN PLSN	0.1MG	A080723	001	
	0.25MG	A080723	002	
	1MG	A080723	003	
SANDRIL				
LILLY	0.1MG	N009376	004	
	0.25MG	N009376	001	
SERPALAN				
LANNETT	0.1MG	N010124	001	
	0.25MG	N010124	002	
SERPANRAY				
PANRAY	0.1MG	N009391	001	
	0.25MG	N009391	002	
	1MG	N009391	004	
SERPASIL				
NOVARTIS	0.1MG	N009115	001	
	0.25MG	N009115	003	
	1MG	N009115	004	
SERPATE				
VALE	0.1MG	N009453	001	
	0.25MG	N009453	002	
SERPIVITE				
VITARINE	0.25MG	N009645	002	

DISCONTINUED DRUG PRODUCT LIST

6-289 (of 337)

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

METATENSIN #2

SANOFI AVENTIS US

0.1MG; 2MG

N012972 001

METATENSIN #4

SANOFI AVENTIS US

0.1MG; 4MG

N012972 002

NAQUIVAL

SCHERING

0.1MG; 4MG

N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS

0.1MG; 4MG

A085248 001

RIBAVIRIN

TABLET; ORAL

COPEGUS

ROCHE

400MG

N021511 002 Jun 21, 2005

RIMANTADINE HYDROCHLORIDE

SYRUP; ORAL

FLUMADINE

FOREST LABS

50MG/5ML

N019650 001 Sep 17, 1993

TABLET; ORAL

RIMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH

100MG

A076375 001 Jan 14, 2003

COREPHARMA

100MG

A075916 001 Nov 02, 2001

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

WARNER CHILCOTT LLC

75MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N020835 004 Apr 16, 2007

RISPERIDONE

TABLET; ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005 Dec 29, 1993

RISPERIDONE

CADISTA PHARMS

0.25MG

A078828 001 Mar 23, 2009

0.5MG

A078828 002 Mar 23, 2009

1MG

A078828 003 Mar 23, 2009

2MG

A078828 004 Mar 23, 2009

3MG

A078828 005 Mar 23, 2009

4MG

A078828 006 Mar 23, 2009

RATIOPHARM

0.25MG

A077784 001 Jun 08, 2010

0.5MG

A077784 002 Jun 08, 2010

1MG

A077784 003 Jun 08, 2010

2MG

A077784 004 Jun 08, 2010

3MG

A077784 005 Jun 08, 2010

4MG

A077784 006 Jun 08, 2010

SYNTHON PHARMS

0.25MG

A078187 001 Oct 22, 2009

0.5MG

A078187 002 Oct 22, 2009

1MG

A078187 003 Oct 22, 2009

2MG

A078187 004 Oct 22, 2009

3MG

A078187 005 Oct 22, 2009

4MG

A078187 006 Oct 22, 2009

WATSON LABS

0.25MG

A077860 001 Dec 05, 2008

0.5MG

A077860 002 Dec 05, 2008

1MG

A077860 003 Dec 05, 2008

2MG

A077860 004 Dec 05, 2008

3MG

A077860 005 Dec 05, 2008

4MG

A077860 006 Dec 05, 2008

WEST WARD PHARMS

0.25MG

A078740 001 May 29, 2009

0.5MG

A078740 002 May 29, 2009

1MG

A078740 003 May 29, 2009

2MG

A078740 004 May 29, 2009

3MG

A078740 005 May 29, 2009

4MG

A078740 006 May 29, 2009

DISCONTINUED DRUG PRODUCT LIST

6-290 (of 337)

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM

10MG/ML

A071188 001 Jul 23, 1987

15MG/ML

A071189 001 Jul 23, 1987

HOSPIRA

10MG/ML

A071618 001 Feb 28, 1991

15MG/ML

A071619 001 Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

30MG/100ML

A071438 001 Jan 22, 1991

YUTOPAR

ASTRAZENECA

10MG/ML

N018580 001

15MG/ML

N018580 002

TABLET; ORAL

YUTOPAR

ASTRAZENECA

10MG

N018555 001

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT

100MG

N020680 001 Mar 01, 1996

RIVASTIGMINE TARTRATE

SOLUTION; ORAL

EXELON

NOVARTIS

EQ 2MG BASE/ML

N021025 001 Apr 21, 2000

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ZEMURON

ORGANON USA INC

50MG/5ML (10MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020214 001 Mar 17, 1994

10MG/ML (10MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020214 002 Mar 17, 1994

100MG/10ML (10MG/ML) **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020214 003 Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001 May 20, 1999

25MG/5ML

N021052 002 May 20, 1999

TABLET; ORAL

VIOXX

MERCK

12.5MG

N021042 001 May 20, 1999

25MG

N021042 002 May 20, 1999

50MG

N021042 003 Feb 25, 2000

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

COREPHARMA

EQ 0.25MG BASE

A078230 001 May 20, 2008

EQ 0.5MG BASE

A078230 002 May 20, 2008

EQ 1MG BASE

A078230 003 May 20, 2008

EQ 2MG BASE

A078230 004 May 20, 2008

EQ 3MG BASE

A078230 005 May 20, 2008

EQ 4MG BASE

A078230 006 May 20, 2008

EQ 5MG BASE

A078230 007 May 20, 2008

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

GLAXOSMITHKLINE LLC

EQ 3MG BASE

N022008 002 Jun 13, 2008

ROSE BENZAL SODIUM I-131

INJECTABLE; INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL

N016224 001

1mCi/VIAL

N016224 002

2mCi/VIAL

N016224 003

SODIUM ROSE BENZAL I 131

SORIN

0.5mCi/ML

N017318 001

DISCONTINUED DRUG PRODUCT LIST

6-291 (of 337)

RUFINAMIDE

TABLET; ORAL

BANZEL

EISAI INC

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021911 001 Nov 14, 2008

SAFFLOWER OIL

INJECTABLE; INJECTION

LIPOSYN 10%

ABBOTT

10% (10GM/100ML)

N018203 001

LIPOSYN 20%

ABBOTT

20% (20GM/100ML)

N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN II 10%

HOSPIRA

5%;5% (5GM/100ML)

N018997 001 Aug 27, 1984

LIPOSYN II 20%

HOSPIRA

10%;10% (10GM/100ML)

N018991 001 Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

SEREVENT

GLAXOSMITHKLINE

EQ 0.021MG BASE/INH

N020236 001 Feb 04, 1994

SAQUINAVIR

CAPSULE; ORAL

FORTOVASE

HOFFMANN LA ROCHE

200MG

N020828 001 Nov 07, 1997

SARALASIN ACETATE

INJECTABLE; INJECTION

SARENIN

PROCTER AND GAMBLE

EQ 0.6MG BASE/ML

N018009 001

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECOBARBITAL SODIUM

ANABOLIC

100MG

A084422 001

BARR

100MG

A084225 001

EVERYLIFE

100MG

A085895 001

HALSEY

100MG

A084676 001

IVAX PHARMS

100MG

A085869 001

KV PHARM

100MG

A085285 001

LANNETT

50MG

A085909 001

100MG

A085903 001

PARKE DAVIS

100MG

A084762 001

PERRIGO

100MG

A084561 001

PUREPAC PHARM

100MG

A085867 001

VALEANT PHARM INTL

100MG

A085477 001

VITARINE

100MG

A085898 001

100MG

A086273 001

WATSON LABS

100MG

A085792 001

WEST WARD

100MG

A084926 001

WHITEWORTH TOWN PLSN

100MG

A085798 001

WYETH AYERST

100MG

A086390 001

INJECTABLE; INJECTION

SECOBARBITAL SODIUM

ELKINS SINN

100MG/VIAL

A083281 001

WYETH AYERST

50MG/ML

A083262 001

SECONAL SODIUM

LILLY

50MG/ML

N007392 002

SUPPOSITORY; RECTAL

SECONAL SODIUM

LILLY

30MG

A086530 001

60MG

A086530 002

120MG

A086530 003

200MG

A086530 004

DISCONTINUED DRUG PRODUCT LIST

6-292 (of 337)

SECRETIN

INJECTABLE; INJECTION

SECRETIN-FERRING

FERRING

75CU/VIAL

N018290 001

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION; INTRAVENOUS

SECREFLO

CHIRHOCLIN

16MCG/VIAL

N021136 001 Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

LANNETT HOLDINGS INC

5MG

A075145 001 Sep 15, 2003

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

DAVA PHARMS INC

5MG

A074641 001 Aug 02, 1996

IVAX SUB TEVA PHARMS

5MG

A074756 001 Nov 25, 1998

SIEGFRIED

5MG

A074672 001 Apr 01, 1997

SOMERSET

5MG

N019334 001 Jun 05, 1989

TEVA

5MG

A074537 001 Aug 02, 1996

5MG

A074744 001 Jan 27, 1997

VINTAGE PHARMS LLC

5MG

A074565 001 Aug 02, 1996

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

EXSEL

ALLERGAN HERBERT

2.5%

A083892 001

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC

2.5%

A084394 001

G AND W LABS INC

2.5%

A086209 001

IVAX PHARMS

2.5%

A085777 001

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE

250uCi/ML

N017257 001

MALLINCKRODT

100uCi/ML

N017098 001

PHARMALUCENCE

500uCi/ML

N017322 001

SETHOTOPE

BRACCO

85-550uCi/ML

N017047 001

SERACTIDE ACETATE

INJECTABLE; INJECTION

ACTHAR GEL-SYNTHETIC

ARMOUR PHARM

40 UNITS/ML

N017861 001

80 UNITS/ML

N017861 002

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

EMD SERONO

EQ 0.05MG BASE/AMP **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N019863 001 Dec 28, 1990

EMD SERONO INC

EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020443 001 Sep 26, 1997

EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

N020443 002 Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD

EQ 20MG BASE/ML

A078053 001 Feb 05, 2007

ROXANE

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 25MG BASE

A077345 001 Feb 06, 2007

EQ 50MG BASE

A077345 002 Feb 06, 2007

EQ 100MG BASE

A077345 003 Feb 06, 2007

CIPLA LTD

EQ 25MG BASE

A077162 001 Feb 06, 2007

EQ 50MG BASE

A077162 002 Feb 06, 2007

EQ 100MG BASE

A077162 003 Feb 06, 2007

DISCONTINUED DRUG PRODUCT LIST

6-293 (of 337)

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

DR REDDYS LABS LTD	EQ 25MG BASE	A076442 001	Apr 30, 2007
	EQ 50MG BASE	A076442 002	Apr 30, 2007
	EQ 100MG BASE	A076442 003	Apr 30, 2007
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719 003	Jun 30, 2006
	EQ 50MG BASE	A075719 001	Jun 30, 2006
	EQ 100MG BASE	A075719 002	Jun 30, 2006
MUTUAL PHARM	EQ 25MG BASE	A077818 001	Feb 06, 2007
	EQ 50MG BASE	A077818 002	Feb 06, 2007
	EQ 100MG BASE	A077818 003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007
	EQ 50MG BASE	A076540 002	Mar 20, 2007
	EQ 100MG BASE	A076540 003	Mar 20, 2007
PLIVA HRVATSKA DOO	EQ 25MG BASE	A077299 001	Feb 06, 2007
	EQ 50MG BASE	A077299 002	Feb 06, 2007
	EQ 100MG BASE	A077299 003	Feb 06, 2007
ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007
	EQ 50MG BASE	A076881 002	Feb 06, 2007
	EQ 100MG BASE	A076881 003	Feb 06, 2007
SANDOZ	EQ 25MG BASE	A077713 001	Feb 06, 2007
	EQ 50MG BASE	A077713 002	Feb 06, 2007
	EQ 100MG BASE	A077713 003	Feb 06, 2007
WATSON LABS	EQ 25MG BASE	A077663 001	Feb 06, 2007
	EQ 50MG BASE	A077663 002	Feb 06, 2007
	EQ 100MG BASE	A077663 003	Feb 06, 2007
ZOLOFT			
PFIZER	EQ 150MG BASE	N019839 003	Dec 30, 1991
	EQ 200MG BASE	N019839 004	Dec 30, 1991

SEVELAMER HYDROCHLORIDE

CAPSULE; ORAL

RENAGEL

GENZYME	403MG	N020926 001	Oct 30, 1998
---------	-------	-------------	--------------

SIBUTRAMINE HYDROCHLORIDE

CAPSULE; ORAL

MERIDIA

ABBOTT	5MG	N020632 001	Nov 22, 1997
	10MG	N020632 002	Nov 22, 1997
	15MG	N020632 003	Nov 22, 1997

SILVER SULFADIAZINE

DRESSING; TOPICAL

SILDAFLO

FRANKLIN PHARMS	1%	N019608 001	Nov 30, 1989
-----------------	----	-------------	--------------

SIMETHICONE-CELLULOSE

SUSPENSION; ORAL

SONORX

BRACCO	7.5MG/ML	N020773 001	Oct 29, 1998
--------	----------	-------------	--------------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

SANDOZ INC	5MG	A077766 001	Dec 20, 2006
	10MG	A077766 002	Dec 20, 2006
	20MG	A077766 003	Dec 20, 2006
	40MG	A077766 004	Dec 20, 2006
	80MG	A077766 005	Dec 20, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

SIMVASTATIN

SYNTHON PHARMS	10MG	N021961 001	Oct 09, 2007
	20MG	N021961 002	Oct 09, 2007
	40MG	N021961 003	Oct 09, 2007
	80MG	N021961 004	Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

MERCK SHARP DOHME	10MG; EQ 50MG BASE	N202343 004	Sep 18, 2012
	10MG; EQ 100MG BASE	N202343 001	Oct 07, 2011
	20MG; EQ 50MG BASE	N202343 005	Sep 18, 2012
	20MG; EQ 100MG BASE	N202343 002	Oct 07, 2011

DISCONTINUED DRUG PRODUCT LIST

6-294 (of 337)

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYN

40MG; EQ 50MG BASE
40MG; EQ 100MG BASEN202343 006 Sep 18, 2012
N202343 003 Oct 07, 2011SIROLIMUS

TABLET; ORAL

RAPAMUNE

PF PRISM CV

5MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; ORAL

UCEPHAN

B BRAUN

100MG/ML; 100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE IN PLASTIC CONTAINER

ABBOTT

0.9MEQ/ML
1MEQ/MLN019443 001 Jun 03, 1986
N019443 002 Jun 03, 1986SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM

9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT

20GM/100ML

N017013 001

B BRAUN

20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN

450MG/100ML

N018184 001

MILES

450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9%

MEDEFIL INC

18MG/2ML (9MG/ML)
22.5MG/2.5ML (9MG/ML)
27MG/3ML (9MG/ML)
45MG/5ML (9MG/ML)N202832 002 Jan 06, 2012
N202832 003 Jan 06, 2012
N202832 004 Jan 06, 2012
N202832 005 Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT

9MG/ML

N019218 001 Jul 13, 1984

MEDEFIL INC

9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

MILES

900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ABRAXIS PHARM

234MG/ML

N019329 001 Apr 22, 1987

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

B BRAUN

3GM/100ML

N019635 003 Mar 09, 1988

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML

N019635 004 Mar 09, 1988

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE

450MG/100ML

N017864 001

450MG/100ML

N018497 001 Feb 19, 1982

HOSPIRA

450MG/100ML

N017670 001

450MG/100ML

N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES

900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

BRACCO

2mCi/VIAL
200uCi/MLN013993 002
N013993 001

SODIUM CHROMATE CR 51

MALLINCKRODT

100uCi/ML

N016708 001

DISCONTINUED DRUG PRODUCT LIST

6-295 (of 337)

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

GE HEALTHCARE

2mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N017042 001

SODIUM FLUORIDE F 18

NIH NCI DCTD

10-200mCi/ML

N022494 001 Jan 26, 2011

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

CARDINAL HLTH 414

400uCi

N018671 003 May 27, 1982

GE HEALTHCARE

100uCi

N017630 001

SOLUTION; ORAL

SODIUM IODIDE I 123

GE HEALTHCARE

2mCi/ML

N017630 002

SODIUM IODIDE I-131

CAPSULE; ORAL

IODOTOPE

BRACCO

1-130mCi

N010929 001

1-150mCi

N010929 003

SODIUM IODIDE I 131

CIS

50uCi

N017316 001

100uCi

N017316 002

MALLINCKRODT

0.8-100mCi

N016515 002

15-100uCi

N016517 002

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

2-200mCi

N021305 004 Nov 18, 2004

SOLUTION; ORAL

HICON

JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003

1-500mCi/0.5ML

N021305 003 Jan 24, 2003

1-1000mCi/ML

N021305 005 Apr 04, 2006

IODOTOPE

BRACCO

7-106mCi/BOT

N010929 002

SODIUM IODIDE I 131

CIS

50mCi/ML

N017315 001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN

1.87GM/100ML

N018186 001

HOSPIRA

1.87GM/100ML

N018249 001

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 002 Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS

1.2%

N019518 001 Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE

50MG/VIAL

N017546 001

NITROPRESS

ABBOTT

50MG/VIAL

A071555 001 Nov 16, 1987

ABBVIE

50MG/VIAL

N018450 001

HOSPIRA

50MG/VIAL

A070566 001 Jun 09, 1986

SODIUM NITROPRUSSIDE

ABRAXIS PHARM

50MG/VIAL

A070031 001 Jan 17, 1985

BAXTER HLTHCARE

50MG/VIAL

N018581 001 Jul 28, 1982

TEVA PARENTERAL

25MG/ML

A073465 001 Mar 30, 1992

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO

1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT

0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

DISCONTINUED DRUG PRODUCT LIST

6-296 (of 337)

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS

0.398GM;1.102GM

N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

NOVEL LABS INC

0.398GM;1.102GM

A079247 001 Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA

454GM/BOT

A040909 001 Dec 03, 2008

WOCKHARDT

453.6GM/BOT

A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

MORTON GROVE

15GM/60ML

A088717 001 Sep 11, 1984

ROXANE

15GM/60ML

A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN

30%

A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

ELKINS SINN

1% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N005970 004

3% **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

US ARMY

250MG/ML

N020166 001 Feb 14, 1992

SOMATREM

INJECTABLE; INJECTION

PROTROPIN

GENENTECH

5MG/VIAL

N019107 001 Oct 17, 1985

10MG/VIAL

N019107 002 Oct 24, 1989

SOMATROPIN

INJECTABLE; INJECTION

ASELLACRIN 10

SERONO

10 IU/VIAL

N017726 001

ASELLACRIN 2

SERONO

2 IU/VIAL

N017726 002 Jul 21, 1983

CRESCORMON

GENENTECH

4 IU/VIAL

N017992 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

EMERGENT

5MG/ML (5MG/ML)

N021538 001 Jan 23, 2008

BIO-TROPIN

FERRING

4.8MG/VIAL

N019774 001 May 25, 1995

HUMATROPE

LILLY

2MG/VIAL

N019640 001 Jun 23, 1987

NORDITROPIN

NOVO NORDISK INC

4MG/VIAL

N019721 001 May 08, 1995

5MG/1.5ML

N021148 001 Jun 20, 2000

8MG/VIAL

N019721 002 May 08, 1995

10MG/1.5ML

N021148 002 Jun 20, 2000

15MG/1.5ML

N021148 003 Jun 20, 2000

NORDITROPIN NORDIFLEX

NOVO NORDISK INC

5MG/1.5ML

N021148 004 Oct 01, 2004

10MG/1.5ML

N021148 005 Oct 01, 2004

15MG/1.5ML

N021148 006 Oct 01, 2004

NUTROPIN DEPOT

GENENTECH

13.5MG/VIAL

N021075 001 Dec 22, 1999

DISCONTINUED DRUG PRODUCT LIST

6-297 (of 337)

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NUTROPIN DEPOT

18MG/VIAL
22.5MG/VIALN021075 002 Dec 22, 1999
N021075 003 Dec 22, 1999

SAIZEN

EMD SERONO

4MG/VIAL
6MG/VIALN019764 005 Jan 16, 2007
N019764 001 Oct 08, 1996

SEROSTIM

EMD SERONO

8.8MG/VIAL

N020604 004 Sep 06, 2001

ZORBTIVE

EMD SERONO

4MG/VIAL
5MG/VIAL
6MG/VIALN021597 001 Dec 01, 2003
N021597 002 Dec 01, 2003
N021597 003 Dec 01, 2003

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

EMD SERONO

6MG/0.5ML (6MG/0.5ML)

N020604 005 Feb 11, 2005

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE

3GM/100ML

N018512 001 May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

BAYER HLTHCARE

320MG

N019865 004 Oct 30, 1992

BETAPACE AF

COVIS PHARMA SARL

40MG
60MG
100MGN021151 006 Apr 02, 2003
N021151 007 Apr 02, 2003
N021151 005 Mar 14, 2003

SOTALOL HYDROCHLORIDE

MUTUAL PHARM

80MG
80MG
120MG
120MG
160MG
160MG
240MGA075515 001 Oct 15, 2001
A076576 001 Apr 08, 2004
A075515 004 Oct 15, 2001
A076576 002 Apr 08, 2004
A075515 002 Oct 15, 2001
A076576 003 Apr 08, 2004
A075515 003 Oct 15, 2001

WATSON LABS

80MG
120MG
160MG
240MGA075238 001 Jul 13, 2000
A075238 002 Jul 13, 2000
A075238 003 Jul 13, 2000
A075238 004 Jul 13, 2000SOYBEAN OIL

INJECTABLE; INJECTION

LIPOSYN III 10%

HOSPIRA

10%

N018969 001 Sep 24, 1984

LIPOSYN III 20%

HOSPIRA

20%

N018970 001 Sep 25, 1984

LIPOSYN III 30%

HOSPIRA

30%

N020181 001 Jan 13, 1998

SOYACAL 10%

ALPHA THERA

10%

N018465 001 Jun 29, 1983

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL
EQ 4GM BASE/VIALN050347 001
N050347 002

DISCONTINUED DRUG PRODUCT LIST

6-298 (of 337)

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ASCOT

25MG

A087687 001 Oct 20, 1982

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANQZOLOL

TABLET; ORAL

WINSTROL

LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

ZERIT

BRISTOL MYERS SQUIBB

5MG

N020412 001 Jun 24, 1994

CAPSULE, EXTENDED RELEASE; ORAL

ZERIT XR

BRISTOL MYERS SQUIBB

37.5MG

N021453 001 Dec 31, 2002

50MG

N021453 002 Dec 31, 2002

75MG

N021453 003 Dec 31, 2002

100MG

N021453 004 Dec 31, 2002

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM

100%

A089099 001 Dec 29, 1987

100%

A089100 001 Dec 29, 1987

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN

100%

N019077 001 Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID; IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES

100%

N018246 001

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

COPANOS

EQ 500MG BASE/ML

A060684 001

LILLY

EQ 1GM BASE/VIAL

A060107 001

EQ 1GM BASE/2ML

A060404 001

EQ 5GM BASE/VIAL

A060107 002

PFIZER

EQ 1GM BASE/VIAL

A060076 001

EQ 1GM BASE/2.5ML

A060111 001

EQ 5GM BASE/VIAL

A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

ANECTINE

SANDOZ

1GM/VIAL

N008453 004

50MG/ML

N008453 003

500MG/VIAL

N008453 001

QUELICIN PRESERVATIVE FREE

HOSPIRA

50MG/ML

N008845 002

SUCCINYLCHOLINE CHLORIDE

INTL MEDICATION

100MG/VIAL

A085400 001 Feb 04, 1982

ORGANON USA INC

20MG/ML

A080997 001

DISCONTINUED DRUG PRODUCT LIST

6-299 (of 337)

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCOSTRIN

APOTHECON

20MG/ML

N008847 001

100MG/ML

N008847 003

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

SODIUM SULAMYD

SCHERING

10%

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

SCHERING

10%

N005963 001

30%

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

10%

A040215 001 May 25, 1999

30%

A040216 001 May 25, 1999

ALCON PHARMS LTD

30%

A089068 001 May 05, 1987

PHARMAFAIR

10%

A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001 Feb 03, 1983

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE

300MG

N004125 005

EVERYLIFE

500MG

A080088 001

IMPAX LABS

500MG

A080081 001

LANNETT

500MG

A080084 001

LEDERLE

500MG

N004054 001

LILLY

500MG

N004122 002

DISCONTINUED DRUG PRODUCT LIST

6-300 (of 337)

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM

LEDERLE

250MG/ML

N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX

LILLY

250MG/5ML; 250MG/5ML

N006317 007

SULFAMETER

TABLET; ORAL

SULLA

BAYER HLTHCARE

500MG

N016000 002

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS

1GM

A086012 001

PROKLAR

FOREST PHARMS

500MG

A080273 001

THIOSULFIL

WYETH AYERST

250MG

N008565 001

500MG

N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE

500MG/5ML

N013664 002

TABLET; ORAL

GANTANOL

ROCHE

500MG

N012715 002

GANTANOL-DS

ROCHE

1GM

N012715 003

SULFAMETHOXAZOLE

ASCOT

500MG

A087662 001 Oct 20, 1982

BARR

500MG

A087189 001 Jul 25, 1983

HEATHER

500MG

A086163 001

SANDOZ

500MG

A085844 001

WATSON LABS

1GM

A086000 001

500MG

A085053 001

UROBAK

SHIONOGI

500MG

A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

MUTUAL PHARM

80MG/ML; 16MG/ML

N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML; 16MG/ML

N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML; 16MG/ML

A070223 001 Dec 29, 1987

BEDFORD

80MG/ML; 16MG/ML

A072383 001 Apr 29, 1992

HIKMA MAPLE

80MG/ML; 16MG/ML

A070627 001 Dec 29, 1987

80MG/ML; 16MG/ML

A070628 001 Dec 29, 1987

HOSPIRA

80MG/ML; 16MG/ML

A073199 001 Sep 11, 1992

WATSON LABS

80MG/ML; 16MG/ML

A071556 001 Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 001

BACTRIM PEDIATRIC

MUTUAL PHARM

200MG/5ML; 40MG/5ML

N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML; 40MG/5ML

N017598 002 Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

TEVA

200MG/5ML; 40MG/5ML

A070028 001 Jun 02, 1987

200MG/5ML; 40MG/5ML

N018812 001 Jan 28, 1983

200MG/5ML; 40MG/5ML

N018812 002 Jun 10, 1983

TEVA PHARMS

200MG/5ML; 40MG/5ML

A077612 001 Nov 13, 2006

SULFATRIM

STI PHARMA LLC

200MG/5ML; 40MG/5ML

N018615 002 Jan 07, 1983

DISCONTINUED DRUG PRODUCT LIST

6-301 (of 337)

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULMEPRIM

USL PHARMA 200MG/5ML; 40MG/5ML A070063 001 Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA 200MG/5ML; 40MG/5ML A070064 001 Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS 200MG/5ML; 40MG/5ML A072289 001 May 23, 1988

200MG/5ML; 40MG/5ML A072398 001 May 23, 1988

NASKA 200MG/5ML; 40MG/5ML A072399 001 May 23, 1988

TABLET; ORAL

COTRIM

TEVA 400MG; 80MG A070034 001 May 16, 1985

COTRIM D.S.

TEVA 800MG; 160MG A070048 001 Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC 400MG; 80MG A070022 001 Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC 800MG; 160MG A070032 001 Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

HEATHER 400MG; 80MG N018946 001 Aug 10, 1984

800MG; 160MG N018946 002 Aug 10, 1984

INTERPHARM 400MG; 80MG A071299 001 Oct 27, 1987

800MG; 160MG A071300 001 Oct 27, 1987

MARTEC USA LLC 400MG; 80MG A072408 001 Dec 07, 1988

MUTUAL PHARM 400MG; 80MG A070006 001 Nov 14, 1984

400MG; 80MG A071016 001 Aug 25, 1986

PLIVA 400MG; 80MG A070215 001 Sep 10, 1985

800MG; 160MG A070216 001 Sep 10, 1985

ROXANE 400MG; 80MG A072768 001 Aug 30, 1991

SANDOZ 400MG; 80MG A070889 001 Nov 13, 1986

400MG; 80MG N018598 003 May 19, 1982

800MG; 160MG A070890 001 Nov 13, 1986

TEVA 400MG; 80MG N018242 001

800MG; 160MG N018242 002

USL PHARMA 400MG; 80MG A070203 001 Nov 08, 1985

800MG; 160MG A070204 001 Nov 08, 1985

WATSON LABS 400MG; 80MG A070002 001 Nov 07, 1984

400MG; 80MG N018852 001 May 09, 1983

800MG; 160MG A070000 001 Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

MARTEC USA LLC 800MG; 160MG A072417 001 Dec 07, 1988

MUTUAL PHARM 800MG; 160MG A070007 001 Nov 14, 1984

ROXANE 800MG; 160MG A072769 001 Aug 30, 1991

SANDOZ 800MG; 160MG N018598 004 May 19, 1982

WATSON LABS 800MG; 160MG N018854 001 May 09, 1983

SULFATRIM-DS

SUPERPHARM 800MG; 160MG A070066 001 Jun 24, 1985

SULFATRIM-SS

SUPERPHARM 400MG; 80MG A070065 002 Jun 24, 1985

UROPLUS DS

SHIONOGI 800MG; 160MG A071816 001 Sep 28, 1987

UROPLUS SS

SHIONOGI 400MG; 80MG A071815 001 Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

SULFANILAMIDE

TEVA 15% A088718 001 Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

MEDA PHARMS 1.05GM N006530 004 Jan 27, 1987

SULFAPHENAZOLE

SUSPENSION; ORAL

SULFABID

PHARM RES ASSOC 500MG/5ML N013093 001

TABLET; ORAL

SULFABID

PURDUE FREDERICK 500MG N013092 002

DISCONTINUED DRUG PRODUCT LIST

6-302 (of 337)

SULFAPYRIDINE

TABLET; ORAL

SULFAPYRIDINE

LILLY

500MG

N000159 001

SULFASALAZINE

SUSPENSION; ORAL

AZULFIDINE

PHARMACIA AND UPJOHN

250MG/5ML

N018605 001

TABLET; ORAL

S.A.S.-500

SOLVAY

500MG

A083450 001

SULFASALAZINE

HERITAGE PHARMS INC

500MG

A080197 001

MUTUAL PHARM

500MG

A089590 001

Oct 19, 1987

SANDOZ

500MG

A086184 001

SUPERPHARM

500MG

A089339 001

Oct 26, 1987

WATSON LABS

500MG

A084964 001

500MG

A087197 001

TABLET, DELAYED RELEASE; ORAL

SULFASALAZINE

WATSON LABS

500MG

A088052 001

May 24, 1983

SULFINPYRAZONE

CAPSULE; ORAL

ANTURANE

NOVARTIS

200MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011556 004

SULFINPYRAZONE

BARR

200MG

A087666 001

Sep 17, 1982

IVAX PHARMS

200MG

A087770 001

Nov 19, 1982

PAR PHARM

200MG

A088934 001

Sep 06, 1985

VANGARD

200MG

A088666 001

Feb 17, 1984

TABLET; ORAL

ANTURANE

NOVARTIS

100MG **Federal Register determination
that product was not discontinued or
withdrawn for safety or efficacy
reasons**

N011556 003

SULFINPYRAZONE

BARR

100MG

A087665 001

Sep 17, 1982

IVAX PHARMS

100MG

A087769 001

Jun 01, 1982

PAR PHARM

100MG

A088933 001

Sep 06, 1985

WATSON LABS

100MG

A087667 001

May 26, 1982

SULFISOXAZOLE

TABLET; ORAL

GANTRISIN

ROCHE

500MG

N006525 001

SOSOL

MK LABS

500MG

A080036 001

SOXAZOLE

ALRA

500MG

A080366 001

SULFALAR

PARKE DAVIS

500MG

A084955 001

SULFISOXAZOLE

BARR

500MG

A084031 001

HEATHER

500MG

A080189 001

IMPAX LABS

500MG

A080109 001

IVAX SUB TEVA PHARMS

500MG

A080142 001

LANNETT

500MG

A080085 001

LEDERLE

500MG

A087649 001

PHARMERAL

500MG

A084385 001

PUREPAC PHARM

500MG

A080087 001

ROXANE

500MG

A080082 001

SANDOZ

500MG

A085628 001

VALEANT PHARM INTL

500MG

A080268 002

VITARINE

500MG

A087332 001

WATSON LABS

500MG

A085534 001

WEST WARD

500MG

A080379 001

SULSOXIN

SOLVAY

500MG

A080040 001

DISCONTINUED DRUG PRODUCT LIST

6-303 (of 337)

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE

EQ 1GM BASE/5ML

N009182 009

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE

EQ 500MG BASE/5ML

N009182 004

SYRUP; ORAL

GANTRISIN

ROCHE

EQ 500MG BASE/5ML

N009182 002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE

EQ 400MG BASE/ML

N006917 001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N008414 002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND

EQ 4% BASE

A084148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE

165MG

N006044 003

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS

33.32%

N002918 001

SULINDAC

TABLET; ORAL

CLINORIL

MERCK

150MG

N017911 001

SULINDAC

SANDOZ

150MG

A072712 001 Aug 30, 1991

200MG

A072713 001 Aug 30, 1991

TEVA

150MG

A072972 001 Feb 28, 1992

200MG

A072973 001 Feb 28, 1992

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

SANDOZ

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

TABLET; ORAL

SUMATRIPTAN SUCCINATE

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

DISCONTINUED DRUG PRODUCT LIST

6-304 (of 337)

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

SUTILAINS

OINTMENT;TOPICAL

TRAVASE

ABBOTT

82,000 UNITS/GM **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N012828 001

TACRINE HYDROCHLORIDE

CAPSULE;ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010

TALBUTAL

TABLET;ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET;ORAL

NOLVADEX

ASTRAZENECA

EQ 10MG BASE

N017970 001

EQ 20MG BASE

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TECHNETIUM TC-99M ALBUMIN AGGREGATED

INJECTABLE;INJECTION

TC 99M-LUNGAGGREGATE

GE HEALTHCARE

5mCi/ML

N017848 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

A-N STANNOUS AGGREGATED ALBUMIN

SYNCOR PHARMS

N/A

N017916 001

AN-MAA

PHARMALUCENCE

N/A

N017792 001

LUNGAGGREGATE REAGENT

GE HEALTHCARE

N/A

N017838 001

MACROTEC

BRACCO

N/A

N017833 001

TECHNISCAN MAA

MALLINCKRODT

N/A

N017842 001

TECHNETIUM TC 99M MAA

GE HEALTHCARE

N/A

N017773 001

TECHNETIUM TC-99M ALBUMIN COLLOID KIT

INJECTABLE;INJECTION

MICROLITE

PHARMALUCENCE

N/A

N018263 001 Mar 25, 1983

DISCONTINUED DRUG PRODUCT LIST

6-305 (of 337)

TECHNETIUM TC-99M ALBUMIN KIT

INJECTABLE; INJECTION

TECHNETIUM TC 99M HSA

GE HEALTHCARE N/A

N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT

INJECTABLE; INJECTION

INSTANT MICROSPHERES

3M N/A

N017832 001

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA N/A

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE N/A

N017667 001

OSTEOSCAN

MALLINCKRODT N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE N/A

N017562 001

TECHNETIUM TC-99M FERMENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO N/A

N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNISCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT

INJECTABLE; INJECTION

TECHNISCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT DRAXIMAGE N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

DISCONTINUED DRUG PRODUCT LIST

6-306 (of 337)

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

GE HEALTHCARE 2-100mCi/ML **Federal Register notice
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017471 001

MALLINCKRODT 10-60mCi/ML **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons** N017725 001

PHARMALUCENCE 12mCi/ML N017321 001
24mCi/ML N017321 002
48mCi/ML N017321 003

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL

MINITEC

BRACCO 0.22-2.22 CI/GENERATOR N017339 001

SOLUTION; INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL 0.0083-2.7 CI/GENERATOR N017771 001

ULTRA-TECHNEKOW FM

MALLINCKRODT 0.25-3 CI/GENERATOR N017243 002

SOLUTION; INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

GE HEALTHCARE 830-16600mCi/GENERATOR N017693 001

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION; INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE 4mCi/ML N017456 001

SOLUTION; ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT 3mCi/ML N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

TECHNECOLL

MALLINCKRODT N/A N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE N/A N017784 001

TESULOID

BRACCO N/A N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE; INJECTION

CARDIOTEC

BRACCO N/A

N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET; ORAL

ZELNORM

NOVARTIS EQ 2MG BASE

N021200 001 Jul 24, 2002

EQ 6MG BASE

N021200 002 Jul 24, 2002

DISCONTINUED DRUG PRODUCT LIST

6-307 (of 337)

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009

TEMAZEPA

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS

15MG

A070564 001 Oct 15, 1985

30MG

A070547 001 Oct 15, 1985

TEMAZEPA

DURAMED PHARMS BARR

15MG

A071708 001 Sep 29, 1988

30MG

A071709 001 Sep 29, 1988

MUTUAL PHARM

15MG

A071174 001 Jul 10, 1986

30MG

A071175 001 Jul 10, 1986

USL PHARMA

15MG

A070489 001 Jul 07, 1986

30MG

A070490 001 Jul 07, 1986

WATSON LABS

15MG

A070383 001 Mar 23, 1987

15MG

A071446 001 May 21, 1993

30MG

A070384 001 Mar 23, 1987

30MG

A071447 001 May 21, 1993

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 001 Dec 14, 1994

EQ 2MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 002 Dec 14, 1994

EQ 5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 003 Dec 14, 1994

EQ 10MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020347 004 Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

MYLAN TECHNOLOGIES

EQ 1MG BASE

A075384 001 Dec 01, 2000

EQ 2MG BASE

A075384 002 Dec 01, 2000

EQ 5MG BASE

A075384 003 Dec 01, 2000

EQ 10MG BASE

A075384 004 Dec 01, 2000

RANBAXY LABS LTD

EQ 1MG BASE

A076021 001 Aug 22, 2002

EQ 2MG BASE

A076021 002 Aug 22, 2002

EQ 5MG BASE

A076021 003 Aug 22, 2002

EQ 10MG BASE

A076021 004 Aug 22, 2002

SANDOZ

EQ 1MG BASE

A075667 001 Jul 28, 2000

EQ 2MG BASE

A075667 002 Jul 28, 2000

EQ 5MG BASE

A075667 003 Jul 28, 2000

EQ 10MG BASE

A075667 004 Jul 28, 2000

TABLET; ORAL

HYTRIN

ABBOTT

EQ 1MG BASE

N019057 001 Aug 07, 1987

EQ 2MG BASE

N019057 002 Aug 07, 1987

EQ 5MG BASE

N019057 003 Aug 07, 1987

EQ 10MG BASE

N019057 004 Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A074530 001 Apr 21, 2000

EQ 2MG BASE

A074530 002 Apr 21, 2000

EQ 5MG BASE

A074530 003 Apr 21, 2000

EQ 10MG BASE

A074530 004 Apr 21, 2000

SANDOZ

EQ 1MG BASE

A074315 001 Dec 31, 1998

EQ 1MG BASE

A074657 001 Apr 28, 2000

EQ 2MG BASE

A074315 002 Dec 31, 1998

EQ 2MG BASE

A074657 002 Apr 28, 2000

EQ 5MG BASE

A074315 003 Dec 31, 1998

EQ 5MG BASE

A074657 003 Apr 28, 2000

EQ 10MG BASE

A074315 004 Dec 31, 1998

EQ 10MG BASE

A074657 004 Apr 28, 2000

TEVA

EQ 1MG BASE

A074446 001 May 18, 2000

EQ 2MG BASE

A074446 002 May 18, 2000

DISCONTINUED DRUG PRODUCT LIST

6-308 (of 337)

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

TERAZOSIN HYDROCHLORIDE

EQ 5MG BASE
EQ 10MG BASEA074446 003 May 18, 2000
A074446 004 May 18, 2000TERBINAFINE

GEL; TOPICAL

LAMISIL

NOVARTIS

1%

N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS

1%

N020192 001 Dec 30, 1992

SOLUTION; TOPICAL

LAMISIL

NOVARTIS

1%

N020749 001 Oct 17, 1997

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA

EQ 250MG BASE

A077065 001 Jul 02, 2007

MYLAN

EQ 250MG BASE

A077136 001 Jul 02, 2007

ROXANE

EQ 250MG BASE

A077223 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS

0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US

0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

AAIPHARMA LLC

1MG/ML

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

TERBUTALINE SULFATE

TEVA PHARMS USA

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRETHINE

LEHIGH VALLEY

2.5MG
5MGN017849 001
N017849 002

BRICANYL

SANOFI AVENTIS US

2.5MG
5MGN017618 001
N017618 002TERCONAZOLE

SUPPOSITORY; VAGINAL

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TARO

80MG

A077553 001 Mar 09, 2007

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US

200 UNITS/VIAL

N019498 001 Dec 23, 1987

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS

FORTEO

LILLY

0.75MG/3ML (0.25MG/ML)

N021318 001 Nov 26, 2002

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

THERATECHNOLOGIES

EQ 2MG BASE/VIAL

N022505 002 Nov 29, 2011

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB

100MG/ML

N016119 001

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB

50MG
250MGN016118 001
N016118 002

DISCONTINUED DRUG PRODUCT LIST

6-309 (of 337)

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

ACTAVIS LABS UT INC 2.5MG/24HR
5MG/24HRN020489 001 Sep 29, 1995
N020489 002 May 02, 1997

TESTODERM

ALZA 4MG/24HR
6MG/24HRN019762 001 Oct 12, 1993
N019762 002 Oct 12, 1993

TESTODERM TTS

ALZA 5MG/24HR

N020791 001 Dec 18, 1997

GEL;TRANSDERMAL

TESTOSTERONE

PAR PHARM 1% (2.5GM/PACKET)
1% (5GM/PACKET)
WATSON LABS 1% (2.5GM/PACKET)
1% (5GM/PACKET)A076744 001 May 23, 2007
A076744 002 May 23, 2007
A076737 001 Jan 27, 2006
A076737 002 Jan 27, 2006

INJECTABLE;INJECTION

TESTOSTERONE

WATSON LABS 25MG/ML
50MG/ML
100MG/MLA086420 001 May 10, 1983
A086419 001 Aug 23, 1983
A086417 001 Jul 07, 1983TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

PHARMACIA AND UPJOHN 50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

WATSON LABS 100MG/ML
100MG/ML
200MG/MLA084401 001
A086029 001
A084401 002TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTYL

ENDO PHARMS 200MG/ML

N009165 001

TESTOSTERONE ENANTHATE

WATSON LABS 100MG/ML
100MG/ML
200MG/MLA083667 001
A085599 001
A083667 002TESTOSTERONE PROPIONATE

INJECTABLE;INJECTION

TESTOSTERONE PROPIONATE

BEL MAR 25MG/ML
50MG/ML
100MG/ML
ELKINS SINN 25MG/ML
LILLY 50MG/ML
WATSON LABS 25MG/ML
25MG/ML
50MG/ML
50MG/ML
100MG/ML
100MG/MLA080741 001
A080742 001
A080743 001
A080276 001
A080254 002
A080188 001
A085490 001
A080188 002
A085490 002
A080188 003
A083595 003TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BRISTACYCLINE

BRISTOL 250MG
250MG
500MG
500MGA061658 001
A061888 001
A061658 002
A061888 002

CYCLOPAR

WARNER CHILCOTT 250MG
250MG
250MG
500MG
500MGA061725 001
A062175 001
A062332 001
A061725 002
A062332 002

PANMYCIN

PHARMACIA AND UPJOHN 250MG

A060347 001

RETET

SOLVAY 250MG
500MGA061443 001
A061443 002

DISCONTINUED DRUG PRODUCT LIST

6-310 (of 337)

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ROBITET

WYETH AYERST	250MG	A061734	001
	500MG	A061734	002

SUMYCIN

APOTHECON	100MG	A060429	002
	125MG	A060429	004
	250MG	A060429	001
	500MG	A060429	003

TETRACHEL

ANGUS	250MG	A060343	001
	500MG	A060343	003

TETRACYCLINE HYDROCHLORIDE

ABBOTT	250MG	A061802	001
	500MG	A061802	002

ELKINS SINN	250MG	A060059	001
-------------	-------	---------	-----

FERRANTE	125MG	A060173	001
----------	-------	---------	-----

	250MG	A060173	002
--	-------	---------	-----

HEATHER	250MG	A061148	001
---------	-------	---------	-----

	500MG	A061148	002
--	-------	---------	-----

HIKMA PHARMS LLC	250MG	A060768	001
------------------	-------	---------	-----

	500MG	A060768	002
--	-------	---------	-----

LABS ATRAL	250MG	A062752	001
------------	-------	---------	-----

	500MG	A062752	002
--	-------	---------	-----

MAST MM	250MG	A062085	001
---------	-------	---------	-----

MUTUAL PHARM	250MG	A060736	001
--------------	-------	---------	-----

	500MG	A060736	002
--	-------	---------	-----

MYLAN	250MG	A060783	001
-------	-------	---------	-----

	500MG	A060783	002
--	-------	---------	-----

PUREPAC PHARM	250MG	A060290	001
---------------	-------	---------	-----

	500MG	A060290	002
--	-------	---------	-----

PVT FORM	250MG	A062686	001
----------	-------	---------	-----

	500MG	A062686	002
--	-------	---------	-----

ROXANE	500MG	A061214	002
--------	-------	---------	-----

SANDOZ	250MG	A061471	001
--------	-------	---------	-----

SUPERPHARM	250MG	A062540	001
------------	-------	---------	-----

	500MG	A062540	002
--	-------	---------	-----

VALEANT PHARM INTL	250MG	A060471	001
--------------------	-------	---------	-----

	500MG	A060471	002
--	-------	---------	-----

WARNER CHILCOTT	250MG	A062300	001
-----------------	-------	---------	-----

	500MG	A062300	002
--	-------	---------	-----

WATSON LABS	250MG	A062103	001
-------------	-------	---------	-----

	250MG	A062343	001
--	-------	---------	-----

	500MG	A062103	002
--	-------	---------	-----

	500MG	A062343	002
--	-------	---------	-----

WYETH AYERST	250MG	A061685	001
--------------	-------	---------	-----

	500MG	A061685	002
--	-------	---------	-----

TETRACYN

PFIPHARMECS	250MG	A060082	003
	500MG	A060082	004

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994
---------------	--------------	---------	-----	--------------

FOR SOLUTION; TOPICAL

TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001
-------	----------	---------	-----

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002
	500MG/VIAL	N050273	003

TETRACYN

PFIZER	250MG/VIAL	A060096	001
	500MG/VIAL	A060096	002

OINTMENT; OPHTHALMIC

ACHROMYCIN

STORZ	10MG/GM	N050266	001
-------	---------	---------	-----

SUSPENSION; ORAL

ACHROMYCIN V

LEDERLE	125MG/5ML	N050263	002
---------	-----------	---------	-----

SUMYCIN

PAR PHARM	125MG/5ML	A060400	001
-----------	-----------	---------	-----

DISCONTINUED DRUG PRODUCT LIST

6-311 (of 337)

TETRACYCLINE HYDROCHLORIDE

SUSPENSION; ORAL

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS	125MG/5ML	A060633	001
FERRANTE	125MG/5ML	A060174	001
PROTER	125MG/5ML	A060446	001
PUREPAC PHARM	125MG/5ML	A060291	001

TETRACYN

PFIPHARMECS	125MG/5ML	A060095	001
-------------	-----------	---------	-----

TETRAMED

IVAX SUB TEVA PHARMS	125MG/5ML	A061468	001
----------------------	-----------	---------	-----

SUSPENSION/DROPS; OPHTHALMIC

ACHROMYCIN

STORZ	1%	N050268	001
-------	----	---------	-----

TABLET; ORAL

PANMYCIN

PHARMACIA AND UPJOHN	250MG	A061705	001
	500MG	A061705	002

SUMYCIN

PAR PHARM	50MG	A061147	003
	100MG	A061147	002
	250MG	A061147	001
	500MG	A061147	004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL

TETREX

BRISTOL	EQ 100MG HCL	A061653	001
	EQ 250MG HCL	A061653	002
	EQ 250MG HCL	A061889	002
	EQ 250MG HCL	N050212	002
	EQ 500MG HCL	A061653	003
	EQ 500MG HCL	A061889	001
	EQ 500MG HCL	N050212	003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

BRACCO	1mCi/ML	N018548	001	Dec 30, 1982
TRACE LIFE	1mCi/ML	A075569	001	Nov 21, 2001

INJECTABLE; INTRAVENOUS

THALLOUS CHLORIDE TL 201

MALLINCKRODT	2mCi/ML	A077698	001	Nov 09, 2006
--------------	---------	---------	-----	--------------

THEOPHYLLINE

CAPSULE; ORAL

BRONKODYL

SANOFI AVENTIS US	100MG	A085264	001
	200MG	A085264	002

ELIXOPHYLLIN

FOREST LABS	100MG	A085545	001	Jul 31, 1984
	200MG	A083921	001	Jul 31, 1984

SOMOPHYLLIN-T

FISONS	100MG	A087155	001	Feb 25, 1985
	200MG	A087155	002	Feb 25, 1985
	250MG	A087155	003	Feb 25, 1985

THEOPHYLLINE

KV PHARM	100MG	A085263	001	
	200MG	A085263	002	
SCHERER RP	100MG	A084731	002	Nov 07, 1986
	200MG	A084731	001	Nov 07, 1986
	250MG	A084731	003	Nov 07, 1986

CAPSULE, EXTENDED RELEASE; ORAL

AEROLATE III

FLEMING PHARMS	65MG	A085075	003	Nov 24, 1986
----------------	------	---------	-----	--------------

AEROLATE JR

FLEMING PHARMS	130MG	A085075	002	Nov 24, 1986
----------------	-------	---------	-----	--------------

AEROLATE SR

FLEMING PHARMS	260MG	A085075	001	Nov 24, 1986
----------------	-------	---------	-----	--------------

ELIXOPHYLLIN SR

FOREST LABS	125MG	A086826	001	Jan 29, 1985
	250MG	A086826	002	Jan 29, 1985

DISCONTINUED DRUG PRODUCT LIST

6-312 (of 337)

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

SLO-BID

SANOFI AVENTIS US	50MG	A088269	001	Jan 31, 1985
	75MG	A089539	001	May 10, 1989
	100MG	A087892	001	Jan 31, 1985
	125MG	A089540	001	May 10, 1989
	200MG	A087893	001	Jan 31, 1985
	300MG	A087894	001	Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	60MG	A085206	001	May 24, 1982
	125MG	A085203	001	May 24, 1982
	250MG	A085205	001	May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM	50MG	A087763	001	Feb 27, 1985
	100MG	A087194	001	
	200MG	A088382	001	Feb 27, 1985
	250MG	A087193	001	
	300MG	A088383	001	Feb 27, 1985

THEO-DUR

SCHERING	50MG	A088022	001	Sep 10, 1985
	75MG	A088015	001	Sep 10, 1985
	125MG	A088016	001	Sep 10, 1985
	200MG	A087995	001	Sep 10, 1985

THEOBID

WHITBY	260MG	A085983	001	Mar 20, 1985
--------	-------	---------	-----	--------------

THEOBID JR.

WHITBY	130MG	A087854	001	Mar 20, 1985
--------	-------	---------	-----	--------------

THEOCLEAR L.A.-130

SCHWARZ PHARMA	130MG	A086569	001	May 27, 1982
----------------	-------	---------	-----	--------------

THEOCLEAR L.A.-260

SCHWARZ PHARMA	260MG	A086569	002	May 27, 1982
----------------	-------	---------	-----	--------------

THEOPHYL-SR

ORTHO MCNEIL PHARM	125MG	A086480	001	Feb 08, 1985
	250MG	A086471	001	Feb 08, 1985

THEOPHYLLINE

CENT PHARMS	125MG	A088654	001	Feb 12, 1985
	250MG	A088689	001	Feb 12, 1985
HOSPIRA	100MG	A089976	001	Jan 04, 1995
	200MG	A089977	001	Jan 04, 1995
	300MG	A089932	001	Jan 04, 1995
INWOOD LABS	100MG	A040052	001	Feb 14, 1994
	125MG	A040052	002	Feb 14, 1994
	200MG	A040052	003	Feb 14, 1994
	300MG	A040052	004	Feb 14, 1994
SANDOZ	260MG	A087462	001	May 11, 1982

THEOPHYLLINE-SR

SCHERER RP	300MG	A088255	001	Jun 12, 1986
------------	-------	---------	-----	--------------

THEOVENT

SCHERING	125MG	A087010	001	Jan 31, 1985
	250MG	A087910	001	Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN

CENCI	80MG/15ML	A088303	001	Jan 25, 1984
-------	-----------	---------	-----	--------------

LANOPHYLLIN

LANNETT	80MG/15ML	A084578	001	
---------	-----------	---------	-----	--

THEOLIXIR

PANRAY	80MG/15ML	A084559	001	
--------	-----------	---------	-----	--

THEOPHYL-225

ORTHO MCNEIL PHARM	112.5MG/15ML	A086485	001	
--------------------	--------------	---------	-----	--

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
HALSEY	80MG/15ML	A085169	001	
PERRIGO	80MG/15ML	A085952	001	
PHARM ASSOC	80MG/15ML	A086720	001	
PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

DISCONTINUED DRUG PRODUCT LIST

6-313 (of 337)

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	40MG/100ML	N019083 001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	80MG/100ML	N019083 002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	160MG/100ML	N019083 003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	200MG/100ML	N019212 001	Nov 07, 1984
	200MG/100ML	N019826 004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	4MG/ML	N019212 003	Nov 07, 1984
	400MG/100ML	N019212 002	Nov 07, 1984
	400MG/100ML	N019826 005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982
	40MG/100ML	N018649 001	Jul 26, 1982
	80MG/100ML	N018649 002	Jul 26, 1982
	160MG/100ML	N018649 003	Jul 26, 1982
	200MG/100ML	N018649 004	Jul 26, 1982
	320MG/100ML	N018649 006	Nov 13, 1985
	400MG/100ML	N018649 005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA INC	80MG/100ML	N019211 002	Dec 14, 1984
	200MG/100ML	N019211 004	Dec 14, 1984
	400MG/100ML	N019211 005	Dec 14, 1984

SOLUTION; ORAL

AEROLATE			
FLEMING PHARMS	150MG/15ML	A089141 001	Dec 03, 1986
THEOLAIR			
3M	80MG/15ML	A086107 001	
THEOPHYLLINE			
ROXANE	80MG/15ML	A087449 001	Sep 15, 1983

SUSPENSION; ORAL

ELIXICON			
FOREST LABS	100MG/5ML	A085502 001	

SYRUP; ORAL

ACCURBRON			
SANOFI AVENTIS US	150MG/15ML	A088746 001	Nov 22, 1985
AQUAPHYLLIN			
FERNDAL LABS	80MG/15ML	A087917 001	Jan 18, 1983
SLO-PHYLLIN			
SANOFI AVENTIS US	80MG/15ML	A085187 001	
THEOCLEAR-80			
CENT PHARMS	80MG/15ML	A087095 001	Mar 01, 1982
THEOPHYLLINE			
ALPHARMA US PHARMS	80MG/15ML	A086001 001	
	150MG/15ML	A086545 001	

TABLET; ORAL

QUIBRON-T			
MONARCH PHARMS	300MG	A088656 001	Aug 22, 1985
SLO-PHYLLIN			
SANOFI AVENTIS US	100MG	A085202 001	
	200MG	A085204 001	
THEOCLEAR-100			
CENT PHARMS	100MG	A085353 002	
THEOCLEAR-200			
CENT PHARMS	200MG	A085353 001	
THEOPHYL-225			
ORTHO MCNEIL PHARM	225MG	A084726 001	

TABLET, CHEWABLE; ORAL

THEOPHYL			
ORTHO MCNEIL PHARM	100MG	A086506 001	Sep 12, 1985

TABLET, EXTENDED RELEASE; ORAL

DURAPHYL			
FOREST LABS	100MG	A088503 001	Apr 03, 1985
	200MG	A088504 001	Apr 03, 1985
	300MG	A088505 001	Apr 03, 1985

LABID

WARNER CHILCOTT	250MG	A087225 001	
-----------------	-------	-------------	--

DISCONTINUED DRUG PRODUCT LIST

6-314 (of 337)

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING

100MG

A085328 001

200MG

A086998 001

300MG

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOCHRON

SUN PHARM INDS INC

300MG

A087400 002 Jan 11, 1983

THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOPHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME

500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001 Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

HIKMA MAPLE

100MG/ML

A080575 001

HOSPIRA

100MG/ML

A040079 001 May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A080571 001

100MG/ML

A083534 001

200MG/ML

A080571 002

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

DISCONTINUED DRUG PRODUCT LIST

6-315 (of 337)

THIETHYLPERAZINE MALATE

INJECTABLE; INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY; RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET; ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION; RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION; ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HCL/5ML

N017923 001

EQ 100MG HCL/5ML

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

MELLARIL

NOVARTIS

30MG/ML

N011808 012

100MG/ML

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001 Aug 23, 1983

ALPHARMA US PHARMS

30MG/ML

A087766 001 Apr 26, 1983

ANI PHARMS INC

100MG/ML

A089603 001 Nov 09, 1987

HI TECH PHARMA

30MG/ML

A040125 001 Aug 16, 1996

100MG/ML

A040126 001 Aug 16, 1996

PHARM ASSOC

30MG/ML

A040187 001 Aug 28, 1997

100MG/ML

A040213 001 May 29, 1998

SANDOZ

30MG/ML

A088307 001 Nov 23, 1983

100MG/ML

A088308 001 Nov 23, 1983

TEVA PHARMS

30MG/ML

A089602 001 Nov 09, 1987

WOCKHARDT

30MG/ML

A088258 001 Jul 25, 1983

100MG/ML

A088227 001 Jul 05, 1983

THIORIDAZINE HYDROCHLORIDE INTENSOL

ROXANE

30MG/ML

A088941 001 Dec 16, 1985

100MG/ML

A088942 001 Dec 16, 1985

TABLET; ORAL

MELLARIL

NOVARTIS

10MG

N011808 003

15MG

N011808 016

25MG

N011808 006

50MG

N011808 011

100MG

N011808 009

150MG

N011808 017

200MG

N011808 015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS INC

10MG

A088270 001 Apr 14, 1983

10MG

A088493 001 May 17, 1985

15MG

A088271 001 Apr 14, 1983

25MG

A088272 001 Apr 14, 1983

50MG

A088194 001 Apr 14, 1983

100MG

A088273 001 Oct 03, 1983

100MG

A088456 001 May 17, 1985

MUTUAL PHARM

10MG

A088375 001 Nov 18, 1983

15MG

A088461 001 Nov 18, 1983

25MG

A087264 001 Nov 18, 1983

50MG

A088370 001 Nov 18, 1983

100MG

A088379 001 Nov 16, 1983

150MG

A088737 001 Sep 26, 1984

200MG

A088738 001 Oct 16, 1984

MYLAN

10MG

A088332 001 Jun 27, 1983

25MG

A088333 001 Jun 27, 1983

50MG

A088334 001 Jun 27, 1983

100MG

A088335 001 Nov 18, 1983

PAR PHARM

10MG

A088351 001 Dec 05, 1983

DISCONTINUED DRUG PRODUCT LIST

6-316 (of 337)

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988
ROXANE	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985
SANDOZ	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986
SUPERPHARM	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985
WATSON LABS	10MG	A088412	001	Sep 12, 1983
	10MG	A088476	001	Nov 08, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983
	15MG	A088477	001	Nov 08, 1983
	15MG	A088562	001	May 11, 1984
	25MG	A088296	001	Jul 28, 1983
	25MG	A088478	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	25MG	A088755	001	Jul 24, 1984
	50MG	A088323	001	Jul 28, 1983
	50MG	A088479	001	Nov 08, 1983
	50MG	A088563	001	May 11, 1984
	100MG	A088284	001	Aug 25, 1983
	100MG	A088564	001	May 11, 1984
	100MG	A088736	001	Jul 24, 1984
	150MG	A088410	001	Mar 05, 1984
	150MG	A088869	001	Jun 28, 1985
	200MG	A088381	001	Mar 14, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

IMMUNEX	15MG/VIAL	N020058	001	Dec 22, 1994
---------	-----------	---------	-----	--------------

THIOTEPA

FRESENIUS KABI USA	15MG/VIAL	A075698	001	Sep 20, 2001
IMMUNEX	15MG/VIAL	N011683	001	
TEVA PARENTERAL	15MG/VIAL	A075730	001	Apr 20, 2001
	30MG/VIAL	A075730	002	Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

PFIZER	20MG	N016584	005	
--------	------	---------	-----	--

THIOTHIXENE

AM THERAP	1MG	A071884	001	Aug 12, 1987
	2MG	A071885	001	Aug 12, 1987
	5MG	A071886	001	Aug 12, 1987
	10MG	A071887	001	Aug 12, 1987
	20MG	A072200	001	Dec 17, 1987
WATSON LABS	1MG	A070600	001	Jun 05, 1987
	2MG	A070601	001	Jun 05, 1987
	2MG	A071626	001	Jun 25, 1987
	5MG	A070602	001	Jun 05, 1987
	5MG	A071627	001	Jun 25, 1987

DISCONTINUED DRUG PRODUCT LIST

6-317 (of 337)

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

10MG

A070603 001 Jun 05, 1987

10MG

A071628 001 Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

PFIZER

EQ 5MG BASE/ML

N016758 001

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS

EQ 5MG BASE/ML

A070969 001 Oct 16, 1987

PACO

EQ 1MG BASE/ML

A071917 001 Sep 20, 1989

EQ 5MG BASE/ML

A071939 001 Dec 16, 1988

TEVA

EQ 5MG BASE/ML

A071184 001 Jun 22, 1987

TEVA PHARMS

EQ 5MG BASE/ML

A071554 001 Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

CYCLE PHARMS LTD

EQ 5MG BASE/ML

A073494 001 Jun 30, 1992

INJECTABLE; INJECTION

NAVANE

PFIZER

EQ 2MG BASE/ML

N016904 001

EQ 10MG BASE/VIAL

N016904 002

THYROGLOBULIN

TABLET; ORAL

PROLOID

PARKE DAVIS

16MG

N002245 009

32MG

N002245 005

65MG

N002245 002

100MG

N002245 008

130MG

N002245 010

200MG

N002245 007

325MG

N002245 004

THYROGLOBULIN

IMPAX LABS

64.8MG

A080151 001

THYROTROPIN

INJECTABLE; INJECTION

THYTROPAR

SANOFI AVENTIS US

10 IU/VIAL

N008682 001

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON

6MG

N020646 006 Nov 29, 2005

8MG

N020646 007 Nov 29, 2005

10MG

N020646 008 Nov 29, 2005

20MG

N020646 004 Sep 30, 1997

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050497 001

EQ 3GM BASE/VIAL

A062690 001 Dec 19, 1986

EQ 3GM BASE/VIAL

N050497 002

EQ 6GM BASE/VIAL

N050497 003

EQ 20GM BASE/VIAL

N050497 004

EQ 30GM BASE/VIAL

N050497 005 Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO

125MG

N019979 001 Mar 24, 1993

250MG

N019979 002 Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

250MG

A075253 001 Aug 20, 1999

MYLAN

250MG

A075161 001 Sep 13, 1999

250MG

A075316 001 Nov 02, 1999

SANDOZ

250MG

A075318 001 Aug 20, 1999

250MG

A075326 001 Aug 20, 1999

WATSON LABS

250MG

A075309 001 Apr 26, 2000

DISCONTINUED DRUG PRODUCT LIST

6-318 (of 337)

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

SANOFI AVENTIS US

EQ 200MG BASE

N020707 001 Mar 07, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

AKORN

EQ 0.25% BASE

A074465 001 Mar 25, 1997

EQ 0.25% BASE

A074515 001 Mar 25, 1997

APOTEX INC

EQ 0.25% BASE

A075411 001 Sep 08, 2000

EQ 0.5% BASE

A075412 001 Sep 08, 2000

FOUGERA

EQ 0.25% BASE

A074667 001 Mar 25, 1997

EQ 0.5% BASE

A074668 001 Mar 25, 1997

TABLET; ORAL

BLOCADREN

MERCK

5MG

N018017 001

10MG

N018017 002

20MG

N018017 004

TIMOLOL MALEATE

QUANTUM PHARMICS

5MG

A072466 001 May 19, 1989

10MG

A072467 001 May 19, 1989

20MG

A072468 001 May 19, 1989

SANDOZ

5MG

A072550 001 Apr 13, 1989

10MG

A072551 001 Apr 13, 1989

20MG

A072552 001 Apr 13, 1989

TEVA

5MG

A072648 001 Jun 16, 1993

10MG

A072649 001 Jun 16, 1993

20MG

A072650 001 Jun 16, 1993

USL PHARMA

5MG

A072001 001 Apr 11, 1989

10MG

A072002 001 Apr 11, 1989

20MG

A072003 001 Apr 11, 1989

WATSON LABS

5MG

A072269 001 Apr 11, 1989

5MG

A072917 001 Jul 31, 1991

10MG

A072270 001 Apr 11, 1989

10MG

A072918 001 Jul 31, 1991

20MG

A072271 001 Apr 11, 1989

20MG

A072919 001 Jul 31, 1991

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000

TIOCONAZOLE

CREAM; TOPICAL

TZ-3

PFIZER

1%

N018682 001 Feb 18, 1983

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

MEDICURE

EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)

N020912 001 May 14, 1998

EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)

N020913 001 May 14, 1998

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 2MG BASE

A076283 001 Jul 12, 2002

EQ 4MG BASE

A076283 002 Jul 12, 2002

BARR

EQ 2MG BASE

A076371 001 Apr 09, 2003

EQ 4MG BASE

A076371 002 Apr 09, 2003

IVAX SUB TEVA PHARMS

EQ 2MG BASE

A076321 001 Sep 30, 2004

EQ 4MG BASE

A076321 002 Sep 30, 2004

MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003

EQ 4MG BASE

A076282 002 Dec 16, 2003

ZANAFLEX

ACORDA

EQ 2MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020397 002 Feb 04, 2000

DISCONTINUED DRUG PRODUCT LIST

6-319 (of 337)

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD

0.3%

A063176 001 May 25, 1994

APOTEX INC

0.3%

A065087 001 Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

NEBCIN

LILLY

EQ 1.2GM BASE/VIAL

N050519 001

EQ 10MG BASE/ML

A062008 004

EQ 10MG BASE/ML

A062707 001 Apr 29, 1987

EQ 10MG BASE/ML

N050477 005

EQ 40MG BASE/ML

A062008 001

TOBRAMYCIN SULFATE

APOTHECON

EQ 10MG BASE/ML

A064021 001 May 31, 1994

EQ 40MG BASE/ML

A064021 002 May 31, 1994

EQ 40MG BASE/ML

A064026 001 May 31, 1994

ASTRAZENECA

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994

HIKMA MAPLE

EQ 10MG BASE/ML

A063113 001 Apr 26, 1991

EQ 10MG BASE/ML

A063128 001 Nov 27, 1991

EQ 40MG BASE/ML

A063118 001 Jul 29, 1991

EQ 40MG BASE/ML

A063127 001 Nov 27, 1991

HOSPIRA

EQ 10MG BASE/ML

A063080 001 Apr 30, 1991

EQ 40MG BASE/ML

A063161 001 May 29, 1991

WATSON LABS INC

EQ 10MG BASE/ML

A062945 001 Aug 09, 1989

EQ 40MG BASE/ML

A062945 002 Aug 09, 1989

TOCAINIDE HYDROCHLORIDE

TABLET;ORAL

TONOCARD

ASTRAZENECA

400MG

N018257 001 Nov 09, 1984

600MG

N018257 002 Nov 09, 1984

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

BARR

100MG

A070162 001 Jan 14, 1986

250MG

A070163 001 Jan 14, 1986

500MG

A070164 001 Jan 14, 1986

DURAMED PHARMS BARR

100MG

A070165 001 Jan 10, 1986

250MG

A070166 001 Jan 10, 1986

500MG

A070167 001 Jan 10, 1986

INTERPHARM

250MG

A071270 001 Sep 23, 1986

500MG

A071271 001 Sep 23, 1986

IVAX SUB TEVA PHARMS

100MG

N018894 001 Nov 02, 1984

250MG

N018894 002 Nov 02, 1984

500MG

N018894 003 Nov 02, 1984

MUTUAL PHARM

100MG

A071357 001 Jul 16, 1987

250MG

A071358 001 Jul 16, 1987

500MG

A071359 001 Jul 16, 1987

PAR PHARM

100MG

A070159 001 Jan 06, 1986

250MG

A070160 001 Jan 06, 1986

500MG

A070161 001 Jan 06, 1986

SANDOZ

100MG

A071633 001 Dec 09, 1987

250MG

A070289 001 Mar 13, 1986

500MG

A070290 001 Mar 13, 1986

SUPERPHARM

250MG

A070763 001 Jun 16, 1986

500MG

A070764 001 Jun 16, 1986

USL PHARMA

100MG

A071355 001 Jan 11, 1988

250MG

A070168 001 Apr 02, 1986

500MG

A070169 001 Apr 02, 1986

WATSON LABS

100MG

A070242 001 Aug 01, 1986

100MG

A070513 001 Jan 09, 1986

250MG

A070243 001 Aug 01, 1986

250MG

A070514 001 Jan 09, 1986

500MG

A070244 001 Aug 01, 1986

500MG

A070515 001 Jan 09, 1986

TOLINASE

PHARMACIA AND UPJOHN

100MG **Federal Register determination
that product was not discontinued or

N015500 002

DISCONTINUED DRUG PRODUCT LIST

6-320 (of 337)

TOLAZAMIDE

TABLET; ORAL

TOLINASE

withdrawn for safety or efficacy
reasons**

250MG

N015500 004

500MG

N015500 005

TOLAZOLINE HYDROCHLORIDE

INJECTABLE; INJECTION

PRISCOLINE

NOVARTIS

25MG/ML

N006403 005 Feb 22, 1985

TOLBUTAMIDE

TABLET; ORAL

ORINASE

PHARMACIA AND UPJOHN

250MG

N010670 002

500MG

N010670 001

TOLBUTAMIDE

ALRA

500MG

A086141 001

ASCOT

500MG

A087541 001 Mar 01, 1983

BARR

500MG

A087121 001

DAVA PHARMS INC

500MG

A086926 001

IVAX PHARMS

500MG

A087093 001

PARKE DAVIS

500MG

A086047 001

PUREPAC PHARM

500MG

A088950 001 Jun 17, 1985

SANDOZ

500MG

A086574 001

500MG

N012678 001

SUPERPHARM

500MG

A088893 001 Nov 19, 1984

VANGARD

500MG

A087876 001 Apr 20, 1982

WATSON LABS

250MG

A089110 001 May 29, 1987

500MG

A086109 001

500MG

A087318 001

500MG

A089111 001 May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

N012095 001

TOLCAPONE

TABLET; ORAL

TASMAR

VALEANT PHARMS LLC

200MG

N020697 002 Jan 29, 1998

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

ORTHO MCNEIL JANSSEN

EQ 400MG BASE

N018084 001

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 400MG BASE

A073308 001 Jan 24, 1992

IVAX SUB TEVA PHARMS

EQ 400MG BASE

A073392 001 Jan 24, 1992

MUTUAL PHARM

EQ 400MG BASE

A073311 001 Nov 27, 1991

SANDOZ

EQ 400MG BASE

A073462 001 Apr 30, 1992

TEVA

EQ 400MG BASE

A073519 001 May 29, 1992

TABLET; ORAL

TOLECTIN

ORTHO MCNEIL JANSSEN

EQ 200MG BASE

N017628 001

TOLECTIN 600

ORTHO MCNEIL JANSSEN

EQ 600MG BASE

N017628 002 Mar 08, 1989

TOLMETIN SODIUM

ACTAVIS ELIZABETH

EQ 600MG BASE

A073527 001 Jun 30, 1992

IVAX SUB TEVA PHARMS

EQ 600MG BASE

A074399 001 Mar 28, 1996

SANDOZ

EQ 200MG BASE

A073588 001 Jul 31, 1992

EQ 600MG BASE

A074002 001 Sep 27, 1993

TEVA

EQ 600MG BASE

A074729 001 Feb 27, 1997

TOLVAPTAN

TABLET; ORAL

SAMSCA

OTSUKA AMERICA PHARM

60MG

N022275 003 May 19, 2009

DISCONTINUED DRUG PRODUCT LIST

6-321 (of 337)

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS

50MG

N020844 003 Oct 26, 1998

TOPIRAMATE

BARR

15MG

A076448 001 Apr 15, 2009

25MG

A076448 002 Apr 15, 2009

SANDOZ

15MG

A079206 001 Oct 14, 2009

25MG

A079206 002 Oct 14, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS

300MG

N020505 003 Dec 24, 1996

400MG

N020505 006 Dec 24, 1996

TOPIRAMATE

BARR

25MG

A076315 001 Mar 27, 2009

100MG

A076315 002 Mar 27, 2009

200MG

A076315 003 Mar 27, 2009

PLIVA HRVATSKA DOO

25MG

A077905 001 Mar 30, 2009

50MG

A077905 002 Mar 30, 2009

100MG

A077905 003 Mar 30, 2009

200MG

A077905 004 Mar 30, 2009

ROXANE

25MG

A076306 001 Mar 27, 2009

50MG

A076306 002 Mar 27, 2009

100MG

A076306 003 Mar 27, 2009

200MG

A076306 004 Mar 27, 2009

WATSON LABS

25MG

A077643 001 Mar 27, 2009

50MG

A077643 002 Mar 27, 2009

100MG

A077643 003 Mar 27, 2009

200MG

A077643 004 Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI ONCOL

EQ 4MG BASE/VIAL

A091376 001 Nov 29, 2010

SOLUTION; INTRAVENOUS

TOPOTECAN

SANDOZ INC

EQ 1MG BASE/ML (EQ 1MG BASE/ML)

N200199 001 Feb 25, 2011

EQ 3MG BASE/3ML (EQ 1MG BASE/ML)

N200199 002 Feb 25, 2011

EQ 4MG BASE/4ML (EQ 1MG BASE/ML)

N200199 003 Feb 25, 2011

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

ROCHE

50MG/5ML (10MG/ML)

N020137 002 Aug 23, 1993

20MG/2ML (10MG/ML)

N020137 001 Aug 23, 1993

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACTAVIS ELIZABETH

50MG

A075960 001 Jun 19, 2002

ASTA

50MG

A075974 001 Jul 12, 2002

IVAX SUB TEVA PHARMS

50MG

A075963 001 Jul 03, 2002

SANDOZ

50MG

A075968 001 Jun 25, 2002

WATSON LABS

50MG

A075962 001 Jun 24, 2002

ULTRAM

JANSSEN PHARMS

100MG

N020281 001 Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

PURDUE PHARMA

100MG

N021745 001 Dec 30, 2008

200MG

N021745 002 Dec 30, 2008

300MG

N021745 003 Dec 30, 2008

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

SHIONOGI INC

50MG

N021693 001 May 05, 2005

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

CIPLA

1MG

A077307 002 Jun 12, 2007

2MG

A077307 001 Jun 12, 2007

4MG

A077307 003 Jun 12, 2007

COREPHARMA

1MG

A077256 001 Jun 12, 2007

2MG

A077256 002 Jun 12, 2007

4MG

A077256 003 Jun 12, 2007

DISCONTINUED DRUG PRODUCT LIST

6-322 (of 337)

TRANDOLAPRIL

TABLET; ORAL

TRANDOLAPRIL

DR REDDYS LABS LTD

1MG

A078493 001 Aug 25, 2008

2MG

A078493 002 Aug 25, 2008

4MG

A078493 003 Aug 25, 2008

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

FRESENIUS KABI USA

100MG/ML

A091596 001 Mar 02, 2012

TABLET; ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN

500MG

N019280 001 Dec 30, 1986

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

ALCON PHARMS LTD

0.004%

N021257 001 Mar 16, 2001

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

APOTHECON

50MG

N018207 001

100MG

N018207 002

150MG

N018207 003 Mar 25, 1985

300MG

N018207 004 Nov 07, 1988

TRAZODONE HYDROCHLORIDE

AM THERAP

50MG

A071139 001 Oct 29, 1986

100MG

A071140 001 Oct 29, 1986

MYLAN

50MG

A071405 001 Feb 27, 1991

100MG

A071406 001 Feb 27, 1991

QUANTUM PHARMICS

100MG

A070921 001 Dec 01, 1986

SANDOZ

50MG

A072484 001 Apr 30, 1990

100MG

A072483 001 Apr 30, 1990

TEVA

150MG

A074357 001 Apr 30, 1997

USL PHARMA

50MG

A070491 001 Apr 29, 1987

100MG

A070492 001 Apr 29, 1987

WATSON LABS

50MG

A070857 001 Oct 10, 1986

50MG

A071112 001 Nov 17, 1986

100MG

A070858 001 Oct 10, 1986

100MG

A071113 001 Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG

A070942 001 Dec 01, 1986

TRETINOIN

CAPSULE; ORAL

VESANOID

ROCHE

10MG

N020438 001 Nov 22, 1995

SOLUTION; TOPICAL

TRETINOIN

TEVA PHARMS

0.05%

A074873 001 Jun 19, 1998

WOCKHARDT

0.05%

A075260 001 Jan 25, 1999

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

DELCOR ASSET CORP

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

DISCONTINUED DRUG PRODUCT LIST

6-323 (of 337)

TRIAMCINOLONE

TABLET; ORAL

TRIAMCINOLONE

	8MG	A084268	001
	8MG	A084320	001
IMPAX LABS	4MG	A084340	001
IVAX SUB TEVA PHARMS	4MG	A083750	001
MYLAN	2MG	A084406	001
PUREPAC PHARM	2MG	A084020	002
	4MG	A084020	003
ROXANE	2MG	A084708	001
	4MG	A084709	001
	8MG	A084707	001
SANDOZ	4MG	A085601	001
TEVA	4MG	A084775	001
WATSON LABS	4MG	A084270	001
	4MG	A085834	001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE	0.1MG/INH	N018117	001	Apr 23, 1982
--------	-----------	---------	-----	--------------

AEROSOL, METERED; NASAL

NASACORT

SANOFI AVENTIS US	0.055MG/INH	N019798	001	Jul 11, 1991
-------------------	-------------	---------	-----	--------------

CREAM; TOPICAL

ARISTOCORT

ASTELLAS	0.025%	A083017	003
	0.1%	A083016	004
	0.5%	A083015	002

ARISTOCORT A

ASTELLAS	0.025%	A083017	004	
	0.025%	A088818	001	Oct 16, 1984
	0.1%	A083016	005	
	0.1%	A088819	001	Oct 16, 1984
	0.5%	A083015	003	
	0.5%	A088820	001	Oct 16, 1984

FLUTEX

IVAX PHARMS	0.025%	A085539	001
	0.1%	A085539	002
	0.5%	A085539	003

KENALOG

DELCOR ASSET CORP	0.025%	N011601	003
	0.1%	N011601	006
	0.5%	A083943	001

KENALOG-H

DELCOR ASSET CORP	0.1%	A086240	001
-------------------	------	---------	-----

TRIACET

TEVA	0.025%	A084908	001
	0.1%	A084908	002
	0.5%	A084908	003

TRIACORT

SOLVAY	0.1%	A087113	001
--------	------	---------	-----

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982
ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982
AMBIX	0.025%	A087932	001	May 09, 1983
G AND W LABS	0.025%	A089797	001	May 31, 1991
	0.1%	A089798	001	May 31, 1991
MORTON GROVE	0.025%	A088094	001	Sep 01, 1983
	0.1%	A088095	001	Sep 01, 1983
	0.5%	A088096	001	Sep 01, 1983
PHARMADERM	0.025%	A087990	001	Jul 07, 1983
	0.1%	A087991	001	Jul 07, 1983
	0.5%	A087992	001	Jul 07, 1983
PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982
	0.1%	A087912	001	Aug 10, 1982
	0.5%	A087922	001	Aug 10, 1982
TARO	0.025%	A040038	001	Oct 26, 1994
	0.025%	A086277	001	
	0.1%	A086276	001	
	0.5%	A086275	001	
TOPIDERM	0.025%	A089274	001	Feb 21, 1989

DISCONTINUED DRUG PRODUCT LIST

6-324 (of 337)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

0.1%	A089275	001	Feb 21, 1989
0.5%	A089276	001	Feb 21, 1989

TRIALEX

IVAX PHARMS

0.025%	A087430	001	Nov 01, 1988
0.1%	A087429	001	Nov 01, 1988
0.5%	A087428	001	Nov 01, 1988

TRYMEX

SAVAGE LABS

0.025%	A088196	001	Mar 25, 1983
0.1%	A088197	001	Mar 25, 1983
0.5%	A088198	001	Mar 25, 1983

GEL; TOPICAL

ARISTOGEL

ASTELLAS

0.1%	A083380	001	
------	---------	-----	--

INJECTABLE; INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL

3MG/ML	N019503	001	Oct 16, 1987
--------	---------	-----	--------------

SANDOZ

10MG/ML	A090166	001	May 27, 2009
---------	---------	-----	--------------

SANDOZ CANADA INC

40MG/ML	A090164	001	Jun 01, 2009
---------	---------	-----	--------------

WATSON LABS

40MG/ML	A085825	001	
---------	---------	-----	--

INJECTABLE; INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

ALLERGAN

8MG/0.1ML (8MG/0.1ML)	N022220	001	Jun 16, 2008
-----------------------	---------	-----	--------------

LOTION; TOPICAL

KENALOG

DELCOR ASSET CORP

0.025%	A084343	001	
0.025%	N011602	003	
0.1%	A084343	002	
0.1%	N011602	001	

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS

0.025%	A087191	001	Sep 08, 1982
--------	---------	-----	--------------

G AND W LABS INC

0.1%	A087192	001	Sep 08, 1982
------	---------	-----	--------------

OINTMENT; TOPICAL

ARISTOCORT

ASTELLAS

0.1%	A080750	004	
------	---------	-----	--

0.5%	A080745	002	
------	---------	-----	--

ARISTOCORT A

ASTELLAS

0.1%	A080750	003	
------	---------	-----	--

0.1%	A088780	001	Oct 01, 1984
------	---------	-----	--------------

0.5%	A080745	003	
------	---------	-----	--

0.5%	A088781	001	Oct 05, 1984
------	---------	-----	--------------

FLUTEX

IVAX PHARMS

0.025%	A087375	001	Nov 01, 1988
--------	---------	-----	--------------

0.1%	A087377	001	Nov 01, 1988
------	---------	-----	--------------

0.5%	A087376	001	Nov 01, 1988
------	---------	-----	--------------

KENALOG

DELCOR ASSET CORP

0.025%	N011600	003	
--------	---------	-----	--

0.1%	N011600	001	
------	---------	-----	--

0.5%	A083944	001	
------	---------	-----	--

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC

0.1%	A087799	001	Jun 07, 1982
------	---------	-----	--------------

ALPHARMA US PHARMS

0.5%	A089913	001	Dec 23, 1988
------	---------	-----	--------------

G AND W LABS

0.025%	A089795	001	Dec 23, 1988
--------	---------	-----	--------------

0.1%	A089796	001	Dec 23, 1988
------	---------	-----	--------------

MORTON GROVE

0.025%	A088090	001	Sep 01, 1983
--------	---------	-----	--------------

0.1%	A088091	001	Sep 01, 1983
------	---------	-----	--------------

0.5%	A088092	001	Sep 01, 1983
------	---------	-----	--------------

PHARMADERM

0.025%	A088692	001	Aug 02, 1984
--------	---------	-----	--------------

0.1%	A088690	001	Aug 02, 1984
------	---------	-----	--------------

TARO

0.025%	A040040	001	Sep 30, 1994
--------	---------	-----	--------------

0.025%	A040374	001	Jun 05, 2001
--------	---------	-----	--------------

0.1%	A087902	001	Dec 27, 1982
------	---------	-----	--------------

0.5%	A040386	001	Jun 05, 2001
------	---------	-----	--------------

TRYMEX

SAVAGE LABS

0.025%	A088693	001	Aug 02, 1984
--------	---------	-----	--------------

0.1%	A088691	001	Aug 02, 1984
------	---------	-----	--------------

PASTE; DENTAL

KENALOG IN ORABASE

DELCOR ASSET CORP

0.1%	N012097	001	
------	---------	-----	--

DISCONTINUED DRUG PRODUCT LIST

6-325 (of 337)

TRIAMCINOLONE ACETONIDE

PASTE; DENTAL

ORALONE

TARO

0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS

0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US

0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

SANDOZ

25MG/ML

N011685 003

40MG/ML **Federal Register

N012802 001

determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

TRIAMCINOLONE DIACETATE

AKORN

25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS

40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS

2MG/5ML

N011960 004

KENACORT

DELCOR ASSET CORP

EQ 4MG BASE/5ML

N012515 001

TRIAZOLAM

TABLET; ORAL

HALCION

PHARMACIA AND UPJOHN

0.5MG

N017892 002 Nov 15, 1982

TRIAZOLAM

WATSON LABS

0.125MG

A074445 001 Oct 20, 1995

0.25MG

A074445 002 Oct 20, 1995

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

TG UNITED LABS

4MG

A085568 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

DISCONTINUED DRUG PRODUCT LIST

6-326 (of 337)

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL

PATHILON

LEDERLE

25MG

N009489 005

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

SANDOZ

EQ 10MG BASE/ML

A085787 001 Apr 15, 1982

WOCKHARDT

EQ 10MG BASE/ML

A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

GLAXOSMITHKLINE

EQ 2MG BASE/ML

N011552 005

TABLET; ORAL

STELAZINE

GLAXOSMITHKLINE

EQ 1MG BASE

N011552 001

EQ 2MG BASE

N011552 002

EQ 5MG BASE

N011552 003

EQ 10MG BASE

N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

DURAMED PHARMS BARR

EQ 1MG BASE

A088967 001 Apr 23, 1985

EQ 2MG BASE

A088968 001 Apr 23, 1985

EQ 5MG BASE

A088969 001 Apr 23, 1985

EQ 10MG BASE

A088970 001 Apr 23, 1985

IVAX PHARMS

EQ 1MG BASE

A087612 001 Nov 19, 1982

EQ 2MG BASE

A087613 001 Nov 19, 1982

EQ 5MG BASE

A087328 001 Nov 19, 1982

EQ 10MG BASE

A087614 001 Nov 19, 1982

SANDOZ

EQ 1MG BASE

A040153 001 Oct 25, 1996

EQ 2MG BASE

A040153 002 Oct 25, 1996

EQ 5MG BASE

A040153 003 Oct 25, 1996

EQ 10MG BASE

A040153 004 Oct 25, 1996

WATSON LABS

EQ 1MG BASE

A085975 001 Jun 23, 1988

EQ 2MG BASE

A085976 001 Jun 23, 1988

EQ 5MG BASE

A085973 001 Jun 23, 1988

EQ 10MG BASE

A088710 001 Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON

EQ 50MG HCL/5ML

N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON

3MG/ML

N011325 005

10MG/ML

N011325 004

20MG/ML

N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB

10MG

N011123 001

25MG

N011123 002

50MG

N011123 003

TRIHXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE

5MG

N006773 010

5MG

N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE

2MG/5ML

N006773 009

TRIHXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES

2MG/5ML

A089514 001 Apr 07, 1989

TABLET; ORAL

ARTANE

LEDERLE

2MG

N006773 005

5MG

N006773 003

DISCONTINUED DRUG PRODUCT LIST

6-327 (of 337)

TRIHXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TREMID

SCHERING

2MG

A080381 001

5MG

A080381 003

TRIHXYPHENIDYL HYDROCHLORIDE

HIKMA PHARMS LLC

2MG

A040337 002 Feb 16, 2000

5MG

A040337 001 Feb 16, 2000

NYLOS

5MG

A085622 001

VANGARD

2MG

A088035 001 Jul 30, 1982

WATSON LABS

2MG

A040184 001 Feb 06, 1998

2MG

A085117 001

5MG

A040184 002 Feb 06, 1998

5MG

A085105 001

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION

30MG

N018719 002 Dec 31, 1984

60MG

N018719 001 Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001 Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE

200MG/5ML

N005856 002

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE

50MG/ML

N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

HOSPIRA

100MG/ML

A088804 001 Apr 03, 1987

SMITH AND NEPHEW

100MG/ML

A088960 001 Apr 04, 1986

100MG/ML

A089043 001 Apr 04, 1986

SOLOPAK

100MG/ML

A089094 001 Apr 04, 1986

WATSON LABS

100MG/ML

A086577 001 Oct 19, 1982

100MG/ML

A087939 001 Dec 28, 1982

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS

100MG

N017943 001

200MG

N017943 003 Jul 14, 1982

TRIMETHOPRIM

MUTUAL PHARM

100MG

A070494 001 Jan 22, 1986

200MG

A070495 001 Sep 24, 1986

TEVA

200MG

A071259 001 Jun 18, 1987

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002 Nov 09, 1982

DISCONTINUED DRUG PRODUCT LIST

6-328 (of 337)

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

FSC

EQ 25MG BASE/5ML

A074374 001 Jun 23, 1995

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HCL/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

G AND W LABS

2.86%; 3.42%; 3.7%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

2.86%; 3.42%; 3.7%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

2.86%; 3.42%; 3.7%

A087864 001 Sep 01, 1982

FOUGERA

2.86%; 3.42%; 3.7%

A086424 001

PERRIGO NEW YORK

2.86%; 3.42%; 3.7%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

2.86%; 3.42%; 3.7%

A087887 001 Jul 23, 1982

VAGILIA

TEVA

3.42%; 3.42%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

143.75MG; 172.5MG; 184MG

N005794 002

TRIPLE SULFA

FOUGERA

172.5MG; 172.5MG; 172.5MG

A088463 001 Jan 03, 1985

PHARMADERM

172.5MG; 172.5MG; 172.5MG

A088462 001 Jan 03, 1985

DISCONTINUED DRUG PRODUCT LIST

6-329 (of 337)

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML

N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA 1.25MG/5ML

A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML

A085940 001

HALSEY 1.25MG/5ML

A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML

A087514 001 Feb 10, 1982

TABLET; ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG

N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG

A085610 001

WATSON LABS 2.5MG

A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE; SULFAMERAZINE; SULFAMETHAZINE)

SUSPENSION; ORAL

LANTRISUL

LANNETT 167MG/5ML; 167MG/5ML; 167MG/5ML

A080123 002

NEOTRIZINE

LILLY 167MG/5ML; 167MG/5ML; 167MG/5ML

N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML; 167MG/5ML; 167MG/5ML

A080100 001

SULFOSE

WYETH AYERST 167MG/5ML; 167MG/5ML; 167MG/5ML

A080013 002

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML; 167MG/5ML; 167MG/5ML

N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/ML; 167MG/ML; 167MG/ML

A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML; 167MG/5ML; 167MG/5ML

N006920 003

TABLET; ORAL

NEOTRIZINE

LILLY 167MG; 167MG; 167MG

N006317 011

SULFA-TRIPLE #2

IMPAX LABS 167MG; 167MG; 167MG

A080079 001

SULFALOID

FOREST PHARMS 167MG; 167MG; 167MG

A080099 001

SULFOSE

WYETH AYERST 167MG; 167MG; 167MG

A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG; 167MG; 167MG

N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG; 167MG; 167MG

A080086 001

TRIPLE SULFAS

LEDERLE 167MG; 167MG; 167MG

N006920 002

TRIPLE SULFOID

PAL PAK 167MG; 167MG; 167MG

A080094 001

TROGLITAZONE

TABLET; ORAL

PRELAY

SANKYO 200MG

N020719 001 Jan 29, 1997

300MG

N020719 003 Aug 04, 1997

400MG

N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG

N020720 001 Jan 29, 1997

300MG

N020720 003 Aug 04, 1997

400MG

N020720 002 Jan 29, 1997

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS; OTIC

CERUMENEX

PHARM RES ASSOC 10%

N011340 002

TROLEANDOMYCIN

CAPSULE; ORAL

TAO

PFIZER EQ 250MG BASE

N050336 002

SUSPENSION; ORAL

TAO

PFIZER EQ 125MG BASE/5ML

N050332 001

DISCONTINUED DRUG PRODUCT LIST

6-330 (of 337)

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON

0.5%

N012111 002

1%

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001 Sep 16, 1983

1%

A088230 001 Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001 Aug 28, 1985

ALCON PHARMS LTD

1%

A089172 001 Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001 Jul 30, 1982

1%

A087637 001 Aug 09, 1982

WATSON LABS

0.5%

A089171 001 Dec 28, 1990

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001 Dec 18, 1997

EQ 200MG BASE

N020759 002 Dec 18, 1997

TUBOCURARINE CHLORIDE

INJECTABLE;INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE;ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

URACIL MUSTARD

CAPSULE;ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE;INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA

EQ 75MG/POUCH

N020586 002 May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS

125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA

125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES

100MG/VIAL

N020900 001 Feb 04, 1999

UROFOLLITROPIN

INJECTABLE;INTRAMUSCULAR

METRODIN

SERONO

75 IU/AMP

N019415 002 Sep 18, 1986

150 IU/AMP

N019415 003 Sep 18, 1986

INJECTABLE;SUBCUTANEOUS

FERTINEX

SERONO

75 IU/AMP

N019415 005 Aug 23, 1996

150 IU/AMP

N019415 004 Aug 23, 1996

UROKINASE

INJECTABLE;INJECTION

KINLYTIC

MICROBIX BIOSYSTEMS

5,000 IU/VIAL

N021846 003

9,000 IU/VIAL

N021846 002

250,000 IU/VIAL

N021846 001

DISCONTINUED DRUG PRODUCT LIST

6-331 (of 337)

URSODIOL

CAPSULE; ORAL

ACTIGALL

WATSON PHARMS

150MG

N019594 001 Dec 31, 1987

TABLET; ORAL

URSODIOL

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALDECOXIB

TABLET; ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PAR PHARM

250MG

A070431 001 Feb 28, 1986

SCHERER RP

250MG

A070195 001 Jul 02, 1987

USL PHARMA

250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE; ORAL

STAVZOR

BANNER PHARMACAPS

125MG

N022152 001 Jul 29, 2008

250MG

N022152 002 Jul 29, 2008

500MG

N022152 003 Jul 29, 2008

SYRUP; ORAL

VALPROIC ACID

APOTEX INC

250MG/5ML

A077105 001 Jul 29, 2005

VALSARTAN

CAPSULE; ORAL

DIOVAN

NOVARTIS

80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

VANCOMYCIN HYDROCHLORIDE

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE

EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC

EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL

A062812 003 Nov 17, 1987

EQ 500MG BASE/VIAL

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL

A062812 001 Nov 17, 1987

VANCOLED

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062682 002 Mar 30, 1988

EQ 2GM BASE/VIAL

A062682 003 May 11, 1988

EQ 5GM BASE/VIAL

A062682 004 May 11, 1988

EQ 10GM BASE/VIAL

A062682 005 May 11, 1988

EQ 500MG BASE/VIAL

A062682 001 Jul 22, 1986

VANCOMYCIN HYDROCHLORIDE

HIKMA MAPLE

EQ 1GM BASE/VIAL

A062879 002 Aug 02, 1988

EQ 500MG BASE/VIAL

A062879 001 Aug 02, 1988

VANCOR

PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL

A062956 002 Aug 01, 1988

EQ 500MG BASE/VIAL

A062956 001 Aug 01, 1988

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

PARKE DAVIS

5PRESSOR UNITS/ML

N003402 001

DISCONTINUED DRUG PRODUCT LIST

6-332 (of 337)

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

ORGANON USA INC

10MG/VIAL

N018776 002 Apr 30, 1984

20MG/VIAL

N018776 003 Jan 03, 1992

VECURONIUM BROMIDE

HIKMA MAPLE

10MG/VIAL

A075218 001 Aug 23, 1999

20MG/VIAL

A075218 002 Aug 23, 1999

HOSPIRA

4MG/VIAL

A075558 001 Sep 11, 2001

WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

20MG/VIAL

A074334 002 Aug 31, 1995

VELAGLUCERASE ALFA

POWDER; IV (INFUSION)

VPRIV

SHIRE HUMAN GENETIC

200 UNITS/VIAL

N022575 002 Feb 26, 2010

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

WYETH PHARMS INC

EQ 100MG BASE

N020699 003 Oct 20, 1997

TABLET; ORAL

EFFEXOR

WYETH PHARMS INC

EQ 12.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 001 Dec 28, 1993

EQ 25MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 002 Dec 28, 1993

EQ 37.5MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 006 Dec 28, 1993

EQ 50MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 003 Dec 28, 1993

EQ 75MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 004 Dec 28, 1993

EQ 100MG BASE **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N020151 005 Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

PLIVA HRVATSKA DOO

EQ 25MG BASE

A078517 001 Jun 13, 2008

EQ 37.5MG BASE

A078517 002 Jun 13, 2008

EQ 50MG BASE

A078517 003 Jun 13, 2008

EQ 75MG BASE

A078517 004 Jun 13, 2008

EQ 100MG BASE

A078517 005 Jun 13, 2008

SANDOZ

EQ 25MG BASE

A077515 001 Jun 13, 2008

EQ 37.5MG BASE

A077515 002 Jun 13, 2008

EQ 50MG BASE

A077515 003 Jun 13, 2008

EQ 75MG BASE

A077515 004 Jun 13, 2008

EQ 100MG BASE

A077515 005 Jun 13, 2008

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC

2.5MG/ML

N018925 001 Mar 30, 1984

2.5MG/ML

N019038 001 Mar 30, 1984

ISOPTIN

FSC

2.5MG/ML

N018485 001

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM

2.5MG/ML

A070348 001 May 01, 1986

BEDFORD

2.5MG/ML

A072888 001 Jul 28, 1995

HOSPIRA

2.5MG/ML

A070577 001 Feb 02, 1987

2.5MG/ML

A070739 001 May 06, 1987

2.5MG/ML

A070740 001 May 06, 1987

INTL MEDICATION

2.5MG/ML

A070451 001 Dec 16, 1985

LUITPOLD

2.5MG/ML

A070225 001 Nov 12, 1985

2.5MG/ML

A070617 001 Nov 12, 1985

MARSAM PHARMS LLC

2.5MG/ML

A072233 001 Feb 26, 1993

DISCONTINUED DRUG PRODUCT LIST

6-333 (of 337)

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

	2.5MG/ML	A073485 001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696 001	Jul 31, 1987
	2.5MG/ML	A070697 001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695 001	Jul 31, 1987

TABLET; ORAL

CALAN

GD SEARLE LLC	160MG	N018817 004	Feb 23, 1988
---------------	-------	-------------	--------------

ISOPTIN

FSC	40MG	N018593 003	Nov 23, 1987
	80MG	N018593 001	Mar 08, 1982
	120MG	N018593 002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019 001	Sep 24, 1986
	120MG	A070468 001	Sep 24, 1986
MUTUAL PHARM	80MG	A070482 001	Sep 24, 1986
	80MG	A071489 002	Jan 13, 1988
	120MG	A070483 001	Sep 24, 1986
	120MG	A071489 001	Jan 13, 1988
PLIVA	40MG	A072751 001	Feb 23, 1996
	80MG	A072124 001	Jan 26, 1989
	120MG	A072125 001	Jan 26, 1989
SANDOZ	40MG	A073168 001	Jul 31, 1992
	80MG	A071423 001	May 24, 1988
	120MG	A071424 001	May 25, 1988
WARNER CHILCOTT	80MG	A070340 001	Sep 24, 1986
	120MG	A070341 001	Sep 24, 1986
WATSON LABS	40MG	A072799 001	Apr 28, 1989
	40MG	A072923 001	Jun 29, 1993
	80MG	A070855 001	Sep 24, 1986
	80MG	A071366 001	Oct 01, 1986
	120MG	A070856 001	Sep 24, 1986
	120MG	A071367 001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

PLIVA	240MG	A072922 001	Mar 01, 1996
-------	-------	-------------	--------------

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691 002	
---------------------	-------------	-------------	--

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE	EQ 187.4MG BASE/ML	N050523 001	
-----------	--------------------	-------------	--

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE	3%	N050486 001	
-----------	----	-------------	--

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

LILLY	10MG/VIAL	N012665 001	
-------	-----------	-------------	--

VINBLASTINE SULFATE

ABRAXIS PHARM	10MG/VIAL	A089011 001	Nov 18, 1985
HOSPIRA	10MG/VIAL	A089565 001	Aug 18, 1987

VINCRIStINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

LILLY	1MG/VIAL	N014103 001	
	1MG/ML	N014103 003	Mar 07, 1984
	5MG/VIAL	N014103 002	

VINCASAR PFS

TEVA PARENTERAL	1MG/ML	A071426 001	Jul 17, 1987
-----------------	--------	-------------	--------------

VINCREX

BRISTOL MYERS SQUIBB	5MG/VIAL	A070867 001	Jul 12, 1988
----------------------	----------	-------------	--------------

VINCRIStINE SULFATE

ABIC	1MG/ML	A070873 001	Feb 19, 1987
ABRAXIS PHARM	1MG/ML	A070411 001	Sep 10, 1986
FRESENIUS KABI USA	1MG/ML	A076296 001	Dec 20, 2002

DISCONTINUED DRUG PRODUCT LIST

6-334 (of 337)

VINCRIStINE SULFATEINJECTABLE; INJECTION
VINCRIStINE SULFATE

	1MG/ML	A076401	001	Oct 28, 2003
HOSPIRA	1MG/VIAL	A071559	001	Apr 11, 1988
	2MG/VIAL	A071560	001	Apr 11, 1988
	5MG/VIAL	A071561	001	Apr 11, 1988

VINOReLBINE TARTRATEINJECTABLE; INJECTION
VINOReLBINE TARTRATE
EBEWE PHARMA

EQ 10MG BASE/ML	A078408	001	Feb 13, 2008
-----------------	---------	-----	--------------

VIOMYCIN SULFATEINJECTABLE; INJECTION
VIOCIN SULFATE

PFIZER	EQ 1GM BASE/VIAL	A061086	001
	EQ 5GM BASE/VIAL	A061086	002

VITAMIN ACAPSULE; ORAL
AQUASOL A

ASTRAZENECA	25,000USP UNITS	A083080	002
	50,000USP UNITS	A083080	001

VITAMIN A

BANNER PHARMACAPS	50,000USP UNITS	A083973	001
CHASE CHEM	50,000 IU	A083351	001
EVERYLIFE	50,000 IU	A083134	001
IMPAX LABS	50,000USP UNITS	A080952	001
WEST WARD	50,000USP UNITS	A080985	001

VITAMIN A PALMITATECAPSULE; ORAL
AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187	001
-------------------	----------------------	---------	-----

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883	001
-------	----------------------	---------	-----

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830	001
--------------	----------------------	---------	-----

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972	001
--------------	----------------------	---------	-----

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702	001
BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860	001
CHASE CHEM	EQ 50,000 UNITS BASE	A080746	001
	EQ 50,000 UNITS BASE	A083207	001
ELKINS SINN	EQ 50,000 UNITS BASE	A085479	001
EVERYLIFE	EQ 50,000 UNITS BASE	A080943	001
	EQ 50,000 UNITS BASE	A083114	001
IMPAX LABS	EQ 50,000 UNITS BASE	A080953	001
	EQ 50,000 UNITS BASE	A080955	001
IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035	001
	EQ 50,000 UNITS BASE	A083190	001
MK LABS	EQ 25,000 UNITS BASE	A083457	002
	EQ 50,000 UNITS BASE	A083457	001
WEST WARD	EQ 50,000 UNITS BASE	A080967	001
WHARTON LABS	EQ 50,000 UNITS BASE	A083665	001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311	001
	EQ 50,000 UNITS BASE	A083321	001
BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948	001
	EQ 50,000 UNITS BASE	A083981	001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921	001
------	----------------------	---------	-----

INJECTABLE; INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001
---------	-------------------------	---------	-----

WARFARIN POTASSIUM

TABLET; ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771	007
	5MG	N011771	004
	10MG	N011771	005
	25MG	N011771	006

DISCONTINUED DRUG PRODUCT LIST

6-335 (of 337)

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB	5MG/VIAL	N009218 024	Feb 07, 1995
	50MG/VIAL	N009218 020	
	75MG/VIAL	N009218 012	

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC	5MG	N011771 003
	10MG	N011771 002
	25MG	N011771 001

PANWARFIN

ABBOTT	2MG	N017020 001
	2.5MG	N017020 002
	5MG	N017020 003
	7.5MG	N017020 004
	10MG	N017020 005

WARFARIN SODIUM

SANDOZ

1MG	A040196 001	Sep 30, 1997
2MG	A040196 002	Sep 30, 1997
2.5MG	A040196 003	Sep 30, 1997
3MG	A040196 008	Jul 26, 2000
4MG	A040196 004	Sep 30, 1997
5MG	A040196 005	Sep 30, 1997
6MG	A040196 009	Jul 26, 2000
7.5MG	A040196 006	Sep 30, 1997
10MG	A040196 007	Sep 30, 1997

USL PHARMA

2MG	A088719 001	Jun 27, 1985
2.5MG	A088720 001	Aug 06, 1985

WATSON LABS

5MG	A088721 001	Jul 02, 1985
2MG	A086123 001	Aug 17, 1982
2.5MG	A086120 001	Aug 17, 1982
5MG	A086119 001	Aug 17, 1982
7.5MG	A086118 001	Aug 17, 1982
10MG	A086122 001	Aug 17, 1982

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT	5mCi/VIAL	N018536 001	Oct 01, 1982
	10mCi/VIAL	N018536 002	Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE	1 CI/AMP	N017256 002	
	10mCi/VIAL	N017687 002	
	20mCi/VIAL	N017687 003	
GEN ELECTRIC	5-100 CI/CYLINDER	N017550 001	
	0.25-5 CI/AMP	N017550 003	
MALLINCKRODT	10mCi/VIAL	N018327 001	Mar 09, 1982
	20mCi/VIAL	N018327 002	Mar 09, 1982

XENON XE 133-V.S.S.

GE HEALTHCARE	10mCi/VIAL	N017687 001
---------------	------------	-------------

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE	1.3-1.7 CI/AMP	N017256 001
LANTHEUS MEDCL	6.3mCi/ML	N017283 001

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT	18-25mCi/AMP	N017262 002
--------------	--------------	-------------

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS	25GM/BOT	N017605 001
-------------	----------	-------------

XYLOSE

LYNE	25GM/BOT	N018856 001	Mar 26, 1987
------	----------	-------------	--------------

DISCONTINUED DRUG PRODUCT LIST

6-336 (of 337)

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

SANDOZ

5MG

A078095 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

JAZZ PHARMS INTL

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

TABLET; ORAL

RETROVIR

VIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

300MG

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI USA INC

300MG

N020471 001 Dec 09, 1996

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

NOVARTIS

EQ 4MG BASE/VIAL **Federal Register
determination that product was not
discontinued or withdrawn for safety or
efficacy reasons**

N021223 001 Aug 20, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD

5MG

A077985 001 Apr 23, 2007

10MG

A077985 002 Apr 23, 2007

MUTUAL PHARMA

5MG

A077288 001 Apr 23, 2007

10MG

A077288 002 Apr 23, 2007

MYLAN PHARMS INC

5MG

A078016 001 Apr 23, 2007

10MG

A078016 002 Apr 23, 2007

SYNTHON PHARMS

5MG

A077540 001 Apr 23, 2007

10MG

A077540 002 Apr 23, 2007

VIVIMED LABS

5MG

A076062 001 Apr 23, 2007

10MG

A076062 002 Apr 23, 2007

WATSON LABS

5MG

A077773 001 Apr 23, 2007

10MG

A077773 002 Apr 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

TOVALT ODT

BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007

10MG

N021412 002 Apr 25, 2007

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

ANI PHARMS INC

25MG

A077639 001 Dec 22, 2005

25MG

A077641 003 Dec 22, 2005

50MG

A077639 002 Dec 22, 2005

50MG

A077641 002 Dec 22, 2005

100MG

A077639 003 Dec 22, 2005

100MG

A077641 001 Dec 22, 2005

DISCONTINUED DRUG PRODUCT LIST

6-337 (of 337)

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

COREPHARMA	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
DR REDDYS LABS LTD	25MG	A077645 002	Sep 29, 2006
	50MG	A077645 003	Sep 29, 2006
	100MG	A077645 001	Dec 22, 2005
MUTUAL PHARM	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005
	100MG	A077635 003	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SANDOZ	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005
WATSON LABS	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:
<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
 ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 160-165MG;160-165MG;50MG
 325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
 CAFFEINE
 CAPSULE OR TABLET; ORAL
 160-165MG;160-165MG;50MG;40MG
 325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
 TABLET; ORAL
 325MG;200MG

ACETAMINOPHEN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG;50MG

ASPIRIN;CARISOPRODOL;
 CODEINE PHOSPHATE
 TABLET; ORAL
 325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
 TABLET; ORAL
 325MG;200MG

AMINOPHYLLINE
 TABLET; ORAL
 100MG;200MG

ASPIRIN;METHOCARBAMOL
 TABLET; ORAL
 325MG;400MG

ASPIRIN;BUTALBITAL
 CAPSULE OR TABLET; ORAL
 325MG;50MG
 650MG;50MG

CHLOROTHIAZIDE
 TABLET; ORAL
 250MG

ASPIRIN;BUTALBITAL;CAFFEINE
 CAPSULE OR TABLET; ORAL
 325MG;50MG;40MG
 650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
 TABLET; ORAL
 10MG;25MG;
 50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
 TABLET; ORAL
 160MG;32MG;200MG

PREDNISONE
 TABLET; ORAL
 1MG;2.5MG;5MG;10MG;
 20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX**** 8 ****

8-MOP, METHOXSALEN

**** A ****

A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIRAZOLE
ABILIFY MAINTENA KIT, ARIPIRAZOLE
ABLAVAR, GADOFOSVESET TRISODIUM
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEON, PERINDOPRIL ERBUMINE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACOVA, ARGATROBAN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIQUAT
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADRENAClick, EPINEPHRINE
ADRENALIN, EPINEPHRINE HYDROCHLORIDE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVICOR, LOVASTATIN
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFREZZA, INSULIN RECOMBINANT HUMAN
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOL, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AK-FLUOR 10%, FLUORESCCEIN SODIUM
AK-FLUOR 25%, FLUORESCCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKINETON, BIPERIDEN HYDROCHLORIDE
AKNE-MYCIN, ERYTHROMYCIN
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAIN HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALSUMA, SUMATRIPTAN SUCCINATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX**** A ****

AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTEC, AMPHOTERICIN B
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMTURNIDE, ALISKIREN HEMIFUMARATE
AMYVID, FLORBETAPIR F-18
AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX, NAPROXEN SODIUM
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANSAID, FLURBIPROFEN
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** A ****

ANTIZOL, FOMEPIZOLE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APIDRA, INSULIN GLULISINE RECOMBINANT
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREPITANT, APREPITANT
APRISO, MESALAMINE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARALEN, CHLOROQUINE PHOSPHATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARCAPTA NEOHALER, INDACATEROL MALEATE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARICEPT, DONEPEZIL HYDROCHLORIDE
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARIMIDEX, ANASTROZOLE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ARIXTRA, FONDAPARINUX SODIUM
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARTHROTEC, DICLOFENAC SODIUM
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ASACOL, MESALAMINE
ASACOL HD, MESALAMINE
ASCLERA, POLIDOCANOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN, ASPIRIN (OTC)
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASTAGRAF XL, TACROLIMUS
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATIVAN, LORAZEPAM
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRAURIUM BESYLATE, ATRACURIUM BESYLATE
ATRAURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROVENT, IPRATROPIUM BROMIDE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN

APPENDIX A - PRODUCT NAME INDEX**** A ****

AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVEED, TESTOSTERONE UNDECANOATE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVINZA, MORPHINE SULFATE
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AXERT, ALMOTRIPTAN MALATE
AXID, NIZATIDINE
AXID AR, NIZATIDINE (OTC)
AXIRON, TESTOSTERONE
AYGESTIN, NORETHINDRONE ACETATE
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BELEODAQ, BELINOSTAT

APPENDIX A - PRODUCT NAME INDEX**** B ****

BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAFLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZAMYCIN PAK, BENZOYL PEROXIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BIAXIN, CLARITHROMYCIN
BIAXIN XL, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONTRIL, PHENDIMETRAZINE TARTRATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BOSULIF, BOSUTINIB MONOHYDRATE
BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
BRAVELLE, UROFOLLITROPIN
BREGO ELLIPTA, FLUTICASONE FUROATE
BRETILUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETILUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIELLYN, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** B ****

BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRINTELLIX, VORTIOXETINE HYDROBROMIDE
BRISDELLE, PAROXETINE MESYLATE
BROMDAY, BROMFENAC SODIUM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTISOL SODIUM, BUTABARBITAL SODIUM
BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

C-SOLVE-2, ERYTHROMYCIN
CABERGOLINE, CABERGOLINE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIJEX, CALCITRIOL
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALDOLOR, IBUPROFEN
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPRAL, ACAMPROSATE CALCIUM

APPENDIX A - PRODUCT NAME INDEX**** C ****

CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANTIL, MEPENZOLATE BROMIDE
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL AND CODEINE, ACETAMINOPHEN
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPOTEN, CAPTOPRIL
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CASODEX, BICALUTAMIDE
CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEDAX, CEFTIBUTEN DIHYDRATE
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETAMIDE, SULFACETAMIDE SODIUM
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CEVIMELINE, CEVIMELINE HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** C ****

CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN, CEFOTAXIME SODIUM
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLINORIL, SULINDAC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLOPIDOGREL, CLOPIDOGREL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLOROTHALIDONE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE, POLYETHYLENE GLYCOL 3350
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT, ALBUTEROL SULFATE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONSTULOSE, LACTULOSE
CONTRACE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDARONE, AMIODARONE HYDROCHLORIDE
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** C ****

COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COUMADIN, WARFARIN SODIUM
COVERA-HS, VERAPAMIL HYDROCHLORIDE
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOSAR-U, CYTARABINE
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM
CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DAUNOXOME, DAUNORUBICIN CITRATE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSE, METYROSINE
DENA VIR, PENCICLOVIR SODIUM
DENDRID, IDOXURIDINE
DEPA CON, VALPROATE SODIUM
DEPA KENE, VALPROIC ACID
DEPA KOTE, DIVALPROEX SODIUM
DEPA KOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DES LorATADINE, DES LorATADINE
DES LorATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DES LorATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DES OXYN, METHAMPHETAMINE HYDROCHLORIDE
DES VENLAFAXINE, DES VENLAFAXINE
DES VENLAFAXINE, DES VENLAFAXINE FUMARATE
DETROL, TOLTERODINE TARTRATE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM , DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
DIDRONEL, ETIDRONATE DISODIUM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILT-CD, DILTIAZEM HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DISULFIRAM , DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCEFREZ, DOCETAXEL
DOCETAXEL, DOCETAXEL
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORIBAX, DORIPENEM
DORYX, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXTERIC, DOXYCYCLINE HYCLATE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROXIA, HYDROXYUREA
DTIC-DOME, DACARBAZINE
DTPA, TECHNETIUM TC-99M PENTETATE KIT

APPENDIX A - PRODUCT NAME INDEX**** D ****

DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUONEB, ALBUTEROL SULFATE
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYLOJECT, DICLOFENAC SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELIDEL, PIMECROLIMUS
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCES, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE

APPENDIX A - PRODUCT NAME INDEX**** E ****

EMBEDA, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRIVA, EMTRICITABINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENFLURANE, ENFLURANE
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENULOSE, LACTULOSE
EOVIST, GADOXETATE DISODIUM
EPANED KIT, ENALAPRIL MALEATE
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
EPIDUO, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHRO-STATIN, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN

APPENDIX A - PRODUCT NAME INDEX**** E ****

ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADERM, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHRANE, ENFLURANE
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVZIO, NALOXONE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE

APPENDIX A - PRODUCT NAME INDEX**** F ****

FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FASLODEX, FULVESTRANT
FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)
FEMTRACE, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIC CITRATE, FERRIC CITRATE
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRMAGON, DEGARELIX ACETATE
FLAGYL, METRONIDAZOLE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLO-PRED, PREDNISOLONE ACETATE
FLOLAN, EPOPROSTENOL SODIUM
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE, FLUTICASONE PROPIONATE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

APPENDIX A - PRODUCT NAME INDEX**** F ****

FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXIN OTIC, OFLOXACIN
FLOXURIDINE, FLOXURIDINE
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCIEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORADIL, FORMOTEROL FUMARATE
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FORTICAL, CALCITONIN SALMON RECOMBINANT
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS

APPENDIX A - PRODUCT NAME INDEX**** F ****

FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULYZAQ, CROFELEMER
FURADANTIN, NITROFURANTOIN
FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GELNIQUE 3%, OXYBUTYNIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD
GILOTRIF, AFATINIB DIMALEATE
GLEEVEC, IMATINIB MESYLATE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON RECOMBINANT
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUCOVANCE, GLYBURIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE

APPENDIX A - PRODUCT NAME INDEX**** G ****

GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRIFULVIN V, GRISEOFULVIN, MICROSIZE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
GYNE-LOTRIMIN, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
HABITROL, NICOTINE (OTC)
HALAVEN, ERIBULIN MESYLATE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
HEPSERA, ADEFOVIR DIPIVOXIL
HERPLEX, IDOXURIDINE

APPENDIX A - PRODUCT NAME INDEX**** H ****

HETLIOZ, TASIMELTEON
HEXABRIX, IOXAGLATE MEGLUMINE
HEXALEN, ALTRETAMINE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
HICON, SODIUM IODIDE I-131
HIPREX, METHENAMINE HIPPURATE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HORIZANT, GABAPENTIN ENACARBIL
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HYCANTIN, TOPOTECAN HYDROCHLORIDE
HYDERGINE, ERGOLOID MESYLATES
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDREA, HYDROXYUREA
HYDRO-RX, HYDROCORTISONE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
HYDROCORTISONE, HYDROCORTISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN
HYSINGLA, HYDROCODONE BITARTRATE
HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBU-TAB, IBUPROFEN
IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)

APPENDIX A - PRODUCT NAME INDEX**** I ****

IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILUVIEN, FLUOCINOLONE ACETONIDE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM, LOPERAMIDE HYDROCHLORIDE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPLANON, ETNOGESTREL
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCIVEK, TELAPREVIR
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INJECTAFER, FERRIC CARBOXYMALTOSIDE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSPIRA, EPLERENONE
INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE

APPENDIX A - PRODUCT NAME INDEX**** I ****

INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IOPIDINE, APRACLOINIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN RECOMBINANT
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE
IZBA, TRAVOPROST

**** J ****

JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JUBLIA, EFINAACONAZOLE
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** J ****

JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE

**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETEK, TELITHROMYCIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KHEDEZLA, DESVENLAFAXINE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYNAMRO, MIPOMERSEN SODIUM
KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCLORIDE, LABETALOL HYDROCHLORIDE
LAC-HYDRIN, AMMONIUM LACTATE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE

APPENDIX A - PRODUCT NAME INDEX**** L ****

LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPRENE, CLOFAZIMINE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE , LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LESCOL, FLUVASTATIN SODIUM
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVAQUIN, LEVOFLOXACIN
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHROID, LEVOTHYROXINE SODIUM **

APPENDIX A - PRODUCT NAME INDEX**** L ****

LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIPTRUZET, ATORVASTATIN CALCIUM
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LO/OVRAL-28, ETHINYL ESTRADIOL
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOMOTIL, ATROPINE SULFATE
LONOX, ATROPINE SULFATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX

APPENDIX A - PRODUCT NAME INDEX**** L ****

LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUFYLLIN, DYPHYLLINE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUVOX CR, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYRICA, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10%, MANNITOL
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
MANNITOL 15%, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL

APPENDIX A - PRODUCT NAME INDEX**** M ****

MANNITOL 20%, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAXAIR, PIRBUTEROL ACETATE
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-76R, DIATRIZOATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MEBENDAZOLE, MEBENDAZOLE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE, MEGESTROL ACETATE
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MELOXICAM, MELOXICAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMBRANEBLUE, TRYPTAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** M ****

METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** M ****

MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)

APPENDIX A - PRODUCT NAME INDEX**** M ****

MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOZOBIL, PLERIXAFOR
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN
MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYSOLINE, PRIMIDONE
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE

APPENDIX A - PRODUCT NAME INDEX**** N ****

NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE MONOHYDRATE
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATRECOR, NESIRITIDE RECOMBINANT
NATROBA, SPINOSAD
NAVANE, THIOTHIXENE
NAVELBINE, VINORELBINE TARTRATE
NAVSTEL, CALCIUM CHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETNOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NIPENT, PENTOSTATIN
NISOLDIPINE, NISOLDIPINE

APPENDIX A - PRODUCT NAME INDEX**** N ****

NITHIODE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDETTE-28, ETHINYL ESTRADIOL
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORFLEX, ORPHENADRINE CITRATE
NORGESIC, ASPIRIN
NORGESIC FORTE, ASPIRIN
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORITATE, METRONIDAZOLE
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
NORPACE, DISOPYRAMIDE PHOSPHATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
NORTHERA, DROXIDOPA
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NORVASC, AMLODIPINE BESYLATE
NORVIR, RITONAVIR
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOXAFIL, POSACONAZOLE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

APPENDIX A - PRODUCT NAME INDEX**** N ****

NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
NUTRACORT, HYDROCORTISONE
NUTRESTORE, GLUTAMINE
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
NUTROPIN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUVARING, ETHINYL ESTRADIOL
NUVIGIL, ARMODAFINIL
NYMALIZE, NIMODIPINE
NYSTATIN, NYSTATIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTOP, NYSTATIN

**** O ****

OBREDON, GUAIFENESIN
OCTOCAINE, EPINEPHRINE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
OCUFEN, FLURBIPROFEN SODIUM
OCUFLOX, OFLOXACIN
OCUPRESS, CARTEOLOL HYDROCHLORIDE
OFEV, NINTEDANIB
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLAPARIB, OLAPARIB
OLEPTRO, TRAZODONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OLYSIO, SIMEPREVIR SODIUM
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
OMTRYG, OMEGA-3-ACID ETHYL ESTERS
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** O ****

ONMEL, ITRACONAZOLE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIMARK, GADOVERSETAMIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPTIVAR, AZELASTINE HYDROCHLORIDE
ORABLOC, ARTICAIN HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAP, PIMOZIDE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORETIC, HYDROCHLOROTHIAZIDE
ORFADIN, NITISINONE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORSYTHIA, ETHINYL ESTRADIOL
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO EVRA, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO-CEPT, DESOGESTREL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
ORVATEN, MIDODRINE HYDROCHLORIDE
OSEN, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
OSPHENA, OSPEMIFENE
OTEZLA, APREMILAST
OTICAIR, HYDROCORTISONE
OTREXUP, METHOTREXATE
OVCON-35, ETHINYL ESTRADIOL
OVIDE, MALATHION
OVIDREL, CHORIOGONADOTROPIN ALFA
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXANDRIN, OXANDROLONE
OXANDROLONE, OXANDROLONE
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE, OXYCODONE HYDROCHLORIDE
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

APPENDIX A - PRODUCT NAME INDEX**** O ****

OXISTAT, OXICONAZOLE NITRATE
OXSORALEN, METHOXSALEN
OXSORALEN-ULTRA, METHOXSALEN
OXTELLAR XR, OXCARBAZEPINE
OXYBUTYNIN, OXYBUTYNIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCONTIN, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
OXYTROL, OXYBUTYNIN
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PAMINE, METHSCOPOLAMINE BROMIDE
PAMINE FORTE, METHSCOPOLAMINE BROMIDE
PANCREAZE, PANCRELIPASE (AMYLASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAFON FORTE DSC, CHLORZOXAZONE
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANLYCYPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEDIOTIC, HYDROCORTISONE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL 3350
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM

APPENDIX A - PRODUCT NAME INDEX**** P ****

PENTAM, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERTZYE, PANCRELIPASE (AMYLASE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHILITH, ETHINYL ESTRADIOL
PHISOHEX, HEXACHLOROPHENE
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITOCIN, OXYTOCIN
PLAN B, LEVONORGESTREL (OTC)
PLAN B, LEVONORGESTREL
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

APPENDIX A - PRODUCT NAME INDEX**** P ****

PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLENDIL, FELODIPINE
PLETAL, CILOSTAZOL
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE

** P **

[illegible]

APPENDIX A - PRODUCT NAME INDEX**** P ****

POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISON, PREDNISON
PREDNISON INTENSOL, PREDNISON
PREGABALIN, PREGABALIN
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINAPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PUR-WASH, PURIFIED WATER (OTC)
PURIXAN, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL
QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUIXIN, LEVOFLOXACIN
QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REGITINE, PHENTOLAMINE MESYLATE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE

APPENDIX A - PRODUCT NAME INDEX**** R ****

RELPAK, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
REVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPREXAIN, HYDROCODONE BITARTRATE
REPRONEX, MENOTROPINS (FSH
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESCULA, UNOPROSTONE ISOPROPYL
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESERPINE, RESERPINE
RESTASIS, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVIA, NALTREXONE HYDROCHLORIDE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT, BUDESONIDE
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCEPHIN, CEFTRIAXONE SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

APPENDIX A - PRODUCT NAME INDEX**** R ****

ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROWASA, MESALAMINE
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
RYANODEX, DANTROLENE SODIUM
RYTHMOL, PROPAFENONE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SALURON, HYDROFLUMETHIAZIDE
SAMSCA, TOLVAPTAN
SANCTURA, TROSPIMUM CHLORIDE
SANCTURA XR, TROSPIMUM CHLORIDE
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELFEMRA, FLUOXETINE HYDROCHLORIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SEROMYCIN, CYCLOSERINE
SEROPHENE, CLOMIPHENE CITRATE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVOFLURANE, SEVOFLURANE
SFROWASA, MESALAMINE
SHADE UVAGUARD, AVOBENZONE (OTC)
SIGNIFOR, PASIREOTIDE DIASPARTATE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SIGNIFOR LAR, PASIREOTIDE PAMOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMCOR, NIACIN
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM IODIDE I-131, SODIUM IODIDE I-131
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA, CARISOPRODOL
SOMA COMPOUND, ASPIRIN
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTRET, ISOTRETINOIN

APPENDIX A - PRODUCT NAME INDEX**** S ****

SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPECTRACEF, CEFDITOREN PIVOXIL
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD, SILVER SULFADIAZINE
SSD AF, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCLEAR, MAGNESIUM SULFATE
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
SUNITINIB MALATE, SUNITINIB MALATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPRENZA, PHENTERMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS
SURFAXIN, LUCINACTANT
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMLIN, PRAMLINTIDE ACETATE
SYNACORT, HYDROCORTISONE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNAREL, NAFARELIN ACETATE
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TAFINLAR, DABRAFENIB MESYLATE
TAGAMET HB, CIMETIDINE (OTC)
TALC, TALC
TALWIN, PENTAZOCINE LACTATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKTRNA, ALISKIREN HEMIFUMARATE
TEKTRNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOVATE, CLOBETASOL PROPIONATE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TEMOVATE E, CLOBETASOL PROPIONATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENSILON, EDROPHONIUM CHLORIDE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEV-TROPIN, SOMATROPIN RECOMBINANT
TEVETEN, EPROSARTAN MESYLATE
TEVETEN HCT, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALITONE, CHLORTHALIDONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOLAIR, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA
THYROLAR-0.25, LIOTRIX (T4
THYROLAR-0.5, LIOTRIX (T4
THYROLAR-1, LIOTRIX (T4
THYROLAR-2, LIOTRIX (T4
THYROLAR-3, LIOTRIX (T4
THYROSAFE, POTASSIUM IODIDE (OTC)
THYROSHIELD, POTASSIUM IODIDE (OTC)
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TIAZAC, DILTIAZEM HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TIKOSYN, DOFETILIDE
TIMENTIN, CLAVULANATE POTASSIUM
TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
TINDAMAX, TINIDAZOLE
TINIDAZOLE, TINIDAZOLE
TIOCONAZOLE, TIOCONAZOLE (OTC)
TIROSINT, LEVOTHYROXINE SODIUM
TIS-U-SOL, MAGNESIUM SULFATE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIVICAY, DOLUTEGRAVIR SODIUM
TIVORBEX, INDOMETHACIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBI, TOBRAMYCIN
TOBI PODHALER, TOBRAMYCIN
TOBRADEX, DEXAMETHASONE
TOBRADEX ST, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBREX, TOBRAMYCIN
TODAY, NONOXYNOL-9 (OTC)
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOFRANIL-PM, IMIPRAMINE PAMOATE
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPIRAMATE , TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOTECT, DEXRAZOXANE HYDROCHLORIDE
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSDERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TRECATOR, ETHIONAMIDE
TRELSTAR, TRIPTORELIN PAMOATE
TRETINOIN, TRETINOIN
Trexall, METHOTREXATE SODIUM
Treximet, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHXYPHENIDYL HYDROCHLORIDE, TRIHXYPHENIDYL HYDROCHLORIDE
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRIOSTAT, LIOTHYRONINE SODIUM
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
Trokendi XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS
TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPiUM CHLORIDE, TROSPiUM CHLORIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE
TWINSTA, AMLODIPINE BESYLATE
TYBOST, COBICISTAT
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL, ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYVASO, TREPROSTINIL
TYZEKA, TELBIVUDINE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE

UCERIS, BUDESONIDE

ULESFIA, BENZYL ALCOHOL

ULORIC, FEBUXOSTAT

ULTANE, SEVOFLURANE

ULTIVA, REMIFENTANIL HYDROCHLORIDE

ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

ULTRACET, ACETAMINOPHEN

ULTRAM, TRAMADOL HYDROCHLORIDE

ULTRAM ER, TRAMADOL HYDROCHLORIDE

ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT

ULTRAVATE, HALOBETASOL PROPIONATE

ULTRAVIST (PHARMACY BULK), IOPROMIDE

ULTRAVIST 150, IOPROMIDE

ULTRAVIST 240, IOPROMIDE

ULTRAVIST 300, IOPROMIDE

ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE

ULTRAVIST 370, IOPROMIDE

ULTRESA, PANCRELIPASE (AMYLASE

UNASYN, AMPICILLIN SODIUM

UNIPHYL, THEOPHYLLINE

UNIRETIC, HYDROCHLOROTHIAZIDE

UNISOM, DOXYLAMINE SUCCINATE (OTC)

UNITHROID, LEVOTHYROXINE SODIUM **

UNIVASC, MOEXIPRIL HYDROCHLORIDE

URECHOLINE, BETHANECHOL CHLORIDE

UREX, METHENAMINE HIPPURATE

UROCIT-K, POTASSIUM CITRATE

UROXATRAL, ALFUZOSIN HYDROCHLORIDE

URSO 250, URSODIOL

URSO FORTE, URSODIOL

URSODIOL, URSODIOL

UVADEX, METHOXSALEN

**** V ****

VAGIFEM, ESTRADIOL

VAGISTAT-1, TIOCONAZOLE (OTC)

VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

VALCYTE, VALGANCICLOVIR HYDROCHLORIDE

VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

VALIUM, DIAZEPAM

VALNAC, BETAMETHASONE VALERATE

VALPROATE SODIUM, VALPROATE SODIUM

VALPROIC ACID, VALPROIC ACID

VALSARTAN, VALSARTAN

VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

VALSTAR PRESERVATIVE FREE, VALRUBICIN

VALTREX, VALACYCLOVIR HYDROCHLORIDE

VALTROPIN, SOMATROPIN RECOMBINANT

VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

VANDAZOLE, METRONIDAZOLE

VANIQA, EFLORNITHINE HYDROCHLORIDE

VANOS, FLUOCINONIDE

VANTAS, HISTRELIN ACETATE

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

VARITHENA, POLIDOCANOL

VASCEPA, ICOSAPENT ETHYL

VASERETIC, ENALAPRIL MALEATE

APPENDIX A - PRODUCT NAME INDEX**** V ****

VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTIN, CLINDAMYCIN PHOSPHATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAMYST, FLUTICASONE FUROATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERSACLOZ, CLOZAPINE
VESICARE, SOLIFENACIN SUCCINATE
VEXOL, RIMEXOLONE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICOPROFEN, HYDROCODONE BITARTRATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VICTRELIS, BOCEPREVIR
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE, VINORELBINE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTIDE, CIDOFOVIR
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITEKTA, ELVITEGRAVIR
VITRASE, HYALURONIDASE

APPENDIX A - PRODUCT NAME INDEX**** V ****

VITUZ, CHLORPHENIRAMINE MALEATE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIZAMYL, FLUTEMETAMOL F-18
VOGELXO, TESTOSTERONE
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VUMON, TENIPOSIDE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**** W ****

WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN, BUPROPION HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WOMEN'S ROGAINE, MINOXIDIL (OTC)

**** X ****

XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARELTO, RIVAROXABAN
KARTEMIS XR, ACETAMINOPHEN
XELJANZ, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENON XE 133, XENON XE-133
XERESE, ACYCLOVIR
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN
XOFIGO, RADIUM RA-223 DICHLORIDE
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XTANDI, ENZALUTAMIDE
XTORO, FINAFLOXACIN
XULANE, ETHINYL ESTRADIOL
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

**** Y ****

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEBETA, BISOPROLOL FUMARATE
ZECUITY, SUMATRIPTAN SUCCINATE
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZERBAXA, CEFTOLOZANE SULFATE
ZERIT, STAVUDINE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINAPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZINACEF, CEFUROXIME SODIUM
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUPLENZ, ONDANSETRON
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC, CETIRIZINE HYDROCHLORIDE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3M**

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)
- * 3M PHARMACEUTICALS INC
PROVENTIL-HFA, ALBUTEROL SULFATE

**** A ******AAIPHARMA LLC**

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ADVICOR, LOVASTATIN
AKINETON, BIPERIDEN HYDROCHLORIDE
ANDROGEL, TESTOSTERONE
BIAXIN XL, CLARITHROMYCIN
BIAXIN, CLARITHROMYCIN
CALCIJEX, CALCITRIOL
CREON, PANCRELIPASE (AMYLASE
CYCLOSPORINE, CYCLOSPORINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
ORETIC, HYDROCHLOROTHIAZIDE
SIMCOR, NIACIN
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TEVETEN HCT, EPROSARTAN MESYLATE
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
VICOPROFEN, HYDROCODONE BITARTRATE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE

- * ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

ABBVIE INC

- * ABBVIE INC
PROMETRIUM, PROGESTERONE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM

ABRAXIS BIOSCIENCE

- * ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

ABRAXIS PHARM

- * ABRAXIS PHARMACEUTICAL PRODUCTS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ABRAXIS PHARMACEUTICAL PRODUCTS**

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACADEMIC PHARMS*** ACADEMIC PHARMACEUTICALS INC**

SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ACCELRX LABS*** ACCELRX LABS LLC**

CARISOPRODOL, CARISOPRODOL

ACCORD HLTHCARE*** ACCORD HEALTHCARE INC**

ALLOPURINOL, ALLOPURINOL

AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

ANASTROZOLE, ANASTROZOLE

BICALUTAMIDE, BICALUTAMIDE

BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

CARBIDOPA AND LEVODOPA, CARBIDOPA

CLONAZEPAM, CLONAZEPAM

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

DOCETAXEL, DOCETAXEL

DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

ETOPOSIDE, ETOPOSIDE

FINASTERIDE, FINASTERIDE

FLUOROURACIL, FLUOROURACIL

GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

GLIMEPIRIDE, GLIMEPIRIDE

GLIPIZIDE, GLIPIZIDE

HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

LETROZOLE, LETROZOLE

LEVETIRACETAM, LEVETIRACETAM

LISINAPRIL, LISINAPRIL

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

METHYLDOPA, METHYLDOPA

MITOMYCIN, MITOMYCIN

MONTELUKAST SODIUM, MONTELUKAST SODIUM

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE

PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

SIMVASTATIN, SIMVASTATIN

TACROLIMUS, TACROLIMUS

TOPIRAMATE, TOPIRAMATE

TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

ACCORD HLTHCARE INC*** ACCORD HEALTHCARE INC USA**

FINASTERIDE, FINASTERIDE

RAMIPRIL, RAMIPRIL

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACELLA PHARMS LLC*** ACELLA PHARMACEUTICALS LLC**

GABAPENTIN, GABAPENTIN

ACI HEALTHCARE LTD*** ACI HEALTHCARE LTD**

GABAPENTIN, GABAPENTIN

ACIC FINE CHEMS*** ACIC FINE CHEMICALS INC**

TRANEXAMIC ACID, TRANEXAMIC ACID

ACORDA*** ACORDA THERAPEUTICS INC**

AMPYRA, DALFAMPRIDINE

QUTENZA, CAPSAICIN

ZANAFLEX, TIZANIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ACS DOBFAR**

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
KEFZOL, CEFZOLIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR INFO SA

* ACS DOBFAR INFO SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCANAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM

ACTAVIS

* ACTAVIS SOUTHATLANTIC LLC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
MORPHINE SULFATE, MORPHINE SULFATE
NIFEDIPINE, NIFEDIPINE
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS GRP PTC

* ACTAVIS GROUP PTC EHF
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS GROUP PTC EHF
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

ACTAVIS INC

* ACTAVIS INC
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACTAVIS LABS FL INC

* ACTAVIS LABORATORIES FL INC
ALPRAZOLAM, ALPRAZOLAM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FLUTAMIDE, FLUTAMIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KETOPROFEN, KETOPROFEN
LEVETIRACETAM, LEVETIRACETAM
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NORCO, ACETAMINOPHEN
OMEPRazole, OMEPRazole
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS NY INC

* ACTAVIS LABORATORIES NY INC
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
ANDRODERM, TESTOSTERONE

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
ACETASOL HC, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS MID ATLANTIC LLC
 CICLOPIROX, CICLOPIROX
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 CONSTULOSE, LACTULOSE
 ENULOSE, LACTULOSE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
 PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 VALNAC, BETAMETHASONE VALERATE

ACTAVIS TOTOWA

* ACTAVIS TOTOWA LLC
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FINASTERIDE, FINASTERIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 REPAGLINIDE, REPAGLINIDE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION PHARMS LTD

* ACTELION PHARMACEUTICALS LTD
 OPSUMIT, MACITENTAN
 TRACLEER, BOSENTAN
 VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
 VELETRI, EPOPROSTENOL SODIUM
 VENTAVIS, ILOPROST
 ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

* ACTIENT PHARMACEUTICALS LLC
 TESTOPEL, TESTOSTERONE
 THEO-24, THEOPHYLLINE

ACTIVIS TOTOWA LLC

* ACTIVIS TOTOWA LLC
 TOPIRAMATE, TOPIRAMATE

ACURA PHARMS INC

* ACURA PHARMACEUTICALS INC
 OXECTA, OXYCODONE HYDROCHLORIDE

AEGERION

* AEGERION PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

AGILA SPECLTS

* AGILA SPECIALTIES PRIVATE LTD
ADENOSINE, ADENOSINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
ETOMIDATE, ETOMIDATE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MESNA, MESNA
NAFCILLIN SODIUM, NAFCILLIN SODIUM
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
RIFAMPIN, RIFAMPIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AGOURON

* AGOURON PHARMACEUTICALS INC
VIRACEPT, NELFINAVIR MESYLATE

AJANTA PHARMA

* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
RISPERIDONE, RISPERIDONE

AKORN

* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCCEIN SODIUM
AK-FLUOR 25%, FLUORESCCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CROMOLYN SODIUM, CROMOLYN SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENDOSOL EXTRA, CALCIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN INC**

ERYTHROMYCIN, ERYTHROMYCIN
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

AKORN INC*** AKORN INC**

APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAZONE, CEFTRIAZONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DRONABINOL, DRONABINOL
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALARA PHARM*** ALARA PHARMACEUTICAL CORPORATION**

LEVO-T, LEVOTHYROXINE SODIUM **

ALCON*** ALCON INC**

TRIESENCE, TRIAMCINOLONE ACETONIDE

*** ALCON LABORATORIES INC**

ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CETAMIDE, SULFACETAMIDE SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALCON LABORATORIES INC**

CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DENDRID, IDOXURIDINE
EMADINE, EMEDASTINE DIFUMARATE
FLAREX, FLUOROMETHOLONE ACETATE
IOPIDINE, APRACLOMIDINE HYDROCHLORIDE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MIOSTAT, CARBACHOL
MYDRIACYL, TROPICAMIDE
NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NATACYN, NATAMYCIN
OMNIPRED, PREDNISOLONE ACETATE
PATANOL, OLOPATADINE HYDROCHLORIDE
PILOPINE HS, PILOCARPINE HYDROCHLORIDE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
VEXOL, RIMEXOLONE

ALCON LABS INC*** ALCON LABORATORIES INC**

CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
IZBA, TRAVOPROST

ALCON PHARMA*** ALCON RESEARCH LTD**

AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
ZADITOR, KETOTIFEN FUMARATE (OTC)

ALCON PHARMS LTD*** ALCON PHARMACEUTICALS LTD**

AZOPT, BRINZOLAMIDE
BETADINE, POVIDONE-IODINE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DUREZOL, DIFLUPREDNATE
FLUORESCITE, FLUORESCIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
NAVSTEL, CALCIUM CHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVANAC, NEPAFENAC
OFLOXACIN, OFLOXACIN
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
QOLIANA, BRIMONIDINE TARTRATE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TOBRADEX ST, DEXAMETHASONE
TRAVATAN Z, TRAVOPROST
TRIFLURIDINE, TRIFLURIDINE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE

ALCON RES*** ALCON RESEARCH LTD**

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
LATANOPROST, LATANOPROST

ALCON RES LTD*** ALCON RESEARCH LTD**

GENTAMICIN SULFATE, GENTAMICIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALCON RESEARCH LTD**

ILEVRO, NEPAFENAC

LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE

METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE

SIMBRINZA, BRIMONIDINE TARTRATE

TIMOLOL MALEATE, TIMOLOL MALEATE

XTORO, FINAFOXACIN

ALEMBIC LTD*** ALEMBIC LTD**

IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LITHIUM CARBONATE, LITHIUM CARBONATE

METRONIDAZOLE, METRONIDAZOLE

MODAFINIL, MODAFINIL

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

THEOPHYLLINE, THEOPHYLLINE

VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

ALEMBIC PHARMS LTD*** ALEMBIC PHARMACEUTICALS LTD**

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

DESVENLAFAXINE, DESVENLAFAXINE

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE

FAMOTIDINE, FAMOTIDINE

FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

IRBESARTAN, IRBESARTAN

LAMOTRIGINE, LAMOTRIGINE

LEFLUNOMIDE, LEFLUNOMIDE

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

MEPROBAMATE, MEPROBAMATE

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

METOPROLOL TARTRATE, METOPROLOL TARTRATE

METRONIDAZOLE, METRONIDAZOLE

QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

TELMISARTAN, TELMISARTAN

VALSARTAN, VALSARTAN

VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALIMERA SCIENCES INC*** ALIMERA SCIENCES INC**

ILUVIEN, FLUOCINOLONE ACETONIDE

ALKEM*** ALKEM LABORATORIES LTD**

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

GABAPENTIN, GABAPENTIN

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD*** ALKEM LABORATORIES LTD**

CEFUROXIME AXETIL, CEFUROXIME AXETIL

CEPHALEXIN, CEPHALEXIN

HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

LAMOTRIGINE, LAMOTRIGINE

MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALKERMES*** ALKERMES INC**

VIVITROL, NALTREXONE

ALKERMES GAINESVILLE*** ALKERMES GAINESVILLE LLC**

VERELAN PM, VERAPAMIL HYDROCHLORIDE

VERELAN, VERAPAMIL HYDROCHLORIDE

ALKOPHARMA USA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALKOPHARMA USA INC
AMPHOTEC, AMPHOTERICIN B

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
Zymaxid, Gatifloxacin

* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS, CYCLOSPORINE
SANCTURA XR, TROSPIMUM CHLORIDE
SANCTURA, TROSPIMUM CHLORIDE
TAZORAC, TAZAROTENE
Zymar, Gatifloxacin

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
HERPLEX, IDOXURIDINE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

ALLERQUEST

* ALLERQUEST LLC
PRE-PEN, BENZYL PENICILLOYL POLYLYSINE

ALLIED PHARMA INC

* ALLIED PHARMA INC
CLARITHROMYCIN, CLARITHROMYCIN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ALLOS

* ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

ALMATICA PHARMA INC

* ALMATICA PHARMA INC
NAPRELAN, NAPROXEN SODIUM

ALPHARMA

* ALPHARMA USPD INC
PREDNISOLONE, PREDNISOLONE
VALPROIC ACID, VALPROIC ACID

ALPHARMA PHARMS

* ALPHARMA PHARMACEUTICALS LLC
EMBEDA, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ALRA**

- * ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

ALTAIRE PHARMS INC

- * ALTAIRE PHARMACEUTICALS INC
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

ALVOGEN

- * ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

ALVOGEN INC

- * ALVOGEN INC
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EXEMESTANE, EXEMESTANE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

ALVOGEN PINE BROOK

- * ALVOGEN PINE BROOK INC
DISULFIRAM, DISULFIRAM

AM ANTIBIOTICS

- * AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

AMAG PHARMS INC

- * AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL

AMARIN PHARMS

- * AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

AMEDRA PHARMS

- * AMEDRA PHARMACEUTICALS LLC
ADRENALICK, EPINEPHRINE
ALBENZA, ALBENDAZOLE
DARAPRIM, PYRIMETHAMINE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
HYDROCORTISONE, HYDROCORTISONE
TWINJECT 0.15, EPINEPHRINE
TWINJECT 0.3, EPINEPHRINE

AMEDRA PHARMS LLC

- * AMEDRA PHARMACEUTICALS LLC
MEBENDAZOLE, MEBENDAZOLE

AMERIGEN PHARMS LTD

- * AMERIGEN PHARMACEUTICALS LTD
CARBIDOPA, CARBIDOPA

AMGEN

- * AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

AMNEAL PHARM

- * AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AMNEAL PHARMACEUTICALS**

ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ATOVAQUONE, ATOVAQUONE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL, CLOPIDOGREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 IBUPROFEN, IBUPROFEN (OTC)
 INDOMETHACIN, INDOMETHACIN
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE
 NITROFURANTOIN, NITROFURANTOIN
 NIZATIDINE, NIZATIDINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

*** AMNEAL PHARMACEUTICALS LLC**

TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

*** AMNEAL PHARMACEUTICALS OF NEW YORK LLC**

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL

AMNEAL PHARMS CO*** AMNEAL PHARMACEUTICALS CO GMBH**

FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM

AMNEAL PHARMS LLC*** AMNEAL PHARMACEUTICALS LLC**

ACTIVELLA, ESTRADIOL
 AZATHIOPRINE, AZATHIOPRINE

AMNEAL PHARMS NY*** AMNEAL PHARMACEUTICALS NY LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS NY LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN

AMPOLGEN

* AMPOLGEN PHARMACEUTICALS LLC
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
KERYDIN, TAVABOROLE

ANBEX

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
ALTOPREV, LOVASTATIN
FORTAMET, METFORMIN HYDROCHLORIDE

ANGELINI PHARMA

* ANGELINI PHARMA INC
OLEPTRO, TRAZODONE HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

ANI PHARMS INC

* ANI PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ANI PHARMACEUTICALS INC**

ALPRAZOLAM, ALPRAZOLAM

CHLORPROPAMIDE, CHLORPROPAMIDE

CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE

ETODOLAC, ETODOLAC

FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

GUANABENZ ACETATE, GUANABENZ ACETATE

ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

LITHOBID, LITHIUM CARBONATE

METHAZOLAMIDE, METHAZOLAMIDE

NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

NIZATIDINE, NIZATIDINE

PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE

PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

RISPERIDONE, RISPERIDONE

VALPROIC ACID, VALPROIC ACID

VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ANTARES PHARMA INC*** ANTARES PHARMA INC**

OTREXUP, METHOTREXATE

ANTIBIOTICE*** ANTIBIOTICE SA**

AMPICILLIN SODIUM, AMPICILLIN SODIUM

NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANTIBIOTICOS BRASIL*** ANTIBIOTICOS DO BRASIL LTDA**

CEFOXITIN, CEFOXITIN SODIUM

APGDI*** ASTELLAS PHARMA GLOBAL DEVELOPMENT INC**

MYRBETRIQ, MIRABEGRON

APOPHARMA INC*** APOPHARMA INC**

FERRIPROX, DEFERIPRONE

APOTEX*** APOTEX CORP**

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

*** APOTEX INC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM

AMLODIPINE BESYLATE, AMLDIPINE BESYLATE

CAPTOPRIL, CAPTOPRIL

CARBIDOPA AND LEVODOPA, CARBIDOPA

CEFUROXIME AXETIL, CEFUROXIME AXETIL

CIMETIDINE, CIMETIDINE

CIMETIDINE, CIMETIDINE (OTC)

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

CYCLOSPORINE, CYCLOSPORINE

DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM

DILT-CD, DILTIAZEM HYDROCHLORIDE

DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE

ENALAPRIL MALEATE, ENALAPRIL MALEATE

EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE

EPLERENONE, EPLERENONE

ETODOLAC, ETODOLAC

FAMCICLOVIR, FAMCICLOVIR

FAMOTIDINE, FAMOTIDINE

FLUCONAZOLE, FLUCONAZOLE

FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE

GEMFIBROZIL, GEMFIBROZIL

GLIPIZIDE, GLIPIZIDE

HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LAMIVUDINE, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* APOTEX INC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPiUM CHLORIDE, TROSPiUM CHLORIDE

APOTEX CORP*** APOTEX CORP**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
CABERGOLINE, CABERGOLINE
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APOTEX INC*** APOTEX INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCITONIN-SALMON, CALCITONIN SALMON
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CEVIMELINE, CEVIMELINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIQUIMOD, IMIQUIMOD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX INC
IRBESARTAN, IRBESARTAN
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIZAC, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * APOTEX INC ETOBICOKE SITE
 - SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 - SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - TORSEMIDE, TORSEMIDE
 - ZONISAMIDE, ZONISAMIDE
- * APOTEX INC RICHMOND HILL
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - BUDESONIDE, BUDESONIDE
 - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 - FLUNISOLIDE, FLUNISOLIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - RISPERIDONE, RISPERIDONE
- * APOTEX INC.
 - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

APOTEX TECHNOLOGIES

- * APOTEX TECHNOLOGIES INC
 - PAXIL CR, PAROXETINE HYDROCHLORIDE
 - PAXIL, PAROXETINE HYDROCHLORIDE

APOTHECON

- * APOTHECON INC DIV BRISTOL MYERS SQUIBB
 - KENALOG-10, TRIAMCINOLONE ACETONIDE
 - KENALOG-40, TRIAMCINOLONE ACETONIDE

APP PHARMS

- * APP PHARMACEUTICALS LLC
 - DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APTALIS PHARMA US

- * APTALIS PHARMA US INC
 - BENTYL, DICYCLOMINE HYDROCHLORIDE

APTALIS PHARMATECH

- * APTALIS PHARMATECH INC
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

AQUA PHARMS

- * AQUA PHARMACEUTICALS
 - CORDRAN SP, FLURANDRENOLIDE
 - CORDRAN, FLURANDRENOLIDE
 - MONODOX, DOXYCYCLINE
 - VERDESO, DESONIDE
- * AQUA PHARMACEUTICALS LLC
 - FLUOROPLEX, FLUOROURACIL
 - XOLEGEL, KETOCONAZOLE

AQUA PHARMS LLC

- * AQUA PHARMACEUTICALS LLC
 - ACTICLATE, DOXYCYCLINE HYCLATE

ARBOR PHARMS IRELAND

- * ARBOR PHARMACEUTICALS IRELAND LTD
 - EDARBI, AZILSARTAN KAMEDOXOMIL
 - EDARBYCLOR, AZILSARTAN KAMEDOXOMIL

ARBOR PHARMS LLC

- * ARBOR PHARMACEUTICALS LLC
 - AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 - BIDIL, HYDRALAZINE HYDROCHLORIDE
 - E.E.S. 200, ERYTHROMYCIN ETHYLSUCCINATE
 - E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 - E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
 - ERY-TAB, ERYTHROMYCIN
 - ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
 - ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 - ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 - ERYTHROMYCIN, ERYTHROMYCIN
 - GLIADEL, CARMUSTINE
 - NYMALIZE, NIMODIPINE
 - PCE, ERYTHROMYCIN
 - PEDIAMYCIN 400, ERYTHROMYCIN ETHYLSUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ARBOR PHARMACEUTICALS LLC
PEDIAMYCIN, ERYTHROMYCIN ETHYLSUCCINATE
SOTYLIZE, SOTALOL HYDROCHLORIDE

ARCO PHARMS LLC

* ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

ARIAD

* ARIAD PHARMACEUTICALS INC
ICLUSIG, PONATINIB HYDROCHLORIDE

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
ESTROGEL, ESTRADIOL

ASPEN GLOBAL

* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
LEUKERAN, CHLORAMBUCIL
THIOGUANINE, THIOGUANINE

ASTELLAS

* ASTELLAS PHARMA US INC
ADENOCARD, ADENOSINE
ADENOSCAN, ADENOSINE
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
PROTOPIC, TACROLIMUS
VESICARE, SOLIFENACIN SUCCINATE
XTANDI, ENZALUTAMIDE

ASTRAZENECA

* ASTRAZENECA LP
ENTOCORT EC, BUDESONIDE
PULMICORT FLEXHALER, BUDESONIDE
SEROQUEL, QUETIAPINE FUMARATE
SYMBICORT, BUDESONIDE
TENORMIN, ATENOLOL

* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
FASLODEX, FULVESTRANT
PLENDIL, FELODIPINE
SEROQUEL XR, QUETIAPINE FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN

* ASTRAZENECA UK LTD
ACCOLATE, ZAFIRLUKAST
ARIMIDEX, ANASTROZOLE
CASODEX, BICALUTAMIDE
MERREM, MEROPENEM
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZOLADEX, GOSERELIN ACETATE

ASTRAZENECA AB

* ASTRAZENECA AB
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
FARXIGA, DAPAGLIFLOZIN
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ASTRAZENECA AB
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
BRILINTA, TICAGRELOR
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ASTRAZENECA PHARMS

* ASTRAZENECA PHARMACEUTICALS LP
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
MOVANTIK, NALOXEGOL OXALATE
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
OLAPARIB, OLAPARIB
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRILOSEC, OMEPRAZOLE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PULMICORT RESPULES, BUDESONIDE
RHINOCORT, BUDESONIDE
TOPROL-XL, METOPROLOL SUCCINATE

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATON

* ATON PHARMA INC
CUPRIMINE, PENICILLAMINE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
LACRISERT, HYDROXYPROPYL CELLULOSE
LODOSYN, CARBIDOPA
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE

ATON PHARMA VPNA

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DEMSEER, METYROSINE

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DIDANOSINE, DIDANOSINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARM

* AUROBINDO PHARMA USA INC
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

AUROBINDO PHARMA

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 ATENOLOL, ATENOLOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIDANOSINE, DIDANOSINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RIBAVARIN, RIBAVIRIN
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD

* AUROBINDO PHARMA LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROBINDO PHARMA LTD**

AMOXICILLIN, AMOXICILLIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FAMCICLOVIR, FAMCICLOVIR
FELODIPINE, FELODIPINE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GLIMEPIRIDE, GLIMEPIRIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
REPAGLINIDE, REPAGLINIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN

*** AUROBINDO PHARMA LTD INC**

CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
MIRTAZAPINE, MIRTAZAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA*** AUROBINDO PHARMA USA INC**

ALPRAZOLAM, ALPRAZOLAM
NAPROXEN, NAPROXEN

AUROLIFE PHARMA LLC*** AUROLIFE PHARMA LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROLIFE PHARMA LLC**

HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

AUSTARPHARMA LLC*** AUSTARPHARMA LLC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

AUXILIUM PHARMS*** AUXILIUM PHARMACEUTICALS INC**

TESTIM, TESTOSTERONE

AUXILIUM PHARMS LLC*** AUXILIUM PHARMACEUTICALS LLC**

DILATRATE-SR, ISOSORBIDE DINITRATE
EDEX, ALPROSTADIL
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
STRIANT, TESTOSTERONE

AVACOR PRODS*** AVACOR PRODUCTS LLC**

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

AVANIR PHARMS*** AVANIR PHARMACEUTICALS INC**

NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC*** AVANTHI INC**

CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA*** AVEMA PHARMA SOLUTIONS**

IBUPROFEN, IBUPROFEN (OTC)

AVENT*** AVENT INC**

PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEVA*** AVEVA DRUG DELIVERY SYSTEMS INC**

CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC*** AVID RADIOPHARMACEUTICALS INC**

AMYVID, FLORBETAPIR F-18

**** B ******B BRAUN***** B BRAUN MEDICAL INC**

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ALCOHOL 10% AND DEXTROSE 5%, ALCOHOL
ALCOHOL 5% AND DEXTROSE 5%, ALCOHOL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER, BRETYLIUM TOSYLATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
 CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
 CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
 DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
 DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 ISOLYTE E IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, MANNITOL
 MANNITOL 10%, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%, MANNITOL
 MANNITOL 15%, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%, MANNITOL
MANNITOL 5%, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RESECTISOL IN PLASTIC CONTAINER, MANNITOL
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

BAJAJ MEDICAL LLC*** BAJAJ MECICAL LLC**

DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

BANNER PHARMACAPS*** BANNER PHARMACAPS INC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 CALCITRIOL, CALCITRIOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDOL LIQUID GELS, IBUPROFEN (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NIMODIPINE, NIMODIPINE
 PARICALCITOL, PARICALCITOL
 PROGESTERONE, PROGESTERONE
 VALPROIC ACID, VALPROIC ACID
 VITAMIN D, ERGOCALCIFEROL
 ZONISAMIDE, ZONISAMIDE

BARR*** BARR LABORATORIES INC**

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 ARANELLE, ETHINYL ESTRADIOL
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BALZIVA-28, ETHINYL ESTRADIOL
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CAMILA, NORETHINDRONE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORZOXAZONE, CHLORZOXAZONE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE, CLONIDINE
 DANAZOL, DANAZOL
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DIDANOSINE, DIDANOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BARR LABORATORIES INC
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DUTASTERIDE, DUTASTERIDE
 ERRIN, NORETHINDRONE
 ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, ERYTHROMYCIN ETHYLSUCCINATE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ESTRADIOL AND NORGESTIMATE, ESTRADIOL
 ESTROPIRATE, ESTROPIRATE
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 ISONIAZID, ISONIAZID
 JUNEL 1.5/30, ETHINYL ESTRADIOL
 JUNEL 1/20, ETHINYL ESTRADIOL
 JUNEL FE 1.5/30, ETHINYL ESTRADIOL
 JUNEL FE 1/20, ETHINYL ESTRADIOL
 KARIVA, DESOGESTREL
 KELNOR, ETHINYL ESTRADIOL
 LEFLUNOMIDE, LEFLUNOMIDE
 LESSINA-28, ETHINYL ESTRADIOL
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 ONDANSETRON, ONDANSETRON
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PORTIA-28, ETHINYL ESTRADIOL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 SPRINTC, ETHINYL ESTRADIOL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TREXALL, METHOTREXATE SODIUM
 TRI-LEGEST 21, ETHINYL ESTRADIOL
 TRI-LEGEST FE, ETHINYL ESTRADIOL
 TRI-SPRINTC, ETHINYL ESTRADIOL
 WARFARIN SODIUM, WARFARIN SODIUM

* BARR PHARMACEUTICALS
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS DIV TEVA

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 BUDESONIDE, BUDESONIDE
 OXYBUTYNIN, OXYBUTYNIN

BARR LABS INC

* BARR LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
TRETINOIN, TRETINOIN

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTE Prednol Etabonate
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTE MAX, LOTE Prednol Etabonate
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VITRASE, HYALURONIDASE
ZIRGAN, GANCICLOVIR
ZYLET, LOTE Prednol Etabonate

* BAUSCH AND LOMB PHARMACEUTICALS INC
ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE, ACETIC ACID, GLACIAL
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROLOM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAUSCH AND LOMB PHARMACEUTICALS INC
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
 BEPREVE, BEPOTASTINE BESILATE
 BROMDAY, BROMFENAC SODIUM
 LOTEMAX, LOTEPREDNOL ETABONATE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP
 ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
 BRANCHAMIN 4% IN PLASTIC CONTAINER, AMINO ACIDS
 BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 BREVIBLOC, ESMOLOL HYDROCHLORIDE
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
 CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
 CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
 CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINIMIX E 5/35 SULFITE-FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
 CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
 CLINOLIPID 20%, OLIVE OIL
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYTOXAN (LYOPHILIZED), CYCLOPHOSPHAMIDE
 DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND ELECTROLYTE NO.48 IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 ETHRANE, ENFLURANE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 IFEX, IFOSFAMIDE
 ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 PLASMA-LYTE 56 IN PLASTIC CONTAINER, MAGNESIUM ACETATE TETRAHYDRATE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLASMA-LYTE R IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER, SODIUM LACTATE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

*** BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV**
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP

*** BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE**
 PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
FEMSTAT 3, BUTOCONAZOLE NITRATE (OTC)

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
GYNE-LOTTRIMIN 3 COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN 3, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC
ADALAT CC, NIFEDIPINE
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN HYDROCHLORIDE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
DESONATE, DESONIDE
DTIC-DOME, DACARBAZINE
EOVIST, GADOXETATE DISODIUM
FINACEA, AZELAIC ACID
GADAVIST, GADOBUTROL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
PRECOSE, ACARBOSE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 150, IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300 IN PLASTIC CONTAINER, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

- * BAYSHORE PHARMACEUTICALS LLC
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BD RX**

- * BD RX INC
 - DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

BECTON DICKINSON

- * BECTON DICKINSON AND CO
 - CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
 - E-Z SCRUB 201, POVIDONE-IODINE (OTC)
 - E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BEDFORD

- * BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
 - ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 - ADENOSINE, ADENOSINE
 - BUMETANIDE, BUMETANIDE
 - BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 - BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIPYRIDAMOLE, DIPYRIDAMOLE
 - DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - ETOMIDATE, ETOMIDATE
 - FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 - FAMOTIDINE, FAMOTIDINE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - MITOMYCIN, MITOMYCIN
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - RIFAMPIN, RIFAMPIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - VALPROATE SODIUM, VALPROATE SODIUM
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VINORELBINE TARTRATE, VINORELBINE TARTRATE

BEDFORD LABS

- * BEDFORD LABORATORIES
 - DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 - FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUMAZENIL, FLUMAZENIL
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE

BELCHER PHARMS

- * BELCHER PHARMACEUTICALS LLC
 - CEPHALEXIN, CEPHALEXIN
 - DESLORATADINE, DESLORATADINE

BELCHER PHARMS LLC

- * BELCHER PHARMACEUTICALS LLC
 - EPINEPHRINE, EPINEPHRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BEXIMCO USA**

* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BICON PHARM

* BICON PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID

BIO NUCLEONICS

* BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

BIO PHARM INC

* BIO PHARM INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

BIOALLIANCE PHARMA

* BIOALLIANCE PHARMA
ORAVIG, MICONAZOLE

BIOCODEX INC

* BIOCODEX INC
TOTECT, DEXRAZOXANE HYDROCHLORIDE

BIOCRIST

* BIOCRIST PHARMACEUTICALS INC
RAPIVAB, PERAMIVIR

BIODELIVERY SCI INTL

* BIODELIVERY SCIENCES INTERNATIONAL INC
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

BIOGEN IDEC INC

* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

BIOKEY

* BIOKEY INC
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL

BIOMARIN PHARM

* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

BIOMEDCL RES FDN

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BLAIREX

* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

BLU CARIBE

* BLU CARIBE INC
GEMFIBROZIL, GEMFIBROZIL
SIMVASTATIN, SIMVASTATIN

BLU CARIBE INC

* BLU CARIBE INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

BOEHRINGER INGELHEIM

* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
GILOTRIF, AFATINIB DIMALEATE
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
* BOEHRINGER INGELHEIM PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOL, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
ATROVENT, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVENT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
TRADJENTA, LINAGLIPTIN
TWINSTA, AMLODIPINE BESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

BRACCO

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLOGRAFIN MEGLUMINE, IODIPAMIDE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINICALIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
SINOGRAPHIN, DIATRIZOATE MEGLUMINE

BRAINTREE

* BRAINTREE LABORATORIES INC
AXID, NIZATIDINE
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
SUCLEAR, MAGNESIUM SULFATE
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE ANHYDROUS

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LEVETIRACETAM, LEVETIRACETAM
MEFENAMIC ACID, MEFENAMIC ACID
MELOXICAM, MELOXICAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRECKENRIDGE PHARMACEUTICAL INC
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
OXCARBAZEPINE, OXCARBAZEPINE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
GLUCOVANCE, GLYBURIDE
LYSODREN, MITOTANE
MEGACE, MEGESTROL ACETATE
PRAVACHOL, PRAVASTATIN SODIUM

* BRISTOL MYERS SQUIBB CO
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
DROXIA, HYDROXYUREA
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
IXEMPRA KIT, IXABEPILONE
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE

* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
VIDEX, DIDANOSINE
ZERIT, STAVUDINE

* BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

BRYAN

* BRYAN CORP
SCLEROSOL, TALC
TALC, TALC

**** C ******CADENCE PHARMS**

* CADENCE PHARMACEUTICALS INC
OFIRMEV, ACETAMINOPHEN

CADILA PHARMS LTD

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
FOLIC ACID, FOLIC ACID
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
OFLOXACIN, OFLOXACIN

CADISTA PHARMS

* CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OXCARBAZEPINE, OXCARBAZEPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CARACO**

- * CARACO PHARMACEUTICAL LABORATORIES LTD
BACLOFEN, BACLOFEN
FLUMADINE, RIMANTADINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SYNALGOS-DC, ASPIRIN

CARDINAL HEALTH 414

- * CARDINAL HEALTH 414 LLC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
- * CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
AMMONIA N 13, AMMONIA N-13

CARDINAL HLTH 414

- * CARDINAL HEALTH 414
SODIUM IODIDE I 123, SODIUM IODIDE I-123

CAREFUSION

- * CAREFUSION 213 LLC
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
PHARMASEAL SCRUB CARE, CHLORHEXIDINE GLUCONATE (OTC)

CARLSBAD

- * CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN
MELOXICAM, MELOXICAM
MODAFINIL, MODAFINIL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CAROLINA MEDCL

- * CAROLINA MEDICAL PRODUCTS CO
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

CATALENT

- * CATALENT PHARMA SOLUTIONS LLC
VALPROIC ACID, VALPROIC ACID

CEDAR PHARMS

- * CEDAR PHARMACEUTICALS LLC
METHIMAZOLE, METHIMAZOLE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

CELGENE

- * CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

CELGENE CORP

- * CELGENE CORP
OTEZLA, APREMILAST

CEPHALON

- * CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CEPHALON INC**

GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

CEREXA*** CEREXA INC**

TEFLARO, CEFTAROLINE FOSAMIL

CHARTWELL LIFE SCI*** CHARTWELL LIFE SCIENCE LLC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

CHATTEM*** CHATTEM INC**

SELSUN, SELENIUM SULFIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHEMISCH FBRK KRSSLR*** CHEMISCHE FABRIK KREUSSLER & CO. GMBH**

ASCLERA, POLIDOCANOL

CHIESI USA INC*** CHIESI USA INC**

BETHKIS, TOBRAMYCIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CUROSURF, PORACTANT ALFA
ZYPLO CR, ZILEUTON
ZYPLO, ZILEUTON

CHILDRENS HOSP MI*** CHILDRENS HOSP MICHIGAN**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHIRHOCLIN*** CHIRHOCLIN INC**

CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CIPHER PHARMS INC*** CIPHER PHARMACEUTICALS INC**

CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA*** CIPLA LTD**

NEVIRAPINE, NEVIRAPINE
RISPERIDONE, RISPERIDONE
ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD*** CIPLA LTD**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
CARBOPLATIN, CARBOPLATIN
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FAMCICLOVIR, FAMCICLOVIR
FINASTERIDE, FINASTERIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
STAVUDINE, STAVUDINE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CITIUS PHARMS*** CITIUS PHARMACEUTICALS LLC**

SUPRENZA, PHENTERMINE HYDROCHLORIDE

CITRON PHARMA LLC*** CITRON PHARMA LLC**

CORTISPORIN, HYDROCORTISONE
THALITONE, CHLORTHALIDONE

CLARIS LIFESCIENCES*** CLARIS LIFESCIENCES LIMITED**

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

*** CLARIS LIFESCIENCES LTD**

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE

CLINIGEN HLTHCARE*** CLINIGEN HEALTHCARE LTD**

ETHYOL, AMIFOSTINE
FOSCAVIR, FOSCARNET SODIUM

CLOVER PHARMS*** CLOVER PHARMACEUTICALS CORP**

AMICAR, AMINOCAPROIC ACID

CNTY LINE PHARMS*** COUNTY LINE PHARMACEUTICALS LLC**

DYNACIN, MINOCYCLINE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LOPROX, CICLOPIROX
TRANDATE, LABETALOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE

COASTAL PHARMS*** COASTAL PHARMACEUTICALS**

BROMFENAC SODIUM, BROMFENAC SODIUM
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

COLGATE*** COLGATE ORAL PHARMACEUTICALS INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COLGATE ORAL PHARMACEUTICALS INC
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLGATE PALMOLIVE

* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

CONCORDIA LABS INC

* CONCORDIA LABORATORIES INC
PHOTOFRIN, PORFIMER SODIUM

CONCORDIA PHARMS INC

* CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAPRED, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CIMETIDINE, CIMETIDINE (OTC)
FOLIC ACID, FOLIC ACID
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PREDNISONE, PREDNISONE
PROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

CORCEPT THERAP

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

CORDEN PHARMA

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
ALPRAZOLAM, ALPRAZOLAM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LEVOCARNITINE, LEVOCARNITINE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
URSODIOL, URSODIOL

COVIS INJECTABLES

* COVIS INJECTABLES SARL
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COVIS INJECTABLES SARL
ZINACEF, CEFUROXIME SODIUM

COVIS PHARMA

* COVIS PHARMA SARL
LANOXIN, DIGOXIN
PARNATE, TRANYLCPROMINE SULFATE

COVIS PHARMA SARL

* COVIS PHARMA SARL
BETAPACE AF, SOTALOL HYDROCHLORIDE
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
KAYEXALATE, SODIUM POLYSTYRENE SULFONATE
NILANDRON, NILUTAMIDE
RILUTEK, RILUZOLE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

CPDC

* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

CRANFORD PHARMS LLC

* CRANFORD PHARMACEUTICALS LLC
INDERAL LA, PROPRANOLOL HYDROCHLORIDE

CREALTA PHARMS LLC

* CREALTA PHARMACEUTICALS LLC
MIGERGOT, CAFFEINE
OXANDRIN, OXANDROLONE

CROWN LABS

* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

CSL BEHRING

* CSL BEHRING LLC
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CUBIST

* CUBIST PHARMACEUTICALS INC
CUBICIN, DAPTOMYCIN

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
DIFICID, FIDAXOMICIN
ENTEREG, ALVIMOPAN
ZERBAXA, CEFTOLOZANE SULFATE

CUBIST PHARMS INC

* CUBIST PHARMACEUTICALS INC
SIVEXTRO, TEDIZOLID PHOSPHATE

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

CYPRESS BIOSCIENCE

* CYPRESS BIOSCIENCE INC
SAVELLA, MILNACIPRAN HYDROCHLORIDE

CYPRESS PHARM

* CYPRESS PHARMACEUTICAL INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ELIPHOS, CALCIUM ACETATE
REZIRA, HYDROCODONE BITARTRATE
VITUZ, CHLORPHENIRAMINE MALEATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**** D ******DAIICHI**

* DAIICHI PHARMACEUTICAL CORP
FLOXIN OTIC, OFLOXACIN

DAIICHI SANKYO

* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
EVOXAC, CEVIMELINE HYDROCHLORIDE
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARA BIOSCIENCES

* DARA BIOSCIENCES INC
SOLTAMOX, TAMOXIFEN CITRATE

DAVA INTL INC

* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GEMFIBROZIL, GEMFIBROZIL
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

DAVIS AND GECK

* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DELCOR ASSET

* DELCOR ASSET CORP
EVOCLIN, CLINDAMYCIN PHOSPHATE
LUXIQ, BETAMETHASONE VALERATE
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
VUSION, MICONAZOLE NITRATE
ZOVIRAX, ACYCLOVIR

DELCOR ASSET CORP

* DELCOR ASSET CORP
ERYGEL, ERYTHROMYCIN
EXTINA, KETOCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******DENCO ASSET**

- * DENCO ASSET LLC
DENAVIR, PENCICLOVIR SODIUM

DENTSPLY PHARM

- * DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPOMED INC

- * DEPOMED INC
CAMBIA, DICLOFENAC POTASSIUM
GRALISE, GABAPENTIN
LAZANDA, FENTANYL CITRATE
ZIPSOR, DICLOFENAC POTASSIUM

DEPROCO

- * DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DEXCEL LTD

- * DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

- * DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRazole, OMEPRazole (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

DIALYSIS SUPS

- * DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DIGESTIVE CARE INC

- * DIGESTIVE CARE INC
PERTZY, PANCRELIPASE (AMYLASE)

DISCOVERY LABS

- * DISCOVERY LABORATORIES INC
SURFAXIN, LUCINACTANT

DORADO PHARMA

- * DORADO PHARMA LLC
KETOPROFEN, KETOPROFEN

DORC

- * DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

DOUGLAS PHARMS

- * DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

- * DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE
AKNE-MYCIN, ERYTHROMYCIN
ATRALIN, TRETINOIN
JUBLIA, EFINACONAZOLE
NUTRACORT, HYDROCORTISONE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN

DR REDDYS LA

- * DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******DR REDDYS LABS INC***** DR REDDYS LABORATORIES INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '200', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '400', AMOXICILLIN
AUGMENTIN '500', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HABITROL, NICOTINE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LAROTID, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD*** DR REDDYS LABORATORIES LIMITED**

LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

*** DR REDDYS LABORATORIES LTD**

ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DECITABINE, DECITABINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ESZOPICLONE, ESZOPICLONE
FAMOTIDINE, FAMOTIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******* DR REDDYS LABORATORIES LTD**

FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA*** DR REDDYS LABORATORIES SA**

FENOFIBRATE (MICRONIZED), FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******DRAXIMAGE**

- * DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

DUCHESNAY

- * DUCHESNAY INC
DICLEGIS, DOXYLAMINE SUCCINATE

DURAMED PHARMS BARR

- * DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAMOX, ACETAZOLAMIDE
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

DURAMED RES

- * DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE

DURATA THERAPS INTL

- * DURATA THERAPEUTICS INTERNATIONAL BV
DALVANCE, DALBAVANCIN HYDROCHLORIDE

DUSA

- * DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

REDDYS

- * DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******EAGLE PHARMS**

- * EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
RYANODEX, DANTROLENE SODIUM

EASTMAN KODAK

- * EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

EBEWE PHARMA

- * EBEWE PHARMA GES MBH NFG KG
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL

ECLAT PHARMS LLC

- * ECLAT PHARMACEUTICALS LLC
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

ECOLAB

- * ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

ECR

- * ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

ECR PHARMA

- * ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

EDENBRIDGE PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EDENBRIDGE PHARMACEUTICALS LLC
IVERMECTIN, IVERMECTIN

EDGEMONT PHARMS LLC

* EDGEMONT PHARMACEUTICALS LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE

EDISON THERAPS LLC

* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

EI INC

* EI INC
THEROXIDIL, MINOXIDIL (OTC)

EISAI INC

* EISAI INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
DACOGEN, DECITABINE
FRAGMIN, DALTEPARIN SODIUM
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE

ELAN PHARMA INTL LTD

* ELAN PHARMA INTERNATIONAL LTD
CLINDESSE, CLINDAMYCIN PHOSPHATE
EVAMIST, ESTRADIOL

ELI LILLY AND CO

* ELI LILLY AND CO
AXIRON, TESTOSTERONE
EFFIENT, PRASUGREL HYDROCHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
SARAFEM, FLUOXETINE HYDROCHLORIDE

ELI LILLY CO

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

* ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

* ELITE LABORATORIES INC
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

EMCURE PHARMS

* EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

EMCURE PHARMS INDIA

* EMCURE PHARMACEUTICALS LTD INDIA
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EMCURE PHARMACEUTICALS LTD**

CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
ETOMIDATE, ETOMIDATE
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

EMCURE PHARMS USA*** EMCURE PHARMACEUTICALS USA INC**

DIFLUNISAL, DIFLUNISAL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

EMCURE USA*** EMCURE PHARMACEUTICALS USA INC**

BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

EMD SERONO*** EMD SERONO INC**

GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROPHENE, CLOMIPHENE CITRATE
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

EMD SERONO INC*** EMD SERONO INC**

CETROTIDE, CETRORELIX

EMMAUS MEDCL*** EMMAUS MEDICAL INC**

NUTRESTORE, GLUTAMINE

ENDO PHARM*** ENDO PHARMACEUTICAL SOLUTIONS INC**

SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

ENDO PHARMS*** ENDO PHARMACEUTICALS INC**

DELATESTRYL, TESTOSTERONE ENANTHATE
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
OPANA ER, OXYMORPHONE HYDROCHLORIDE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCODAN, ASPIRIN

ENDO PHARMS INC*** ENDO PHARMACEUTICALS INC**

AVEED, TESTOSTERONE UNDECANOATE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

ENDO VENTURES LTD*** ENDO VENTURES LTD**

NATESTO, TESTOSTERONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ENDO VENTURES LTD IRELAND
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

EPIC PHARMA

* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

* EPIC PHARMA INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

ERGOJECT

* ERGOJECT LLC
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE

ESSENTIAL ISOTOPES

* ESSENTIAL ISOTOPES LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM

* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

EURAND

* EURAND AMERICA INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

EUROHLTH INTL

* EUROHEALTH INTERNATIONAL SARL
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMRINONE LACTATE, INAMRINONE LACTATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZTREONAM, AZTREONAM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFCIT, CAFFEINE CITRATE
CARBOPLATIN, CARBOPLATIN
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE), DICYCLOMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EUROHEALTH INTERNATIONAL SARL
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLOXURIDINE, FLOXURIDINE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOSTATIN, PENTOSTATIN
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 TORSEMIDE, TORSEMIDE
 VINBLASTINE SULFATE, VINBLASTINE SULFATE

EXALENZ BIOSCIENCE

* EXALENZ BIOSCIENCE LTD
 IDKIT:HP, CITRIC ACID

EXCELLIUM

* EXCELLIUM PHARMACEUTICAL INC
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM

EXELA PHARMA SCIENCE

* EXELA PHARMA SCIENCES
 CAFFEINE CITRATE, CAFFEINE CITRATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

EXELA PHARMA SCS LLC

* EXELA PHARMA SCIENCES LLC
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE

EXELIXIS

* EXELIXIS INC
 COMETRIQ, CABOZANTINIB S-MALATE

FOUGERA

* E FOUGERA DIV ALTANA INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* E FOUGERA DIV ALTANA INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

LILLY

* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN RECOMBINANT HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ******FALCON PHARMS**

* FALCON PHARMACEUTICALS LTD
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE

FAMY CARE LTD

* FAMY CARE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE

FDC LTD

* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FEINSTEIN

* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

FERA PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FERA PHARMACEUTICALS LLC
OFLOXACIN, OFLOXACIN
TOBRAMYCIN, TOBRAMYCIN

FERNDALE LABS

* FERNDALE LABORATORIES INC
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE

FERRING

* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, MENOTROPINS (FSH
MINIRIN, DESMOPRESSIN ACETATE
REPRONEX, MENOTROPINS (FSH
TEV-TROPIN, SOMATROPIN RECOMBINANT

FERRING CONTROLLED

* FERRING CONTROLLED THERAPEUTICS LTD
CERVIDIL, DINOPROSTONE

FERRING PHARMS AS

* FERRING PHARMACEUTICALS AS
LYSTEDA, TRANEXAMIC ACID
PREPOPIK, CITRIC ACID

FERRING PHARMS INC

* FERRING PHARMACEUTICALS INC
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE

FOREST LABS

* FOREST LABORATORIES INC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CAMPRAL, ACAMPROSATE CALCIUM
CELEXA, CITALOPRAM HYDROBROMIDE
LEXAPRO, ESCITALOPRAM OXALATE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
THYROLAR-0.25, LIOTRIX (T4
THYROLAR-0.5, LIOTRIX (T4
THYROLAR-1, LIOTRIX (T4
THYROLAR-2, LIOTRIX (T4
THYROLAR-3, LIOTRIX (T4

FOREST LABS INC

* FOREST LABORATORIES INC
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CANASA, MESALAMINE
CARAFATE, SUCRALFATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
LINZESS, LINACLOTIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
RECTIV, NITROGLYCERIN
SAPHRIS, ASENAPINE MALEATE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
ULTRESA, PANCRELIPASE (AMYLASE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIOKACE, PANCRELIPASE (AMYLASE
ZENPEP, PANCRELIPASE (AMYLASE

FOREST RES INST INC

* FOREST RESEARCH INSTITUTE INC
DALIRESP, ROFLUMILAST

FOUGERA PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FOUGERA PHARMACEUTICALS INC**

ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMCINONIDE, AMCINONIDE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 C-SOLVE-2, ERYTHROMYCIN
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CUTIVATE, FLUTICASONE PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 OXISTAT, OXICONAZOLE NITRATE
 PAMINE FORTE, METHSCOPOLAMINE BROMIDE
 PAMINE, METHSCOPOLAMINE BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PREDNICARBATE, PREDNICARBATE
 SOLARAZE, DICLOFENAC SODIUM
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TEMOVATE E, CLOBETASOL PROPIONATE
 TEMOVATE, CLOBETASOL PROPIONATE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE
 ZONALON, DOXEPIN HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
 FLUOCINONIDE, FLUOCINONIDE
 TACROLIMUS, TACROLIMUS

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL

FRESENIUS KABI

* FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI ONCOL

* FRESENIUS KABI ONCOLOGY PLC
 ANASTROZOLE, ANASTROZOLE
 BICALUTAMIDE, BICALUTAMIDE
 CARBOPLATIN, CARBOPLATIN
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LETROZOLE, LETROZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI ONCOLOGY PLC
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ASTRAMORPH PF, MORPHINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACITRACIN, BACITRACIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CEFOTETAN, CEFOTETAN DISODIUM
CEFTRIAZONE, CEFTRIAZONE SODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DIMENHYDRINATE, DIMENHYDRINATE
DIPRIVAN, PROPOFOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FRESENIUS KABI USA LLC**

HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IOPAMIDOL-250, IOPAMIDOL
IOPAMIDOL-300, IOPAMIDOL
IOPAMIDOL-370, IOPAMIDOL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESENIUS KABI USA LLC
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINOELBINE TARTRATE, VINOELBINE TARTRATE
 XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE

FRESENIUS MEDCL

* FRESENIUS MEDICAL CARE NORTH AMERICA
 CALCITRIOL, CALCITRIOL
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOSLO GELCAPS, CALCIUM ACETATE
 PHOSLYRA, CALCIUM ACETATE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

FSC

* FSC LABORATORIES INC
 PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**** G ******G AND W LABS**

* G AND W LABORATORIES INC
 ACEPHEN, ACETAMINOPHEN (OTC)
 CICLOPIROX, CICLOPIROX
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 INDOMETHACIN, INDOMETHACIN
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 PROCHLORPERAZINE, PROCHLORPERAZINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHGAN, PROMETHAZINE HYDROCHLORIDE

G AND W LABS INC

* G AND W LABORATORIES INC
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 FLUOCINONIDE, FLUOCINONIDE
 METRONIDAZOLE, METRONIDAZOLE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

GALDERMA LABS

* GALDERMA LABORATORIES INC
 CLOBEX, CLOBETASOL PROPIONATE

GALDERMA LABS LP

* GALDERMA LABORATORIES L P
 CLOBEX, CLOBETASOL PROPIONATE
 * GALDERMA LABORATORIES LP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GALDERMA LABORATORIES LP
 CAPEX, FLUOCINOLONE ACETONIDE
 CLOBEX, CLOBETASOL PROPIONATE
 DESOWEN, DESONIDE
 DIFFERIN, ADAPALENE
 EPIDUO, ADAPALENE
 METROCREAM, METRONIDAZOLE
 METROGEL, METRONIDAZOLE
 METROLOTION, METRONIDAZOLE
 MIRVASO, BRIMONIDINE TARTRATE
 ORACEA, DOXYCYCLINE
 PLIAGLIS, LIDOCAINE
 SOOLANTRA, IVERMECTIN
 TRI-LUMA, FLUOCINOLONE ACETONIDE
 VECTICAL, CALCITRIOL

GALEN (UK)

* GALEN LTD
 DAUNOXOME, DAUNORUBICIN CITRATE

GALEN SPECIALTY

* GALEN SPECIALTY PHARMA US LLC
 SYNERA, LIDOCAINE

GALENA BIOPHARMA

* GALENA BIOPHARMA
 ABSTRAL, FENTANYL CITRATE

GALENA BIOPHARMA INC

* GALENA BIOPHARMA INC
 ZUPLENZ, ONDANSETRON

GAMBRO RENAL PRODS

* GAMBRO RENAL PRODUCTS
 PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

GASTROENTERO

* GASTROENTERO LOGIC LLC
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

GATE PHARMS

* GATE PHARMACEUTICALS
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

GAVIS PHARMS

* GAVIS PHARMACEUTICALS LLC
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 QUINARETIC, HYDROCHLOROTHIAZIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

GAVIS PHARMS LLC

* GAVIS PHARMACEUTICALS LLC
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE

GD SEARLE

* GD SEARLE LLC
 CELEBREX, CELECOXIB
 DAYPRO, OXAPROZIN

GD SEARLE LLC

* GD SEARLE LLC
 ALDACTAZIDE, HYDROCHLOROTHIAZIDE
 ALDACTONE, SPIRONOLACTONE
 ARTHROTEC, DICLOFENAC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GD SEARLE LLC**

CALAN, VERAPAMIL HYDROCHLORIDE
COVERA-HS, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
INSPIRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

GE HEALTHCARE*** GE HEALTHCARE**

ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN-111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI DMSA KIDNEY REAGENT, TECHNETIUM TC-99M SUCCIMER KIT
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC*** GE HEALTHCARE INC**

DATSCAN, IOFLUPANE I-123

GEDEON RICHTER USA*** GEDEON RICHTER USA INC**

FINASTERIDE, FINASTERIDE

GENENTECH*** GENENTECH INC**

ERIVEDGE, VISMODEGIB
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT
NUTROPIN AQ, SOMATROPIN RECOMBINANT
NUTROPIN, SOMATROPIN RECOMBINANT

GENZYME*** GENZYME CORP**

CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
REVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

GENZYME CORP*** GENZYME CORP**

CERDELGA, ELIGLUSTAT TARTRATE
HECTOROL, DOXERCALCIFEROL
KYNAMRO, MIPOMERSEN SODIUM

GILEAD*** GILEAD SCIENCES INC**

ATRIPLA, EFAVIRENZ
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GILEAD SCIENCES INC
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
COMPLERA, EMTRICITABINE
HARVONI, LEDIPASVIR
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VISTIDE, CIDOFOVIR
VITEKTA, ELVITEGRAVIR
ZYDELIG, IDELALISIB

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
HALOPERIDOL, HALOPERIDOL LACTATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAXO GRP ENGLAND

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
ALTABAX, RETAPAMULIN
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE

GLAXO WELLCOME

* GLAXOSMITHKLINE
HYCANTIN, TOPOTECAN HYDROCHLORIDE

GLAXOSMITHKLINE

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
ALKERAN, MELPHALAN
ALKERAN, MELPHALAN HYDROCHLORIDE
AVODART, DUTASTERIDE
BACTROBAN, MUPIROCIN
BACTROBAN, MUPIROCIN CALCIUM
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
CEFTIN, CEFUROXIME AXETIL
EPIVIR-HBV, LAMIVUDINE
FLONASE, FLUTICASONE PROPIONATE
HYCANTIN, TOPOTECAN HYDROCHLORIDE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLAXOSMITHKLINE
 - JALYN, DUTASTERIDE
 - MALARONE PEDIATRIC, ATOVAQUONE
 - MALARONE, ATOVAQUONE
 - NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)
 - POTIGA, EZOGABINE
 - PROMACTA, ELTROMBOPAG OLAMINE
 - RELENZA, ZANAMIVIR
 - TAFINLAR, DABRAFENIB MESYLATE
 - TIMENTIN IN PLASTIC CONTAINER, CLAVULANATE POTASSIUM
 - TIMENTIN, CLAVULANATE POTASSIUM
 - VALTREX, VALACYCLOVIR HYDROCHLORIDE
 - VERAMYST, FLUTICASONE FUROATE
 - VOTRIENT, PAZOPANIB HYDROCHLORIDE
 - WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
 - WELLBUTRIN, BUPROPION HYDROCHLORIDE
 - ZOFRAN ODT, ONDANSETRON
 - ZOFRAN PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ZOFRAN, ONDANSETRON HYDROCHLORIDE
 - ZYBAN, BUPROPION HYDROCHLORIDE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
 - ANORO ELLIPTA, UMECLIDINIUM BROMIDE
 - ARNUITY ELLIPTA, FLUTICASONE FUROATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
 - SEREVENT, SALMETEROL XINAFOATE
 - VENTOLIN HFA, ALBUTEROL SULFATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
 - TIMENTIN, CLAVULANATE POTASSIUM

GLAXOSMITHKLINE CONS

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE
 - ALLI, ORLISTAT (OTC)
 - COMMIT, NICOTINE POLACRILEX (OTC)
 - FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
 - NICORETTE, NICOTINE POLACRILEX (OTC)

GLAXOSMITHKLINE LLC

- * GLAXOSMITHKLINE LLC
 - AMERGE, NARATRIPTAN HYDROCHLORIDE
 - DYAZIDE, HYDROCHLOROTHIAZIDE
 - FLOLAN, EPOPROSTENOL SODIUM
 - INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 - LAMICTAL CD, LAMOTRIGINE
 - LAMICTAL ODT, LAMOTRIGINE
 - LAMICTAL XR, LAMOTRIGINE
 - LAMICTAL, LAMOTRIGINE
 - MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
 - MEPRON, ATOVAQUONE
 - REQUIP XL, ROPINIROLE HYDROCHLORIDE
 - REQUIP, ROPINIROLE HYDROCHLORIDE
 - RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
 - RYTHMOL, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

- * GLENMARK GENERICS INC USA
 - ADAPALENE, ADAPALENE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CALCIPOTRIENE, CALCIPOTRIENE
 - IMIQUIMOD, IMIQUIMOD
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MUPIROCIN, MUPIROCIN CALCIUM
 - NIZATIDINE, NIZATIDINE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - ZONISAMIDE, ZONISAMIDE
- * GLENMARK GENERICS LIMITED
 - BRIELLYN, ETHINYL ESTRADIOL
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK GENERICS LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
GABAPENTIN, GABAPENTIN
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TELMISARTAN, TELMISARTAN
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
ZOLMITRIPTAN, ZOLMITRIPTAN

* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
LITHIUM CARBONATE, LITHIUM CARBONATE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

GLENMARK PHARMS

* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN

* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

GLENMARK PHARMS LTD

* GLENMARK PHARMACEUTICALS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GLENMARK PHARMACEUTICALS LTD
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

GLOBAL ISOTOPES LLC

* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

GRANULES INDIA

* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GUARDIAN DRUG

* GUARDIAN DRUG CO INC
FOAMCOAT, ALUMINUM HYDROXIDE (OTC)

GUERBET

* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
HEXABRIX, IOXAGLATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL
OXILAN-300, IOXILAN
OXILAN-350, IOXILAN

HANFORD GC

* GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

**** H ******HAEMONETICS**

* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HALOCARBON PRODS

* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HALOZYME THERAP

* HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

HAMELN RDS GMBH

* HAMELN RDS GMBH
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

HANMI PHARM CO LTD

* HANMI PHARMACEUTICAL CO LTD
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

HARRIS PHARM

* HARRIS PHARMACEUTICAL INC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

HAUPT PHARMA

* HAUPT PHARMA INC
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE

HELSINN HLTHCARE

* HELSINN HEALTHCARE SA
AKYNZEO, NETUPITANT
ALOXI, PALONOSETRON HYDROCHLORIDE

HERCON PHARM

* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HERITAGE PHARMACEUTICALS INC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 FELODIPINE, FELODIPINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LEFLUNOMIDE, LEFLUNOMIDE
 MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 SULINDAC, SULINDAC
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HETERO LABS LTD III*** HETERO LABS LTD UNIT III**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METHOCARBAMOL, METHOCARBAMOL
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN
 STAVUDINE, STAVUDINE
 TORSEMIDE, TORSEMIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V*** HETERO LABS LTD UNIT V**

ACYCLOVIR, ACYCLOVIR
 FAMCICLOVIR, FAMCICLOVIR
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VALSARTAN, VALSARTAN

HEYL CHEMISCH*** HEYL CHEMISCH PHARMAZEUTISCHE FABRIK**

RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HI TECH PHARMA*** HI TECH PHARMACAL CO INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CICLOPIROX, CICLOPIROX
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CORMAX, CLOBETASOL PROPIONATE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HI TECH PHARMACAL CO INC
 EMBELINE E, CLOBETASOL PROPIONATE
 EMBELINE, CLOBETASOL PROPIONATE
 ERYTHRO-STATIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL

HI TECH PHARMA CO

* HI TECH PHARMACAL CO INC
 FLUNISOLIDE, FLUNISOLIDE
 PREDNISOLONE, PREDNISOLONE

HI-TECH PHARMA CO

* HI-TECH PHARMACAL CO INC
 FAMOTIDINE, FAMOTIDINE
 GATIFLOXACIN, GATIFLOXACIN
 LORAZEPAM, LORAZEPAM
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

HI-TECH PHARMACAL

* HI-TECH PHARMACAL CO INC
 BROMFENAC SODIUM, BROMFENAC SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE

HIGH TECH PHARMA

* HIGH TECHNOLOGY PHARMACAL CO INC
 VALPROIC ACID, VALPROIC ACID

HIKMA

* HIKMA FARMACEUTICA LDA
 CEFOTAXIME, CEFOTAXIME SODIUM
 * HIKMA PHARMACEUTICALS
 AMOXICILLIN, AMOXICILLIN
 CARVEDILOL, CARVEDILOL
 CEFACLOX, CEFACLOX
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEPHALEXIN, CEPHALEXIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYBURIDE (MICRONIZED), GLYBURIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

HIKMA (MAPLE)

* HIKMA (MAPLE) LTD
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

HIKMA FARMACEUTICA

* HIKMA FARMACEUTICA (PORTUGAL) SA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HIKMA FARMACEUTICA (PORTUGAL) SA
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 - BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 - CEFOXITIN, CEFOXITIN SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPROFLOXACIN, CIPROFLOXACIN
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - GRANISTERON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROGESTERONE, PROGESTERONE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - VALPROATE SODIUM, VALPROATE SODIUM
 - * HIKMA FARMACEUTICA PORTUGAL LDA
 - CEFAZOLIN SODIUM, CEFZOLIN SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 - * HIKMA FARMACEUTICA PORTUGAL SA
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - OXYTOCIN, OXYTOCIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 - * HIKMA FARMACEUTICA SA
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID
- HIKMA INTL PHARMS**
- * HIKMA INTERNATIONAL PHARMACEUTICALS LLC
 - BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 - CORTISONE ACETATE, CORTISONE ACETATE
 - DIGOXIN, DIGOXIN
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 - ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LITHIUM CARBONATE, LITHIUM CARBONATE
 - METHOCARBAMOL, METHOCARBAMOL
 - NAPROXEN, NAPROXEN
- HIKMA MAPLE**
- * HIKMA MAPLE LTD
 - ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, ACYCLOVIR SODIUM
 - ADENOSINE, ADENOSINE
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - ATIVAN, LORAZEPAM
 - BUMETANIDE, BUMETANIDE
 - CEFOXITIN, CEFOXITIN SODIUM
 - CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HIKMA MAPLE LTD**

DIGOXIN, DIGOXIN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DURAMORPH PF, MORPHINE SULFATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLUMAZENIL, FLUMAZENIL
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 INFUMORPH, MORPHINE SULFATE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 ROBAXIN, METHOCARBAMOL
 ROBINUL, GLYCOPYRROLATE
 SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

HIKMA PHARM CO LTD*** HIKMA PHARM CO LTD**

ARGATROBAN, ARGATROBAN

HIKMA PHARMS*** HIKMA PHARMACEUTICALS**

AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 GABAPENTIN, GABAPENTIN
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 MODAFINIL, MODAFINIL
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TOPIRAMATE , TOPIRAMATE

*** HIKMA PHARMACEUTICALS CO LTD**

PARICALCITOL, PARICALCITOL

*** HIKMA PHARMACEUTICALS LLC**

PREDNISON, PREDNISON
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX

HIKMA PHARMS LLC*** HIKMA PHARMACEUTICALS LLC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CAPTOPRIL, CAPTOPRIL
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 DOXERCALCIFEROL, DOXERCALCIFEROL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS LLC
FOLIC ACID, FOLIC ACID
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE
ZALEPLON, ZALEPLON

HILL DERMAC

* HILL DERMACEUTICALS INC
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

HISAMITSU PHARM CO

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

HOFFMAN LA ROCHE

* HOFFMAN LA ROCHE INC
INVIRASE, SAQUINAVIR MESYLATE

HOFFMANN LA ROCHE

* HOFFMANN LA ROCHE INC
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
BONIVA, IBANDRONATE SODIUM
INVIRASE, SAQUINAVIR MESYLATE
ROCEPHIN, CEFTRIAXONE SODIUM
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
XENICAL, ORLISTAT
ZELBORAF, VEMURAFENIB

HOPE PHARMS

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON PHARMA

* HORIZON PHARMA INC
DUEXIS, FAMOTIDINE
RAYOS, PREDNISONE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
* HORIZON PHARMA IRELAND LTD
PENNSAID, DICLOFENAC SODIUM

HOSPIRA

* HOSPIRA INC
A-HYDROCORT, HYDROCORTISONE SODIUM SUCCINATE
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AQUASOL A, VITAMIN A PALMITATE
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FOSCARNET SODIUM, FOSCARNET SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LTA II KIT, LIDOCAINE HYDROCHLORIDE
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
M.V.I.-12 (WITHOUT VITAMIN K), ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE IN PLASTIC CONTAINER, POTASSIUM ACETATE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

PROPOFOL, PROPOFOL
 QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM ACETATE IN PLASTIC CONTAINER, SODIUM ACETATE ANHYDROUS
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
 SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TALWIN, PENTAZOCINE LACTATE
 TAZICEF, CEFTAZIDIME
 THAM, TROMETHAMINE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 VITAMIN K1, PHYTONADIONE
 ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

*** HOSPIRA WORLDWIDE, INC**

DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 NITROPRESS, SODIUM NITROPRUSSIDE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC*** HOSPIRA INC**

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
 ADENOSINE, ADENOSINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME SODIUM, CEFUROXIME SODIUM
 DAPTOMYCIN, DAPTOMYCIN
 DOCETAXEL, DOCETAXEL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 MAXIPIME, CEFEPIME HYDROCHLORIDE
 MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
 MEROPENEM, MEROPENEM
 MILRINONE LACTATE, MILRINONE LACTATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIPENT, PENTOSTATIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HOSPIRA INC
OXALIPLATIN, OXALIPLATIN
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

HOUSTON CYCLOTRON

* HOUSTON CYCLOTRON PARTNERS LP
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

* HQ SPECIALTY PHARMA CORP
CISPLATIN, CISPLATIN
TAXOL, PACLITAXEL

HQ SPECIALITY PHARMA

* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

* HQ SPECIALTY PHARMA
VUMON, TENIPOSIDE

HRA PHARMA

* HRA PHARMA LLC
METOPIRONE, METYRAPONE

HYPERION THERAP INC

* HYPERION THERAPEUTICS INC
RAVICTI, GLYCEROL PHENYLBUTYRATE

HYPERION THERAPS INC

* HYPERION THERAPEUTICS INC
BUPHENYL, SODIUM PHENYLBUTYRATE

ROCHE

* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
COPEGUS, RIBAVIRIN
FUZEON, ENFUVIRTIDE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

**** I ******IDENTI PHARMS INC**

* IDENTI PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

IGI LABS INC

* IGI LABORATORIES INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

IMPAX LABS

* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ALPRAZOLAM, ALPRAZOLAM
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IMPAX LABORATORIES INC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

IMPAX LABS INC

* IMPAX LABORATORIES INC
 CABERGOLINE, CABERGOLINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 LAMOTRIGINE, LAMOTRIGINE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 URSODIOL, URSODIOL

IMPAX PHARMS

* IMPAX PHARMACEUTICALS
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 GEMFIBROZIL, GEMFIBROZIL
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

INCYTE CORP

* INCYTE CORP
 JAKAFI, RUXOLITINIB PHOSPHATE

INDICUS PHARMA

* INDICUS PHARMA LLC
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

INDOCO REMEDIES

* INDOCO REMEDIES LTD
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 GLIMEPIRIDE, GLIMEPIRIDE

INJECTALIA

* INJECTALIA SRL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

INNOCUTIS HOLDINGS

* INNOCUTIS HOLDINGS LLC
SITAVIG, ACYCLOVIR

INNOPHARMA LICENSING

* INNOPHARMA LICENSING LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

INO

* INO THERAPEUTICS INC
INOMAX, NITRIC OXIDE

INST BIOCHEM

* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

INST BIOCHIMIQUE

* INSTITUTE BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

INSTITUT BIOCHIMIQUE

* INSTITUT BIOCHIMIQUE SA IBSA
TIROSINT, LEVOTHYROXINE SODIUM

INSYS THERAP

* INSYS THERAPEUTICS INC
DRONABINOL, DRONABINOL
SUBSYS, FENTANYL

INTELLIPHARMACEUTICS

* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE

INTERGEL PHARM

* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

INTERMUNE INC

* INTERMUNE INC
ESBRIET, PIRFENIDONE

INTL MEDICATED

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

INTL MEDICATION

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

INTL MEDICATION SYS

* INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM

INVAGEN PHARMS

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* INVAGEN PHARMACEUTICALS INC
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LISINAPRIL, LISINAPRIL
 MEPROBAMATE, MEPROBAMATE
 NABUMETONE, NABUMETONE
 NAPROXEN, NAPROXEN
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL
 WARFARIN SODIUM, WARFARIN SODIUM
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

INVENTIA HLTHCARE

* INVENTIA HEALTHCARE PRIVATE LTD
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

IPCA LABS LTD

* IPCA LABORATORIES LTD
 ALLOPURINOL, ALLOPURINOL
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

IPR

* IPR PHARMACEUTICALS INC
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 CRESTOR, ROSUVASTATIN CALCIUM
 ZOMIG, ZOLMITRIPTAN

IPR PHARMS INC

* IPR PHARMACEUTICALS INC
 CAPRELSA, VANDETANIB

IPSEN INC

* IPSEN BIOPHARMACEUTICALS INC
 INCRELEX, MECASERMIN RECOMBINANT

IPSEN PHARMA

* IPSEN PHARMA BIOTECH SAS
 SOMATULINE DEPOT, LANREOTIDE ACETATE

IROKO PHARMS

* IROKO PHARMACEUTICALS LLC
 INDOCIN, INDOMETHACIN

IROKO PHARMS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IROKO PHARMACEUTICALS LLC
TIVORBEX, INDOMETHACIN
ZORVOLEX, DICLOFENAC

ISO TEX

* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

ISOTEX

* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA

* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

IVAX INTL

* IVAX INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

IVAX PHARMS

* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

IVAX SUB TEVA PHARMS

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OXAPROZIN, OXAPROZIN
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 SIMVASTATIN, SIMVASTATIN
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******JACOBUS**

* JACOBUS PHARMACEUTICAL CO
 DAPSONE, DAPSONE
 PASER, AMINOSALICYLIC ACID

JANSSEN BIOTECH

* JANSSEN BIOTECH INC
 ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

* JANSSEN PHARMACEUTICALS INC
 AXERT, ALMOTRIPTAN MALATE
 CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 DITROPAN XL, OXYBUTYNIN CHLORIDE
 DURAGESIC-100, FENTANYL
 DURAGESIC-12, FENTANYL
 DURAGESIC-25, FENTANYL
 DURAGESIC-50, FENTANYL
 DURAGESIC-75, FENTANYL
 ELMIRON, PENTOSAN POLYSULFATE SODIUM
 HALDOL, HALOPERIDOL DECANOATE
 HALDOL, HALOPERIDOL LACTATE
 INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 INVEGA, PALIPERIDONE
 INVOKAMET, CANAGLIFLOZIN
 INVOKANA, CANAGLIFLOZIN
 LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVAQUIN, LEVOFLOXACIN
 MICRONOR, NORETHINDRONE
 MODICON 28, ETHINYL ESTRADIOL
 NIZORAL, KETOCONAZOLE
 NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
 NUCYNTA, TAPENTADOL HYDROCHLORIDE
 ORTHO CYCLEN-28, ETHINYL ESTRADIOL
 ORTHO EVRA, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
 ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
 ORTHO-CEPT, DESOGESTREL
 ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
 ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
 PANCREAZE, PANCRELIPASE (AMYLASE
 RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 RAZADYNE, GALANTAMINE HYDROBROMIDE
 RISPERDAL CONSTA, RISPERIDONE
 RISPERDAL, RISPERIDONE
 SPORANOX, ITRACONAZOLE
 TERAZOL 3, TERCONAZOLE
 TERAZOL 7, TERCONAZOLE
 TOPAMAX, TOPIRAMATE
 TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
 TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
 ULTRACET, ACETAMINOPHEN
 ULTRAM, TRAMADOL HYDROCHLORIDE
 XARELTO, RIVAROXABAN

JANSSEN PRODS

* JANSSEN PRODUCTS LP
 EDURANT, RILPIVIRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JANSSEN PRODUCTS LP
OLYSIO, SIMEPREVIR SODIUM
PREZISTA, DARUNAVIR ETHANOLATE

JANSSEN R AND D

- * JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE
PARAFON FORTE DSC, CHLORZOXAZONE

JANSSEN RES AND DEV

- * JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

JANSSEN THERAP

- * JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

JAVELIN PHARMS INC

- * JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC
DYLOJECT, DICLOFENAC SODIUM

JAZZ PHARMS

- * JAZZ PHARMACEUTICALS INC
LUVOX CR, FLUVOXAMINE MALEATE
XYREM, SODIUM OXYBATE

JAZZ PHARMS III

- * JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE
- * JAZZ PHARMACEUTICALS INTERNATIONAL III
VERSACLOZ, CLOZAPINE

JAZZ PHARMS INTL

- * JAZZ PHARMACEUTICALS INTERNATIONAL LTD
PRIALT, ZICONOTIDE ACETATE

JIANGSU HANSON PHARM

- * JIANGSU HANSON PHARMACEUTICAL CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JIANGSU HENGRUI MED

- * JIANGSU HENGRUI MEDICINE CO LTD
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN

JOHNS HOPKINS UNIV

- * JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
- * JOHNSON AND JOHNSON HEALTHCARE PRODUCTS
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
- * JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

JUBILANT CADISTA

- * JUBILANT CADISTA PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JUBILANT DRAXIMAGE INC
 AN-DTPA, TECHNETIUM TC-99M PENTETATE KIT
 DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
 HICON, SODIUM IODIDE I-131
 PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
 SODIUM IODIDE I-131, SODIUM IODIDE I-131

JUBILANT GENERICS

* JUBILANT GENERICS LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 LAMOTRIGINE, LAMOTRIGINE
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SPIRONOLACTONE, SPIRONOLACTONE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 DIGOXIN, DIGOXIN
 METHOCARBAMOL AND ASPIRIN, ASPIRIN
 UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

* KW GRIFFEN CO
 BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KALEO INC

* KALEO INC
 EVZIO, NALOXONE HYDROCHLORIDE

KEN LIFESCIENCE

* KEN LIFESCIENCE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
 FERRIC CITRATE, FERRIC CITRATE

KING PHARMS

* KING PHARMACEUTICALS INC
 ALTACE, RAMIPRIL
 BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
 BICILLIN C-R, PENICILLIN G BENZATHINE
 BICILLIN L-A, PENICILLIN G BENZATHINE
 CORGARD, NADOLOL
 CORZIDE, BENDROFLUMETHIAZIDE
 PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
 SILVADENE, SILVER SULFADIAZINE
 SKELAXIN, METAXALONE
 SYNERCID, DALFOPRISTIN
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC SUB KING PHARMACEUTICALS INC
 TAPAZOLE, METHIMAZOLE
 TUSSIGON, HOMATROPINE METHYLBROMIDE

KING PHARMS LLC

* KING PHARMACEUTICALS LLC
 AVINZA, MORPHINE SULFATE

KING PHARMS R AND D

* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC
 CYTOMEL, LIOTHYRONINE SODIUM
 LEVOXYL, LEVOTHYROXINE SODIUM **

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ******KNIGHT THERAPS**

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KREITCHMAN PET CTR

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13

KREMERS URBAN DEV

* KREMERS URBAN DEVELOPMENT CO
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM

KREMERS URBAN PHARMS

* KREMERS URBAN PHARMACEUTICALS INC
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MONOKET, ISOSORBIDE MONONITRATE
OMEPRazole, OMEPRazole

KRKA TOVARNA ZDRAVIL

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
LANSOPRAZOLE, LANSOPRAZOLE

KUDCO IRELAND

* KUDCO IRELAND LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
LETROZOLE, LETROZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

KVK TECH

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**** L ******L PERRIGO CO**

* L PERRIGO CO
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

LAB HRA PHARMA

* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

LANDELA PHARM

* LANDELA PHARMACEUTICAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

LANNETT

* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
* LANNETT HOLDINGS INC
BACLOFEN, BACLOFEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LANNETT HOLDINGS INC**

BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
TERBUTALINE SULFATE, TERBUTALINE SULFATE
URSODIOL, URSODIOL

LANNETT HOLDINGS INC*** LANNETT HOLDINGS INC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CODEINE SULFATE, CODEINE SULFATE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LETROZOLE, LETROZOLE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHOCARBAMOL, METHOCARBAMOL
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTERMINE RESIN COMPLEX, PHENTERMINE RESIN COMPLEX
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LANTHEUS MEDCL*** LANTHEUS MEDICAL IMAGING INC**

ABLAVAR, GADOFOSVESET TRISODIUM
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

LANTHEUS MEDICAL*** LANTHEUS MEDICAL IMAGING INC**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

LARKEN LABS*** LARKEN LABORATORIES INC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

LAVIPHARM LABS*** LAVIPHARM LABORATORIES INC**

FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

LEHIGH VALLEY*** LEHIGH VALLEY TECHNOLOGIES INC**

OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

LEK PHARMS*** LEK PHARMACEUTICALS D D**

BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE

LEK PHARMS DD*** LEK PHARMACEUTICALS DD**

ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******LEO PHARMA AS**

- * LEO PHARMA AS
DOVONEX, CALCIPOTRIENE
PICATO, INGENOL MEBUTATE
TACLONEX, BETAMETHASONE DIPROPIONATE

LG LIFE

- * LG LIFE SCIENCES LTD
VALTROPIN, SOMATROPIN RECOMBINANT

LG LIFE SCIENCES

- * LG LIFE SCIENCES LTD
FACTIVE, GEMIFLOXACIN MESYLATE

LLOYD

- * LLOYD INC
LEVOTHROID, LEVOTHYROXINE SODIUM **

LNK

- * LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOREAL USA

- * LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

- * LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM

LUITPOLD

- * LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DACTINOMYCIN, DACTINOMYCIN
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
INJECTAFER, FERRIC CARBOXYMALTOSIDE
LATANOPROST, LATANOPROST
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUITPOLD PHARMACEUTICALS INC
 LEVOCARNITINE, LEVOCARNITINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MANNITOL 25%, MANNITOL
 METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROGESTERONE, PROGESTERONE
 SPRIX, KETOROLAC TROMETHAMINE
 TORSEMIDE, TORSEMIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 VENOFER, IRON SUCROSE
 ZIDOVUDINE, ZIDOVUDINE

LUKARE MEDICAL LLC

* LUKARE MEDICAL LLC
 ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUMARA HEALTH INC

* LUMARA HEALTH INC
 MAKENA, HYDROXYPROGESTERONE CAPROATE

LUNDBECK LLC

* LUNDBECK LLC
 ONFI, CLOBAZAM
 SABRIL, VIGABATRIN

LUNDBECK NA LTD

* LUNDBECK NA LTD
 NORTHERA, DROXIDOPA

LUPIN

* LUPIN LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTRIAZONE, CEFTRIAZONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOVASTATIN, LOVASTATIN
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TOPIRAMATE, TOPIRAMATE
 TRANDOLAPRIL, TRANDOLAPRIL

LUPIN ATLANTIS

* LUPIN ATLANTIS HOLDINGS SA
 ANTARA (MICRONIZED), FENOFIBRATE

LUPIN LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LIMITED**

LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

*** LUPIN LTD**

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN, CIPROFLOXACIN
 DAYSEE, ETHINYL ESTRADIOL
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE, FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GATIFLOXACIN, GATIFLOXACIN
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEFENAMIC ACID, MEFENAMIC ACID
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 NIACIN, NIACIN
 NIKKI, DROSPIRENONE
 NORETHINDRONE, NORETHINDRONE
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RIFABUTIN, RIFABUTIN
 SUPRAX, CEFIXIME
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VYFEMLA, ETHINYL ESTRADIOL
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS*** LUPIN PHARMACEUTICALS INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLDIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN PHARMACEUTICALS INC**

RIFAMPIN, RIFAMPIN

SUPRAX, CEFIXIME

ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE*** LYNE LABORATORIES INC**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

DEXAMETHASONE, DEXAMETHASONE

HYDROCORTISONE, HYDROCORTISONE

LEVOCARNITINE, LEVOCARNITINE

TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO*** L PERRIGO CO**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)

ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)

CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)

CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)

DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)

FAMOTIDINE, FAMOTIDINE (OTC)

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)

IBUPROFEN, IBUPROFEN (OTC)

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)

LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LORATADINE, LORATADINE (OTC)

MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)

MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TAB-PROFEN, IBUPROFEN (OTC)

TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP***** MASSACHUSETTS GENERAL HOSP**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD*** MACLEODS PHARMACEUTICALS LTD**

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

FAMCICLOVIR, FAMCICLOVIR

IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

IRBESARTAN, IRBESARTAN

LEVOFLOXACIN, LEVOFLOXACIN

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

MONTELUKAST SODIUM, MONTELUKAST SODIUM

OLANZAPINE, OLANZAPINE

PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE

RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

SILDENAFIL CITRATE, SILDENAFIL CITRATE

VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

MALLINCKRODT*** MALLINCKRODT CHEMICAL INC**

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

METHADOSE, METHADONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MALLINCKRODT INC**

ANEXSIA 5/325, ACETAMINOPHEN
 ANEXSIA 7.5/325, ACETAMINOPHEN
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
 OPTIMARK, GADOVERSETAMIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

*** MALLINCKRODT MEDICAL INC**

CONRAY 30, IOTHALAMATE MEGLUMINE
 CONRAY 43, IOTHALAMATE MEGLUMINE
 CONRAY, IOTHALAMATE MEGLUMINE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
 MD-76R, DIATRIZOATE MEGLUMINE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OPTIRAY 240, IOVERSOL
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
 SODIUM IODIDE I 131, SODIUM IODIDE I-131
 TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
 TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT

MALLINCKRODT INC*** MALLINCKRODT INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 EXALGO, HYDROMORPHONE HYDROCHLORIDE
 FENTANYL-100, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-75, FENTANYL
 GABLOFEN, BACLOFEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE
 TOFRANIL-PM, IMIPRAMINE PAMOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MALLINCKRODT INC
XARTEMIS XR, ACETAMINOPHEN

MALLINCKRODT LLC

* MALLINCKRODT LLC
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE

MARATHON PHARMS

* MARATHON PHARMACEUTICALS LLC
PEPCID, FAMOTIDINE
SECONAL SODIUM, SECOBARBITAL SODIUM

MARATHON PHARMS LLC

* MARATHON PHARMACEUTICALS LLC
IPRIVASK, DESIRUDIN RECOMBINANT

MARKSANS PHARMA

* MARKSANS PHARMA LTD
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN

MATAWAN PHARMS

* MATAWAN PHARMACEUTICALS LLC
TRETINOIN, TRETINOIN

MATRIX LABS LTD

* MATRIX LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
NIFEDIPINE, NIFEDIPINE
STAVUDINE, STAVUDINE

MAYER LABS INC

* MAYER LABORATORIES INC
TODAY, NONOXYNOL-9 (OTC)

MAYNE PHARMA

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX, DOXYCYCLINE HYCLATE
DOXTERIC, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IMODIUM A-D EZ CHEWS, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
MOTRIN IB, IBUPROFEN (OTC)
MOTRIN MIGRAINE PAIN, IBUPROFEN (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

MCNEIL CONS

* MCNEIL CONSUMER HEALTHCARE
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM, LOPERAMIDE HYDROCHLORIDE
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL, ACETAMINOPHEN (OTC)

MCNEIL CONSUMER

* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MCNEIL CONSUMER HEALTHCARE DIV MCNEIL PPC INC
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC, CETIRIZINE HYDROCHLORIDE

MCPRF

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N-13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F-18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MEDA PHARMS

* MEDA PHARMACEUTICALS
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE

* MEDA PHARMACEUTICALS INC
ANADROL-50, OXYMETHOLONE
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
AVC, SULFANILAMIDE
BUTISOL SODIUM, BUTABARBITAL SODIUM
CESAMET, NABILONE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COLYTE, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEMADEX, TORSEMIDE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LUFYLLIN, DYPHYLLINE
MUSE, ALPROSTADIL
OPTIVAR, AZELASTINE HYDROCHLORIDE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
TRILYTE, POLYETHYLENE GLYCOL 3350

* MEDA PHARMACEUTICALS MEDA PHARMACEUTICALS INC
SOMA COMPOUND W/ CODEINE, ASPIRIN
SOMA COMPOUND, ASPIRIN
SOMA, CARISOPRODOL

MEDA PHARMS INC

* MEDA PHARMACEUTICALS INC
AEROSPAN HFA, FLUNISOLIDE

MEDAC PHARMA INC

* MEDAC PHARMA INC
RASUVO, METHOTREXATE

MEDEFIL INC

* MEDEFIL INC
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

MEDICIS

* MEDICIS PHARMACEUTICAL CORP
ALDARA, IMIQUIMOD
AMMONUL, SODIUM BENZOATE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESTRASORB, ESTRADIOL HEMIHYDRATE
LOPROX, CICLOPIROX
LUZU, LULICONAZOLE
MAXAIR, PIRBUTEROL ACETATE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
NORFLEX, ORPHENADRINE CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEDICIS PHARMACEUTICAL CORP
NORGESIC FORTE, ASPIRIN
NORGESIC, ASPIRIN
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SYNACORT, HYDROCORTISONE
THEOLAIR, THEOPHYLLINE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZYCLARA, IMIQUIMOD

MEDICURE

* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE

MEDIGENE AG

* MEDIGENE AG
VEREGEN, SINECATECHINS

MEDIMETRIKS PHARMS

* MEDIMETRIKS PHARMACEUTICALS INC
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDTECH PRODUCTS

* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT-3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEDTRONIC NEURO

* MEDTRONIC NEUROMODULATION
LIORESAL, BACLOFEN

MERCK

* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMAX, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
ZOLINZA, VORINOSTAT
* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
CLINORIL, SULINDAC
PRINIVIL, LISINAPRIL
PRINZIDE, HYDROCHLOROTHIAZIDE
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
ZOCOR, SIMVASTATIN

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

MERCK SANTE SAS

* MERCK SANTE SAS
CYANOKIT, HYDROXOCOBALAMIN

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
ASMANEX HFA, MOMETASONE FUROATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MERCK SHARP AND DOHME CORP
 ASMANEX TWISTHALER, MOMETASONE FUROATE
 BELSOMRA, SUVOREXANT
 CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
 CLARINEX D 24 HOUR, DESLORATADINE
 CLARINEX, DESLORATADINE
 CLARINEX-D 12 HOUR, DESLORATADINE
 COZAAR, LOSARTAN POTASSIUM
 CRIXIVAN, INDINAVIR SULFATE
 DIPROLENE AF, BETAMETHASONE DIPROPIONATE
 DIPROLENE, BETAMETHASONE DIPROPIONATE
 DULERA, FORMOTEROL FUMARATE
 ELOCON, MOMETASONE FUROATE
 GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
 HYZAAR, HYDROCHLOROTHIAZIDE
 INVANZ, ERTAPENEM SODIUM
 ISENTRESS, RALTEGRAVIR POTASSIUM
 JANUMET XR, METFORMIN HYDROCHLORIDE
 JANUMET, METFORMIN HYDROCHLORIDE
 JANUVIA, SITAGLIPTIN PHOSPHATE
 LIPTRUZET, ATORVASTATIN CALCIUM
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 NASONEX, MOMETASONE FUROATE MONOHYDRATE
 NITRO-DUR, NITROGLYCERIN
 NOXAFIL, POSACONAZOLE
 REBETOL, RIBAVIRIN
 SINEMET CR, CARBIDOPA
 SINEMET, CARBIDOPA
 STROMEKTOL, IVERMECTIN
 TEMODAR, TEMOZOLOMIDE
 VICTRELIS, BOCEPREVIR
 ZONTIVITY, VORAPAXAR SULFATE

MERIDIAN MEDCL

* MERIDIAN MEDICAL TECHNOLOGIES INC
 DUODOTE, ATROPINE
 * MERIDIAN MEDICAL TECHNOLOGIES INC SUB KING PHARMACEUTICALS INC
 ALSUMA, SUMATRIPTAN SUCCINATE

MERIDIAN MEDCL TECHN

* MERIDIAN MEDICAL TECHNOLOGIES INC
 ATROPEN, ATROPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

MERRO PHARM

* MERRO PHARMACEUTICAL CO LTD
 IBUPROFEN, IBUPROFEN (OTC)

MERZ PHARMS

* MERZ PHARMACEUTICALS LLC
 CUVPOSA, GLYCOPYRROLATE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 ONMEL, ITRACONAZOLE

METHAPHARM

* METHAPHARM INC
 LEVETIRACETAM, LEVETIRACETAM
 PROVOCHOLINE, METHACHOLINE CHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
 MEFENAMIC ACID, MEFENAMIC ACID
 NEVIRAPINE, NEVIRAPINE
 SIMVASTATIN, SIMVASTATIN

MICRO LABS LTD INDIA

* MICRO LABS LTD INDIA
 CROMOLYN SODIUM, CROMOLYN SODIUM
 GLIMEPIRIDE, GLIMEPIRIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MICRO LABS LTD INDIA

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIKAH PHARMA

* MIKAH PHARMA LLC

DANTROLENE SODIUM, DANTROLENE SODIUM

ISRADIPINE, ISRADIPINE

LOXAPINE SUCCINATE, LOXAPINE SUCCINATE

PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

MIKART

* MIKART INC

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

AMINOCAPROIC ACID, AMINOCAPROIC ACID

AMINOCAPROIC, AMINOCAPROIC ACID

BENZONATATE, BENZONATATE

BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN

BUTAPAP, ACETAMINOPHEN

CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

CHLORZOXAZONE, CHLORZOXAZONE

DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE

ETHOSUXIMIDE, ETHOSUXIMIDE

HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

METHAZOLAMIDE, METHAZOLAMIDE

OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

PYRAZINAMIDE, PYRAZINAMIDE

TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

MILLENNIUM PHARMS

* MILLENNIUM PHARMACEUTICALS INC

VELCADE, BORTEZOMIB

MIPS CRF

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY

AMMONIA N 13, AMMONIA N-13

MIRROR PHARMS

* MIRROR PHARMACEUTICALS LLC

CARISOPRODOL AND ASPIRIN, ASPIRIN

CARISOPRODOL, CARISOPRODOL

PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

PROBENECID AND COLCHICINE, COLCHICINE

MISSION PHARMA

* MISSION PHARMACAL CO

BINOSTO, ALENDRONATE SODIUM

LITHOSTAT, ACETOHYDROXAMIC ACID

PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

TEXACORT, HYDROCORTISONE

THIOLA, TIOPRONIN

TINDAMAX, TINIDAZOLE

UROKIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

* MISSION PHARMACAL CO

CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

MIST PHARMS LLC

* MIST PHARMACEUTICALS LLC

NITROMIST, NITROGLYCERIN

MOBERG PHARMA NORTH

* MOBERG PHARMA NORTH AMERICA LLC

CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

MOBIUS THERAP

* MOBIUS THERAPEUTICS LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

* MONARCH PHARMACEUTICALS INC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
PEDIOTIC, HYDROCORTISONE
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MORTON GROVE

* MORTON GROVE PHARMACEUTICALS INC
LACTULOSE, LACTULOSE

MORTON GROVE PHARMS

* MORTON GROVE PHARMACEUTICALS INC
GENERLAC, LACTULOSE

MSD CONSUMER

* MSD CONSUMER CARE INC
ZEGERID OTC, OMEPRAZOLE (OTC)

MSD INTL

* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

MSD INTL GMBH

* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

MUSTAFA NEVSAT

* MUSTAFA NEVSAT ILAC SANAYII AS
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

MUSTAFA NEVZAT

* MUSTAFA NEVZAT ILAC SANAYII AS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
VECURONIUM BROMIDE, VECURONIUM BROMIDE

MUSTAFA NEVZAT ILAC

* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

MUTUAL PHARM

* MUTUAL PHARMACEUTICAL CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MUTUAL PHARMACEUTICAL CO INC
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ERGOLOID MESYLATES, ERGOLOID MESYLATES
 FELODIPINE, FELODIPINE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL, MINOXIDIL
 NYSTATIN, NYSTATIN
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PINDOLOL, PINDOLOL
 PIROXICAM, PIROXICAM
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 TEMAZEPAM, TEMAZEPAM
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

MUTUAL PHARM CO INC

* MUTUAL PHARMACEUTICAL CO INC
 FIBRICOR, FENOFIBRIC ACID
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 LEVETIRACETAM, LEVETIRACETAM
 QUALAQUIN, QUININE SULFATE

MUTUAL PHARMA

* MUTUAL PHARMACAL CO
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

MYLAN

* MYLAN LABORATORIES INC
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 ETODOLAC, ETODOLAC
 OLANZAPINE, OLANZAPINE
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

* MYLAN PHARMACEUTICALS
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

* MYLAN PHARMACEUTICALS INC
 ACARBOSE, ACARBOSE
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALLOPURINOL, ALLOPURINOL
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
ANASTROZOLE, ANASTROZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
AVITA, TRETINOIN
AZATHIOPRINE, AZATHIOPRINE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESTRADIOL, ESTRADIOL
ESTROPIRATE, ESTROPIRATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETOPOSIDE, ETOPOSIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN PHARMACEUTICALS INC**

FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUTAMIDE, FLUTAMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MELOXICAM, MELOXICAM
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NISOLDIPINE, NISOLDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN PHARMACEUTICALS INC**

NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PENTOXIFYLLINE, PENTOXIFYLLINE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PROBENECID, PROBENECID
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 STAVUDINE, STAVUDINE
 SULINDAC, SULINDAC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 URSODIOL, URSODIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

MYLAN INSTITUTIONAL*** MYLAN INSTITUTIONAL INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN INSTITUTIONAL INC
SULFAMYLON, MAFENIDE ACETATE

* MYLAN INSTITUTIONAL LLC
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
CARBOPLATIN, CARBOPLATIN
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENLON-PLUS, ATROPINE SULFATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
FOMEPIZOLE, FOMEPIZOLE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PENTOSTATIN, PENTOSTATIN
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM

MYLAN LABS

* MYLAN LABORATORIES LTD
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
NEVIRAPINE, NEVIRAPINE

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
VALSARTAN, VALSARTAN

MYLAN PHARMS INC

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMNESTEEM, ISOTRETINOIN
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
AVITA, TRETINOIN
BACLOFEN, BACLOFEN
CABERGOLINE, CABERGOLINE
CAPECITABINE, CAPECITABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN PHARMACEUTICALS INC**

CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIDANOSINE, DIDANOSINE
DIGOXIN, DIGOXIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENTACAPONE, ENTACAPONE
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESZOPICLONE, ESZOPICLONE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LITHIUM CARBONATE, LITHIUM CARBONATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RAMIPRIL, RAMIPRIL
 REPAGLINIDE, REPAGLINIDE
 RILUZOLE, RILUZOLE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIMVASTATIN, SIMVASTATIN
 SUNITINIB MALATE, SUNITINIB MALATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLAZAMIDE, TOLAZAMIDE
 TOLBUTAMIDE, TOLBUTAMIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VORICONAZOLE, VORICONAZOLE
 ZIDOVUDINE, ZIDOVUDINE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZONISAMIDE, ZONISAMIDE

* MYLAN PHARMACEUTICALS INC.
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 NIZATIDINE, NIZATIDINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

MYLAN SPECIALT

* MYLAN SPECIALTY LP
 ACCUNEB, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DUONEB, ALBUTEROL SULFATE
 EPIPEN JR., EPINEPHRINE
 EPIPEN, EPINEPHRINE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 PERFORMIST, FORMOTEROL FUMARATE

MYLAN TECHNOLOGIES

* MYLAN TECHNOLOGIES
 XULANE, ETHINYL ESTRADIOL

* MYLAN TECHNOLOGIES INC
 CLONIDINE, CLONIDINE
 ESTRADIOL, ESTRADIOL
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN TECHNOLOGIES INC
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NITROGLYCERIN, NITROGLYCERIN

**** N ******NATCO PHARMA**

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
LANSOPRAZOLE, LANSOPRAZOLE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE

NAVIDEA BIOPHARMS

* NAVIDEA BIOPHARMACEUTICALS INC
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT

NAVINTA LLC

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

NCM USA BRONX LLC

* NCM USA BRONX LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAP INC

* NEOS THERAPEUTICS INC
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

NEPHRON

* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

NESHER PHARMS

* NESHER PHARMACEUTICALS USA LLC
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

NEW RIVER

* NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

NEXGEN PHARMA

* NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NEXGEN PHARMA INC
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NEXGEN PHARMA INC

* NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

NEXTWAVE PHARMS

* NEXTWAVE PHARMACEUTICALS INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS

* NEXUS PHARMACEUTICALS INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
LEVOFLOXACIN, LEVOFLOXACIN

NIAGARA PHARMS

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NORTEC DEV ASSOC

* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR HLTHCARE

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

NOSTRUM

* NOSTRUM PHARMACEUTICALS INC
CARBAMAZEPINE, CARBAMAZEPINE
THEOPHYLLINE, THEOPHYLLINE

NOSTRUM LABS

* NOSTRUM LABORATORIES INC
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPYRIMIDINE

NOVADEL

* NOVADEL PHARMA INC
ZOLPIDEM, ZOLPIDEM TARTRATE

NOVARTIS

* NOVARTIS CONSUMER HEALTH INC
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
LAMISIL AT, TERBINAFINA (OTC)
LAMISIL AT, TERBINAFINA HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINA HYDROCHLORIDE (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)
TRANSDERM SCOP, SCOPOLAMINE
VAGISTAT-1, TIOCONAZOLE (OTC)
VOLTAREN, DICLOFENAC SODIUM
* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
AMTURNIDE, ALISKIREN HEMIFUMARATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
ARCAPTA NEOHALER, INDACATEROL MALEATE
CATAFLAM, DICLOFENAC POTASSIUM
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
ESTRADERM, ESTRADIOL
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FAMVIR, FAMCICLOVIR
FANAPT, ILOPERIDONE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FORADIL, FORMOTEROL FUMARATE
GILENYA, FINGOLIMOD
GLEEVEC, IMATINIB MESYLATE
HYDERGINE, ERGOLOID MESYLATES
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMPRENE, CLOFAZIMINE
LESCOL XL, FLUVASTATIN SODIUM
LESCOL, FLUVASTATIN SODIUM
LOPRESSOR, METOPROLOL TARTRATE
LOTREL, AMLODIPINE BESYLATE
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
OCUPRESS, CARTEOLOL HYDROCHLORIDE
RECLAST, ZOLEDRONIC ACID
REGITINE, PHENTOLAMINE MESYLATE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKAMLO, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE
TOBI PODHALER, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
TYZEKA, TELBIVUDINE
VIVELLE, ESTRADIOL
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
VOLTAREN-XR, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE
TOBI, TOBRAMYCIN

NOVARTIS PHARMS CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
SIGNIFOR LAR, PASIREOTIDE PAMOATE
ZYKADIA, CERITINIB

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE

NOVAST LABS LTD

* NOVAST LABORATORIES LTD
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MONO-LINYAH, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
PHILITH, ETHINYL ESTRADIOL
PIMTREA, DESOGESTREL
SETLAKIN, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
WEA, ETHINYL ESTRADIOL
YELA, DROSPIRENONE

NOVEL LABS INC

* NOVEL LABORATORIES INC
FAMOTIDINE, FAMOTIDINE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
NITROFURANTOIN, NITROFURANTOIN
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,
PEG-3350;POTASSIUM CHLORIDE;SODIUM BICARBONATE;SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIMETHOPRIM, TRIMETHOPRIM

NOVEN

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

NOVEN PHARMS INC

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE

NOVEN THERAP

* NOVEN THERAPEUTICS LLC
BRISDELLE, PAROXETINE MESYLATE
PEXEVA, PAROXETINE MESYLATE

NOVEX

* NOVEX PHARMA
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE

NOVO NORDISK

* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

NOVO NORDISK INC

* NOVO NORDISK INC
LEVEMIR FLEXPEN, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVO NORDISK INC**

LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPOR, SOMATROPIN RECOMBINANT
NORDITROPIN NORDIFLEX, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
PRANDIMET, METFORMIN HYDROCHLORIDE
PRANDIN, REPAGLINIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL*** NOVOCOL PHARMACEUTICAL INC**

ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE

NOVOCOL INC*** NOVOCOL INC**

LIDOCAINE, LIDOCAINE

NPS PHARMS INC*** NPS PHARMACEUTICALS INC**

GATTEX KIT, TEDUGLUTIDE RECOMBINANT

NU PHARM*** NU PHARM INC**

DIVALPROEX SODIUM, DIVALPROEX SODIUM

NUVO PHARM INC*** NUVO PHARMACEUTICAL INC**

SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

NUVO RES INC*** NUVO RESEARCH INC**

PENNSAID, DICLOFENAC SODIUM

NYCOMED US*** NYCOMED US INC**

TERCONAZOLE, TERCONAZOLE

**** O ******OAK PHARMS***** OAK PHARMACEUTICALS INC**

NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

OAK PHARMS AKORN*** OAK PHARMACEUTICALS INC SUB AKORN INC**

COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

OAK PHARMS INC*** OAK PHARMACEUTICALS INC**

ZIOPTAN, TAFLUPROST

*** OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC**

AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

ODYSSEY PHARMS*** ODYSSEY PHARMACEUTICALS INC**

ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

* ODYSSEY PHARMACEUTICALS INC
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
VALSARTAN, VALSARTAN

OLTA PHARMS

* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

OMAN PHARM PRODUCTS

* OMAN PHARMACEUTICAL PRODUCTS CO LLC
NEOMYCIN SULFATE, NEOMYCIN SULFATE

OMEROS

* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

ONCO THERAPIES LTD

* ONCO THERAPIES LTD
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CYTARABINE, CYTARABINE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE, VINORELBINE

ONY

* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

ONYX PHARMS

* ONYX PHARMACEUTICALS INC
KYPROLIS, CARFILZOMIB

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORCHID HLTHCARE

* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFdinir
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** O **

*** ORCHID HEALTHCARE**

ESZOPICLONE, ESZOPICLONE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON

OREXO AB

* OREXO AB
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON USA INC

* ORGANON USA INC
CYCLESSA, DESOGESTREL
DESOGEN, DESOGESTREL
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
IMPLANON, ETNOGESTREL
NEXPLANON, ETNOGESTREL
NUVARING, ETHINYL ESTRADIOL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL

ORION CORP ORION

* ORION CORP ORION PHARMA
SPIRONOLACTONE, SPIRONOLACTONE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

ORIT LABS LLC

* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
LEVETIRACETAM, LEVETIRACETAM

ORPHAN EUROPE

* ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID

OSI PHARMS

* OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA PHARM

* OSMOTICA PHARMACEUTICAL CORP
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM CORP

* OSMOTICA PHARMACEUTICAL CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

* OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

OTSUKA

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE
PLETAL, CILOSTAZOL

* OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC
ABILIFY, ARIPIPRAZOLE

OTSUKA AMERICA PHARM

* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

OTSUKA PHARM

* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE

OUTLOOK PHARMS

* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**** P ******P AND L DEV LLC**

* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE

* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

* PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

PACK PHARMS LLC

* PACK PHARMACEUTICALS LLC
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM

PADDOCK

* PADDOCK LABORATORIES INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

PADDOCK LABS

* PADDOCK LABORATORIES INC
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE

PADDOCK LLC

* PADDOCK LABORATORIES LLC
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ERYTHRA-DERM, ERYTHROMYCIN
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
INDOMETHACIN, INDOMETHACIN
KIONEX, SODIUM POLYSTYRENE SULFONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PADDOCK LABORATORIES LLC**

LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LORAZEPAM, LORAZEPAM
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PALADIN LABS

*** PALADIN LABS USA INC**
ANTIZOL, FOMEPIZOLE

PANACEA BIOTEC LTD

*** PANACEA BIOTEC LTD**
TACROLIMUS, TACROLIMUS

PAR FORM

*** PAR FORMULATIONS PRIVATE LTD**
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE

PAR PHARM

*** PAR PHARMACEUTICAL**
NABUMETONE, NABUMETONE
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

*** PAR PHARMACEUTICAL INC**
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLDIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CAPOTEN, CAPTOPRIL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PAR PHARMACEUTICAL INC**

MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NASCOBAL, CYANOCOBALAMIN
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXANDROLONE, OXANDROLONE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVOPROST, TRAVOPROST
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

PAR PHARM INC*** PAR PHARMACEUTICAL INC**

AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

PAR STERILE PRODUCTS*** PAR STERILE PRODUCTS LLC**

ADRENALIN, EPINEPHRINE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
KETALAR, KETAMINE HYDROCHLORIDE
PITOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIOSTAT, LIOTHYRONINE SODIUM
VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK*** PARAGON BIOTECK INC**

PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC*** PARAPRO LLC**

NATROBA, SPINOSAD

PARKE DAVIS*** PARKE DAVIS DIV WARNER LAMBERT CO**

CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
DILANTIN, PHENYTOIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PARKE DAVIS DIV WARNER LAMBERT CO
DILANTIN-125, PHENYTOIN
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
ZARONTIN, ETHOSUXIMIDE
- * PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO
ZARONTIN, ETHOSUXIMIDE

PERNIX IRELAND LTD

- * PERNIX IRELAND LTD
TREXIMET, NAPROXEN SODIUM

PERNIX THERAP

- * PERNIX THERAPEUTICS LLC
CEDAX, CEFTIBUTEN DIHYDRATE

PERNIX THERAPS LLC

- * PERNIX THERAPEUTICS LLC
SILENOR, DOXEPIN HYDROCHLORIDE

PERRIGO

- * PERRIGO CO
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CICLOPIROX, CICLOPIROX
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
STIE-CORT, HYDROCORTISONE

PERRIGO CO TENNESSEE

- * PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

PERRIGO ISRAEL

- * PERRIGO ISRAEL PHARMACEUTICALS
FLUOCINONIDE, FLUOCINONIDE
- * PERRIGO ISRAEL PHARMACEUTICALS LTD
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUTOCONAZOLE NITRATE, BUTOCONAZOLE NITRATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PERRIGO ISRAEL PHARMACEUTICALS LTD
 NITROGLYCERIN, NITROGLYCERIN
 TESTOSTERONE, TESTOSTERONE

PERRIGO NEW YORK

* PERRIGO NEW YORK INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMMONIUM LACTATE, AMMONIUM LACTATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CENTANY, MUPIROCIN
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 KETOCONAZOLE, KETOCONAZOLE
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 NYSTATIN, NYSTATIN
 PERMETHRIN, PERMETHRIN
 PERMETHRIN, PERMETHRIN (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO R AND D

* PERRIGO R AND D CO
 CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DESLORATADINE, DESLORATADINE
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVONORGESTREL, LEVONORGESTREL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAPROXEN, NAPROXEN
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

PERRIGO UK FINCO

* PERRIGO UK FINCO LTD PARTNERSHIP
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

PETNET

* PETNET SOLUTIONS INC
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PF PRISM CV

* PF PRISM CV
 LYRICA, PREGABALIN
 RAPAMUNE, SIROLIMUS
 TORISEL, TEMSIROLIMUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PF PRISM CV**

TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE
ZMAX, AZITHROMYCIN

PFIZER*** PFIZER CENTRAL RESEARCH**

DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN

*** PFIZER CHEMICALS DIV PFIZER INC**

DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN

*** PFIZER INC**

ACOVA, ARGATROBAN
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CADUET, AMLODIPINE BESYLATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
DIFLUCAN IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
ELELYSO, TALIGLUCERASE ALFA
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
INLYTA, AXITINIB
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LIPITOR, ATORVASTATIN CALCIUM
LORATADINE, LORATADINE (OTC)
NAVANE, THIOETHIXENE
NORVASC, AMLODIPINE BESYLATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
SONATA, ZALEPLON
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
ZITHROMAX, AZITHROMYCIN

*** PFIZER LABORATORIES DIV PFIZER INC**
CARDURA, DOXAZOSIN MESYLATE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PERMAPEN, PENICILLIN G BENZATHINE
PFIZERPEN, PENICILLIN G POTASSIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PFIZER LABORATORIES DIV PFIZER INC
PROCARDIA XL, NIFEDIPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
- * PFIZER PHARMACEUTICALS INC
ZOLOFT, SERTRALINE HYDROCHLORIDE
- * PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

PFIZER CONS HLTHCARE

- * PFIZER CONSUMER HEALTHCARE
ADVIL, IBUPROFEN SODIUM (OTC)

PFIZER INC

- * PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
ELLENC, EPIRUBICIN HYDROCHLORIDE
GEODON, ZIPRASIDONE HYDROCHLORIDE
NICOTROL, NICOTINE

PFIZER IRELAND

- * PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE
VIAGRA, SILDENAFIL CITRATE

PFIZER LABS

- * PFIZER LABS
DOCETAXEL, DOCETAXEL

PFIZER PHARMS

- * PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
DILANTIN, PHENYTOIN
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

PHARM ASSOC

- * PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
- * PHARMACEUTICAL ASSOC INC DIV BEACH PRODUCTS
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LACTULOSE, LACTULOSE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TRIHENXYPHENIDYL HYDROCHLORIDE, TRIHENXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
- * PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

PHARMA-MED INC

- * PHARMA-MED INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PHARMACEUTICS**

* PHARMACEUTICS INTERNATIONAL INC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

PHARMACHEMIE BV

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
ANSAID, FLURBIPROFEN
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
COLESTID, COLESTIPOL HYDROCHLORIDE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DIDREX, BENZPHETAMINE HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN .625, ESTROPIPATE
OGEN 1.25, ESTROPIPATE
OGEN 2.5, ESTROPIPATE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
XALATAN, LATANOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PHARMACIA AND UPJOHN CO
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID
- * PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

PHARMACYCLICS INC

- * PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

PHARMAFORCE

- * PHARMAFORCE INC
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE

PHARMALUCENCE

- * PHARMALUCENCE INC
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

PHARMAX

- * PHARMAX GROUP INC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE

PHARMS

- * PHARMACEUTICALS INTERNATIONAL
ZOLEDRONIC ACID, ZOLEDRONIC ACID

PHOTOCURE ASA

- * PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE

- * PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

PIERRE FABRE DERMA

- * PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

- * PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

PIRAMAL CRITICAL

- * PIRAMAL CRITICAL CARE INC
ENFLURANE, ENFLURANE
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE

PIRAMAL ENT

- * PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

PIRAMAL IMAGING

- * PIRAMAL IMAGING SA
NEURACEQ, FLORBETABEN F-18

PLIVA

- * PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
PENTOXIFYLLINE, PENTOXIFYLLINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PLIVA INC**

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

PLIVA HRVATSKA DOO*** PLIVA HRVATSKA DOO**

ADAPALENE, ADAPALENE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

PLIVA LACHEMA*** PLIVA LACHEMA AS**

CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

PLIVA PHARM IND*** PLIVA PHARMACEUTICAL INDUSTRY INC**

TORSEMIDE, TORSEMIDE

PLX PHARMA*** PLX PHARMA INC**

ASPIRIN, ASPIRIN (OTC)

POHL BOSKAMP*** POHL BOSKAMP**

NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYMEDICA*** POLYMEDICA INDUSTRIES INC**

NEOPAP, ACETAMINOPHEN (OTC)

POWDER PHARMS*** POWDER PHARMACEUTICALS INC**

ZINGO, LIDOCAINE HYDROCHLORIDE

PRAGMA PHARMS LLC*** PRAGMA PHARMACEUTICALS LLC**

MOXATAG, AMOXICILLIN

PRECISION DERMAT*** PRECISION DERMATOLOGY INC**

CLINDAGEL, CLINDAMYCIN PHOSPHATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE
PODOFILOX, PODOFILOX

PRECISION DOSE*** PRECISION DOSE INC**

RISPERIDONE, RISPERIDONE

PRINSTON INC*** PRINSTON PHARMACEUTICAL INC**

BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
PAROXETINE, PAROXETINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PROCTER AND GAMBLE**

- * PROCTER AND GAMBLE PHARMACEUTICALS INC SUB PROCTER AND GAMBLE CO
DIDRONEL, ETIDRONATE DISODIUM

PROF DSPLS

- * PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

PROMETHEUS LABS

- * PROMETHEUS LABORATORIES INC
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
RIDAURA, AURANOFIN
ZYLOPRIM, ALLOPURINOL

PROMIUS PHARMA

- * PROMIUS PHARMA LLC
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

PROMIUS PHARMA LLC

- * PROMIUS PHARMA LLC
CLODERM, CLOCORTOLONE PIVALATE

PROSAM LABS

- * PROSAM LABS LLC
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

PROSTRAKAN INC

- * PROSTRAKAN INC
FARESTON, TOREMIFENE CITRATE
SANCUSO, GRANISETRON

PROVENSIS

- * PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVIDENT PHARM

- * PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

PULMOFLOW INC

- * PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PULSION MEDCL

- * PULSION MEDICAL SYSTEMS AG
INDOCYANINE GREEN, INDOCYANINE GREEN

PURACAP PHARM

- * PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURDUE GMP

- * PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

PURDUE PHARM PRODS

- * PURDUE PHARMACEUTICAL PRODUCTS LP
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE

PURDUE PHARMA

- * PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

PURDUE PHARMA LP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PUREPAC PHARM

* PUREPAC PHARMACEUTICAL CO
DIPYRIDAMOLE, DIPYRIDAMOLE

PVT FORM

* PRIVATE FORMULATIONS INC
PROPOXYPHENE HYDROCHLORIDE, PROPOXYPHENE HYDROCHLORIDE

**** Q ******QILU PHARM CO LTD**

* QILU PHARMACEUTICAL CO LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

QUESTCOR PHARMS

* QUESTCOR PHARMACEUTICALS INC
H.P. ACTHAR GEL, CORTICOTROPIN

**** R ******RANBAXY**

* RANBAXY INC
ABSORICA, ISOTRETINOIN
GLYCOPYRROLATE, GLYCOPYRROLATE

* RANBAXY LABORATORIES INC
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
FAMOTIDINE, FAMOTIDINE (OTC)
HALOG, HALCINONIDE
KENALOG, TRIAMCINOLONE ACETONIDE
LAC-HYDRIN, AMMONIUM LACTATE
RISPERIDONE, RISPERIDONE
ULTRAVATE, HALOBETASOL PROPIONATE

* RANBAXY LABORATORIES LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

- * RANBAXY LABORATORIES LTD
 - LORATADINE REDIDOSE, LORATADINE (OTC)
 - LORATADINE, LORATADINE (OTC)
 - LORAZEPAM, LORAZEPAM
 - MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 - ONDANSETRON, ONDANSETRON
 - OXCARBAZEPINE, OXCARBAZEPINE
 - PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SIMVASTATIN, SIMVASTATIN
 - SOTRET, ISOTRETINOIN
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TOPIRAMATE, TOPIRAMATE
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * RANBAXY PHARMACEUTICALS INC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - AMOXICILLIN, AMOXICILLIN
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 - RIOMET, METFORMIN HYDROCHLORIDE
 - SOTRET, ISOTRETINOIN

RANBAXY LABS LTD

- * RANBAXY LABORATORIES LIMITED
 - NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
- * RANBAXY LABORATORIES LTD
 - ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - FELODIPINE, FELODIPINE
 - FENOFIBRATE, FENOFIBRATE
 - MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

RAPTOR INC

- * RAPTOR PHARMACEUTICALS INC
 - PROCYSBI, CYSTEAMINE BITARTRATE

RARE DIS THERAP

- * RARE DISEASE THERAPEUTICS INC
 - CYSTADANE, BETAINES HYDROCHLORIDE

RECIP

- * RECIP AB
 - THYROSAFE, POTASSIUM IODIDE (OTC)

RECKITT BENCKISER

- * RECKITT BENCKISER LLC
 - DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
 - MUCINEX D, GUAIFENESIN (OTC)
 - MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 - MUCINEX, GUAIFENESIN (OTC)
- * RECKITT BENCKISER PHARMACEUTICALS INC
 - BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 - SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

RECORDATI RARE

- * RECORDATI RARE DISEASES INC
 - CHEMET, SUCCIMER
 - COSMEGEN, DACTINOMYCIN
 - DESOXYN, METHAMPHETAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RECORDATI RARE DISEASES INC
INDOCIN, INDOMETHACIN SODIUM
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

REMPEX PHARMS INC

* REMPEX PHARMACEUTICALS INC
MINOCIN, MINOCYCLINE HYDROCHLORIDE

RENAISSANCE PHARMA

* RENAISSANCE PHARMA US HOLDINGS INC
ELIMITE, PERMETHRIN

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
UNIPHYL, THEOPHYLLINE

RICONPHARMA LLC

* RICONPHARMA LLC
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE

RISING PHARMS INC

* RISING PHARMACEUTICALS INC
PARICALCITOL, PARICALCITOL

ROCHE PALO

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

ROCKWELL MEDCL

* ROCKWELL MEDICAL TECHNOLOGIES INC
CALCITRIOL, CALCITRIOL

ROMARK

* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

ROSEDALE THERAPEUTIC

* ROSEDALE THERAPEUTICS
ERGOMAR, ERGOTAMINE TARTRATE

ROUSES POINT PHARMS

* ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

ROXANE

* ROXANE LABORATORIES INC
ACARBOSE, ACARBOSE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******* ROXANE LABORATORIES INC**

CODEINE SULFATE, CODEINE SULFATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIGOXIN, DIGOXIN
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DISULFIRAM, DISULFIRAM
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ESZOPICLONE, ESZOPICLONE
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPYRINE, MERCAPTOPYRINE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* ROXANE LABORATORIES INC
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROXICET, ACETAMINOPHEN
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TINIDAZOLE, TINIDAZOLE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIDOVUDINE, ZIDOVUDINE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

RUBICON RES PVT LTD

* RUBICON RESEARCH PVT LTD
 METOPROLOL TARTRATE, METOPROLOL TARTRATE

**** S ******SAGE PRODS**

* SAGE PRODUCTS INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGENT AGILA

* SAGENT AGILA LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SAGENT PHARMS

* SAGENT PHARMACEUTICALS INC
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CARBOPLATIN, CARBOPLATIN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MESNA, MESNA
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXYTOCIN, OXYTOCIN
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

SAGENT STRIDES

* SAGENT STRIDES LLC
 ADENOSINE, ADENOSINE
 AZITHROMYCIN, AZITHROMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SAGENT STRIDES LLC
 BACITRACIN, BACITRACIN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

SALIX PHARMS

* SALIX PHARMACEUTICALS INC
 ANUSOL HC, HYDROCORTISONE
 APRISO, MESALAMINE
 COLAZAL, BALSALAZIDE DISODIUM
 DIURIL, CHLOROTHIAZIDE
 FULYZAQ, CROFELEMER
 GIAZO, BALSALAZIDE DISODIUM
 METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 PEPCID, FAMOTIDINE
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SALIX PHARMS INC

* SALIX PHARMACEUTICALS INC
 UCERIS, BUDESONIDE

SAMSON MEDCL

* SAMSON MEDICAL TECHNOLOGIES LLC
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFTRIAXONE, CEFTRIAXONE SODIUM

SANDOZ

* SANDOZ
 DOCETAXEL, DOCETAXEL

* SANDOZ CANADA INC
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FLUMAZENIL, FLUMAZENIL
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

* SANDOZ INC
 ALPRAZOLAM, ALPRAZOLAM
 ALTAVERA, ETHINYL ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ANASTROZOLE, ANASTROZOLE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFERGOT, CAFFEINE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinir
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DECITABINE, DECITABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ESTARYLLA, ETHINYL ESTRADIOL
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
INTROVALE, ETHINYL ESTRADIOL
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LONOX, ATROPINE SULFATE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRazole, OMEPRazole
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RESERPINE, RESERPINE
RIBAVIRIN, RIBAVIRIN
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE, SULFADIAZINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SYEDA, DROSPIRENONE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC*** SANDOZ CANADA INC**

PARICALCITOL, PARICALCITOL

SANDOZ INC*** SANDOZ INC**

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

SANOCHEMIA CORP USA

* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

SANOFI AVENTIS

* SANOFI AVENTIS
AFREZZA, INSULIN RECOMBINANT HUMAN

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL

* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
ANZEMET, DOLASETRON MESYLATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARALEN, CHLOROQUINE PHOSPHATE
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AUVI-Q, EPINEPHRINE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CANTIL, MEPENZOLATE BROMIDE
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER, CEFOTAXIME SODIUM
CLAFORAN, CEFOTAXIME SODIUM
CLOMID, CLOMIPHENE CITRATE
DDAVP, DESMOPRESSIN ACETATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DIABETA, GLYBURIDE
DRISDOL, ERGOCALCIFEROL
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
HIPREX, METHENAMINE HIPPURATE
KETEK, TELITHROMYCIN
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LASIX, FUROSEMIDE
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PHISOHEX, HEXACHLOROPHENE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TAXOTERE, DOCETAXEL

SANOFI PASTEUR INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANOFI PASTEUR INC
SKLICE, IVERMECTIN

SANTARUS INC

* SANTARUS INC
FENOGLIDE, FENOFIBRATE
GLUMETZA, METFORMIN HYDROCHLORIDE
UCERIS, BUDESONIDE
ZEGERID, OMEPRAZOLE

SANTEN

* SANTEN INC
QUIXIN, LEVOFLOXACIN

SANTOS BIOTECH

* SANTOS BIOTECH INDUSTRIES INC
ANASTROZOLE, ANASTROZOLE

SB PHARMCO

* SB PHARMCO PUERTO RICO INC
AVANDAMET, METFORMIN HYDROCHLORIDE
AVANDARYL, GLIMEPIRIDE
AVANDIA, ROSIGLITAZONE MALEATE
COREG CR, CARVEDILOL PHOSPHATE

SCHERING

* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN

SCHERING PLOUGH

* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
GYNE-LOTTRIMIN 3, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN COMBINATION PACK, CLOTRIMAZOLE (OTC)
GYNE-LOTTRIMIN, CLOTRIMAZOLE (OTC)
LOTTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
OCUCLEAR, OXYMETAZOLINE HYDROCHLORIDE (OTC)
SHADE UVAGUARD, AVOBENZONE (OTC)

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
DORAL, QUAZEPAM

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

SCIOS LLC

* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

SEBELA IRELAND LTD

* SEBELA IRELAND LTD
MIACALCIN, CALCITONIN SALMON
MICORT-HC, HYDROCORTISONE ACETATE
PRAMOSONE, HYDROCORTISONE ACETATE

SECAN PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SECAN PHARMACEUTICALS INC

AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

SEPTODONT

* SEPTODONT INC

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

SEPTODONT HOLDING

* SEPTODONT HOLDING SAS

ORAVERSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

* SEPTODONT INC

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SETON PHARM

* SETON PHARMACEUTICAL LLC

PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SHASUN CHEMS

* SHASUN CHEMICALS AND DRUGS LTD

RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SHASUN USA

* SHASUN USA INC

IBUPROFEN, IBUPROFEN

SHENZHEN TECHDOW

* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD

HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

* SHERTECH LABORATORIES LLC

AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHIONOGI INC

* SHIONOGI INC

DORIBAX, DORIPENEM
FURADANTIN, NITROFURANTOIN
KEFLEX, CEPHALEXIN
OSPHENA, OSPEMIFENE
PONSTEL, MEFENAMIC ACID
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
SULAR, NISOLDIPINE
ULESFIA, BENZYL ALCOHOL

SHIRE

* SHIRE DEVELOPMENT INC

ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

SHIRE DEV LLC

* SHIRE DEVELOPMENT LLC

FOSRENOL, LANTHANUM CARBONATE

SHIRE DEVELOPMENT

* SHIRE DEVELOPMENT INC

VYVANSE, LISDEXAMFETAMINE DIMESYLATE

SHIRE HUMAN GENETIC

* SHIRE HUMAN GENETIC THERAPIES INC

VPRIV, VELAGLUCERASE ALFA

SHIRE LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SHIRE DEVELOPMENT LLC
 AGRYLIN, ANAGRELIDE HYDROCHLORIDE
 FOSRENOL, LANTHANUM CARBONATE
 SALURON, HYDROFLUMETHIAZIDE

SHIRE ORPHAN THERAP

* SHIRE ORPHAN THERAPIES INC
 FIRAZYR, ICATIBANT ACETATE

SIGMA TAU

* SIGMA TAU PHARMACEUTICALS INC
 ABELCET, AMPHOTERICIN B
 ADAGEN, PEGADEMASE BOVINE
 CARNITOR SF, LEVOCARNITINE
 CARNITOR, LEVOCARNITINE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 MATULANE, PROCARBAZINE HYDROCHLORIDE

SIGMAPHARM LABS LLC

* SIGMAPHARM LABORATORIES LLC
 ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 DISULFIRAM, DISULFIRAM
 ERGOCALCIFEROL, ERGOCALCIFEROL
 FLUCYTOSINE, FLUCYTOSINE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SILARX

* SILARX PHARMACEUTICALS INC
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE, LORATADINE (OTC)
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 THEOPHYLLINE, THEOPHYLLINE

SILARX PHARMS INC

* SILARX PHARMACEUTICALS INC
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 RISPERIDONE, RISPERIDONE

SILVERGATE PHARMS

* SILVERGATE PHARMACEUTICALS INC
 EPANED KIT, ENALAPRIL MALEATE

SKINMEDICA

* SKINMEDICA INC
 VANIQA, EFLORNITHINE HYDROCHLORIDE

SKYEPHARMA AG

* SKYEPHARMA AG
 TRIGLIDE, FENOFIBRATE

SMITHKLINE BEECHAM

* SMITHKLINE BEECHAM
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 * SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
 ARRANON, NELARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SMITHKLINE BEECHAM CORP DBA GLAXOSMITHKLINE
COREG, CARVEDILOL
TYKERB, LAPATINIB DITOSYLATE

SOAPCO

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

SOFGEN PHARMS

* SOFGEN PHARMACEUTICALS LLC
PROGESTERONE, PROGESTERONE

SOMERSET

* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
EMSAM, SELEGILINE

SOVEREIGN PHARMS

* SOVEREIGN PHARMACEUTICALS LLC
OBREDON, GUAIFENESIN

SPEAR PHARMS

* SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL

SPEAR PHARMS INC

* SPEAR PHARMACEUTICALS INC
TRETINOIN, TRETINOIN

SPECTRUM PHARMS

* SPECTRUM PHARMACEUTICALS INC
BELEODAQ, BELINOSTAT
FUSILEV, LEVOLEUCOVORIN CALCIUM

STAND HOMEOPATH

* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON

* STASON INDUSTRIAL CORP
ACYCLOVIR, ACYCLOVIR
CAPTOPRIL, CAPTOPRIL
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

STASON PHARMS

* STASON PHARMACEUTICALS INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

STERI PHARMA

* STERI PHARMA LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

STI PHARMA LLC

* STI PHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
TRIAcin-C, CODEINE PHOSPHATE

STIEFEL

* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STIEFEL GSK

* STIEFEL A GSK CO
VELTIN, CLINDAMYCIN PHOSPHATE

STIEFEL LABS INC

* STIEFEL LABORATORIES INC
FABIOR, TAZAROTENE
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE

STRIDES ARCOLAB LTD

* STRIDES ARCOLAB LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRIDES ARCOLAB LTD
AMPICILLIN SODIUM, AMPICILLIN SODIUM
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL

STRIDES PHARMA

* STRIDES PHARMA GLOBAL PTE LTD
ACARBOSE, ACARBOSE
ERGOCALCIFEROL, ERGOCALCIFEROL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IMIQUIMOD, IMIQUIMOD
MELOXICAM, MELOXICAM
METHOXSALEN, METHOXSALEN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
TACROLIMUS, TACROLIMUS
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SUCAMPO PHARMA LLC

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

SUCAMPO PHARMS

* SUCAMPO PHARMACEUTICALS INC
RESCULA, UNOPROSTONE ISOPROPYL

SUMMERS

* SUMMERS LABORATORIES INC
CROTAN, CROTAMITON

SUN PHARM INDS

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TORSEMIDE, TORSEMIDE

SUN PHARM INDS (IN)

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC

* SUN PHARMACEUTICAL INDUSTRIES INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES INC**

BENZONATATE, BENZONATATE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 ELIXOPHYLLIN, THEOPHYLLINE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 FLURBIPROFEN, FLURBIPROFEN
 FUROSEMIDE, FUROSEMIDE
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLIPIZIDE, GLIPIZIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MELOXICAM, MELOXICAM
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 MORPHINE SULFATE, MORPHINE SULFATE
 NIMODIPINE, NIMODIPINE
 NITROFURANTOIN, NITROFURANTOIN
 OXAPROZIN, OXAPROZIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 RISPERIDONE, RISPERIDONE
 THEOCHRON, THEOPHYLLINE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS LTD*** SUN PHARMACEUTICAL INDUSTRIES LTD**

AZITHROMYCIN, AZITHROMYCIN
 CARISOPRODOL, CARISOPRODOL
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 GABAPENTIN, GABAPENTIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SUN PHARMACEUTICAL INDUSTRIES LTD
 - IBANDRONATE SODIUM, IBANDRONATE SODIUM
 - LETROZOLE, LETROZOLE
 - LEVETIRACETAM, LEVETIRACETAM
 - NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 - ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 - OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RILUZOLE, RILUZOLE
 - RISPERIDONE, RISPERIDONE
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 - VALPROIC ACID, VALPROIC ACID
- * SUN PHARMACEUTICAL INDUSTRIES LTD.
 - ANASTROZOLE, ANASTROZOLE

SUN PHARMA GLOBAL

- * SUN PHARMA GLOBAL FZE
 - ALENDRONATE SODIUM, ALENDRONATE SODIUM
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CAFFEINE CITRATE, CAFFEINE CITRATE
 - CARBIDOPA AND LEVODOPA, CARBIDOPA
 - CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 - CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 - DECITABINE, DECITABINE
 - DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 - DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DOCEFREZ, DOCETAXEL
 - DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 - DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 - ENTACAPONE, ENTACAPONE
 - ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 - ESZOPICLONE, ESZOPICLONE
 - FINASTERIDE, FINASTERIDE
 - GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 - LANSOPRAZOLE, LANSOPRAZOLE
 - LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 - NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 - NIACIN, NIACIN
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 - OXALIPLATIN, OXALIPLATIN
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 - RISEDRONATE SODIUM, RISEDRONATE SODIUM
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TEMOZOLOMIDE, TEMOZOLOMIDE
 - TOPIRAMATE, TOPIRAMATE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID
 - ZOLMITRIPTAN, ZOLMITRIPTAN
- * SUN PHARMA GLOBAL INC
 - ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 - ALPRAZOLAM, ALPRAZOLAM
 - AMIFOSTINE, AMIFOSTINE
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMA GLOBAL INC
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

SUNEVA MEDCL

* SUNEVA MEDICAL INC
TRETINOIN, TRETINOIN

SUNOVION

* SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
APTOM, ESLICARBAZEPINE ACETATE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE

SUNSHINE LAKE

* SUNSHINE LAKE PHARMA CO LTD
ZIDOVUDINE, ZIDOVUDINE

SUNSTAR AMERICAS

* SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
TOKENDI XR, TOPIRAMATE

SUVEN LIFE

* SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

SVADS HOLDINGS SA

* SVADS HOLDINGS SA
IBUPROFEN, IBUPROFEN (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

SVC PHARMA

* SVC PHARMA LP
DRONABINOL, DRONABINOL

SWEDISH ORPHAN

* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYMLMED PHARMS LLC

* SYMLMED PHARMACEUTICALS LLC
ACEON, PERINDOPRIL ERBUMINE

SYNTHON PHARMS

* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**** T ******MEDICINES CO**

* THE MEDICINES CO
ANGIOMAX, BIVALIRUDIN
CLEVIPREX, CLEVIDIPINE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

RTEDOSE CORP

* THE RTEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

TAKEDA GMBH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TAKEDA GMBH**

ALVESCO, CICLESONIDE
OMNARIS, CICLESONIDE
ZETONNA, CICLESONIDE

TAKEDA PHARMS USA*** TAKEDA PHARMACEUTICALS USA INC**

ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
BRINTELLIX, VORTIOXETINE HYDROBROMIDE
COLCRYS, COLCHICINE
CONTRAVE, BUPROPION HYDROCHLORIDE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSEN, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
ULORIC, FEBUXOSTAT

TALON THERAP*** TALON THERAPEUTICS INC**

MARQIBO KIT, VINCRISTINE SULFATE

TAMARANG*** TAMARANG SA**

ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO*** TARO PHARMACEUTICAL INDUSTRIES LTD**

ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DESONIDE, DESONIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
PHENYTOIN, PHENYTOIN

*** TARO PHARMACEUTICALS INC**

BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TARO PHARMACEUTICALS INC
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 - TOPICORT, DESOXIMETASONE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - WARFARIN SODIUM, WARFARIN SODIUM
- * TARO PHARMACEUTICALS USA INC
 - ACETIC ACID, ACETIC ACID, GLACIAL
 - ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CICLOPIROX, CICLOPIROX
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 - CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CLOTRIMAZOLE, CLOTRIMAZOLE
 - DERMABET, BETAMETHASONE VALERATE
 - DESONIDE, DESONIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 - ECONAZOLE NITRATE, ECONAZOLE NITRATE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - FLO-PRED, PREDNISOLONE ACETATE
 - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 - FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 - FLUOCINONIDE, FLUOCINONIDE
 - FLUOROURACIL, FLUOROURACIL
 - GENTAMICIN SULFATE, GENTAMICIN SULFATE
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 - HYDROCORTISONE, HYDROCORTISONE
 - KETOZOLE, KETOCONAZOLE
 - LIDOCAINE, LIDOCAINE
 - LORATADINE, LORATADINE (OTC)
 - MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MUPIROCIN, MUPIROCIN
 - NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 - NYSTATIN, NYSTATIN
 - PHENYTOIN, PHENYTOIN
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - RISPERIDONE, RISPERIDONE
 - SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
 - TERCONAZOLE, TERCONAZOLE
 - TERIL, CARBAMAZEPINE
 - TOPICORT, DESOXIMETASONE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 - U-CORT, HYDROCORTISONE ACETATE
- * TARO PHARMACEUTICALS, INC.
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 - TOPICORT, DESOXIMETASONE

TARO PHARM INDS

- * TARO PHARMACEUTICAL INDUSTRIES LTD
 - AMCINONIDE, AMCINONIDE
 - CARBAMAZEPINE, CARBAMAZEPINE
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

TARO PHARMS IRELAND

* TARO PHARMACEUTICALS IRELAND LTD
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION

TARO PHARMS NORTH

* TARO PHARMACEUTICALS NORTH AMERICA INC
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 OVIDE, MALATHION
 TOPICORT, DESOXIMETASONE

TEDOR PHARM

* TEDOR PHARMA INC
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

TEDOR PHARMA INC

* TEDOR PHARMA INC
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
 LIDODERM, LIDOCAINE

TEVA

* TEVA NEUROSCIENCE INC
 AZILECT, RASAGILINE MESYLATE

* TEVA PHARMACEUTICALS USA INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACYCLOVIR, ACYCLOVIR
 ADIPEX-P, PHENTERMINE HYDROCHLORIDE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN PEDIATRIC, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPHETAMINE ASP AMPHETAMINE SULF DEXTROAMPHET SACCHARATE & DEXTR SULF, AMPHETAMINE
 ATENOLOL, ATENOLOL
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BETA-VAL, BETAMETHASONE VALERATE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BICALUTAMIDE, BICALUTAMIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CALCITRIOL, CALCITRIOL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
 CAPTOPRIL, CAPTOPRIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CEFACLOL, CEFACLOL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CILOSTAZOL, CILOSTAZOL
 CIMETIDINE, CIMETIDINE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPITOL, CARBAMAZEPINE
ESTAZOLAM, ESTAZOLAM
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 ORAP, PIMOZIDE
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLMETIN SODIUM, TOLMETIN SODIUM
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 CENESTIN, ESTROGENS, CONJUGATED SYNTHETIC A
 LOSEASONIQUE, ETHINYL ESTRADIOL
 NORDETTE-28, ETHINYL ESTRADIOL
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAN B, LEVONORGESTREL
 PLAN B, LEVONORGESTREL (OTC)
 PROAIR HFA, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 QVAR 40, BECLOMETHASONE DIPROPIONATE
 QVAR 80, BECLOMETHASONE DIPROPIONATE
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 ZECUITY, SUMATRIPTAN SUCCINATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARMS

* TEVA PHARMACEUTICALS USA
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE
ANASTROZOLE, ANASTROZOLE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFdinIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEpin HYDROCHLORIDE, DOXEpin HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PREGABALIN, PREGABALIN
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TEVA PHARMACEUTICALS USA**

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
THEOPHYLLINE, THEOPHYLLINE
TRANDOLAPRIL, TRANDOLAPRIL
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZALEPLON, ZALEPLON

TEVA PHARMS USA*** TEVA PHARMACEUTICALS USA**

ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
COPAXONE, GLATIRAMER ACETATE
CYTOSAR-U, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ENTECAVIR, ENTECAVIR
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETOPOSIDE, ETOPOSIDE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IFOSFAMIDE/MESNA KIT, IFOSFAMIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PROPOFOL, PROPOFOL
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RISEDRONATE SODIUM, RISEDRONATE SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINCRIStINE SULFATE PFS, VINCRIStINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOcIN
ZOLMITRIPTAN, ZOLMITRIPTAN

* TEVA PHARMACEUTICALS USA INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
IMIQUIMOD, IMIQUIMOD
METRONIDAZOLE, METRONIDAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SELFEMRA, FLUOXETINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
ADASUVE, LOXAPINE

TEVA WOMENS

* TEVA WOMENS HEALTH INC
ENJUVIA, ESTROGENS, CONJUGATED SYNTHETIC B
PARAGARD T 380A, COPPER
REVIA, NALTREXONE HYDROCHLORIDE
ZEBETA, BISOPROLOL FUMARATE
ZIAC, BISOPROLOL FUMARATE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE PHARMA NETWORK

* THE PHARMA NETWORK LLC
BENZONATATE, BENZONATATE

THE PHARMANETWORK

* THE PHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERAKOS

* THERAKOS INC
UVADEX, METHOXSALEN

THERATECHNOLOGIES

* THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******THERAVANCE BIOPHARMA**

- * THERAVANCE BIOPHARMA ANTIBIOTICS INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

THREE RIVERS PHARMS

- * THREE RIVERS PHARMACEUTICALS LLC
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN

TOLMAR

- * TOLMAR INC
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM , DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

TOLMAR THERAP

- * TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

TORPHARM

- * TORPHARM INC
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TORRENT PHARM

- * TORRENT PHARMA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

TORRENT PHARMS

- * TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
- * TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

TORRENT PHARMS LLC

- * TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS LTD

- * TORRENT PHARMACEUTICALS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******* TORRENT PHARMACEUTICALS LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 VALSARTAN, VALSARTAN

TRIS PHARMA INC*** TRIS PHARMA INC**

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 KARBINAL ER, CARBINOXAMINE MALEATE
 LEVETIRACETAM, LEVETIRACETAM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA*** TRUSTEES OF THE UNIV OF PENNSYLVANIA**

FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TRYGG*** TRYGG PHARMA INC**

OMTRYG, OMEGA-3-ACID ETHYL ESTERS

TWI PHARMS INC*** TWI PHARMACEUTICALS INC**

CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 NIFEDIPINE, NIFEDIPINE

**** U ******UCB INC***** UCB INC**

KEPPRA XR, LEVETIRACETAM
 KEPPRA, LEVETIRACETAM
 METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
 METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEUPRO, ROTIGOTINE
 TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
 UNIRETIC, HYDROCHLOROTHIAZIDE
 UNIVASC, MOEXIPRIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

* UCB INC
VIMPAT, LACOSAMIDE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
ZAROXOLYN, METOLAZONE

UCLA BIOMEDICAL

* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RADIOPHARM

* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UIHC PET IMAGING

* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNICHEM

* UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
ZALEPLON, ZALEPLON

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
LAMOTRIGINE, LAMOTRIGINE
METRONIDAZOLE, METRONIDAZOLE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

UNICHEM PHARMS (USA)

* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE PHARM LABS

* UNIQUE PHARMACEUTICAL LABORATORIES
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUCONAZOLE, FLUCONAZOLE
TINIDAZOLE, TINIDAZOLE

UNITED BIOMEDCL

* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED THERAP

* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV TX MD ANDERSON

* UNIV TEXAS MD ANDERSON CANCER CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

- * UNIV TEXAS MD ANDERSON CANCER CENTER
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UPSHER SMITH

- * UPSHER SMITH LABORATORIES INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FORTICAL, CALCITONIN SALMON RECOMBINANT
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MORPHINE SULFATE, MORPHINE SULFATE
NIACOR, NIACIN
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUDEXY XR, TOPIRAMATE
SORINE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VOGELXO, TESTOSTERONE
ZALEPLON, ZALEPLON

UPSHER SMITH LABS

- * UPSHER SMITH LABORATORIES INC
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE

UPSHER-SMITH LABS

- * UPSHER-SMITH LABORATORIES INC
KLOR-CON, POTASSIUM CHLORIDE

US PHARMS HOLDINGS I

- * US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

US WORLDMEDS

- * US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

USL PHARMA

- * USL PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
ESTRADIOL, ESTRADIOL
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

USV NORTH AMERICA

- * USV NORTH AMERICA INC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ******VALEANT**

- * VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BONTRIL, PHENDIMETRAZINE TARTRATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VALEANT PHARMACEUTICALS INTERNATIONAL
MOTOFEN, ATROPINE SULFATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA

* VALEANT INTERNATIONAL BERMUDA
APLENZIN, BUPROPION HYDROBROMIDE
BENZACLIN, BENZOYL PEROXIDE
CARAC, FLUOROURACIL
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMATOP, PREDNICARBATE
ELIDEL, PIMECROLIMUS
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
NORITATE, METRONIDAZOLE
PENLAC, CICLOPIROX
PENTOXIFYLLINE, PENTOXIFYLLINE
RETIN-A, TRETINOIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE
XERESE, ACYCLOVIR
ZOVIRAX, ACYCLOVIR

VALEANT INTL

* VALEANT INTERNATIONAL BARBADOS SRL
ATIVAN, LORAZEPAM
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
NIFEDIPINE, NIFEDIPINE
RENOVA, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
TIAZAC, DILTIAZEM HYDROCHLORIDE
ULTRAM ER, TRAMADOL HYDROCHLORIDE
VASERETIC, ENALAPRIL MALEATE
VASOTEC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE

* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
BENZAMYCIN PAK, BENZOYL PEROXIDE
ERTACZO, SERTACONAZOLE NITRATE
GRIFULVIN V, GRISEOFULVIN, MICROSIZE
TARGRETIN, BEXAROTENE

VALEANT PHARM INTL

* VALEANT PHARMACEUTICALS INTERNATIONAL
8-MOP, METHOXSALEN
ANDROID 10, METHYLTESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
OXSORALEN, METHOXSALEN
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

VALEANT PHARM NORTH

* VALEANT PHARMACEUTICAL NORTH AMERICA LLC
MESTINON, PYRIDOSTIGMINE BROMIDE
MINITRAN, NITROGLYCERIN

VALEANT PHARMS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE
TENSILON PRESERVATIVE FREE, EDROPHONIUM CHLORIDE
TENSILON, EDROPHONIUM CHLORIDE

VALEANT PHARMS INC

* VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
VISUDYNE, VERTEPORFIN

VALEANT PHARMS LLC

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CAPITAL AND CODEINE, ACETAMINOPHEN
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

VALEANT PHARMS NORTH

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM

VALIDUS PHARMS

* VALIDUS PHARMACEUTICALS LLC
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
EQUETRO, CARBAMAZEPINE
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
HETLIOZ, TASIMELTEON

VANSEN PHARMA

* VANSEN PHARMA
SPECTRACEF, CEFEDITOREN PIVOXIL

VELDANA MEDICAL SA

* VELDANA MEDICAL SA
ECOZA, ECONAZOLE NITRATE

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERSAPHARM

* VERSAPHARM INC
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
ERYTHROMYCIN, ERYTHROMYCIN
ETHOSUXIMIDE, ETHOSUXIMIDE
RIFAMPIN, RIFAMPIN

VERSAPHARM INC

* VERSAPHARM INC
DESOXIMETASONE, DESOXIMETASONE
RIFAMPIN, RIFAMPIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
* VERSAPHARM INCORPORATED
TRANEXAMIC ACID, TRANEXAMIC ACID

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
INCIVEK, TELAPREVIR
KALYDECO, IVACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VICURON

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******VIFOR FRESENIUS**

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

VIIIV HLTHCARE

* VIIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

VINTAGE

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOLIC ACID, FOLIC ACID
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

VINTAGE PHARMS

* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
DISULFIRAM, DISULFIRAM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LEVETIRACETAM, LEVETIRACETAM
METHIMAZOLE, METHIMAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ******* VINTAGE PHARMACEUTICALS**

METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

*** VINTAGE PHARMACEUTICALS INC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 CARISOPRODOL, CARISOPRODOL
 CLONAZEPAM, CLONAZEPAM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCORTISONE, HYDROCORTISONE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LORAZEPAM, LORAZEPAM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PRIMIDONE, PRIMIDONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SULFASALAZINE, SULFASALAZINE
 TORSEMIDE, TORSEMIDE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

VINTAGE PHARMS LLC*** VINTAGE PHARMACEUTICALS LLC**

CYCLAFEM 1/35, ETHINYL ESTRADIOL
 CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
 EMOQUETTE, DESOGESTREL
 FELODIPINE, FELODIPINE
 GILDESS 1.5/30, ETHINYL ESTRADIOL
 GILDESS 1/20, ETHINYL ESTRADIOL
 GILDESS FE 1.5/30, ETHINYL ESTRADIOL
 GILDESS FE 1/20, ETHINYL ESTRADIOL
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 MEFENAMIC ACID, MEFENAMIC ACID
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MORPHINE SULFATE, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VINTAGE PHARMACEUTICALS LLC
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYZILRA, ETHINYL ESTRADIOL
ORSYTHIA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM

* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE

VISTA PHARMS

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN

VIVIMED LABS

* VIVIMED LABS ALATHUR PRIVATE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE
STENDRA, AVANAFIL

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13

WARNER CHILCOTT

* WARNER CHILCOTT CO LLC
LO MINASTRIN FE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
* WARNER CHILCOTT INC
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL

WARNER CHILCOTT LLC

* WARNER CHILCOTT CO LLC
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ASACOL, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
CHOLEDYL SA, OXTRIPHYLLINE
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMTRACE, ESTRADIOL ACETATE
LO LOESTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
OVCON-35, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WARNER CHILCOTT US**

* WARNER CHILCOTT US LLC
ESTRACE, ESTRADIOL

WARNER IRELAND

* WARNER CHILCOTT IRELAND LTD
FEMRING, ESTRADIOL ACETATE

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORCO, ACETAMINOPHEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
ALORA, ESTRADIOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLDIPINE BESYLATE
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
BACLOFEN, BACLOFEN
BREVICON 28-DAY, ETHINYL ESTRADIOL
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COL-PROBENECID, COLCHICINE
CRINONE, PROGESTERONE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILACOR XR, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GELNIQUE, OXYBUTYNIN CHLORIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISRADIPINE, ISRADIPINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MICROZIDE, HYDROCHLOROTHIAZIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
NORINYL 1+50 28-DAY, MESTRANOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISON, PREDNISON
PRIMIDONE, PRIMIDONE
PROBENECID, PROBENECID
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RAPAFLO, SILODOSIN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TELMISARTAN, TELMISARTAN
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
TRELSTAR, TRIPTORELIN PAMOATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WATSON LABORATORIES INC
 - TRIVORA-28, ETHINYL ESTRADIOL
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - ZOVIA 1/35E-28, ETHINYL ESTRADIOL
 - ZOVIA 1/50E-28, ETHINYL ESTRADIOL
- * WATSON LABS INC
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS (UTAH)

- * WATSON LABORATORIES INC
 - INFED, IRON DEXTRAN
 - NOR-QD, NORETHINDRONE
 - OXYTROL, OXYBUTYNIN
 - PROGESTERONE, PROGESTERONE

WATSON LABS FLORIDA

- * WATSON LABORATORIES INC FLORIDA
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

WATSON LABS INC

- * WATSON LABORATORIES INC
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - BUDESONIDE, BUDESONIDE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CLONIDINE, CLONIDINE
 - CORDRAN, FLURANDRENOLIDE
 - CYCLOSPORINE, CYCLOSPORINE
 - DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 - DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 - EMLA, LIDOCAINE
 - FIORICET W/ CODEINE, ACETAMINOPHEN
 - FIORINAL W/CODEINE, ASPIRIN
 - FIORINAL, ASPIRIN
 - GELNIQUE 3%, OXYBUTYNIN
 - IBANDRONATE SODIUM, IBANDRONATE SODIUM
 - INDOMETHACIN, INDOMETHACIN
 - IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - IRBESARTAN, IRBESARTAN
 - KADIAN, MORPHINE SULFATE
 - LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 - LEVOFLOXACIN, LEVOFLOXACIN
 - LEVONORGESTREL, LEVONORGESTREL
 - LEVONORGESTREL, LEVONORGESTREL (OTC)
 - LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 - LIDOCAINE, LIDOCAINE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - METRONIDAZOLE, METRONIDAZOLE
 - PREGABALIN, PREGABALIN
 - PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SILDENAFIL CITRATE, SILDENAFIL CITRATE
 - TRETINOLIN, TRETINOLIN
 - VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 - VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - VALSARTAN, VALSARTAN

WATSON PHARMS

- * WATSON PHARMACEUTICALS
 - TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
 - TENUATE, DIETHYLPROPION HYDROCHLORIDE
- * WATSON PHARMACEUTICALS INC
 - ACTIGALL, URSODIOL
 - CONDYLOX, PODOFILOX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WEST WARD PHARM CORP**

* WEST WARD PHARMACEUTICAL CORP
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

WEST-WARD PHARM CORP

* WEST-WARD PHARMACEUTICAL CORP
 CEFOTETAN, CEFOTETAN DISODIUM

WI MEDCL CYCLOTRON

* WISCONSIN MEDICAL CYCLOTRON LLC
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WILSHIRE PHARMS INC

* WILSHIRE PHARMACEUTICALS INC
 LAMOTRIGINE, LAMOTRIGINE

WOCKHARDT

* WOCKHARDT AMERICAS INC
 CAPTOPRIL, CAPTOPRIL
 FAMOTIDINE, FAMOTIDINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

* WOCKHARDT EU OPERATIONS (SWISS) AG
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETIC ACID, ACETIC ACID, GLACIAL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FUROSEMIDE, FUROSEMIDE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINDANE, LINDANE
 LITHIUM CITRATE, LITHIUM CITRATE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PHENYTOIN, PHENYTOIN
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALPROIC ACID, VALPROIC ACID

* WOCKHARDT LTD
 ADENOSINE, ADENOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT LTD**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AZITHROMYCIN, AZITHROMYCIN
 BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
 CEFOTAXIME, CEFOTAXIME SODIUM
 CEFPROZIL, CEFPROZIL
 CEFTAZIDIME, CEFTAZIDIME
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FAMOTIDINE, FAMOTIDINE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL, LISINAPRIL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RISPERIDONE, RISPERIDONE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
 ZONISAMIDE, ZONISAMIDE

WOCKHARDT EU OPERATN*** WOCKHARDT EU OPERATIONS SWISS AG**

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 DEXAMETHASONE, DEXAMETHASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

WOCKHARDT LTD*** WOCKHARDT LTD**

ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ENTACAPONE, ENTACAPONE
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 LAMOTRIGINE, LAMOTRIGINE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******WOCKHARDT USA**

- * WOCKHARDT USA INC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
- * WOCKHARDT USA LLC
ENALAPRIL MALEATE, ENALAPRIL MALEATE
LANSOPRAZOLE, LANSOPRAZOLE
TOPIRAMATE, TOPIRAMATE

WRASER PHARMS

- * WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WRASER PHARMS LLC

- * WRASER PHARMACEUTICALS LLC
TREZIX, ACETAMINOPHEN

WUSM CYCLOTRON

- * WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS

- * WYETH PHARMACEUTICALS INC SUB PFIZER INC
LO/OVRAL-28, ETHINYL ESTRADIOL

WYETH PHARMS INC

- * WYETH PHARMACEUTICALS INC
BOSULIF, BOSUTINIB MONOHYDRATE
CORDARONE, AMIODARONE HYDROCHLORIDE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INDERIDE-40/25, HYDROCHLOROTHIAZIDE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

WYETH PHARMS PFIZER

- * WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
DUAVEE, BAZEDOXIFENE ACETATE

**** X ******X GEN PHARMS**

- * X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
BACIIM, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
HYDRO-RX, HYDROCORTISONE
HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEO-FRADIN, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

X-GEN PHARMS

- * X-GEN PHARMACEUTICALS INC
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ******X-GEN PHARMS INC**

* X-GEN PHARMACEUTICALS INC
TRANEXAMIC ACID, TRANEXAMIC ACID

XELLIA PHARMS APS

* XELLIA PHARMACEUTICALS APS
BACITRACIN, BACITRACIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

XENOPORT INC

* XENOPORT INC
HORIZANT, GABAPENTIN ENACARBIL

XSPIRE

* XSPIRE LLC
NALFON, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

**** Y ******YUNG SHIN PHARM**

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOX, CEFACLOX
CEPHALEXIN, CEPHALEXIN

**** Z ******ZACH SYSTEMS**

* ZACH SYSTEMS SPA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE

ZAMBON SPA

* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

ZOGENIX INC

* ZOGENIX INC
ZOHYDRO ER, HYDROCODONE BITARTRATE

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******ZYDUS PHARMS USA INC**

* ZYDUS PHARMACEUTICALS USA INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRazole, OMEPRazole
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

APPENDIX C**UNIFORM TERMS*****DOSAGE FORMS***

AEROSOL	OIL
AEROSOL, FOAM	OIL/DROPS
AEROSOL, METERED	OINTMENT
CAPSULE	OINTMENT, AUGMENTED
CAPSULE, DELAYED REL PELLETS	PASTE
CAPSULE, DELAYED RELEASE	PATCH
CAPSULE, EXTENDED RELEASE	PELLET
CLOTH	POWDER
CONCENTRATE	POWDER, EXTENDED RELEASE
CREAM	POWDER, METERED
CREAM, AUGMENTED	RING
ELIXIR	SHAMPOO
EMULSION	SOLUTION
ENEMA	SOLUTION FOR SLUSH
FILM	SOLUTION, GEL FORMING/DROPS
FILM, EXTENDED RELEASE	SOLUTION, METERED
FOR SOLUTION	SOLUTION/DROPS
FOR SUSPENSION	SPONGE
FOR SUSPENSION, DELAYED RELEASE	SPRAY
FOR SUSPENSION, EXTENDED RELEASE	SPRAY, METERED
GAS	SUPPOSITORY
GEL	SUSPENSION
GEL, AUGMENTED	SUSPENSION, EXTENDED RELEASE
GEL, METERED	SUSPENSION/DROPS
GRANULE	SWAB
GRANULE, DELAYED RELEASE	SYRUP
GUM, CHEWING	SYSTEM
IMPLANT	SYSTEM, EXTENDED RELEASE
INHALANT	TABLET
INJECTABLE	TABLET, CHEWABLE
INJECTABLE, LIPID COMPLEX	TABLET, COATED PARTICLES
INJECTABLE, LIPOSOMAL	TABLET, DELAYED RELEASE
INSERT	TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
INSERT, EXTENDED RELEASE	TABLET, EFFERVESCENT
INTRAUTERINE DEVICE	TABLET, EXTENDED RELEASE
JELLY	TABLET, FOR SUSPENSION
LIQUID	TABLET, ORALLY DISINTEGRATING
LOTION	TAPE
LOTION, AUGMENTED	TROCHE/LOZENGE
LOTION/SHAMPOO	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	IRRIGATION
DENTAL	IV (INFUSION)
ENDOCERVICAL	N/A
FOR RX COMPOUNDING	NASAL
IMPLANTATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTRA-ANAL	ORAL-28
INTRACRANIAL	OTIC
INTRADERMAL	PERFUSION, CARDIAC
INTRAMUSCULAR	PERIODONTAL
INTRAOCULAR	RECTAL
INTRAPERITONEAL	SPINAL
INTRAPLEURAL	SUBCUTANEOUS
INTRATHECAL	SUBLINGUAL
INTRATRACHEAL	TOPICAL
INTRAUTERINE	TRANSDERMAL
INTRAVENOUS	TRANSMUCOSAL
INTRAVESICAL	URETHRAL
INTRAVITREAL	VAGINAL
IONTOPHORESIS	

Note: Terms comprise currently marketed products

APPENDIX**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOURLY
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
MCI	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
UCI	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act (1984 Amendments) for periods of exclusivity, during which abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (the Act) for those drug products may, in some instances, not be submitted or made effective as described below, and provides patent information concerning the listed drug products. Those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the Act, and those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the Act are also included in this *Addendum*. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. Exclusivity prevents the submission or effective approval of ANDAs or applications described in Section 505(b)(2) of the Act. It does not prevent the submission or approval of a second 505(b)(1) application except in the case of Orphan Drug exclusivity. Applications qualifying for periods of exclusivity are:

- (1) A new drug application approved after September 24, 1984, for a drug product (including an ester or salt of the active ingredient) of which has never been approved in any other new drug application under Section 505 (b) of the Act. No subsequent ANDA or application described in Section 505(b)(2) of the Act for the same drug may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought.
- (2) A new drug application approved after September 24, 1984, for a drug product containing an active ingredient (including any ester or salt of that active ingredient) that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, the approval of a subsequent ANDA or an application described in Section 505(b)(2) of the Act may not be *made effective* for the same drug or use, if for a new indication, before the expiration of *three years* from the date of approval of the original application. If an applicant has exclusivity for a new application or 505(b)(2) application for the drug product with indications or use, this does not preclude the approval of an ANDA or 505(b)(2) application not covered by the exclusivity.
- (3) A supplement to a new drug application for a drug containing a previously approved active ingredient including (any ester or salt of the active ingredient) approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or

sponsored by the applicant. The approval of a subsequent ANDA or 505(b)(2) application for a change approved in the supplement may not be made effective for three years from the date of approval of the original supplement.

The Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using FDA Form 3524a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the agency within 30 days of approval on FDA Form 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement". Patent information on unapproved applications or on patents beyond the scope of the Act (i.e., process or manufacturing patents) will not be published. FDA form 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents which include formulation/composition patents; use patents for a particular approved indication or method of using the product; and certain other patents as detailed on FDA Form 3542. This information, as provided by the sponsor on FDA form 3542, will be published as described above.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under section 4(b)(1) of the Q1 Act. A guidance for industry on this subject is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048345.pdf>

Upon approval, patent numbers and expiration dates, in addition to certain other information on appropriate patents claiming drug products that are the subject of approved applications, will be published daily in the [Electronic Orange Book Query](#). The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Electronic Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001	6294540	May 14, 2018	DS DP U-65			
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001	6294540	May 14, 2018	DS DP U-65			
	6641843	Feb 04, 2019	DP			
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	5905082	May 18, 2016	DS DP		NCE	Aug 12, 2018
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP U-1572			
	6294540*PED	Nov 14, 2018				
	6417191	Mar 28, 2016	DP U-1572			
	8129385	Oct 05, 2027	DS DP			
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	5905082	May 18, 2016	DS DP			
	6294540	May 14, 2018	DS DP U-257			
	6417191	Mar 28, 2016	DP U-257			
<u>ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR</u>						
N 021205 001	5905082	May 18, 2016	DS DP U-248			
	6294540	May 14, 2018	DS DP U-65			
	6417191	Mar 28, 2016	DP U-248			
<u>ABARELIX - PLENAXIS</u>						
N 021320 001	5843901	Dec 01, 2015	DS DP			
	5968895	Dec 11, 2016	DP			
	6180608	Dec 11, 2016	DP U-549			
	6423686	Jun 07, 2015	DS			
	6455499	Jun 07, 2015	U-549			
	6699833	Dec 11, 2016	DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	5604213	Dec 13, 2016	DS DP U-1126		I-663	Dec 10, 2015
	5604213	Dec 13, 2016	DS DP U-1314		NCE	Apr 28, 2016
	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	6028222	Aug 05, 2017	DP			
	6992218	Jun 06, 2021	DP			
<u>ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE)</u>						
N 020802 001	5972916	Jul 14, 2017	U-296			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025	U-1373			
	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACYCLOVIR - SITAVIG</u>						
N 203791	001	8592434	Jun 16, 2030	DP U-1460	NP	Apr 12, 2016
		8747896	Jun 03, 2027	DP U-1460		
		8791127	Mar 23, 2027	DP U-1460		
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436	001	6514980	Jan 24, 2019	DP U-1006	NPP	Jan 22, 2017
		6514980	Jan 24, 2019	DP U-1484		
		7223387	May 13, 2023	DP U-1006		
		7223387	May 13, 2023	DP U-1484		
		RE39264	Aug 02, 2016	DP U-1006		
		RE39264	Aug 02, 2016	DP U-1484		
<u>ADAPALENE - ADAPALENE</u>						
A 200298	001				PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753	001	7579377	Feb 23, 2025	U-818		
		7737181	Aug 29, 2024	DP		
		7834060	Mar 12, 2023	U-1078		
		7838558	Mar 12, 2023	DP		
		7868044	Mar 12, 2023	U-1078		
		8703820	Mar 12, 2023	U-1078		
<u>ADAPALENE - DIFFERIN</u>						
N 022502	001	7998467	May 31, 2028	DP U-1078		
		8435502	Sep 15, 2026	DP U-1078		
		8709392	Sep 15, 2026	DP U-1078		
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320	001	7820186	Nov 23, 2025	DP	NPP	Feb 01, 2016
		7964202	Sep 01, 2024	DP U-1078		
		8071644	Jul 18, 2027	DP U-1078		
		8080537	Jul 18, 2027	U-1078		
		8105618	Dec 23, 2022	U-1078		
		8129362	Jul 18, 2027	U-1078		
		8241649	Dec 23, 2022	DP		
		8445543	Jul 12, 2027	U-1078		
		8809305	Dec 23, 2022	U-1078		
<u>ADEFOVIR DIPIVOXIL - HEPSERA</u>						
N 021449	001	5663159	Sep 02, 2014	DS DP		
		6451340	Jul 23, 2018	DS DP U-470		
<u>ADENOSINE - ADENOSCAN</u>						
N 020059	001	5731296	Mar 24, 2015	U-221		
<u>ADENOSINE - ADENOSCAN</u>						
N 020059	002	5731296	Mar 24, 2015	U-221		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	001	6251912	Jul 29, 2018	DS DP U-1067	NCE ODE	Jul 12, 2018 Jul 12, 2020
		8426586	Oct 10, 2029	DS DP		
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	002	6251912	Jul 29, 2018	DS DP U-1067	NCE ODE	Jul 12, 2018 Jul 12, 2020
		8426586	Oct 10, 2029	DS DP		
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292	003	6251912	Jul 29, 2018	DS DP U-1067	NCE ODE	Jul 12, 2018 Jul 12, 2020
		8426586	Oct 10, 2029	DS DP		
		8545884	Dec 19, 2029	DP		
		RE43431	Jan 22, 2022	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 001	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALATROFLOXACIN MESYLATE - TROVAN PRESERVATIVE FREE</u>						
N 020760 002	5763454	Jun 15, 2015	U-282			
	6080756	Jul 05, 2016				
	6194429	Jul 23, 2018				
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899 001	6723303	Apr 20, 2021	DP		M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROVENTIL-HFA</u>						
N 020503 001	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
<u>ALBUTEROL SULFATE - ACCUNEER</u>						
N 020949 001	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - ACCUNEER</u>						
N 020949 002	6702997	Dec 28, 2021	U-558			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6558651	Dec 19, 2016	DP		U-716	
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021			U-716	
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	6446627	Dec 18, 2017	DP			
	7105152	Sep 12, 2023	DP			
	7566445	Jun 04, 2017	DP			
	8132712	Sep 07, 2028	DP			
	8834849	Jun 04, 2017	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT</u>						
N 020291 001	5603918	Jun 09, 2015				
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEER</u>						
N 020950 001	6632842	Dec 28, 2021	U-532			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	5662271	Sep 02, 2014	DP		NP	Oct 07, 2014
	5964416	Oct 04, 2016	DP			
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	5468743	Apr 20, 2016	DS DP		NCE	Jul 28, 2015
	8664215	Oct 05, 2029	U-1493			
<u>ALCOHOL; CHLORHEXIDINE GLUCONATE - AVAGARD</u>						
N 021074 001	5897031	Jun 21, 2016				
	6090395	Jun 22, 2015	DP			
	6534069	Jun 22, 2015	DP			
	6623744	Jun 23, 2015		U-1008		
	7081246	Aug 03, 2016	DP			
	7566460	Jun 22, 2015	DP	U-1008		
<u>ALENDRONATE SODIUM - FOSAMAX</u>						
N 021575 001	5994329	Jul 17, 2018		Y		
	6015801	Jul 17, 2018		Y		
	6225294	Jul 17, 2018		Y		
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>						
N 021762 001	5994329	Jul 17, 2018		U-647	Y	
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>						
N 021287 001	6149940	Aug 22, 2017				
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	5559111	Jul 21, 2018	DS DP	U-3		
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	5559111	Jul 21, 2018	DS DP	U-3		
	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	5559111	Jul 21, 2018	DS DP	U-3		
	8613949	Dec 21, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	5559111	Jul 21, 2018	DS DP U-3			
	8183295	May 16, 2023	DP			
	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 001	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 002	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 003	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107 004	5559111	Jul 21, 2018	DS DP U-3			
	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217 001	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217 002	5559111	Jul 21, 2018	DS DP U-3			
	8168616	Jul 03, 2026	DP			
<u>ALITRETINOIN - PANRETIN</u>						
N 020886 001	5932622	Aug 03, 2016				U-562
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 001	5565447	May 07, 2015	DS DP U-969			
<u>ALMOTRIPTAN MALATE - AXERT</u>						
N 021001 002	5565447	May 07, 2015	DS DP U-969			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jan 22, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002	5965584	Jun 19, 2016	U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8900638	May 24, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	5965584	Jun 19, 2016	DP U-1339		NC	Jan 25, 2016
	6150383	Jun 19, 2016	U-1330		NCE	Jan 25, 2018
	6150384	Jun 19, 2016	U-1340			
	6166042	Jun 19, 2016	U-1341			
	6166043	Jun 19, 2016	U-1342			
	6172090	Jun 19, 2016	U-1343			
	6211205	Jun 19, 2016	U-1331			
	6271243	Jun 19, 2016	U-1344			
	6303640	Aug 09, 2016	U-1332			
	6303661	Apr 24, 2017	U-1333			
	6329404	Jun 19, 2016	DP U-1334			
	6890898	Feb 02, 2019	U-1335			
	7078381	Feb 02, 2019	U-1335			
	7459428	Feb 02, 2019	U-1336			
	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jan 23, 2029	DP			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 001	6284770	Oct 05, 2018	U-405			
<u>ALOSETRON HYDROCHLORIDE - LOTRONEX</u>						
N 021107 002	6284770	Oct 05, 2018	U-405			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 003	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPRAZOLAM - NIRAVAM</u>						
N 021726 004	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 001	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 002	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 003	5741523	Apr 21, 2015				
<u>ALPROSTADIL - CAVERJECT</u>						
N 020379 004	5741523	Apr 21, 2015				
<u>ALPROSTADIL - MUSE</u>						
N 020700 001	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 002	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 003	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - MUSE</u>						
N 020700 004	5886039	Mar 23, 2016	DP U-155			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 001	5716338	Feb 10, 2015	DP			
<u>ALPROSTADIL - CAVERJECT IMPULSE</u>						
N 021212 002	5716338	Feb 10, 2015	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	5250542	Mar 29, 2016	DS DP U-878		M-128	Oct 18, 2016
	6469030	Nov 29, 2020	U-879			
	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	5703017	Dec 30, 2014	DS			
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	5703017	Dec 30, 2014	DS			
	5840722	Nov 24, 2015		U-821		
	5840722	Nov 24, 2015		U-1297		
	7109205	Oct 07, 2015	DS DP			
	7601730	Oct 07, 2015		U-1080		
	8349843	Oct 07, 2015	DS DP			
	RE42462	Jul 29, 2018	DS			
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 001	5994409	Dec 08, 2017	U-305			
<u>AMIFOSTINE - ETHYOL</u>						
N 020221 002	5994409	Dec 08, 2017	U-305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	5954703	Oct 31, 2017	U-289			
	6709446	May 01, 2018	U-289			
	7723910	Jun 17, 2019	U-289			
	8216289	May 01, 2018	U-289			
	8758418	May 01, 2018	U-289			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 001	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	6869939	May 04, 2022	DP			
	7635773	Mar 13, 2029	DP			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 001	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 002	6828339	Nov 20, 2022	DS			
<u>AMLODIPINE BESYLATE - AMLODIPINE BESYLATE</u>						
N 022026 003	6828339	Nov 20, 2022	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 001	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 002	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 003	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 004	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 005	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 006	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 007	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 008	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 009	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 010	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET</u>						
N 021540 011	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
	6455574	Aug 11, 2018	U-552			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 002	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 003	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 004	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 005	6162802	Dec 19, 2017	U-367			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 006	6162802	Dec 19, 2017	DS DP U-185			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>						
N 020364 007	6162802	Dec 19, 2017	DS DP U-185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 001	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 002	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 003	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 004	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - TRIBENZOR</u>						
N 200175 005	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 001	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 002	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 003	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 004	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314 005	6294197	Jun 18, 2017	DP U-3			
	8101599	May 16, 2023	DP			
	8475839	May 16, 2023	DP			
	8475839*PED	Nov 16, 2023				
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 001	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 002	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 003	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL - AZOR</u>						
N 022100 004	5616599	Apr 25, 2016	DS DP U-3			
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 001					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 002					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 004					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090144 001					PC	Mar 29, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 002	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 003	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 004	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE BESYLATE; VALSARTAN - EXFORGE</u>						
N 021990 005	6294197	Jun 18, 2017	DP U-3			
	6395728	Jul 08, 2019	DP			
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 001					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 002					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 003					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 004					PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435 005					PC	May 30, 2015
					PC	May 30, 2015
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	6544555	Oct 13, 2020	DS DP U-897			
	6669948	Oct 13, 2020	DS DP U-897			
	6723341	Oct 13, 2020	DS DP U-897			
	8299052	May 07, 2027	U-1304			
	8357394	Dec 08, 2026	DP			
<u>AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR</u>						
N 050785 001	6746692	Apr 04, 2020	DP			
	6783773	Apr 04, 2020	DP			
	6878386	Apr 04, 2020	U-926			
	7217430	Apr 04, 2020	DP U-926			
	7250176	Apr 04, 2020	U-926			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10</u>						
N 011522 007	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20</u>						
N 011522 008	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5</u>						
N 011522 009	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30</u>						
N 011522 010	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5</u>						
N 011522 011	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5</u>						
N 011522 012	6384020	Jul 06, 2020				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15</u>						
N 011522 013	6384020	Jul 06, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N 021303 001	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N 021303 002	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N 021303 003	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N 021303 004	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N 021303 005	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N 021303 006	6322819	Oct 21, 2018				
	6605300	Oct 21, 2018				
	RE41148	Oct 21, 2018	DP			
	RE42096	Oct 21, 2018	DP			
<u>AMPHOTERICIN B - ABELCET</u>						
N 050724 001	6406713	Jun 18, 2019	DS			
<u>AMPHOTERICIN B - AMBISOME</u>						
N 050740 001	5874104	Feb 23, 2016	DP	U-922		
	5965156	Oct 12, 2016	DP	U-922		
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 001	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021007 002	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
	6730679	Nov 11, 2017	DP			
<u>AMPRENAVIR - AGENERASE</u>						
N 021039 001	5646180	Jul 08, 2014		U-257		
	5723490	Mar 03, 2015		U-257		
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001	5965525	Feb 17, 2020	DS	DP	U-540	
	6960564	Apr 12, 2021		DP	U-540	
	7709444	Apr 12, 2021		DP	U-540	
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002	5965525	Feb 17, 2020	DS	DP	U-540	
	6960564	Apr 12, 2021		DP	U-540	
	7709444	Apr 12, 2021		DP	U-540	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1167		NCE	Dec 28, 2017
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1200		I-690	Aug 21, 2017
	6967208	Feb 03, 2023	DS DP U-1323		I-691	Aug 21, 2017
					NCE	Dec 28, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>APREPITANT - EMEND</u>						
N 021549 001	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 002	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N 021549 003	5719147	Apr 17, 2015	DS DP U-853			
	6096742	Jul 01, 2018	DS DP U-745			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N 021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6667344	Jun 22, 2021	DP			
	6720453	Nov 09, 2021	DS			
	6814953	Jun 22, 2021		U-793		
	7145036	Nov 09, 2021	DS			
	7348362	Jun 22, 2021	DP	U-793		
	7462645	Jun 22, 2021		U-793		
	7465756	Jun 22, 2021	DP			
	7473710	Jun 22, 2021		U-793		
	7541385	Jun 22, 2021		U-793		
	8110706	Nov 09, 2021	DP			
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434 001	7589106	Sep 26, 2027	DP	U-1163		
	7687516	Sep 26, 2027	DP	U-1164		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY						
N 021436 001	5006528	Oct 20, 2014	DS DP U-761	U-839	I-700	Dec 12, 2017
	7053092	Jan 28, 2022			M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 002	5006528	Oct 20, 2014	DS DP U-761	U-839	I-700	Dec 12, 2017
	7053092	Jan 28, 2022			M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 003	5006528	Oct 20, 2014	DS DP U-761	U-839	I-700	Dec 12, 2017
	7053092	Jan 28, 2022			M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 004	5006528	Oct 20, 2014	DS DP U-761	U-839	I-700	Dec 12, 2017
	7053092	Jan 28, 2022			M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
ARIPIPRAZOLE - ABILIFY						
N 021436 005	5006528	Oct 20, 2014	DS DP U-761	U-839	I-700	Dec 12, 2017
	7053092	Jan 28, 2022			M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-761		M-137	Jun 09, 2017
	6977257	Apr 24, 2022	DS DP			
	7053092	Jan 28, 2022	U-839			
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005	5006528	Oct 20, 2014	DS DP U-761		I-700	Dec 12, 2017
	7053092	Jan 28, 2022	U-839		M-137	Jun 09, 2017
	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8518421	Jan 24, 2021	DP			
	8518421*PED	Jul 24, 2021				
	8580796	Sep 25, 2022	DS			
	8580796*PED	Mar 25, 2023				
	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-763		I-700	Dec 12, 2017
	7115587	Jul 21, 2024	DS DP U-764		M-137	Jun 09, 2017
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Apr 20, 2015	DS DP U-543		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Apr 20, 2015	DS DP U-543		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Apr 20, 2015	DS DP U-1530		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Apr 20, 2015	DS DP U-1530		M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	DP U-820			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018		U-573		
	6855339	Nov 10, 2018		U-617		
	6861076	Nov 10, 2018		U-617		
	6884439	Nov 10, 2018		U-651		
	6982096	Nov 10, 2018		U-651		
	8273379	Nov 10, 2018		U-1291		
<u>ARTEMETHER; LUMEFANTRINE - COARTEM</u>						
N 022268 001	5677331	Oct 14, 2014	DP U-977		ODE	Apr 07, 2016
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		NCE	Aug 13, 2014
	7741358	Apr 06, 2026	DS DP U-1064			
	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		NCE	Aug 13, 2014
	7741358	Apr 06, 2026	DS DP U-1064			
	8022228	Apr 06, 2026	DS DP			
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	8865187	Mar 23, 2022	DP			
<u>ASPIRIN; DIPYRIDAMOLE - AGGRENOLX</u>						
N 020884 001	6015577	Jan 18, 2017		U-302		
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 001	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 002	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 003	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 004	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 005	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 006	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 007	5658590	Nov 26, 2016	U-494			
<u>ATOMOXETINE HYDROCHLORIDE - STRATTERA</u>						
N 021411 008	5658590	Nov 26, 2016	U-494			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 001	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 002	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 003	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM - LIPITOR</u>						
N 020702 004	5686104	Nov 11, 2014	DP U-213			
	5969156	Jul 08, 2016	DS			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104	Nov 11, 2014	DP U-1400		NC	May 03, 2016
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104	Nov 11, 2014	DP U-1400		NC	May 03, 2016
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104	Nov 11, 2014	DP U-1400		NC	May 03, 2016
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104	Nov 11, 2014	DP U-1400		NC	May 03, 2016
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
	RE42461	Oct 25, 2016	DS DP U-1400			
	RE42461*PED	Apr 25, 2017				
<u>ATOVAQUONE - MEPRON</u>						
N 020500 001	6649659	Jul 10, 2016	DS DP U-69			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Sep 13, 2020	DS DP U-155		D-140	Sep 17, 2017
	7501409	May 05, 2023	DP		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020		U-1220		
	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020		U-1220		
	8791140	Aug 05, 2030	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 021470 001	6534070	Nov 18, 2018				
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025		U-1430	NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022371 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025		U-1430		
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023		U-77	NC	May 01, 2015
	8163723	Aug 29, 2023		U-81		
	8163723	Aug 29, 2023		U-644		
	8163723	Aug 29, 2023		U-707		
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025		DP U-3		
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	7157584	May 22, 2025	DS		NCE	Feb 25, 2016
	7572920	Jan 07, 2025		DP U-3		
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	7157584	May 22, 2025	DS		NC	Dec 20, 2014
	7572920	Jan 07, 2025		DP U-3	NCE	Feb 25, 2016
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	7157584	May 22, 2025	DS		NC	Dec 20, 2014
	7572920	Jan 07, 2025		DP U-3	NCE	Feb 25, 2016
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050693 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050710 002	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050711 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050730 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050733 001	6268489	Jul 31, 2018	DS			
<u>AZITHROMYCIN - ZITHROMAX</u>						
N 050784 001	6268489	Jul 31, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZMAX</u>						
N 050797 001	6068859	May 30, 2017	DP			
	6268489	Jul 31, 2018	DS			
	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
<u>AZITHROMYCIN - AZASITE</u>						
N 050810 001	6159458	Nov 04, 2017	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
<u>AZTREONAM - CAYSTON</u>						
N 050814 001	7208141	Dec 20, 2021	DP U-1031		ODE	Feb 22, 2017
	7214364	Dec 20, 2021	DP			
	7427633	Dec 20, 2021	DP U-1031			
	8399496	Dec 20, 2021	DP U-1377			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BACLOFEN - KEMSTRO</u>						
N 021589 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2017	DS DP U-594		NP	Oct 03, 2016
	6479535	May 06, 2019	DP U-594			
	6479535	May 06, 2019	DP U-904			
	7138392	Apr 04, 2017	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
	8815934	May 06, 2019	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	5683677	Nov 04, 2014	DP		NP	Mar 23, 2015
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	5776432	Jul 07, 2015	DP		NP	Mar 23, 2015
	7780038	Jan 24, 2027	DP		NS	Dec 17, 2017
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Oct 02, 2024	DS DP U-1321		NCE	Dec 28, 2017
	8546428	Mar 19, 2029	DS DP U-1321		ODE	Dec 28, 2019
<u>BELINOSTAT - BELEODAQ</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP		ODE	Mar 20, 2015
	8436190*PED	Apr 26, 2031			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP		ODE	Mar 20, 2015
	8436190*PED	Apr 26, 2031			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS DP U-1402		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402		ODE	Mar 20, 2015
	8344006*PED	Mar 23, 2030			ODE	Oct 31, 2015
	8445524	Mar 26, 2029	DS		PED	Sep 20, 2015
	8445524*PED	Sep 26, 2029			PED	May 01, 2016
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	5733886	Mar 31, 2015	DP U-124			
	5733886	Mar 31, 2015	DP			
	8288434	Aug 05, 2029	DP U-124			
	8663699	Jun 03, 2029	U-124			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	5733886	Mar 31, 2015	DP			
	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	8288434	Aug 05, 2029	DP U-1033			
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129 001	5858383	Aug 11, 2017	U-970			
	6139859	Aug 11, 2017	U-970			
	6793931	Jul 11, 2022	DP U-970			
	7294342	May 19, 2024	U-970			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	6780877	Sep 19, 2019	DS DP		NCE	Sep 08, 2014
	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	5447926	Apr 13, 2016	DS DP U-80			
	6685958	Jun 29, 2021	DP U-80			
	6699492	Mar 31, 2019	DP U-80			
	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852 001	5763426	Jun 09, 2015	DS DP		NPP	Dec 23, 2017
	6753013	Jan 27, 2020	DP U-88			
	6753013	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88		I-659	Oct 17, 2015
	6753013	Jan 27, 2020	DP U-193		NPP	Aug 29, 2017
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	RE39706	Jun 09, 2015	DS DP			
<u>BETAMETHASONE VALERATE - LUXIO</u>						
N 020934 001	6126920	Mar 01, 2016	U-484			
	7078058	May 24, 2017	DP			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001	5780676	Jul 14, 2015	U-509			
	5962731	Oct 05, 2016	U-475			
<u>BEXAROTENE - TARGRETIN</u>						
N 021056 001	5780676	Jul 14, 2015	U-510			
	5962731	Oct 05, 2016				
<u>BIMATOPROST - LUMIGAN</u>						
N 021275 001	5688819	Aug 19, 2014	U-446			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	5688819	Aug 19, 2014	U-1081			
	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025	U-1295			
	8309605	Mar 16, 2025	U-1293			
	8309605	Mar 16, 2025	U-1294			
	8338479	Mar 16, 2025	DP U-1295			
	8524777	Mar 16, 2025	U-1235			
	8586630	Mar 16, 2025	U-1458			
	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939		M-140	Sep 04, 2017
	7388029	Jan 21, 2022	U-938			
	8038988	Aug 25, 2023	DS DP U-1208			
	8101161	May 25, 2024	U-1217			
	8101161	May 25, 2024	U-1218			
	8263054	Jan 15, 2023	U-1277			
	8541466	Jan 21, 2022	U-1217			
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
	8906962	Jan 31, 2021	U-1217			
	8926953	Jan 15, 2023	U-1217			
<u>BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY</u>						
N 021551 003	7291324	Oct 22, 2022	U-837			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA</u>						
N 050786 001	6350468	Dec 14, 2018	U-932			
	6350468	Dec 14, 2018	U-956			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873 001	5196404	Dec 15, 2014	DS DP U-1040			
	5196404	Dec 15, 2014	DS DP U-1232			
	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	7772178	Nov 11, 2027	DP U-1128		M-126	Feb 27, 2016
	8119602	Mar 17, 2027	U-1233		NCE	May 13, 2016
	RE43298	Feb 22, 2022	DS DP U-1128		NPP	Feb 13, 2016
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	6083903	Oct 28, 2014	DP U-515		D-142	Oct 08, 2017
	6297217	Oct 28, 2014	U-515		I-695	Oct 08, 2017
	6297217	Oct 28, 2014	U-884		M-139	Aug 08, 2017
	6297217	Oct 28, 2014	U-885		NR	Jan 23, 2015
	6617317	Oct 28, 2014	DS DP		ODE	Jun 20, 2015
	6713446	Jan 25, 2022	DS DP		ODE	Oct 08, 2021
	6747150	Oct 28, 2014	DP			
	6958319	Jan 25, 2022	DS DP			
	7119080	Oct 28, 2014	DP			
<u>BOSENTAN - TRACLEER</u>						
N 021290 001	5292740	Nov 20, 2015				
<u>BOSENTAN - TRACLEER</u>						
N 021290 002	5292740	Nov 20, 2015				
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	6562873	Jul 10, 2021				
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
<u>BRIMONIDINE TARTRATE - QOLIANA</u>						
N 021764 001	7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	6562873	Jul 10, 2021	DP			
	6627210	Jul 18, 2021	DP			
	6641834	Jul 28, 2021	DP			
	6673337	Jul 26, 2021	DP			
	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	7439241	Aug 25, 2025	U-1428		NDF	Aug 23, 2016
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	6316441	Dec 07, 2019	U-778		NC	Apr 19, 2016
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	7030149	Apr 19, 2022	U-849			
	7320976	Apr 19, 2022	U-849			
	7323463	Jan 19, 2023	DP	Y		
	7642258	Apr 19, 2022	DS DP U-1024			
	8133890	Apr 19, 2022	U-1235			
	8354409	Apr 19, 2022	DP U-1371			
	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8129431	Sep 11, 2025	DS DP		NP	Apr 05, 2016
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-810			
	8927606	Jan 16, 2024	U-1095			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	5679685	Oct 21, 2014	DP			
	5716957	Feb 10, 2015	U-976			
	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 001	6291445	Apr 29, 2017		Y		
	6686346	Apr 29, 2017	DP U-557	Y		
	6986904	Apr 29, 2017	DP U-699	Y		
<u>BUDESONIDE - RHINOCORT</u>						
N 020746 002	6291445	Apr 29, 2017				
	6686346	Apr 29, 2017	DP U-557			
	6986904	Apr 29, 2017	DP U-699			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 001	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 002	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - PULMICORT RESPULES</u>						
N 020929 003	6598603	Dec 23, 2018	U-529			
	6899099	Dec 23, 2018	U-529			
	7524834	Nov 11, 2018	DP U-966			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001	5643602	Jul 01, 2014	U-655			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 001	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - PULMICORT FLEXHALER</u>						
N 021949 002	6027714	Jan 09, 2018	DP U-787			
	6142145	May 08, 2018	DP			
	6287540	Jan 09, 2018	DP			
	7143764	Mar 13, 2018	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	7410651	Jun 09, 2020	DP U-1325		NDF	Jan 14, 2016
	7431943	Jun 09, 2020	DP			
	8293273	Jun 09, 2020	DP			
	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
	RE43799	Jun 09, 2020	DP U-1325			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001					NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	5674860	Oct 07, 2014	DP U-1075			
	6123924	Sep 26, 2017	DP			
	7367333	Nov 11, 2018	DP			
	7587988	Apr 10, 2026	DP			
	7759328	Jan 29, 2023	DP U-1073			
	7897646	Sep 09, 2018	U-1118			
	7967011	Aug 11, 2021	DP			
	8143239	Jan 29, 2023	DP U-1073			
	8387615	Nov 10, 2024	DP			
	8461211	Sep 09, 2018	U-1118			
	8528545	Oct 16, 2028	DP			
	8575137	Jan 29, 2023	DP U-1073			
	8616196	Apr 07, 2029	DP			
	8875699	Nov 10, 2024	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	8182835	Sep 18, 2018	DP U-1246		NP	Oct 28, 2014
	8834921	Sep 18, 2018	DP U-1587			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	8182835	Sep 18, 2018	DP U-1246		NP	Oct 28, 2014
	8834921	Sep 18, 2018	DP U-1587			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8454996	Sep 24, 2019	U-1421			
	8470361	Oct 14, 2029	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 001	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - WELLBUTRIN XL</u>						
N 021515 002	6096341	Oct 30, 2018				
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497 001	7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
<u>BUTOCONAZOLE NITRATE - GYNAZOLE-1</u>						
N 019881 001	5993856	Nov 17, 2017	DP U-457			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP		NCE	Jun 17, 2015
	6331635	Mar 26, 2016	DS DP			
	6372780	Mar 26, 2016	U-1067			
	6387946	Mar 26, 2016	U-1067			
	7241907	Dec 10, 2025	DS			
	8927592	Oct 27, 2030	U-1630			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8877776	Oct 08, 2030	DS DP U-1617		ODE	Nov 29, 2019
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020554 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			
<u>CALCIPOTRIENE - DOVONEX</u>						
N 020611 001	5763426	Jun 09, 2015	DS DP			
	RE39706	Jun 09, 2015	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280		I-657	Sep 27, 2015
	8269128	May 26, 2026	DP U-1280			
<u>CALCITONIN SALMON - MIACALCIN</u>						
N 020313 002	5733569	Mar 31, 2015	U-227			
	5759565	Mar 31, 2015				
<u>CALCITONIN SALMON RECOMBINANT - FORTICAL</u>						
N 021406 001	6440392	Feb 02, 2021	DP U-227			
	RE40812	Feb 02, 2021	DP			
	RE43580	Feb 02, 2021	DP U-227			
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 001	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCITRIOL - CALCIJEX</u>						
N 018874 002	6051567	Aug 02, 2019				
	6265392	Aug 02, 2019				
	6274169	Aug 02, 2019				
<u>CALCIUM ACETATE - PHOSLO</u>						
N 021160 002	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6576665	Apr 03, 2021				
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
N 020958 001	5989588	Sep 30, 2015	U-349			
	6814978	Aug 26, 2021	DP			
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>						
N 021823 001	5994329	Jul 17, 2018	U-353			
	6015801	Jul 17, 2018	U-353			
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018	U-595			
	6465443	Aug 14, 2018	DP			
<u>CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL</u>						
N 022193 001	7084130	Nov 29, 2021	DP U-891			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-493		NCE	Mar 29, 2018
	7943788	Jul 14, 2027	DS DP			
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 001	5721263	Feb 24, 2015	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 002	5721263	Feb 24, 2015	DP U-3			
<u>CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE - ATACAND HCT</u>						
N 021093 003	5721263	Feb 24, 2015	DP U-3			
<u>CAPECITABINE - XELODA</u>						
N 020896 001					M-131 PED	Dec 10, 2016 Jun 10, 2017
<u>CAPECITABINE - XELODA</u>						
N 020896 002					M-131 PED	Dec 10, 2016 Jun 10, 2017
<u>CAPSAICIN - QUTENZA</u>						
N 022395 001	6239180	Nov 06, 2016	DP		NCE ODE	Nov 16, 2014 Nov 16, 2016
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 001	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 002	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - CARBATROL</u>						
N 020712 003	5912013	Jun 15, 2016	U-277			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 001	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 002	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 003	5912013	Jun 15, 2016	DP			
	6977253	May 19, 2024	U-693			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50</u>						
N 021485 001	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100</u>						
N 021485 002	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150</u>						
N 021485 003	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200</u>						
N 021485 004	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75</u>						
N 021485 005	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125</u>						
N 021485 006	6500867	Jun 29, 2020	DP U-219			
	6797732	Jun 29, 2020	DP			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025		U-1260		
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026		U-1260		
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025		U-1260		
	8207297	Apr 14, 2025	DS DP			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					NCE	Mar 18, 2015
					ODE	Mar 18, 2017
<u>CARVEDILOL - COREG</u>						
N 020297 001	RE40000	Jun 07, 2015		U-233		
<u>CARVEDILOL - COREG</u>						
N 020297 002	RE40000	Jun 07, 2015		U-233		
<u>CARVEDILOL - COREG</u>						
N 020297 003	RE40000	Jun 07, 2015		U-233		
<u>CARVEDILOL - COREG</u>						
N 020297 004	RE40000	Jun 07, 2015		U-233		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 001	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015		U-777		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 002	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015		U-777		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 003	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015		U-777		
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 004	6022562	Oct 17, 2015	DP		Y	
	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
	RE40000	Jun 07, 2015		U-777		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 001	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CASPOFUNGIN ACETATE - CANCIDAS</u>						
N 021227 002	5514650	Jan 26, 2015	DP U-607			
	5952300	Mar 28, 2017	DP			
	6136783	Mar 28, 2017	U-607			
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222 001	5958915	Oct 14, 2016				
<u>CEFditoren PIVOXIL - SPECTRACEF</u>						
N 021222 002	5958915	Oct 14, 2016	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Dec 17, 2018	DS DP U-282		NCE	Oct 29, 2015
	6906055	Dec 15, 2021	DS DP			
	7419973	Dec 15, 2021	DP			
	8247400	Feb 10, 2031	DP U-282			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	7129232	Oct 21, 2024	DS DP U-36		NCE	Dec 19, 2019
	8476425	Sep 27, 2032	DS		GAIN	Dec 19, 2024
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
<u>CELECOXIB - CELEBREX</u>						
N 020998 001	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 002	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 003	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				
<u>CELECOXIB - CELEBREX</u>						
N 020998 004	5760068	Jun 02, 2015	U-672			
	RE44048	Jun 02, 2015	U-247			
	RE44048	Jun 02, 2015	U-1348			
	RE44048	Jun 02, 2015	U-1349			
	RE44048	Jun 02, 2015	U-1350			
	RE44048	Jun 02, 2015	U-1351			
	RE44048	Jun 02, 2015	U-1352			
	RE44048*PED	Dec 02, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027		U-1179		
	8703787	Feb 02, 2032		U-1179		
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 003	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY</u>						
N 021621 004	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 005	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF</u>						
N 021621 006	6455533	Jul 02, 2018	DP U-295			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>						
N 021150 002	6469009	Jul 13, 2019	DP U-295			
	6489329	Apr 08, 2016	DP			
	7014867	Jun 10, 2022	DP			
	7226614	Jun 10, 2022		U-295		
<u>CETRORELIX - CETROTIDE</u>						
N 021197 001	6319192	Apr 23, 2019		U-426		
<u>CETRORELIX - CETROTIDE</u>						
N 021197 002	6319192	Apr 23, 2019		U-426		
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669 001	7066916	Feb 17, 2024		U-737		
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP U-1022			
	7717889	Feb 27, 2025	DP U-1022			
	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 001	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	5690958	Sep 30, 2016	DP			
	6729786	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP FREPP</u>						
N 020832 003	5538353	Aug 25, 2015	DP			
	5690958	Sep 30, 2016	DP			
	5772346	Apr 22, 2017	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 004	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 006	5690958	Sep 30, 2016	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	5690958	Sep 30, 2016	DP			
	6536975	Nov 10, 2020	DP			
	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003	D468424	Jan 07, 2017				
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP SEPP</u>						
N 021555 001	5690958	Sep 30, 2016	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441 001	7863287	Feb 28, 2027	DP			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N 203155 001					NCE W	Sep 12, 2017 Sep 12, 2017
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 002	7259186	Jan 07, 2025	DS			
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 001	5767251	Jun 16, 2015				
<u>CHORIOGONADOTROPIN ALFA - OVIDREL</u>						
N 021149 002	5767251	Jun 16, 2015	DS			
	6706681	Mar 16, 2021	DP			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	5482934	Oct 24, 2017	DS DP U-1002		M-125	Dec 17, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	5482934	Oct 24, 2017	DS DP U-557			
	6767901	Oct 21, 2020	DP			
	6939559	Apr 21, 2019	DP			
	7235247	Apr 21, 2019	DP			
	8371292	Aug 25, 2027	U-1356			
	8383611	Oct 20, 2020	DP			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
	8371292	Aug 25, 2027	U-1357			
<u>CICLOPIROX - LOPROX</u>						
N 020519 001	7018656	Sep 05, 2018	DP			
	7026337	Nov 21, 2016	U-714			
<u>CICLOPIROX - LOPROX</u>						
N 021159 001	7981909	Sep 16, 2017	U-1162			
	8227490	Sep 16, 2017	U-1256			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP U-560			
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016			ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP U-560			
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	6011068	Mar 08, 2018	DS DP		ODE	Feb 25, 2018
	6031003	Dec 14, 2016	U-559		ODE	Nov 21, 2021
	6211244	Oct 23, 2015	DS DP U-560			
	6313146	Dec 14, 2016	DS DP			
	7829595	Sep 22, 2026	DP U-1098			
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 001	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN - CIPRO</u>						
N 020780 002	5695784	Dec 09, 2014				
<u>CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR</u>						
N 021744 001	5972389	Sep 19, 2016	DP U-663			
	6340475	Sep 19, 2016	DP U-663			
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP U-663			
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPRO HC</u>						
N 020805 001	5843930	Jun 06, 2015	U-646			
	5965549	Jun 06, 2015	DP			
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 001	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR</u>						
N 021473 002	7709022	Jun 23, 2021	DP			
	8187632	Jun 23, 2021	DP			
	8187632*PED	Dec 23, 2021				
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	6284804	Aug 10, 2020				
	6359016	Aug 10, 2020				
	8846650	Jun 04, 2025	DP U-1578			
<u>CISAPRIDE MONOHYDRATE - PROPULSID QUICKSOLV</u>						
N 020767 001	5648093	Jul 15, 2014				
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 020535 001	8450338	Oct 10, 2028	DP		NP	Jul 16, 2015
	8481083	Oct 10, 2028	DP			
<u>CLARITHROMYCIN - BIAXIN XL</u>						
N 050775 001	6010718	Apr 11, 2017	DP U-924			
	6551616	Jun 15, 2017	U-924			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLINDAMYCIN PHOSPHATE - CLEOCIN</u>						
N 050767 001	6495157	Jul 20, 2020	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAGEL</u>						
N 050782 001	6387383	Aug 03, 2020	DP U-818			
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793 001	5993856	Nov 17, 2017	DP U-137			
	6899890	Apr 27, 2023	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801 001	7141237	Jan 23, 2024	DS DP			
	7374747	Aug 09, 2026	DS DP U-921			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA</u>						
N 050802 001	6387383	Aug 03, 2020	DP U-916			
	RE41134	Feb 24, 2015	DP U-1033			
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN - VELTIN</u>						
N 050803 001	5690923	Nov 25, 2014	DP			
<u>CLOBAZAM - ONFI</u>						
N 202067 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 002					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 202067 003					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBAZAM - ONFI</u>						
N 203993 001					NCE	Oct 21, 2016
					ODE	Oct 21, 2018
<u>CLOBETASOL PROPIONATE - OLUX</u>						
N 021142 001	6126920	Mar 01, 2016	U-484			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021535 001	6106848	Sep 22, 2017				
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021644 001	7316810	Jun 17, 2019	DP			
	7700081	Jan 03, 2022	U-1044			
	8066975	Jun 17, 2019	DP			
	8066976	Jun 17, 2019	DP			
<u>CLOBETASOL PROPIONATE - CLOBEX</u>						
N 021835 001	5972920	Feb 12, 2018	DP			
	5990100	Mar 24, 2018	DP U-742			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1410			
<u>CLOFARABINE - CLOLAR</u>						
N 021673 001	5661136	Jan 14, 2018	U-626			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	003				M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331	004				M-149	Nov 20, 2017
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	001	6429210	Jun 10, 2019	DS DP	PED	Nov 06, 2014
		6504030	Jun 10, 2019	DS		
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N 020839	002	6429210	Jun 10, 2019	DS DP	PED	Nov 06, 2014
		6504030	Jun 10, 2019	DS		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	001	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	002	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	003	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	004	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	005	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>CLOZAPINE - FAZACLO ODT</u>						
N 021590	006	6024981	Apr 09, 2018	DP		
		6106861	Dec 05, 2017	DP		
		6221392	Apr 09, 2018	DP		
<u>COBICISTAT - TYBOST</u>						
N 203094	001	8148374	Sep 03, 2029	DS DP U-1279	NP	Sep 24, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100	001	5814639	Sep 29, 2015	DS DP	NP	Aug 27, 2015
		5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS U-257		
		5935946	Jul 25, 2017	DS DP U-257		
		5977089	Jul 25, 2017	DS DP U-257		
		6043230	Jul 25, 2017	U-257		
		6642245	Nov 04, 2020	U-257		
		6703396	Mar 09, 2021	DS DP		
		7176220	Nov 20, 2023	DS DP U-257		
		7635704	Oct 26, 2026	DS DP U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
		8592397	Jan 13, 2024	DP U-257		
		8633219	Oct 11, 2031	DP U-257		
		8716264	Jan 13, 2024	DP U-257		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029	U-1007		ODE	Jul 29, 2016
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021141 001	5693675	Dec 02, 2014				
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 021176 001	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022	U-851			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022	U-493			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002	5693675	Dec 02, 2014	DS			
	7229613	Apr 17, 2022	U-493			
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>						
N 021697 001	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER</u>						
N 021697 002	5723606	Dec 15, 2019	DS DP	U-698		
	5723606	Dec 15, 2019	DS DP	U-868		
<u>CORTICOTROPIN - H.P. ACTHAR GEL</u>						
N 008372 008					ODE	Oct 15, 2017
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Mar 01, 2025	DS		NCE	Aug 26, 2016
	7825137	May 12, 2027	U-1179		ODE	Aug 26, 2018
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	7323195	Jun 07, 2018	DP		NCE	Dec 31, 2017
	7341744	Jun 16, 2018	U-1319			
	8574634	Jan 11, 2018	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Jun 11, 2024	DP	U-817		
	7404489	Mar 12, 2024	DP			
	7879349	Jun 01, 2024	DP	U-1152		
	8003353	Jun 11, 2024	U-817			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 002	7387793	Feb 26, 2025	DP			
	7544372	Nov 14, 2023	U-979			
	7790199	Nov 14, 2023	DP			
	7820203	Nov 14, 2023	DP			
	7829121	Nov 14, 2023	U-1088			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 002	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050715 003	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - NEORAL</u>						
N 050716 001	5985321	Sep 26, 2014	DP			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8629111	Aug 27, 2024	DP			
	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP		ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	8026284	Sep 22, 2027	U-1399		NDF	Apr 30, 2016
	8129433	Jan 26, 2027	DP		ODE	Apr 30, 2020
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N 200740 001					NP	Oct 02, 2015
					ODE	Oct 02, 2019
<u>CYTARABINE - DEPOCYT</u>						
N 021041 001	5723147	Mar 03, 2015	DP U-806			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		NCE	Oct 19, 2015
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Feb 18, 2018	DS DP U-1089		I-682	Apr 04, 2017
	7866474	Aug 31, 2027	DP		I-683	Apr 04, 2017
	7932273	Sep 07, 2025	DS DP		NCE	Oct 19, 2015
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
					ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	7994185	Jan 20, 2030	DS DP U-1406		I-678	Jan 08, 2017
	8415345	Jan 20, 2030	DS DP U-1406		NCE	May 29, 2018
					ODE	May 29, 2020
					ODE	Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023	U-1517			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	5540938	Jul 30, 2018	U-1030		NCE	Jan 22, 2015
	8007826	May 26, 2027	U-1030		ODE	Jan 22, 2017
	8354437	Dec 22, 2026	U-1030			
	8440703	Apr 08, 2025	U-1030			
	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP			
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 021794 001	5863560	Sep 11, 2016	DP			
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 001	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8058238	Nov 28, 2020	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	6468967	Sep 24, 2019	U-282			
	6852689	Sep 24, 2019	U-282			
	8003673	Sep 04, 2028	U-1180			
	8058238	Nov 28, 2020	DS DP			
	8129342	Nov 28, 2020	DS DP			
	RE39071	Jun 15, 2016	DS DP U-728			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 001	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			
<u>DARIFENACIN HYDROBROMIDE - ENABLEX</u>						
N 021513 002	5096890	Mar 13, 2015	DS DP U-631			
	6106864	Aug 21, 2016	DP U-630			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	5843946	Dec 01, 2015	DP U-744		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-903		NPP	Dec 16, 2014
	5843946	Dec 01, 2015	DP U-935		PED	Jun 16, 2015
	5843946	Dec 01, 2015	DP U-1209		PED	Aug 01, 2016
	5843946	Dec 01, 2015	DP U-1305			
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-1305			
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	5843946	Dec 01, 2015	DP U-1209		D-135	Feb 01, 2016
	5843946	Dec 01, 2015	DP U-1305		NDF	Dec 16, 2014
	6037157	Jun 26, 2016	U-1209		PED	Jun 16, 2015
	6037157	Jun 26, 2016	U-1305		PED	Aug 01, 2016
	6248775	Aug 13, 2014	DS			
	6703403	Jun 26, 2016	U-1209			
	6703403	Jun 26, 2016	U-1305			
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-1305			
	7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE43596	May 09, 2017	DS DP			
	RE43802	Oct 19, 2016	U-1305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001				NCE	Dec 19, 2019
<u>DASATINIB - SPRYCEL</u>						
N 021986	001	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	002	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	003	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	004	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	005	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DASATINIB - SPRYCEL</u>						
N 021986	006	6596746	Jun 28, 2020	DS DP U-748		
		6596746	Jun 28, 2020	DS DP U-780		
		7125875	Apr 13, 2020	U-779		
		7125875	Apr 13, 2020	U-780		
		7153856	Apr 28, 2020	U-780		
		7491725	Mar 28, 2026	DS DP		
		8680103	Feb 04, 2025	DP		
<u>DEFERASIROX - EXJADE</u>						
N 021882	001	6465504	Apr 05, 2019	DS DP	I-665	Jan 23, 2016
		6596750	Jun 24, 2017	DS U-735		
<u>DEFERASIROX - EXJADE</u>						
N 021882	002	6465504	Apr 05, 2019	DS DP	I-665	Jan 23, 2016
		6596750	Jun 24, 2017	DS U-735		
<u>DEFERASIROX - EXJADE</u>						
N 021882	003	6465504	Apr 05, 2019	DS DP	I-665	Jan 23, 2016
		6596750	Jun 24, 2017	DS U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825	001				NCE	Oct 14, 2016
					ODE	Oct 14, 2018

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DELAVIDINE MESYLATE - RESCRIPTOR</u>						
N 020705 002	6177101	Jun 07, 2019				
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N 021271 001	5733874	Mar 31, 2015				
<u>DESLORATADINE - CLARINEX</u>						
N 021165 001	6100274	Jul 07, 2019				
	7211582	Dec 30, 2014	U-809			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
	7405223	Jul 07, 2019	U-886			
<u>DESLORATADINE - CLARINEX</u>						
N 021300 001	6514520	Jun 01, 2018	DP			
	7211582	Dec 30, 2014	U-809			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 001	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014	U-809			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
	7618649	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE - CLARINEX</u>						
N 021312 002	5607697	Jun 07, 2015	DP			
	6100274	Jul 07, 2019	DP			
	7211582	Dec 30, 2014	U-809			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
	7618649	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N 021313 001	6100274	Jul 07, 2019	DP			
	6709676	Feb 18, 2021	DP U-707			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
	7618649	Dec 19, 2020	DP U-1017			
	8187630	Dec 19, 2020	DP U-1017			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>						
N 021605 001	6100274	Jul 07, 2019	DP			
	6979463	Mar 28, 2022	DP			
	7214683	Dec 30, 2014	DP			
	7214684	Dec 30, 2014	U-138			
	7618649	Dec 19, 2020	DP U-1017			
	7820199	Mar 28, 2022	DP			
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 001	7022340	Apr 30, 2023	DP	Y		
<u>DESMOPRESSIN ACETATE - DDAVP</u>						
N 019955 002	7022340	Apr 30, 2023	DP	Y		
<u>DESONIDE - DESONATE</u>						
N 021844 001	6387383	Aug 03, 2020	DS DP U-783			
<u>DESONIDE - VERDESO</u>						
N 021978 001	6730288	Sep 08, 2019	DP			
	7029659	Sep 08, 2019	DP			
	8460641	Nov 05, 2028	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	5990100	Mar 24, 2018	DP U-1408		NDF	Apr 11, 2016
	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860		I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860		I-675	Feb 14, 2016
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	6726918	Oct 20, 2020	DP U-1204		I-686 ODE	Jun 29, 2017
	6726918	Oct 20, 2020	DP U-1205			Sep 24, 2017
	6899717	Nov 01, 2023	U-1206			
	7033605	Oct 20, 2020	DP			
	7767223	Nov 28, 2021	DP			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8043628	Oct 20, 2020	DP U-1205			
	8063031	Oct 20, 2020	DP			
	8088407	Oct 20, 2020	DP U-1205			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8871273	Jan 11, 2028	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6462058	Jun 15, 2020	DS DP U-949			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	7285668	Jun 15, 2020	DS			
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	6716867	Mar 31, 2019	U-1472		M-61	Jun 17, 2016
	6716867*PED	Oct 01, 2019			PED	Dec 17, 2016
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 001					PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 001	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 002	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN</u>						
N 021278 003	5908850	Dec 04, 2015	U-422			
	6355656	Dec 04, 2015				
	6528530	Dec 04, 2015	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 001	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 002	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 003	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 004	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015		U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 005	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 006	5837284	Dec 04, 2015	DP	U-677		
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 007	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP	U-678		
	6228398	Nov 01, 2019	DP	U-676		
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP	U-677		
	6730325	Nov 01, 2019	DP	U-676		
	7431944	Dec 04, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N 021802 008	5837284	Dec 04, 2015	DP			
	5908850	Dec 04, 2015	DP U-678			
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXRAZOXANE HYDROCHLORIDE - TOTECT</u>						
N 022025 001	6727253	Mar 13, 2020	U-829		ODE	Sep 06, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM</u>						
N 021620 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-685			
	7838032	Apr 28, 2020	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
	RE38115	Jan 26, 2016	DP	Y		
<u>DEXTROMETHORPHAN POLISTIREX - DELSYM</u>						
N 018658 001	5980882	Apr 16, 2017	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692 NP	Aug 22, 2017 Oct 18, 2016
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692 NP	Aug 22, 2017 Oct 18, 2016
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	6974595	May 15, 2017	U-436			
	7482377	May 15, 2017	DS DP U-436			
	7759394	Jun 16, 2026	DS DP U-436			
	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	6365180	Jul 15, 2019	DP U-980			
	7662858	Feb 24, 2029	U-1035			
	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
	8110606	Feb 24, 2029	U-980			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
N 020809 001	5603929	Nov 16, 2014	U-239			
	5653972	Nov 16, 2014	U-239			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8217078	Jul 10, 2029	U-1248			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N 021005 001	5792753	Aug 11, 2015				
	5914322	Aug 11, 2015				
	5985850	Aug 11, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396	001				NP	Dec 23, 2017
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623	001	8217078	Jul 10, 2029	U-1477	NP	Jan 16, 2017
		8252838	Apr 21, 2028	DP U-1489		
		8546450	Aug 09, 2030	U-1435		
		8546450	Aug 09, 2030	U-1436		
		8563613	Oct 17, 2027	DP U-1488		
		8618164	Jul 10, 2029	U-1477		
		8741956	Jul 10, 2029	U-1435		
		8871809	Oct 17, 2027	U-1614		
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252	001	6133251	Oct 25, 2016	DP U-1	Y	I-648
		6133251	Oct 25, 2016	DP U-112	Y	
		6133251	Oct 25, 2016	DP U-828	Y	
		6884793	Oct 25, 2016	DP	Y	
		8071577	May 13, 2026	DP U-1		
		8153616	Jan 30, 2028	U-1240		
<u>DIFLUPREDNATE - DUREZOL</u>						
N 022212	001	6114319	May 18, 2019	DP	I-653	Jun 13, 2015
		6114319*PED	Nov 18, 2019		M-127	Mar 22, 2016
					ODE	Jun 13, 2019
					PED	Dec 13, 2015
					PED	Sep 22, 2016
					PED	Dec 13, 2019
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	001	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	002	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	003	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	004	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	005	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DILTIAZEM HYDROCHLORIDE - CARDIZEM LA</u>						
N 021392	006	6923984	Feb 25, 2021	DP		
		7108866	Dec 17, 2019	DP U-107		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	6509376	Oct 29, 2019	DP	NCE	Mar 27, 2018
		7320999	May 18, 2020	U-1384		
		7619001	Apr 01, 2018	U-1384		
		7803840	Apr 01, 2018	U-1385		
		8399514	Feb 07, 2028	U-1384		
		8524773	Apr 01, 2018	U-1384		
		8759393	Oct 29, 2019	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIMYRISTOYL LECITHIN; PERFLEXANE - IMAGENT</u>						
N 021191 001	5695741	Dec 09, 2014	U-458			
	5720938	Feb 24, 2015				
	5798091	Aug 25, 2015	U-458			
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N 021394 001	8263647	May 30, 2022	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	8883849	Jan 17, 2022	U-1618			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 001	6419953	Dec 18, 2018				
	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6528091	Dec 18, 2018	U-106			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DIVALPROEX SODIUM - DEPAKOTE ER</u>						
N 021168 002	6511678	Dec 18, 2018				
	6528090	Dec 18, 2018	DP			
	6713086	Dec 18, 2018	DP U-579			
	6720004	Dec 18, 2018	DP			
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 001	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 002	6124363	Oct 09, 2018				
<u>DOFETILIDE - TIKOSYN</u>						
N 020931 003	6124363	Oct 09, 2018				
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP		NCE	Aug 12, 2018
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720 001	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>						
N 021720 002	7727548	Jun 23, 2022	DP U-1062			
	7727552	Mar 26, 2018	DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DORIPENEM - DORIBAX</u>						
N 022106 001	5317016	Jun 05, 2015	DS DP U-282			
	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N 022106 002	5317016	Jun 05, 2015	DS DP U-282			
	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N 202667 001					NP	Feb 01, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020		U-620		
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027		U-620		
	8513299	Apr 14, 2030		U-620		
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	5585115	Jan 09, 2015	DP			
	5725884	Jan 09, 2015	DP			
	5866166	Jan 09, 2015	DP			
	5948438	Jan 09, 2015	DP			
	6103219	Jan 09, 2015	DP			
	6211229	Feb 17, 2020		U-620		
	6217909	Jan 09, 2015	DP			
	7915307	Aug 24, 2027		U-620		
	8513299	Apr 14, 2030		U-620		
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002	6903083	Jul 18, 2021	DS DP		Y	
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	5789395	Aug 30, 2016		U-925	Y	
	5919775	Aug 30, 2016		U-925	Y	
	7211267	Apr 05, 2022		U-925		
	7232572	Apr 05, 2022		U-925		
	7749532	Dec 19, 2027	DP	U-1063		
	8206740	Dec 24, 2025	DP	U-925		
	8394405	Apr 07, 2024	DP	U-925		
	8394406	Apr 07, 2024	DP	U-925		
	8470364	Apr 07, 2024	DP	U-925		
	8603506	Apr 05, 2022		U-1063		
	8709478	Apr 07, 2024		U-1063		
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	6958161	Dec 15, 2022	DP	U-918		
	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	6958161	Dec 15, 2022	DP	U-918	D-136	Apr 11, 2016
	8715724	Feb 03, 2028	DP		NS	Apr 11, 2016
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS</u>						
N 021876 001	6340695	Jun 21, 2021	DP	U-1382	NP	Apr 08, 2016
	7560122	Jan 25, 2019	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	5223510	Jul 26, 2016	DS DP	U-992	NCE	Jul 01, 2014
	5223510	Jul 26, 2016	DS DP	U-1261		
	7323493	Jun 19, 2018	DP			
	8318800	Jun 19, 2018	DP			
	8410167	Apr 16, 2029		U-1387		
	8410167	Apr 16, 2029		U-1388		
	8602215	Jun 30, 2031		U-1473		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 001	8906890	Oct 22, 2031	DP		NS	Mar 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 002	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN</u>						
N 021098 001	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DS			
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>						
N 021676 001	5798338	Jul 10, 2015	DP			
	6787531	Aug 31, 2020	DP			
	6933395	Aug 11, 2017	DP			
	6958326	Dec 20, 2021	DP			
	6987101	Dec 22, 2017	U-758			
	7163931	Dec 20, 2021	U-1			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004	5508276	Jul 18, 2014	DP		M-61	Oct 18, 2015
	6596756	Sep 10, 2019	U-882		NPP	Oct 16, 2017
					NPP	Oct 16, 2017
					PED	Apr 18, 2016
<u>DUTASTERIDE - AVODART</u>						
N 021319 001	5565467	Nov 20, 2015	DS DP			
<u>DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE - JALYN</u>						
N 022460 001	5565467	Nov 20, 2015	DS DP			
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	5993830	Jan 16, 2018	DP U-1449		NDF	Oct 24, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFVIRENZ - SUSTIVA</u>						
N 020972 001	5663169	Sep 02, 2014		U-257	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFVIRENZ - SUSTIVA</u>						
N 020972 002	5663169	Sep 02, 2014		U-257		
	5663169*PED	Mar 02, 2015				
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFVIRENZ - SUSTIVA</u>						
N 020972 003	5663169	Sep 02, 2014		U-257	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6238695	Apr 06, 2019	DP			
	6238695*PED	Oct 06, 2019				
	6555133	Apr 06, 2019		U-248		
	6555133*PED	Oct 06, 2019				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFVIRENZ - SUSTIVA</u>						
N 021360 001	5663169	Sep 02, 2014				
	5663169*PED	Mar 02, 2015				
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
<u>EFVIRENZ - SUSTIVA</u>						
N 021360 002	5663169	Sep 02, 2014		U-248	NPP	May 02, 2016
	5663169*PED	Mar 02, 2015			PED	Nov 02, 2016
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFVIRENIZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5663169*PED	Mar 02, 2015				
	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6639071	Feb 14, 2018	DS			
	6639071*PED	Aug 14, 2018				
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	6939964	Jan 20, 2018	DS			
	6939964*PED	Jul 20, 2018				
	8592397	Jan 13, 2024	DP U-750			
	8592397	Jan 13, 2024	DP U-1170			
	8598185	May 01, 2028	DP			
	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>EFLORNITHINE HYDROCHLORIDE - VANIQ</u>						
N 021145 001	5648394	Jul 15, 2014	U-334			
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 001	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELETRIPTAN HYDROBROMIDE - RELPAX</u>						
N 021016 002	5545644	Dec 26, 2016	DS DP U-876			
	6110940	Aug 29, 2017				
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		I-664	Nov 16, 2015
	6280959	Oct 30, 2018	DS DP U-1306		ODE	Nov 20, 2015
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7452874	May 24, 2021	DS DP			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021500 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6642245	Nov 04, 2020	U-541			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE - EMTRIVA</u>						
N 021896 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	5814639	Sep 29, 2015	DS DP		NCE	May 20, 2016
	5914331	Jul 02, 2017	DS		NPP	Dec 13, 2016
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS DP U-248			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6703396	Mar 09, 2021	DS DP			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8592397	Jan 13, 2024	DP U-1170			
	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-185			
<u>ENFUVRTIDE - FUZEON</u>						
N 021481 001	6133418	Nov 17, 2014	DS DP			
	6475491	Jun 07, 2015	U-248			
<u>ENTACAPONE - COMTAN</u>						
N 020796 001	6599530	Sep 14, 2018	DP U-219			
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 001					PC	Feb 21, 2015
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 002					PC	Feb 21, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001	5206244	Feb 21, 2015	DS		NPP	Oct 12, 2015
	5206244*PED	Aug 21, 2015			NPP	Mar 20, 2017
					PED	Apr 12, 2016
					PED	Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP		I-693	Sep 10, 2017
	8183274	May 15, 2026	U-1281		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1588			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT</u>						
N 021504 001	6629968	Jun 30, 2020	DS DP			
	6635045	Jun 29, 2021	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPLERENONE - INSPRA</u>						
N 021437 001	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 002	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPLERENONE - INSPRA</u>						
N 021437 003	6410054	Dec 08, 2019	U-3			
	6410054	Dec 08, 2019	U-537			
	6410524	Nov 05, 2019	U-467			
	6495165	Dec 08, 2019	U-3			
	6495165	Dec 08, 2019	U-537			
	6534093	Dec 08, 2019	U-3			
	6534093	Dec 08, 2019	U-537			
	6558707	Dec 08, 2019	DP U-537			
	6747020	Nov 05, 2019	U-587			
	7157101	Dec 08, 2019	DP U-664			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 004	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 005	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE - TEVETEN</u>						
N 020738 006	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 001	5656650	Aug 12, 2014	U-3			
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE - TEVETEN HCT</u>						
N 021268 002	5656650	Aug 12, 2014	U-3			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 001	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			
<u>EPTIFIBATIDE - INTEGRILIN</u>						
N 020718 002	5686570	Nov 11, 2014				
	5747447	May 05, 2015				
	5756451	Nov 11, 2014				
	5807825	Sep 15, 2015	U-244			
	5968902	Jun 02, 2015	U-453			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jun 16, 2019	DS		NCE	Nov 15, 2015
	6469182	Jun 16, 2019	U-1096			
	7470720	Jun 16, 2019	DP			
	8097648	Jan 22, 2021	U-1096			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	RE41065	Nov 08, 2018	DS DP			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	RE41065	Nov 08, 2018	DS DP			
<u>ERTAPENEM SODIUM - INVANZ</u>						
N 021337 001	5478820	Nov 21, 2015	DS DP U-160			
	5952323	May 15, 2017	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 001	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 002	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESCITALOPRAM OXALATE - LEXAPRO</u>						
N 021323 003	6916941	Aug 12, 2022	DS DP			
	7420069	Aug 12, 2022	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		NCE	Nov 08, 2018
	8372431	Apr 17, 2030	DP			
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER</u>						
N 019386 004	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 019386 005	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 006	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				
<u>ESMOLOL HYDROCHLORIDE - BREVIBLOC</u>						
N 019386 007	6310094	Jan 12, 2021				
	6528540	Jan 12, 2021				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 001	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021153 002	5690960	Nov 25, 2014	DP U-373			
	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-770			
	5714504	Feb 03, 2015	DP U-373			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-770			
	5900424	May 04, 2016	DS U-373			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-770			
	6147103	Oct 09, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-770			
	6428810	Nov 03, 2019	DP U-469			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-770			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 001	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-773			
	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 002	5690960	Nov 25, 2014	DP U-729			
	5690960	Nov 25, 2014	DP U-773			
	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-729			
	5714504	Feb 03, 2015	DP U-773			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-729			
	5900424	May 04, 2016	DS U-773			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-729			
	6369085	May 25, 2018	DS DP U-773			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-729			
	6428810	Nov 03, 2019	DP U-773			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
	8466175	May 25, 2018	U-1417			
	8466175*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 003	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 021957 004	5690960	Nov 25, 2014	DP U-1207			
	5714504	Feb 03, 2015	DP U-1207			
	5900424	May 04, 2016	DS U-1207			
	6369085	May 25, 2018	DS DP U-1207			
	6428810	Nov 03, 2019	DP U-1207			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N 022101 001	5690960	Nov 25, 2014	DP U-858			
	5714504	Feb 03, 2015	DP U-858			
	5900424	May 04, 2016	DS U-858			
	6369085	May 25, 2018	DS DP U-858			
	6428810	Nov 03, 2019	DP U-858			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	7411070	May 25, 2018	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	5714504	Feb 03, 2015	DP U-1053			
	5900424	May 04, 2016	DS U-1053			
	6369085	May 25, 2018	DS DP U-1053			
	6926907	Feb 28, 2023	DP U-1052			
	7411070	May 25, 2018	DS U-1053			
	7745466	Oct 13, 2018	DP U-1053			
	8557285	May 31, 2022	DP			
	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192*PED	Nov 27, 2014			D-138	Mar 04, 2017
	6143771	May 27, 2015	DP U-643		I-679	Mar 04, 2017
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192*PED	Nov 27, 2014			D-138	Mar 04, 2017
	6143771	May 27, 2015	DP U-643		I-679	Mar 04, 2017
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 005	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 006	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 007	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 008	5656286	Aug 12, 2014				
<u>ESTRADIOL - VIVELLE-DOT</u>						
N 020538 009	5656286	Aug 12, 2014	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N 020908 002	5860946	Jul 01, 2017	DP			
	7018992	Sep 17, 2022	U-1023			
<u>ESTRADIOL - MENOSTAR</u>						
N 021674 001	5891868	Nov 21, 2017	DP U-594			
	6692763	Nov 21, 2017	DP U-594			
<u>ESTRADIOL - ELESTRIN</u>						
N 021813 001	7198801	Jun 25, 2022	DP			
	7470433	Aug 03, 2021	DP			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6299900	Feb 19, 2017	DP U-888			
	6299900	Feb 19, 2017	DP U-889			
	6818226	Feb 19, 2017	DP U-888			
	6818226	Feb 19, 2017	DP U-889			
	6923983	Feb 19, 2017	DP U-888			
	6923983	Feb 19, 2017	DP U-889			
	6978945	Jul 31, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	5656286	Aug 12, 2014	DS DP			
	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 001	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMRING</u>						
N 021367 002	5855906	Dec 19, 2015		U-508		
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 001	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 002	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 003	6962908	Dec 21, 2021	DP			
	7572779	Oct 02, 2025		U-904		
	7799771	Dec 21, 2021	DP			
<u>ESTRADIOL HEMIHYDRATE - ESTRASORB</u>						
N 021371 001	5629021	Jan 31, 2015	DP			
<u>ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST</u>						
N 021040 001	6747019	Mar 20, 2020		U-311		
	7320970	Mar 30, 2020	DP	U-844		
<u>ESTRADIOL; LEVONORGESTREL - CLIMARA PRO</u>						
N 021258 001	5676968	Oct 14, 2014	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 001	5656286	Aug 12, 2014				
<u>ESTRADIOL; NORETHINDRONE ACETATE - COMBIPATCH</u>						
N 020870 002	5656286	Aug 12, 2014				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 001	5908638	Jul 26, 2015	DP			
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 002	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 003	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 004	5908638	Jul 26, 2015				
<u>ESTROGENS, CONJUGATED SYNTHETIC A - CENESTIN</u>						
N 020992 005	5908638	Jul 26, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 001	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 002	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 003	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 004	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA</u>						
N 021443 005	6660726	Mar 08, 2021	DS DP U-904			
	6660726	Mar 08, 2021	DS DP U-905			
	6855703	Feb 12, 2021	DS DP U-904			
	6855703	Feb 12, 2021	DS DP U-905			
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPHASE 14/14</u>						
N 020527 002	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 001	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 003	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 004	5547948	Jan 17, 2015				
<u>ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE - PREMPRO</u>						
N 020527 005	5547948	Jan 17, 2015				
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 001					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 002					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ESZOPICLONE - LUNESTA</u>						
N 021476 003					M-61 PED	Oct 10, 2015 Apr 10, 2016
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO</u>						
N 021241 001	6214815	Jun 09, 2019	U-112			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024	U-828			
	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING</u>						
N 021187 001	5989581	Apr 08, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT</u>						
N 020946 001	6156742	Dec 05, 2020	U-374			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONALE</u>						
N 021544 001	5898032	Jun 23, 2017	U-1			
	RE39861	Jun 23, 2017	U-828			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL</u>						
N 021864 001	6500814	Sep 03, 2018	U-1			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP		NP	Mar 28, 2016
	8450299	Oct 07, 2025	U-1			
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>						
N 021180 001	5876746	Nov 20, 2015	DP U-514			
	5972377	Jun 07, 2015	U-514			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE</u>						
N 021490 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>						
N 021871 001	5552394	Jul 22, 2014	U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501 001	5552394	Jul 22, 2014	U-1090			
	7704984	Feb 02, 2029	U-1090			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	5552394	Jul 22, 2014	U-1		NDF	May 08, 2016
	6667050	Apr 06, 2019	DP U-1			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N 204426 001	5552394	Jul 22, 2014	U-1			
	6652880	Mar 29, 2020	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	5552394	Jul 22, 2014	U-1			
	6667050	Apr 06, 2019	DP U-1			
	7704984	Feb 02, 2029	U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
	8888745	Aug 28, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>ETRAVIRINE - INTELENCE</u>						
N 022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1016			
	6878717	Nov 05, 2019	U-1237			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - ZORTRESS</u>						
N 021560 001	5665772	Sep 09, 2019	DS DP U-1049		I-668 PED	Feb 15, 2016 Sep 30, 2014
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
	<u>EVEROLIMUS - ZORTRESS</u>					
N 021560 002	5665772	Sep 09, 2019	DS DP U-1049		I-668 PED	Feb 15, 2016 Sep 30, 2014
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				
	<u>EVEROLIMUS - ZORTRESS</u>					
N 021560 003	5665772	Sep 09, 2019	DS DP U-1049		I-668 PED	Feb 15, 2016 Sep 30, 2014
	5665772	Sep 09, 2019	DS DP U-1365			
	5665772*PED	Mar 09, 2020				
	6004973	Jul 12, 2016	DP U-1049			
	6004973	Jul 12, 2016	DP U-1365			
	6004973*PED	Jan 12, 2017				
	6239124	Aug 11, 2017	U-1049			
	6455518	Jul 29, 2017	U-1049			
	6455518	Jul 29, 2017	U-1365			
	6455518*PED	Jan 29, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022	U-1541		PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022	U-1541		PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022	U-1541		PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	5665772	Sep 09, 2019	DS DP		I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-655	Jul 20, 2015
	7297703	Dec 06, 2019	DP		ODE	Oct 29, 2017
	7741338	Dec 06, 2019	DP		ODE	May 05, 2018
	8410131	May 22, 2025	DS DP U-1368		ODE	Apr 26, 2019
	8410131*PED	Nov 22, 2025			PED	Sep 30, 2014
	8436010	Feb 22, 2022	DS DP U-1396		PED	Nov 05, 2014
	8436010*PED	Aug 22, 2022			PED	Oct 26, 2015
	8778962	Feb 18, 2022	U-1541		PED	Apr 29, 2018
	8778962*PED	Aug 18, 2022			PED	Nov 05, 2018
					PED	Oct 26, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	5665772	Sep 09, 2019	DS DP		ODE	Oct 29, 2017
	6004973	Jul 12, 2016	DP		PED	Sep 30, 2014
	7297703	Dec 06, 2019	DP		PED	Apr 29, 2018
	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656	M-148	Nov 24, 2017
	6858576	Jan 06, 2017		U-1108		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	6956026	Jan 07, 2018		U-1074		
	6956026	Jan 07, 2018		U-1623		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-653		
	7741269	Jan 07, 2018		U-1074		
	7741269	Jan 07, 2018		U-1108		
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002	5424286	Dec 01, 2016		U-653	M-111	Oct 19, 2014
	5424286	Dec 01, 2016		U-1108	M-113	Oct 19, 2014
	6858576	Jan 06, 2017		U-656	M-148	Nov 24, 2017
	6858576	Jan 06, 2017		U-1108		
	6872700	Jan 14, 2020		U-654		
	6902744	Jan 14, 2020	DP			
	6956026	Jan 07, 2018		U-687		
	6956026	Jan 07, 2018		U-1074		
	6956026	Jan 07, 2018		U-1623		
	7297761	Oct 15, 2017	DP			
	7521423	Oct 15, 2017	DP			
	7741269	Jan 07, 2018		U-653		
	7741269	Jan 07, 2018		U-1074		
	7741269	Jan 07, 2018		U-1108		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP			
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP			
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7030106	Jan 25, 2022	DP		M-109	Jan 24, 2015
	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-473			
	RE42461	Oct 25, 2016	DS DP U-1173			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 001	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 002	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 003	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N 021687 004	RE37721	Oct 25, 2016	DS DP U-473		M-109	Jan 24, 2015
	RE42461	Oct 25, 2016	DS DP U-473			
<u>EZOAGABINE - POTIGA</u>						
N 022345 001					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 002					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 003					NCE	Jun 10, 2016
<u>EZOAGABINE - POTIGA</u>						
N 022345 004					NCE	Jun 10, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 001	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 002	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMCICLOVIR - FAMVIR</u>						
N 020363 003	5840763	Sep 01, 2015	U-96		M-112	Feb 09, 2015
	5866581	Oct 04, 2014	U-96			
	5916893	Sep 01, 2015	U-96			
	6124304	Oct 04, 2014	U-96			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020325 001	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 001	5667794	May 02, 2015		Y		
	5854267	Dec 29, 2015	U-267			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020801 002	6814978	Aug 26, 2021	DP			
<u>FAMOTIDINE - PEPCID AC</u>						
N 020902 001	5854267	Dec 29, 2015	U-368			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE - FLUXID</u>						
N 021712 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8067033	Jul 18, 2026	DP			
	8067451	Jul 18, 2026	DP	U-1196		
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026		U-1196		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	5614520	Mar 25, 2019	DS DP	U-954		
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031		U-1346		
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	5614520	Mar 25, 2019	DS DP	U-954		
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031		U-1346		
<u>FENOFIBRATE - TRICOR</u>						
N 021203 001	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
<u>FENOFIBRATE - TRICOR</u>						
N 021203 003	6074670	Jan 09, 2018				
	6277405	Jan 09, 2018				
	6589552	Jan 09, 2018				
	6652881	Jan 09, 2018	DP			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 001	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - TRIGLIDE</u>						
N 021350 002	6696084	Sep 11, 2021	DS DP U-680			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 001	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 002	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - LIPOFEN</u>						
N 021612 003	5545628	Jan 10, 2015	DP U-701			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 001	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 002	6277405	Jan 09, 2018	DS			
	6375986	Sep 21, 2020	DP U-615			
	6652881	Jan 09, 2018	DS			
	7037529	Jan 09, 2018	DP			
	7041319	Jan 09, 2018	DP			
	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 001	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 003	7101574	Aug 20, 2020	DS DP			
	7863331	Aug 08, 2020	U-1106			
	7863331	Aug 08, 2020	U-1107			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP		NP	Jan 04, 2015
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		
	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
	8728441	Mar 26, 2019		U-1514		
	8753611	Mar 26, 2019		U-1514		
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 006	6200604	Mar 26, 2019		U-767		
	6974590	Mar 26, 2019		U-767		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	6159498	Oct 18, 2016	DP			
	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N 022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	6432440	Apr 20, 2018	DP U-1169			
	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2014	DP			
	5843014	Dec 01, 2015	DP			
	6169920	Jan 02, 2018	DP			
	6171294	Jun 05, 2015	U-736			
	6181963	Nov 02, 2019	DP			
	6195582	Jan 28, 2019	DP U-736			
	6216033	Jun 05, 2015	DP			
	6425892	Jun 05, 2015	U-736			
	6842640	Jun 02, 2015	DP			
	6881208	Apr 19, 2022	U-736			
	6975902	Apr 01, 2024	DP			
	7018370	Jun 05, 2015	U-736			
	7027859	Sep 26, 2014	DP			
	7302293	Jun 05, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2024	DS DP		NP	Jul 25, 2016
	7754702	Feb 13, 2027	DP U-1432			
	8895612	Jan 08, 2027	DP U-1620			
<u>FERRIC CITRATE - FERRIC CITRATE</u>						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026		U-1577		
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024		U-1577		
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
	7553479	Mar 08, 2020	DS DP			
	7871597	Mar 08, 2020	DS DP			
	8501158	Mar 08, 2020		U-1422		
	8591864	Mar 08, 2020	DP			
	8926947	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	6858650	Jul 03, 2022	DS	U-913		
	7384980	May 11, 2019	DS DP	U-913		
	7807715	Jun 07, 2027	DP	U-913		
	7855230	May 11, 2019		U-913		
	7985772	May 11, 2019	DS DP	U-913		
	8088398	Jun 07, 2027	DP	U-913		
	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	6858650	Jul 03, 2022	DS	U-913		
	7384980	May 11, 2019	DS DP	U-913		
	7807715	Jun 07, 2027	DP	U-913		
	7855230	May 11, 2019		U-913		
	7985772	May 11, 2019	DS DP	U-913		
	8088398	Jun 07, 2027	DP	U-913		
	8338478	May 11, 2019	DS DP	U-913		
	8501723	Jun 07, 2027	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY</u>						
A 203330 001					PC	Jun 20, 2015
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES</u>						
A 203330 002					PC	Jun 20, 2015
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 020625 001	5738872	Feb 28, 2015				
	5855912	Feb 28, 2015				
	5932247	Feb 28, 2015				
	6037353	Mar 14, 2017		U-138		
	6113942	Feb 28, 2015				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 020872 005	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 020872 006	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 007	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 008	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N 020872 009	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N 020872 010	5855912	Feb 28, 2015	DP			
	5932247	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1160		
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 021909 002	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1158		
	6037353	Mar 14, 2017		U-1466		
	6723348	Nov 26, 2021	DP	U-1466		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 021909 003	5738872	Feb 28, 2015	DP			
	6037353	Mar 14, 2017				
	6723348	Nov 26, 2021	DP			
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA</u>						
N 021963 001	6037353	Mar 14, 2017		U-772		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	6037353	Mar 14, 2017		U-1157		
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	6037353	Mar 14, 2017		U-1157		
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N 020786 002	5855912	Feb 28, 2015	DP			
	6037353	Mar 14, 2017		U-1159		
	6039974	Jul 31, 2018	DP			
	6113942	Feb 28, 2015	DP			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N 021704 002	6037353	Mar 14, 2017		U-1159		
	6613357	Dec 25, 2020	DP	U-1159		
	RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	7378508	Jul 31, 2027	DS DP		NCE	May 27, 2016
	7863249	Jul 31, 2027	DS DP			
	7906489	Mar 04, 2027		U-319		
	8586551	Apr 12, 2024	DS DP			
	8859510	Jul 31, 2027		U-319		
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001					NCE	Dec 17, 2019
					PED	Jun 17, 2020
<u>FINASTERIDE - PROSCAR</u>						
N 020180 001	5942519	Oct 23, 2018		U-280		
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	5604229	Feb 18, 2019	DS	U-1086	M-106	Jul 20, 2014
	6004565	Sep 23, 2017		U-1086	NCE	Sep 21, 2015
	8324283	Mar 29, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
	8506929	Apr 30, 2027	DS DP U-1423			
<u>FLUDARABINE PHOSPHATE - OFORTA</u>						
N 022273 001	7148207	Dec 20, 2022	DP U-944		ODE	Dec 18, 2015
	7547776	Dec 10, 2018	DS			
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N 021247 001	5776433	Jul 07, 2015	DP		M-128	Aug 28, 2016
<u>FLUOCINOLONE ACETONIDE - RETISERT</u>						
N 021737 001	6217895	Mar 22, 2019	DP U-708			
	6548078	Mar 22, 2019	DP U-708			
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
	8247395	Oct 22, 2022	DP			
	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUOCINONIDE - VANOS</u>						
N 021758 001	6765001	Dec 21, 2021	DP			
	7220424	Jan 07, 2023	U-861			
	7794738	Sep 11, 2022	U-1084			
	8232264	Mar 09, 2023	DP			
<u>FLUOROURACIL - CARAC</u>						
N 020985 001	6670335	Jun 02, 2021	DP U-68			
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 001	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 003	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 004					NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC</u>						
N 018936 006	6960577	Nov 01, 2017	U-963		NPP	Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY</u>						
N 021235 001	5910319	May 29, 2017	U-396			
	5985322	May 29, 2017	U-397			
	RE39030	May 29, 2017	DP U-396			
	RE39030	May 29, 2017	DP U-397			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001	6960577	Nov 01, 2017	U-962		M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005	5945416 6960577	Mar 24, 2017 Nov 01, 2017	DS DP U-962	Y	M-142 NPP	Oct 10, 2017 Jul 26, 2016
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800 7351401 8236282 8691185	Jan 24, 2023 Jan 24, 2023 May 21, 2024 Jan 24, 2023	DS DP U-336 DS DP U-336 DS DP U-336		NCE	Oct 25, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800 7351401 8236282 8691185	Jan 24, 2023 Jan 24, 2023 May 21, 2024 Jan 24, 2023	DS DP U-336 DS DP U-336 DS DP U-336		NCE	Oct 25, 2018
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	6858596 7101866 7541350 8062264 8147461 8347879 8752543	Aug 03, 2021 Aug 03, 2021 Aug 03, 2021 Apr 05, 2026 Oct 15, 2028 Jul 15, 2028 Apr 05, 2026	DP U-808 DS DP U-808 DP U-988 DP DP DP DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360 7101866 7629335 8113199 8161968 8201556 8534281 8746242	Feb 23, 2016 Aug 03, 2021 Aug 03, 2021 Oct 23, 2027 Feb 05, 2028 Feb 05, 2029 Aug 10, 2029 Oct 11, 2030	DP DS DP U-1559 DP DP DP DP DP		NP	Aug 20, 2017
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360 7101866 7629335 8113199 8161968 8201556 8534281 8746242	Feb 23, 2016 Aug 03, 2021 Aug 03, 2021 Oct 23, 2027 Feb 05, 2028 Feb 05, 2029 Aug 10, 2029 Oct 11, 2030	DP DS DP U-1559 DP DP DP DP DP		NP	Aug 20, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	5873360	Feb 23, 2016	DP		NP	May 10, 2016
	6537983	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1401			
	6878698	Aug 03, 2021	U-1401			
	7101866	Aug 03, 2021	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1401			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Nov 11, 2025	DP U-1424			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 50</u>						
N 020833 001	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 100</u>						
N 020833 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT DISKUS 250</u>						
N 020833 003	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001	7300669	Oct 20, 2019	DP U-835			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	5658549	Aug 19, 2014	DP U-710			
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434 001					M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50</u>						
N 021077 001	5873360	Feb 23, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50</u>						
N 021077 002	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50</u>						
N 021077 003	5873360	Feb 23, 2016	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	5658549	Aug 19, 2014	DP	U-738		
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017				
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	5658549	Aug 19, 2014	DP	U-738		
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	5658549	Aug 19, 2014	DP	U-738		
	5674472	Oct 07, 2014	DP			
	6161724	Jan 16, 2018	DP			
	6170717	Dec 23, 2017	DP			
	6315173	Dec 23, 2017	DP			
	6431168	Jun 08, 2018	DP			
	6435372	Jan 16, 2018	DP			
	6510969	Dec 23, 2017	DP			
	6596260	Aug 10, 2014	DP			
	6743413	Jun 01, 2021		U-1591		
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6966467	Dec 23, 2017	DP			
	6997349	Jan 16, 2018	DP			
	7107986	Jun 08, 2018	DP			
	7143908	Jan 16, 2018	DP			
	7350676	Aug 24, 2018	DP			
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUVASTATIN SODIUM - LESCOL XL</u>						
N 021192 001	6242003	Apr 13, 2020				
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 001	7465462	May 10, 2020	DP U-929			
<u>FLUVOXAMINE MALEATE - LUVOX CR</u>						
N 022033 002	7465462	May 10, 2020	DP U-929			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 002	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 003	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 004	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 020378 005	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7563763	Aug 23, 2019	DP			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 001	5767251	Jun 16, 2015				
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM</u>						
N 020582 002	5767251	Jun 16, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 001	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 002	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 003	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021211 004	5767251	Jun 16, 2015	DS		D-133	Aug 22, 2014
	5929028	Jan 14, 2018	DP U-567			
	5929028	Jan 14, 2018	DP U-1366			
	7446090	Aug 23, 2019	DP			
	7563763	Aug 23, 2019	U-993			
	7563763	Aug 23, 2019	U-1183			
	7563763	Aug 23, 2019	U-1367			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 001	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - FOLLISTIM AQ</u>						
N 021273 002	5767251	Jun 16, 2015	DS			
	5929028	Jan 14, 2018	DP U-1366			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 001	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT</u>						
N 021684 003	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
	7446090	Aug 23, 2019	DP			
	7741268	Apr 02, 2024	DP			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 001	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F RFF</u>						
N 021765 002	5767067	Jun 16, 2015	DS			
	5767251	Jun 16, 2015	DS			
<u>FOLLITROPIN ALFA/BETA - GONAL-F</u>						
N 021765 003	5767251	Jun 16, 2015	DS			
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FORMOTEROL FUMARATE - FORADIL</u>						
N 020831 001	6488027	Mar 08, 2019				
	6887459	Nov 28, 2020	U-762			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	DP U-813			
	7348362	Jun 22, 2021	DP			
	7462645	Jun 22, 2021	DP U-813			
	8623922	Jun 22, 2021	DP			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	6068832	Aug 27, 2017	DP U-1068			
	7067502	May 21, 2020	DP U-1068			
	7566705	May 21, 2020	DP U-1068			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 021548 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
	6514953	Jul 15, 2019	DS DP U-257		PED	Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N 022116 001	6436989	Dec 24, 2017	DS DP U-257		NPP	Apr 27, 2015
					PED	Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	5691336	Mar 04, 2019	DS DP			
	5716942	Feb 10, 2015	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N 022244 001	6204257	Jul 01, 2022	DS DP U-945			
	6872838	Aug 07, 2018	DS			
<u>FROVATRIPTAN SUCCINATE - FROVA</u>						
N 021006 001	5464864	Nov 07, 2015	U-436			
	5827871	Oct 27, 2015	U-436			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-596		M-123	Nov 09, 2015
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	8329680	Jan 09, 2021	U-596			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020235 003	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 001	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 020882 002	6054482	Apr 25, 2017				
<u>GABAPENTIN - NEURONTIN</u>						
N 021129 001	6054482	Apr 25, 2017				
	7256216	May 28, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	6340475	Sep 19, 2016	DP		ODE	Jan 28, 2018
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
	8333992	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247	ODE	Jun 06, 2019
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Nov 06, 2022	DS DP		I-652	Jun 06, 2015
	8026279	Nov 10, 2026	DS DP		NCE	Apr 06, 2016
	8048917	Nov 06, 2022	DS DP	U-1247	ODE	Jun 06, 2019
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE</u>						
N 021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N 021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHCANCE MULTIPACK</u>						
N 021358 002					I-654	Jul 06, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005	5980864	Nov 09, 2016	DS DP U-1119		I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 001	6676929	May 04, 2020	DP			
	7011815	Feb 01, 2015		U-1112		
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015		U-1112		
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015		U-1112		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N 021711 002	6676929	May 04, 2020	DP			
	7011815	Feb 01, 2015		U-1112		
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015		U-1112		
	8017105	May 26, 2015	DS			
	8394356	Feb 01, 2015		U-1112		
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 001					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 002					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 003					NCE	Mar 20, 2018
<u>GADOTERATE MEGLUMINE - DOTAREM</u>						
N 204781 004					NCE	Mar 20, 2018
<u>GADOTERIDOL - PROHANCE</u>						
N 020131 001	5846519	Dec 08, 2015				
<u>GADOTERIDOL - PROHANCE MULTIPACK</u>						
N 021489 001	5846519	Dec 08, 2015				
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021		U-1239		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 001	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 002	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE</u>						
N 021169 003	6099863	Jun 06, 2017				
	6358527	Jun 06, 2017	DP	U-322		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 001	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 002	7160559	Dec 20, 2019	DP			
<u>GALANTAMINE HYDROBROMIDE - RAZADYNE ER</u>						
N 021615 003	7160559	Dec 20, 2019	DP			
<u>GANCICLOVIR - ZIRGAN</u>						
N 022211 001					ODE	Sep 15, 2016
<u>GANIRELIX ACETATE - GANIRELIX ACETATE</u>						
N 021057 001	5767082	Jun 16, 2015				
	6653286	Jun 16, 2018	U-1354			
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493 001	5880283	Dec 05, 2015				
	6333045	Aug 20, 2019	DP			
<u>GATIFLOXACIN - ZYMAXID</u>						
N 022548 001	5880283	Dec 05, 2015	DS			
	6333045	Aug 20, 2019	DS DP			
<u>GEFITINIB - IRESSA</u>						
N 021399 001	5770599	May 05, 2017	DS DP U-881			
<u>GEMIFLOXACIN MESYLATE - FACTIVE</u>						
N 021158 001	5633262	Jun 15, 2015				
	5776944	Apr 04, 2017	DS DP			
	5962468	Jun 15, 2015	U-282			
	6262071	Sep 21, 2019	U-513			
	6331550	Sep 21, 2019	U-511			
	6340689	Sep 14, 2019	U-512			
	6455540	Sep 21, 2019	U-511			
	6723734	Mar 20, 2018	DS DP			
	6803376	Sep 21, 2019	DS DP U-608			
	6803376	Sep 21, 2019	DS DP U-609			
<u>GEMTUZUMAB OZOGAMICIN - MYLOTARG</u>						
N 021174 001	5693762	Dec 02, 2014				
	5739116	Apr 14, 2015				
	5767285	Jun 16, 2015				
	5773001	Jun 30, 2015	U-320			
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8232250	Aug 19, 2030	U-441		NP	Jan 28, 2017
	8399413	Aug 19, 2030	U-441			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 001	6150383	Jun 19, 2016	U-753			
	6211205	Jun 19, 2016	U-753			
	6303640	Aug 09, 2016	U-753			
	6329404	Jun 19, 2016	DP U-753			
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 002	6150383	Jun 19, 2016	U-753			
	6211205	Jun 19, 2016	U-753			
	6303640	Aug 09, 2016	U-753			
	6329404	Jun 19, 2016	DP U-753			
	7538125	Jun 19, 2016	DP			
	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	5741803	Apr 21, 2015	DS DP U-690			
	5741803	Apr 21, 2015	DS DP U-781			
	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 001	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 002	RE44459	Mar 26, 2019	U-1431			
<u>GLIPIZIDE - GLUCOTROL XL</u>						
N 020329 003	RE44459	Mar 26, 2019	U-1431			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 001	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 002	6303146	Jul 14, 2019	U-412			
<u>GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE</u>						
N 021178 003	6303146	Jul 14, 2019	U-412			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Feb 07, 2015	DS DP U-1378		NE	Feb 01, 2016
	8404215	Mar 09, 2032	U-1383		ODE	Feb 01, 2020
	8642012	Sep 22, 2030	U-1383			
<u>GLYCOPYRROLATE - ROBINUL</u>						
N 012827 001	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - ROBINUL FORTE</u>						
N 012827 002	7091236	Apr 24, 2024	U-877	Y		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571 001	7638552	Aug 20, 2023	U-1076		ODE	Jul 28, 2017
	7816396	Aug 20, 2023	U-1076			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 019726 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GOSERELIN ACETATE - ZOLADEX</u>						
N 020578 001	7118552	Apr 13, 2022	DP			
	7220247	Apr 09, 2022	DP			
	7500964	Feb 26, 2021	DP			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Oct 22, 2024	DP U-1011			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 001	5952340	Sep 14, 2016	U-519			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 002	5952340	Sep 14, 2016	U-519			
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N 020239 004	5952340	Sep 14, 2016	U-519			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 001	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN - MUCINEX</u>						
N 021282 002	6372252	Apr 28, 2020	U-489			
	6955821	Apr 28, 2020	DP U-489			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 001	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D</u>						
N 021585 002	6372252	Apr 28, 2020	DP			
	6955821	Apr 28, 2020	DP U-686			
	7838032	Apr 28, 2020	DP			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			PED	May 19, 2018
	6287599	Dec 20, 2020	DP			
	6287599*PED	Jun 20, 2021				
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	6034267	Mar 08, 2016	U-1087			
	7247655	Mar 08, 2016	DP U-1087			
	7348361	Nov 06, 2020	DP U-1087			
	7530461	Jan 11, 2017	DP U-1087			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058 001	8062652	Jun 16, 2026	U-1197			
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
N 021859 001	7767429	Sep 23, 2027	DS DP			
<u>HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL</u>						
N 020727 001	6465463	Sep 08, 2020	U-71			
	6784177	Sep 08, 2020	U-71			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 001	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 002	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 003	5994348	Jun 07, 2015				
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - AVALIDE</u>						
N 020758 004	5994348	Jun 07, 2015	DP			
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 002	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL - BENICAR HCT</u>						
N 021532 005	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 001	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT</u>						
N 021162 002	6358986	Jan 10, 2020				
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 001	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 002	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 003	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 004	6294197	Jun 18, 2017	U-3			
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
N 020818 005	6294197	Jun 18, 2017	U-3			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP		NP	Oct 25, 2016
	6902742	Nov 01, 2019	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE; IBUPROFEN - VICOPROFEN</u>						
N 020716 001	6348216	Jun 10, 2017				
	6599531	Jun 10, 2017				
<u>HYDROCORTISONE BUTYRATE - LOCROID</u>						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	6589960	Nov 09, 2020	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019891 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 001	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 002	6589960	Nov 09, 2020	DS DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019892 003	6589960	Nov 09, 2020	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 001	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 002	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 003	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - PALLADONE</u>						
N 021044 004	5958452	Nov 04, 2014	DP			
	5965161	Nov 04, 2014	DP U-616			
	6335033	Nov 04, 2014	DP U-616			
	6589960	Nov 09, 2020	DP			
	6706281	Nov 04, 2014	DP U-616			
	6743442	Nov 04, 2014	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 001	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 002	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 003	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N 021217 004	5702725	Jul 07, 2014	DP U-1043			
	5914131	Jul 07, 2014	DP U-1043			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 001	5834448	Nov 14, 2016	DP			
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N 022041 002	5834448	Nov 14, 2016	DP U-789			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N 021945 001					ODE	Feb 03, 2018
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 001	6143326	Apr 21, 2017	U-642			
	6294196	Oct 07, 2019	DP			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 002	6294196	Oct 07, 2019	DP			
	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021858 001	5662918	Sep 02, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	7514444	Dec 28, 2026	DS DP		I-680	Feb 12, 2017
	8008309	Dec 28, 2026	DS DP		I-689	Jul 28, 2017
	8476284	Dec 28, 2026	U-1456		NCE	Nov 13, 2018
	8476284	Dec 28, 2026	U-1491		ODE	Nov 13, 2020
	8497277	Dec 28, 2026	U-1456		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1491		ODE	Jul 28, 2021
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - MIDOL LIQUID GELS</u>						
N 021472 001	6251426	Jun 25, 2018				
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001	6727286	Nov 27, 2021	DP U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	6727286	Nov 27, 2021	DP U-981			
	8735452	Sep 30, 2029	U-981			
	8871810	Aug 27, 2030	U-1599			
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
	8415337	Mar 02, 2032	DS DP			
<u>IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD</u>						
N 021128 001	6211246	Jun 10, 2019				
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187		NCE	Aug 25, 2016
					ODE	Aug 25, 2018
<u>ICODEXTRIN - EXTRANEAL</u>						
N 021321 001	6077836	Jun 20, 2017	U-495			
	6248726	Jun 19, 2018	U-495			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8188146	Jan 27, 2020	DS DP		NP	Jul 26, 2015
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8501225	Apr 29, 2030	U-1287			
	8518929	Apr 29, 2030	U-1287			
	8524698	Apr 29, 2030	U-1287			
	8546372	Apr 29, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1478			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	RE39198	Nov 15, 2016	DS DP U-971			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	5521184	Jan 04, 2015	DS DP			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	5521184	Jan 04, 2015	DS DP U-649			
	6894051	May 23, 2019	DS DP U-649			
	6958335	Dec 19, 2021	U-791			
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	5521184	Jan 04, 2015	DS DP		I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Dec 19, 2015
	6958335	Dec 19, 2021	U-791		ODE	Jan 25, 2020
	7544799	Jan 16, 2019	DS DP	Y		
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	5521184	Jan 04, 2015			I-666	Jan 25, 2016
	6894051	May 23, 2019	DS DP U-649		ODE	Dec 19, 2015
	6958335	Dec 19, 2021	U-791		ODE	Jan 25, 2020
	7544799	Jan 16, 2019	DS DP	Y		
	7544799*PED	Jul 16, 2019				
	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMIQUIMOD - ALDARA</u>						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-172			
	8598196	Aug 18, 2029	U-1455			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	8222270	Dec 11, 2029	U-68		NS	Jul 15, 2014
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Oct 10, 2020	DS DP U-1168		NCE	Jul 01, 2016
	8067437	Jun 02, 2020	U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 001	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 003	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 005	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDINAVIR SULFATE - CRIXIVAN</u>						
N 020685 006	6645961	Mar 04, 2018	DP			
	6689761	Feb 10, 2021	U-554			
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N 020314 001	5753627	May 19, 2015			U-1125	
	5776894	Jul 07, 2015	DS DP			
	6123916	Sep 26, 2017	U-1125			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026		U-1440		
	8716271	Dec 18, 2026		U-1440		
	8735375	Dec 18, 2026		U-1440		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	6432452	Aug 19, 2018	DS	U-68	NCE	Jan 23, 2017
	6844013	Dec 13, 2018	DS DP	U-1221		
	7410656	Aug 19, 2018	DS	U-1222		
	8278292	Feb 20, 2027	DS DP			
	8372827	Dec 18, 2026	DS DP			
	8372828	Dec 18, 2026	DS DP			
	8377919	Dec 18, 2026	DS DP			
	8536163	Dec 18, 2026		U-1440		
	8716271	Dec 18, 2026		U-1440		
	8735375	Dec 18, 2026		U-1440		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N 021172 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 002	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N 021172 003	5866538	Jun 19, 2017	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 50/50</u>						
N 021810 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG</u>						
N 020986 001	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	5693027	Dec 02, 2014	DP			
	5866538	Jun 20, 2017	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	5866538	Jun 20, 2017	DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N 020986 004	5866538	Jun 20, 2017	DP			
	RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N 021536 001	5750497	Jun 16, 2019	DS DP U-668		M-115	Apr 06, 2015
	5866538	Jun 20, 2017	DS DP		M-117	May 18, 2015
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
	6004297	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N 021536 003	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N 021536 004	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DS DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N 021081 001	5656722	Aug 12, 2014	DS DP U-948			
	7476652	Jul 23, 2023	DP			
	7713930	Jun 13, 2023	DP			
	7918833	Sep 23, 2027	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 001	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA</u>						
N 021629 002	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	6221633	Jun 18, 2018	DS DP U-471			
	6960561	Jan 25, 2023	DP U-471			
	7452860	Mar 22, 2022	DP			
	7696162	Mar 22, 2022	DP U-471			
	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN</u>						
N 021017 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN</u>						
N 021018 002	7291132	Aug 09, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N 020563 001					NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N 020563 002					NR	Oct 12, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 020563 003	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 001	5740794	Apr 21, 2015	DP			
	6257233	May 14, 2019		U-704		
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
N 021868 002	5740794	Apr 21, 2015	DP			
	6257233	May 14, 2019		U-704		
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6685967	Sep 11, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30</u>						
N 019717 001	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN</u>						
N 019717 002	7291132	Aug 09, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N</u>						
N 018781 001	7291132	Aug 09, 2024	DP			
<u>IOBENGUANE SULFATE I-123 - ADREVIEW</u>						
N 022290 001					I-669 ODE	Mar 20, 2016 Sep 19, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS		NCE	Jan 14, 2016
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	5676930	Oct 14, 2014	DP			
	5683677	Nov 04, 2014	DP			
	6739333	May 26, 2020	DP			
	6983743	May 26, 2020	DP			
<u>IRBESARTAN - AVAPRO</u>						
N 020757 001	6342247	Jun 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N 020757 002	6342247	Jun 07, 2015				
<u>IRBESARTAN - AVAPRO</u>						
N 020757 003	6342247	Jun 07, 2015				
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 001	6403569	Apr 28, 2020	U-449			
	6794370	May 01, 2020	U-606			
<u>IRINOTECAN HYDROCHLORIDE - CAMPTOSAR</u>						
N 020571 002	6403569	Apr 28, 2020	U-449			
	6794370	May 01, 2020	U-606			
<u>IRON DEXTRAN - DEXFERRUM</u>						
N 040024 001	5624668	Sep 29, 2015				
<u>IRON SUCROSE - VENOFER</u>						
N 021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135 002					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N 021135 005					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
	8367102	Sep 21, 2021	U-1347			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
	8367102	Sep 21, 2021	U-1347			
<u>ITRACONAZOLE - SPORANOX</u>						
N 020657 001	5707975	Jan 13, 2015				
	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - SPORANOX</u>						
N 020966 001	6407079	Jun 18, 2019				
<u>ITRACONAZOLE - ONMEL</u>						
N 022484 001	6509038	May 12, 2017	DP	U-1054		
	7081255	May 12, 2017	DP	U-1054		
	8486456	Oct 03, 2028	DP	U-1054		
	8591948	May 12, 2017	DP	U-1054		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	7495103	May 20, 2027	DS DP		NCE	Jan 31, 2017
	8324242	Apr 18, 2027	U-1311		ODE	Jan 31, 2019
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
	8791153	Oct 12, 2027	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001					NP	Dec 19, 2017
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 001	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 002	6670384	Jan 23, 2022	DP U-959		M-61	Oct 18, 2014
	6670384	Jan 23, 2022	DP U-960		PED	Apr 18, 2015
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	7312237	Aug 21, 2024	U-965			
	RE41393	Feb 08, 2022	U-961			
	RE41911	Sep 28, 2020	DS DP U-961			
<u>KETOCONAZOLE - EXTINA</u>						
N 021738 001	7553835	Oct 19, 2018	DP U-245			
	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	7179475	Dec 04, 2018	DP U-792			
	8232276	Nov 24, 2020	DP			
	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
<u>KETOROLAC TROMETHAMINE - SPRIX</u>						
N 022382 001	6333044	Dec 25, 2018	DP U-1057			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001	5654301	Aug 05, 2014	DS DP U-911		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1565		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	5654301	Aug 05, 2014	DS DP U-914		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1566		D-144	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		I-696	Aug 29, 2017
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	6004968	Mar 20, 2018				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021003 001	5905082	May 18, 2016				
<u>LAMIVUDINE - EPIVIR-HBV</u>						
N 021004 001	6004968	Mar 20, 2018				
<u>LAMIVUDINE; ZIDOVUDINE - COMBIVIR</u>						
N 020857 001	5905082	May 18, 2016	DS DP U-248			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	7919115	Jan 04, 2029	DS DP			
	8840925	Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001	5595760	Mar 08, 2020	DP U-831		I-701 ODE ODE	Dec 19, 2017 Aug 30, 2014 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002	5595760	Mar 08, 2020	DP U-831		I-701 ODE ODE	Dec 19, 2017 Aug 30, 2014 Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003	5595760	Mar 08, 2020	DP U-831		I-701 ODE ODE	Dec 19, 2017 Aug 30, 2014 Dec 16, 2021
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	6328994	May 17, 2019				
	7399485	May 26, 2018	DP			
	7431942	May 17, 2019	DP			
	7875292	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID IV</u>						
N 021566 001	7396841	Aug 17, 2021	DP U-947			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	5968976	Oct 26, 2018	DP U-613			
	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	5968976	Oct 26, 2018	DP U-1592			
	7465465	Aug 26, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	6391874	Jul 11, 2017	DS DP U-800			
	6391874	Jul 11, 2017	DS DP U-1429			
	6713485	Sep 29, 2020	DS DP U-800			
	6713485	Sep 29, 2020	DS DP U-1429			
	6727256	Jan 08, 2019	DS DP U-800			
	6727256	Jan 08, 2019	DS DP U-1429			
	6828320	Jul 11, 2017	U-800			
	6828320	Jul 11, 2017	U-1429			
	7157466	Nov 19, 2021	DS DP			
	8513262	Jan 08, 2019	DS DP			
	8821927	Jun 12, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Oct 10, 2019
	8088368	May 12, 2030	DS DP			
	8273341	May 12, 2030	U-1470			
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8735372	Mar 21, 2028	U-1470			
	8822430	May 12, 2030	DS DP U-1470			
	8841278	May 12, 2030	DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	5635517	Oct 04, 2019	DS	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1212		
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS DP	U-1211	I-672	Jun 05, 2016
	6045501	Aug 28, 2018		U-1210	NS	Jun 05, 2016
	6281230	Jul 24, 2016		U-1212	ODE	Jun 05, 2020
	6281230	Jul 24, 2016		U-1414		
	6315720	Oct 23, 2020		U-1210		
	6555554	Jul 24, 2016	DP	U-1211		
	6561976	Aug 28, 2018		U-1210		
	6561977	Oct 23, 2020		U-1210		
	6755784	Oct 23, 2020		U-1210		
	6908432	Aug 28, 2018		U-1210		
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023		U-1215		
	7465800	Apr 27, 2027	DS DP			
	7468363	Oct 07, 2023		U-1414		
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023		U-1216		
	8204763	Aug 28, 2018		U-1249		
	8288415	Jul 24, 2016	DS DP			
	8315886	Oct 23, 2020		U-1249		
	8404717	Apr 11, 2023		U-1215		
	8530498	May 15, 2023		U-1216		
	8589188	Aug 28, 2018		U-1210		
	8626531	Oct 23, 2020		U-1210		
	8648095	May 15, 2023		U-1216		
	8741929	Mar 08, 2028		U-1414		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 019732 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 002	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 005	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 006	6036976	Dec 13, 2016			M-107	Oct 08, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 007	6036976	Dec 13, 2016	DP		NP	Aug 15, 2014
<u>LEUPROLIDE ACETATE - LUPRON DEPOT-PED</u>						
N 020263 008	6036976	Dec 13, 2016	DP		NP	Aug 15, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 002	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	6036976	Dec 13, 2016	DP			
	7429559	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020708 001	6036976	Dec 13, 2016				
<u>LEUPROLIDE ACETATE - VIADUR</u>						
N 021088 001	5728396	Jan 30, 2017	U-316			
	5932547	Jun 13, 2017				
	5985305	Jan 30, 2017				
	6113938	Jul 24, 2018				
	6124261	Jun 13, 2017				
	6132420	Jan 30, 2017				
	6156331	Jan 30, 2017				
	6235712	Jun 13, 2017				
	6375978	Dec 17, 2018				
	6395292	Jan 30, 2017				
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021343 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	6565874	Oct 28, 2018	DP U-801			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	DP U-801			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	6565874	Oct 28, 2018	DP U-621			
	6626870	Mar 27, 2020	DP			
	6773714	Oct 28, 2018	U-621			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 001	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 002	6036976	Dec 13, 2016	DP			
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003	6451289	Mar 21, 2021				
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004	6451289	Mar 21, 2021	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001	5836299	Nov 17, 2015	DP			
	7256310	Oct 08, 2024	DS DP U-636			
	8765153	Dec 08, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP		NPP	Dec 16, 2014
	8802142*PED	Dec 07, 2031			PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N 021505 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 002	7858122	Sep 17, 2028	DP			
<u>LEVOPUVIVACAIN HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 001	5708011	Oct 13, 2014	U-276			
<u>LEVOPUVIVACAIN HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 002	5708011	Oct 13, 2014	U-276			
<u>LEVOPUVIVACAIN HYDROCHLORIDE - CHIROCAINE</u>						
N 020997 003	5708011	Oct 13, 2014	U-276			
<u>LEVOCARNITINE - CARNITOR</u>						
N 020182 001	6335369	Jan 18, 2021	U-433			
	6429230	Jan 18, 2021	U-433			
	6696493	Jan 18, 2021	U-433			
<u>LEVOFLOXACIN - LEVAQUIN</u>						
N 021721 001	6806256	Feb 26, 2022	DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 001	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 002	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N 020140 003	6500829	Mar 07, 2022	DS DP		ODE	Mar 07, 2015
					ODE	Apr 29, 2018
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839		NCE*	Jul 25, 2018
	8865937	May 23, 2032	DS DP			
	RE43879	Jun 03, 2023	U-839			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	5785053	Dec 05, 2015	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - PLAN B ONE-STEP</u>						
N 021998 001					RTO*	Apr 30, 2016
					RTO**	Apr 30, 2016
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	5785053	Dec 05, 2015	DP		NP	Jan 09, 2016
	7252839	Nov 13, 2023	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	6555581	Feb 15, 2022				
	7067148	Feb 15, 2022	DP			
	7101569	Oct 02, 2023		U-759		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 001	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 002	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 003	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 004	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 005	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 006	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 007	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 008	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 009	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 010	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - LEVO-T</u>						
N 021342 011	6399101	Mar 30, 2020				
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 022121 001	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - LIDODERM</u>						
N 020612 001	5827529	Oct 27, 2015	U-486			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	5899880	May 04, 2016	DP			
	6004286	Mar 17, 2017	DP			
	6881200	Jun 11, 2016	DP			
	8540665	Oct 22, 2029	U-1438			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
<u>LIDOCAINE; PRILOCAINE - ORAOIX</u>						
N 021451 001	6031007	Apr 01, 2017	DP U-553			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N 021623 001	5658583	Jul 28, 2015	DP			
	5919479	Jul 28, 2015	DP			
	6306431	Jul 28, 2015	DP			
	6465006	Jul 28, 2015	DP			
	6465709	Jul 07, 2020	DP			
	6546281	Jul 28, 2015	DP			
	6780426	Jul 28, 2015	DP			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717 001	5919479	Jul 28, 2015	DP			
	6528086	Sep 28, 2019	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	6303661	Apr 24, 2017	U-774		M-118	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-121	Aug 13, 2015
	6890898	Feb 02, 2019	U-493		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1270			
	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	6303661	Apr 24, 2017	U-802		M-146	Jul 30, 2017
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039		NCE	May 02, 2016
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
<u>LINEZOLID - ZYVOX</u>						
N 021130 001	5688792	Nov 18, 2014	DS U-319			
	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021130 002	5688792	Nov 18, 2014	DS U-319			
	6514529	Mar 15, 2021	DP			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021131 001	5688792	Nov 18, 2014	U-319			
	6559305	Jan 29, 2021	DS			
<u>LINEZOLID - ZYVOX</u>						
N 021132 001	5688792	Nov 18, 2014	DS U-319			
	6559305	Jan 29, 2021	DS			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6004297	Jan 28, 2019	DP		M-115	Apr 06, 2015
	6268343	Aug 22, 2022	DS DP U-968		NCE	Jan 25, 2015
	6458924	Aug 22, 2017	DS DP U-968			
	7235627	Aug 22, 2017	DS DP			
	8114833	Aug 13, 2025	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NCE	Jan 25, 2015
					NP	Jan 25, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Jun 29, 2023		U-727	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Jun 29, 2023		U-842	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Jun 29, 2023		U-842	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Jun 29, 2023		U-842	I-645	Jan 31, 2015
	7223735	Jun 29, 2023		DP		
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023		U-1034		
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		
	7671030	Feb 24, 2023	DP	U-727		
	7671031	Feb 28, 2023		U-727		
	7674774	Mar 18, 2023	DP	U-842		
	7678770	Mar 25, 2023		U-842		
	7678771	Mar 25, 2023	DP	U-842		
	7687466	Feb 24, 2023	DP			
	7687467	Apr 08, 2023	DP	U-842		
	7700561	Jun 29, 2023	DP			
	7713936	Feb 24, 2023		U-727		
	7718619	Feb 24, 2023	DP	U-842		
	7723305	Feb 24, 2023	DP	U-842		
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-645	Jan 31, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2015	DS U-1317		NCE	Dec 21, 2017
	5739135	Apr 14, 2015	DS U-1317		ODE	Dec 21, 2019
	6492365	Dec 10, 2019	U-1318			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS</u>						
N 020448 001	6814978	Aug 26, 2021	DP			
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 020606 001	5679376	Oct 21, 2014				Y
<u>LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF</u>						
N 021140 001	6103260	Jul 17, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021226 001	5648497	Jul 15, 2014				
	5914332	Dec 13, 2015	U-351			
	6037157	Jun 26, 2016	U-346			
	6232333	Nov 07, 2017				
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-688			
	6458818	Nov 07, 2017				
	6521651	Nov 07, 2017	DP			
	6703403	Jun 26, 2016	U-257			
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021251 001	5648497	Jul 15, 2014	DS			
	5914332	Dec 13, 2015	DS DP U-351			
	5914332	Dec 13, 2015	DS DP U-895			
	6037157	Jun 26, 2016	U-346			
	6037157	Jun 26, 2016	U-895			
	6284767	Feb 15, 2016	DP U-401			
	6284767	Feb 15, 2016	DP U-895			
	6703403	Jun 26, 2016	U-257			
	6703403	Jun 26, 2016	U-895			
	6911214	Nov 28, 2021	DP U-895			
	8501219	Nov 28, 2021	DP			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	5648497	Jul 15, 2014	DS DP			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016	U-688			
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	5648497	Jul 15, 2014	DS DP			
	5914332	Dec 13, 2015	DS DP U-688			
	6037157	Jun 26, 2016	U-688			
	6284767	Feb 15, 2016	DP U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8025899	Dec 14, 2027	DP			
	8025899*PED	Jun 14, 2028				
	8268349	Aug 25, 2024	DP			
	8309613	Dec 24, 2024	U-688			
	8377952	Oct 22, 2027	U-1372			
	8377952*PED	Apr 22, 2028				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	6953787	Apr 10, 2023	DS DP U-1252		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1253			
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
	8273734	Apr 10, 2023	U-1255			
	8367657	Apr 10, 2023	DS DP U-1252			
	8367657	Apr 10, 2023	DS DP U-1253			
	8367657	Apr 10, 2023	DS DP U-1254			
	8367657	Apr 10, 2023	DS DP U-1255			
	8546379	Apr 10, 2023	DS DP U-1252			
	8546379	Apr 10, 2023	DS DP U-1253			
	8546379	Apr 10, 2023	DS DP U-1254			
	8546379	Apr 10, 2023	DS DP U-1255			
	8575149	Apr 10, 2023	U-1452			
	8697686	Dec 20, 2025	DS DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 200738 001					PED	Oct 15, 2014
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N 202872 001	5800807	Jan 29, 2017	DP		NDF	Sep 28, 2015
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 001	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 002	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 003	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			
<u>LOVASTATIN - ALTOPREV</u>						
N 021316 004	5916595	Dec 12, 2017				
	6080778	Mar 23, 2018	U-456			
	6485748	Dec 12, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 001	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 002	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 003	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N 021249 004	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1130			
	6469035	Mar 15, 2018	U-1131			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	6716416	May 20, 2022	DP		NDF	Dec 21, 2015
	7052679	Oct 26, 2021	DP			
	7078020	Oct 26, 2021	DP U-1375			
	7090830	Oct 26, 2021	DP			
	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	7585493	Oct 26, 2021	DP			
	7601337	Oct 26, 2021	DP			
	8074644	Jul 25, 2022	DP			
	8173107	Oct 26, 2021	DP			
	8235037	Oct 26, 2021	DP			
	8387612	Oct 23, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	5284858	Jul 14, 2014	DS		I-670	Apr 19, 2016
	6414016	Sep 05, 2020		U-717		
	6414016	Sep 05, 2020		U-1392		
	6583174	Oct 16, 2020	DP			
	6982283	Dec 04, 2022		U-1391		
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-1404		
	7417067	Oct 16, 2020	DP			
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1203		
	8071613	Sep 05, 2020		U-1393		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022		U-1214		
	8097653	Nov 14, 2022		U-1394		
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8389542	Nov 14, 2022	DP	U-1345		
	8389542	Nov 14, 2022	DP	U-1395		
	8748481	Sep 01, 2025		U-1520		
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	5284858	Jul 14, 2014	DS			
	6414016	Sep 05, 2020		U-874		
	6583174	Oct 16, 2020	DP			
	7064148	Aug 30, 2022		U-739		
	7064148	Aug 30, 2022		U-873		
	7417067	Oct 16, 2020	DP			
	7795312	Sep 17, 2024		U-1085		
	8026393	Oct 25, 2027	DP			
	8071613	Sep 05, 2020		U-1202		
	8088934	May 18, 2021	DS			
	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025		U-1519		
	8779187	Jan 23, 2027	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N 021746 001	5407914	Nov 17, 2014	DS DP	U-1242		
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2016	DS DP	U-540	NCE	Nov 14, 2018
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS		D-134	Apr 26, 2015
	8729085	May 26, 2026	DP		I-674	Jun 28, 2016
	8883794	May 26, 2026	DP		NCE	Oct 28, 2015
<u>LUTROPIN ALFA - LUVERIS</u>						
N 021322 001	5767251	Jun 16, 2015	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	7094781	Oct 12, 2022	DS DP		NCE	Oct 18, 2018
	8268847	Apr 18, 2029	U-1446		ODE	Oct 18, 2020
	8367685	Oct 04, 2028	DP U-1445			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910 001	5945449	Oct 31, 2017	DP U-785			
	7300674	Mar 04, 2023	DP U-785			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35</u>						
N 021910 002	5945449	Oct 31, 2017	DP U-785			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 001	6489346	Jul 16, 2016	DS DP U-588			
	6645988	Jul 16, 2016	DS DP U-588			
	6699885	Jul 16, 2016	U-588			
	7399772	Jul 16, 2016	U-588			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021850 002	6489346	Jul 16, 2016	DS DP U-623			
	6645988	Jul 16, 2016	DS DP U-623			
	6699885	Jul 16, 2016	U-623			
	7399772	Jul 16, 2016	U-623			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 001	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE</u>						
N 022456 002	6489346	Jul 16, 2016	DP U-588			
	6489346	Jul 16, 2016	DP U-1021			
	6645988	Jul 16, 2016	DP			
	6699885	Jul 16, 2016	DP U-588			
	6699885	Jul 16, 2016	DP U-1021			
	7399772	Jul 16, 2016	DP U-588			
	7399772	Jul 16, 2016	DP U-1021			
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372 001	6946149	Mar 07, 2023	DP U-837			
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE - SUCLEAR</u>						
N 203595 001					NC	Jan 18, 2016
<u>MALATHION - OVIDE</u>						
N 018613 001	7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MANNITOL - ARIDOL KIT</u>						
N 022368 001	5817028	Feb 23, 2015	U-1091			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 001	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MARAVIROC - SELZENTRY</u>						
N 022128 002	6586430	Dec 01, 2019	DS DP U-824			
	6667314	Aug 06, 2021	DS DP U-824			
	7368460	Nov 25, 2022	U-824			
	7576097	May 25, 2021	DS			
<u>MECASERMIN RECOMBINANT - INCRELEX</u>						
N 021839 001	5681814	Sep 18, 2017	DP			
	5824642	Jul 08, 2014	U-681			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>						
N 021884 001	5681818	Oct 28, 2014	U-697			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 020317 001	7838564	Mar 07, 2026	DP		NDF	Aug 23, 2016
	7872050	Jul 08, 2029	U-1427		ODE	Aug 23, 2020
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
<u>MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104</u>						
N 021583 001	6495534	May 15, 2020	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	6592903	Sep 21, 2020	DP			
	7101576	Apr 22, 2024	U-755			
<u>MELOXICAM - MOBIC</u>						
N 021530 001	6184220	Mar 25, 2019	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MEMANTINE HYDROCHLORIDE - NAMENDA XR						
N 021663 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
MENOTROPINS (FSH;LH); MENOTROPINS (FSH;LH) - MENOPUR						
N 021663 001					D-139	Feb 19, 2017

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	8809615	Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	8809615	Jan 03, 2030	DP			
<u>MEQUINOL; TRETINOIN - SOLAGE</u>						
N 020922 001	6353029	Aug 24, 2020				
<u>MERCAPTOPURINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>MESALAMINE - SFROWASA</u>						
N 019618 002	7645801	Jul 24, 2027	DS DP			
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	6893662	Nov 15, 2021	DP U-141			
	8580302	Nov 15, 2021	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000 001	6773720	Jun 08, 2020	DP		I-640	Jul 14, 2014
<u>MESALAMINE - APRISO</u>						
N 022301 001	6551620	Apr 20, 2018	DS DP U-907			
	8337886	Apr 20, 2018	DP U-1310			
	8496965	Apr 20, 2018	DP			
	8865688	May 01, 2030	U-1310			
	8911778	Apr 20, 2018	DP U-1310			
<u>MESALAMINE - DELZICOL</u>						
N 204412 001	6649180	Apr 13, 2020	DP			
<u>METAXALONE - SKELAXIN</u>						
N 013217 003	7122566	Feb 06, 2026	U-915			
	7714006	Dec 03, 2021	U-1050			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202 001	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR</u>						
N 021202 004	6475521	Mar 19, 2018				
	6660300	Mar 19, 2018	U-542			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 001	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N 021574 002	6099859	Mar 20, 2018	DP			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-604			
	6866866	Mar 17, 2021	DP			
	7919116	Mar 20, 2018	DP			
	8475841	Mar 20, 2018	U-604			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Sep 14, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 001	6340475	Sep 19, 2016	DS DP U-669			
	6488962	Jun 20, 2020	DS DP			
	6635280	Sep 19, 2016	DS DP			
	6723340	Oct 25, 2021	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	6488962	Jun 20, 2020	DS DP			
	7780987	Mar 23, 2025	DS DP			
	8323692	Mar 23, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	5965584	Jun 19, 2016	DP U-1055		M-116	May 17, 2015
	6166042	Jun 19, 2016	U-679			
	6166043	Jun 19, 2016	U-679			
	6172090	Jun 19, 2016	U-679			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	5965584	Jun 19, 2016	DP U-973			
	6099859	Mar 20, 2018	DP			
	6166042	Jun 19, 2016	U-973			
	6166043	Jun 19, 2016	U-973			
	6172090	Jun 19, 2016	U-973			
	6495162	Mar 20, 2018	DP			
	6790459	Mar 17, 2021	U-974			
	6866866	Mar 17, 2021	DP			
	7785627	Jul 31, 2026	DP			
	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8475841	Mar 20, 2018	U-973			
	8668931	Sep 19, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	5965584	Jun 19, 2016	U-493	Y		
	6166042	Jun 19, 2016	U-493	Y		
	6288095	Feb 11, 2017	U-493	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	5741803	Apr 21, 2015	DS DP U-493	Y		
	5741803	Apr 21, 2015	DS DP U-734	Y		
	7358366	Apr 19, 2020	DS			
	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
	RE44186	Jul 31, 2023	DS DP U-1097		NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-134	May 24, 2016
					NCE	Jul 31, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6303661	Apr 24, 2017			U-802	
	6699871	Jul 26, 2022	DS DP		U-802	
	6890898	Feb 02, 2019			U-803	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1038	
	7078381	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022	DP		U-803	
	7125873	Jul 26, 2022	DP		U-1036	
	7125873	Jul 26, 2022	DP		U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
	7459428	Feb 02, 2019			U-1036	
	8414921	Jul 21, 2028	DP		U-1036	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6303661	Apr 24, 2017			U-802	
	6699871	Jul 26, 2022	DS DP		U-802	
	6890898	Feb 02, 2019			U-803	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1038	
	7078381	Feb 02, 2019			U-803	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022	DP		U-803	
	7125873	Jul 26, 2022	DP		U-1036	
	7125873	Jul 26, 2022	DP		U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
	7459428	Feb 02, 2019			U-1036	
	8414921	Jul 21, 2028	DP		U-1036	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6303661	Apr 24, 2017			U-1227	
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP		U-1227	
	6890898	Feb 02, 2019			U-1228	
	7078381	Feb 02, 2019			U-1227	
	7125873	Jul 26, 2022	DP		U-1227	
	7326708	Apr 11, 2026	DS DP		U-1227	
	7459428	Feb 02, 2019			U-1227	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	6746429	Apr 12, 2020	DP			
	7744582	Aug 10, 2019	DP U-1442			
	7776015	Aug 10, 2019	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYL AMINOLEVULINATE HYDROCHLORIDE - METVIXIA</u>						
N 021415 001	6034267	Mar 08, 2016	U-804			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	6559158	Nov 03, 2017	U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	6210705	Sep 30, 2018	DP U-727			
	6348211	Sep 30, 2018	DP U-727			
	8632802	Oct 07, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	6919373	Jul 31, 2017			U-666	
	6930129	Jul 31, 2017			U-666	
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	6919373	Jul 31, 2017			U-666	
	6930129	Jul 31, 2017			U-666	
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	6919373	Jul 31, 2017			U-666	
	6930129	Jul 31, 2017			U-666	
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	6919373	Jul 31, 2017			U-666	
	6930129	Jul 31, 2017			U-666	
	8163798	Jul 31, 2017	DP			
	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 001	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 002	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 003	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METADATE CD</u>						
N 021259 004	6344215	Oct 27, 2020	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 001	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP		U-472	
	6635284	Dec 04, 2015	DP		U-591	
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 002	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP		U-472	
	6635284	Dec 04, 2015	DP		U-591	
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 003	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP		U-472	
	6635284	Dec 04, 2015	DP		U-591	
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA</u>						
N 021284 004	5837284	Dec 04, 2015	DP			
	6228398	Nov 01, 2019	DP		U-472	
	6635284	Dec 04, 2015	DP		U-591	
	7431944	Dec 04, 2015	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP		NDF	Sep 27, 2015
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 001	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT</u>						
N 021793 002	6024981	Apr 09, 2018	DP			
	6221392	Apr 09, 2018	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 001	6413549	Jul 11, 2017	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT</u>						
N 022246 002	6413549	Jul 11, 2017	DP			
<u>METRONIDAZOLE - METROGEL</u>						
N 021789 001	6881726	Feb 21, 2022	DP U-743			
	7348317	Feb 21, 2022	DP U-743			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806 001	7456207	Sep 22, 2024	DP			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 002	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICAFUNGIN SODIUM - MYCAMINE</u>						
N 021506 003	6107458	Mar 16, 2019	DS DP U-650			
	6107458	Mar 16, 2019	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6774104	Jan 08, 2021	DP U-650			
	6774104	Jan 08, 2021	DP U-845			
<u>MICONAZOLE - ORAVIG</u>						
N 022404 001	6916485	Sep 11, 2022	DP U-1051			
	7651698	Sep 11, 2022	U-1051			
	8518442	Sep 11, 2022	DP			
<u>MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK</u>						
N 021308 001	6153635	Nov 28, 2020			Y	
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001					NP	Feb 17, 2015
					ODE	Feb 17, 2019

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 001	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 002	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 003	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 004	6602911	Jan 14, 2023	U-882			
	6992110	Nov 05, 2021	U-882			
	7888342	Nov 05, 2021	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE	Mar 19, 2019
					ODE	Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	6682348	Mar 29, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 002	5908838	Feb 19, 2018				U-917
	7541347	Apr 02, 2027				U-917
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 003	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
	8722650	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
	8722650	Jun 24, 2025				U-1078
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	5908838	Feb 19, 2018				U-917
	7790705	Jun 24, 2025				U-1078
	7919483	Mar 07, 2027				U-1078
	8252776	Jun 24, 2025				U-124
	8268804	Jun 24, 2025				U-1078
	8722650	Jun 24, 2025				U-1078

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	5908838	Feb 19, 2018	U-1376			
	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOXIDIL - MEN'S ROGAINE</u>						
N 021812 001	6946120	Apr 20, 2019	DP U-702			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	6166197	Dec 26, 2017	DS		NCE	Jan 29, 2018
	6222025	Mar 06, 2015	DS		ODE	Jan 29, 2020
	6451991	Feb 11, 2017	DS			
	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7407943	Aug 01, 2021	U-1353			
	7511131	Dec 13, 2025	DS			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	U-255			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
	RE37516	Oct 06, 2014	U-255			
<u>MOMETASONE FUROATE - ELOCON</u>						
N 019625 002					NP	Apr 19, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 001	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N 021067 002	5687710	Nov 18, 2014	DP			
	5829434	Nov 03, 2015	DP			
	6240918	Feb 20, 2017	DP			
	6503537	Mar 17, 2018	DP			
	8173172	Mar 17, 2018	DP			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015*PED	Jul 27, 2014				
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015*PED	Jul 27, 2014				
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N 020762 001	6127353	Oct 03, 2017	DS DP			
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N 021409 001	8007830	Oct 24, 2022	DP		NPP	Mar 26, 2015
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 001	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 002	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			
<u>MORPHINE SULFATE - DEPODUR</u>						
N 021671 003	5723147	Mar 03, 2015	DP U-584			
	5807572	Sep 15, 2015	DP			
	5891467	Jan 31, 2017	DP			
	5931809	Jul 14, 2015	U-584			
	5962016	Jan 31, 2017	DP U-584			
	5997899	Sep 01, 2016	DP			
	6171613	Oct 01, 2016	DP			
	6193998	Sep 01, 2016	DP			
	6241999	Sep 01, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027			U-1510	
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027			U-1510	
	8685443	Jul 03, 2025			U-1508	
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
N 021085 001	5849752	Dec 05, 2016			U-298	
	6610327	Oct 29, 2019	DP		U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
N 021277 001	5849752	Dec 05, 2016			U-298	
	6548079	Jul 25, 2020	DP		U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
N 021598 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019			U-709	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	6716830	Sep 29, 2019	DP			
	7671070	Sep 29, 2019	DP U-709			
	8450311	May 29, 2029	DP			
<u>MUPIROCIN - CENTANY</u>						
N 050788 001	6013657	Jul 08, 2018	DP			
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N 050746 001	6025389	Oct 20, 2014	DP U-1122			
<u>MYCOPHENOLATE MOFETIL - CELLCEPT</u>						
N 050759 001	5688529	Nov 18, 2014	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 001	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>MYCOPHENOLIC ACID - MYFORTIC</u>						
N 050791 002	6025391	Apr 10, 2017	DP U-908			
	6172107	Apr 10, 2017	DP U-908			
	6306900	Feb 27, 2018	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 019599 002					NS	Jan 13, 2015
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP		NP	Jun 27, 2016
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALTREXONE - VIVITROL</u>						
N 021897 001	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6264987	May 19, 2020	DP			
	6331317	Nov 12, 2019	DP			
	6379703	Dec 30, 2018	DP			
	6379704	May 19, 2020	DP			
	6395304	Nov 12, 2019	DP			
	6403114	May 02, 2017	DP			
	6495164	May 25, 2020	DP			
	6495166	Nov 12, 2019	DP			
	6534092	May 19, 2020	DP			
	6537586	Nov 12, 2019	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
	6713090	Nov 12, 2019	DP			
	6939033	Nov 12, 2019	DP			
	7799345	May 25, 2020	DP			
	7919499	Oct 15, 2029			U-1123	
	7919499	Oct 15, 2029			U-1124	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP		U-867	
	6586458	Aug 14, 2017	DP		U-867	
	7332183	Oct 02, 2025	DP		U-867	
	8022095	Aug 14, 2017	DP		U-867	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NATEGLINIDE - STARLIX</u>						
N 021204 001	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NATEGLINIDE - STARLIX</u>						
N 021204 002	6559188	Sep 15, 2020	DP U-827			
	6641841	Nov 14, 2017	DP U-214			
	6844008	Nov 14, 2017	DP U-214			
	6878749	Sep 15, 2020	DP			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 002	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 003	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 004	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NEBIVOLOL HYDROCHLORIDE - BYSTOLIC</u>						
N 021742 005	5759580	Jun 02, 2015	DP			
	6545040	Dec 17, 2021	DP U-3			
<u>NELARABINE - ARRANON</u>						
N 021877 001	5424295	Jun 13, 2017	DS DP			
<u>NEPAFENAC - NEVANAC</u>						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	6403609	Jul 17, 2018	DP		NP	Oct 16, 2015
	7947295	Jun 08, 2024	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	5202333	Apr 13, 2015	DS DP U-528		NCE	Oct 10, 2019
	6297375	Feb 22, 2020	DS			
	8623826	Nov 18, 2030	U-528			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409		NPP	Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 002					NPP	Nov 08, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N 020381 001	6080428	May 27, 2017	U-331			
<u>NIACIN - NIASPAN</u>						
N 020381 002	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 003	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN</u>						
N 020381 004	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1143			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-1145			
<u>NIACIN - NIASPAN TITRATION STARTER PACK</u>						
N 020381 005	6080428	May 27, 2017	U-331			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N 022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1132			
	6080428	May 27, 2017	U-1134			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1149			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8075911	May 22, 2021	DP			
	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICOTROL</u>						
N 020385 001	5656255	Aug 12, 2014				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612 002	8323683	Apr 30, 2028				
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066 002	8323683	Apr 30, 2028	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		ODE	Oct 29, 2014
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		ODE	Oct 29, 2014
	8163904	Aug 23, 2028	DS DP			
	8293756	Sep 25, 2027	DP			
	8389537	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8501760	Jul 18, 2026	DS DP			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 001					ODE	May 10, 2020
<u>NINTEDANIB - OFEV</u>						
N 205832 001	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NINTEDANIB - OFEV</u>						
N 205832 002	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NISOLDIPINE - SULAR</u>						
N 020356 005	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 006	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 007	5626874	Nov 30, 2014	DP			
<u>NISOLDIPINE - SULAR</u>						
N 020356 008	5626874	Nov 30, 2014	DP			
<u>NITAZOXANIDE - ALINIA</u>						
N 021497 001	5968961	May 07, 2017	DP			
	6020353	Sep 18, 2014	DS DP			
<u>NITAZOXANIDE - ALINIA</u>						
N 021498 001	5578621	Sep 08, 2014	U-525			
	5965590	Jul 03, 2017	U-523			
	5968961	May 07, 2017				
	6020353	Sep 08, 2014				
	6117894	May 07, 2017				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	5732693	Dec 13, 2016	DP U-1230			
	5752504	Dec 13, 2016	DP U-1230			
	6125846	May 16, 2017	DP U-1457			
	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 14, 2028	DP U-39			
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 001	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 002	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROSTAT</u>						
N 021134 003	6500456	Sep 16, 2018				
<u>NITROGLYCERIN - NITROMIST</u>						
N 021780 001	5869082	Apr 16, 2016	DP			
<u>NIZATIDINE - AXID</u>						
N 021494 001	6930119	Jul 17, 2022	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 001	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 002	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 003	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 004	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
N 019667 005	5753618	May 19, 2015				
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 001	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 002	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
N 021008 003	5688530	Nov 18, 2014		U-268		
	5922338	Jul 13, 2016	DP			
	5922682	Jul 13, 2016	DP			
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 001	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 002	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 003	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 004	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 005	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA</u>						
N 020592 006	6960577	Nov 01, 2017		U-963	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 001	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 002	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 003	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N 021086 004	6960577	Nov 01, 2017		U-964	NPP	Jul 26, 2016
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 001	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 002	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLANZAPINE PAMOATE - ZYPREXA RELPREVV</u>						
N 022173 003	6169084	Sep 30, 2018	DS DP	U-1026		
<u>OLAPARIB - OLAPARIB</u>						
N 206162 001					NCE	Dec 19, 2019
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 001	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 003	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLMESARTAN MEDOXOMIL - BENICAR</u>						
N 021286 004	5616599	Apr 25, 2016	DS DP U-500			
	6878703	Nov 19, 2021	U-3	Y		
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATANOL</u>						
N 020688 001	5641805	Jun 06, 2015	U-184			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
	6995186	Nov 12, 2023	DP U-765			
	7402609	Jun 19, 2022	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508	Sep 17, 2022	U-726			
	8399508*PED	Mar 17, 2023				
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	RE45128	Mar 16, 2019	DS DP U-1576		ODE	Oct 26, 2019
<u>OMEGA-3-ACID ETHYL ESTERS - LOVAZA</u>						
N 021654 001	5656667	Apr 10, 2017	DS DP U-822			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 001	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 002	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE - PRILOSEC</u>						
N 019810 003	6147103	Oct 09, 2018				
	6150380	Nov 10, 2018				
	6166213	Oct 09, 2018				
	6191148	Oct 09, 2018				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC OTC</u>						
N 021229 001	5690960	Nov 25, 2014				
	5753265	Jun 07, 2015				
	5817338	Oct 06, 2015				
	5900424	May 04, 2016				
	6403616	Nov 15, 2019				
	6428810	Nov 03, 2019				
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5690960	Nov 25, 2014		DP U-864		
	5900424	May 04, 2016	DS	U-864		
	6428810	Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5690960	Nov 25, 2014		DP U-864		
	5900424	May 04, 2016	DS	U-864		
	6428810	Nov 03, 2019		DP U-864		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 16, 2016		U-588		
	6489346	Jul 16, 2016	DS DP	U-588		Y
	6645988	Jul 16, 2016	DS DP			Y
	6699885	Jul 16, 2016		U-588		Y
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016		U-588		
	RE45198	Jul 16, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 16, 2016		U-623		
	5840737	Jul 16, 2016		U-624		
	6489346	Jul 16, 2016	DS DP	U-623		Y
	6489346	Jul 16, 2016	DS DP	U-624		Y
	6645988	Jul 16, 2016	DS DP			Y
	6699885	Jul 16, 2016		U-623		Y
	6699885	Jul 16, 2016		U-624		Y
	6780882	Jul 16, 2016	DS DP			
	7399772	Jul 16, 2016		U-623		
	7399772	Jul 16, 2016		U-624		
	RE45198	Jul 16, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 16, 2016		U-588		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 16, 2016		U-623		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022281 001	6489346	Jul 15, 2016	DP	U-1025		Y
	6645988	Jul 15, 2016	DP			Y
	6699885	Jul 15, 2016	DP			Y
	7399772	Jul 15, 2016		U-1025		
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 16, 2016		U-1025		
	6780882	Jul 16, 2016	DP			
	7399772	Jul 16, 2016		U-1025		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N 020781 001	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZOFTRAN ODT</u>						
N 020781 002	5955488	Nov 14, 2015				
	6063802	Nov 14, 2015				
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
<u>ONDANSETRON HYDROCHLORIDE - ZOFTRAN</u>						
N 020605 001	5854270	Nov 20, 2015	DP U-44			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2015	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
<u>ORLISTAT - XENICAL</u>						
N 020766 001	6004996	Jan 06, 2018				
<u>ORLISTAT - ALLI</u>						
N 021887 001	6004996	Jan 06, 2018	DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 001	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 002	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021087 003	5763483	Dec 27, 2016	DS U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 001	5763483	Dec 27, 2016	DS U-376		NPP	Dec 21, 2015
	5763483	Dec 27, 2016	DS U-1113			
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Dec 27, 2016	DS DP U-1113		NPP	Dec 21, 2015
	5866601	Feb 02, 2016	DS DP			
	5952375	Feb 27, 2015	DS DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2020	U-1369		NCE	Feb 26, 2018
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 001	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021492 002	5420319	Aug 09, 2016	DS			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 001	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 002	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXALIPLATIN - ELOXATIN</u>						
N 021759 003	5420319	Aug 09, 2016	DS			
	5716988	Aug 07, 2015	DP			
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 001	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXANDROLONE - OXANDRIN</u>						
N 013718 002	5872147	Dec 05, 2017		U-585		
	6090799	Jul 18, 2017		U-585		
	6576659	Dec 05, 2017		U-585		
	6828313	Dec 05, 2017		U-585		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 001	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 002	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021014 003	7037525	Feb 12, 2018		U-724		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N 021285 001	7037525	Feb 12, 2018		U-724		
	8119148	Dec 19, 2020	DP	U-724		
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	7722898	Apr 13, 2027	DP		NDF	Oct 19, 2015
	7910131	Apr 13, 2027		U-1298		
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
<u>OXYBUTYNIN - OXYTROL</u>						
N 021351 002	5601839	Apr 26, 2015				
	5834010	Apr 26, 2015				
	6743441	Apr 26, 2020	DP	U-318		
	7081249	Apr 26, 2020	DP	U-318		
	7081250	Apr 26, 2020	DP	U-318		
	7081251	Apr 26, 2020	DP	U-318		
	7081252	Apr 26, 2020	DP	U-318		
	7179483	Apr 26, 2020	DS	DP U-318		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN - OXYTROL FOR WOMEN</u>						
N 202211 001	5601839	Apr 26, 2015	DP U-1329		NP	Jan 25, 2016
	5834010	Apr 26, 2015	DP U-1329			
	6743441	Apr 26, 2020	DP U-1329			
	7081249	Apr 26, 2020	DP U-1329			
	7081250	Apr 26, 2020	DP U-1329			
	7081251	Apr 26, 2020	DP U-1329			
	7081252	Apr 26, 2020	DP U-1329			
	7179483	Apr 26, 2020	U-1329			
<u>OXYBUTYNIN - GELNIQUE 3%</u>						
N 202513 001	7029694	Apr 26, 2020	DP U-318		NP	Dec 07, 2014
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 001	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 002	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - DITROPAN XL</u>						
N 020897 003	5674895	May 22, 2015				
	5840754	May 22, 2015				
	5912268	May 22, 2015				
	6262115	May 22, 2015	U-393			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	8241662	Apr 26, 2020	U-318			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	6488963	Jun 24, 2017	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	7776314	Apr 19, 2025	DP	Y		
	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-1556			
	8337888	Aug 06, 2022	DP			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	7276250	Feb 04, 2023	DP U-826			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-1598		
	8871779	Nov 22, 2029	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434		I-658	Oct 11, 2015
	7820788	Mar 03, 2024	DP U-1092		I-676	Sep 06, 2016
	7820788	Mar 03, 2024	DP U-1290		ODE	Sep 06, 2020
	7820788	Mar 03, 2024	DP U-1434			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8853260	Aug 14, 2020	DP			
	RE41884	Aug 14, 2016	U-1117			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1434			
<u>PALIPERIDONE - INVEGA</u>						
N 021999 001					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 002					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 003					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 004					PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N 021999 006					PED	Oct 06, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	6077843	May 12, 2017	DP U-543		I-698	Nov 12, 2017
	6555544	Nov 10, 2018	DP U-543		M-119	Aug 29, 2015
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 022233 001	5202333	Apr 13, 2015	DS DP U-528			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N 022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 001					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 002					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 003					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE</u>						
N 022523 004					NCE	Apr 12, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 004					M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005					M-93	Jul 29, 2019
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	7658918	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP	U-1274		
	8562980	Feb 20, 2028	DP	U-1274		
	8562981	Feb 20, 2028		U-1274		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N 022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N 022542 002					NCE	Mar 01, 2017
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987 001	5997903	Dec 07, 2016				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 020987 002	5997903	Dec 07, 2016				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	6780881	Nov 17, 2021	DP			
	7351723	Nov 17, 2021	DP			
	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024	U-859			
	7553498	Sep 30, 2024	U-859			
	7838027	Sep 30, 2024	DP U-859			
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001	5597815	Jul 13, 2015	U-1195			
	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002	5597815	Jul 13, 2015	U-1195			
	6136799	Apr 08, 2018				
	6361758	Apr 08, 2018	DP			
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003	5597815	Jul 13, 2015	U-1195			
	5597815*PED	Jan 13, 2016				
	6136799	Apr 08, 2018				
	6136799*PED	Oct 08, 2018				
	6361758	Apr 08, 2018	DP			
	6361758*PED	Oct 08, 2018				
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001	5597815	Jul 13, 2015	U-1195			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 002	5597815	Jul 13, 2015	U-1195			
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 003	5597815	Jul 13, 2015	U-1195			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020031 005	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6113944	Dec 14, 2014				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020710 001	5811436	Sep 22, 2015				
	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017	U-286			
	6121291	Mar 17, 2017	U-431			
	6133289	May 19, 2015	U-358			
	6172233	Jan 15, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL</u>						
N 020885 004	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6063927	Apr 23, 2019				
	6080759	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6121291	Mar 17, 2017		U-431		
	6133289	May 19, 2015		U-358		
	6172233	Jan 15, 2018				
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 001	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 002	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE HYDROCHLORIDE - PAXIL CR</u>						
N 020936 003	5872132	May 19, 2015				
	5900423	May 19, 2015				
	6121291	Mar 17, 2017		U-286		
	6133289	May 19, 2015		U-286		
	6548084	Jul 19, 2016				
	7229640	Jul 19, 2016	DP	U-816		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 001	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 002	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 003	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - PEKEVA</u>						
N 021299 004	5874447	Jun 10, 2017		U-46		
	5874447	Jun 10, 2017		U-286		
	5874447	Jun 10, 2017		U-518		
	7598271	Feb 12, 2023	DS	DP		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	5874447	Jun 10, 2017	DS		NP	Jun 28, 2016
	7598271	Feb 12, 2023	DS			
	8658663	Apr 06, 2029	DS	DP	U-904	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 001	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 002	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677 003	6225284	Jun 28, 2016	DS DP		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		ODE	Dec 14, 2019
	8299209	Dec 27, 2025	DS DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	6225284	Jun 28, 2016	DS DP U-1628		NCE	Dec 14, 2017
	7473761	Jul 29, 2025	DS DP		NP	Dec 15, 2017
	7759308	Oct 25, 2026	DP		ODE	Dec 15, 2021
	8822637	Aug 06, 2023	U-1629			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 001	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 002	7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	7262203	Dec 19, 2021	DS DP		NCE	Oct 19, 2014
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGAPTANIB SODIUM - MACUGEN</u>						
N 021756 001	5932462	Aug 03, 2016	DS			
	6011020	Jan 04, 2017	DS			
	6051698	May 19, 2015	DS	U-622		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 001	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 002	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 003	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535 6057292	Mar 25, 2017 Sep 21, 2015	DS U-507			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 001	5344932 7772209 7772209	Jul 24, 2016 Nov 24, 2021 Nov 24, 2021	DS DP U-1077 U-1296		M-122 PED	Oct 17, 2015 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N 021462 002	5344932 7772209	Jul 24, 2016 Nov 24, 2021	DS DP U-1296		M-122 PED	Oct 17, 2015 Sep 17, 2014
<u>PENCICLOVIR SODIUM - DENAVIR</u>						
N 020629 001	5840763 5866581 5916893 6124304 6469015 6579981	Sep 01, 2015 Oct 04, 2014 Sep 01, 2015 Oct 04, 2014 Oct 22, 2019 Jun 17, 2020	U-501 U-501 U-501 U-501 U-501 U-501			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	6503745 6562861 8778997	Nov 05, 2019 Dec 17, 2018 May 07, 2027	DS DS U-1627		NCE	Dec 19, 2019
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571 8772497	Jun 08, 2021 May 16, 2026	DS DP U-106 DS		NCE	Oct 22, 2017
<u>PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE - SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS</u>						
N 021084 001	5607979	May 30, 2015				
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	5527521 6033645 8658205 8685441	Feb 22, 2015 Jun 19, 2016 Apr 20, 2019 Jan 13, 2019	DP U-665 U-665 DP U-665			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	6149938	Jul 23, 2018	DP			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	6149938	Jul 23, 2018	DP U-1243			
	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 001	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 002	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 003	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - OSYMIA</u>						
N 022580 004	6071537	Jun 23, 2017		U-1262	NC	Jul 17, 2015
	7056890	Jun 14, 2020	DP	U-1262		
	7553818	Jun 14, 2020		U-1262		
	7659256	Jun 14, 2020	DP	U-1262		
	7674776	Jun 14, 2020	DP	U-1262		
	8580298	May 15, 2029	DP			
	8580299	Jun 14, 2029		U-1262		
	8895057	Jun 09, 2028		U-1262		
	8895058	Jun 09, 2028	DP			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	6764678	May 11, 2021		U-967		
	6872390	May 11, 2021	DP			
	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023		U-967		
	7575757	Apr 21, 2025	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033		U-1594		
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033		U-1594		
<u>PIMECROLIMUS - ELIDEL</u>						
N 021302 001	5912238	Jun 15, 2016				
	6352998	Oct 26, 2015				
	6423722	Jun 26, 2018				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 001	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 002	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIOGLITAZONE HYDROCHLORIDE - ACTOS</u>						
N 021073 003	5965584	Jun 19, 2016	U-753			
	6150383	Jun 19, 2016	U-418			
	6150384	Jun 19, 2016	U-419			
	6166042	Jun 19, 2016	U-414			
	6166043	Jun 19, 2016	U-415			
	6172090	Jun 19, 2016	U-416			
	6211205	Jun 19, 2016	U-410			
	6271243	Jun 19, 2016	U-411			
	6303640	Aug 09, 2016	U-425			
	6329404	Jun 19, 2016	U-753			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 001	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 002	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6207661	Feb 22, 2019	DP			
	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029		U-1600	NCE	Oct 16, 2019
	7635707	Apr 22, 2029		U-1609	ODE	Oct 15, 2021
	7696326	Dec 18, 2027		U-1601		
	7767225	Sep 22, 2026	DP	U-1602		
	7767700	Dec 18, 2027		U-1601		
	7816383	Jan 08, 2030		U-1603		
	7910610	Jan 08, 2030		U-1604		
	7988994	Sep 22, 2026	DP	U-1602		
	8013002	Jan 08, 2030		U-1603		
	8084475	Jan 08, 2030		U-1605		
	8318780	Jan 08, 2030		U-1606		
	8383150	Sep 22, 2026	DP	U-1607		
	8420674	Dec 18, 2027	DP	U-1608		
	8592462	Apr 22, 2029		U-1609		
	8609701	Apr 22, 2029		U-1610		
	8648098	Jan 08, 2030		U-1611		
	8753679	Sep 22, 2026	DP	U-1602		
	8754109	Jan 08, 2030		U-1612		
	8778947	Aug 30, 2033		U-1613		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024		DP		
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5753675	May 19, 2015	DS DP	U-998	NCE	Aug 03, 2014
	5854259	Dec 29, 2015		DP		
	5856336	Dec 25, 2020	DS	U-998		
	6465477	Dec 20, 2016		DP		
	7022713	Feb 19, 2024		U-998		
	8557993	Feb 02, 2024	DS DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023		U-936	ODE	Dec 15, 2015
	7897590	Jul 22, 2023		U-936		
	RE42152	Dec 10, 2018		DP		
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 001					NCE	Mar 30, 2015
<u>POLIDOCANOL - ASCLERA</u>						
N 021201 002					NCE	Mar 30, 2015
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	6572873	May 26, 2020		U-1461		
	6846412	Jul 19, 2022		DP		
	6942165	May 26, 2020		DP		
	7025290	May 26, 2020		DP U-1461		
	7357336	May 26, 2020		U-1461		
	7604185	May 26, 2020	DS DP	U-1462		
	7731986	Nov 17, 2024	DS DP	U-1463		
	7814943	Nov 19, 2027		DP U-1461		
	7842282	May 26, 2020		U-1461		
	7842283	May 26, 2020		DP		
	8122917	Sep 09, 2024		DP		
	8323677	May 26, 2020	DS			
	8734833	May 26, 2020	DS DP			
	RE38919	Oct 14, 2014	DS DP			
	RE40640	Oct 14, 2015	DS DP	U-1462		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5635517	Jul 24, 2016		U-1359	NCE	Feb 08, 2018
	6045501	Aug 28, 2018		U-1361	ODE	Feb 08, 2020
	6315720	Oct 23, 2020		U-1361		
	6316471	Aug 10, 2016	DP	U-1360		
	6476052	Jul 24, 2016	DP	U-1360		
	6561976	Aug 28, 2018		U-1361		
	6561977	Oct 23, 2020		U-1361		
	6755784	Oct 23, 2020		U-1361		
	6908432	Aug 28, 2018		U-1361		
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024		U-1360		
	8204763	Aug 28, 2018		U-1361		
	8315886	Oct 23, 2020		U-1361		
	8589188	Aug 28, 2018		U-1361		
	8626531	Oct 23, 2020		U-1361		
	8673939	May 15, 2023		U-1360		
	8735428	May 15, 2023		U-1360		
	8828427	Jun 21, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5635517	Jul 24, 2016	U-1359		NCE	Feb 08, 2018
	6045501	Aug 28, 2018	U-1361		ODE	Feb 08, 2020
	6315720	Oct 23, 2020	U-1361			
	6316471	Aug 10, 2016	DP U-1360			
	6476052	Jul 24, 2016	DP U-1360			
	6561976	Aug 28, 2018	U-1361			
	6561977	Oct 23, 2020	U-1361			
	6755784	Oct 23, 2020	U-1361			
	6908432	Aug 28, 2018	U-1361			
	8158653	Aug 10, 2016	DP			
	8198262	Oct 19, 2024	U-1360			
	8204763	Aug 28, 2018	U-1361			
	8315886	Oct 23, 2020	U-1361			
	8589188	Aug 28, 2018	U-1361			
	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
					ODE	Dec 14, 2019
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	8114874	Dec 22, 2026	DS DP		NCE	Dec 14, 2017
					ODE	Dec 14, 2019
<u>POSACONAZOLE - NOXAFIL</u>						
N 022003 001	5661151	Jul 19, 2019	DS DP U-760			
	5703079	Aug 26, 2014	DS DP U-760			
	6958337	Oct 05, 2018	DS DP U-760			
	8263600	Apr 01, 2022	DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	6028071	Jul 16, 2022	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	6028071	Jul 16, 2022	DS DP U-1004		NCE	Sep 24, 2014
	7622470	May 31, 2025	U-1015		ODE	Sep 24, 2016
	8299078	May 31, 2025	U-1004			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 001	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 002	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 003	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 005	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 006	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N 020667 007	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 001	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 002	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			
<u>PRAMLINTIDE ACETATE - SYMLIN</u>						
N 021332 003	5686411	Mar 16, 2019	DS DP U-638			
	5814600	Sep 29, 2015	U-637			
	5814600	Sep 29, 2015	U-638			
	5814600	Sep 29, 2015	U-639			
	6114304	Sep 05, 2017	U-637			
	6114304	Sep 05, 2017	U-640			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991		NCE	Jul 10, 2014
	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 001					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 002					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 003					PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 001	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 002	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT</u>						
N 021959 003	6024981	Apr 09, 2018	DP	Y		
	6221392	Apr 09, 2018	DP	Y		
	6740341	Nov 24, 2019	DP			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	6488960	Mar 14, 2020	DP U-1267		M-128	Jul 26, 2015
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8168218	Jan 07, 2028	DP U-1269		M-128	Jul 26, 2015
	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>PREGABALIN - LYRICA</u>							
N 021446	001	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	002	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	003	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	004	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	005	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	006	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	007	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 021446	008	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>							
N 022488	001	6001876	Dec 30, 2018	U-55	Y	I-651	Jun 20, 2015
		6001876	Dec 30, 2018	U-819	Y		
		6197819	Dec 30, 2018	DS DP			
		RE41920	Dec 30, 2018	U-1250			
<u>PROGESTERONE - ENDOMETRIN</u>							
N 022057	001	7300664	Nov 17, 2019	U-856			
		7320800	Nov 17, 2019	U-856			
		7393543	Nov 17, 2019	DP U-880			
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>							
N 021416	001	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>							
N 021416	002	5681588	Oct 28, 2014				
<u>PROPAFENONE HYDROCHLORIDE - RYTHMOL SR</u>							
N 021416	003	5681588	Oct 28, 2014				
<u>PROPOFOL - DIPRIVAN</u>							
N 019627	002	5714520	Mar 22, 2015				
		5731355	Mar 22, 2015	U-217			
		5731356	Mar 22, 2015	U-218			
		5908869	Mar 22, 2015	U-270			
		8476010	Dec 01, 2024	DS DP			
		8476010*PED	Jun 01, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 001	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N 021438 002	6500454	Oct 04, 2021	DP			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>QUAZEPAM - DORAL</u>						
N 018708 001	7608616	Jun 03, 2028	U-1012			
<u>QUAZEPAM - DORAL</u>						
N 018708 003	7608616	Jun 03, 2028	U-1012			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 001	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 002	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 003	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 004	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUETIAPINE FUMARATE - SEROQUEL XR</u>						
N 022047 005	5948437	May 28, 2017	DP U-601			
	5948437	May 28, 2017	DP U-814			
	5948437	May 28, 2017	DP U-839			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 001	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 002	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 003	5684016	Nov 04, 2014	U-210			
<u>QUINAPRIL HYDROCHLORIDE - ACCUPRIL</u>						
N 019885 004	5684016	Nov 04, 2014	U-210			
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 001					NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RABEPRAZOLE SODIUM - ACIPHEX SPRINKLE</u>						
N 204736 002					NDF PED	Mar 26, 2016 Sep 26, 2016
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001	6635234	Jan 03, 2020	U-1405		NCE	May 15, 2018
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALOXIFENE HYDROCHLORIDE - EVISTA</u>						
N 020815 001	6458811	Mar 10, 2017	DS DP U-825		ODE	Sep 13, 2014
	6797719	Mar 10, 2017	DP			
	6894064	Mar 10, 2017	DP U-657			
	8030330	Mar 10, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NPP	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-900			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257		NDF	Dec 21, 2014
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP		NDF	Dec 20, 2016
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RAMELTEON - ROZEREM</u>						
N 021782 001	6034239	Jul 22, 2019	DS DP U-674			
<u>RAMIPRIL - ALTACE</u>						
N 019901 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 019901 004	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 001	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 002	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 003	7368469	Aug 30, 2020	U-871			
<u>RAMIPRIL - ALTACE</u>						
N 022021 004	7368469	Aug 30, 2020	U-871			
<u>RANOLAZINE - RANEXA</u>						
N 021526 001	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP	Y		
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			
<u>RANOLAZINE - RANEXA</u>						
N 021526 002	6303607	May 27, 2019	U-705			
	6369062	May 27, 2019	DP			
	6479496	May 27, 2019	U-705			
	6503911	May 27, 2019	DP			
	6525057	May 27, 2019	U-705			
	6562826	May 27, 2019	U-705			
	6617328	May 27, 2019	DP			
	6620814	May 27, 2019	U-705			
	6852724	May 27, 2019	U-705			
	6864258	May 27, 2019	U-705			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002	5453446	Feb 07, 2017	U-219		I-685	May 29, 2017
	6126968	Sep 18, 2016	DP			
	7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	6403567	Apr 10, 2022	DS DP U-869			
	6642210	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-116			
	7144872	Jun 22, 2019	DS DP U-869			
	7144872	Jun 22, 2019	DS DP U-870			
	7183264	Jun 22, 2019	DP U-116			
	7183264	Jun 22, 2019	DP U-869			
	7183264	Jun 22, 2019	DP U-870			
	7582617	Jun 22, 2019	U-1003			
	7655636	Jun 22, 2019	U-869			
	7655637	Jun 22, 2019	DS DP U-869			
	7683037	Jun 22, 2019	U-1042			
	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
	8470801	Jun 22, 2019	U-116			
	8536150	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	7351834	Jan 12, 2020	DS		I-667	Feb 25, 2016
	8637553	Jul 08, 2029	DS DP		NCE	Sep 27, 2017
	8680124	Jul 20, 2028	U-1506		ODE	Feb 25, 2020
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 001	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 002	5866591	Sep 10, 2017	DP			
<u>REMIFENTANIL HYDROCHLORIDE - ULTIVA</u>						
N 020630 003	5866591	Sep 10, 2017	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIBAVIRIN - VIRAZOLE</u>						
N 018859 001	6150337	Nov 21, 2017	U-400			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIBAVIRIN - REBETOL</u>						
N 020903 001	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
<u>RIBAVIRIN - REBETOL</u>						
N 020903 002	6172046	Sep 21, 2017	U-377			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-454			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-478			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-479			
	6472373	Sep 21, 2017	U-1014			
	6524570	Nov 01, 2016	U-499			
	6524570	Nov 01, 2016	U-1013			
<u>RIBAVIRIN - COPEGUS</u>						
N 021511 001					NPP	Aug 09, 2014
<u>RIBAVIRIN - REBETOL</u>						
N 021546 001	6172046	Sep 21, 2017	U-521			
	6172046	Sep 21, 2017	U-1014			
	6177074	Nov 01, 2016	U-1013			
	6461605	Nov 01, 2016	U-521			
	6461605	Nov 01, 2016	U-1013			
	6472373	Sep 21, 2017	U-521			
	6524570	Nov 01, 2016	U-1013			
	6790837	Apr 05, 2023	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029			U-1121	
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS		U-1526	
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	7045620	Jun 19, 2024	DS		ODE	Mar 24, 2017
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029			U-1481	
	8741904	Feb 27, 2026	DS		U-1526	
	8829017	Jul 24, 2029			U-1562	
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7125879	Apr 14, 2023	DS DP U-1307			
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	6743798	Jul 16, 2019	DS DP		NCE	Oct 08, 2018
	7173037	Apr 25, 2023	DS DP		ODE	Oct 08, 2020
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 001	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 002	6165513	Jun 10, 2018				
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 003	5994329	Jul 17, 2018		U-353		
	6015801	Jul 17, 2018		U-353		
	6165513	Jun 10, 2018	DP			
	6432932	Jul 17, 2018		U-595		
	6465443	Aug 14, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 004	6165513	Jun 10, 2018	DP			
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	6165513	Jun 10, 2018	DP			
	7192938	May 06, 2023		U-353		
	7718634	May 06, 2023		U-662		
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 020588 001	5453425	Jul 11, 2014	DP			
	RE39181	Jul 11, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 001	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 002	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 003	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
	6667061	May 25, 2020	DP			
<u>RISPERIDONE - RISPERDAL CONSTA</u>						
N 021346 004	5688801	Nov 18, 2014		U-543		
	5688801	Nov 18, 2014		U-972		
	5792477	May 02, 2017	DP			
	5916598	May 02, 2017	DP			
	6194006	Dec 30, 2018	DP			
	6379703	Dec 30, 2018	DP			
	6403114	May 02, 2017	DP			
	6596316	Dec 30, 2018	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 001	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 002	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 003	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 004	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			
<u>RISPERIDONE - RISPERDAL</u>						
N 021444 005	5648093	Jul 15, 2014	DP			
	6224905	Jun 10, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N 020659 001	5648497	Jul 15, 2014				
	6037157	Jun 26, 2016				
	6703403	Jun 26, 2016	U-564			
<u>RITONAVIR - NORVIR</u>						
N 020680 001	5648497	Jul 15, 2014				
<u>RITONAVIR - NORVIR</u>						
N 020945 001	5648497	Jul 15, 2014				
	6037157	Jun 26, 2016	U-895			
	6232333	Nov 07, 2017				
	6703403	Jun 26, 2016	U-564			
	7141593	May 22, 2020	DP			
	7432294	May 22, 2020	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	5648497	Jul 15, 2014	DS			
	6037157	Jun 26, 2016	U-688			
	6703403	Jun 26, 2016	U-688			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP U-688			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8470347	Sep 17, 2026	DP			
	8470347*PED	Mar 17, 2027				
	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Feb 08, 2021	DS DP U-1301		I-660	Nov 02, 2015
	7157456	Feb 08, 2021	DS DP U-1302		I-661	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1200			
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Feb 08, 2021	DS DP U-1301		I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP U-1302		I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-661	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1200		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Feb 08, 2021	DS DP U-1301		I-643	Nov 04, 2014
	7157456	Feb 08, 2021	DS DP U-1302		I-660	Nov 02, 2015
	7585860	Dec 11, 2020	DS U-1303		I-661	Nov 02, 2015
	7592339	Dec 11, 2020	U-1167		I-662	Nov 02, 2015
	7592339	Dec 11, 2020	U-1200		NCE	Jul 01, 2016
	7592339	Dec 11, 2020	U-1301			
	7592339	Dec 11, 2020	U-1302			
	7592339	Dec 11, 2020	U-1303			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 001	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 002	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIVASTIGMINE - EXELON</u>						
N 022083 005	6316023	Jan 08, 2019	DP		NPP	Jun 27, 2016
	6335031	Jan 08, 2019	DP		NS	Aug 31, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N 020864 002					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N 020865 002					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>ROFECOXIB - VIOXX</u>						
N 021042 001	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 002	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021042 003	5691374 6063811	May 18, 2015 May 06, 2017	U-602			
<u>ROFECOXIB - VIOXX</u>						
N 021052 001	5691374 6063811	May 18, 2015 May 06, 2017	U-266			
<u>ROFECOXIB - VIOXX</u>						
N 021052 002	5691374 6063811	May 18, 2015 May 06, 2017	U-266			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298 8431154 8536206 8604064 8618142	Jan 27, 2015 Feb 19, 2023 Mar 08, 2024 Mar 08, 2024 Mar 08, 2024	DS DP U-1115 DP U-1115 U-1115 DP		NCE	Feb 28, 2016
<u>ROMIDEPSIN - ISTODAX</u>						
N 022393 001	7608280 7611724	Aug 22, 2021 Aug 22, 2021	DS DS		NCE ODE ODE	Nov 05, 2014 Nov 05, 2016 Jun 16, 2018
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 001	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 002	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 003	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 004	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 005	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N 022008 006	7927624 8303986	Dec 02, 2021 Apr 12, 2021	DP U-20 DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	5670524	Sep 23, 2014	DS DP U-833			
	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 003	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 004	5670524	Sep 23, 2014	DS DP U-833			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 005	5670524	Sep 23, 2014	DS DP U-833			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	5741803	Apr 21, 2015	DS DP U-329	Y		
	5741803	Apr 21, 2015	DS DP U-628	Y		
	6288095	Feb 11, 2017	U-420	Y		
	7358366	Apr 19, 2020	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005	6316460	Aug 04, 2020	DP			
	6858618	Dec 17, 2021	U-618			
	7030152	Apr 02, 2018	U-1032			
	7964614	Apr 02, 2018	U-1032			
	RE37314	Jan 08, 2016	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	6699498	Nov 27, 2020	DP		I-646	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-647	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				
	8076362	Jun 08, 2018	DP			
	8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669	Nov 14, 2022	DS DP		ODE	Nov 14, 2015
	6740669*PED	May 14, 2023			PED	May 14, 2016
	7750028	Oct 19, 2018	U-106			
	7750028*PED	Apr 19, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257	Dec 24, 2027	DS DP U-1201		I-699	Dec 04, 2017
	7598257	Dec 24, 2027	DS DP U-1622		NCE	Nov 16, 2016
	8415362	Dec 24, 2027	DS DP		ODE	Nov 16, 2018
	8722693	Jun 12, 2028	DS DP		ODE	Dec 04, 2021
	8822481	Jun 12, 2028	U-1573			
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
<u>SALMETEROL XINAFOATE - SEREVENT</u>						
N 020692 001	5873360	Feb 23, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7612073	Nov 17, 2024	U-1010			
	8067416	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
<u>SAQUINAVIR - FORTOVASE</u>						
N 020828 001	6008228	Jun 06, 2015				
	6352717	Nov 16, 2019				
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 020628 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAQUINAVIR MESYLATE - INVIRASE</u>						
N 021785 001					M-61	Nov 30, 2015
					PED	May 30, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	7951400	Nov 30, 2028	DP		M-108	Dec 16, 2014
	RE44186	Jul 31, 2023	DS DP U-995		M-134	May 24, 2016
					NCE	Jul 31, 2014
<u>SELEGILINE - EMSAM</u>						
N 021336 001	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 002	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE - EMSAM</u>						
N 021336 003	7070808	May 10, 2018	DS DP			
	7150881	Jun 12, 2018	DS DP			
	7638140	May 10, 2018	DP			
<u>SELEGILINE HYDROCHLORIDE - ZELAPAR</u>						
N 021479 001	5648093	Jul 15, 2014	DP			
	6423342	Mar 01, 2016	DP			
<u>SERTRALINE HYDROCHLORIDE - ZOLOFT</u>						
N 020990 001	6727283	Oct 11, 2019	DP U-580			
	7067555	Oct 11, 2019	DP			
	7067555*PED	Apr 11, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001	5667775	Sep 16, 2014	U-246			
	7985418	Oct 27, 2025	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 020926 001	5667775	Sep 16, 2014	U-246			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 001	5667775	Sep 16, 2014	U-246			
	6733780	Oct 18, 2020	DP			
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>						
N 021179 002	5667775	Sep 16, 2014	U-246			
	6733780	Oct 18, 2020	DP			
<u>SEVOFLURANE - ULTANE</u>						
N 020478 001	5990176	Jan 27, 2017				
	6074668	Jan 09, 2018				
	6288127	Jan 27, 2017				
	6444859	Jan 27, 2017				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 001	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 002	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N 020895 003	6469012	Oct 22, 2019	U-155			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					M-61	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILODOSIN - RAPAFLO</u>						
N 022206 001	5387603	Dec 01, 2018	DS DP			
<u>SILODOSIN - RAPAFLO</u>						
N 022206 002	5387603	Dec 01, 2018	DS DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	7671032	May 19, 2025	DS DP		I-697	Nov 05, 2017
	8148399	Sep 05, 2029	DS DP	U-1467	NCE	Nov 22, 2018
	8349869	Jul 28, 2026	DS DP	U-1467		
	8741926	Jul 28, 2026	DS	U-1467		
	8754106	Jul 28, 2026	DS	U-1467		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 001	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 002	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 003	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 004	6303661	Apr 24, 2017				U-1188
	6699871	Jul 26, 2022	DS DP			U-1188
	6890898	Feb 02, 2019				U-1189
	6890898	Feb 02, 2019				U-1190
	6890898	Feb 02, 2019				U-1191
	7078381	Feb 02, 2019				U-1188
	7125873	Jul 26, 2022	DP			U-1189
	7125873	Jul 26, 2022	DP			U-1190
	7125873	Jul 26, 2022	DP			U-1192
	7125873	Jul 26, 2022	DP			U-1193
	7326708	Apr 11, 2026	DS DP			U-1188
	7459428	Feb 02, 2019				U-1189
	8168637	Jun 26, 2022	DP			U-1188

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 005	6303661	Apr 24, 2017			U-1188	
	6699871	Jul 26, 2022	DS DP		U-1188	
	6890898	Feb 02, 2019			U-1189	
	6890898	Feb 02, 2019			U-1190	
	6890898	Feb 02, 2019			U-1191	
	7078381	Feb 02, 2019			U-1188	
	7125873	Jul 26, 2022	DP		U-1189	
	7125873	Jul 26, 2022	DP		U-1190	
	7125873	Jul 26, 2022	DP		U-1192	
	7125873	Jul 26, 2022	DP		U-1193	
	7326708	Apr 11, 2026	DS DP		U-1188	
	7459428	Feb 02, 2019			U-1189	
	8168637	Jun 26, 2022	DP		U-1188	
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343 006	6303661	Apr 24, 2017			U-1188	
	6699871	Jul 26, 2022	DS DP		U-1188	
	6890898	Feb 02, 2019			U-1189	
	6890898	Feb 02, 2019			U-1190	
	6890898	Feb 02, 2019			U-1191	
	7078381	Feb 02, 2019			U-1188	
	7125873	Jul 26, 2022	DP		U-1189	
	7125873	Jul 26, 2022	DP		U-1190	
	7125873	Jul 26, 2022	DP		U-1192	
	7125873	Jul 26, 2022	DP		U-1193	
	7326708	Apr 11, 2026	DS DP		U-1188	
	7459428	Feb 02, 2019			U-1189	
	8168637	Jun 26, 2022	DP		U-1188	
<u>SINCALIDE - KINEVAC</u>						
N 017697 001	6803046	Aug 16, 2022	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	5795911	Oct 31, 2020			U-172	
	5968973	Apr 10, 2017			U-172	
	7858662	Oct 02, 2026	DP		U-172	
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003	5989591	Mar 11, 2018	DP			
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004	5989591	Mar 11, 2018	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	6303661	Apr 24, 2017			U-774	
	6699871	Jul 26, 2022	DS DP		U-774	
	6890898	Feb 02, 2019			U-775	
	6890898	Feb 02, 2019			U-1036	
	6890898	Feb 02, 2019			U-1039	
	7078381	Feb 02, 2019			U-775	
	7078381	Feb 02, 2019			U-1036	
	7078381	Feb 02, 2019			U-1037	
	7078381	Feb 02, 2019			U-1038	
	7125873	Jul 26, 2022			U-775	
	7125873	Jul 26, 2022			U-1036	
	7125873	Jul 26, 2022			U-1037	
	7125873	Jul 26, 2022			U-1038	
	7326708	Apr 11, 2026	DS DP		U-802	
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP		ODE	Jan 14, 2018
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	8496973	Mar 29, 2031	DS DP	U-1419	ODE	Jan 14, 2018
	8568793	Dec 24, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
	7668730	Jun 16, 2024	U-1110			
	7765106	Jun 16, 2024	U-1069			
	7765107	Jun 16, 2024	U-1070			
	7851506	Dec 22, 2019	U-1101			
	7851506	Dec 22, 2019	U-1102			
	7895059	Dec 17, 2022	U-1110			
	8263650	Dec 22, 2019	DP U-1101			
	8263650	Dec 22, 2019	DP U-1102			
	8324275	Dec 22, 2019	U-1101			
	8324275	Dec 22, 2019	U-1102			
	8457988	Dec 17, 2022	U-1110			
	8589182	Dec 17, 2022	U-1110			
	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
	8859619	Dec 22, 2019	DP			
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	8496973	Mar 29, 2031	DS DP U-1419		ODE	Jan 14, 2018
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		NCE	Dec 06, 2018
	8334270	Mar 21, 2028	DS DP U-1470			
	8580765	Mar 21, 2028	DS DP U-1470			
	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 001	6017927	Nov 19, 2018	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE</u>						
N 021518 002	6017927	Nov 19, 2018	DS DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SAIZEN</u>						
N 019764 003	5898030	Apr 27, 2016	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 001	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 002	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 003	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 005	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 008	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 009	5716338	Feb 10, 2015	DP			
	6152897	Nov 20, 2018	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 010	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 011	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 012	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE</u>						
N 020280 013	5716338	Feb 10, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ</u>						
N 020522 001	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN AQ PEN</u>						
N 020522 002	5763394	Jun 09, 2015	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 001	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 002	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 003	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - SEROSTIM</u>						
N 020604 004	5898030	Apr 27, 2016	DP			
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 001	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 002	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NUTROPIN DEPOT</u>						
N 021075 003	5654010	Aug 05, 2014				
	5656297	Jul 25, 2014				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 001	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 002	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				
<u>SOMATROPIN RECOMBINANT - NORDITROPIN</u>						
N 021148 003	5849700	Dec 15, 2015		U-340		
	5849704	Dec 15, 2015				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 004	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 005	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 006	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	6235004	Jan 28, 2019	DP			
	RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
	6004297	Jan 28, 2019	DP			
	8841252	Dec 26, 2017	DP			
	RE41956	Jan 21, 2021	DP			
	RE43834	Jan 28, 2019	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 008	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 009	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 010	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - ZORBTIVE</u>						
N 021597 004	5898030	Apr 27, 2016	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	7235576	Jan 12, 2020	DS DP		I-677	Nov 22, 2016
	7351834	Jan 12, 2020	DS		ODE	Nov 16, 2014
	7897623	Jan 12, 2020	DP		ODE	Nov 22, 2020
	8124630	Jul 13, 2022		U-1459		
	8618141	Feb 11, 2023		U-1480		
	8877933	Dec 24, 2027	DS DP	U-1624		
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001					ODE	Jul 02, 2016

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jun 22, 2019	DP U-1105		NCE	Jan 18, 2016
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 001	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 002	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 003	7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453 004	7135465	Feb 18, 2023	DP U-167			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	6174442	Dec 19, 2016	DS U-1468		NP	Nov 27, 2016
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					NCE	Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	5891086	Jul 27, 2014	DP			
	5957886	Mar 08, 2016	DP			
	6135979	Mar 21, 2017	DP			
	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
	8343130	Oct 18, 2022	DP			
	8491524	Nov 21, 2022	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP		NDF	Jan 17, 2016
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			
	8597272	Apr 12, 2027	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154			
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 001	5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - PROTOPIC</u>						
N 050777 002	5665727	Sep 09, 2014	U-919			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003	6440458	Mar 25, 2019	DP		NDF	Jul 19, 2016
	6576259	Mar 25, 2019	DP U-1420			
	6884433	Mar 25, 2019	DP U-1420			
	8551522	Mar 25, 2019	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-1184			
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-1184			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	6943166	Apr 26, 2020	U-1184			
	7182958	Apr 26, 2020	DP U-155			
	7182958	Apr 26, 2020	DP U-1184			
<u>TADALAFIL - CIALIS</u>						
N 021368 002	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-614			
	7182958	Apr 26, 2020	DP U-155			
<u>TADALAFIL - CIALIS</u>						
N 021368 004	5859006	Nov 21, 2017	DS DP		I-641	Oct 06, 2014
	6140329	Jul 11, 2016	DP U-155		I-642	Oct 06, 2014
	6821975	Nov 19, 2020	DS DP U-533			
	6821975	Nov 19, 2020	DS DP U-614			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - ADCIRCA</u>						
N 022332 001	5859006	Nov 21, 2017	DS DP U-975		ODE	May 22, 2016
	6821975	Nov 19, 2020	DS DP			
	7182958	Apr 26, 2020	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
<u>TAMOXIFEN CITRATE - SOLTAMOX</u>						
N 021807 001	6127425	Jun 26, 2018	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 001	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 002	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 022304 003	6071970	Jun 06, 2017	U-931			
	7994364	Jun 27, 2025	DS DP U-931			
	RE39593	Aug 05, 2022	DS DP U-931			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 001	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	6071970	Jun 06, 2017	U-1178		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1276		NDF	Aug 25, 2014
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 203794 001	6071970	Jun 06, 2017	U-1289			
	7994364	Jun 27, 2025	DS DP U-1289			
	RE39593	Aug 05, 2022	DS DP U-1289			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	8808716	Feb 24, 2030	DP		NDF	May 11, 2015
<u>TECHNETIUM TC-99M APCITIDE - ACUTECT</u>						
N 020887 001	5645815	Jul 08, 2014				
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N 017858 001					ODE	Aug 13, 2019
<u>TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC</u>						
N 019928 001	6056941	Jul 28, 2019	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001	6409990	May 12, 2020	DS		I-687 NCE ODE	Jun 13, 2017 Mar 13, 2018 Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2015	DS DP U-1320		NCE	Dec 21, 2017
	7056886	Sep 18, 2022	DP U-1320		ODE	Dec 21, 2019
	7847061	Nov 01, 2025	U-1320			
<u>TELAPREVIR - INCIVEK</u>						
N 201917 001	7820671	Feb 25, 2025	DS DP		NCE	May 23, 2016
	8431615	May 30, 2028	U-1398			
	8529882	Aug 31, 2021	U-1398			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 001	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110 002	6635618	Sep 11, 2023	DS DP U-728		I-673	Jun 21, 2016
	6858584	Aug 24, 2022	DP		NCE	Sep 11, 2014
	6872701	Jun 05, 2021	DP			
	7008923	May 06, 2021		U-1005		
	7208471	May 01, 2021	DS DP			
	7351691	May 01, 2021	DS DP U-728			
	7531623	Jan 01, 2027	DS			
	7544364	May 01, 2021	DP			
	7700550	May 01, 2021		U-282		
	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N 022011 001	6395716	Aug 10, 2019		U-782	M-124	Jan 28, 2016
	6444652	Aug 10, 2019		U-782		
	6566344	Aug 10, 2019		U-782		
	6569837	Oct 25, 2020		U-782		
	6569837	Oct 25, 2020		U-999		
	7589079	Sep 11, 2023	DS DP U-999			
	7795238	Aug 10, 2019		U-999		
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELBIVUDINE - TYZEKA</u>						
N 022154 001	6395716	Aug 10, 2019		U-999	M-124	Jan 28, 2016
	6444652	Aug 10, 2019		U-999		
	6566344	Aug 10, 2019		U-999		
	6569837	Oct 25, 2020		U-999		
	7795238	Aug 10, 2019		U-999		
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 001	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELITHROMYCIN - KETEK</u>						
N 021144 002	5635485	Apr 01, 2018	DS DP U-578			
	D459798	Sep 24, 2015	DP			
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TELMISARTAN - MICARDIS</u>						
N 020850 001	6358986	Jan 10, 2020				
<u>TELMISARTAN - MICARDIS</u>						
N 020850 002	6358986	Jan 10, 2020				
	7998953	Jun 06, 2020		U-1177		
	8003679	Oct 06, 2022		U-1176		
<u>TELMISARTAN - MICARDIS</u>						
N 020850 003	6358986	Jan 10, 2020				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y	M-61	May 30, 2015
	5362718*PED	Aug 15, 2019			PED	Nov 30, 2014
	8026276	Jan 20, 2026	DP		PED	Nov 30, 2015
	8299116	Jul 25, 2023	DP			
	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 002	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 003	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 021356 004	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N 022577 001	5922695	Jul 25, 2017	DS U-248		M-128	Jul 24, 2016
	5922695	Jul 25, 2017	DS U-250		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-999		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946	Jul 25, 2017	DS DP U-1275			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-1275			
<u>TERBINAFINE - LAMISIL</u>						
N 020846 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFINE - LAMISIL AT</u>						
N 021958 001	5681849	Oct 28, 2014	DP			
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 001	5681849	Oct 28, 2014				
<u>TERBINAFINE HYDROCHLORIDE - LAMISIL AT</u>						
N 021124 002	5681849	Oct 28, 2014				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			
	8802735	Sep 14, 2030	DP			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	5679709	Oct 21, 2014	DP U-1285		NCE	Sep 12, 2017
	6794410	Apr 15, 2022	U-1285			
	8802735	Sep 14, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	6770623	Dec 08, 2018	DP U-597			
	6977077	Aug 19, 2019	U-597			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-790			
	7351414	Aug 19, 2019	U-865			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	6770623	Dec 08, 2018	DP U-982			
	6977077	Aug 19, 2019	U-982			
	6977077	Aug 19, 2019	U-994			
	7144861	Dec 08, 2018	DP			
	7163684	Aug 19, 2019	U-983			
	7163684	Aug 19, 2019	U-994			
	7351414	Aug 19, 2019	U-984			
	7351414	Aug 19, 2019	U-994			
	7517334	Mar 25, 2025	DP			
	7550434	Dec 08, 2018	DP U-982			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 001	5840327	Aug 15, 2016				
<u>TESTOSTERONE - TESTODERM</u>						
N 019762 002	5840327	Aug 15, 2016				
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 003					NS	Oct 20, 2014
<u>TESTOSTERONE - ANDRODERM</u>						
N 020489 004					NS	Oct 20, 2014
<u>TESTOSTERONE - TESTODERM TTS</u>						
N 020791 001	6348210	Nov 10, 2019	U-440			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	6503894	Aug 30, 2020	U-490			
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025	U-843			
	7608605	Apr 21, 2023	U-1009			
	7608606	Apr 21, 2023	U-1009			
	7608607	Apr 21, 2023	U-1009			
	7608608	Apr 21, 2023	U-1009			
	7608609	Apr 21, 2023	U-1009			
	7608610	Apr 21, 2023	U-1009			
	7935690	Apr 21, 2023	U-1009			
	8063029	Apr 21, 2023	U-843			
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - FORTESTA</u>						
N 021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - STRIANT</u>						
N 021543 001	6248358	Aug 23, 2019	U-527			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	6299900	Feb 19, 2017	DP U-1103			
	6818226	Feb 19, 2017	DP U-1103			
	6923983	Feb 19, 2017	DP U-1103			
	8071075	Feb 19, 2017	DP U-1103			
	8419307	Feb 26, 2027	U-1386			
	8435944	Jul 05, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 202763 001					NP	Feb 14, 2015
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 001					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 002					NP	Jan 31, 2016
<u>TESTOSTERONE - TESTOSTERONE</u>						
N 203098 003					NP	Jan 31, 2016
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026	U-1500			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TETRABENAZINE - XENAZINE</u>						
N 021894	001				ODE	Aug 15, 2015
<u>TETRABENAZINE - XENAZINE</u>						
N 021894	002				ODE	Aug 15, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	6045501	Aug 28, 2018	U-371			
	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-442			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-371			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-371			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-371			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-371			
	6869399	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-732			
	6869399	Oct 23, 2020	U-733			
	6908432	Aug 28, 2018	U-371			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-371			
	7141018	Oct 23, 2020	U-731			
	7141018	Oct 23, 2020	U-732			
	7141018	Oct 23, 2020	U-733			
	7230012	Dec 09, 2023	DP			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	6045501	Aug 28, 2018	U-731			
	6315720	Oct 23, 2020	U-731			
	6561976	Aug 28, 2018	U-731			
	6561977	Oct 23, 2020	U-731			
	6755784	Oct 23, 2020	U-731			
	6869399	Oct 23, 2020	U-731			
	6908432	Aug 28, 2018	U-731			
	7141018	Oct 23, 2020	U-731			
	7435745	Nov 03, 2017	U-899			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-1109			
	7959566	Oct 23, 2020	U-1155			
	8204763	Aug 28, 2018	U-1249			
	8315886	Oct 23, 2020	U-1249			
	8589188	Aug 28, 2018	U-1465			
	8626531	Oct 23, 2020	U-1465			
<u>THYROTROPIN ALFA - THYROGEN</u>						
N 020898 001	5840566	Nov 24, 2015			ODE	Dec 14, 2014

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 001	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 002	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 003	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 004	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TIAGABINE HYDROCHLORIDE - GABITRIL</u>						
N 020646 005	5866590	Apr 29, 2016				
	5958951	Jun 10, 2017				
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171			
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	RE40183	Apr 09, 2016	DS DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 001	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
N 020963 002	6174524	Mar 26, 2019	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6335335	Nov 02, 2018	DP			
	6645963	Nov 16, 2018	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	6777423	Sep 24, 2021	DS DP			
	6908928	Sep 24, 2021	DS DP U-566			
	6908928	Sep 24, 2021	DS DP U-762			
	7070800	Jan 22, 2022	DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7642268	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
	8022082	Jan 19, 2026	DP U-1186			
	RE38912	Oct 11, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-566			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP			
	6176242	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-1593			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPRANA VIR - APTIVUS</u>						
N 021814 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
	6231887	Jul 27, 2018	DP			
<u>TIPRANA VIR - APTIVUS</u>						
N 022292 001	5852195	Jun 22, 2019	DS			
	6147095	Oct 29, 2019		U-670		
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	May 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	5733919	Oct 23, 2016				
	5965581	Oct 23, 2016				
	5972967	Oct 23, 2016				
	5978698	Oct 08, 2017				
	6136794	Jan 29, 2019				
	6770660	Jun 01, 2023				
<u>TOBRAMYCIN - TOBI</u>						
N 050753 001	5508269	Oct 19, 2014	DP	U-909		
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	7097827	Apr 16, 2016	DP		NP	Mar 22, 2016
	7368102	Dec 19, 2022	DP	U-909		
	7442388	May 10, 2020	DP			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8349294	May 10, 2020	DP			
	8715623	Dec 19, 2022	DP	U-909		
<u>TOBRAMYCIN - BETHKIS</u>						
N 201820 001	6987094	Sep 22, 2022	DP			
	7696178	Mar 17, 2023	DP			
	7939502	Jun 14, 2022		U-1324		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	6956041	Dec 08, 2020	DP		M-135	Feb 21, 2017
	6965027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	7091208	Dec 08, 2020		U-247		
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 001	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLTERODINE TARTRATE - DETROL LA</u>						
N 021228 002	6630162	Nov 11, 2019	DP U-544			
	6770295	Aug 26, 2019	DP U-544			
	6911217	Nov 11, 2019	DP U-544			
	6911217*PED	May 11, 2020				
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020		U-978		
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002	5998380	Oct 13, 2015	U-598		NPP	Jul 15, 2014
	6503884	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003	5998380	Oct 13, 2015	U-598		NPP	Mar 28, 2017
	6503884	Oct 13, 2015	U-598			
	7018983	Oct 13, 2015	U-723			
	7125560	Mar 01, 2019	U-766			
	7498311	Oct 13, 2015	U-955			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Mar 18, 2029	DP U-106			
	8298580	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020671 001	5674872	Oct 07, 2014	U-910			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCANTIN</u>						
N 020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 001	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - ULTRAM</u>						
N 020281 002	6339105	Oct 12, 2019	U-435			
<u>TRAMADOL HYDROCHLORIDE - RYBIX ODT</u>						
N 021693 001	6106861	Dec 05, 2017	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 001	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 002	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 003	6607748	Jun 29, 2020	DP			
	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 001	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 002	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMADOL HYDROCHLORIDE - CONZIP</u>						
N 022370 003	7858118	Apr 11, 2022	DP U-1104			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	7378423	Sep 13, 2025	DS DP		I-678	Jan 08, 2017
	8580304	Jan 28, 2032	DP		NCE	May 29, 2018
	8835443	Sep 13, 2025		U-1581	ODE	May 29, 2020
	8835443	Sep 13, 2025		U-1582	ODE	Jan 08, 2021
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 001	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 002	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL - MAVIK</u>						
N 020528 003	5744496	Apr 28, 2015	U-229			
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 001	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 002	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 003	5721244	Feb 24, 2015				
<u>TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE - TARKA</u>						
N 020591 004	5721244	Feb 24, 2015				
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025		U-1182		
	8273795	Mar 04, 2025		U-1182		
	8487005	Mar 04, 2025	DP	U-1182		
	8791160	Mar 04, 2025	DP	U-1182		
	8809394	Mar 04, 2025	DP	U-1182		
<u>TRAVOPROST - TRAVATAN</u>						
N 021257 001	5631287	Dec 22, 2014	U-382			
	5849792	Dec 22, 2014	DP U-383			
	5889052	Dec 02, 2014	DP U-383			
	6011062	Dec 22, 2014	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994 001	5889052	Dec 02, 2014	DP U-383			
	8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 001	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 002	6607748	Jun 29, 2020	DP			
	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	5153222	Oct 06, 2014		U-455		
	6765117	Oct 24, 2017	DS			
	7999007	Mar 29, 2029	DP U-1437			
	8497393	Dec 15, 2028	DS			
	8653137	Sep 05, 2028		U-1437		
	8658694	Sep 05, 2028		U-1437		
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	5153222	Oct 16, 2014		U-1019	M-145	May 20, 2017
	6521212	Nov 13, 2018		U-1018	ODE	Jul 30, 2016
	6756033	Nov 13, 2018		U-1018		
	6765117	Oct 24, 2017	DS			
	8497393	Dec 15, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024		U-1475		
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	5153222	Oct 16, 2014		U-1475	NDF	Dec 20, 2016
	6765117	Oct 24, 2017	DS			
	7417070	Aug 30, 2026	DS			
	7544713	Jul 14, 2024				
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS			
	8747897	Oct 08, 2029	DP			
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 001	5955109	Sep 21, 2016	DP	U-134		
<u>TRETINOIN - RETIN-A MICRO</u>						
N 020475 002	5955109	Sep 21, 2016		U-134		
<u>TRETINOIN - RENOVA</u>						
N 021108 001	6531141	Mar 07, 2020				
<u>TRETINOIN - ATRALIN</u>						
N 022070 001	5670547	Sep 23, 2014	DP			
<u>TRIAMCINOLONE ACETONIDE - NASACORT ALLERGY 24 HOUR</u>						
N 020468 002	5976573	Jul 03, 2016	DP			
	6143329	Jul 03, 2016	DP			
	7977045	Jul 03, 2016	DP			
<u>TRIAMCINOLONE ACETONIDE - TRISENC</u>						
N 022048 001	6395294	Jan 13, 2020	DP	U-846		
	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029		U-1257		
	8211880	Mar 10, 2029		U-1258		
<u>TRIMETHOPRIM HYDROCHLORIDE - PRIMSQL</u>						
N 074973 001	5763449	Aug 07, 2016				
	5962461	Aug 07, 2016				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 001	6017922	May 18, 2018				
<u>TRIMETREXATE GLUCURONATE - NEUTREXIN</u>						
N 020326 002	6017922	May 18, 2018				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 020715 001	5776885	Jul 07, 2015				
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 021288 001	5776885	Jul 07, 2015	DP			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	5776885	Jul 07, 2015	DP			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 001	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 002	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - PRELAY</u>						
N 020719 003	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 001	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 002	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROGLITAZONE - REZULIN</u>						
N 020720 003	5859037	Nov 13, 2017	U-251			
	6011049	Nov 13, 2017	U-301			
<u>TROSPIMUM CHLORIDE - SANCTURA XR</u>						
N 022103 001	7410978	Feb 01, 2025	DP			
	7759359	Nov 04, 2024	U-1071			
	7763635	Nov 04, 2024	U-1071			
	7781448	Nov 04, 2024	U-1071			
	7781449	Nov 04, 2024	U-1071			
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 001	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TROVAFLOXACIN MESYLATE - TROVAN</u>						
N 020759 002	5763454	Jun 15, 2015	U-282			
	6187341	Jan 20, 2019				
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N 022278 001					ODE	Feb 20, 2016
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8426392	Jun 12, 2030	U-1389		NCE	Aug 13, 2015
	8512745	Feb 14, 2030	DP			
	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	5873360	Feb 23, 2016	DP		NP	Dec 18, 2016
	7439393	Sep 11, 2022	DS DP U-1476			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Nov 11, 2025	DP U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UNOPROSTONE ISOPROPYL - RESCULA</u>						
N 021214 001	6458836	Jul 09, 2021	U-333			
	6458836	Jul 09, 2021	U-1315			
	6770675	Nov 24, 2018	DP U-1322			
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 004	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - FERTINEX</u>						
N 019415 005	5767067	Jun 16, 2015				
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 001	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALACYCLOVIR HYDROCHLORIDE - VALTREX</u>						
N 020487 002	5879706	Jan 19, 2016	DP U-530			
	5879706	Jan 19, 2016	DP U-894			
	6107302	Jan 19, 2016	DS U-530			
	6107302	Jan 19, 2016	DS U-894			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 002	5633272	Feb 13, 2015	U-462			
<u>VALDECOXIB - BEXTRA</u>						
N 021341 003	5633272	Feb 13, 2015	U-462			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001	6083953	Mar 29, 2015	DS DP U-384			
	6083953	Mar 29, 2015	DS DP U-854			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	6083953	Mar 29, 2015	DS DP U-384			
	6083953	Mar 29, 2015	DS DP U-854			
	6083953*PED	Sep 29, 2015				
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALSARTAN - DIOVAN</u>						
N 021283 001	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 002	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 003	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VALSARTAN - DIOVAN</u>						
N 021283 004	5972990	Oct 26, 2016	U-692			
	6294197	Jun 18, 2017	U-3			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	8642608	Feb 06, 2022	U-1490			
	RE42353	Sep 23, 2017	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	8067427	Aug 08, 2028	DP		ODE	Apr 06, 2018
	8642608	Feb 06, 2022	U-1490			
	RE42353	Sep 23, 2017	DS DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	6362178	Oct 31, 2018	DS DP U-533			
	7696206	Oct 31, 2018	DS DP U-533			
	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	6362178	Oct 31, 2018	U-155			
	7696206	Oct 31, 2018	U-155			
	8613950	Dec 23, 2028	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56		M-143	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-144	Oct 15, 2017
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002	6410550	May 10, 2020	DS DP U-56		M-105	Jul 22, 2014
	6890927	May 06, 2022	DS DP U-56		M-143	Oct 15, 2017
	7265119	Aug 03, 2022	DS DP U-56		M-144	Oct 15, 2017
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 001					M-130	Nov 21, 2016
					NCE	Feb 26, 2015
<u>VELAGLUCERASE ALFA - VPRIV</u>						
N 022575 002					M-130	Nov 21, 2016
					NCE	Feb 26, 2015

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	7504509	Oct 22, 2026	DS DP		NCE	Aug 17, 2016
	7863288	Jun 20, 2029	DS DP		ODE	Aug 17, 2018
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026		U-1418		
	8741920	Jul 27, 2030	DS DP			
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 001	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 002	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 003	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - EFFEXOR XR</u>						
N 020699 004	6274171	Mar 20, 2017				
	6403120	Mar 20, 2017		U-451		
	6403120	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-459		
	6419958	Mar 20, 2017		U-535		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 001	6403120	Mar 20, 2017		U-535		
	6403120	Mar 20, 2017		U-839		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 002	6403120	Mar 20, 2017		U-535		
	6403120	Mar 20, 2017		U-839		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 003	6403120	Mar 20, 2017		U-535		
	6403120	Mar 20, 2017		U-839		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-839		
<u>VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE</u>						
N 022104 004	6403120	Mar 20, 2017		U-535		
	6403120	Mar 20, 2017		U-839		
	6419958	Mar 20, 2017		U-535		
	6419958	Mar 20, 2017		U-839		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 001	6096339	Apr 04, 2017		U-365		
<u>VERAPAMIL HYDROCHLORIDE - COVERA-HS</u>						
N 020552 002	6096339	Apr 04, 2017		U-365		
<u>VERTEPORFIN - VISUDYNE</u>						
N 021119 001	5707608	Aug 02, 2015				
	5756541	Mar 11, 2016		U-357		
	5770619	Jan 06, 2015		U-357		
	5798349	Aug 25, 2015		U-357		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VIGABATRIN - SABRIL</u>						
N 020427	001				NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					PED	Feb 21, 2015
					PED	Apr 26, 2017
<u>VIGABATRIN - SABRIL</u>						
N 022006	001				NCE	Aug 21, 2014
					NPP	Oct 26, 2016
					ODE	Aug 21, 2016
					PED	Feb 21, 2015
					PED	Feb 21, 2017
					PED	Apr 26, 2017
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	001	5532241	Sep 29, 2019	DS DP	NCE	Jan 21, 2016
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	002	5532241	Sep 29, 2019	DS DP	NCE	Jan 21, 2016
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567	003	5532241	Sep 29, 2019	DS DP	NCE	Jan 21, 2016
		7834020	Jun 05, 2022	DS DP U-839		
		8193195	Jun 05, 2022	U-839		
		8236804	Jun 05, 2022	U-839		
		8673921	Jun 05, 2022	DS DP		
<u>VINCISTINE SULFATE - MARQIBO KIT</u>						
N 020497	001	6723338	Mar 31, 2020	U-1271	NP	Aug 09, 2015
		7247316	Sep 25, 2020	DP	ODE	Aug 09, 2019
		7887836	Mar 31, 2020	U-1271		
<u>VISMODEGIB - ERIVEDGE</u>						
N 023388	001	7888364	Nov 11, 2028	DS DP	NCE	Jan 30, 2017
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 0204886	001	7235567	Jun 13, 2021	DS DP	NCE	May 08, 2019
		7304078	Apr 06, 2024	DS DP U-1512		
<u>VORICONAZOLE - VFEND</u>						
N 021266	001	5567817	May 24, 2016	DS DP U-540		
<u>VORICONAZOLE - VFEND</u>						
N 021266	002	5567817	May 24, 2016	DS DP U-540		
<u>VORICONAZOLE - VFEND</u>						
N 021267	001	5567817	May 24, 2016	DS DP U-540		
		6632803	Jun 02, 2018	DP		
<u>VORICONAZOLE - VFEND</u>						
N 021630	001	5567817	May 24, 2016	DS DP U-540		
<u>VORINOSTAT - ZOLINZA</u>						
N 021991	001	7399787	Feb 09, 2025	U-892		
		7456219	Mar 11, 2027	DS		
		7652069	Mar 04, 2023	DP		
		7732490	Mar 04, 2023	U-892		
		7851509	Feb 21, 2024	DP U-892		
		8067472	Mar 04, 2023	U-892		
		8093295	May 16, 2026	DP		
		8101663	Mar 04, 2023	U-892		
		8450372	Mar 18, 2028	U-892		
		RE38506	Jul 07, 2015	DS DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	7144884	Jan 09, 2023	DS DP U-1439		NCE	Sep 30, 2018
	8476279	Oct 02, 2022	DP U-1439			
	8722684	Nov 11, 2030	DS DP			
<u>ZANAMIVIR - RELENZA</u>						
N 021036 001	5648379	Jul 15, 2014		U-274		
	5648379	Jul 15, 2014		U-721		
	5648379	Jul 15, 2014		U-722		
	6294572	Dec 15, 2014	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	5364842	Dec 30, 2016		U-48		
	5364842	Dec 30, 2016		U-55		
	5795864	Jun 27, 2015	DP			
	8653033	Oct 01, 2024		U-48		
	8653033	Oct 01, 2024		U-55		
	8765680	Oct 01, 2024		U-48		
	8765680	Oct 01, 2024		U-55		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004	6150366	May 27, 2019	DP			
	6245766	Dec 18, 2018	U-601			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 021483 001	6150366	May 27, 2019	DP	U-719		
	6245766	Dec 18, 2018	U-601			
	7175855	May 18, 2020	DP			
<u>ZIPRASIDONE MESYLATE - GEODON</u>						
N 020919 001	6110918	Mar 26, 2017				
	6232304	Apr 01, 2017				
	6399777	Apr 01, 2017				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 002	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223 003	7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-53			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817 001	7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004	6750237	Nov 28, 2020	DP			
	7220767	Nov 28, 2020	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 001	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - AMBIEN CR</u>						
N 021774 002	6514531	Dec 01, 2019	DP			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	6761910	Sep 24, 2019	DP	U-674		
	8512747	Sep 24, 2019	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	7632517	Oct 01, 2017	U-70			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 001	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328 002	7658945	Apr 15, 2027	DP U-1194		NP	Nov 23, 2014
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 67

PATENT & EXCLUSIVITY ABBREVIATIONS

D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL
D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PHOPHYLAXIX AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

PATENT AND EXCLUSIVITY TERMS

ADB 2 of 67

EXCLUSIVITY DOSING SCHEDULE

D-34 EVERY FOUR MONTHS DOSAGE REGIMEN

D-35 FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS

D-36 FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY

D-37 DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)

D-38 CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION

D-39 CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."

D-40 ONCE-A-DAY DOSING REGIMEN

D-41 DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS

D-42 TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

D-43 INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD

D-44 IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED

D-45 ONCE DAILY DOSING FOR MAINTENANCE ONLY

D-46 NEW DOSING REGIMEN OF 80MG DAILY

D-47 PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL

D-48 ADMINISTRATION OF CISATRICURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL

D-49 PEDIATRIC DOSING GUIDELINES

D-50 INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS

D-51 OPTIONAL STARTING DOSE OF 40MG/DAY

D-52 ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY

D-53 USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE

D-54 USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS

D-55 ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)

D-56 ADDITION OF POSTPRANDIAL DOSING

D-57 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER

D-58 CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION

D-59 REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY

D-60 ADDITION OF A POST-OPERATIVE DOSING REGIMEN

D-61 ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

D-62 ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

D-63 TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE

D-64 INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML

D-65 CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS

D-66 DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI

D-67 SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES

D-68 CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

D-69 SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS

D-70 80MG ONCE DAILY DOSING REGIMEN

D-71 EIGHT WEEK DOSING REGIMEN

D-72 INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPAON

D-73 ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

D-74 ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

D-75 INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH

PATENT AND EXCLUSIVITY TERMS

ADB 3 of 67

EXCLUSIVITY DOSING SCHEDULE

NEW CYCLE

- D-76 FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
- D-77 ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
- D-78 USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
- D-79 NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
- D-80 CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
- D-81 NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-82 USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- D-83 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
- D-84 ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS (AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
- D-85 LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
- D-86 FOR USE IN SELECT EXTERNAL INSULIN PUMPS
- D-87 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-88 NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
- D-89 USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
- D-90 ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
- D-91 ALTERNATE INTERMITTENT DOSING REGIMEN
- D-92 ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
- D-93 ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
- D-94 NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFECIT HYPERACTIVITY DISORDER (ADHD)
- D-95 BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
- D-96 ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
- D-97 PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFPRE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
- D-98 DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
- D-99 ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
- D-100 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
- D-101 ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- D-102 NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
- D-103 NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
- D-104 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
- D-105 USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
- D-106 FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
- D-107 PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
- D-108 TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
- D-109 PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 67

EXCLUSIVITY DOSING SCHEDULE

D-110 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17

D-111 PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION

D-112 PROVIDES FOR PEDIATRIC PUMP USE

D-113 ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN

D-114 NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS

D-115 STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED

D-116 ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULFATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

D-117 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER

D-118 TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR

D-119 DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE

D-120 DOSING REGIMEN ADJUSTMENTS

D-121 CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION

D-122 USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

D-123 ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS

D-124 ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

D-125 EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.

D-126 CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG

D-127 DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE

D-128 SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO

D-129 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT -EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS

D-130 DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN

D-131 EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG

D-132 45MG FOR 6 MONTH ADMINISTRATION

D-133 NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE

D-134 INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY

D-135 UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE

D-136 ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS

D-137 NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS

D-138 80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

D-139 Additional information added to the Dosing and Administration section of the labeling regarding the administration of Bravelle and Menopur in the same syringe to ovulatory women as part of an ART cycle

D-140 REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY

D-141 DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA

D-142 DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE

D-143 INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG

D-144 LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION

D-145 UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 67

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEROSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS
I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 6 of 67

EXCLUSIVITY INDICATION

I-51 TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

I-52 PEDIATRIC EXCRETORY UROGRAPHY

I-53 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

I-54 RENAL CONCENTRATION CAPACITY TEST

I-55 HYPERTENSION

I-56 EROSIIVE GASTROESOPHAGEAL REFLUX DISEASE

I-57 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER

I-58 INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS

I-59 ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE

I-60 SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE

I-61 FEMALE ANDROGENETIC ALOPECIA

I-62 PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-63 ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION

I-64 PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS

I-65 PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

I-66 UNCOMPLICATED GONORRHEA

I-67 TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER

I-68 CENTRAL PRECOCIOUS PUBERTY

I-69 SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY

I-70 USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER

I-71 VARICELLA INFECTIONS (CHICKENPOX)

I-72 PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE

I-73 INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES

I-74 INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY

I-75 TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIIVE ESOPHAGITIS

I-76 PREVENTION OF OSTEOPOROSIS

I-77 DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM

I-78 CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY

I-79 MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM

I-80 DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE

I-81 PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS

I-82 TREATMENT OF TRAVELERS' DIARRHEA

I-83 ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN

I-84 INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION

I-85 TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

I-86 TREATMENT OF SECONDARY CARNITINE DEFICIENCY

I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN

I-88 MANAGEMENT OF ENDOMETRIOSIS

I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE

I-90 INTENSIVE CARE UNIT SEDATION

I-91 MONOTHERAPY USE FOR HYPERTENSION

I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE

I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS

I-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]

I-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

I-97 ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT

I-98 TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY

I-99 PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER

I-100 TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 7 of 67

EXCLUSIVITY INDICATION

I-101 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
 I-102 TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
 I-103 PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
 I-104 TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
 I-105 TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
 I-106 TREATMENT OF ACROMEGALY
 I-107 VAGINAL CANDIDIASIS
 I-108 EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
 I-109 TYPHOID FEVER
 I-110 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
 I-111 TREATMENT OF PAGET'S DISEASE OF BONE
 I-112 MANAGEMENT OF MODERATE TO SEVERE PAIN
 I-113 TREATMENT OF PROSTATITIS
 I-114 USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
 I-115 USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
 I-116 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
 I-117 TO SLOW THE PROGRESSION FO CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
 I-118 PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
 I-119 TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
 I-120 MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
 I-121 EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
 I-122 PSORIASIS OF THE SCALP
 I-123 RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
 I-124 LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
 I-125 EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
 I-126 ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY
 I-127 TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
 I-128 IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
 I-129 TREATMENT OF ALCOHOL DEPENDENCE
 I-130 MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
 I-131 PERIPHERAL ARTERIOGRAPHY
 I-132 TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
 I-133 MANAGEMENT OF CHRONIC STABLE ANGINA
 I-134 HEART FAILURE POST MYOCARDIAL INFARCTION
 I-135 BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
 I-136 IDIOPATHIC CHRONIC URTICARIA
 I-137 PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
 I-138 TREATMENT OF ACUTE RECURRENT GENITAL HERPES
 I-139 PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
 I-140 PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
 I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
 I-142 LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
 I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
 I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
 I-145 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
 I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS

PATENT AND EXCLUSIVITY TERMS

ADB 8 of 67

EXCLUSIVITY INDICATION

I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
 I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS
 WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO₂) IS LESS THAN OR EQUAL TO 55 TORR
 I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
 I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
 I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN
 PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
 I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE
 CORONARY EVENTS
 I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASES SPINAL AND CEREBRAL ORIGIN]
 I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
 I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH
 OR WITHOUT FINGERNAIL INVOLVEMENT
 I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
 I-157 TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
 I-158 TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
 I-159 FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE
 THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO
 CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
 I-160 TREATMENT OF BACTERIAL CORNEAL ULCERS
 I-161 TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
 I-162 FOR USE IN PATIENTS 6-11 YEARS OF AGE
 I-163 TREATMENT OF PHOTOPHOBIA
 I-164 CHRONIC BACTERIAL PROSTATITIS
 I-165 MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO
 HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE
 TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
 I-166 TREATMENT OF BULIMIA
 I-167 COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE)
 CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
 I-168 MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN
 COMBINATION WITH LHRH AGONISTS)
 I-169 USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT
 OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
 I-170 PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
 I-171 RELIEF OF SYMPTOMS OF THE COMMON COLD
 I-172 TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
 I-173 PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
 I-174 PELVIC INFLAMMATORY DISEASE
 I-175 TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
 I-176 TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT
 EXTRACTION
 I-177 TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE
 NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE
 ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
 I-178 TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF
 THE TOENAIL WITH A PULSE DOSING REGIMEN
 I-179 NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE
 OR KLEBSIELLA PNEUMONIAE
 I-180 TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
 I-181 TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY
 GENERALIZATION
 I-182 TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
 I-183 MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC
 PATIENTS AGES 6-11
 I-184 TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM
 OF 4MG)
 I-185 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 I-186 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY
 PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
 I-187 PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
 I-188 TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
 I-189 TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
 I-190 PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE
 EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE
 BREAST MASS

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 67

EXCLUSIVITY INDICATION

I-191 ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING

I-192 THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION

I-193 TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY

I-194 CONGESTIVE HEART FAILURE

I-195 FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER

I-196 ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

I-197 MAINTENANCE OF HEALING OF DUODENAL ULCER

I-198 FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER

I-199 MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYL UREAS IN THE TREATMENT OF TYPE II DIABETES

I-200 TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR

I-201 EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS

I-202 SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA

I-203 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-204 USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-205 INITIAL ANTICONSULSANT TREATMENT OF STATUS EPILEPTICUS

I-206 TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE

I-207 FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS

I-208 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION

I-209 PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)

I-210 TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS

I-211 FOR USE IN PEDIATRIC POPULATION

I-212 TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME

I-213 TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY

I-214 TREATMENT OF OSTEOPOROSIS

I-215 PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS

I-216 FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-217 PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-218 USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)

I-219 USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET

I-220 TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH

I-221 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY

I-222 PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN

I-223 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS

I-224 FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS

I-225 USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

I-226 FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN

I-227 SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)

I-228 PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL

I-229 PRILOSEC (OMEPRazole), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 10 of 67

EXCLUSIVITY INDICATION

I-230 IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION

I-231 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY

I-232 TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY

I-233 PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY

I-234 FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER

I-235 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER

I-236 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-237 MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

I-238 ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS

I-239 TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

I-240 MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS

I-241 USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER

I-242 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS

I-243 USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS

I-244 REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER

I-245 TREATMENT OF ACUTE SINUSITIS

I-246 TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH

PATENT AND EXCLUSIVITY TERMS

ADB 11 of 67

EXCLUSIVITY INDICATION

PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY

I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY

I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES

I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES

I-277 TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA

I-278 TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)

I-279 TREATMENT OF POST-TRAUMATIC STRESS DISORDER

I-280 USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

I-281 INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-282 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY

I-283 TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS

I-284 TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE

I-285 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER

I-286 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III

I-287 USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH

I-288 CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE

I-289 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL

I-290 PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-291 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-292 TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

I-293 TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS

I-294 TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS

I-295 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS

I-296 LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY

I-297 SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-298 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA

I-299 USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM

I-300 PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE

I-301 TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS

I-302 TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME

I-303 INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS

I-304 TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV

PATENT AND EXCLUSIVITY TERMS

ADB 12 of 67

EXCLUSIVITY INDICATION

I-305 TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT
STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA

I-306 INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC
HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR
FAILURE

I-307 NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES

I-308 TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID
ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS

I-309 USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-310 REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR
CAUSES

I-311 ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE
3 TO 12 YEARS

I-312 FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR
HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-313 EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE

I-314 TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND
AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES

I-315 THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY
EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE
TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

I-316 TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND
REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF
DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID

I-317 PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER

I-318 FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR
HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

I-319 USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION
WITH HEMODIALYSIS

I-320 TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)

I-321 JUVENILE RHEUMATOID ARTHRITIS

I-322 USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS

I-323 COLORECTAL CANCER

I-324 REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS
WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING
RELAPSING-REMITTING MULTIPLE SCLEROSIS

I-325 PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION

I-326 GENERALIZED ANXIETY DISORDER

I-327 SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN
PATIENTS 5 YEARS AND OLDER

I-328 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE

I-329 UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS

I-330 MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME
HEARTBURN SYSTEMS IN PATIENTS WITH GERD

I-331 TREATMENT OF MODERATE ACNE VULGARIS

I-332 EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS
(EFTN)

I-333 TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR
(FORMERLY PITYROSPORUM ORBICULARE)

I-334 LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE
WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE

I-335 ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH
LENNOX-GASTAUT SYNDROME

I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY
CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR
PRESUMED OCULAR HISTOPLASMOSIS

I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME

I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA

I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS

I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5

I-341 BREAST CANCER COMBINATION THERAPY

I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN
THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING
CHRONIC BRONCHITIS AND EMPHYSEMA

I-343 USE OF COREG FOR SEVERE HEART FAILURE

I-344 ACNE VULGARIS

I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 13 of 67

EXCLUSIVITY INDICATION

I-346 TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
 I-347 TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
 I-348 LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
 I-349 ACUTE CORONARY SYNDROME
 I-350 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
 I-351 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
 I-352 ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
 I-353 TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
 I-354 MANAGEMENT OF POST HERPETIC NEURALGIA
 I-355 PREMENSTRUAL DYSPHORIC DISORDER
 I-356 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
 I-357 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
 I-358 TREATMENT OF PANIC DISORDER
 I-359 TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH THE MENOPAUSE
 I-360 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
 I-361 TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
 I-362 TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
 I-363 ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
 I-364 TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
 I-365 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
 I-366 PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
 I-367 COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS:METFORMIN,SULFONYLUREAS,REPAGLINIDE,OR THIAZOLIDINEDIONES
 I-368 USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
 I-369 PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
 I-370 TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
 I-371 HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
 I-372 NOSOCOMIAL PNEUMONIA
 I-373 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
 I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
 I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
 I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
 I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
 I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
 I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
 I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR
 I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
 I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
 I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
 I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

PATENT AND EXCLUSIVITY TERMS

ADB 14 of 67

EXCLUSIVITY INDICATION

MELLITUS

- I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING
- I-386 PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE
- I-387 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE
- I-388 WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS
- I-389 CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
- I-390 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL
- I-391 TO 2 YEARS OF AGE
- I-392 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL
- I-393 INFARCTION
- I-394 SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
- I-395 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART
- I-396 DISEASE,DIABETES,PERIPHERAL VESSEL DISEASE,STROKE HISTORY,OTHER CV DISEASE TO
- I-397 REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH,REDUCE NONFATAL MI &
- I-398 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT
- I-399 UNDERGO ESOPHAGECTOMY
- I-400 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECUR AFTER STEM CELL TRNSPLT
- I-401 OR RESIST TO INTERFERON ALPHA THERAPY.NO CONTROLLED TRIALS DEMONSTRATING A
- I-402 CLINICAL BENEFIT SUCH AS IMPROVE IN DISEASE RELATED SX OR INCREASED SURVIVAL
- I-403 CHRONIC BACTERIAL PROSTATITIS
- I-404 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING
- I-405 CORONARY REVASCULARIZATION PROCEDURES
- I-406 TO IMPROVE PHYSICAL FUNCTION
- I-407 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS
- I-408 BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
- I-409 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
- I-410 IDIOPATHIC SHORT STATURE
- I-411 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL
- I-412 ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
- I-413 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF
- I-414 ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
- I-415 LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
- I-416 DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
- I-417 USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE
- I-418 RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE
- I-419 PARTNER IN A HETEROSEXUAL COUPLE
- I-420 MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF
- I-421 MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED
- I-422 FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
- I-423 TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING
- I-424 REGIMEN
- I-425 PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS
- I-426 TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV
- I-427 SERONEGATIVE)
- I-428 IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
- I-429 (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER
- I-430 AN ACUTE MYOCARDIAL INFARCTION
- I-431 STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE
- I-432 AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-
- I-433 PANCREATOGRAPHY (ERCP)
- I-434 ESOPHAGEAL CANDIDIASIS
- I-435 USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- I-436 ASSOCIATED WITH CHRONIC BRONCHITIS
- I-437 EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE
- I-438 THIAZOLIDINEDIONE CLASS
- I-439 MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES
- I-440 ASSOCIATED WITH BIPOLAR I DISORDER
- I-441 ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES
- I-442 ASSOCIATED WITH BIPOLAR I DISORDER
- I-443 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM
- I-444 (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO
- I-445 SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
- I-446 SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL
- I-447 EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
- I-448 THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE
- I-449 UNCOMPLICATED PYELONEPHRITIS
- I-450 USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
- I-451 ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF

PATENT AND EXCLUSIVITY TERMS

ADB 15 of 67

EXCLUSIVITY INDICATION

ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS

I-419 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER

I-420 TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS

I-421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE

I-422 INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS

I-423 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

I-424 MANAGEMENT OF SECONDARY HYPERTHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS

I-425 FLOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER

I-426 TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM

I-427 TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM

I-428 FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED

I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER

I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE

I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)

I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

I-435 CHRONIC IDIOPATHIC CONSTIPATION

I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS

I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY

I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS

I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS

I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER

I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS

I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)

I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS

I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)

I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE

I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER

I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 67

EXCLUSIVITY INDICATION

RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT

I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN

I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)

I-454 MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CHRON'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS

I-455 MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)

I-456 TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR

I-457 TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS

I-458 USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)

I-459 NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN

I-460 TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER

I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED

I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE

I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION

I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME

I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER

I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS

I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES

I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION

I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER

I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN

I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE

I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE

I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER

I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN

I-475 PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY

I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS

I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE

I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS

I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES

I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE

I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES

I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS

I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION

PATENT AND EXCLUSIVITY TERMS

ADB 17 of 67

EXCLUSIVITY INDICATION

I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF
CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF
PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF
GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED
DISEASE
I-491 INFLUENZA PROPHYLAXIS
I-492 MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I
DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493 ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR
THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH
MIXED HYPERLIPIDEMIA
I-494 CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO
IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT
WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495 ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST
CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR
COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496 LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS
WHO HAVE OPEN EPIPHYSES
I-497 PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL
AFFECTIVE DISORDER
I-498 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499 USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH
ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF
PLATINUM-BASED THERAPY
I-500 FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA
PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS
WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502 FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE
RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH,
REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY
ANGIOPLASTY
I-503 TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504 TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON
SYNDROME
I-505 TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING
THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE
AND METHICILLIN-RESISTANT ISOLATES
I-506 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER
WITH JUVENILE MYOCLONIC EPILEPSY
I-507 ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND
GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH
HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508 PREMENSTRUAL DYSPHONIC DISORDER
I-509 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510 ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP)
I-511 ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512 ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513 ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514 ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515 PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516 PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS
OF AGE AND OLDER
I-517 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518 TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE
HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519 USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN
AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED
SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-520 USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A
THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED
ADEQUATE GLYCEMIC CONTROL

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 67

EXCLUSIVITY INDICATION

I-521 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY

I-522 TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.

I-523 USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE

I-524 GENERALIZED ANXIETY DISORDER (GAD)

I-525 USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS

I-526 TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS

I-527 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-528 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE

I-529 TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE

I-530 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER

I-531 MAINTENANCE TREATMENT OF SCHIZOPHRENIA

I-532 TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES

I-533 ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

I-534 EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECCURENCE OF VTE IN PATIENTS WITH CANCER

I-535 MANAGEMENT OF FIBROMYALGIA

I-536 FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME

I-537 LONG TERM TREATMENT OF PANIC DISORDER

I-538 SHORT TERM TREATMENT OF PANIC DISORDER

I-539 REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER

I-540 TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17

I-541 TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17

I-542 EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS

I-543 USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

I-544 ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY

I-545 ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

I-546 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

I-547 ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS

I-548 SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE

I-549 USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-550 TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE

I-551 TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

I-552 ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER

I-553 FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

I-554 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESES

I-555 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS

I-556 PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY

I-557 USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD

I-558 MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-559 ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF

PATENT AND EXCLUSIVITY TERMS

ADB 19 of 67

EXCLUSIVITY INDICATION

BIPOLAR DISORDER, MANIC OR MIXED

I-560 MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX

I-561 LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER

I-562 MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS

I-563 ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY

I-564 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-565 USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)

I-566 MANAGEMENT OF FIBROMYALGIA

I-567 INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS

I-568 USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR

I-569 TREATMENT OF CHRONIC HEPATITIS B

I-570 TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE

I-571 NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQUAMOUS NON-SMALL CELL LUNG CANCER

I-572 TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.

I-573 TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET

I-574 MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION

I-575 MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA

I-576 ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA

I-577 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

I-578 EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS

I-579 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION

I-580 INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN

I-581 TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

I-582 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

I-583 ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)

I-584 TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOID FOR AT LEAST 12 MONTHS

I-585 TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS

I-586 COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

I-587 ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION

I-588 ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION

I-589 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE

I-590 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)

I-591 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE

I-592 ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)

I-593 TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)

I-594 INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

I-595 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-596 USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-597 MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

I-598 TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING

I-599 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS

I-600 FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO

PATENT AND EXCLUSIVITY TERMS

ADB 20 of 67

EXCLUSIVITY INDICATION

	ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS
I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 67

EXCLUSIVITY INDICATION

PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER

I-638 FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.

I-639 TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE

I-640 MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS

I-641 TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-642 TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

I-643 REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.

I-644 MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)

I-645 MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

I-646 SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)

I-647 SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

I-648 TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION

I-649 TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY

I-650 TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY

I-651 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY

I-652 MANAGEMENT OF POSTHERPETIC NEURALGIA

I-653 TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS

I-654 MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE

I-655 TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE

I-656 MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

I-657 PLAQUE PSORIASIS OF THE SCALP

I-658 FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY

I-659 PLAQUE PSORIASIS OF THE BODY

I-660 TREATMENT OF DEEP VEIN THROMBOSIS

I-661 TREATMENT OF PULMONARY EMBOLISM

I-662 REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM

I-663 IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

I-664 TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY

I-665 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT) SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L

I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY

I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE

I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA- APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL

PATENT AND EXCLUSIVITY TERMS

ADB 22 of 67

EXCLUSIVITY INDICATION

- PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCL. METHICILLIN-SUSCEPTIBLE AND -RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
- I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
- I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
- I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
- I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
- I-679 RISK REDUCTION OF BLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
- I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
- I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
- I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
- I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
- I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
- I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
- I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
- I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
- I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
- I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
- I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
- I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
- I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
- I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
- I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
- I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
- I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
- I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
- I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
- I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSIONFREE SURVIVAL.

EXCLUSIVITY MISCELLANEOUS

- M-1 INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
- M-2 APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
- M-3 ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 67

EXCLUSIVITY MISCELLANEOUS

CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

M-4 CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD

M-5 INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION

M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION

M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION

M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY

M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING

M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

M-12 NEW LANGUAGE FOR PEDIATRIC USE

M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION

M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

M-15 LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA

M-16 CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT

M-17 INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE

M-18 INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)

M-19 INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER

M-20 LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME

M-21 COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR

M-22 CHANGE IN TIME TO ONSET OF ACTION

M-23 INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT

M-24 INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION

M-25 ADDITIONAL SAFETY & PK INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PKG INSERT

M-26 INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01

M-27 INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY

M-28 INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION

M-29 LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS

M-30 CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION

M-31 INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)

M-32 ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES

M-33 INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA

M-34 EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-35 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY

M-36 ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE

M-37 INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS

M-38 SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL

M-39 FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 67

EXCLUSIVITY MISCELLANEOUS

M-40 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS

M-41 REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"

M-42 ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION

M-43 INCLUSION OF RESULTS OF STUDY-"PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION

M-44 CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18

M-45 INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING - EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY

M-46 PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY

M-47 PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS

M-48 CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES

M-49 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN

M-50 NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION

M-51 INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY

M-52 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

M-53 FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT

M-54 INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL

M-55 INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.

M-56 INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL

M-57 CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS

M-58 CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS

M-59 RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS

M-60 CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WITH HYPERCHOLESTEROLEMIA

M-61 REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST

M-62 CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES

M-63 DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY

M-64 CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS

M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)

M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER

M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL

M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY

M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY

M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 25 of 67

EXCLUSIVITY MISCELLANEOUS

M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLSCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGAGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 67

EXCLUSIVITY MISCELLANEOUS

M-102 PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."

M-103 SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY

M-104 NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE

M-106 ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT

M-107 INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED,1-MONTH,BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516, ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".

M-108 CHANGES ARE BASED ON RESULTS FROM STUDY CV181057

M-109 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL

M-110 CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL

M-111 LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS

M-112 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS

M-113 LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS

M-114 CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)

M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES

M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008

M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL

M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

M-119 LABELING CHANGES REGARDING MISSED DOSES

M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS

M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43

M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL

M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS

M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE

M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086

M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004

M-128 CLINICAL TRIAL STUDY RESULTS

M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE

M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT

M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

PATENT AND EXCLUSIVITY TERMS

ADB 27 of 67

EXCLUSIVITY MISCELLANEOUS

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING

M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS

M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES

M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM

M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD

M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE

PATENT USE

U-1 PREVENTION OF PREGNANCY

U-2 TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA

U-3 TREATMENT OF HYPERTENSION

U-4 PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS

U-5 METHOD OF PRODUCING BRONCHODILATION

U-6 METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS

U-7 INCREASING CARDIAC CONTRACTILITY

U-8 ACUTE MYOCARDIAL INFARCTION

U-9 CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT

U-10 DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS

U-11 TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

U-12 METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION

U-13 A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT

U-14 ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES

U-15 METHOD OF LOWERING INTRAOCULAR PRESSURE

U-16 USE IN LUNG SCANNING PROCEDURES

U-17 TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS

U-18 METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS

U-19 TREATMENT OF INFLAMMATION

U-20 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT

U-21 TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS

U-22 METHOD OF COMBATING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS

U-23 METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE

U-24 METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST

U-25 REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 67

PATENT USE

U-26 REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27 DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28 CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29 CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30 CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31 INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32 PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33 TREATING VIRAL INFECTIONS IN A MAMMAL
U-34 TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35 TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36 METHODS OF TREATING BACTERIAL ILLNESSES
U-37 METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38 TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39 ANGINA PECTORIS
U-40 METHOD OF TREATMENT OF BURNS
U-41 METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42 ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43 MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44 RELIEF OF NAUSEA AND VOMITING
U-45 TREATMENT OF INFLAMMATION AND ANALGESIA
U-46 TREATMENT OF PANIC DISORDER
U-47 STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48 ANALGESIA
U-49 SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
U-50 USE IN TREATING INFLAMMATORY DERMATOSES
U-51 BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53 HYPERCALCEMIA OF MALIGNANCY
U-54 REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55 TREATMENT OF PAIN
U-56 AID TO SMOKING CESSATION
U-57 OPHTHALMIC USE OF NORFLOXACIN
U-58 METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59 METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60 NASAL ADMINISTRATION OF BUTORPHANOL
U-61 CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62 CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63 ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64 TREATMENT OF VIRAL INFECTIONS
U-65 METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66 TRIPHASIC REGIMEN
U-67 METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68 TREATMENT OF ACTINIC KERATOSIS
U-69 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70 TREATMENT OF TRANSIENT INSOMNIA
U-71 METHOD OF TREATMENT OF HEART FAILURE
U-72 TREATMENT OF MIGRAINE
U-73 METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74 METHOD OF PROVIDING HYPNOTIC EFFECT
U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78 ULCERATIVE COLITIS
U-79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
U-80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83 TREATMENT OF SEIZURES

PATENT AND EXCLUSIVITY TERMS

ADB 29 of 67

PATENT USE

U-84 A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
 U-85 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-86 METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
 U-87 METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
 U-88 TREATMENT OF MODERATE PLAQUE PSORIASIS
 U-89 TREATMENT OR PROPHYLAXIS OF EMESIS
 U-90 TREATMENT OF PYSCHOTIC DISORDERS
 U-91 ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
 U-92 TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
 U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT
 U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
 U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
 U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
 U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
 U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
 U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
 U-100 METHOD OF TREATING OCULAR INFLAMMATION
 U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
 U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
 U-103 TREATMENT OF OCULAR HYPERTENSION
 U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
 U-105 EMESIS
 U-106 TREATMENT OF EPILEPSY
 U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
 U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
 U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
 U-110 USE AS A RETRIEVABLE PERSSARY
 U-111 DIABETES
 U-112 CONTRACEPTION
 U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
 U-114 USE FOR INHIBITING BONE RESORPTION
 U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
 U-116 METHOD OF MYOCARDIAL IMAGING
 U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
 U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL
 U-119 TREATMENT OF NASAL HYPERSECRETION
 U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
 U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
 U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
 U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
 U-124 TREATMENT OF ACNE
 U-125 TREATMENT NEUROGENERATIVE DISEASES
 U-126 TREATMENT OF GASTRITIS
 U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
 U-128 METHOD FOR TREATMENT OF TUMORS
 U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
 U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
 U-131 PHOTODAMAGED SKIN
 U-132 INHIBITING HIV PROTEASE
 U-133 MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 67

PATENT USE

REDUCED-CALORIE DIET

U-134 TREATMENT OF ACNE VULGARIS

U-135 ANTITUMOR AGENT

U-136 PROCESS FOR WASTE NITROGEN REMOVAL

U-137 METHOD OF TREATING BACTERIAL VAGINOSIS

U-138 TREATMENT OF ALLERGIC RHINITIS

U-139 TREATMENT OF ALLERGIC REACTIONS

U-140 USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION

U-141 TREATMENT OF ULCERATIVE COLITIS

U-142 METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE

U-143 BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING

U-144 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS

U-145 BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS

U-146 METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS

U-147 DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$

U-148 DEVICE FOR COLLECTING A BREATH SAMPLE

U-149 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES

U-150 METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE

U-151 RELIEF OF SYMPTOMS OF THE COMMON COLD

U-152 METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER

U-153 TREATMENT OF INITIAL EPISODE GENITAL HERPES

U-154 METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER

U-155 TREATMENT OF ERECTILE DYSFUNCTION

U-156 METHOD OF PROVIDING ANESTHESIA

U-157 TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY

U-158 ANGINA

U-159 TREATMENT OF INTERSTITIAL CYSTITIS

U-160 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-161 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT

U-162 METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA

U-163 METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS

U-164 METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS

U-165 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

U-166 TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER

U-167 METHOD FOR TREATING HIV-1 INFECTION

U-168 METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

U-169 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING

U-170 METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

U-171 METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT

U-172 TREATMENT OF GENITAL WARTS

U-173 ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES

U-174 USE AS AN ANTIHISTAMINE AGENT

U-175 METHOD OF TREATING MALIGNANT TUMORS

U-176 METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES

U-177 FUNGICIDE

U-178 FACILITATED ADHERENCE OF AGENTS TO SKIN

U-179 ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT

U-180 TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION

U-181 PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 67

PATENT USE

U-182 USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
 U-183 TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
 U-184 TREATING ALLERGIC EYE DISEASES IN HUMANS
 U-185 METHOD OF TREATING HYPERTENSION
 U-186 METHOD FOR TREATING GI DISORDERS CAUSED BY H.PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
 U-187 THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
 U-188 TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
 U-189 ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
 U-190 USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
 U-191 METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
 U-192 USE IN TREATING ALLERGIC REACTIONS
 U-193 PSORIASIS
 U-194 TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
 U-195 METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
 U-196 TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
 U-197 USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
 U-198 TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
 U-199 METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
 U-200 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
 U-201 METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
 U-202 METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
 U-203 TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
 U-204 USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
 U-205 METHOD FOR TREATING HEARTBURN
 U-206 METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
 U-207 USE AS NASAL SPRAY
 U-208 VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
 U-209 VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
 U-210 METHOD OF TREATING CONGESTIVE HEART FAILURE
 U-211 USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
 U-212 METHOD OF TREATMENT OF PARKINSON'S DISEASE
 U-213 METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
 U-214 USE AS A BLOOD GLUCOSE-LOWERING AGENT
 U-215 TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
 U-216 TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
 U-217 METHOD OF PRODUCING ANESTHESIA
 U-218 METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
 U-219 TREATMENT OF PARKINSON'S DISEASE
 U-220 METHOD OF DIAGNOSIS
 U-221 SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
 U-222 METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
 U-223 TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
 U-224 CONTROLLING INTRAOCULAR PRESSURE
 U-225 METHOD FOR DELIVERY
 U-226 METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE

PATENT AND EXCLUSIVITY TERMS

ADB 32 of 67

PATENT USE

U-227 NASAL ADMINISTRATION
 U-228 ASTHMA
 U-229 CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
 U-230 PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
 U-231 USE IN PARKINSON'S DISEASE
 U-232 METHOD OF TREATING MIGRAINE
 U-233 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
 U-234 METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
 U-235 METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN
 COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE
 TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
 U-236 TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
 U-237 METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE
 PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
 U-238 IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF
 PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES
 UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
 U-239 TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING
 TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM
 COMPOUND AND BORIC ACID
 U-240 TREATMENT OF ACUTE MIGRAINE ATTACKS
 U-241 FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL
 ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM
 TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY
 CONDITIONS
 U-242 USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
 U-243 TOPICAL ADMINISTRATION
 U-244 PLATELET AGGREGATION INHIBITORS
 U-245 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
 U-246 PHOSPHATE BINDING
 U-247 TREATMENT OF RHEUMATOID ARTHRITIS
 U-248 TREATMENT OF HIV
 U-249 METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING
 AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
 U-250 TREATMENT OF HEPATITIS B INFECTION
 U-251 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II
 DIABETES
 U-252 METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
 U-253 ORAL TRANSMUCOSAL USE
 U-254 USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
 U-255 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH
 NARCOLEPSY
 U-256 TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV
 ANTIVIRAL AGENTS
 U-257 TREATMENT OF HIV INFECTION
 U-258 TREATMENT OF NEURODEGENERATIVE DISEASES
 U-259 TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
 U-260 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR
 HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR
 INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
 U-261 TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING
 FINASTERIDE
 U-262 TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
 U-263 METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF
 BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE
 MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
 U-264 METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF
 BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT
 THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
 U-265 USE AS LAXATIVE
 U-266 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND
 SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS;
 TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
 U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING
 FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE
 FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 67

PATENT USE

U-268 ACROMEGALY
 U-269 EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
 U-270 METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
 U-271 METHOD OF TREATING TUMORS
 U-272 METHOD OF TREATING CARCINOMA
 U-273 CUTANEOUS T-CELL LYMPHOMA
 U-274 ZANAMIVIR FOR INHALATION
 U-275 METHOD OF USE OF THE DRUG SUBSTANCE
 U-276 METHOD OF USE OF LEVOBUPIVACAINE
 U-277 NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
 U-278 METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
 U-279 METHOD OF USE OF THE APPROVED PRODUCT
 U-280 TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
 U-281 ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
 U-282 METHOD OF TREATING BACTERIAL INFECTIONS
 U-283 METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
 U-284 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
 U-285 DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
 U-286 DEPRESSION
 U-287 TREATMENT OR PREVENTION OF OSTEOPOROSIS
 U-288 THERAPY OF INFLUENZA
 U-289 TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
 U-290 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
 U-291 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
 U-292 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
 U-293 INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
 U-294 TREATMENT OF HYPERPIGMENTARY DISORDERS
 U-295 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-296 TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
 U-297 PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
 U-298 METHOD OF COMBATING BACTERIA IN A PATIENT
 U-299 TREATMENT OF ADENOMATOUS POLYPS
 U-300 INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
 U-301 USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
 U-302 TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
 U-303 METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
 U-304 A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
 U-305 METHODS FOR USING THE DRUG PRODUCT
 U-306 TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
 U-307 CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
 U-308 CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
 U-309 TREATING SJOEGREN SYNDROME
 U-310 TREATMENT OF XEROSTOMIA
 U-311 HORMONE REPLACEMENT
 U-312 PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
 U-313 TREATMENT OF CONGESTIVE HEART FAILURE
 U-314 METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY

PATENT AND EXCLUSIVITY TERMS

ADB 34 of 67

PATENT USE

U-315 METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
 U-316 METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
 U-317 METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
 U-318 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY
 FREQUENCY, URGENCY, OR URGE INCONTINENCE
 U-319 TREATMENT OF MICROBIAL INFECTIONS
 U-320 INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
 U-321 REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN
 PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
 U-322 TREATMENT OF ALZHEIMER'S DEMENTIA
 U-323 USE AS A BILE ACID SEQUESTRANT
 U-324 METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO
 PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
 U-325 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS,
 INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
 U-326 METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
 U-327 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC
 CONDITONS EMPLOYING OLANZAPINE
 U-328 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS
 INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
 U-329 USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION
 WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
 MELLITUS
 U-330 TREATMENT OF NAUSEA AND VOMITING
 U-331 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN
 THE EVENING OR AT NIGHT
 U-332 TREATMENT OR PREVENTION OF BRONCHOSPASM
 U-333 METHOD OF TREATING OCULAR HYPERTENSION
 U-334 TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
 U-335 USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND
 WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
 U-336 DIAGNOSTIC RADIOIMAGING
 U-337 USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
 U-338 METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED
 MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
 U-339 PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
 U-340 THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS
 GROWTH HORMONE SECRETION IN CHILDREN
 U-341 METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
 U-342 METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
 U-343 REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
 U-344 METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH
 ANOTHER HIV PROTEASE INHIBITOR
 U-345 RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR
 THE TREATMENT OF AN HIV INFECTION
 U-346 METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD
 FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450
 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
 U-347 METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
 U-348 METHOD OF USE FOR INHIBITING HIV INFECTION
 U-349 METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
 U-350 PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE
 TRANSCRIPTASE INHIBITOR
 U-351 INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
 U-352 INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE
 TRANSCRIPTASE INHIBITOR
 U-353 PREVENTION AND TREATMENT OF OSTEOPOROSIS
 U-354 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-
 LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY
 DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
 U-355 METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE
 VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
 U-356 DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
 U-357 USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF
 AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED
 NEOVASCULATURE IN THE EYE

PATENT AND EXCLUSIVITY TERMS

ADB 35 of 67

PATENT USE

U-358 DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER

U-359 METHOD OF USE OF VISICOL

U-360 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-361 MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY

U-362 USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS

U-363 METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011

U-364 TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011

U-365 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION

U-366 METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION

U-367 TREATMENT OF CARDIOVASCULAR DISORDERS

U-368 HEARTBURN

U-369 METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE

U-370 INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS

U-371 APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABILIZING PROSTAGLANDIN

U-383 METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION

U-384 TREATMENT OF CMV RETINITIS

U-385 TREATMENT OF PEPTIC ULCERS

U-386 TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA

U-387 TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS

U-388 SMOKING CESSATION AID APPLIED TO THE SKIN

U-389 SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS

U-390 METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)

U-391 USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER

U-392 TREATMENT OF PATIENTS FOR INFLAMMATION

U-393 MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

U-394 METHOD OF USE OF ALPHAGAN

U-395 METHOD OF USE OF ALPHAGAN P

U-396 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION

U-397 METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA

PATENT AND EXCLUSIVITY TERMS

ADB 36 of 67

PATENT USE

U-398 TREATMENT OF GENERALIZED ANXIETY DISORDER

U-399 IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS

U-400 USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS

U-401 USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS

U-402 TREATMENT OF ACTINIC KERATOSES

U-403 ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES

U-404 TREATMENT OF ALLERGIC CONJUNCTIVITIS

U-405 FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)

U-406 METHOD OF USE OF ATOVAQUONE AND PROGUANIL

U-407 METHOD OF TREATING OTOPATHY

U-408 FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION

U-409 METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE

U-410 METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION

U-412 TREATMENT OF TYPE 2 DIABETES

U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS

U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS

U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE

U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE

U-420 METHOD OF TREATMENT OF TYPE II DIABETES

U-421 USE FOR SEDATION

U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER

U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA

U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS

U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION

U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS

U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE

U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS

U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER

U-431 POSTTRAUMATIC STRESS DISORDER

U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE

U-433 USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS

U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF

PATENT AND EXCLUSIVITY TERMS

ADB 37 of 67

PATENT USE

ABOUT 25MG

U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION

U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE

U-439 TREATMENT OF OBESITY

U-440 METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE

U-441 METHOD OF TREATING MS BY ADMINISTERING COPAXONE

U-442 METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG

U-443 MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME

U-444 TREATMENT OF MIGRAINE

U-445 USE AS AN ANTIMYCOTIC AGENT

U-446 TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

U-447 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-448 METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-449 USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER

U-450 INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS, SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING

U-451 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-452 USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)

U-453 TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS

U-454 METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN

U-455 TREATMENT OF PULMONARY HYPERTENSION WITH UT-15

U-456 METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE

U-457 METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN

U-458 METHOD OF USE OF IMAGENT

U-459 TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER

U-460 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE

U-461 METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE

U-462 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA

U-463 VENOGRAPHY

U-464 PERIPHERAL ARTERIOGRAPHY

U-465 CT IMAGING OF THE HEAD

U-466 TREATMENT OF IRRITABLE BOWEL SYNDROME

U-467 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION

U-468 METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS

U-469 TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE

U-470 THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

U-471 METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS

U-472 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES

U-473 TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL

U-474 TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN

U-475 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO

PATENT AND EXCLUSIVITY TERMS

ADB 38 of 67

PATENT USE

ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-476 METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-477 METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA

U-478 METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B

U-479 METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY

U-480 CONTRAST AGENT FOR MRI

U-481 DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY

U-482 METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....

U-483 METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND

U-484 METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION

U-485 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-486 EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE

U-487 METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)

U-488 METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA

U-489 EXPECTORANT

U-490 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-491 METHOD OF DELIVERING A DRUG TO THE LUNG

U-492 METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID

U-493 TREATMENT OF TYPE 2 DIABETES MELLITUS

U-494 TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER

U-495 PERITONEAL DIALYSIS SOLUTION

U-496 METHOD FOR TREATING CHRONIC RENAL FAILURE

U-497 RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

U-498 INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST

U-499 METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION

U-500 USE AS AN ANTIHYPERTENSIVE AGENT

U-501 TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505 ULTRASOUND CONTRAST AGENT

U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..

U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES

U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA

U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA

PATENT AND EXCLUSIVITY TERMS

ADB 39 of 67

PATENT USE

U-514 PREVENTION OF OVULATION IN A WOMAN
U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY
U-516 METHOD OF TREATING A PSYCHOTIC DISEASE
U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS
U-518 OBSESSIVE COMPULSIVE DISORDER
U-519 POST OPERATIVE NAUSEA AND VOMITING
U-520 PREMENOPAUSAL OSTEOPOROSIS
U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA
U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL
U-524 METHOD OF TREATING DIARRHEA
U-525 METHOD OF TREATING PARASITIC INFECTIONS
U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION
U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE
U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES
U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES
U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
U-533 ERECTILE DYSFUNCTION
U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA
U-535 TREATMENT OF SOCIAL ANXIETY DISORDER
U-536 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-537 TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538 FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539 TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540 TREATMENT OF FUNGAL INFECTIONS
U-541 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542 METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543 TREATMENT OF SCHIZOPHRENIA
U-544 TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545 METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546 USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547 MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548 A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549 USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551 METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553 MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIODONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIODONTAL POCKETS
U-554 TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556 USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 67

PATENT USE

U-558 INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)

U-559 METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION; METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL

U-560 METHOD OF DECREASING PARATHYROID HORMONE LEVEL; METHOD OF TREATING HYPERPARATHYROIDISM

U-561 COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS

U-562 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA

U-563 MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS

U-564 TREATMENT OF HIV IN CONCOMITANT THERAPY

U-565 TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA

U-566 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

U-567 METHOD OF TREATING INFERTILITY

U-568 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION

U-569 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED

U-570 METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG

U-571 TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA

U-572 INTENSIVE CARE UNIT SEDATION

U-573 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-574 PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-575 LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.

U-576 ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.

U-577 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN

U-578 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.

U-579 TREATMENT OF EPILEPSY AND/OR MIGRAINE.

U-580 TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS

U-581 METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413

U-582 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762

U-583 METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928

U-584 SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY

U-585 TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS

U-586 AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH

U-587 USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION

U-588 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS

U-589 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 67

PATENT USE

U-590 METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955

U-591 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG

U-592 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

U-593 TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

U-594 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS

U-595 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-596 TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY

U-597 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE

U-598 PROPHYLACTIC TREATMENT OF MIGRAINE

U-599 METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS

U-600 A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN

U-601 TREATMENT OF BIPOLAR DISORDER

U-602 SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS

U-603 METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION

U-604 METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION

U-605 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS

U-606 USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLRECTAL CANCER

U-607 CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.

U-608 USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA

U-609 USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA

U-610 ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.

U-611 METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER

U-612 TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-613 REDUCTION OF SERUM PHOSPHATE

U-614 TREATMENT OF SEXUAL DYSFUNCTION

U-615 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)

U-616 MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER

U-617 TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)

U-618 USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.

U-619 TREATMENT OF MALIGNANT NEOPLASM

U-620 TREATMENT OF INSOMNIA

U-621 METHOD OF TREATING CANCER

U-622 TREATMENT OF VEGF MEDIATED OCULAR DISEASE.

U-623 SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

U-624 REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

U-625 ALLERGIC RHINITIS OR NASAL POLYPS

U-626 CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS

U-627 TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE

PATENT AND EXCLUSIVITY TERMS

ADB 42 of 67

PATENT USE

U-628 USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

U-629 METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE

U-630 TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN

U-631 TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN

U-632 METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING

U-633 METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR

U-634 METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL

U-635 TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS

U-636 TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

U-637 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST

U-638 TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN

U-639 TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE

U-640 USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA

U-641 USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION

U-642 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-643 THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE

U-644 TREATMENT OF SEASONAL ALLERGIC RHINITIS

U-645 TREATMENT OF ASTHMA

U-646 METHOD OF TREATING OTITIS

U-647 TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-648 THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN

U-649 A METHOD FOR TREATING A TUMOR DISEASE

U-650 TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS

U-651 TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)

U-652 TREATMENT OF CARDIAC ARRHYTHMIA

U-653 STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE

U-654 LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXEDIN OR ANALOG, SUCH AS EXENDIN-4

U-655 TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS

U-656 REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4

U-657 PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-658 TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER

U-659 TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN

U-660 TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE

U-661 TREATMENT OF SEIZURE DISORDER

U-662 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

U-663 THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS

U-664 TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION

U-665 METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING

U-666 METHOD OF TREATING ADHD

U-667 MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE

U-668 LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 67

PATENT USE

U-669 INDICATION OF TYPE II DIABETES
 U-670 TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
 U-671 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
 U-672 TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
 U-673 METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
 U-674 METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
 U-675 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
 U-676 METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
 U-677 A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
 U-678 METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
 U-679 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
 U-680 A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
 U-681 TREATMENT OF PRIMARY IGF-1 DEFICIENCY
 U-682 NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
 U-683 PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
 U-684 TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
 U-685 EXPECTORANT AND COUGH SUPPRESSANT
 U-686 EXPECTORANT AND NASAL DECONGESTANT
 U-687 REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
 U-688 TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
 U-689 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
 U-690 TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
 U-691 USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
 U-692 USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
 U-693 THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
 U-694 LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
 U-695 TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
 U-696 TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
 U-697 A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY
 U-698 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATEINTS WITH EUVOLEMIC HYONATREMIA
 U-699 NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
 U-700 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
 U-701 TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
 U-702 TOPICAL AEROSOL HAIR REGROWTH TREATMENT
 U-703 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
 U-704 METHOD OF ADMINISTERING INSULIN VIA INHALATION
 U-705 TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
 U-706 TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
 U-707 ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS

ADB 44 of 67

PATENT USE

U-708 TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

U-709 METHOD OF COMBATING BACTERIA IN A PATIENT

U-710 A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549

U-711 ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER

U-712 A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA

U-713 TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

U-714 TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM

U-715 FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER

U-716 THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER

U-717 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-718 TREATMENT OF FUNGAL INFECTIONS

U-719 TREATMENT OF PSYCHOSIS

U-720 TREATMENT OF NEUROLEPTIC DISEASES

U-721 TREATMENT OF INFLUENZA

U-722 PROPHYLAXIS OF INFLUENZA

U-723 PROPHYLACTIC TREATMENT OF MIGRAINE

U-724 METHOD OF TREATING SEIZURES

U-725 ALLERGIC RHINITIS AND URTICARIA

U-726 ALLERGIC RHINITIS

U-727 FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

U-728 METHOD FOR TREATING BACTERIAL INFECTION

U-729 TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-730 USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS

U-731 USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-732 ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)

U-733 MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE

U-734 FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS

U-735 METHOD OF TREATING CHRONIC IRON OVERLOAD

U-736 METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE

U-737 DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE

U-738 INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER

U-739 METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT

U-740 FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS

U-741 COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER

U-742 TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.

U-743 ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA

U-744 TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS

U-745 TREATMENT OR PREVENTION OF EMESIS

U-746 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT

U-747 PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-748 A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER

U-749 METHOD OF CONTRACEPTION

U-750 TREATMENT OF HIV-1 INFECTION IN ADULTS

U-751 ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA

U-752 SUNSCREEN

U-753 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES

U-754 USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA

U-755 TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN

PATENT AND EXCLUSIVITY TERMS

ADB 45 of 67

PATENT USE

PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

U-756 ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-757 USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL

U-758 TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

U-759 METHOD OF USE OF ADMINISTERING LEVOTHYROXINE

U-760 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-761 TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA

U-762 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

U-763 ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION

U-764 TREATMENT OF SCHIZOPHRENIA

U-765 METHOD OF TREATING ALLERGIC CONJUNCTIVITIS

U-766 TREATMENT OF SEIZURES

U-767 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

U-768 A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID

U-769 REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

U-770 LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-771 METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT

U-772 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS

U-773 PATHOLOGICAL HYPERSECRETORY CONDITIONS

U-774 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

U-775 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA

U-776 TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.

U-777 DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE

U-778 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-779 A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA

U-780 A METHOD FOR THE TREATMENT OF CANCER

U-781 FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY

U-782 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE

U-783 DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER

U-784 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)

U-785 USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY

U-786 PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS

U-787 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA

U-788 METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE

U-789 TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

U-790 FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS

U-791 GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)

U-792 TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS

U-793 FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 67

PATENT USE

DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
 U-794 CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS
 WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN
 USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
 U-795 METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
 U-796 METHOD OF TREATING DEPRESSION
 U-797 METHOD OF TREATING ANXIETY
 U-798 TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY
 ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF
 IBANDRONIC ACID
 U-799 METHOD FOR INHIBITING SEROTONIN UPTAKE
 U-800 TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS
 OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A
 TAXANE AND TRASTUZUMAB
 U-801 METHOD OF TREATING CANCER
 U-802 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL
 PEPTIDASE-IV INHIBITOR
 U-803 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL
 PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
 U-804 TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
 U-805 TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
 U-806 INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
 U-807 PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
 U-808 THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN
 PATIENTS 2 YEARS OF AGE AND OLDER
 U-809 TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
 U-810 METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
 U-811 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND
 TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
 U-812 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
 U-813 MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE
 PULMONARY DISEASE (COPD)
 U-814 TREATMENT OF SCHIZOPHRENIA
 U-815 TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND
 DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
 U-816 DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
 U-817 NASAL ADMINISTRATION OF CYANOCOBALAMIN
 U-818 TOPICAL TREATMENT OF ACNE VULGARIS
 U-819 MANAGEMENT OF FIBROMYALGIA
 U-820 IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH
 NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP
 DISORDER
 U-821 METHOD OF INHIBITING ENTHOHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A
 PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.
 U-822 USE IN LIPID MANAGEMENT
 U-823 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE
 TREATMENT OF UNCOMPLCATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN
 CHILDREN 6 TO 11 YEARS OF AGE
 U-824 METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
 U-825 USE FOR PREVENTION OF BREAST CANCER
 U-826 RELIEF OF MODERATE TO SEVERE PAIN
 U-827 USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
 U-828 PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD
 OF CONTRACEPTION
 U-829 TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
 U-830 TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
 U-831 METHOD OF ADMINISTERING LANREOTIDE ACETATE
 U-832 ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO
 VENIPUNCTURE OR INTRAVENOUS CANNULATION.
 U-833 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE
 AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF
 ROPIVACAINE
 U-834 INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS
 INDICATED FOR THE TREATMENT OF HIV INFECTION
 U-835 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN
 PATIENTS ONE YEAR OF AGE OR OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 47 of 67

PATENT USE

U-836 A METHOD FOR THE TREATMENT OF LEUKEMIAS
 U-837 GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
 U-838 METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
 U-839 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
 U-840 TREATMENT FOR TYPE 2 DIABETES MELLITUS
 U-841 INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
 U-842 INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
 U-843 METHOD FOR ADMINISTRATION OF TESTOSTERONE
 U-844 PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
 U-845 TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES
 U-846 USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
 U-847 ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
 U-848 ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
 U-849 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
 U-850 PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
 U-851 TREATMENT OF TYPE 2 DIABETES MELLITUS
 U-852 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
 U-853 TREATMENT OR PREVENTION OF EMESIS
 U-854 PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
 U-855 METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
 U-856 SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
 U-857 INHIBITION OF TRANSPLANT REJECTION
 U-858 PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIIVE ESOPHAGITIS
 U-859 EROSIIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
 U-860 FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
 U-861 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
 U-862 ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
 U-863 TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
 U-864 PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIIVE ESOPHAGITIS
 U-865 TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
 U-866 THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
 U-867 TREATMENT OF MIGRAINE
 U-868 METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
 U-869 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
 U-870 METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
 U-871 METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
 U-872 TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
 U-873 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
 U-874 METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

PATENT AND EXCLUSIVITY TERMS

ADB 48 of 67

PATENT USE

U-875 FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE

U-876 TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

U-877 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER

U-878 A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR

U-879 A METHOD OF TREATING OR PREVENTING ILEUS

U-880 ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN

U-881 TREATMENT OF NON-SMALL CELL LUNG CANCER

U-882 MANAGEMENT OF FIBROMYALGIA (FM)

U-883 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB

U-884 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

U-885 TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

U-886 ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

U-887 TREATMENT AND PREVENTION OF OSTEOPOROSIS

U-888 FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN

U-889 MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)

U-890 REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

U-891 USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE

U-892 TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)

U-893 CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE

U-894 TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER

U-895 TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-896 TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER

U-897 METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT

U-898 USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

U-899 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-900 INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION

U-901 PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING

U-902 USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)

U-903 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS

U-904 TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

U-905 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

U-906 PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS

U-907 FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER

U-908 PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS

U-909 TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-910 TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY

U-911 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE

U-912 SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-913 TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY

U-914 METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER

U-915 TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-916 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER

U-917 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS

PATENT AND EXCLUSIVITY TERMS

ADB 49 of 67

PATENT USE

U-918 TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-
RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS
INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL
OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA
OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING
PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF
PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO
ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL
ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS
BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE
HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT
AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND
TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF
AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE
HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT
AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE
MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR
GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR
GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION
IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL
GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
(GERD) FOR 4 WEEKS

U-952 USE AS AN ANALGESIC

U-953 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-954 CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE
TREATMENT OF ASYMPTOMATIC HYPERURICEMIA

U-955 PROPHYLACTIC TREATMENT OF MIGRAINE

U-956 TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE

U-957 A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR
PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE

U-958 METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT
COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION,
DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR

PATENT AND EXCLUSIVITY TERMS

ADB 50 of 67

PATENT USE

PT

U-959 METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHYLIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML

U-960 METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT

U-961 METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE

U-962 SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-963 PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-964 ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS

U-965 USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER

U-966 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)

U-967 A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC

U-968 A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-969 TREATMENT OF MIGRAINE

U-970 TOPICAL TREATMENT OF LICE INFESTATIONS

U-971 INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA

U-972 MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

U-973 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE

U-974 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

U-975 TREATMENT OF PULMONARY HYPERTENSION

U-976 IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES

U-977 TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE

U-978 METHOD OF TREATING HYPONATREMIA

U-979 RELIEF OF MUSCLE SPASM

U-980 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-981 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY

U-982 A METHOD OF TREATING OSTEOPOROSIS

U-983 METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE

U-984 METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE

U-985 TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)

U-986 TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR

U-987 TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

U-988 TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350

U-989 FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA

U-990 TREATMENT OF PROTOZOAL INFECTION

U-991 TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS

U-992 REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION

U-993 METHOD OF TREATING INFERTILITY

U-994 METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED

U-995 METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN

U-996 AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHLORESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA

U-997 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS

PATENT AND EXCLUSIVITY TERMS

ADB 51 of 67

PATENT USE

U-998 ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

U-999 TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

U-1000 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS

U-1001 METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION

U-1002 METHOD OF TREATING INFLAMMATORY CONDITIONS

U-1003 A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW

U-1004 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1005 METHOD OF TREATING A STAPHYLOCOCCAL INFECTION

U-1006 NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

U-1007 METHOD OF TREATING GOUT FLARES

U-1008 APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION

U-1009 METHOD FOR ADMINISTRATION OF TESTOSTERONE

U-1010 TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION

U-1011 USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

U-1012 METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION

U-1013 METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1014 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-1015 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

U-1016 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS

U-1017 A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS

U-1018 TREATMENT OF PULMONARY HYPERTENSION BY INHALATION

U-1019 TREATMENT OF PULMONARY HYPERTENSION

U-1020 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES

U-1021 SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER

U-1022 FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION

U-1023 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE

U-1024 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP

U-1025 TREATING FREQUENT HEARTBURN

U-1026 A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

U-1027 REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL

U-1028 A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY

U-1029 METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

U-1030 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

U-1031 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA

U-1032 USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS

U-1033 TOPICAL TREATMENT OF ACNE VULGARIS

U-1034 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS

U-1035 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1036 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

U-1037 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST

PATENT AND EXCLUSIVITY TERMS

ADB 52 of 67

PATENT USE

U-1038 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL
 U-1039 PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL
 U-1040 PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
 INHIBITION OF THROMBIN IN A PATIENT
 U-1041 TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
 U-1042 METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
 U-1043 MANAGEMENT OF MODERATE TO SEVERE PAIN
 U-1044 TOPICAL TREATMENT OF SCALP PSORIASIS
 U-1045 MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO
 HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
 U-1046 MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE
 DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
 U-1047 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
 U-1048 WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
 U-1049 PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK
 RECEIVING A RENAL TRANSPLANT
 U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS
 U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS
 U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED
 GASTRIC ULCER
 U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER
 U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON
 MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS
 U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2
 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND
 METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
 U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
 U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE
 U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS
 WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
 U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA
 U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID
 LEVELS
 U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
 U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE
 U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA
 U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
 U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY
 ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY
 ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
 U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY
 ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF
 DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
 U-1067 TREATMENT OF CANCER
 U-1068 TREATMENT OF ASTHMA
 U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE
 COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
 U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER
 PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL
 PHARMACY THAT MAINTAINS A CENTRAL DATABASE
 U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION
 U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A
 CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME
 U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD
 U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT
 U-1075 USE FOR THE TREATMENT OF ASTHMA
 U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC
 CONDITIONS ASSOCIATED WITH PROBLEM DROOLING
 U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED
 DISODIUM ADMINISTRATION
 U-1078 TREATMENT OF ACNE
 U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH
 TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
 U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT
 U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED

PATENT AND EXCLUSIVITY TERMS

ADB 53 of 67

PATENT USE

U-1082 INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION
WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF
CLUSTER HEADACHE EPISODES

U-1084 RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID
RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

U-1085 METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL
DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

U-1086 TREATMENT OF AUTOIMMUNE DISEASE

U-1087 DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC
CYSTOSCOPY

U-1088 RELIEF OF MUSCLE SPASM

U-1089 INHIBITION OF THROMBIN

U-1090 LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO
USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION

U-1091 ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER
WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA

U-1092 TREATMENT OF BREAST CANCER

U-1093 TREATMENT OF PSEUDOBULBAR AFFECT

U-1094 MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN

U-1095 METHOD OF TREATING OCULAR INFLAMMATION

U-1096 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

U-1097 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2
DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS
APPROPRIATE

U-1098 METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA

U-1099 TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL
NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA

U-1100 REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY

U-1101 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1102 METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY

U-1103 TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A
DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE

U-1104 USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN

U-1105 TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND
OLDER

U-1106 TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT

U-1107 TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT

U-1108 TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE

U-1109 TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN
CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE
EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)

U-1110 METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN
A COMPUTER SYSTEM FOR DISTRIBUTION

U-1111 NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE
PAIN

U-1112 METHOD OF MR IMAGING OF A MAMMAL

U-1113 TREATMENT AND PROPHYLAXIS OF INFLUENZA

U-1114 TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING
NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA

U-1115 TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD
ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

U-1116 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS

U-1117 TREATMENT OF BREAST CANCER

U-1118 USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING
CHRONIC BRONCHITIS AND EMPHYSEMA

U-1119 CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING

U-1120 TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE
ADMINISTER ONCE DAILY WITH EVENING MEAL

U-1121 METHOD OF TREATING TRAVELERS' DIARRHEA

U-1122 TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S.
PYOGENES

U-1123 TREATMENT OF ALCOHOL DEPENDENCE

U-1124 PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION

U-1125 METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

PATENT AND EXCLUSIVITY TERMS

ADB 54 of 67

PATENT USE

U-1126 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL

U-1127 TREATMENT OF PATENT DUCTUS ARTERIOSUS

U-1128 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (≥ 18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE

U-1129 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1130 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1131 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1132 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1133 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1134 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1135 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C

U-1136 SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1137 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1138 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1139 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1140 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1141 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1142 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1143 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1144 REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1145 REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1146 REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT

U-1147 TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C

U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN

U-1150 TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C

U-1151 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C

U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION

U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION

U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)

U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)

U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES

PATENT AND EXCLUSIVITY TERMS

ADB 55 of 67

PATENT USE

(URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER

U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER

U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER

U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP

U-1163 METHOD OF TREATING THROMBOSIS

U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION

U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS

U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA

U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN

U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME

U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN

U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE

U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION

U-1175 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION

U-1176 TREATMENT OR PREVENTION OF STROKE

U-1177 REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION

U-1178 RELIEF OF MODERATE TO SEVERE CHRONIC PAIN

U-1179 TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

U-1180 TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS

U-1181 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

U-1182 TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING

U-1183 A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN

U-1184 TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA

U-1185 TREATMENT OF OPIOID-INDUCED CONSTIPATION

U-1186 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE

U-1187 TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)

U-1188 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE

U-1189 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN

U-1190 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN

U-1191 METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)

U-1192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)

U-1193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH

PATENT AND EXCLUSIVITY TERMS

ADB 56 of 67

PATENT USE

BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)

U-1194 METHOD FOR TREATING INSOMNIA

U-1195 PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA

U-1196 RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

U-1197 METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY

U-1198 RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE

U-1199 TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

U-1200 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

U-1201 FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS

U-1202 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME

U-1203 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT

U-1204 TREATMENT OF UVEITIS

U-1205 TREATMENT OF MACULAR EDEMA

U-1206 DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX

U-1207 INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIIVE ESOPHAGITIS

U-1208 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-1209 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER

U-1210 USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)

U-1211 USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA

U-1212 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1213 TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER

U-1214 METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1215 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1216 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

U-1217 METHOD OF INCREASING HAIR GROWTH

U-1218 METHOD OF STIMULATING HAIR GROWTH

U-1219 METHOD OF INCREASING THE NUMBER OF HAIRS

U-1220 TREATMENT OF RENAL CELL CARCINOMA

U-1221 TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION

U-1222 TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS

U-1223 METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE

U-1224 REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE

U-1225 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS

U-1226 A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT

U-1227 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE

U-1228 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN

U-1229 TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS

U-1230 A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT

U-1231 TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS

U-1232 USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN

U-1233 TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH

PATENT AND EXCLUSIVITY TERMS

ADB 57 of 67

PATENT USE

FOOD

U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MOR ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY

PATENT AND EXCLUSIVITY TERMS

ADB 58 of 67

PATENT USE

SYSTEM

U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA

PATENT AND EXCLUSIVITY TERMS

ADB 59 of 67

PATENT USE

U-1316 A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

U-1317 TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1318 TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

U-1319 SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA

U-1320 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT

U-1321 TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS

U-1322 METHOD OF REDUCING OCULAR HYPERTENSION

U-1323 REDUCING THE RISK OF STROKE

U-1324 MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

U-1325 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

U-1326 METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE

U-1327 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION

U-1328 METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF

U-1329 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER

U-1330 METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1331 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1332 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1333 METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR

U-1334 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

U-1335 METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN

U-1336 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN

U-1337 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

U-1338 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN

U-1339 METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1340 METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1341 METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1342 METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1343 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN

U-1344 METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION

U-1345 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT

U-1346 USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE

PATENT AND EXCLUSIVITY TERMS

ADB 60 of 67

PATENT USE

U-1347 TREATMENT OF A SKIN DISORDER
 U-1348 TREATMENT OF OSTEOARTHRITIS
 U-1349 TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
 U-1350 TREATMENT OF ANKYLOSING SPONDYLITIS
 U-1351 TREATMENT OF ACUTE PAIN
 U-1352 TREATMENT OF PRIMARY DYSMENORRHEA
 U-1353 ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
 U-1354 INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
 U-1355 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
 U-1356 TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
 U-1357 TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
 U-1358 TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S.AUREUS
 U-1359 USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
 U-1360 USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
 U-1361 USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
 U-1362 TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
 U-1363 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
 U-1364 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
 U-1365 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
 U-1366 TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
 U-1367 METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
 U-1368 TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
 U-1369 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
 U-1370 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
 U-1371 REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
 U-1372 ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
 U-1373 METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
 U-1374 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
 U-1375 ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
 U-1376 TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
 U-1377 IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
 U-1378 TREATMENT OF A NITROGEN METABOLISM DISORDER
 U-1379 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
 U-1380 IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
 U-1381 USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
 U-1382 TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
 U-1383 DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
 U-1384 METHOD OF TREATING MULTIPLE SCLEROSIS
 U-1385 METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS

PATENT AND EXCLUSIVITY TERMS

ADB 61 of 67

PATENT USE

U-1386 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387 REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR
PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY
ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS
U-1388 TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE
HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH
MORNING AND EVENING MEALS
U-1389 ELLA IS AN PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR
THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR
SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390 A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN
NEED THEREOF
U-1391 METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392 METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-
INDUCED CONSTIPATION
U-1393 METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED
CONSTIPATION
U-1394 METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG+/-
10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395 USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED
CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE
AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396 TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN
COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR
ANASTROZOLE
U-1397 USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398 METHOD OF TREATING CHRONIC HEPATITIS C
U-1399 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO
DIVIDED DOSES
U-1400 FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS
FAMILIAL HYPERCHOLESTEROLEMIA
U-1401 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION
IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE
EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403 FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR
EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-
APPROVED TEST
U-1404 METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY
OPENING CIC CHANNELS
U-1405 THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406 TREATMENT OF MELANOMA
U-1407 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID
LEUKEMIA (PH + CML)
U-1408 TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409 TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410 TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411 THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT
OF OPIOID DEPENDENCE
U-1412 TREATMENT OF ATOPIC DERMATITIS
U-1413 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE
DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414 USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415 TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH
METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS
1 OR 2
U-1416 USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-
LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES
U-1417 USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E
MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419 TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420 METHOD OF ONCE A DAY ADMINISTRATION
U-1421 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422 METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT

PATENT AND EXCLUSIVITY TERMS

ADB 62 of 67

PATENT USE

U-1423 AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1424 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS

U-1425 SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1426 USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS

U-1427 ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

U-1428 TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA

U-1429 TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR

U-1430 TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS

U-1431 METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE

U-1432 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX

U-1433 IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

U-1434 TREATMENT OF PANCREATIC CANCER

U-1435 COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.

U-1436 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT

U-1437 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION

U-1438 ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

U-1439 METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION

U-1440 USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS

U-1441 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING

U-1442 SUBCUTANEOUS INJECTION OF METHOTREXATE

U-1443 ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1444 A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS

U-1445 METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION

U-1446 METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES

U-1447 TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA

U-1448 TREATING SEVERE HYPERTRIGLYCERIDEMIA

U-1449 METHOD OF ALLEVIATING A SKIN CONDITION

U-1450 TREATMENT OF ALLERGIC RHINITIS SYMPTOMS

U-1451 APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY

U-1452 METHOD FOR CHRONIC WEIGHT MANAGEMENT

U-1453 A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT

U-1454 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS

U-1455 TREATMENT OF PERIANAL WARTS

U-1456 TREATMENT OF MANTLE CELL LYMPHOMA

U-1457 A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM

U-1458 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1459 TREATMENT OF CARCINOMA OF THE THYROID

U-1460 TREATMENT OF HERPES LABIALIS

U-1461 A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

U-1462 A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT

PATENT AND EXCLUSIVITY TERMS

ADB 63 of 67

PATENT USE

SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE

U-1463 A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

U-1464 TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION

U-1465 USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE

U-1466 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER

U-1467 METHOD OF TREATING HEPATITIS C

U-1468 CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS

U-1469 USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

U-1470 FOR THE TREATMENT OF HEPATITIS C

U-1471 A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.

U-1472 INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES

U-1473 MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

U-1474 A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT

U-1475 USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).

U-1476 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

U-1477 USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE

U-1478 METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA

U-1479 INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1480 TREATMENT OF ADVANCED RENAL CELL CARCINOMA

U-1481 REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1482 DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN

U-1483 INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).

U-1484 COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)

U-1485 TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

U-1486 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER

U-1487 METHOD OF INCREASING EYELASH GROWTH

U-1488 USE OF TOPICAL DICLOFENAC FOR TREATING PAIN

U-1489 USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS

U-1490 FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE

U-1491 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

U-1492 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

U-1493 METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS

U-1494 SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE

U-1495 RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.

U-1496 METHOD TO TREAT HEMANGIOMA.

U-1497 NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT

U-1498 METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM

U-1499 MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

U-1500 TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

PATENT AND EXCLUSIVITY TERMS

ADB 64 of 67

PATENT USE

U-1501 PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
 U-1502 PROPHYLAXIS OF PULMONARY EMBOLISM
 U-1503 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
 U-1504 USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
 U-1505 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
 U-1506 TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
 U-1507 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
 U-1508 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
 U-1509 TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
 U-1510 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.
 U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA
 U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
 U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
 U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL
 U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.
 U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.
 U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.
 U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
 U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
 U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
 U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
 U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
 U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE
 U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
 U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
 U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
 U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
 U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE
 U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
 U-1530 USE OF ARIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
 U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE
 U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.
 U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.
 U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.
 U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.
 U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.
 U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.
 U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.
 U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.
 U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
 U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.
 U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
 U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR

PATENT AND EXCLUSIVITY TERMS

ADB 65 of 67

PATENT USE

CLAIM 23

- U-1544 TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
- U-1545 A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
- U-1546 FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
- U-1547 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
- U-1548 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
- U-1549 FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
- U-1550 METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
- U-1551 METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
- U-1552 FOR HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE)
- U-1553 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
- U-1554 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
- U-1555 MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1556 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
- U-1557 A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
- U-1558 FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
- U-1559 INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
- U-1560 A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
- U-1561 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
- U-1562 TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
- U-1563 A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
- U-1564 A METHOD OF TREATING GAUCHER'S DISEASE
- U-1565 METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
- U-1566 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
- U-1567 METHOD OF TREATING, AS INTITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARITAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
- U-1568 METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
- U-1569 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
- U-1570 TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
- U-1571 TREATMENT OF GAUCHER DISEASE TYPE 1
- U-1572 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
- U-1573 USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
- U-1574 A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
- U-1575 PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
- U-1576 TREATMENT OF LEUKEMIA
- U-1577 CONTROL OF SERUM PHOSPHOROUS LEVELS
- U-1578 TREATMENT OF ACUTE OTITIS MEDIA
- U-1579 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- U-1580 USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
- U-1581 IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.

PATENT AND EXCLUSIVITY TERMS

ADB 66 of 67

PATENT USE

U-1582 TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
 U-1583 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
 U-1584 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT
 MANAGEMENT FOR AFFECTING WEIGHT LOSS
 U-1585 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
 U-1586 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
 U-1587 SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
 U-1588 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
 (CRPC).
 U-1589 METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM
 HYPERPHENYLALANINEMIA
 U-1590 KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH
 HYPERPHENYLALANINEMIA
 U-1591 TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
 U-1592 TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
 U-1593 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC
 BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
 U-1594 DILATION OF THE PUPIL
 U-1595 USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
 U-1596 LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY
 IN PATIENTS ≥ 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-
 CLONIC SEIZURES
 U-1597 TREATMENT OF DIABETIC MACULAR EDEMA
 U-1598 METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
 U-1599 MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN
 ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY,
 ANALGESIC, AND ANTIPYRETIC ACTIVITY
 U-1600 DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC
 PULMONARY FIBROSIS
 U-1601 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
 U-1602 METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
 U-1603 METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
 U-1604 METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG
 INHIBITOR OF CYP1A2
 U-1605 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING
 SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
 U-1606 METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT
 USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME
 INVOLVED IN PIRFENIDONE METABOLISM
 U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF
 PIRFENIDONE TO TREAT A FIBROTIC CONDITION
 U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
 U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN
 TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
 U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF
 PIRFENIDONE
 U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING
 SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
 U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING
 OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
 U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH
 CIPROFLOXACIN
 U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
 U-1615 FOR THE TREATMENT OF PATIENTS WITH CCL, FL, OR SLL
 U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A
 CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
 U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER
 U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE
 COMPRISING ADMINISTERING A LIQUID COMPOSITION FOMULATED INSIDE A SOFT GEL
 CAPSULE, AS CLAIMED, TO THE PATIENT
 U-1619 TREATMENT OF IMMUNE (IDIOPATIC) THROMBOCYTOPENIA (ITP)
 U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF
 ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-
 IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
 U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING
 AGENT.
 U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA

PATENT AND EXCLUSIVITY TERMS

ADB 67 of 67

PATENT USE

U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.

U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.

U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6

U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING

U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS

U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION

U-1629 METHOD OF TREATING ACROMEGALY

U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL

U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.

U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1633 USE OF ARIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR

U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION

U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.

U-1637 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

U-1638 TREATMENT OF HCV INFECTION USING PARITAPREVIR

U-1639 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

U-1640 TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED

U-1641 MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

U-1642 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN